Symfony Profiler

Settings

PlaceholderAction

Request

GET Parameters

Key	Value
client_id	"59"
containers_id	"18"
locale	"de"
pagination	"false"

POST Parameters

No POST parameters

Uploaded Files

No files were uploaded

Request Attributes

Key	Value
_api_collection_operation_name	"get_all"
_api_exception_to_status	[]
_api_has_composite_identifier	false
_api_identifiers	[`"id"`]
_api_normalization_context	["groups" => [ "Company:Read" ] "skip_null_values" => false "operation_type" => "collection" "collection_operation_name" => "get_all" "iri_only" => false "input" => null "output" => null "resource_class" => "App\Entity\Company" "request_uri" => "/api/companies/get-all?client.id=59&containers.id=18&pagination=false&locale=de" "uri" => "https://apiprod.expertshare.live/api/companies/get-all?client.id=59&containers.id=18&locale=de&pagination=false" "resources" => ApiPlatform\Serializer\ResourceList {#7038 storage: [ "/public-api/companies/get/1" => "/public-api/companies/get/1" "/api/clients/59" => "/api/clients/59" "/api/common_categories/1068" => "/api/common_categories/1068" "/public-api/users/get/1271" => "/public-api/users/get/1271" "/api/special_titles/53" => "/api/special_titles/53" "/public-api/users/get/7904" => "/public-api/users/get/7904" "/public-api/users/get/8724" => "/public-api/users/get/8724" "/public-api/users/get/9414" => "/public-api/users/get/9414" "/public-api/users/get/27470" => "/public-api/users/get/27470" "/public-api/users/get/79205" => "/public-api/users/get/79205" "/public-api/users/get/95256" => "/public-api/users/get/95256" "/api/special_titles/52" => "/api/special_titles/52" "/api/user_academic_titles/14108" => "/api/user_academic_titles/14108" "/api/academic_titles/24" => "/api/academic_titles/24" "/public-api/users/get/95380" => "/public-api/users/get/95380" "/public-api/companies/get/2" => "/public-api/companies/get/2" "/public-api/companies/get/3" => "/public-api/companies/get/3" "/public-api/users/get/77971" => "/public-api/users/get/77971" "/public-api/companies/get/4" => "/public-api/companies/get/4" "/public-api/users/get/16307" => "/public-api/users/get/16307" "/public-api/companies/get/5" => "/public-api/companies/get/5" "/public-api/users/get/8853" => "/public-api/users/get/8853" "/public-api/users/get/97452" => "/public-api/users/get/97452" "/api/user_academic_titles/15722" => "/api/user_academic_titles/15722" "/public-api/companies/get/6" => "/public-api/companies/get/6" "/public-api/users/get/16162" => "/public-api/users/get/16162" "/public-api/companies/get/7" => "/public-api/companies/get/7" "/public-api/companies/get/8" => "/public-api/companies/get/8" "/public-api/companies/get/9" => "/public-api/companies/get/9" "/public-api/users/get/11722" => "/public-api/users/get/11722" "/api/user_academic_titles/3008" => "/api/user_academic_titles/3008" "/api/academic_titles/25" => "/api/academic_titles/25" "/public-api/users/get/15899" => "/public-api/users/get/15899" "/public-api/companies/get/10" => "/public-api/companies/get/10" "/public-api/companies/get/11" => "/public-api/companies/get/11" "/public-api/users/get/7817" => "/public-api/users/get/7817" "/public-api/users/get/7837" => "/public-api/users/get/7837" "/public-api/companies/get/12" => "/public-api/companies/get/12" "/public-api/users/get/8207" => "/public-api/users/get/8207" "/api/user_academic_titles/2775" => "/api/user_academic_titles/2775" "/api/academic_titles/19" => "/api/academic_titles/19" "/public-api/users/get/8212" => "/public-api/users/get/8212" "/public-api/companies/get/13" => "/public-api/companies/get/13" "/public-api/users/get/7885" => "/public-api/users/get/7885" "/public-api/users/get/8630" => "/public-api/users/get/8630" "/public-api/users/get/9433" => "/public-api/users/get/9433" "/public-api/companies/get/14" => "/public-api/companies/get/14" "/public-api/users/get/77905" => "/public-api/users/get/77905" "/public-api/companies/get/15" => "/public-api/companies/get/15" "/public-api/users/get/10644" => "/public-api/users/get/10644" "/public-api/companies/get/16" => "/public-api/companies/get/16" "/public-api/users/get/11083" => "/public-api/users/get/11083" "/public-api/companies/get/17" => "/public-api/companies/get/17" "/public-api/companies/get/18" => "/public-api/companies/get/18" "/public-api/users/get/8949" => "/public-api/users/get/8949" "/public-api/users/get/10516" => "/public-api/users/get/10516" "/public-api/users/get/11371" => "/public-api/users/get/11371" "/public-api/companies/get/19" => "/public-api/companies/get/19" "/public-api/users/get/7825" => "/public-api/users/get/7825" "/public-api/users/get/8802" => "/public-api/users/get/8802" "/public-api/companies/get/20" => "/public-api/companies/get/20" "/public-api/users/get/9403" => "/public-api/users/get/9403" "/public-api/users/get/10299" => "/public-api/users/get/10299" "/public-api/users/get/10302" => "/public-api/users/get/10302" "/public-api/users/get/10303" => "/public-api/users/get/10303" "/public-api/companies/get/21" => "/public-api/companies/get/21" "/public-api/users/get/74348" => "/public-api/users/get/74348" "/public-api/companies/get/22" => "/public-api/companies/get/22" "/public-api/users/get/7846" => "/public-api/users/get/7846" "/public-api/users/get/25433" => "/public-api/users/get/25433" "/public-api/users/get/25443" => "/public-api/users/get/25443" "/public-api/companies/get/24" => "/public-api/companies/get/24" "/public-api/users/get/7892" => "/public-api/users/get/7892" "/public-api/companies/get/25" => "/public-api/companies/get/25" "/public-api/users/get/7843" => "/public-api/users/get/7843" "/public-api/users/get/78894" => "/public-api/users/get/78894" "/public-api/companies/get/26" => "/public-api/companies/get/26" "/public-api/users/get/8159" => "/public-api/users/get/8159" "/public-api/users/get/8160" => "/public-api/users/get/8160" "/public-api/users/get/8166" => "/public-api/users/get/8166" "/public-api/companies/get/27" => "/public-api/companies/get/27" "/public-api/users/get/15969" => "/public-api/users/get/15969" "/public-api/companies/get/28" => "/public-api/companies/get/28" "/public-api/companies/get/29" => "/public-api/companies/get/29" "/public-api/users/get/9695" => "/public-api/users/get/9695" "/public-api/companies/get/30" => "/public-api/companies/get/30" "/public-api/users/get/12532" => "/public-api/users/get/12532" "/public-api/users/get/16068" => "/public-api/users/get/16068" "/public-api/companies/get/31" => "/public-api/companies/get/31" "/public-api/users/get/7908" => "/public-api/users/get/7908" "/public-api/users/get/79541" => "/public-api/users/get/79541" "/public-api/users/get/79542" => "/public-api/users/get/79542" "/public-api/companies/get/32" => "/public-api/companies/get/32" "/public-api/users/get/26469" => "/public-api/users/get/26469" "/public-api/companies/get/33" => "/public-api/companies/get/33" "/public-api/users/get/8795" => "/public-api/users/get/8795" "/public-api/users/get/9237" => "/public-api/users/get/9237" "/public-api/users/get/9334" => "/public-api/users/get/9334" "/public-api/companies/get/34" => "/public-api/companies/get/34" "/public-api/users/get/15979" => "/public-api/users/get/15979" "/public-api/users/get/15980" => "/public-api/users/get/15980" "/api/user_academic_titles/3294" => "/api/user_academic_titles/3294" "/public-api/users/get/15981" => "/public-api/users/get/15981" "/public-api/companies/get/35" => "/public-api/companies/get/35" "/public-api/users/get/7804" => "/public-api/users/get/7804" "/public-api/users/get/7906" => "/public-api/users/get/7906" "/public-api/companies/get/36" => "/public-api/companies/get/36" "/public-api/users/get/11225" => "/public-api/users/get/11225" "/public-api/companies/get/37" => "/public-api/companies/get/37" "/public-api/users/get/7835" => "/public-api/users/get/7835" "/public-api/users/get/10166" => "/public-api/users/get/10166" "/public-api/companies/get/38" => "/public-api/companies/get/38" "/public-api/users/get/9333" => "/public-api/users/get/9333" "/public-api/companies/get/39" => "/public-api/companies/get/39" "/public-api/users/get/74433" => "/public-api/users/get/74433" "/api/user_academic_titles/4237" => "/api/user_academic_titles/4237" "/public-api/companies/get/40" => "/public-api/companies/get/40" "/public-api/users/get/7853" => "/public-api/users/get/7853" "/public-api/companies/get/41" => "/public-api/companies/get/41" "/public-api/users/get/7848" => "/public-api/users/get/7848" "/public-api/companies/get/42" => "/public-api/companies/get/42" "/public-api/users/get/25911" => "/public-api/users/get/25911" "/public-api/users/get/25941" => "/public-api/users/get/25941" "/public-api/users/get/27083" => "/public-api/users/get/27083" "/public-api/companies/get/43" => "/public-api/companies/get/43" "/public-api/users/get/7844" => "/public-api/users/get/7844" "/public-api/companies/get/44" => "/public-api/companies/get/44" "/public-api/users/get/7867" => "/public-api/users/get/7867" "/public-api/users/get/8147" => "/public-api/users/get/8147" "/public-api/users/get/8154" => "/public-api/users/get/8154" "/public-api/companies/get/45" => "/public-api/companies/get/45" "/public-api/users/get/7894" => "/public-api/users/get/7894" "/public-api/companies/get/46" => "/public-api/companies/get/46" "/public-api/users/get/20379" => "/public-api/users/get/20379" "/public-api/users/get/76063" => "/public-api/users/get/76063" "/public-api/users/get/79270" => "/public-api/users/get/79270" "/public-api/companies/get/47" => "/public-api/companies/get/47" "/public-api/companies/get/48" => "/public-api/companies/get/48" "/public-api/users/get/85844" => "/public-api/users/get/85844" "/public-api/companies/get/49" => "/public-api/companies/get/49" "/public-api/users/get/8541" => "/public-api/users/get/8541" "/public-api/users/get/12316" => "/public-api/users/get/12316" "/public-api/users/get/12318" => "/public-api/users/get/12318" "/public-api/companies/get/50" => "/public-api/companies/get/50" "/public-api/users/get/9370" => "/public-api/users/get/9370" "/public-api/users/get/77772" => "/public-api/users/get/77772" "/public-api/users/get/77777" => "/public-api/users/get/77777" "/public-api/companies/get/51" => "/public-api/companies/get/51" "/public-api/users/get/85819" => "/public-api/users/get/85819" "/api/user_academic_titles/6358" => "/api/user_academic_titles/6358" "/api/academic_titles/31" => "/api/academic_titles/31" "/public-api/companies/get/52" => "/public-api/companies/get/52" "/public-api/users/get/9246" => "/public-api/users/get/9246" "/public-api/users/get/11202" => "/public-api/users/get/11202" "/public-api/users/get/11283" => "/public-api/users/get/11283" "/api/user_academic_titles/2928" => "/api/user_academic_titles/2928" "/api/academic_titles/27" => "/api/academic_titles/27" "/public-api/companies/get/53" => "/public-api/companies/get/53" "/public-api/users/get/8767" => "/public-api/users/get/8767" "/public-api/companies/get/54" => "/public-api/companies/get/54" "/public-api/users/get/20221" => "/public-api/users/get/20221" "/public-api/users/get/20287" => "/public-api/users/get/20287" "/public-api/users/get/25435" => "/public-api/users/get/25435" "/public-api/companies/get/55" => "/public-api/companies/get/55" "/public-api/users/get/16203" => "/public-api/users/get/16203" "/public-api/companies/get/56" => "/public-api/companies/get/56" "/public-api/users/get/9364" => "/public-api/users/get/9364" "/public-api/companies/get/57" => "/public-api/companies/get/57" "/public-api/users/get/8738" => "/public-api/users/get/8738" "/public-api/users/get/77948" => "/public-api/users/get/77948" "/public-api/companies/get/58" => "/public-api/companies/get/58" "/public-api/users/get/7869" => "/public-api/users/get/7869" "/public-api/users/get/19709" => "/public-api/users/get/19709" "/public-api/companies/get/59" => "/public-api/companies/get/59" "/public-api/users/get/7836" => "/public-api/users/get/7836" "/public-api/users/get/8812" => "/public-api/users/get/8812" "/public-api/users/get/9452" => "/public-api/users/get/9452" "/public-api/users/get/97557" => "/public-api/users/get/97557" "/public-api/companies/get/60" => "/public-api/companies/get/60" "/public-api/companies/get/61" => "/public-api/companies/get/61" "/public-api/companies/get/63" => "/public-api/companies/get/63" "/public-api/companies/get/64" => "/public-api/companies/get/64" "/public-api/users/get/15874" => "/public-api/users/get/15874" "/public-api/companies/get/65" => "/public-api/companies/get/65" "/public-api/companies/get/68" => "/public-api/companies/get/68" "/public-api/users/get/95357" => "/public-api/users/get/95357" "/api/special_titles/51" => "/api/special_titles/51" "/public-api/users/get/95695" => "/public-api/users/get/95695" "/api/user_academic_titles/14327" => "/api/user_academic_titles/14327" "/api/academic_titles/28" => "/api/academic_titles/28" "/api/user_academic_titles/14328" => "/api/user_academic_titles/14328" "/public-api/companies/get/69" => "/public-api/companies/get/69" "/public-api/companies/get/70" => "/public-api/companies/get/70" "/public-api/users/get/98179" => "/public-api/users/get/98179" "/public-api/companies/get/71" => "/public-api/companies/get/71" "/public-api/companies/get/81" => "/public-api/companies/get/81" "/public-api/companies/get/85" => "/public-api/companies/get/85" "/public-api/companies/get/279" => "/public-api/companies/get/279" "/public-api/companies/get/306" => "/public-api/companies/get/306" "/api/common_categories/1144" => "/api/common_categories/1144" "/public-api/users/get/8065" => "/public-api/users/get/8065" "/public-api/users/get/100170" => "/public-api/users/get/100170" ] flag::STD_PROP_LIST: false flag::ARRAY_AS_PROPS: false iteratorClass: "ArrayIterator" } "exclude_from_cache_key" => [ "resources" "resources_to_push" ] "resources_to_push" => ApiPlatform\Serializer\ResourceList {#7039 storage: [] flag::STD_PROP_LIST: false flag::ARRAY_AS_PROPS: false iteratorClass: "ArrayIterator" }]
_api_operation_name	"api_companies_get_all_collection"
_api_resource_class	"App\Entity\Company"
_controller	"api_platform.action.get_collection"
_firewall_context	"security.firewall.map.context.api"
_format	null
_links	Symfony\Component\WebLink\GenericLinkProvider {#18553`-links: [ 18552 => Symfony\Component\WebLink\Link {#18552 -href: "https://apiprod.expertshare.live/api/docs.jsonld" -rel: [ "http://www.w3.org/ns/hydra/core#apiDocumentation" => "http://www.w3.org/ns/hydra/core#apiDocumentation" ] -attributes: [] } ]`}
_nelmio_cors_should_allow_origin	true
_resources	["/public-api/companies/get/1" => "/public-api/companies/get/1" "/api/clients/59" => "/api/clients/59" "/api/common_categories/1068" => "/api/common_categories/1068" "/public-api/users/get/1271" => "/public-api/users/get/1271" "/api/special_titles/53" => "/api/special_titles/53" "/public-api/users/get/7904" => "/public-api/users/get/7904" "/public-api/users/get/8724" => "/public-api/users/get/8724" "/public-api/users/get/9414" => "/public-api/users/get/9414" "/public-api/users/get/27470" => "/public-api/users/get/27470" "/public-api/users/get/79205" => "/public-api/users/get/79205" "/public-api/users/get/95256" => "/public-api/users/get/95256" "/api/special_titles/52" => "/api/special_titles/52" "/api/user_academic_titles/14108" => "/api/user_academic_titles/14108" "/api/academic_titles/24" => "/api/academic_titles/24" "/public-api/users/get/95380" => "/public-api/users/get/95380" "/public-api/companies/get/2" => "/public-api/companies/get/2" "/public-api/companies/get/3" => "/public-api/companies/get/3" "/public-api/users/get/77971" => "/public-api/users/get/77971" "/public-api/companies/get/4" => "/public-api/companies/get/4" "/public-api/users/get/16307" => "/public-api/users/get/16307" "/public-api/companies/get/5" => "/public-api/companies/get/5" "/public-api/users/get/8853" => "/public-api/users/get/8853" "/public-api/users/get/97452" => "/public-api/users/get/97452" "/api/user_academic_titles/15722" => "/api/user_academic_titles/15722" "/public-api/companies/get/6" => "/public-api/companies/get/6" "/public-api/users/get/16162" => "/public-api/users/get/16162" "/public-api/companies/get/7" => "/public-api/companies/get/7" "/public-api/companies/get/8" => "/public-api/companies/get/8" "/public-api/companies/get/9" => "/public-api/companies/get/9" "/public-api/users/get/11722" => "/public-api/users/get/11722" "/api/user_academic_titles/3008" => "/api/user_academic_titles/3008" "/api/academic_titles/25" => "/api/academic_titles/25" "/public-api/users/get/15899" => "/public-api/users/get/15899" "/public-api/companies/get/10" => "/public-api/companies/get/10" "/public-api/companies/get/11" => "/public-api/companies/get/11" "/public-api/users/get/7817" => "/public-api/users/get/7817" "/public-api/users/get/7837" => "/public-api/users/get/7837" "/public-api/companies/get/12" => "/public-api/companies/get/12" "/public-api/users/get/8207" => "/public-api/users/get/8207" "/api/user_academic_titles/2775" => "/api/user_academic_titles/2775" "/api/academic_titles/19" => "/api/academic_titles/19" "/public-api/users/get/8212" => "/public-api/users/get/8212" "/public-api/companies/get/13" => "/public-api/companies/get/13" "/public-api/users/get/7885" => "/public-api/users/get/7885" "/public-api/users/get/8630" => "/public-api/users/get/8630" "/public-api/users/get/9433" => "/public-api/users/get/9433" "/public-api/companies/get/14" => "/public-api/companies/get/14" "/public-api/users/get/77905" => "/public-api/users/get/77905" "/public-api/companies/get/15" => "/public-api/companies/get/15" "/public-api/users/get/10644" => "/public-api/users/get/10644" "/public-api/companies/get/16" => "/public-api/companies/get/16" "/public-api/users/get/11083" => "/public-api/users/get/11083" "/public-api/companies/get/17" => "/public-api/companies/get/17" "/public-api/companies/get/18" => "/public-api/companies/get/18" "/public-api/users/get/8949" => "/public-api/users/get/8949" "/public-api/users/get/10516" => "/public-api/users/get/10516" "/public-api/users/get/11371" => "/public-api/users/get/11371" "/public-api/companies/get/19" => "/public-api/companies/get/19" "/public-api/users/get/7825" => "/public-api/users/get/7825" "/public-api/users/get/8802" => "/public-api/users/get/8802" "/public-api/companies/get/20" => "/public-api/companies/get/20" "/public-api/users/get/9403" => "/public-api/users/get/9403" "/public-api/users/get/10299" => "/public-api/users/get/10299" "/public-api/users/get/10302" => "/public-api/users/get/10302" "/public-api/users/get/10303" => "/public-api/users/get/10303" "/public-api/companies/get/21" => "/public-api/companies/get/21" "/public-api/users/get/74348" => "/public-api/users/get/74348" "/public-api/companies/get/22" => "/public-api/companies/get/22" "/public-api/users/get/7846" => "/public-api/users/get/7846" "/public-api/users/get/25433" => "/public-api/users/get/25433" "/public-api/users/get/25443" => "/public-api/users/get/25443" "/public-api/companies/get/24" => "/public-api/companies/get/24" "/public-api/users/get/7892" => "/public-api/users/get/7892" "/public-api/companies/get/25" => "/public-api/companies/get/25" "/public-api/users/get/7843" => "/public-api/users/get/7843" "/public-api/users/get/78894" => "/public-api/users/get/78894" "/public-api/companies/get/26" => "/public-api/companies/get/26" "/public-api/users/get/8159" => "/public-api/users/get/8159" "/public-api/users/get/8160" => "/public-api/users/get/8160" "/public-api/users/get/8166" => "/public-api/users/get/8166" "/public-api/companies/get/27" => "/public-api/companies/get/27" "/public-api/users/get/15969" => "/public-api/users/get/15969" "/public-api/companies/get/28" => "/public-api/companies/get/28" "/public-api/companies/get/29" => "/public-api/companies/get/29" "/public-api/users/get/9695" => "/public-api/users/get/9695" "/public-api/companies/get/30" => "/public-api/companies/get/30" "/public-api/users/get/12532" => "/public-api/users/get/12532" "/public-api/users/get/16068" => "/public-api/users/get/16068" "/public-api/companies/get/31" => "/public-api/companies/get/31" "/public-api/users/get/7908" => "/public-api/users/get/7908" "/public-api/users/get/79541" => "/public-api/users/get/79541" "/public-api/users/get/79542" => "/public-api/users/get/79542" "/public-api/companies/get/32" => "/public-api/companies/get/32" "/public-api/users/get/26469" => "/public-api/users/get/26469" "/public-api/companies/get/33" => "/public-api/companies/get/33" "/public-api/users/get/8795" => "/public-api/users/get/8795" "/public-api/users/get/9237" => "/public-api/users/get/9237" "/public-api/users/get/9334" => "/public-api/users/get/9334" "/public-api/companies/get/34" => "/public-api/companies/get/34" "/public-api/users/get/15979" => "/public-api/users/get/15979" "/public-api/users/get/15980" => "/public-api/users/get/15980" "/api/user_academic_titles/3294" => "/api/user_academic_titles/3294" "/public-api/users/get/15981" => "/public-api/users/get/15981" "/public-api/companies/get/35" => "/public-api/companies/get/35" "/public-api/users/get/7804" => "/public-api/users/get/7804" "/public-api/users/get/7906" => "/public-api/users/get/7906" "/public-api/companies/get/36" => "/public-api/companies/get/36" "/public-api/users/get/11225" => "/public-api/users/get/11225" "/public-api/companies/get/37" => "/public-api/companies/get/37" "/public-api/users/get/7835" => "/public-api/users/get/7835" "/public-api/users/get/10166" => "/public-api/users/get/10166" "/public-api/companies/get/38" => "/public-api/companies/get/38" "/public-api/users/get/9333" => "/public-api/users/get/9333" "/public-api/companies/get/39" => "/public-api/companies/get/39" "/public-api/users/get/74433" => "/public-api/users/get/74433" "/api/user_academic_titles/4237" => "/api/user_academic_titles/4237" "/public-api/companies/get/40" => "/public-api/companies/get/40" "/public-api/users/get/7853" => "/public-api/users/get/7853" "/public-api/companies/get/41" => "/public-api/companies/get/41" "/public-api/users/get/7848" => "/public-api/users/get/7848" "/public-api/companies/get/42" => "/public-api/companies/get/42" "/public-api/users/get/25911" => "/public-api/users/get/25911" "/public-api/users/get/25941" => "/public-api/users/get/25941" "/public-api/users/get/27083" => "/public-api/users/get/27083" "/public-api/companies/get/43" => "/public-api/companies/get/43" "/public-api/users/get/7844" => "/public-api/users/get/7844" "/public-api/companies/get/44" => "/public-api/companies/get/44" "/public-api/users/get/7867" => "/public-api/users/get/7867" "/public-api/users/get/8147" => "/public-api/users/get/8147" "/public-api/users/get/8154" => "/public-api/users/get/8154" "/public-api/companies/get/45" => "/public-api/companies/get/45" "/public-api/users/get/7894" => "/public-api/users/get/7894" "/public-api/companies/get/46" => "/public-api/companies/get/46" "/public-api/users/get/20379" => "/public-api/users/get/20379" "/public-api/users/get/76063" => "/public-api/users/get/76063" "/public-api/users/get/79270" => "/public-api/users/get/79270" "/public-api/companies/get/47" => "/public-api/companies/get/47" "/public-api/companies/get/48" => "/public-api/companies/get/48" "/public-api/users/get/85844" => "/public-api/users/get/85844" "/public-api/companies/get/49" => "/public-api/companies/get/49" "/public-api/users/get/8541" => "/public-api/users/get/8541" "/public-api/users/get/12316" => "/public-api/users/get/12316" "/public-api/users/get/12318" => "/public-api/users/get/12318" "/public-api/companies/get/50" => "/public-api/companies/get/50" "/public-api/users/get/9370" => "/public-api/users/get/9370" "/public-api/users/get/77772" => "/public-api/users/get/77772" "/public-api/users/get/77777" => "/public-api/users/get/77777" "/public-api/companies/get/51" => "/public-api/companies/get/51" "/public-api/users/get/85819" => "/public-api/users/get/85819" "/api/user_academic_titles/6358" => "/api/user_academic_titles/6358" "/api/academic_titles/31" => "/api/academic_titles/31" "/public-api/companies/get/52" => "/public-api/companies/get/52" "/public-api/users/get/9246" => "/public-api/users/get/9246" "/public-api/users/get/11202" => "/public-api/users/get/11202" "/public-api/users/get/11283" => "/public-api/users/get/11283" "/api/user_academic_titles/2928" => "/api/user_academic_titles/2928" "/api/academic_titles/27" => "/api/academic_titles/27" "/public-api/companies/get/53" => "/public-api/companies/get/53" "/public-api/users/get/8767" => "/public-api/users/get/8767" "/public-api/companies/get/54" => "/public-api/companies/get/54" "/public-api/users/get/20221" => "/public-api/users/get/20221" "/public-api/users/get/20287" => "/public-api/users/get/20287" "/public-api/users/get/25435" => "/public-api/users/get/25435" "/public-api/companies/get/55" => "/public-api/companies/get/55" "/public-api/users/get/16203" => "/public-api/users/get/16203" "/public-api/companies/get/56" => "/public-api/companies/get/56" "/public-api/users/get/9364" => "/public-api/users/get/9364" "/public-api/companies/get/57" => "/public-api/companies/get/57" "/public-api/users/get/8738" => "/public-api/users/get/8738" "/public-api/users/get/77948" => "/public-api/users/get/77948" "/public-api/companies/get/58" => "/public-api/companies/get/58" "/public-api/users/get/7869" => "/public-api/users/get/7869" "/public-api/users/get/19709" => "/public-api/users/get/19709" "/public-api/companies/get/59" => "/public-api/companies/get/59" "/public-api/users/get/7836" => "/public-api/users/get/7836" "/public-api/users/get/8812" => "/public-api/users/get/8812" "/public-api/users/get/9452" => "/public-api/users/get/9452" "/public-api/users/get/97557" => "/public-api/users/get/97557" "/public-api/companies/get/60" => "/public-api/companies/get/60" "/public-api/companies/get/61" => "/public-api/companies/get/61" "/public-api/companies/get/63" => "/public-api/companies/get/63" "/public-api/companies/get/64" => "/public-api/companies/get/64" "/public-api/users/get/15874" => "/public-api/users/get/15874" "/public-api/companies/get/65" => "/public-api/companies/get/65" "/public-api/companies/get/68" => "/public-api/companies/get/68" "/public-api/users/get/95357" => "/public-api/users/get/95357" "/api/special_titles/51" => "/api/special_titles/51" "/public-api/users/get/95695" => "/public-api/users/get/95695" "/api/user_academic_titles/14327" => "/api/user_academic_titles/14327" "/api/academic_titles/28" => "/api/academic_titles/28" "/api/user_academic_titles/14328" => "/api/user_academic_titles/14328" "/public-api/companies/get/69" => "/public-api/companies/get/69" "/public-api/companies/get/70" => "/public-api/companies/get/70" "/public-api/users/get/98179" => "/public-api/users/get/98179" "/public-api/companies/get/71" => "/public-api/companies/get/71" "/public-api/companies/get/81" => "/public-api/companies/get/81" "/public-api/companies/get/85" => "/public-api/companies/get/85" "/public-api/companies/get/279" => "/public-api/companies/get/279" "/public-api/companies/get/306" => "/public-api/companies/get/306" "/api/common_categories/1144" => "/api/common_categories/1144" "/public-api/users/get/8065" => "/public-api/users/get/8065" "/public-api/users/get/100170" => "/public-api/users/get/100170"]
_route	"api_companies_get_all_collection"
_route_params	[`"_format" => null "_stateless" => null "_api_resource_class" => "App\Entity\Company" "_api_identifiers" => [ "id" ] "_api_has_composite_identifier" => false "_api_exception_to_status" => [] "_api_operation_name" => "api_companies_get_all_collection" "_api_collection_operation_name" => "get_all"`]
_stateless	null
_stopwatch_token	"79f364"
data	[App\Entity\Company {#4257 -id: 1 -name: "AbbVie AG" -website: "https://abbvie.ch" -description: """ Das AbbVie Medical Institute (AMI) bietet anatomische Auffrischungskurse über Diagnose, Behandlungsplanung und Ausführung der Injektionstechniken bis hin zu komplexen und progressiven Protokollen und dem Management schwieriger Patientenfälle.\n \n Für mehr Informationen zu AMI besuchen Sie bitte www.ami-neuroscience.ch.\n \n Für weitere Informationen zu Duodopa besuchen Sie bitte www.duodopa.ch.\n \n Weitere Informatione zu Therapiebereichen von AbbVie finden Sie unter www.abbvie.ch. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4259 …} -companyTags: Doctrine\ORM\PersistentCollection {#4261 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4264 …} -users: Doctrine\ORM\PersistentCollection {#4266 …} -logoImageName: "20250226124450-abbvie-logo-67befeb20dac1323023029.jpg" -coverImageName: "20250226124450-abbv-43b0eee3-67befeb293f82010774326.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4286 …} -tagline: "AbbVie Medical Institute: Expertenkurse zum Thema BoNT-A-Injektionen für fortgeschrittene Injektionstechniken und Patientenmanagement" -contactEmail: "judith.kirchhofer@abbvie.com" -phone: null -streamUrl: "" -streamType: "YOUTUBE" -followers: Doctrine\ORM\PersistentCollection {#4288 …} -totalFollowers: 0 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4290 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4292 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "CH" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4294 …} #createdAt: DateTime @1740039874 {#4052 date: 2025-02-20 08:24:34.0 UTC (+00:00) } #updatedAt: DateTime @1759390011 {#4048 date: 2025-10-02 07:26:51.0 UTC (+00:00) } } App\Entity\Company {#4304 -id: 2 -name: "Abbott Health Products Inc" -website: "https://abbott.com" -description: "Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, in the United States." -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4305 …} -companyTags: Doctrine\ORM\PersistentCollection {#4307 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4309 …} -users: Doctrine\ORM\PersistentCollection {#4311 …} -logoImageName: "20250226150543-abott-logo-67bf1fb7e87c6881014854.png" -coverImageName: "20250227155916-abott-favicon-67c07dc415cc8987826861.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4313 …} -tagline: "Pioneering Healthcare Innovations with Cutting-Edge Pharmaceuticals, Medical Devices & Nutritional Science" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4315 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4317 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4319 …} -industry: "" -size: null -address1: null -address2: null -city: null -postalCode: null -state: null -country: "United States" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4321 …} #createdAt: DateTime @1740042853 {#4303 date: 2025-02-20 09:14:13.0 UTC (+00:00) } #updatedAt: DateTime @1759390366 {#4302 date: 2025-10-02 07:32:46.0 UTC (+00:00) } } App\Entity\Company {#4325 -id: 3 -name: "Alexion Pharma GmbH" -website: "https://rarediseaseknowledge.com" -description: "Alexion, AstraZeneca Rare Disease ist der Unternehmensbereich von AstraZeneca, der sich auf seltene Krankheiten konzentriert und durch die Übernahme von Alexion Pharmaceuticals, Inc. im Jahr 2021 entstand. Unsere Mission ist es, das Leben von Menschen mit seltenen, schwerwiegenden Erkrankungen zu verbessern, indem wir innovative Arzneimittel, unterstützende Technologien und Gesundheitsdienstleistungen erforschen, entwickeln und bereitstellen. Aufbauend auf 30 Jahren Pionierarbeit im Bereich der Komplementbiologie setzen wir unser Bemühen fort, mehr Patienten schneller mit Medikamenten zu versorgen." -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4326 …} -companyTags: Doctrine\ORM\PersistentCollection {#4328 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4330 …} -users: Doctrine\ORM\PersistentCollection {#4332 …} -logoImageName: "20250227160058-20230201110047-alexion-logo-260x160-63da384f380fe233822711-67c07e2a7ef74422857218.jpg" -coverImageName: "20250227160146-alexion-favicon-67c07e5a926a7673008464.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4334 …} -tagline: "AstraZenecas Spezialist für seltene Krankheiten und Komplementbiologie" -contactEmail: "alexion.switzerland@alexion.com" -phone: "41044457400" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4336 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4338 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4340 …} -industry: "" -size: "" -address1: "Neuhofstrasse 34" -address2: "" -city: "Baar" -postalCode: "6340" -state: "" -country: "CH" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4342 …} #createdAt: DateTime @1740043553 {#4324 date: 2025-02-20 09:25:53.0 UTC (+00:00) } #updatedAt: DateTime @1759390376 {#4323 date: 2025-10-02 07:32:56.0 UTC (+00:00) } } App\Entity\Company {#4346 -id: 4 -name: "Almirall AG" -website: "https://almirall.ch" -description: """ Almirall engagiert sich in den Indikationen Dermatologie und Neurologie, um für die Gesundheit und das Wohlbefinden der Patienten zu sorgen. Neben einem umfassenden Forschungsprogramm und der innovativen Entwicklung neuer Medikamente, unterstützen wir die Gesundheitsbranche auch weltweit finanziell.\n \n In der Neurologie bietet die Almirall AG innovative Medikamente für Patienten mit MS-induzierter Spastik sowie für Patienten mit Migräne-Kopfschmerzen an.\n \n Sorgfältig sucht Almirall förderungswürdige Initiativen aus den Programmen zahlreicher Patientenverbände sowie medizinischer und akademischer Organisationen in der ganzen Welt aus. Unsere Unterstützung dieser Initiativen legen wir gemäß des EFPIA Code of Practice und nach Maßgabe nationaler Verordnungen offen. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4347 …} -companyTags: Doctrine\ORM\PersistentCollection {#4349 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4351 …} -users: Doctrine\ORM\PersistentCollection {#4353 …} -logoImageName: "20250227160312-20211119135433-848ea1034a4e1a707533702b7aa5fffc-202101201800-1-61979e89a788e506615242-67c07eb063385970161988.png" -coverImageName: "20250227160312-frame-114-67c07eb0c56a1504226312.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4355 …} -tagline: "Fortschritt in Dermatologie & Neurologie – Innovative Therapien und weltweites Engagement für die Patientenversorgung" -contactEmail: "gisela.grames@almirall.com" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4357 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4359 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4361 …} -industry: "" -size: "" -address1: "Alte Winterthurerstrasse 14" -address2: "" -city: "Wallisellen" -postalCode: "8304" -state: "" -country: "CH" -socialLinkedin: "https://www.linkedin.com/in/gisela-grames-130053118/" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4363 …} #createdAt: DateTime @1740043797 {#4345 date: 2025-02-20 09:29:57.0 UTC (+00:00) } #updatedAt: DateTime @1759390385 {#4344 date: 2025-10-02 07:33:05.0 UTC (+00:00) } } App\Entity\Company {#4367 -id: 5 -name: "Alnylam Pharmaceuticals" -website: "https://alnylam.com" -description: """ ALNYLAM Pharmaceuticals entwickelt Therapien auf Basis der RNA-Interferenz (RNAi). Das Unternehmen wurde 2002 gegründet und entwickelt RNAi-Therapeutika für Krankheiten, für die es nur begrenzte oder unzureichende Behandlungsmöglichkeiten gibt. Die RNA-Interferenz kann die Proteinbiosynthese verhindern, indem die für das Ziel-Protein kodierende mRNA durch einen zelleigenen Enzymkomplex spezifisch aufgefunden und sodann abgebaut wird. \n \n Der Prozess ist reversibel und greift nicht in die DNA ein. Wir bringen eine umfangreiche Pipeline innovativer RNAi-basierter Arzneimittel in vier Therapiebereichen voran: genetische Erkrankungen, kardio-metabolische Erkrankungen, Infektionskrankheiten sowie Erkrankungen des zentralen Nervensystems (ZNS) und des Auges. \n \n Unsere Wissenschaft verändert die Art und Weise, wie die Medizin Krankheiten behandelt. """ -externalId: "8900492" -details: [ "id" => 8900492 "url" => "https://www.linkedin.com/company/alnylam-pharmaceuticals" "hash" => "c0a8a95b106226d9179f42636b956a1d" "name" => "Alnylam Pharmaceuticals" "website" => "http://www.alnylam.com" "size" => "1,001-5,000 employees" "industry" => "Biotechnology Research" "description" => null "followers" => 221580 "founded" => 2002 "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://media.licdn.com/dms/image/v2/D4E0BAQGUEWkWJAsJwQ/company-logo_200_200/company-logo_200_200/0/1720441881388/alnylam_pharmaceuticals_logo?e=2147483647&v=beta&t=ixiiUxu-JnoCcL7yvp05nWy0ZD-KTBrxdRMWsWUfZSg" "created" => "2016-06-25 14:20:01" "last_updated" => "2025-02-15 03:09:52" "last_response_code" => 200 "type" => "Public Company" "headquarters_new_address" => "Cambridge, Massachusetts" "employees_count" => 2444 "headquarters_country_restored" => "United States" "headquarters_country_parsed" => "United States" "company_shorthand_name" => "alnylam-pharmaceuticals" "company_shorthand_name_hash" => "20bf83ad035152992a85c6a5967a5ed3" "canonical_url" => "https://www.linkedin.com/company/alnylam-pharmaceuticals" "canonical_hash" => "c0a8a95b106226d9179f42636b956a1d" "canonical_shorthand_name" => "alnylam-pharmaceuticals" "canonical_shorthand_name_hash" => "20bf83ad035152992a85c6a5967a5ed3" "deleted" => 0 "last_updated_ux" => 1739588992 "source_id" => 48171 "company_affiliated_collection" => [] "company_also_viewed_collection" => [ [ "id" => 33718351 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/biogen-" "viewed_company_id" => null "created" => "2016-06-25 14:20:01" "last_updated" => "2019-10-19 15:23:30" "deleted" => 1 ] [ "id" => 33718352 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/vertex-pharmaceuticals" "viewed_company_id" => null "created" => "2016-06-25 14:20:01" "last_updated" => "2018-07-10 10:51:57" "deleted" => 1 ] [ "id" => 33718353 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/bluebirdbio" "viewed_company_id" => null "created" => "2016-06-25 14:20:01" "last_updated" => "2019-10-19 15:23:30" "deleted" => 1 ] [ "id" => 33718354 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/shire" "viewed_company_id" => null "created" => "2016-06-25 14:20:01" "last_updated" => "2016-12-09 02:35:31" "deleted" => 1 ] [ "id" => 33718355 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/takeda-pharmaceuticals" "viewed_company_id" => null "created" => "2016-06-25 14:20:01" "last_updated" => "2016-12-09 02:35:31" "deleted" => 1 ] [ "id" => 33718356 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/agios" "viewed_company_id" => null "created" => "2016-06-25 14:20:01" "last_updated" => "2017-11-15 00:43:11" "deleted" => 1 ] [ "id" => 39262222 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/moderna-therapeutics" "viewed_company_id" => null "created" => "2016-12-09 02:35:31" "last_updated" => "2018-10-03 18:46:07" "deleted" => 1 ] [ "id" => 39262223 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/alexion-pharmaceuticals" "viewed_company_id" => null "created" => "2016-12-09 02:35:31" "last_updated" => "2017-07-29 04:34:27" "deleted" => 1 ] [ "id" => 93463078 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/juno-therapeutics" "viewed_company_id" => null "created" => "2017-07-29 04:34:27" "last_updated" => "2019-03-12 09:15:01" "deleted" => 1 ] [ "id" => 116578612 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/sage-therapeutics" "viewed_company_id" => null "created" => "2017-11-15 00:43:11" "last_updated" => "2019-06-02 13:11:03" "deleted" => 1 ] [ "id" => 140069764 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/alexion-pharmaceuticals" "viewed_company_id" => null "created" => "2018-07-10 10:51:57" "last_updated" => "2019-01-05 20:09:26" "deleted" => 1 ] [ "id" => 163970555 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/moderna-" "viewed_company_id" => null "created" => "2018-10-03 18:46:06" "last_updated" => "2019-10-19 15:23:30" "deleted" => 1 ] [ "id" => 183370360 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/vertex-pharmaceuticals" "viewed_company_id" => null "created" => "2019-01-05 20:09:26" "last_updated" => "2019-03-12 09:15:01" "deleted" => 1 ] [ "id" => 195248214 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/alexion-pharmaceuticals" "viewed_company_id" => null "created" => "2019-03-12 09:15:01" "last_updated" => "2019-10-19 15:23:30" "deleted" => 1 ] [ "id" => 195248215 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/sarepta-therapeutics" "viewed_company_id" => null "created" => "2019-03-12 09:15:01" "last_updated" => "2019-04-05 01:14:24" "deleted" => 1 ] [ "id" => 200251715 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/vertex-pharmaceuticals" "viewed_company_id" => null "created" => "2019-04-05 01:14:24" "last_updated" => "2019-10-19 15:23:30" "deleted" => 1 ] [ "id" => 230830510 "company_id" => 8900492 "viewed_company_url" => "https://www.linkedin.com/company/sarepta-therapeutics" "viewed_company_id" => null "created" => "2019-06-02 13:11:03" "last_updated" => "2019-10-19 15:23:30" "deleted" => 1 ] ] "company_crunchbase_info_collection" => [ [ "id" => 33874 "company_id" => 8900492 "cb_url" => "https://www.crunchbase.com/organization/alnylam-pharmaceuticals" "created" => "2020-09-10 17:14:16" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 176908 "company_id" => 8900492 "cb_url" => "https://www.crunchbase.com/organization/alnylam-pharmaceuticals" "created" => "2022-07-06 23:52:12" "last_updated" => "2022-07-17 23:49:36" "deleted" => 1 ] [ "id" => 255814 "company_id" => 8900492 "cb_url" => "https://www.crunchbase.com/organization/alnylam-pharmaceuticals" "created" => "2023-02-06 13:36:28" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] ] "company_featured_employees_collection" => [ [ "id" => 10882232 "company_id" => 8900492 "url" => "https://www.linkedin.com/in/rena-nassr-denoncourt-61033" "created" => "2019-10-19 15:23:30" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 10882236 "company_id" => 8900492 "url" => "https://www.linkedin.com/in/tatumabe" "created" => "2019-10-19 15:23:30" "last_updated" => "2020-01-26 09:41:28" "deleted" => 1 ] [ "id" => 10882240 "company_id" => 8900492 "url" => "https://www.linkedin.com/in/carrie-partlan-192b7" "created" => "2019-10-19 15:23:30" "last_updated" => "2020-01-26 09:41:28" "deleted" => 1 ] [ "id" => 10882245 "company_id" => 8900492 "url" => "https://www.linkedin.com/in/uma-robbie-245128" "created" => "2019-10-19 15:23:30" "last_updated" => "2020-01-26 09:41:28" "deleted" => 1 ] [ "id" => 33339929 "company_id" => 8900492 "url" => "https://www.linkedin.com/in/rick-falzone-7a2139" "created" => "2020-01-26 09:41:28" "last_updated" => "2021-04-27 02:59:44" "deleted" => 1 ] [ "id" => 33339931 "company_id" => 8900492 "url" => "https://www.linkedin.com/in/cara-hesse-755212" "created" => "2020-01-26 09:41:28" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 33339933 "company_id" => 8900492 "url" => "https://www.linkedin.com/in/timcareyfullprofile" "created" => "2020-01-26 09:41:28" "last_updated" => "2021-03-11 00:39:41" "deleted" => 1 ] [ "id" => 61668982 "company_id" => 8900492 "url" => "https://www.linkedin.com/in/john-c-morris" "created" => "2021-03-11 00:39:41" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 64700323 "company_id" => 8900492 "url" => "https://www.linkedin.com/in/carlos-pagnano-5b527b" "created" => "2021-04-27 02:59:44" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 93762998 "company_id" => 8900492 "url" => "https://www.linkedin.com/in/rena-nassr-denoncourt-61033" "created" => "2022-07-06 23:52:12" "last_updated" => "2024-09-13 23:09:15" "deleted" => 1 ] [ "id" => 93762999 "company_id" => 8900492 "url" => "https://www.linkedin.com/in/cara-hesse-755212" "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 93763000 "company_id" => 8900492 "url" => "https://www.linkedin.com/in/john-c-morris" "created" => "2022-07-06 23:52:12" "last_updated" => "2024-02-28 14:37:00" "deleted" => 1 ] [ "id" => 93763001 "company_id" => 8900492 "url" => "https://www.linkedin.com/in/carlos-pagnano-5b527b" "created" => "2022-07-06 23:52:12" "last_updated" => "2022-07-17 23:49:36" "deleted" => 1 ] [ "id" => 100402705 "company_id" => 8900492 "url" => "https://se.linkedin.com/in/thomas-wallman-269a6" "created" => "2022-07-17 23:49:36" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 202596671 "company_id" => 8900492 "url" => "https://ch.linkedin.com/in/carlos-pagnano-5b527b" "created" => "2024-02-28 14:37:00" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 212660689 "company_id" => 8900492 "url" => "https://www.linkedin.com/in/humaira-merchant-527309" "created" => "2024-09-13 23:09:15" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] ] "company_featured_investors_collection" => [ [ "id" => 15577 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 51985 "created" => "2020-09-10 17:14:16" "last_updated" => "2020-10-13 08:20:38" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 60359 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 51985 "created" => "2020-10-13 08:20:38" "last_updated" => "2020-11-21 02:47:30" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 119213 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 181580 "created" => "2020-11-21 02:47:30" "last_updated" => "2020-12-12 22:36:27" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 147145 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 313976 "created" => "2020-12-12 22:36:27" "last_updated" => "2021-01-10 19:29:16" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 196816 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 378165 "created" => "2021-01-10 19:29:16" "last_updated" => "2021-02-23 18:44:23" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 265141 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 487179 "created" => "2021-02-23 18:44:23" "last_updated" => "2021-03-11 00:39:41" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 275226 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 636512 "created" => "2021-03-11 00:39:41" "last_updated" => "2021-03-15 21:30:11" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 288822 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 659381 "created" => "2021-03-15 21:30:11" "last_updated" => "2021-04-27 02:59:44" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 363303 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 688822 "created" => "2021-04-27 02:59:44" "last_updated" => "2021-05-24 18:38:42" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 411279 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 854990 "created" => "2021-05-24 18:38:42" "last_updated" => "2021-06-02 15:23:04" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 415338 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 962616 "created" => "2021-06-02 15:23:04" "last_updated" => "2021-07-21 22:05:27" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 507924 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 971532 "created" => "2021-07-21 22:05:27" "last_updated" => "2021-09-12 16:15:50" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 627887 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 1173249 "created" => "2021-09-12 16:15:50" "last_updated" => "2021-09-14 11:18:39" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 634955 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 1428002 "created" => "2021-09-14 11:18:39" "last_updated" => "2021-10-01 08:17:39" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 684292 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 1443560 "created" => "2021-10-01 08:17:39" "last_updated" => "2021-10-12 13:15:18" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 706309 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 1552445 "created" => "2021-10-12 13:15:18" "last_updated" => "2021-10-25 19:26:52" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 741007 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 1595668 "created" => "2021-10-25 19:26:52" "last_updated" => "2021-11-05 17:19:14" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 751940 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 1672118 "created" => "2021-11-05 17:19:14" "last_updated" => "2021-11-29 16:16:13" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 813513 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 1695924 "created" => "2021-11-29 16:16:13" "last_updated" => "2021-12-28 09:15:02" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 866280 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 1824610 "created" => "2021-12-28 09:15:02" "last_updated" => "2022-01-03 11:40:42" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 914476 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 1939555 "created" => "2022-01-03 11:40:42" "last_updated" => "2022-02-07 11:02:19" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 978285 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 2044502 "created" => "2022-02-07 11:02:19" "last_updated" => "2022-02-09 15:25:42" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 1000514 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 2177703 "created" => "2022-02-09 15:25:42" "last_updated" => "2022-03-01 11:56:27" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 1046228 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 2227586 "created" => "2022-03-01 11:56:27" "last_updated" => "2022-03-01 23:46:09" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 1052760 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 2319125 "created" => "2022-03-01 23:46:09" "last_updated" => "2022-03-08 10:44:07" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 1091165 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 2332717 "created" => "2022-03-08 10:44:07" "last_updated" => "2022-04-02 07:02:38" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 1125673 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 2416758 "created" => "2022-04-02 07:02:38" "last_updated" => "2022-04-08 12:50:09" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 1185076 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 2483580 "created" => "2022-04-08 12:50:09" "last_updated" => "2022-05-02 10:36:55" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 1192573 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 2606642 "created" => "2022-05-02 10:36:55" "last_updated" => "2022-05-10 20:41:11" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 1243792 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 2620625 "created" => "2022-05-10 20:41:11" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 1359616 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 2966582 "created" => "2022-07-06 23:52:12" "last_updated" => "2022-07-17 23:49:36" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 1382533 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 2966582 "created" => "2022-07-17 23:49:36" "last_updated" => "2022-08-03 14:54:24" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 1437787 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 3013504 "created" => "2022-08-03 14:54:24" "last_updated" => "2022-09-03 15:02:41" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] [ "id" => 1502372 "company_id" => 8900492 "investor_id" => 4502 "round_id" => 3127913 "created" => "2022-09-03 15:02:41" "last_updated" => "2022-10-19 00:52:13" "deleted" => 1 "company_investors_list" => [ "id" => 4502 "name" => "Blackstone Life Sciences" "hash" => "5751195c77c2b304b4066f8f3faae6d2" "cb_url" => "https://www.crunchbase.com/organization/blackstone-life-science" "created" => "2020-09-09 18:35:52" "last_updated" => "2022-02-07 10:18:31" ] ] ] "company_funding_rounds_collection" => [ [ "id" => 51985 "last_round_investors_count" => 1 "total_rounds_count" => 7 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 150.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2020-09-10 17:14:16" "last_updated" => "2020-10-13 08:20:38" "deleted" => 1 ] [ "id" => 181580 "last_round_investors_count" => 1 "total_rounds_count" => 7 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 150.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2020-10-13 08:20:38" "last_updated" => "2020-11-21 02:47:30" "deleted" => 1 ] [ "id" => 313976 "last_round_investors_count" => 1 "total_rounds_count" => 7 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 150.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2020-11-21 02:47:30" "last_updated" => "2020-12-12 22:36:27" "deleted" => 1 ] [ "id" => 378165 "last_round_investors_count" => 1 "total_rounds_count" => 7 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 150.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2020-12-12 22:36:27" "last_updated" => "2021-01-10 19:29:16" "deleted" => 1 ] [ "id" => 487179 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-01-10 19:29:16" "last_updated" => "2021-02-23 18:44:23" "deleted" => 1 ] [ "id" => 636512 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-02-23 18:44:23" "last_updated" => "2021-03-11 00:39:41" "deleted" => 1 ] [ "id" => 659381 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-03-11 00:39:41" "last_updated" => "2021-03-15 21:30:11" "deleted" => 1 ] [ "id" => 688822 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-03-15 21:30:11" "last_updated" => "2021-04-27 02:59:44" "deleted" => 1 ] [ "id" => 854990 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-04-27 02:59:44" "last_updated" => "2021-05-24 18:38:42" "deleted" => 1 ] [ "id" => 962616 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-05-24 18:38:42" "last_updated" => "2021-06-02 15:23:04" "deleted" => 1 ] [ "id" => 971532 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-06-02 15:23:04" "last_updated" => "2021-07-21 22:05:27" "deleted" => 1 ] [ "id" => 1173249 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-07-21 22:05:27" "last_updated" => "2021-09-12 16:15:50" "deleted" => 1 ] [ "id" => 1428002 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-09-12 16:15:50" "last_updated" => "2021-09-14 11:18:39" "deleted" => 1 ] [ "id" => 1443560 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-09-14 11:18:39" "last_updated" => "2021-10-01 08:17:39" "deleted" => 1 ] [ "id" => 1552445 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-10-01 08:17:39" "last_updated" => "2021-10-12 13:15:18" "deleted" => 1 ] [ "id" => 1595668 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-10-12 13:15:18" "last_updated" => "2021-10-25 19:26:52" "deleted" => 1 ] [ "id" => 1672118 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-10-25 19:26:52" "last_updated" => "2021-11-05 17:19:14" "deleted" => 1 ] [ "id" => 1695924 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-11-05 17:19:14" "last_updated" => "2021-11-29 16:16:13" "deleted" => 1 ] [ "id" => 1824610 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-11-29 16:16:13" "last_updated" => "2021-12-28 09:15:02" "deleted" => 1 ] [ "id" => 1939555 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2021-12-28 09:15:02" "last_updated" => "2022-01-03 11:40:42" "deleted" => 1 ] [ "id" => 2044502 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2022-01-03 11:40:42" "last_updated" => "2022-02-07 11:02:19" "deleted" => 1 ] [ "id" => 2177703 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => """ US$\n 250.0M """ "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2022-02-07 11:02:19" "last_updated" => "2022-02-09 15:25:42" "deleted" => 1 ] [ "id" => 2227586 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => """ US$\n 250.0M """ "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2022-02-09 15:25:42" "last_updated" => "2022-03-01 11:56:27" "deleted" => 1 ] [ "id" => 2319125 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => """ US$\n 250.0M """ "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2022-03-01 11:56:27" "last_updated" => "2022-03-01 23:46:09" "deleted" => 1 ] [ "id" => 2332717 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => """ US$\n 250.0M """ "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2022-03-01 23:46:09" "last_updated" => "2022-03-08 10:44:07" "deleted" => 1 ] [ "id" => 2416758 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => """ US$\n 250.0M """ "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2022-03-08 10:44:07" "last_updated" => "2022-04-02 07:02:38" "deleted" => 1 ] [ "id" => 2483580 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => """ US$\n 250.0M """ "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2022-04-02 07:02:38" "last_updated" => "2022-04-08 12:50:09" "deleted" => 1 ] [ "id" => 2606642 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => """ US$\n 250.0M """ "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2022-04-08 12:50:09" "last_updated" => "2022-05-02 10:36:55" "deleted" => 1 ] [ "id" => 2620625 "last_round_investors_count" => 1 "total_rounds_count" => 6 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => """ US$\n 250.0M """ "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2022-05-02 10:36:55" "last_updated" => "2022-05-10 20:41:11" "deleted" => 1 ] [ "id" => 2726617 "last_round_investors_count" => 1 "total_rounds_count" => 7 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => """ US$\n 250.0M """ "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2022-05-10 20:41:11" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 2966582 "last_round_investors_count" => 1 "total_rounds_count" => 7 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-04-13 00:00:00" "last_round_money_raised" => """ US$\n 250.0M """ "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2022-07-06 23:52:12" "last_updated" => "2022-07-17 23:49:36" "deleted" => 1 ] [ "id" => 3013504 "last_round_investors_count" => 1 "total_rounds_count" => 7 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2022-07-17 23:49:36" "last_updated" => "2022-08-03 14:54:24" "deleted" => 1 ] [ "id" => 3127913 "last_round_investors_count" => 1 "total_rounds_count" => 7 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2022-08-03 14:54:24" "last_updated" => "2022-09-03 15:02:41" "deleted" => 1 ] [ "id" => 3257775 "last_round_investors_count" => 1 "total_rounds_count" => 7 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-13 00:00:00" "last_round_money_raised" => "US$ 250.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-equity--633ed7de" "created" => "2022-09-03 15:02:41" "last_updated" => "2022-10-19 00:52:13" "deleted" => 1 ] [ "id" => 3505036 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2022-10-19 00:52:13" "last_updated" => "2022-11-22 22:28:10" "deleted" => 1 ] [ "id" => 3632396 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2022-11-22 22:28:10" "last_updated" => "2022-12-05 07:21:18" "deleted" => 1 ] [ "id" => 3686530 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2022-12-05 07:21:18" "last_updated" => "2023-01-09 09:06:46" "deleted" => 1 ] [ "id" => 3855897 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2023-01-09 09:06:46" "last_updated" => "2023-02-06 13:36:28" "deleted" => 1 ] [ "id" => 3977061 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2023-02-06 13:36:28" "last_updated" => "2023-02-16 07:58:18" "deleted" => 1 ] [ "id" => 4095112 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2023-02-16 07:58:18" "last_updated" => "2023-03-03 12:20:26" "deleted" => 1 ] [ "id" => 4168407 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2023-03-03 12:20:26" "last_updated" => "2023-04-12 22:18:16" "deleted" => 1 ] [ "id" => 4358354 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2023-04-12 22:18:16" "last_updated" => "2023-04-30 06:42:20" "deleted" => 1 ] [ "id" => 4462607 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2023-04-30 06:42:20" "last_updated" => "2023-05-11 01:18:47" "deleted" => 1 ] [ "id" => 4554859 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2023-05-11 01:18:47" "last_updated" => "2023-06-04 14:23:10" "deleted" => 1 ] [ "id" => 4660263 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2023-06-04 14:23:10" "last_updated" => "2023-07-20 19:58:37" "deleted" => 1 ] [ "id" => 5115890 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2023-07-20 19:58:37" "last_updated" => "2023-08-07 01:19:17" "deleted" => 1 ] [ "id" => 5269168 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2023-08-07 01:19:17" "last_updated" => "2023-09-20 10:36:02" "deleted" => 1 ] [ "id" => 5573008 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2023-09-20 10:36:02" "last_updated" => "2023-10-09 18:12:25" "deleted" => 1 ] [ "id" => 5657932 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2023-10-09 18:12:25" "last_updated" => "2023-11-26 21:41:04" "deleted" => 1 ] [ "id" => 5971895 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2023-11-26 21:41:04" "last_updated" => "2023-12-01 19:33:48" "deleted" => 1 ] [ "id" => 5989432 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2023-12-01 19:33:48" "last_updated" => "2024-01-05 16:02:26" "deleted" => 1 ] [ "id" => 6205779 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-01-05 16:02:26" "last_updated" => "2024-02-28 14:37:00" "deleted" => 1 ] [ "id" => 6540975 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-02-28 14:37:00" "last_updated" => "2024-03-27 22:26:09" "deleted" => 1 ] [ "id" => 6742242 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-03-27 22:26:09" "last_updated" => "2024-04-15 22:40:51" "deleted" => 1 ] [ "id" => 6857335 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-04-15 22:40:51" "last_updated" => "2024-05-25 15:27:57" "deleted" => 1 ] [ "id" => 7097493 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-05-25 15:27:57" "last_updated" => "2024-06-08 15:45:12" "deleted" => 1 ] [ "id" => 7183161 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-06-08 15:45:12" "last_updated" => "2024-07-14 00:19:40" "deleted" => 1 ] [ "id" => 7430062 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-07-14 00:19:40" "last_updated" => "2024-08-19 09:34:14" "deleted" => 1 ] [ "id" => 7709143 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-08-19 09:34:14" "last_updated" => "2024-09-01 06:07:02" "deleted" => 1 ] [ "id" => 7899237 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-09-01 06:07:02" "last_updated" => "2024-09-13 23:09:15" "deleted" => 1 ] [ "id" => 8095888 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-09-13 23:09:15" "last_updated" => "2024-10-10 01:26:28" "deleted" => 1 ] [ "id" => 8328750 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-10-10 01:26:28" "last_updated" => "2024-10-24 06:46:05" "deleted" => 1 ] [ "id" => 8511963 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-10-24 06:46:05" "last_updated" => "2024-11-17 09:52:53" "deleted" => 1 ] [ "id" => 8721285 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-11-17 09:52:53" "last_updated" => "2024-11-28 05:05:32" "deleted" => 1 ] [ "id" => 8936896 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-11-28 05:05:32" "last_updated" => "2024-11-28 08:33:29" "deleted" => 1 ] [ "id" => 8952392 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-11-28 08:33:29" "last_updated" => "2024-12-12 11:21:48" "deleted" => 1 ] [ "id" => 9173369 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-13 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2024-12-12 11:21:48" "last_updated" => "2025-01-20 21:32:58" "deleted" => 1 ] [ "id" => 9449913 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-12 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2025-01-20 21:32:58" "last_updated" => "2025-02-15 03:09:52" "deleted" => 1 ] [ "id" => 9700429 "last_round_investors_count" => 0 "total_rounds_count" => 8 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-10-12 00:00:00" "last_round_money_raised" => "US$ 900.0M" "cb_url" => "https://www.crunchbase.com/funding_round/alnylam-pharmaceuticals-post-ipo-debt--94ffa05f" "created" => "2025-02-15 03:09:52" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] ] "company_locations_collection" => [ [ "id" => 4423293 "company_id" => 8900492 "location_address" => "300 Third Street; Cambridge, MA 02142, US" "is_primary" => 1 "created" => "2019-10-19 15:23:30" "last_updated" => "2019-11-24 07:08:58" "deleted" => 1 ] [ "id" => 4423294 "company_id" => 8900492 "location_address" => "Braywick Gate Road; Maidenhead,, Berkshire SL6 1DA, GB" "is_primary" => 0 "created" => "2019-10-19 15:23:30" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 4423295 "company_id" => 8900492 "location_address" => "Maximilianstraße 35a; Munich, Bavaria 80539, DE" "is_primary" => 0 "created" => "2019-10-19 15:23:30" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 4423296 "company_id" => 8900492 "location_address" => "Strawinskylaan 3051; Strawinskylaan 3051 ; Amsterdam, North Holland 1077 ZX, NL" "is_primary" => 0 "created" => "2019-10-19 15:23:30" "last_updated" => "2020-08-13 16:35:27" "deleted" => 1 ] [ "id" => 4423297 "company_id" => 8900492 "location_address" => "Grafenauweg 4; Zug, Zug 6300, CH" "is_primary" => 0 "created" => "2019-10-19 15:23:30" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 11937025 "company_id" => 8900492 "location_address" => "675 W Kendall St; Cambridge, Massachusetts 02142, US" "is_primary" => 1 "created" => "2019-11-24 07:08:58" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 11937026 "company_id" => 8900492 "location_address" => "Strawinskylaan 3051; Amsterdam, North Holland 1077, NL" "is_primary" => 0 "created" => "2019-11-24 07:08:58" "last_updated" => "2020-10-13 08:20:38" "deleted" => 1 ] [ "id" => 11937027 "company_id" => 8900492 "location_address" => "Av. Pres. Juscelino Kubitscheck 2041; 5° Andar Bloco B – Vila Olímpia ; São Paulo, SP 04543-011, BR" "is_primary" => 0 "created" => "2019-11-24 07:08:58" "last_updated" => "2020-08-13 16:35:27" "deleted" => 1 ] [ "id" => 22068711 "company_id" => 8900492 "location_address" => "Strawinskylaan 3051; Strawinskylaan 3051; Amsterdam, North Holland 1077 ZX, NL" "is_primary" => 0 "created" => "2020-08-13 16:35:27" "last_updated" => "2020-10-13 08:20:38" "deleted" => 1 ] [ "id" => 22068712 "company_id" => 8900492 "location_address" => "Av. Pres. Juscelino Kubitscheck 2041; 5° Andar Bloco B – Vila Olímpia; São Paulo, SP 04543-011, BR" "is_primary" => 0 "created" => "2020-08-13 16:35:27" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 24864015 "company_id" => 8900492 "location_address" => "20 Commerce Way; Norton, MA 02766, US" "is_primary" => 0 "created" => "2020-10-13 08:20:38" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 24864016 "company_id" => 8900492 "location_address" => "Antonio Vivaldistraat 150; Amsterdam, North Holland 1083, NL" "is_primary" => 0 "created" => "2020-10-13 08:20:38" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 35721383 "company_id" => 8900492 "location_address" => "Pacific Century Place Marunouchi; 1 Chome-11-1 Marunouchi; Tokyo, JP" "is_primary" => 0 "created" => "2021-09-12 16:15:50" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 69256610 "company_id" => 8900492 "location_address" => "675 W Kendall St; Cambridge, Massachusetts 02142, US" "is_primary" => 1 "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 69256611 "company_id" => 8900492 "location_address" => "Braywick Gate Road; Maidenhead,, Berkshire SL6 1DA, GB" "is_primary" => 0 "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 69256612 "company_id" => 8900492 "location_address" => "Maximilianstraße 35a; Munich, Bavaria 80539, DE" "is_primary" => 0 "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 69256613 "company_id" => 8900492 "location_address" => "20 Commerce Way; Norton, MA 02766, US" "is_primary" => 0 "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 69256614 "company_id" => 8900492 "location_address" => "Antonio Vivaldistraat 150; Amsterdam, North Holland 1083, NL" "is_primary" => 0 "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 69256615 "company_id" => 8900492 "location_address" => "Av. Pres. Juscelino Kubitscheck 2041; 5° Andar Bloco B – Vila Olímpia; São Paulo, SP 04543-011, BR" "is_primary" => 0 "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 69256616 "company_id" => 8900492 "location_address" => "Grafenauweg 4; Zug, Zug 6300, CH" "is_primary" => 0 "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 69256617 "company_id" => 8900492 "location_address" => "Pacific Century Place Marunouchi; 1 Chome-11-1 Marunouchi; Tokyo, JP" "is_primary" => 0 "created" => "2022-07-06 23:52:12" "last_updated" => "2023-09-20 10:36:02" "deleted" => 1 ] [ "id" => 117098199 "company_id" => 8900492 "location_address" => "Via Melchiorre Gioia, 26; Milan, Lombardy 20124, IT" "is_primary" => 0 "created" => "2023-04-12 22:18:16" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 137416777 "company_id" => 8900492 "location_address" => "Pacific Century Place Marunouchi; 1 Chome-11-1 Marunouchi; Tokyo, 100-0005, JP" "is_primary" => 0 "created" => "2023-09-20 10:36:02" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] ] "company_similar_collection" => [ [ "id" => 16645396 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/bluebirdbio" "created" => "2019-10-19 15:23:30" "last_updated" => "2021-07-21 22:05:27" "deleted" => 1 ] [ "id" => 16645399 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/alexion-pharmaceuticals" "created" => "2019-10-19 15:23:30" "last_updated" => "2021-07-21 22:05:27" "deleted" => 1 ] [ "id" => 16645402 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/vertex-pharmaceuticals" "created" => "2019-10-19 15:23:30" "last_updated" => "2021-07-21 22:05:27" "deleted" => 1 ] [ "id" => 16645407 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/biogen-" "created" => "2019-10-19 15:23:30" "last_updated" => "2021-07-21 22:05:27" "deleted" => 1 ] [ "id" => 16645412 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/sarepta-therapeutics" "created" => "2019-10-19 15:23:30" "last_updated" => "2021-07-21 22:05:27" "deleted" => 1 ] [ "id" => 16645417 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/sage-therapeutics" "created" => "2019-10-19 15:23:30" "last_updated" => "2020-10-13 08:20:38" "deleted" => 1 ] [ "id" => 74169968 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/regeneron-pharmaceuticals" "created" => "2020-01-26 09:41:28" "last_updated" => "2021-07-21 22:05:27" "deleted" => 1 ] [ "id" => 74169969 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/amgen" "created" => "2020-01-26 09:41:28" "last_updated" => "2021-02-23 18:44:23" "deleted" => 1 ] [ "id" => 74169971 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/takeda-pharmaceuticals" "created" => "2020-01-26 09:41:28" "last_updated" => "2020-11-21 02:47:30" "deleted" => 1 ] [ "id" => 74169974 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/moderna-" "created" => "2020-01-26 09:41:28" "last_updated" => "2020-09-10 17:14:16" "deleted" => 1 ] [ "id" => 225898317 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/modernatx" "created" => "2020-09-10 17:14:16" "last_updated" => "2021-07-21 22:05:27" "deleted" => 1 ] [ "id" => 248238315 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/gilead-sciences" "created" => "2020-10-13 08:20:38" "last_updated" => "2021-01-10 19:29:16" "deleted" => 1 ] [ "id" => 288178839 "company_id" => 8900492 "url" => "https://jp.linkedin.com/company/takeda-pharmaceuticals" "created" => "2020-11-21 02:47:30" "last_updated" => "2021-07-21 22:05:27" "deleted" => 1 ] [ "id" => 351855585 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/agios" "created" => "2021-01-10 19:29:16" "last_updated" => "2021-07-21 22:05:27" "deleted" => 1 ] [ "id" => 379937714 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-" "created" => "2021-02-23 18:44:23" "last_updated" => "2021-07-21 22:05:27" "deleted" => 1 ] [ "id" => 493419669 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/vertex-pharmaceuticals" "created" => "2021-09-12 16:15:50" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 493419670 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/alexion-pharmaceuticals" "created" => "2021-09-12 16:15:50" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 493419671 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/biogen-" "created" => "2021-09-12 16:15:50" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 493419672 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/sarepta-therapeutics" "created" => "2021-09-12 16:15:50" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 493419673 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/bluebirdbio" "created" => "2021-09-12 16:15:50" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 493419674 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/modernatx" "created" => "2021-09-12 16:15:50" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 493419675 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/regeneron-pharmaceuticals" "created" => "2021-09-12 16:15:50" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 493419676 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-" "created" => "2021-09-12 16:15:50" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 493419677 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/agios" "created" => "2021-09-12 16:15:50" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 493419678 "company_id" => 8900492 "url" => "https://jp.linkedin.com/company/takeda-pharmaceuticals" "created" => "2021-09-12 16:15:50" "last_updated" => "2022-03-01 11:56:27" "deleted" => 1 ] [ "id" => 558032282 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/apellis" "created" => "2022-03-01 11:56:27" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 658325376 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/vertex-pharmaceuticals" "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 658325377 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/alexion-pharmaceuticals" "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 658325378 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/sarepta-therapeutics" "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 658325379 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/biogen-" "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 658325380 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/agios" "created" => "2022-07-06 23:52:12" "last_updated" => "2024-11-17 09:52:53" "deleted" => 1 ] [ "id" => 658325381 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/apellis" "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 658325382 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/ultragenyx-pharmaceutical-inc-" "created" => "2022-07-06 23:52:12" "last_updated" => "2023-07-20 19:58:37" "deleted" => 1 ] [ "id" => 658325383 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/bluebirdbio" "created" => "2022-07-06 23:52:12" "last_updated" => "2023-06-04 14:23:10" "deleted" => 1 ] [ "id" => 658325384 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/sage-therapeutics" "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 658325385 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/modernatx" "created" => "2022-07-06 23:52:12" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 829430530 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/amgen" "created" => "2023-06-04 14:23:10" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 853665263 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/bluebirdbio" "created" => "2023-07-20 19:58:37" "last_updated" => "2023-11-26 21:41:04" "deleted" => 1 ] [ "id" => 917318545 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/beamtx" "created" => "2023-11-26 21:41:04" "last_updated" => "2024-03-27 22:26:09" "deleted" => 1 ] [ "id" => 977611714 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/bristol-myers-squibb" "created" => "2024-03-27 22:26:09" "last_updated" => "2025-01-20 21:32:58" "deleted" => 1 ] [ "id" => 1106938755 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/abbvie" "created" => "2024-11-17 09:52:53" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 1141151770 "company_id" => 8900492 "url" => "https://www.linkedin.com/company/regeneron-pharmaceuticals" "created" => "2025-01-20 21:32:58" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] ] "company_specialties_collection" => [ [ "id" => 24982915 "company_id" => 8900492 "specialty" => "Biotech" "created" => "2019-03-12 09:15:01" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 24982916 "company_id" => 8900492 "specialty" => "Pharmaceuticals" "created" => "2019-03-12 09:15:01" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 24982917 "company_id" => 8900492 "specialty" => "Biopharma" "created" => "2019-03-12 09:15:01" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 24982918 "company_id" => 8900492 "specialty" => "Drug Development" "created" => "2019-03-12 09:15:01" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 24982919 "company_id" => 8900492 "specialty" => "Rare Diseases" "created" => "2019-03-12 09:15:01" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 24982920 "company_id" => 8900492 "specialty" => "RNAi" "created" => "2019-03-12 09:15:01" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 76068519 "company_id" => 8900492 "specialty" => "Biotech" "created" => "2022-07-06 23:52:12" "last_updated" => "2022-07-17 23:49:36" "deleted" => 1 ] [ "id" => 76068520 "company_id" => 8900492 "specialty" => "Pharmaceuticals" "created" => "2022-07-06 23:52:12" "last_updated" => "2022-07-17 23:49:36" "deleted" => 1 ] [ "id" => 76068521 "company_id" => 8900492 "specialty" => "Biopharma" "created" => "2022-07-06 23:52:12" "last_updated" => "2022-07-17 23:49:36" "deleted" => 1 ] [ "id" => 76068522 "company_id" => 8900492 "specialty" => "Drug Development" "created" => "2022-07-06 23:52:12" "last_updated" => "2022-07-17 23:49:36" "deleted" => 1 ] [ "id" => 76068523 "company_id" => 8900492 "specialty" => "Rare Diseases" "created" => "2022-07-06 23:52:12" "last_updated" => "2022-07-17 23:49:36" "deleted" => 1 ] [ "id" => 76068524 "company_id" => 8900492 "specialty" => "RNAi" "created" => "2022-07-06 23:52:12" "last_updated" => "2022-07-17 23:49:36" "deleted" => 1 ] [ "id" => 84869884 "company_id" => 8900492 "specialty" => "Biotech" "created" => "2022-08-03 14:54:24" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 84869885 "company_id" => 8900492 "specialty" => "Pharmaceuticals" "created" => "2022-08-03 14:54:24" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 84869886 "company_id" => 8900492 "specialty" => "Biopharma" "created" => "2022-08-03 14:54:24" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 84869887 "company_id" => 8900492 "specialty" => "Drug Development" "created" => "2022-08-03 14:54:24" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 84869888 "company_id" => 8900492 "specialty" => "Rare Diseases" "created" => "2022-08-03 14:54:24" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 84869889 "company_id" => 8900492 "specialty" => "RNAi" "created" => "2022-08-03 14:54:24" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] ] "company_stock_info_collection" => [ [ "id" => 1640 "company_id" => 8900492 "ticker" => "ALNY" "exchange" => "NASDAQ" "created" => "2020-04-25 04:50:53" "last_updated" => "2021-03-11 00:39:41" "deleted" => 1 ] [ "id" => 11233 "company_id" => 8900492 "ticker" => "ALNY" "exchange" => "NASDAQ" "created" => "2021-03-15 21:30:11" "last_updated" => "2021-09-12 16:15:50" "deleted" => 1 ] [ "id" => 13660 "company_id" => 8900492 "ticker" => "ALNY" "exchange" => "NASDAQ" "created" => "2021-12-28 09:15:04" "last_updated" => "2022-04-02 07:02:38" "deleted" => 1 ] [ "id" => 19837 "company_id" => 8900492 "ticker" => "ALNY" "exchange" => "NASDAQ" "created" => "2022-04-08 12:50:09" "last_updated" => "2022-06-22 18:24:10" "deleted" => 1 ] [ "id" => 21190 "company_id" => 8900492 "ticker" => "ALNY" "exchange" => "NASDAQ" "created" => "2022-07-06 23:52:13" "last_updated" => "2022-07-17 23:49:36" "deleted" => 1 ] [ "id" => 25190 "company_id" => 8900492 "ticker" => "NASDAQ" "exchange" => "ALNY" "created" => "2022-10-19 00:52:13" "last_updated" => "2023-01-09 09:06:46" "deleted" => 1 ] [ "id" => 27426 "company_id" => 8900492 "ticker" => "ALNY" "exchange" => "NASDAQ" "created" => "2023-01-09 09:06:47" "last_updated" => "2023-02-16 07:58:18" "deleted" => 1 ] [ "id" => 29012 "company_id" => 8900492 "ticker" => "ALNY" "exchange" => "NASDAQ" "created" => "2023-03-03 12:20:26" "last_updated" => "2023-05-11 01:18:47" "deleted" => 1 ] [ "id" => 30596 "company_id" => 8900492 "ticker" => "ALNY" "exchange" => "NASDAQ" "created" => "2023-06-04 14:23:10" "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] ] "company_updates_collection" => [ [ "id" => 3998771 "company_id" => 8900492 "urn" => "urn:li:activity:7004470811705102336" "followers" => 140645 "date" => "2d" "description" => """ Team Alnylam and theirSpecial Olympics Massachusetts teammates had a great time competing in the #Bioball finals yesterday at TD Garden! The event featured hoops, laughs, community, and a special visit from the Boston Celtics' Derek White.\n \n #bioball #SpecialOlympics #biotech """ "reactions_count" => 198 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-09 09:06:46" "deleted" => 1 ] [ "id" => 3998772 "company_id" => 8900492 "urn" => "urn:li:activity:7004059936871579649" "followers" => 140645 "date" => "3d" "description" => """ We’re deeply honored and so#AlnylamProud to be ranked Boston Globe Media’s #1 Largest Employer in Massachusetts for the 2nd year in a row and a Top Place to Work 8 years in a row!\n \n Read more: http://bit.ly/3FhbOZJ. \n \n #WorkBoston """ "reactions_count" => 450 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-09 09:06:46" "deleted" => 1 ] [ "id" => 3998773 "company_id" => 8900492 "urn" => "urn:li:activity:7003825049505783808" "followers" => 140645 "date" => "4d" "description" => """ During National Family Caregivers Month, we celebrate the stories of caregivers like Renee, whose father Julio was diagnosed with#hATTR #amyloidosis after she encouraged him to speak with his doctor about his symptoms. Learn more about their story in a sponsored segment on The Portuguese Channel: http://bit.ly/3fD8MFe. \n \n #NFCMonth #CaregivingHappens """ "reactions_count" => 47 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-09 09:06:46" "deleted" => 1 ] [ "id" => 3998774 "company_id" => 8900492 "urn" => "urn:li:activity:7003453785763127297" "followers" => 140645 "date" => "5d" "description" => "We're#AlnylamProud of our team in the UK for their continued partnership and support of Refugee Action. #GivingDay #GivingTuesday" "reactions_count" => 68 "comments_count" => null "reshared_post_author" => "Refugee Action" "reshared_post_author_url" => "https://uk.linkedin.com/company/refugee-action" "reshared_post_author_headline" => null "reshared_post_description" => """ A huge thank you to our partnerAlnylam Pharmaceuticals for bringing together a group of extremely efficient packers last week who put together festive wellbeing boxes for people seeking safety. They managed to pack 60 boxes in a record 20 minutes and donated supermarket vouchers, powerbanks and chocolate for the boxes too.\n \n A big thank you also to anyone who's donated to our Christmas appeal or returned a welcome message bauble this year. You are helping us to provide these wellbeing boxes at Christmas time to ensure people feel part of a community during the festive period. \n \n If you've not seen it yet, you can be a part of this too - find our Christmas appeal here: https://lnkd.in/epg4aQJd \n \n #thankyou #community #wellbeing #volunteering """ "reshared_post_followers" => 23740 "reshared_post_date" => "6d" "last_updated" => "2023-01-09 09:06:46" "deleted" => 1 ] [ "id" => 3998775 "company_id" => 8900492 "urn" => "urn:li:activity:7003368134938140673" "followers" => 140645 "date" => "5d" "description" => """ #GivingTuesday is a global day of giving that we and our employees around the world enthusiastically embrace as part of our year-round commitment to making a positive contribution to the health of humanity beyond the medicines we make. This year, through our ongoing partnership with Benevity, we’re matching our employees’ donations one to one to support the charitable organizations of their choice. How will you be #GivingBack today? #GivingDay #AlnylamProud\n \n Learn more about Giving Tuesday and how you can participate at givingtuesday.org. """ "reactions_count" => 77 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-09 09:06:46" "deleted" => 1 ] [ "id" => 3998776 "company_id" => 8900492 "urn" => "urn:li:activity:7003048460828463104" "followers" => 140645 "date" => "6d" "description" => "HCPs:#hATTR #amyloidosis is a progressive and often fatal disease that affects multiple organs and tissues, resulting in a highly varied symptom presentation. Learn more about some different patient types that could be in your practice: https://bit.ly/3NuMgL9." "reactions_count" => 124 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-09 09:06:46" "deleted" => 1 ] [ "id" => 3998777 "company_id" => 8900492 "urn" => "urn:li:activity:7001940351947005952" "followers" => 140645 "date" => "1w" "description" => """ Heard the news? We're one ofBioSpace's Best Places to Work for 2023, ranked #7 on the list for large employers! Inclusion and ranking are determined by a survey completed by #LifeSciences professionals, asking them which companies they consider ideal #biopharma employers. \n \n #AlnylamProud #BestPlaceToWork #RNAi #RNAiTherapeutics\n \n http://bit.ly/3u5MLCd """ "reactions_count" => 258 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-09 09:06:46" "deleted" => 1 ] [ "id" => 3998778 "company_id" => 8900492 "urn" => "urn:li:activity:7000454889063481345" "followers" => 140645 "date" => "1w" "description" => """ We're very proud to share that our CEODr. Yvonne Greenstreet has been named one of the 100 People Transforming Business for 2022 by Business Insider, recognizing her extensive industry experience, leadership at Alnylam and as a role model for women in #biopharma. \n \n #T100 #AlnylamProud #RNAi #RNAiTherapeutics #RNAiRevolution #WomenInLeadership #WomenInPharma #BusinessLeaders #Insider """ "reactions_count" => 552 "comments_count" => 13 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-09 09:06:46" "deleted" => 1 ] [ "id" => 3998779 "company_id" => 8900492 "urn" => "urn:li:activity:6999385447323860992" "followers" => 140645 "date" => "2w" "description" => """ How it started ➡️ How it’s going: Celebrating 20 years of Alnylam.\n \n In 2001-02, our pioneering founders performed the earliest experiments to try to synthesize small-interfering RNA (#siRNA), which #RNAi-based medicines use to silence disease-causing genes. Those experiments led to the founding of Alnylam.\n \n Today, we have 5 approved #RNAiTherapeutics and a robust pipeline of investigational medicines. Learn more about our first 2 decades at Alnylam20th.com and what's next in the #RNAiRevolution.\n \n #Alnylam20th #biotech """ "reactions_count" => 148 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-09 09:06:46" "deleted" => 1 ] [ "id" => 3998780 "company_id" => 8900492 "urn" => "urn:li:activity:6999096365951664128" "followers" => 140645 "date" => "2w" "description" => """ Despite having three children with the same inherited#RareDisease, disease management looks different for each one of them. This #NFCMonth, learn more about how the Skinner family has navigated their children’s primary #hyperoxaluria type 1 (PH1) diagnoses: http://bit.ly/3TgXh3I.\n \n #CaregivingHappen """ "reactions_count" => 86 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-09 09:06:46" "deleted" => 1 ] [ "id" => 37567921 "company_id" => 8900492 "urn" => "urn:li:activity:7017989564157820928" "followers" => 142950 "date" => "9h" "description" => """ This afternoon, we announced preliminary Q4 and full year 2022 global net product revenues and additional updates. Tune into our live #JPM23 webcast tomorrow at 9:45 AM PT to learn more. Access the live webcast here: http://bit.ly/374c75E.\n \n #RNAi #RNAiTherapeutics """ "reactions_count" => 72 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:36:28" "deleted" => 1 ] [ "id" => 37567922 "company_id" => 8900492 "urn" => "urn:li:activity:7017128643579498496" "followers" => 142950 "date" => "2d" "description" => """ Join us this coming Monday at 9:45 AM PT when our CEO, Dr. Yvonne Greenstreet will provide a program update and discuss what's next in the #RNAi revolution at the 2023 J.P. Morgan Healthcare Conference: https://bit.ly/374c75E. \n \n #JPM23 #RNAitherapeutics #siRNA """ "reactions_count" => 123 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:36:28" "deleted" => 1 ] [ "id" => 37567923 "company_id" => 8900492 "urn" => "urn:li:activity:7016875966840885248" "followers" => 142950 "date" => "3d" "description" => "We’ve announced the appointment of Nobel Laureate Carolyn Bertozzi, Ph.D. to our Board of Directors and existing board member Amy Schulman as the new Chair of the Board. Michael Bonney will step down as Executive Chair but continue to serve on the Board. https://bit.ly/3WQRR2f" "reactions_count" => 306 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:36:28" "deleted" => 1 ] [ "id" => 37567924 "company_id" => 8900492 "urn" => "urn:li:activity:7016842022451830784" "followers" => 142950 "date" => "3d" "description" => """ We vieren feast (we’re celebrating) the news that our #Netherlands office has made the #GPTWCertified list for the second year in a row! 🎉 Our office in #Amsterdam is critical to our operations in Europe and our mission around the globe. We couldn’t be more #AlnylamProud!\n \n #GPTWNL #GreatPlaceToWork #CompanyCulture #GreatPlaceToWorkCertified #Nederland Great Place To Work® Nederland """ "reactions_count" => 126 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:36:28" "deleted" => 1 ] [ "id" => 37567925 "company_id" => 8900492 "urn" => "urn:li:activity:7016510132788281345" "followers" => 142950 "date" => "4d" "description" => """ We believe strongly in the power of storytelling - not only to humanize an experience but to inform and connect people in ways that transcend geography and language. This is especially true when it comes to telling the stories of people living with or impacted by #RareDisease.\n \n MM+M believes this too and we're thrilled that they've recognized our documentary "Two of Me: Living with #Porphyria" as one of the Best Health Media Stories of 2022.\n \n https://bit.ly/3ClVSTS """ "reactions_count" => 77 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:36:28" "deleted" => 1 ] [ "id" => 37567926 "company_id" => 8900492 "urn" => "urn:li:activity:7016411097150676992" "followers" => 142950 "date" => "4d" "description" => """ Today we celebrate the 40th anniversary of the landmark passage of the Orphan Drug Act of 1983, which fostered innovation and investment in research and development for rare disease treatments. Since 1983, >650 orphan drugs have been approved by the FDA to treat rare diseases but there are millions of patients worldwide still waiting for new treatments.\n \n #ODAat40 #OrphanDrugAct #OneRareVoice #RNAi #RNAiTherapeutics """ "reactions_count" => 134 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:36:28" "deleted" => 1 ] [ "id" => 37567927 "company_id" => 8900492 "urn" => "urn:li:activity:7015343785731579904" "followers" => 142950 "date" => "1w" "description" => """ In 2022, we celebrated 20 years of Alnylam. 🎉20 years of advancing science, bringing innovative medicines to patients in need, and strengthening our award-winning culture. We are so proud of everything our colleagues have achieved this past year, and look forward to the new year with all that lies ahead. \n \n Happy #NewYear to all and to our colleagues and peers in #biopharma, sending our best wishes for a productive, prosperous and patient-focused 2023! \n \n #RNAi #RNAiRevolution #siRNA\n #RNAiTherapeutics #biotech\n #Alnylam20th """ "reactions_count" => 633 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:36:28" "deleted" => 1 ] [ "id" => 37567928 "company_id" => 8900492 "urn" => "urn:li:activity:7014155604831162368" "followers" => 142950 "date" => "1w" "description" => "Although kidney stones are the most common symptom of primary #hyperoxaluria type 1 (PH1), not all people with PH1 experience stones. When you have PH1, your kidneys are at risk for damage even if you’re not getting stones. Learn more about this #RareDisease. https://bit.ly/3gdtAO7" "reactions_count" => 60 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:36:28" "deleted" => 1 ] [ "id" => 37567929 "company_id" => 8900492 "urn" => "urn:li:activity:7013462290003812352" "followers" => 142950 "date" => "1w" "description" => "Many symptoms of #hATTR #amyloidosis resemble those of other more common conditions. This means it often takes years before an accurate diagnosis is made. The Bridge provides educational resources to help recognize the signs and symptoms of this #RareDisease. https://bit.ly/35CiPCH" "reactions_count" => 101 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:36:28" "deleted" => 1 ] [ "id" => 37567930 "company_id" => 8900492 "urn" => "urn:li:activity:7013099888422854656" "followers" => 142950 "date" => "1w" "description" => "Acute hepatic #porphyria (AHP) is a complex genetic #raredisease with a wide array of symptoms that mirror those of more common conditions, making it difficult to diagnose. Get answers about AHP by downloading our brochure from PinpointAHP.com. https://bit.ly/3MZ5XJ8" "reactions_count" => 73 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:36:28" "deleted" => 1 ] [ "id" => 56061868 "company_id" => 8900492 "urn" => "urn:li:activity:7027663025251721217" "followers" => 145631 "date" => "1d" "description" => """ How are you celebrating #RareDiseaseDay? With 24 days until Rare Disease Day, all month long, we’re illuminating our corporate HQ in Cambridge, MA to #LightUpForRare! But, for the ~300 million people worldwide living with a #RareDisease and their families, friends, caregivers, healthcare professionals plus those focused on developing new treatments, every day is rare disease day. \n \n Learn about how you can participate all this month and #ShareYourColors at RareDiseaseDay.org. """ "reactions_count" => 155 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-16 07:58:18" "deleted" => 1 ] [ "id" => 56061869 "company_id" => 8900492 "urn" => "urn:li:activity:7027328101462220800" "followers" => 145631 "date" => "2d" "description" => "Nearly 400 colleagues from around the world tuned into our 1st #DEI Town Hall of the year to hear from our CEO Dr. Yvonne Greenstreet, Chief DE&I Officer Saraswathy (Sara) Nochur, and other DE&I leaders. The session included discussion of recent events, our #diversity, #equity & #inclusion goals for 2023, and a lively Q&A. #AlnylamProud" "reactions_count" => 134 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-16 07:58:18" "deleted" => 1 ] [ "id" => 56061870 "company_id" => 8900492 "urn" => "urn:li:activity:7027024071326334976" "followers" => 145631 "date" => "3d" "description" => """ We’ve been recognized as one of the world’s most dynamic innovators by LexisNexis Intellectual Property Solutions. Check out their new report: Innovation Momentum 2023: The Global Top 100, to learn more and see the full list: http://bit.ly/3JC8n2d. \n \n The Top 100 recognizes companies advancing innovative solutions to today’s challenges and laying the #IntellectualProperty foundations for further breakthroughs.\n \n #InnovationMomentum2023 #biotechnology #RNAiRevolution """ "reactions_count" => 34 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-16 07:58:18" "deleted" => 1 ] [ "id" => 56061871 "company_id" => 8900492 "urn" => "urn:li:activity:7026988405297172480" "followers" => 145631 "date" => "3d" "description" => """ Alnylam Netherlands recently hosted a #mentoring matchmaking event with partner Forward·Inc, a non-profit organization that works closely with aspiring #refugee entrepreneurs.\n \n Alnylam mentors and the entrepreneurs talked through their business ideas and discussed steps for bringing them to life. We’re so excited to see these fresh ideas become reality and are #AlnylamProud of our Netherlands team for being a small part of these refugees’ journeys.\n \n #CorporateResponsibility #entrepreneurism """ "reactions_count" => 175 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-16 07:58:18" "deleted" => 1 ] [ "id" => 56061872 "company_id" => 8900492 "urn" => "urn:li:activity:7026547261547380736" "followers" => 145631 "date" => "4d" "description" => """ To kick off #BlackHistoryMonth, members of our DE&I leadership team visited "The Embrace" which honors Dr. Martin Luther King Jr. and Coretta Scott King. Created by Hank Willis Thomas and located on #BostonCommon, this newly unveiled sculpture depicts four intertwined arms, representing the hug the couple shared after Dr. King was awarded the Nobel Peace Prize. We look forward to a variety of internal events in February celebrating Black History Month.\n \n #TheEmbrace #BHM #BlackHistory #MLK """ "reactions_count" => 213 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-16 07:58:18" "deleted" => 1 ] [ "id" => 56061873 "company_id" => 8900492 "urn" => "urn:li:activity:7026184948982149120" "followers" => 145631 "date" => "5d" "description" => """ For the 3rd year in a row, we’ve been named to the #BloombergGEI list! GEI companies are recognized for their commitment to building diverse, equitable, and inclusive work cultures, and being accountable through data transparency. \n \n Learn more: http://bit.ly/3HLjNzx. \n \n Bloomberg Bloomberg News #ESG #inclusion #GenderEquity #biotech """ "reactions_count" => 159 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-16 07:58:18" "deleted" => 1 ] [ "id" => 56061874 "company_id" => 8900492 "urn" => "urn:li:activity:7026012561858785280" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Dr. Akshay Vaishnaw" "reshared_post_author_url" => "https://www.linkedin.com/in/dr-akshay-vaishnaw-36768a14" "reshared_post_author_headline" => "President at Alnylam Pharmaceuticals" "reshared_post_description" => "There’s a commonly used saying in #biopharma: “drug development is not for the faint of heart”… to which I would also add “nor is it a pursuit for the impatient soul.” What we do in our industry must be done, but it is incredibly difficult, and so I’m quite thrilled to see that the Oligonucleotide Therapeutics Society recently shared the longer-form version of the Alnylam Pharmaceuticals story. They did a great job highlighting our successes but also the numerous challenges we’ve faced and had to overcome (many of which could have ended our story) in our 20 year journey to unlock the potential of RNA interference and deliver a new class of medicines. I hope that it serves as inspiration to OTS members and budding biotechs to stay the course if they believe in an idea that could have an important impact on human health. #RNAi #RNAiTherapeutics #biotech #drugdevelopment #Alnylam20th http://bit.ly/3JsEwt6" "reshared_post_followers" => null "reshared_post_date" => "6d" "last_updated" => "2023-02-16 07:58:18" "deleted" => 1 ] [ "id" => 56061875 "company_id" => 8900492 "urn" => "urn:li:activity:7025914119731978240" "followers" => 145631 "date" => "6d" "description" => """ #AlnylamScienceSpotlight: Paul Nioi, who leads our Alnylam Human Genetics group, will deliver a keynote talk at the upcoming RNA Leaders Europe Congress in March. Check out the agenda below for what promises to be a fascinating meeting.\n \n Alnylam is leveraging large sets of genetic data, the latest analytical and computational technologies, the expertise of a multi-disciplinary team and strategic partnerships, to disrupt the traditional drug discovery and development process. We believe our approach, investments, and commitment to pursuing genetically validated targets have the potential to increase our success rate and accelerate the development of targeted medicines for patients with both rare and common diseases. Learn more about our science: http://bit.ly/3oR8r2l. \n \n #RNAiTherapeutics #TranslationalResearch #DrugDevelopment #siRNA #RNAiRevolution #RNAi """ "reactions_count" => 106 "comments_count" => 1 "reshared_post_author" => "RNA Leaders" "reshared_post_author_url" => "https://ch.linkedin.com/showcase/rnaleaders" "reshared_post_author_headline" => null "reshared_post_description" => """ Excited to announce that Paul Nioi, VP of Discovery and Translational Research at Alnylam Pharmaceuticals, will be presenting on Advancing RNAi Therapeutics for Cardiometabolic Disease. \n \n He'll be discussing the use of human genetics as a new approach for target discovery in cardiometabolic disease, giving a case study of a new RNAi-target for metabolic syndrome, and how this approach is being translated into clinical reality\n \n ✨Make sure to catch his presentation! ✨\n \n 👉 See the agenda:https://lnkd.in/eU3e52M9\n \n #RNAi #CardiometabolicDisease #Therapeutics #Discovery #TranslationalResearch """ "reshared_post_followers" => 3138 "reshared_post_date" => "1w" "last_updated" => "2023-02-16 07:58:18" "deleted" => 1 ] [ "id" => 56061876 "company_id" => 8900492 "urn" => "urn:li:activity:7024399779421908992" "followers" => 145631 "date" => "1w" "description" => "Boston Business Journal has honored Alnylam and our CEO, Dr. Yvonne Greenstreet as part of the 2023 Middle Market Awards. Yvonne has been recognized as Middle Market Executive of the Year! And as a company, we’ve been named one of Massachusetts’ Fastest Growing Companies in the #BBJMiddleMarket." "reactions_count" => 91 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-16 07:58:18" "deleted" => 1 ] [ "id" => 56061877 "company_id" => 8900492 "urn" => "urn:li:activity:7024124459355635712" "followers" => 145631 "date" => "1w" "description" => "The Balancing Act went #BehindtheMystery of acute hepatic #porphyria (AHP) with porphyria expert Dr. Angelika Erwin and Nicole, who is living with AHP and spent 12 years searching for a diagnosis until she found a doctor who suspected this #RareDisease. Watch the sponsored segment today: http://bit.ly/3R8uDCD." "reactions_count" => 69 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-16 07:58:18" "deleted" => 1 ] [ "id" => 77934453 "company_id" => 8900492 "urn" => "urn:li:activity:7031644924819177473" "followers" => 146612 "date" => "15h" "description" => """ Proud to sponsor Boston Globe Media’s first-ever Health & Biotech Week! We’re looking forward to important conversations, including those diversifying #Boston’s science and tech leadership and meeting patients where they are. Plus, we’ll hear from patients, advocates, HCPs, and Dr. Fauci.\n \n Check out the full agenda, and save your spot today: https://bit.ly/3S1ctD2.\n \n #biotech #LifeSciences #BostonGlobe #GlobeEvents """ "reactions_count" => 74 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-03 12:20:26" "deleted" => 1 ] [ "id" => 77934454 "company_id" => 8900492 "urn" => "urn:li:activity:7030924489001431040" "followers" => 146612 "date" => "2d" "description" => "Julio, who has been diagnosed with #hATTR #amyloidosis, saw several doctors in search of a diagnosis. His daughter discusses what led them to suspect this #RareDisease, get tested, and arrive at an accurate diagnosis in a sponsored news segment on The Portuguese Channel: https://bit.ly/3sBgVxl." "reactions_count" => 64 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-03 12:20:26" "deleted" => 1 ] [ "id" => 77934455 "company_id" => 8900492 "urn" => "urn:li:activity:7030169879248797696" "followers" => 146612 "date" => "4d" "description" => """ On International Day of Women and Girls in Science, we recognize the importance of the leaders, educators, mentors, and volunteers working to ensure full and equal access to and participation in science for women and girls.\n \n Our R&D team, in person, and our colleagues around the world celebrated #February11 in a big way, honoring trailblazers, pioneers, and innovators who are role models for the next generation of #WomenInSTEM. They shared stories about their own role models, careers, and the progress that has been made. #UNWomen """ "reactions_count" => 347 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-03 12:20:26" "deleted" => 1 ] [ "id" => 77934456 "company_id" => 8900492 "urn" => "urn:li:activity:7028443469660442624" "followers" => 146612 "date" => "1w" "description" => """ Healthcare Professionals: A combination of multisystem symptoms and family history are red flags of #hATTR #amyloidosis and require urgent action. If your patient’s family has a history of the disease or is experiencing a combination of these multisystem symptoms, consider hATTR amyloidosis.\n \n Learn more about this rapidly progressive, often fatal rare disease: http://bit.ly/3zFjbH5. """ "reactions_count" => 89 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-03 12:20:26" "deleted" => 1 ] [ "id" => 77934457 "company_id" => 8900492 "urn" => "urn:li:activity:7027663025251721217" "followers" => 146612 "date" => "1w" "description" => """ How are you celebrating #RareDiseaseDay? With 24 days until Rare Disease Day, all month long, we’re illuminating our corporate HQ in Cambridge, MA to #LightUpForRare! But, for the ~300 million people worldwide living with a #RareDisease and their families, friends, caregivers, healthcare professionals plus those focused on developing new treatments, every day is rare disease day. \n \n Learn about how you can participate all this month and #ShareYourColors at RareDiseaseDay.org. """ "reactions_count" => 198 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-03 12:20:26" "deleted" => 1 ] [ "id" => 77934458 "company_id" => 8900492 "urn" => "urn:li:activity:7027328101462220800" "followers" => 146612 "date" => "1w" "description" => "Nearly 400 colleagues from around the world tuned into our 1st #DEI Town Hall of the year to hear from our CEO Dr. Yvonne Greenstreet, Chief DE&I Officer Saraswathy (Sara) Nochur, and other DE&I leaders. The session included discussion of recent events, our #diversity, #equity & #inclusion goals for 2023, and a lively Q&A. #AlnylamProud" "reactions_count" => 186 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-03 12:20:26" "deleted" => 1 ] [ "id" => 77934459 "company_id" => 8900492 "urn" => "urn:li:activity:7027024071326334976" "followers" => 146612 "date" => "1w" "description" => """ We’ve been recognized as one of the world’s most dynamic innovators by LexisNexis Intellectual Property Solutions. Check out their new report: Innovation Momentum 2023: The Global Top 100, to learn more and see the full list: http://bit.ly/3JC8n2d. \n \n The Top 100 recognizes companies advancing innovative solutions to today’s challenges and laying the #IntellectualProperty foundations for further breakthroughs.\n \n #InnovationMomentum2023 #biotechnology #RNAiRevolution """ "reactions_count" => 38 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-03 12:20:26" "deleted" => 1 ] [ "id" => 77934460 "company_id" => 8900492 "urn" => "urn:li:activity:7026988405297172480" "followers" => 146612 "date" => "1w" "description" => """ Alnylam Netherlands recently hosted a #mentoring matchmaking event with partner Forward·Inc, a non-profit organization that works closely with aspiring #refugee entrepreneurs.\n \n Alnylam mentors and the entrepreneurs talked through their business ideas and discussed steps for bringing them to life. We’re so excited to see these fresh ideas become reality and are #AlnylamProud of our Netherlands team for being a small part of these refugees’ journeys.\n \n #CorporateResponsibility #entrepreneurism """ "reactions_count" => 212 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-03 12:20:26" "deleted" => 1 ] [ "id" => 77934461 "company_id" => 8900492 "urn" => "urn:li:activity:7026547261547380736" "followers" => 146612 "date" => "2w" "description" => """ To kick off #BlackHistoryMonth, members of our DE&I leadership team visited "The Embrace" which honors Dr. Martin Luther King Jr. and Coretta Scott King. Created by Hank Willis Thomas and located on #BostonCommon, this newly unveiled sculpture depicts four intertwined arms, representing the hug the couple shared after Dr. King was awarded the Nobel Peace Prize. We look forward to a variety of internal events in February celebrating Black History Month.\n \n #TheEmbrace #BHM #BlackHistory #MLK """ "reactions_count" => 241 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-03 12:20:26" "deleted" => 1 ] [ "id" => 77934462 "company_id" => 8900492 "urn" => "urn:li:activity:7026184948982149120" "followers" => 146612 "date" => "2w" "description" => """ For the 3rd year in a row, we’ve been named to the #BloombergGEI list! GEI companies are recognized for their commitment to building diverse, equitable, and inclusive work cultures, and being accountable through data transparency. \n \n Learn more: http://bit.ly/3HLjNzx. \n \n Bloomberg Bloomberg News #ESG #inclusion #GenderEquity #biotech """ "reactions_count" => 178 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-03 12:20:26" "deleted" => 1 ] [ "id" => 93422175 "company_id" => 8900492 "urn" => "urn:li:activity:7037141608206622720" "followers" => 147985 "date" => "13h" "description" => null "reactions_count" => 16 "comments_count" => null "reshared_post_author" => "RNA Leaders" "reshared_post_author_url" => "https://ch.linkedin.com/showcase/rnaleaders" "reshared_post_author_headline" => null "reshared_post_description" => """ Join our opening Keynote Panel: Navigating the Future Outlook of Successful RNA Vaccines & Therapeutics, where our industry experts will discuss the progress, challenges, and opportunities in the field of RNA medicine.\n \n With RNA medicines targeting Cancer, Infectious, Rare and Respiratory Diseases, our panellists will explore the new technologies that offer exciting contributions to the field and where the major technology gaps still need to be filled.\n \n You'll hear from: \n Marie Wikström Lindholm, SVP and Head of Molecular Design, Silence Therapeutics plc \n Paul Nioi, VP Discovery & Translational Research, Alnylam Pharmaceuticals\n Nagy Habib, Co-Founder & Head of R&D, MiNA Therapeutics\n Dan STANER, VP, Head of Europe, Middle East & Africa, Moderna\n \n Our moderator, Miroslav Gasparek, Co-founder & CEO of Sensible Biotechnologies, will guide the discussion as our panellists share their perspectives and visions for the future of RNA medicine.\n \n 👉 Only 2 weeks to go so hurry up and book your tickets: https://lnkd.in/dqSRjp54 """ "reshared_post_followers" => 3363 "reshared_post_date" => "1d" "last_updated" => "2023-04-12 22:18:16" "deleted" => 1 ] [ "id" => 93422176 "company_id" => 8900492 "urn" => "urn:li:activity:7037074817132449792" "followers" => 147985 "date" => "18h" "description" => """ We're honored to be recognized again by Fast Company as one of the world's Most Innovative Companies and ranked number 5 in the Medicines and Therapeutics category. This marks our second time on this #FastCompany list.\n \n Our focus on sustained innovation is necessary to continue advancing the #RNAiRevolution so that as many patients as possible can benefit from this revolutionary new class of medicines. \n \n Read more about this recognition: http://bit.ly/3mjWJzu.\n \n #FCMostInnovative #RNAi #RNAiTherapeutics #siRNA #innovation #LifeSciences """ "reactions_count" => 202 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 22:18:16" "deleted" => 1 ] [ "id" => 93422177 "company_id" => 8900492 "urn" => "urn:li:activity:7037027555903721472" "followers" => 147985 "date" => "21h" "description" => "#hATTR #amyloidosis is an inherited #RareDisease that disproportionately affects people of #Portuguese descent. Watch the sponsored news segment from The Portuguese Channel now available on YouTube to learn more: https://bit.ly/3sBgVxl." "reactions_count" => 47 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 22:18:16" "deleted" => 1 ] [ "id" => 93422178 "company_id" => 8900492 "urn" => "urn:li:activity:7036402265993150464" "followers" => 147985 "date" => "2d" "description" => "Patient and caregiver #SelfAdvocacy is a critical tool in ensuring an accurate and timely #RareDisease diagnosis. However, at Alnylam we believe the burden should not solely fall on the shoulders of patients and caregivers and are committed to supporting this community. Read more about our commitment and the importance of self-advocacy. #RareDiseaseDay http://bit.ly/3IyKMgI" "reactions_count" => 78 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 22:18:16" "deleted" => 1 ] [ "id" => 93422179 "company_id" => 8900492 "urn" => "urn:li:activity:7036333921566883840" "followers" => 147985 "date" => "2d" "description" => "Today on #RareDiseaseDay, and every day, we are inspired by the resilience of families living with #RareDiseases, like the Clements. In an upcoming episode of PBS Medical Stories, witness their strength firsthand as they navigate life with primary #hyperoxaluria type 1 (PH1): http://bit.ly/3xIC9Lo." "reactions_count" => 207 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 22:18:16" "deleted" => 1 ] [ "id" => 93422180 "company_id" => 8900492 "urn" => "urn:li:activity:7036072452497506304" "followers" => 147985 "date" => "3d" "description" => """ Acute hepatic #porphyria (AHP) is an unpredictable and unforgiving #RareDisease that can interfere with daily life. \n \n Tomorrow on #RareDiseaseDay, watch “Two of Me: Living with Porphyria” to hear from people living with AHP about the hardships of this rare disease, and #Tell15 to help shorten the time to diagnosis: http://bit.ly/3vi2LTI. """ "reactions_count" => 67 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 22:18:16" "deleted" => 1 ] [ "id" => 93422181 "company_id" => 8900492 "urn" => "urn:li:activity:7035977970104049664" "followers" => 147985 "date" => "3d" "description" => """ An accurate #RareDisease diagnosis, such as #hATTR #amyloidosis, can take years to receive. \n \n For Jean, her symptoms had been worsening for years until she reached her tipping point and pressed for answers, which helped lead to her diagnosis. This #RareDiseaseDay, learn more about hATTR amyloidosis on The Bridge: http://bit.ly/3oBRbw9. """ "reactions_count" => 137 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 22:18:16" "deleted" => 1 ] [ "id" => 93422182 "company_id" => 8900492 "urn" => "urn:li:activity:7035327557411463168" "followers" => 147985 "date" => "5d" "description" => "In recognition of #BlackHistoryMonth, we asked employees and members of our Global Black Initiative ERN what the month means to them. At Alnylam, we’re committed to fostering a culture of inclusion that enables all our employees to feel they belong and have the opportunity to contribute to our mission. #BHM #BHM23 #DiverstiyEquityInclusion" "reactions_count" => 125 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 22:18:16" "deleted" => 1 ] [ "id" => 93422183 "company_id" => 8900492 "urn" => "urn:li:activity:7034508268160864256" "followers" => 147985 "date" => "1w" "description" => """ This morning, we reported Q4 2022 financial results and highlights of recent period activity. We will host a LIVE webcast TODAY at 8:30 AM ET to discuss them and a replay will be available following. Access the webcast and replay here: http://bit.ly/374c75E $ALNY #RNAi #siRNA \n \n Read our Q4 2022 financial results press release: http://bit.ly/3ZhyyQe """ "reactions_count" => 154 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 22:18:16" "deleted" => 1 ] [ "id" => 93422184 "company_id" => 8900492 "urn" => "urn:li:activity:7033920030455021568" "followers" => 147985 "date" => "1w" "description" => "This Thursday, 2/23 at 8:30 AM ET, we'll be sharing 4th Quarter 2022 financial results during a LIVE webcast. A replay will be available at the link below later in the day. #RNAi #RNAitherapeutics #siRNA" "reactions_count" => 34 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 22:18:16" "deleted" => 1 ] [ "id" => 128822540 "company_id" => 8900492 "urn" => "urn:li:activity:7051287223467413504" "followers" => 151551 "date" => "11h" "description" => """ #AlnylamScienceSpotlight: New research published in Nature Portfolio details non-clinical results exploring the utility of RNAi-mediated knockdown with our REVERSIR technology in modulating adeno-associated virus (AAV) transgene expression in the setting of gene therapy.\n \n #GeneTherapy #RNAi #RNAiTherapeutics #RNAiRevolution #genetics https://lnkd.in/es56ta-Q """ "reactions_count" => 383 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-30 06:42:20" "deleted" => 1 ] [ "id" => 128822541 "company_id" => 8900492 "urn" => "urn:li:activity:7050150264913223680" "followers" => 151551 "date" => "3d" "description" => """ Today is #WorldHealthDay and this year’s theme is #HealthForAll. At Alnylam, we believe that all patients deserve the opportunity to live longer, healthier and fuller lives, regardless of diagnosis. That’s why we pioneered #RNAi therapeutics and are working tirelessly to develop new medicines to treat diseases for which there are limited or inadequate treatment options and to bring our medicines to those who may benefit from them.\n \n #RNAiTherapeutics #RNAiRevolution #WHO75 World Health Organization """ "reactions_count" => 58 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-30 06:42:20" "deleted" => 1 ] [ "id" => 128822542 "company_id" => 8900492 "urn" => "urn:li:activity:7050098090803884032" "followers" => 151551 "date" => "3d" "description" => """ Our Global Commercial team recently gathered to assemble backpacks filled with educational #STEM items for Cambridge’s Science Club for Girls. At Alnylam, we believe we can only thrive when the communities surrounding us are resilient and sustainable.\n \n Throughout the year, our teams worldwide dedicate time to support local non-profit organizations. Learn more about our community-driven mission: http://bit.ly/3MpXSjX.\n \n #GirlsInSTEM #WomenInSTEM #CommunityEngagement """ "reactions_count" => 248 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-30 06:42:20" "deleted" => 1 ] [ "id" => 128822543 "company_id" => 8900492 "urn" => "urn:li:activity:7049082614984384512" "followers" => 151551 "date" => "6d" "description" => """ Primary #hyperoxaluria (PH) is an inherited #raredisease that causes overproduction of oxalate in the body. Primary hyperoxaluria type 1 (PH1) is the most common form of PH. Learn more about the signs and symptoms of PH1, including recurrent #KidneyStones, at TakeOnPH1.com.\n \n https://bit.ly/3BBoVU7 """ "reactions_count" => 109 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-30 06:42:20" "deleted" => 1 ] [ "id" => 128822544 "company_id" => 8900492 "urn" => "urn:li:activity:7048743631683231745" "followers" => 151551 "date" => "1w" "description" => "We recently presented post hoc analyses from the ENVISION study of our #RNAi therapeutic for the treatment of acute hepatic porphyria (AHP) in adults at the #HTRS2023 Scientific Symposium. Learn more about our findings: http://bit.ly/3MdCDlb." "reactions_count" => 177 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-30 06:42:20" "deleted" => 1 ] [ "id" => 128822545 "company_id" => 8900492 "urn" => "urn:li:activity:7048587436343349248" "followers" => 151551 "date" => "2w" "description" => "Healthcare Professionals: Timely diagnosis of #hATTR #amyloidosis is critical, as the disease can progress rapidly and lead to long-term complications. Learn more from Dr. Michael Polydefkis in a sponsored article, who explains the polyneuropathy manifestations of this #RareDisease and what physicians should look out for to ensure a prompt diagnosis – including family history and symptoms like neuropathic pain, numbness and difficulty walking – and an available treatment option. http://bit.ly/3iztOpt" "reactions_count" => 55 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-30 06:42:20" "deleted" => 1 ] [ "id" => 128822546 "company_id" => 8900492 "urn" => "urn:li:activity:7047549940603961344" "followers" => 151551 "date" => "1w" "description" => null "reactions_count" => 39 "comments_count" => null "reshared_post_author" => "Dr. Yvonne Greenstreet" "reshared_post_author_url" => "https://www.linkedin.com/in/dr-yvonne-greenstreet-2b00389" "reshared_post_author_headline" => "Chief Executive Officer, Alnylam Pharmaceuticals" "reshared_post_description" => """ Today I was happy to participate in a panel discussion on Eos Foundation's Women's Power Gap report, "Breaking Through to the Top: Diversity Among Executive Leadership at Massachusetts’ Largest Public Companies” to discuss current data trends and the responsibility we all have to accelerate progress toward gender and racial equity across industries. \n \n We remain committed to making Alnylam Pharmaceuticals a better and more inclusive place which is why gatherings and information sharing conversations like the one we had today are critical. When we take drops from each of our companies and turn that into a river, that’s how we influence society. \n \n Thank you to our moderator Andrea Silbert (President of Eos Foundation) and my co-panelists Reshma Kewalramani, MD FASN (CEO & President of Vertex Pharmaceuticals) and Bob Rivers (CEO & Board Chair, Eastern Bank). \n \n For more, read the full report: https://lnkd.in/e2qGrccT\n \n #diversityequityinclusion #representationmatters """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2023-04-30 06:42:20" "deleted" => 1 ] [ "id" => 128822547 "company_id" => 8900492 "urn" => "urn:li:activity:7047507822908985344" "followers" => 151551 "date" => "1w" "description" => """ So, you know what #genetics are, but do you know how they’re used in drug development to identify therapeutic targets and improve the probability of success of investigational medicines in the human clinic? \n \n Since our founding, we've leveraged #HumanGenetics and pursued genetically validated targets yielding a success rate in clinical trials 6x the industry average. Now, this approach is powering the next wave of Alnylam #RNAiTherapeutics and our expansion from rare into more prevalent diseases. #RNAi #RNAiRevolution #biotech #DrugDevelopment http://bit.ly/40IHyi0 """ "reactions_count" => 254 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-30 06:42:20" "deleted" => 1 ] [ "id" => 128822548 "company_id" => 8900492 "urn" => "urn:li:activity:7047236745981022208" "followers" => 151551 "date" => "1w" "description" => """ At Alnylam, we believe representation matters. We're proud to be ranked #1 among MA companies in board of directors #GenderDiversity and #3 in #ExecutiveLeadership gender diversity. \n \n Thank you Eos Foundation for continuing to provide important data as part of the Women's Power Gap Initiative to help companies achieve #GenderParityNow. http://bit.ly/3M7i2z0 """ "reactions_count" => 111 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-30 06:42:20" "deleted" => 1 ] [ "id" => 128822549 "company_id" => 8900492 "urn" => "urn:li:activity:7046883160919298048" "followers" => 151551 "date" => "1w" "description" => "In the latest issue of RARE Revolution Magazine, Alnylam’s Thirusha Lane reflects on 15 years as a nurse and patient advocacy professional in the field of #ATTR #amyloidosis. Hear her perspectives on the remaining and emerging needs for those impacted by this #RareDisease." "reactions_count" => 72 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-30 06:42:20" "deleted" => 1 ] [ "id" => 156313793 "company_id" => 8900492 "urn" => "urn:li:activity:7057743844368379904" "followers" => 153374 "date" => "1d" "description" => """ During the Pediatric Academic Societies Meeting, we will present new 30-month results from the ILLUMINATE-B Phase 3 study of our #RNAi therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1). Learn more about our findings. https://bit.ly/3Hoq2Zo\n \n #PAS2023 #RNAiTherapeutics #siRNA #pediatrics #nephrology #urology """ "reactions_count" => 68 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-11 01:18:47" "deleted" => 1 ] [ "id" => 156313794 "company_id" => 8900492 "urn" => "urn:li:activity:7057662249007554560" "followers" => 153374 "date" => "2d" "description" => """ As a long-time supporter of @CASPAR’s mission to support our homeless neighbors in Massachusetts, we look forward to attending their upcoming “Strengthening Our Community” event at MIT Museum on May 4. We encourage our neighbors and #biotech peers to learn more about CASPAR’s incredible impact in the communities where we live and work. https://bit.ly/4286j8h \n \n Bay Cove Human Services #CASPAR #CommunityPartners """ "reactions_count" => 28 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-11 01:18:47" "deleted" => 1 ] [ "id" => 156313795 "company_id" => 8900492 "urn" => "urn:li:activity:7057336191607545856" "followers" => 153374 "date" => "2d" "description" => """ ICYMI: Yesterday, with our partner Regeneron, we shared interim Phase 1 clinical data on ALN-APP, an investigational #RNAi therapeutic in development for the treatment of #AlzheimersDisease and cerebral amyloid angiopathy (CAA). We’ll present full results at an upcoming medical meeting. https://bit.ly/41ENj13\n \n #RNAitherapeutics #siRNA #CNS #neurology #neuroscience #Alzheimers """ "reactions_count" => 77 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-11 01:18:47" "deleted" => 1 ] [ "id" => 156313796 "company_id" => 8900492 "urn" => "urn:li:activity:7057115149999984640" "followers" => 153374 "date" => "3d" "description" => "We’ve shared interim Phase 1 clinical data on ALN-APP, an investigational #RNAi therapeutic in development with our partner Regeneron for the treatment of #AlzheimersDisease and cerebral amyloid angiopathy. We’ll present full results at an upcoming medical meeting. #RNAiTherapeutics #siRNA #CNS #biotechnology https://bit.ly/41ENj13" "reactions_count" => 123 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-11 01:18:47" "deleted" => 1 ] [ "id" => 156313797 "company_id" => 8900492 "urn" => "urn:li:activity:7057084317969063937" "followers" => 153374 "date" => "3d" "description" => "This afternoon at 4:30 pm ET, we’ll be providing information about the interim Phase 1 clinical data on ALN-APP, an investigational #RNAi therapeutic in development for the treatment of #AlzheimersDisease and cerebral amyloid angiopathy. w/ Regeneron #RNAitherapeutics #siRNA http://bit.ly/374c75E" "reactions_count" => 75 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-11 01:18:47" "deleted" => 1 ] [ "id" => 156313798 "company_id" => 8900492 "urn" => "urn:li:activity:7057083789398683648" "followers" => 153374 "date" => "3d" "description" => "With our partner Regeneron, we are pleased to share interim Phase 1 clinical data on ALN-APP, an investigational #RNAi therapeutic in development for the treatment of #AlzheimersDisease and cerebral amyloid angiopathy. #RNAitherapeutics #siRNA https://lnkd.in/emBaVchb" "reactions_count" => 611 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-11 01:18:47" "deleted" => 1 ] [ "id" => 156313799 "company_id" => 8900492 "urn" => "urn:li:activity:7056975231168483328" "followers" => 153374 "date" => "4d" "description" => "We’re excited to share that PM360 Magazine named AmaliasStory.com a #MasterclassOfStorytelling Winner in addition to a Pharma Choice Award Silver Winner. The website features artwork from Alnylam Patient Ambassador Amalia, depicting her journey with acute hepatic #porphyria (AHP)." "reactions_count" => 52 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-11 01:18:47" "deleted" => 1 ] [ "id" => 156313800 "company_id" => 8900492 "urn" => "urn:li:activity:7056605269463638017" "followers" => 153374 "date" => "5d" "description" => "2022 was an exciting year for Alnylam with significant milestones as we continue leading the #RNAiRevolution. Our CEO Dr. Yvonne Greenstreet reflects on last year’s highlights and the next chapter for #RNAiTherapeutics. Download our 2022 annual report to learn more. #RNAi #siRNA https://bit.ly/3AsglFg" "reactions_count" => 90 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-11 01:18:47" "deleted" => 1 ] [ "id" => 156313801 "company_id" => 8900492 "urn" => "urn:li:activity:7056328110023041024" "followers" => 153374 "date" => "5d" "description" => """ We recently presented new data for vutrisiran and patisiran during the 2023 AAN Annual Meeting.\n \n American Academy of Neurology #AANAM #RNAiTherapeutics https://bit.ly/3L0QEk9 """ "reactions_count" => 173 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-11 01:18:47" "deleted" => 1 ] [ "id" => 156313802 "company_id" => 8900492 "urn" => "urn:li:activity:7056205144329179138" "followers" => 153374 "date" => "1w" "description" => "The Alnylam Assist® program offers support services to patients who are prescribed one of our products. Our team of experts are here to help patients access and understand treatment. https://bit.ly/3URXbSy" "reactions_count" => 128 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-11 01:18:47" "deleted" => 1 ] [ "id" => 172766294 "company_id" => 8900492 "urn" => "urn:li:activity:7062045369362173952" "followers" => 154195 "date" => "5h" "description" => """ As part of our commitment to #CorporateResponsibility and protecting our planet, last month our Green Team helped Alnylam colleagues celebrate #EarthDay around the world. \n \n In Massachusetts, volunteers cleaned up with the Esplanade Association and helped Norton Land Preservation Society and Attleboro Norton YMCA with kid-friendly environmental activities. \n \n Plus, our facilities team collected over 1,600LB of E-waste across the International region. Thank you to all who participated! """ "reactions_count" => 78 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-04 14:23:10" "deleted" => 1 ] [ "id" => 172766295 "company_id" => 8900492 "urn" => "urn:li:activity:7061765690877190144" "followers" => 154195 "date" => "1d" "description" => "We want to help people with #hATTR #amyloidosis ‘Bridge the Gap’ in awareness of the condition by providing resources and guidance for having important and difficult conversations with friends and family about the disease. Learn more: https://bit.ly/3iqkSxr." "reactions_count" => 70 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-04 14:23:10" "deleted" => 1 ] [ "id" => 172766296 "company_id" => 8900492 "urn" => "urn:li:activity:7060131003964489729" "followers" => 154195 "date" => "2w" "description" => "After a doctor prescribes one of our products to a patient, they are partnered with an Alnylam Case Manager who has expertise in helping patients get started on treatment and providing product support. https://bit.ly/3URXbSy" "reactions_count" => 127 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-04 14:23:10" "deleted" => 1 ] [ "id" => 172766297 "company_id" => 8900492 "urn" => "urn:li:activity:7059942270812250112" "followers" => 154195 "date" => "6d" "description" => """ We've made #HealthEquity a key component of corporate responsibility efforts. You can read about our programs and partnerships in our just-released 2022 report, which details our progress in #ESG and patient-focused innovation. #CorporateResponsibility\n \n Download the report: https://bit.ly/44iczw5. """ "reactions_count" => 124 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-04 14:23:10" "deleted" => 1 ] [ "id" => 172766298 "company_id" => 8900492 "urn" => "urn:li:activity:7059866773243801601" "followers" => 154195 "date" => "6d" "description" => """ Alnylam’s 2022 Corporate Responsibility Report is now available for download. Read more about our efforts and progress in #ESG, patient-focused innovation and #HealthEquity. #CSR \n \n Download the report: https://bit.ly/44iczw5. """ "reactions_count" => 177 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-04 14:23:10" "deleted" => 1 ] [ "id" => 172766299 "company_id" => 8900492 "urn" => "urn:li:activity:7059860945753264128" "followers" => 154195 "date" => "6d" "description" => """ This morning, we reported Q1 2023 financial results and highlights of recent period activity. We will host a LIVE webcast TODAY at 8:30 AM ET to discuss them and a replay will be available following. Access the webcast and replay here: https://bit.ly/374c75E\n \n #RNAi #RNAiTherapeutics #siRNA\n https://bit.ly/42mnaV0 """ "reactions_count" => 93 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-04 14:23:10" "deleted" => 1 ] [ "id" => 172766300 "company_id" => 8900492 "urn" => "urn:li:activity:7059605755045322752" "followers" => 154195 "date" => "6d" "description" => """ Just published: Alnylam’s 2022 Corporate Responsibility Report. Download to read more about our #ESG efforts and progress in our six areas of focus: patients, sciences, employees, communities, planet, and governance. \n \n Download the report: https://bit.ly/44iczw5\n \n #CorporateResponsibility """ "reactions_count" => 81 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-04 14:23:10" "deleted" => 1 ] [ "id" => 172766301 "company_id" => 8900492 "urn" => "urn:li:activity:7059498563378003968" "followers" => 154195 "date" => "1w" "description" => "At Alnylam, we endeavor to make a positive impact on our communities and the planet beyond the innovative medicines we make. Each year, we report on our #CorporateResponsibility mission and progress in our 6 key areas of focus: patients, sciences, employees, communities, planet and governance. #ESG" "reactions_count" => 43 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-04 14:23:10" "deleted" => 1 ] [ "id" => 172766302 "company_id" => 8900492 "urn" => "urn:li:activity:7059157530198827008" "followers" => 154195 "date" => "1w" "description" => "This Thursday, 5/4 at 8:30 AM ET, we'll be sharing 1st Quarter 2023 financial results during a LIVE webcast. A replay will be available at the link below later in the day. #RNAi #RNAiTherapeutics #siRNA" "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-04 14:23:10" "deleted" => 1 ] [ "id" => 172766303 "company_id" => 8900492 "urn" => "urn:li:activity:7057743844368379904" "followers" => 154195 "date" => "1w" "description" => """ During the Pediatric Academic Societies Meeting, we will present new 30-month results from the ILLUMINATE-B Phase 3 study of our #RNAi therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1). Learn more about our findings. https://bit.ly/3Hoq2Zo\n \n #PAS2023 #RNAiTherapeutics #siRNA #pediatrics #nephrology #urology """ "reactions_count" => 129 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-04 14:23:10" "deleted" => 1 ] [ "id" => 192288754 "company_id" => 8900492 "urn" => "urn:li:activity:7070323194867380224" "followers" => 156192 "date" => "1mo" "description" => "Through the Alnylam Assist® program, patients have access to Alnylam Patient Education Liaisons (PELs), professionals who are experienced in providing disease and production education to patients and their family members. https://bit.ly/3URXbSy" "reactions_count" => 13 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-20 19:58:37" "deleted" => 1 ] [ "id" => 192288755 "company_id" => 8900492 "urn" => "urn:li:activity:7070107445750034432" "followers" => 156192 "date" => "1d" "description" => """ Happy #PrideMonth! We’re #AlnylamProud to have SAGA, Alnylam’s #LGBTQ+ employee resource network, lead our global celebrations to bring our colleagues together all month long.\n \n This year’s theme, Diverse Equal Proud, is about recognizing the diversity of people within the LGBTQ+ community and the fact that everyone deserves to be proud of who they are and to be treated with equal respect and dignity, regardless of gender, sexuality, ethnicity, or background. \n \n #Pride #Pride2023 """ "reactions_count" => 135 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-20 19:58:37" "deleted" => 1 ] [ "id" => 192288756 "company_id" => 8900492 "urn" => "urn:li:activity:7069613481905246208" "followers" => 156192 "date" => "3w" "description" => "One of the earliest signs of primary #hyperoxaluria type 1 (PH1) is recurrent #KidneyStones. If you think you or your family member may have PH1, use this discussion guide to help you have a productive conversation with your healthcare provider. #RareDisease https://bit.ly/3a4Wezw" "reactions_count" => 21 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-20 19:58:37" "deleted" => 1 ] [ "id" => 192288757 "company_id" => 8900492 "urn" => "urn:li:activity:7069553132803895296" "followers" => 156192 "date" => "3d" "description" => """ Led by our SHADES: InspirASIAN Employee Resource Network, we’re proud to Celebrate #AAPIHeritageMonth. All year long, InspirASIAN helps us acknowledge and honor Asian and Asian American Pacific Islander heritage, through education and celebrations. \n \n #AAPI #AAPIMonth """ "reactions_count" => 89 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-20 19:58:37" "deleted" => 1 ] [ "id" => 192288758 "company_id" => 8900492 "urn" => "urn:li:activity:7069313618613280768" "followers" => 156192 "date" => "3d" "description" => """ At Alnylam, we're recognizing #MentalHealth Awareness Month while also recognizing that employee health and well-being must be a focus year-round. We're proud of the range of resources available to our employees, including colleagues who exemplify our 'commitment to people' core value.\n \n Learn more about our approach to health and well-being and why it’s part of what makes us a globally recognized #BestPlaceToWork: https://bit.ly/43cZFhU. """ "reactions_count" => 104 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-20 19:58:37" "deleted" => 1 ] [ "id" => 192288759 "company_id" => 8900492 "urn" => "urn:li:activity:7069228454889582592" "followers" => 156192 "date" => "3w" "description" => "Tootie Bueser, a cardiac genetic nurse, has expert advice for anyone with questions about living with #hATTR #amyloidosis. Find out more about this #RareDisease at our ‘Bridge the Gap’ website: https://bit.ly/3jLtlfv." "reactions_count" => 35 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-20 19:58:37" "deleted" => 1 ] [ "id" => 192288760 "company_id" => 8900492 "urn" => "urn:li:activity:7067851858257563648" "followers" => 156192 "date" => "1w" "description" => """ Great Place to Work® Italia has ranked Alnylam as the #1 #BestWorkplace in Pharma & Biotechnology! We’re so #AlnylamProud of our colleagues in Italy who have created a special culture that always puts people first and enables us to do the best we can on behalf of the patients who depend on us. Congratulazioni team!\n \n #GPTW #GreatPlaceToWork #CompanyCulture """ "reactions_count" => 291 "comments_count" => 14 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-20 19:58:37" "deleted" => 1 ] [ "id" => 192288761 "company_id" => 8900492 "urn" => "urn:li:activity:7067599876418613248" "followers" => 156192 "date" => "1w" "description" => """ Engaged employees are not only productive employees but collectively, an incredible force for social change and doing good in our communities. We're so proud of how our employees have been the driving force behind our corporate responsibility efforts. \n \n Learn more by downloading our most recent CR report: https://bit.ly/44iczw5.\n \n #CorporateResponsibility #HealthEquity #CommunityPartners #RNAiTherapeutics """ "reactions_count" => 79 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-20 19:58:37" "deleted" => 1 ] [ "id" => 192288762 "company_id" => 8900492 "urn" => "urn:li:activity:7067155636739788800" "followers" => 156192 "date" => "1w" "description" => "Members of our Latinx-focused Employee Resource Network, Armonia, attended #HFGala23 last month. As a sponsor, Alnylam supports the Hispanic Federation’s mission of championing various economic development and educational opportunities for the Hispanic community. We’re inspired by the #HispanicFederation’s work and thrilled our team had the opportunity to be surrounded by many #Latinx leaders." "reactions_count" => 142 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-20 19:58:37" "deleted" => 1 ] [ "id" => 192288763 "company_id" => 8900492 "urn" => "urn:li:activity:7067106977398579200" "followers" => 156192 "date" => "1mo" "description" => "Alnylam Patient Education Liaisons (PELs) help patients who are prescribed one of our products by providing disease and product education, connecting patients to additional resources, and answering questions about treatment with our products. https://bit.ly/3URXbSy" "reactions_count" => 54 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-20 19:58:37" "deleted" => 1 ] [ "id" => 249843708 "company_id" => 8900492 "urn" => "urn:li:activity:7087540256777867264" "followers" => 160189 "date" => "8h" "description" => "We are proud to share that NEJM Group has published the Phase 1 study results for zilebesiran - an investigational #RNAi therapeutic in development for the treatment of #hypertension targeting liver-expressed angiotensinogen (AGT). #RNAiTherapeutics #siRNA #cardiology #BloodPressure https://bit.ly/3pWQoMy" "reactions_count" => 174 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-07 01:19:17" "deleted" => 1 ] [ "id" => 249843709 "company_id" => 8900492 "urn" => "urn:li:activity:7086674228426498048" "followers" => 160189 "date" => "2d" "description" => "Today, at the 2023 Alzheimer's Association® International Conference (#AAIC23), we presented updated interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic in development w/ @Regeneron for the treatment of #AlzheimersDisease and cerebral #amyloid angiopathy (CAA). #RNAi #RNAiTherapeutics https://bit.ly/43vpCbU" "reactions_count" => 605 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-07 01:19:17" "deleted" => 1 ] [ "id" => 249843710 "company_id" => 8900492 "urn" => "urn:li:activity:7085224607300890624" "followers" => 160189 "date" => "6d" "description" => "Years after watching his father battle debilitating symptoms of #hATTR #amyloidosis, John began to experience similar symptoms and was eventually diagnosed with this inherited #RareDisease. Watch an Alnylam-sponsored Access Health episode airing on Lifetime Television to learn more about John’s story and how he was his own superhero when it came to advocating for his health. https://bit.ly/3CQ8XVG" "reactions_count" => 122 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-07 01:19:17" "deleted" => 1 ] [ "id" => 249843711 "company_id" => 8900492 "urn" => "urn:li:activity:7084900273025908736" "followers" => 160189 "date" => "1w" "description" => "At Alnylam, we’re committed to doing our part to increase diversity in #ClinicalTrials, which is why we’re proud to be part of the Beacon of Hope Initiative. Led by Novartis and the Novartis US Foundation, Beacon of Hope seeks to address root causes of disparities in health and education and help create greater diversity, equity, inclusion and trust across the research and development ecosystem. With this collaboration, Alnylam will work with Historically Black Medical School Centers of Excellence and offer fellowship opportunities to students. Learn more about the Initiative: https://bit.ly/3pLQJ4C #HBCUBeaconofHope" "reactions_count" => 78 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-07 01:19:17" "deleted" => 1 ] [ "id" => 249843712 "company_id" => 8900492 "urn" => "urn:li:activity:7084631050865258496" "followers" => 160189 "date" => "1w" "description" => """ Thank you Fast Company for recognizing Alnylam as a Best Workplace for Innovators 3x in a row! Without innovative people (and a workplace culture that nurtures innovation), a company can't innovate. Our team's focus on sustained innovation is necessary to continue advancing the #RNAiRevolution so that as many patients as possible can benefit from this revolutionary new class of medicines. \n \n Read more about this recognition ➡️ https://bit.ly/44xnuS0\n \n #FCBestWorkplaces #RNAi #RNAiTherapeutics #siRNA #innovation #LifeSciences """ "reactions_count" => 171 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-07 01:19:17" "deleted" => 1 ] [ "id" => 249843713 "company_id" => 8900492 "urn" => "urn:li:activity:7084525010647703552" "followers" => 160189 "date" => "1w" "description" => "Last week we attended the Communiqué Awards and won! #AlnylamProud to take home the “Leadership Award for Action on Workforce Diversity and Inclusion.” From the inside out, we’re building a strong #DEI platform to ensure employees feel they belong and can bring their authentic selves to work. Congrats team! #CommuniquéAwards2023" "reactions_count" => 254 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-07 01:19:17" "deleted" => 1 ] [ "id" => 249843714 "company_id" => 8900492 "urn" => "urn:li:activity:7083058974727512064" "followers" => 160189 "date" => "1w" "description" => "Healthcare Professionals: Although kidney stones are the most common, and often the first symptom of primary #hyperoxaluria type 1 (PH1), not all people with PH1 will have stones. Learn to recognize the signs and symptoms of PH1 in children and adults and how you can test for this #RareDisease. http://bit.ly/2Sbnc0N" "reactions_count" => 96 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-07 01:19:17" "deleted" => 1 ] [ "id" => 249843715 "company_id" => 8900492 "urn" => "urn:li:activity:7082720708585213952" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "CASPAR, Inc. (Cambridge & Somerville Programs for Addiction Recovery)" "reshared_post_author_url" => "https://www.linkedin.com/company/casparinc" "reshared_post_author_headline" => null "reshared_post_description" => """ Our friends at Alnylam Pharmaceuticals had a blast #CookinWithCASPAR\n 🌮 The Alnylam team delighted the guests at our CASPAR Emergency Shelter in Cambridge with a scrumptious meal!\n \n Discover how your team can also get involved in the rewarding experience of #CookinWithCASPAR by visiting https://lnkd.in/dwF2afW7\n \n #Alnylamproud #Homelessness #Neighbors #CommunityService #VolunteerWork #CorporateSocialResponsibility #TeamBuilding """ "reshared_post_followers" => 98 "reshared_post_date" => "1w" "last_updated" => "2023-08-07 01:19:17" "deleted" => 1 ] [ "id" => 249843716 "company_id" => 8900492 "urn" => "urn:li:activity:7080548614355210241" "followers" => 160189 "date" => "2w" "description" => """ Around the globe, Alnylam colleagues celebrated #Pride2023 all month long. Our Sexuality and Gender Alliance (SAGA) employee resource network led the way with various events, including tie-dye parties, discussion panels, and of course, attending #BostonPride for the People in our home state!\n \n We’re #AlnylamProud of our employees who show their pride and continue to advance, advocate for and support diversity, equity and inclusion at Alnylam and in our communities. #PrideMonth #Pride """ "reactions_count" => 196 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-07 01:19:17" "deleted" => 1 ] [ "id" => 249843717 "company_id" => 8900492 "urn" => "urn:li:activity:7079866047880650753" "followers" => 160189 "date" => "3w" "description" => "#ICYMI: Earlier today, a new episode of Access Health aired on Lifetime Television featuring John’s journey to being diagnosed with #hATTR #amyloidosis, an inherited #RareDisease, and expert insights from Dr. Robert Gottlieb, who discusses common signs and symptoms, diagnostic approaches, and an available treatment option. https://bit.ly/3CQ8XVG" "reactions_count" => 59 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-07 01:19:17" "deleted" => 1 ] [ "id" => 277398876 "company_id" => 8900492 "urn" => "urn:li:activity:7092837276971331584" "followers" => 162642 "date" => "2d" "description" => """ This morning, we reported Q2 2023 financial results and highlights of recent period activity. We’re proud of the progress we’ve made across our business and how we continue to push the #RNAiRevolution forward. Join us for a LIVE webcast TODAY at 8:30 AM ET to hear from our leadership or access the replay later in the day at: https://bit.ly/374c75E. \n \n Read the Q2 financial results press release: https://bit.ly/3QnGvCg\n \n #RNAi #siRNA """ "reactions_count" => 298 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-20 10:36:02" "deleted" => 1 ] [ "id" => 277398877 "company_id" => 8900492 "urn" => "urn:li:activity:7092260560775299073" "followers" => 162642 "date" => "4d" "description" => "The New England Journal of Medicine (NEJM Group) published results from the Phase 1 study of our investigational #RNAi therapeutic in development for treatment of # hypertension. Learn more about the study and its findings in the NEJM Quick Take video." "reactions_count" => 287 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-20 10:36:02" "deleted" => 1 ] [ "id" => 277398878 "company_id" => 8900492 "urn" => "urn:li:activity:7092142024539131904" "followers" => 162642 "date" => "4d" "description" => """ This year we celebrate #RNADay and the 5th anniversary of the world’s 1st approved #RNAi therapeutic (and our 1st commercial medicine), approved by the FDA on Aug. 10, 2018, ushering in the #RNAiRevolution.\n \n Expand your RNA knowledge by learning more about #RNAiTherapeutics and our pipeline: https://bit.ly/3oR8r2l.\n \n #GeneSilencing #siRNA #DNA #mRNA """ "reactions_count" => 276 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-20 10:36:02" "deleted" => 1 ] [ "id" => 277398879 "company_id" => 8900492 "urn" => "urn:li:activity:7091812308481363968" "followers" => 162642 "date" => "5d" "description" => "This Thursday, 8/3 at 8:30 AM ET, we'll be sharing 2nd Quarter 2023 financial results during a LIVE webcast. A replay will be available at the link below later in the day. #RNAi #RNAitherapeutics #siRNA https://bit.ly/374c75E" "reactions_count" => 21 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-20 10:36:02" "deleted" => 1 ] [ "id" => 277398880 "company_id" => 8900492 "urn" => "urn:li:activity:7090702958253756416" "followers" => 162642 "date" => "1w" "description" => """ #NowHiring: Commercial Business Account Executives, TTR and Rare focused. More about these BAE opportunities. ⬇\n \n Within their territories, these roles will:\n - Build relationships with healthcare professionals\n - Identify market development opportunities\n - Work closely with stakeholders across commercial, compliance, legal, market access, and patient care centers\n \n Learn more about Alnylam’s award-winning culture, pioneering science, and how you can be part of the #RNAiRevolution that’s transforming the lives of patients worldwide: Alnylam.com/Careers.\n \n BAE, TTR - Sarasota, FL: https://bit.ly/3YctjSz\n BAE, TTR - Nashville, TN: https://bit.ly/477rjPG\n BAE, TTR - Grand Rapids, ML: https://bit.ly/45mD1o7\n BAE, Rare - San Diego, CA: https://bit.ly/3OwycTh\n \n #Sarasota #GrandRapids #Nashville #SanDiego """ "reactions_count" => 37 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-20 10:36:02" "deleted" => 1 ] [ "id" => 277398881 "company_id" => 8900492 "urn" => "urn:li:activity:7090579129892302849" "followers" => 162642 "date" => "2w" "description" => "Healthcare Professionals: Timely diagnosis of #hATTR #amyloidosis is critical, as the disease can progress rapidly and lead to long-term complications. Learn more from Dr. Michael Polydefkis in a sponsored article, who explains the polyneuropathy manifestations of this #RareDisease and what physicians should look out for to ensure a prompt diagnosis – including family history and symptoms like neuropathic pain, numbness and difficulty walking – and an available treatment option. http://bit.ly/3iztOpt" "reactions_count" => 57 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-20 10:36:02" "deleted" => 1 ] [ "id" => 277398882 "company_id" => 8900492 "urn" => "urn:li:activity:7090357216569876480" "followers" => 162642 "date" => "1w" "description" => "This summer, Alnylam employees joined Courageous Sailing's Corporate Challenge in support of the Courageous Sailing Center for Youth, Inc. summer program! Our sailors competed in 4 races in the #BostonHarbor with 15 other corporate teams. Through this Charity Regatta, we're #AlnylamProud to help #Boston kids dive into hands-on science, develop leadership skills, gain confidence and explore the Boston Harbor! #CSR" "reactions_count" => 344 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-20 10:36:02" "deleted" => 1 ] [ "id" => 277398883 "company_id" => 8900492 "urn" => "urn:li:activity:7089976246742183936" "followers" => 162642 "date" => "1w" "description" => """ #DYK? July is #DisabilityPride Month! Led by our recently launched ACCESS disability ERN (employee resource network), Alnylam employees work year-round to promote #accessibility and equity by fostering a culture where disabled individuals feel safe, inspired and empowered to be themselves while advancing their career and our mission. #DisabilityPrideMonth #a11y #DisabilityInclusion\n \n Video description in comments. """ "reactions_count" => 111 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-20 10:36:02" "deleted" => 1 ] [ "id" => 277398884 "company_id" => 8900492 "urn" => "urn:li:activity:7089693044425244672" "followers" => 162642 "date" => "1w" "description" => "Fortune and Great Place To Work US named Alnylam a Best Workplace for Millennials for 2023! #AlnylamProud to be #19 out of the top 100 “Large” companies, making us the highest ranked #Biotechnology & Pharmaceuticals company listed." "reactions_count" => 302 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-20 10:36:02" "deleted" => 1 ] [ "id" => 277398885 "company_id" => 8900492 "urn" => "urn:li:activity:7089329374394511360" "followers" => 162642 "date" => "1w" "description" => "#AlnylamProud our CEO Dr. Yvonne Greenstreet has been named by endpts as one of the top 20 women leading #biopharma R&D. She shares Alnylam's outlook on the #RNAiRevolution and her plans for the next 20 years." "reactions_count" => 154 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-20 10:36:02" "deleted" => 1 ] [ "id" => 337921878 "company_id" => 8900492 "urn" => "urn:li:activity:7117110231800627201" "followers" => null "date" => "6h" "description" => "This morning, we shared an update on our supplemental New Drug Application (sNDA) for patisiran for the treatment of the cardiomyopathy of ATTR amyloidosis. https://bit.ly/3tpdug8" "reactions_count" => 136 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 21:41:04" "deleted" => 1 ] [ "id" => 337921879 "company_id" => 8900492 "urn" => "urn:li:activity:7115411693978927104" "followers" => null "date" => "4d" "description" => "Our dedicated uLearn with Alnylam team had another successful weekend at the Cambridge Science Festival, championing #STEM education! 🚀 Our team had a blast educating young minds about #RNA complementarity by building #DNA with pipe cleaners. Thank you to all the volunteers who made this event a…" "reactions_count" => 134 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 21:41:04" "deleted" => 1 ] [ "id" => 337921880 "company_id" => 8900492 "urn" => "urn:li:activity:7115229130865917952" "followers" => null "date" => "1mo" "description" => "People living with #hATTR #amyloidosis can experience symptoms that affect many different parts of the body which resemble those of other conditions. Cece reached her tipping point and talked to her doctor seeking the right diagnosis. Learn more: https://bit.ly/2SQrDgK" "reactions_count" => 65 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 21:41:04" "deleted" => 1 ] [ "id" => 337921881 "company_id" => 8900492 "urn" => "urn:li:activity:7113540700511584257" "followers" => null "date" => "1w" "description" => "Alnylam Assist® is committed to providing support to patients throughout their treatment with an Alnylam product. Alnylam Case Managers can help verify insurance coverage benefits, discuss financial assistance options and provide educational resources. https://bit.ly/3URXbSy" "reactions_count" => 82 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 21:41:04" "deleted" => 1 ] [ "id" => 337921882 "company_id" => 8900492 "urn" => "urn:li:activity:7113235038195851266" "followers" => null "date" => "1w" "description" => "Healthcare Professionals: Although kidney stones are the most common, and often the first symptom of primary #hyperoxaluria type 1 (PH1), not all people with PH1 will have stones. Learn to recognize the signs and symptoms of PH1 in children and adults and how you can test for this #RareDisease. http://bit.ly/2Sbnc0N" "reactions_count" => 130 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 21:41:04" "deleted" => 1 ] [ "id" => 337921883 "company_id" => 8900492 "urn" => "urn:li:activity:7112144512151375872" "followers" => null "date" => "1w" "description" => """ #DYK?: As the most common form of #dementia, #AlzheimersDisease (AD) affects over 30 million people worldwide. During #WorldAlzheimersMonth, take time to learn more about the signs, symptoms and risk factors for Alzheimers Disease and dementia: https://bit.ly/3AXoOjN.\n \n #WorldAlzMonth """ "reactions_count" => 122 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 21:41:04" "deleted" => 1 ] [ "id" => 337921884 "company_id" => 8900492 "urn" => "urn:li:activity:7110991140341907458" "followers" => null "date" => "2w" "description" => """ ¡Feliz mes de la herencia hispana y latina! Happy #HispanicHeritage Month!\n \n All year long at Alnylam, we celebrate Hispanic and Latin American culture with Armonía, our Latine-based employee resource network. \n \n To celebrate #HispanicHeritageMonth2023, we’re partnering with our #biopharma neighbors Takeda alongside Latinos in Bio, a non-profit dedicated to creating opportunities for Latine professionals in the #LifeSciences industry. We’re bringing together Hispanic and Latine professionals and allies for an immersive celebration of culture through music, food, and salsa dancing!\n \n Learn more about Alnylam culture: https://bit.ly/3LAhbpv """ "reactions_count" => 85 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 21:41:04" "deleted" => 1 ] [ "id" => 337921885 "company_id" => 8900492 "urn" => "urn:li:activity:7110721855522496512" "followers" => null "date" => "1mo" "description" => "Symptoms of #hATTR #amyloidosis can vary widely and resemble other many other conditions. The tipping point is where symptoms can no longer be overlooked. Learn more about this #RareDisease and how it affects different parts of the body: https://bit.ly/2SQrDgK" "reactions_count" => 131 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 21:41:04" "deleted" => 1 ] [ "id" => 337921886 "company_id" => 8900492 "urn" => "urn:li:activity:7110261443257581568" "followers" => null "date" => "2w" "description" => "Exciting advances and clinical successes have ushered in a new era for nucleic acid #medicines. We’re proud to be partnering with Nature Portfolio, UMass Chan Medical School, Worcester Polytechnic Institute and Moderna to organize the upcoming (Oct 17-19) Cracking the Code: The Dawn of Nucleic Acid Medicines conference. This in-person conference features an A-list group of keynoters and panelists from across our #biopharma ecosystem. It aims to foster important dialog about opportunities and upcoming challenges and to create connections that can lead to new collaborations. Learn more and secure your seat today! #biotechnology #RNA #RNAi #RNAiTherapeutics #CrackingTheCode23" "reactions_count" => 125 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 21:41:04" "deleted" => 1 ] [ "id" => 337921887 "company_id" => 8900492 "urn" => "urn:li:activity:7109882289248985088" "followers" => null "date" => "2w" "description" => "Herzlichen glückwunsch, congratulations, to our German team who is celebrating the opening of our new office in #Munich! We’re #AlnylamProud and thrilled for them as they begin a new chapter together in a city of science and innovation." "reactions_count" => 670 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 21:41:04" "deleted" => 1 ] [ "id" => 393747707 "company_id" => 8900492 "urn" => "urn:li:activity:7133422190565171202" "followers" => null "date" => "3d" "description" => "As November comes to a close, we’d like to pause to recognize the family members, friends and others who are #caregivers to people living with #RareDiseases and other conditions during #NationalCaregiversMonth and every day. #NFCM #CaringAroundTheClock" "reactions_count" => 74 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-01 19:33:48" "deleted" => 1 ] [ "id" => 393747708 "company_id" => 8900492 "urn" => "urn:li:activity:7133124840902811649" "followers" => null "date" => "4d" "description" => "#hATTR #amyloidosis can impact multiple organs and symptoms can become more severe over time. So early diagnosis and treatment are crucial to treat this #RareDisease. #ATTR https://bit.ly/3QPAr4l" "reactions_count" => 57 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-01 19:33:48" "deleted" => 1 ] [ "id" => 393747709 "company_id" => 8900492 "urn" => "urn:li:activity:7132776960421748738" "followers" => null "date" => "5d" "description" => """ Congratulations to the graduates of MassBioEd Foundation's #Biomanufacturing Apprenticeship program! This graduating class included five new apprentices who are joining the Alnylam team.\n \n We’re #AlnylamProud to be an education partner for this important high-tech workforce development program in Massachusetts, and excited for all of the graduates!\n \n #RNAiTherapeutics #RNAi #RNAiRevolution """ "reactions_count" => 94 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-01 19:33:48" "deleted" => 1 ] [ "id" => 393747710 "company_id" => 8900492 "urn" => "urn:li:activity:7132726353912590339" "followers" => null "date" => "5d" "description" => "Colin began to have a myriad of health problems as an adult, including abdominal pain, seizures and eventually episodes of paralysis in his arms and legs. Finally, he was diagnosed with acute hepatic #porphyria (AHP) after years of searching for answers and multiple misdiagnoses. Learn more about Colin and AHP – an inherited #RareDisease – in Porphyria News (BioNews Inc.), sponsored by Alnylam: https://bit.ly/47gm3Zq" "reactions_count" => 20 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-01 19:33:48" "deleted" => 1 ] [ "id" => 393747711 "company_id" => 8900492 "urn" => "urn:li:activity:7132369718748831744" "followers" => null "date" => "6d" "description" => """ Congratulations to Team Nephrogen - winners of the second-ever Alnylam Bioventure Challenge. Developed in partnership with Nucleate, the Challenge is a #biotechnology #entrepreneurship competition that seeks to support promising #biotech founders as they grow and scale their early-stage companies.\n \n Finalist teams from Nucleate’s Activator program competed for the John Maraganore Science Entrepreneurship Award, named in honor of our former and founding CEO. Thank you to all of the impressive finalists who pitched! It was an incredible and inspiring day. """ "reactions_count" => 271 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-01 19:33:48" "deleted" => 1 ] [ "id" => 393747712 "company_id" => 8900492 "urn" => "urn:li:activity:7132363900125089792" "followers" => null "date" => "6d" "description" => "The symptoms of #hATTR #amyloidosis can vary widely. Learn more about the signs to help identify this #RareDisease more quickly and shorten the time to diagnosis. #ATTR https://bit.ly/40LQHHU" "reactions_count" => 79 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-01 19:33:48" "deleted" => 1 ] [ "id" => 393747713 "company_id" => 8900492 "urn" => "urn:li:activity:7131716959506702337" "followers" => null "date" => "1w" "description" => """ For Alnylam, a big part of pioneering #RNAiTherapeutics was developing the platform technology that makes this innovative new class of medicines possible, and figuring out how to manufacture a type of medicine no one had ever manufactured before. That’s why it’s so gratifying to be recognized by Deloitte as part of their Technology #Fast500 for the fourth year in a row.\n \n Read the list: https://bit.ly/3XipbQm\n \n #RNAi #RNAiRevolution #siRNA #biomanufacturing #TechnologyFast500 #Deloitte """ "reactions_count" => 76 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-01 19:33:48" "deleted" => 1 ] [ "id" => 393747714 "company_id" => 8900492 "urn" => "urn:li:activity:7131336543859810305" "followers" => null "date" => "1w" "description" => "Our CEO Dr. Yvonne Greenstreet joined industry leaders at #FTPharma, FT Live's Global Pharma and Biotech Summit. Speaking on embracing disruption as a leader in #LifeSciences, Yvonne was thrilled to talk about the impact and responsibility executive leaders have on company culture." "reactions_count" => 97 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-01 19:33:48" "deleted" => 1 ] [ "id" => 393747715 "company_id" => 8900492 "urn" => "urn:li:activity:7131036770560823296" "followers" => null "date" => "1w" "description" => "The Alnylam Assist® program offers support services to patients who are prescribed one of our products. Our team of experts are here to help patients access and understand treatment. https://bit.ly/3URXbSy" "reactions_count" => 88 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-01 19:33:48" "deleted" => 1 ] [ "id" => 393747716 "company_id" => 8900492 "urn" => "urn:li:activity:7130935052653207552" "followers" => null "date" => "1w" "description" => "Healthcare Professionals: The symptoms of #hATTR #amyloidosis can mirror those of more common conditions, often leading to misdiagnosis and delays in diagnosis that can result in significant disease progression. In a new sponsored article in NeurologyLive, Dr. Michael Polydefkis explains why early diagnosis and management of this #RareDisease is so crucial, and an available treatment option. http://bit.ly/3XlAW7W" "reactions_count" => 50 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-01 19:33:48" "deleted" => 1 ] [ "id" => 396354960 "company_id" => 8900492 "urn" => "urn:li:activity:7136279013181792256" "followers" => null "date" => "7h" "description" => """ You probably know that genetics is the study of genes and that genes affect our health, appearance and more. But did you know that studying genes can help scientists develop new medicines and increase the likelihood that those medicines will reach patients?\n \n At Alnylam, we’ve been utilizing genetics, and a process called “genetic validation” since our founding. All of our approved medicines address genetically validated disease-targets. Now, this focus on human genetics is powering the next wave of Alnylam RNAi therapeutics.\n \n Our article (in bio) explains how. \n \n #RNAi #siRNA #biotech #RNAiRevolution #siRNA #RNAITherapeutics #genetics """ "reactions_count" => 46 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-05 16:02:26" "deleted" => 1 ] [ "id" => 396354961 "company_id" => 8900492 "urn" => "urn:li:activity:7136031867442520065" "followers" => null "date" => "1d" "description" => """ When talented, dedicated people and pioneering science come together, incredible things happen. All of us at Alnylam are so proud to be recognized by The Boston Globe as the #1 Largest Employer for the third consecutive year! This unprecedented achievement is testament to our exceptional people and the high-performing, vibrant and inclusive culture we’ve built together. I am honored to work alongside such brilliant, passionate and caring colleagues who are committed to each other and to making a positive impact for patients around the world. See this year’s list: https://bit.ly/40ZIeBa\n #AlnylamProud #CompanyCulture #RNAiRevolution """ "reactions_count" => 264 "comments_count" => 20 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-05 16:02:26" "deleted" => 1 ] [ "id" => 396354962 "company_id" => 8900492 "urn" => "urn:li:activity:7135980513093181440" "followers" => null "date" => "1d" "description" => "#AlnylamProud to be ranked Boston Globe Media's #1 Largest Employer in Massachusetts for the THIRD year in a row! This makes us a Boston Globe top place to work nine years in a row. Thank you to our incredible employees. It’s YOU that makes Alnylam a great place to work!" "reactions_count" => 224 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-05 16:02:26" "deleted" => 1 ] [ "id" => 396354963 "company_id" => 8900492 "urn" => "urn:li:activity:7135660212417400832" "followers" => null "date" => "2d" "description" => "To help prevent others from having a long and painful road to diagnosis like Colin did with acute hepatic #porphyria (AHP), he approached his State Senator to pass legislation in Oklahoma requiring newborns to be screened for a variety of #RareDiseases. Colin shares how his journey served as inspiration to advocate for others in an Alnylam-sponsored Porphyria News (BioNews Inc.) article: https://bit.ly/47gm3Zq" "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-05 16:02:26" "deleted" => 1 ] [ "id" => 396354964 "company_id" => 8900492 "urn" => "urn:li:activity:7135654974293757952" "followers" => null "date" => "2d" "description" => """ Amalia’s acute intermittent #porphyria (AIP) symptoms grew increasingly severe during her sophomore year of college. Explore Amalia’s artwork and hear her explain how she tried to claw her way back to health while experiencing monthly AHP attacks and anxiety between attacks: https://bit.ly/3zGyoXD. \n \n #RareDisease """ "reactions_count" => 45 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-05 16:02:26" "deleted" => 1 ] [ "id" => 396354965 "company_id" => 8900492 "urn" => "urn:li:activity:7135312980354695169" "followers" => null "date" => "2d" "description" => "The hereditary nature of #hATTR #amyloidosis means patients’ families are also at risk of developing this #RareDisease. David sheds light on the impact of this disease on his loved ones. #ATTR https://bit.ly/3SOxeEL" "reactions_count" => 78 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-05 16:02:26" "deleted" => 1 ] [ "id" => 396354966 "company_id" => 8900492 "urn" => "urn:li:activity:7135245955724914689" "followers" => null "date" => "3d" "description" => "On #GivingTuesday we invite you to learn more about the organizations we partner with throughout the year and around the globe to help improve the health and wellbeing of humanity." "reactions_count" => 58 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-05 16:02:26" "deleted" => 1 ] [ "id" => 396354967 "company_id" => 8900492 "urn" => "urn:li:activity:7133422190565171202" "followers" => null "date" => "1w" "description" => "As November comes to a close, we’d like to pause to recognize the family members, friends and others who are #caregivers to people living with #RareDiseases and other conditions during #NationalCaregiversMonth and every day. #NFCM #CaringAroundTheClock" "reactions_count" => 82 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-05 16:02:26" "deleted" => 1 ] [ "id" => 396354968 "company_id" => 8900492 "urn" => "urn:li:activity:7133124840902811649" "followers" => null "date" => "1w" "description" => "#hATTR #amyloidosis can impact multiple organs and symptoms can become more severe over time. So early diagnosis and treatment are crucial to treat this #RareDisease. #ATTR https://bit.ly/3QPAr4l" "reactions_count" => 68 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-05 16:02:26" "deleted" => 1 ] [ "id" => 396354969 "company_id" => 8900492 "urn" => "urn:li:activity:7132776960421748738" "followers" => null "date" => "1w" "description" => """ Congratulations to the graduates of MassBioEd Foundation's #Biomanufacturing Apprenticeship program! This graduating class included five new apprentices who are joining the Alnylam team.\n \n We’re #AlnylamProud to be an education partner for this important high-tech workforce development program in Massachusetts, and excited for all of the graduates!\n \n #RNAiTherapeutics #RNAi #RNAiRevolution """ "reactions_count" => 125 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-05 16:02:26" "deleted" => 1 ] [ "id" => 431039658 "company_id" => 8900492 "urn" => "urn:li:activity:7148752634055708675" "followers" => null "date" => "20h" "description" => "What exactly is #HealthEquity and what are our community partners doing to help residents? Recognizing each community is different, GenUnity ensures that those who are proximal to the challenges are at the forefront of shaping the solutions. https://bit.ly/3TNEsJF" "reactions_count" => 30 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-28 14:37:00" "deleted" => 1 ] [ "id" => 431039659 "company_id" => 8900492 "urn" => "urn:li:activity:7148731815103537152" "followers" => null "date" => "22h" "description" => "Join us this coming Monday at 9:45 AM PT when our CEO, Dr. Yvonne Greenstreet will provide a program update and discuss what's next in the #RNAi revolution at the 2024 J.P. Morgan Healthcare Conference. #JPM24 #RNAitherapeutics #siRNA" "reactions_count" => 119 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-28 14:37:00" "deleted" => 1 ] [ "id" => 431039660 "company_id" => 8900492 "urn" => "urn:li:activity:7147993123632160768" "followers" => null "date" => "2d" "description" => "Symptoms of #hATTR #amyloidosis can vary widely and resemble other many other conditions. The tipping point is where symptoms can no longer be overlooked. Learn more about this #RareDisease and how it affects different parts of the body: https://bit.ly/2SQrDgK" "reactions_count" => 73 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-28 14:37:00" "deleted" => 1 ] [ "id" => 431039661 "company_id" => 8900492 "urn" => "urn:li:activity:7147324825244430336" "followers" => null "date" => "4d" "description" => """ This past year has been truly remarkable as we celebrated important advancements in the science of #RNAi, worked to deliver innovative medicines for patients who need them and strengthened our award-winning culture.\n \n We take immense pride in our collective accomplishments this past year and eagerly anticipate the opportunities the new year holds. Wishing everyone a joyful new year and sending our best wishes for a fantastic 2024! 🎉 """ "reactions_count" => 503 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-28 14:37:00" "deleted" => 1 ] [ "id" => 431039662 "company_id" => 8900492 "urn" => "urn:li:activity:7145840683491237888" "followers" => null "date" => "1w" "description" => """ Since our founding, Alnylam has taken deliberate steps to understand the environmental impact of our growing footprint. We have taken substantive actions to be a steward of our planet, including how we design and expand our drug #manufacturing operations. Timothy Maines, Chief Technical Operations and Quality Officer, explains how, as part of those efforts, we’re sourcing renewable energy for energy-intensive operations.\n \n #CorporateSocialResponsibility #CSR #ESG https://bit.ly/3GsyLJ3 """ "reactions_count" => 64 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-28 14:37:00" "deleted" => 1 ] [ "id" => 431039663 "company_id" => 8900492 "urn" => "urn:li:activity:7143691941040361472" "followers" => null "date" => "2w" "description" => """ During this year’s R&D Day, we shared updates demonstrating our continued innovation and leadership in #RNAi. Our robust pipeline is primed to deliver 9 or more INDs by 2025. Read the full press release: https://bit.ly/RDDay23\n \n #RNAiTherapeutics #biotech """ "reactions_count" => 160 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-28 14:37:00" "deleted" => 1 ] [ "id" => 431039664 "company_id" => 8900492 "urn" => "urn:li:activity:7143273779417329665" "followers" => null "date" => "2w" "description" => "This week, employees at HQ got together for one of our favorite holiday traditions! They packed up donations in support of CASPAR Shelters' #GiveHomelessnessTheBOOT campaign. Our team supported over 100 of our neighbors with bags of coats, boots and other essential winter gear." "reactions_count" => 202 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-28 14:37:00" "deleted" => 1 ] [ "id" => 431039665 "company_id" => 8900492 "urn" => "urn:li:activity:7142627254580178944" "followers" => null "date" => "2w" "description" => """ We’re so #AlnylamProud to have been named one of Fortune’s Best Workplaces for Women for 2023 by Fortune and Great Place To Work US! Thank you to all of our incredibly smart, talented, and passionate women employees for all they do every day to advance our mission.\n \n At Alnylam, we believe that our long-term success and ability to deliver transformative medicines to patients requires a diverse, equitable and inclusive environment where all employees are enabled to achieve their full potential.\n \n Learn more and see the full #BestWorkplaces list: https://bit.ly/3txUNqS """ "reactions_count" => 179 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-28 14:37:00" "deleted" => 1 ] [ "id" => 431039666 "company_id" => 8900492 "urn" => "urn:li:activity:7141156459987234816" "followers" => null "date" => "3w" "description" => "Amy had taken her son, Owen, to countless providers until a doctor suspected primary #hyperoxaluria type 1 (PH1). However, Owen’s PH1 diagnosis was just the start of a long journey ahead. Learn more about the caregiver’s role in advocating for a child’s health on The Mighty. https://bit.ly/3GTfRLm" "reactions_count" => 41 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-28 14:37:00" "deleted" => 1 ] [ "id" => 431039667 "company_id" => 8900492 "urn" => "urn:li:activity:7140847510213808128" "followers" => null "date" => "3w" "description" => "Today during our 2023 R&D Day, we highlighted #RNAi therapeutic platform advances, clinical pipeline updates and more. You can access the replay of the webcast and presentation at alnylam.com/events. #RNAiTherapeutics #siRNA #RNAiRevolution" "reactions_count" => 118 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-28 14:37:00" "deleted" => 1 ] [ "id" => 490689365 "company_id" => 8900492 "urn" => "urn:li:activity:7168006595212230656" "followers" => null "date" => "1d" "description" => """ In honor of #BlackHistoryMonth, our SHADES multi-cultural ERN and Global Black Initiative (GBI) group hosted a celebration of Black culture at our headquarters in Cambridge, MA. Attended by both Alnylam colleagues and the broader community, the evening included food, music, paintings from our featured guest artist, Jaleel Draws, poetry and networking. \n \n Our CEO Dr. Yvonne Greenstreet and others, spoke about the importance of #BlackHistory and representation in #STEM. The theme was reinforced by the presentation of checks for $5k each to The Possible Zone and Science Club for Girls – two long-time community partners focusing on providing educational and entrepreneurial opportunities for under-served youth. """ "reactions_count" => 165 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-27 22:26:09" "deleted" => 1 ] [ "id" => 490689366 "company_id" => 8900492 "urn" => "urn:li:activity:7167935508977819649" "followers" => null "date" => "1d" "description" => """ #KidneyStones are one of several different signs of primary #hyperoxaluria type 1 (PH1). Throughout Kim’s life, she struggled to find answers to explain her recurrent and painful kidney stones. It wasn’t until her sister passed away from PH1 that Kim learned her stones were the result of the same inherited #RareDisease. \n \n As we approach #RareDiseaseDay, take a moment to learn more about PH1 and help us spread awareness of this rare disease: https://bit.ly/3gdtAO7 \n \n #ShareYourColors """ "reactions_count" => 57 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-27 22:26:09" "deleted" => 1 ] [ "id" => 490689367 "company_id" => 8900492 "urn" => "urn:li:activity:7167232221328699392" "followers" => null "date" => "3d" "description" => """ We’re thrilled to sponsor the MassBioEd Foundation #LifeSciences Workforce conference for the 7th year! At Alnylam we’re committed to helping build tomorrow’s high-tech workforce in our home state of #Massachusetts, making our continued support of Mass BioEd's #WorkforceDevelopment efforts important and impactful.\n \n #LSWC24 #WFD #BioManufacturing #Biotech #Biopharma """ "reactions_count" => 77 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-27 22:26:09" "deleted" => 1 ] [ "id" => 490689368 "company_id" => 8900492 "urn" => "urn:li:activity:7166882931699892224" "followers" => null "date" => "4d" "description" => "Alnylam Patient Education Liaisons (PELs) help patients who are prescribed one of our products by providing disease and product education, connecting patients to additional resources, and answering questions about treatment with our products. https://bit.ly/3URXbSy" "reactions_count" => 58 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-27 22:26:09" "deleted" => 1 ] [ "id" => 490689369 "company_id" => 8900492 "urn" => "urn:li:activity:7166800586363883520" "followers" => null "date" => "5d" "description" => "The challenges of #HealthEquity are daunting but social entrepreneurs like Emily Brown from Attane Health and Jonathan Kumar from samaritan in partnership with Acumen and Alnylam’s Challengers Program are tackling them with innovative solutions. During our first-ever Alnylam Challengers Health Equity Symposium, Saraswathy (Sara) Nochur, our Chief Diversity, Equity and Inclusion Officer, hosted a panel with Emily, Jonathan and Accumen America’s Amon Anderson to learn about bold new ideas to improve health equity." "reactions_count" => 52 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-27 22:26:09" "deleted" => 1 ] [ "id" => 490689370 "company_id" => 8900492 "urn" => "urn:li:activity:7166491868380278785" "followers" => null "date" => "5d" "description" => "At Alnylam, we are harnessing the potential of RNAi to transform cardiovascular care. We are confident that our proven ability to disrupt disease will put us at the heart of cardiac innovation. During #HeartMonth, and throughout the year, we are working to advance novel treatment options for patients with cardiovascular diseases that often negatively impact their quality of life and even carry substantial risks for mortality." "reactions_count" => 122 "comments_count" => 1 "reshared_post_author" => "Pushkal Garg" "reshared_post_author_url" => "https://www.linkedin.com/in/pushkal-garg-5161453" "reshared_post_author_headline" => "Chief Medical Officer at Alnylam Pharmaceuticals" "reshared_post_description" => """ When I used to see patients, one of my greatest frustrations was that despite available therapies to lower blood pressure or cholesterol, many patients, even those who already had established cardiovascular disease, did not receive them or did not continue them – leaving them at high risk for an MI or stroke. We’ve really needed a solution – some innovative leap in thinking or technology – to address this intractable problem.\n \n It’s #HeartMonth, and I’m proud to be leading a team at Alnylam Pharmaceuticals that’s approaching the world’s #1 killer from a different angle. We’re exploring the use of #RNAi technology to treat a number of cardiometabolic diseases. One of the exciting features of RNAi therapeutics is that they can durably reduce the levels of disease-related proteins for months at a time, which means that they can be administered infrequently – quarterly, biannually and possibly even annually in the future. This has the potential to greatly improve adherence with obviously positive implications for reducing cardiovascular risk and CV morbidity and mortality. Exciting things are happening, and medicine is changing! """ "reshared_post_followers" => null "reshared_post_date" => "6d" "last_updated" => "2024-03-27 22:26:09" "deleted" => 1 ] [ "id" => 490689371 "company_id" => 8900492 "urn" => "urn:li:activity:7166419240869183488" "followers" => null "date" => "6d" "description" => """ We’re celebrating Alnylam Italy on receiving SIX recognitions at the Life Science Excellence Awards (LSEA)! LSEA honors companies contributing to excellence and innovation in the #LifeSciences industry.\n \n We're extremely #AlnylamProud of these awards, but more than that, these recognitions motivate and inspire us in the work we do every day to improve diagnosis and enable better access to treatment for patients in need.\n \n Learn more about the awards: https://bit.ly/3SR0F7z """ "reactions_count" => 133 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-27 22:26:09" "deleted" => 1 ] [ "id" => 490689372 "company_id" => 8900492 "urn" => "urn:li:activity:7166133510452244480" "followers" => null "date" => "6d" "description" => """ We’re committed to raising awareness of #hATTR #amyloidosis, including the symptoms that Catilena experienced, which can vary widely and resemble other, often common conditions.\n \n In recognition of #RareDiseaseDay, learn more about hATTR amyloidosis and how people like Catilena have navigated life with a #RareDisease: https://bit.ly/3JgRfMs \n \n #ShareYourColors """ "reactions_count" => 86 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-27 22:26:09" "deleted" => 1 ] [ "id" => 490689373 "company_id" => 8900492 "urn" => "urn:li:activity:7166103534529146880" "followers" => null "date" => "6d" "description" => "Healthcare Professionals: Early diagnosis of #RareDiseases like primary #hyperoxaluria type 1 (PH1) is crucial given the progressive nature of the disease. Read a publication in the Journal of Pediatric Urology to learn about the clinical features exhibited in children with PH1. https://bit.ly/3wpGrdc" "reactions_count" => 76 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-27 22:26:09" "deleted" => 1 ] [ "id" => 490689374 "company_id" => 8900492 "urn" => "urn:li:activity:7165824915080740864" "followers" => null "date" => "1w" "description" => "9️⃣ days until #RareDiseaseDay! We’re sharing our colors for the #RareDisease community by lighting up our headquarters in Cambridge, MA all month long. How will you #LightUpForRare this year?" "reactions_count" => 113 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-27 22:26:09" "deleted" => 1 ] [ "id" => 523676345 "company_id" => 8900492 "urn" => "urn:li:activity:7178740557165326336" "followers" => null "date" => "9h" "description" => """ #AlnylamProud to be recognized as a 2024 USA TODAY #TopWorkplace, ranking 13 out of 100 in our category! This recognition highlights our continued commitment to fostering a positive and engaging work environment. \n \n Learn more about the Top Workplaces list: https://bit.ly/4cvk8Ua """ "reactions_count" => 147 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 22:40:51" "deleted" => 1 ] [ "id" => 523676346 "company_id" => 8900492 "urn" => "urn:li:activity:7178433687825367041" "followers" => null "date" => "1d" "description" => "Join genealogist and health education specialist Bernice Bennett on a cross-country Family Health History Road Trip as she meets members of the #hATTR #amyloidosis community to learn about the important role knowledge of family health history can play in receiving a timely diagnosis and improving health outcomes. Follow along at https://bit.ly/497sHBT. #hATTRoadTrip" "reactions_count" => 43 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 22:40:51" "deleted" => 1 ] [ "id" => 523676347 "company_id" => 8900492 "urn" => "urn:li:activity:7178044299584884736" "followers" => null "date" => "2d" "description" => """ Kidney stones in children are a common sign of primary #hyperoxaluria type 1 (PH1) in children. However, not all children with PH1 experience kidney stones. \n \n Learn more about this #RareDisease and the clinical characteristics that set it apart during #NationalKidneyMonth https://bit.ly/3gdtAO7 """ "reactions_count" => 79 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 22:40:51" "deleted" => 1 ] [ "id" => 523676348 "company_id" => 8900492 "urn" => "urn:li:activity:7177329579022274560" "followers" => null "date" => "4d" "description" => "The hereditary nature of #hATTR #amyloidosis means patients’ families are also at risk of developing this #RareDisease. David sheds light on the impact of this disease on his loved ones. #ATTR https://bit.ly/3SOxeEL" "reactions_count" => 88 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 22:40:51" "deleted" => 1 ] [ "id" => 523676349 "company_id" => 8900492 "urn" => "urn:li:activity:7177028573768101889" "followers" => null "date" => "5d" "description" => "Today we visit Julio and Renee in Somerset, Massachusetts for the last stop of the Family Health History Road Trip to hear how Julio’s #hATTR #amyloidosis diagnosis uncovered a long-standing health mystery in his family. Learn more at https://bit.ly/497sHBT. #hATTRoadTrip" "reactions_count" => 75 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 22:40:51" "deleted" => 1 ] [ "id" => 523676350 "company_id" => 8900492 "urn" => "urn:li:activity:7176941612759973889" "followers" => null "date" => "5d" "description" => """ We're incredibly proud of our ongoing partnership with Refugee Action which is helping #refugees seeking asylum build safe, happy and productive lives in the UK. This partnership is a key component of our Alnylam Challengers program and reflects the passion our people have for having a positive impact in the world beyond the medicines we make.\n \n Our corporate donation supports the ‘Pathways to Work’ program, which to date has provided nearly 400 people with vital support through mentorship by Alnylam employees and access to supplies to gain employment or start businesses. """ "reactions_count" => 136 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 22:40:51" "deleted" => 1 ] [ "id" => 523676351 "company_id" => 8900492 "urn" => "urn:li:activity:7176618966759428096" "followers" => null "date" => "6d" "description" => "We are committed to raising awareness and understanding of Acute Hepatic #Porphyria (AHP). At Alnylam, we showcase real stories of people living with this #RareDisease in our documentary Two of Me: Living with Porphyria. Watch the short film: https://bit.ly/3dMY8Cw" "reactions_count" => 76 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 22:40:51" "deleted" => 1 ] [ "id" => 523676352 "company_id" => 8900492 "urn" => "urn:li:activity:7176268180095414272" "followers" => null "date" => "1w" "description" => "Welcome to Indianapolis – the third stop of the Family Health History Road Trip! Christine tells us about her journey with #hATTR #amyloidosis and how discussing her uncle’s health history with her doctor ultimately led to her own diagnosis. Follow along the journey at https://bit.ly/497sHBT. #hATTRoadTrip" "reactions_count" => 54 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 22:40:51" "deleted" => 1 ] [ "id" => 523676353 "company_id" => 8900492 "urn" => "urn:li:activity:7176214003323404288" "followers" => null "date" => "1w" "description" => "(Answer in the comments!)" "reactions_count" => 18 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 22:40:51" "deleted" => 1 ] [ "id" => 523676354 "company_id" => 8900492 "urn" => "urn:li:activity:7175969041218441216" "followers" => null "date" => "1w" "description" => "Alnylam Patient Education Liaisons (PELs) help patients who are prescribed one of our products by providing disease and product education, connecting patients to additional resources, and answering questions about treatment with our products. https://bit.ly/3URXbSy" "reactions_count" => 70 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 22:40:51" "deleted" => 1 ] [ "id" => 542179622 "company_id" => 8900492 "urn" => "urn:li:activity:7185761684643282944" "followers" => null "date" => "29m" "description" => """ Will you be at #AMCP2024 this year? This Wednesday, April 17th at 10:45 CT Alnylam’s Sami Nasrawi, PharmD is leading a spotlight presentation: “ATTR Amyloidosis - Disease State Overview.” Join us in Theater 2 to learn more about ATTR #Amyloidosis epidemiology, clinical presentation and diagnosis of both cardiomyopathy and polyneuropathy manifestations.\n \n Learn more about AMCP: https://bit.ly/49BEjx1 """ "reactions_count" => 6 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 15:27:57" "deleted" => 1 ] [ "id" => 542179623 "company_id" => 8900492 "urn" => "urn:li:activity:7185652090604593153" "followers" => null "date" => "7h" "description" => "2023 saw significant milestones for Alnylam with exciting advances in our #RNAiTherapeutics pipeline and platform, and meaningful impact for patients around the world with our approved medicines. In her annual reflection, our CEO Dr. Yvonne Greenstreet shares her thoughts on the year that was and what she’s looking forward to in 2024. #RNAi https://bit.ly/4cV0nWi" "reactions_count" => 115 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 15:27:57" "deleted" => 1 ] [ "id" => 542179624 "company_id" => 8900492 "urn" => "urn:li:activity:7184597608047235072" "followers" => null "date" => "3d" "description" => """ US Healthcare Professionals: Going to American Academy of Neurology Annual Meeting this weekend? \n \n Come find us at booth 725 to meet our team and learn about exciting advancements in the use of #RNAinterference (RNAi) for treating the polyneuropathy of #hATTR #amyloidosis. Learn more: https://bit.ly/3Jh4xdq\n \n #AANAM """ "reactions_count" => 66 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 15:27:57" "deleted" => 1 ] [ "id" => 542179625 "company_id" => 8900492 "urn" => "urn:li:activity:7183865222309281792" "followers" => null "date" => "5d" "description" => "Although Amalia was relieved to finally know her diagnosis of acute intermittent #porphyria (AIP), she continued to struggle with painful, severe AHP attacks and frequent hospitalizations. Learn more about her journey with AHP at Alnylam’s online gallery: https://bit.ly/3zGyoXD" "reactions_count" => 72 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 15:27:57" "deleted" => 1 ] [ "id" => 542179626 "company_id" => 8900492 "urn" => "urn:li:activity:7183561933667602432" "followers" => null "date" => "6d" "description" => "Another successful ACC in the books! We were thrilled to present important new data on #RNAi therapeutics in #cardiology and interact with so many cardiologists interested in learning more about how we’re pushing the boundaries of science with this technology to improve patient outcomes. #RNAiTherapeutics #siRNA #cardiology #ACC24" "reactions_count" => 292 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 15:27:57" "deleted" => 1 ] [ "id" => 542179627 "company_id" => 8900492 "urn" => "urn:li:activity:7183137020792197121" "followers" => null "date" => "1w" "description" => "After a doctor prescribes one of our products to a patient, they are partnered with an Alnylam Case Manager who has expertise in helping patients get started on treatment and providing product support. https://bit.ly/3URXbSy" "reactions_count" => 62 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 15:27:57" "deleted" => 1 ] [ "id" => 542179628 "company_id" => 8900492 "urn" => "urn:li:activity:7182814447344742400" "followers" => null "date" => "1w" "description" => """ Earlier today at the American College of Cardiology Annual Scientific Session, we shared full results from our KARDIA-2 Phase 2 study of zilebesiran, an investigational #RNAi therapeutic for the treatment of #hypertension. \n \n These results add to the robust body of evidence from the KARDIA clinical program, showing how this investigational RNAi therapeutic may help patients with hypertension who do not respond to current standard of care antihypertensives. Join our investor webcast today at 7:00 p.m. ET to learn more: https://bit.ly/43N1OSm \n \n #siRNA #ACC24 """ "reactions_count" => 83 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 15:27:57" "deleted" => 1 ] [ "id" => 542179629 "company_id" => 8900492 "urn" => "urn:li:activity:7182710250234376193" "followers" => null "date" => "1w" "description" => """ Today, we presented full results of our KARDIA-2 Phase 2 study as a late-breaking clinical trial at the American College of Cardiology Annual Scientific Session. The study evaluated zilebesiran, an investigational #RNAi therapeutic for the treatment of #hypertension, when added to standard of care antihypertensives. Learn more: https://bit.ly/43N1OSm \n \n #siRNA #ACC24 """ "reactions_count" => 441 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 15:27:57" "deleted" => 1 ] [ "id" => 542179630 "company_id" => 8900492 "urn" => "urn:li:activity:7182475408800415745" "followers" => null "date" => "1w" "description" => "US Healthcare Professionals: Have a medical inquiry? Connect with Alnylam Medical via our RNAiScience website to use our MSL Locator tool or submit a Medical Information Request." "reactions_count" => 96 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 15:27:57" "deleted" => 1 ] [ "id" => 542179631 "company_id" => 8900492 "urn" => "urn:li:activity:7182346565766762497" "followers" => null "date" => "1w" "description" => """ With one Alnylam-discovered CV medicine already approved and a robust pipeline of investigational #RNAi therapeutics, we believe that Alnylam (and RNAi) are at the heart of cardiac innovation. \n \n We’re excited to be at the American College of Cardiology Scientific Session this weekend sharing data in #hypertension and #ATTR #cardiomyopathy and invite #cardiologists to learn more about the science of #RNAiTherapeutics: https://bit.ly/3oR8r2l \n \n #ACC24 #RNAinterference #siRNA #cardiology #GeneSilencing """ "reactions_count" => 413 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 15:27:57" "deleted" => 1 ] [ "id" => 585519487 "company_id" => 8900492 "urn" => "urn:li:activity:7199756225943588865" "followers" => null "date" => "9h" "description" => """ In recognition of Global Porphyria Day, our employees around the world showed their support for the acute hepatic #porphyria (AHP) community by going #PurpleForPorphyria. \n \n Earlier this week, we also had the opportunity to sit down with Heather, who is living with AHP, along with patient advocacy leaders Nicole Castellano of the American Porphyria Foundation and Kristen Wheeden of the United Porphyrias Association, and porphyria expert Dr. Rebecca Karp. Together, they shared their #MyPorphyria stories and discussed the important role of advocacy, barriers to diagnosing AHP and how we can help raise awareness of this #RareDisease. \n \n #GPD2024 """ "reactions_count" => 62 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 15:45:12" "deleted" => 1 ] [ "id" => 585519488 "company_id" => 8900492 "urn" => "urn:li:activity:7199441631022886914" "followers" => null "date" => "1d" "description" => "With warmer months and family gatherings ahead, summer is the perfect time to discuss health with your loved ones. Hear from Renee and her father, Julio, who uncovered a health mystery that goes back generations at a family reunion. Learn more about #hATTR #amyloidosis here: https://bit.ly/3QPohJd #hATTRoadTrip" "reactions_count" => 33 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 15:45:12" "deleted" => 1 ] [ "id" => 585519489 "company_id" => 8900492 "urn" => "urn:li:activity:7199404123857829888" "followers" => null "date" => "1d" "description" => "We shared new 54-month results from our Phase 2 open-label extension study to evaluate the long-term administration of our #RNAi therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1) at the 61st European Renal Association Congress (#ERA24). Learn more about the findings: https://bit.ly/3VbFQpJ" "reactions_count" => 182 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 15:45:12" "deleted" => 1 ] [ "id" => 585519490 "company_id" => 8900492 "urn" => "urn:li:activity:7199027043592740865" "followers" => null "date" => "2d" "description" => """ Across our offices, we’re recognizing #MentalHealth awareness month with programming and activities. In our Cambridge HQ and other offices yesterday, employees had the opportunity to build their own mental health kits and our CEO Dr. Yvonne Greenstreet got in on the action! \n \n #MentalHealthAwearenessMonth #CorporateWellness """ "reactions_count" => 111 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 15:45:12" "deleted" => 1 ] [ "id" => 585519491 "company_id" => 8900492 "urn" => "urn:li:activity:7198721757128572929" "followers" => null "date" => "3d" "description" => """ Can we geek out for a sec?! Among the many breakthroughs that our founders made when they started collaborating at the Massachusetts Institute of Technology (MIT) in 2000 was the ability to synthesize small interfering RNAs (siRNAs) and transfect them into cells. This pioneering work in #RNAinterference kicked off an era of intense development of #RNAiTherapeutics led by Alnylam, which they founded in 2002. That spirit of discovery and commitment to R&D leadership in RNAi drives us to this day and with it, the #RNAiRevolution. \n \n Read all about Alnylam's, and RNAi's, journey from interesting science to transformative new class of medicines in a new open access article from MIT News: https://bit.ly/3QNfcRd\n \n #RNAi #siRNA #MITnews #biotech #DrugDiscovery #RNAiRevolution #AlnylamScienceSpotlight """ "reactions_count" => 171 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 15:45:12" "deleted" => 1 ] [ "id" => 585519492 "company_id" => 8900492 "urn" => "urn:li:activity:7197434748405772288" "followers" => null "date" => "1w" "description" => "It was inspiring to celebrate our remarkable CEO, Dr. Yvonne Greenstreet, HBA’s 2024 Woman of the Year, along with our outstanding Rising Stars, Lauren Sheik and Agnes Qerimi. I am especially proud of this well-deserved recognition of Lauren, an integral member of our HR team. It is an honor to work alongside such dedicated and passionate women who are making a transformative impact both at Alnylam Pharmaceuticals and in the #healthcare industry. Congratulations to these extraordinary women! #womeninleadership #HBA #AlnylamProud" "reactions_count" => 39 "comments_count" => 1 "reshared_post_author" => "Dr. Yvonne Greenstreet" "reshared_post_author_url" => "https://www.linkedin.com/in/dr-yvonne-greenstreet-2b00389" "reshared_post_author_headline" => "Chief Executive Officer, Alnylam Pharmaceuticals" "reshared_post_description" => """ A huge thank you to the Healthcare Businesswomen’s Association for an incredibly inspiring event on Friday to recognize the contributions of women in our industry who are making an extraordinary impact. And congratulations to all of this year’s HBA honorees including Alnylam Pharmaceuticals’s own Rising Stars, Lauren Sheik and Agnes Qerimi.\n \n The enormous promise we hold in health care to develop medicines that create hope and transform the lives of millions will require the kind of transformational leadership that HBA celebrates and enables.\n \n I am proud to serve as HBA’s 2024 Woman of the Year and look forward to supporting the critical work of this amazing community so deeply committed to advancing the impact of women in our field and in society. \n \n #HBAWOTY2024 """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2024-06-08 15:45:12" "deleted" => 1 ] [ "id" => 585519493 "company_id" => 8900492 "urn" => "urn:li:activity:7197268911552110593" "followers" => null "date" => "1w" "description" => """ We’re #AlnylamProud proud to have supported the American Heart Association (AHA) Heart Ball in Boston earlier this month. \n \n At Alnylam, we strive to be at the heart of cardiac innovation, however, we cannot do it alone. Our collective effort with the patient community is vital to making a true impact. \n \n Together we are committed to making better health outcomes a reality for people living with #cardiovascular diseases, including #hypertension. #WorldHypertensionDay """ "reactions_count" => 161 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 15:45:12" "deleted" => 1 ] [ "id" => 585519494 "company_id" => 8900492 "urn" => "urn:li:activity:7197196750892269568" "followers" => null "date" => "1w" "description" => """ In our recently published 2023 Corporate Responsibility Report, we detail our efforts to help address health inequities and remove barriers to medicines and health care around the globe. \n \n Through our own work, and by partnering with a broad range of stakeholders, we believe that together, we can unleash the power of pioneering science, entrepreneurial ideas, and social investments to improve health outcomes for all. Learn more and download the report at https://bit.ly/3MpXSjX \n \n #CorporateResponsibility #CSR #ESG """ "reactions_count" => 160 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 15:45:12" "deleted" => 1 ] [ "id" => 585519495 "company_id" => 8900492 "urn" => "urn:li:activity:7196830584029990912" "followers" => null "date" => "1w" "description" => "Living with a #RareDisease like acute hepatic #porphyria (AHP) can be a challenging and isolating experience. Hear from Veronica to find out how she found strength in her loved ones while coping with her illness. https://bit.ly/44DICan #MyPorphyria #GPD2024" "reactions_count" => 86 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 15:45:12" "deleted" => 1 ] [ "id" => 585519496 "company_id" => 8900492 "urn" => "urn:li:activity:7196542883833757696" "followers" => null "date" => "1w" "description" => """ Today is International #HuntingtonsDisease Awareness Day – an important day for spreading awareness of this devastating neurodegenerative disease.\n \n We recently sponsored the Huntington Disease Society of America (HDSA), Northeast chapter’s “New England Celebration of Hope” fundraiser, which was held in Lexington, MA with a murder mystery theme. Our team was incredibly thankful for the opportunity to meet people impacted by this disease, including patient caregivers such as Cheryl (center). We thank and applaud the HDSA and its members for their leadership and advocacy efforts!\n \n Learn more about Huntington's Disease: https://hdsa.org/ """ "reactions_count" => 172 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 15:45:12" "deleted" => 1 ] [ "id" => 599474517 "company_id" => 8900492 "urn" => "urn:li:activity:7202702191806009346" "followers" => null "date" => "2d" "description" => "Through the Alnylam Assist® program, patients have access to Alnylam Patient Education Liaisons (PELs), professionals who are experienced in providing disease and product education to patients and their family members. https://bit.ly/3URXbSy" "reactions_count" => 74 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-14 00:19:40" "deleted" => 1 ] [ "id" => 599474518 "company_id" => 8900492 "urn" => "urn:li:activity:7202300382071402496" "followers" => null "date" => "4d" "description" => """ Headed to Philadelphia for the American Transplant Congress (ATC)? Stop by Booth 218 to learn more about our work in primary #hyperoxaluria type 1 (PH1) and join us on Sunday, June 2 at 2:30 p.m. ET for our PH1 symposium. Learn more: https://bit.ly/3R71XLz\n \n #ATC2024Philly #RNAiTherapeutics #RNAi #siRNA """ "reactions_count" => 63 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-14 00:19:40" "deleted" => 1 ] [ "id" => 599474519 "company_id" => 8900492 "urn" => "urn:li:activity:7201568054353215488" "followers" => null "date" => "6d" "description" => """ Led by our SHADES: InspirASIAN Employee Resource Network, we’re proud to Celebrate #AAPIHeritageMonth. All year long, InspirASIAN, as part of our SHADES multicultural network, works to foster connections, professional development and mentoring while celebrating the diverse cultures represented by the Asian and Asian American Pacific Islander community.\n \n #AAPI #AAPIMonth """ "reactions_count" => 87 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-14 00:19:40" "deleted" => 1 ] [ "id" => 599474520 "company_id" => 8900492 "urn" => "urn:li:activity:7201252775685410817" "followers" => null "date" => "6d" "description" => """ Did you know that RNA interference (RNAi) is a naturally occurring cellular process that’s already at work inside your body? It has two primary functions – to regulate gene expression (i.e., making new proteins) and viral defense. Alnylam scientists have harnessed this natural process to treat specific diseases. \n \n Are you #ScienceCurious to know more? Read this Nature Portfolio article (sponsored content) to learn how RNAi therapeutics, and Alnylam, are disrupting disease. https://bit.ly/49YgpNq\n \n #RNAi #RNAinterference #siRNA #GeneSilencing #RNAiAmScienceCurious """ "reactions_count" => 245 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-14 00:19:40" "deleted" => 1 ] [ "id" => 599474521 "company_id" => 8900492 "urn" => "urn:li:activity:7200810978567946240" "followers" => null "date" => "1w" "description" => """ We recently shared new subgroup results from the KARDIA-1 Phase 2 study of zilebesiran, an investigational #RNAi therapeutic for the treatment of #hypertension. Learn more: https://bit.ly/3QJU66w\n \n #siRNA """ "reactions_count" => 151 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-14 00:19:40" "deleted" => 1 ] [ "id" => 599474522 "company_id" => 8900492 "urn" => "urn:li:activity:7199756225943588865" "followers" => null "date" => "1w" "description" => """ In recognition of Global Porphyria Day, our employees around the world showed their support for the acute hepatic #porphyria (AHP) community by going #PurpleForPorphyria. \n \n Earlier this week, we also had the opportunity to sit down with Heather, who is living with AHP, along with patient advocacy leaders Nicole Castellano of the American Porphyria Foundation and Kristen Wheeden of the United Porphyrias Association, and porphyria expert Dr. Rebecca Karp. Together, they shared their #MyPorphyria stories and discussed the important role of advocacy, barriers to diagnosing AHP and how we can help raise awareness of this #RareDisease. \n \n #GPD2024 """ "reactions_count" => 105 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-14 00:19:40" "deleted" => 1 ] [ "id" => 599474523 "company_id" => 8900492 "urn" => "urn:li:activity:7199441631022886914" "followers" => null "date" => "1w" "description" => "With warmer months and family gatherings ahead, summer is the perfect time to discuss health with your loved ones. Hear from Renee and her father, Julio, who uncovered a health mystery that goes back generations at a family reunion. Learn more about #hATTR #amyloidosis here: https://bit.ly/3QPohJd #hATTRoadTrip" "reactions_count" => 53 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-14 00:19:40" "deleted" => 1 ] [ "id" => 599474524 "company_id" => 8900492 "urn" => "urn:li:activity:7199404123857829888" "followers" => null "date" => "1w" "description" => "We shared new 54-month results from our Phase 2 open-label extension study to evaluate the long-term administration of our #RNAi therapeutic for the treatment of primary #hyperoxaluria type 1 (PH1) at the 61st European Renal Association Congress (#ERA24). Learn more about the findings: https://bit.ly/3VbFQpJ" "reactions_count" => 262 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-14 00:19:40" "deleted" => 1 ] [ "id" => 599474525 "company_id" => 8900492 "urn" => "urn:li:activity:7199027043592740865" "followers" => null "date" => "1w" "description" => """ Across our offices, we’re recognizing #MentalHealth awareness month with programming and activities. In our Cambridge HQ and other offices yesterday, employees had the opportunity to build their own mental health kits and our CEO Dr. Yvonne Greenstreet got in on the action! \n \n #MentalHealthAwearenessMonth #CorporateWellness """ "reactions_count" => 130 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-14 00:19:40" "deleted" => 1 ] [ "id" => 599474526 "company_id" => 8900492 "urn" => "urn:li:activity:7198721757128572929" "followers" => null "date" => "1w" "description" => """ Can we geek out for a sec?! Among the many breakthroughs that our founders made when they started collaborating at the Massachusetts Institute of Technology (MIT) in 2000 was the ability to synthesize small interfering RNAs (siRNAs) and transfect them into cells. This pioneering work in #RNAinterference kicked off an era of intense development of #RNAiTherapeutics led by Alnylam, which they founded in 2002. That spirit of discovery and commitment to R&D leadership in RNAi drives us to this day and with it, the #RNAiRevolution. \n \n Read all about Alnylam's, and RNAi's, journey from interesting science to transformative new class of medicines in a new open access article from MIT News: https://bit.ly/3QNfcRd\n \n #RNAi #siRNA #MITnews #biotech #DrugDiscovery #RNAiRevolution #AlnylamScienceSpotlight """ "reactions_count" => 227 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-14 00:19:40" "deleted" => 1 ] [ "id" => 640553528 "company_id" => 8900492 "urn" => "urn:li:activity:7216428720717213696" "followers" => null "date" => "4d" "description" => """ Sometimes, proteins your body makes can cause or contribute to disease. These proteins can be either be faulty, or healthy. RNAi therapeutics are a type of medicine, pioneered by Alnylam, that treats disease by targeting and disabling specific mRNA (messenger RNA) which tell your body how to make these unwanted proteins. #ScienceCurious to learn more about the science of #RNAi? Click here: https://bit.ly/3oR8r2l\n \n #RNAiTherapeutics #siRNA #GeneSilencing #science """ "reactions_count" => 146 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-19 09:34:14" "deleted" => 1 ] [ "id" => 640553529 "company_id" => 8900492 "urn" => "urn:li:activity:7216184091765846016" "followers" => null "date" => "5d" "description" => "With warmer months and family gatherings ahead, summer is the perfect time to discuss health with your loved ones. Hear from Renee and her father, Julio, who uncovered a health mystery that goes back generations at a family reunion. Learn more about #hATTR #amyloidosis here: https://bit.ly/3QPohJd #hATTRoadTrip" "reactions_count" => 45 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-19 09:34:14" "deleted" => 1 ] [ "id" => 640553530 "company_id" => 8900492 "urn" => "urn:li:activity:7214258478645657600" "followers" => null "date" => "1w" "description" => """ Proteins are the "workers" in the biochemistry of life and are critical to almost everything your body does, but sometimes, they can also cause or contribute to disease. RNAi therapeutics, which were pioneered by Alnylam, work by preventing the production of specific unwanted proteins. #ScienceCurious to learn more about the science of #RNAi? Read more here: https://bit.ly/3oR8r2l\n \n #RNAiTherapeutics #siRNA #GeneSilencing #science """ "reactions_count" => 277 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-19 09:34:14" "deleted" => 1 ] [ "id" => 640553531 "company_id" => 8900492 "urn" => "urn:li:activity:7214001384898097153" "followers" => null "date" => "1w" "description" => """ What a week last week! Every Alnylam achievement, RNAi therapeutics advancement and milestone (such as our HELIOS-B topline data, which we were celebrating), is made possible because of the passion, innovation and perseverance of our 2,000+ employees who are unwavering in their dedication to our mission. Together, we are leading the #RNAiRevolution.\n \n #RNAiTherapeutics #RNAi #siRNA #CompanyCulture """ "reactions_count" => 710 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-19 09:34:14" "deleted" => 1 ] [ "id" => 640553532 "company_id" => 8900492 "urn" => "urn:li:activity:7213899359732576256" "followers" => null "date" => "1w" "description" => "Healthcare Professionals: #hATTR #amyloidosis is a progressive and often fatal disease that affects multiple organs and tissues, resulting in a highly varied symptom presentation. Learn more about some different patient types that could be in your practice. https://bit.ly/3NuMgL9" "reactions_count" => 128 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-19 09:34:14" "deleted" => 1 ] [ "id" => 640553533 "company_id" => 8900492 "urn" => "urn:li:activity:7212481228589936641" "followers" => null "date" => "2w" "description" => """ RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l\n \n #RNAiTherapeutics #siRNA #GeneSilencing #RNA """ "reactions_count" => 413 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-19 09:34:14" "deleted" => 1 ] [ "id" => 640553534 "company_id" => 8900492 "urn" => "urn:li:activity:7212171283638231041" "followers" => null "date" => "2w" "description" => """ An Alnylam team took steps to raise funds for the Huntington's Disease Society of America —literally. 👣 With kids in tow, colleagues participated in Team Hope Walk last weekend on Castle Island in Boston. We’re raising awareness about this devastating #RareDisease.\n \n Learn more about #HuntingtonsDisease: https://hdsa.org/ """ "reactions_count" => 233 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-19 09:34:14" "deleted" => 1 ] [ "id" => 640553535 "company_id" => 8900492 "urn" => "urn:li:activity:7212169604708675585" "followers" => null "date" => "2w" "description" => """ It gives me immense PRIDE to attend events like today’s ‘Show your PRIDE’ lunch at Alnylam in Zug. \n \n At @AlnylamPharmaceuticals, our PRIDE theme is Diverse Equal Proud. It’s about recognizing the diversity of people within the LGBTQ+ community and the fact that everyone deserves to be proud of who they are and treated with equal respect and dignity, regardless of gender, ethnicity or background. As an Executive Sponsor of our employee network SAGA – the Sexuality And Gender Alliance – it’s wonderful to see the company come together to celebrate PRIDE Month, showing our support and allyship. Throughout June, Alnylam has been proudly decorated with rainbows – from rainbow Zoom backgrounds to rainbow lanyards, and a variety of colorful PRIDE-themed events have been held across our offices globally to celebrate acceptance and diversity.\n I’m very proud to be an ally and to work at a company that lives and breathes its commitment to inclusivity as strongly as Alnylam does. \n \n It is so important that everyone feels able to bring their authentic self to work, and to be accepted and respected for who they truly are. I have such huge admiration for everyone who has trailblazed the path to improving LGBTQ+ acceptance across the world, and to all those I know – at Alnylam and beyond – who have been on their own personal LGBTQ+ journeys. But I also know so much progress is still to be made, and each and every one of us needs to play a part in supporting this. #PRIDEmonth #PRIDE2024 #alnylamproud """ "reactions_count" => 110 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-19 09:34:14" "deleted" => 1 ] [ "id" => 640553536 "company_id" => 8900492 "urn" => "urn:li:activity:7211425928634081280" "followers" => null "date" => "2w" "description" => "Dr. Fontana, an investigator on the HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis with cardiomyopathy, shares her thoughts on the positive topline results. Full results will be presented at an upcoming medical meeting. #RNAiTherapeutics" "reactions_count" => 376 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-19 09:34:14" "deleted" => 1 ] [ "id" => 640553537 "company_id" => 8900492 "urn" => "urn:li:activity:7211058287587328000" "followers" => null "date" => "2w" "description" => "Our CEO Dr. Yvonne Greenstreet shares her thoughts on the positive Phase 3 topline results from our HELIOS-B study of vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis w/ cardiomyopathy. Read the press release: https://bit.ly/3VwvRtY #RNAitherapeutics #siRNA" "reactions_count" => 901 "comments_count" => 21 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-19 09:34:14" "deleted" => 1 ] [ "id" => 689389591 "company_id" => 8900492 "urn" => "urn:li:activity:7212481228589936641" "followers" => null "date" => "1mo" "description" => """ RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l\n \n #RNAiTherapeutics #siRNA #GeneSilencing #RNA """ "reactions_count" => 469 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-13 23:09:15" "deleted" => 1 ] [ "id" => 689389592 "company_id" => 8900492 "urn" => "urn:li:activity:7230245406708830209" "followers" => null "date" => "2d" "description" => """ We're honored to be a #Humankind100 Top 100 company for the 3rd year in a row! \n \n The commitment to having a positive impact through the innovative medicines we make and extensive community engagement, while operating ethically and transparently, is deeply personal for our employees and is engrained in every aspect of our business. Learn more about this recognition from Humankind Investments: https://bit.ly/3M7zGRV \n \n #CorporateResponsibility #ESG #Sustainability """ "reactions_count" => 142 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-13 23:09:15" "deleted" => 1 ] [ "id" => 689389593 "company_id" => 8900492 "urn" => "urn:li:activity:7230221276080939008" "followers" => null "date" => "2d" "description" => """ The sheer scale of people who continue to be displaced due to economic, social, and military conflicts is shocking. Through our Alnylam Challengers social impact program, we support organizations in Spain, the UK, the Netherlands, and Italy, providing critical services to #refugees so they can rebuild their lives with dignity. \n \n I recently visited with our Alnylam Challengers partners Refugee Action, Forward·Inc and Soleterre to hear more about the successes, challenges, and ongoing needs in each country. They described the critical work they do to help refugees prepare for careers in their new homes, from amplifying digital skills to providing language support and much more. They also highlighted how grateful they are for our employees who serve as volunteer mentors and help raise charitable donations to bolster their work. \n \n Thanks to my colleagues Marco Fossatelli Fiona McMillan Federica Stucchi Philip Davey Domenico Guajana Christine Regan Lindenboom Brendon Pires Samip Dhakal Seth Levine Sergio Bullón Marta Calomarde for their leadership and support.\n \n To learn more about our Challengers program, read this article written by Phil Davey, Alnyalm Country Manager for the UK & Ireland, and Tim Naor Hilton, Chief Executive, Refugee Action - https://lnkd.in/eRHb4nUf """ "reactions_count" => 94 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-13 23:09:15" "deleted" => 1 ] [ "id" => 689389594 "company_id" => 8900492 "urn" => "urn:li:activity:7227308186440011778" "followers" => null "date" => "1w" "description" => """ As a pioneer in RNA-based therapeutics, we relish the opportunity to engage with peers and discuss what's new and next in nucleic acid medicines. If you do too, join us and co-organizers Nature Biotechnology, Ionis Pharmaceuticals, Inc. and UC San Diego School of Medicine at the #RNAbench2bedside conference happening Dec 9-11. Learn more: https://lnkd.in/e5DmnhGA and submit an abstract through Oct 9: https://bit.ly/3WJddzQ \n \n #RNA #RNAi #RNAinterference #RNAiTherapeutics #siRNA """ "reactions_count" => 142 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-13 23:09:15" "deleted" => 1 ] [ "id" => 689389595 "company_id" => 8900492 "urn" => "urn:li:activity:7226921517874302976" "followers" => null "date" => "1w" "description" => "We’re harnessing the potential of RNA interference (RNAi) and will be presenting new data at the European Society of Cardiology Congress 2024 8/30-9/2 in London. Learn more: https://bit.ly/3X4wxZL" "reactions_count" => 279 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-13 23:09:15" "deleted" => 1 ] [ "id" => 689389596 "company_id" => 8900492 "urn" => "urn:li:activity:7224806325413683200" "followers" => null "date" => "2w" "description" => """ Happy #RNAday! RNA is truly A-mazing. It’s responsible for many things but primary among them is facilitating protein synthesis - the process by which your body makes new proteins, which are the "workers" in the biochemistry of life. But sometimes, faulty proteins, or too much of a protein, can cause or contribute to disease. \n \n Fortunately, a type of RNA can be used to treat disease! RNA interference (RNAi) therapeutics utilize small interfering RNA (siRNA) to prevent the production of these unwanted proteins. Watch this video to learn how. #ScienceCurious to learn even more? Click here: https://bit.ly/3oR8r2l\n \n #RNA #RNAi #RNAinterference #RNAiTherapeutics #siRNA #science """ "reactions_count" => 280 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-13 23:09:15" "deleted" => 1 ] [ "id" => 689389597 "company_id" => 8900492 "urn" => "urn:li:activity:7224747171697303552" "followers" => null "date" => "2w" "description" => """ We've reported Q2 2024 financial results and highlights of recent period activity. Join us LIVE TODAY at 8:30 AM ET to hear from our leadership and/or access the replay later today at: https://bit.ly/374c75E. Read the Q2 2024 financial results press release: https://bit.ly/4dpnec6\n \n #RNAi #RNAiTherapeutics #siRNA """ "reactions_count" => 244 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-13 23:09:15" "deleted" => 1 ] [ "id" => 689389598 "company_id" => 8900492 "urn" => "urn:li:activity:7223732691492315139" "followers" => null "date" => "2w" "description" => "We'll be sharing 2nd Quarter 2024 financial results this Thursday, 8/1 at 8:30 AM ET, during a LIVE webcast. Register here: https://bit.ly/374c75E and access the replay at the same link later in the day. #RNAi #RNAitherapeutics #siRNA" "reactions_count" => 58 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-13 23:09:15" "deleted" => 1 ] [ "id" => 689389599 "company_id" => 8900492 "urn" => "urn:li:activity:7222275950468587520" "followers" => null "date" => "3w" "description" => """ It's #NationalInternDay and we're celebrating the contributions of our #interns who represent the incredible potential of the next generation of #biopharma professionals! We believe that the seeds of tomorrow's breakthroughs are planted today through inclusive programs that provide opportunities to early career individuals from diverse backgrounds, including those who come to us from our partner Project Onramp.\n \n You can learn more about our Internship program here: https://bit.ly/3W6LHM8 """ "reactions_count" => 244 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-13 23:09:15" "deleted" => 1 ] [ "id" => 689389600 "company_id" => 8900492 "urn" => "urn:li:activity:7221184989307039744" "followers" => null "date" => "3w" "description" => "Innovative science is only part of the equation when it comes to developing new medicines. Clinical research relies on partnerships with health care professionals and patient advocates but most importantly, the people who choose to participate in #ClinicalTrials. Learn more about Alnylam's clinical trials: https://bit.ly/35jLcrU" "reactions_count" => 81 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-13 23:09:15" "deleted" => 1 ] [ "id" => 721992856 "company_id" => 8900492 "urn" => "urn:li:activity:7212481228589936641" "followers" => null "date" => "2mo" "description" => """ RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l\n \n #RNAiTherapeutics #siRNA #GeneSilencing #RNA """ "reactions_count" => 490 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-10 01:26:28" "deleted" => 1 ] [ "id" => 721992857 "company_id" => 8900492 "urn" => "urn:li:activity:7240013800609918976" "followers" => null "date" => "1d" "description" => "Healthcare Professionals: Check out this interactive acute hepatic #porphyria (AHP) case study to review a hypothetical diagnostic journey with AHP — see how your knowledge of this #RareDisease compares with other physicians: https://bit.ly/4dtbS7a" "reactions_count" => 43 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-10 01:26:28" "deleted" => 1 ] [ "id" => 721992858 "company_id" => 8900492 "urn" => "urn:li:activity:7239292966169718785" "followers" => null "date" => "3d" "description" => """ Have you heard the news? We're a Fast Company Best Workplace for Innovators for the 4th year in a row! 💡 🏆 🎉 This kind of recognition never gets old, especially when, according to Fast Co. it "celebrates company cultures that empower employees at all levels to improve processes, create new products, or invent new ways of doing business." Learn more and check out the full list: https://bit.ly/4gir3Sn\n \n #FastCompany #BestWorkplaces #CompanyCulture #biotech #biotechnology #biopharma """ "reactions_count" => 254 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-10 01:26:28" "deleted" => 1 ] [ "id" => 721992859 "company_id" => 8900492 "urn" => "urn:li:activity:7237482701027520514" "followers" => null "date" => "1w" "description" => """ Healthcare Professionals: Characterized by severe, diffuse abdominal pain and a range of other seemingly unrelated symptoms, acute hepatic #porphyria (AHP) can be misleading and is often misdiagnosed. \n \n Learn what to look for to better detect this #RareDisease: https://bit.ly/3mpod2h """ "reactions_count" => 84 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-10 01:26:28" "deleted" => 1 ] [ "id" => 721992860 "company_id" => 8900492 "urn" => "urn:li:activity:7237095842338238464" "followers" => null "date" => "1w" "description" => "Our team was thrilled to be in London at the European Society of Cardiology Congress discussing RNA interference (RNAi) with the global cardiology community!" "reactions_count" => 268 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-10 01:26:28" "deleted" => 1 ] [ "id" => 721992861 "company_id" => 8900492 "urn" => "urn:li:activity:7236777301001035777" "followers" => null "date" => "1w" "description" => "Managing a #RareDisease like primary #hyperoxaluria type 1 (PH1) can be difficult, so it can be helpful to work with patient advocacy groups and community members to answer questions and get more information. Hear from Kim Hollander of the Oxalosis and Hyperoxaluria Foundation in an episode of Medical Stories airing on PBS stations. https://bit.ly/3ATSDVR" "reactions_count" => 102 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-10 01:26:28" "deleted" => 1 ] [ "id" => 721992862 "company_id" => 8900492 "urn" => "urn:li:activity:7234916293731110912" "followers" => null "date" => "2w" "description" => """ Healthcare Professionals: Do you have a patient presenting with severe, diffuse abdominal pain and seemingly unrelated symptoms? It could be acute hepatic #porphyria (AHP). Random (spot) urine tests are the primary method to help diagnose AHP and a genetic test can determine the type. \n \n Learn more about testing for AHP: https://bit.ly/2RCBrKF """ "reactions_count" => 78 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-10 01:26:28" "deleted" => 1 ] [ "id" => 721992863 "company_id" => 8900492 "urn" => "urn:li:activity:7232408601321967616" "followers" => null "date" => "3w" "description" => """ Unlocking the full potential of #RNAiTherapeutics, ensuring that patients at the center of all we do and delivering value to healthcare stakeholders are what drive us to innovate. Our Chief Commercial Officer Tolga Tanguler discusses our approach to patient access in this article where you can also view our latest Patient Access Philosophy Report: https://bit.ly/3WdnzsO\n \n #PatientAccess #RNAi #RNAinterference #biotech #biopharma """ "reactions_count" => 115 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-10 01:26:28" "deleted" => 1 ] [ "id" => 721992864 "company_id" => 8900492 "urn" => "urn:li:activity:7230245406708830209" "followers" => null "date" => "4w" "description" => """ We're honored to be a #Humankind100 Top 100 company for the 3rd year in a row! \n \n The commitment to having a positive impact through the innovative medicines we make and extensive community engagement, while operating ethically and transparently, is deeply personal for our employees and is engrained in every aspect of our business. Learn more about this recognition from Humankind Investments: https://bit.ly/3M7zGRV \n \n #CorporateResponsibility #ESG #Sustainability """ "reactions_count" => 186 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-10 01:26:28" "deleted" => 1 ] [ "id" => 721992865 "company_id" => 8900492 "urn" => "urn:li:activity:7230221276080939008" "followers" => null "date" => "4w" "description" => """ The sheer scale of people who continue to be displaced due to economic, social, and military conflicts is shocking. Through our Alnylam Challengers social impact program, we support organizations in Spain, the UK, the Netherlands, and Italy, providing critical services to #refugees so they can rebuild their lives with dignity. \n \n I recently visited with our Alnylam Challengers partners Refugee Action, Forward·Inc and Soleterre to hear more about the successes, challenges, and ongoing needs in each country. They described the critical work they do to help refugees prepare for careers in their new homes, from amplifying digital skills to providing language support and much more. They also highlighted how grateful they are for our employees who serve as volunteer mentors and help raise charitable donations to bolster their work. \n \n Thanks to my colleagues Marco Fossatelli Fiona McMillan Federica Stucchi Philip Davey Domenico Guajana Christine Regan Lindenboom Brendon Pires Samip Dhakal Seth Levine Sergio Bullón Marta Calomarde for their leadership and support.\n \n To learn more about our Challengers program, read this article written by Phil Davey, Alnyalm Country Manager for the UK & Ireland, and Tim Naor Hilton, Chief Executive, Refugee Action - https://lnkd.in/eRHb4nUf """ "reactions_count" => 138 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-10 01:26:28" "deleted" => 1 ] [ "id" => 753378023 "company_id" => 8900492 "urn" => "urn:li:activity:7212481228589936641" "followers" => null "date" => "3mo" "description" => """ RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l\n \n #RNAiTherapeutics #siRNA #GeneSilencing #RNA """ "reactions_count" => 496 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-24 06:46:05" "deleted" => 1 ] [ "id" => 753378024 "company_id" => 8900492 "urn" => "urn:li:activity:7244714031222071296" "followers" => null "date" => "3d" "description" => "This World Alzheimer’s Month, take a few minutes to learn about #AlzheimersDisease (AD) and dementia. We're working with urgency to explore the potential for our RNAi therapeutics in helping to change the outlook for people living with AD. #WorldAlzMonth" "reactions_count" => 136 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-24 06:46:05" "deleted" => 1 ] [ "id" => 753378025 "company_id" => 8900492 "urn" => "urn:li:activity:7244345608105336833" "followers" => null "date" => "4d" "description" => "We shared new results from a post hoc subgroup analysis of the ENVISION Phase 3 study evaluating long-term impact of our #RNAi therapeutic for the treatment of acute hepatic #porphyria (AHP) in adults at The International Congress of Porphyrins and Porphyrias (ICPP 2024). Learn more: https://bit.ly/4ehVnLQ" "reactions_count" => 244 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-24 06:46:05" "deleted" => 1 ] [ "id" => 753378026 "company_id" => 8900492 "urn" => "urn:li:activity:7243949549415804929" "followers" => null "date" => "5d" "description" => """ We’re en route to the 56th Annual Meeting of the European Society for Pediatric Nephrology (ESPN). We hope to see you there!\n \n #ESPN2024 #RNAiTherapeutics #RNAi #siRNA """ "reactions_count" => 88 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-24 06:46:05" "deleted" => 1 ] [ "id" => 753378027 "company_id" => 8900492 "urn" => "urn:li:activity:7242874720268730368" "followers" => null "date" => "1w" "description" => """ We’re thrilled to be heading to The International Congress of Porphyrins and Porphyrias (ICPP 2024) together with members of the acute hepatic #porphyria (AHP) community, including patients and their families, caregivers, patient advocacy group leaders, clinicians, researchers and scholars. \n \n #RNAiTherapeutics #RNAi #siRNA """ "reactions_count" => 94 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-24 06:46:05" "deleted" => 1 ] [ "id" => 753378028 "company_id" => 8900492 "urn" => "urn:li:activity:7242509490363711488" "followers" => null "date" => "1w" "description" => """ 📢 Calling all researchers working on RNA-based therapeutics! Submit an abstract to the upcoming event "RNA at the Bench and Bedside IV" through Oct 9 for a chance to present your work to leaders, experts and peers in the nucleic acid medicines field. We're proud to be co-organizing this Nature Conference event with Nature Biotechnology, Ionis Pharmaceuticals, Inc. and UC San Diego School of Medicine! Attend: https://bit.ly/4glouyZ Submit: https://bit.ly/3WJddzQ \n \n #RNAbench2bedside #RNA #RNAi #RNAinterference #RNAiTherapeutics #siRNA """ "reactions_count" => 102 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-24 06:46:05" "deleted" => 1 ] [ "id" => 753378029 "company_id" => 8900492 "urn" => "urn:li:activity:7241846026649702400" "followers" => null "date" => "1w" "description" => "HCPs: Early diagnosis is critical in managing a #RareDisease like primary #hyperoxaluria type 1 (PH1). Left undiagnosed, patients are at increased risk for serious downstream health complications. Learn more from Dr. David J. Sas, pediatric nephrologist, in an episode of Medical Stories airing on PBS stations. https://bit.ly/3ATSDVR" "reactions_count" => 109 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-24 06:46:05" "deleted" => 1 ] [ "id" => 753378030 "company_id" => 8900492 "urn" => "urn:li:activity:7240774154373804032" "followers" => null "date" => "2w" "description" => "I recently had a chance to visit our UK office and connect with an amazing group of talented colleagues about our pipeline and our Company. Alnylam employees around the world show up every day with a “Challenge Accepted” mindset, committed to bringing our pioneering RNAi technology to additional patients. It’s inspiring—and a great reminder that our work is more than a job. Together, we’re changing medicine." "reactions_count" => 298 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-24 06:46:05" "deleted" => 1 ] [ "id" => 753378031 "company_id" => 8900492 "urn" => "urn:li:activity:7240013800609918976" "followers" => null "date" => "2w" "description" => "Healthcare Professionals: Check out this interactive acute hepatic #porphyria (AHP) case study to review a hypothetical diagnostic journey with AHP — see how your knowledge of this #RareDisease compares with other physicians: https://bit.ly/4dtbS7a" "reactions_count" => 70 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-24 06:46:05" "deleted" => 1 ] [ "id" => 753378032 "company_id" => 8900492 "urn" => "urn:li:activity:7239292966169718785" "followers" => null "date" => "2w" "description" => """ Have you heard the news? We're a Fast Company Best Workplace for Innovators for the 4th year in a row! 💡 🏆 🎉 This kind of recognition never gets old, especially when, according to Fast Co. it "celebrates company cultures that empower employees at all levels to improve processes, create new products, or invent new ways of doing business." Learn more and check out the full list: https://bit.ly/4gir3Sn\n \n #FastCompany #BestWorkplaces #CompanyCulture #biotech #biotechnology #biopharma """ "reactions_count" => 290 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-24 06:46:05" "deleted" => 1 ] [ "id" => 776352724 "company_id" => 8900492 "urn" => "urn:li:activity:7212481228589936641" "followers" => null "date" => "3mo" "description" => """ RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l\n \n #RNAiTherapeutics #siRNA #GeneSilencing #RNA """ "reactions_count" => 510 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 09:52:53" "deleted" => 1 ] [ "id" => 776352725 "company_id" => 8900492 "urn" => "urn:li:activity:7250551274582994944" "followers" => null "date" => "4h" "description" => """ Our research colleagues showed up strong this week at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society in Montreal. More than 25 Alnylam scientists attended to share their work, exchange ideas, and celebrate community members’ achievements as the field grows. \n \n Highlights included principal scientist Mikyung Yu, PhD presenting an OTS Paper of the Year detailing progress toward oral delivery of #RNAiTherapeutics in preclinical models, Senior Director of Clinical Research Ishir Bhan presented on an investigational #RNAi therapeutic in development for hypertension and current and former Alnylam colleagues gathering on stage to celebrate former and founding CEO John Maraganore on receiving the OTS Lifetime Achievement Award. Congrats to all!\n \n #RNAiTherapeutics #RNAinterference #siRNA """ "reactions_count" => 113 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 09:52:53" "deleted" => 1 ] [ "id" => 776352726 "company_id" => 8900492 "urn" => "urn:li:activity:7250124920179822592" "followers" => null "date" => "1d" "description" => """ U.S. Healthcare Professionals: Learn more about helping your patients manage acute hepatic #porphyria (AHP) in a PeerDirect program led by Dr. Angelika Erwin. \n \n Dr. Erwin will discuss symptoms that suggest a diagnosis of AHP, disease management options for this #RareDisease and findings from recent clinical trials of patients living with porphyria. \n \n View the session here: https://bit.ly/4e2O9ui """ "reactions_count" => 76 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 09:52:53" "deleted" => 1 ] [ "id" => 776352727 "company_id" => 8900492 "urn" => "urn:li:activity:7249738307394244608" "followers" => null "date" => "2d" "description" => """ We are pleased to announce that we have submitted a supplemental New Drug Application (sNDA) to the U.S. FDA for vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR #amyloidosis with cardiomyopathy (ATTR-CM). Read the release: https://bit.ly/47YJckw\n \n #cardiology #RNAiTherapeutics #RNAinterference """ "reactions_count" => 1018 "comments_count" => 16 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 09:52:53" "deleted" => 1 ] [ "id" => 776352728 "company_id" => 8900492 "urn" => "urn:li:activity:7249483172822880257" "followers" => null "date" => "3d" "description" => """ Congratulations to our former and founding CEO John Maraganore on being awarded the Lifetime Achievement Award by the Oligonucleotide Therapeutics Society for his incredible contributions to the advancement of #oligonucleotide therapeutics and pioneering leadership in the #RNAiRevolution! \n \n #ots24 #RNAi #RNAiTherapeutics """ "reactions_count" => 357 "comments_count" => 8 "reshared_post_author" => "Oligonucleotide Therapeutics Society" "reshared_post_author_url" => "https://www.linkedin.com/company/oligotherapeutics" "reshared_post_author_headline" => null "reshared_post_description" => """ Congratulations to John Maraganore, Ph.D. for winning the OTS Lifetime Achievement Award! \n \n #ots24 #ots #oligomeeting #oligotherapeutics #biotech #biotechnology #science #research\n \n John Maraganore """ "reshared_post_followers" => null "reshared_post_date" => "3d" "last_updated" => "2024-11-17 09:52:53" "deleted" => 1 ] [ "id" => 776352729 "company_id" => 8900492 "urn" => "urn:li:activity:7249149572076253184" "followers" => null "date" => "4d" "description" => "We extend our heartfelt congratulations to Victor Ambros and Gary Ruvkun of UMass Chan Medical School and Harvard Medical School respectively on receiving this year's #NobelPrize in Physiology or Medicine for the discovery of microRNAs. This breakthrough research helped pave the way for the incredible era of RNA-based medicines we're living in and are proud to be part of! #RNA #RNAi #RNA #science" "reactions_count" => 337 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 09:52:53" "deleted" => 1 ] [ "id" => 776352730 "company_id" => 8900492 "urn" => "urn:li:activity:7248016498214977536" "followers" => null "date" => "1w" "description" => """ Happy #ManufacturingDay! We’d like to celebrate and thank our dedicated manufacturing team whose passion for innovation and unwavering commitment to excellence bring our #RNAi therapeutics to patients around the world. Your teamwork and relentless drive to deliver on our mission for patients inspires us every day!\n \n #RNAiTherapeutics #Biotech #Biopharma #Manufacturing """ "reactions_count" => 175 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 09:52:53" "deleted" => 1 ] [ "id" => 776352731 "company_id" => 8900492 "urn" => "urn:li:activity:7247613447410978816" "followers" => null "date" => "1w" "description" => """ Healthcare Professionals: Every acute hepatic #porphyria (AHP) attack matters. Your patient’s next attack could have life-changing consequences, like irreversible neurologic damage and respiratory paralysis. \n \n Learn how timely diagnosis and management can help avoid potentially devastating outcomes: https://bit.ly/4cNnDEv """ "reactions_count" => 71 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 09:52:53" "deleted" => 1 ] [ "id" => 776352732 "company_id" => 8900492 "urn" => "urn:li:activity:7246937447471681537" "followers" => null "date" => "1w" "description" => "Healthcare Professionals: #hATTR #amyloidosis is a progressive and often fatal disease that affects multiple organs and tissues, resulting in a highly varied symptom presentation. Learn more about some different patient types that could be in your practice." "reactions_count" => 122 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 09:52:53" "deleted" => 1 ] [ "id" => 776352733 "company_id" => 8900492 "urn" => "urn:li:activity:7246575280960466945" "followers" => null "date" => "1w" "description" => """ Yesterday, we presented additional data from the HELIOS-B Phase 3 study of vutrisiran, an investigational #RNAiTherapeutic in development for the treatment of #ATTR #amyloidosis with cardiomyopathy (ATTR-CM) during the Heart Failure Society of America Annual Scientific Meeting 2024 (#HFSA24). See the data: https://bit.ly/4gDqJOm \n \n #cardiology #RNAi #RNAinterference """ "reactions_count" => 144 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 09:52:53" "deleted" => 1 ] [ "id" => 812791006 "company_id" => 8900492 "urn" => "urn:li:activity:7212481228589936641" "followers" => null "date" => "4mo" "description" => """ RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l\n \n #RNAiTherapeutics #siRNA #GeneSilencing #RNA """ "reactions_count" => 532 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-28 05:05:32" "deleted" => 1 ] [ "id" => 812791007 "company_id" => 8900492 "urn" => "urn:li:activity:7263190303203803136" "followers" => null "date" => "16h" "description" => """ We’re excited to join the American Association for the Study of Liver Diseases (AASLD) at The Liver Meeting 2024. Stop by Booth 1141 to meet the Alnylam team and learn more. We hope to see you there!\n \n #TLM24 #RNAiTherapeutics #RNAi #siRNA """ "reactions_count" => 48 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-28 05:05:32" "deleted" => 1 ] [ "id" => 812791008 "company_id" => 8900492 "urn" => "urn:li:activity:7262122798318333952" "followers" => null "date" => "3d" "description" => """ Did you know that sometimes, proteins your body makes can cause or contribute to disease? These proteins can be either be faulty, or healthy. RNAi therapeutics are a type of medicine, pioneered by Alnylam, that treats disease by targeting and disabling specific mRNA (messenger RNA) which tell your body how to make these unwanted proteins. #ScienceCurious to learn more about the science of #RNAi? Click here: https://bit.ly/3oR8r2l\n \n #RNAiTherapeutics #siRNA #GeneSilencing #science """ "reactions_count" => 142 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-28 05:05:32" "deleted" => 1 ] [ "id" => 812791009 "company_id" => 8900492 "urn" => "urn:li:activity:7261800076119805952" "followers" => null "date" => "4d" "description" => """ Last week during #Hyperoxaluria Awareness Week, Alnylam colleagues around the world wore blue to show our support for Hyperoxaluria Warriors and the primary #hyperoxaluria type 1 (PH1) community.\n \n We stand by the Oxalosis and Hyperoxaluria Foundation and join them in their commitment to raising awareness and generating change for people worldwide living with hyperoxaluria, their families and caregivers. """ "reactions_count" => 73 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-28 05:05:32" "deleted" => 1 ] [ "id" => 812791010 "company_id" => 8900492 "urn" => "urn:li:activity:7261730894619578370" "followers" => null "date" => "4d" "description" => "On #VeteransDay, we express our deepest gratitude to all #veterans, especially those who are part of our Alnylam family. Your dedication, honor and service make us #AlnylamProud." "reactions_count" => 279 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-28 05:05:32" "deleted" => 1 ] [ "id" => 812791011 "company_id" => 8900492 "urn" => "urn:li:activity:7260637377537232897" "followers" => null "date" => "1w" "description" => """ During #Hyperoxaluria Awareness Week, Dr. Shabbir Moochhala shares a message of hope for those living with primary hyperoxaluria type 1 (PH1).\n \n While being diagnosed with a #RareDisease like PH1 can be overwhelming, Dr. Moochhala highlights that there are resources available to support patients and their families as they navigate this journey.\n \n Learn more about PH1 and access educational resources here: https://bit.ly/40yhqJS """ "reactions_count" => 84 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-28 05:05:32" "deleted" => 1 ] [ "id" => 812791012 "company_id" => 8900492 "urn" => "urn:li:activity:7259912645414125568" "followers" => null "date" => "1w" "description" => """ It’s #Hyperoxaluria Awareness Week and we’re joining the Oxalosis and Hyperoxaluria Foundation in sending strength to Hyperoxaluria Warriors like Ziggy, who is living with primary hyperoxaluria type 1 (PH1). \n \n Hear Ziggy’s parents, Jackie and Colin, discuss his PH1 journey and learn more about the importance of raising awareness of this #RareDisease.\n \n Find out how you can get involved in showing your support for the global PH1 community: https://bit.ly/32n5ATZ """ "reactions_count" => 91 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-28 05:05:32" "deleted" => 1 ] [ "id" => 812791013 "company_id" => 8900492 "urn" => "urn:li:activity:7259203115864715264" "followers" => null "date" => "1w" "description" => """ This #Hyperoxaluria Awareness Week, hear from Hyperoxaluria Warrior Seth, who shares his journey navigating unexplained kidney failure and how genetic testing confirmed his diagnosis of primary hyperoxaluria type 1 (PH1).\n \n Learn more about PH1: https://bit.ly/3gdtAO7 """ "reactions_count" => 104 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-28 05:05:32" "deleted" => 1 ] [ "id" => 812791014 "company_id" => 8900492 "urn" => "urn:li:activity:7258116873593008130" "followers" => null "date" => "2w" "description" => "Taking strides together in the fight against #Alzheimers disease! 💜 Alnylamites recently participated in the #Walk2EndAlz. Along with colleagues around the world, they proudly raised funds in support of the Alzheimer's Association® and its mission to provide education and support to the millions of people impacted by dementia and support research to finally #ENDALZ." "reactions_count" => 219 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-28 05:05:32" "deleted" => 1 ] [ "id" => 812791015 "company_id" => 8900492 "urn" => "urn:li:activity:7257724797302853632" "followers" => null "date" => "2w" "description" => """ We've reported Q3 2024 financial results and highlights of recent period activity. Join us LIVE TODAY at 8:30 AM ET to hear from our leadership and/or access the replay later today at: https://bit.ly/374c75E. Read the Q3 2024 financial results press release: https://bit.ly/3YvCM8p\n \n #RNAi #RNAiTherapeutics #siRNA """ "reactions_count" => 159 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-28 05:05:32" "deleted" => 1 ] [ "id" => 830153041 "company_id" => 8900492 "urn" => "urn:li:activity:7212481228589936641" "followers" => null "date" => "5mo" "description" => """ RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l\n \n #RNAiTherapeutics #siRNA #GeneSilencing #RNA """ "reactions_count" => 539 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-12 11:21:48" "deleted" => 1 ] [ "id" => 830153042 "company_id" => 8900492 "urn" => "urn:li:activity:7266785059163058176" "followers" => null "date" => "2d" "description" => """ We are excited to share that the U.S. FDA has accepted our supplemental New Drug Application (sNDA) for vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR-CM. https://bit.ly/412lQJn\n \n #RNAiTherapeutics #RNAinterference #amyloidosis """ "reactions_count" => 1488 "comments_count" => 26 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-12 11:21:48" "deleted" => 1 ] [ "id" => 830153043 "company_id" => 8900492 "urn" => "urn:li:activity:7265415422798114819" "followers" => null "date" => "6d" "description" => "Another wonderful AHA is in the books! Sharing new data from our #ATTR franchise and #hypertension program alongside fellow leaders in cardiology was truly inspiring. #RNAiTherapeutics #RNAi" "reactions_count" => 293 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-12 11:21:48" "deleted" => 1 ] [ "id" => 830153044 "company_id" => 8900492 "urn" => "urn:li:activity:7264997507082948608" "followers" => null "date" => "1w" "description" => """ It was a privilege to be part of a “Big Biotech – Where Is It Going?” panel last week at the #GalienForum2024. Thank you to Phil Sharp for facilitating a fascinating conversation on the past, present and future of our industry—and thank you to fellow panelists Jane Grogan, Ray Deshaies, Ph.D., and george yancopoulos for deepening my outlook. I walked away more convinced than ever that biotech will continue to be the source of breakthrough innovation, and that it will take experienced R&D leadership, a connected ecosystem and tenacity to deliver it.\n #Biotechnology #FutureOfMedicine """ "reactions_count" => 149 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-12 11:21:48" "deleted" => 1 ] [ "id" => 830153045 "company_id" => 8900492 "urn" => "urn:li:activity:7264351811854024704" "followers" => null "date" => "1w" "description" => """ In case you missed it: We presented new data from our #ATTR franchise and #hypertension program at the American Heart Association Scientific Sessions 2024. Learn more: https://bit.ly/3OzzVGZ\n \n #AHA24 #RNAiTherapeutics #RNAi """ "reactions_count" => 126 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-12 11:21:48" "deleted" => 1 ] [ "id" => 830153046 "company_id" => 8900492 "urn" => "urn:li:activity:7264290304785100801" "followers" => null "date" => "1w" "description" => """ Drug development is a long and perilous journey with a historically high failure rate. Advances in genomic sequencing and a more human-focused approach using genetic validation of disease targets are changing that.\n \n "Our focus on genetic validation has helped our drug candidates achieve a clinical trial success rate that's six times the industry average," says Paul Nioi, Alnylam's SVP of Discovery and Translational Research.\n \n Science curious to learn more? Read about how Alnylam and others who are embracing this approach are improving the speed and odds of success in drug development in this Nature Portfolio article (sponsored content): https://bit.ly/4hJnLbJ\n \n #RNAiTherapeutics #RNAinterference #RNAi #DrugDevelopment #genetics #genomics #biotechnology #pharmaceuticals #biopharma """ "reactions_count" => 113 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-12 11:21:48" "deleted" => 1 ] [ "id" => 830153047 "company_id" => 8900492 "urn" => "urn:li:activity:7263923090617733120" "followers" => null "date" => "1w" "description" => """ At the American Heart Association Scientific Sessions 2024 (#AHA24) we presented new data on nucresiran (ALN-TTRsc04), a next-generation #RNAi therapeutic, in development for the treatment of transthyretin amyloidosis (#ATTR). See the findings: https://bit.ly/3UVskGi\n \n #RNAiTherapeutics """ "reactions_count" => 267 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-12 11:21:48" "deleted" => 1 ] [ "id" => 830153048 "company_id" => 8900492 "urn" => "urn:li:activity:7263564521124851712" "followers" => null "date" => "1w" "description" => """ We’re thrilled to connect with thousands of cardiology professionals at the American Heart Association Scientific Sessions 2024 (#AHA24) this week in Chicago.\n \n Visit us at Booth 2321 to learn more about our recent innovations in #ATTR #amyloidosis, ATTR-CM and #hypertension #RNAiTherapeutics """ "reactions_count" => 128 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-12 11:21:48" "deleted" => 1 ] [ "id" => 830153049 "company_id" => 8900492 "urn" => "urn:li:activity:7263190303203803136" "followers" => null "date" => "1w" "description" => """ We’re excited to join the American Association for the Study of Liver Diseases (AASLD) at The Liver Meeting 2024. Stop by Booth 1141 to meet the Alnylam team and learn more. We hope to see you there!\n \n #TLM24 #RNAiTherapeutics #RNAi #siRNA """ "reactions_count" => 70 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-12 11:21:48" "deleted" => 1 ] [ "id" => 830153050 "company_id" => 8900492 "urn" => "urn:li:activity:7262122798318333952" "followers" => null "date" => "2w" "description" => """ Did you know that sometimes, proteins your body makes can cause or contribute to disease? These proteins can be either be faulty, or healthy. RNAi therapeutics are a type of medicine, pioneered by Alnylam, that treats disease by targeting and disabling specific mRNA (messenger RNA) which tell your body how to make these unwanted proteins. #ScienceCurious to learn more about the science of #RNAi? Click here: https://bit.ly/3oR8r2l\n \n #RNAiTherapeutics #siRNA #GeneSilencing #science """ "reactions_count" => 167 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-12 11:21:48" "deleted" => 1 ] [ "id" => 858527412 "company_id" => 8900492 "urn" => "urn:li:activity:7212481228589936641" "followers" => null "date" => "5mo" "description" => """ RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l\n \n #RNAiTherapeutics #siRNA #GeneSilencing #RNA """ "reactions_count" => 544 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-20 21:32:58" "deleted" => 1 ] [ "id" => 858527413 "company_id" => 8900492 "urn" => "urn:li:activity:7270872935349862400" "followers" => null "date" => "4d" "description" => """ I have so much respect and gratitude for Dr. Akshay Vaishnaw, our Chief Innovation Officer and former President, who is retiring from Alnylam Pharmaceuticals next week after 19 incredible years with the company. \n \n Akshay has played a central role in Alnylam’s history. He helped to build and lead the remarkable team that pioneered a new class of medicines, and his work led to the approval of the first five RNAi therapeutics in the world. Akshay has shaped a platform, pipeline, team, and culture that will carry us into the future as we work to write Alnylam’s next chapter and help many more patients in the years to come. \n \n On a personal level, I will miss Akshay and his wise counsel, quick wit, and amazing ability to tell the Alnylam story. \n \n Thank you, Akshay, for your extraordinary contributions! """ "reactions_count" => 1341 "comments_count" => 85 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-20 21:32:58" "deleted" => 1 ] [ "id" => 858527414 "company_id" => 8900492 "urn" => "urn:li:activity:7270094590811029504" "followers" => null "date" => "6d" "description" => "Primary #hyperoxaluria type 1 (PH1) is an inherited disease and can affect family members in different ways. For one family with three children diagnosed with PH1, each has had a different experience. Hear from Aubrey, diagnosed with PH1,in an episode of Medical Stories airing on PBS stations. https://bit.ly/3ATSDVR" "reactions_count" => 58 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-20 21:32:58" "deleted" => 1 ] [ "id" => 858527415 "company_id" => 8900492 "urn" => "urn:li:activity:7266785059163058176" "followers" => null "date" => "2w" "description" => """ We are excited to share that the U.S. FDA has accepted our supplemental New Drug Application (sNDA) for vutrisiran, an investigational #RNAi therapeutic in development for the treatment of #ATTR-CM. https://bit.ly/412lQJn\n \n #RNAiTherapeutics #RNAinterference #amyloidosis """ "reactions_count" => 1700 "comments_count" => 29 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-20 21:32:58" "deleted" => 1 ] [ "id" => 858527416 "company_id" => 8900492 "urn" => "urn:li:activity:7265415422798114819" "followers" => null "date" => "2w" "description" => "Another wonderful AHA is in the books! Sharing new data from our #ATTR franchise and #hypertension program alongside fellow leaders in cardiology was truly inspiring. #RNAiTherapeutics #RNAi" "reactions_count" => 330 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-20 21:32:58" "deleted" => 1 ] [ "id" => 858527417 "company_id" => 8900492 "urn" => "urn:li:activity:7264997507082948608" "followers" => null "date" => "3w" "description" => """ It was a privilege to be part of a “Big Biotech – Where Is It Going?” panel last week at the #GalienForum2024. Thank you to Phil Sharp for facilitating a fascinating conversation on the past, present and future of our industry—and thank you to fellow panelists Jane Grogan, Ray Deshaies, Ph.D., and george yancopoulos for deepening my outlook. I walked away more convinced than ever that biotech will continue to be the source of breakthrough innovation, and that it will take experienced R&D leadership, a connected ecosystem and tenacity to deliver it.\n #Biotechnology #FutureOfMedicine """ "reactions_count" => 168 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-20 21:32:58" "deleted" => 1 ] [ "id" => 858527418 "company_id" => 8900492 "urn" => "urn:li:activity:7264351811854024704" "followers" => null "date" => "3w" "description" => """ In case you missed it: We presented new data from our #ATTR franchise and #hypertension program at the American Heart Association Scientific Sessions 2024. Learn more: https://bit.ly/3OzzVGZ\n \n #AHA24 #RNAiTherapeutics #RNAi """ "reactions_count" => 158 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-20 21:32:58" "deleted" => 1 ] [ "id" => 858527419 "company_id" => 8900492 "urn" => "urn:li:activity:7264290304785100801" "followers" => null "date" => "3w" "description" => """ Drug development is a long and perilous journey with a historically high failure rate. Advances in genomic sequencing and a more human-focused approach using genetic validation of disease targets are changing that.\n \n "Our focus on genetic validation has helped our drug candidates achieve a clinical trial success rate that's six times the industry average," says Paul Nioi, Alnylam's SVP of Discovery and Translational Research.\n \n Science curious to learn more? Read about how Alnylam and others who are embracing this approach are improving the speed and odds of success in drug development in this Nature Portfolio article (sponsored content): https://bit.ly/4hJnLbJ\n \n #RNAiTherapeutics #RNAinterference #RNAi #DrugDevelopment #genetics #genomics #biotechnology #pharmaceuticals #biopharma """ "reactions_count" => 120 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-20 21:32:58" "deleted" => 1 ] [ "id" => 858527420 "company_id" => 8900492 "urn" => "urn:li:activity:7263923090617733120" "followers" => null "date" => "3w" "description" => """ At the American Heart Association Scientific Sessions 2024 (#AHA24) we presented new data on nucresiran (ALN-TTRsc04), a next-generation #RNAi therapeutic, in development for the treatment of transthyretin amyloidosis (#ATTR). See the findings: https://bit.ly/3UVskGi\n \n #RNAiTherapeutics """ "reactions_count" => 298 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-20 21:32:58" "deleted" => 1 ] [ "id" => 858527421 "company_id" => 8900492 "urn" => "urn:li:activity:7263564521124851712" "followers" => null "date" => "3w" "description" => """ We’re thrilled to connect with thousands of cardiology professionals at the American Heart Association Scientific Sessions 2024 (#AHA24) this week in Chicago.\n \n Visit us at Booth 2321 to learn more about our recent innovations in #ATTR #amyloidosis, ATTR-CM and #hypertension #RNAiTherapeutics """ "reactions_count" => 136 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-20 21:32:58" "deleted" => 1 ] [ "id" => 901469140 "company_id" => 8900492 "urn" => "urn:li:activity:7212481228589936641" "followers" => null "date" => "6mo" "description" => """ RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l\n \n #RNAiTherapeutics #siRNA #GeneSilencing #RNA """ "reactions_count" => 572 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 1 ] [ "id" => 901469141 "company_id" => 8900492 "urn" => "urn:li:activity:7286088861099720704" "followers" => null "date" => "2d" "description" => "Doctors appointments, tests, pharmacy visits, medication routines - the sounds of these things make living with disease noisy. But when disease is silenced, these things become less prevalent and the everyday joys of life can be amplified. We've pioneered #RNAi therapeutics to do just that - #SilenceDisease to #AmplifyLife." "reactions_count" => 35 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 1 ] [ "id" => 901469142 "company_id" => 8900492 "urn" => "urn:li:activity:7285345829098274816" "followers" => null "date" => "4d" "description" => """ She's worked hard all season to get to the championship game. You want to be there to see her play AND you also want to be fully present. Living with disease makes that difficult. \n \n Not only can disease hold you back but over time, the sounds of disease - doctor visits, tests, trips to the pharmacy and medication routines - they all mute the joy of life. But what is the sound of disease silenced?\n \n #SilenceDisease #AmplifyLife #RNAi """ "reactions_count" => 61 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 1 ] [ "id" => 901469143 "company_id" => 8900492 "urn" => "urn:li:activity:7285298438718566400" "followers" => null "date" => "5d" "description" => """ Yesterday from #JPM25, our CEO Dr. Yvonne Greenstreet joined CNBC's Angelica Peebles to talk about the continued advancement of our #RNAiTherapeutics platform, our deep pipeline of investigational medicines and what's next for Alnylam in 2025. https://cnb.cx/3WevSnl\n \n #RNAi #siRNA #biotechnology #biotech #DrugDevelopment """ "reactions_count" => 218 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 1 ] [ "id" => 901469144 "company_id" => 8900492 "urn" => "urn:li:activity:7284949417009283072" "followers" => null "date" => "5d" "description" => """ Living with disease is noisy. Day-to-day life is filled with the sounds of endless doctor appointments, tests, managing medication and having to decline invitations to participate in the things you really want to do. Over time, these sounds mute the joy of life. But what happens when disease is silenced? \n \n #SilenceDisease #AmplifyLife #RNAi """ "reactions_count" => 126 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 1 ] [ "id" => 901469145 "company_id" => 8900492 "urn" => "urn:li:activity:7283563026790723585" "followers" => null "date" => "1w" "description" => """ Healthcare Professionals: With hereditary #ATTR (#hATTR), toxic misfolded TTR accumulates at multiple sites in the body, including the nerves, heart and digestive system, and ultimately causes symptoms of the disease. Because the deposition of toxic misfolded TTR can lead to irreversible damage, it is important that physicians take a comprehensive and rapid approach to disease management. Learn more about this inherited #RareDisease and an available treatment option for the polyneuropathy of hATTR in a new Alnylam-sponsored article in Healio: https://bit.ly/4f9H9fu\n \n #Amyloidosis """ "reactions_count" => 98 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 1 ] [ "id" => 901469146 "company_id" => 8900492 "urn" => "urn:li:activity:7283494136861655040" "followers" => null "date" => "1w" "description" => "Don’t miss Dr. Yvonne Greenstreet in conversation with Noubar Afeyan during FutureCast at #JPM25! They’ll explore the future of therapeutic development, pioneering innovation, and what it takes to lead multi-product platform companies." "reactions_count" => 59 "comments_count" => null "reshared_post_author" => "Flagship Pioneering" "reshared_post_author_url" => "https://www.linkedin.com/company/flagship-pioneering" "reshared_post_author_headline" => null "reshared_post_description" => """ Check out the newly added programming being livestreamed from our studio at JPM the week of January 13: \n \n 🔹Pioneering Partnerships: Early-Stage Deals \n 🔹AI in Action \n 🔹Lessons in Leadership: Angela Hwang in Conversation with Joy Right \n 🔹FutureCast: Noubar Afeyan in Conversation with Dr. Yvonne Greenstreet \n 🔹Halting the Trajectory of Disease with Preemptive Health \n \n For more on our studio programming and to register for livestreamed events: bit.ly/FlagshipatJPM25 \n \n #FlagshipStudio #JPM25 """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2025-02-15 03:09:52" "deleted" => 1 ] [ "id" => 901469147 "company_id" => 8900492 "urn" => "urn:li:activity:7282493033365868546" "followers" => null "date" => "1w" "description" => """ Tune in on January 14 at 11am PT/2pm ET for a conversation between Flagship Pioneering Founder and CEO Noubar Afeyan and Dr. Yvonne Greenstreet, CEO of Alnylam Pharmaceuticals, on leading multi-product platform companies, pioneering innovation to bring about novel medicines for patients across multiple disease areas, and the future of therapeutic development. Learn more and register for the livestream: https://lnkd.in/e_9tjdrk \n \n For more on our studio programming and livestreamed events at JPM: https://lnkd.in/emncrHdx \n \n #JPM25 #FlagshipJPM """ "reactions_count" => 104 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 1 ] [ "id" => 901469148 "company_id" => 8900492 "urn" => "urn:li:activity:7281026568301211648" "followers" => null "date" => "2w" "description" => "HCPs: Conversations about family health history can help your patients understand inherited diseases, like hereditary #ATTR (#hATTR) #amyloidosis. Encourage your patients to discuss health conditions that run in their families to better understand their health. https://bit.ly/3QPohJd #hATTRoadTrip" "reactions_count" => 69 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 1 ] [ "id" => 901469149 "company_id" => 8900492 "urn" => "urn:li:activity:7275567659117641728" "followers" => null "date" => "1mo" "description" => """ HCPs: This holiday season is a perfect opportunity to encourage patients to have discussions about family health history. Meet Dr. Saurabh Malhotra, an expert on hereditary #ATTR (#hATTR) #amyloidosis. Watch as he discusses the importance of genetic testing and how understanding family health history can empower patients and help guide their healthcare decisions. https://bit.ly/3QPohJd\n \n #hATTRoadTrip """ "reactions_count" => 88 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 1 ] [ "id" => 937815116 "company_id" => 8900492 "urn" => "urn:li:activity:7212481228589936641" "followers" => null "date" => "7mo" "description" => """ RNA interference (RNAi) is a naturally occurring process of gene regulation that is already at work inside your body. RNAi therapeutics, which were pioneered by Alnylam, utilize this process to silence the genes that cause or contribute to disease. #ScienceCurious to learn more about #RNAi? Click here: https://bit.ly/3oR8r2l\n \n #RNAiTherapeutics #siRNA #GeneSilencing #RNA """ "reactions_count" => 593 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 937815117 "company_id" => 8900492 "urn" => "urn:li:activity:7295568887494950914" "followers" => null "date" => "1d" "description" => "HCPs: Conversations about family health history can help your patients understand inherited diseases, like hereditary #ATTR (#hATTR) #amyloidosis. Encourage your patients to discuss health conditions that run in their families to better understand their health. https://bit.ly/3QPohJd #hATTRoadTrip" "reactions_count" => 36 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 937815118 "company_id" => 8900492 "urn" => "urn:li:activity:7292900209901068289" "followers" => null "date" => "1w" "description" => """ RNAi therapies are changing lives, and its pioneers say there’s more to come.\n [Sponsored by Alnylam Pharmaceuticals]\n https://lnkd.in/g6i6tMVd """ "reactions_count" => 30 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 937815119 "company_id" => 8900492 "urn" => "urn:li:activity:7292584980000432129" "followers" => null "date" => "1w" "description" => """ Healthcare Professionals: With hereditary #ATTR (#hATTR), toxic misfolded TTR accumulates at multiple sites in the body, including the nerves, heart and digestive system, and ultimately causes symptoms of the disease. Because the deposition of toxic misfolded TTR can lead to irreversible damage, it is important that physicians take a comprehensive and rapid approach to disease management. Learn more about this inherited #RareDisease and an available treatment option for the polyneuropathy of hATTR in a new Alnylam-sponsored article in Healio: https://bit.ly/4f9H9fu\n \n #Amyloidosis """ "reactions_count" => 127 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 937815120 "company_id" => 8900492 "urn" => "urn:li:activity:7290759422560096256" "followers" => null "date" => "2w" "description" => """ U.S. Healthcare Professionals: Navigating a #RareDisease like primary #hyperoxaluria type 1 (PH1) takes a well-coordinated care team. In this article, pediatric nephrologist, Dr. Raymond Quigley, shares how collaboration among specialists can support accurate, timely diagnosis and highlights advancements in disease management that are supporting patient care. Additionally, learn more from Courtney, who discusses her son’s journey with this rare disease.\n \n Read the full story: https://bit.ly/49wLl7S """ "reactions_count" => 87 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 937815121 "company_id" => 8900492 "urn" => "urn:li:activity:7290395046527332354" "followers" => null "date" => "2w" "description" => "Healthcare Professionals: Hereditary #ATTR (#hATTR) is often misdiagnosed because symptoms can resemble those of other conditions. This can delay critical intervention as toxic misfolded TTR continues to accumulate in the body and cause disease progression. Read more in an Alnylam-sponsored Healio article: https://bit.ly/4f9H9fu #Amyloidois" "reactions_count" => 92 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 937815122 "company_id" => 8900492 "urn" => "urn:li:activity:7287858597319868416" "followers" => null "date" => "3w" "description" => "HCPs: Conversations about family health history can help your patients understand inherited diseases, like hereditary #ATTR (#hATTR) #amyloidosis. Encourage your patients to discuss health conditions that run in their families to better understand their health. https://bit.ly/3QPohJd #hATTRoadTrip" "reactions_count" => 88 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 937815123 "company_id" => 8900492 "urn" => "urn:li:activity:7287173314932801536" "followers" => null "date" => "3w" "description" => """ Healthcare Professionals: People living with hereditary #ATTR (#hATTR) often experience significant and irreversible disease progression before an accurate diagnosis is made. In a new Alnylam-sponsored Healio article, Johanna Contreras, MD, MSc and Said Beydoun, MD, FAAN discuss the urgency to diagnose and manage this inherited #RareDisease. Learn more: https://bit.ly/4f9H9fu\n #Amyloidois """ "reactions_count" => 156 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 937815124 "company_id" => 8900492 "urn" => "urn:li:activity:7286088861099720704" "followers" => null "date" => "3w" "description" => "Doctors appointments, tests, pharmacy visits, medication routines - the sounds of these things make living with disease noisy. But when disease is silenced, these things become less prevalent and the everyday joys of life can be amplified. We've pioneered #RNAi therapeutics to do just that - #SilenceDisease to #AmplifyLife." "reactions_count" => 77 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] [ "id" => 937815125 "company_id" => 8900492 "urn" => "urn:li:activity:7285345829098274816" "followers" => null "date" => "4w" "description" => """ She's worked hard all season to get to the championship game. You want to be there to see her play AND you also want to be fully present. Living with disease makes that difficult. \n \n Not only can disease hold you back but over time, the sounds of disease - doctor visits, tests, trips to the pharmacy and medication routines - they all mute the joy of life. But what is the sound of disease silenced?\n \n #SilenceDisease #AmplifyLife #RNAi """ "reactions_count" => 109 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 03:09:52" "deleted" => 0 ] ] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4368 …} -companyTags: Doctrine\ORM\PersistentCollection {#4370 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4372 …} -users: Doctrine\ORM\PersistentCollection {#4374 …} -logoImageName: "20250904135304-test1-68b97da0087c4536383702.png" -coverImageName: "20250227160409-20240327143234-alnylam-corporate-logo-mark-only-color-003-66041ff24c572528735916-67c07ee972f9e936009424.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4376 …} -tagline: "Pionier der RNA-Interferenz – Innovative Therapien für bislang unzureichend behandelbare Krankheiten" -contactEmail: "mclapes@alnylam.com" -phone: "41796183508" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4378 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4380 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4382 …} -industry: "" -size: "2444" -address1: "Grafenauweg 4" -address2: null -city: "Zug" -postalCode: "6300" -state: null -country: "CH" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4384 …} #createdAt: DateTime @1740044117 {#4366 date: 2025-02-20 09:35:17.0 UTC (+00:00) } #updatedAt: DateTime @1759390397 {#4365 date: 2025-10-02 07:33:17.0 UTC (+00:00) } } App\Entity\Company {#4388 -id: 6 -name: "Amgen Switzerland AG" -website: "https://amgen.ch" -description: "" -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4389 …} -companyTags: Doctrine\ORM\PersistentCollection {#4391 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4393 …} -users: Doctrine\ORM\PersistentCollection {#4395 …} -logoImageName: "20250227160517-amgen-logo-67c07f2d9eb91117148888.png" -coverImageName: "20250227160518-amgn-10e15ed0-67c07f2e02b9d976833656.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4397 …} -tagline: "Biotechnologie-Pionier für innovative Therapien in der Medizin" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4399 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4401 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4403 …} -industry: "" -size: "" -address1: "Suurstoffi 22" -address2: "" -city: "Rotkreuz" -postalCode: "6343" -state: "" -country: "CH" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4405 …} #createdAt: DateTime @1740044408 {#4387 date: 2025-02-20 09:40:08.0 UTC (+00:00) } #updatedAt: DateTime @1759390412 {#4386 date: 2025-10-02 07:33:32.0 UTC (+00:00) } } App\Entity\Company {#4409 -id: 7 -name: "Angelini Pharma" -website: "https://angelinipharma.com" -description: """ At Angelini Pharma, we work every day to grow as a leading Pharma Company that makes a difference in patients’ life. Since 1919. \n We aim at becoming a leading European player, offering people, patients and their beloved ones new medicines and solutions to achieve better health outcomes and higher quality of life. \n We make our vision real through robust pipeline growth, strong collaborations with best-in-class Research Institutes and valuable partnerships with our strategic allies.\n We pledge to successfully develop distinctive treatments for CNS and Mental Health disorders while preserving our leading position in the Consumer Health segment.\n Angelini Pharma is part of Angelini Industries.\n \n Social media privacy notice: https://bit.ly/socialmediaprivacynotice """ -externalId: "25495456" -details: [ "id" => 25495456 "url" => "https://www.linkedin.com/company/angelinipharma" "hash" => "ab74ae7f775a8a03fdf21d6cd136b97d" "name" => "Angelini Pharma" "website" => "https://www.angelinipharma.com/" "size" => "5,001-10,000 employees" "industry" => "Pharmaceutical Manufacturing" "description" => """ At Angelini Pharma, we work every day to grow as a leading Pharma Company that makes a difference in patients’ life. Since 1919. \n We aim at becoming a leading European player, offering people, patients and their beloved ones new medicines and solutions to achieve better health outcomes and higher quality of life. \n We make our vision real through robust pipeline growth, strong collaborations with best-in-class Research Institutes and valuable partnerships with our strategic allies.\n We pledge to successfully develop distinctive treatments for CNS and Mental Health disorders while preserving our leading position in the Consumer Health segment.\n Angelini Pharma is part of Angelini Industries.\n \n Social media privacy notice: https://bit.ly/socialmediaprivacynotice """ "followers" => 143856 "founded" => null "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://media.licdn.com/dms/image/v2/D4D0BAQFrSBlgU-lLYA/company-logo_200_200/company-logo_200_200/0/1733129809355/angelinipharma_logo?e=2147483647&v=beta&t=6ly8090ROAOh5QetQHooO9yo3nRulANoes1R1MjonpU" "created" => "2020-03-20 06:55:07" "last_updated" => "2025-02-09 04:11:58" "last_response_code" => 200 "type" => "Privately Held" "headquarters_new_address" => "Rome, RM" "employees_count" => null "headquarters_country_restored" => null "headquarters_country_parsed" => "Italy" "company_shorthand_name" => "angelinipharma" "company_shorthand_name_hash" => "24fb4af9063fa6549e000e5d32136e75" "canonical_url" => "https://www.linkedin.com/company/angelinipharma" "canonical_hash" => "ab74ae7f775a8a03fdf21d6cd136b97d" "canonical_shorthand_name" => "angelinipharma" "canonical_shorthand_name_hash" => "24fb4af9063fa6549e000e5d32136e75" "deleted" => 0 "last_updated_ux" => 1739074317 "source_id" => 42134318 "company_affiliated_collection" => [ [ "id" => 3490835 "company_id" => 25495456 "affiliated_company_url" => "https://www.linkedin.com/company/angelini-holding" "affiliated_company_id" => 27760414 "created" => "2020-05-21 00:20:15" "last_updated" => "2020-11-13 15:00:30" "deleted" => 1 ] [ "id" => 3677347 "company_id" => 25495456 "affiliated_company_url" => "https://it.linkedin.com/company/angelini-holding" "affiliated_company_id" => 27760414 "created" => "2020-11-13 15:00:31" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 3677348 "company_id" => 25495456 "affiliated_company_url" => "https://www.linkedin.com/company/angelini-pharma-inc" "affiliated_company_id" => 19970579 "created" => "2020-11-13 15:00:31" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 3677349 "company_id" => 25495456 "affiliated_company_url" => "https://es.linkedin.com/company/angelinipharmaespana" "affiliated_company_id" => 9309132 "created" => "2020-11-13 15:00:31" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 3677350 "company_id" => 25495456 "affiliated_company_url" => "https://gr.linkedin.com/company/angelini-pharma-hellas-s-a-" "affiliated_company_id" => 9245626 "created" => "2020-11-13 15:00:31" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 3677351 "company_id" => 25495456 "affiliated_company_url" => "https://pl.linkedin.com/company/angelini-pharma-polska" "affiliated_company_id" => 28231909 "created" => "2020-11-13 15:00:31" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 4311949 "company_id" => 25495456 "affiliated_company_url" => "https://it.linkedin.com/company/angelini-fine-chemicals" "affiliated_company_id" => 20466042 "created" => "2021-02-03 12:57:52" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 4311950 "company_id" => 25495456 "affiliated_company_url" => "https://tr.linkedin.com/company/angelini-pharma-turkiye" "affiliated_company_id" => 29349385 "created" => "2021-02-03 12:57:52" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 4343041 "company_id" => 25495456 "affiliated_company_url" => "https://cz.linkedin.com/company/angelini-pharma-cz" "affiliated_company_id" => 32715281 "created" => "2021-03-15 11:16:06" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 4343042 "company_id" => 25495456 "affiliated_company_url" => "https://de.linkedin.com/company/angelini-pharma-deutschland" "affiliated_company_id" => 32727453 "created" => "2021-03-15 11:16:06" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 4403102 "company_id" => 25495456 "affiliated_company_url" => "https://www.linkedin.com/company/angelinipharmaportugal" "affiliated_company_id" => null "created" => "2021-05-24 16:12:08" "last_updated" => "2021-06-02 20:55:19" "deleted" => 1 ] [ "id" => 4405872 "company_id" => 25495456 "affiliated_company_url" => "https://www.linkedin.com/company/angelinipharmaportugal" "affiliated_company_id" => 33420072 "created" => "2021-06-02 20:55:19" "last_updated" => "2021-07-24 02:16:16" "deleted" => 1 ] [ "id" => 4446053 "company_id" => 25495456 "affiliated_company_url" => "https://ch.linkedin.com/company/arvelle-therapeutics-inc" "affiliated_company_id" => 13006779 "created" => "2021-07-24 02:16:17" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 4446054 "company_id" => 25495456 "affiliated_company_url" => "https://pt.linkedin.com/company/angelinipharmaportugal" "affiliated_company_id" => 33420072 "created" => "2021-07-24 02:16:17" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 6100199 "company_id" => 25495456 "affiliated_company_url" => "https://it.linkedin.com/company/angelini-industries/" "affiliated_company_id" => 88102122 "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 6100200 "company_id" => 25495456 "affiliated_company_url" => "https://es.linkedin.com/company/angelinipharmaespana/" "affiliated_company_id" => 9309132 "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 6100201 "company_id" => 25495456 "affiliated_company_url" => "https://www.linkedin.com/company/angelini-pharma-inc/" "affiliated_company_id" => 19970579 "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 6100202 "company_id" => 25495456 "affiliated_company_url" => "https://ch.linkedin.com/company/arvelle-therapeutics-inc/" "affiliated_company_id" => 13006779 "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 6100203 "company_id" => 25495456 "affiliated_company_url" => "https://it.linkedin.com/company/angelini-fine-chemicals/" "affiliated_company_id" => 20466042 "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 6100204 "company_id" => 25495456 "affiliated_company_url" => "https://gr.linkedin.com/company/angelini-pharma-hellas-s-a-/" "affiliated_company_id" => 9245626 "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 6100205 "company_id" => 25495456 "affiliated_company_url" => "https://pt.linkedin.com/company/angelinipharmaportugal/" "affiliated_company_id" => 33420072 "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 6100206 "company_id" => 25495456 "affiliated_company_url" => "https://pl.linkedin.com/company/angelini-pharma-polska/" "affiliated_company_id" => 28231909 "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 6100207 "company_id" => 25495456 "affiliated_company_url" => "https://tr.linkedin.com/company/angelini-pharma-turkiye/" "affiliated_company_id" => 29349385 "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 6100208 "company_id" => 25495456 "affiliated_company_url" => "https://cz.linkedin.com/company/angelini-pharma-cz/" "affiliated_company_id" => 32715281 "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 6100209 "company_id" => 25495456 "affiliated_company_url" => "https://de.linkedin.com/company/angelini-pharma-deutschland/" "affiliated_company_id" => 32727453 "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 6209142 "company_id" => 25495456 "affiliated_company_url" => "https://it.linkedin.com/company/angelini-industries" "affiliated_company_id" => 88102122 "created" => "2022-04-05 16:23:08" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 6209143 "company_id" => 25495456 "affiliated_company_url" => "https://es.linkedin.com/company/angelinipharmaespana" "affiliated_company_id" => 9309132 "created" => "2022-04-05 16:23:08" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 6209144 "company_id" => 25495456 "affiliated_company_url" => "https://www.linkedin.com/company/angelini-pharma-inc" "affiliated_company_id" => 19970579 "created" => "2022-04-05 16:23:08" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 6209145 "company_id" => 25495456 "affiliated_company_url" => "https://ch.linkedin.com/company/arvelle-therapeutics-inc" "affiliated_company_id" => 13006779 "created" => "2022-04-05 16:23:08" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 6209146 "company_id" => 25495456 "affiliated_company_url" => "https://it.linkedin.com/company/angelini-fine-chemicals" "affiliated_company_id" => 20466042 "created" => "2022-04-05 16:23:08" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 6209147 "company_id" => 25495456 "affiliated_company_url" => "https://gr.linkedin.com/company/angelini-pharma-hellas-s-a-" "affiliated_company_id" => 9245626 "created" => "2022-04-05 16:23:08" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 6209148 "company_id" => 25495456 "affiliated_company_url" => "https://pt.linkedin.com/company/angelinipharmaportugal" "affiliated_company_id" => 33420072 "created" => "2022-04-05 16:23:08" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 6209149 "company_id" => 25495456 "affiliated_company_url" => "https://pl.linkedin.com/company/angelini-pharma-polska" "affiliated_company_id" => 28231909 "created" => "2022-04-05 16:23:08" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 6209150 "company_id" => 25495456 "affiliated_company_url" => "https://tr.linkedin.com/company/angelini-pharma-turkiye" "affiliated_company_id" => 29349385 "created" => "2022-04-05 16:23:08" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 6209151 "company_id" => 25495456 "affiliated_company_url" => "https://cz.linkedin.com/company/angelini-pharma-cz" "affiliated_company_id" => 32715281 "created" => "2022-04-05 16:23:08" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 6209152 "company_id" => 25495456 "affiliated_company_url" => "https://de.linkedin.com/company/angelini-pharma-deutschland" "affiliated_company_id" => 32727453 "created" => "2022-04-05 16:23:08" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 6453545 "company_id" => 25495456 "affiliated_company_url" => "https://it.linkedin.com/company/angelini-industries" "affiliated_company_id" => 88102122 "created" => "2022-08-05 09:35:12" "last_updated" => "2024-10-20 16:17:30" "deleted" => 1 ] [ "id" => 6453546 "company_id" => 25495456 "affiliated_company_url" => "https://es.linkedin.com/company/angelinipharmaespana" "affiliated_company_id" => 9309132 "created" => "2022-08-05 09:35:12" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 6453547 "company_id" => 25495456 "affiliated_company_url" => "https://www.linkedin.com/company/angelini-pharma-inc" "affiliated_company_id" => 19970579 "created" => "2022-08-05 09:35:12" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 6453548 "company_id" => 25495456 "affiliated_company_url" => "https://ch.linkedin.com/company/arvelle-therapeutics-inc" "affiliated_company_id" => 13006779 "created" => "2022-08-05 09:35:12" "last_updated" => "2023-02-12 02:50:30" "deleted" => 1 ] [ "id" => 6453549 "company_id" => 25495456 "affiliated_company_url" => "https://it.linkedin.com/company/angelini-fine-chemicals" "affiliated_company_id" => 20466042 "created" => "2022-08-05 09:35:12" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 6453550 "company_id" => 25495456 "affiliated_company_url" => "https://pt.linkedin.com/company/angelinipharmaportugal" "affiliated_company_id" => 33420072 "created" => "2022-08-05 09:35:12" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 6453551 "company_id" => 25495456 "affiliated_company_url" => "https://gr.linkedin.com/company/angelini-pharma-hellas-s-a-" "affiliated_company_id" => 9245626 "created" => "2022-08-05 09:35:12" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 6453552 "company_id" => 25495456 "affiliated_company_url" => "https://pl.linkedin.com/company/angelini-pharma-polska" "affiliated_company_id" => 28231909 "created" => "2022-08-05 09:35:12" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 6453553 "company_id" => 25495456 "affiliated_company_url" => "https://tr.linkedin.com/company/angelini-pharma-turkiye" "affiliated_company_id" => 29349385 "created" => "2022-08-05 09:35:12" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 6453554 "company_id" => 25495456 "affiliated_company_url" => "https://de.linkedin.com/company/angelini-pharma-deutschland" "affiliated_company_id" => 32727453 "created" => "2022-08-05 09:35:12" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 6453555 "company_id" => 25495456 "affiliated_company_url" => "https://cz.linkedin.com/company/angelini-pharma-cz" "affiliated_company_id" => 32715281 "created" => "2022-08-05 09:35:12" "last_updated" => "2023-02-12 02:50:30" "deleted" => 1 ] [ "id" => 8142409 "company_id" => 25495456 "affiliated_company_url" => "https://ch.linkedin.com/company/angelini-pharma-switzerland" "affiliated_company_id" => null "created" => "2023-02-12 02:50:30" "last_updated" => "2023-03-02 21:02:50" "deleted" => 1 ] [ "id" => 8142410 "company_id" => 25495456 "affiliated_company_url" => "https://cz.linkedin.com/company/angelini-pharma-cz-sk" "affiliated_company_id" => null "created" => "2023-02-12 02:50:30" "last_updated" => "2023-03-02 21:02:50" "deleted" => 1 ] [ "id" => 8317050 "company_id" => 25495456 "affiliated_company_url" => "https://ch.linkedin.com/company/angelini-pharma-switzerland" "affiliated_company_id" => 90053628 "created" => "2023-03-02 21:02:50" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 8317051 "company_id" => 25495456 "affiliated_company_url" => "https://cz.linkedin.com/company/angelini-pharma-cz-sk" "affiliated_company_id" => 89986408 "created" => "2023-03-02 21:02:50" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 10842239 "company_id" => 25495456 "affiliated_company_url" => "https://at.linkedin.com/company/angelini-pharma-%C3%B6sterreich" "affiliated_company_id" => 89745687 "created" => "2024-10-20 16:17:30" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 10842240 "company_id" => 25495456 "affiliated_company_url" => "https://uk.linkedin.com/company/angelini-pharma-uk-ireland" "affiliated_company_id" => 90449898 "created" => "2024-10-20 16:17:30" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 10842241 "company_id" => 25495456 "affiliated_company_url" => "https://ro.linkedin.com/company/angelini-pharma-romania" "affiliated_company_id" => 92561838 "created" => "2024-10-20 16:17:30" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 10842242 "company_id" => 25495456 "affiliated_company_url" => "https://bg.linkedin.com/company/angelini-pharma-bulgaria" "affiliated_company_id" => 89865841 "created" => "2024-10-20 16:17:30" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] ] "company_also_viewed_collection" => [] "company_crunchbase_info_collection" => [ [ "id" => 408514 "company_id" => 25495456 "cb_url" => "https://www.crunchbase.com/organization/angelini-pharma-magyarország" "created" => "2023-08-03 09:35:33" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] ] "company_featured_employees_collection" => [ [ "id" => 39993345 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/anna-mistewicz-6b15921" "created" => "2020-03-20 06:55:06" "last_updated" => "2022-02-17 15:43:30" "deleted" => 1 ] [ "id" => 39993346 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/roberto-lombardo-4a54884" "created" => "2020-03-20 06:55:06" "last_updated" => "2020-07-11 11:50:29" "deleted" => 1 ] [ "id" => 39993347 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/cermes" "created" => "2020-03-20 06:55:06" "last_updated" => "2020-05-26 15:42:33" "deleted" => 1 ] [ "id" => 39993348 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/matteo-vernia-809a4b5" "created" => "2020-03-20 06:55:06" "last_updated" => "2020-04-18 00:01:51" "deleted" => 1 ] [ "id" => 42418516 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/pedro-rocha-775b50" "created" => "2020-04-18 00:01:51" "last_updated" => "2020-06-09 06:57:08" "deleted" => 1 ] [ "id" => 45219973 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/pierluigi-antonelli-25751" "created" => "2020-05-26 15:42:33" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 45816453 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/gaye-ercaliskan-mba-msc-b459422" "created" => "2020-06-09 06:57:08" "last_updated" => "2020-07-11 11:50:29" "deleted" => 1 ] [ "id" => 46854180 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/manuela-aresta-944658" "created" => "2020-07-11 11:50:29" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 46854181 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/pavel-martinec-b7a0582" "created" => "2020-07-11 11:50:29" "last_updated" => "2021-03-24 10:26:15" "deleted" => 1 ] [ "id" => 62695920 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/enrico-giaquinto-31214b" "created" => "2021-03-24 10:26:15" "last_updated" => "2021-07-24 02:16:16" "deleted" => 1 ] [ "id" => 70003479 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/pavel-martinec-b7a0582" "created" => "2021-07-24 02:16:16" "last_updated" => "2021-11-19 01:10:49" "deleted" => 1 ] [ "id" => 79150239 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/henrikahlqvist" "created" => "2021-11-19 01:10:49" "last_updated" => "2022-01-11 23:53:13" "deleted" => 1 ] [ "id" => 82087076 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/thomasthestrup" "created" => "2022-01-11 23:53:13" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 86218456 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/mette-k%C3%B8lb%C3%A6k-957672" "created" => "2022-02-17 15:43:30" "last_updated" => "2022-07-25 14:04:30" "deleted" => 1 ] [ "id" => 116755656 "company_id" => 25495456 "url" => "https://it.linkedin.com/in/pierluigi-antonelli-25751" "created" => "2022-07-25 14:04:30" "last_updated" => "2022-11-17 15:51:06" "deleted" => 1 ] [ "id" => 116755657 "company_id" => 25495456 "url" => "https://dk.linkedin.com/in/thomasthestrup" "created" => "2022-07-25 14:04:30" "last_updated" => "2022-10-10 02:44:34" "deleted" => 1 ] [ "id" => 116755658 "company_id" => 25495456 "url" => "https://it.linkedin.com/in/manuela-aresta-944658" "created" => "2022-07-25 14:04:30" "last_updated" => "2023-04-17 17:17:18" "deleted" => 1 ] [ "id" => 116755659 "company_id" => 25495456 "url" => "https://dk.linkedin.com/in/mette-k%C3%B8lb%C3%A6k-957672" "created" => "2022-07-25 14:04:30" "last_updated" => "2023-01-03 10:59:17" "deleted" => 1 ] [ "id" => 145472398 "company_id" => 25495456 "url" => "https://www.linkedin.com/in/philippebefferal" "created" => "2022-10-10 02:44:34" "last_updated" => "2023-08-03 09:35:33" "deleted" => 1 ] [ "id" => 153959010 "company_id" => 25495456 "url" => "https://pl.linkedin.com/in/anna-mistewicz-6b15921" "created" => "2022-11-17 15:51:06" "last_updated" => "2023-02-12 02:50:30" "deleted" => 1 ] [ "id" => 157187856 "company_id" => 25495456 "url" => "https://se.linkedin.com/in/fr%C3%A4s-anna-andersson-6157671" "created" => "2023-01-03 10:59:17" "last_updated" => "2023-03-02 21:02:50" "deleted" => 1 ] [ "id" => 159170747 "company_id" => 25495456 "url" => "https://pl.linkedin.com/in/anna-mistewicz-she-her-6b15921" "created" => "2023-02-12 02:50:30" "last_updated" => "2024-11-07 12:12:58" "deleted" => 1 ] [ "id" => 160481151 "company_id" => 25495456 "url" => "https://it.linkedin.com/in/luigi-boltri-68028b1" "created" => "2023-03-02 21:02:50" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 162582270 "company_id" => 25495456 "url" => "https://be.linkedin.com/in/sergetailler" "created" => "2023-04-17 17:17:18" "last_updated" => "2024-01-17 10:39:03" "deleted" => 1 ] [ "id" => 185794324 "company_id" => 25495456 "url" => "https://se.linkedin.com/in/fr%C3%A4s-anna-andersson-6157671" "created" => "2023-08-03 09:35:33" "last_updated" => "2023-12-12 18:38:02" "deleted" => 1 ] [ "id" => 197970320 "company_id" => 25495456 "url" => "https://it.linkedin.com/in/luca-manaigo-734292" "created" => "2023-12-12 18:38:02" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 199905063 "company_id" => 25495456 "url" => "https://se.linkedin.com/in/fr%C3%A4s-anna-andersson-6157671" "created" => "2024-01-17 10:39:03" "last_updated" => "2024-05-10 01:21:09" "deleted" => 1 ] [ "id" => 205811605 "company_id" => 25495456 "url" => "https://it.linkedin.com/in/liana-allitto-9b82a01" "created" => "2024-05-10 01:21:09" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 215375160 "company_id" => 25495456 "url" => "https://it.linkedin.com/in/claudia-bertolotti-4264741" "created" => "2024-11-07 12:12:58" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] ] "company_featured_investors_collection" => [ [ "id" => 2369932 "company_id" => 25495456 "investor_id" => 301 "round_id" => 5218998 "created" => "2023-08-03 09:35:33" "last_updated" => "2023-09-01 04:34:38" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 2455203 "company_id" => 25495456 "investor_id" => 301 "round_id" => 5218998 "created" => "2023-09-01 04:34:38" "last_updated" => "2023-10-14 22:14:13" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 2574022 "company_id" => 25495456 "investor_id" => 301 "round_id" => 5416337 "created" => "2023-10-14 22:14:13" "last_updated" => "2023-11-02 14:46:48" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 2623484 "company_id" => 25495456 "investor_id" => 301 "round_id" => 5691867 "created" => "2023-11-02 14:46:48" "last_updated" => "2023-12-12 18:38:02" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 2757753 "company_id" => 25495456 "investor_id" => 301 "round_id" => 5806866 "created" => "2023-12-12 18:38:02" "last_updated" => "2024-01-17 10:39:03" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 2859080 "company_id" => 25495456 "investor_id" => 301 "round_id" => 6088223 "created" => "2024-01-17 10:39:03" "last_updated" => "2024-02-13 12:24:56" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 2926317 "company_id" => 25495456 "investor_id" => 301 "round_id" => 6292470 "created" => "2024-02-13 12:24:56" "last_updated" => "2024-03-02 13:23:04" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 2994548 "company_id" => 25495456 "investor_id" => 301 "round_id" => 6427636 "created" => "2024-03-02 13:23:04" "last_updated" => "2024-04-05 12:22:19" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 3102502 "company_id" => 25495456 "investor_id" => 301 "round_id" => 6563955 "created" => "2024-04-05 12:22:19" "last_updated" => "2024-05-10 01:21:09" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 3197714 "company_id" => 25495456 "investor_id" => 301 "round_id" => 6780860 "created" => "2024-05-10 01:21:09" "last_updated" => "2024-06-08 20:27:05" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 3304825 "company_id" => 25495456 "investor_id" => 301 "round_id" => 6971840 "created" => "2024-06-08 20:27:05" "last_updated" => "2024-07-20 13:20:59" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 3452784 "company_id" => 25495456 "investor_id" => 301 "round_id" => 7185736 "created" => "2024-07-20 13:20:59" "last_updated" => "2024-08-12 22:26:37" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 3524380 "company_id" => 25495456 "investor_id" => 301 "round_id" => 7480156 "created" => "2024-08-12 22:26:37" "last_updated" => "2024-08-28 06:53:41" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 3628934 "company_id" => 25495456 "investor_id" => 301 "round_id" => 7621438 "created" => "2024-08-28 06:53:41" "last_updated" => "2024-09-11 06:05:28" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 3740723 "company_id" => 25495456 "investor_id" => 301 "round_id" => 7828528 "created" => "2024-09-11 06:05:28" "last_updated" => "2024-10-20 16:17:30" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 3950426 "company_id" => 25495456 "investor_id" => 301 "round_id" => 8049849 "created" => "2024-10-20 16:17:30" "last_updated" => "2024-11-07 12:12:58" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 4039255 "company_id" => 25495456 "investor_id" => 301 "round_id" => 8464400 "created" => "2024-11-07 12:12:58" "last_updated" => "2024-12-08 02:24:38" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 4275466 "company_id" => 25495456 "investor_id" => 301 "round_id" => 8639524 "created" => "2024-12-08 02:24:38" "last_updated" => "2025-01-16 04:02:35" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 4419152 "company_id" => 25495456 "investor_id" => 301 "round_id" => 9092886 "created" => "2025-01-16 04:02:35" "last_updated" => "2025-02-09 04:11:57" "deleted" => 1 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] [ "id" => 4545295 "company_id" => 25495456 "investor_id" => 301 "round_id" => 9376905 "created" => "2025-02-09 04:11:57" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 "company_investors_list" => [ "id" => 301 "name" => "European Commission" "hash" => "281a8a684e9eef364b5b8da009ea3509" "cb_url" => "https://www.crunchbase.com/organization/european-commission" "created" => "2020-09-07 13:47:39" "last_updated" => "2022-02-08 05:18:03" ] ] ] "company_funding_rounds_collection" => [ [ "id" => 5218998 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2023-08-03 09:35:33" "last_updated" => "2023-09-01 04:34:38" "deleted" => 1 ] [ "id" => 5416337 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2023-09-01 04:34:38" "last_updated" => "2023-10-14 22:14:13" "deleted" => 1 ] [ "id" => 5691867 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2023-10-14 22:14:13" "last_updated" => "2023-11-02 14:46:48" "deleted" => 1 ] [ "id" => 5806866 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2023-11-02 14:46:48" "last_updated" => "2023-12-12 18:38:02" "deleted" => 1 ] [ "id" => 6088223 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2023-12-12 18:38:02" "last_updated" => "2024-01-17 10:39:03" "deleted" => 1 ] [ "id" => 6292470 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2024-01-17 10:39:03" "last_updated" => "2024-02-13 12:24:56" "deleted" => 1 ] [ "id" => 6427636 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2024-02-13 12:24:56" "last_updated" => "2024-03-02 13:23:04" "deleted" => 1 ] [ "id" => 6563955 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2024-03-02 13:23:04" "last_updated" => "2024-04-05 12:22:19" "deleted" => 1 ] [ "id" => 6780860 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2024-04-05 12:22:19" "last_updated" => "2024-05-10 01:21:09" "deleted" => 1 ] [ "id" => 6971840 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2024-05-10 01:21:09" "last_updated" => "2024-06-08 20:27:05" "deleted" => 1 ] [ "id" => 7185736 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2024-06-08 20:27:05" "last_updated" => "2024-07-20 13:20:59" "deleted" => 1 ] [ "id" => 7480156 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2024-07-20 13:20:59" "last_updated" => "2024-08-12 22:26:37" "deleted" => 1 ] [ "id" => 7621438 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2024-08-12 22:26:37" "last_updated" => "2024-08-28 06:53:41" "deleted" => 1 ] [ "id" => 7828528 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2024-08-28 06:53:41" "last_updated" => "2024-09-11 06:05:28" "deleted" => 1 ] [ "id" => 8049849 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2024-09-11 06:05:28" "last_updated" => "2024-10-20 16:17:30" "deleted" => 1 ] [ "id" => 8464400 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2024-10-20 16:17:30" "last_updated" => "2024-11-07 12:12:58" "deleted" => 1 ] [ "id" => 8639524 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2024-11-07 12:12:58" "last_updated" => "2024-12-08 02:24:38" "deleted" => 1 ] [ "id" => 9092886 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2024-12-08 02:24:38" "last_updated" => "2025-01-16 04:02:35" "deleted" => 1 ] [ "id" => 9376905 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2025-01-16 04:02:35" "last_updated" => "2025-02-09 04:11:57" "deleted" => 1 ] [ "id" => 9624154 "last_round_investors_count" => 1 "total_rounds_count" => 1 "last_round_type" => "Grant" "last_round_date" => "2023-08-14 00:00:00" "last_round_money_raised" => "US$ 1.7M" "cb_url" => "https://www.crunchbase.com/funding_round/angelini-pharma-magyarország-grant--e639f205" "created" => "2025-02-09 04:11:57" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] ] "company_locations_collection" => [ [ "id" => 21614380 "company_id" => 25495456 "location_address" => "Viale Amelia, 70; Rome, RM 00181, IT" "is_primary" => 1 "created" => "2020-08-09 17:22:49" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 28295730 "company_id" => 25495456 "location_address" => "Martin-Greif Straße 1; Munich, Baviera 80336, DE" "is_primary" => 0 "created" => "2021-07-24 02:16:16" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 28295731 "company_id" => 25495456 "location_address" => "Júnová 33, 831 01 – Bratislava 3; Bratislava, Bratislava 3, SK" "is_primary" => 0 "created" => "2021-07-24 02:16:16" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 28295732 "company_id" => 25495456 "location_address" => "Palachovo náměstí 799/5; Brno-Starý Lískovec, Brno-Starý Lískovec 625 00, CZ" "is_primary" => 0 "created" => "2021-07-24 02:16:16" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 28295733 "company_id" => 25495456 "location_address" => "Strada Doctor Carol Davila 9; Sectorul 5, Bucarest, RO" "is_primary" => 0 "created" => "2021-07-24 02:16:16" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 28295734 "company_id" => 25495456 "location_address" => "Carrer d'osi, 7; Barcellona, Catalogna 08034, ES" "is_primary" => 0 "created" => "2021-07-24 02:16:16" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 28295735 "company_id" => 25495456 "location_address" => "R. João Chagas 53 Piso, 3; Alges, Cruz Quebrada 1499-040 , PT" "is_primary" => 0 "created" => "2021-07-24 02:16:16" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 28295736 "company_id" => 25495456 "location_address" => "1231 Wyandotte Dr; Albany, Georgia 31705, US" "is_primary" => 0 "created" => "2021-07-24 02:16:16" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 28295737 "company_id" => 25495456 "location_address" => "Via Pontasso, 1; Casella, Liguria 16015, IT" "is_primary" => 0 "created" => "2021-07-24 02:16:16" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 28295738 "company_id" => 25495456 "location_address" => "Via Vecchia del Pinocchio, 22; Ancona, Marche 60131, IT" "is_primary" => 0 "created" => "2021-07-24 02:16:16" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 28295739 "company_id" => 25495456 "location_address" => "Podleśna 83; Łazy, Masovia 05-552, PL" "is_primary" => 0 "created" => "2021-07-24 02:16:16" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 28295740 "company_id" => 25495456 "location_address" => "Trekhprudnyy Pereulok, 9с1; Moscow, Moscow 123001, OO" "is_primary" => 0 "created" => "2021-07-24 02:16:16" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 28295741 "company_id" => 25495456 "location_address" => "бул. Асен Йорданов № 10; Sofia, Sofia 1592, BG" "is_primary" => 0 "created" => "2021-07-24 02:16:16" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 28295742 "company_id" => 25495456 "location_address" => "Brigittenauer Lände 50-54; Wien , Wien 1200, AT" "is_primary" => 0 "created" => "2021-07-24 02:16:16" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 28295743 "company_id" => 25495456 "location_address" => "4 Roupel; Kifisià, GR" "is_primary" => 0 "created" => "2021-07-24 02:16:16" "last_updated" => "2023-09-01 04:34:38" "deleted" => 1 ] [ "id" => 125491207 "company_id" => 25495456 "location_address" => "4 Roupel; Kifisià, 145 64, GR" "is_primary" => 0 "created" => "2023-09-01 04:34:38" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 125491208 "company_id" => 25495456 "location_address" => "Via Guardapasso; Aprilia, Latium 04011, IT" "is_primary" => 0 "created" => "2023-09-01 04:34:38" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 125491209 "company_id" => 25495456 "location_address" => "Carrer de sa Dragonera; Sant Quirze del Vallès, Catalonia 08192, ES" "is_primary" => 0 "created" => "2023-09-01 04:34:38" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 125491210 "company_id" => 25495456 "location_address" => "24 High Holborn; Napier House; London, England, GB" "is_primary" => 0 "created" => "2023-09-01 04:34:38" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 125491211 "company_id" => 25495456 "location_address" => "Zählerweg 6; Zug, ZG 6300, CH" "is_primary" => 0 "created" => "2023-09-01 04:34:38" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 125491212 "company_id" => 25495456 "location_address" => "Birger Jarlsgatan 6d; Stockholm, Stockholm County 11435, SE" "is_primary" => 0 "created" => "2023-09-01 04:34:38" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] ] "company_similar_collection" => [ [ "id" => 114155209 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/angelini" "created" => "2020-03-20 06:55:06" "last_updated" => "2020-04-18 00:01:51" "deleted" => 1 ] [ "id" => 114155210 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/angelini-pharma-inc" "created" => "2020-03-20 06:55:06" "last_updated" => "2020-10-08 20:50:00" "deleted" => 1 ] [ "id" => 114155211 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/menarini" "created" => "2020-03-20 06:55:06" "last_updated" => "2020-11-13 15:00:30" "deleted" => 1 ] [ "id" => 114155212 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/angelini-pharma-hellas-s-a-" "created" => "2020-03-20 06:55:06" "last_updated" => "2020-04-18 00:01:51" "deleted" => 1 ] [ "id" => 114155213 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/angelini-pharmaceuticals" "created" => "2020-03-20 06:55:06" "last_updated" => "2020-04-18 00:01:51" "deleted" => 1 ] [ "id" => 114155214 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/sanofi" "created" => "2020-03-20 06:55:06" "last_updated" => "2020-11-13 15:00:30" "deleted" => 1 ] [ "id" => 114155215 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/angelinipharmaespana" "created" => "2020-03-20 06:55:06" "last_updated" => "2020-04-18 00:01:51" "deleted" => 1 ] [ "id" => 114155216 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/idesa-parfums" "created" => "2020-03-20 06:55:06" "last_updated" => "2020-08-09 17:22:49" "deleted" => 1 ] [ "id" => 114155217 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/nestle-s-a-" "created" => "2020-03-20 06:55:06" "last_updated" => "2020-04-18 00:01:51" "deleted" => 1 ] [ "id" => 114155218 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/catalent-pharma-solutions" "created" => "2020-03-20 06:55:06" "last_updated" => "2020-04-18 00:01:51" "deleted" => 1 ] [ "id" => 133399125 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/angelini-group-careers" "created" => "2020-04-18 00:01:51" "last_updated" => "2020-05-21 00:20:15" "deleted" => 1 ] [ "id" => 133399126 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/pfizer" "created" => "2020-04-18 00:01:51" "last_updated" => "2021-07-24 02:16:16" "deleted" => 1 ] [ "id" => 133399127 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/bsp-pharmaceuticals" "created" => "2020-04-18 00:01:51" "last_updated" => "2020-05-21 00:20:15" "deleted" => 1 ] [ "id" => 133399128 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/dompe" "created" => "2020-04-18 00:01:51" "last_updated" => "2020-11-13 15:00:30" "deleted" => 1 ] [ "id" => 133399129 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/eli-lilly-and-company" "created" => "2020-04-18 00:01:51" "last_updated" => "2020-05-21 00:20:15" "deleted" => 1 ] [ "id" => 133399130 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/chiesi-italia" "created" => "2020-04-18 00:01:51" "last_updated" => "2020-05-21 00:20:15" "deleted" => 1 ] [ "id" => 154255538 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/angelini-holding" "created" => "2020-05-21 00:20:15" "last_updated" => "2020-11-13 15:00:30" "deleted" => 1 ] [ "id" => 154255539 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/alfasigma" "created" => "2020-05-21 00:20:15" "last_updated" => "2020-11-13 15:00:30" "deleted" => 1 ] [ "id" => 154255540 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/angelinipharmaespana" "created" => "2020-05-21 00:20:15" "last_updated" => "2020-08-09 17:22:49" "deleted" => 1 ] [ "id" => 154255541 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/chiesi-group" "created" => "2020-05-21 00:20:15" "last_updated" => "2020-06-09 06:57:08" "deleted" => 1 ] [ "id" => 165750159 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/glaxosmithkline" "created" => "2020-06-09 06:57:08" "last_updated" => "2021-07-24 02:16:16" "deleted" => 1 ] [ "id" => 203258570 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/angelini-beauty" "created" => "2020-08-09 17:22:49" "last_updated" => "2020-10-08 20:50:00" "deleted" => 1 ] [ "id" => 203258571 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2020-08-09 17:22:49" "last_updated" => "2020-09-09 14:41:32" "deleted" => 1 ] [ "id" => 222521929 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/novartisitalia" "created" => "2020-09-09 14:41:32" "last_updated" => "2020-11-13 15:00:30" "deleted" => 1 ] [ "id" => 245158056 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/chiesi-group" "created" => "2020-10-08 20:50:00" "last_updated" => "2020-11-13 15:00:30" "deleted" => 1 ] [ "id" => 245158057 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2020-10-08 20:50:00" "last_updated" => "2020-11-13 15:00:30" "deleted" => 1 ] [ "id" => 272946774 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/angelini-holding" "created" => "2020-11-13 15:00:30" "last_updated" => "2021-07-24 02:16:16" "deleted" => 1 ] [ "id" => 272946775 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/menarini" "created" => "2020-11-13 15:00:30" "last_updated" => "2021-07-24 02:16:16" "deleted" => 1 ] [ "id" => 272946776 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/dompe" "created" => "2020-11-13 15:00:30" "last_updated" => "2021-07-24 02:16:16" "deleted" => 1 ] [ "id" => 272946777 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/alfasigma" "created" => "2020-11-13 15:00:30" "last_updated" => "2021-07-24 02:16:16" "deleted" => 1 ] [ "id" => 272946778 "company_id" => 25495456 "url" => "https://fr.linkedin.com/company/sanofi" "created" => "2020-11-13 15:00:30" "last_updated" => "2021-07-24 02:16:16" "deleted" => 1 ] [ "id" => 272946779 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/novartisitalia" "created" => "2020-11-13 15:00:30" "last_updated" => "2021-07-24 02:16:16" "deleted" => 1 ] [ "id" => 272946780 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/chiesi-group" "created" => "2020-11-13 15:00:30" "last_updated" => "2021-07-24 02:16:16" "deleted" => 1 ] [ "id" => 272946781 "company_id" => 25495456 "url" => "https://ch.linkedin.com/company/roche" "created" => "2020-11-13 15:00:30" "last_updated" => "2020-12-06 13:01:19" "deleted" => 1 ] [ "id" => 308989179 "company_id" => 25495456 "url" => "https://de.linkedin.com/company/bayer" "created" => "2020-12-06 13:01:19" "last_updated" => "2021-01-10 11:52:10" "deleted" => 1 ] [ "id" => 351542771 "company_id" => 25495456 "url" => "https://ch.linkedin.com/company/roche" "created" => "2021-01-10 11:52:10" "last_updated" => "2021-04-25 06:02:12" "deleted" => 1 ] [ "id" => 403819787 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/zambon" "created" => "2021-04-25 06:02:12" "last_updated" => "2021-07-24 02:16:16" "deleted" => 1 ] [ "id" => 480655901 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/angelini-holding" "created" => "2021-09-09 18:01:50" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 480655902 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/menarini" "created" => "2021-09-09 18:01:50" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 480655903 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/alfasigma" "created" => "2021-09-09 18:01:50" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 480655905 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/dompe" "created" => "2021-09-09 18:01:50" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 480655907 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/pfizer" "created" => "2021-09-09 18:01:50" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 480655909 "company_id" => 25495456 "url" => "https://fr.linkedin.com/company/sanofi" "created" => "2021-09-09 18:01:50" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 480655912 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/novartisitalia" "created" => "2021-09-09 18:01:50" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 480655914 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/chiesi-group" "created" => "2021-09-09 18:01:50" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 480655915 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/glaxosmithkline" "created" => "2021-09-09 18:01:50" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 480655917 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/zambon" "created" => "2021-09-09 18:01:50" "last_updated" => "2022-03-22 11:43:09" "deleted" => 1 ] [ "id" => 607296840 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/menarini/" "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 607296841 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/alfasigma/" "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 607296842 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/angelini-industries/" "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 607296843 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/dompe/" "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 607296844 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/pfizer/" "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 607296845 "company_id" => 25495456 "url" => "https://fr.linkedin.com/company/sanofi/" "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 607296846 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/novartisitalia/" "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 607296847 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/chiesi-group/" "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 607296848 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/glaxosmithkline/" "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 607296849 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/zambon/" "created" => "2022-03-22 11:43:09" "last_updated" => "2022-04-05 16:23:07" "deleted" => 1 ] [ "id" => 617094928 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/menarini" "created" => "2022-04-05 16:23:07" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 617094929 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/alfasigma" "created" => "2022-04-05 16:23:07" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 617094930 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/angelini-industries" "created" => "2022-04-05 16:23:07" "last_updated" => "2023-12-12 18:38:02" "deleted" => 1 ] [ "id" => 617094931 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/dompe" "created" => "2022-04-05 16:23:07" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 617094932 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/pfizer" "created" => "2022-04-05 16:23:07" "last_updated" => "2023-08-03 09:35:33" "deleted" => 1 ] [ "id" => 617094933 "company_id" => 25495456 "url" => "https://fr.linkedin.com/company/sanofi" "created" => "2022-04-05 16:23:07" "last_updated" => "2023-04-17 17:17:18" "deleted" => 1 ] [ "id" => 617094934 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/novartisitalia" "created" => "2022-04-05 16:23:07" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 617094935 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/chiesi-group" "created" => "2022-04-05 16:23:07" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 617094936 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/glaxosmithkline" "created" => "2022-04-05 16:23:07" "last_updated" => "2022-06-25 01:33:34" "deleted" => 1 ] [ "id" => 617094937 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/zambon" "created" => "2022-04-05 16:23:07" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 648927987 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/fidia-farmaceutici-spa" "created" => "2022-06-25 01:33:34" "last_updated" => "2024-07-20 13:20:59" "deleted" => 1 ] [ "id" => 806234149 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/ibsa-farmaceutici" "created" => "2023-04-17 17:17:18" "last_updated" => "2023-08-03 09:35:33" "deleted" => 1 ] [ "id" => 860873410 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/ibsa-italy" "created" => "2023-08-03 09:35:33" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 860873411 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/roche-italia" "created" => "2023-08-03 09:35:33" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 923653483 "company_id" => 25495456 "url" => "https://www.linkedin.com/company/pfizer" "created" => "2023-12-12 18:38:02" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 1036633373 "company_id" => 25495456 "url" => "https://it.linkedin.com/company/fidia-pharma" "created" => "2024-07-20 13:20:59" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] ] "company_specialties_collection" => [ [ "id" => 119784774 "company_id" => 25495456 "specialty" => "consumer healthcare" "created" => "2023-02-12 02:50:30" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 119784775 "company_id" => 25495456 "specialty" => "brain health" "created" => "2023-02-12 02:50:30" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 119784776 "company_id" => 25495456 "specialty" => "epilepsy" "created" => "2023-02-12 02:50:30" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 131125379 "company_id" => 25495456 "specialty" => "mental health" "created" => "2024-06-08 20:27:05" "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] ] "company_stock_info_collection" => [] "company_updates_collection" => [ [ "id" => 2909176 "company_id" => 25495456 "urn" => "urn:li:activity:7004740166137331712" "followers" => 95802 "date" => "18h" "description" => """ At Angelini Pharma, we believe in equality and guarantee equal opportunities for all our people. On#InternationalDayofPersonswithDisabilities, we renew our commitment to foster an inclusive workplace that supports the diversity, well-being, and growth of Angeliners. As our colleague Samanta Stradella, Clinical Supply Support Analyst, says: "people with disabilities, through resilience, hard work, and passion, are capable of achieving great results by facing difficulties. I am proud to be part of this community."\n #EveryStepCloser """ "reactions_count" => 59 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-03 10:59:17" "deleted" => 1 ] [ "id" => 2909177 "company_id" => 25495456 "urn" => "urn:li:activity:7004415279506042880" "followers" => 95802 "date" => "1d" "description" => """ How does a pharmaceutical idea come about?\n In this interviewRafal Kaminski, Chief Scientific Officer of Angelini Pharma, explains the main steps of the medicine development process and the changes that are taking place as a result of technological progress. \n "Nice to meet you" is our podcast created to give voice to Angelini Pharma Leaders. The Italian journalist Barbara Serra will talk with them about their vision, values, and commitment within the company.\n \n Listen to our podcast here 👉 https://lnkd.in/dgmsYuAf\n #EveryStepCloser """ "reactions_count" => 54 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-03 10:59:17" "deleted" => 1 ] [ "id" => 2909178 "company_id" => 25495456 "urn" => "urn:li:activity:7004381020070285312" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Unindustria Roma - Frosinone - Latina - Rieti - Viterbo" "reshared_post_author_url" => "https://it.linkedin.com/company/unindustria-roma" "reshared_post_author_headline" => null "reshared_post_description" => """ Una giornata importante per valorizzare il talento femminile e il contributo delle#donne al mondo del #lavoro e al progresso della società.\n \n Oggi abbiamo ospitato la seconda edizione del "Premio Minerva Roma Donna Manager & Impresa d’Eccellenza", organizzato insieme a Federmanager Roma in collaborazione con Luiss Business School\n \n 4 le imprese premiate e 17 le menzioni speciali per le aziende del Lazio: premiate inoltre 4 Donne Manager che si sono distinte nel loro percorso manageriale. Ecco tutti i vincitori:\n \n 🏆 Categoria “Grandi imprese”\n Abbott e Gruppo Ferrovie dello Stato Italiane\n \n 🏆 Categoria “PMI”\n #Optikon2000 e ploomia\n \n ➡️ Menzione speciale per "Azioni a supporto della Leadership femminile e della valorizzazione dei talenti femminili”\n Autostrade per l'Italia \| BAT \| Enel Group \| Oracle \| Birra Peroni \| Philip Morris International \| Procter & Gamble \| Vodafone \| Wind Tre\n \n ➡️ Menzione speciale per "Strumenti a supporto del work-life balance e della condivisione delle responsabilità familiari e parentali"\n BAT \| Elettronica Group \| Enel Group \| Pfizer \| Philip Morris International \| Procter & Gamble \| Vodafone \| Wind Tre\n \n 🏆 Queste le Donne Manager premiate: \n Francesca Reich, AD Poligrafico e Zecca dello Stato Italiano\n Francesca Zanninotti, AD Medea Italgas\n Patrizia Ravaioli, DG Formez PA\n Calabrese Rosita, Country Manager Italy Angelini Pharma\n \n "La nostra Associazione continua a farsi parte attiva in un’ottica di valorizzazione dell’#empowermentfemminile, anche per le piccole imprese”, ha commentato Fausto Bianchi. \n \n Per tutte le informazioni, visita il nostro sito ⬇️\n https://lnkd.in/ds_Qc8-2 """ "reshared_post_followers" => 6936 "reshared_post_date" => "2d" "last_updated" => "2023-01-03 10:59:17" "deleted" => 1 ] [ "id" => 2909179 "company_id" => 25495456 "urn" => "urn:li:activity:7003672767430602754" "followers" => 95802 "date" => "3d" "description" => """ Angelini Pharma España and the NGO Banco Farmacéutico collaborated to distribute more than 9,000 health resources to people in vulnerable situations.\n During the event, 25% of the pharmaceutical company brought parapharmacy and OTC products to social entities in Barcelona and Madrid.\n This volunteer action aims to assist people in vulnerable situations who suffer from inequality in access to medicines for economic reasons.\n In particular, according to Nour Hammouch Benabdellah, a colleague from the Communications & Public Affairs Department at Angelini Pharma España who attended the activity, "the fact that all the departments have coordinated so well shows me what a great team I work with".\n #EveryStepCloser """ "reactions_count" => 37 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-03 10:59:17" "deleted" => 1 ] [ "id" => 2909180 "company_id" => 25495456 "urn" => "urn:li:activity:7003309047256887296" "followers" => 95802 "date" => "4d" "description" => """ 📅Leading experts will come together for the 3rd Psychiatry Innovation Summit on 1-2 December 2022 in Rome, Italy. \n The meeting aims at fostering new collaborations, developing innovative digital health solutions, and accelerating the general adoption of a digital perspective in brain health. \n The speakers will focus on the growing importance of digital solutions in diagnosing, treating, predicting, and preventing mental disorders.#EveryStepCloser #WithYouInMind #PSYSUM2022 """ "reactions_count" => 48 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-03 10:59:17" "deleted" => 1 ] [ "id" => 2909181 "company_id" => 25495456 "urn" => "urn:li:activity:7002943005733056512" "followers" => 95802 "date" => "5d" "description" => """ We strongly believe that our people can make the difference and contribute to our continuous improvement. We have recently launched the#Call4Ideas of our program #ChallengeTheStatusQuo. Open to all the Angeliners, the challenge aims at unlocking their hidden potential in an #OpenInnovation perspective. \n Until early 2023 Angeliners will have the occasion to step up, present visionary ideas and let our Group Values (Innovation, Engagement, Performance, Ethics and Responsibility) lead our future. \n We will keep working to make our company innovative. We can’t wait to see the outcomes of this exciting journey! \n #EveryStepCloser """ "reactions_count" => 71 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-03 10:59:17" "deleted" => 1 ] [ "id" => 2909182 "company_id" => 25495456 "urn" => "urn:li:activity:7001839914094870528" "followers" => 95802 "date" => "1w" "description" => """ As theUnited Nations claims, violence against women and girls is one of today's most widespread, persistent, and devastating human rights violations. It remains unreported mainly due to the impunity, silence, stigma, and shame surrounding it. \n Today, on the International day for the Elimination of Violence against Women, we want to express our support to every woman victim of violence and renew our commitment concerning such an important issue because we believe that together we can build a better society and future.\n #InternationalDayfortheEliminationofViolenceAgainstWomen\n #EveryStepCloser """ "reactions_count" => 97 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-03 10:59:17" "deleted" => 1 ] [ "id" => 2909183 "company_id" => 25495456 "urn" => "urn:li:activity:7000854442006753280" "followers" => 95802 "date" => "1w" "description" => """ "Jacopo Andreose has a wealth of experience in top roles within the pharmaceutical industry".\n The Pharma Letter announces the appointment of our new #CEO.\n \n Read more here 👇 """ "reactions_count" => 123 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-03 10:59:17" "deleted" => 1 ] [ "id" => 2909184 "company_id" => 25495456 "urn" => "urn:li:activity:7000775114787045378" "followers" => 95802 "date" => "1w" "description" => "📣We have a big announcement today! Please welcome our new#CEO Jacopo Andreose, who will take on the role from February 6, bringing over twenty years of experience in top management positions in the pharmaceutical industry." "reactions_count" => 553 "comments_count" => 174 "reshared_post_author" => "Angelini Industries" "reshared_post_author_url" => "https://it.linkedin.com/company/angelini-industries" "reshared_post_author_headline" => null "reshared_post_description" => """ Angelini Industries announces the appointment ofJacopo Andreose as new Chief Executive Officer of Angelini Pharma, the pharmaceutical company active in brain health, including mental health and epilepsy, and consumer healthcare, which is part of our industrial group. \n With more than twenty years of international experience in top management positions within the pharmaceutical industry, Jacopo Andreose will take on the role starting from 6 February, 2023. \n \n Read the press release: https://lnkd.in/dr5YfAX8 \n \n #AngeliniIndustries #IndustryOfCare """ "reshared_post_followers" => 129281 "reshared_post_date" => "1w" "last_updated" => "2023-01-03 10:59:17" "deleted" => 1 ] [ "id" => 2909185 "company_id" => 25495456 "urn" => "urn:li:activity:7000413522744520704" "followers" => 95802 "date" => "1w" "description" => """ Angelini Pharma España and Impact Hub Barcelona collaborated in the organization of the hackathon "Global Goals Jam". It is a global collective intelligence initiative to design solutions that help advance Sustainable Development Goals.\n In this project, 25 young people from all over Spain joined in Barcelona to form 5 multidisciplinary teams from the health sciences and social and humanities fields. The challenge presented had to answer the question: "How can young people help their environment with Brain Health to prevent and destigmatize mental disorders"?\n This initiative represents another step forward in our commitment to promoting Brain Health through research and innovation.\n #EveryStepCloser """ "reactions_count" => 39 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-03 10:59:17" "deleted" => 1 ] [ "id" => 27086395 "company_id" => 25495456 "urn" => "urn:li:activity:7011999334263078912" "followers" => 97901 "date" => "1w" "description" => """ The holidays are coming, and we are ready to spend them with our beloved ones. It has been a tough year, which has confronted us with new challenges and the need for change. We will continue seeking innovative solutions to improve people's lives and overcome the stigma many diseases bring with them. With optimism and confidence, we approach the beginning of a new year.\n Happy Holidays to all of you! 🎁\n #EveryStepCloser """ "reactions_count" => 64 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-12 02:50:30" "deleted" => 1 ] [ "id" => 27086396 "company_id" => 25495456 "urn" => "urn:li:activity:7010920474356420609" "followers" => 97901 "date" => "2w" "description" => """ 🔬 How is a new medicine born? From the discovery of the molecule to its placement on the market, it's a long journey that goes through four different stages. The first and most fascinating is the research. \n Let's find out how a new cure is born behind the scenes.\n 👉 https://lnkd.in/dtn4ZwWg\n #EveryStepCloser """ "reactions_count" => 60 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-12 02:50:30" "deleted" => 1 ] [ "id" => 27086397 "company_id" => 25495456 "urn" => "urn:li:activity:7010884965416464384" "followers" => 97901 "date" => "2w" "description" => """ Did you know that music can be one of our best #study companion? Several researches show that music can help us focusing and improving our study performances. Music is in fact one of the most powerful medicine for our #mentalhealth, being able to either relax or activate our minds. Have you ever heard of #Musictherapy? It’s a discipline based on the use of music as an #educational, rehabilitative and #therapeutic tool, which exploits the healing power of sounds, in order to influence our cognitive and motorial functions. This means we were practically born to love #music!\n #EveryStepCloser """ "reactions_count" => 64 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-12 02:50:30" "deleted" => 1 ] [ "id" => 27086398 "company_id" => 25495456 "urn" => "urn:li:activity:7010635704099622912" "followers" => 97901 "date" => "2w" "description" => """ 🎧 La violenza contro le donne, e in particolare la violenza nelle relazioni di intimità, ha degli effetti devastanti sulla #salutementale.\n La nuova puntata di #BuoneNuove è dedicata alla storia di Lucia Annibali, che ha fatto della sua ferita un motivo di lotta e di riscatto.\n Ascolta il #podcast di Massimiliano Coccia prodotto per noi da Storielibere.fm qui 👉 https://lnkd.in/gy2iedCv\n #EveryStepCloser """ "reactions_count" => 30 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-12 02:50:30" "deleted" => 1 ] [ "id" => 27086399 "company_id" => 25495456 "urn" => "urn:li:activity:7009487569939771393" "followers" => 97901 "date" => "2w" "description" => """ Our medical professionals have a central role, especially when it comes to improvement and #innovation of new drugs and medical treatments. Surprisingly, most #medicalstudents are not aware of the opportunities to undertake a professional career in the pharmaceutical sector. Would you like to know more about our medical roles? \n Here come the interviews from our #medicalprofessionals! They will share with us their experience and you will have the chance to get an inside look into our medical department, knowing more about our physician's role, passions, and career paths. \n Stay tuned to know more! \n #AMedicalLeadershipStory #EveryStepCloser """ "reactions_count" => 49 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-12 02:50:30" "deleted" => 1 ] [ "id" => 27086400 "company_id" => 25495456 "urn" => "urn:li:activity:7009116073098686464" "followers" => 97901 "date" => "2w" "description" => """ "What I love about my job is being in touch with the different realities in different countries and helping them develop customized communications strategies." \n Our International Communication Specialist Claudia Blass talks about her carrier in the Global Communications team and what she likes about her job in our new format #WhenIGrowUp. A series of short video interviews through which our Angeliners will explain how they came to work in the pharmaceutical world and their role inside our company. \n \n Watch the full interview here 👉 https://lnkd.in/dexYTFMD\n #EveryStepCloser """ "reactions_count" => 29 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-12 02:50:30" "deleted" => 1 ] [ "id" => 27086401 "company_id" => 25495456 "urn" => "urn:li:activity:7006281622249451520" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Motore Sanità" "reshared_post_author_url" => "https://it.linkedin.com/in/motore-sanit%C3%A0-19437390/en" "reshared_post_author_headline" => "Organizzazione no profit" "reshared_post_description" => """ L'epilessia comporta ancora uno stigma a livello individuale e sociale, con importanti limitazioni per quanto riguarda l’autonomia personale, in ambito scolastico e lavorativo. Ne parleremo durante il webinar di Motore Sanità "Persone con epilessia: presa in carico assistenziale - Calabria" lunedì 12 dicembre 2022 dalle ore 10:00. Per maggiori informazioni e per iscriversi, visitate il sito www.motoresanita.it.\n \n Oriano Mecarelli Emilio Russo Marcello Pani simona loizzo Angelini Pharma #epilessia #calabria #webinar #motoresanità #innovazione #medicina """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2023-02-12 02:50:30" "deleted" => 1 ] [ "id" => 27086402 "company_id" => 25495456 "urn" => "urn:li:activity:7006217323434897408" "followers" => 97901 "date" => "3w" "description" => """ We’ve always been committed to providing our people with the best possible employee experience and allowing them to unveiling their potential to make the difference.\n Being part of our #MedicalFaculty requires passion, devotion, while also embracing an innovative and agile mindset. We strongly believe in the individual and his or her potential, and being an Angeliner as a physician means having the opportunity to grow both internally and externally, becoming a point of scientific reference.\n #AMedicalLeadershipStory\n Have you ever thought about undertaking a professional path in the pharmaceutical world? \n Learn more about us visiting Angelini Pharma’s Career Page 👇 \n https://lnkd.in/d_Vhrh3H\n #EveryStepCloser """ "reactions_count" => 47 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-12 02:50:30" "deleted" => 1 ] [ "id" => 27086403 "company_id" => 25495456 "urn" => "urn:li:activity:7005545403374821376" "followers" => 97901 "date" => "4w" "description" => """ Welcome to Angelini Pharma Österreich!\n \n #EveryStepCloser """ "reactions_count" => 35 "comments_count" => null "reshared_post_author" => "Angelini Pharma Österreich" "reshared_post_author_url" => "https://at.linkedin.com/company/angelini-pharma-%C3%B6sterreich" "reshared_post_author_headline" => null "reshared_post_description" => """ Herzlich Willkommen auf unserem LinkedIn-Account! \n \n Wir Angeliners freuen uns, Ihnen die Welt von Angelini Pharma näher zu bringen und mit Ihnen hier unsere Werte, unsere Ziele und die interessantesten Aktivitäten unserer wertvollen Mitarbeiter:innen zu teilen. Folgen Sie uns und lassen Sie sich von unserer Vision und Mission überzeugen! \n \n Neuigkeiten finden Sie auf unserer Webseite: https://lnkd.in/dvmCh5nE """ "reshared_post_followers" => 198 "reshared_post_date" => "4w" "last_updated" => "2023-02-12 02:50:30" "deleted" => 1 ] [ "id" => 27086404 "company_id" => 25495456 "urn" => "urn:li:activity:7004740166137331712" "followers" => 97901 "date" => "1mo" "description" => """ At Angelini Pharma, we believe in equality and guarantee equal opportunities for all our people. On #InternationalDayofPersonswithDisabilities, we renew our commitment to foster an inclusive workplace that supports the diversity, well-being, and growth of Angeliners. As our colleague Samanta Stradella, Clinical Supply Support Analyst, says: "people with disabilities, through resilience, hard work, and passion, are capable of achieving great results by facing difficulties. I am proud to be part of this community."\n #EveryStepCloser """ "reactions_count" => 81 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-12 02:50:30" "deleted" => 1 ] [ "id" => 68151307 "company_id" => 25495456 "urn" => "urn:li:activity:7029811579021869056" "followers" => 101374 "date" => "1d" "description" => """ Profound health inequities compound the high burden associated with neurological disorders.\n Nearly 80% of the 50 million people with epilepsy live in low-and middle-income countries, where treatment gaps exceed 75% in most low-income countries and 50% in most middle-income countries.\n We joined the INTERNATIONAL BUREAU FOR EPILEPSY campaign #50MillionSteps to raise awareness of #epilepsy. \n We support the mission of our colleague Serena F.L. Zucchetta because we must respond to these people's needs, starting with increasing understanding and awareness and combating stigma and discrimination, barriers to seeking health care.\n #StampOutStigma \n #EveryStepCloser #WithYouInMind """ "reactions_count" => 48 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-02 21:02:50" "deleted" => 1 ] [ "id" => 68151308 "company_id" => 25495456 "urn" => "urn:li:activity:7029400801437462528" "followers" => 101374 "date" => "2d" "description" => """ 🎧 What is your go-to music to stay focused on your exams preparation?\n \n College students often face challenging circumstances and the resulting anxiety and stress can generate a physiological and behavioral response that negatively affects concentration and academic performance. Music can help you cope with this negative emotional state: listening to calm, slow-paced music reduces anxiety and facilitates relaxation, positively influencing the limbic system the brain area which controls emotions. \n \n What are you waiting for? Click and experience our music playlist on Spotify 🎶 https://spoti.fi/3RQFnWz\n \n #AMedicalLeadershipStory #EveryStepCloser """ "reactions_count" => 23 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-02 21:02:50" "deleted" => 1 ] [ "id" => 68151309 "company_id" => 25495456 "urn" => "urn:li:activity:7029089413951369216" "followers" => 101374 "date" => "3d" "description" => """ As reported by the ESMO - European Society for Medical Oncology, patients with cancer commonly experience pain. This latter can affect even more than 60% of patients, depending on the tumor stage. During the #WorldCancerDay 2023, on February 4th, we renewed its effort and commitment for cancer patients’ wellbeing by encouraging a proper doctor-patient communication aimed at improving the management of cancer pain.\n Say no to pain: talk to your oncologist!\n Read more here 👉 https://lnkd.in/dc25_EVR\n #SayNoToPain #EveryStepCloser """ "reactions_count" => 20 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-02 21:02:50" "deleted" => 1 ] [ "id" => 68151310 "company_id" => 25495456 "urn" => "urn:li:activity:7028653480353361920" "followers" => 101374 "date" => "4d" "description" => """ More than 3 million steps walked by our people, 50 million steps to raise #epilepsy awareness.\n Today we want to thank all the colleagues of Angelini Pharma and Angelini Industries for contributing to the INTERNATIONAL BUREAU FOR EPILEPSY campaign because we believe that together we can overcome the stigma and support people with epilepsy and their caregiver, improving their quality of life.\n More steps. More awareness. More lives improved.\n #50MillionSteps #StampOutStigma\n #EveryStepCloser #WithYouInMind """ "reactions_count" => 51 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-02 21:02:50" "deleted" => 1 ] [ "id" => 68151311 "company_id" => 25495456 "urn" => "urn:li:activity:7028395316064247808" "followers" => 101374 "date" => "5d" "description" => """ A new year with the same mission: taking care of people's lives. We start 2023 with renewed enthusiasm and a new CEO Jacopo Andreose at the helm of our company. We will continue to work to overcome the stigma and prejudices that many diseases bring, make our work environment increasingly inclusive, and enhance our people's talent. \n Towards new goals, #EveryStepCloser. """ "reactions_count" => 62 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-02 21:02:50" "deleted" => 1 ] [ "id" => 68151312 "company_id" => 25495456 "urn" => "urn:li:activity:7028311560242507776" "followers" => 101374 "date" => "5d" "description" => """ We are delighted to welcome our new Chief Executive Officer, Jacopo Andreose, today. We look forward to working with him to strengthen our pioneering trajectory in the brain health space, blazing a new trail to shift treatment paradigms and positively impact the patient journey. \n #EveryStepCloser """ "reactions_count" => 323 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-02 21:02:50" "deleted" => 1 ] [ "id" => 68151313 "company_id" => 25495456 "urn" => "urn:li:activity:7027574872197185536" "followers" => 101374 "date" => "1w" "description" => """ As stated by the ESMO - European Society for Medical Oncology, it is important to understand that cancer pain can be effectively managed: multiple treatments are currently available, and patients should not have to tolerate it. A proper physician-patient communication could improve cancer pain management. If cancer patients spoke more openly about their pain, doctors could better understand and help them. \n During the #WorldCancerDay 2023, we encourages cancer patients to talk more about their pain, and oncologists to be more eager to ask patients about it. \n Say no to pain: talk to your oncologist!\n \n #SayNoToPain #EveryStepCloser """ "reactions_count" => 109 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-02 21:02:50" "deleted" => 1 ] [ "id" => 68151314 "company_id" => 25495456 "urn" => "urn:li:activity:7027236277527715840" "followers" => 101374 "date" => "1w" "description" => """ The incidence of mental disorders in European countries is rising: one in six people will experience a similar problem in their lifetime. This data highlights the need for improved #mentalhealth services and support systems, particularly in the workplace. Taking this into account, we have developed the report #Headway - #MentalHealthIndex, in partnership with The European House-Ambrosetti. This study aims to support people with mental health issues, helping them lead fulfilling lives. \n \n Read more here 👉 https://lnkd.in/d9euKjum\n \n #EveryStepCloser #WithYouInMind """ "reactions_count" => 42 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-02 21:02:50" "deleted" => 1 ] [ "id" => 68151315 "company_id" => 25495456 "urn" => "urn:li:activity:7025834157297516544" "followers" => 101374 "date" => "1w" "description" => """ We've already achieved over a million steps thanks to the efforts of our Group people. But our desire to contribute to the INTERNATIONAL BUREAU FOR EPILEPSY campaign "50 million steps" and to raise awareness of #epilepsy continues. Together with Angelini Industries’ colleagues we will keep walking and working to overcome the stigma and prejudices that people with epilepsy carry with them.\n More steps. More awareness. More lives improved.\n \n #50MillionSteps #StampOutStigma\n #EveryStepCloser #WithYouInMind """ "reactions_count" => 41 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-02 21:02:50" "deleted" => 1 ] [ "id" => 68151316 "company_id" => 25495456 "urn" => "urn:li:activity:7025777408003706880" "followers" => 101374 "date" => "1w" "description" => """ Our #medicalleadershipstory continues. Let’s meet Tiago Guerreiro! He’s a #MedicalDoctor and has been working in our Company for 2 years. In the interview he tells us about his career within Angelini Pharma. In his experience “Collaboration, creativity and passion are important pillars, where patient centricity is the focus of my work having the ability now to impact the health of a larger scale of patients.”\n What are you waiting for? Watch the video and find out more about our Medical leadership reality.\n Learn more about us visiting our Career Page\n https://lnkd.in/d_Vhrh3H\n \n #AMedicalLeadershipStory #EveryStepCloser """ "reactions_count" => 34 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-02 21:02:50" "deleted" => 1 ] [ "id" => 92244633 "company_id" => 25495456 "urn" => "urn:li:activity:7036669150290751488" "followers" => 102888 "date" => "1d" "description" => """ A new Welcome Aboard announcement kicks off the month of March, and it's Luigi Boltri joining us as our new Global R&D Product Lifecycle Management Executive Director. As Luigi has worked at both the high and low ends of the pharmaceutical industry - from Formulation Development Area, BD Support, and Technology Scouting, up to Senior Director of Pharmaceutical Sciences - he brings a variety of skills to the table. \n \n "I believe that change should be seen as an opportunity, and that is one of the many reasons why I chose to join Angelini Pharma. I am thrilled to be part of an exceptional team and contribute to improving patients' lives," said Luigi. """ "reactions_count" => 51 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-17 17:17:18" "deleted" => 1 ] [ "id" => 92244634 "company_id" => 25495456 "urn" => "urn:li:activity:7036337743081160705" "followers" => 102888 "date" => "2d" "description" => """ Our Chief Scientific Officer, Rafal Kaminski, participated in the "Italy-Sweden Life Science Seminar", organized by Business Sweden and Ambasciata di Svezia in Italia.\n The event aimed to promote knowledge and exchange experience between the two countries in precision medicine, future drug development & diagnostics, and digital transformation. \n The seminar represented an opportunity to describe our commitment to innovation and the development of innovative treatments, to meet patient's needs and improve their quality of life.\n #EveryStepCloser """ "reactions_count" => 88 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-17 17:17:18" "deleted" => 1 ] [ "id" => 92244635 "company_id" => 25495456 "urn" => "urn:li:activity:7034484636881727488" "followers" => 102888 "date" => "1w" "description" => """ What music do you listen to get pumped up before the exam session?\n When we listen to music, our brain is activated by releasing dopamine, a substance able to intervene in attention and learning capacity and allows us to gain strength and energy. Indeed, there are songs that can stimulate specific states of mind that allow us to make the most out of our brain's potential.\n \n We asked our people what songs motivate them during their days. Here is the result that will energize your study days!\n What are you waiting for? Click and experience our music playlist on Spotify 🎶\n 👉 https://spoti.fi/3SlRgUE\n \n #AMedicalLeadershipStory #EveryStepCloser """ "reactions_count" => 28 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-17 17:17:18" "deleted" => 1 ] [ "id" => 92244636 "company_id" => 25495456 "urn" => "urn:li:activity:7033388102140276736" "followers" => 102888 "date" => "1w" "description" => """ Environmental factors play a crucial role in shaping and impacting European #mentalhealth. Poverty, unemployment, urbanization, and climate change can cause stress, anxiety, depression and lead to social isolation. \n We have developed the report #Headway - #MentalHealthIndex, in partnership with The European House-Ambrosetti, to support people with mental health issues, helping them lead fulfilling lives. Read more here 👉 https://lnkd.in/d9euKjum\n \n #EveryStepCloser #WithYouInMind """ "reactions_count" => 54 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-17 17:17:18" "deleted" => 1 ] [ "id" => 92244637 "company_id" => 25495456 "urn" => "urn:li:activity:7032292854651588608" "followers" => 102888 "date" => "1w" "description" => """ We are close to the communities of Turkey and Syria affected by the earthquake. Our hearts go out to them and our colleagues and their families. It is crucial to stand together in times of crisis, and we are committed to offering concrete assistance. We have launched a fundraising campaign with UNHCR, the UN Refugee Agency, inviting our colleagues worldwide to contribute. Our primary purpose is to provide urgent aid to those in need, including food, shelter, and medical supplies. \n In the upcoming days and weeks ahead, together with our Group Angelini Industries, we will continue to monitor the situation closely and take additional action where possible.\n Read the news: https://lnkd.in/d_ap575U\n #EveryStepCloser """ "reactions_count" => 116 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-17 17:17:18" "deleted" => 1 ] [ "id" => 92244638 "company_id" => 25495456 "urn" => "urn:li:activity:7031645775184969729" "followers" => 102888 "date" => "2w" "description" => """ According to the latest OECD - OCDE figures, the cost of mental health in Europe exceeded 600 billion euros, accounting for 4% of the EU's total GDP. By 2030, #mentalhealth disorders will account for more than half of the global economic burden due to non-communicable diseases. \n These are the results of our report #Headway - #MentalHealthIndex, produced in partnership with The European House-Ambrosetti: a comprehensive approach to addressing mental health in the workplace and schools. The initiative aims to promote mental wellness, reduce mental illness's burden, transform how we approach mental health, and make it a top priority in our communities.\n Read more here 👉 https://lnkd.in/dSHsXSZF\n \n #EveryStepCloser #WithYouInMind """ "reactions_count" => 38 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-17 17:17:18" "deleted" => 1 ] [ "id" => 92244639 "company_id" => 25495456 "urn" => "urn:li:activity:7031207697081327616" "followers" => 102888 "date" => "2w" "description" => """ 🔬 How a Digital innovation is possible in Healthcare System?In this interview, Fabrizio Caranci, Global Digital Medicines Executive Director, explains how Angelini Pharma is promoting a digital culture between its people to take care of life. "Nice to meet you" is our podcast presented by Barbara Serra and created to give voice to Angelini Pharma Leaders about their vision, values, and commitment within the company.\n 🎧 Listen to our podcast here 👉 https://lnkd.in/dwjC23my\n #EveryStepCloser """ "reactions_count" => 70 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-17 17:17:18" "deleted" => 1 ] [ "id" => 92244640 "company_id" => 25495456 "urn" => "urn:li:activity:7030918078905397248" "followers" => 102888 "date" => "2w" "description" => """ More steps. More awareness. More lives improved.\n On #InternationalEpilepsyDay, we thank all the colleagues of Angelini Pharma and Angelini Industries’s companies for their passion and commitment. We joined the INTERNATIONAL BUREAU FOR EPILEPSY campaign #50MillionSteps to overcome the stigma and prejudice surrounding people with epilepsy. Through research and innovation, we can improve the lives of people with epilepsy and their caregivers.\n #StampOutStigma\n #EveryStepCloser #WithYouInMind """ "reactions_count" => 53 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-17 17:17:18" "deleted" => 1 ] [ "id" => 92244641 "company_id" => 25495456 "urn" => "urn:li:activity:7030842834790268928" "followers" => 102888 "date" => "2w" "description" => """ On #InternationalEpilepsyDay, we support INTERNATIONAL BUREAU FOR EPILEPSY #50MillionSteps campaign and renew our commitment to helping people with this disease by meeting their needs and improving their quality of life. With our new CEO Jacopo Andreose, we will continue to research and innovate in the field of brain health. \n We aim to raise awareness of neurological pathologies and overcome the stigma and prejudices that often surround them.\n #StampOutStigma \n #EveryStepCloser #WithYouInMind\n \n Angelini Industries """ "reactions_count" => 222 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-17 17:17:18" "deleted" => 1 ] [ "id" => 92244642 "company_id" => 25495456 "urn" => "urn:li:activity:7029811579021869056" "followers" => 102888 "date" => "2w" "description" => """ Profound health inequities compound the high burden associated with neurological disorders.\n Nearly 80% of the 50 million people with epilepsy live in low-and middle-income countries, where treatment gaps exceed 75% in most low-income countries and 50% in most middle-income countries.\n We joined the INTERNATIONAL BUREAU FOR EPILEPSY campaign #50MillionSteps to raise awareness of #epilepsy. \n We support the mission of our colleague Serena F.L. Zucchetta because we must respond to these people's needs, starting with increasing understanding and awareness and combating stigma and discrimination, barriers to seeking health care.\n #StampOutStigma \n #EveryStepCloser #WithYouInMind """ "reactions_count" => 64 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-17 17:17:18" "deleted" => 1 ] [ "id" => 136925352 "company_id" => 25495456 "urn" => "urn:li:activity:7053254443516977152" "followers" => 105487 "date" => "6h" "description" => """ We are proud to join the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023), the largest international forum for clinical microbiology research, this Sunday 16 April.\n \n Joining us are leading industry experts, Penka Stefanova and\n Matteo Bassetti, to discuss antibiotic therapies for children and treatment options for community-acquired skin infections in adults.\n \n #AngeliniPharma\n #EveryStepCloser """ "reactions_count" => 43 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 20:29:16" "deleted" => 1 ] [ "id" => 136925353 "company_id" => 25495456 "urn" => "urn:li:activity:7052631861172264960" "followers" => 105487 "date" => "1d" "description" => """ As one of our Formulation Development Senior Scientists, Danilo D'Amico researches to find the most stable, effective and safe pharmaceutical product formula. When asked what he loves about his job, teamwork and the personal gratification when a product he worked on comes to the market came to mind. Read more how his passion for pharmaceutical research comes through in his work.\n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 78 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 20:29:16" "deleted" => 1 ] [ "id" => 136925354 "company_id" => 25495456 "urn" => "urn:li:activity:7052181173753495553" "followers" => 105487 "date" => "3d" "description" => """ We believe that to win as one we shall stay close to our employees, listen to their voices and establish a speak up culture. Having a deep understanding of our people expectations will be instrumental to build up the Angelini Pharma of the future.\n Which is why today our employees are asked to answer a global opinion survey that will help us to develop our organization starting from each of our 3.000 employees.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 94 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 20:29:16" "deleted" => 1 ] [ "id" => 136925355 "company_id" => 25495456 "urn" => "urn:li:activity:7045073094935232514" "followers" => 105487 "date" => "3w" "description" => """ This week we held a special #PurpleDay2023 celebration. With the goal of raising awareness about the challenges of living with epilepsy, we involved our colleagues in various events and gave away some purple accessories. Thank you to everyone who participated with enthusiasm and passion, and thank you for your incredible support and creating a sense of community for an issue that needs to be talked about more so that it becomes a public priority.\n \n INTERNATIONAL BUREAU FOR EPILEPSY\n #EveryStepCloser #WithYouInMind """ "reactions_count" => 158 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 20:29:16" "deleted" => 1 ] [ "id" => 136925356 "company_id" => 25495456 "urn" => "urn:li:activity:7044956002718298113" "followers" => 105487 "date" => "3w" "description" => """ Get ready to celebrate #PurpleDay2023 with us on March 26. This global initiative is designed to raise awareness about epilepsy, a neurological disease that affects millions of people of all ages.\n \n The impact on the lives of those living with epilepsy can vary depending on the severity of the condition, making it difficult to find a one-fits-all solution to dealing with it. Increased support for the affected plays a vital role, in this case literally. Our vision is a world where the disease doesn't prevent people from living fulfilling lives. So get a quick read of some of the key facts about epilepsy and join the purple movement. """ "reactions_count" => 74 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 20:29:16" "deleted" => 1 ] [ "id" => 136925357 "company_id" => 25495456 "urn" => "urn:li:activity:7044694506595569664" "followers" => 105487 "date" => "3w" "description" => """ We show up all in purple as we celebrate #PurpleDay2023, which falls on March 26, to raise awareness for epilepsy. We organized a series of in-house events where our employees wore something purple as a sign of support for people with epilepsy.\n \n We believe that a better public understanding of this brain disease will help eliminate the stigma that surround it. With more than 50 million people diagnosed with epilepsy worldwide, it's likely that you know someone living with the day-to-day challenges it brings. That's why education and research are key to lifting the discrimination and finding appropriate treatment.\n \n Aside from learning about the challenges of this neurological disorder, our colleagues also got informed about Purple Day, a movement started by Cassidy Megan out of her own struggle to give epileptics a sense of community and let them know they are not alone in this. Join us in advocating for support.\n \n INTERNATIONAL BUREAU FOR EPILEPSY\n #EveryStepCloser #WithYouInMind """ "reactions_count" => 273 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 20:29:16" "deleted" => 1 ] [ "id" => 136925358 "company_id" => 25495456 "urn" => "urn:li:activity:7044322398157840384" "followers" => 105487 "date" => "3w" "description" => """ We are excited to once again be represented at #DCATweek in New York City. This is a great opportunity for us to showcase Angelini Fine Chemicals and our R&D projects, and to hold high-level private strategic meetings with customers, suppliers and new partners involved in the development and manufacture of active pharmaceutical ingredients. Our delegation is here to present the developments and studies in custom HPAPI, flow chemistry and production capacity expansion. Do not miss to meet us in person to get a deeper insight.\n \n DCAT (Drug, Chemical & Associated Technologies Association) """ "reactions_count" => 48 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 20:29:16" "deleted" => 1 ] [ "id" => 136925359 "company_id" => 25495456 "urn" => "urn:li:activity:7042451918958268416" "followers" => 105487 "date" => "1mo" "description" => """ We are excited to taking part in #Dreiländertagung 2023 and be present with our countries Germany, Austria and Switzerland.\n In the words of our Chief Scientific Officer, Rafal Kaminski, the level of scientific exchanges at this congress is "just amazing". And we feel honoured to make our contribution for people living with epilepsy.\n #EveryStepCloser #WithYouInMind """ "reactions_count" => 44 "comments_count" => null "reshared_post_author" => "Angelini Pharma Deutschland" "reshared_post_author_url" => "https://de.linkedin.com/company/angelini-pharma-deutschland" "reshared_post_author_headline" => null "reshared_post_description" => """ Wir freuen uns, Rafal Kaminski, Chief Scientific Officer Angelini Pharma, bei uns am Stand auf der #Dreiländertagung begrüssen zu dürfen.\n \n „Die Dreiländertagung 2023 ist eine einzigartige Möglichkeit zum wissenschaftlichen Austausch und Angelini Pharmas Beitrag in der Epilepsiebehandlung zu präsentieren.“ (Rafal Kaminski)\n \n #onestepcloser\n #epilepsie """ "reshared_post_followers" => 366 "reshared_post_date" => "1mo" "last_updated" => "2023-05-03 20:29:16" "deleted" => 1 ] [ "id" => 136925360 "company_id" => 25495456 "urn" => "urn:li:activity:7039175929989869568" "followers" => 105487 "date" => "1mo" "description" => """ As we mark International Women’s Day today, we are proud to endorse the INTERNATIONAL BUREAU FOR EPILEPSY (IBE) new information campaign ‘Women and Epilepsy’, which aims to close the information gap that young women living with epilepsy have to deal with. Our Chief Medical Officer Agnese Cattaneo highlights the alarming lack of information and support these women face and how this new campaign intends to provide access to appropriate information, so that women living with epilepsy can plan in advance and get pregnant with confidence.\n \n #IWD2023 #EmbraceEquity \n #Epilepsy #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 24 "comments_count" => 1 "reshared_post_author" => "Agnese Cattaneo" "reshared_post_author_url" => "https://it.linkedin.com/in/agnese-cattaneo-26767166/en" "reshared_post_author_headline" => "Chief Medical Officer presso Angelini" "reshared_post_description" => """ As we mark International Women’s Day globally today, I invite you to join me in raising awareness about the unique challenges women living with epilepsy face. Seizures can be influenced by female hormones and due to a lack of information and support, many women who live with epilepsy and want to have a child feel frightened and confused or decide not to have a child at all. That’s why we’re supporting the INTERNATIONAL BUREAU FOR EPILEPSY’s new information campaign ‘Women and Epilepsy’. \n Read more in my article.\n \n #IWD2023 #EmbraceEquity \n #AngeliniPharma #Epilepsy #EveryStepCloser #WithYouInMind """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-05-03 20:29:16" "deleted" => 1 ] [ "id" => 136925361 "company_id" => 25495456 "urn" => "urn:li:activity:7038504463518568449" "followers" => 105487 "date" => "1mo" "description" => """ We are excited to announce the launch event of #ThermaCareInnova on March 17th, an open call dedicated to start-ups and small and medium-sized enterprises (SMEs) from all over Europe who are interested in identifying innovative solutions. We are inviting start-ups and SMEs to propose new ideas that focus on three specific areas: a new technology, a new patient experience and an innovative design.\n Stay tuned to find out more! """ "reactions_count" => 197 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 20:29:16" "deleted" => 1 ] [ "id" => 162977286 "company_id" => 25495456 "urn" => "urn:li:activity:7059049096937975808" "followers" => 106403 "date" => "21h" "description" => """ Bringing nearly 30 years of global experience across the pharmaceutical industry, including precision technology and bioscience, we are pleased to welcome Erik Lommerde as the new International Chief Commercial Operations Officer. \n \n "I am very pleased to join Angelini Pharma. It’s my strong wish to drive our growth and improve the lives of our patients and families.”\n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 117 "comments_count" => 13 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-14 06:25:11" "deleted" => 1 ] [ "id" => 162977287 "company_id" => 25495456 "urn" => "urn:li:activity:7057603502075731968" "followers" => 106403 "date" => "4d" "description" => """ In partnership with The European House-Ambrosetti, five years ago we launched Headway: A new roadmap in Brain Health which aims to create a common ground for strategic reflection and dialogue on Epilepsy and Mental Health as experienced from different European perspectives. \n \n The next event takes place on 28 April at the Sala Clara Campoamor, in Madrid, Spain with industry experts speaking on both #epilepsy and #mentalhealth. To register: https://bit.ly/3ojBQFF\n \n Celso Arango, Narcís Cardoner, Ana Cabrera Cifuentes, Mar Carreno, Elvira Vacas Montero, Maria Tajes, Vicente Enrique Villaneuva Haba\n #Headway2023\n #AngeliniPharma\n #EveryStepCloser #WithYouInMind """ "reactions_count" => 64 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-14 06:25:11" "deleted" => 1 ] [ "id" => 162977288 "company_id" => 25495456 "urn" => "urn:li:activity:7056913855607648257" "followers" => 106403 "date" => "6d" "description" => """ We're looking for an innovative solution to enhance musculoskeletal pain medical devices. We have launched three challenges to improve, technology, patient experience, design and material of the medical devices.\n \n If you have solutions that fit these needs, take advantage of the opportunity to work with us and bring your project to life. We're looking for cutting-edge ideas that can make a real difference in patients' lives. This is an opportunity to present your innovation and obtain financial support, mentorship and resources to bring your ideas to market.\n \n Apply now and help shape the future of healthcare: https://lnkd.in/dxsK8iTt \n #ThermaCareInnova\n #AngeliniPharma\n #EveryStepCloser """ "reactions_count" => 80 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-14 06:25:11" "deleted" => 1 ] [ "id" => 162977289 "company_id" => 25495456 "urn" => "urn:li:activity:7055790989818368000" "followers" => 106403 "date" => "1w" "description" => """ Each year, we host a competition, the Angelini University Award, to foster innovative projects in the health field and promote youth entrepreneurship. Over the past 13 years, 510 projects have been created by nearly 3,000 participants.\n \n This year’s theme focuses on #epilepsy and solutions for better disease management. At the end of the competition, groups are invited to share their projects in front of a panel of judges for the opportunity to win a monetary prize. For more information visit http://bit.ly/43vyNu3\n \n #AngeliniPharma\n #EveryStepCloser """ "reactions_count" => 91 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-14 06:25:11" "deleted" => 1 ] [ "id" => 162977290 "company_id" => 25495456 "urn" => "urn:li:activity:7055434326850568192" "followers" => 106403 "date" => "1w" "description" => """ How can a pharmaceutical company contribute to a cleaner world? This #WorldEarthDay, we are excited to share our chemical business unit, Angelini Fine Chemicals, has been awarded the Horizon Europe project ETERNAL, which aims to reduce the environmental impact of pharmaceutical products throughout their entire life cycle.\n \n Our team is actively working to leverage public funding to further support our environmental journey in manufacturing, through main national and European programs (PNRR, Horizon Europe, LIFE).\n \n The plant, where we create our active pharmaceutical ingredients, is part of a larger green scientific-technological revolution and represents the start of how we can make our production activities more sustainable.\n \n Our CEO, Jacopo Andreose, shares some key facts below. Learn more about it: http://bit.ly/3MJ6Ed6\n \n #AngeliniPharma\n #EveryStepCloser """ "reactions_count" => 66 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-14 06:25:11" "deleted" => 1 ] [ "id" => 162977291 "company_id" => 25495456 "urn" => "urn:li:activity:7054699604260397056" "followers" => 106403 "date" => "1w" "description" => """ It was our pleasure to have joined the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023) with leading industry experts, Matteo Bassetti and Penka Stefanova. \n \n Their research on Antimicrobial Resistance (AMR), which has as been declared by WHO a top 10 global public health threat for both adults and children, is fundamental to assess proper treatment for both adult and pediatric patients.\n \n #AngeliniPharma\n #ECCMID2023 """ "reactions_count" => 64 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-14 06:25:11" "deleted" => 1 ] [ "id" => 162977292 "company_id" => 25495456 "urn" => "urn:li:activity:7053254443516977152" "followers" => 106403 "date" => "2w" "description" => """ We are proud to join the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2023), the largest international forum for clinical microbiology research, this Sunday 16 April.\n \n Joining us are leading industry experts, Penka Stefanova and\n Matteo Bassetti, to discuss antibiotic therapies for children and treatment options for community-acquired skin infections in adults.\n \n #AngeliniPharma\n #EveryStepCloser """ "reactions_count" => 115 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-14 06:25:11" "deleted" => 1 ] [ "id" => 162977293 "company_id" => 25495456 "urn" => "urn:li:activity:7052631861172264960" "followers" => 106403 "date" => "2w" "description" => """ As one of our Formulation Development Senior Scientists, Danilo D'Amico researches to find the most stable, effective and safe pharmaceutical product formula. When asked what he loves about his job, teamwork and the personal gratification when a product he worked on comes to the market came to mind. Read more how his passion for pharmaceutical research comes through in his work.\n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 118 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-14 06:25:11" "deleted" => 1 ] [ "id" => 162977294 "company_id" => 25495456 "urn" => "urn:li:activity:7052181173753495553" "followers" => 106403 "date" => "2w" "description" => """ We believe that to win as one we shall stay close to our employees, listen to their voices and establish a speak up culture. Having a deep understanding of our people expectations will be instrumental to build up the Angelini Pharma of the future.\n Which is why today our employees are asked to answer a global opinion survey that will help us to develop our organization starting from each of our 3.000 employees.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 107 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-14 06:25:11" "deleted" => 1 ] [ "id" => 162977295 "company_id" => 25495456 "urn" => "urn:li:activity:7045073094935232514" "followers" => 106403 "date" => "1mo" "description" => """ This week we held a special #PurpleDay2023 celebration. With the goal of raising awareness about the challenges of living with epilepsy, we involved our colleagues in various events and gave away some purple accessories. Thank you to everyone who participated with enthusiasm and passion, and thank you for your incredible support and creating a sense of community for an issue that needs to be talked about more so that it becomes a public priority.\n \n INTERNATIONAL BUREAU FOR EPILEPSY\n #EveryStepCloser #WithYouInMind """ "reactions_count" => 159 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-14 06:25:11" "deleted" => 1 ] [ "id" => 205156267 "company_id" => 25495456 "urn" => "urn:li:activity:7072160768514756610" "followers" => 108722 "date" => "5d" "description" => """ Today we join Jefferies 2023 Healthcare Conference to share our company's success and direction in #brainhealth, with our CEO Jacopo Andreose, our CSO Rafal Kaminski and CBDO Antonio Mazzeo.\n \n We have over 50 years of expertise in R&D, Access and Commercialization. To continue towards our goal of being a partner of choice in brain health, we are partnering with true innovators to develop advancements in neurology and psychiatry. Most recently, we partnered with JCR Pharmaceuticals Co Ltd. to work towards the development of therapies in epilepsy using JCR’s proprietary blood-brain barrier crossing technology. \n \n We look forward to building on our success and heritage in brain health.\n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 49 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-04 11:10:56" "deleted" => 1 ] [ "id" => 205156268 "company_id" => 25495456 "urn" => "urn:li:activity:7071496658299101184" "followers" => 108722 "date" => "1w" "description" => """ What is green chemistry and how can it contribute to a more sustainable pharmaceutical industry? \n \n On #WorldEnvironmentDay we are excited to share our fine chemical business unit, Angelini Fine Chemicals, has been awarded the LIFE-GREENAPI project under the EU LIFE Program, the EU’s funding instrument dedicated to the environment and climate action.\n \n The project aims to integrate green engineering principles into the production processes of active pharmaceutical ingredients.\n \n It is another step in a larger green scientific-technological revolution for how we can become more sustainable and contribute to a cleaner world.\n \n #AngeliniPharma\n #EveryStepCloser """ "reactions_count" => 31 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-04 11:10:56" "deleted" => 1 ] [ "id" => 205156269 "company_id" => 25495456 "urn" => "urn:li:activity:7070290573936443392" "followers" => 108722 "date" => "1w" "description" => """ Today Elena Alvarez-Baron, PhD, MBA., our Global Medical Affairs Specialty Care Director, joins the INTERNATIONAL BUREAU FOR EPILEPSY’s Women and Epilepsy virtual conference to give a perspective on how the pharmaceutical and biotech industry drives research and innovation and helps further understand the different impact of epilepsy in men and women. \n \n Learn more: https://bit.ly/IBEwebinar\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 118 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-04 11:10:56" "deleted" => 1 ] [ "id" => 205156270 "company_id" => 25495456 "urn" => "urn:li:activity:7069626160136994816" "followers" => 108722 "date" => "1w" "description" => """ The diary of our first communication meeting: the impressions of our ambassadors, the energy it gave us to be together and share our experiences, the passion that unites us in telling the story of our international commitment to health. \n \n #AngeliniPharma #EveryStepCloser\n #WinAsOne """ "reactions_count" => 78 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-04 11:10:56" "deleted" => 1 ] [ "id" => 205156271 "company_id" => 25495456 "urn" => "urn:li:activity:7067897077053161472" "followers" => 108722 "date" => "2w" "description" => """ Oggi il nostro CEO Jacopo Andreose ha partecipato al Festival Economia Trento dove - in occasione del lancio della pagina Instagram di Angelini Industries - ha rilasciato un’intervista a Starting Finance e alla sua community Instagram sul nostro impegno nella salute del cervello, raccontando i nostri investimenti nella ricerca e nell’empowerment.\n \n #AngeliniPharma #EveryStepCloser\n #FestivalEconomiaTrento """ "reactions_count" => 169 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-04 11:10:56" "deleted" => 1 ] [ "id" => 205156272 "company_id" => 25495456 "urn" => "urn:li:activity:7067205113043410944" "followers" => 108722 "date" => "2w" "description" => """ Schizophrenia is one of the most misunderstood mental disorders. Those who live with #schizophrenia often face judgement because of commonly associated misconceptions. It's for this we continue to fight for our patients to help end the stigma.\n \n We encouraged our team to share their thoughts on how we can fight the stigma with "A letter to schizophrenia", a week-long display at our headquarters in Rome.\n \n What did they say? Compassion, honesty and care, among many others.\n #WorldSchizophreniaAwarenessDay #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 142 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-04 11:10:56" "deleted" => 1 ] [ "id" => 205156273 "company_id" => 25495456 "urn" => "urn:li:activity:7066812263352909824" "followers" => 108722 "date" => "2w" "description" => null "reactions_count" => 9 "comments_count" => null "reshared_post_author" => "Angelini Industries" "reshared_post_author_url" => "https://it.linkedin.com/company/angelini-industries" "reshared_post_author_headline" => null "reshared_post_description" => """ "A tavola con", la rubrica domenicale de Il Sole 24 Ore, ha dedicato l'approfondimento di domenica scorsa a Sergio Marullo di Condojanni.\n \n L'articolo-intervista, a cura di Paolo Bricco, traccia un profilo a tuttotondo del nostro CEO e racconta la realtà di Angelini Industries oggi: un gruppo da 2 mld di euro di ricavi nel 2022, con specializzazioni verticali nei campi della salute, dei beni di consumo e della tecnologia industriale.\n \n Leggi l'articolo qui: https://lnkd.in/e8M6gBW5\n \n #AngeliniIndustries #IndustryOfCare """ "reshared_post_followers" => 132047 "reshared_post_date" => "2w" "last_updated" => "2023-07-04 11:10:56" "deleted" => 1 ] [ "id" => 205156274 "company_id" => 25495456 "urn" => "urn:li:activity:7064988562332483584" "followers" => 108722 "date" => "3w" "description" => """ ONE International Alliance in Brain Health in 2023 is a step forward in stimulating debate on the management of Depression and Schizophrenia.\n \n The pathway consists of highly interactive residential meetings and digital appointments, to support young psychiatrists in the discussion on recent advances and evidence-based practices in brain health.\n \n #AngeliniPharma\n #EveryStepCloser\n #WithYouInMind """ "reactions_count" => 95 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-04 11:10:56" "deleted" => 1 ] [ "id" => 205156275 "company_id" => 25495456 "urn" => "urn:li:activity:7064538171815923712" "followers" => 108722 "date" => "3w" "description" => """ As Clinical Study Manager, Rosita Molinario manages and \n oversees clinical trials on drugs, clinical investigations on medical devices and clinical tests on cosmetics in order to ensure product efficacy and safety. The ability to work with team members across different departments and be an ally for patient empowerment are a few things she loves about her job!\n \n Discover a position that matches your passion. https://bit.ly/3mQRh7K \n \n #AngeliniPharma \n #EveryStepCloser """ "reactions_count" => 31 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-04 11:10:56" "deleted" => 1 ] [ "id" => 205156276 "company_id" => 25495456 "urn" => "urn:li:activity:7064535799051993088" "followers" => 108722 "date" => "3w" "description" => """ In qualità di Clinical Study Manager, Rosita Molinario gestisce e supervisiona sperimentazioni cliniche su farmaci, indagini cliniche su dispositivi medici e test clinici su cosmetici per garantire l’efficacia e la sicurezza dei prodotti. La possibilità di lavorare con i membri di dipartimenti diversi e promuovere l'empowerment dei pazienti sono alcune caratteristiche che ama del suo lavoro! \n \n Scopri la posizione in linea con le tue passioni qui: https://bit.ly/3mQRh7K\n \n #AngeliniPharma\n #EveryStepCloser """ "reactions_count" => 78 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-04 11:10:56" "deleted" => 1 ] [ "id" => 229871310 "company_id" => 25495456 "urn" => "urn:li:activity:7075378888146587649" "followers" => 110017 "date" => "2w" "description" => """ Today we join a panel of experts in Helsinki, Finland, for our next event in Headway: A new roadmap in Brain Health. Together, to understand future actions and epilepsy priorities in the Nordics.\n \n Understanding brain health as a driver for economic and societal developement, care and research priorities and innovative approaches to epilepsy management are among the topics to be discussed.\n \n Headway was created in partnership with The European House-Ambrosetti to facilitate dialogue on epilepsy and mental health from different European perspectives.\n \n #Headway2023 #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 44 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-03 09:35:33" "deleted" => 1 ] [ "id" => 229871311 "company_id" => 25495456 "urn" => "urn:li:activity:7075125952338436096" "followers" => 110017 "date" => "2w" "description" => """ We’re grateful for the incredible participation in the Headway UK summit hosted earlier this week by Angelini Pharma UK & Ireland and The European House-Ambrosetti, where a panel of experts across research and patient care discussed the need for a new roadmap for Brain Health in the UK and beyond. Thank you to all of our panellists for the insights and perspectives shared, and we look forward to continuing working together to shed light on this urgent public health priority and advance care and for all people living with epilepsy worldwide.\n \n #AngeliniPharma #WithYouInMind #Headway2023 """ "reactions_count" => 100 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-03 09:35:33" "deleted" => 1 ] [ "id" => 229871312 "company_id" => 25495456 "urn" => "urn:li:activity:7074340033750515714" "followers" => 110017 "date" => "2w" "description" => """ In partnership with The European House-Ambrosetti, we continue our series of Headway: A new roadmap in Brain Health today in London, United Kingdom to discuss a new roadmap for epilepsy in the UK.\n \n The dialogue will focus on making epilepsy research a priority in the UK, patient empowerment and priorities for future action. The panel of speakers includes experts across research and patient care.\n \n Headway is an important event to facilitate a common space for strategic reflection and dialogue on Epilepsy and Mental Health from different European perspectives.\n \n #Headway2023 #AngeliniPharma #EveryStepCloser #WithYouInMind Angelini Pharma UK & Ireland """ "reactions_count" => 58 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-03 09:35:33" "deleted" => 1 ] [ "id" => 229871313 "company_id" => 25495456 "urn" => "urn:li:activity:7072160768514756610" "followers" => 110017 "date" => "3w" "description" => """ Today we join Jefferies 2023 Healthcare Conference to share our company's success and direction in #brainhealth, with our CEO Jacopo Andreose, our CSO Rafal Kaminski and CBDO Antonio Mazzeo.\n \n We have over 50 years of expertise in R&D, Access and Commercialization. To continue towards our goal of being a partner of choice in brain health, we are partnering with true innovators to develop advancements in neurology and psychiatry. Most recently, we partnered with JCR Pharmaceuticals Co Ltd. to work towards the development of therapies in epilepsy using JCR’s proprietary blood-brain barrier crossing technology. \n \n We look forward to building on our success and heritage in brain health.\n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 51 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-03 09:35:33" "deleted" => 1 ] [ "id" => 229871314 "company_id" => 25495456 "urn" => "urn:li:activity:7071496658299101184" "followers" => 110017 "date" => "4w" "description" => """ What is green chemistry and how can it contribute to a more sustainable pharmaceutical industry? \n \n On #WorldEnvironmentDay we are excited to share our fine chemical business unit, Angelini Fine Chemicals, has been awarded the LIFE-GREENAPI project under the EU LIFE Program, the EU’s funding instrument dedicated to the environment and climate action.\n \n The project aims to integrate green engineering principles into the production processes of active pharmaceutical ingredients.\n \n It is another step in a larger green scientific-technological revolution for how we can become more sustainable and contribute to a cleaner world.\n \n #AngeliniPharma\n #EveryStepCloser """ "reactions_count" => 33 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-03 09:35:33" "deleted" => 1 ] [ "id" => 229871315 "company_id" => 25495456 "urn" => "urn:li:activity:7070290573936443392" "followers" => 110017 "date" => "1mo" "description" => """ Today Elena Alvarez-Baron, PhD, MBA., our Global Medical Affairs Specialty Care Director, joins the INTERNATIONAL BUREAU FOR EPILEPSY’s Women and Epilepsy virtual conference to give a perspective on how the pharmaceutical and biotech industry drives research and innovation and helps further understand the different impact of epilepsy in men and women. \n \n Learn more: https://bit.ly/IBEwebinar\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 124 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-03 09:35:33" "deleted" => 1 ] [ "id" => 229871316 "company_id" => 25495456 "urn" => "urn:li:activity:7069626160136994816" "followers" => 110017 "date" => "1mo" "description" => """ The diary of our first communication meeting: the impressions of our ambassadors, the energy it gave us to be together and share our experiences, the passion that unites us in telling the story of our international commitment to health. \n \n #AngeliniPharma #EveryStepCloser\n #WinAsOne """ "reactions_count" => 79 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-03 09:35:33" "deleted" => 1 ] [ "id" => 229871317 "company_id" => 25495456 "urn" => "urn:li:activity:7067897077053161472" "followers" => 110017 "date" => "1mo" "description" => """ Oggi il nostro CEO Jacopo Andreose ha partecipato al Festival Economia Trento dove - in occasione del lancio della pagina Instagram di Angelini Industries - ha rilasciato un’intervista a Starting Finance e alla sua community Instagram sul nostro impegno nella salute del cervello, raccontando i nostri investimenti nella ricerca e nell’empowerment.\n \n #AngeliniPharma #EveryStepCloser\n #FestivalEconomiaTrento """ "reactions_count" => 171 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-03 09:35:33" "deleted" => 1 ] [ "id" => 229871318 "company_id" => 25495456 "urn" => "urn:li:activity:7067205113043410944" "followers" => 110017 "date" => "1mo" "description" => """ Schizophrenia is one of the most misunderstood mental disorders. Those who live with #schizophrenia often face judgement because of commonly associated misconceptions. It's for this we continue to fight for our patients to help end the stigma.\n \n We encouraged our team to share their thoughts on how we can fight the stigma with "A letter to schizophrenia", a week-long display at our headquarters in Rome.\n \n What did they say? Compassion, honesty and care, among many others.\n #WorldSchizophreniaAwarenessDay #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 144 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-03 09:35:33" "deleted" => 1 ] [ "id" => 229871319 "company_id" => 25495456 "urn" => "urn:li:activity:7066812263352909824" "followers" => 110017 "date" => "1mo" "description" => null "reactions_count" => 10 "comments_count" => null "reshared_post_author" => "Angelini Industries" "reshared_post_author_url" => "https://it.linkedin.com/company/angelini-industries" "reshared_post_author_headline" => null "reshared_post_description" => """ "A tavola con", la rubrica domenicale de Il Sole 24 Ore, ha dedicato l'approfondimento di domenica scorsa a Sergio Marullo di Condojanni.\n \n L'articolo-intervista, a cura di Paolo Bricco, traccia un profilo a tuttotondo del nostro CEO e racconta la realtà di Angelini Industries oggi: un gruppo da 2 mld di euro di ricavi nel 2022, con specializzazioni verticali nei campi della salute, dei beni di consumo e della tecnologia industriale.\n \n Leggi l'articolo qui: https://lnkd.in/e8M6gBW5\n \n #AngeliniIndustries #IndustryOfCare """ "reshared_post_followers" => 132343 "reshared_post_date" => "1mo" "last_updated" => "2023-08-03 09:35:33" "deleted" => 1 ] [ "id" => 268598565 "company_id" => 25495456 "urn" => "urn:li:activity:7091809890175729664" "followers" => 111834 "date" => "1d" "description" => """ From March onwards, we've continued our journey towards our fundamental mission: providing innovative solutions to improve people's lives worldwide. \n We've strengthened our dedication to supporting initiatives for mental and brain health and sustainability, recognizing the importance of holistic care for overall wellness.\n \n We've focused on research and developing cutting-edge solutions, putting patients' needs and quality of life at the heart of our activities. Collaboration with industry professionals, partnerships with strong institutions, support and enthusiasm of the Angeliners have been crucial in making significant progress.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 41 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 04:34:38" "deleted" => 1 ] [ "id" => 268598566 "company_id" => 25495456 "urn" => "urn:li:activity:7088133335620759552" "followers" => 111834 "date" => "1w" "description" => """ How does the world of drug regulation and pharmacovigilance work? We uncover the industry's intricacies in this interview with Patrizia Ciavatta, Global Regulatory and Pharmacovigilance Chief. Explore her journey and the distinctive aspects of her role as we delve into the challenges, responsibilities, and opportunities to ensure safety, efficacy, and regulatory compliance for pharmaceutical products\n "Nice to meet you" is our podcast presented by Barbara Serra and created to give voice to Angeliners.\n 🎧 Listen to our podcast here 👉 https://lnkd.in/dgmsYuAf\n \n #AngeliniPharma #EveryStepCloser #NiceToMeetYou """ "reactions_count" => 159 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 04:34:38" "deleted" => 1 ] [ "id" => 268598567 "company_id" => 25495456 "urn" => "urn:li:activity:7087370191923216384" "followers" => 111834 "date" => "1w" "description" => """ At Angelini Pharma, patients are at the heart of everything we do. \n Our Global patient advocacy annual workshop is a truly inspiring experience for us. Our main goal is to translate our efforts into meaningful benefits to make a real difference in patients' lives and ensure they always maintain their dignity.\n We recognize the weight of our responsibility and strive to offer hope to people and their carers. Our unwavering passion drives us to stand by patients, listen to their needs and work tirelessly to meet them.\n Together, we could drive positive change with passion.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne\n #PatientAdvocacy #Workshop """ "reactions_count" => 141 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 04:34:38" "deleted" => 1 ] [ "id" => 268598568 "company_id" => 25495456 "urn" => "urn:li:activity:7086635068307177472" "followers" => 111834 "date" => "2w" "description" => """ In collaboration with The European House-Ambrosetti, findings from the second edition of the “Headway – A new roadmap in Brain Health: Focus Epilepsy” report were shared today as part of a multidisciplinary and cross-functional panel event hosted at Spazio Europa in Rome, a public space managed by the Office of the European Parliament in Italy and the European Commission's Representation in Italy of the European Commission. \n We extend our gratitude to our panelists for the insights and perspectives shared as we work together to encourage more investigation and dialogue around the state of epilepsy care in Europe.\n Download the full report: https://lnkd.in/di-umnKZ\n #AngeliniPharma #EveryStepCloser #WithYouInMind #Headway2023 """ "reactions_count" => 88 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 04:34:38" "deleted" => 1 ] [ "id" => 268598569 "company_id" => 25495456 "urn" => "urn:li:activity:7085591440679927811" "followers" => 111834 "date" => "2w" "description" => """ Only 3 days left until the next stage of Headway series: A new roadmap in Brain Health, Focus Epilepsy, in partnership with The European House-Ambrosetti.\n \n On Monday, July 17th we will discuss the state of the art one year after the adoption of the Global Intersectoral Action Plan on Epilepsy and other Neurological Disorders (IGAP) by the WHO in European countries, and the challenges that people with epilepsy face in workplaces, schools, and society. \n \n Among the speakers will be Francesca Sofia, President of INTERNATIONAL BUREAU FOR EPILEPSY; Nicola Specchio, Head of the Rare and Complex Epilepsy Unit at the Department of Neuroscience, Ospedale Pediatrico Bambino Gesù in Rome; Matilde Leonardi, Director of Neurology in the Public Health Unit of the FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA in Milan. \n \n Headway fosters a European platform for strategic reflection and dialogue, building on a multi-stakeholder and multi-dimensional analysis from various sectors such as healthcare, private industry, academia and government while also gathering personal perspectives from patient associations, clinicians and policy makers, among others. \n \n Register here: bit.ly/3Des0ZS \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #HeadwaySeries #BrainHealth #Epilepsy """ "reactions_count" => 60 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 04:34:38" "deleted" => 1 ] [ "id" => 268598570 "company_id" => 25495456 "urn" => "urn:li:activity:7085187435352977409" "followers" => 111834 "date" => "2w" "description" => """ 🍃 We are proud to announce the launch of our three-year initiative, LIFE-GREENAPI, made possible thanks to a generous €1.5M grant from the European Commission LIFE Programme. In partnership with the Universiteit Leiden, we aim to deploy a more efficient and greener process for producing Active Pharmaceutical Ingredients (API) using flow chemistry technology. \n \n This initiative forms part of our broader green transition strategy, and we continue to evaluate and address the environmental impact of our products at every stage of their life cycle.\n \n Read more: http://bitly.ws/Lgtv \n \n #AngeliniPharma #EveryStepCloser #APIs #LIFEprojects #ClimateNeutralEU #CleanEnergyEU #EU2050 #EnergyTransition #LIFEprogramme """ "reactions_count" => 145 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 04:34:38" "deleted" => 1 ] [ "id" => 268598571 "company_id" => 25495456 "urn" => "urn:li:activity:7082001926325682176" "followers" => 111834 "date" => "4w" "description" => """ We have been supporting the scientific and medical community for years in the research for therapeutic solutions for #epilepsy and in the promotion of information and education initiatives.\n Today is the last day we host a satellite symposium as part of the European Academy of Neurology Congress, Neurology beyond Big Data. \n Prof. Dr. Bernhard Steinhoff and Dr. Mar Carreno joined us to provide insights on new treatment options for patients with focal onset seizures. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 106 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 04:34:38" "deleted" => 1 ] [ "id" => 268598572 "company_id" => 25495456 "urn" => "urn:li:activity:7075378888146587649" "followers" => 111834 "date" => "1mo" "description" => """ Today we join a panel of experts in Helsinki, Finland, for our next event in Headway: A new roadmap in Brain Health. Together, to understand future actions and epilepsy priorities in the Nordics.\n \n Understanding brain health as a driver for economic and societal developement, care and research priorities and innovative approaches to epilepsy management are among the topics to be discussed.\n \n Headway was created in partnership with The European House-Ambrosetti to facilitate dialogue on epilepsy and mental health from different European perspectives.\n \n #Headway2023 #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 49 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 04:34:38" "deleted" => 1 ] [ "id" => 268598573 "company_id" => 25495456 "urn" => "urn:li:activity:7075125952338436096" "followers" => 111834 "date" => "1mo" "description" => """ We’re grateful for the incredible participation in the Headway UK summit hosted earlier this week by Angelini Pharma UK & Ireland and The European House-Ambrosetti, where a panel of experts across research and patient care discussed the need for a new roadmap for Brain Health in the UK and beyond. Thank you to all of our panellists for the insights and perspectives shared, and we look forward to continuing working together to shed light on this urgent public health priority and advance care and for all people living with epilepsy worldwide.\n \n #AngeliniPharma #WithYouInMind #Headway2023 """ "reactions_count" => 103 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 04:34:38" "deleted" => 1 ] [ "id" => 268598574 "company_id" => 25495456 "urn" => "urn:li:activity:7074340033750515714" "followers" => 111834 "date" => "1mo" "description" => """ In partnership with The European House-Ambrosetti, we continue our series of Headway: A new roadmap in Brain Health today in London, United Kingdom to discuss a new roadmap for epilepsy in the UK.\n \n The dialogue will focus on making epilepsy research a priority in the UK, patient empowerment and priorities for future action. The panel of speakers includes experts across research and patient care.\n \n Headway is an important event to facilitate a common space for strategic reflection and dialogue on Epilepsy and Mental Health from different European perspectives.\n \n #Headway2023 #AngeliniPharma #EveryStepCloser #WithYouInMind Angelini Pharma UK & Ireland """ "reactions_count" => 60 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 04:34:38" "deleted" => 1 ] [ "id" => 301811983 "company_id" => 25495456 "urn" => "urn:li:activity:7101841180363042816" "followers" => null "date" => "3d" "description" => """ Defining and living our behaviours - how our team interacts with each other, our daily work - is how we win as one. Acting with responsibility, pushing ourselves, being forward thinkers and always giving passion to our work are a few of the behaviours we encourage our team to live, every day. \n \n #AngeliniPharma #EveryStepCloser \n #WinAsOne """ "reactions_count" => 82 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-14 22:14:13" "deleted" => 1 ] [ "id" => 301811984 "company_id" => 25495456 "urn" => "urn:li:activity:7100763747299844096" "followers" => null "date" => "4w" "description" => """ Epilepsy, a significant neurological disorder, affects approximately 50 million people globally, manifesting in 150 different forms, with around one-third of cases remaining uncontrolled. \n Recognizing its importance, we reaffirm our commitment in reducing the burden of epilepsy by participating in the 35th ILAE (International League Against Epilepsy) Congress with a Satellite Symposium titled: “The Impact of Time Lost in Achieving Seizure Control in Adult Patients with Epilepsy”.\n \n Join us on September 4th at Wicklow Hall 2 in Dublin, Ireland, alongside four internationally renowned Key Opinion Leaders specializing in epilepsy - Patrick Kwan (chairman), Manuel Toledo, Norman Delanty, and Rhys Thomas. \n \n To register online: bit.ly/ILEAregistration\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind Norman Delanty """ "reactions_count" => 98 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-14 22:14:13" "deleted" => 1 ] [ "id" => 301811985 "company_id" => 25495456 "urn" => "urn:li:activity:7096777479742251009" "followers" => null "date" => "4w" "description" => """ 🌞 Taking a Summer Break! 🌞\n As we embark on #SummerBreak to recharge, we look back on the remarkable achievements we've accomplished so far. We are excited about the journey that lies ahead and are committed to delivering even greater value in the future.\n We wish you all a fantastic summer ahead! Whether you're exploring new destinations or enjoying the warmth of your hometown, we hope you find time for relaxation and cherished moments with your loved ones.\n Thank you for being a part of our journey. See you refreshed and energized after the break!\n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 78 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-14 22:14:13" "deleted" => 1 ] [ "id" => 301811986 "company_id" => 25495456 "urn" => "urn:li:activity:7093878364721025025" "followers" => null "date" => "4w" "description" => """ 🎉 Today we celebrate a joyful moment: the 25th anniversary of Angelini Austria! 🇦🇹\n \n We believe in celebrating successes together and we commemorate this special milestone, looking forward to the challenges and goals that await us as a global company. We are ready to grow, united by shared values and the determination to make a difference. \n Thanks to the commitment, dedication, and collaboration of all the Angeliners, we can face new challenges with confidence and determination.\n \n Congratulations to Angelini Austria on these first 25 years of success, whose team spirit makes every goal achievable! 🎈👨👩👧👦 \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 178 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-14 22:14:13" "deleted" => 1 ] [ "id" => 301811987 "company_id" => 25495456 "urn" => "urn:li:activity:7091809890175729664" "followers" => null "date" => "1mo" "description" => """ From March onwards, we've continued our journey towards our fundamental mission: providing innovative solutions to improve people's lives worldwide. \n We've strengthened our dedication to supporting initiatives for mental and brain health and sustainability, recognizing the importance of holistic care for overall wellness.\n \n We've focused on research and developing cutting-edge solutions, putting patients' needs and quality of life at the heart of our activities. Collaboration with industry professionals, partnerships with strong institutions, support and enthusiasm of the Angeliners have been crucial in making significant progress.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 60 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-14 22:14:13" "deleted" => 1 ] [ "id" => 301811988 "company_id" => 25495456 "urn" => "urn:li:activity:7088133335620759552" "followers" => null "date" => "1mo" "description" => """ How does the world of drug regulation and pharmacovigilance work? We uncover the industry's intricacies in this interview with Patrizia Ciavatta, Global Regulatory and Pharmacovigilance Chief. Explore her journey and the distinctive aspects of her role as we delve into the challenges, responsibilities, and opportunities to ensure safety, efficacy, and regulatory compliance for pharmaceutical products\n "Nice to meet you" is our podcast presented by Barbara Serra and created to give voice to Angeliners.\n 🎧 Listen to our podcast here 👉 https://lnkd.in/dgmsYuAf\n \n #AngeliniPharma #EveryStepCloser #NiceToMeetYou """ "reactions_count" => 169 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-14 22:14:13" "deleted" => 1 ] [ "id" => 301811989 "company_id" => 25495456 "urn" => "urn:li:activity:7087370191923216384" "followers" => null "date" => "1mo" "description" => """ At Angelini Pharma, patients are at the heart of everything we do. \n Our Global patient advocacy annual workshop is a truly inspiring experience for us. Our main goal is to translate our efforts into meaningful benefits to make a real difference in patients' lives and ensure they always maintain their dignity.\n We recognize the weight of our responsibility and strive to offer hope to people and their carers. Our unwavering passion drives us to stand by patients, listen to their needs and work tirelessly to meet them.\n Together, we could drive positive change with passion.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne\n #PatientAdvocacy #Workshop """ "reactions_count" => 150 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-14 22:14:13" "deleted" => 1 ] [ "id" => 301811990 "company_id" => 25495456 "urn" => "urn:li:activity:7086635068307177472" "followers" => null "date" => "1mo" "description" => """ In collaboration with The European House-Ambrosetti, findings from the second edition of the “Headway – A new roadmap in Brain Health: Focus Epilepsy” report were shared today as part of a multidisciplinary and cross-functional panel event hosted at Spazio Europa in Rome, a public space managed by the Office of the European Parliament in Italy and the European Commission's Representation in Italy of the European Commission. \n We extend our gratitude to our panelists for the insights and perspectives shared as we work together to encourage more investigation and dialogue around the state of epilepsy care in Europe.\n Download the full report: https://lnkd.in/di-umnKZ\n #AngeliniPharma #EveryStepCloser #WithYouInMind #Headway2023 """ "reactions_count" => 87 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-14 22:14:13" "deleted" => 1 ] [ "id" => 301811991 "company_id" => 25495456 "urn" => "urn:li:activity:7085591440679927811" "followers" => null "date" => "1mo" "description" => """ Only 3 days left until the next stage of Headway series: A new roadmap in Brain Health, Focus Epilepsy, in partnership with The European House-Ambrosetti.\n \n On Monday, July 17th we will discuss the state of the art one year after the adoption of the Global Intersectoral Action Plan on Epilepsy and other Neurological Disorders (IGAP) by the WHO in European countries, and the challenges that people with epilepsy face in workplaces, schools, and society. \n \n Among the speakers will be Francesca Sofia, President of INTERNATIONAL BUREAU FOR EPILEPSY; Nicola Specchio, Head of the Rare and Complex Epilepsy Unit at the Department of Neuroscience, Ospedale Pediatrico Bambino Gesù in Rome; Matilde Leonardi, Director of Neurology in the Public Health Unit of the FONDAZIONE IRCCS ISTITUTO NEUROLOGICO CARLO BESTA in Milan. \n \n Headway fosters a European platform for strategic reflection and dialogue, building on a multi-stakeholder and multi-dimensional analysis from various sectors such as healthcare, private industry, academia and government while also gathering personal perspectives from patient associations, clinicians and policy makers, among others. \n \n Register here: bit.ly/3Des0ZS \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #HeadwaySeries #BrainHealth #Epilepsy """ "reactions_count" => 60 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-14 22:14:13" "deleted" => 1 ] [ "id" => 301811992 "company_id" => 25495456 "urn" => "urn:li:activity:7085187435352977409" "followers" => null "date" => "1mo" "description" => """ 🍃 We are proud to announce the launch of our three-year initiative, LIFE-GREENAPI, made possible thanks to a generous €1.5M grant from the European Commission LIFE Programme. In partnership with the Universiteit Leiden, we aim to deploy a more efficient and greener process for producing Active Pharmaceutical Ingredients (API) using flow chemistry technology. \n \n This initiative forms part of our broader green transition strategy, and we continue to evaluate and address the environmental impact of our products at every stage of their life cycle.\n \n Read more: http://bitly.ws/Lgtv \n \n #AngeliniPharma #EveryStepCloser #APIs #LIFEprojects #ClimateNeutralEU #CleanEnergyEU #EU2050 #EnergyTransition #LIFEprogramme """ "reactions_count" => 156 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-14 22:14:13" "deleted" => 1 ] [ "id" => 344000404 "company_id" => 25495456 "urn" => "urn:li:activity:7117795192102883329" "followers" => null "date" => "3d" "description" => """ Coinciding with #WorldMentalHealthDay, our CEO Jacopo Andreose shared the latest findings from our #Headway Report surrounding mental health in the workplace and in schools in an article on Euractiv. \n Read more here: https://lnkd.in/dABcWWbK """ "reactions_count" => 81 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-02 14:46:48" "deleted" => 1 ] [ "id" => 344000405 "company_id" => 25495456 "urn" => "urn:li:activity:7117437923456618496" "followers" => null "date" => "4d" "description" => """ Keeping the mental health conversation alive across the EU remains a big part of what we do. We're digging deeper into what affects people's mental well-being, making sure we make a real difference and leave no one out. \n We've got some exciting stuff on the way, and we can't wait to share it with you all.\n \n #WorldMentalHealthDay\n #AngeliniPharma #EveryStepCloser #WithYouInMind\n \n The European House-Ambrosetti """ "reactions_count" => 91 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-02 14:46:48" "deleted" => 1 ] [ "id" => 344000406 "company_id" => 25495456 "urn" => "urn:li:activity:7115266812946100225" "followers" => null "date" => "1w" "description" => """ Angeliners are our greatest treasure. Thanks to their vibrant and passionate daily work, we can celebrate innovation, collaboration, and the pursuit of excellence. \n Step into our people world with "When I Grow Up" series and meet our remarkable team members who are transforming theory into practice, innovating for a brighter and healthier future, and contributing to our collective success in the health world. Their stories are truly inspiring.\n \n Explore "When I Grow Up": https://lnkd.in/dexYTFMD \n \n #AngeliniPharma #EveryStepCloser\n #WinAsOne """ "reactions_count" => 82 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-02 14:46:48" "deleted" => 1 ] [ "id" => 344000407 "company_id" => 25495456 "urn" => "urn:li:activity:7114611385572954112" "followers" => null "date" => "1w" "description" => null "reactions_count" => 34 "comments_count" => null "reshared_post_author" => "Angelini Industries" "reshared_post_author_url" => "https://it.linkedin.com/company/angelini-industries" "reshared_post_author_headline" => null "reshared_post_description" => """ 🇮🇹 “Piacere, siamo Angelini Industries” è il claim della nuova campagna corporate del Gruppo, on air da oggi.\n \n Un messaggio attraverso cui abbiamo scelto di raccontarci per valorizzare il DNA multibusiness che contraddistingue il nostro Gruppo. \n La campagna - realizzata da TBWA\Worldwide con il planning media di \n Carat - si articola in quattro soggetti diversi pensati per evidenziare il percorso evolutivo del nostro Gruppo che, nato come laboratorio farmaceutico ad Ancona oltre un secolo fa, opera oggi in 21 Paesi del mondo nei campi della Salute, della Tecnologia Industriale e del Largo Consumo. \n Un gruppo diversificato ma con un unico obiettivo: prendersi cura delle persone e delle famiglie nella vita di tutti i giorni.\n \n Quotidiani, piattaforme digital, social media e affissioni i mezzi che da oggi a metà novembre ospiteranno l’adv che, per quotidiani e affissioni, contiene inoltre l’endorsement alla candidatura di Roma per Expo 2030, che Angelini Industries sostiene attraverso la Fondazione Roma Expo 2030.\n \n Conosciamoci per tutto quello che siamo, non solo una parte.\n Sfoglia le immagini per scoprire le creatività e scopri di più sulla campagna: \n https://lnkd.in/d7tq-y8d\n \n Angelini Pharma, Angelini Beauty, Angelini Wines & Estates, Angelini Ventures, Fater, Angelini Technologies - FAMECCANICA.\n \n #AngeliniIndustries #IndustryOfCare #PiacereSiamoAngeliniIndustries """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2023-11-02 14:46:48" "deleted" => 1 ] [ "id" => 344000408 "company_id" => 25495456 "urn" => "urn:li:activity:7114527274799968258" "followers" => null "date" => "1w" "description" => """ It's with great pleasure that we introduce John Bothmer, PhD as our new Translational Medicine Head.\n \n John holds a Biology Degree (Drs) from the University of Nijmegen (Netherlands) and a PhD in Neuropsychology & Psychobiology from the University of Maastricht (Netherlands).\n \n With over a decade of leadership roles in the pharmaceutical industry, including several years as an international clinical lead, John is well-equipped to drive our innovation forward. He is deeply committed to advancing healthcare, particularly in mental health disorders and epilepsy, with the ultimate goal of improving the quality of life for patients and finding optimal solutions.\n \n As John aptly puts it, “I am looking forward to working with all of you at Angelini Pharma on developing innovative drugs for the treatment of mental disorders and epilepsy. The challenge is to make the right choices and to use the right science to guide a drug candidate through critical phases in the R&D process efficiently. I am convinced that together we can do this and create benefit for the patients suffering from these debilitating diseases.”\n \n Please join us in extending a warm welcome to John Bothmer, and together, we're ready to make a difference.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 226 "comments_count" => 44 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-02 14:46:48" "deleted" => 1 ] [ "id" => 344000409 "company_id" => 25495456 "urn" => "urn:li:activity:7110185842756759552" "followers" => null "date" => "3w" "description" => """ In November 2022, with the support of EY we launched our Open Call, #ThermaCareInnova, dedicated to enhancing technology, patient experience, design, and materials for medical devices, all with the goal of improving musculoskeletal pain management.\n \n The winning companies revealed remarkable solutions in March 2023. These solutions have the potential to revolutionize ThermaCare products, significantly improving the patient experience and effectiveness. Their innovative approaches and cutting-edge technology set them apart. \n \n How will these innovations take shape? What new horizons will they unlock? We are proud to be part of this journey, and we look forward to how these innovative proposals will shape the future of pain management.\n \n #AngeliniPharma #EveryStepCloser #FitForTheFuture\n \n MARIO CUCCHETTI TESSUTI\n Linari Engineering\n Inhoc Signo """ "reactions_count" => 64 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-02 14:46:48" "deleted" => 1 ] [ "id" => 344000410 "company_id" => 25495456 "urn" => "urn:li:activity:7109838790663258112" "followers" => null "date" => "3w" "description" => """ It's been just under two weeks since we attended the 35th International Epilepsy Congress #IEC2023, featuring a satellite symposium titled 'The Impact of Time Lost on Achieving Meaningful Seizure Control in Adult Patients with Epilepsy.'\n \n The impressive attendance was a resounding success, reaffirming our commitment to Brain Health and allowing us to present crucial data and results. This continues to support professionals in the fields of neurology and epilepsy on their career journeys, all while sharing the common goal of making a difference in the lives of epileptic patients.\n \n Reinforcing this dedication were the words of Key Opinion Leader Rhys Thomas, who, alongside esteemed colleagues Patrick Kwan, Manuel Toledo, and Norman Delanty, delivered the symposium.\n \n This was undoubtedly a significant milestone. What lies ahead for us, and what can we do to keep making a difference?\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 45 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-02 14:46:48" "deleted" => 1 ] [ "id" => 344000411 "company_id" => 25495456 "urn" => "urn:li:activity:7109469152066568192" "followers" => null "date" => "3w" "description" => """ We are thrilled to welcome Lena Tagmose to our team as the Executive Director of External Global Innovation.\n \n With her specialized background in Computational Medicinal Chemistry and extensive leadership experience, she will share her profound expertise, particularly in the field of brain health, to help us explore innovative pathways built upon solid scientific foundations.\n \n Her words truly reflect her commitment to patients: "Embarking on global innovation is crucial for unlocking brighter tomorrows for patients in need. Therefore, it is both a personal and professional pleasure for me to contribute to Angelini Pharma's exciting transformative R&D journey, building a comprehensive pipeline of innovative medicines and delivering novel, life-changing treatments for people with brain disorders." \n \n Let's extend a warm welcome to Lena Tagmose and look forward to achieving new milestones together, driven by our shared determination to make a difference.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 199 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-02 14:46:48" "deleted" => 1 ] [ "id" => 344000412 "company_id" => 25495456 "urn" => "urn:li:activity:7106561945557684224" "followers" => null "date" => "1mo" "description" => """ Around 703,000 lives are lost to suicide worldwide every year. Shockingly, 58% of these suicides occur before age 50, ranking it as the 4th leading cause of death among young people aged 15 to 29.\n \n The Sustainable Development Goals (SDGs) remark in Goal 3: "Ensure healthy lives and promote well-being for all at all ages." Target 3.4 calls for reducing premature mortality from non-communicable diseases, including promoting mental health. Within this target, the suicide rate is a crucial indicator (3.4.2).\n Through our actions we can encourage hope.\n Suicide prevention demands a comprehensive public health approach.\n Suicide is preventable through accessible care, emotional support, and messages of hope that break the stigma; it's a shared responsibility and a top priority for a more sustainable society.\n Small gestures can profoundly impact someone's life. Let's support each other. Together, with even small actions, EVERYONE can make a difference.\n \n The #WorldSuicidePreventionDay is an initiative by the International Association for Suicide Prevention (IASP) and in partnership with the World Health Organization.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #SuicidePrevention """ "reactions_count" => 167 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-02 14:46:48" "deleted" => 1 ] [ "id" => 344000413 "company_id" => 25495456 "urn" => "urn:li:activity:7104498276686569473" "followers" => null "date" => "1mo" "description" => """ People living with uncontrolled focal seizures are often overlooked in the healthcare system. \n We are committed to helping as many people living with #epilepsy as possible to the right to live their daily lives with dignity.\n \n Live from the 35th International Epilepsy Congress #IEC2023 in Dublin, hosting a Satellite Symposium entitled “The Impact of Time Lost on Achieving Meaningful Seizure Control in Adult Patients with Epilepsy.”\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind\n \n Read more here >> https://lnkd.in/dDMTj4RV """ "reactions_count" => 218 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-02 14:46:48" "deleted" => 1 ] [ "id" => 364871886 "company_id" => 25495456 "urn" => "urn:li:activity:7125777659027992577" "followers" => null "date" => "5h" "description" => """ Persons living with mental health conditions can face significant disadvantages at work. Discrimination, unequal pay, and reduced responsibilities can make mental health problems worse. \n \n With “Headway - Mental Health Index 3.0” we are making strides in understanding the interaction between work and mental well-being. \n We are promoting open dialogue and driving change. \n Together, we can make a significant impact! 👉 https://lnkd.in/dM8Jedth\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #Headway2023 """ "reactions_count" => 28 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 18:38:02" "deleted" => 1 ] [ "id" => 364871887 "company_id" => 25495456 "urn" => "urn:li:activity:7124779504077520897" "followers" => null "date" => "3d" "description" => """ Over the last three months, we embarked on a journey of growth, dedication, and innovation that has been truly inspiring.\n We're working hard to shape a future that's inclusive and sustainable while supporting brain and mental health. Our mission continues to guide us on this path, serving as a constant reminder that through our collective efforts, we can make a positive impact on people's lives.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 91 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 18:38:02" "deleted" => 1 ] [ "id" => 364871888 "company_id" => 25495456 "urn" => "urn:li:activity:7122937109690093568" "followers" => null "date" => "1w" "description" => """ From Greece to Italy, Germany to Bulgaria, climate disasters have hit hard, with their indirect impact on mental health becoming increasingly evident. Many young people experience eco-anxiety, a genuine fear of a future compromised by a barren and lifeless environment - a natural response to our reality. \n We are firmly committed to understand every aspect of mental health at the European level and sharing our progress through the report “Headway - Mental Health Index 3.0” 👉 https://lnkd.in/dM8Jedth\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #Headway2023 """ "reactions_count" => 94 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 18:38:02" "deleted" => 1 ] [ "id" => 364871889 "company_id" => 25495456 "urn" => "urn:li:activity:7122510408321515521" "followers" => null "date" => "1w" "description" => """ Key Opinion Leaders and Junior Researchers across Europe will gather in Rome on October 26th-27th, 2023, for the 4th Digital Psychiatry Innovation Summit. A pivotal occasion for dynamic discussions on innovative digital mental healthcare solutions, advancing research, fostering innovation, and enhancing the quality of life through expertise-sharing and collaboration.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #PSYSUM2023 """ "reactions_count" => 85 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 18:38:02" "deleted" => 1 ] [ "id" => 364871890 "company_id" => 25495456 "urn" => "urn:li:activity:7121116707414249472" "followers" => null "date" => "1w" "description" => """ Siamo orgogliosi di aver contribuito a una iniziativa volta a combattere lo stigma e a creare una consapevolezza diversa nelle nuove generazioni. \n \n Le parole del Direttore Medico Italia Michela Procaccini MD per il nostro impegno a favore delle persone con Epilessia. """ "reactions_count" => 34 "comments_count" => null "reshared_post_author" => "Forum Sistema Salute\| Firenze, Stazione Leopolda" "reshared_post_author_url" => "https://it.linkedin.com/showcase/forum-sistema-salute-stazione-leopolda" "reshared_post_author_headline" => null "reshared_post_description" => """ 📌 Michela Procaccini MD, 𝗗𝗶𝗿𝗲𝘁𝘁𝗼𝗿𝗲 𝗠𝗲𝗱𝗶𝗰𝗼 𝗜𝘁𝗮𝗹𝗶𝗮 𝗱𝗶 Angelini Pharma 𝗰𝗶 𝗿𝗮𝗰𝗰𝗼𝗻𝘁𝗮 𝗹'𝗶𝗺𝗽𝗲𝗴𝗻𝗼 𝗱𝗲𝗹𝗹'𝗮𝘇𝗶𝗲𝗻𝗱𝗮 𝗽𝗲𝗿 𝗰𝗼𝗺𝗯𝗮𝘁𝘁𝗲𝗿𝗲 𝗹𝗼 𝘀𝘁𝗶𝗴𝗺𝗮 𝗰𝗵𝗲 𝗮𝗻𝗰𝗼𝗿𝗮 𝗰𝗼𝗶𝗻𝘃𝗼𝗹𝗴𝗲 𝗹'𝗲𝗽𝗶𝗹𝗲𝘀𝘀𝗶𝗮 𝗲, 𝗻𝗲𝗹𝗹'𝗶𝗻𝘁𝗲𝗿𝘃𝗶𝘀𝘁𝗮 𝗮 𝗰𝘂𝗿𝗮 𝗱𝗶 Beatrice Curci, 𝘀𝗼𝘁𝘁𝗼𝗹𝗶𝗻𝗲𝗮 𝗹'𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘇𝗮 𝗱𝗲𝗹𝗹'𝗮𝗻𝗮𝗹𝗶𝘀𝗶 𝗱𝗲𝗶 𝗯𝗶𝘀𝗼𝗴𝗻𝗶 𝗱𝗶 𝗰𝗶𝗮𝘀𝗰𝘂𝗻 𝗽𝗮𝘇𝗶𝗲𝗻𝘁𝗲.\n #Fss_23 #Ri_evoluzione """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2023-12-12 18:38:02" "deleted" => 1 ] [ "id" => 364871891 "company_id" => 25495456 "urn" => "urn:li:activity:7121088364119769088" "followers" => null "date" => "1w" "description" => """ Behind every great success, there lies a great dedication. From a mechanical engineer to a Maintenance & Engineering Lead at Angelini Pharma, Juan Arbelaez shares his extraordinary story in the "When I Grow Up" series, where passion steers the journey, fueling innovation, collaboration, and the pursuit of excellence: https://lnkd.in/dexYTFMD.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 35 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 18:38:02" "deleted" => 1 ] [ "id" => 364871892 "company_id" => 25495456 "urn" => "urn:li:activity:7120412581525082112" "followers" => null "date" => "2w" "description" => """ In just one week, with The European House-Ambrosetti we will have the honour of presenting “Headway - Mental Health Index 3.0” to the European Parliament. Our index provides a comprehensive view of mental health in Europe, and supports us and our stakeholders to map mental well-being in various States.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 85 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 18:38:02" "deleted" => 1 ] [ "id" => 364871893 "company_id" => 25495456 "urn" => "urn:li:activity:7117795192102883329" "followers" => null "date" => "3w" "description" => """ Coinciding with #WorldMentalHealthDay, our CEO Jacopo Andreose shared the latest findings from our #Headway Report surrounding mental health in the workplace and in schools in an article on Euractiv. \n Read more here: https://lnkd.in/dABcWWbK """ "reactions_count" => 139 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 18:38:02" "deleted" => 1 ] [ "id" => 364871894 "company_id" => 25495456 "urn" => "urn:li:activity:7117437923456618496" "followers" => null "date" => "3w" "description" => """ Keeping the mental health conversation alive across the EU remains a big part of what we do. We're digging deeper into what affects people's mental well-being, making sure we make a real difference and leave no one out. \n We've got some exciting stuff on the way, and we can't wait to share it with you all.\n \n #WorldMentalHealthDay\n #AngeliniPharma #EveryStepCloser #WithYouInMind\n \n The European House-Ambrosetti """ "reactions_count" => 105 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 18:38:02" "deleted" => 1 ] [ "id" => 364871895 "company_id" => 25495456 "urn" => "urn:li:activity:7115266812946100225" "followers" => null "date" => "4w" "description" => """ Angeliners are our greatest treasure. Thanks to their vibrant and passionate daily work, we can celebrate innovation, collaboration, and the pursuit of excellence. \n Step into our people world with "When I Grow Up" series and meet our remarkable team members who are transforming theory into practice, innovating for a brighter and healthier future, and contributing to our collective success in the health world. Their stories are truly inspiring.\n \n Explore "When I Grow Up": https://lnkd.in/dexYTFMD \n \n #AngeliniPharma #EveryStepCloser\n #WinAsOne """ "reactions_count" => 86 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 18:38:02" "deleted" => 1 ] [ "id" => 411201230 "company_id" => 25495456 "urn" => "urn:li:activity:7138567432951988225" "followers" => null "date" => "5d" "description" => """ Powerful words from Prof. Pavel klein during our recent international event "From Now On", held in Milan. His insightful message reminds us of the challenges faced by those with uncontrolled epilepsy. \n Let's raise awareness and support initiatives that improve the lives of those affected. Together, we can make a difference! \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 84 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-17 10:39:03" "deleted" => 1 ] [ "id" => 411201231 "company_id" => 25495456 "urn" => "urn:li:activity:7137757015069589504" "followers" => null "date" => "1w" "description" => """ Women’s brain health is understudied, and often underfunded too. But sex is a biological variable: a woman’s brain is different from a man’s brain and must be recognized and treated as such.\n \n To do our part, yesterday our Global Medical department hosted a special event on female brain health, delving into the topic with international experts Prof. Domenica Lorusso, Prof. Kamilla Woznica Miskowiak, Prof. Bettina Schmitz and Prof. Adam Wichniack. We also paid attention to what patients have to say, welcoming Torie Robinson: patient advocate, podcast host and Epilepsy Sparks CEO, she has an interesting perspective to offer.\n \n Let’s get to work to make neuroscience inclusive.\n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 108 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-17 10:39:03" "deleted" => 1 ] [ "id" => 411201232 "company_id" => 25495456 "urn" => "urn:li:activity:7135922923185291264" "followers" => null "date" => "2w" "description" => """ We're not just heading towards the future; we're on a shared expedition towards perpetual growth. Beyond our daily responsibilities, we're committed to fostering a workspace where every team member's aspirations are not only heard but also shared and nurtured. Our journey forward is shaped by actively listening to the aspirations of Angeliners.\n \n #EveryStepCloser #WinAsOne #AngeliniPharma\n Alessandra Boari Attilio De Sario """ "reactions_count" => 45 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-17 10:39:03" "deleted" => 1 ] [ "id" => 411201233 "company_id" => 25495456 "urn" => "urn:li:activity:7135560565082513408" "followers" => null "date" => "2w" "description" => """ Developing a strong sense of belonging among our people means experiencing personal fulfillment in their tasks and collaborating together with them toward common goals. The Angeliners feel a deep connection to us and that definitely indicates us how to become a caring company.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne \n Attilio De Sario Alessandro Tagliapietra Cristian Ragnini """ "reactions_count" => 104 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-17 10:39:03" "deleted" => 1 ] [ "id" => 411201234 "company_id" => 25495456 "urn" => "urn:li:activity:7135220365215027200" "followers" => null "date" => "2w" "description" => """ Renewing our commitment to Brain Health, on November 28th and 29th, 2023, we have the pleasure of hosting in Milan the “From Now On” event along with some of the foremost international Opinion Leaders in the field of epilepsy. It is a significant opportunity for scientific updates aimed at fostering dialogue and sharing real-world experience results regarding new clinical perspectives in the epilepsy field.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 159 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-17 10:39:03" "deleted" => 1 ] [ "id" => 411201235 "company_id" => 25495456 "urn" => "urn:li:activity:7133386240279609344" "followers" => null "date" => "2w" "description" => """ Valentina Villano unfolds her captivating journey from a young doctor to becoming a Medical Advisor at Angelini Pharma in our "When I Grow Up" series: \n https://lnkd.in/dexYTFMD \n Fueled by curiosity, dedication, collaboration, and research, Valentina's everyday work makes a meaningful impact on the quality of many people's lives—a significant achievement as a medical professional.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 79 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-17 10:39:03" "deleted" => 1 ] [ "id" => 411201236 "company_id" => 25495456 "urn" => "urn:li:activity:7133106951424516097" "followers" => null "date" => "2w" "description" => """ Prioritizing mental health is not just a mission – it's our way of life. \n The well-being of our employees is at the forefront, both within and outside our walls. Every insight shared by our team, every mood, and every success story holds immense value for us. It's a two-way learning street – just as they learn from us, we learn from them. \n Because, at the end of the day, we win as one.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 101 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-17 10:39:03" "deleted" => 1 ] [ "id" => 411201237 "company_id" => 25495456 "urn" => "urn:li:activity:7129762324168531968" "followers" => null "date" => "1mo" "description" => """ We warmly welcome Liana Allitto, our new Contry Italy Epilepsy Franchise Lead.\n \n With rich experience in marketing within the pharmaceutical and biotechnology sectors, Liana brings her expertise to our team, including valuable skills in change management. This expertise is crucial as we strive to better understand Epilepsy and make a real impact on people's lives.\n \n As Liana states “For me, it's an honor to become a part of a highly recognized company like Angelini Pharma. The opportunity to collaborate with a successful team, while continuing to strengthen our position in Epilepsy, aware that it's a healthcare challenge of today and tomorrow, and serving our patients to the best of our abilities, is a source of inspiration and motivation for me. I look forward to joining the people, culture, and team at Angelini Pharma and sharing future successes together.”\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 193 "comments_count" => 28 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-17 10:39:03" "deleted" => 1 ] [ "id" => 411201238 "company_id" => 25495456 "urn" => "urn:li:activity:7128675201893986304" "followers" => null "date" => "1mo" "description" => """ His story radiates passion, dedication, and a profound love for diversity, emphasizing the importance of a patient-centric vision and a commitment to making a real impact on people's lives.\n \n In this new episode of the "Nice to Meet You" podcast, we delve into the journey of Erik Lommerde, our International Chief Commercial Operations Officer.\n \n 👉 https://lnkd.in/dgmsYuAf \n \n #AngeliniPharma #EveryStepCloser #WinAsOne #NiceToMeetYou """ "reactions_count" => 133 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-17 10:39:03" "deleted" => 1 ] [ "id" => 411201239 "company_id" => 25495456 "urn" => "urn:li:activity:7125777659027992577" "followers" => null "date" => "1mo" "description" => """ Persons living with mental health conditions can face significant disadvantages at work. Discrimination, unequal pay, and reduced responsibilities can make mental health problems worse. \n \n With “Headway - Mental Health Index 3.0” we are making strides in understanding the interaction between work and mental well-being. \n We are promoting open dialogue and driving change. \n Together, we can make a significant impact! 👉 https://lnkd.in/dM8Jedth\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #Headway2023 """ "reactions_count" => 102 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-17 10:39:03" "deleted" => 1 ] [ "id" => 446570518 "company_id" => 25495456 "urn" => "urn:li:activity:7147179626988032000" "followers" => null "date" => "3w" "description" => """ As 2023 comes to an end, we look back at the past year acknowledging our globally-shared challenges and unsolved questions. Yet, Science has gone one step forward: 365 days are enough time to make new discoveries, to reach longed-for goals, and to ignite new hopes. \n \n We are ready to welcome 2024, never ceasing to question and learn. \n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 144 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 12:24:56" "deleted" => 1 ] [ "id" => 446570519 "company_id" => 25495456 "urn" => "urn:li:activity:7143989996201431040" "followers" => null "date" => "3w" "description" => """ On November 24th, the “Brain Health Innovation Summit” took place in Rome, bringing together international key experts working in brain health. Prof Kevin Talbot's words point out the exciting journey ahead.\n \n It’s a challenge, but research keeps paving the way!\n \n #AngeliniPharma #BrainHealthSummit #EveryStepCloser #WithYouInMind """ "reactions_count" => 46 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 12:24:56" "deleted" => 1 ] [ "id" => 446570520 "company_id" => 25495456 "urn" => "urn:li:activity:7143257099765035008" "followers" => null "date" => "3w" "description" => """ Epilepsy is a chronic brain disorder that affects approximately 50 million people around the world. In Italy only, it affects about one person in every 100. However, although it is certainly not rare, epilepsy is still surrounded by fear, social stigma and painful discrimination. \n \n To shed some light on the matter, on our blog we’re dispelling seven epilepsy myths through a dedicated fact-checking and debunking report.\n \n https://lnkd.in/dKxfzjqn\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 99 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 12:24:56" "deleted" => 1 ] [ "id" => 446570521 "company_id" => 25495456 "urn" => "urn:li:activity:7140720791981121537" "followers" => null "date" => "1mo" "description" => """ Prof. Paul Boon words at our recent international event "From Now On" held in Milan a few weeks ago, where we shed light on the critical role of early action in preserving neurological health for more fulfilling lives. \n Together, we promote understanding and support for brain health.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 68 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 12:24:56" "deleted" => 1 ] [ "id" => 446570522 "company_id" => 25495456 "urn" => "urn:li:activity:7138567432951988225" "followers" => null "date" => "1mo" "description" => """ Powerful words from Prof. Pavel klein during our recent international event "From Now On", held in Milan. His insightful message reminds us of the challenges faced by those with uncontrolled epilepsy. \n Let's raise awareness and support initiatives that improve the lives of those affected. Together, we can make a difference! \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 108 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 12:24:56" "deleted" => 1 ] [ "id" => 446570523 "company_id" => 25495456 "urn" => "urn:li:activity:7137757015069589504" "followers" => null "date" => "1mo" "description" => """ Women’s brain health is understudied, and often underfunded too. But sex is a biological variable: a woman’s brain is different from a man’s brain and must be recognized and treated as such.\n \n To do our part, yesterday our Global Medical department hosted a special event on female brain health, delving into the topic with international experts Prof. Domenica Lorusso, Prof. Kamilla Woznica Miskowiak, Prof. Bettina Schmitz and Prof. Adam Wichniack. We also paid attention to what patients have to say, welcoming Torie Robinson: patient advocate, podcast host and Epilepsy Sparks CEO, she has an interesting perspective to offer.\n \n Let’s get to work to make neuroscience inclusive.\n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 119 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 12:24:56" "deleted" => 1 ] [ "id" => 446570524 "company_id" => 25495456 "urn" => "urn:li:activity:7135922923185291264" "followers" => null "date" => "1mo" "description" => """ We're not just heading towards the future; we're on a shared expedition towards perpetual growth. Beyond our daily responsibilities, we're committed to fostering a workspace where every team member's aspirations are not only heard but also shared and nurtured. Our journey forward is shaped by actively listening to the aspirations of Angeliners.\n \n #EveryStepCloser #WinAsOne #AngeliniPharma\n Alessandra Boari Attilio De Sario """ "reactions_count" => 52 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 12:24:56" "deleted" => 1 ] [ "id" => 446570525 "company_id" => 25495456 "urn" => "urn:li:activity:7135560565082513408" "followers" => null "date" => "1mo" "description" => """ Developing a strong sense of belonging among our people means experiencing personal fulfillment in their tasks and collaborating together with them toward common goals. The Angeliners feel a deep connection to us and that definitely indicates us how to become a caring company.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne \n Attilio De Sario Alessandro Tagliapietra Cristian Ragnini """ "reactions_count" => 105 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 12:24:56" "deleted" => 1 ] [ "id" => 446570526 "company_id" => 25495456 "urn" => "urn:li:activity:7135220365215027200" "followers" => null "date" => "1mo" "description" => """ Renewing our commitment to Brain Health, on November 28th and 29th, 2023, we have the pleasure of hosting in Milan the “From Now On” event along with some of the foremost international Opinion Leaders in the field of epilepsy. It is a significant opportunity for scientific updates aimed at fostering dialogue and sharing real-world experience results regarding new clinical perspectives in the epilepsy field.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 163 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 12:24:56" "deleted" => 1 ] [ "id" => 446570527 "company_id" => 25495456 "urn" => "urn:li:activity:7133386240279609344" "followers" => null "date" => "1mo" "description" => """ Valentina Villano unfolds her captivating journey from a young doctor to becoming a Medical Advisor at Angelini Pharma in our "When I Grow Up" series: \n https://lnkd.in/dexYTFMD \n Fueled by curiosity, dedication, collaboration, and research, Valentina's everyday work makes a meaningful impact on the quality of many people's lives—a significant achievement as a medical professional.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 81 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 12:24:56" "deleted" => 1 ] [ "id" => 469892190 "company_id" => 25495456 "urn" => "urn:li:activity:7162794612741337088" "followers" => null "date" => "23h" "description" => """ Today, February 12, is #EpilepsyDay. \n \n We couldn't think of a better way to celebrate than by looking back on the past few weeks, in which our support for the #50MillionSteps campaign organized by the INTERNATIONAL BUREAU FOR EPILEPSY has been constant and passionate, both as a company and as individuals. \n \n A big thank you to everyone that took part in the challenge, fighting against the stigma. By acting together, we can achieve greater awareness and better health for all. \n \n More steps. More awareness. More lives improved. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #StepAgainstStigma """ "reactions_count" => 45 "comments_count" => 1 "reshared_post_author" => "Jacopo Andreose" "reshared_post_author_url" => "https://it.linkedin.com/in/andreose" "reshared_post_author_headline" => null "reshared_post_description" => """ Today we celebrate International Epilepsy Day, a crucial time to raise awareness on a neurological disorder that affects over 50 million people worldwide, with around 400,000 new cases diagnosed each year in Europe alone.\n \n Many European countries need to improve their plans to effectively address stigma discrimination and ensure access to treatment for people living with epilepsy. This is why we actively support the implementation of the 10-year cross-sectoral Global Action Plan for epilepsy and other neurological diseases (IGAP).\n Initiatives like #50MillionSteps, promoted by the INTERNATIONAL BUREAU FOR EPILEPSY, play a key role in raising public awareness. This year, Angelini Pharma’s leaders like Erik Lommerde, Rafal Kaminski and Calabrese Rosita together with our passionate colleagues collected over 6 million steps joining the campaign, a wonderful result I'm very grateful for. \n Our efforts are not limited to raising awareness but also aim to influence European legislative frameworks. Since 2017, we have been engaged in Headway, in partnership with The The European House-Ambrosetti Think Tank, a strategic platform that aims to improve the approach to brain health in Europe by producing annual reports and promoting dialogue between the various actors in the field, as recently done in France and Germany with institutional, multistakeholder roundtables.\n \n Our commitment goes beyond every single step: we will continue to work tirelessly until we see tangible changes in every European country.\n To make the world a more inclusive and aware place for people living with epilepsy, their carers, and their families.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #StepAgainstStigma """ "reshared_post_followers" => null "reshared_post_date" => "23h" "last_updated" => "2024-03-02 13:23:04" "deleted" => 1 ] [ "id" => 469892191 "company_id" => 25495456 "urn" => "urn:li:activity:7160935237517033472" "followers" => null "date" => "6d" "description" => """ It makes us so happy to see Angeliners supporting the #50MillionSteps campaign with passion and dedication. This is our special way to contribute to the campaign launched by INTERNATIONAL BUREAU FOR EPILEPSY to raise awareness on this disease and break the stigma that surrounds it. \n \n Let’s keep moving towards #EpilepsyDay on February 12! \n \n More steps. More awareness. More lives improved. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #StepAgainstStigma """ "reactions_count" => 73 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 13:23:04" "deleted" => 1 ] [ "id" => 469892192 "company_id" => 25495456 "urn" => "urn:li:activity:7160655895570325505" "followers" => null "date" => "6d" "description" => """ We have been working hard in recent months to renovate our approach, embracing a new look and redefining our vision. Always keeping in mind our mission: health is a human right for all and a prerequisite for sustainable development. \n \n We continue to promote awareness of brain health and other neurological disorders, truly believing in the importance of connecting with real people. \n \n Because the stronger the connection, the better the future that lies ahead. An inclusive, sustainable and healthy future for all. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 74 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 13:23:04" "deleted" => 1 ] [ "id" => 469892193 "company_id" => 25495456 "urn" => "urn:li:activity:7158398214520385536" "followers" => null "date" => "1w" "description" => """ We are so proud of all the Angeliners that are showing their passionate support to the #50MillionSteps campaign, organised by INTERNATIONAL BUREAU FOR EPILEPSY to raise awareness on this disease and break the stigma that surrounds it. \n \n While we approach #EpilepsyDay on February 12, here’s a small demonstration of what it means to walk together toward a common goal, seeking better health for all people. \n \n More steps. More awareness. More lives improved. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #StepAgainstStigma """ "reactions_count" => 77 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 13:23:04" "deleted" => 1 ] [ "id" => 469892194 "company_id" => 25495456 "urn" => "urn:li:activity:7158142000259596289" "followers" => null "date" => "1w" "description" => """ In partnership with The European House-Ambrosetti, “#Headway: A new roadmap in Brain Health” aims to foster a common ground for strategic reflection and dialogue on Epilepsy and Neurogical Diseases as experienced from different European perspectives.\n \n Today January 30, Headway was in Berlin and we had the opportunity to discuss with excellent experts and patients about living with #epilepsy, best practices and prioritize areas of intervention.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 44 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 13:23:04" "deleted" => 1 ] [ "id" => 469892195 "company_id" => 25495456 "urn" => "urn:li:activity:7158064045005123584" "followers" => null "date" => "2w" "description" => """ With the #50MillionSteps campaign now in full swing, our Italy Country Manager Calabrese Rosita reminds us how working for a company that aims to improve people's health involves daily responsibilities— and taking a step against stigma is one of them. \n \n Reducing the burden of epilepsy is a priority. \n \n INTERNATIONAL BUREAU FOR EPILEPSY\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #StepAgainstStigma """ "reactions_count" => 202 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 13:23:04" "deleted" => 1 ] [ "id" => 469892196 "company_id" => 25495456 "urn" => "urn:li:activity:7156304403497467904" "followers" => null "date" => "2w" "description" => """ In partnership with The European House-Ambrosetti, we launched #Headway: A new roadmap in Brain Health which aims to create a common ground for strategic reflection and dialogue on Epilepsy and Neurogical Diseases as experienced from different European perspectives.\n \n Today January 25, Headway is in Paris, welcoming excellent experts to speak on the impacts of living with #epilepsy in work place.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 87 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 13:23:04" "deleted" => 1 ] [ "id" => 469892197 "company_id" => 25495456 "urn" => "urn:li:activity:7155133501783126017" "followers" => null "date" => "3w" "description" => """ Our Chief Scientific Officer Rafal Kaminski is joining the #50MillionSteps campaign launched by the INTERNATIONAL BUREAU FOR EPILEPSY and sharing his personal experience to reduce the stigma, impact and burden of epilepsy. \n \n As he says, knowledge is the key to jump over erase the stigma. \n #AngeliniPharma #EveryStepCloser #WithYouInMind #StepAgainstStigma """ "reactions_count" => 58 "comments_count" => 1 "reshared_post_author" => "Rafal Kaminski" "reshared_post_author_url" => "https://it.linkedin.com/in/rafal-kaminski-373867" "reshared_post_author_headline" => null "reshared_post_description" => """ We can all do something to help reduce the stigma, impact and burden of epilpesy and other neurological disorders. \n That’s why as an Angeliner, I’m proud to take part to this year #50MillionSteps campaign, organized by the INTERNATIONAL BUREAU FOR EPILEPSY.\n \n More steps. More awareness. More lives improved. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #StepAgainstStigma """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2024-03-02 13:23:04" "deleted" => 1 ] [ "id" => 469892198 "company_id" => 25495456 "urn" => "urn:li:activity:7154097417934516226" "followers" => null "date" => "3w" "description" => """ Our International Chief Commercial Operations Officer Erik Lommerde’s mission is to lead our organization in its continuous work to improve people’s life.\n \n Supporting the #50MillionSteps campaign is yet another way of sharing his time contribution and his experience support to overcome the stigma associated with epilepsy and other neurological disorders. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #StepAgainstStigma """ "reactions_count" => 71 "comments_count" => 1 "reshared_post_author" => "Erik Lommerde" "reshared_post_author_url" => "https://es.linkedin.com/in/eriklommerde" "reshared_post_author_headline" => "Result oriented people manager with 30 years of experiences and successes in several geographic areas! Culture, Leadership, Respect, Commercial Execution, Teamplayer" "reshared_post_description" => """ I’m glad to have the opportunity to raise awareness on epilepsy and other neurological diseases. Together with the INTERNATIONAL BUREAU FOR EPILEPSY and Angelini Pharma, I’m proud to support the #50MillionSteps campaign.\n \n More steps. More awareness. More lives improved.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #StepAgainstStigma """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2024-03-02 13:23:04" "deleted" => 1 ] [ "id" => 469892199 "company_id" => 25495456 "urn" => "urn:li:activity:7153762751713009664" "followers" => null "date" => "3w" "description" => """ We are thrilled to announce that we achieved the #TopEmployerEurope2024 certification for the fifth year in a row! \n \n Our people are always at the top of our priorities. \n Hear seven of them explaining why they feel "on top".\n \n Susana Vicente Balbás İlker Örsal Paolo Lamagna Yvette Brandmaier Emanuela Federenciuc João Amaral Jakub Kowalczyk Stefano Vermiglio\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 322 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 13:23:04" "deleted" => 1 ] [ "id" => 494165168 "company_id" => 25495456 "urn" => "urn:li:activity:7168892813072449536" "followers" => null "date" => "2d" "description" => """ Earlier this month, we launched an Open Innovation Challenge, focused on digital approaches for the identification of drug targets in epilepsy, building on existing bioinformatics and artificial technologies. \n \n As our Chief Scientific Officer Rafal Kaminski says, “The identification of the right drug target remains challenging, particularly for brain diseases. However, digital approaches and advances data anlyses are rapidly progressing to better inform about innovative drug targets. This recent initiative aims to make progress in Brain Health by leveraging the power of a global community with particular focus on drug-resistant epilepsy”. \n \n We can’t wait to see the results. \n \n #AngeliniPharma #EveryStepCloser \n \n https://lnkd.in/dnpDnm7q """ "reactions_count" => 95 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:22:19" "deleted" => 1 ] [ "id" => 494165169 "company_id" => 25495456 "urn" => "urn:li:activity:7168183067369586688" "followers" => null "date" => "4d" "description" => """ The European Pharmaceutical Sector is recognized as one of the most difficult sectors to decarbonize, given the stringent regulatory limits. \n \n As part of our ongoing green transition strategy, the LIFE-GREENAPI project conducted with Leiden University - Institute of Environmental Sciences (CML) represents a shared effort to lower the environmental impact of pharma production, as well as optimizing its processes. \n \n #AngeliniPharma #EveryStepCloser #LIFEprogramme #LIFEproject #LIFEprojects #EUGreenDeal \n \n https://lnkd.in/d2fqfvZS """ "reactions_count" => 34 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:22:19" "deleted" => 1 ] [ "id" => 494165170 "company_id" => 25495456 "urn" => "urn:li:activity:7167805514477780993" "followers" => null "date" => "5d" "description" => """ With our “When I Grow Up” series we step into the world of Angeliners, who are our greatest treasure and the fuel of everything we do. \n \n In the latest episode, Global RA Specialist Marianna Del Sorbo recounts how her career began with the ambitious goal of joining the regulatory team. Her unwavering dedication to the regulatory landscape involves navigating complex regulations to ensure pharmaceutical products meet global market standards. \n \n https://bit.ly/3uGzILw\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 56 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:22:19" "deleted" => 1 ] [ "id" => 494165171 "company_id" => 25495456 "urn" => "urn:li:activity:7166375493896806402" "followers" => null "date" => "1w" "description" => """ Back in 2021, we took a leap into the world of brain health. Since then, we’ve been working hard to tackle #Epilepsy from different angles, not only finding clinical solutions but also continuously searching for health solutions that can positively impact the life of people suffering from neurological diseases. \n \n Our Chief Medical Officer Agnese Cattaneo looks back on our journey, reminding all of us that health goes beyond specific diseases: it concerns our quality of life, and it’s strictly connected to the community we live in, to its awareness and its social instruments. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #MyEpilepsyJourney INTERNATIONAL BUREAU FOR EPILEPSY """ "reactions_count" => 40 "comments_count" => null "reshared_post_author" => "Agnese Cattaneo" "reshared_post_author_url" => "https://it.linkedin.com/in/agnese-cattaneo-26767166" "reshared_post_author_headline" => "Chief Medical Officer presso Angelini Pharma" "reshared_post_description" => """ World Health Organization defines health as “a state of complete physical, mental and social well-being": health goes beyond specific diseases, it’s not the absence of infirmity but the presence of well-being indeed. That’s why I’m proud to be part of a company that has always been guided by this vital mindset. \n \n Looking back at what Angelini Pharma has done since entering the world of brain health back in 2021, makes me want to tell you all about it. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #MyEpilepsyJourney INTERNATIONAL BUREAU FOR EPILEPSY """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2024-04-05 12:22:19" "deleted" => 1 ] [ "id" => 494165172 "company_id" => 25495456 "urn" => "urn:li:activity:7162794612741337088" "followers" => null "date" => "2w" "description" => """ Today, February 12, is #EpilepsyDay. \n \n We couldn't think of a better way to celebrate than by looking back on the past few weeks, in which our support for the #50MillionSteps campaign organized by the INTERNATIONAL BUREAU FOR EPILEPSY has been constant and passionate, both as a company and as individuals. \n \n A big thank you to everyone that took part in the challenge, fighting against the stigma. By acting together, we can achieve greater awareness and better health for all. \n \n More steps. More awareness. More lives improved. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #StepAgainstStigma """ "reactions_count" => 68 "comments_count" => 1 "reshared_post_author" => "Jacopo Andreose" "reshared_post_author_url" => "https://it.linkedin.com/in/andreose" "reshared_post_author_headline" => null "reshared_post_description" => """ Today we celebrate International Epilepsy Day, a crucial time to raise awareness on a neurological disorder that affects over 50 million people worldwide, with around 400,000 new cases diagnosed each year in Europe alone.\n \n Many European countries need to improve their plans to effectively address stigma discrimination and ensure access to treatment for people living with epilepsy. This is why we actively support the implementation of the 10-year cross-sectoral Global Action Plan for epilepsy and other neurological diseases (IGAP).\n Initiatives like #50MillionSteps, promoted by the INTERNATIONAL BUREAU FOR EPILEPSY, play a key role in raising public awareness. This year, Angelini Pharma’s leaders like Erik Lommerde, Rafal Kaminski and Calabrese Rosita together with our passionate colleagues collected over 6 million steps joining the campaign, a wonderful result I'm very grateful for. \n Our efforts are not limited to raising awareness but also aim to influence European legislative frameworks. Since 2017, we have been engaged in Headway, in partnership with The The European House-Ambrosetti Think Tank, a strategic platform that aims to improve the approach to brain health in Europe by producing annual reports and promoting dialogue between the various actors in the field, as recently done in France and Germany with institutional, multistakeholder roundtables.\n \n Our commitment goes beyond every single step: we will continue to work tirelessly until we see tangible changes in every European country.\n To make the world a more inclusive and aware place for people living with epilepsy, their carers, and their families.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #StepAgainstStigma """ "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2024-04-05 12:22:19" "deleted" => 1 ] [ "id" => 494165173 "company_id" => 25495456 "urn" => "urn:li:activity:7160935237517033472" "followers" => null "date" => "3w" "description" => """ It makes us so happy to see Angeliners supporting the #50MillionSteps campaign with passion and dedication. This is our special way to contribute to the campaign launched by INTERNATIONAL BUREAU FOR EPILEPSY to raise awareness on this disease and break the stigma that surrounds it. \n \n Let’s keep moving towards #EpilepsyDay on February 12! \n \n More steps. More awareness. More lives improved. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #StepAgainstStigma """ "reactions_count" => 82 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:22:19" "deleted" => 1 ] [ "id" => 494165174 "company_id" => 25495456 "urn" => "urn:li:activity:7160655895570325505" "followers" => null "date" => "3w" "description" => """ We have been working hard in recent months to renovate our approach, embracing a new look and redefining our vision. Always keeping in mind our mission: health is a human right for all and a prerequisite for sustainable development. \n \n We continue to promote awareness of brain health and other neurological disorders, truly believing in the importance of connecting with real people. \n \n Because the stronger the connection, the better the future that lies ahead. An inclusive, sustainable and healthy future for all. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 79 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:22:19" "deleted" => 1 ] [ "id" => 494165175 "company_id" => 25495456 "urn" => "urn:li:activity:7158398214520385536" "followers" => null "date" => "1mo" "description" => """ We are so proud of all the Angeliners that are showing their passionate support to the #50MillionSteps campaign, organised by INTERNATIONAL BUREAU FOR EPILEPSY to raise awareness on this disease and break the stigma that surrounds it. \n \n While we approach #EpilepsyDay on February 12, here’s a small demonstration of what it means to walk together toward a common goal, seeking better health for all people. \n \n More steps. More awareness. More lives improved. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #StepAgainstStigma """ "reactions_count" => 76 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:22:19" "deleted" => 1 ] [ "id" => 494165176 "company_id" => 25495456 "urn" => "urn:li:activity:7158142000259596289" "followers" => null "date" => "1mo" "description" => """ In partnership with The European House-Ambrosetti, “#Headway: A new roadmap in Brain Health” aims to foster a common ground for strategic reflection and dialogue on Epilepsy and Neurogical Diseases as experienced from different European perspectives.\n \n Today January 30, Headway was in Berlin and we had the opportunity to discuss with excellent experts and patients about living with #epilepsy, best practices and prioritize areas of intervention.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 45 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:22:19" "deleted" => 1 ] [ "id" => 494165177 "company_id" => 25495456 "urn" => "urn:li:activity:7158064045005123584" "followers" => null "date" => "1mo" "description" => """ With the #50MillionSteps campaign now in full swing, our Italy Country Manager Calabrese Rosita reminds us how working for a company that aims to improve people's health involves daily responsibilities— and taking a step against stigma is one of them. \n \n Reducing the burden of epilepsy is a priority. \n \n INTERNATIONAL BUREAU FOR EPILEPSY\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #StepAgainstStigma """ "reactions_count" => 205 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:22:19" "deleted" => 1 ] [ "id" => 529380758 "company_id" => 25495456 "urn" => "urn:li:activity:7180927616827146240" "followers" => null "date" => "2d" "description" => """ On March 26, we came together in our HQ to celebrate #PurpleDay and give our contribution to raising awareness around epilepsy.\n \n All people from Casa Angelini got involved and showed their passionate support by wearing purple and participating in different games and activities specially organised for the day.\n \n We strongly believe in the power of education, conversation, and human connection to fight stigma— thanks to everyone that helped us celebrate, raising awareness together around epilepsy.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind Angelini Industries """ "reactions_count" => 89 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 01:21:09" "deleted" => 1 ] [ "id" => 529380759 "company_id" => 25495456 "urn" => "urn:li:activity:7178323255500410880" "followers" => null "date" => "1w" "description" => """ Today is #PurpleDay, a global initiative to raise awareness around epilepsy and fight the stigma that still surrounds this neurological disease. \n \n Beyond delivering effective treatments, as a pharma company we are committed to cultivate an empathetic and inclusive environment for those impacted by epilepsy. \n \n This year, we’re celebrating March 26 by wearing purple to symbolize epilepsy awareness, and we’re proud to share a special contribution by Cassidy Megan, the young creator of Purple Day. Amplifying Cassidy's voice and that of people with epilepsy is a mission that propels our actions— today and every day. \n \n Happy Purple Day everyone! 💜 And thanks Cassidy for your precious contribution. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 143 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 01:21:09" "deleted" => 1 ] [ "id" => 529380760 "company_id" => 25495456 "urn" => "urn:li:activity:7176902984600088576" "followers" => null "date" => "2w" "description" => """ As climate change impacts increase, and population grows, there is an urgent need, to protect and conserve our most precious resource: water.\n \n Today is #WorldWaterDay and we want to acknowledge the presence of pharmaceutical compounds in aquatic ecosystems as a topic of growing concern in the last decade.\n \n We’re proud to be part of the European reasearch project PharmaSea (Presence, behavior and risk assessment of pharmaceuticals in marine ecosystems), coordinated by the Department of Life and Environmental Sciences of the Polytechnic University of Marche. The project integrates international expertise to answer key research questions on fate and biological effects of active pharmaceutical ingredients (APIs) on marine ecosystem.\n \n It proposes new environmental strategies and ecotoxicological approaches to promote public awareness related to key aspects of environmental sustainability.\n \n #AngeliniPharma #EveryStepCloser\n \n https://lnkd.in/dD2CXdPT """ "reactions_count" => 60 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 01:21:09" "deleted" => 1 ] [ "id" => 529380761 "company_id" => 25495456 "urn" => "urn:li:activity:7176601190917406720" "followers" => null "date" => "2w" "description" => """ In the occasion of upcoming #PurpleDay on March 26, don’t miss the podcast host and epilepsy patient expert Torie Robinson in conversation with the Purple Day founder Cassidy Megan in a new episode of the Epilepsy Sparks Insights, very soon live.\n \n Epilepsy affects over 50 million people around the world, yet it’s still surrounded by stigma and misconceptions. We believe in the power of human connections to fight stigma and raise awareness around this condition — through the simple acts of talking, sharing experiences, and supporting each other. \n \n Torie Robinson and Cassidy Megan will do all the above, on March 26. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 98 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 01:21:09" "deleted" => 1 ] [ "id" => 529380762 "company_id" => 25495456 "urn" => "urn:li:activity:7175502283428798465" "followers" => null "date" => "2w" "description" => """ Information and support are the foundation of “Women and Epilepsy”, our initiative born to make another step to eradicate the stigma.\n \n Through the words of our Chief Medical Officer Agnese Cattaneo, we reiterate our commitment to counteract disinformation and to create a supportive community for all.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #MyEpilepsyJourney \n INTERNATIONAL BUREAU FOR EPILEPSY """ "reactions_count" => 32 "comments_count" => null "reshared_post_author" => "Agnese Cattaneo" "reshared_post_author_url" => "https://it.linkedin.com/in/agnese-cattaneo-26767166" "reshared_post_author_headline" => "Chief Medical Officer presso Angelini Pharma" "reshared_post_description" => """ Recent studies led by the INTERNATIONAL BUREAU FOR EPILEPSY reveal fear and a lack of resources surrounding the provision of information about pregnancy in women affected by epilepsy. This gap drives us to launch "Women and Epilepsy" initiative, a platform that aims to inform and empower women that are facing epilepsy-related challenges. \n I'm very proud to be part of this initiative by Angelini Pharma that prioritizes information as a stable foundation for starting the eradication of the stigma around epilepsy. \n \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #MyEpilepsyJourney """ "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2024-05-10 01:21:09" "deleted" => 1 ] [ "id" => 529380763 "company_id" => 25495456 "urn" => "urn:li:activity:7174351162022772736" "followers" => null "date" => "3w" "description" => """ The brain plays a central role as the control center for emotions, thoughts, and behaviors. Today, it's crucial to grasp a comprehensive analysis of the intricate relationship between the brain and mental health. \n \n The interactive guide developed by GAMIAN-Europe on the occasion of the #BrainAwarenessWeek2024 is a valuable resource for understanding the complex interaction between biological and psychosocial factors that determine mental health status.\n \n https://lnkd.in/dmWXC2P5\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 76 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 01:21:09" "deleted" => 1 ] [ "id" => 529380764 "company_id" => 25495456 "urn" => "urn:li:activity:7173682528304721920" "followers" => null "date" => "3w" "description" => """ Acting to eradicate the stigma currently surrounding brain health is a big part of what we do, every day. \n \n Through the words of our Chief Medical Officer Agnese Cattaneo, we’re proud to reiterate the importance of education in this process: we consider it the main way to not only raise awareness of conditions but also foster a supportive community for everyone. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #MyEpilepsyJourney \n \n INTERNATIONAL BUREAU FOR EPILEPSY """ "reactions_count" => 32 "comments_count" => null "reshared_post_author" => "Agnese Cattaneo" "reshared_post_author_url" => "https://it.linkedin.com/in/agnese-cattaneo-26767166" "reshared_post_author_headline" => "Chief Medical Officer presso Angelini Pharma" "reshared_post_description" => """ Stigma surrounding brain health currently represents a significant barrier to patient well-being. Patients with neurological and psychiatric conditions often face discrimination and this is something that cannot be ignored as a society, as a company, as individuals, we must act for a more inclusive and supportive approach to brain health. \n \n I’m very proud of Angelini Pharma’s continuous commitment to education and I believe in it as the most powerful means we have to eradicate stigma. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #MyEpilepsyJourney INTERNATIONAL BUREAU FOR EPILEPSY """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2024-05-10 01:21:09" "deleted" => 1 ] [ "id" => 529380765 "company_id" => 25495456 "urn" => "urn:li:activity:7173029784376098816" "followers" => null "date" => "3w" "description" => """ 🌟 We're thrilled to share an important milestone in our journey towards enhancing lives and championing brain health!🎉\n \n Together with SK Biopharmaceuticals and SK Life Science, Inc. we're glad to announce that over 100,000 people worldwide have benefitted from our innovative treatment for epilepsy. We are making waves in the medical community, offering hope and relief to those affected by epilepsy.\n \n Our mission has always been centered on empowering individuals living with central nervous system disorders and since 2021 we've been embarking on a transformative journey to redefine epilepsy management.\n \n Through our unwavering commitment to raising awareness and improving access to vital treatment options, we're honored to witness the tangible impact of our daily work on countless lives. Every milestone achieved reaffirms our dedication to driving positive change and fostering a brighter future for human beings fighting epilepsy.\n \n The resilience and determination of the scientific community and patients’organizations inspire us to continue pushing boundaries and striving for excellence in everything we do.\n Together, we can make a profound difference in the lives of millions worldwide and spread hope for a healthier future! 💙\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 238 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 01:21:09" "deleted" => 1 ] [ "id" => 529380766 "company_id" => 25495456 "urn" => "urn:li:activity:7172914703013298176" "followers" => null "date" => "3w" "description" => """ Our Chief Scientific Officer Rafal Kaminski will be featured in the web magazine Euractiv today with an important editorial, talking about the commencement of EBC Brain Awareness Week Event 2024: No Health Without Brain Health", hosted by European Brain Council (EBC) in the European Parliament in Brussels. \n \n His article underscores our ongoing commitment to scientific research and our dedication to supporting communities affected by schizophrenia, epilepsy and depression. \n \n https://lnkd.in/dKWpnaXB\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind \n \n The European House-Ambrosetti GAMIAN-Europe European College of Neuropsychopharmacology (ECNP) European Academy of Neurology Lundbeck European Federation of Neurological Associations Federation of European Neuroscience Societies - FENS European Psychiatric Association European Association of Neurosurgical Societies (EANS) International Brain Research Organization """ "reactions_count" => 66 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 01:21:09" "deleted" => 1 ] [ "id" => 529380767 "company_id" => 25495456 "urn" => "urn:li:activity:7171800597229170689" "followers" => null "date" => "4w" "description" => """ This March 8, we want to remind ourselves that #InternationalWomensDay is not only an occasion to celebrate, but also one to reflect, challenge, and act. \n \n Despite the progress made in many areas, gender inequality is still undeniably present in our society, negatively affecting women’s mental health and well-being. \n \n The road to gender equality is still long, let's work on it together. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 82 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 01:21:09" "deleted" => 1 ] [ "id" => 563031221 "company_id" => 25495456 "urn" => "urn:li:activity:7193622411366297601" "followers" => null "date" => "2d" "description" => """ We keep working to build good health for all—one that encompasses body and mind, leaving nobody behind.\n \n The past few months have been busy with many of our disease awareness activities, and we're particularly proud to count on Angeliners' voices to encourage a more informed and inclusive community, speaking from people to people.\n \n We truly believe that the stronger the connection between people, the better the future that lies ahead.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 38 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:27:05" "deleted" => 1 ] [ "id" => 563031222 "company_id" => 25495456 "urn" => "urn:li:activity:7193189283187318785" "followers" => null "date" => "3d" "description" => """ It's with great pleasure that we introduce Klára Kotyzová as our new Global PV Director.\n \n With solid experience in clinical safety and pharmacovigilance roles across different pharmaceutical companies in Europe, Klara brings to our team her expertise as well as her attention for patient’s lives.\n \n As Klara states, “I am very pleased to join Angelini Pharma and help to improve quality of life of patients and make a difference in patients’ life by developing effective and safe drugs. I am ready to leverage my experience to provide the state of art operations in Clinical safety and Pharmacovigilance and enhace the cross-functional collaboration.”\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 77 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:27:05" "deleted" => 1 ] [ "id" => 563031223 "company_id" => 25495456 "urn" => "urn:li:activity:7189548810203774976" "followers" => null "date" => "1w" "description" => """ We continue to explore the life of Angeliners, with a new episode of our “When I Grow Up” series. \n \n Global Brand Manager Alice Paremain unveils how her initial aspirations have seamlessly merged with her current pharmaceutical pursuits, driven by her unwavering passion to positively impact people's health every day.\n \n https://lnkd.in/dexYTFMD\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 88 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:27:05" "deleted" => 1 ] [ "id" => 563031224 "company_id" => 25495456 "urn" => "urn:li:activity:7188461644153319427" "followers" => null "date" => "2w" "description" => """ In this new episode of our “Nice to meet You” podcast, we chat with Global General Counsel Enza Maria Cristina Onnis about the responsibilities of her role, the importance of people management and retention, and finally the major legal challenges that pharmaceutical companies face. \n \n The full episode is available on our website 👉 https://lnkd.in/dgmsYuAf \n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 63 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:27:05" "deleted" => 1 ] [ "id" => 563031225 "company_id" => 25495456 "urn" => "urn:li:activity:7188078772816863233" "followers" => null "date" => "2w" "description" => """ Today is #EarthDay, and we want to take this occasion to reinforce our commitment towards a better sustainability — both within our production cycle, and the broader pharmaceutical sector. \n \n We're proud to say that collective efforts such as our SMART PHARMA project are now leading the way for greener practices in the pharma world. Innovative manufacturing technologies and sustainable packaging practices can be powerful allies in reducing waste and enhancing productivity, trying to lower the environmental impact of pharma production on our planet.\n \n There’s still a long way to go, but we’re aware that every step counts in building a future where pharmaceuticals and sustainability go hand in hand. 🤝\n \n https://lnkd.in/dCMmMg7m\n \n SMART PHARMA is supported by the Ministry of Enterprises and Made in Italy and is aimed to introduce innovative technologies in Angelini Pharma Italian production sites to facilitate green and digital transition. \n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 75 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:27:05" "deleted" => 1 ] [ "id" => 563031226 "company_id" => 25495456 "urn" => "urn:li:activity:7185976487076872193" "followers" => null "date" => "3w" "description" => """ Our journey towards sustainability continues.\n We're happy to share that our Product Analytical Development Lab has achieved the #MyGreenLabCertification released by non-profit My Green Lab.\n After a thorough assessment of our lab practices, equipment, waste, and procurement, we were awarded the 'Green' certificate, the highest of the five levels of certification.\n This significant achievement reinforces our commitment to minimizing the environmental impact of our laboratory space, making us very proud to join a network of hundreds of other certified green labs all over the world. \n \n https://lnkd.in/dshMA6Tp """ "reactions_count" => 86 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:27:05" "deleted" => 1 ] [ "id" => 563031227 "company_id" => 25495456 "urn" => "urn:li:activity:7180927616827146240" "followers" => null "date" => "1mo" "description" => """ On March 26, we came together in our HQ to celebrate #PurpleDay and give our contribution to raising awareness around epilepsy.\n \n All people from Casa Angelini got involved and showed their passionate support by wearing purple and participating in different games and activities specially organised for the day.\n \n We strongly believe in the power of education, conversation, and human connection to fight stigma— thanks to everyone that helped us celebrate, raising awareness together around epilepsy.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind Angelini Industries """ "reactions_count" => 109 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:27:05" "deleted" => 1 ] [ "id" => 563031228 "company_id" => 25495456 "urn" => "urn:li:activity:7178323255500410880" "followers" => null "date" => "1mo" "description" => """ Today is #PurpleDay, a global initiative to raise awareness around epilepsy and fight the stigma that still surrounds this neurological disease. \n \n Beyond delivering effective treatments, as a pharma company we are committed to cultivate an empathetic and inclusive environment for those impacted by epilepsy. \n \n This year, we’re celebrating March 26 by wearing purple to symbolize epilepsy awareness, and we’re proud to share a special contribution by Cassidy Megan, the young creator of Purple Day. Amplifying Cassidy's voice and that of people with epilepsy is a mission that propels our actions— today and every day. \n \n Happy Purple Day everyone! 💜 And thanks Cassidy for your precious contribution. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 147 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:27:05" "deleted" => 1 ] [ "id" => 563031229 "company_id" => 25495456 "urn" => "urn:li:activity:7176902984600088576" "followers" => null "date" => "1mo" "description" => """ As climate change impacts increase, and population grows, there is an urgent need, to protect and conserve our most precious resource: water.\n \n Today is #WorldWaterDay and we want to acknowledge the presence of pharmaceutical compounds in aquatic ecosystems as a topic of growing concern in the last decade.\n \n We’re proud to be part of the European reasearch project PharmaSea (Presence, behavior and risk assessment of pharmaceuticals in marine ecosystems), coordinated by the Department of Life and Environmental Sciences of the Polytechnic University of Marche. The project integrates international expertise to answer key research questions on fate and biological effects of active pharmaceutical ingredients (APIs) on marine ecosystem.\n \n It proposes new environmental strategies and ecotoxicological approaches to promote public awareness related to key aspects of environmental sustainability.\n \n #AngeliniPharma #EveryStepCloser\n \n https://lnkd.in/dD2CXdPT """ "reactions_count" => 61 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:27:05" "deleted" => 1 ] [ "id" => 563031230 "company_id" => 25495456 "urn" => "urn:li:activity:7176601190917406720" "followers" => null "date" => "1mo" "description" => """ In the occasion of upcoming #PurpleDay on March 26, don’t miss the podcast host and epilepsy patient expert Torie Robinson in conversation with the Purple Day founder Cassidy Megan in a new episode of the Epilepsy Sparks Insights, very soon live.\n \n Epilepsy affects over 50 million people around the world, yet it’s still surrounded by stigma and misconceptions. We believe in the power of human connections to fight stigma and raise awareness around this condition — through the simple acts of talking, sharing experiences, and supporting each other. \n \n Torie Robinson and Cassidy Megan will do all the above, on March 26. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 98 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:27:05" "deleted" => 1 ] [ "id" => 599832480 "company_id" => 25495456 "urn" => "urn:li:activity:7199779547645456384" "followers" => null "date" => "1w" "description" => """ According to the World Health Organization (WHO), schizophrenia affects approximately 24 million people worldwide, which is about 1 in 300 people or 0.32%. Of these, about 37% are affected by severe stigma and negative stereotypes.\n \n Today, on World Schizophrenia Awareness Day, it is crucial to stand against stigma and discrimination, raising awareness and fighting misinformation about this pathology.\n \n To shed some light on the matter, on our blog we’re dispelling six schizophrenia myths through a dedicated fact-checking and debunking report.\n \n https://lnkd.in/epBZXKEj\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #WorldSchizophreniaDay """ "reactions_count" => 36 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-20 13:20:59" "deleted" => 1 ] [ "id" => 599832481 "company_id" => 25495456 "urn" => "urn:li:activity:7198313814923075585" "followers" => null "date" => "1w" "description" => """ Today, May 20th, is #InternationalClinicalTrialsDay. Promoted by the ACRP - Association of Clinical Research Professionals, it's an occasion to remember of what is often considered the start of the first randomized clinical trial occurred in 1747, and to celebrate the vital role of clinical trials in driving medical and clinical progress and improving patient care.\n \n Clinical trials are essential for developing new treatments or assessing the existing ones, ensuring safety, tolerability and efficacy, and enhancing quality of life. In 2024, as Angelini Pharma we proudly sponsored 23 clinical trials across 13 countries, aiming to provide increasingly effective therapeutic solutions in Brain Health and Consumer Healthcare.\n \n A big thank you to the researchers, healthcare professionals, and volunteers who make this vital work possible.\n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 66 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-20 13:20:59" "deleted" => 1 ] [ "id" => 599832482 "company_id" => 25495456 "urn" => "urn:li:activity:7195719425575026688" "followers" => null "date" => "2w" "description" => """ #EuropeanMentalHealthWeek takes place every year in May and represents the largest opportunity for the whole of Europe to come together and focus on positive change for mental health.\n \n This year’s theme is “Better Together: Co-creating the Future of Mental Health”: an invitation to work together towards the same purpose, answering people’s needs by listening to people’s voices, and promoting a positive mental health with the meaningful involvement of each of us. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 40 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-20 13:20:59" "deleted" => 1 ] [ "id" => 599832483 "company_id" => 25495456 "urn" => "urn:li:activity:7194755024546103298" "followers" => null "date" => "3w" "description" => """ Now three months in, our Open Innovation Challenge has received several submissions.\n \n Focused on digital approaches for identifying drug targets in epilepsy, we're challenging experts and change makers to leverage bioinformatics and AI technologies and propose innovative ideas to drive progress in Brain Health.\n \n https://lnkd.in/ddXPWsEf\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 33 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-20 13:20:59" "deleted" => 1 ] [ "id" => 599832484 "company_id" => 25495456 "urn" => "urn:li:activity:7193622411366297601" "followers" => null "date" => "3w" "description" => """ We keep working to build good health for all—one that encompasses body and mind, leaving nobody behind.\n \n The past few months have been busy with many of our disease awareness activities, and we're particularly proud to count on Angeliners' voices to encourage a more informed and inclusive community, speaking from people to people.\n \n We truly believe that the stronger the connection between people, the better the future that lies ahead.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 47 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-20 13:20:59" "deleted" => 1 ] [ "id" => 599832485 "company_id" => 25495456 "urn" => "urn:li:activity:7193189283187318785" "followers" => null "date" => "3w" "description" => """ It's with great pleasure that we introduce Klára Kotyzová as our new Global PV Director.\n \n With solid experience in clinical safety and pharmacovigilance roles across different pharmaceutical companies in Europe, Klara brings to our team her expertise as well as her attention for patient’s lives.\n \n As Klara states, “I am very pleased to join Angelini Pharma and help to improve quality of life of patients and make a difference in patients’ life by developing effective and safe drugs. I am ready to leverage my experience to provide the state of art operations in Clinical safety and Pharmacovigilance and enhace the cross-functional collaboration.”\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 88 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-20 13:20:59" "deleted" => 1 ] [ "id" => 599832486 "company_id" => 25495456 "urn" => "urn:li:activity:7189548810203774976" "followers" => null "date" => "1mo" "description" => """ We continue to explore the life of Angeliners, with a new episode of our “When I Grow Up” series. \n \n Global Brand Manager Alice Paremain unveils how her initial aspirations have seamlessly merged with her current pharmaceutical pursuits, driven by her unwavering passion to positively impact people's health every day.\n \n https://lnkd.in/dexYTFMD\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 88 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-20 13:20:59" "deleted" => 1 ] [ "id" => 599832487 "company_id" => 25495456 "urn" => "urn:li:activity:7188461644153319427" "followers" => null "date" => "1mo" "description" => """ In this new episode of our “Nice to meet You” podcast, we chat with Global General Counsel Enza Maria Cristina Onnis about the responsibilities of her role, the importance of people management and retention, and finally the major legal challenges that pharmaceutical companies face. \n \n The full episode is available on our website 👉 https://lnkd.in/dgmsYuAf \n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 63 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-20 13:20:59" "deleted" => 1 ] [ "id" => 599832488 "company_id" => 25495456 "urn" => "urn:li:activity:7188078772816863233" "followers" => null "date" => "1mo" "description" => """ Today is #EarthDay, and we want to take this occasion to reinforce our commitment towards a better sustainability — both within our production cycle, and the broader pharmaceutical sector. \n \n We're proud to say that collective efforts such as our SMART PHARMA project are now leading the way for greener practices in the pharma world. Innovative manufacturing technologies and sustainable packaging practices can be powerful allies in reducing waste and enhancing productivity, trying to lower the environmental impact of pharma production on our planet.\n \n There’s still a long way to go, but we’re aware that every step counts in building a future where pharmaceuticals and sustainability go hand in hand. 🤝\n \n https://lnkd.in/dCMmMg7m\n \n SMART PHARMA is supported by the Ministry of Enterprises and Made in Italy and is aimed to introduce innovative technologies in Angelini Pharma Italian production sites to facilitate green and digital transition. \n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 79 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-20 13:20:59" "deleted" => 1 ] [ "id" => 599832489 "company_id" => 25495456 "urn" => "urn:li:activity:7185976487076872193" "followers" => null "date" => "1mo" "description" => """ Our journey towards sustainability continues.\n We're happy to share that our Product Analytical Development Lab has achieved the #MyGreenLabCertification released by non-profit My Green Lab.\n After a thorough assessment of our lab practices, equipment, waste, and procurement, we were awarded the 'Green' certificate, the highest of the five levels of certification.\n This significant achievement reinforces our commitment to minimizing the environmental impact of our laboratory space, making us very proud to join a network of hundreds of other certified green labs all over the world. \n \n https://lnkd.in/dshMA6Tp """ "reactions_count" => 88 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-20 13:20:59" "deleted" => 1 ] [ "id" => 649651886 "company_id" => 25495456 "urn" => "urn:li:activity:7219687604563124225" "followers" => null "date" => "2d" "description" => """ Celebrating our collective achievements with our Group.\n As Angelini Pharma, we are proud in contributing to the positive 2023 results of Angelini Industries.\n For a detailed overview of the results, please visit the press release here: https://lnkd.in/ewmdiEbi \n \n 🇮🇹 Celebriamo i successi del nostro Gruppo.\n Ad Angelini Pharma siamo orgogliosi di contribuire ai risultati positivi del 2023 di Angelini Industries.\n Per maggiori dettagli sui risultati, potete visitare il comunicato stampa: https://lnkd.in/e7K22fBn \n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 26 "comments_count" => null "reshared_post_author" => "Angelini Industries" "reshared_post_author_url" => "https://it.linkedin.com/company/angelini-industries" "reshared_post_author_headline" => null "reshared_post_description" => """ 🇮🇹 L'Assemblea dei Soci di Angelini Holding, la capogruppo di Angelini Industries, ha approvato il bilancio consolidato dell'esercizio 2023, che si chiude con una sensibile crescita rispetto ai valori di fine 2022. Infatti, per la prima volta nella storia del Gruppo, i ricavi sono pari a euro 2.149,6 milioni. Un risultato che si inserisce in un percorso di costante crescita che ha caratterizzato gli ultimi 4 anni di Angelini Industries.\n \n Il CEO, Sergio Marullo di Condojanni: "Fondamentali gli investimenti in innovazione e ricerca, strategiche le acquisizioni nel Pharma e nella Tecnologia Industriale. Focus sulla crescita anche in futuro".\n \n 👉 Leggi il comunicato stampa: https://lnkd.in/e7K22fBn\n \n 🇬🇧 The Shareholders' Meeting of Angelini Holding, the parent company of Angelini Industries, approved the consolidated financial statements for FY 2023, which closed with considerable growth compared to the end of 2022. For the first time in the Group's history, revenues amounted to 2,149.6 million euros, an increase of over 7% compared to 2022. This result is part of a process of constant growth that characterized Angelini Industries' last 4 years.\n \n CEO Sergio Marullo di Condojanni stated, "Investments in innovation and research have been fundamental, acquisitions in Pharma and Industrial Technology, strategic. Further focus on future growth".\n \n 👉 Read the press release: https://lnkd.in/ewmdiEbi\n \n #AngeliniIndustries #IndustryOfCare #AnnualReport """ "reshared_post_followers" => null "reshared_post_date" => "2d" "last_updated" => "2024-08-12 22:26:37" "deleted" => 1 ] [ "id" => 649651887 "company_id" => 25495456 "urn" => "urn:li:activity:7219353556921794561" "followers" => null "date" => "2d" "description" => """ We are thrilled to share that we achieved the Legal Team International Expansion of the year award, as part of the XI Edition of TopLegal Corporate Counsel Awards. \n \n Thanks to TopLegal for recognizing our commitment and dedication in building a company focused on improvement and growth. A special thanks to Enza Maria Cristina Onnis and our Global Legal & Compliance Team.\n \n Our everyday promise is to stay focused on our patients’ needs and on the future of our company.\n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 130 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 22:26:37" "deleted" => 1 ] [ "id" => 649651888 "company_id" => 25495456 "urn" => "urn:li:activity:7218601066064465934" "followers" => null "date" => "5d" "description" => """ Today we officially launch "#FuturePills", our monthly newsletter dedicated to the latest advancements in pharmaceuticals and medicine.\n \n In this first edition, we dive deep into neurotechnology innovations and new findings regarding epilepsy, we explore the role of positive emotions and experiences in brain health... and so much more. \n Subscribe to get access to a monthly dose of good news from the pharma world, and feel free to share with anyone you think might be interested! """ "reactions_count" => 127 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 22:26:37" "deleted" => 1 ] [ "id" => 649651889 "company_id" => 25495456 "urn" => "urn:li:activity:7216065120739704832" "followers" => null "date" => "1w" "description" => """ As part of our ongoing effort to raise awareness and promote education about #epilepsy, we explore the seizure spectrum and delve deep into the epileptic pathways.\n \n In the hope that it can be a useful resource to gain a comprehensive understanding of epilepsy and its impact on the lives of those who suffer from it.\n \n https://lnkd.in/dK_SFpEj\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 56 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 22:26:37" "deleted" => 1 ] [ "id" => 649651890 "company_id" => 25495456 "urn" => "urn:li:activity:7213459156341518338" "followers" => null "date" => "2w" "description" => """ In partnership with The European House-Ambrosetti, we launched Headway: A new roadmap in Brain Health, a project that aims to create a common ground for strategic reflection and dialogue on Epilepsy and Mental Health, as experienced from different European perspectives. \n \n Today 1st July, Headway is in Helsinki, welcoming local and global experts to talk about the implementation of the Intersectoral Global Action Plan on epilepsy & other neurological disorders (IGAP), with a special focus on how to break the barriers of stigma, fostering inclusion and rights for people with epilepsy. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 76 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 22:26:37" "deleted" => 1 ] [ "id" => 649651891 "company_id" => 25495456 "urn" => "urn:li:activity:7213171943632470016" "followers" => null "date" => "2w" "description" => """ Our Symposium “The fine line between under treatment and over treatment in uncontrolled epilepsy”, part of the European Academy of Neurology Congress 2024 in Helsinki, has just finished.\n \n Dr. Angel Aledo-Serrano has explored the topic of under treatment and the missed opportunities for reducing the seizure burden.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #EAN2024 """ "reactions_count" => 51 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 22:26:37" "deleted" => 1 ] [ "id" => 649651892 "company_id" => 25495456 "urn" => "urn:li:activity:7213149306088808449" "followers" => null "date" => "2w" "description" => """ As part of the European Academy of Neurology Congress 2024 in Helsinki, our Symposium “The fine line between under treatment and over treatment in uncontrolled epilepsy” will host MD PhD Magdalena Bosak as speaker.\n \n Dr. Bosak is focusing on over treatment and the missed opportunities for reducing the treatment burden.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #EAN2024 """ "reactions_count" => 47 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 22:26:37" "deleted" => 1 ] [ "id" => 649651893 "company_id" => 25495456 "urn" => "urn:li:activity:7213103982947233793" "followers" => null "date" => "2w" "description" => """ Today, we’re at the European Academy of Neurology Congress 2024 in Helsinki, Finland.\n \n Our Symposium “The fine line between under treatment and over treatment in uncontrolled epilepsy” is starting in a few hours and it will be chaired by Professor and Chief Physician Jukka Peltola.\n \n Prof. Peltola is focusing on “How to balance patient needs in the shifting epilepsy management.”\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #EAN2024 """ "reactions_count" => 102 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 22:26:37" "deleted" => 1 ] [ "id" => 649651894 "company_id" => 25495456 "urn" => "urn:li:activity:7212022195231854593" "followers" => null "date" => "3w" "description" => """ We're proud to announce the launch of our second crowdsourcing campaign in partnership with Wazoku.\n \n This Open Innovation Challenge aims to identify innovative Drug Delivery Systems (DDS) and Treatments Approaches to significantly improve the lives of people with epilepsy, especially elderly and pediatric patients.\n \n With 50 million people worldwide affected by epilepsy, non-adherence to anti-seizure medication among adult patients ranges from 29 to 39%, and is even lower in elderly and pediatric populations. Identifying new options to increase adherence is vital to the epilepsy community, and research is key.\n \n Researchers, scientists, and PhD students: we need your help! If you have novel approaches to using available anti-seizure medications for patients with epilepsy, join the challenge and contribute. The research journey never ends! \n \n The challenge closes on August 26. Good luck!\n \n To know more: https://lnkd.in/dJvgkyjr\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 102 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 22:26:37" "deleted" => 1 ] [ "id" => 649651895 "company_id" => 25495456 "urn" => "urn:li:activity:7211707287214690306" "followers" => null "date" => "3w" "description" => """ We’re proud to announce that in a few days we will be joining the European Academy of Neurology Congress 2024 in Helsinki, Finland, to champion neurological excellence and epilepsy care.\n \n On Sunday 30th June, as Angelini Pharma, we will hold a Symposium entitled: “The fine line between under treatment and over treatment in uncontrolled epilepsy”. Together with Professor and Chief Physician Jukka Peltola, MD PhD Angel Aledo-Serrano and MD PhD Magdalena Bosak, we will explore new perspectives in epilepsy treatment.\n \n To know more: https://lnkd.in/dmnEvp8f\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #EAN2024 """ "reactions_count" => 119 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 22:26:37" "deleted" => 1 ] [ "id" => 673746667 "company_id" => 25495456 "urn" => "urn:li:activity:7227591952215531521" "followers" => null "date" => "3d" "description" => """ Time for a well-deserved break! \n We’re stepping away for a few weeks, reminding ourselves and our community of the importance of total rest, relaxation, and recharging.\n \n We'll be back at the end of the month, ready to continue our journey together.\n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 149 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 06:05:28" "deleted" => 1 ] [ "id" => 673746668 "company_id" => 25495456 "urn" => "urn:li:activity:7222525780788989956" "followers" => null "date" => "2w" "description" => """ Our second crowdsourcing campaign in partnership with Wazoku is getting closer to the end. There’s only one month before submissions are closed!\n \n This Open Innovation Challenge aims to identify innovative Drug Delivery Systems (DDS) and Treatment Approaches to significantly improve the lives of people with epilepsy, especially elderly and pediatric patients.\n \n Research is key and any help from researchers, scientists, and PhD students is vital for progress. If you have novel approaches to using available anti-seizure medications for patients with epilepsy, we need your help.\n \n The challenge closes in a month, on August 26. Good luck!\n \n To know more: https://lnkd.in/dJvgkyjr\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 47 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 06:05:28" "deleted" => 1 ] [ "id" => 673746669 "company_id" => 25495456 "urn" => "urn:li:activity:7221895348867235841" "followers" => null "date" => "2w" "description" => """ At Angelini Pharma, we care for people’s health every single day. We invest in research and education to foster growth and create lasting value for a healthier society.\n \n We proudly present our 2023 key financial results, showcasing our dedication to global health and a significant step towards realizing our vision.\n \n Driven by our commitment to advancing healthcare and improving quality of lives, we thank our team and partners for their continued support and hard work.\n \n Here's to our shared data: https://lnkd.in/dKSQQPkU\n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 51 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 06:05:28" "deleted" => 1 ] [ "id" => 673746670 "company_id" => 25495456 "urn" => "urn:li:activity:7221081646442176512" "followers" => null "date" => "3w" "description" => """ Today is World Brain Day: a global initiative promoted by the World Federation Of Neurology to raise awareness on brain health and neurological disorders.\n \n This year’s focus being prevention, we decided to celebrate by going practical, always with the special involvement of our people.\n \n Here’s a collection of tips to maintain good brain health, with the words of Bioanalytical Study Manager Patrizia Dragone, Senior Study Manager Valeria Tellone, and Senior Clinical Fellow John Paul Leach.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #WorldBrainDay2024 """ "reactions_count" => 58 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 06:05:28" "deleted" => 1 ] [ "id" => 673746671 "company_id" => 25495456 "urn" => "urn:li:activity:7221080636340527104" "followers" => null "date" => "3w" "description" => """ On World Brain Day, we continue our exploration of the topic, with the help of our expert voices.\n \n With Global Medical Advisor Valeria Di Franco, we delve into the importance of spreading information widely, with an education activity that includes schools, workplaces, and media channels.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #WorldBrainDay2024 World Federation Of Neurology """ "reactions_count" => 61 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 06:05:28" "deleted" => 1 ] [ "id" => 673746672 "company_id" => 25495456 "urn" => "urn:li:activity:7221079249800093696" "followers" => null "date" => "3w" "description" => """ July 22nd is World Brain Day: an annual event promoted by the World Federation Of Neurology aimed at promoting awareness and education for neurological disorders that affect individuals worldwide.\n \n This year's theme is Prevention and we decided to get our people involved and explore this delicate topic together.\n \n We start with Pharmacokinetics researcher Marcello C. Laurenti, with whom we get over some of the most important numbers concerning brain health, as well as exploring what prevention means.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #WorldBrainDay2024 """ "reactions_count" => 71 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 06:05:28" "deleted" => 1 ] [ "id" => 673746673 "company_id" => 25495456 "urn" => "urn:li:activity:7219687604563124225" "followers" => null "date" => "3w" "description" => """ Celebrating our collective achievements with our Group.\n As Angelini Pharma, we are proud in contributing to the positive 2023 results of Angelini Industries.\n For a detailed overview of the results, please visit the press release here: https://lnkd.in/ewmdiEbi \n \n 🇮🇹 Celebriamo i successi del nostro Gruppo.\n Ad Angelini Pharma siamo orgogliosi di contribuire ai risultati positivi del 2023 di Angelini Industries.\n Per maggiori dettagli sui risultati, potete visitare il comunicato stampa: https://lnkd.in/e7K22fBn \n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 46 "comments_count" => null "reshared_post_author" => "Angelini Industries" "reshared_post_author_url" => "https://it.linkedin.com/company/angelini-industries" "reshared_post_author_headline" => null "reshared_post_description" => """ 🇮🇹 L'Assemblea dei Soci di Angelini Holding, la capogruppo di Angelini Industries, ha approvato il bilancio consolidato dell'esercizio 2023, che si chiude con una sensibile crescita rispetto ai valori di fine 2022. Infatti, per la prima volta nella storia del Gruppo, i ricavi sono pari a euro 2.149,6 milioni. Un risultato che si inserisce in un percorso di costante crescita che ha caratterizzato gli ultimi 4 anni di Angelini Industries.\n \n Il CEO, Sergio Marullo di Condojanni: "Fondamentali gli investimenti in innovazione e ricerca, strategiche le acquisizioni nel Pharma e nella Tecnologia Industriale. Focus sulla crescita anche in futuro".\n \n 👉 Leggi il comunicato stampa: https://lnkd.in/e7K22fBn\n \n 🇬🇧 The Shareholders' Meeting of Angelini Holding, the parent company of Angelini Industries, approved the consolidated financial statements for FY 2023, which closed with considerable growth compared to the end of 2022. For the first time in the Group's history, revenues amounted to 2,149.6 million euros, an increase of over 7% compared to 2022. This result is part of a process of constant growth that characterized Angelini Industries' last 4 years.\n \n CEO Sergio Marullo di Condojanni stated, "Investments in innovation and research have been fundamental, acquisitions in Pharma and Industrial Technology, strategic. Further focus on future growth".\n \n 👉 Read the press release: https://lnkd.in/ewmdiEbi\n \n #AngeliniIndustries #IndustryOfCare #AnnualReport """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2024-09-11 06:05:28" "deleted" => 1 ] [ "id" => 673746674 "company_id" => 25495456 "urn" => "urn:li:activity:7219353556921794561" "followers" => null "date" => "3w" "description" => """ We are thrilled to share that we achieved the Legal Team International Expansion of the year award, as part of the XI Edition of TopLegal Corporate Counsel Awards. \n \n Thanks to TopLegal for recognizing our commitment and dedication in building a company focused on improvement and growth. A special thanks to Enza Maria Cristina Onnis and our Global Legal & Compliance Team.\n \n Our everyday promise is to stay focused on our patients’ needs and on the future of our company.\n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 164 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 06:05:28" "deleted" => 1 ] [ "id" => 673746675 "company_id" => 25495456 "urn" => "urn:li:activity:7218601066064465934" "followers" => null "date" => "4w" "description" => """ Today we officially launch "#FuturePills", our monthly newsletter dedicated to the latest advancements in pharmaceuticals and medicine.\n \n In this first edition, we dive deep into neurotechnology innovations and new findings regarding epilepsy, we explore the role of positive emotions and experiences in brain health... and so much more. \n Subscribe to get access to a monthly dose of good news from the pharma world, and feel free to share with anyone you think might be interested! """ "reactions_count" => 146 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 06:05:28" "deleted" => 1 ] [ "id" => 673746676 "company_id" => 25495456 "urn" => "urn:li:activity:7216065120739704832" "followers" => null "date" => "1mo" "description" => """ As part of our ongoing effort to raise awareness and promote education about #epilepsy, we explore the seizure spectrum and delve deep into the epileptic pathways.\n \n In the hope that it can be a useful resource to gain a comprehensive understanding of epilepsy and its impact on the lives of those who suffer from it.\n \n https://lnkd.in/dK_SFpEj\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 65 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 06:05:28" "deleted" => 1 ] [ "id" => 714179838 "company_id" => 25495456 "urn" => "urn:li:activity:7239187080508039169" "followers" => null "date" => "16h" "description" => """ Every year, 703,000 lives are lost to suicide worldwide, reminding us how crucial it is to unite in the fight against this preventable tragedy.\n \n Today is World Suicide Prevention Day, a global initiative established by the International Association for Suicide Prevention and World Health Organization in 2003.\n \n By raising awareness, reducing stigma, and fostering open conversations, each of us can play a role in preventing suicide and supporting those who are struggling.\n \n Let’s change the narrative on suicide — together, we can make a difference.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #WSPD2024 """ "reactions_count" => 42 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 16:17:30" "deleted" => 1 ] [ "id" => 714179839 "company_id" => 25495456 "urn" => "urn:li:activity:7238917334613016576" "followers" => null "date" => "1d" "description" => """ After yesterday’s Symposium, we’re back today at the 15th European Epilepsy Congress (ILAE 2024) in Rome, to host another special Symposium entitled “Seizures beget more than seizures: the impact of uncontrolled epilepsy.”\n \n We’re going to talk about the impact of seizures at many levels: from the cellular/network level with Prof. Heinz Beck analyzing the consequences of repeated seizure activity, to Dr. Marian Galovic talking about the changes in human brain structure and function, and finally Prof. Dr. Adam Strzelczyk exploring the consequences uncontrolled seizures have at individual but also society level.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #ILAE2024 """ "reactions_count" => 58 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 16:17:30" "deleted" => 1 ] [ "id" => 714179840 "company_id" => 25495456 "urn" => "urn:li:activity:7238910757508182019" "followers" => null "date" => "1d" "description" => """ Clinical trials are crucial in advancing medical research and ensuring safe, effective treatments. What we discover from them can truly make a difference in people’s lives.\n \n That’s why we’re particularly proud today to share some positive findings from our most recent clinical trials in epilepsy.\n \n From higher efficacy to better tolerability and higher retention rates, we found some very promising data regarding adjunctive treatment of focal-onset seizures.\n \n To discover more: https://lnkd.in/dKDMVdTP\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 45 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 16:17:30" "deleted" => 1 ] [ "id" => 714179841 "company_id" => 25495456 "urn" => "urn:li:activity:7238476940385374208" "followers" => null "date" => "2d" "description" => """ Today, as part of the 15th European Epilepsy Congress (ILAE 2024) in Rome, we’re hosting a special Symposium entitled “Seizure freedom: is the theory matching the practice?”. \n \n Our panel of speakers is ready to delve into the topic. We will explore which are the main challenges to achieve seizure freedom, the theory vs practice with Dr. Simona Lattanzi and analyze the impact of overtreatment through the clinical experience of Dr. Shanika Samarasekera. We will also discuss how to maximize treatment efficacy with Dr. Vicente Villanueva and hear about the personal experience of Prof. Dr. Bernhard Steinhoff in dealing with treatment nihilism. \n \n https://lnkd.in/dQndC-yG\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #ILAE2024 """ "reactions_count" => 74 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 16:17:30" "deleted" => 1 ] [ "id" => 714179842 "company_id" => 25495456 "urn" => "urn:li:activity:7237109629359390721" "followers" => null "date" => "6d" "description" => """ Siamo lieti di annunciare che tra pochi giorni saremo parte attiva del 15° Congresso Europeo sull'Epilessia a Roma, in Italia. \n \n Riconoscendo l'importanza dell'epilessia, uno dei disturbi neurologici più comuni che colpisce circa 50 milioni di persone a livello globale, riaffermiamo il nostro impegno per il confronto scientifico e lo studio dell’epilessia ospitando due simposi satellite: \n \n - "Libertà dalle crisi epilettiche: la teoria corrisponde alla pratica?", 8 settembre \n - “Le crisi oltre le crisi: l’impatto dell’epilessia non controllata.”, 9 settembre\n \n Con noi ci saranno alcuni dei più importanti esperti, lavorando insieme per una migliore comprensione dell'epilessia. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #ILAE2024 """ "reactions_count" => 80 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 16:17:30" "deleted" => 1 ] [ "id" => 714179843 "company_id" => 25495456 "urn" => "urn:li:activity:7236675310337818625" "followers" => null "date" => "1w" "description" => """ We’re pleased to announce that in a few days we will be joining the 15th European Epilepsy Congress in Rome, Italy.\n \n Recognizing the importance of epilepsy, one of the most common neurological disorders, affecting approximately 50 million people globally, we are reaffirming our commitment to medical education about the burden of epilepsy by hosting two Satellite Symposia:\n \n - “Seizure freedom: is the theory matching the practice?”, 8th September \n - “Seizures beget more than seizures: the impact of uncontrolled epilepsy”, 9th September \n \n We will have experts on stage, working together towards a better understanding of epilepsy.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #ILAE2024 """ "reactions_count" => 84 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 16:17:30" "deleted" => 1 ] [ "id" => 714179844 "company_id" => 25495456 "urn" => "urn:li:activity:7235224150041128963" "followers" => null "date" => "1w" "description" => """ Welcome back with the 2nd edition of #FuturePills, our monthly newsletter dedicated to the latest advancements in pharmaceuticals and medicine.\n \n This month we will explore several interesting topics: reviewed criteria for Alzheimer diagnosis, new findings regarding healthy daily habits, an insight about young people mental health and much more.\n Subscribe to stay up to date every month and discover good news from the pharma world and share #FuturePills with your network to disseminate research! """ "reactions_count" => 116 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 16:17:30" "deleted" => 1 ] [ "id" => 714179845 "company_id" => 25495456 "urn" => "urn:li:activity:7235211254728933376" "followers" => null "date" => "1w" "description" => """ It's with great pleasure that we introduce Daniel Gheorghe as Country Manager at Angelini Pharma España, from September 1st.\n \n With solid experience both in consumer healthcare and in the commercial area and after more than two years leading the Romanian unit, Daniel is ready to start a new chapter in Angelini Spain, guided by his expertise and his strong attention to Angelini’s values.\n \n As Daniel states, “I am thrilled to take on this new role in our Spanish organization, after four successful years with the Romanian team, to which I take this opportunity to show my gratitude. Spain has always been a key market for our company, and I am committed to leveraging our collective strengths to achieve new milestones. Every day, we strive to care for people's health, and this purpose will guide our actions and decisions as we move forward.\n \n In this new role, my objectives will be to realize our full potential, grow the business while developing our people, continue to build on a successful case, and foster a culture of success and high performance. Collaboration and open communication will be at the heart of my approach, and I am confident that, together, we can continue to build on our successes and create even greater achievements for Angelini Spain.”\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 349 "comments_count" => 70 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 16:17:30" "deleted" => 1 ] [ "id" => 714179846 "company_id" => 25495456 "urn" => "urn:li:activity:7234536407191478272" "followers" => null "date" => "1w" "description" => """ On 10th April 2024, the European Parliament adopted two reports on the Revision of the General Pharmaceutical Legislation (GPL), initially presented by the European Commission in April 2023.\n \n Our CEO, Jacopo Andreose, as an active member of EUCOPE - European Confederation of Pharmaceutical Entrepreneurs, is continuously working with the confederation to build a robust ecosystem for the development of medicine and research in Europe.\n \n EUCOPE helps pharmaceutical and biotech companies in Europe connect with the European Commission and the European Parliament, aiming to improve and save the lives of European patients through groundbreaking therapies and medical technology. This purpose aligns closely with our mission at Angelini Pharma. \n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 32 "comments_count" => null "reshared_post_author" => "EUCOPE - European Confederation of Pharmaceutical Entrepreneurs" "reshared_post_author_url" => "https://be.linkedin.com/company/eucope" "reshared_post_author_headline" => null "reshared_post_description" => """ 📜 In April 2023, the European Commission proposed the revision of the General Pharmaceutical Legislation (#GPL). Less than a year later, the European Parliament adopted its reports on this proposal, while the Council of the European Union is currently scrutinising it. \n \n 🗣️ We reached out to EUCOPE’s Members to gather their reflections on key elements of the revision of the GPL, and how it will impact small and mid-sized companies in the #EU. \n \n 🔬On this Wednesday’s #GPLinsights, Jacopo Andreose, CEO of Angelini Pharma, shared his thoughts on what is needed to invest in pharmaceutical R&D. He emphasised that only a strong #incentives framework can support #innovation, ensure patient #access and restore EU’s #competitiveness. """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2024-10-20 16:17:30" "deleted" => 1 ] [ "id" => 714179847 "company_id" => 25495456 "urn" => "urn:li:activity:7227591952215531521" "followers" => null "date" => "1mo" "description" => """ Time for a well-deserved break! \n We’re stepping away for a few weeks, reminding ourselves and our community of the importance of total rest, relaxation, and recharging.\n \n We'll be back at the end of the month, ready to continue our journey together.\n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 175 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 16:17:30" "deleted" => 1 ] [ "id" => 770209577 "company_id" => 25495456 "urn" => "urn:li:activity:7248977398904344577" "followers" => null "date" => "16h" "description" => """ We’re happy to support the participation of Angelini Industries in the 12th edition of Il Salone della CSR e dell'innovazione sociale, with representatives from the group. \n \n Under the theme “Challenging Contradictions” and a program of over 100 events across three days, the Salone brings together businesses, institutions, and experts for a strategic dialogue on how to build a future that values people and ensures environmental protection. \n \n In particular, our Global Patient Advocacy Specialist Barbara Nadine De Gol will be host in the event “Well-being, Health, and Sustainability” on 10th October at 4.30pm. With Barbara, we will delve into the crucial role of mental health in the workplace and explore how investing in psychological well-being not only enhances employee satisfaction and productivity but also drives long-term organizational success. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #SaloneCSR """ "reactions_count" => 33 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-07 12:12:58" "deleted" => 1 ] [ "id" => 770209578 "company_id" => 25495456 "urn" => "urn:li:activity:7246528800992223232" "followers" => null "date" => "1w" "description" => """ 𝗦𝗵𝗮𝗽𝗶𝗻𝗴 𝗮 𝗳𝘂𝘁𝘂𝗿𝗲-𝗿𝗲𝗮𝗱𝘆 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗲𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺 𝘁𝗼 𝗲𝗺𝗽𝗼𝘄𝗲𝗿 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 & 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗰𝗮𝗿𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗘𝗨\n \n We are proud to join forward-thinking pharmaceutical companies in signing EUCOPE - European Confederation of Pharmaceutical Entrepreneurs’ open letter to EU Institutions and Member States, advocating for a future-proofed ecosystem that fosters progress, research, and access to cutting-edge therapies.\n \n Together, we call on the leaders of the EU Institutions to take decisive actions, ensuring the EU leads the way in pharmaceutical innovation. A stronger, more supportive framework will enable groundbreaking advancements that improve patients’ lives across Europe and beyond.\n \n #AngeliniPharma #EveryStepCloser #EUPharma """ "reactions_count" => 23 "comments_count" => 2 "reshared_post_author" => "EUCOPE - European Confederation of Pharmaceutical Entrepreneurs" "reshared_post_author_url" => "https://be.linkedin.com/company/eucope" "reshared_post_author_headline" => null "reshared_post_description" => """ 🌍 Building a Competitive & Innovative Pharmaceutical Ecosystem for the EU \n \n As the EU looks ahead to the next decades, it's crucial to prepare the European pharmaceutical sector to tackle emerging challenges and seize new opportunities. \n \n ✒️ By signing EUCOPE - European Confederation of Pharmaceutical Entrepreneurs’s open letter to the Presidents of the European Commission, European Parliament, and Council of the European Union, 23 EUCOPE members urge the EU Institutions and Member States to collaborate in creating a competitive and attractive pharmaceutical landscape. 🏥✨ \n \n 🔬 To remain globally competitive, pharmaceutical companies need a robust, predictable and strong investment and industrial ecosystem. \n \n 💊 Special emphasis should be placed on small and mid-sized innovative companies, which are pivotal in driving technology and medical advancements across Europe. \n \n #PharmaInnovation #EUPharma #InnovationEcosystem #RareDiseases \n \n 👓 Read the open letter here: \n 👉 https://lnkd.in/eCeJk8U5 \n \n Alexion Pharmaceuticals, Inc. Amgen Angelini Pharma AOP Health Biogen BioMarin Pharmaceutical Inc. Blueprint Medicines Chiesi Group Circius Pharma CSL Emergent BioSolutions Incyte MENARINI Group Miltenyi Biomedicine MSD Norgine Orion Corporation Sanofi Santen Shionogi Europe Sobi - Swedish Orphan Biovitrum AB (publ) Takeda """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2024-11-07 12:12:58" "deleted" => 1 ] [ "id" => 770209579 "company_id" => 25495456 "urn" => "urn:li:activity:7246453380355657728" "followers" => null "date" => "1w" "description" => """ The "When I Grow Up" series gives us the chance to get to know our people a little better. \n \n In this episode, Packaging Operator Federico Manzoni shares insights into his role and discusses how being the youngest on the team involves both learning and contributing.\n \n Full video here 👉 https://lnkd.in/dexYTFMD\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 33 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-07 12:12:58" "deleted" => 1 ] [ "id" => 770209580 "company_id" => 25495456 "urn" => "urn:li:activity:7245464527268438017" "followers" => null "date" => "1w" "description" => """ On 27th September we celebrate the European Researchers’ Night, an opportunity to spotlight science and research and allow citizens to discover, in an engaging and fun way, how European researchers work to face and solve the challenges for a sustainable future.\n \n Research is a fundamental part of our work at Angelini Pharma and something we strongly believe in as an essential ingredient to keep progressing towards better health for all.\n \n To celebrate this special night, nothing better than let our researchers speak and get a glimpse of what a life dedicated to research looks like for Andrea Saltalamacchia, PhD, Computational Chemistry Scientist, Medicinal & Computational Chemistry; Jennifer Bausch, Global Medical Excellence Manager, International Medical Operations; Marilena Saviano, Preformulation Lab. Junior Scientist, Pharma Formulation Development.\n \n Researchers’ work is pivotal in so many fields of human knowledge and this is our way to thank them all.\n \n https://lnkd.in/dfN8HkWp\n \n #AngeliniPharma #EveryStepCloser #EuropeanResearchersNight #SOCIETYreAGIAMO #WeReACT #NDR """ "reactions_count" => 100 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-07 12:12:58" "deleted" => 1 ] [ "id" => 770209581 "company_id" => 25495456 "urn" => "urn:li:activity:7244623240592019456" "followers" => null "date" => "1w" "description" => """ Today we’re in Brussels for the fourth edition of #Headway - A new roadmap in Brain Health: Focus Mental Health.\n \n Headway is a project we launched in partnership with The European House-Ambrosetti, aimed at fostering strategic reflection and dialogue on Brain and Mental Health across Europe. In this edition, we’re focusing on mental health, analyzing it specifically from an economic perspective.\n \n The latest edition of our Headway Report, in fact, shows that increased investment in mental health care can avoid costs of more than €122 billion across Europe!\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 114 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-07 12:12:58" "deleted" => 1 ] [ "id" => 770209582 "company_id" => 25495456 "urn" => "urn:li:activity:7242841814456561664" "followers" => null "date" => "2w" "description" => """ #Headway: A new roadmap in Brain Health is a project we launched in partnership with The European House-Ambrosetti, to create a common ground for strategic reflection and dialogue on Brain and Mental Health, as experienced from different European perspectives. \n \n On 25th September, the latest edition of “Headway: Focus Mental Health” will be presented in Brussels. Together with local and global experts, we’ll address the immense burden mental health conditions place on European societies and healthcare systems, and we'll present key data showing how increased investment in mental health care could help avoid significant costs across Europe.\n \n Register to watch the streaming > https://lnkd.in/dDES-GBn \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #MentalHealth """ "reactions_count" => 67 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-07 12:12:58" "deleted" => 1 ] [ "id" => 770209583 "company_id" => 25495456 "urn" => "urn:li:activity:7241719103151886336" "followers" => null "date" => "2w" "description" => """ Today is World Patient Safety Day, an annual recurrence promoted by the World Health Organization that aims to raise global awareness about patient safety and calls all countries to come together for patients' safeguard. \n \n On this occasion, we entailed our people and asked Pamela Rossi, Klára Kotyzová and Patrizia Ciavatta to share our approach and explain how our company protects and ensures patient safety. \n \n #AngeliniPharma #EveryStepCloser #WorldPatientSafetyDay #WPSD2024 """ "reactions_count" => 101 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-07 12:12:58" "deleted" => 1 ] [ "id" => 770209584 "company_id" => 25495456 "urn" => "urn:li:activity:7239588619651317760" "followers" => null "date" => "3w" "description" => """ The study of sex and gender is crucial in the medical field. In fact, according to the WHO, both sex and gender significantly impact health outcomes, influencing disease prevalence, healthcare access, and treatment responses.\n \n We had the pleasure to reflect on this with Neuroscientist and senior biomedical researcher Dr. Maria Teresa Ferretti, exploring together the importance of #gendermedicine as an opportunity to unlock new therapeutic approaches and innovations in healthcare, with a special focus on brain and mental health.\n \n By embracing gender medicine, we can address the substantial unmet medical needs and achieve a more equitable and effective medicine.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 35 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-07 12:12:58" "deleted" => 1 ] [ "id" => 770209585 "company_id" => 25495456 "urn" => "urn:li:activity:7239187080508039169" "followers" => null "date" => "3w" "description" => """ Every year, 703,000 lives are lost to suicide worldwide, reminding us how crucial it is to unite in the fight against this preventable tragedy.\n \n Today is World Suicide Prevention Day, a global initiative established by the International Association for Suicide Prevention and World Health Organization in 2003.\n \n By raising awareness, reducing stigma, and fostering open conversations, each of us can play a role in preventing suicide and supporting those who are struggling.\n \n Let’s change the narrative on suicide — together, we can make a difference.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #WSPD2024 """ "reactions_count" => 70 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-07 12:12:58" "deleted" => 1 ] [ "id" => 770209586 "company_id" => 25495456 "urn" => "urn:li:activity:7238917334613016576" "followers" => null "date" => "4w" "description" => """ After yesterday’s Symposium, we’re back today at the 15th European Epilepsy Congress (ILAE 2024) in Rome, to host another special Symposium entitled “Seizures beget more than seizures: the impact of uncontrolled epilepsy.”\n \n We’re going to talk about the impact of seizures at many levels: from the cellular/network level with Prof. Heinz Beck analyzing the consequences of repeated seizure activity, to Dr. Marian Galovic talking about the changes in human brain structure and function, and finally Prof. Dr. Adam Strzelczyk exploring the consequences uncontrolled seizures have at individual but also society level.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #ILAE2024 """ "reactions_count" => 81 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-07 12:12:58" "deleted" => 1 ] [ "id" => 798043290 "company_id" => 25495456 "urn" => "urn:li:activity:7259513981839560704" "followers" => null "date" => "1d" "description" => """ Our latest Sustainability Report showcases our 2023 activities, projects, and key achievements in the ESG domain.\n \n Aligned with Angelini Industries’ Sustainability Report, this document presents a growth narrative focused on a sustainable, inclusive, and innovative approach that prioritizes employee well-being, community support, and environmental protection.\n \n #AngeliniPharma #EveryStepCloser #SustainabilityReport """ "reactions_count" => 42 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-08 02:24:38" "deleted" => 1 ] [ "id" => 798043291 "company_id" => 25495456 "urn" => "urn:li:activity:7257679591765360640" "followers" => null "date" => "1w" "description" => """ As part of Angelini Industries, we are pleased to share the launch of the Group's very first #ESG Strategic Plan, marking a critical step toward sustainable growth for a healthier future. This plan reinforces our commitment to putting human well-being at the heart of our everyday work, ensuring better quality of life for patients, support for families, and care for those who need it most.\n \n At Angelini Pharma, we align closely with our Group’s ESG roadmap, advancing initiatives that positively impact People, Patients, Customers, Communities, Ecosystems, and the Planet. Our dedication to sustainability focuses on environmental responsibility, ethical innovation, and social impact.\n \n For a deeper look into the full news, we invite you to read the press release in the post below. """ "reactions_count" => 16 "comments_count" => null "reshared_post_author" => "Angelini Industries" "reshared_post_author_url" => "https://it.linkedin.com/company/angelini-industries" "reshared_post_author_headline" => null "reshared_post_description" => """ 🇮🇹 Nell’anno record per ricavi, a 2,1 miliardi di euro (+7,6%), aumenta anche il valore economico generato (+7,5%) da Angelini Industries, che raggiunge i 2,3 miliardi di euro, di cui l’86% distribuito agli stakeholder.\n \n È quanto emerge dal Bilancio di Sostenibilità 2023, che misura gli impatti delle attività del Gruppo in ambito ESG. Contestualmente, è stato inoltre annunciato il primo Piano ESG, con obiettivi e target al 2026 e un orizzonte al 2030: focus su Persone, Pazienti Clienti e Comunità, Ecosistemi e Pianeta.\n \n Azioni che dimostrano come la sostenibilità sia un driver di crescita per il gruppo e le società operative, le cui performance sono rendicontate nei Bilanci e Profili di Sostenibilità di Angelini Pharma, Angelini Technologies - FAMECCANICA, Angelini Ventures, Angelini Wines & Estates.\n \n 👉 Leggi il comunicato stampa: https://lnkd.in/d6_F2MqD\n \n 🇬🇧 In a record-breaking year for revenue, which reached 2.1 billion euros (+7.6%), the economic value generated by Angelini Industries also increased (+7.5%) to 2.3 billion euros, of which 86% was distributed to stakeholders.\n \n These results are highlighted in the 2023 Sustainability Report, which showcases the Group’s ESG impact. Alongside, Angelini Industries announced its first ESG Plan, with objectives and targets set for 2026 and a timeline to 2030: focus on people, patients, customers, community, ecosystems and planet. \n \n These actions demonstrate how sustainability drives growth within the Group and its operating companies, whose performance is reported in the sustainability reports and profiles of Angelini Pharma, Angelini Technologies - FAMECCANICA, Angelini Ventures, and Angelini Wines & Estates.\n \n 👉 Read the press release: https://lnkd.in/d6w-PCDB\n \n #AngeliniIndustries #IndustryOfCare #SustainabilityReport2023 #PianoESG """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2024-12-08 02:24:38" "deleted" => 1 ] [ "id" => 798043292 "company_id" => 25495456 "urn" => "urn:li:activity:7257017962929213440" "followers" => null "date" => "1w" "description" => """ We are back with the 3rd edition of #FuturePills, our monthly newsletter dedicated to the latest advancements in pharmaceuticals and medicine.\n \n This month we will delve into several good news, with a particular focus on the role of technology and AI: we will explore how they can be helpful in research and prevention, but also for specific treatments. \n Sign up for monthly updates about the latest happenings in the pharmaceutical industry and do not forget to share #FuturePills to spread research advances! """ "reactions_count" => 123 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-08 02:24:38" "deleted" => 1 ] [ "id" => 798043293 "company_id" => 25495456 "urn" => "urn:li:activity:7255487550776131584" "followers" => null "date" => "1w" "description" => """ We continue to explore the life of the people at Angelini, with a new episode of our “Nice to Meet You” video series.\n \n In this new episode, Packaging Coordinator Marta Casini shares the different facets of her role that has the goal of delivering the best quality product to the customer.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 60 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-08 02:24:38" "deleted" => 1 ] [ "id" => 798043294 "company_id" => 25495456 "urn" => "urn:li:activity:7254033545633931265" "followers" => null "date" => "2w" "description" => """ We’re happy to announce that we entered into an exclusive option agreement with 𝐂𝐮𝐫𝐞𝐯𝐞𝐫𝐬𝐞 for the development and the commercialization of CV-01, a novel clinical Phase 1-ready investigational compound with broad potential to treat brain health diseases, including epilepsy.\n \n While significant progress has been achieved in the past 15 years, many people living with epilepsy are still unable to reach seizure control despite combination treatment of several anti-seizure medications.\n \n Our strategic collaboration with Cureverse will hopefully allow us to help people around the world living with brain conditions with unmet medical needs.\n #AngeliniPharma #EveryStepCloser #WithYouInMind\n \n Press Release here >> https://lnkd.in/dYH-dBXm """ "reactions_count" => 232 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-08 02:24:38" "deleted" => 1 ] [ "id" => 798043295 "company_id" => 25495456 "urn" => "urn:li:activity:7251944319215919105" "followers" => null "date" => "3w" "description" => """ Mental illness can affect anyone — even geniuses. In fact, it may even be part of what makes them extraordinary.\n \n Through our “Crazy Talents” project we want to dismantle the stigma surrounding mental illness and explore the lives of iconic historical figures and contemporary characters all of which have struggled with their #mentalhealth— from Michelangelo and Caravaggio to Billie Eilish and Leonardo DiCaprio.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind \n \n https://lnkd.in/dxxCs8ZE """ "reactions_count" => 66 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-08 02:24:38" "deleted" => 1 ] [ "id" => 798043296 "company_id" => 25495456 "urn" => "urn:li:activity:7250506358662332416" "followers" => null "date" => "3w" "description" => """ Following our participation as part of Angelini Industries in the 12th edition of Il Salone della CSR e dell'innovazione sociale, we’d like to thank everyone who joined us in discussing the vital intersection of well-being, health, and sustainability.\n \n Barbara Nadine De Gol, Global Patient Advocacy Specialist at Angelini Pharma, shared powerful insights on the importance of prioritizing brain health—not just for individual well-being, but as a cornerstone for sustainable development.\n \n We’re proud to continue contributing to this essential dialogue, driving forward initiatives that enhance mental health and well-being in the workplace and beyond.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #SaloneCSR """ "reactions_count" => 97 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-08 02:24:38" "deleted" => 1 ] [ "id" => 798043297 "company_id" => 25495456 "urn" => "urn:li:activity:7250052494834237440" "followers" => null "date" => "4w" "description" => """ 10th October is #WorldMentalHealthDay, the result of a global advocacy and awareness program started by the World Federation for Mental Health in 1992 and acknowledged and supported by World Health Organization.\n \n It is an enormous opportunity to raise awareness of mental health issues around the world, show support for people who are struggling, and mobilize efforts in support of mental health care.\n \n For us and all other stakeholders working in the field, today is also an important opportunity to talk about our work and findings, as well as highlight what more needs to be done to make mental health care a reality accessible for all people worldwide.\n \n For this reason, we’re sharing some insights from our latest Headway Mental Health Index 4.0 - in partnership with The European House-Ambrosetti, which points out how the right investment in mental health care in Europe would bring considerable savings and better mental health support for all.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 84 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-08 02:24:38" "deleted" => 1 ] [ "id" => 798043298 "company_id" => 25495456 "urn" => "urn:li:activity:7248977398904344577" "followers" => null "date" => "1mo" "description" => """ We’re happy to support the participation of Angelini Industries in the 12th edition of Il Salone della CSR e dell'innovazione sociale, with representatives from the group. \n \n Under the theme “Challenging Contradictions” and a program of over 100 events across three days, the Salone brings together businesses, institutions, and experts for a strategic dialogue on how to build a future that values people and ensures environmental protection. \n \n In particular, our Global Patient Advocacy Specialist Barbara Nadine De Gol will be host in the event “Well-being, Health, and Sustainability” on 10th October at 4.30pm. With Barbara, we will delve into the crucial role of mental health in the workplace and explore how investing in psychological well-being not only enhances employee satisfaction and productivity but also drives long-term organizational success. \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #SaloneCSR """ "reactions_count" => 53 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-08 02:24:38" "deleted" => 1 ] [ "id" => 798043299 "company_id" => 25495456 "urn" => "urn:li:activity:7246528800992223232" "followers" => null "date" => "1mo" "description" => """ 𝗦𝗵𝗮𝗽𝗶𝗻𝗴 𝗮 𝗳𝘂𝘁𝘂𝗿𝗲-𝗿𝗲𝗮𝗱𝘆 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗲𝘂𝘁𝗶𝗰𝗮𝗹 𝗲𝗰𝗼𝘀𝘆𝘀𝘁𝗲𝗺 𝘁𝗼 𝗲𝗺𝗽𝗼𝘄𝗲𝗿 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 & 𝗮𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗰𝗮𝗿𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗘𝗨\n \n We are proud to join forward-thinking pharmaceutical companies in signing EUCOPE - European Confederation of Pharmaceutical Entrepreneurs’ open letter to EU Institutions and Member States, advocating for a future-proofed ecosystem that fosters progress, research, and access to cutting-edge therapies.\n \n Together, we call on the leaders of the EU Institutions to take decisive actions, ensuring the EU leads the way in pharmaceutical innovation. A stronger, more supportive framework will enable groundbreaking advancements that improve patients’ lives across Europe and beyond.\n \n #AngeliniPharma #EveryStepCloser #EUPharma """ "reactions_count" => 29 "comments_count" => 2 "reshared_post_author" => "EUCOPE - European Confederation of Pharmaceutical Entrepreneurs" "reshared_post_author_url" => "https://be.linkedin.com/company/eucope" "reshared_post_author_headline" => null "reshared_post_description" => """ 🌍 Building a Competitive & Innovative Pharmaceutical Ecosystem for the EU \n \n As the EU looks ahead to the next decades, it's crucial to prepare the European pharmaceutical sector to tackle emerging challenges and seize new opportunities. \n \n ✒️ By signing EUCOPE - European Confederation of Pharmaceutical Entrepreneurs’s open letter to the Presidents of the European Commission, European Parliament, and Council of the European Union, 23 EUCOPE members urge the EU Institutions and Member States to collaborate in creating a competitive and attractive pharmaceutical landscape. 🏥✨ \n \n 🔬 To remain globally competitive, pharmaceutical companies need a robust, predictable and strong investment and industrial ecosystem. \n \n 💊 Special emphasis should be placed on small and mid-sized innovative companies, which are pivotal in driving technology and medical advancements across Europe. \n \n #PharmaInnovation #EUPharma #InnovationEcosystem #RareDiseases \n \n 👓 Read the open letter here: \n 👉 https://lnkd.in/eCeJk8U5 \n \n Alexion Pharmaceuticals, Inc. Amgen Angelini Pharma AOP Health Biogen BioMarin Pharmaceutical Inc. Blueprint Medicines Chiesi Group Circius Pharma CSL Emergent BioSolutions Incyte MENARINI Group Miltenyi Biomedicine MSD Norgine Orion Corporation Sanofi Santen Shionogi Europe Sobi - Swedish Orphan Biovitrum AB (publ) Takeda """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-12-08 02:24:38" "deleted" => 1 ] [ "id" => 846856101 "company_id" => 25495456 "urn" => "urn:li:activity:7270080078024228864" "followers" => null "date" => "2d" "description" => """ We start this new month with the 4th issue of #FuturePills, our monthly newsletter dedicated to the latest advancements in pharmaceuticals and science.\n \n November news deepen several mental health topics, including insights about youth depression, schizophrenia and maternal stress, but there is certainly no shortage of some brain health subjects. \n \n Enjoy #FuturePills and subscribe for monthly updates on the latest developments in the pharmaceutical industry. Don't forget to share to help spread advancements in research! """ "reactions_count" => 93 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-16 04:02:35" "deleted" => 1 ] [ "id" => 846856102 "company_id" => 25495456 "urn" => "urn:li:activity:7266742594691375104" "followers" => null "date" => "1w" "description" => """ Today, November 25th, on the International Day for the Elimination of Violence against Women, we focus on a critical yet invisible impact of gender violence: its toll on mental health. \n \n Beyond physical harm, survivors often face lasting mental health challenges, including depression, anxiety, PTSD, and even heightened suicide risk. \n \n In a dedicated article for Angelini Industries, our Chief Medical Officer, Agnese Cattaneo, delves into the data, shares key insights, and highlights actionable proposals to address this pressing issue. \n \n Mental health is not secondary— it is a cornerstone of recovery for survivors of gender violence. \n \n https://lnkd.in/dKmnCduF\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 107 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-16 04:02:35" "deleted" => 1 ] [ "id" => 846856103 "company_id" => 25495456 "urn" => "urn:li:activity:7259513981839560704" "followers" => null "date" => "1mo" "description" => """ Our latest Sustainability Report showcases our 2023 activities, projects, and key achievements in the ESG domain.\n \n Aligned with Angelini Industries’ Sustainability Report, this document presents a growth narrative focused on a sustainable, inclusive, and innovative approach that prioritizes employee well-being, community support, and environmental protection.\n \n #AngeliniPharma #EveryStepCloser #SustainabilityReport """ "reactions_count" => 58 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-16 04:02:35" "deleted" => 1 ] [ "id" => 846856104 "company_id" => 25495456 "urn" => "urn:li:activity:7257679591765360640" "followers" => null "date" => "1mo" "description" => """ As part of Angelini Industries, we are pleased to share the launch of the Group's very first #ESG Strategic Plan, marking a critical step toward sustainable growth for a healthier future. This plan reinforces our commitment to putting human well-being at the heart of our everyday work, ensuring better quality of life for patients, support for families, and care for those who need it most.\n \n At Angelini Pharma, we align closely with our Group’s ESG roadmap, advancing initiatives that positively impact People, Patients, Customers, Communities, Ecosystems, and the Planet. Our dedication to sustainability focuses on environmental responsibility, ethical innovation, and social impact.\n \n For a deeper look into the full news, we invite you to read the press release in the post below. """ "reactions_count" => 19 "comments_count" => null "reshared_post_author" => "Angelini Industries" "reshared_post_author_url" => "https://it.linkedin.com/company/angelini-industries" "reshared_post_author_headline" => null "reshared_post_description" => """ 🇮🇹 Nell’anno record per ricavi, a 2,1 miliardi di euro (+7,6%), aumenta anche il valore economico generato (+7,5%) da Angelini Industries, che raggiunge i 2,3 miliardi di euro, di cui l’86% distribuito agli stakeholder.\n \n È quanto emerge dal Bilancio di Sostenibilità 2023, che misura gli impatti delle attività del Gruppo in ambito ESG. Contestualmente, è stato inoltre annunciato il primo Piano ESG, con obiettivi e target al 2026 e un orizzonte al 2030: focus su Persone, Pazienti Clienti e Comunità, Ecosistemi e Pianeta.\n \n Azioni che dimostrano come la sostenibilità sia un driver di crescita per il gruppo e le società operative, le cui performance sono rendicontate nei Bilanci e Profili di Sostenibilità di Angelini Pharma, Angelini Technologies - FAMECCANICA, Angelini Ventures, Angelini Wines & Estates.\n \n 👉 Leggi il comunicato stampa: https://lnkd.in/d6_F2MqD\n \n 🇬🇧 In a record-breaking year for revenue, which reached 2.1 billion euros (+7.6%), the economic value generated by Angelini Industries also increased (+7.5%) to 2.3 billion euros, of which 86% was distributed to stakeholders.\n \n These results are highlighted in the 2023 Sustainability Report, which showcases the Group’s ESG impact. Alongside, Angelini Industries announced its first ESG Plan, with objectives and targets set for 2026 and a timeline to 2030: focus on people, patients, customers, community, ecosystems and planet. \n \n These actions demonstrate how sustainability drives growth within the Group and its operating companies, whose performance is reported in the sustainability reports and profiles of Angelini Pharma, Angelini Technologies - FAMECCANICA, Angelini Ventures, and Angelini Wines & Estates.\n \n 👉 Read the press release: https://lnkd.in/d6w-PCDB\n \n #AngeliniIndustries #IndustryOfCare #SustainabilityReport2023 #PianoESG """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2025-01-16 04:02:35" "deleted" => 1 ] [ "id" => 846856105 "company_id" => 25495456 "urn" => "urn:li:activity:7257017962929213440" "followers" => null "date" => "1mo" "description" => """ We are back with the 3rd edition of #FuturePills, our monthly newsletter dedicated to the latest advancements in pharmaceuticals and medicine.\n \n This month we will delve into several good news, with a particular focus on the role of technology and AI: we will explore how they can be helpful in research and prevention, but also for specific treatments. \n Sign up for monthly updates about the latest happenings in the pharmaceutical industry and do not forget to share #FuturePills to spread research advances! """ "reactions_count" => 134 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-16 04:02:35" "deleted" => 1 ] [ "id" => 846856106 "company_id" => 25495456 "urn" => "urn:li:activity:7255487550776131584" "followers" => null "date" => "1mo" "description" => """ We continue to explore the life of the people at Angelini, with a new episode of our “Nice to Meet You” video series.\n \n In this new episode, Packaging Coordinator Marta Casini shares the different facets of her role that has the goal of delivering the best quality product to the customer.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 68 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-16 04:02:35" "deleted" => 1 ] [ "id" => 846856107 "company_id" => 25495456 "urn" => "urn:li:activity:7254033545633931265" "followers" => null "date" => "1mo" "description" => """ We’re happy to announce that we entered into an exclusive option agreement with 𝐂𝐮𝐫𝐞𝐯𝐞𝐫𝐬𝐞 for the development and the commercialization of CV-01, a novel clinical Phase 1-ready investigational compound with broad potential to treat brain health diseases, including epilepsy.\n \n While significant progress has been achieved in the past 15 years, many people living with epilepsy are still unable to reach seizure control despite combination treatment of several anti-seizure medications.\n \n Our strategic collaboration with Cureverse will hopefully allow us to help people around the world living with brain conditions with unmet medical needs.\n #AngeliniPharma #EveryStepCloser #WithYouInMind\n \n Press Release here >> https://lnkd.in/dYH-dBXm """ "reactions_count" => 248 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-16 04:02:35" "deleted" => 1 ] [ "id" => 846856108 "company_id" => 25495456 "urn" => "urn:li:activity:7251944319215919105" "followers" => null "date" => "1mo" "description" => """ Mental illness can affect anyone — even geniuses. In fact, it may even be part of what makes them extraordinary.\n \n Through our “Crazy Talents” project we want to dismantle the stigma surrounding mental illness and explore the lives of iconic historical figures and contemporary characters all of which have struggled with their #mentalhealth— from Michelangelo and Caravaggio to Billie Eilish and Leonardo DiCaprio.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind \n \n https://lnkd.in/dxxCs8ZE """ "reactions_count" => 71 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-16 04:02:35" "deleted" => 1 ] [ "id" => 846856109 "company_id" => 25495456 "urn" => "urn:li:activity:7250506358662332416" "followers" => null "date" => "1mo" "description" => """ Following our participation as part of Angelini Industries in the 12th edition of Il Salone della CSR e dell'innovazione sociale, we’d like to thank everyone who joined us in discussing the vital intersection of well-being, health, and sustainability.\n \n Barbara Nadine De Gol, Global Patient Advocacy Specialist at Angelini Pharma, shared powerful insights on the importance of prioritizing brain health—not just for individual well-being, but as a cornerstone for sustainable development.\n \n We’re proud to continue contributing to this essential dialogue, driving forward initiatives that enhance mental health and well-being in the workplace and beyond.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind #SaloneCSR """ "reactions_count" => 99 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-16 04:02:35" "deleted" => 1 ] [ "id" => 846856110 "company_id" => 25495456 "urn" => "urn:li:activity:7250052494834237440" "followers" => null "date" => "1mo" "description" => """ 10th October is #WorldMentalHealthDay, the result of a global advocacy and awareness program started by the World Federation for Mental Health in 1992 and acknowledged and supported by World Health Organization.\n \n It is an enormous opportunity to raise awareness of mental health issues around the world, show support for people who are struggling, and mobilize efforts in support of mental health care.\n \n For us and all other stakeholders working in the field, today is also an important opportunity to talk about our work and findings, as well as highlight what more needs to be done to make mental health care a reality accessible for all people worldwide.\n \n For this reason, we’re sharing some insights from our latest Headway Mental Health Index 4.0 - in partnership with The European House-Ambrosetti, which points out how the right investment in mental health care in Europe would bring considerable savings and better mental health support for all.\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 84 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-16 04:02:35" "deleted" => 1 ] [ "id" => 888057403 "company_id" => 25495456 "urn" => "urn:li:activity:7276974866321358848" "followers" => null "date" => "3w" "description" => """ A year to remember, a future to envision.\n \n From groundbreaking research to impactful partnerships, 2024 has been a remarkable year of innovation, collaboration, and progress for Angelini Pharma.\n Driven by our unwavering commitment to well-being and holistic health, we’ve worked tirelessly to create meaningful value for patients, consumers, the scientific community, institutions, and the entire healthcare ecosystem across the fields of Brain and Consumer Health.\n \n None of this would have been possible without the dedication, passion, and expertise of our incredible teams across the world. 💙 As we close the year, we reflect with pride on the extraordinary milestones we’ve achieved together and look forward with gratitude and excitement to 2025 but always to make a difference, one step at a time.\n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 170 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 1 ] [ "id" => 888057404 "company_id" => 25495456 "urn" => "urn:li:activity:7275805283908493312" "followers" => null "date" => "3w" "description" => """ Our Inside LIFE-GREENAPI Project video series continues, exploring how we’re reducing the environmental impact of pharma production. \n \n In this third episode, Kristie Tjokro, PhD candidate at Leiden University, explains how the Life Cycle Assessment (LCA) methodology is used to quantify the environmental impact associated with the life cycle of API, from raw materials to the production output.\n \n The second part of the video is available on our YouTube channel: https://lnkd.in/d4FMjdnY\n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 41 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 1 ] [ "id" => 888057405 "company_id" => 25495456 "urn" => "urn:li:activity:7274346317047357440" "followers" => null "date" => "1mo" "description" => """ Our Inside LIFE-GREENAPI Project video series continues, exploring how we’re reducing the environmental impact of pharma production. \n \n In this second episode, Stefano Germini, Angelini Pharma’s Sustainability Manager, highlights the LIFE-GREENAPI project’s essential contribution to our ESG strategy. \n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 61 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 1 ] [ "id" => 888057406 "company_id" => 25495456 "urn" => "urn:li:activity:7273259517574860800" "followers" => null "date" => "1mo" "description" => """ The European pharmaceutical sector is one of the most challenging industries to decarbonize due to stringent regulatory requirements. As part of our green transition strategy, the LIFE-GREENAPI project reflects our collective commitment to reducing the environmental impact of pharma production while optimizing processes. \n \n In the first episode of our Inside LIFE-GREENAPI Project video series, Tommaso Iacoangeli, Angelini Pharma’s Fine Chemicals Business Project Manager, shares insights into the project’s foundation and its critical role in advancing sustainable practices. \n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 77 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 1 ] [ "id" => 888057407 "company_id" => 25495456 "urn" => "urn:li:activity:7270080078024228864" "followers" => null "date" => "1mo" "description" => """ We start this new month with the 4th issue of #FuturePills, our monthly newsletter dedicated to the latest advancements in pharmaceuticals and science.\n \n November news deepen several mental health topics, including insights about youth depression, schizophrenia and maternal stress, but there is certainly no shortage of some brain health subjects. \n \n Enjoy #FuturePills and subscribe for monthly updates on the latest developments in the pharmaceutical industry. Don't forget to share to help spread advancements in research! """ "reactions_count" => 109 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 1 ] [ "id" => 888057408 "company_id" => 25495456 "urn" => "urn:li:activity:7266742594691375104" "followers" => null "date" => "1mo" "description" => """ Today, November 25th, on the International Day for the Elimination of Violence against Women, we focus on a critical yet invisible impact of gender violence: its toll on mental health. \n \n Beyond physical harm, survivors often face lasting mental health challenges, including depression, anxiety, PTSD, and even heightened suicide risk. \n \n In a dedicated article for Angelini Industries, our Chief Medical Officer, Agnese Cattaneo, delves into the data, shares key insights, and highlights actionable proposals to address this pressing issue. \n \n Mental health is not secondary— it is a cornerstone of recovery for survivors of gender violence. \n \n https://lnkd.in/dKmnCduF\n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 116 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 1 ] [ "id" => 888057409 "company_id" => 25495456 "urn" => "urn:li:activity:7259513981839560704" "followers" => null "date" => "2mo" "description" => """ Our latest Sustainability Report showcases our 2023 activities, projects, and key achievements in the ESG domain.\n \n Aligned with Angelini Industries’ Sustainability Report, this document presents a growth narrative focused on a sustainable, inclusive, and innovative approach that prioritizes employee well-being, community support, and environmental protection.\n \n #AngeliniPharma #EveryStepCloser #SustainabilityReport """ "reactions_count" => 58 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 1 ] [ "id" => 888057410 "company_id" => 25495456 "urn" => "urn:li:activity:7257679591765360640" "followers" => null "date" => "2mo" "description" => """ As part of Angelini Industries, we are pleased to share the launch of the Group's very first #ESG Strategic Plan, marking a critical step toward sustainable growth for a healthier future. This plan reinforces our commitment to putting human well-being at the heart of our everyday work, ensuring better quality of life for patients, support for families, and care for those who need it most.\n \n At Angelini Pharma, we align closely with our Group’s ESG roadmap, advancing initiatives that positively impact People, Patients, Customers, Communities, Ecosystems, and the Planet. Our dedication to sustainability focuses on environmental responsibility, ethical innovation, and social impact.\n \n For a deeper look into the full news, we invite you to read the press release in the post below. """ "reactions_count" => 19 "comments_count" => null "reshared_post_author" => "Angelini Industries" "reshared_post_author_url" => "https://it.linkedin.com/company/angelini-industries" "reshared_post_author_headline" => null "reshared_post_description" => """ 🇮🇹 Nell’anno record per ricavi, a 2,1 miliardi di euro (+7,6%), aumenta anche il valore economico generato (+7,5%) da Angelini Industries, che raggiunge i 2,3 miliardi di euro, di cui l’86% distribuito agli stakeholder.\n \n È quanto emerge dal Bilancio di Sostenibilità 2023, che misura gli impatti delle attività del Gruppo in ambito ESG. Contestualmente, è stato inoltre annunciato il primo Piano ESG, con obiettivi e target al 2026 e un orizzonte al 2030: focus su Persone, Pazienti Clienti e Comunità, Ecosistemi e Pianeta.\n \n Azioni che dimostrano come la sostenibilità sia un driver di crescita per il gruppo e le società operative, le cui performance sono rendicontate nei Bilanci e Profili di Sostenibilità di Angelini Pharma, Angelini Technologies - FAMECCANICA, Angelini Ventures, Angelini Wines & Estates.\n \n 👉 Leggi il comunicato stampa: https://lnkd.in/d6_F2MqD\n \n 🇬🇧 In a record-breaking year for revenue, which reached 2.1 billion euros (+7.6%), the economic value generated by Angelini Industries also increased (+7.5%) to 2.3 billion euros, of which 86% was distributed to stakeholders.\n \n These results are highlighted in the 2023 Sustainability Report, which showcases the Group’s ESG impact. Alongside, Angelini Industries announced its first ESG Plan, with objectives and targets set for 2026 and a timeline to 2030: focus on people, patients, customers, community, ecosystems and planet. \n \n These actions demonstrate how sustainability drives growth within the Group and its operating companies, whose performance is reported in the sustainability reports and profiles of Angelini Pharma, Angelini Technologies - FAMECCANICA, Angelini Ventures, and Angelini Wines & Estates.\n \n 👉 Read the press release: https://lnkd.in/d6w-PCDB\n \n #AngeliniIndustries #IndustryOfCare #SustainabilityReport2023 #PianoESG """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2025-02-09 04:11:57" "deleted" => 1 ] [ "id" => 888057411 "company_id" => 25495456 "urn" => "urn:li:activity:7257017962929213440" "followers" => null "date" => "2mo" "description" => """ We are back with the 3rd edition of #FuturePills, our monthly newsletter dedicated to the latest advancements in pharmaceuticals and medicine.\n \n This month we will delve into several good news, with a particular focus on the role of technology and AI: we will explore how they can be helpful in research and prevention, but also for specific treatments. \n Sign up for monthly updates about the latest happenings in the pharmaceutical industry and do not forget to share #FuturePills to spread research advances! """ "reactions_count" => 134 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 1 ] [ "id" => 888057412 "company_id" => 25495456 "urn" => "urn:li:activity:7255487550776131584" "followers" => null "date" => "2mo" "description" => """ We continue to explore the life of the people at Angelini, with a new episode of our “Nice to Meet You” video series.\n \n In this new episode, Packaging Coordinator Marta Casini shares the different facets of her role that has the goal of delivering the best quality product to the customer.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne """ "reactions_count" => 68 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 1 ] [ "id" => 926147805 "company_id" => 25495456 "urn" => "urn:li:activity:7293232196906020864" "followers" => null "date" => "1d" "description" => """ As part of our virtual marathon in support of INTERNATIONAL BUREAU FOR EPILEPSY's #50MillionSteps campaign to raise awareness on epilepsy, we’ve involved our Global Medical Advisor Paloma Pérez-Domper, PhD to go over the basics of epilepsy together.\n \n We believe in raising awareness through information and education, both inside and outside our company, and involving our expert medical colleagues is one of the most efficient ways to do it. 🧠 \n \n From its definition to how it can affect people’s lives, here’s what we all should know about epilepsy. \n \n Let’s make every step count, together. 💜 \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 48 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 926147806 "company_id" => 25495456 "urn" => "urn:li:activity:7292579008259489792" "followers" => null "date" => "2d" "description" => """ Welcome back in 2025 with the fifth issue of Future Pills, our monthly dose of good news about the latest advancements in pharmaceuticals and science.\n \n This month, we discuss brain aging and risk factors for depression, we talk about the role of AI in different scenarios... and much more!\n \n If we have intrigued you, check out #FuturePills and subscribe for monthly updates on the latest news in the pharmaceutical industry. Be sure to share and help spread the word about research advancements! """ "reactions_count" => 56 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 926147807 "company_id" => 25495456 "urn" => "urn:li:activity:7292150175408484352" "followers" => null "date" => "4d" "description" => """ We’re one step further in our virtual #50MillionSteps marathon, walking together with INTERNATIONAL BUREAU FOR EPILEPSY for their global campaign to raise awareness on epilepsy.\n \n As Angelini Pharma, we have now reached more than 5 million steps and it’s time to dispel some of epilepsy's most common myths. To do so, we involved our Senior Clinical Fellow John Paul Leach, who’s clearing out those doubts and false assumptions that often nurture stigma and discrimination.\n \n Walking together towards a brighter future. 💜 \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 48 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 926147808 "company_id" => 25495456 "urn" => "urn:li:activity:7290039722326872066" "followers" => null "date" => "1w" "description" => """ Our virtual marathon in support of the #50MillionSteps campaign organized by INTERNATIONAL BUREAU FOR EPILEPSY is now in full swing. With the participation of all our colleagues, we’re counting our steps every day for a good cause: to raise awareness about epilepsy and support those suffering from this serious, chronic, neurological disorder. \n \n So far, we’ve walked over 1 million steps — and we’re not stopping! Every step is a symbol of our commitment to reducing the stigma surrounding epilepsy. Together, we’re not only making strides but also spreading knowledge and compassion. \n \n Let’s keep moving forward, one step at a time, for a brighter future. 🌟 \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 49 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 926147809 "company_id" => 25495456 "urn" => "urn:li:activity:7287759387467681793" "followers" => null "date" => "2w" "description" => """ We are delighted to once again join INTERNATIONAL BUREAU FOR EPILEPSY in their annual #50MillionSteps campaign to raise awareness about epilepsy and people living with this chronic neurological disease. \n \n As Angelini Pharma, we embrace the moment to frame our ongoing work to raise awareness of the disease within a global and collective cause, joining forces with like-minded individuals and companies towards a common goal: reducing the stigma and discrimination against epilepsy. \n \n Every year, our leaders and colleagues from all countries walk through January with enthusiasm for a good cause, and this year will be no exception. \n \n From now until February 10th, we will count our steps every day, in a big, shared virtual marathon, starting from our headquarters in Rome and running all the way to our farthest plant in Albany, Georgia. \n \n Last year we reached 7 million steps. Let's see where we get to this year! 💜 \n \n #AngeliniPharma #EveryStepCloser #WithYouInMind """ "reactions_count" => 170 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 926147810 "company_id" => 25495456 "urn" => "urn:li:activity:7287510980698214401" "followers" => null "date" => "2w" "description" => """ Once again this year we are proud to participate in 50 Million Steps, the campaign ideated by the INTERNATIONAL BUREAU FOR EPILEPSY as a symbol of the fight against stigma and discrimination towards those living with epilepsy.\n \n To learn more about this campaign and about Angelini Pharma’s #50MillionSteps for 2025, don’t miss the special edition of #FuturePills. """ "reactions_count" => 154 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 926147811 "company_id" => 25495456 "urn" => "urn:li:activity:7287034884953415680" "followers" => null "date" => "2w" "description" => """ It's with great pleasure that we introduce Radosław Pilipczuk as our new Angelini Pharma Romania Country Manager.\n \n With over 15 years of experience in sales and business leadership across the pharmaceutical industry, Radosław brings a wealth of expertise in both general medicine and specialty pharmaceuticals. His successful track record at Angelini Pharma Polska, where he has led strategic business units across various therapeutic areas, makes him the ideal person to lead our operations in Romania.\n \n As Radosław says, “Collaboration, active listening, and empowering ideas from within the organization have consistently been the foundation of my leadership approach, and they will remain central as we move forward. I strongly believe, together with my new Romanian team, we will continue to grow the business, nurture our people, and promote a culture of excellence and high performance.” \n \n Welcome aboard, Radosław! We look forward to achieving great things together. 🚀 \n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 140 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 926147812 "company_id" => 25495456 "urn" => "urn:li:activity:7285581563268861953" "followers" => null "date" => "3w" "description" => """ We’re proud to share that we have been recognized as a Top Employer 2025 for the 6th consecutive year! 🎉\n This recognition brings our ambition to life: making Angelini Pharma one of the top ten European companies. Being certified by an external organization for our HR practice holds significant meaning in our daily work and provides all our employees with a senso of trust and engagement.\n \n 🏆We are 10th Top Employer Europe for the very first time!🏆\n \n 🏅 3rd Top Employer in Turkey\n 🏅 5th Top Employer in Portugal\n 🏅 14th Top Employer in Italy\n \n This recognition inspires us to keep raising the bar and striving for excellence, every single day.\n \n #AngeliniPharma #EveryStepCloser #WinAsOne #EvolveOurCulture #TopEmployer2025 """ "reactions_count" => 237 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 926147813 "company_id" => 25495456 "urn" => "urn:li:activity:7276974866321358848" "followers" => null "date" => "1mo" "description" => """ A year to remember, a future to envision.\n \n From groundbreaking research to impactful partnerships, 2024 has been a remarkable year of innovation, collaboration, and progress for Angelini Pharma.\n Driven by our unwavering commitment to well-being and holistic health, we’ve worked tirelessly to create meaningful value for patients, consumers, the scientific community, institutions, and the entire healthcare ecosystem across the fields of Brain and Consumer Health.\n \n None of this would have been possible without the dedication, passion, and expertise of our incredible teams across the world. 💙 As we close the year, we reflect with pride on the extraordinary milestones we’ve achieved together and look forward with gratitude and excitement to 2025 but always to make a difference, one step at a time.\n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 179 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] [ "id" => 926147814 "company_id" => 25495456 "urn" => "urn:li:activity:7275805283908493312" "followers" => null "date" => "1mo" "description" => """ Our Inside LIFE-GREENAPI Project video series continues, exploring how we’re reducing the environmental impact of pharma production. \n \n In this third episode, Kristie Tjokro, PhD candidate at Leiden University, explains how the Life Cycle Assessment (LCA) methodology is used to quantify the environmental impact associated with the life cycle of API, from raw materials to the production output.\n \n The second part of the video is available on our YouTube channel: https://lnkd.in/d4FMjdnY\n \n #AngeliniPharma #EveryStepCloser """ "reactions_count" => 43 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 04:11:57" "deleted" => 0 ] ] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4410 …} -companyTags: Doctrine\ORM\PersistentCollection {#4412 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4414 …} -users: Doctrine\ORM\PersistentCollection {#4416 …} -logoImageName: "20250226143641-angelini-industries-1-67bf18e95bab7027459951.png" -coverImageName: "20250227161252-angelini-favicon-67c080f437a73975216892.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4418 …} -tagline: "Innovation für bessere Gesundheit und führend in CNS & Mental Health seit 1919" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4420 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4422 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4424 …} -industry: "" -size: null -address1: null -address2: null -city: null -postalCode: null -state: null -country: "Italy" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4426 …} #createdAt: DateTime @1740044758 {#4408 date: 2025-02-20 09:45:58.0 UTC (+00:00) } #updatedAt: DateTime @1750924472 {#4407 date: 2025-06-26 07:54:32.0 UTC (+00:00) } } App\Entity\Company {#4430 -id: 8 -name: "argenx" -website: "https://argenx.com" -description: """ argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer. By translating immunology breakthroughs into innovative drug candidates, argenx is building a world-class portfolio of first-in-class antibodies in both early and late clinical-stages of development. argenx is evaluating efgartigimod in multiple serious autoimmune indications and cusatuzumab in hematological malignancies in collaboration with Janssen, along with advancing earlier stage assets within its therapeutic franchises. \n \n argenx is listed on the Euronext Brussels exchange under the symbol ARGX. """ -externalId: "8862185" -details: [ "id" => 8862185 "url" => "https://www.linkedin.com/company/argen-x" "hash" => "20baed6a493fe7895a85a5802c9d36a4" "name" => "argenx" "website" => "http://www.argenx.com" "size" => "51-200 employees" "industry" => "Biotechnology" "description" => """ argenx is a global immunology company developing antibody-based medicines for patients suffering from severe autoimmune diseases and cancer. By translating immunology breakthroughs into innovative drug candidates, argenx is building a world-class portfolio of first-in-class antibodies in both early and late clinical-stages of development. argenx is evaluating efgartigimod in multiple serious autoimmune indications and cusatuzumab in hematological malignancies in collaboration with Janssen, along with advancing earlier stage assets within its therapeutic franchises. \n \n argenx is listed on the Euronext Brussels exchange under the symbol ARGX. """ "followers" => null "founded" => 2008 "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://media-exp1.licdn.com/dms/image/C4E0BAQFH9mP28baEAQ/company-logo_200_200/0?e=2159024400&v=beta&t=wlRFPAAnwh1aMicgdZ7QsJdV_Nza_IakiypBFsj_gig" "created" => "2016-06-25 13:50:05" "last_updated" => "2021-11-26 15:05:47" "last_response_code" => 200 "type" => "Public Company" "headquarters_new_address" => null "employees_count" => 190 "headquarters_country_restored" => "Belgium" "headquarters_country_parsed" => "Belgium" "company_shorthand_name" => "argen-x" "company_shorthand_name_hash" => "49c80690bedfb0cb4b84b8c6adc2b6b8" "canonical_url" => "https://www.linkedin.com/company/argen-x" "canonical_hash" => "20baed6a493fe7895a85a5802c9d36a4" "canonical_shorthand_name" => "argen-x" "canonical_shorthand_name_hash" => "49c80690bedfb0cb4b84b8c6adc2b6b8" "deleted" => 0 "last_updated_ux" => 1580031410 "source_id" => null "company_affiliated_collection" => [] "company_also_viewed_collection" => [ [ "id" => 33554819 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/ablynx" "viewed_company_id" => null "created" => "2016-06-25 13:50:05" "last_updated" => "2019-07-31 11:20:45" "deleted" => 1 ] [ "id" => 33554820 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/celyad" "viewed_company_id" => null "created" => "2016-06-25 13:50:05" "last_updated" => "2017-02-27 20:12:32" "deleted" => 1 ] [ "id" => 33554821 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/thrombogenics" "viewed_company_id" => null "created" => "2016-06-25 13:50:05" "last_updated" => "2018-10-03 17:21:27" "deleted" => 1 ] [ "id" => 33554822 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/promethera-biosciences" "viewed_company_id" => null "created" => "2016-06-25 13:50:05" "last_updated" => "2017-11-16 16:08:25" "deleted" => 1 ] [ "id" => 33554823 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/bone-therapeutics-s-a-" "viewed_company_id" => null "created" => "2016-06-25 13:50:05" "last_updated" => "2017-11-16 16:08:25" "deleted" => 1 ] [ "id" => 33554824 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/actogenix-n.v." "viewed_company_id" => null "created" => "2016-06-25 13:50:05" "last_updated" => "2016-12-09 13:57:45" "deleted" => 1 ] [ "id" => 39574756 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/masthercell" "viewed_company_id" => null "created" => "2016-12-09 13:57:45" "last_updated" => "2017-01-17 12:37:31" "deleted" => 1 ] [ "id" => 71744434 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/biofocus" "viewed_company_id" => null "created" => "2017-01-17 12:37:31" "last_updated" => "2019-07-31 11:20:45" "deleted" => 1 ] [ "id" => 86875632 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/biocartis" "viewed_company_id" => null "created" => "2017-02-27 20:12:31" "last_updated" => "2019-07-31 11:20:45" "deleted" => 1 ] [ "id" => 116819954 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/confo-therapeutics" "viewed_company_id" => null "created" => "2017-11-16 16:08:25" "last_updated" => "2019-07-31 11:20:45" "deleted" => 1 ] [ "id" => 116819955 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/complix-n.v." "viewed_company_id" => null "created" => "2017-11-16 16:08:25" "last_updated" => "2018-03-12 19:30:21" "deleted" => 1 ] [ "id" => 133483145 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/vib" "viewed_company_id" => null "created" => "2018-03-12 19:30:20" "last_updated" => "2018-07-11 07:27:41" "deleted" => 1 ] [ "id" => 143390522 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/tigenix" "viewed_company_id" => null "created" => "2018-07-11 07:27:40" "last_updated" => "2018-08-01 23:05:58" "deleted" => 1 ] [ "id" => 149650718 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/vib" "viewed_company_id" => null "created" => "2018-08-01 23:05:58" "last_updated" => "2018-10-03 17:21:27" "deleted" => 1 ] [ "id" => 163926265 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/oxurion2" "viewed_company_id" => null "created" => "2018-10-03 17:21:27" "last_updated" => "2019-07-31 11:20:45" "deleted" => 1 ] [ "id" => 163926269 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/argenx-se" "viewed_company_id" => null "created" => "2018-10-03 17:21:27" "last_updated" => "2018-12-12 16:34:14" "deleted" => 1 ] [ "id" => 176830348 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/etherna-immunotherapeutics" "viewed_company_id" => null "created" => "2018-12-12 16:34:13" "last_updated" => "2019-07-31 11:20:45" "deleted" => 1 ] [ "id" => 249774021 "company_id" => 8862185 "viewed_company_url" => "https://ca.linkedin.com/company/ablynx" "viewed_company_id" => null "created" => "2019-07-31 11:20:45" "last_updated" => "2019-09-03 05:04:47" "deleted" => 1 ] [ "id" => 249774023 "company_id" => 8862185 "viewed_company_url" => "https://ca.linkedin.com/company/biofocus" "viewed_company_id" => null "created" => "2019-07-31 11:20:45" "last_updated" => "2019-09-03 05:04:47" "deleted" => 1 ] [ "id" => 249774025 "company_id" => 8862185 "viewed_company_url" => "https://ca.linkedin.com/company/oxurion2" "viewed_company_id" => null "created" => "2019-07-31 11:20:45" "last_updated" => "2019-09-03 05:04:47" "deleted" => 1 ] [ "id" => 249774027 "company_id" => 8862185 "viewed_company_url" => "https://ca.linkedin.com/company/confo-therapeutics" "viewed_company_id" => null "created" => "2019-07-31 11:20:45" "last_updated" => "2019-09-03 05:04:47" "deleted" => 1 ] [ "id" => 249774029 "company_id" => 8862185 "viewed_company_url" => "https://ca.linkedin.com/company/biocartis" "viewed_company_id" => null "created" => "2019-07-31 11:20:45" "last_updated" => "2019-09-03 05:04:47" "deleted" => 1 ] [ "id" => 249774030 "company_id" => 8862185 "viewed_company_url" => "https://ca.linkedin.com/company/etherna-immunotherapeutics" "viewed_company_id" => null "created" => "2019-07-31 11:20:45" "last_updated" => "2019-09-03 05:04:47" "deleted" => 1 ] [ "id" => 278398353 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/ablynx" "viewed_company_id" => null "created" => "2019-09-03 05:04:47" "last_updated" => "2019-10-19 14:09:17" "deleted" => 1 ] [ "id" => 278398354 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/biofocus" "viewed_company_id" => null "created" => "2019-09-03 05:04:47" "last_updated" => "2019-10-19 14:09:17" "deleted" => 1 ] [ "id" => 278398355 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/oxurion2" "viewed_company_id" => null "created" => "2019-09-03 05:04:47" "last_updated" => "2019-10-19 14:09:17" "deleted" => 1 ] [ "id" => 278398356 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/biocartis" "viewed_company_id" => null "created" => "2019-09-03 05:04:47" "last_updated" => "2019-10-19 14:09:17" "deleted" => 1 ] [ "id" => 278398357 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/confo-therapeutics" "viewed_company_id" => null "created" => "2019-09-03 05:04:47" "last_updated" => "2019-10-19 14:09:17" "deleted" => 1 ] [ "id" => 278398358 "company_id" => 8862185 "viewed_company_url" => "https://www.linkedin.com/company/etherna-immunotherapeutics" "viewed_company_id" => null "created" => "2019-09-03 05:04:47" "last_updated" => "2019-10-19 14:09:17" "deleted" => 1 ] ] "company_crunchbase_info_collection" => [] "company_featured_employees_collection" => [ [ "id" => 10819666 "company_id" => 8862185 "url" => "https://www.linkedin.com/in/gdsteinhauser" "created" => "2019-10-19 14:09:17" "last_updated" => "2020-01-26 09:36:50" "deleted" => 1 ] [ "id" => 10819668 "company_id" => 8862185 "url" => "https://www.linkedin.com/in/elisabeth-minko-028359" "created" => "2019-10-19 14:09:17" "last_updated" => "2020-01-26 09:36:50" "deleted" => 1 ] [ "id" => 10819670 "company_id" => 8862185 "url" => "https://www.linkedin.com/in/natalie-de-jonge-3604261" "created" => "2019-10-19 14:09:17" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 10819671 "company_id" => 8862185 "url" => "https://www.linkedin.com/in/sara-mannle-0456291" "created" => "2019-10-19 14:09:17" "last_updated" => "2020-01-26 09:36:50" "deleted" => 1 ] [ "id" => 33323859 "company_id" => 8862185 "url" => "https://www.linkedin.com/in/marieke-louwers-3359081" "created" => "2020-01-26 09:36:50" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 33323860 "company_id" => 8862185 "url" => "https://www.linkedin.com/in/audrey-perna-22b9181" "created" => "2020-01-26 09:36:50" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 33323861 "company_id" => 8862185 "url" => "https://www.linkedin.com/in/kristin-cuccio-1851942" "created" => "2020-01-26 09:36:50" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] ] "company_featured_investors_collection" => [] "company_funding_rounds_collection" => [] "company_locations_collection" => [ [ "id" => 4399433 "company_id" => 8862185 "location_address" => "Technologiepark 30; Zwijnaarde, BE" "is_primary" => 1 "created" => "2019-10-19 14:09:17" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 4399436 "company_id" => 8862185 "location_address" => "33 Arch Street; Suite 3201; Boston, MA 02110, US" "is_primary" => 0 "created" => "2019-10-19 14:09:17" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] ] "company_similar_collection" => [ [ "id" => 16559578 "company_id" => 8862185 "url" => "https://www.linkedin.com/company/ablynx" "created" => "2019-10-19 14:09:17" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 16559582 "company_id" => 8862185 "url" => "https://www.linkedin.com/company/biofocus" "created" => "2019-10-19 14:09:17" "last_updated" => "2019-12-20 23:13:32" "deleted" => 1 ] [ "id" => 16559585 "company_id" => 8862185 "url" => "https://www.linkedin.com/company/oxurion2" "created" => "2019-10-19 14:09:17" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 16559587 "company_id" => 8862185 "url" => "https://www.linkedin.com/company/biocartis" "created" => "2019-10-19 14:09:17" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 16559589 "company_id" => 8862185 "url" => "https://www.linkedin.com/company/confo-therapeutics" "created" => "2019-10-19 14:09:17" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 16559591 "company_id" => 8862185 "url" => "https://www.linkedin.com/company/alexion-pharmaceuticals" "created" => "2019-10-19 14:09:17" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 59032505 "company_id" => 8862185 "url" => "https://www.linkedin.com/company/glpg" "created" => "2019-12-20 23:13:32" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 74110694 "company_id" => 8862185 "url" => "https://www.linkedin.com/company/celyad" "created" => "2020-01-26 09:36:50" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 74110700 "company_id" => 8862185 "url" => "https://www.linkedin.com/company/etherna-immunotherapeutics" "created" => "2020-01-26 09:36:50" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 74110702 "company_id" => 8862185 "url" => "https://www.linkedin.com/company/vib" "created" => "2020-01-26 09:36:50" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 74110704 "company_id" => 8862185 "url" => "https://www.linkedin.com/company/complix-n.v." "created" => "2020-01-26 09:36:50" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] ] "company_specialties_collection" => [ [ "id" => 12536207 "company_id" => 8862185 "specialty" => "Differentiated antibodies" "created" => "2016-06-25 13:50:05" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 12536208 "company_id" => 8862185 "specialty" => "Niche indications" "created" => "2016-06-25 13:50:05" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 12536209 "company_id" => 8862185 "specialty" => "Oncology" "created" => "2016-06-25 13:50:05" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 12536210 "company_id" => 8862185 "specialty" => "Autoimmune diseases" "created" => "2016-06-25 13:50:05" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] [ "id" => 12536211 "company_id" => 8862185 "specialty" => "Antibody-based drugs" "created" => "2016-06-25 13:50:05" "last_updated" => "2020-01-26 09:36:50" "deleted" => 0 ] ] "company_stock_info_collection" => [] "company_updates_collection" => [] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4431 …} -companyTags: Doctrine\ORM\PersistentCollection {#4433 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4435 …} -users: Doctrine\ORM\PersistentCollection {#4437 …} -logoImageName: "20250226143704-argenx-logo-67bf19000dfb8719168246.png" -coverImageName: "20250227161330-argx-2cce0009-67c0811aaec6b891247191.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4439 …} -tagline: "Globale Immunologie-Innovationen für Autoimmunerkrankungen und Krebs" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4441 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4443 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4445 …} -industry: "" -size: "190" -address1: null -address2: null -city: null -postalCode: null -state: null -country: "Belgium" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4447 …} #createdAt: DateTime @1740044914 {#4300 date: 2025-02-20 09:48:34.0 UTC (+00:00) } #updatedAt: DateTime @1759390425 {#4301 date: 2025-10-02 07:33:45.0 UTC (+00:00) } } App\Entity\Company {#4451 -id: 9 -name: "AstraZeneca MEA" -website: "https://astrazeneca.com" -description: "Wegweisende Innovationen in der Onkologie, Atemwegserkrankungen und Herz-Kreislauf-Gesundheit" -externalId: "8750222" -details: [ "id" => 8750222 "url" => "https://www.linkedin.com/company/astrazeneca-mea" "hash" => "a428b8f79c399159eddab93a4a47a1da" "name" => "AstraZeneca MEA" "website" => "http://www.astrazeneca.com" "size" => "1001-5000 employees" "industry" => "Pharmaceuticals" "description" => """ PAGE CLOSURE: \n \n We will be closing this page shortly. The good news is that we’ve launched a new global page at https://lnkd.in/gncSUGs\n \n So, want to know our latest news? Keen to come to one of our events? Or apply for new career opportunity? Just head over to our global page and click on ‘Follow’. """ "followers" => 5415 "founded" => 2012 "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://media.licdn.com/dms/image/C4E0BAQHDt_lYHQY8Tg/company-logo_200_200/0?e=2159024400&v=beta&t=zALdXgjZVfrUayxle4WYk2jzfzMIp4p1hNe2tZpGR48" "created" => "2016-06-25 12:23:31" "last_updated" => "2025-02-09 01:56:21" "last_response_code" => 404 "type" => "Public Company" "headquarters_new_address" => "Dubai Healthcare City" "employees_count" => 128 "headquarters_country_restored" => "United Arab Emirates" "headquarters_country_parsed" => "United Arab Emirates" "company_shorthand_name" => "astrazeneca-mea" "company_shorthand_name_hash" => "71d1c226807c8c71d66d27eb7f2b1ea2" "canonical_url" => "https://www.linkedin.com/company/astrazeneca-mea" "canonical_hash" => "a428b8f79c399159eddab93a4a47a1da" "canonical_shorthand_name" => "astrazeneca-mea" "canonical_shorthand_name_hash" => "71d1c226807c8c71d66d27eb7f2b1ea2" "deleted" => 1 "last_updated_ux" => 1739066180 "source_id" => 9448684 "company_affiliated_collection" => [] "company_also_viewed_collection" => [ [ "id" => 33077812 "company_id" => 8750222 "viewed_company_url" => "https://www.linkedin.com/company/astrazeneca" "viewed_company_id" => null "created" => "2016-06-25 12:23:31" "last_updated" => "2019-05-28 00:24:10" "deleted" => 1 ] [ "id" => 33077813 "company_id" => 8750222 "viewed_company_url" => "https://www.linkedin.com/company/pfizer" "viewed_company_id" => null "created" => "2016-06-25 12:23:31" "last_updated" => "2019-05-28 00:24:10" "deleted" => 1 ] [ "id" => 33077814 "company_id" => 8750222 "viewed_company_url" => "https://www.linkedin.com/company/gulf-pharmaceutical-industry-julphar-" "viewed_company_id" => null "created" => "2016-06-25 12:23:31" "last_updated" => "2017-11-23 10:18:14" "deleted" => 1 ] [ "id" => 33077815 "company_id" => 8750222 "viewed_company_url" => "https://www.linkedin.com/company/biopharma-mea" "viewed_company_id" => null "created" => "2016-06-25 12:23:31" "last_updated" => "2017-11-23 10:18:14" "deleted" => 1 ] [ "id" => 33077816 "company_id" => 8750222 "viewed_company_url" => "https://www.linkedin.com/company/sanofi-" "viewed_company_id" => null "created" => "2016-06-25 12:23:31" "last_updated" => "2016-12-10 11:45:28" "deleted" => 1 ] [ "id" => 33077817 "company_id" => 8750222 "viewed_company_url" => "https://www.linkedin.com/company/novartis" "viewed_company_id" => null "created" => "2016-06-25 12:23:31" "last_updated" => "2016-12-10 11:45:28" "deleted" => 1 ] [ "id" => 41697346 "company_id" => 8750222 "viewed_company_url" => "https://www.linkedin.com/company/dayarn-pharma" "viewed_company_id" => null "created" => "2016-12-10 11:45:28" "last_updated" => "2017-07-31 21:16:24" "deleted" => 1 ] [ "id" => 41697347 "company_id" => 8750222 "viewed_company_url" => "https://www.linkedin.com/company/sanofi" "viewed_company_id" => null "created" => "2016-12-10 11:45:28" "last_updated" => "2018-07-16 10:28:16" "deleted" => 1 ] [ "id" => 95014057 "company_id" => 8750222 "viewed_company_url" => "https://www.linkedin.com/company/novartis" "viewed_company_id" => null "created" => "2017-07-31 21:16:24" "last_updated" => "2019-05-28 00:24:10" "deleted" => 1 ] [ "id" => 117953647 "company_id" => 8750222 "viewed_company_url" => "https://www.linkedin.com/company/glaxosmithkline" "viewed_company_id" => null "created" => "2017-11-23 10:18:13" "last_updated" => "2019-05-28 00:24:10" "deleted" => 1 ] [ "id" => 117953648 "company_id" => 8750222 "viewed_company_url" => "https://www.linkedin.com/company/roche" "viewed_company_id" => null "created" => "2017-11-23 10:18:13" "last_updated" => "2018-08-03 23:58:55" "deleted" => 1 ] [ "id" => 145504989 "company_id" => 8750222 "viewed_company_url" => "https://www.linkedin.com/company/hikma-pharmaceuticals" "viewed_company_id" => null "created" => "2018-07-16 10:28:16" "last_updated" => "2019-05-28 00:24:10" "deleted" => 1 ] [ "id" => 150509976 "company_id" => 8750222 "viewed_company_url" => "https://www.linkedin.com/company/sanofi" "viewed_company_id" => null "created" => "2018-08-03 23:58:54" "last_updated" => "2019-05-28 00:24:10" "deleted" => 1 ] ] "company_crunchbase_info_collection" => [] "company_featured_employees_collection" => [] "company_featured_investors_collection" => [] "company_funding_rounds_collection" => [] "company_locations_collection" => [] "company_similar_collection" => [] "company_specialties_collection" => [ [ "id" => 12359141 "company_id" => 8750222 "specialty" => "Pharmaceutical" "created" => "2016-06-25 12:23:31" "last_updated" => "2019-05-28 00:24:10" "deleted" => 1 ] [ "id" => 12359142 "company_id" => 8750222 "specialty" => "Biopharmaceutical" "created" => "2016-06-25 12:23:31" "last_updated" => "2019-05-28 00:24:10" "deleted" => 1 ] [ "id" => 12359143 "company_id" => 8750222 "specialty" => "Innovation" "created" => "2016-06-25 12:23:31" "last_updated" => "2019-05-28 00:24:10" "deleted" => 1 ] [ "id" => 12359144 "company_id" => 8750222 "specialty" => "Research and development" "created" => "2016-06-25 12:23:31" "last_updated" => "2019-05-28 00:24:10" "deleted" => 1 ] [ "id" => 12359145 "company_id" => 8750222 "specialty" => "Science" "created" => "2016-06-25 12:23:31" "last_updated" => "2019-05-28 00:24:10" "deleted" => 1 ] [ "id" => 12359146 "company_id" => 8750222 "specialty" => "Global business" "created" => "2016-06-25 12:23:31" "last_updated" => "2019-05-28 00:24:10" "deleted" => 1 ] ] "company_stock_info_collection" => [] "company_updates_collection" => [] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4452 …} -companyTags: Doctrine\ORM\PersistentCollection {#4454 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4456 …} -users: Doctrine\ORM\PersistentCollection {#4458 …} -logoImageName: "20250226143728-astrazeneca-logo-svg-67bf19180014c162077901.png" -coverImageName: "20250227161353-5968253-67c0813114690909152396.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4460 …} -tagline: "Wegweisende Innovationen in der Onkologie, Atemwegserkrankungen und Herz-Kreislauf-Gesundheit" -contactEmail: "naveed.khan@astrazeneca.com" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4462 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4464 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4466 …} -industry: "AstraZeneca MEA" -size: "128" -address1: null -address2: null -city: null -postalCode: null -state: null -country: "United Arab Emirates" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4468 …} #createdAt: DateTime @1740045479 {#4450 date: 2025-02-20 09:57:59.0 UTC (+00:00) } #updatedAt: DateTime @1750924509 {#4449 date: 2025-06-26 07:55:09.0 UTC (+00:00) } } App\Entity\Company {#4472 -id: 10 -name: "Azafaros Switzerland AG" -website: "https://azafaros.com" -description: """ Founded in 2018, Azafaros has leveraged on decades of discovery by professors Hans Aerts, Hermen Overkleeft, and Stan van Boeckel at Leiden University and the Academic Medical Center in the Netherlands. Expanding on their research and led by highly experienced industry experts in rare diseases, Azafaros is working on building a pipeline of disease-modifying therapeutics to offer new treatment options to patients and their families.\n \n Our lead clinical-stage program is nizubaglustat, an orally available, brain-penetrant small molecule with a unique dual mode of action which has the potential to treat GM1 and GM2 gangliosidoses, Niemann-Pick disease type C, and other metabolic disorders. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4473 …} -companyTags: Doctrine\ORM\PersistentCollection {#4475 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4477 …} -users: Doctrine\ORM\PersistentCollection {#4479 …} -logoImageName: "20250227161411-azafaros-logo-67c08143c5e57175424562.png" -coverImageName: "20250227161435-favicon-cropped-aza-favicon-1-32x3250-67c0815b9ea5c917491817.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4481 …} -tagline: "Pionier in der Entwicklung von Therapien für seltene Stoffwechselerkrankungen" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4483 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4485 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4487 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4489 …} #createdAt: DateTime @1740045900 {#4429 date: 2025-02-20 10:05:00.0 UTC (+00:00) } #updatedAt: DateTime @1750924527 {#4428 date: 2025-06-26 07:55:27.0 UTC (+00:00) } } App\Entity\Company {#4493 -id: 11 -name: "Bayer Business Services" -website: "https://bayer.com" -description: """ \n Herzlich Willkommen! \n \n Besuchen Sie den digitalen Bayer-Kongressstand. \n \n Hier finden Sie Webinare, Expertenberichte zur Anwendung von Rivaroxaban als auch die digitale Anwendungskarte zum Download auf Ihr Smartphone. \n \n Weitere Informationen zu Xarelto und Xarelto vascular finden Sie auf dem virtuellen Kongressstand von Bayer: \n \n https://www.xarelto.ch/de/congress-hcp-entry/index.php\n \n Bitte beachten Sie, dass sich die Inhalte am virtuellen Stand der Bayer (Schweiz) AG ausschließlich an medizinische Fachpersonen aus der Schweiz richten. """ -externalId: "346012" -details: [ "id" => 346012 "url" => "https://www.linkedin.com/company/bayer-business-services" "hash" => "9fad1363d341c5e49911ca4d7fda777b" "name" => "Bayer Business Services" "website" => "https://www.bayer.com" "size" => "5001-10,000 employees" "industry" => "Information Technology & Services" "description" => """ Business Services serves as Bayer’s global in-house competence center for integrated business solutions and business support processes. Its portfolio comprises the development, implementation and management of IT-based solutions and end-to-end processes as well as in-house management consulting. Business Services devises innovative solutions with a clear user focus and helps shape organizational, technological and operational changes within the Group.\n \n As an integral part of the Group, Business Services supports Bayer along the entire value chain through a network that spans the whole organization. Active in over 80 countries, Business Services has a global presence. Its headquarters are located in Leverkusen, Germany.\n \n Data Privacy Statement & Imprint: https://www.bayer.com/en/glob-li-bayerbs-en-dps-imprint.aspx """ "followers" => null "founded" => 2002 "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://media-exp1.licdn.com/dms/image/C560BAQHkL1ETfrs_JA/company-logo_200_200/0/1564473662699?e=2159024400&v=beta&t=65y-lDla1rCxzfAasbLb7JTMBgdlzKfQ1pfYGE9HUws" "created" => "2016-06-18 07:32:20" "last_updated" => "2025-02-04 01:21:48" "last_response_code" => 404 "type" => "Privately Held" "headquarters_new_address" => "Leverkusen" "employees_count" => 2442 "headquarters_country_restored" => "Germany" "headquarters_country_parsed" => "Germany" "company_shorthand_name" => "bayer-business-services" "company_shorthand_name_hash" => "361442f9c4ed7a7634cb4e380a33b937" "canonical_url" => "https://www.linkedin.com/company/bayer-business-services" "canonical_hash" => "9fad1363d341c5e49911ca4d7fda777b" "canonical_shorthand_name" => "bayer-business-services" "canonical_shorthand_name_hash" => "361442f9c4ed7a7634cb4e380a33b937" "deleted" => 1 "last_updated_ux" => 1738632107 "source_id" => 201503 "company_affiliated_collection" => [ [ "id" => 1434 "company_id" => 346012 "affiliated_company_url" => "https://www.linkedin.com/company/bayer" "affiliated_company_id" => null "created" => "2016-06-18 07:32:20" "last_updated" => "2020-02-28 11:31:48" "deleted" => 1 ] [ "id" => 819015 "company_id" => 346012 "affiliated_company_url" => "https://www.linkedin.com/company/bayer" "affiliated_company_id" => 10152279 "created" => "2020-02-28 11:31:48" "last_updated" => "2020-12-20 02:10:46" "deleted" => 1 ] [ "id" => 4233626 "company_id" => 346012 "affiliated_company_url" => "https://de.linkedin.com/company/bayer" "affiliated_company_id" => 10152279 "created" => "2020-12-20 02:10:46" "last_updated" => "2021-08-25 17:09:12" "deleted" => 1 ] [ "id" => 4796262 "company_id" => 346012 "affiliated_company_url" => "https://de.linkedin.com/company/bayer" "affiliated_company_id" => 10152279 "created" => "2021-09-09 11:14:52" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] ] "company_also_viewed_collection" => [ [ "id" => 1394481 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/bayer" "viewed_company_id" => null "created" => "2016-06-18 07:32:20" "last_updated" => "2019-11-14 08:33:56" "deleted" => 1 ] [ "id" => 1394482 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/michael-page" "viewed_company_id" => null "created" => "2016-06-18 07:32:20" "last_updated" => "2017-01-17 10:18:52" "deleted" => 1 ] [ "id" => 1394483 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/bayer-pharmaceuticals" "viewed_company_id" => null "created" => "2016-06-18 07:32:20" "last_updated" => "2019-11-14 08:33:56" "deleted" => 1 ] [ "id" => 1394484 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/bayer-cropscience" "viewed_company_id" => null "created" => "2016-06-18 07:32:20" "last_updated" => "2019-11-14 08:33:56" "deleted" => 1 ] [ "id" => 1394485 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/roche" "viewed_company_id" => null "created" => "2016-06-18 07:32:20" "last_updated" => "2017-07-28 09:14:30" "deleted" => 1 ] [ "id" => 1394486 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/page-personnel---spain" "viewed_company_id" => null "created" => "2016-06-18 07:32:20" "last_updated" => "2016-12-08 17:37:12" "deleted" => 1 ] [ "id" => 38638259 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/basf" "viewed_company_id" => null "created" => "2016-12-08 17:37:11" "last_updated" => "2017-07-28 09:14:30" "deleted" => 1 ] [ "id" => 71251071 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/novartis" "viewed_company_id" => null "created" => "2017-01-17 10:18:52" "last_updated" => "2017-02-23 07:18:37" "deleted" => 1 ] [ "id" => 85876929 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/nunhems" "viewed_company_id" => null "created" => "2017-02-23 07:18:37" "last_updated" => "2018-08-23 22:34:45" "deleted" => 1 ] [ "id" => 93097476 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/bayer-technology-services" "viewed_company_id" => null "created" => "2017-07-28 09:14:30" "last_updated" => "2018-03-13 05:03:33" "deleted" => 1 ] [ "id" => 93097477 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/pfizer" "viewed_company_id" => null "created" => "2017-07-28 09:14:30" "last_updated" => "2018-07-11 05:36:30" "deleted" => 1 ] [ "id" => 137150785 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/bayer4animals" "viewed_company_id" => null "created" => "2018-03-13 05:03:33" "last_updated" => "2019-11-14 08:33:56" "deleted" => 1 ] [ "id" => 143275832 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/bayer-holding-ltd-" "viewed_company_id" => null "created" => "2018-07-11 05:36:29" "last_updated" => "2018-11-28 21:07:19" "deleted" => 1 ] [ "id" => 155851240 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/basf-vegetable-seeds-business" "viewed_company_id" => null "created" => "2018-08-23 22:34:45" "last_updated" => "2018-11-28 21:07:19" "deleted" => 1 ] [ "id" => 169401613 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/novartis" "viewed_company_id" => null "created" => "2018-11-28 21:07:19" "last_updated" => "2019-08-05 14:56:10" "deleted" => 1 ] [ "id" => 169401614 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/nestle-s-a-" "viewed_company_id" => null "created" => "2018-11-28 21:07:19" "last_updated" => "2019-01-06 15:05:18" "deleted" => 1 ] [ "id" => 183960134 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/pfizer" "viewed_company_id" => null "created" => "2019-01-06 15:05:17" "last_updated" => "2019-03-18 06:34:06" "deleted" => 1 ] [ "id" => 196535069 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/bayer-holding-ltd-" "viewed_company_id" => null "created" => "2019-03-18 06:34:06" "last_updated" => "2019-11-14 08:33:56" "deleted" => 1 ] [ "id" => 259974824 "company_id" => 346012 "viewed_company_url" => "https://www.linkedin.com/company/bayer-technology-services" "viewed_company_id" => null "created" => "2019-08-05 14:56:10" "last_updated" => "2019-11-14 08:33:56" "deleted" => 1 ] ] "company_crunchbase_info_collection" => [] "company_featured_employees_collection" => [ [ "id" => 26693357 "company_id" => 346012 "url" => "https://www.linkedin.com/in/michael-haupt-408a0" "created" => "2019-11-14 08:33:56" "last_updated" => "2020-02-28 11:31:48" "deleted" => 1 ] [ "id" => 26693358 "company_id" => 346012 "url" => "https://www.linkedin.com/in/irenemendelson" "created" => "2019-11-14 08:33:56" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 26693360 "company_id" => 346012 "url" => "https://www.linkedin.com/in/voelker" "created" => "2019-11-14 08:33:56" "last_updated" => "2020-04-25 13:17:46" "deleted" => 1 ] [ "id" => 26693362 "company_id" => 346012 "url" => "https://www.linkedin.com/in/lloydhinnant" "created" => "2019-11-14 08:33:56" "last_updated" => "2020-01-11 03:54:06" "deleted" => 1 ] [ "id" => 30642999 "company_id" => 346012 "url" => "https://www.linkedin.com/in/chad-osborne-548169" "created" => "2020-01-11 03:54:06" "last_updated" => "2020-02-28 11:31:48" "deleted" => 1 ] [ "id" => 38968275 "company_id" => 346012 "url" => "https://www.linkedin.com/in/dione-aquino-537171" "created" => "2020-02-28 11:31:48" "last_updated" => "2020-08-09 02:54:58" "deleted" => 1 ] [ "id" => 38968277 "company_id" => 346012 "url" => "https://www.linkedin.com/in/stephentin" "created" => "2020-02-28 11:31:48" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 43100208 "company_id" => 346012 "url" => "https://www.linkedin.com/in/florenciajacovella" "created" => "2020-04-25 13:17:46" "last_updated" => "2021-09-14 12:32:16" "deleted" => 1 ] [ "id" => 49664603 "company_id" => 346012 "url" => "https://www.linkedin.com/in/m%C3%A1rcio-single-974413" "created" => "2020-08-09 02:54:58" "last_updated" => "2021-03-25 03:55:18" "deleted" => 1 ] [ "id" => 62754791 "company_id" => 346012 "url" => "https://www.linkedin.com/in/marcelo-colonno-pmo" "created" => "2021-03-25 03:55:18" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 72938312 "company_id" => 346012 "url" => "https://www.linkedin.com/in/m%C3%A1rcio-single-974413" "created" => "2021-09-14 12:32:16" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] ] "company_featured_investors_collection" => [] "company_funding_rounds_collection" => [] "company_locations_collection" => [ [ "id" => 11733643 "company_id" => 346012 "location_address" => "Düsseldorfer Straße 600; Leverkusen, DE" "is_primary" => 1 "created" => "2019-11-14 08:33:56" "last_updated" => "2021-08-25 17:09:12" "deleted" => 1 ] [ "id" => 28469381 "company_id" => 346012 "location_address" => "Düsseldorfer Straße 600; Leverkusen, DE" "is_primary" => 1 "created" => "2021-08-26 14:22:38" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] ] "company_similar_collection" => [ [ "id" => 45717505 "company_id" => 346012 "url" => "https://www.linkedin.com/company/bayer" "created" => "2019-11-14 08:33:56" "last_updated" => "2020-12-20 02:10:46" "deleted" => 1 ] [ "id" => 45717507 "company_id" => 346012 "url" => "https://www.linkedin.com/company/bayer-pharmaceuticals" "created" => "2019-11-14 08:33:56" "last_updated" => "2020-12-20 02:10:46" "deleted" => 1 ] [ "id" => 45717508 "company_id" => 346012 "url" => "https://www.linkedin.com/company/bayer-cropscience" "created" => "2019-11-14 08:33:56" "last_updated" => "2020-12-20 02:10:46" "deleted" => 1 ] [ "id" => 45717510 "company_id" => 346012 "url" => "https://www.linkedin.com/company/bayer4animals" "created" => "2019-11-14 08:33:56" "last_updated" => "2020-12-20 02:10:46" "deleted" => 1 ] [ "id" => 45717513 "company_id" => 346012 "url" => "https://www.linkedin.com/company/bayer-holding-ltd-" "created" => "2019-11-14 08:33:56" "last_updated" => "2020-11-08 20:45:58" "deleted" => 1 ] [ "id" => 45717515 "company_id" => 346012 "url" => "https://www.linkedin.com/company/bayer-technology-services" "created" => "2019-11-14 08:33:56" "last_updated" => "2020-08-09 02:54:58" "deleted" => 1 ] [ "id" => 103423519 "company_id" => 346012 "url" => "https://www.linkedin.com/company/roche" "created" => "2020-02-28 11:31:48" "last_updated" => "2020-10-13 17:24:27" "deleted" => 1 ] [ "id" => 103423520 "company_id" => 346012 "url" => "https://www.linkedin.com/company/pfizer" "created" => "2020-02-28 11:31:48" "last_updated" => "2020-05-07 13:51:40" "deleted" => 1 ] [ "id" => 103423522 "company_id" => 346012 "url" => "https://www.linkedin.com/company/bayer-pharmaceuticals-asia-pacific" "created" => "2020-02-28 11:31:48" "last_updated" => "2020-12-20 02:10:46" "deleted" => 1 ] [ "id" => 103423523 "company_id" => 346012 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2020-02-28 11:31:48" "last_updated" => "2020-05-07 13:51:40" "deleted" => 1 ] [ "id" => 144245848 "company_id" => 346012 "url" => "https://www.linkedin.com/company/monsanto" "created" => "2020-05-07 13:51:40" "last_updated" => "2020-06-10 11:48:41" "deleted" => 1 ] [ "id" => 144245849 "company_id" => 346012 "url" => "https://www.linkedin.com/company/novartis" "created" => "2020-05-07 13:51:40" "last_updated" => "2020-06-10 11:48:41" "deleted" => 1 ] [ "id" => 166905217 "company_id" => 346012 "url" => "https://www.linkedin.com/company/bayer-consulting-llc" "created" => "2020-06-10 11:48:41" "last_updated" => "2020-08-09 02:54:58" "deleted" => 1 ] [ "id" => 166905218 "company_id" => 346012 "url" => "https://www.linkedin.com/company/bayer-strategic-consulting" "created" => "2020-06-10 11:48:41" "last_updated" => "2020-07-13 00:00:34" "deleted" => 1 ] [ "id" => 181054070 "company_id" => 346012 "url" => "https://www.linkedin.com/company/bayer-healthcare-diabetes-care" "created" => "2020-07-13 00:00:34" "last_updated" => "2020-12-20 02:10:46" "deleted" => 1 ] [ "id" => 202920634 "company_id" => 346012 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2020-08-09 02:54:58" "last_updated" => "2021-06-19 23:08:51" "deleted" => 1 ] [ "id" => 202920635 "company_id" => 346012 "url" => "https://www.linkedin.com/company/pfizer" "created" => "2020-08-09 02:54:58" "last_updated" => "2020-09-09 15:51:27" "deleted" => 1 ] [ "id" => 222641437 "company_id" => 346012 "url" => "https://www.linkedin.com/company/bayer-consulting-llc" "created" => "2020-09-09 15:51:27" "last_updated" => "2020-09-30 15:01:54" "deleted" => 1 ] [ "id" => 240095707 "company_id" => 346012 "url" => "https://www.linkedin.com/company/pfizer" "created" => "2020-09-30 15:01:54" "last_updated" => "2021-06-19 23:08:51" "deleted" => 1 ] [ "id" => 248865183 "company_id" => 346012 "url" => "https://www.linkedin.com/company/sanofi" "created" => "2020-10-13 17:24:27" "last_updated" => "2020-12-20 02:10:46" "deleted" => 1 ] [ "id" => 264546423 "company_id" => 346012 "url" => "https://www.linkedin.com/company/nova" "created" => "2020-11-08 20:45:58" "last_updated" => "2020-12-20 02:10:46" "deleted" => 1 ] [ "id" => 337557318 "company_id" => 346012 "url" => "https://de.linkedin.com/company/bayer" "created" => "2020-12-20 02:10:46" "last_updated" => "2021-06-19 23:08:51" "deleted" => 1 ] [ "id" => 337557319 "company_id" => 346012 "url" => "https://de.linkedin.com/company/bayer-pharmaceuticals" "created" => "2020-12-20 02:10:46" "last_updated" => "2021-06-19 23:08:51" "deleted" => 1 ] [ "id" => 337557320 "company_id" => 346012 "url" => "https://de.linkedin.com/company/bayer-cropscience" "created" => "2020-12-20 02:10:46" "last_updated" => "2021-06-19 23:08:51" "deleted" => 1 ] [ "id" => 337557321 "company_id" => 346012 "url" => "https://de.linkedin.com/company/bayer4animals" "created" => "2020-12-20 02:10:46" "last_updated" => "2021-06-19 23:08:51" "deleted" => 1 ] [ "id" => 337557322 "company_id" => 346012 "url" => "https://es.linkedin.com/company/nova" "created" => "2020-12-20 02:10:46" "last_updated" => "2021-04-09 00:48:28" "deleted" => 1 ] [ "id" => 337557323 "company_id" => 346012 "url" => "https://sg.linkedin.com/company/bayer-pharmaceuticals-asia-pacific" "created" => "2020-12-20 02:10:46" "last_updated" => "2021-02-03 10:46:38" "deleted" => 1 ] [ "id" => 337557324 "company_id" => 346012 "url" => "https://www.linkedin.com/company/ibm" "created" => "2020-12-20 02:10:46" "last_updated" => "2021-04-09 00:48:28" "deleted" => 1 ] [ "id" => 337557325 "company_id" => 346012 "url" => "https://ie.linkedin.com/company/accenture" "created" => "2020-12-20 02:10:46" "last_updated" => "2021-01-11 04:06:53" "deleted" => 1 ] [ "id" => 352222447 "company_id" => 346012 "url" => "https://fr.linkedin.com/company/sanofi" "created" => "2021-01-11 04:06:53" "last_updated" => "2021-02-03 10:46:38" "deleted" => 1 ] [ "id" => 363522588 "company_id" => 346012 "url" => "https://ch.linkedin.com/company/roche" "created" => "2021-02-03 10:46:38" "last_updated" => "2021-06-19 23:08:51" "deleted" => 1 ] [ "id" => 363522589 "company_id" => 346012 "url" => "https://ch.linkedin.com/company/nestle-s-a-" "created" => "2021-02-03 10:46:38" "last_updated" => "2021-03-15 06:11:54" "deleted" => 1 ] [ "id" => 381539848 "company_id" => 346012 "url" => "https://www.linkedin.com/company/unilever" "created" => "2021-03-15 06:11:54" "last_updated" => "2021-06-19 23:08:51" "deleted" => 1 ] [ "id" => 389823380 "company_id" => 346012 "url" => "https://fr.linkedin.com/company/sanofi" "created" => "2021-04-09 00:48:28" "last_updated" => "2021-06-19 23:08:51" "deleted" => 1 ] [ "id" => 389823381 "company_id" => 346012 "url" => "https://ch.linkedin.com/company/nestle-s-a-" "created" => "2021-04-09 00:48:28" "last_updated" => "2021-06-19 23:08:51" "deleted" => 1 ] [ "id" => 478908864 "company_id" => 346012 "url" => "https://de.linkedin.com/company/bayer" "created" => "2021-09-09 11:14:52" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 478908865 "company_id" => 346012 "url" => "https://de.linkedin.com/showcase/bayer-pharmaceuticals" "created" => "2021-09-09 11:14:52" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 478908866 "company_id" => 346012 "url" => "https://de.linkedin.com/showcase/bayer-cropscience" "created" => "2021-09-09 11:14:52" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 478908867 "company_id" => 346012 "url" => "https://www.linkedin.com/company/pfizer" "created" => "2021-09-09 11:14:52" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 478908868 "company_id" => 346012 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2021-09-09 11:14:52" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 478908869 "company_id" => 346012 "url" => "https://ch.linkedin.com/company/roche" "created" => "2021-09-09 11:14:52" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 478908870 "company_id" => 346012 "url" => "https://fr.linkedin.com/company/sanofi" "created" => "2021-09-09 11:14:52" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 478908871 "company_id" => 346012 "url" => "https://ch.linkedin.com/company/nestle-s-a-" "created" => "2021-09-09 11:14:52" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 478908872 "company_id" => 346012 "url" => "https://de.linkedin.com/company/bayer4animals" "created" => "2021-09-09 11:14:52" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 478908873 "company_id" => 346012 "url" => "https://www.linkedin.com/company/unilever" "created" => "2021-09-09 11:14:52" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] ] "company_specialties_collection" => [ [ "id" => 499220 "company_id" => 346012 "specialty" => "IT Infrastructure and Applications" "created" => "2016-06-18 07:32:20" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 499221 "company_id" => 346012 "specialty" => "Procurement & Trade Services" "created" => "2016-06-18 07:32:20" "last_updated" => "2018-03-13 05:03:33" "deleted" => 1 ] [ "id" => 499222 "company_id" => 346012 "specialty" => "Personnel Services" "created" => "2016-06-18 07:32:20" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 499223 "company_id" => 346012 "specialty" => "Finance and Accounting" "created" => "2016-06-18 07:32:20" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 499224 "company_id" => 346012 "specialty" => "Management Consulting" "created" => "2016-06-18 07:32:20" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 15678739 "company_id" => 346012 "specialty" => "Business Solutions" "created" => "2017-02-23 07:18:37" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 15678740 "company_id" => 346012 "specialty" => "Business Support Processes" "created" => "2017-02-23 07:18:37" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 15678741 "company_id" => 346012 "specialty" => "Digital Innovation" "created" => "2017-02-23 07:18:37" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 18319047 "company_id" => 346012 "specialty" => "Operational Excellence" "created" => "2017-10-11 14:29:13" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 18319048 "company_id" => 346012 "specialty" => "Customer Centricity" "created" => "2017-10-11 14:29:13" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] [ "id" => 20774723 "company_id" => 346012 "specialty" => "Procurement & Trade Services" "created" => "2018-03-13 05:03:33" "last_updated" => "2019-11-14 08:33:56" "deleted" => 1 ] [ "id" => 47050368 "company_id" => 346012 "specialty" => "Procurement & Trade Services" "created" => "2019-11-14 08:33:56" "last_updated" => "2021-10-01 08:29:23" "deleted" => 1 ] ] "company_stock_info_collection" => [] "company_updates_collection" => [] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4494 …} -companyTags: Doctrine\ORM\PersistentCollection {#4496 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4498 …} -users: Doctrine\ORM\PersistentCollection {#4500 …} -logoImageName: "20250227161451-bayer-logo-67c0816bbd0c5699946609.png" -coverImageName: "20250227161452-bayer-favicon-67c0816c23ef0868067543.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4502 …} -tagline: "Innovationen für die Gesundheitsversorgung – Führend in Onkologie, Kardiologie und mehr" -contactEmail: "" -phone: "41" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4504 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4506 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4508 …} -industry: "" -size: "2442" -address1: "" -address2: null -city: "" -postalCode: "" -state: null -country: "Germany" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4510 …} #createdAt: DateTime @1740046221 {#4471 date: 2025-02-20 10:10:21.0 UTC (+00:00) } #updatedAt: DateTime @1750924546 {#4470 date: 2025-06-26 07:55:46.0 UTC (+00:00) } } App\Entity\Company {#4514 -id: 12 -name: "BIAL S.A." -website: "https://bial.ch" -description: """ Das Unternehmen wurde 1924 in Portugal gegründet. \n \n BIALs Mission besteht in der Forschung, Entwicklung und Bereitstellung therapeutischer Lösungen im Gesundheitsbereich. In den letzten Jahrzehnten hat sich BIAL strategisch auf Qualität, Innovation und Internationalisierung fokussiert. BIAL engagiert sich stark für Innovationen in der Therapie und investiert mehr als 20% seines jährlichen Umsatzes in Forschung und Entwicklung im Bereich der Neurowissenschaften und des Herz-Kreislauf-Systems. Das Unternehmen rechnet damit, in den kommenden Jahren neue Medikamente auf den Markt zu bringen, seine internationale Präsenz, die auf patentrechtlich geschützten Medikamenten beruht, zu stärken und so sein Ziel zu erreichen, Patient/innen weltweit mit innovativen Produkten zu versorgen. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4515 …} -companyTags: Doctrine\ORM\PersistentCollection {#4517 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4519 …} -users: Doctrine\ORM\PersistentCollection {#4521 …} -logoImageName: "20250226143803-bial-logo-67bf193b42f10788587206.png" -coverImageName: "20250227161525-bial-favicon-67c0818db38d8915198572.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4523 …} -tagline: "Innovation und Forschung für Neurowissenschaften und Herz-Kreislauf-Gesundheit – Therapeutische Lösungen seit 1924" -contactEmail: "andre.lehnherr@bial.com" -phone: "41" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4525 …} -totalFollowers: 0 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4527 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4529 …} -industry: "" -size: "" -address1: "Rue de la Gare 28" -address2: "" -city: "Nyon" -postalCode: "1260 " -state: "" -country: "" -socialLinkedin: "https://ch.linkedin.com/company/bial" -socialX: "" -socialFacebook: "https://www.facebook.com/BialParkinsons" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4531 …} #createdAt: DateTime @1740046983 {#4513 date: 2025-02-20 10:23:03.0 UTC (+00:00) } #updatedAt: DateTime @1750924562 {#4512 date: 2025-06-26 07:56:02.0 UTC (+00:00) } } App\Entity\Company {#4535 -id: 13 -name: "Biogen Switzerland AG" -website: "https://biogenlinc.ch" -description: """ Biogen wurde 1978 in Genf gegründet und ist ein führendes globales Biotechnologieunternehmen, das zahlreiche banhbrechende Innovationen hervorgebracht hat, darunter ein breites Portfolio von Medikamenten zur Behandlung von Multipler Sklerose sowie die erste zugelassene Behandlung für spinale Muskelatrophie. Biogen ist auch im Bereich Alzheimer-Krankheit tätig und hat eine Pipeline, welche potenziell neuartige Therapien in den Bereichen Neurologie, Neuropsychiatrie, spezialisierte Immunologie und seltene Krankheiten umfasst. Damit konzentriert sich das Unternehmen weiterhin auf sein Ziel, der Menschheit durch Wissenschaftz u dienen und gleichzeitig eine gesündere, nachhaltigere und gerechtere Welt zu fördern.\n \n \n Für weitere Informationen besuchen Sie: www.biogen.ch\n \n Informationen für medizinisches Fachpersonal:: www.biogenlinc.ch. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4536 …} -companyTags: Doctrine\ORM\PersistentCollection {#4538 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4540 …} -users: Doctrine\ORM\PersistentCollection {#4542 …} -logoImageName: "20250226143823-biogen-logo-67bf194f83b95767221710.png" -coverImageName: "20250227161601-biib-c54e2f33-67c081b14d4fc579826355.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4544 …} -tagline: "Wegweisende Biotechnologie-Innovationen in der Neurologie – Pioniere in MS, SMA und Alzheimer" -contactEmail: "sibylle.gotz@biogen.com" -phone: "41791288358" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4546 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4548 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4550 …} -industry: "" -size: "" -address1: "Neuhofstrasse 30" -address2: "" -city: "Baar" -postalCode: "6340" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4552 …} #createdAt: DateTime @1740047380 {#4492 date: 2025-02-20 10:29:40.0 UTC (+00:00) } #updatedAt: DateTime @1760006932 {#4491 date: 2025-10-09 10:48:52.0 UTC (+00:00) } } App\Entity\Company {#4556 -id: 14 -name: "Bioprojekt Pharma SAS" -website: "https://bioprojet.com" -description: "" -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4557 …} -companyTags: Doctrine\ORM\PersistentCollection {#4559 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4561 …} -users: Doctrine\ORM\PersistentCollection {#4563 …} -logoImageName: "20250227161644-bioprojet-logo-67c081dcb2036649204898.jpg" -coverImageName: "20250227161645-bioprojet-pharma-logo-67c081dd2029d489964499.jpeg" -companyProducts: Doctrine\ORM\PersistentCollection {#4565 …} -tagline: "Innovationen in der pharmazeutischen Forschung für seltene Erkrankungen und neuartige Therapien" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4567 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4569 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4571 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4573 …} #createdAt: DateTime @1740047572 {#4534 date: 2025-02-20 10:32:52.0 UTC (+00:00) } #updatedAt: DateTime @1750924599 {#4533 date: 2025-06-26 07:56:39.0 UTC (+00:00) } } App\Entity\Company {#4577 -id: 15 -name: "Biotest Farmaceutica Ltda." -website: "https://biotest.com" -description: "Biotest ist ein weltweit tätiger Spezialist für Klinische Immunologie, Intensiv- und Notfallmedizin sowie Hämophilie mit über 70-jähriger Erfahrung. Biotest stellt Präparate her, die mit Hilfe modernster biotechnischer Verfahren aus humanem Blutplasma gewonnen werden. Unsere Produkte retten Leben und geben chronisch Kranken neue Perspektiven. Qualität, Anwendernutzen, Verlässlichkeit und Sicherheit stehen bei uns an erster Stelle. Patienten, Kliniken, Praxen, Labors und Unternehmen in über 80 Länder der Erde vertrauen auf Qualität und Zuverlässigkeit von Biotest." -externalId: "476402" -details: [ "id" => 476402 "url" => "https://www.linkedin.com/company/biotest-farmaceutica-ltda-" "hash" => "7bdef2e2417453ede5fd0d43e5ab5171" "name" => "Biotest Farmaceutica Ltda." "website" => "http://www.biotest.com/" "size" => "2-10 employees" "industry" => "Pharmaceutical Manufacturing" "description" => "Biotest is a global company that supplies plasma protein products and biotherapeutic drugs. Our products are primarily used in the therapeutic areas of clinical immunology, haematology and intensive care medicine." "followers" => 66 "founded" => null "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://static.licdn.com/aero-v1/sc/h/cs8pjfgyw96g44ln9r7tct85f" "created" => "2016-06-18 13:53:52" "last_updated" => "2025-02-16 13:38:41" "last_response_code" => 200 "type" => null "headquarters_new_address" => "Valinhos, Sp" "employees_count" => 2 "headquarters_country_restored" => "Brazil" "headquarters_country_parsed" => "Brazil" "company_shorthand_name" => "biotest-farmaceutica-ltda-" "company_shorthand_name_hash" => "4474759c66c5bedfa76c684f53b49232" "canonical_url" => "https://br.linkedin.com/company/biotest-farmaceutica-ltda-" "canonical_hash" => "8a00d370fde7f38c21f15ea4a7e95f1b" "canonical_shorthand_name" => "biotest-farmaceutica-ltda-" "canonical_shorthand_name_hash" => "4474759c66c5bedfa76c684f53b49232" "deleted" => 0 "last_updated_ux" => 1739713120 "source_id" => 6553317 "company_affiliated_collection" => [] "company_also_viewed_collection" => [ [ "id" => 1920489 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/pharma-nord" "viewed_company_id" => null "created" => "2016-06-18 13:53:52" "last_updated" => "2016-12-14 08:10:33" "deleted" => 1 ] [ "id" => 1920490 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/octapharma-plasma-inc." "viewed_company_id" => null "created" => "2016-06-18 13:53:52" "last_updated" => "2016-12-14 08:10:33" "deleted" => 1 ] [ "id" => 1920491 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/biotest-ag" "viewed_company_id" => null "created" => "2016-06-18 13:53:52" "last_updated" => "2016-12-14 08:10:33" "deleted" => 1 ] [ "id" => 1920492 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/octapharma" "viewed_company_id" => null "created" => "2016-06-18 13:53:52" "last_updated" => "2016-12-14 08:10:33" "deleted" => 1 ] [ "id" => 1920493 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/chylos-therapeutics-inc-" "viewed_company_id" => null "created" => "2016-06-18 13:53:52" "last_updated" => "2016-12-14 08:10:33" "deleted" => 1 ] [ "id" => 1920494 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/house-of-diagnosis" "viewed_company_id" => null "created" => "2016-06-18 13:53:52" "last_updated" => "2016-12-14 08:10:33" "deleted" => 1 ] [ "id" => 52266604 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/blausiegel" "viewed_company_id" => null "created" => "2016-12-14 08:10:32" "last_updated" => "2017-08-11 20:23:32" "deleted" => 1 ] [ "id" => 52266605 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/althaia-s-a-industria-farmaceutica" "viewed_company_id" => null "created" => "2016-12-14 08:10:32" "last_updated" => "2017-08-11 20:23:32" "deleted" => 1 ] [ "id" => 52266606 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/biosintetica-farmaceutica" "viewed_company_id" => null "created" => "2016-12-14 08:10:32" "last_updated" => "2017-08-11 20:23:32" "deleted" => 1 ] [ "id" => 52266607 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/besins-healthcare" "viewed_company_id" => null "created" => "2016-12-14 08:10:32" "last_updated" => "2017-08-11 20:23:32" "deleted" => 1 ] [ "id" => 52266608 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/bioagri" "viewed_company_id" => null "created" => "2016-12-14 08:10:32" "last_updated" => "2017-02-03 23:48:37" "deleted" => 1 ] [ "id" => 52266609 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/arese-pharma" "viewed_company_id" => null "created" => "2016-12-14 08:10:32" "last_updated" => "2017-02-03 23:48:37" "deleted" => 1 ] [ "id" => 78559913 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/biotest-ag" "viewed_company_id" => null "created" => "2017-02-03 23:48:37" "last_updated" => "2018-03-13 09:52:34" "deleted" => 1 ] [ "id" => 78559914 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/biotest-pharmaceuticals-corporation" "viewed_company_id" => null "created" => "2017-02-03 23:48:37" "last_updated" => "2018-03-13 09:52:34" "deleted" => 1 ] [ "id" => 101313213 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/biotest" "viewed_company_id" => null "created" => "2017-08-11 20:23:32" "last_updated" => "2018-03-13 09:52:34" "deleted" => 1 ] [ "id" => 101313214 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/csl-behring" "viewed_company_id" => null "created" => "2017-08-11 20:23:32" "last_updated" => "2018-03-13 09:52:34" "deleted" => 1 ] [ "id" => 101313215 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/biotest-microbiology-corporation" "viewed_company_id" => null "created" => "2017-08-11 20:23:32" "last_updated" => "2018-03-13 09:52:34" "deleted" => 1 ] [ "id" => 101313216 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/biotest-italia" "viewed_company_id" => null "created" => "2017-08-11 20:23:32" "last_updated" => "2018-03-13 09:52:34" "deleted" => 1 ] [ "id" => 139061288 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/tks-farmaceutica" "viewed_company_id" => null "created" => "2018-03-13 09:52:34" "last_updated" => "2018-09-01 15:29:45" "deleted" => 1 ] [ "id" => 139061290 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/gerbras-qu-mica-farmac-utica-ltda" "viewed_company_id" => null "created" => "2018-03-13 09:52:34" "last_updated" => "2018-11-29 07:57:28" "deleted" => 1 ] [ "id" => 139061291 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/pic-quimica-ltda" "viewed_company_id" => null "created" => "2018-03-13 09:52:34" "last_updated" => "2018-09-01 15:29:45" "deleted" => 1 ] [ "id" => 139061292 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/segmenta-farmac-utica-ltda" "viewed_company_id" => null "created" => "2018-03-13 09:52:34" "last_updated" => "2018-09-01 15:29:45" "deleted" => 1 ] [ "id" => 139061293 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/valeant-farmac%C3%AAutica-do-brasil" "viewed_company_id" => null "created" => "2018-03-13 09:52:34" "last_updated" => "2018-09-01 15:29:45" "deleted" => 1 ] [ "id" => 139061294 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/ativus-farmac-utica" "viewed_company_id" => null "created" => "2018-03-13 09:52:34" "last_updated" => "2018-09-01 15:29:45" "deleted" => 1 ] [ "id" => 157298143 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/torrent-do-brasil" "viewed_company_id" => null "created" => "2018-09-01 15:29:44" "last_updated" => "2019-01-02 00:28:16" "deleted" => 1 ] [ "id" => 157298144 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/supera-farma" "viewed_company_id" => null "created" => "2018-09-01 15:29:44" "last_updated" => "2019-01-02 00:28:16" "deleted" => 1 ] [ "id" => 157298145 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/laboris-farmac-utica-ltda" "viewed_company_id" => null "created" => "2018-09-01 15:29:44" "last_updated" => "2018-11-29 07:57:28" "deleted" => 1 ] [ "id" => 157298146 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/ambio-farmac%C3%AAutica" "viewed_company_id" => null "created" => "2018-09-01 15:29:44" "last_updated" => "2018-11-29 07:57:28" "deleted" => 1 ] [ "id" => 157298147 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/qu-mica-farmac-utica-gaspar-viana-s-a" "viewed_company_id" => null "created" => "2018-09-01 15:29:44" "last_updated" => "2018-11-29 07:57:28" "deleted" => 1 ] [ "id" => 169529261 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/grupocimed" "viewed_company_id" => null "created" => "2018-11-29 07:57:28" "last_updated" => "2019-04-03 06:00:49" "deleted" => 1 ] [ "id" => 169529263 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/hypera" "viewed_company_id" => null "created" => "2018-11-29 07:57:28" "last_updated" => "2019-04-03 06:00:49" "deleted" => 1 ] [ "id" => 169529265 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/cifarma-cientifica-farmaceutica" "viewed_company_id" => null "created" => "2018-11-29 07:57:28" "last_updated" => "2019-04-03 06:00:49" "deleted" => 1 ] [ "id" => 169529267 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/grupo-panpharma" "viewed_company_id" => null "created" => "2018-11-29 07:57:28" "last_updated" => "2019-04-03 06:00:49" "deleted" => 1 ] [ "id" => 181257137 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/apsen" "viewed_company_id" => null "created" => "2019-01-02 00:28:15" "last_updated" => "2019-05-30 08:06:13" "deleted" => 1 ] [ "id" => 181257139 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/laboratorio-neo-quimica" "viewed_company_id" => null "created" => "2019-01-02 00:28:15" "last_updated" => "2019-04-03 06:00:49" "deleted" => 1 ] [ "id" => 199918742 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/biotest-pharmaceuticals-corporation" "viewed_company_id" => null "created" => "2019-04-03 06:00:49" "last_updated" => "2019-05-30 08:06:13" "deleted" => 1 ] [ "id" => 199918743 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/distribuidora-farmaceutica-leridana-s-a-" "viewed_company_id" => null "created" => "2019-04-03 06:00:49" "last_updated" => "2019-05-30 08:06:13" "deleted" => 1 ] [ "id" => 199918744 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/nova-qu-mica-farmac-utica" "viewed_company_id" => null "created" => "2019-04-03 06:00:49" "last_updated" => "2019-05-30 08:06:13" "deleted" => 1 ] [ "id" => 199918745 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/cifarma-cient%C3%ADfica-farmac%C3%AAutica-ltda." "viewed_company_id" => null "created" => "2019-04-03 06:00:49" "last_updated" => "2019-05-30 08:06:13" "deleted" => 1 ] [ "id" => 199918746 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/blausiegel" "viewed_company_id" => null "created" => "2019-04-03 06:00:49" "last_updated" => "2019-05-30 08:06:13" "deleted" => 1 ] [ "id" => 229499667 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/stendhal-pharma" "viewed_company_id" => null "created" => "2019-05-30 08:06:13" "last_updated" => "2019-07-31 18:55:02" "deleted" => 1 ] [ "id" => 229499668 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/laboratorio-atlas-farmaceutica" "viewed_company_id" => null "created" => "2019-05-30 08:06:13" "last_updated" => "2019-06-04 23:38:55" "deleted" => 1 ] [ "id" => 229499669 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/msd-farmaceutica-c-a-" "viewed_company_id" => null "created" => "2019-05-30 08:06:13" "last_updated" => "2019-07-31 18:55:02" "deleted" => 1 ] [ "id" => 229499670 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/tecmol-farmaceutica-s-a-s" "viewed_company_id" => null "created" => "2019-05-30 08:06:13" "last_updated" => "2019-10-08 15:18:01" "deleted" => 1 ] [ "id" => 229499672 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/cellerafarma" "viewed_company_id" => null "created" => "2019-05-30 08:06:13" "last_updated" => "2019-06-04 23:38:55" "deleted" => 1 ] [ "id" => 229499673 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/comsa-cleanroom-technology" "viewed_company_id" => null "created" => "2019-05-30 08:06:13" "last_updated" => "2019-06-04 23:38:55" "deleted" => 1 ] [ "id" => 233166671 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/tks-farmaceutica" "viewed_company_id" => null "created" => "2019-06-04 23:38:55" "last_updated" => "2019-07-31 18:55:02" "deleted" => 1 ] [ "id" => 233166672 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/sofar-s.p.a." "viewed_company_id" => null "created" => "2019-06-04 23:38:55" "last_updated" => "2019-07-31 18:55:02" "deleted" => 1 ] [ "id" => 233166673 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/generis-farmaceutica-sa" "viewed_company_id" => null "created" => "2019-06-04 23:38:55" "last_updated" => "2019-08-31 03:33:43" "deleted" => 1 ] [ "id" => 251329728 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/takeda-farmaceutica-espana" "viewed_company_id" => null "created" => "2019-07-31 18:55:02" "last_updated" => "2019-08-31 03:33:43" "deleted" => 1 ] [ "id" => 251329730 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/cellerafarma" "viewed_company_id" => null "created" => "2019-07-31 18:55:02" "last_updated" => "2019-10-08 15:18:01" "deleted" => 1 ] [ "id" => 251329732 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/ems" "viewed_company_id" => null "created" => "2019-07-31 18:55:02" "last_updated" => "2019-10-08 15:18:01" "deleted" => 1 ] [ "id" => 251329734 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/nortis-farmaceutica" "viewed_company_id" => null "created" => "2019-07-31 18:55:02" "last_updated" => "2019-08-31 03:33:43" "deleted" => 1 ] [ "id" => 273600277 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/farmabrasilfarmaceutica" "viewed_company_id" => null "created" => "2019-08-31 03:33:43" "last_updated" => "2019-10-08 15:18:01" "deleted" => 1 ] [ "id" => 273600281 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/vidora-farmac%C3%AAutica-ltda-" "viewed_company_id" => null "created" => "2019-08-31 03:33:43" "last_updated" => "2019-10-08 15:18:01" "deleted" => 1 ] [ "id" => 273600295 "company_id" => 476402 "viewed_company_url" => "https://www.linkedin.com/company/zeta-farmac%C3%AAutica" "viewed_company_id" => null "created" => "2019-08-31 03:33:43" "last_updated" => "2019-10-08 15:18:01" "deleted" => 1 ] [ "id" => 295861227 "company_id" => 476402 "viewed_company_url" => "https://zw.linkedin.com/company/farmabrasilfarmaceutica" "viewed_company_id" => null "created" => "2019-10-08 15:18:01" "last_updated" => "2019-11-14 12:44:16" "deleted" => 1 ] [ "id" => 295861232 "company_id" => 476402 "viewed_company_url" => "https://zw.linkedin.com/company/tecmol-farmaceutica-s-a-s" "viewed_company_id" => null "created" => "2019-10-08 15:18:01" "last_updated" => "2019-11-14 12:44:16" "deleted" => 1 ] [ "id" => 295861237 "company_id" => 476402 "viewed_company_url" => "https://zw.linkedin.com/company/cellerafarma" "viewed_company_id" => null "created" => "2019-10-08 15:18:01" "last_updated" => "2019-11-14 12:44:16" "deleted" => 1 ] [ "id" => 295861240 "company_id" => 476402 "viewed_company_url" => "https://zw.linkedin.com/company/vidora-farmac%C3%AAutica-ltda-" "viewed_company_id" => null "created" => "2019-10-08 15:18:01" "last_updated" => "2019-11-14 12:44:16" "deleted" => 1 ] [ "id" => 295861242 "company_id" => 476402 "viewed_company_url" => "https://zw.linkedin.com/company/zeta-farmac%C3%AAutica" "viewed_company_id" => null "created" => "2019-10-08 15:18:01" "last_updated" => "2019-11-14 12:44:16" "deleted" => 1 ] [ "id" => 295861245 "company_id" => 476402 "viewed_company_url" => "https://zw.linkedin.com/company/ems" "viewed_company_id" => null "created" => "2019-10-08 15:18:01" "last_updated" => "2019-11-14 12:44:16" "deleted" => 1 ] ] "company_crunchbase_info_collection" => [] "company_featured_employees_collection" => [ [ "id" => 26850840 "company_id" => 476402 "url" => "https://www.linkedin.com/in/danilo-kabata-9b37051b" "created" => "2019-11-14 12:44:16" "last_updated" => "2020-02-22 22:03:49" "deleted" => 1 ] [ "id" => 26850841 "company_id" => 476402 "url" => "https://www.linkedin.com/in/leide-antunes-de-oliveira-07b4606b" "created" => "2019-11-14 12:44:16" "last_updated" => "2020-02-22 22:03:49" "deleted" => 1 ] [ "id" => 26850842 "company_id" => 476402 "url" => "https://www.linkedin.com/in/leide-antunes-de-oliveira-b3b7276b" "created" => "2019-11-14 12:44:16" "last_updated" => "2020-02-22 22:03:49" "deleted" => 1 ] [ "id" => 26850843 "company_id" => 476402 "url" => "https://www.linkedin.com/in/roberto-xavier-leme-leme-53038971" "created" => "2019-11-14 12:44:16" "last_updated" => "2020-02-22 22:03:49" "deleted" => 1 ] [ "id" => 47449321 "company_id" => 476402 "url" => "https://www.linkedin.com/in/nat%C3%A1lia-almeida-792998176" "created" => "2020-07-22 10:12:58" "last_updated" => "2020-08-26 00:51:53" "deleted" => 1 ] [ "id" => 52954695 "company_id" => 476402 "url" => "https://www.linkedin.com/in/nat%C3%A1lia-r-almeida" "created" => "2020-08-26 00:51:53" "last_updated" => "2022-06-24 01:34:11" "deleted" => 1 ] [ "id" => 79344429 "company_id" => 476402 "url" => "https://www.linkedin.com/in/caroline-genova-3ba06a226" "created" => "2021-11-20 18:02:23" "last_updated" => "2022-06-24 01:34:11" "deleted" => 1 ] [ "id" => 107424180 "company_id" => 476402 "url" => "https://br.linkedin.com/in/nat%C3%A1lia-r-almeida/en" "created" => "2022-07-22 07:44:59" "last_updated" => "2023-06-17 00:55:07" "deleted" => 1 ] [ "id" => 107424181 "company_id" => 476402 "url" => "https://br.linkedin.com/in/caroline-genova-3ba06a226/en" "created" => "2022-07-22 07:44:59" "last_updated" => "2023-06-17 00:55:07" "deleted" => 1 ] [ "id" => 173687396 "company_id" => 476402 "url" => "https://br.linkedin.com/in/nat%C3%A1lia-r-almeida" "created" => "2023-06-17 00:55:07" "last_updated" => "2024-04-01 00:52:23" "deleted" => 1 ] [ "id" => 173687397 "company_id" => 476402 "url" => "https://br.linkedin.com/in/caroline-genova-3ba06a226" "created" => "2023-06-17 00:55:07" "last_updated" => "2025-02-16 13:38:40" "deleted" => 0 ] ] "company_featured_investors_collection" => [] "company_funding_rounds_collection" => [] "company_locations_collection" => [ [ "id" => 11798183 "company_id" => 476402 "location_address" => "Valinhos, Sp 13271-570, BR" "is_primary" => 0 "created" => "2019-11-14 12:44:16" "last_updated" => "2022-06-24 01:34:11" "deleted" => 1 ] [ "id" => 83348560 "company_id" => 476402 "location_address" => "Valinhos, Sp 13271-570, BR" "is_primary" => 0 "created" => "2022-07-22 07:44:59" "last_updated" => "2025-02-16 13:38:40" "deleted" => 0 ] ] "company_similar_collection" => [ [ "id" => 45932230 "company_id" => 476402 "url" => "https://www.linkedin.com/company/farmabrasilfarmaceutica" "created" => "2019-11-14 12:44:16" "last_updated" => "2020-07-22 10:12:58" "deleted" => 1 ] [ "id" => 45932231 "company_id" => 476402 "url" => "https://www.linkedin.com/company/tecmol-farmaceutica-s-a-s" "created" => "2019-11-14 12:44:16" "last_updated" => "2020-05-07 17:56:21" "deleted" => 1 ] [ "id" => 45932232 "company_id" => 476402 "url" => "https://www.linkedin.com/company/vidora-farmac%C3%AAutica-ltda-" "created" => "2019-11-14 12:44:16" "last_updated" => "2020-07-22 10:12:58" "deleted" => 1 ] [ "id" => 45932233 "company_id" => 476402 "url" => "https://www.linkedin.com/company/cellerafarma" "created" => "2019-11-14 12:44:16" "last_updated" => "2020-05-07 17:56:21" "deleted" => 1 ] [ "id" => 45932234 "company_id" => 476402 "url" => "https://www.linkedin.com/company/zeta-farmac%C3%AAutica" "created" => "2019-11-14 12:44:16" "last_updated" => "2020-07-22 10:12:58" "deleted" => 1 ] [ "id" => 45932235 "company_id" => 476402 "url" => "https://www.linkedin.com/company/ems" "created" => "2019-11-14 12:44:16" "last_updated" => "2020-06-12 11:07:30" "deleted" => 1 ] [ "id" => 98558197 "company_id" => 476402 "url" => "https://www.linkedin.com/company/angelinipharmaespana" "created" => "2020-02-22 22:03:49" "last_updated" => "2020-05-07 17:56:21" "deleted" => 1 ] [ "id" => 98558198 "company_id" => 476402 "url" => "https://www.linkedin.com/company/multilab---ind--e-com--de-prod--farmac-uticos" "created" => "2020-02-22 22:03:49" "last_updated" => "2020-05-07 17:56:21" "deleted" => 1 ] [ "id" => 98558199 "company_id" => 476402 "url" => "https://www.linkedin.com/company/grupo-natulab" "created" => "2020-02-22 22:03:49" "last_updated" => "2020-05-07 17:56:21" "deleted" => 1 ] [ "id" => 98558200 "company_id" => 476402 "url" => "https://www.linkedin.com/company/grupo-alter" "created" => "2020-02-22 22:03:49" "last_updated" => "2020-05-07 17:56:21" "deleted" => 1 ] [ "id" => 144321927 "company_id" => 476402 "url" => "https://www.linkedin.com/company/sdsb-farmac%C3%AAutica" "created" => "2020-05-07 17:56:21" "last_updated" => "2020-07-22 10:12:58" "deleted" => 1 ] [ "id" => 144321928 "company_id" => 476402 "url" => "https://www.linkedin.com/company/ranbaxy-farmaceutica-ltda" "created" => "2020-05-07 17:56:21" "last_updated" => "2020-07-22 10:12:58" "deleted" => 1 ] [ "id" => 144321929 "company_id" => 476402 "url" => "https://www.linkedin.com/company/globo-farmaceutica" "created" => "2020-05-07 17:56:21" "last_updated" => "2020-07-22 10:12:58" "deleted" => 1 ] [ "id" => 144321930 "company_id" => 476402 "url" => "https://www.linkedin.com/company/kressfarmaceutica-sa" "created" => "2020-05-07 17:56:21" "last_updated" => "2020-07-22 10:12:58" "deleted" => 1 ] [ "id" => 144321931 "company_id" => 476402 "url" => "https://www.linkedin.com/company/chiesi-group" "created" => "2020-05-07 17:56:21" "last_updated" => "2020-06-12 11:07:30" "deleted" => 1 ] [ "id" => 144321932 "company_id" => 476402 "url" => "https://www.linkedin.com/company/sanofi-aventis-farmaceutica" "created" => "2020-05-07 17:56:21" "last_updated" => "2020-07-22 10:12:58" "deleted" => 1 ] [ "id" => 168517253 "company_id" => 476402 "url" => "https://www.linkedin.com/company/biotest-ag" "created" => "2020-06-12 11:07:30" "last_updated" => "2020-11-13 03:13:01" "deleted" => 1 ] [ "id" => 168517254 "company_id" => 476402 "url" => "https://www.linkedin.com/company/biotest-pharmaceuticals-corporation" "created" => "2020-06-12 11:07:30" "last_updated" => "2020-08-26 00:51:53" "deleted" => 1 ] [ "id" => 271505789 "company_id" => 476402 "url" => "https://de.linkedin.com/company/biotest-ag" "created" => "2020-11-13 03:13:01" "last_updated" => "2021-06-20 17:28:05" "deleted" => 1 ] [ "id" => 443644589 "company_id" => 476402 "url" => "https://de.linkedin.com/company/biotest-ag" "created" => "2021-08-31 01:06:06" "last_updated" => "2022-03-04 18:58:37" "deleted" => 1 ] [ "id" => 576288118 "company_id" => 476402 "url" => "https://br.linkedin.com/company/consulfarma" "created" => "2022-03-04 18:58:37" "last_updated" => "2022-06-24 01:34:11" "deleted" => 1 ] [ "id" => 576288119 "company_id" => 476402 "url" => "https://br.linkedin.com/company/grow-quimica-e-farmaceutica" "created" => "2022-03-04 18:58:37" "last_updated" => "2022-06-24 01:34:11" "deleted" => 1 ] [ "id" => 576288120 "company_id" => 476402 "url" => "https://br.linkedin.com/company/bionovis-s.a.---companhia-brasileira-de-biotecnologia-farmaceutica" "created" => "2022-03-04 18:58:37" "last_updated" => "2022-06-24 01:34:11" "deleted" => 1 ] [ "id" => 576288121 "company_id" => 476402 "url" => "https://br.linkedin.com/company/rhobifarma-industria-farmaceutica" "created" => "2022-03-04 18:58:37" "last_updated" => "2022-06-24 01:34:11" "deleted" => 1 ] [ "id" => 576288122 "company_id" => 476402 "url" => "https://br.linkedin.com/company/nova-qu-mica-farmac-utica" "created" => "2022-03-04 18:58:37" "last_updated" => "2022-06-24 01:34:11" "deleted" => 1 ] [ "id" => 576288123 "company_id" => 476402 "url" => "https://br.linkedin.com/company/relthy-labs" "created" => "2022-03-04 18:58:37" "last_updated" => "2022-06-24 01:34:11" "deleted" => 1 ] [ "id" => 576288124 "company_id" => 476402 "url" => "https://br.linkedin.com/company/zay-servi%C3%A7os-de-an%C3%A1lises-qu%C3%ADmicas" "created" => "2022-03-04 18:58:37" "last_updated" => "2022-06-24 01:34:11" "deleted" => 1 ] [ "id" => 576288125 "company_id" => 476402 "url" => "https://br.linkedin.com/company/caeplab" "created" => "2022-03-04 18:58:37" "last_updated" => "2022-06-24 01:34:11" "deleted" => 1 ] [ "id" => 576288126 "company_id" => 476402 "url" => "https://br.linkedin.com/company/abl-antibioticosdobrasil" "created" => "2022-03-04 18:58:37" "last_updated" => "2022-06-24 01:34:11" "deleted" => 1 ] [ "id" => 576288127 "company_id" => 476402 "url" => "https://br.linkedin.com/company/trb-pharma" "created" => "2022-03-04 18:58:37" "last_updated" => "2022-06-24 01:34:11" "deleted" => 1 ] [ "id" => 677260552 "company_id" => 476402 "url" => "https://br.linkedin.com/company/consulfarma" "created" => "2022-07-22 07:44:59" "last_updated" => "2023-02-07 04:48:40" "deleted" => 1 ] [ "id" => 677260553 "company_id" => 476402 "url" => "https://br.linkedin.com/company/bionovis-s.a.---companhia-brasileira-de-biotecnologia-farmaceutica" "created" => "2022-07-22 07:44:59" "last_updated" => "2023-06-17 00:55:07" "deleted" => 1 ] [ "id" => 677260554 "company_id" => 476402 "url" => "https://br.linkedin.com/company/rhobifarma-industria-farmaceutica" "created" => "2022-07-22 07:44:59" "last_updated" => "2023-07-09 06:00:36" "deleted" => 1 ] [ "id" => 677260555 "company_id" => 476402 "url" => "https://br.linkedin.com/company/quantica-anal-tica-representa-es-comercias-ltda." "created" => "2022-07-22 07:44:59" "last_updated" => "2022-11-16 08:07:16" "deleted" => 1 ] [ "id" => 677260556 "company_id" => 476402 "url" => "https://br.linkedin.com/company/caeplab" "created" => "2022-07-22 07:44:59" "last_updated" => "2022-11-16 08:07:16" "deleted" => 1 ] [ "id" => 677260557 "company_id" => 476402 "url" => "https://br.linkedin.com/company/zay-servi%C3%A7os-de-an%C3%A1lises-qu%C3%ADmicas" "created" => "2022-07-22 07:44:59" "last_updated" => "2022-11-16 08:07:16" "deleted" => 1 ] [ "id" => 677260558 "company_id" => 476402 "url" => "https://br.linkedin.com/company/trb-pharma" "created" => "2022-07-22 07:44:59" "last_updated" => "2022-11-16 08:07:16" "deleted" => 1 ] [ "id" => 677260559 "company_id" => 476402 "url" => "https://br.linkedin.com/company/grow-quimica-e-farmaceutica" "created" => "2022-07-22 07:44:59" "last_updated" => "2022-09-17 17:33:29" "deleted" => 1 ] [ "id" => 677260560 "company_id" => 476402 "url" => "https://br.linkedin.com/company/synvia" "created" => "2022-07-22 07:44:59" "last_updated" => "2022-11-16 08:07:16" "deleted" => 1 ] [ "id" => 677260561 "company_id" => 476402 "url" => "https://br.linkedin.com/company/althaia-s-a-industria-farmaceutica" "created" => "2022-07-22 07:44:59" "last_updated" => "2023-03-04 19:45:57" "deleted" => 1 ] [ "id" => 711080228 "company_id" => 476402 "url" => "https://br.linkedin.com/company/sanvetanimalhealth" "created" => "2022-09-17 17:33:29" "last_updated" => "2022-11-16 08:07:16" "deleted" => 1 ] [ "id" => 736432162 "company_id" => 476402 "url" => "https://br.linkedin.com/company/ecc-controle-e-certifica%C3%A7%C3%A3o-de-ambientes" "created" => "2022-11-16 08:07:16" "last_updated" => "2023-07-09 06:00:36" "deleted" => 1 ] [ "id" => 736432163 "company_id" => 476402 "url" => "https://fr.linkedin.com/company/biotestfrance" "created" => "2022-11-16 08:07:16" "last_updated" => "2023-08-11 16:57:21" "deleted" => 1 ] [ "id" => 736432164 "company_id" => 476402 "url" => "https://br.linkedin.com/company/ami-automa%C3%A7%C3%A3o-e-manuten%C3%A7%C3%A3o-ind-ltda" "created" => "2022-11-16 08:07:16" "last_updated" => "2023-07-09 06:00:36" "deleted" => 1 ] [ "id" => 736432165 "company_id" => 476402 "url" => "https://br.linkedin.com/company/unica-medical" "created" => "2022-11-16 08:07:16" "last_updated" => "2023-07-09 06:00:36" "deleted" => 1 ] [ "id" => 736432166 "company_id" => 476402 "url" => "https://br.linkedin.com/company/abefarma-associacao-brasileira-de-educacao-farmaceutica-nutraceutica-e-cosmeticos" "created" => "2022-11-16 08:07:16" "last_updated" => "2023-07-09 06:00:36" "deleted" => 1 ] [ "id" => 736432167 "company_id" => 476402 "url" => "https://br.linkedin.com/company/nobel-do-brasil" "created" => "2022-11-16 08:07:16" "last_updated" => "2023-03-04 19:45:57" "deleted" => 1 ] [ "id" => 769359978 "company_id" => 476402 "url" => "https://br.linkedin.com/company/biocen-do-brasil" "created" => "2023-02-07 04:48:40" "last_updated" => "2023-07-09 06:00:36" "deleted" => 1 ] [ "id" => 787085283 "company_id" => 476402 "url" => "https://br.linkedin.com/company/consulfarma" "created" => "2023-03-04 19:45:57" "last_updated" => "2023-07-09 06:00:36" "deleted" => 1 ] [ "id" => 787085284 "company_id" => 476402 "url" => "https://br.linkedin.com/company/quantica-anal-tica-representa-es-comercias-ltda." "created" => "2023-03-04 19:45:57" "last_updated" => "2023-07-09 06:00:36" "deleted" => 1 ] [ "id" => 837346158 "company_id" => 476402 "url" => "https://www.linkedin.com/company/bionovis-s.a.---companhia-brasileira-de-biotecnologia-farmaceutica" "created" => "2023-06-17 00:55:07" "last_updated" => "2023-07-09 06:00:36" "deleted" => 1 ] [ "id" => 847597779 "company_id" => 476402 "url" => "https://br.linkedin.com/company/fresenius-kabi-br" "created" => "2023-07-09 06:00:36" "last_updated" => "2023-08-11 16:57:21" "deleted" => 1 ] [ "id" => 866912778 "company_id" => 476402 "url" => "https://es.linkedin.com/company/centro-de-fisioterapia-y-osteopat%C3%ADa-grifols" "created" => "2023-08-11 16:57:21" "last_updated" => "2024-08-19 10:44:41" "deleted" => 1 ] [ "id" => 866912779 "company_id" => 476402 "url" => "https://es.linkedin.com/company/fisioterapia-grifols" "created" => "2023-08-11 16:57:21" "last_updated" => "2024-08-19 10:44:41" "deleted" => 1 ] [ "id" => 866912780 "company_id" => 476402 "url" => "https://es.linkedin.com/company/hemo-institut-grifols-sa" "created" => "2023-08-11 16:57:21" "last_updated" => "2024-01-02 10:23:43" "deleted" => 1 ] [ "id" => 866912781 "company_id" => 476402 "url" => "https://www.linkedin.com/company/jose-antonio-grifols-lucas-foundation-inc" "created" => "2023-08-11 16:57:21" "last_updated" => "2024-08-19 10:44:41" "deleted" => 1 ] [ "id" => 866912782 "company_id" => 476402 "url" => "https://ch.linkedin.com/company/medion-grifols-diagnostics-ag" "created" => "2023-08-11 16:57:21" "last_updated" => "2023-11-16 00:44:32" "deleted" => 1 ] [ "id" => 866912783 "company_id" => 476402 "url" => "https://au.linkedin.com/company/lateral-grifols-diagnostics-pty-ltd." "created" => "2023-08-11 16:57:21" "last_updated" => "2024-08-19 10:44:41" "deleted" => 1 ] [ "id" => 866912784 "company_id" => 476402 "url" => "https://es.linkedin.com/company/marca-grifols-sl" "created" => "2023-08-11 16:57:21" "last_updated" => "2024-08-19 10:44:41" "deleted" => 1 ] [ "id" => 866912785 "company_id" => 476402 "url" => "https://es.linkedin.com/company/grifols-viajes-sa" "created" => "2023-08-11 16:57:21" "last_updated" => "2024-08-19 10:44:41" "deleted" => 1 ] [ "id" => 866912786 "company_id" => 476402 "url" => "https://www.linkedin.com/company/grifols-diagnostic-solutions-laboratories" "created" => "2023-08-11 16:57:21" "last_updated" => "2023-10-12 15:12:10" "deleted" => 1 ] [ "id" => 866912787 "company_id" => 476402 "url" => "https://es.linkedin.com/company/grupo-grifols-sa" "created" => "2023-08-11 16:57:21" "last_updated" => "2024-08-19 10:44:41" "deleted" => 1 ] [ "id" => 891791418 "company_id" => 476402 "url" => "https://www.linkedin.com/company/grifols-cafe" "created" => "2023-10-12 15:12:10" "last_updated" => "2024-08-19 10:44:41" "deleted" => 1 ] [ "id" => 907566719 "company_id" => 476402 "url" => "https://br.linkedin.com/company/labovet-produtos-veterinarios" "created" => "2023-11-16 00:44:32" "last_updated" => "2025-02-16 13:38:40" "deleted" => 0 ] [ "id" => 930621526 "company_id" => 476402 "url" => "https://ch.linkedin.com/company/medion-grifols-diagnostics-ag" "created" => "2024-01-02 10:23:43" "last_updated" => "2024-02-21 17:41:47" "deleted" => 1 ] [ "id" => 953343519 "company_id" => 476402 "url" => "https://www.linkedin.com/company/grifols-diagnostic-solutions-laboratories" "created" => "2024-02-21 17:41:47" "last_updated" => "2024-03-11 07:53:33" "deleted" => 1 ] [ "id" => 965886804 "company_id" => 476402 "url" => "https://www.linkedin.com/company/biotest-gmbh" "created" => "2024-03-11 07:53:33" "last_updated" => "2024-04-01 00:52:23" "deleted" => 1 ] [ "id" => 977990812 "company_id" => 476402 "url" => "https://br.linkedin.com/company/ecc-controle-e-certifica%C3%A7%C3%A3o-de-ambientes" "created" => "2024-04-01 00:52:23" "last_updated" => "2024-06-18 14:52:47" "deleted" => 1 ] [ "id" => 1021470027 "company_id" => 476402 "url" => "https://br.linkedin.com/company/bomserv-bombas-industriais" "created" => "2024-06-18 14:52:47" "last_updated" => "2025-02-16 13:38:40" "deleted" => 0 ] [ "id" => 1055527170 "company_id" => 476402 "url" => "https://br.linkedin.com/company/ecc-controle-e-certifica%C3%A7%C3%A3o-de-ambientes" "created" => "2024-08-19 10:44:41" "last_updated" => "2024-11-15 10:38:27" "deleted" => 1 ] [ "id" => 1055527171 "company_id" => 476402 "url" => "https://br.linkedin.com/company/conecta-gente-e-gest%C3%A3o" "created" => "2024-08-19 10:44:41" "last_updated" => "2025-01-20 11:40:23" "deleted" => 1 ] [ "id" => 1055527172 "company_id" => 476402 "url" => "https://ao.linkedin.com/company/climed-solu%C3%A7%C3%B5es-em-sa%C3%BAde" "created" => "2024-08-19 10:44:41" "last_updated" => "2025-01-20 11:40:23" "deleted" => 1 ] [ "id" => 1055527173 "company_id" => 476402 "url" => "https://br.linkedin.com/company/meq-farma" "created" => "2024-08-19 10:44:41" "last_updated" => "2024-11-15 10:38:27" "deleted" => 1 ] [ "id" => 1055527174 "company_id" => 476402 "url" => "https://br.linkedin.com/company/zay-servi%C3%A7os-de-an%C3%A1lises-qu%C3%ADmicas" "created" => "2024-08-19 10:44:41" "last_updated" => "2025-02-16 13:38:40" "deleted" => 0 ] [ "id" => 1055527175 "company_id" => 476402 "url" => "https://de.linkedin.com/company/biotest-ag" "created" => "2024-08-19 10:44:41" "last_updated" => "2025-02-16 13:38:40" "deleted" => 0 ] [ "id" => 1055527176 "company_id" => 476402 "url" => "https://br.linkedin.com/company/jedis" "created" => "2024-08-19 10:44:41" "last_updated" => "2024-11-15 10:38:27" "deleted" => 1 ] [ "id" => 1055527177 "company_id" => 476402 "url" => "https://br.linkedin.com/company/gruposertecrh" "created" => "2024-08-19 10:44:41" "last_updated" => "2025-01-20 11:40:23" "deleted" => 1 ] [ "id" => 1104144209 "company_id" => 476402 "url" => "https://br.linkedin.com/company/spani-atacadista" "created" => "2024-11-15 10:38:27" "last_updated" => "2025-01-20 11:40:23" "deleted" => 1 ] [ "id" => 1104144210 "company_id" => 476402 "url" => "https://br.linkedin.com/company/althaia-s-a-industria-farmaceutica" "created" => "2024-11-15 10:38:27" "last_updated" => "2025-01-20 11:40:23" "deleted" => 1 ] [ "id" => 1104144211 "company_id" => 476402 "url" => "https://br.linkedin.com/company/cobasi" "created" => "2024-11-15 10:38:27" "last_updated" => "2025-01-20 11:40:23" "deleted" => 1 ] [ "id" => 1140600074 "company_id" => 476402 "url" => "https://br.linkedin.com/company/panferindustrial" "created" => "2025-01-20 11:40:23" "last_updated" => "2025-02-16 13:38:40" "deleted" => 0 ] [ "id" => 1140600075 "company_id" => 476402 "url" => "https://br.linkedin.com/company/leman-br-ltda" "created" => "2025-01-20 11:40:23" "last_updated" => "2025-02-16 13:38:40" "deleted" => 0 ] [ "id" => 1140600076 "company_id" => 476402 "url" => "https://br.linkedin.com/company/pmiba" "created" => "2025-01-20 11:40:23" "last_updated" => "2025-02-16 13:38:40" "deleted" => 0 ] [ "id" => 1140600077 "company_id" => 476402 "url" => "https://br.linkedin.com/company/novaminaslogistica" "created" => "2025-01-20 11:40:23" "last_updated" => "2025-02-16 13:38:40" "deleted" => 0 ] [ "id" => 1140600078 "company_id" => 476402 "url" => "https://br.linkedin.com/company/ciplabrasil" "created" => "2025-01-20 11:40:23" "last_updated" => "2025-02-16 13:38:40" "deleted" => 0 ] [ "id" => 1140600079 "company_id" => 476402 "url" => "https://br.linkedin.com/company/vaxxinovabr" "created" => "2025-01-20 11:40:23" "last_updated" => "2025-02-16 13:38:40" "deleted" => 0 ] ] "company_specialties_collection" => [] "company_stock_info_collection" => [] "company_updates_collection" => [] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4578 …} -companyTags: Doctrine\ORM\PersistentCollection {#4580 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4582 …} -users: Doctrine\ORM\PersistentCollection {#4584 …} -logoImageName: "20250226143851-biotest-logo-67bf196b880a0798588068.png" -coverImageName: "20250227161704-bio-f-f920cd7a-67c081f06cbda265886022.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4586 …} -tagline: "Führend in klinischer Immunologie und Hämophilie – Leben retten mit innovativen Plasma-basierten Therapien" -contactEmail: "vanina.heinrich@biotest.com" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4588 …} -totalFollowers: 2 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4590 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4592 …} -industry: "Biotest Farmaceutica Ltda." -size: "2" -address1: "Schützenstrasse 17" -address2: null -city: "Rupperswil" -postalCode: "5102" -state: null -country: "Brazil" -socialLinkedin: "https://www.linkedin.com/company/biotest-ag" -socialX: "" -socialFacebook: "https://www.facebook.com/pages/category/Medical-Research-Center/Biotest-AG-622320914576725/" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4594 …} #createdAt: DateTime @1740047817 {#4555 date: 2025-02-20 10:36:57.0 UTC (+00:00) } #updatedAt: DateTime @1760693426 {#4554 date: 2025-10-17 09:30:26.0 UTC (+00:00) } } App\Entity\Company {#4598 -id: 16 -name: "Boston Scientific" -website: "https://bostonscientific.com" -description: """ Boston Scientific hat es sich zum Ziel gesetzt, mit innovativen medizinischen Lösungen zur Verbesserung der Gesundheit von Patienten auf der ganzen Welt Leben zu verändern.\n \n Unsere Verpflichtung, Leben durch sinnvolle Innovationen zu verändern, ist mehr als nur ein Ziel - es ist unsere Art, wie wir wissenschaftlichen Fortschritt für ein besseres Leben fördern. Wir erfüllen unser Markenversprechen, indem wir uns auf die besten Lösungen konzentrieren. Dabei streben wir nach Spitzenleistungen und arbeiten mit Fachkräften aus dem Gesundheitswesen zusammen. """ -externalId: "35408" -details: [ "id" => 35408 "url" => "https://www.linkedin.com/company/boston-scientific" "hash" => "b6da6739509aee122cee1d82c6ba34da" "name" => "Boston Scientific" "website" => "http://www.bostonscientific.com" "size" => "10,001+ employees" "industry" => "Medical Equipment Manufacturing" "description" => """ Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 40 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of health care. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions.\n \n For more information, visit www.bostonscientific.com and connect with us on X, Instagram, and Facebook. \n \n At Boston Scientific, you will find purpose, a place to grow and opportunities to cultivate your passions. To search and apply for open positions, visit https://bostonscientific.eightfold.ai/careers. \n \n You may also review our social media guidelines at http://www.bostonscientific.com/social. """ "followers" => 1098794 "founded" => null "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://media.licdn.com/dms/image/v2/D560BAQF3enIGxQaa7Q/company-logo_200_200/company-logo_200_200/0/1688306370403?e=2147483647&v=beta&t=lu07kM4Q08Cxn1UcEGonFfe1L4GS_5jYSn2cyK9IQxc" "created" => "2016-06-17 16:37:38" "last_updated" => "2025-02-04 21:15:52" "last_response_code" => 200 "type" => "Public Company" "headquarters_new_address" => "Marlborough, MA" "employees_count" => null "headquarters_country_restored" => "United States" "headquarters_country_parsed" => "United States" "company_shorthand_name" => "boston-scientific" "company_shorthand_name_hash" => "80b26f9b9988c4f8c93d4dcc50c3983d" "canonical_url" => "https://www.linkedin.com/company/boston-scientific" "canonical_hash" => "b6da6739509aee122cee1d82c6ba34da" "canonical_shorthand_name" => "boston-scientific" "canonical_shorthand_name_hash" => "80b26f9b9988c4f8c93d4dcc50c3983d" "deleted" => 0 "last_updated_ux" => 1738703752 "source_id" => 1637 "company_affiliated_collection" => [ [ "id" => 502558 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/company/boston-scientific-cardiology" "affiliated_company_id" => null "created" => "2019-10-23 03:22:58" "last_updated" => "2020-04-06 00:59:48" "deleted" => 1 ] [ "id" => 502559 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/company/boston-scientific-peripheral-interventions" "affiliated_company_id" => null "created" => "2019-10-23 03:22:58" "last_updated" => "2020-04-06 00:59:48" "deleted" => 1 ] [ "id" => 502560 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/company/bsc-women%27s-health" "affiliated_company_id" => null "created" => "2019-10-23 03:22:58" "last_updated" => "2020-04-06 00:59:48" "deleted" => 1 ] [ "id" => 502561 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/company/boston-scientific-endoscopy" "affiliated_company_id" => null "created" => "2019-10-23 03:22:59" "last_updated" => "2020-04-06 00:59:48" "deleted" => 1 ] [ "id" => 502562 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/company/boston-scientific-rhythm-management-uk-and-ireland" "affiliated_company_id" => null "created" => "2019-10-23 03:22:59" "last_updated" => "2020-04-06 00:59:48" "deleted" => 1 ] [ "id" => 502563 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/company/boston-scientific-latam" "affiliated_company_id" => null "created" => "2019-10-23 03:22:59" "last_updated" => "2020-04-06 00:59:48" "deleted" => 1 ] [ "id" => 2296707 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-cardiology" "affiliated_company_id" => 26436000 "created" => "2020-04-06 00:59:48" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 2296708 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-peripheral-interventions" "affiliated_company_id" => 25428947 "created" => "2020-04-06 00:59:48" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 2296709 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-endoscopy" "affiliated_company_id" => 25428946 "created" => "2020-04-06 00:59:48" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 2296710 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-latam" "affiliated_company_id" => 25428945 "created" => "2020-04-06 00:59:48" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 2296711 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-rhythm-management-uk-and-ireland" "affiliated_company_id" => 25428954 "created" => "2020-04-06 00:59:48" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 2296712 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/bsc-women's-health" "affiliated_company_id" => 25434869 "created" => "2020-04-06 00:59:48" "last_updated" => "2020-04-24 10:16:39" "deleted" => 1 ] [ "id" => 3233166 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/bsc-uroph" "affiliated_company_id" => null "created" => "2020-04-24 10:16:39" "last_updated" => "2020-05-07 21:09:44" "deleted" => 1 ] [ "id" => 3233167 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-pain-management" "affiliated_company_id" => null "created" => "2020-04-24 10:16:39" "last_updated" => "2021-09-30 10:01:05" "deleted" => 1 ] [ "id" => 3458476 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/bsc-uroph" "affiliated_company_id" => 25434869 "created" => "2020-05-07 21:09:44" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 3458477 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-dbs" "affiliated_company_id" => null "created" => "2020-05-07 21:09:44" "last_updated" => "2021-10-12 10:16:55" "deleted" => 1 ] [ "id" => 3517712 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-dorado" "affiliated_company_id" => 20646179 "created" => "2020-06-09 20:58:53" "last_updated" => "2020-12-16 08:38:29" "deleted" => 1 ] [ "id" => 4172957 "company_id" => 35408 "affiliated_company_url" => "https://pr.linkedin.com/showcase/boston-scientific-dorado" "affiliated_company_id" => 20646179 "created" => "2020-12-16 08:38:30" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5224155 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-pain-management" "affiliated_company_id" => 39519290 "created" => "2021-09-30 10:01:05" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5506480 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-dbs" "affiliated_company_id" => 60059865 "created" => "2021-10-12 10:16:55" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 6365801 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-cardiology" "affiliated_company_id" => 26436000 "created" => "2022-07-13 07:52:31" "last_updated" => "2022-07-22 03:21:36" "deleted" => 1 ] [ "id" => 6365802 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-latam" "affiliated_company_id" => 25428945 "created" => "2022-07-13 07:52:31" "last_updated" => "2022-07-22 03:21:36" "deleted" => 1 ] [ "id" => 6365803 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-peripheral-interventions" "affiliated_company_id" => 25428947 "created" => "2022-07-13 07:52:31" "last_updated" => "2022-07-22 03:21:36" "deleted" => 1 ] [ "id" => 6365804 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-endoscopy" "affiliated_company_id" => 25428946 "created" => "2022-07-13 07:52:31" "last_updated" => "2022-07-22 03:21:36" "deleted" => 1 ] [ "id" => 6365805 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/bsc-uroph" "affiliated_company_id" => 25434869 "created" => "2022-07-13 07:52:31" "last_updated" => "2022-07-22 03:21:36" "deleted" => 1 ] [ "id" => 6365806 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-pain-management" "affiliated_company_id" => 39519290 "created" => "2022-07-13 07:52:31" "last_updated" => "2022-07-22 03:21:36" "deleted" => 1 ] [ "id" => 6365807 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-dbs" "affiliated_company_id" => 60059865 "created" => "2022-07-13 07:52:31" "last_updated" => "2022-07-22 03:21:36" "deleted" => 1 ] [ "id" => 6365808 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-rhythm-management-uk-and-ireland" "affiliated_company_id" => 25428954 "created" => "2022-07-13 07:52:31" "last_updated" => "2022-07-22 03:21:36" "deleted" => 1 ] [ "id" => 6365809 "company_id" => 35408 "affiliated_company_url" => "https://pr.linkedin.com/showcase/boston-scientific-dorado" "affiliated_company_id" => 20646179 "created" => "2022-07-13 07:52:31" "last_updated" => "2022-07-22 03:21:36" "deleted" => 1 ] [ "id" => 6658921 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-cardiology" "affiliated_company_id" => 26436000 "created" => "2022-08-09 16:55:05" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 6658922 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-latam" "affiliated_company_id" => 25428945 "created" => "2022-08-09 16:55:05" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 6658923 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-peripheral-interventions" "affiliated_company_id" => 25428947 "created" => "2022-08-09 16:55:05" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 6658924 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-endoscopy" "affiliated_company_id" => 25428946 "created" => "2022-08-09 16:55:05" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 6658925 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/bsc-uroph" "affiliated_company_id" => 25434869 "created" => "2022-08-09 16:55:05" "last_updated" => "2024-07-22 12:53:15" "deleted" => 1 ] [ "id" => 6658926 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-pain-management" "affiliated_company_id" => 39519290 "created" => "2022-08-09 16:55:05" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 6658927 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-dbs" "affiliated_company_id" => 60059865 "created" => "2022-08-09 16:55:05" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 6658928 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/boston-scientific-rhythm-management-uk-and-ireland" "affiliated_company_id" => 25428954 "created" => "2022-08-09 16:55:05" "last_updated" => "2022-10-15 07:10:29" "deleted" => 1 ] [ "id" => 6658929 "company_id" => 35408 "affiliated_company_url" => "https://pr.linkedin.com/showcase/boston-scientific-dorado" "affiliated_company_id" => 20646179 "created" => "2022-08-09 16:55:05" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 7333607 "company_id" => 35408 "affiliated_company_url" => "https://uk.linkedin.com/showcase/boston-scientific-rhythm-management-uk-and-ireland" "affiliated_company_id" => 25428954 "created" => "2022-10-15 07:10:30" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 10452223 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/bsc-uro" "affiliated_company_id" => null "created" => "2024-07-22 12:53:15" "last_updated" => "2024-08-08 15:10:43" "deleted" => 1 ] [ "id" => 10528576 "company_id" => 35408 "affiliated_company_url" => "https://www.linkedin.com/showcase/bsc-uro" "affiliated_company_id" => 96121085 "created" => "2024-08-08 15:10:43" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] ] "company_also_viewed_collection" => [ [ "id" => 142300 "company_id" => 35408 "viewed_company_url" => "https://www.linkedin.com/company/medtronic" "viewed_company_id" => null "created" => "2016-06-17 16:37:38" "last_updated" => "2019-08-02 11:04:07" "deleted" => 1 ] [ "id" => 142301 "company_id" => 35408 "viewed_company_url" => "https://www.linkedin.com/company/stryker" "viewed_company_id" => null "created" => "2016-06-17 16:37:38" "last_updated" => "2019-08-02 11:04:07" "deleted" => 1 ] [ "id" => 142302 "company_id" => 35408 "viewed_company_url" => "https://www.linkedin.com/company/st--jude-medical" "viewed_company_id" => null "created" => "2016-06-17 16:37:38" "last_updated" => "2019-03-13 09:16:32" "deleted" => 1 ] [ "id" => 142303 "company_id" => 35408 "viewed_company_url" => "https://www.linkedin.com/company/johnson-&-johnson" "viewed_company_id" => null "created" => "2016-06-17 16:37:38" "last_updated" => "2019-08-02 11:04:07" "deleted" => 1 ] [ "id" => 142304 "company_id" => 35408 "viewed_company_url" => "https://www.linkedin.com/company/baxter-healthcare" "viewed_company_id" => null "created" => "2016-06-17 16:37:38" "last_updated" => "2016-12-08 17:38:55" "deleted" => 1 ] [ "id" => 142305 "company_id" => 35408 "viewed_company_url" => "https://www.linkedin.com/company/abbott-" "viewed_company_id" => null "created" => "2016-06-17 16:37:38" "last_updated" => "2019-08-02 11:04:07" "deleted" => 1 ] [ "id" => 38640939 "company_id" => 35408 "viewed_company_url" => "https://www.linkedin.com/company/zimmerbiomet" "viewed_company_id" => null "created" => "2016-12-08 17:38:55" "last_updated" => "2019-08-02 11:04:07" "deleted" => 1 ] [ "id" => 195461571 "company_id" => 35408 "viewed_company_url" => "https://www.linkedin.com/company/gehealthcare" "viewed_company_id" => null "created" => "2019-03-13 09:16:32" "last_updated" => "2019-08-02 11:04:07" "deleted" => 1 ] [ "id" => 256907887 "company_id" => 35408 "viewed_company_url" => "https://sg.linkedin.com/company/medtronic" "viewed_company_id" => null "created" => "2019-08-02 11:04:07" "last_updated" => "2019-10-23 03:22:58" "deleted" => 1 ] [ "id" => 256907888 "company_id" => 35408 "viewed_company_url" => "https://sg.linkedin.com/company/stryker" "viewed_company_id" => null "created" => "2019-08-02 11:04:07" "last_updated" => "2019-10-23 03:22:58" "deleted" => 1 ] [ "id" => 256907889 "company_id" => 35408 "viewed_company_url" => "https://sg.linkedin.com/company/abbott-" "viewed_company_id" => null "created" => "2019-08-02 11:04:07" "last_updated" => "2019-10-23 03:22:58" "deleted" => 1 ] [ "id" => 256907890 "company_id" => 35408 "viewed_company_url" => "https://sg.linkedin.com/company/johnson-&-johnson" "viewed_company_id" => null "created" => "2019-08-02 11:04:07" "last_updated" => "2019-10-23 03:22:58" "deleted" => 1 ] [ "id" => 256907891 "company_id" => 35408 "viewed_company_url" => "https://sg.linkedin.com/company/zimmerbiomet" "viewed_company_id" => null "created" => "2019-08-02 11:04:07" "last_updated" => "2019-10-23 03:22:58" "deleted" => 1 ] [ "id" => 256907892 "company_id" => 35408 "viewed_company_url" => "https://sg.linkedin.com/company/gehealthcare" "viewed_company_id" => null "created" => "2019-08-02 11:04:07" "last_updated" => "2019-10-23 03:22:58" "deleted" => 1 ] ] "company_crunchbase_info_collection" => [ [ "id" => 25473 "company_id" => 35408 "cb_url" => "https://www.crunchbase.com/organization/boston-scientific" "created" => "2020-09-10 05:31:35" "last_updated" => "2021-10-12 13:16:57" "deleted" => 1 ] [ "id" => 141178 "company_id" => 35408 "cb_url" => "https://www.crunchbase.com/organization/boston-scientific" "created" => "2021-10-17 17:15:23" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 178920 "company_id" => 35408 "cb_url" => "https://www.crunchbase.com/organization/boston-scientific" "created" => "2022-07-13 07:52:31" "last_updated" => "2022-07-22 03:21:36" "deleted" => 1 ] [ "id" => 202116 "company_id" => 35408 "cb_url" => "https://www.crunchbase.com/organization/boston-scientific" "created" => "2022-09-06 14:12:16" "last_updated" => "2022-09-15 12:15:11" "deleted" => 1 ] [ "id" => 259077 "company_id" => 35408 "cb_url" => "https://www.crunchbase.com/organization/boston-scientific" "created" => "2023-02-06 14:19:35" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] ] "company_featured_employees_collection" => [ [ "id" => 14441762 "company_id" => 35408 "url" => "https://www.linkedin.com/in/rossvenook" "created" => "2019-10-23 03:22:58" "last_updated" => "2020-01-27 22:32:13" "deleted" => 1 ] [ "id" => 14441763 "company_id" => 35408 "url" => "https://www.linkedin.com/in/qi-gigi-fan-5b718" "created" => "2019-10-23 03:22:58" "last_updated" => "2020-01-27 22:32:13" "deleted" => 1 ] [ "id" => 14441764 "company_id" => 35408 "url" => "https://www.linkedin.com/in/brianjmoss" "created" => "2019-10-23 03:22:58" "last_updated" => "2020-01-27 22:32:13" "deleted" => 1 ] [ "id" => 14441765 "company_id" => 35408 "url" => "https://www.linkedin.com/in/jruben01" "created" => "2019-10-23 03:22:58" "last_updated" => "2020-01-27 22:32:13" "deleted" => 1 ] [ "id" => 34312902 "company_id" => 35408 "url" => "https://www.linkedin.com/in/monapatel2" "created" => "2020-01-27 22:32:13" "last_updated" => "2021-11-22 16:27:22" "deleted" => 1 ] [ "id" => 34312903 "company_id" => 35408 "url" => "https://www.linkedin.com/in/lesliebywaterbishop" "created" => "2020-01-27 22:32:13" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 34312904 "company_id" => 35408 "url" => "https://www.linkedin.com/in/bob-neidermire-75480" "created" => "2020-01-27 22:32:13" "last_updated" => "2020-11-06 11:59:46" "deleted" => 1 ] [ "id" => 34312905 "company_id" => 35408 "url" => "https://www.linkedin.com/in/don-chennavasin-7b087" "created" => "2020-01-27 22:32:13" "last_updated" => "2021-04-14 23:45:49" "deleted" => 1 ] [ "id" => 60438417 "company_id" => 35408 "url" => "https://www.linkedin.com/in/eduardo-sessa-a8390" "created" => "2021-02-12 17:06:57" "last_updated" => "2021-03-15 08:12:43" "deleted" => 1 ] [ "id" => 63966540 "company_id" => 35408 "url" => "https://www.linkedin.com/in/ryan-spang-44b38" "created" => "2021-04-14 23:45:49" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 66907801 "company_id" => 35408 "url" => "https://www.linkedin.com/in/noopurpandey" "created" => "2021-06-21 11:39:09" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 79738910 "company_id" => 35408 "url" => "https://www.linkedin.com/in/charles-ho-6a141" "created" => "2021-11-29 15:55:08" "last_updated" => "2022-06-16 10:11:15" "deleted" => 1 ] [ "id" => 91600455 "company_id" => 35408 "url" => "https://www.linkedin.com/in/don-chennavasin-7b087" "created" => "2022-06-16 10:11:15" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 94320644 "company_id" => 35408 "url" => "https://www.linkedin.com/in/ryan-spang-44b38" "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 94320645 "company_id" => 35408 "url" => "https://www.linkedin.com/in/lesliebywaterbishop" "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 94320646 "company_id" => 35408 "url" => "https://www.linkedin.com/in/noopurpandey" "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 94320647 "company_id" => 35408 "url" => "https://www.linkedin.com/in/don-chennavasin-7b087" "created" => "2022-07-13 07:52:31" "last_updated" => "2023-01-12 13:16:17" "deleted" => 1 ] [ "id" => 157970535 "company_id" => 35408 "url" => "https://www.linkedin.com/in/bjholtgrewe" "created" => "2023-01-12 13:16:17" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] ] "company_featured_investors_collection" => [] "company_funding_rounds_collection" => [ [ "id" => 38991 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2018-02-27 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--c0caa83c" "created" => "2020-09-10 05:31:35" "last_updated" => "2020-10-07 05:37:35" "deleted" => 1 ] [ "id" => 157905 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2018-02-27 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--c0caa83c" "created" => "2020-10-07 05:37:35" "last_updated" => "2020-11-06 11:59:46" "deleted" => 1 ] [ "id" => 263763 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2018-02-27 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--c0caa83c" "created" => "2020-11-06 11:59:46" "last_updated" => "2020-12-16 08:38:29" "deleted" => 1 ] [ "id" => 394802 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2018-02-27 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--c0caa83c" "created" => "2020-12-16 08:38:29" "last_updated" => "2020-12-17 02:19:38" "deleted" => 1 ] [ "id" => 408387 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2018-02-27 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--c0caa83c" "created" => "2020-12-17 02:19:38" "last_updated" => "2021-01-09 03:35:24" "deleted" => 1 ] [ "id" => 473915 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2018-02-27 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--c0caa83c" "created" => "2021-01-09 03:35:24" "last_updated" => "2021-01-11 13:30:13" "deleted" => 1 ] [ "id" => 494093 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2018-02-27 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--c0caa83c" "created" => "2021-01-11 13:30:13" "last_updated" => "2021-02-12 17:06:57" "deleted" => 1 ] [ "id" => 590433 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2018-02-27 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--c0caa83c" "created" => "2021-02-12 17:06:57" "last_updated" => "2021-03-15 08:12:43" "deleted" => 1 ] [ "id" => 685196 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2018-02-27 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--c0caa83c" "created" => "2021-03-15 08:12:43" "last_updated" => "2021-03-18 14:52:05" "deleted" => 1 ] [ "id" => 705598 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2018-02-27 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--c0caa83c" "created" => "2021-03-18 14:52:05" "last_updated" => "2021-03-24 14:58:57" "deleted" => 1 ] [ "id" => 731659 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2018-02-27 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--c0caa83c" "created" => "2021-03-24 14:58:57" "last_updated" => "2021-04-14 23:45:49" "deleted" => 1 ] [ "id" => 810427 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2018-02-27 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--c0caa83c" "created" => "2021-04-14 23:45:49" "last_updated" => "2021-05-15 02:55:23" "deleted" => 1 ] [ "id" => 920061 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2018-02-27 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--c0caa83c" "created" => "2021-05-15 02:55:23" "last_updated" => "2021-06-21 11:39:09" "deleted" => 1 ] [ "id" => 1025020 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 1.5B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-06-21 11:39:09" "last_updated" => "2021-07-15 03:06:33" "deleted" => 1 ] [ "id" => 1102769 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 1.5B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-07-15 03:06:33" "last_updated" => "2021-07-15 15:04:14" "deleted" => 1 ] [ "id" => 1110127 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 1.5B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-07-15 15:04:14" "last_updated" => "2021-08-10 02:23:49" "deleted" => 1 ] [ "id" => 1231636 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 1.5B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-08-10 02:23:49" "last_updated" => "2021-08-11 11:02:10" "deleted" => 1 ] [ "id" => 1238320 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 1.5B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-08-11 11:02:10" "last_updated" => "2021-09-09 01:08:11" "deleted" => 1 ] [ "id" => 1404074 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 1.5B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-09-09 01:08:11" "last_updated" => "2021-09-09 16:54:32" "deleted" => 1 ] [ "id" => 1410688 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 1.5B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-09-09 16:54:32" "last_updated" => "2021-09-14 10:45:46" "deleted" => 1 ] [ "id" => 1440895 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 1.5B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-09-14 10:45:46" "last_updated" => "2021-09-30 10:01:05" "deleted" => 1 ] [ "id" => 1526075 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 1.5B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-09-30 10:01:05" "last_updated" => "2021-10-12 10:16:55" "deleted" => 1 ] [ "id" => 1585067 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 1.5B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-10-12 10:16:55" "last_updated" => "2021-10-12 13:16:57" "deleted" => 1 ] [ "id" => 1622753 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 2.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-10-17 17:15:23" "last_updated" => "2021-11-05 16:59:41" "deleted" => 1 ] [ "id" => 1693244 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 2.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-11-05 16:59:41" "last_updated" => "2021-11-22 16:27:22" "deleted" => 1 ] [ "id" => 1807768 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 2.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-11-22 16:27:22" "last_updated" => "2021-11-29 15:55:08" "deleted" => 1 ] [ "id" => 1821516 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 2.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-11-29 15:55:08" "last_updated" => "2021-12-28 09:02:23" "deleted" => 1 ] [ "id" => 1936203 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 2.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2021-12-28 09:02:23" "last_updated" => "2022-01-03 11:04:10" "deleted" => 1 ] [ "id" => 2041220 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 2.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2022-01-03 11:04:10" "last_updated" => "2022-01-19 16:16:12" "deleted" => 1 ] [ "id" => 2163405 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => "US$ 2.0B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2022-01-19 16:16:12" "last_updated" => "2022-02-07 10:18:18" "deleted" => 1 ] [ "id" => 2174336 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => """ US$\n 2.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2022-02-07 10:18:18" "last_updated" => "2022-02-09 18:21:46" "deleted" => 1 ] [ "id" => 2232689 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => """ US$\n 2.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2022-02-09 18:21:46" "last_updated" => "2022-03-01 11:01:17" "deleted" => 1 ] [ "id" => 2315496 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => """ US$\n 2.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2022-03-01 11:01:17" "last_updated" => "2022-03-01 22:49:46" "deleted" => 1 ] [ "id" => 2329248 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => """ US$\n 2.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2022-03-01 22:49:46" "last_updated" => "2022-03-04 09:44:38" "deleted" => 1 ] [ "id" => 2384724 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => """ US$\n 2.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2022-03-04 09:44:38" "last_updated" => "2022-03-08 13:54:56" "deleted" => 1 ] [ "id" => 2423066 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2020-05-21 00:00:00" "last_round_money_raised" => """ US$\n 2.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-equity--ccc872e6" "created" => "2022-03-08 13:54:56" "last_updated" => "2022-03-30 08:50:46" "deleted" => 1 ] [ "id" => 2479563 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-04 00:00:00" "last_round_money_raised" => """ US$\n 3.3B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-03-30 08:50:46" "last_updated" => "2022-04-02 06:55:56" "deleted" => 1 ] [ "id" => 2480404 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-04 00:00:00" "last_round_money_raised" => """ US$\n 3.3B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-04-02 06:55:56" "last_updated" => "2022-04-08 07:59:45" "deleted" => 1 ] [ "id" => 2593562 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-04 00:00:00" "last_round_money_raised" => """ US$\n 3.3B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-04-08 07:59:45" "last_updated" => "2022-05-02 13:24:43" "deleted" => 1 ] [ "id" => 2627909 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-04 00:00:00" "last_round_money_raised" => """ US$\n 3.3B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-05-02 13:24:43" "last_updated" => "2022-05-09 13:12:00" "deleted" => 1 ] [ "id" => 2698686 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-04 00:00:00" "last_round_money_raised" => """ US$\n 3.3B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-05-09 13:12:00" "last_updated" => "2022-05-09 16:17:47" "deleted" => 1 ] [ "id" => 2701544 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-04 00:00:00" "last_round_money_raised" => """ US$\n 3.3B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-05-09 16:17:47" "last_updated" => "2022-06-03 12:22:35" "deleted" => 1 ] [ "id" => 2817225 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-04 00:00:00" "last_round_money_raised" => """ US$\n 3.3B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-06-03 12:22:35" "last_updated" => "2022-06-16 10:11:15" "deleted" => 1 ] [ "id" => 2841622 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-04 00:00:00" "last_round_money_raised" => """ US$\n 3.3B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-06-16 10:11:15" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 2979269 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-04 00:00:00" "last_round_money_raised" => """ US$\n 3.3B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-07-13 07:52:31" "last_updated" => "2022-07-22 03:21:36" "deleted" => 1 ] [ "id" => 3043303 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-07-22 03:21:36" "last_updated" => "2022-08-02 09:06:25" "deleted" => 1 ] [ "id" => 3106853 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-08-02 09:06:25" "last_updated" => "2022-08-09 16:55:05" "deleted" => 1 ] [ "id" => 3186195 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-08-09 16:55:05" "last_updated" => "2022-09-06 14:12:16" "deleted" => 1 ] [ "id" => 3282383 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-04 00:00:00" "last_round_money_raised" => """ US$\n 3.3B """ "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-09-06 14:12:16" "last_updated" => "2022-09-15 12:15:11" "deleted" => 1 ] [ "id" => 3315489 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-09-15 12:15:11" "last_updated" => "2022-10-15 07:10:29" "deleted" => 1 ] [ "id" => 3485353 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-10-15 07:10:29" "last_updated" => "2022-11-09 07:52:48" "deleted" => 1 ] [ "id" => 3545739 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-11-09 07:52:48" "last_updated" => "2022-11-09 07:52:51" "deleted" => 1 ] [ "id" => 3545740 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-11-09 07:52:51" "last_updated" => "2022-12-17 16:24:52" "deleted" => 1 ] [ "id" => 3751070 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2022-12-17 16:24:52" "last_updated" => "2023-01-12 13:16:17" "deleted" => 1 ] [ "id" => 3875933 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2023-01-12 13:16:17" "last_updated" => "2023-01-16 19:33:08" "deleted" => 1 ] [ "id" => 3908185 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2023-01-16 19:33:08" "last_updated" => "2023-02-06 14:19:35" "deleted" => 1 ] [ "id" => 3980394 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2023-02-06 14:19:35" "last_updated" => "2023-02-11 06:55:53" "deleted" => 1 ] [ "id" => 4042695 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2023-02-11 06:55:53" "last_updated" => "2023-03-10 19:51:19" "deleted" => 1 ] [ "id" => 4228292 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2023-03-10 19:51:19" "last_updated" => "2023-04-04 07:36:15" "deleted" => 1 ] [ "id" => 4305199 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2023-04-04 07:36:15" "last_updated" => "2023-05-10 07:09:31" "deleted" => 1 ] [ "id" => 4549308 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2023-05-10 07:09:31" "last_updated" => "2023-06-09 18:26:32" "deleted" => 1 ] [ "id" => 4686108 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2023-06-09 18:26:32" "last_updated" => "2023-07-13 23:05:04" "deleted" => 1 ] [ "id" => 5070085 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2023-07-13 23:05:04" "last_updated" => "2023-08-16 04:12:24" "deleted" => 1 ] [ "id" => 5373044 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2023-08-16 04:12:24" "last_updated" => "2023-09-17 21:38:30" "deleted" => 1 ] [ "id" => 5557909 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2023-09-17 21:38:30" "last_updated" => "2023-10-07 04:37:25" "deleted" => 1 ] [ "id" => 5644219 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2023-10-07 04:37:25" "last_updated" => "2023-11-06 10:37:36" "deleted" => 1 ] [ "id" => 5834263 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2023-11-06 10:37:36" "last_updated" => "2023-12-02 05:33:23" "deleted" => 1 ] [ "id" => 5993493 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2023-12-02 05:33:23" "last_updated" => "2024-01-15 14:45:59" "deleted" => 1 ] [ "id" => 6278965 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2024-01-15 14:45:59" "last_updated" => "2024-02-15 10:50:34" "deleted" => 1 ] [ "id" => 6439521 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-04-04 00:00:00" "last_round_money_raised" => "US$ 3.3B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--0da52696" "created" => "2024-02-15 10:50:34" "last_updated" => "2024-03-23 04:43:56" "deleted" => 1 ] [ "id" => 6710748 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2024-03-23 04:43:56" "last_updated" => "2024-04-26 16:58:05" "deleted" => 1 ] [ "id" => 6920650 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2024-04-26 16:58:05" "last_updated" => "2024-05-25 21:16:38" "deleted" => 1 ] [ "id" => 7101888 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2024-05-25 21:16:38" "last_updated" => "2024-06-06 19:33:51" "deleted" => 1 ] [ "id" => 7159412 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2024-06-06 19:33:51" "last_updated" => "2024-07-22 12:53:15" "deleted" => 1 ] [ "id" => 7495199 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2024-07-22 12:53:15" "last_updated" => "2024-08-08 15:10:43" "deleted" => 1 ] [ "id" => 7589512 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2024-08-08 15:10:43" "last_updated" => "2024-08-25 16:17:31" "deleted" => 1 ] [ "id" => 7785855 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2024-08-25 16:17:31" "last_updated" => "2024-09-06 13:50:46" "deleted" => 1 ] [ "id" => 7972481 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2024-09-06 13:50:46" "last_updated" => "2024-09-28 16:58:38" "deleted" => 1 ] [ "id" => 8205345 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2024-09-28 16:58:38" "last_updated" => "2024-10-18 13:27:00" "deleted" => 1 ] [ "id" => 8434732 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2024-10-18 13:27:00" "last_updated" => "2024-11-01 06:28:40" "deleted" => 1 ] [ "id" => 8539887 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2024-11-01 06:28:40" "last_updated" => "2024-11-26 16:48:42" "deleted" => 1 ] [ "id" => 8779486 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2024-11-26 16:48:42" "last_updated" => "2024-11-26 17:05:42" "deleted" => 1 ] [ "id" => 8780632 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2024-11-26 17:05:42" "last_updated" => "2024-12-03 10:56:12" "deleted" => 1 ] [ "id" => 9023477 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2024-12-03 10:56:12" "last_updated" => "2025-01-01 12:29:44" "deleted" => 1 ] [ "id" => 9197319 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2025-01-01 12:29:44" "last_updated" => "2025-01-12 08:07:51" "deleted" => 1 ] [ "id" => 9324462 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2025-01-12 08:07:51" "last_updated" => "2025-02-04 21:15:52" "deleted" => 1 ] [ "id" => 9566322 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-22 00:00:00" "last_round_money_raised" => "US$ 2.2B" "cb_url" => "https://www.crunchbase.com/funding_round/boston-scientific-post-ipo-debt--cdb5fefd" "created" => "2025-02-04 21:15:52" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] ] "company_locations_collection" => [ [ "id" => 5944448 "company_id" => 35408 "location_address" => "100 Boston Scientific Way; Marlborough, MA 01752, US" "is_primary" => 1 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944449 "company_id" => 35408 "location_address" => "160 Knowles Dr; Los Gatos, CA 95032, US" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944450 "company_id" => 35408 "location_address" => "25155 Rye Canyon Loop; Santa Clarita, CA 91355, US" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2020-02-22 10:14:52" "deleted" => 1 ] [ "id" => 5944451 "company_id" => 35408 "location_address" => "47215 Lakeview Blvd; Fremont, California 94538, US" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944452 "company_id" => 35408 "location_address" => "150 Baytech Dr; San Jose, California 95134, US" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944453 "company_id" => 35408 "location_address" => "Breakspear Way; Hemel Hempstead, England HP2 4TZ, GB" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944454 "company_id" => 35408 "location_address" => "Sohna Road; Gurgaon, Haryana 122018, IN" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944455 "company_id" => 35408 "location_address" => "Avenue des Champs-Pierreux; Nanterre, IdF 92000, FR" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944456 "company_id" => 35408 "location_address" => "2, Rue René Caudron; Voisins-le-Bretonneux, Ile-de-France 78960, FR" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944457 "company_id" => 35408 "location_address" => "780 Brookside Dr; Spencer, Indiana 47460, US" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944458 "company_id" => 35408 "location_address" => "Vestastraat 6; Spekholzerheide, Limburg 6468 EX, NL" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944459 "company_id" => 35408 "location_address" => "Viale Enrico Forlanini, 23; Milan, Lomb. 20134, IT" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944460 "company_id" => 35408 "location_address" => "4100 N Hamline Ave; St Paul, Minnesota 55112, US" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944461 "company_id" => 35408 "location_address" => "One Scimed Place; Maple Grove, MN 55311, US" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944462 "company_id" => 35408 "location_address" => "191 O'Riordan St; Sydney, NSW 2020, AU" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944463 "company_id" => 35408 "location_address" => "Road 698; Lot. No. 12; Dorado, Puerto Rico 00646, PR" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944464 "company_id" => 35408 "location_address" => "Cashel Road; Clonmel, Tipperary, IE" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944465 "company_id" => 35408 "location_address" => "Model Farm Road; Cork, IE" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944466 "company_id" => 35408 "location_address" => "Ballybrit; Galway, IE" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 5944467 "company_id" => 35408 "location_address" => "9 N Buona Vista Dr; Singapore, SG" "is_primary" => 0 "created" => "2019-10-23 03:22:58" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 13735954 "company_id" => 35408 "location_address" => "25155 Rye Canyon Loop; Santa Clarita, CA 91355, US" "is_primary" => 0 "created" => "2020-03-10 20:28:47" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 70002995 "company_id" => 35408 "location_address" => "100 Boston Scientific Way; Marlborough, MA 01752, US" "is_primary" => 1 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70002996 "company_id" => 35408 "location_address" => "160 Knowles Dr; Los Gatos, CA 95032, US" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70002997 "company_id" => 35408 "location_address" => "25155 Rye Canyon Loop; Santa Clarita, CA 91355, US" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70002998 "company_id" => 35408 "location_address" => "47215 Lakeview Blvd; Fremont, California 94538, US" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70002999 "company_id" => 35408 "location_address" => "150 Baytech Dr; San Jose, California 95134, US" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003000 "company_id" => 35408 "location_address" => "Breakspear Way; Hemel Hempstead, England HP2 4TZ, GB" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003001 "company_id" => 35408 "location_address" => "Sohna Road; Gurgaon, Haryana 122018, IN" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003002 "company_id" => 35408 "location_address" => "Avenue des Champs-Pierreux; Nanterre, IdF 92000, FR" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003003 "company_id" => 35408 "location_address" => "2, Rue René Caudron; Voisins-le-Bretonneux, Ile-de-France 78960, FR" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003004 "company_id" => 35408 "location_address" => "780 Brookside Dr; Spencer, Indiana 47460, US" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003005 "company_id" => 35408 "location_address" => "Vestastraat 6; Spekholzerheide, Limburg 6468 EX, NL" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003006 "company_id" => 35408 "location_address" => "Viale Enrico Forlanini, 23; Milan, Lomb. 20134, IT" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003007 "company_id" => 35408 "location_address" => "4100 N Hamline Ave; St Paul, Minnesota 55112, US" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003008 "company_id" => 35408 "location_address" => "One Scimed Place; Maple Grove, MN 55311, US" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003009 "company_id" => 35408 "location_address" => "191 O'Riordan St; Sydney, NSW 2020, AU" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003010 "company_id" => 35408 "location_address" => "Road 698; Lot. No. 12; Dorado, Puerto Rico 00646, PR" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003011 "company_id" => 35408 "location_address" => "Cashel Road; Clonmel, Tipperary, IE" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003012 "company_id" => 35408 "location_address" => "Model Farm Road; Cork, IE" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003013 "company_id" => 35408 "location_address" => "Ballybrit; Galway, IE" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 70003014 "company_id" => 35408 "location_address" => "9 N Buona Vista Dr; Singapore, SG" "is_primary" => 0 "created" => "2022-07-13 07:52:31" "last_updated" => "2023-09-17 21:38:30" "deleted" => 1 ] [ "id" => 136155318 "company_id" => 35408 "location_address" => "9 N Buona Vista Dr; Singapore, 13, SG" "is_primary" => 0 "created" => "2023-09-17 21:38:30" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] ] "company_similar_collection" => [ [ "id" => 22585506 "company_id" => 35408 "url" => "https://www.linkedin.com/company/medtronic" "created" => "2019-10-23 03:22:58" "last_updated" => "2021-06-21 11:39:09" "deleted" => 1 ] [ "id" => 22585507 "company_id" => 35408 "url" => "https://www.linkedin.com/company/abbott-" "created" => "2019-10-23 03:22:58" "last_updated" => "2021-06-21 11:39:09" "deleted" => 1 ] [ "id" => 22585508 "company_id" => 35408 "url" => "https://www.linkedin.com/company/stryker" "created" => "2019-10-23 03:22:58" "last_updated" => "2021-06-21 11:39:09" "deleted" => 1 ] [ "id" => 22585509 "company_id" => 35408 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2019-10-23 03:22:58" "last_updated" => "2021-06-21 11:39:09" "deleted" => 1 ] [ "id" => 22585510 "company_id" => 35408 "url" => "https://www.linkedin.com/company/gehealthcare" "created" => "2019-10-23 03:22:58" "last_updated" => "2021-06-21 11:39:09" "deleted" => 1 ] [ "id" => 22585511 "company_id" => 35408 "url" => "https://www.linkedin.com/company/bd1" "created" => "2019-10-23 03:22:58" "last_updated" => "2021-06-21 11:39:09" "deleted" => 1 ] [ "id" => 78757527 "company_id" => 35408 "url" => "https://www.linkedin.com/company/philips" "created" => "2020-01-27 22:32:13" "last_updated" => "2020-12-16 08:38:29" "deleted" => 1 ] [ "id" => 78757529 "company_id" => 35408 "url" => "https://www.linkedin.com/company/baxter-healthcare" "created" => "2020-01-27 22:32:13" "last_updated" => "2021-06-21 11:39:09" "deleted" => 1 ] [ "id" => 78757532 "company_id" => 35408 "url" => "https://www.linkedin.com/company/zimmerbiomet" "created" => "2020-01-27 22:32:13" "last_updated" => "2021-06-21 11:39:09" "deleted" => 1 ] [ "id" => 78757534 "company_id" => 35408 "url" => "https://www.linkedin.com/company/smith-&-nephew" "created" => "2020-01-27 22:32:13" "last_updated" => "2021-06-21 11:39:09" "deleted" => 1 ] [ "id" => 328470993 "company_id" => 35408 "url" => "https://nl.linkedin.com/company/philips" "created" => "2020-12-16 08:38:29" "last_updated" => "2021-06-21 11:39:09" "deleted" => 1 ] [ "id" => 476539952 "company_id" => 35408 "url" => "https://www.linkedin.com/company/medtronic" "created" => "2021-09-09 01:08:11" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 476539953 "company_id" => 35408 "url" => "https://www.linkedin.com/company/abbott-" "created" => "2021-09-09 01:08:11" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 476539954 "company_id" => 35408 "url" => "https://www.linkedin.com/company/stryker" "created" => "2021-09-09 01:08:11" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 476539955 "company_id" => 35408 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2021-09-09 01:08:11" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 476539956 "company_id" => 35408 "url" => "https://www.linkedin.com/company/bd1" "created" => "2021-09-09 01:08:11" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 476539957 "company_id" => 35408 "url" => "https://www.linkedin.com/company/gehealthcare" "created" => "2021-09-09 01:08:11" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 476539958 "company_id" => 35408 "url" => "https://nl.linkedin.com/company/philips" "created" => "2021-09-09 01:08:11" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 476539959 "company_id" => 35408 "url" => "https://www.linkedin.com/company/smith-&-nephew" "created" => "2021-09-09 01:08:11" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 476539960 "company_id" => 35408 "url" => "https://www.linkedin.com/company/baxter-healthcare" "created" => "2021-09-09 01:08:11" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 476539961 "company_id" => 35408 "url" => "https://www.linkedin.com/company/zimmerbiomet" "created" => "2021-09-09 01:08:11" "last_updated" => "2022-03-01 11:01:17" "deleted" => 1 ] [ "id" => 557750570 "company_id" => 35408 "url" => "https://de.linkedin.com/company/siemens-healthineers" "created" => "2022-03-01 11:01:17" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 660241324 "company_id" => 35408 "url" => "https://www.linkedin.com/company/medtronic" "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 660241325 "company_id" => 35408 "url" => "https://www.linkedin.com/company/abbott-" "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 660241326 "company_id" => 35408 "url" => "https://www.linkedin.com/company/stryker" "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 660241327 "company_id" => 35408 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 660241328 "company_id" => 35408 "url" => "https://www.linkedin.com/company/bd1" "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 660241329 "company_id" => 35408 "url" => "https://www.linkedin.com/company/gehealthcare" "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 660241330 "company_id" => 35408 "url" => "https://www.linkedin.com/company/smith-&-nephew" "created" => "2022-07-13 07:52:31" "last_updated" => "2022-10-15 07:10:29" "deleted" => 1 ] [ "id" => 660241331 "company_id" => 35408 "url" => "https://nl.linkedin.com/company/philips" "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 660241332 "company_id" => 35408 "url" => "https://www.linkedin.com/company/baxter-healthcare" "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 660241333 "company_id" => 35408 "url" => "https://de.linkedin.com/company/siemens-healthineers" "created" => "2022-07-13 07:52:31" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 726977380 "company_id" => 35408 "url" => "https://uk.linkedin.com/company/smith-&-nephew" "created" => "2022-10-15 07:10:29" "last_updated" => "2024-05-25 21:16:38" "deleted" => 1 ] [ "id" => 1007640601 "company_id" => 35408 "url" => "https://uk.linkedin.com/company/smith-nephew" "created" => "2024-05-25 21:16:38" "last_updated" => "2025-02-04 21:15:52" "deleted" => 1 ] [ "id" => 1147681699 "company_id" => 35408 "url" => "https://www.linkedin.com/company/intuitivesurgical" "created" => "2025-02-04 21:15:52" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] ] "company_specialties_collection" => [] "company_stock_info_collection" => [ [ "id" => 2808 "company_id" => 35408 "ticker" => "BSX" "exchange" => "NYSE" "created" => "2020-05-07 21:09:44" "last_updated" => "2020-05-13 10:28:35" "deleted" => 1 ] [ "id" => 3370 "company_id" => 35408 "ticker" => "BSX" "exchange" => "NYSE" "created" => "2020-05-21 14:08:32" "last_updated" => "2020-07-03 12:21:15" "deleted" => 1 ] [ "id" => 5043 "company_id" => 35408 "ticker" => "BSX" "exchange" => "NYSE" "created" => "2020-07-14 17:08:48" "last_updated" => "2021-07-15 03:06:33" "deleted" => 1 ] [ "id" => 12934 "company_id" => 35408 "ticker" => "BSX" "exchange" => "NYSE" "created" => "2021-07-15 15:04:14" "last_updated" => "2021-09-09 01:08:11" "deleted" => 1 ] [ "id" => 15307 "company_id" => 35408 "ticker" => "BSX" "exchange" => "NYSE" "created" => "2022-01-03 11:04:11" "last_updated" => "2022-02-07 10:18:18" "deleted" => 1 ] [ "id" => 17488 "company_id" => 35408 "ticker" => "BSX" "exchange" => "NYSE" "created" => "2022-02-09 18:21:47" "last_updated" => "2022-07-09 15:02:10" "deleted" => 1 ] [ "id" => 21282 "company_id" => 35408 "ticker" => "BSX" "exchange" => "NYSE" "created" => "2022-07-13 07:52:31" "last_updated" => "2022-07-22 03:21:36" "deleted" => 1 ] [ "id" => 21889 "company_id" => 35408 "ticker" => "BSX" "exchange" => "NYSE" "created" => "2022-09-06 14:12:17" "last_updated" => "2022-09-15 12:15:11" "deleted" => 1 ] [ "id" => 22456 "company_id" => 35408 "ticker" => "NYSE" "exchange" => "BSX" "created" => "2022-09-15 12:15:12" "last_updated" => "2022-12-17 16:24:52" "deleted" => 1 ] [ "id" => 26263 "company_id" => 35408 "ticker" => "BSX" "exchange" => "NYSE" "created" => "2022-12-17 16:24:52" "last_updated" => "2023-02-06 14:19:35" "deleted" => 1 ] [ "id" => 28610 "company_id" => 35408 "ticker" => "BSX" "exchange" => "NYSE" "created" => "2023-02-11 06:55:53" "last_updated" => "2023-08-16 04:12:24" "deleted" => 1 ] [ "id" => 32601 "company_id" => 35408 "ticker" => "BSX" "exchange" => "NYSE" "created" => "2023-09-17 21:38:30" "last_updated" => "2024-07-22 12:53:15" "deleted" => 1 ] [ "id" => 33622 "company_id" => 35408 "ticker" => "BSX" "exchange" => "NYSE" "created" => "2024-08-08 15:10:43" "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] ] "company_updates_collection" => [ [ "id" => 16910934 "company_id" => 35408 "urn" => "urn:li:activity:7008866307710337024" "followers" => 764836 "date" => "2d" "description" => "How do we improve health outcomes in Black communities? The answer may lay at the intersection of data and something more human. Paige Bingham, National Program Director of Close the Gap explores possible solutions with STAT. https://bit.ly/3Wi1tlT" "reactions_count" => 53 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-12 13:16:17" "deleted" => 1 ] [ "id" => 16910935 "company_id" => 35408 "urn" => "urn:li:activity:7008128535240339456" "followers" => 764836 "date" => "4d" "description" => "We are creating a healthier, brighter future for one another and for our planet and thanks to our employees work to fulfill our mission as a global corporate citizen, we have been included in the S&P Global 2022 Dow Jones Sustainability Index North America. Learn more: https://bit.ly/3VQdOxR #DJSI" "reactions_count" => 65 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-12 13:16:17" "deleted" => 1 ] [ "id" => 16910936 "company_id" => 35408 "urn" => "urn:li:activity:7008080173480771584" "followers" => 764836 "date" => "5d" "description" => "We’re excited to announce that we will make a partial offer to acquire a majority stake in Acotec, a Chinese medtech leader. Upon close, we believe this strategic investment can create opportunities to increase the scale and reach of both companies to provide more physicians and patients access to our robust and complementary product portfolios. https://lnkd.in/gkN9jj2U" "reactions_count" => 888 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-12 13:16:17" "deleted" => 1 ] [ "id" => 16910937 "company_id" => 35408 "urn" => "urn:li:activity:7007992550007484416" "followers" => 764836 "date" => "5d" "description" => """ Mike Mahoney, Chairman and CEO of Boston Scientific, and Eric Thépaut, Executive Vice President and President of #BSCEMEA, joined the #BSCFrance team last week to inaugurate the new Institute for Advancing Science (IAS) in Paris. At this facility, healthcare professionals will come to receive expert training and guidance on the safe, effective and appropriate use of our products and the disease states they treat.\n \n The Paris IAS is part of a network of seven training centers in the EMEA region, all equipped with an extensive range of #virtualreality simulators. In addition, innovative imaging and diagnostic tools, along with biological and non-biological models, simulate realistic clinical situations.\n Sandrine Bazile Pham-Khac Muriel GRANGER-PASCOT """ "reactions_count" => 1421 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-12 13:16:17" "deleted" => 1 ] [ "id" => 16910938 "company_id" => 35408 "urn" => "urn:li:activity:7004791730931740672" "followers" => 764836 "date" => "2w" "description" => "We’re celebrating International Day of Persons with Disabilities by lighting up our sites around the world in purple to show our support and commitment to disability inclusion. #IDPWD2022" "reactions_count" => 2042 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-12 13:16:17" "deleted" => 1 ] [ "id" => 16910939 "company_id" => 35408 "urn" => "urn:li:activity:7004555547786059776" "followers" => 764836 "date" => "2w" "description" => "Mary Beth Moynihan and Wendy Carruthers were recently recognized by WomenInc. as two of the top fifteen most influential women in corporate America for their professional and philanthropic impact. Congratulations! https://bit.ly/3OVQRqd" "reactions_count" => 802 "comments_count" => 65 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-12 13:16:17" "deleted" => 1 ] [ "id" => 16910940 "company_id" => 35408 "urn" => "urn:li:activity:7003369987100876800" "followers" => 764836 "date" => "2w" "description" => """ We’re excited to announce that we’ve entered into a definitive agreement to acquire Apollo Endosurgery, whose portfolio includes devices used during endoluminal surgery (ELS) procedures to close gastrointestinal defects, manage gastrointestinal complications and aid in weight loss for patients suffering from obesity. \n \n “We intend to expand our global capabilities in ELS with the differentiated innovation that Apollo Endosurgery offers, and we will continue to focus on procedural adoption as well as professional education in this exciting space,” said Mike Jones, president, Endoscopy. https://lnkd.in/eb4jHCd6 """ "reactions_count" => 1912 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-12 13:16:17" "deleted" => 1 ] [ "id" => 16910941 "company_id" => 35408 "urn" => "urn:li:activity:7001249933404098560" "followers" => 764836 "date" => "3w" "description" => "From COVID-19 prevention to baking for a good cause: Here's a snapshot of how employees gave back throughout the year. #BSCCommunity https://bit.ly/3tZOau0" "reactions_count" => 218 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-12 13:16:17" "deleted" => 1 ] [ "id" => 16910942 "company_id" => 35408 "urn" => "urn:li:activity:6999296321375334401" "followers" => 764836 "date" => "4w" "description" => """ Boston Scientific is featured in the 2023 Financial Times Leaders in Diversity Index, at place #58 and #3 in the Health Care Equipment and Services sector.\n \n Diversity Leaders in Europe are identified via an independent survey, conducted by Statista, that evaluates employees’ perception of company diversity, equity and inclusion efforts.\n \n Thank you to our employees who help every day to make #BSCEMEA a place where everyone can feel they belong. \n To learn more about our DE&I efforts: https://bit.ly/3UO7nea\n \n #BSCEmployee """ "reactions_count" => 723 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-12 13:16:17" "deleted" => 1 ] [ "id" => 16910943 "company_id" => 35408 "urn" => "urn:li:activity:6998728933483433984" "followers" => 764836 "date" => "1mo" "description" => "In her first interview as VP of Environmental, Social and Governance (ESG), Kathryn Unger shares what led her to this important role and her thoughts on the progress we’ve made toward our #ESG goals – including an important step forward in our journey to net-zero. https://bit.ly/3TN005b" "reactions_count" => 502 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-12 13:16:17" "deleted" => 1 ] [ "id" => 42784215 "company_id" => 35408 "urn" => "urn:li:activity:7018592564924612608" "followers" => 773328 "date" => "1d" "description" => "Michael R. Jaff, Catherine (Yankelevich) Jennings and David Knapp shed light on why peripheral artery disease (PAD) is more prevalent in Black populations, and how we’re working to close the health disparity gap through research and innovation. The Wall Street Journal https://bit.ly/3iyYS8N" "reactions_count" => 95 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:33:08" "deleted" => 1 ] [ "id" => 42784216 "company_id" => 35408 "urn" => "urn:li:activity:7016449250918109184" "followers" => 773328 "date" => "1w" "description" => "We are creating a healthier, brighter future for one another and for our planet. Thanks to our employees' work to fulfill our mission as a global corporate citizen, we have been included in the S&P Global 2022 Dow Jones Sustainability Index North America. Learn more: https://bit.ly/3G81QsM #DJSI #ESG" "reactions_count" => 240 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:33:08" "deleted" => 1 ] [ "id" => 42784217 "company_id" => 35408 "urn" => "urn:li:activity:7014258971221901312" "followers" => 773328 "date" => "1w" "description" => "From COVID-19 prevention to baking for a good cause: Here's a snapshot of how employees gave back throughout the year. #BSCCommunity https://bit.ly/3WNZO7R" "reactions_count" => 351 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:33:08" "deleted" => 1 ] [ "id" => 42784218 "company_id" => 35408 "urn" => "urn:li:activity:7014002434033287169" "followers" => 773328 "date" => "2w" "description" => "We recently celebrated the grand opening of our new Global Distribution Center in Penang, Malaysia. Congratulations to the many employees who have been working to bring the new site to fruition." "reactions_count" => 1288 "comments_count" => 15 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:33:08" "deleted" => 1 ] [ "id" => 42784219 "company_id" => 35408 "urn" => "urn:li:activity:7011794826136363008" "followers" => 773328 "date" => "2w" "description" => "Warm wishes for a happy, healthy holiday season from all of us at Boston Scientific." "reactions_count" => 985 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:33:08" "deleted" => 1 ] [ "id" => 42784220 "company_id" => 35408 "urn" => "urn:li:activity:7011039807350988801" "followers" => 773328 "date" => "3w" "description" => "Jenny Lee, VP of Global Digital Marketing and Customer Experience, was named to Diversity Woman Media's 2022 Power 100. Congratulations on this well-deserved recognition!" "reactions_count" => 311 "comments_count" => 31 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:33:08" "deleted" => 1 ] [ "id" => 42784221 "company_id" => 35408 "urn" => "urn:li:activity:7008866307710337024" "followers" => 773328 "date" => "4w" "description" => "How do we improve health outcomes in Black communities? The answer may lay at the intersection of data and something more human. Paige Bingham, National Program Director of Close the Gap explores possible solutions with STAT. https://bit.ly/3Wi1tlT" "reactions_count" => 114 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:33:08" "deleted" => 1 ] [ "id" => 42784222 "company_id" => 35408 "urn" => "urn:li:activity:7008128535240339456" "followers" => 773328 "date" => "1mo" "description" => "We are creating a healthier, brighter future for one another and for our planet. Thanks to our employees' work to fulfill our mission as a global corporate citizen, we have been included in the S&P Global 2022 Dow Jones Sustainability Index North America. Learn more: https://bit.ly/3VQdOxR #DJSI #ESG" "reactions_count" => 82 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:33:08" "deleted" => 1 ] [ "id" => 42784223 "company_id" => 35408 "urn" => "urn:li:activity:7008080173480771584" "followers" => 773328 "date" => "1mo" "description" => "We’re excited to announce that we will make a partial offer to acquire a majority stake in Acotec, a Chinese medtech leader. Upon close, we believe this strategic investment can create opportunities to increase the scale and reach of both companies to provide more physicians and patients access to our robust and complementary product portfolios. https://lnkd.in/gkN9jj2U" "reactions_count" => 1001 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:33:08" "deleted" => 1 ] [ "id" => 42784224 "company_id" => 35408 "urn" => "urn:li:activity:7007992550007484416" "followers" => 773328 "date" => "1mo" "description" => """ Mike Mahoney, Chairman and CEO of Boston Scientific, and Eric Thépaut, Executive Vice President and President of #BSCEMEA, joined the #BSCFrance team last week to inaugurate the new Institute for Advancing Science (IAS) in Paris. At this facility, healthcare professionals will come to receive expert training and guidance on the safe, effective and appropriate use of our products and the disease states they treat.\n \n The Paris IAS is part of a network of seven training centers in the EMEA region, all equipped with an extensive range of #virtualreality simulators. In addition, innovative imaging and diagnostic tools, along with biological and non-biological models, simulate realistic clinical situations.\n Sandrine Bazile Pham-Khac Muriel GRANGER-PASCOT """ "reactions_count" => 1731 "comments_count" => 16 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:33:08" "deleted" => 1 ] [ "id" => 48508403 "company_id" => 35408 "urn" => "urn:li:activity:7020751724512501760" "followers" => 774997 "date" => "3h" "description" => "Mary Beth Moynihan, SVP Market Access and CMO, shares her three-step approach for taking control of your career's future with WomenInc. https://bit.ly/3Wdayfh" "reactions_count" => 60 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:19:35" "deleted" => 1 ] [ "id" => 48508404 "company_id" => 35408 "urn" => "urn:li:activity:7019705601999994880" "followers" => 774997 "date" => "3d" "description" => """ Can we better define the individual experience of chronic pain? Our collaboration with IBM Research aims to answer that question. Learn more about how our holistic approach can make an impact on management and treatment of #chronicpain:\n https://bit.ly/3CN44wV """ "reactions_count" => 134 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:19:35" "deleted" => 1 ] [ "id" => 48508405 "company_id" => 35408 "urn" => "urn:li:activity:7018592564924612608" "followers" => 774997 "date" => "6d" "description" => "Michael R. Jaff, Catherine (Yankelevich) Jennings and David Knapp shed light on why peripheral artery disease (PAD) is more prevalent in Black populations, and how we’re working to close the health disparity gap through research and innovation. The Wall Street Journal https://bit.ly/3iyYS8N" "reactions_count" => 133 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:19:35" "deleted" => 1 ] [ "id" => 48508406 "company_id" => 35408 "urn" => "urn:li:activity:7016449250918109184" "followers" => 774997 "date" => "1w" "description" => "We are creating a healthier, brighter future for one another and for our planet. Thanks to our employees' work to fulfill our mission as a global corporate citizen, we have been included in the S&P Global 2022 Dow Jones Sustainability Index North America. Learn more: https://bit.ly/3G81QsM #DJSI #ESG" "reactions_count" => 264 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:19:35" "deleted" => 1 ] [ "id" => 48508407 "company_id" => 35408 "urn" => "urn:li:activity:7014258971221901312" "followers" => 774997 "date" => "2w" "description" => "From COVID-19 prevention to baking for a good cause: Here's a snapshot of how employees gave back throughout the year. #BSCCommunity https://bit.ly/3WNZO7R" "reactions_count" => 368 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:19:35" "deleted" => 1 ] [ "id" => 48508408 "company_id" => 35408 "urn" => "urn:li:activity:7014002434033287169" "followers" => 774997 "date" => "2w" "description" => "We recently celebrated the grand opening of our new Global Distribution Center in Penang, Malaysia. Congratulations to the many employees who have been working to bring the new site to fruition." "reactions_count" => 1360 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:19:35" "deleted" => 1 ] [ "id" => 48508409 "company_id" => 35408 "urn" => "urn:li:activity:7011794826136363008" "followers" => 774997 "date" => "3w" "description" => "Warm wishes for a happy, healthy holiday season from all of us at Boston Scientific." "reactions_count" => 985 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:19:35" "deleted" => 1 ] [ "id" => 48508410 "company_id" => 35408 "urn" => "urn:li:activity:7011039807350988801" "followers" => 774997 "date" => "3w" "description" => "Jenny Lee, VP of Global Digital Marketing and Customer Experience, was named to Diversity Woman Media's 2022 Power 100. Congratulations on this well-deserved recognition!" "reactions_count" => 311 "comments_count" => 31 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:19:35" "deleted" => 1 ] [ "id" => 48508411 "company_id" => 35408 "urn" => "urn:li:activity:7008866307710337024" "followers" => 774997 "date" => "1mo" "description" => "How do we improve health outcomes in Black communities? The answer may lay at the intersection of data and something more human. Paige Bingham, National Program Director of Close the Gap explores possible solutions with STAT. https://bit.ly/3Wi1tlT" "reactions_count" => 115 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:19:35" "deleted" => 1 ] [ "id" => 48508412 "company_id" => 35408 "urn" => "urn:li:activity:7008128535240339456" "followers" => 774997 "date" => "1mo" "description" => "We are creating a healthier, brighter future for one another and for our planet. Thanks to our employees' work to fulfill our mission as a global corporate citizen, we have been included in the S&P Global 2022 Dow Jones Sustainability Index North America. Learn more: https://bit.ly/3VQdOxR #DJSI #ESG" "reactions_count" => 81 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:19:35" "deleted" => 1 ] [ "id" => 56195227 "company_id" => 35408 "urn" => "urn:li:activity:7027214424205660160" "followers" => 784006 "date" => "3d" "description" => "It’s Wear Red Day! Employees around the world are wearing red for the 1 in 5 women who die from heart disease every year. Join us in raising awareness of women’s cardiovascular health. #GoRedBSC" "reactions_count" => 1037 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-11 06:55:53" "deleted" => 1 ] [ "id" => 56195228 "company_id" => 35408 "urn" => "urn:li:activity:7027401093210927104" "followers" => 784006 "date" => "2d" "description" => "Today, employees worldwide showed their commitment to raising awareness for women’s cardiovascular health. Thank you to everyone who made #WearRedDay a success, including many members of our EMPOWHER employee resource group! #GoRedBSC" "reactions_count" => 1557 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-11 06:55:53" "deleted" => 1 ] [ "id" => 56195229 "company_id" => 35408 "urn" => "urn:li:activity:7027305546395353088" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Boston Scientific Cardiology" "reshared_post_author_url" => "https://www.linkedin.com/showcase/boston-scientific-cardiology" "reshared_post_author_headline" => null "reshared_post_description" => "February is American #HeartMonth. ❤ Join us in raising awareness about cardiovascular disease prevention, monitoring and treatment all month long." "reshared_post_followers" => 82818 "reshared_post_date" => "4d" "last_updated" => "2023-02-11 06:55:53" "deleted" => 1 ] [ "id" => 56195230 "company_id" => 35408 "urn" => "urn:li:activity:7026628482596044801" "followers" => 784006 "date" => "4d" "description" => "Our employees work together every day to find innovative solutions to health care’s toughest challenges. It’s because of them that we have been named one of Fortune’s World’s Most Admired Companies for the eighth consecutive year. #MostAdmiredCos https://bit.ly/3JwnXMG" "reactions_count" => 660 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-11 06:55:53" "deleted" => 1 ] [ "id" => 56195231 "company_id" => 35408 "urn" => "urn:li:activity:7026564611655012352" "followers" => 784006 "date" => "4d" "description" => "BSX announces Q4 and Full Year 2022 financial results. Refer to our release for more information & non-GAAP reconciliations: https://bit.ly/3JwrxX6" "reactions_count" => 1276 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-11 06:55:53" "deleted" => 1 ] [ "id" => 56195232 "company_id" => 35408 "urn" => "urn:li:activity:7026224580058902528" "followers" => 784006 "date" => "5d" "description" => "We’re honored to be included in the 2023 Bloomberg Gender-Equality Index for the fifth consecutive year in recognition of our commitment to fostering a more inclusive and equitable workplace. #BloombergGEI" "reactions_count" => 308 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-11 06:55:53" "deleted" => 1 ] [ "id" => 56195233 "company_id" => 35408 "urn" => "urn:li:activity:7020806219112075264" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Camille Chang Gilmore, MBA" "reshared_post_author_url" => "https://www.linkedin.com/in/camille-chang-gilmore-mba-61a04614" "reshared_post_author_headline" => "Vice President, Human Resources and Global Chief Diversity, Equity, & Inclusion Officer at Boston Scientific" "reshared_post_description" => """ As we think about the Reverend Dr. Martin Luther King’s legacy today, remember—it’s not our distant past. This last spring I was honored to take part in a pilgrimage to the Edmund Pettis Bridge in Selma. I marched in reflection of our nation’s progress toward racial equity, walking in the footsteps of those who—in my own lifetime—were brutally beaten for that cause. \n \n Today our feeds will be filled with many of Dr. King’s most loving and, frankly, palatable messages. And we should—I still believe we can pursue his beloved community. \n \n At the same time, my dear sorority Alpha Kappa Alpha Sorority Incorporated yesterday celebrated 115 years of “service to all mankind”. Who would have thought that black women at Howard University could see a vision of service bigger than themselves. As we continue to face deep inequity and injustice all around us, let’s remember the grit and struggle of Dr. King’s legacy and so many others that came before us. \n \n In his words, “Change does not roll in on the wheels of inevitability, but comes through continuous struggle.”\n \n Or as I like to say…progress over time, not overnight. Let’s keep doing the hard work to move forward, together. """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2023-03-10 19:51:19" "deleted" => 1 ] [ "id" => 56195234 "company_id" => 35408 "urn" => "urn:li:activity:7020751724512501760" "followers" => 784006 "date" => "2w" "description" => "Mary Beth Moynihan, SVP Market Access and CMO, shares her three-step approach for taking control of your career's future with WomenInc. https://bit.ly/3Wdayfh" "reactions_count" => 334 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-11 06:55:53" "deleted" => 1 ] [ "id" => 56195235 "company_id" => 35408 "urn" => "urn:li:activity:7019705601999994880" "followers" => 784006 "date" => "3w" "description" => """ Can we better define the individual experience of chronic pain? Our collaboration with IBM Research aims to answer that question. Learn more about how our holistic approach can make an impact on management and treatment of #chronicpain:\n https://bit.ly/3CN44wV """ "reactions_count" => 211 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-11 06:55:53" "deleted" => 1 ] [ "id" => 56195236 "company_id" => 35408 "urn" => "urn:li:activity:7018592564924612608" "followers" => 784006 "date" => "3w" "description" => "Michael R. Jaff, Catherine (Yankelevich) Jennings and David Knapp shed light on why peripheral artery disease (PAD) is more prevalent in Black populations, and how we’re working to close the health disparity gap through research and innovation. The Wall Street Journal https://bit.ly/3iyYS8N" "reactions_count" => 220 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-11 06:55:53" "deleted" => 1 ] [ "id" => 66374652 "company_id" => 35408 "urn" => "urn:li:activity:7029834352154877953" "followers" => 786170 "date" => "5h" "description" => "The Becoming Everything You Are (BEYA) STEM conference helps connect employers with job seekers from diverse backgrounds. When we expand our reach to identify the best and brightest, we all do better. Read R&D Engineer Jenny’s story. #BEYA2023 https://bit.ly/3jPtkfE" "reactions_count" => 20 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-10 19:51:19" "deleted" => 1 ] [ "id" => 66374653 "company_id" => 35408 "urn" => "urn:li:activity:7029745688448016384" "followers" => 786170 "date" => "11h" "description" => """ Boston Scientific and the Boston Scientific Foundation Europe have joined forces to support relief efforts in Turkiye and Syria in response to recent earthquakes. All donations will go toward disaster relief, including providing emergency accommodations, meals, hygiene items and critical emergency supplies.\n \n We have also launched an Employee Matching Programme to double employee donations up to $500 and maximize our impact on the ground. """ "reactions_count" => 712 "comments_count" => 13 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-10 19:51:19" "deleted" => 1 ] [ "id" => 66374654 "company_id" => 35408 "urn" => "urn:li:activity:7028828466917609472" "followers" => 786170 "date" => "3d" "description" => "Thank you to our South Asians in Leadership (SAIL) employee resource group for supporting communities in India while sharing high-fives and smiles along the way. #BSCCommunity" "reactions_count" => 256 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-10 19:51:19" "deleted" => 1 ] [ "id" => 66374655 "company_id" => 35408 "urn" => "urn:li:activity:7027401093210927104" "followers" => 786170 "date" => "6d" "description" => "Today, employees worldwide showed their commitment to raising awareness for women’s cardiovascular health. Thank you to everyone who made #WearRedDay a success, including many members of our EMPOWHER employee resource group! #GoRedBSC" "reactions_count" => 2147 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-10 19:51:19" "deleted" => 1 ] [ "id" => 66374656 "company_id" => 35408 "urn" => "urn:li:activity:7027305546395353088" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Boston Scientific Cardiology" "reshared_post_author_url" => "https://www.linkedin.com/showcase/boston-scientific-cardiology" "reshared_post_author_headline" => null "reshared_post_description" => "February is American #HeartMonth. ❤ Join us in raising awareness about cardiovascular disease prevention, monitoring and treatment all month long." "reshared_post_followers" => 83058 "reshared_post_date" => "1w" "last_updated" => "2023-03-10 19:51:19" "deleted" => 1 ] [ "id" => 66374657 "company_id" => 35408 "urn" => "urn:li:activity:7027214424205660160" "followers" => 786170 "date" => "1w" "description" => "It’s Wear Red Day! Employees around the world are wearing red for the 1 in 5 women who die from heart disease every year. Join us in raising awareness of women’s cardiovascular health. #GoRedBSC" "reactions_count" => 1148 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-10 19:51:19" "deleted" => 1 ] [ "id" => 66374658 "company_id" => 35408 "urn" => "urn:li:activity:7026628482596044801" "followers" => 786170 "date" => "1w" "description" => "Our employees work together every day to find innovative solutions to health care’s toughest challenges. It’s because of them that we have been named one of Fortune’s World’s Most Admired Companies for the eighth consecutive year. #MostAdmiredCos https://bit.ly/3JwnXMG" "reactions_count" => 698 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-10 19:51:19" "deleted" => 1 ] [ "id" => 66374659 "company_id" => 35408 "urn" => "urn:li:activity:7026564611655012352" "followers" => 786170 "date" => "1w" "description" => "BSX announces Q4 and Full Year 2022 financial results. Refer to our release for more information & non-GAAP reconciliations: https://bit.ly/3JwrxX6" "reactions_count" => 1320 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-10 19:51:19" "deleted" => 1 ] [ "id" => 66374660 "company_id" => 35408 "urn" => "urn:li:activity:7026224580058902528" "followers" => 786170 "date" => "1w" "description" => "We’re honored to be included in the 2023 Bloomberg Gender-Equality Index for the fifth consecutive year in recognition of our commitment to fostering a more inclusive and equitable workplace. #BloombergGEI" "reactions_count" => 341 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-10 19:51:19" "deleted" => 1 ] [ "id" => 105478792 "company_id" => 35408 "urn" => "urn:li:activity:7039656295435575296" "followers" => 797954 "date" => "17h" "description" => "We’re excited to be named one of America's Greatest Workplaces for Women 2023 by Newsweek! #WomensHistoryMonth #EmbraceEquity https://bit.ly/423NBiH" "reactions_count" => 161 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 07:36:15" "deleted" => 1 ] [ "id" => 105478793 "company_id" => 35408 "urn" => "urn:li:activity:7039595861227560961" "followers" => 797954 "date" => "21h" "description" => "Life-changing technologies mean little if they don't make their way to the patients that need them. Our EDUCARE program provides opportunities for doctors to advance their education through hands-on training and online courses. https://bit.ly/3J3FJoX" "reactions_count" => 128 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 07:36:15" "deleted" => 1 ] [ "id" => 105478794 "company_id" => 35408 "urn" => "urn:li:activity:7039173113640615936" "followers" => 797954 "date" => "2d" "description" => "Today we #EmbraceEquity for International Women’s Day. Join us in celebrating women’s representation and achievement at Boston Scientific and beyond. #IWD23" "reactions_count" => 610 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 07:36:15" "deleted" => 1 ] [ "id" => 105478795 "company_id" => 35408 "urn" => "urn:li:activity:7034945278893842432" "followers" => 797954 "date" => "1w" "description" => "Congratulations to Nelda Connors for being named one of the Top 25 Black Board Members in the U.S. by BoardProspects." "reactions_count" => 494 "comments_count" => 21 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 07:36:15" "deleted" => 1 ] [ "id" => 105478796 "company_id" => 35408 "urn" => "urn:li:activity:7033797613778866176" "followers" => 797954 "date" => "2w" "description" => "Omar Carter was 25 when his heart stopped on the basketball court. Now, he's teaching others about emergency cardiac care through his foundation. Read his inspiring story: https://bit.ly/3xG0hOL #heartmonth #suddencardiacarrest" "reactions_count" => 313 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 07:36:15" "deleted" => 1 ] [ "id" => 105478797 "company_id" => 35408 "urn" => "urn:li:activity:7032408480875511808" "followers" => 797954 "date" => "2w" "description" => "Jason’s experience at Florida A&M University equipped him with the skills required to excel in his role as an Area Vice President. He knows first-hand the positive impact that HBCU graduates have in the workplace." "reactions_count" => 57 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 07:36:15" "deleted" => 1 ] [ "id" => 105478798 "company_id" => 35408 "urn" => "urn:li:activity:7032348015071821824" "followers" => 797954 "date" => "2w" "description" => "Nearly twenty years ago, our #CloseTheGap program set out to improve health disparities affecting women and people of color. Today, we continue this work by increasing diversity in medical research and deepening our relationships with physicians. Camille Chang Gilmore, MBA and Dr. Michael R. Jaff explain more with MD+DI. https://bit.ly/3Kh4TCK" "reactions_count" => 193 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 07:36:15" "deleted" => 1 ] [ "id" => 105478799 "company_id" => 35408 "urn" => "urn:li:activity:7031985741828165633" "followers" => 797954 "date" => "3w" "description" => "Jasmin’s experience at HBCU Norfolk State University equipped her with the confidence and professional skills to shine in her role as a Product Manager." "reactions_count" => 133 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 07:36:15" "deleted" => 1 ] [ "id" => 105478800 "company_id" => 35408 "urn" => "urn:li:activity:7031638568934510593" "followers" => 797954 "date" => "3w" "description" => "Jeri'Ann Hiller, PhD and George Omae have been named Modern-Day Technology Leaders at the 2023 BEYA (Black Engineer of the Year) STEM Conference. Congratulations to both, and thanks for all you do to help us transform lives through innovative medical solutions. #BEYA" "reactions_count" => 393 "comments_count" => 34 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 07:36:15" "deleted" => 1 ] [ "id" => 105478801 "company_id" => 35408 "urn" => "urn:li:activity:7031315672752144384" "followers" => 797954 "date" => "3w" "description" => "What does a global chief medical officer do? According to Dr. Ken Stein, the job is all about putting patients first. In his first week in the role, find out how he plans to do just that. https://bit.ly/3HZLAuW" "reactions_count" => 543 "comments_count" => 40 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 07:36:15" "deleted" => 1 ] [ "id" => 121925206 "company_id" => 35408 "urn" => "urn:li:activity:7047333468816502784" "followers" => 807806 "date" => "3d" "description" => "We’re excited to introduce our new podcast with DeviceTalks featuring Boston Scientific leaders and innovators. In our first episode, Matthew McDonald and IBM Research's Jeffrey Rogers discuss our collaboration to help patients with chronic pain. https://bit.ly/3nBvzo9" "reactions_count" => 240 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-10 07:09:31" "deleted" => 1 ] [ "id" => 121925207 "company_id" => 35408 "urn" => "urn:li:activity:7044691752363982848" "followers" => 807806 "date" => "1w" "description" => "We aim to improve the health of our communities and advance science for generations to come. Thank you to everyone who made a difference in 2022. #BSCCommunity" "reactions_count" => 220 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-10 07:09:31" "deleted" => 1 ] [ "id" => 121925208 "company_id" => 35408 "urn" => "urn:li:activity:7043567106080051200" "followers" => 807806 "date" => "2w" "description" => "Is workplace competition dead, or just different? Mary Beth Moynihan, our SVP Market Access and CMO, shares her perspective in The Wall Street Journal (subscription required). https://on.wsj.com/3yQN8mF" "reactions_count" => 101 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-10 07:09:31" "deleted" => 1 ] [ "id" => 121925209 "company_id" => 35408 "urn" => "urn:li:activity:7039656295435575296" "followers" => 807806 "date" => "3w" "description" => "We’re excited to be named one of America's Greatest Workplaces for Women 2023 by Newsweek! #WomensHistoryMonth #EmbraceEquity https://bit.ly/423NBiH" "reactions_count" => 340 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-10 07:09:31" "deleted" => 1 ] [ "id" => 121925210 "company_id" => 35408 "urn" => "urn:li:activity:7039595861227560961" "followers" => 807806 "date" => "3w" "description" => "Life-changing technologies mean little if they don't make their way to the patients that need them. Our EDUCARE program provides opportunities for doctors to advance their education through hands-on training and online courses. https://bit.ly/3J3FJoX" "reactions_count" => 322 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-10 07:09:31" "deleted" => 1 ] [ "id" => 121925211 "company_id" => 35408 "urn" => "urn:li:activity:7039173113640615936" "followers" => 807806 "date" => "3w" "description" => "Today we #EmbraceEquity for International Women’s Day. Join us in celebrating women’s representation and achievement at Boston Scientific and beyond. #IWD23" "reactions_count" => 827 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-10 07:09:31" "deleted" => 1 ] [ "id" => 121925212 "company_id" => 35408 "urn" => "urn:li:activity:7034945278893842432" "followers" => 807806 "date" => "1mo" "description" => "Congratulations to Nelda Connors for being named one of the Top 25 Black Board Members in the U.S. by BoardProspects." "reactions_count" => 512 "comments_count" => 23 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-10 07:09:31" "deleted" => 1 ] [ "id" => 121925213 "company_id" => 35408 "urn" => "urn:li:activity:7033797613778866176" "followers" => 807806 "date" => "1mo" "description" => "Omar Carter was 25 when his heart stopped on the basketball court. Now, he's teaching others about emergency cardiac care through his foundation. Read his inspiring story: https://bit.ly/3xG0hOL #heartmonth #suddencardiacarrest" "reactions_count" => 317 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-10 07:09:31" "deleted" => 1 ] [ "id" => 121925214 "company_id" => 35408 "urn" => "urn:li:activity:7032408480875511808" "followers" => 807806 "date" => "1mo" "description" => "Jason’s experience at Florida A&M University equipped him with the skills required to excel in his role as an Area Vice President. He knows first-hand the positive impact that HBCU graduates have in the workplace." "reactions_count" => 62 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-10 07:09:31" "deleted" => 1 ] [ "id" => 121925215 "company_id" => 35408 "urn" => "urn:li:activity:7032348015071821824" "followers" => 807806 "date" => "1mo" "description" => "Nearly twenty years ago, our #CloseTheGap program set out to improve health disparities affecting women and people of color. Today, we continue this work by increasing diversity in medical research and deepening our relationships with physicians. Camille Chang Gilmore, MBA and Dr. Michael R. Jaff explain more with MD+DI. https://bit.ly/3Kh4TCK" "reactions_count" => 194 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-10 07:09:31" "deleted" => 1 ] [ "id" => 171674228 "company_id" => 35408 "urn" => "urn:li:activity:7061324623488946176" "followers" => 823167 "date" => "1d" "description" => "Abi-Gaye was diagnosed with a heart condition that put her at risk for sudden cardiac arrest. Today, she looks forward to a long life, made possible with help from her device. Watch her inspiring story:" "reactions_count" => 163 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-09 18:26:32" "deleted" => 1 ] [ "id" => 171674229 "company_id" => 35408 "urn" => "urn:li:activity:7059874345782837248" "followers" => 823167 "date" => "5d" "description" => "Katie and Yixuan talk about the meaningful connections they’ve made through the Pacific East Asian Resources in Leadership (PEARL) employee resource group, and how a sense of belonging and purpose has helped grow and shape their careers. #AAPIHeritageMonth https://bit.ly/3pbJmCG" "reactions_count" => 248 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-09 18:26:32" "deleted" => 1 ] [ "id" => 171674230 "company_id" => 35408 "urn" => "urn:li:activity:7057700094514507776" "followers" => 823167 "date" => "1w" "description" => "As Apollo Endosurgery officially becomes part of Boston Scientific, Mike Jones, SVP, president of Endoscopy shares his thoughts on how the acquisition stands to benefit patients suffering from gastrointestinal defects and obesity worldwide. https://bit.ly/40N7poE" "reactions_count" => 1312 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-09 18:26:32" "deleted" => 1 ] [ "id" => 171674231 "company_id" => 35408 "urn" => "urn:li:activity:7057337833199439872" "followers" => 823167 "date" => "1w" "description" => "How can our innovations help doctors navigate a high-pressure healthcare landscape? Ken Stein, global chief medical officer, Jodi Euerle Eddy, chief information and digital officer, and Meghan Scanlon, president, Urology sat down with The Wall Street Journal to explain how we’re rising to the challenge: https://bit.ly/3VjgHHZ" "reactions_count" => 176 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-09 18:26:32" "deleted" => 1 ] [ "id" => 171674232 "company_id" => 35408 "urn" => "urn:li:activity:7056978755466006528" "followers" => 823167 "date" => "1w" "description" => "BSX announces Q1 2023 financial results. Here’s a few highlights: https://bit.ly/3Nb8K5L" "reactions_count" => 1359 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-09 18:26:32" "deleted" => 1 ] [ "id" => 171674233 "company_id" => 35408 "urn" => "urn:li:activity:7056676710188023808" "followers" => 823167 "date" => "2w" "description" => "When employees bring their authentic selves to work, we all benefit from diversity of thought and advanced innovation. We are thrilled to be named one of the Best Employers for Diversity by Forbes and Statista for the sixth consecutive year. #BestEmployersforDiversity" "reactions_count" => 242 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-09 18:26:32" "deleted" => 1 ] [ "id" => 171674234 "company_id" => 35408 "urn" => "urn:li:activity:7056345333856944128" "followers" => 823167 "date" => "2w" "description" => "We are dedicated to finding innovative ways to improve the health of people around the world. We’re honored to receive Gold for EXALT™ Model B Single-Use Bronchoscope and Silver for STIMVIEW™ XT Technology at the 2023 Edison Awards. Learn more here: https://bit.ly/41BFI3r" "reactions_count" => 591 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-09 18:26:32" "deleted" => 1 ] [ "id" => 171674235 "company_id" => 35408 "urn" => "urn:li:activity:7056305580021284864" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Ken Stein" "reshared_post_author_url" => "https://www.linkedin.com/in/ken-stein-9a618645" "reshared_post_author_headline" => "Senior Vice President, Global Chief Medical Officer" "reshared_post_description" => "Congratulations, Ian T. Meredith, on your retirement and thank you for your years of service as the Global Chief Medical Officer at Boston Scientific. The legacy you’ve left on our organization, our culture and the many physicians and patients we serve is one of extraordinary leadership, humanity and compassion. I especially want to express my gratitude for how you led us through the challenges of COVID – both in helping guide our decision making but also in caring for our employees – and in developing a strong and deep patient-centered, clinical voice representing all aspects of our business. Wishing you all the best in the years to come. Michael R. Jaff Brian Dunkin Nilesh Patel MD, MBA Ronald Morton" "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2023-06-09 18:26:32" "deleted" => 1 ] [ "id" => 171674236 "company_id" => 35408 "urn" => "urn:li:activity:7055480466992238592" "followers" => 823167 "date" => "2w" "description" => "Today and every day, we challenge ourselves to meet #sustainability goals that support a healthier world for all. In honor of #EarthDay, learn about our path to net-zero and other actions we’re taking to protect the environment: https://bit.ly/3LlLRLv" "reactions_count" => 528 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-09 18:26:32" "deleted" => 1 ] [ "id" => 171674237 "company_id" => 35408 "urn" => "urn:li:activity:7055250592495013888" "followers" => 823167 "date" => "2w" "description" => "With a strong tradition of employees taking ownership of our #ESG impact throughout the company, Boston Scientific is achieving new levels of progress year after year. Kathryn Graves Unger, VP of ESG, shares some key results from our just-released 2022 Performance Report here: https://bit.ly/3UZMuxG" "reactions_count" => 174 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-09 18:26:32" "deleted" => 1 ] [ "id" => 197616937 "company_id" => 35408 "urn" => "urn:li:activity:7072195582538231808" "followers" => 837088 "date" => "17h" "description" => "We're excited to share that we have been named by US News as a 2023-2024 Best Company to Work For! See how you can learn, grow, and advance science for life in a career at Boston Scientific: https://bit.ly/42uKtvc #BCTWF" "reactions_count" => 361 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:05:04" "deleted" => 1 ] [ "id" => 197616938 "company_id" => 35408 "urn" => "urn:li:activity:7071505637246963713" "followers" => 837088 "date" => "2d" "description" => "Our work in health care comes with a responsibility to create positive change in the world around us. In honor of #WorldEnvironmentDay, learn more about our #ESG progress: https://bit.ly/43lSQuh" "reactions_count" => 384 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:05:04" "deleted" => 1 ] [ "id" => 197616939 "company_id" => 35408 "urn" => "urn:li:activity:7070040144963108864" "followers" => 837088 "date" => "6d" "description" => "Three employees from around the globe share what having a supportive and inclusive workplace means to them, and how their involvement in the Promoting Respect, Inclusion, Diversity and Equality (PRIDE) employee resource group has helped them grow personally and professionally. #PrideMonth https://bit.ly/42gvGnV" "reactions_count" => 671 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:05:04" "deleted" => 1 ] [ "id" => 197616940 "company_id" => 35408 "urn" => "urn:li:activity:7069296734002180096" "followers" => 837088 "date" => "1w" "description" => "Meaningful innovation, teamwork and data-driven insights: David Knapp, VP, R&D, Peripheral Interventions, and Catherine (Yankelevich) Jennings, President, Peripheral Vascular, discuss what contributes to the success of our Peripheral Interventions and Vascular businesses. Listen to the Boston Scientific Talks podcast with DeviceTalks: https://bit.ly/3qgcEAR" "reactions_count" => 221 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:05:04" "deleted" => 1 ] [ "id" => 197616941 "company_id" => 35408 "urn" => "urn:li:activity:7067530563636637697" "followers" => 837088 "date" => "1w" "description" => """ The healthcare industry staff shortage is impacting the EMEA region but can also be felt globally. EMEA President Eric Thépaut shares his perspective with Health Tech World on how digital solutions can help address the issue and ultimately keep patients at the forefront.\n \n https://lnkd.in/gNrQnQ2k\n #BSCEMEA """ "reactions_count" => 362 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:05:04" "deleted" => 1 ] [ "id" => 197616942 "company_id" => 35408 "urn" => "urn:li:activity:7067499752241696768" "followers" => 837088 "date" => "1w" "description" => "#ESG, or environmental, social and governance, is more than a corporate buzzword. From confronting climate change to breaking down barriers to care, ESG can encompass a broad range of sustainable business practices. On our latest podcast episode with DeviceTalks, VP ESG Kathryn Graves Unger and EVP Global Operations Brad Sorenson discuss our ESG strategy and how it touches every part of our business. https://bit.ly/3IHTKJn" "reactions_count" => 238 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:05:04" "deleted" => 1 ] [ "id" => 197616943 "company_id" => 35408 "urn" => "urn:li:activity:7067152273734336512" "followers" => 837088 "date" => "2w" "description" => "Our employees find purpose, uncover unique talents, and improve people's lives while enriching their own. See how you can learn and grow in a career at Boston Scientific: https://lnkd.in/ebeDuKd" "reactions_count" => 165 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:05:04" "deleted" => 1 ] [ "id" => 197616944 "company_id" => 35408 "urn" => "urn:li:activity:7065370736223289344" "followers" => 837088 "date" => "2w" "description" => "#Cybersecurity is everyone's responsibility. Check out this episode of the Boston Scientific Talks podcast with Chief Information Security Officer Andrew Bomett. DeviceTalks https://bit.ly/45klGN5" "reactions_count" => 245 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:05:04" "deleted" => 1 ] [ "id" => 197616945 "company_id" => 35408 "urn" => "urn:li:activity:7065340009574260736" "followers" => 837088 "date" => "2w" "description" => """ Today we were proud to welcome Taoiseach Leo Varadkar and Mary Buckley to our 25-year anniversary celebrations in Clonmel where we announced an €80M investment expected to enable around 400 jobs in the coming years. \n \n The funding will increase office and manufacturing space and transition the entire site to source more than 90% of its energy needs from renewable sources. This is part of the company’s broader sustainability commitment to achieve carbon neutrality by 2030.* \n \n Speaking at the event Conor Russell said, “Our team has worked to build strong manufacturing and R&D capabilities and also a high performing and inclusive culture that we are proud to continue to foster as an employer of choice”. https://bit.ly/3Ir5Q9P\n \n Inclusive of all manufacturing and key distribution sites only (scopes 1 and 2). #BSCEMEA """ "reactions_count" => 1024 "comments_count" => 25 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:05:04" "deleted" => 1 ] [ "id" => 197616946 "company_id" => 35408 "urn" => "urn:li:activity:7065310171417247745" "followers" => 837088 "date" => "2w" "description" => "Meet our novel embolization technology that combines the best qualities of both a solid and a liquid. Learn more about this innovation: https://bit.ly/43cMvRs" "reactions_count" => 1124 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:05:04" "deleted" => 1 ] [ "id" => 240134149 "company_id" => 35408 "urn" => "urn:li:activity:7085241774088073218" "followers" => 856625 "date" => "9h" "description" => "Chairman and CEO Mike Mahoney discusses his journey in the medical device industry and the strategies and leadership qualities that are vital for our company’s growth. Tune in to the latest episode of Boston Scientific Talks with DeviceTalks: https://bit.ly/46Je3Ax" "reactions_count" => 345 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-16 04:12:24" "deleted" => 1 ] [ "id" => 240134150 "company_id" => 35408 "urn" => "urn:li:activity:7080535376972451840" "followers" => 856625 "date" => "1w" "description" => "During #Pride month, we find strength in diversity and celebrate what unites us. Thank you to all employees, including members of our PRIDE Employee Resource group, who attended a parade, flag raising, or events across the globe to show their #BostonScientificPride." "reactions_count" => 1254 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-16 04:12:24" "deleted" => 1 ] [ "id" => 240134151 "company_id" => 35408 "urn" => "urn:li:activity:7077993847280074752" "followers" => 856625 "date" => "2w" "description" => "For #InternationalWomeninEngineeringDay, Nichole shares what she’s learned about succeeding as an engineer over 17+ years at Boston Scientific. Lesson #1: Follow your passions. https://bit.ly/3NHqUMf" "reactions_count" => 353 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-16 04:12:24" "deleted" => 1 ] [ "id" => 240134152 "company_id" => 35408 "urn" => "urn:li:activity:7077650289721315328" "followers" => 856625 "date" => "3w" "description" => "Three employees from around the globe share what having a supportive and inclusive workplace means to them, and how their involvement in the Promoting Respect, Inclusion, Diversity and Equality (PRIDE) employee resource group has helped them grow personally and professionally. #PrideMonth https://bit.ly/42SIOA6" "reactions_count" => 381 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-16 04:12:24" "deleted" => 1 ] [ "id" => 240134153 "company_id" => 35408 "urn" => "urn:li:activity:7077304683324723200" "followers" => 856625 "date" => "3w" "description" => "We believe diverse perspectives create clearer pathways to leadership for women and multicultural talent. That’s why we’re thrilled to be recognized as one of Seramount’s Best Companies for Multicultural Women. #SeramountMCW" "reactions_count" => 82 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-16 04:12:24" "deleted" => 1 ] [ "id" => 240134154 "company_id" => 35408 "urn" => "urn:li:activity:7076592987958374402" "followers" => 856625 "date" => "3w" "description" => "Our BRIDGE employee resource group plays an important role in developing a community of Black leaders at Boston Scientific. In honor of #Juneteenth, a few of our BRIDGE employees share what this day means to them." "reactions_count" => 183 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-16 04:12:24" "deleted" => 1 ] [ "id" => 240134155 "company_id" => 35408 "urn" => "urn:li:activity:7074764258734993408" "followers" => 856625 "date" => "4w" "description" => "Our caring value extends not only to patients, but to our communities and our planet. Thank you to the countless employees who live out our caring value each day. #WeekOfCaring #BSCCommunity" "reactions_count" => 556 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-16 04:12:24" "deleted" => 1 ] [ "id" => 240134156 "company_id" => 35408 "urn" => "urn:li:activity:7074385129225289728" "followers" => 856625 "date" => "1mo" "description" => "Medical Design & Outsourcing shares five key leadership themes from Chairman and CEO Mike Mahoney’s DeviceTalks Boston keynote interview. #DTB2023 https://bit.ly/3PhLzaG" "reactions_count" => 394 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-16 04:12:24" "deleted" => 1 ] [ "id" => 240134157 "company_id" => 35408 "urn" => "urn:li:activity:7072950563272851457" "followers" => 856625 "date" => "1mo" "description" => "Peter Pattison, President, Interventional Oncology, and Liza Davis, VP of R&D, Interventional Oncology, share insights into the acquisition of Obsidio and the integration of its unique conformable embolic technology. Learn more on our podcast with DeviceTalks: https://bit.ly/43vWJx0" "reactions_count" => 178 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-16 04:12:24" "deleted" => 1 ] [ "id" => 240134158 "company_id" => 35408 "urn" => "urn:li:activity:7072195582538231808" "followers" => 856625 "date" => "1mo" "description" => "We're excited to share that we have been named by US News as a 2023-2024 Best Company to Work For! See how you can learn, grow, and advance science for life in a career at Boston Scientific: https://bit.ly/42uKtvc #BCTWF" "reactions_count" => 816 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-16 04:12:24" "deleted" => 1 ] [ "id" => 296675670 "company_id" => 35408 "urn" => "urn:li:activity:7096837909286187008" "followers" => null "date" => "1d" "description" => "Nearly twenty years ago, our #CloseTheGap program set out to improve health disparities affecting women and people of color. Today, we continue this work by increasing diversity in medical research and deepening our relationships with physicians. Camille Chang Gilmore, MBA and Dr. Michael R. Jaff explain more with MD+DI. https://bit.ly/3OAadl3" "reactions_count" => 160 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-17 21:38:30" "deleted" => 1 ] [ "id" => 296675672 "company_id" => 35408 "urn" => "urn:li:activity:7095444325353865216" "followers" => null "date" => "5d" "description" => """ On the latest episode of our podcast with DeviceTalks, Urology leaders discuss how to handle the pressure of being first to market with an innovative device. Tune in to learn about the opportunities and challenges of the market, the role of health economics, and the unique contributions of urologists as innovators: https://bit.ly/47u1UzK \n \n Meghan Scanlon, Jennifer Saunders, Ben Cutone, Kristin LaRocca """ "reactions_count" => 207 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-17 21:38:30" "deleted" => 1 ] [ "id" => 296675674 "company_id" => 35408 "urn" => "urn:li:activity:7092545537240936450" "followers" => null "date" => "1w" "description" => "We stand for equality for all and share a commitment to cultivating a culture that prioritizes diversity and openness. See how we’re supporting DEI and the LGTBQ+ community all year long: https://lnkd.in/gD4F_hzB" "reactions_count" => 245 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-17 21:38:30" "deleted" => 1 ] [ "id" => 296675676 "company_id" => 35408 "urn" => "urn:li:activity:7091764546368925697" "followers" => null "date" => "2w" "description" => "We strive to include, accommodate, and advocate for people of all ability levels. Jackie, Quality Systems Engineer, shares how Boston Scientific has allowed her to thrive as her full self in the workplace. Read more in the latest digital issue of CAREERS & disABLED magazine: https://bit.ly/3DAKC6p Equal Opportunity Publications (EOP), Inc." "reactions_count" => 238 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-17 21:38:30" "deleted" => 1 ] [ "id" => 296675677 "company_id" => 35408 "urn" => "urn:li:activity:7090315277065744384" "followers" => null "date" => "2w" "description" => "Here are a few highlights from our second quarter earnings announcement: https://bit.ly/474jNFl" "reactions_count" => 1098 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-17 21:38:30" "deleted" => 1 ] [ "id" => 296675679 "company_id" => 35408 "urn" => "urn:li:activity:7089639468139220992" "followers" => null "date" => "3w" "description" => "Co-founder John Abele unravels Boston Scientific's unique journey from its inception to becoming a global leader in the medical device industry. Tune in to our podcast with DeviceTalks: https://bit.ly/3OvqOI7" "reactions_count" => 414 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-17 21:38:30" "deleted" => 1 ] [ "id" => 296675681 "company_id" => 35408 "urn" => "urn:li:activity:7089285762185134080" "followers" => null "date" => "3w" "description" => "Each year, we honor employees who are dedicated to serving their communities not only through their jobs but off the clock as well through its Global Volunteer Awards. Learn how this year’s winners, Mehak, Precious and Daniela, are on a mission to give back. https://bit.ly/3Osk5OW" "reactions_count" => 273 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-17 21:38:30" "deleted" => 1 ] [ "id" => 296675683 "company_id" => 35408 "urn" => "urn:li:activity:7087416020834922497" "followers" => null "date" => "3w" "description" => "Shani, Director of DE&I, shares how diverse talent from all levels of ability can thrive at Boston Scientific. Read more in the latest digital issue of CAREERS & the disABLED: https://bit.ly/3pX8oGI Equal Opportunity Publications (EOP), Inc." "reactions_count" => 193 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-17 21:38:30" "deleted" => 1 ] [ "id" => 296675685 "company_id" => 35408 "urn" => "urn:li:activity:7085241774088073218" "followers" => null "date" => "1mo" "description" => "Chairman and CEO Mike Mahoney discusses his journey in the medical device industry and the strategies and leadership qualities that are vital for our company’s growth. Tune in to the latest episode of Boston Scientific Talks with DeviceTalks: https://bit.ly/46Je3Ax" "reactions_count" => 943 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-17 21:38:30" "deleted" => 1 ] [ "id" => 296675686 "company_id" => 35408 "urn" => "urn:li:activity:7080535376972451840" "followers" => null "date" => "1mo" "description" => "During #Pride month, we find strength in diversity and celebrate what unites us. Thank you to all employees, including members of our PRIDE Employee Resource group, who attended a parade, flag raising, or events across the globe to show their #BostonScientificPride." "reactions_count" => 1324 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-17 21:38:30" "deleted" => 1 ] [ "id" => 322596895 "company_id" => 35408 "urn" => "urn:li:activity:7108072138820968448" "followers" => null "date" => "3d" "description" => "In 2022, the Boston Scientific Foundation gave 55 financial grants to non-profits in need and 118 college scholarships to our employees. Learn how the Foundation supports the future of our employees and the communities where they live and work. https://bit.ly/48coJsf" "reactions_count" => 242 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-07 04:37:25" "deleted" => 1 ] [ "id" => 322596896 "company_id" => 35408 "urn" => "urn:li:activity:7107002364288454656" "followers" => null "date" => "6d" "description" => "Get a behind-the-scenes look at the research and development work that led to our newly FDA-approved WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device, which was designed with new features to advance performance and safety for people with non-valvular atrial fibrillation. #AFibAwarenessMonth https://bit.ly/45D1TIB" "reactions_count" => 794 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-07 04:37:25" "deleted" => 1 ] [ "id" => 322596897 "company_id" => 35408 "urn" => "urn:li:activity:7103360944516304896" "followers" => null "date" => "2w" "description" => "Advancing science for life includes supporting future STEM leaders. In 2022, our employee STEM councils helped 70,000 young people gain mentors, explore careers, and learn about our devices. Read more about how we’re inspiring the next generation. #BSCCommunity #STEMtember https://bit.ly/44Pudq9" "reactions_count" => 268 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-07 04:37:25" "deleted" => 1 ] [ "id" => 322596898 "company_id" => 35408 "urn" => "urn:li:activity:7102636247000498176" "followers" => null "date" => "2w" "description" => """ Thank you to our interns for your many contributions this summer. We can’t wait to see what’s next for you and how you improve the world around us with your talent and innovation!\n \n Olivia Means, Aishwarya Mantagani, Reagan Hendricks, Lindsay Marcinkevich, Wilson Huang """ "reactions_count" => 1697 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-07 04:37:25" "deleted" => 1 ] [ "id" => 322596899 "company_id" => 35408 "urn" => "urn:li:activity:7102325050149605376" "followers" => null "date" => "2w" "description" => "Oncology Compass asks experts: What’s the future of #AI in healthcare? Dr. Ken Stein, Global Chief Medical Officer, shares his perspective on one important way AI could help doctors. “I see AI as a valuable tool for helping turn data into actionable information that we can apply to patient care,” he says. https://bit.ly/3sx7eCG" "reactions_count" => 227 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-07 04:37:25" "deleted" => 1 ] [ "id" => 322596900 "company_id" => 35408 "urn" => "urn:li:activity:7100099587998179328" "followers" => null "date" => "3w" "description" => "Katie and Yixuan talk about the meaningful connections they’ve made through the Pacific East Asian Resources in Leadership (PEARL) employee resource group, and how a sense of belonging and purpose has helped grow and shape their careers. https://bit.ly/44jrnta" "reactions_count" => 168 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-07 04:37:25" "deleted" => 1 ] [ "id" => 322596901 "company_id" => 35408 "urn" => "urn:li:activity:7099753268100165632" "followers" => null "date" => null "description" => null "reactions_count" => 1168 "comments_count" => 18 "reshared_post_author" => "Sean Oliva" "reshared_post_author_url" => "https://www.linkedin.com/in/sean-oliva" "reshared_post_author_headline" => "Rogue Recruiter \| Former Medical Device Sales Matchmaker \| Collaboration Connoisseur \| Chaos Controller \| Leveraged Leader \| U.S. Army Veteran \| PEARL Leadership Academy Lead" "reshared_post_description" => """ Boston Scientific’s EMPOWHER, LEAD, and VETS Employee Resource Groups hosted Helping Paws, Inc. at our Arden Hills Campus. This was a great event that highlighted both organizations. It was great to see the smiles on employees faces as these fluffy faces wandered the BSC halls! \n \n Helping Paws, Inc. staff and volunteers received a site tour from Justin Riechers and Javier Martinez giving them an inside look at the behind the scenes work that is done to impact patient lives across the globe. \n \n Following the site tour volunteers from #HP shared their stories and the impact that these incredible animals have made on their lives. #BSC employees in-person and virtually were able to see a demonstration of the service dogs skills they perform for their handlers as well as a Q&A. \n \n #community #servicedogs """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-10-07 04:37:25" "deleted" => 1 ] [ "id" => 322596902 "company_id" => 35408 "urn" => "urn:li:activity:7099374754784038912" "followers" => null "date" => "3w" "description" => "Environmental health and human health are connected. Read about our efforts to protect people and the planet through sustainable changes to our supply chain, from VP of ESG Kathryn Graves Unger: https://bit.ly/3QSJyTv" "reactions_count" => 216 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-07 04:37:25" "deleted" => 1 ] [ "id" => 322596903 "company_id" => 35408 "urn" => "urn:li:activity:7097562702302085122" "followers" => null "date" => "1mo" "description" => "Life-changing technologies mean little if they don't make their way to the patients that need them. Our EDUCARE program provides opportunities for doctors to advance their education through hands-on training and online courses. https://bit.ly/3qANa1G" "reactions_count" => 388 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-07 04:37:25" "deleted" => 1 ] [ "id" => 322596904 "company_id" => 35408 "urn" => "urn:li:activity:7096837909286187008" "followers" => null "date" => "1mo" "description" => "Nearly twenty years ago, our #CloseTheGap program set out to improve health disparities affecting women and people of color. Today, we continue this work by increasing diversity in medical research and deepening our relationships with physicians. Camille Chang Gilmore, MBA and Dr. Michael R. Jaff explain more with MD+DI. https://bit.ly/3OAadl3" "reactions_count" => 224 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-07 04:37:25" "deleted" => 1 ] [ "id" => 335542797 "company_id" => 35408 "urn" => "urn:li:activity:7116045200518467584" "followers" => null "date" => "15h" "description" => "In recognition of #ManufacturingMonth, we’re celebrating the people who build quality medical devices at our 15 principal manufacturing facilities around the world. Because of their important work, we’re able to deliver life-changing technology to patients like James." "reactions_count" => 208 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-06 10:37:36" "deleted" => 1 ] [ "id" => 335542798 "company_id" => 35408 "urn" => "urn:li:activity:7115682377623851009" "followers" => null "date" => "1d" "description" => "When English is not your first language, it can be difficult to feel you fit in at work. Learn how the Hispanic Organization for Leadership & Achievement (HOLA) employee resource group is helping all employees overcome cultural barriers through new programs that build communications skills and provide personal mentoring. #HispanicHeritageMonth https://bit.ly/3rHSXD1" "reactions_count" => 186 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-06 10:37:36" "deleted" => 1 ] [ "id" => 335542799 "company_id" => 35408 "urn" => "urn:li:activity:7115320047950016514" "followers" => null "date" => "2d" "description" => "We believe in the power of connections. With each patient success story we celebrated at our Arden Hills, Maple Grove and Marlborough Everyone Makes an Impact (EMAI) events, we recognize it starts with Boston Scientific employees. Thank you for investing your minds, hearts and hands to further our mission and transform lives." "reactions_count" => 836 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-06 10:37:36" "deleted" => 1 ] [ "id" => 335542800 "company_id" => 35408 "urn" => "urn:li:activity:7115011093751586816" "followers" => null "date" => "3d" "description" => "Hospitals today are increasingly targeted by cybercriminals. In his op-ed, Boston Scientific Chief Information Security Officer Andrew Bomett explains one way medical device manufacturers are working together to help reduce those attacks. #CybersecurityAwarenessMonth https://bit.ly/48Djpy7" "reactions_count" => 129 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-06 10:37:36" "deleted" => 1 ] [ "id" => 335542801 "company_id" => 35408 "urn" => "urn:li:activity:7113492895554260992" "followers" => null "date" => "1w" "description" => "From employee to patient: Cynthia is familiar with live-saving Boston Scientific devices in more ways than one. This #WorldHeartDay, we’re sharing her story: https://bit.ly/468rp8Z" "reactions_count" => 330 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-06 10:37:36" "deleted" => 1 ] [ "id" => 335542802 "company_id" => 35408 "urn" => "urn:li:activity:7112862336045957120" "followers" => null "date" => "1w" "description" => """ Meet Erika Rischko, the 83-year old influencer who regularly inspires her followers with her fitness and dance routines. Not long ago, she struggled with daily chronic pain but with help from her Boston Scientific spinal cord stimulator, she’s now stronger than ever and sharing her journey. \n #PainAwarenessMonth https://bit.ly/45aXsnt """ "reactions_count" => 417 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-06 10:37:36" "deleted" => 1 ] [ "id" => 335542803 "company_id" => 35408 "urn" => "urn:li:activity:7112465904038268928" "followers" => null "date" => "1w" "description" => """ At our Boston Scientific Investor Day last week, we shared our plans to deliver next-level performance in the MedTech industry. Together, Boston Scientific Urology Chief Medical Officer Dr. Ronald Morton and I shared our compelling story of meaningful innovation and high performance to continue advancing urology for patients. We had a great time highlighting all the reasons why urology is a great market and the future of our business is bright.\n \n What key takeaways did we aim to deliver to the investors and analysts in attendance? Here are three:\n ✅ Category leadership is embedded in our DNA. \n ✅ We push the boundaries of meaningful innovation. \n ✅ We're investing thoughtfully to help fuel global growth across our entire portfolio.\n \n I couldn't be more excited about the future of our Urology business and our team's commitment to bringing next-level innovations to physicians and their patients. \n \n You can watch the Investor Day recording here: https://lnkd.in/eR4vzmtD """ "reactions_count" => 489 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-06 10:37:36" "deleted" => 1 ] [ "id" => 335542804 "company_id" => 35408 "urn" => "urn:li:activity:7112172488574296064" "followers" => null "date" => "1w" "description" => "“We are on the doorstep of the most exciting chapter of Boston Scientific,” announced Dan Brennan, Chief Financial Officer, at Boston Scientific Investor Day last week. Learn about our plans for next-level innovation, global teamwork and growth by watching the webcast: https://lnkd.in/eS4VNzsC" "reactions_count" => 896 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-06 10:37:36" "deleted" => 1 ] [ "id" => 335542805 "company_id" => 35408 "urn" => "urn:li:activity:7110246991623766016" "followers" => null "date" => "2w" "description" => "As part of our commitment to advance science for life, we’re investing in future generations around the world. Take a look at our global STEM education efforts. #STEMtember" "reactions_count" => 414 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-06 10:37:36" "deleted" => 1 ] [ "id" => 335542806 "company_id" => 35408 "urn" => "urn:li:activity:7109932451396755456" "followers" => null "date" => "2w" "description" => "Our caring value and commitment to quality include both patients and the planet. Take a look at our product flow, and how we’re working to make each step of the journey more sustainable. #ClimateWeek" "reactions_count" => 352 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-06 10:37:36" "deleted" => 1 ] [ "id" => 368889109 "company_id" => 35408 "urn" => "urn:li:activity:7124742017368125441" "followers" => null "date" => "6d" "description" => "Our Costa Rica Manufacturing Sites and Commercial Office were awarded the Gender Equality Seal from INAMU (Instituto Nacional de las Mujeres/National Women’s Institute). Congratulations to our team in Costa Rica and thank you for your important work toward advancing gender equality." "reactions_count" => 275 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-02 05:33:23" "deleted" => 1 ] [ "id" => 368889110 "company_id" => 35408 "urn" => "urn:li:activity:7124379627556343808" "followers" => null "date" => "1w" "description" => "We all work to advance science for life. For some employees, this means helping people lower their risk of stroke. Learn more about three global employees who work with our innovative products to cut down on stroke risk. #WorldStrokeDay https://bit.ly/46U7PgX" "reactions_count" => 241 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-02 05:33:23" "deleted" => 1 ] [ "id" => 368889111 "company_id" => 35408 "urn" => "urn:li:activity:7123293581997416449" "followers" => null "date" => "1w" "description" => "Here are a few highlights from our third quarter earnings announcement: https://bit.ly/471R82Q" "reactions_count" => 975 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-02 05:33:23" "deleted" => 1 ] [ "id" => 368889112 "company_id" => 35408 "urn" => "urn:li:activity:7122617608821989376" "followers" => null "date" => "1w" "description" => """ Our global efforts in combatting the healthcare worker shortage and providing humanitarian aid have earned us the Global Health Partner Award from Project HOPE. Thank you for the recognition and ongoing partnership. \n #BSCCommunity """ "reactions_count" => 254 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-02 05:33:23" "deleted" => 1 ] [ "id" => 368889113 "company_id" => 35408 "urn" => "urn:li:activity:7120875949155340288" "followers" => null "date" => "2w" "description" => "Rafael Carbunaru and Rainer Birkenbach from Brainlab sat down at DeviceTalks West to talk about how our collaboration is advancing therapies for Parkinson’s disease and essential tremor. #DTWest2023" "reactions_count" => 142 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-02 05:33:23" "deleted" => 1 ] [ "id" => 368889114 "company_id" => 35408 "urn" => "urn:li:activity:7119715175011598336" "followers" => null "date" => "2w" "description" => "The heart generates its own electricity to keep itself pumping. In rare but catastrophic instances, faulty or erratic electrical activity in the heart can cause sudden cardiac arrest (SCA). Learn more in recognition of #SCAAwarenessMonth: https://bit.ly/3s2wSz4" "reactions_count" => 690 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-02 05:33:23" "deleted" => 1 ] [ "id" => 368889115 "company_id" => 35408 "urn" => "urn:li:activity:7118219206973612032" "followers" => null "date" => "3w" "description" => "In the newest episode of our podcast with DeviceTalks, Director of Digital Health Platforms and Products Sandra Nagale, Ph.D. discusses the ways AI is poised to transform the medical device industry—and why we're ready: https://lnkd.in/egg7DDkZ" "reactions_count" => 278 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-02 05:33:23" "deleted" => 1 ] [ "id" => 368889116 "company_id" => 35408 "urn" => "urn:li:activity:7117858653394595840" "followers" => null "date" => "3w" "description" => "We are pleased to have received U.S. Food and Drug Administration (FDA) approval for our spinal cord stimulator (SCS) systems for the treatment of painful diabetic peripheral neuropathy (DPN) of the lower extremities, a type of nerve damage that can occur in people living with diabetes. This expanded indication is a positive step forward to help provide relief to more people with our meaningful SCS innovations. #DiabetesPeripheralNeuropathy #SCS https://bit.ly/46pVZem" "reactions_count" => 1565 "comments_count" => 14 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-02 05:33:23" "deleted" => 1 ] [ "id" => 368889117 "company_id" => 35408 "urn" => "urn:li:activity:7117494272102125568" "followers" => null "date" => "3w" "description" => "Get a behind-the-scenes look at the research and development work that led to our newly FDA-approved WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device, which was designed with new features to advance performance and safety for people with non-valvular atrial fibrillation. https://bit.ly/45ukcie" "reactions_count" => 564 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-02 05:33:23" "deleted" => 1 ] [ "id" => 368889118 "company_id" => 35408 "urn" => "urn:li:activity:7117131888078516224" "followers" => null "date" => "3w" "description" => "In 2022, the Boston Scientific Foundation gave 55 financial grants to non-profits in need and 118 college scholarships to our employees. Learn how the Foundation supports the future of our employees and the communities where they live and work: https://bit.ly/48Ir3rf" "reactions_count" => 133 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-02 05:33:23" "deleted" => 1 ] [ "id" => 396907680 "company_id" => 35408 "urn" => "urn:li:activity:7136062747426869249" "followers" => null "date" => "1d" "description" => "We’re proud to be recognized by the Human Rights Campaign Corporate Equality Index for the 9th time. Learn more about our commitment to cultivating a corporate culture that prioritizes equality, diversity and openness: https://bit.ly/3R0S9lf" "reactions_count" => 206 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 14:45:59" "deleted" => 1 ] [ "id" => 396907681 "company_id" => 35408 "urn" => "urn:li:activity:7134903793002930178" "followers" => null "date" => "4d" "description" => "Ken Stein, MD, SVP, Global Chief Medical Officer, and Nick Spadea-Anello, Global President of Electrophysiology, offer a deep dive into the transformative potential of the FARAPULSE Pulsed Field Ablation System, as well as how it complements our portfolio of treatments for Afib patients. Listen to the newest episode of our podcast with DeviceTalks: https://bit.ly/3QP4YyU" "reactions_count" => 174 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 14:45:59" "deleted" => 1 ] [ "id" => 396907682 "company_id" => 35408 "urn" => "urn:li:activity:7133091809118818304" "followers" => null "date" => "1w" "description" => "We recognize the long, rich history of America’s many Indigenous peoples – and acknowledge the challenges they continue to face. For #NativeAmericanHeritageMonth, learn how Fostering Indigenous Resources and Empowerment (FIRE), our newest employee resource group, is raising awareness of these issues and supporting our Indigenous community worldwide. https://bit.ly/40TxLau" "reactions_count" => 121 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 14:45:59" "deleted" => 1 ] [ "id" => 396907683 "company_id" => 35408 "urn" => "urn:li:activity:7132367078409277445" "followers" => null "date" => "1w" "description" => "Pulsed field ablation technology may very well transform #AFib treatment. Fast Company explains why the field is so excited about PFA, including our FARAPULSE™ Pulsed Field Ablation System: https://bit.ly/3R65l9E" "reactions_count" => 385 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 14:45:59" "deleted" => 1 ] [ "id" => 396907684 "company_id" => 35408 "urn" => "urn:li:activity:7131282287941312512" "followers" => null "date" => "2w" "description" => "Relievant Medsystems, Inc. is officially part of Boston Scientific. We are excited to provide physicians and their patients with a more comprehensive and clinically-differentiated suite of interventional chronic pain management solutions, including the only FDA-cleared system for vertebrogenic pain. Learn more here: https://bit.ly/3QHOd90" "reactions_count" => 1102 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 14:45:59" "deleted" => 1 ] [ "id" => 396907685 "company_id" => 35408 "urn" => "urn:li:activity:7130917706718965762" "followers" => null "date" => "2w" "description" => "One in five Americans care for an adult who has a health problem or special needs; nearly one in four say caregiving has made their health worse. Eleanor, whose partner has Parkinson’s disease, shares how finding the right treatment was game-changing for them both. #NationalFamilyCaregiversMonth https://bit.ly/46h7P9J" "reactions_count" => 206 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 14:45:59" "deleted" => 1 ] [ "id" => 396907686 "company_id" => 35408 "urn" => "urn:li:activity:7130555285600890880" "followers" => null "date" => "2w" "description" => "Our efforts to advance diversity, equity and inclusion in the workplace have been recognized by Seramount's 2023 Inclusion Index. #InclusionIndex2023. Read more about our best practices: https://bit.ly/3ue4B9E" "reactions_count" => 223 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 14:45:59" "deleted" => 1 ] [ "id" => 396907687 "company_id" => 35408 "urn" => "urn:li:activity:7124742017368125441" "followers" => null "date" => "1mo" "description" => "Our Costa Rica Manufacturing Sites and Commercial Office were awarded the Gender Equality Seal from INAMU (Instituto Nacional de las Mujeres/National Women’s Institute). Congratulations to our team in Costa Rica and thank you for your important work toward advancing gender equality." "reactions_count" => 319 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 14:45:59" "deleted" => 1 ] [ "id" => 396907688 "company_id" => 35408 "urn" => "urn:li:activity:7124379627556343808" "followers" => null "date" => "1mo" "description" => """ Read the story here: https://lnkd.in/gPGmU87u\n \n We all work to advance science for life. For some employees, this means helping people lower their risk of stroke. Learn more about three global employees who work with our innovative products to cut down on stroke risk. #WorldStrokeDay """ "reactions_count" => 307 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 14:45:59" "deleted" => 1 ] [ "id" => 396907689 "company_id" => 35408 "urn" => "urn:li:activity:7123293581997416449" "followers" => null "date" => "1mo" "description" => "Here are a few highlights from our third quarter earnings announcement: https://bit.ly/471R82Q" "reactions_count" => 1006 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 14:45:59" "deleted" => 1 ] [ "id" => 444052399 "company_id" => 35408 "urn" => "urn:li:activity:7151337723981631489" "followers" => null "date" => "3d" "description" => "We have been named a Best Place to Work in 2024—one of the Employee’s Choice Awards on Glassdoor. Thank you to our employees for sharing your perspective and advancing science for life each day. #GlassdoorBPTW" "reactions_count" => 1487 "comments_count" => 24 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-15 10:50:34" "deleted" => 1 ] [ "id" => 444052400 "company_id" => 35408 "urn" => "urn:li:activity:7150849015666900992" "followers" => null "date" => "5d" "description" => "Learn how a new program is allowing our employees to make a global impact in a sustainable way by sharing their skills with health care nonprofits around the world – and taking back key learnings to their day jobs. https://bit.ly/3ScyVLr" "reactions_count" => 197 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-15 10:50:34" "deleted" => 1 ] [ "id" => 444052401 "company_id" => 35408 "urn" => "urn:li:activity:7150097591836250112" "followers" => null "date" => "1w" "description" => """ Today we announced an agreement to acquire Axonics, Inc., whose portfolio includes differentiated devices, including sacral neuromodulation therapies, to treat urinary and bowel dysfunction.\n \n “We are excited to add Axonics technologies to the Boston Scientific portfolio, a combination that we expect will further strengthen our ability to serve urologists who are treating patients living with these often-chronic conditions,” said Meghan Scanlon, senior vice president and president, Urology. https://lnkd.in/gT84byfY """ "reactions_count" => 2674 "comments_count" => 23 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-15 10:50:34" "deleted" => 1 ] [ "id" => 444052402 "company_id" => 35408 "urn" => "urn:li:activity:7148674767884058624" "followers" => null "date" => "1w" "description" => "We're thrilled to be named to the 2023 American Opportunity Index in recognition of our continued commitment to investing in our employees and helping them thrive at Boston Scientific and in their careers. #AmericanOpportunityIndex" "reactions_count" => 466 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-15 10:50:34" "deleted" => 1 ] [ "id" => 444052403 "company_id" => 35408 "urn" => "urn:li:activity:7145775607568613376" "followers" => null "date" => "2w" "description" => "We all work to advance science for life. For some employees, this means helping people lower their risk of stroke. Learn more about three global employees who work with our innovative products to cut down on stroke risk. https://bit.ly/3RBuJmL" "reactions_count" => 423 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-15 10:50:34" "deleted" => 1 ] [ "id" => 444052404 "company_id" => 35408 "urn" => "urn:li:activity:7143601566653042689" "followers" => null "date" => "3w" "description" => "Our Maple Grove, MN campus is aglow for the holiday season! Warm wishes from all of us at Boston Scientific. #BSCTreeofHope" "reactions_count" => 1889 "comments_count" => 19 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-15 10:50:34" "deleted" => 1 ] [ "id" => 444052405 "company_id" => 35408 "urn" => "urn:li:activity:7143239446123986944" "followers" => null "date" => "3w" "description" => "In 2023, we focused on bringing every part of our business to the next level. Check out our year in review for a closer look at our growth in innovation, education and wellbeing across the globe—all thanks to our outstanding employees." "reactions_count" => 1870 "comments_count" => 16 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-15 10:50:34" "deleted" => 1 ] [ "id" => 444052406 "company_id" => 35408 "urn" => "urn:li:activity:7141064320888594432" "followers" => null "date" => "1mo" "description" => """ The enduring success of the WATCHMAN™ LAAC device is more than the result of a great new idea for reducing stroke risk for #Afib, says Fast Company; it’s the result of two decades of nonstop innovation. \n https://lnkd.in/dqP33Tz9 """ "reactions_count" => 403 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-15 10:50:34" "deleted" => 1 ] [ "id" => 444052407 "company_id" => 35408 "urn" => "urn:li:activity:7140702154192760832" "followers" => null "date" => "1mo" "description" => "On the latest episode of our podcast with DeviceTalks, SVP Global Supply Chain Paudie O'Connor reflects on our efforts to make a more efficient and sustainable supply chain. Listen in to hear how we’re reducing our carbon footprint: https://bit.ly/41h8DKZ" "reactions_count" => 341 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-15 10:50:34" "deleted" => 1 ] [ "id" => 444052408 "company_id" => 35408 "urn" => "urn:li:activity:7138165439406206977" "followers" => null "date" => "1mo" "description" => "Women and people of color tend to have disproportionately high rates of cardiovascular disease, yet are underrepresented in treatment. In an op-ed for Triple Pundit, Camille Chang Gilmore, MBA, VP HR and Chief DEI Officer, discusses health disparities and how our Close the Gap initiative helps health systems take meaningful steps toward greater equity. https://bit.ly/3RdFxrd" "reactions_count" => 172 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-15 10:50:34" "deleted" => 1 ] [ "id" => 471982958 "company_id" => 35408 "urn" => "urn:li:activity:7162807815475032064" "followers" => null "date" => "2d" "description" => "Endoluminal surgery (ELS) is incision-free, scarless, and is being hailed as the next generation of surgery. In the newest episode of our Boston Scientific Talks podcast, Brian Dunkin, Chief Medical Officer of Endoscopy, and Mike Jones, Endoscopy President and SVP, discuss how the ELS products from our Apollo Endosurgery acquisition represent a step forward in GI care, including for the treatment of obesity: https://bit.ly/3UEggtE" "reactions_count" => 233 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-23 04:43:56" "deleted" => 1 ] [ "id" => 471982959 "company_id" => 35408 "urn" => "urn:li:activity:7161358237957570561" "followers" => null "date" => "6d" "description" => "Thermal ablation and pulsed field ablation are two approaches to atrial fibrillation treatment. Learn more about how the innovative products in our portfolio are helping physicians treat more patients with #AFib: https://bit.ly/487zaMA" "reactions_count" => 755 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-23 04:43:56" "deleted" => 1 ] [ "id" => 471982960 "company_id" => 35408 "urn" => "urn:li:activity:7160278628256129025" "followers" => null "date" => "1w" "description" => "What’s it like to work for one of #AmericasMostJUST Companies? Learn more about how we invest in our employees, foster a diverse and inclusive culture and protect the environment: https://lnkd.in/ebeDuKd #JUST100" "reactions_count" => 373 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-23 04:43:56" "deleted" => 1 ] [ "id" => 471982961 "company_id" => 35408 "urn" => "urn:li:activity:7159153781220261889" "followers" => null "date" => "1w" "description" => "We’re celebrating Wear Red Day! Our employees around the world are wearing red to raise awareness of women’s cardiovascular health. #GoRedBSC" "reactions_count" => 1425 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-23 04:43:56" "deleted" => 1 ] [ "id" => 471982962 "company_id" => 35408 "urn" => "urn:li:activity:7158922733660086273" "followers" => null "date" => "1w" "description" => "We’re celebrating our ninth year as one of Fortune’s World’s Most Admired Companies – something that wouldn’t be possible without our employees who challenge the status quo to advance science for life. #MostAdmiredCos" "reactions_count" => 322 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-23 04:43:56" "deleted" => 1 ] [ "id" => 471982963 "company_id" => 35408 "urn" => "urn:li:activity:7158519529009029120" "followers" => null "date" => "2w" "description" => "Here are a few highlights from our fourth quarter earnings announcement: https://bit.ly/3UhNAGA" "reactions_count" => 1184 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-23 04:43:56" "deleted" => 1 ] [ "id" => 471982964 "company_id" => 35408 "urn" => "urn:li:activity:7158460534168637440" "followers" => null "date" => "2w" "description" => """ The FARAPULSE™ Pulsed Field Ablation System is now FDA approved! This innovative, clinically proven technology will help accelerate the growth of our electrophysiology portfolio by expanding access to more physicians to safely and effectively treat patients with #AFib and other cardiac arrhythmias. #PulsedFieldAblation Learn more: https://bit.ly/3OovCOJ \n \n Safety info: https://bit.ly/3SIoK1y """ "reactions_count" => 2136 "comments_count" => 13 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-23 04:43:56" "deleted" => 1 ] [ "id" => 471982965 "company_id" => 35408 "urn" => "urn:li:activity:7158096544791982080" "followers" => null "date" => "2w" "description" => "FDA-approved use cases for spinal cord stimulation have expanded to include diabetic peripheral neuropathy (DPN). With the WaveWriter Alpha™ SCS System, patients can find relief from nerve pain. Learn more about how this technology benefits patients in Fast Company. https://lnkd.in/g8qcZh8H" "reactions_count" => 570 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-23 04:43:56" "deleted" => 1 ] [ "id" => 471982966 "company_id" => 35408 "urn" => "urn:li:activity:7151337723981631489" "followers" => null "date" => "1mo" "description" => "We have been named a Best Place to Work in 2024—one of the Employee’s Choice Awards on Glassdoor. Thank you to our employees for sharing your perspective and advancing science for life each day. #GlassdoorBPTW" "reactions_count" => 2002 "comments_count" => 34 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-23 04:43:56" "deleted" => 1 ] [ "id" => 471982967 "company_id" => 35408 "urn" => "urn:li:activity:7150849015666900992" "followers" => null "date" => "1mo" "description" => "Learn how a new program is allowing our employees to make a global impact in a sustainable way by sharing their skills with health care nonprofits around the world – and taking back key learnings to their day jobs. https://bit.ly/3ScyVLr" "reactions_count" => 244 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-23 04:43:56" "deleted" => 1 ] [ "id" => 517426193 "company_id" => 35408 "urn" => "urn:li:activity:7176236706273144832" "followers" => null "date" => "2d" "description" => "Endoluminal surgery (ELS) is incision-free, scarless, and is being hailed as the next generation of surgery. In the newest episode of our Boston Scientific Talks podcast, Brian Dunkin, Chief Medical Officer of Endoscopy, and Mike Jones, Endoscopy President and SVP, discuss how the ELS products from our Apollo Endosurgery acquisition represent a step forward in GI care, including for the treatment of obesity: https://bit.ly/3vgzGKN" "reactions_count" => 198 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-26 16:58:05" "deleted" => 1 ] [ "id" => 517426194 "company_id" => 35408 "urn" => "urn:li:activity:7173301811808718848" "followers" => null "date" => "1w" "description" => "We strive to ensure all of our employees have equitable opportunities to grow and advance in their careers. Three women in leadership roles around the globe share how the company, and its culture, have encouraged them to thrive. https://bit.ly/3VkqSOJ" "reactions_count" => 237 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-26 16:58:05" "deleted" => 1 ] [ "id" => 517426195 "company_id" => 35408 "urn" => "urn:li:activity:7172939409275744256" "followers" => null "date" => "1w" "description" => "Pain affects more than 30% of people around the globe. As Relievant Medsystems, Inc. officially becomes part of Boston Scientific, Jim Cassidy, president, Neuromodulation, shares his thoughts on how the acquisition stands to benefit patients living with chronic pain. https://bit.ly/3TeE3hq" "reactions_count" => 619 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-26 16:58:05" "deleted" => 1 ] [ "id" => 517426196 "company_id" => 35408 "urn" => "urn:li:activity:7171882618106429440" "followers" => null "date" => "2w" "description" => "We're celebrating women's representation and achievement at Boston Scientific and beyond. Join us as we #InspireInclusion this International Women's Day. #IWD24" "reactions_count" => 951 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-26 16:58:05" "deleted" => 1 ] [ "id" => 517426197 "company_id" => 35408 "urn" => "urn:li:activity:7170780216930226176" "followers" => null "date" => "2w" "description" => ""Own it: No one cares more about your career than you do." Mary Beth Moynihan, SVP Market Access and CMO, shares her three-step approach for taking control of your professional future in WomenInc. https://bit.ly/437mzYW" "reactions_count" => 515 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-26 16:58:05" "deleted" => 1 ] [ "id" => 517426198 "company_id" => 35408 "urn" => "urn:li:activity:7168243461710680064" "followers" => null "date" => "3w" "description" => "The Becoming Everything You Are (BEYA) STEM conference helps connect employers with job seekers from diverse backgrounds. When we expand our reach to identify the best and brightest, we all do better. Read R&D Engineer Jenny’s story. #BEYA2024 #BlackHistoryMonth https://bit.ly/3UV30kb" "reactions_count" => 113 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-26 16:58:05" "deleted" => 1 ] [ "id" => 517426199 "company_id" => 35408 "urn" => "urn:li:activity:7166431593169952768" "followers" => null "date" => "4w" "description" => """ James was a healthy college student. Then one day, during basketball practice, his heart stopped from sudden cardiac arrest.\n \n At the hospital, his doctors suggested he receive an implantable cardioverter-defibrillator (ICD). Today, protected by his Boston Scientific ICD, he's back to shooting hoops without fear. #HeartMonth https://bit.ly/49lRIdb """ "reactions_count" => 465 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-26 16:58:05" "deleted" => 1 ] [ "id" => 517426200 "company_id" => 35408 "urn" => "urn:li:activity:7165729109732511744" "followers" => null "date" => "1mo" "description" => "For physicians to make the best clinical decisions for each patient, they need reliable data. In Fast Company, learn how our continuous pursuit of knowledge led to a novel #AI-powered study to help pulmonary embolism patients. https://lnkd.in/gKk3cTQ8" "reactions_count" => 377 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-26 16:58:05" "deleted" => 1 ] [ "id" => 517426201 "company_id" => 35408 "urn" => "urn:li:activity:7163895443062513664" "followers" => null "date" => "1mo" "description" => "Our BRIDGE employee resource group and Diversity, Equity & Inclusion team are instrumental in helping to develop a community of Black leaders. This month, we asked them to tell us about the people and moments that most inspire them. #BlackHistoryMonth" "reactions_count" => 241 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-26 16:58:05" "deleted" => 1 ] [ "id" => 517426202 "company_id" => 35408 "urn" => "urn:li:activity:7161358237957570561" "followers" => null "date" => "1mo" "description" => "Thermal ablation and pulsed field ablation are two approaches to atrial fibrillation treatment. Learn more about how the innovative products in our portfolio are helping physicians treat more patients with #AFib: https://bit.ly/487zaMA" "reactions_count" => 1182 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-26 16:58:05" "deleted" => 1 ] [ "id" => 554550447 "company_id" => 35408 "urn" => "urn:li:activity:7189288670657462274" "followers" => null "date" => "1d" "description" => """ How does a company ensure their corporate responsibility efforts are moving in the right direction? It starts with a focus on values, says Kathryn Graves Unger, VP, environmental, social and governance. Read her op-ed to learn how we structure our thinking to strategically plan, execute and measure our progress.\n \n https://lnkd.in/da7-48Nb """ "reactions_count" => 70 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 21:16:38" "deleted" => 1 ] [ "id" => 554550448 "company_id" => 35408 "urn" => "urn:li:activity:7188884575912161281" "followers" => null "date" => "2d" "description" => "Here are a few highlights from our first quarter earnings announcement: https://bit.ly/3QfByL3" "reactions_count" => 631 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 21:16:38" "deleted" => 1 ] [ "id" => 554550449 "company_id" => 35408 "urn" => "urn:li:activity:7188567804592177153" "followers" => null "date" => "3d" "description" => "In 2023 alone, we launched nearly 90 products, donated over $76 million to medical research, and delivered life-changing technologies to more than 37 million patients worldwide. Learn more about our progress in advancing science for the health of people and the planet in our latest Performance Report: https://bit.ly/4aOetqU" "reactions_count" => 893 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 21:16:38" "deleted" => 1 ] [ "id" => 554550450 "company_id" => 35408 "urn" => "urn:li:activity:7188159719411240960" "followers" => null "date" => "4d" "description" => "Our employees around the world dedicate their time to improving the health of the planet we all share. From hosting recycling events, to cleaning up beaches and planting trees, thank you for all that you do—not just on #EarthDay, but year-round 🌎" "reactions_count" => 327 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 21:16:38" "deleted" => 1 ] [ "id" => 554550451 "company_id" => 35408 "urn" => "urn:li:activity:7186006568063131648" "followers" => null "date" => "1w" "description" => "Pulsed field ablation is a cutting-edge technology to treat atrial fibrillation – yet it’s expected to be adopted so quickly that by 2028 it may account for more than 60% of all #AFib procedures. Read in The Wall Street Journal why the worldwide medical community is excited about this transformative technology: https://lnkd.in/gJ3q7sXd" "reactions_count" => 351 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 21:16:38" "deleted" => 1 ] [ "id" => 554550452 "company_id" => 35408 "urn" => "urn:li:activity:7185631766399836163" "followers" => null "date" => "1w" "description" => "Women and people of color are severely underrepresented in clinical trial research. That’s a problem, because without their inclusion in clinical trials, it’s harder to know how well medical treatments will work for them. Learn how we're working to improve these numbers. #MinorityHealthMonth https://bit.ly/4aqnu9z" "reactions_count" => 563 "comments_count" => 17 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 21:16:38" "deleted" => 1 ] [ "id" => 554550453 "company_id" => 35408 "urn" => "urn:li:activity:7181331867571261441" "followers" => null "date" => "3w" "description" => "When Camille Chang Gilmore, MBA’s mother developed terrible leg pain, it took several weeks and three doctors until she was finally diagnosed with a heart attack. “No one should struggle to get critical care the way my mother did,” writes Camille, VP Human Resources, Global Chief Diversity, Equity and Inclusion Officer. For National Minority Health month, read her powerful op-ed about health disparities for women and people of color, and how our Close the Gap initiative helps health systems take meaningful steps toward greater equity: https://bit.ly/4aEPead" "reactions_count" => 136 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 21:16:38" "deleted" => 1 ] [ "id" => 554550454 "company_id" => 35408 "urn" => "urn:li:activity:7180600961583706115" "followers" => null "date" => "3w" "description" => """ Through our advanced interventional chronic pain therapies, our aim is to provide physicians with the broadest selection of evidence-based treatment options that address multiple pain targets and change patients' lives. \n \n In case you missed it, watch Matthew McDonald, director of R&D, Boston Scientific at #WIREDHealth 2024 talk about advancing technologies to transform chronic pain care today and in the future. Watch the full video here: https://lnkd.in/g8V9W5XM """ "reactions_count" => 197 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 21:16:38" "deleted" => 1 ] [ "id" => 554550455 "company_id" => 35408 "urn" => "urn:li:activity:7179872072888700929" "followers" => null "date" => "3w" "description" => "Today is National Doctors’ Day in the U.S. As an electrophysiologist, global Chief Medical Officer for Boston Scientific, and the son, brother, and father of physicians – I understand and appreciate the work that all health care providers do. Today and every day, I am grateful for your hard work and unwavering commitment to patients. To the health care providers who work at or partner with Boston Scientific, thank you for helping us advance science for life!" "reactions_count" => 294 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 21:16:38" "deleted" => 1 ] [ "id" => 554550456 "company_id" => 35408 "urn" => "urn:li:activity:7179462384531480576" "followers" => null "date" => "4w" "description" => "From providing employees with a range of inclusive benefits, to educating physicians about caring for LGBTQ+ patients, we are committed to championing equity, diversity and openness. In honor of Transgender Day of Visibility, learn more about how we show our support: https://bit.ly/43FIOVX" "reactions_count" => 308 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-25 21:16:38" "deleted" => 1 ] [ "id" => 586329451 "company_id" => 35408 "urn" => "urn:li:activity:7199090091821064192" "followers" => null "date" => "2d" "description" => "Your way forward is our way forward. At Boston Scientific, you can find purpose, a place to grow, and a way to cultivate your passions. Learn more about working here and explore careers at https://lnkd.in/g66axMU." "reactions_count" => 300 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-06 19:33:51" "deleted" => 1 ] [ "id" => 586329452 "company_id" => 35408 "urn" => "urn:li:activity:7198691719947673600" "followers" => null "date" => "3d" "description" => "VP of Global Digital Marketing and Customer Experience Jenny Lee is raising awareness of the “bamboo ceiling” that many Asian Americans face in the workplace – and shares how she’s been able to break through with the support of her colleagues at Boston Scientific. https://bit.ly/3yDwhXx" "reactions_count" => 169 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-06 19:33:51" "deleted" => 1 ] [ "id" => 586329453 "company_id" => 35408 "urn" => "urn:li:activity:7198351998876823552" "followers" => null "date" => "4d" "description" => "We’re proud to be named a Best-Led Company by Glassdoor! Thank you to our employees for helping us earn this recognition by sharing your positive feedback on our company’s leadership." "reactions_count" => 635 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-06 19:33:51" "deleted" => 1 ] [ "id" => 586329454 "company_id" => 35408 "urn" => "urn:li:activity:7196494753146802177" "followers" => null "date" => "1w" "description" => "We all work to advance science for life. For some employees, this means helping people lower their risk of stroke. Learn more about three global employees who work with our innovative products to cut down on stroke risk. https://bit.ly/3ylAdMy" "reactions_count" => 255 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-06 19:33:51" "deleted" => 1 ] [ "id" => 586329455 "company_id" => 35408 "urn" => "urn:li:activity:7193595567740960768" "followers" => null "date" => "2w" "description" => "We are dedicated to expanding accessible care, including educational materials for patients. Learn more about the ways our employees and the PEARL employee resource group are making strides in inclusivity. #AAPIHeritageMonth https://bit.ly/3y9DjDo" "reactions_count" => 233 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-06 19:33:51" "deleted" => 1 ] [ "id" => 586329456 "company_id" => 35408 "urn" => "urn:li:activity:7192146141155647489" "followers" => null "date" => "3w" "description" => """ Three things we learned from our panelists at DeviceTalks Boston: \n \n -𝐖𝐡𝐲 𝐰𝐞 𝐢𝐧𝐯𝐞𝐬𝐭𝐞𝐝 𝐞𝐚𝐫𝐥𝐲 𝐢𝐧 𝐭𝐡𝐞 𝐅𝐀𝐑𝐀𝐏𝐔𝐋𝐒𝐄™ 𝐏𝐮𝐥𝐬𝐞𝐝 𝐅𝐢𝐞𝐥𝐝 𝐀𝐛𝐥𝐚𝐭𝐢𝐨𝐧 𝐒𝐲𝐬𝐭𝐞𝐦 💓 “When we look at investing, there has to be an unmet need -- a problem we’re trying to solve for patients, operators, the care system and payers. That was true of FARAPULSE. 38 million people worldwide live with atrial fibrillation. So there’s a huge market need for a safe and effective solution, and also an opportunity to provide a more efficient technology and workflow.” –Nick Spadea-Anello, Global President of Electrophysiology (with Sean McNulty, VP, R&D, Electrophysiology) \n \n -𝐎𝐧 𝐭𝐡𝐞 𝐜𝐨𝐦𝐢𝐧𝐠 𝐫𝐨𝐥𝐞 𝐨𝐟 𝐀𝐈 🤖 “The opportunity that artificial intelligence could create in healthcare is significant – but AI is not a replacement for human expertise. Rather, it’s a complement and an assistant that will speed up processes and workflows, and accelerate faster decisions.” –Sandra Nagale, Ph.D., Director of Digital Health Platforms and Products \n \n -𝐎𝐧 𝐨𝐮𝐫 𝐬𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐞𝐟𝐟𝐨𝐫𝐭𝐬 🌲 “I’m proud to say that last year, we achieved 82% renewable electricity in our manufacturing and key distribution sites. Our goal is to be at 100% renewable electricity by the end of 2024.” –Kathryn Graves Unger, VP of Environmental, Social and Governance """ "reactions_count" => 467 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-06 19:33:51" "deleted" => 1 ] [ "id" => 586329457 "company_id" => 35408 "urn" => "urn:li:activity:7191058919132143617" "followers" => null "date" => "3w" "description" => "Ten million people worldwide suffer from Parkinson’s disease. Learn about deep brain stimulation (DBS) – a procedure that can help them regain their quality of life. https://bit.ly/3UESv4g" "reactions_count" => 402 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-06 19:33:51" "deleted" => 1 ] [ "id" => 586329458 "company_id" => 35408 "urn" => "urn:li:activity:7190696531530838017" "followers" => null "date" => "3w" "description" => "We’re achieving new levels of progress in our environmental, social and governance goals. Read the key takeaways from our 2023 Performance Report: https://bit.ly/3w43z1p" "reactions_count" => 208 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-06 19:33:51" "deleted" => 1 ] [ "id" => 586329459 "company_id" => 35408 "urn" => "urn:li:activity:7189288670657462274" "followers" => null "date" => "4w" "description" => """ How does a company ensure their corporate responsibility efforts are moving in the right direction? It starts with a focus on values, says Kathryn Graves Unger, VP, environmental, social and governance. Read her op-ed to learn how we structure our thinking to strategically plan, execute and measure our progress.\n \n https://lnkd.in/da7-48Nb """ "reactions_count" => 144 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-06 19:33:51" "deleted" => 1 ] [ "id" => 586329460 "company_id" => 35408 "urn" => "urn:li:activity:7188884575912161281" "followers" => null "date" => "1mo" "description" => "Here are a few highlights from our first quarter earnings announcement: https://bit.ly/3QfByL3" "reactions_count" => 814 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-06 19:33:51" "deleted" => 1 ] [ "id" => 596294759 "company_id" => 35408 "urn" => "urn:li:activity:7199090091821064192" "followers" => null "date" => "1w" "description" => "Your way forward is our way forward. At Boston Scientific, you can find purpose, a place to grow, and a way to cultivate your passions. Learn more about working here and explore careers at https://lnkd.in/g66axMU." "reactions_count" => 432 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-22 12:53:15" "deleted" => 1 ] [ "id" => 596294760 "company_id" => 35408 "urn" => "urn:li:activity:7198691719947673600" "followers" => null "date" => "1w" "description" => "VP of Global Digital Marketing and Customer Experience Jenny Lee is raising awareness of the “bamboo ceiling” that many Asian Americans face in the workplace – and shares how she’s been able to break through with the support of her colleagues at Boston Scientific. https://bit.ly/3yDwhXx" "reactions_count" => 195 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-22 12:53:15" "deleted" => 1 ] [ "id" => 596294761 "company_id" => 35408 "urn" => "urn:li:activity:7198351998876823552" "followers" => null "date" => "1w" "description" => "We’re proud to be named a Best-Led Company by Glassdoor! Thank you to our employees for helping us earn this recognition by sharing your positive feedback on our company’s leadership." "reactions_count" => 701 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-22 12:53:15" "deleted" => 1 ] [ "id" => 596294762 "company_id" => 35408 "urn" => "urn:li:activity:7196494753146802177" "followers" => null "date" => "2w" "description" => "We all work to advance science for life. For some employees, this means helping people lower their risk of stroke. Learn more about three global employees who work with our innovative products to cut down on stroke risk. https://bit.ly/3ylAdMy" "reactions_count" => 283 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-22 12:53:15" "deleted" => 1 ] [ "id" => 596294763 "company_id" => 35408 "urn" => "urn:li:activity:7193595567740960768" "followers" => null "date" => "3w" "description" => "We are dedicated to expanding accessible care, including educational materials for patients. Learn more about the ways our employees and the PEARL employee resource group are making strides in inclusivity. #AAPIHeritageMonth https://bit.ly/3y9DjDo" "reactions_count" => 231 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-22 12:53:15" "deleted" => 1 ] [ "id" => 596294764 "company_id" => 35408 "urn" => "urn:li:activity:7192146141155647489" "followers" => null "date" => "1mo" "description" => """ Three things we learned from our panelists at DeviceTalks Boston: \n \n -𝐖𝐡𝐲 𝐰𝐞 𝐢𝐧𝐯𝐞𝐬𝐭𝐞𝐝 𝐞𝐚𝐫𝐥𝐲 𝐢𝐧 𝐭𝐡𝐞 𝐅𝐀𝐑𝐀𝐏𝐔𝐋𝐒𝐄™ 𝐏𝐮𝐥𝐬𝐞𝐝 𝐅𝐢𝐞𝐥𝐝 𝐀𝐛𝐥𝐚𝐭𝐢𝐨𝐧 𝐒𝐲𝐬𝐭𝐞𝐦 💓 “When we look at investing, there has to be an unmet need -- a problem we’re trying to solve for patients, operators, the care system and payers. That was true of FARAPULSE. 38 million people worldwide live with atrial fibrillation. So there’s a huge market need for a safe and effective solution, and also an opportunity to provide a more efficient technology and workflow.” –Nick Spadea-Anello, Global President of Electrophysiology (with Sean McNulty, VP, R&D, Electrophysiology) \n \n -𝐎𝐧 𝐭𝐡𝐞 𝐜𝐨𝐦𝐢𝐧𝐠 𝐫𝐨𝐥𝐞 𝐨𝐟 𝐀𝐈 🤖 “The opportunity that artificial intelligence could create in healthcare is significant – but AI is not a replacement for human expertise. Rather, it’s a complement and an assistant that will speed up processes and workflows, and accelerate faster decisions.” –Sandra Nagale, Ph.D., Director of Digital Health Platforms and Products \n \n -𝐎𝐧 𝐨𝐮𝐫 𝐬𝐮𝐬𝐭𝐚𝐢𝐧𝐚𝐛𝐢𝐥𝐢𝐭𝐲 𝐞𝐟𝐟𝐨𝐫𝐭𝐬 🌲 “I’m proud to say that last year, we achieved 82% renewable electricity in our manufacturing and key distribution sites. Our goal is to be at 100% renewable electricity by the end of 2024.” –Kathryn Graves Unger, VP of Environmental, Social and Governance """ "reactions_count" => 471 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-22 12:53:15" "deleted" => 1 ] [ "id" => 596294765 "company_id" => 35408 "urn" => "urn:li:activity:7191058919132143617" "followers" => null "date" => "1mo" "description" => "Ten million people worldwide suffer from Parkinson’s disease. Learn about deep brain stimulation (DBS) – a procedure that can help them regain their quality of life. https://bit.ly/3UESv4g" "reactions_count" => 407 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-22 12:53:15" "deleted" => 1 ] [ "id" => 596294766 "company_id" => 35408 "urn" => "urn:li:activity:7190696531530838017" "followers" => null "date" => "1mo" "description" => "We’re achieving new levels of progress in our environmental, social and governance goals. Read the key takeaways from our 2023 Performance Report: https://bit.ly/3w43z1p" "reactions_count" => 209 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-22 12:53:15" "deleted" => 1 ] [ "id" => 596294767 "company_id" => 35408 "urn" => "urn:li:activity:7189288670657462274" "followers" => null "date" => "1mo" "description" => """ How does a company ensure their corporate responsibility efforts are moving in the right direction? It starts with a focus on values, says Kathryn Graves Unger, VP, environmental, social and governance. Read her op-ed to learn how we structure our thinking to strategically plan, execute and measure our progress.\n \n https://lnkd.in/da7-48Nb """ "reactions_count" => 142 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-22 12:53:15" "deleted" => 1 ] [ "id" => 596294768 "company_id" => 35408 "urn" => "urn:li:activity:7188884575912161281" "followers" => null "date" => "1mo" "description" => "Here are a few highlights from our first quarter earnings announcement: https://bit.ly/3QfByL3" "reactions_count" => 811 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-22 12:53:15" "deleted" => 1 ] [ "id" => 652394508 "company_id" => 35408 "urn" => "urn:li:activity:7219340242158256129" "followers" => null "date" => "4d" "description" => "We are honored to be recognized as a Best Place to Work for Disability Inclusion by Disability:IN for the ninth consecutive year! This achievement reflects our ongoing commitment to fostering an inclusive and supportive workplace. Learn more about our culture from Quality Systems Engineer Jacqueline MacDonald. https://bit.ly/3WqREoI" "reactions_count" => 240 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-08 15:10:43" "deleted" => 1 ] [ "id" => 652394509 "company_id" => 35408 "urn" => "urn:li:activity:7217165979217231873" "followers" => null "date" => "1w" "description" => "On the DeviceTalks Weekly podcast, Dr. Janar Sathananthan, chief medical officer, Interventional Cardiology Therapies, discusses a new treatment option in the U.S. for patients with coronary artery disease who experience in-stent restenosis. Listen here: https://lnkd.in/eEYPGWRm" "reactions_count" => 147 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-08 15:10:43" "deleted" => 1 ] [ "id" => 652394510 "company_id" => 35408 "urn" => "urn:li:activity:7216441172993441793" "followers" => null "date" => "1w" "description" => "Improving the lives of patients includes taking care of the communities they live in and the planet we share. Thank you to our employees for giving back and making a difference by embodying our caring value. #WeekOfCaring #BSCCommunity" "reactions_count" => 568 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-08 15:10:43" "deleted" => 1 ] [ "id" => 652394511 "company_id" => 35408 "urn" => "urn:li:activity:7212526330528071682" "followers" => null "date" => "3w" "description" => "From colorful parades to the symbolic raising of the flag, many of our employees across the globe stood together in solidarity and #pride this month. Thank you to our PRIDE Employee Resource Group and all who showed their support. 🌈" "reactions_count" => 800 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-08 15:10:43" "deleted" => 1 ] [ "id" => 652394512 "company_id" => 35408 "urn" => "urn:li:activity:7211719465233760257" "followers" => null "date" => "3w" "description" => "“This is the right technology at the right time and an exciting step forward in weight loss for patients.” Read in The Wall Street Journal how the Apollo ESG™ System helps patients lose weight by reducing their stomach size without any incisions or scars – and why some say it represents the future of GI procedures. https://lnkd.in/gkPvVeaV" "reactions_count" => 275 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-08 15:10:43" "deleted" => 1 ] [ "id" => 652394513 "company_id" => 35408 "urn" => "urn:li:activity:7211386842116456450" "followers" => null "date" => "3w" "description" => "Many men suffer in silence when they’re struggling with an enlarged prostate, urinary incontinence or erectile dysfunction. “We have to find a way to inspire men to realize there are safe and effective treatments that can improve their quality of life,” says Ronald Morton, M.D., chief medical officer, Urology. #MensHealthMonth https://bit.ly/4cA6dvj" "reactions_count" => 121 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-08 15:10:43" "deleted" => 1 ] [ "id" => 652394514 "company_id" => 35408 "urn" => "urn:li:activity:7209256077886935041" "followers" => null "date" => "1mo" "description" => """ I am honored to serve as Chair of Close the Gap, a Boston Scientific health equity initiative, and to have a fulfilling career in the cardiology med device field. \n \n Neither of those would be true today if someone in 1982 hadn’t asked me: “What’s a nice kid like you doing working in the laundry?” \n \n That person was Emmanuel Angelo – one of the many mentors I’ve been blessed with who didn’t look past me, who saw my potential. \n \n Their life-changing – I’d even say life-saving – encouragement inspires me to want to give back, to help others be seen in the way they saw me. So much has changed since my days in the laundry room at MedStar Washington Hospital Center. But I’m acutely aware of how much more change is needed. \n \n Today, this Juneteenth, let’s celebrate the progress we’ve made as a nation, while also recommitting to seeing us all. \n \n Let’s harness the power of diversity – people with different backgrounds and perspectives – to drive innovation. Throughout my career, I’ve witnessed firsthand how this leads to better problem-solving, more effective decision-making, and, ultimately, improved outcomes. And that is certainly true for healthcare. \n \n Together, we can bridge the gaps for those who are still overlooked. In fact, together we must. #CloseTheGap #Juneteenth #HealthEquity """ "reactions_count" => 384 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-08 15:10:43" "deleted" => 1 ] [ "id" => 652394515 "company_id" => 35408 "urn" => "urn:li:activity:7208896032741445632" "followers" => null "date" => "1mo" "description" => "Without the collective talent and passion of more than 48,000 employees in 52 countries, we could not achieve our goal of delivering solutions that change and save lives. Here are just a few of the ways we work to make our company a place where everyone can belong." "reactions_count" => 327 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-08 15:10:43" "deleted" => 1 ] [ "id" => 652394516 "company_id" => 35408 "urn" => "urn:li:activity:7208808446178058240" "followers" => null "date" => "1mo" "description" => "We’re excited to share that we have entered into a definitive agreement to acquire Silk Road Medical, Inc., a med tech company focused on stroke prevention in patients with carotid artery disease through the TCAR procedure. Upon close, we look forward to bringing this innovative and clinically differentiated technology to vascular surgeons and welcoming the Silk Road team to Boston Scientific and Peripheral Interventions! https://bit.ly/3XtVUVh" "reactions_count" => 3046 "comments_count" => 27 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-08 15:10:43" "deleted" => 1 ] [ "id" => 652394517 "company_id" => 35408 "urn" => "urn:li:activity:7204104982453825536" "followers" => null "date" => "1mo" "description" => "Our cut, convert and compensate strategy, known as C3, guides our progress in cutting greenhouse gas emissions across our full company footprint. For example, 72% of our real estate has been LEED and ISO-certified for energy efficiency. We’re building a sustainable business that protects patients and the planet. #WorldEnvironmentDay" "reactions_count" => 239 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-08 15:10:43" "deleted" => 1 ] [ "id" => 668371134 "company_id" => 35408 "urn" => "urn:li:activity:7226935502531137536" "followers" => null "date" => "1d" "description" => "Patient health is our priority. That’s why we’re building a sustainable business that protects people and the planet. Learn more: https://bit.ly/3Yvke9P" "reactions_count" => 160 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-06 13:50:46" "deleted" => 1 ] [ "id" => 668371135 "company_id" => 35408 "urn" => "urn:li:activity:7226260509291937793" "followers" => null "date" => "2d" "description" => """ Three takeaways from chief information and digital officer Jodi Euerle Eddy’s interview with Fortune: \n \n -𝐎𝐧 𝐨𝐮𝐫 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐢𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧 💻 Jodi restructured IT at Boston Scientific to seamlessly integrate it throughout the company, enabling the sort of collaborative decision-making needed to address complex problems: “There is now a digital leader who sits on the executive management board of every division, every region, and every business function, so they can work together to deploy tech.” \n \n -𝐎𝐧 𝐨𝐮𝐫 𝐜𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐠𝐫𝐨𝐰𝐭𝐡 📈 In the decade since Jodi’s arrival, the market value of Boston Scientific has increased more than 6-fold, from about $17 billion to around $110 billion. That growth has allowed us to scale up our efforts to improve patient care around the world; globally, our products are used to treat more than 37 million patients every year. \n \n -𝐎𝐧 𝐨𝐮𝐫 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐭𝐨 𝐀𝐈 🤖 AI can help consolidate large volumes of medical information to create actionable data for physicians, so they can be more productive and spend more time with patients. However, machines don’t ever have the final say. “We’re very cautious,” says Jodi. “AI never replaces the human, it supports their decisions.” \n \n Read the full article: https://bit.ly/3ypadQU """ "reactions_count" => 151 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-06 13:50:46" "deleted" => 1 ] [ "id" => 668371136 "company_id" => 35408 "urn" => "urn:li:activity:7224825555496361985" "followers" => null "date" => "6d" "description" => "In an interview with CNBC’s Jim Cramer, CEO Mike Mahoney shares why we have a strong track record of consistently delivering great results and what we’re looking forward to next." "reactions_count" => 1445 "comments_count" => 24 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-06 13:50:46" "deleted" => 1 ] [ "id" => 668371137 "company_id" => 35408 "urn" => "urn:li:activity:7224072607115919363" "followers" => null "date" => "1w" "description" => """ We continuously evolve our benefits to help our employees thrive both at work and in their personal lives – which is one reason we’ve been named to Seramount’s list of Top 100 Companies for 2024. From parental leave to mental health support, see how we’re creating a healthy, inclusive workplace. https://bit.ly/3y8CwmF\n \n Benefits vary by region. """ "reactions_count" => 383 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-06 13:50:46" "deleted" => 1 ] [ "id" => 668371138 "company_id" => 35408 "urn" => "urn:li:activity:7222254442732015620" "followers" => null "date" => "2w" "description" => "Today, we celebrate #NationalInternDay, recognizing the 250+ students who have enriched our summer. Their volunteerism and eagerness to learn have made a lasting impact not only on our company but also on the communities we serve. Here's to the next generation of leaders! 🌟" "reactions_count" => 955 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-06 13:50:46" "deleted" => 1 ] [ "id" => 668371139 "company_id" => 35408 "urn" => "urn:li:activity:7221865771423961090" "followers" => null "date" => "2w" "description" => "Here are a few highlights from our second quarter earnings announcement: https://bit.ly/46hU4co" "reactions_count" => 321 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-06 13:50:46" "deleted" => 1 ] [ "id" => 668371140 "company_id" => 35408 "urn" => "urn:li:activity:7221620250876739587" "followers" => null "date" => "2w" "description" => "Tomorrow morning we’ll host a conference call & webcast to discuss Q2 2024 financial results. Tune in here: https://lnkd.in/dBn-JH7H" "reactions_count" => 120 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-06 13:50:46" "deleted" => 1 ] [ "id" => 668371141 "company_id" => 35408 "urn" => "urn:li:activity:7219340242158256129" "followers" => null "date" => "3w" "description" => "We are honored to be recognized as a Best Place to Work for Disability Inclusion by Disability:IN for the ninth consecutive year! This achievement reflects our ongoing commitment to fostering an inclusive and supportive workplace. Learn more about our culture from Quality Systems Engineer Jacqueline MacDonald. https://bit.ly/3WqREoI" "reactions_count" => 285 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-06 13:50:46" "deleted" => 1 ] [ "id" => 668371142 "company_id" => 35408 "urn" => "urn:li:activity:7217165979217231873" "followers" => null "date" => "4w" "description" => "On the DeviceTalks Weekly podcast, Dr. Janar Sathananthan, chief medical officer, Interventional Cardiology Therapies, discusses a new treatment option in the U.S. for patients with coronary artery disease who experience in-stent restenosis. Listen here: https://lnkd.in/eEYPGWRm" "reactions_count" => 178 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-06 13:50:46" "deleted" => 1 ] [ "id" => 668371143 "company_id" => 35408 "urn" => "urn:li:activity:7216441172993441793" "followers" => null "date" => "1mo" "description" => "Improving the lives of patients includes taking care of the communities they live in and the planet we share. Thank you to our employees for giving back and making a difference by embodying our caring value. #WeekOfCaring #BSCCommunity" "reactions_count" => 670 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-06 13:50:46" "deleted" => 1 ] [ "id" => 700755923 "company_id" => 35408 "urn" => "urn:li:activity:7237459643357175809" "followers" => null "date" => "13h" "description" => "We believe in creating a culture of quality in which everyone feels personally invested in the impact they have in transforming lives, no matter their role, region or career level. Learn how our 48,000-plus employees recommit to improving the quality of patient care each year. https://bit.ly/3MA7IP0" "reactions_count" => 139 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-28 16:58:38" "deleted" => 1 ] [ "id" => 700755924 "company_id" => 35408 "urn" => "urn:li:activity:7236734894414966784" "followers" => null "date" => "2d" "description" => "One in six people in the U.S. suffering from chronic back pain is likely to have vertebrogenic pain. Learn more about this common condition and how the Intracept™ Intraosseous Nerve Ablation System provides safe, effective pain relief without any implants or hardware. https://bit.ly/4dQAA1I" "reactions_count" => 196 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-28 16:58:38" "deleted" => 1 ] [ "id" => 700755925 "company_id" => 35408 "urn" => "urn:li:activity:7234560428624797698" "followers" => null "date" => "1w" "description" => """ The AXIOS™ Stent is a groundbreaking endoscopic treatment for high-risk acute cholecystitis patients that eliminates the need for external drains. Read how this innovative solution helps enhance quality of life: https://bit.ly/477NJRu\n \n Indications, safety and warnings can be found here: https://bit.ly/3AL7Jxa """ "reactions_count" => 422 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-28 16:58:38" "deleted" => 1 ] [ "id" => 700755926 "company_id" => 35408 "urn" => "urn:li:activity:7233820554326081537" "followers" => null "date" => "1w" "description" => """ Three teachable moments on embracing equity from Meghan Scanlon, senior vice president and president, Urology:\n \n 𝐄𝐦𝐛𝐫𝐚𝐜𝐢𝐧𝐠 "𝐎𝐭𝐡𝐞𝐫𝐧𝐞𝐬𝐬": In 2020, being an executive committee member with young children at home initially made her feel like "the other." However, embracing this "otherness" allowed her to become a trusted voice for working parents and foster greater empathy and understanding within the team.\n \n 𝐄𝐪𝐮𝐢𝐭𝐲 𝐢𝐬 𝐈𝐧𝐜𝐥𝐮𝐬𝐢𝐯𝐞: In a mentoring session, male managers expressed feelings of alienation regarding DE&I efforts. This highlighted the need to include all demographics in DE&I conversations and provide safe spaces for learning and expressing challenges.\n \n 𝐒𝐦𝐚𝐥𝐥 𝐀𝐜𝐭𝐬 𝐨𝐟 𝐈𝐧𝐜𝐥𝐮𝐬𝐢𝐨𝐧: Incorporating a popular Arabic song in a town hall meeting led to an employee expressing a newfound sense of belonging. This demonstrated that small acts can significantly contribute to an inclusive and equitable work environment.\n \n Read the full article: https://bit.ly/3Ml29E3\n \n #WomensEqualityDay """ "reactions_count" => 118 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-28 16:58:38" "deleted" => 1 ] [ "id" => 700755927 "company_id" => 35408 "urn" => "urn:li:activity:7229471988296126464" "followers" => null "date" => "3w" "description" => "Meet our novel embolization technology that helps doctors stop blood flow in a patient when needed. https://bit.ly/46L5ky9" "reactions_count" => 400 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-28 16:58:38" "deleted" => 1 ] [ "id" => 700755928 "company_id" => 35408 "urn" => "urn:li:activity:7228777250802786304" "followers" => null "date" => "3w" "description" => "Each year, the Boston Scientific Foundation provides financial grants to non-profit organizations that work to improve health and help young people explore science, technology, engineering and math (STEM) careers. Learn about the large impact it has had across the U.S. in the past year." "reactions_count" => 276 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-28 16:58:38" "deleted" => 1 ] [ "id" => 700755929 "company_id" => 35408 "urn" => "urn:li:activity:7226935502531137536" "followers" => null "date" => "4w" "description" => "Patient health is our priority. That’s why we’re building a sustainable business that protects people and the planet. Learn more: https://bit.ly/3Yvke9P" "reactions_count" => 250 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-28 16:58:38" "deleted" => 1 ] [ "id" => 700755930 "company_id" => 35408 "urn" => "urn:li:activity:7226260509291937793" "followers" => null "date" => "1mo" "description" => """ Three takeaways from chief information and digital officer Jodi Euerle Eddy’s interview with Fortune: \n \n -𝐎𝐧 𝐨𝐮𝐫 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐢𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧 💻 Jodi restructured IT at Boston Scientific to seamlessly integrate it throughout the company, enabling the sort of collaborative decision-making needed to address complex problems: “There is now a digital leader who sits on the executive management board of every division, every region, and every business function, so they can work together to deploy tech.” \n \n -𝐎𝐧 𝐨𝐮𝐫 𝐜𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐠𝐫𝐨𝐰𝐭𝐡 📈 In the decade since Jodi’s arrival, the market value of Boston Scientific has increased more than 6-fold, from about $17 billion to around $110 billion. That growth has allowed us to scale up our efforts to improve patient care around the world; globally, our products are used to treat more than 37 million patients every year. \n \n -𝐎𝐧 𝐨𝐮𝐫 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐭𝐨 𝐀𝐈 🤖 AI can help consolidate large volumes of medical information to create actionable data for physicians, so they can be more productive and spend more time with patients. However, machines don’t ever have the final say. “We’re very cautious,” says Jodi. “AI never replaces the human, it supports their decisions.” \n \n Read the full article: https://bit.ly/3ypadQU """ "reactions_count" => 216 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-28 16:58:38" "deleted" => 1 ] [ "id" => 700755931 "company_id" => 35408 "urn" => "urn:li:activity:7224825555496361985" "followers" => null "date" => "1mo" "description" => "In an interview with CNBC’s Jim Cramer, CEO Mike Mahoney shares why we have a strong track record of consistently delivering great results and what we’re looking forward to next." "reactions_count" => 1819 "comments_count" => 29 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-28 16:58:38" "deleted" => 1 ] [ "id" => 700755932 "company_id" => 35408 "urn" => "urn:li:activity:7224072607115919363" "followers" => null "date" => "1mo" "description" => """ We continuously evolve our benefits to help our employees thrive both at work and in their personal lives – which is one reason we’ve been named to Seramount’s list of Top 100 Companies for 2024. From parental leave to mental health support, see how we’re creating a healthy, inclusive workplace. https://bit.ly/3y8CwmF\n \n Benefits vary by region. """ "reactions_count" => 451 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-28 16:58:38" "deleted" => 1 ] [ "id" => 737821701 "company_id" => 35408 "urn" => "urn:li:activity:7241790310693965825" "followers" => null "date" => "4d" "description" => "Silk Road Medical, Inc. is now part of Boston Scientific. We look forward to enhancing our stroke reduction portfolio, enabling physicians to treat carotid artery disease more effectively. Learn more: https://lnkd.in/e6nCyBb5" "reactions_count" => 2183 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 13:27:00" "deleted" => 1 ] [ "id" => 737821702 "company_id" => 35408 "urn" => "urn:li:activity:7239308560755494914" "followers" => null "date" => "1w" "description" => "Color helps us navigate the world and make quick decisions each day 🎨 Meet Keith, Senior R&D Manager, and James, Technical Writer, as they show how simple design concepts like color can make our product packaging more intuitive. #CareersInSTEM #STEMtember" "reactions_count" => 265 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 13:27:00" "deleted" => 1 ] [ "id" => 737821703 "company_id" => 35408 "urn" => "urn:li:activity:7237459643357175809" "followers" => null "date" => "2w" "description" => "We believe in creating a culture of quality in which everyone feels personally invested in the impact they have in transforming lives, no matter their role, region or career level. Learn how our 48,000-plus employees recommit to improving the quality of patient care each year. https://bit.ly/3MA7IP0" "reactions_count" => 261 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 13:27:00" "deleted" => 1 ] [ "id" => 737821704 "company_id" => 35408 "urn" => "urn:li:activity:7236734894414966784" "followers" => null "date" => "2w" "description" => "One in six people in the U.S. suffering from chronic back pain is likely to have vertebrogenic pain. Learn more about this common condition and how the Intracept™ Intraosseous Nerve Ablation System provides safe, effective pain relief without any implants or hardware. https://bit.ly/4dQAA1I" "reactions_count" => 266 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 13:27:00" "deleted" => 1 ] [ "id" => 737821705 "company_id" => 35408 "urn" => "urn:li:activity:7234560428624797698" "followers" => null "date" => "3w" "description" => """ The AXIOS™ Stent is a groundbreaking endoscopic treatment for high-risk acute cholecystitis patients that eliminates the need for external drains. Read how this innovative solution helps enhance quality of life: https://bit.ly/477NJRu\n \n Indications, safety and warnings can be found here: https://bit.ly/3AL7Jxa """ "reactions_count" => 490 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 13:27:00" "deleted" => 1 ] [ "id" => 737821706 "company_id" => 35408 "urn" => "urn:li:activity:7233820554326081537" "followers" => null "date" => "3w" "description" => """ Three teachable moments on embracing equity from Meghan Scanlon, senior vice president and president, Urology:\n \n 𝐄𝐦𝐛𝐫𝐚𝐜𝐢𝐧𝐠 "𝐎𝐭𝐡𝐞𝐫𝐧𝐞𝐬𝐬": In 2020, being an executive committee member with young children at home initially made her feel like "the other." However, embracing this "otherness" allowed her to become a trusted voice for working parents and foster greater empathy and understanding within the team.\n \n 𝐄𝐪𝐮𝐢𝐭𝐲 𝐢𝐬 𝐈𝐧𝐜𝐥𝐮𝐬𝐢𝐯𝐞: In a mentoring session, male managers expressed feelings of alienation regarding DE&I efforts. This highlighted the need to include all demographics in DE&I conversations and provide safe spaces for learning and expressing challenges.\n \n 𝐒𝐦𝐚𝐥𝐥 𝐀𝐜𝐭𝐬 𝐨𝐟 𝐈𝐧𝐜𝐥𝐮𝐬𝐢𝐨𝐧: Incorporating a popular Arabic song in a town hall meeting led to an employee expressing a newfound sense of belonging. This demonstrated that small acts can significantly contribute to an inclusive and equitable work environment.\n \n Read the full article: https://bit.ly/3Ml29E3\n \n #WomensEqualityDay """ "reactions_count" => 132 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 13:27:00" "deleted" => 1 ] [ "id" => 737821707 "company_id" => 35408 "urn" => "urn:li:activity:7229471988296126464" "followers" => null "date" => "1mo" "description" => "Meet our novel embolization technology that helps doctors stop blood flow in a patient when needed. https://bit.ly/46L5ky9" "reactions_count" => 403 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 13:27:00" "deleted" => 1 ] [ "id" => 737821708 "company_id" => 35408 "urn" => "urn:li:activity:7228777250802786304" "followers" => null "date" => "1mo" "description" => "Each year, the Boston Scientific Foundation provides financial grants to non-profit organizations that work to improve health and help young people explore science, technology, engineering and math (STEM) careers. Learn about the large impact it has had across the U.S. in the past year." "reactions_count" => 283 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 13:27:00" "deleted" => 1 ] [ "id" => 737821709 "company_id" => 35408 "urn" => "urn:li:activity:7226935502531137536" "followers" => null "date" => "1mo" "description" => "Patient health is our priority. That’s why we’re building a sustainable business that protects people and the planet. Learn more: https://bit.ly/3Yvke9P" "reactions_count" => 249 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 13:27:00" "deleted" => 1 ] [ "id" => 737821710 "company_id" => 35408 "urn" => "urn:li:activity:7226260509291937793" "followers" => null "date" => "1mo" "description" => """ Three takeaways from chief information and digital officer Jodi Euerle Eddy’s interview with Fortune: \n \n -𝐎𝐧 𝐨𝐮𝐫 𝐝𝐢𝐠𝐢𝐭𝐚𝐥 𝐢𝐧𝐭𝐞𝐠𝐫𝐚𝐭𝐢𝐨𝐧 💻 Jodi restructured IT at Boston Scientific to seamlessly integrate it throughout the company, enabling the sort of collaborative decision-making needed to address complex problems: “There is now a digital leader who sits on the executive management board of every division, every region, and every business function, so they can work together to deploy tech.” \n \n -𝐎𝐧 𝐨𝐮𝐫 𝐜𝐨𝐫𝐩𝐨𝐫𝐚𝐭𝐞 𝐠𝐫𝐨𝐰𝐭𝐡 📈 In the decade since Jodi’s arrival, the market value of Boston Scientific has increased more than 6-fold, from about $17 billion to around $110 billion. That growth has allowed us to scale up our efforts to improve patient care around the world; globally, our products are used to treat more than 37 million patients every year. \n \n -𝐎𝐧 𝐨𝐮𝐫 𝐚𝐩𝐩𝐫𝐨𝐚𝐜𝐡 𝐭𝐨 𝐀𝐈 🤖 AI can help consolidate large volumes of medical information to create actionable data for physicians, so they can be more productive and spend more time with patients. However, machines don’t ever have the final say. “We’re very cautious,” says Jodi. “AI never replaces the human, it supports their decisions.” \n \n Read the full article: https://bit.ly/3ypadQU """ "reactions_count" => 218 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 13:27:00" "deleted" => 1 ] [ "id" => 766561157 "company_id" => 35408 "urn" => "urn:li:activity:7247605783528452097" "followers" => null "date" => "16h" "description" => "When Lia first moved from Miami to Minnesota, “it felt isolating,” she admits. “Miami had a much larger Hispanic population, and it seemed like no one shared my background.” Then she found our Hispanic Organization for Leadership & Achievement (HOLA) employee resource group. She shares how it’s given her a sense of community – and a chance to help communities in and beyond Minnesota. #HispanicHeritageMonth https://bit.ly/3zVfosp" "reactions_count" => 48 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-01 06:28:40" "deleted" => 1 ] [ "id" => 766561158 "company_id" => 35408 "urn" => "urn:li:activity:7246519500269846529" "followers" => null "date" => "3d" "description" => "Relief from vertebrogenic low back pain means being able to participate in life’s meaningful moments again. #PainAwarenessMonth" "reactions_count" => 131 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-01 06:28:40" "deleted" => 1 ] [ "id" => 766561159 "company_id" => 35408 "urn" => "urn:li:activity:7246141798773923841" "followers" => null "date" => "4d" "description" => """ Thermal ablation and pulsed field ablation are two approaches to atrial fibrillation treatment. Learn more about how the innovative products in our portfolio are helping physicians treat more patients with #AFib: https://bit.ly/3zDIGf0 \n \n #WorldHeartDay #AFibAwarenessMonth """ "reactions_count" => 385 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-01 06:28:40" "deleted" => 1 ] [ "id" => 766561160 "company_id" => 35408 "urn" => "urn:li:activity:7244748404151521281" "followers" => null "date" => "1w" "description" => """ Our global commitment to STEM education is unwavering. Here are a few ways our teams are inspiring the next generation of science and technology leaders. #STEMtember 🔬🌎\n \n 💻Coding video games in the U.S.\n 🏥Exploring careers in Costa Rica\n 🥕Learning nutrition fundamentals in Brasil\n 🤖Interacting with robots in Ireland\n 💓Examining heart models in Taiwan\n 🍎Partnering with teachers in Malaysia """ "reactions_count" => 507 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-01 06:28:40" "deleted" => 1 ] [ "id" => 766561161 "company_id" => 35408 "urn" => "urn:li:activity:7244013969361842176" "followers" => null "date" => "1w" "description" => "A healthy planet is vital for patient wellbeing. See how our environmental goals guide our commitment to a healthier world for all." "reactions_count" => 291 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-01 06:28:40" "deleted" => 1 ] [ "id" => 766561162 "company_id" => 35408 "urn" => "urn:li:activity:7241790310693965825" "followers" => null "date" => "2w" "description" => "Silk Road Medical, Inc. is now part of Boston Scientific. We look forward to enhancing our stroke reduction portfolio, enabling physicians to treat carotid artery disease more effectively. Learn more: https://lnkd.in/e6nCyBb5" "reactions_count" => 2379 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-01 06:28:40" "deleted" => 1 ] [ "id" => 766561163 "company_id" => 35408 "urn" => "urn:li:activity:7239308560755494914" "followers" => null "date" => "3w" "description" => "Color helps us navigate the world and make quick decisions each day 🎨 Meet Keith, Senior R&D Manager, and James, Technical Writer, as they show how simple design concepts like color can make our product packaging more intuitive. #CareersInSTEM #STEMtember" "reactions_count" => 305 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-01 06:28:40" "deleted" => 1 ] [ "id" => 766561164 "company_id" => 35408 "urn" => "urn:li:activity:7237459643357175809" "followers" => null "date" => "4w" "description" => "We believe in creating a culture of quality in which everyone feels personally invested in the impact they have in transforming lives, no matter their role, region or career level. Learn how our 48,000-plus employees recommit to improving the quality of patient care each year. https://bit.ly/3MA7IP0" "reactions_count" => 274 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-01 06:28:40" "deleted" => 1 ] [ "id" => 766561165 "company_id" => 35408 "urn" => "urn:li:activity:7236734894414966784" "followers" => null "date" => "1mo" "description" => "One in six people in the U.S. suffering from chronic back pain is likely to have vertebrogenic pain. Learn more about this common condition and how the Intracept™ Intraosseous Nerve Ablation System provides safe, effective pain relief without any implants or hardware. https://bit.ly/4dQAA1I" "reactions_count" => 297 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-01 06:28:40" "deleted" => 1 ] [ "id" => 766561166 "company_id" => 35408 "urn" => "urn:li:activity:7234560428624797698" "followers" => null "date" => "1mo" "description" => """ The AXIOS™ Stent is a groundbreaking endoscopic treatment for high-risk acute cholecystitis patients that eliminates the need for external drains. Read how this innovative solution helps enhance quality of life: https://bit.ly/477NJRu\n \n Indications, safety and warnings can be found here: https://bit.ly/3AL7Jxa """ "reactions_count" => 505 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-01 06:28:40" "deleted" => 1 ] [ "id" => 780063108 "company_id" => 35408 "urn" => "urn:li:activity:7257416993606156290" "followers" => null "date" => "1d" "description" => "How does a company turn great ideas into reality? Boston Scientific co-founder John Abele writes that innovation doesn’t happen by accident; it requires a deliberate #culture that encourages creativity and collaboration. As we mark our 45th year in business, John reflects on why he thinks our culture is our greatest asset, and how leaders can create a culture of #innovation. https://bit.ly/3AazrDA" "reactions_count" => 113 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-26 16:48:42" "deleted" => 1 ] [ "id" => 780063109 "company_id" => 35408 "urn" => "urn:li:activity:7257028501742960642" "followers" => null "date" => "2d" "description" => "Carotid artery disease is one of the leading causes of stroke. As Silk Road Medical, Inc. officially becomes part of Boston Scientific, Catherine (Yankelevich) Jennings, president of Vascular, Peripheral Interventions, shares how the acquisition could potentially help millions of people each year, thanks to an innovative technology called #TCAR. #WorldStrokeDay https://bit.ly/4hrlu4C" "reactions_count" => 416 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-26 16:48:42" "deleted" => 1 ] [ "id" => 780063110 "company_id" => 35408 "urn" => "urn:li:activity:7256695108392083456" "followers" => null "date" => "3d" "description" => "We're proud to be named to the 2024 American Opportunity Index. This recognition reflects our continued investment in our employees and our commitment to helping them thrive in their careers. #AmericanOpportunityIndex" "reactions_count" => 153 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-26 16:48:42" "deleted" => 1 ] [ "id" => 780063111 "company_id" => 35408 "urn" => "urn:li:activity:7255216627699396608" "followers" => null "date" => "1w" "description" => """ Hepatocellular carcinoma (HCC) accounts for 75% of liver cancers and is the 3rd leading cause of cancer deaths worldwide. Learn how TheraSphere™ takes a precision approach to radiation treatment by placing powerful yttrium-90 (Y-90) microspheres inside the tumor – killing cancer cells while also minimizing side effects, often in one outpatient procedure. https://bit.ly/4eYmQCs\n \n Boston Scientific Peripheral Interventions """ "reactions_count" => 185 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-26 16:48:42" "deleted" => 1 ] [ "id" => 780063112 "company_id" => 35408 "urn" => "urn:li:activity:7254843424867045376" "followers" => null "date" => "1w" "description" => "Here are a few highlights from our third quarter earnings announcement: https://bit.ly/3UmMKYb" "reactions_count" => 903 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-26 16:48:42" "deleted" => 1 ] [ "id" => 780063113 "company_id" => 35408 "urn" => "urn:li:activity:7254597511552638976" "followers" => null "date" => "1w" "description" => "Tomorrow morning we’ll host a conference call & webcast to discuss Q3 2024 financial results. Tune in here: https://bit.ly/48i4OZg $BSX" "reactions_count" => 142 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-26 16:48:42" "deleted" => 1 ] [ "id" => 780063114 "company_id" => 35408 "urn" => "urn:li:activity:7254114501971558400" "followers" => null "date" => "1w" "description" => "Our dedication to corporate responsibility means innovating for the benefit of millions of patients, contributing to the communities where we live and work, and improving the health of the planet we all share." "reactions_count" => 249 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-26 16:48:42" "deleted" => 1 ] [ "id" => 780063115 "company_id" => 35408 "urn" => "urn:li:activity:7253032709671866370" "followers" => null "date" => "1w" "description" => """ Three takeaways about chronic lower back pain from Ray Baker, M.D., vice president and chief medical officer of neuromodulation, in his appearances at #DTWest2024 and on the DeviceTalks podcast: \n \n -𝐎𝐧 𝐰𝐡𝐲 𝐢𝐭’𝐬 𝐚𝐧 𝐞𝐱𝐜𝐢𝐭𝐢𝐧𝐠 𝐭𝐢𝐦𝐞 𝐟𝐨𝐫 𝐬𝐩𝐢𝐧𝐞 𝐡𝐞𝐚𝐥𝐭𝐡 🌟 Advances in technology are creating minimally invasive options for patients who want to avoid surgery. Just as importantly, better education for doctors is now allowing them to put that technology to use; and at the same time, a growing evidence base is helping patients feel confident about undergoing these procedures. \n \n -𝐎𝐧 𝐭𝐡𝐞 𝐦𝐢𝐬𝐬𝐢𝐧𝐠 𝐩𝐢𝐞𝐜𝐞 𝐨𝐟 𝐭𝐡𝐞 𝐩𝐚𝐢𝐧 𝐩𝐮𝐳𝐳𝐥𝐞 🔎 Spinal discs were long thought to be the primary cause of some back pain, yet many patients saw no benefit from disc treatment. “That left us scratching our heads,” said Ray. The resulting research led to the discovery of endplates -- bony structures attached to the discs -- as being their own source of inflammation and pain signaling. The pain produced by degenerating endplates is called vertebrogenic pain. \n \n -𝐎𝐧 𝐝𝐢𝐚𝐠𝐧𝐨𝐬𝐭𝐢𝐜 𝐢𝐦𝐩𝐫𝐨𝐯𝐞𝐦𝐞𝐧𝐭𝐬 𝐥𝐞𝐚𝐝𝐢𝐧𝐠 𝐭𝐨 𝐛𝐞𝐭𝐭𝐞𝐫 𝐫𝐞𝐬𝐮𝐥𝐭𝐬 📈 Until recently, the field “didn’t have a great way to separate out the causes of pain. That led to a trial-and-error approach” to patient care. But vertebrogenic pain has an objective biomarker that appears clearly on an MRI. Patients who receive a vertebrogenic pain diagnosis are indicated for treatment with basivertebral nerve ablation, a minimally invasive procedure proven to provide durable relief. \n \n \n Listen to the podcast for more about vertebrogenic pain and the Intracept™ Intraosseous Nerve Ablation System: https://bit.ly/4haLQHZ """ "reactions_count" => 204 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-26 16:48:42" "deleted" => 1 ] [ "id" => 780063116 "company_id" => 35408 "urn" => "urn:li:activity:7252302479420178432" "followers" => null "date" => "2w" "description" => "Last year, the Boston Scientific Foundation gave $2.19 million in grants, scholarships and humanitarian aid – including financial donations to 27 non-profits and programs aimed at improving the health of people in need. Learn more about the health grant program and how it’s helping communities across the U.S.: https://bit.ly/3BMCan4" "reactions_count" => 200 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-26 16:48:42" "deleted" => 1 ] [ "id" => 819481282 "company_id" => 35408 "urn" => "urn:li:activity:7267190963897270273" "followers" => null "date" => "1h" "description" => "Good health allows us to enjoy life, value our loved ones and pursue our passions. We are grateful for the chance to positively impact millions of patients worldwide." "reactions_count" => 54 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-03 10:56:12" "deleted" => 1 ] [ "id" => 819481283 "company_id" => 35408 "urn" => "urn:li:activity:7266873533098561537" "followers" => null "date" => "22h" "description" => """ The AMS 700™ Inflatable Penile Prosthesis provides a long-term treatment option for erectile dysfunction – and its new TENACIO™ Pump component is designed to help improve ease of use for patients. Learn how this groundbreaking innovation is helping people regain their sexual function.\n \n Visit https://bit.ly/4g5ckt8 for important risk information for the AMS 700 Inflatable Penile Prosthesis.\n \n https://bit.ly/4fUsuFQ """ "reactions_count" => 56 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-03 10:56:12" "deleted" => 1 ] [ "id" => 819481284 "company_id" => 35408 "urn" => "urn:li:activity:7266797821046009856" "followers" => null "date" => "1d" "description" => "We’re excited to share that we have entered into a definitive agreement to acquire Intera Oncology Inc. , a medical device company that provides a solution to deliver hepatic artery infusion (HAI) therapy to patients with cancerous tumors that have metastasized to the liver. Upon close, we look forward to welcoming the Intera Oncology team to Boston Scientific and Boston Scientific Peripheral Interventions and are excited to add this complementary therapy, which will expand our offerings to treat both primary and metastatic forms of liver cancer. https://bit.ly/3Oq5a70" "reactions_count" => 1451 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-03 10:56:12" "deleted" => 1 ] [ "id" => 819481285 "company_id" => 35408 "urn" => "urn:li:activity:7265378515997356034" "followers" => null "date" => "5d" "description" => """ Writing for Forbes, our Chief Information and Digital Officer Jodi Euerle Eddy reflects on what it’s like to lead as a woman, why closing the leadership gap is good for business, and ways to help women succeed. Here are three key takeaways on how companies can help women grow into senior leaders:\n \n 𝟏. 𝐆𝐞𝐭 𝐛𝐮𝐲-𝐢𝐧 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐭𝐨𝐩 🌟: Successful inclusion initiatives require strong support and active participation from top leadership. Their day-to-day example will lead your company forward.\n \n 𝟐. 𝐂𝐫𝐞𝐚𝐭𝐞 𝐚 𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞 𝐟𝐨𝐫 𝐦𝐞𝐧𝐭𝐨𝐫𝐬𝐡𝐢𝐩 𝐚𝐧𝐝 𝐬𝐩𝐨𝐧𝐬𝐨𝐫𝐬𝐡𝐢𝐩 🤝: Establish programs that connect women with mentors and advocates who can champion their growth and introduce them to new opportunities.\n \n 𝟑. 𝐈𝐧𝐯𝐞𝐬𝐭 𝐢𝐧 𝐭𝐡𝐞𝐢𝐫 𝐥𝐞𝐚𝐫𝐧𝐢𝐧𝐠 💡: Employee-sponsored learning opportunities help unlock employees’ potential while also improving their job satisfaction and ensuring a diverse pipeline of leadership talent.\n \n Read more and see why we were named a 2024 Top Company for Executive Women by Seramount: https://bit.ly/3Z2Ylgy """ "reactions_count" => 106 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-03 10:56:12" "deleted" => 1 ] [ "id" => 819481286 "company_id" => 35408 "urn" => "urn:li:activity:7265016480356786180" "followers" => null "date" => "6d" "description" => "Our Fostering Indigenous Resources and Empowerment (FIRE) employee resource group celebrates the rich cultures of people native to North America. In honor of #NativeAmericanHeritageMonth, we asked FIRE leaders to share why this time of year is especially meaningful." "reactions_count" => 106 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-03 10:56:12" "deleted" => 1 ] [ "id" => 819481287 "company_id" => 35408 "urn" => "urn:li:activity:7263188022047784960" "followers" => null "date" => "1w" "description" => "We have successfully closed the acquisition of Axonics, Inc. We’re excited to add the company’s clinically differentiated devices to treat urinary and bowel dysfunction to the Boston Scientific Urology portfolio. Learn more here: https://bit.ly/3CvBjr8" "reactions_count" => 2955 "comments_count" => 33 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-03 10:56:12" "deleted" => 1 ] [ "id" => 819481288 "company_id" => 35408 "urn" => "urn:li:activity:7262928339009507331" "followers" => null "date" => "1w" "description" => "The WaveWriter Alpha™ SCS System, approved for the treatment of diabetic peripheral neuropathy (DPN) of the lower extremities, offers patients relief from nerve pain. #WorldDiabetesDay https://bit.ly/3YS8v3y" "reactions_count" => 217 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-03 10:56:12" "deleted" => 1 ] [ "id" => 819481289 "company_id" => 35408 "urn" => "urn:li:activity:7262507198230978563" "followers" => null "date" => "1w" "description" => "The completion of over 40 acquisitions and investment in R&D under the leadership of CEO and Chairman Mike Mahoney has helped position us as a leading medtech company, as noted by The Boston Globe. As we continue to grow, our commitment to improving patient lives remains central to our mission – a mission that fuels our innovation pipeline, our dedication to quality and our values-based culture. #AdvancingTogether https://bit.ly/3Z3WVDJ" "reactions_count" => 1842 "comments_count" => 23 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-03 10:56:12" "deleted" => 1 ] [ "id" => 819481290 "company_id" => 35408 "urn" => "urn:li:activity:7260308855341957124" "followers" => null "date" => "2w" "description" => """ We had the honor of ringing the closing bell at the NYSE to celebrate Boston Scientific’s 45th anniversary. This milestone is a tribute to our dedicated employees, the patients whose lives we’ve impacted, and the global communities we’ve served. Thank you to everyone who has contributed to our legacy over the past 45 years. Here’s to many more years #AdvancingTogether.\n \n Mike Mahoney, Nick Spadea-Anello, Charlie Attlan, Lance Bates, Vance Brown, Rosaleen Burke, Wendy Carruthers, Jodi Euerle Eddy, Mike Jones, Jeff Mirviss, Mary Beth Moynihan, Paudie O'Connor, Scott Olson, Meghan Scanlon, Ken Stein\n \n Photo by NYSE """ "reactions_count" => 3076 "comments_count" => 59 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-03 10:56:12" "deleted" => 1 ] [ "id" => 819481291 "company_id" => 35408 "urn" => "urn:li:activity:7259176392444067840" "followers" => null "date" => "3w" "description" => "We’re excited to announce that we have entered into a definitive agreement to acquire Cortex, a medical technology company focused on the development of a diagnostic mapping solution that may identify triggers and drivers outside the pulmonary veins that are foundational to atrial fibrillation (AF), a heart rhythm disorder that impacts millions of people globally. Upon close, we look forward to advancing this technology and welcoming the Cortex team to Boston Scientific. https://bit.ly/3NTXVnS" "reactions_count" => 2248 "comments_count" => 28 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-03 10:56:12" "deleted" => 1 ] [ "id" => 837422630 "company_id" => 35408 "urn" => "urn:li:activity:7267190963897270273" "followers" => null "date" => "6d" "description" => "Good health allows us to enjoy life, value our loved ones and pursue our passions. We are grateful for the chance to positively impact millions of patients worldwide." "reactions_count" => 154 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-01 12:29:44" "deleted" => 1 ] [ "id" => 837422631 "company_id" => 35408 "urn" => "urn:li:activity:7266873533098561537" "followers" => null "date" => "1w" "description" => """ The AMS 700™ Inflatable Penile Prosthesis provides a long-term treatment option for erectile dysfunction – and its new TENACIO™ Pump component is designed to help improve ease of use for patients. Learn how this groundbreaking innovation is helping people regain their sexual function.\n \n Visit https://bit.ly/4g5ckt8 for important risk information for the AMS 700 Inflatable Penile Prosthesis.\n \n https://bit.ly/4fUsuFQ """ "reactions_count" => 73 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-01 12:29:44" "deleted" => 1 ] [ "id" => 837422632 "company_id" => 35408 "urn" => "urn:li:activity:7266797821046009856" "followers" => null "date" => "1w" "description" => "We’re excited to share that we have entered into a definitive agreement to acquire Intera Oncology Inc. , a medical device company that provides a solution to deliver hepatic artery infusion (HAI) therapy to patients with cancerous tumors that have metastasized to the liver. Upon close, we look forward to welcoming the Intera Oncology team to Boston Scientific and Boston Scientific Peripheral Interventions and are excited to add this complementary therapy, which will expand our offerings to treat both primary and metastatic forms of liver cancer. https://bit.ly/3Oq5a70" "reactions_count" => 1670 "comments_count" => 14 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-01 12:29:44" "deleted" => 1 ] [ "id" => 837422633 "company_id" => 35408 "urn" => "urn:li:activity:7265378515997356034" "followers" => null "date" => "1w" "description" => """ Writing for Forbes, our Chief Information and Digital Officer Jodi Euerle Eddy reflects on what it’s like to lead as a woman, why closing the leadership gap is good for business, and ways to help women succeed. Here are three key takeaways on how companies can help women grow into senior leaders:\n \n 𝟏. 𝐆𝐞𝐭 𝐛𝐮𝐲-𝐢𝐧 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐭𝐨𝐩 🌟: Successful inclusion initiatives require strong support and active participation from top leadership. Their day-to-day example will lead your company forward.\n \n 𝟐. 𝐂𝐫𝐞𝐚𝐭𝐞 𝐚 𝐬𝐭𝐫𝐮𝐜𝐭𝐮𝐫𝐞 𝐟𝐨𝐫 𝐦𝐞𝐧𝐭𝐨𝐫𝐬𝐡𝐢𝐩 𝐚𝐧𝐝 𝐬𝐩𝐨𝐧𝐬𝐨𝐫𝐬𝐡𝐢𝐩 🤝: Establish programs that connect women with mentors and advocates who can champion their growth and introduce them to new opportunities.\n \n 𝟑. 𝐈𝐧𝐯𝐞𝐬𝐭 𝐢𝐧 𝐭𝐡𝐞𝐢𝐫 𝐥𝐞𝐚𝐫𝐧𝐢𝐧𝐠 💡: Employee-sponsored learning opportunities help unlock employees’ potential while also improving their job satisfaction and ensuring a diverse pipeline of leadership talent.\n \n Read more and see why we were named a 2024 Top Company for Executive Women by Seramount: https://bit.ly/3Z2Ylgy """ "reactions_count" => 116 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-01 12:29:44" "deleted" => 1 ] [ "id" => 837422634 "company_id" => 35408 "urn" => "urn:li:activity:7265016480356786180" "followers" => null "date" => "1w" "description" => "Our Fostering Indigenous Resources and Empowerment (FIRE) employee resource group celebrates the rich cultures of people native to North America. In honor of #NativeAmericanHeritageMonth, we asked FIRE leaders to share why this time of year is especially meaningful." "reactions_count" => 124 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-01 12:29:44" "deleted" => 1 ] [ "id" => 837422635 "company_id" => 35408 "urn" => "urn:li:activity:7263188022047784960" "followers" => null "date" => "2w" "description" => "We have successfully closed the acquisition of Axonics, Inc. We’re excited to add the company’s clinically differentiated devices to treat urinary and bowel dysfunction to the Boston Scientific Urology portfolio. Learn more here: https://bit.ly/3CvBjr8" "reactions_count" => 3112 "comments_count" => 35 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-01 12:29:44" "deleted" => 1 ] [ "id" => 837422636 "company_id" => 35408 "urn" => "urn:li:activity:7262928339009507331" "followers" => null "date" => "2w" "description" => "The WaveWriter Alpha™ SCS System, approved for the treatment of diabetic peripheral neuropathy (DPN) of the lower extremities, offers patients relief from nerve pain. #WorldDiabetesDay https://bit.ly/3YS8v3y" "reactions_count" => 225 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-01 12:29:44" "deleted" => 1 ] [ "id" => 837422637 "company_id" => 35408 "urn" => "urn:li:activity:7262507198230978563" "followers" => null "date" => "2w" "description" => "The completion of over 40 acquisitions and investment in R&D under the leadership of CEO and Chairman Mike Mahoney has helped position us as a leading medtech company, as noted by The Boston Globe. As we continue to grow, our commitment to improving patient lives remains central to our mission – a mission that fuels our innovation pipeline, our dedication to quality and our values-based culture. #AdvancingTogether https://bit.ly/3Z3WVDJ" "reactions_count" => 1990 "comments_count" => 23 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-01 12:29:44" "deleted" => 1 ] [ "id" => 837422638 "company_id" => 35408 "urn" => "urn:li:activity:7260308855341957124" "followers" => null "date" => "3w" "description" => """ We had the honor of ringing the closing bell at the NYSE to celebrate Boston Scientific’s 45th anniversary. This milestone is a tribute to our dedicated employees, the patients whose lives we’ve impacted, and the global communities we’ve served. Thank you to everyone who has contributed to our legacy over the past 45 years. Here’s to many more years #AdvancingTogether.\n \n Mike Mahoney, Nick Spadea-Anello, Charlie Attlan, Lance Bates, Vance Brown, Rosaleen Burke, Wendy Carruthers, Jodi Euerle Eddy, Mike Jones, Jeff Mirviss, Mary Beth Moynihan, Paudie O'Connor, Scott Olson, Meghan Scanlon, Ken Stein\n \n Photo by NYSE """ "reactions_count" => 3140 "comments_count" => 62 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-01 12:29:44" "deleted" => 1 ] [ "id" => 837422639 "company_id" => 35408 "urn" => "urn:li:activity:7259176392444067840" "followers" => null "date" => "4w" "description" => "We’re excited to announce that we have entered into a definitive agreement to acquire Cortex, a medical technology company focused on the development of a diagnostic mapping solution that may identify triggers and drivers outside the pulmonary veins that are foundational to atrial fibrillation (AF), a heart rhythm disorder that impacts millions of people globally. Upon close, we look forward to advancing this technology and welcoming the Cortex team to Boston Scientific. https://bit.ly/3NTXVnS" "reactions_count" => 2287 "comments_count" => 27 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-01 12:29:44" "deleted" => 1 ] [ "id" => 862894078 "company_id" => 35408 "urn" => "urn:li:activity:7279511620488183809" "followers" => null "date" => "1d" "description" => "Reflecting on 20+ years of experience, APAC President Stephen Morse shares a key takeaway: Never stop learning. When we stay curious and take advantage of opportunities for collaboration, we keep moving forward. https://bit.ly/3PfjMXc" "reactions_count" => 95 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-12 08:07:51" "deleted" => 1 ] [ "id" => 862894079 "company_id" => 35408 "urn" => "urn:li:activity:7275525914325651457" "followers" => null "date" => "1w" "description" => "We are proud to celebrate a year of remarkable growth and innovation, driven by the winning spirit and dedication of our employees worldwide. Together, we have positively impacted the lives of over 43 million patients globally. As we look ahead to 2025, we remain committed to #AdvancingTogether." "reactions_count" => 1440 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-12 08:07:51" "deleted" => 1 ] [ "id" => 862894080 "company_id" => 35408 "urn" => "urn:li:activity:7275171217999880192" "followers" => null "date" => "1w" "description" => "We were recently named one of America’s Best Employers for Engineers by Forbes. Hear from software testing engineer Brennan on what it’s like to work in R&D for our electrophysiology business. Explore new career opportunities: https://lnkd.in/da7cwZJE. #LifeSciencesJobs #CardiologyCareers #AdvancingTogether" "reactions_count" => 840 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-12 08:07:51" "deleted" => 1 ] [ "id" => 862894081 "company_id" => 35408 "urn" => "urn:li:activity:7272264065161306113" "followers" => null "date" => "3w" "description" => "EP Mapper Celeste shares highlights of her critical role working on our industry-leading FARAPULSE™ Pulsed Field Ablation technology. Join us as we push the boundaries of innovation to solve health care's toughest challenges! https://bit.ly/3BlK86J #LifeSciencesJobs #CardiologyCareers #AdvancingTogether" "reactions_count" => 273 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-12 08:07:51" "deleted" => 1 ] [ "id" => 862894082 "company_id" => 35408 "urn" => "urn:li:activity:7270452192455626753" "followers" => null "date" => "3w" "description" => "Our unwavering commitment to enhancing the quality of patient care is what guides us. Every success story celebrated at our global Everyone Makes an Impact (EMAI) events begins with our dedicated employees who invest their hearts and hands into making a difference in millions of lives. Thank you to our teams around the world for coming together to celebrate another EMAI. #AdvancingTogether" "reactions_count" => 544 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-12 08:07:51" "deleted" => 1 ] [ "id" => 862894083 "company_id" => 35408 "urn" => "urn:li:activity:7270102519987478529" "followers" => null "date" => "4w" "description" => "Small steps toward change add up to cover great distances. That is why at Boston Scientific, we are working to reduce waste, one banana peel, candy wrapper and piece of paper at a time. For anyone taking similar steps toward #zerowaste, I am sharing three tactics we have found useful to create lasting shifts toward greater #sustainability." "reactions_count" => 158 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-12 08:07:51" "deleted" => 1 ] [ "id" => 862894084 "company_id" => 35408 "urn" => "urn:li:activity:7269767382452035585" "followers" => null "date" => "4w" "description" => "In honor of International Day of Persons with Disabilities, we’re illuminating our global sites in purple. Thank you to our LEAD (Leadership, Education and Allies for Disabilities) Employee Resource Group for your dedication and commitment to inclusion. #IDPWD" "reactions_count" => 686 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-12 08:07:51" "deleted" => 1 ] [ "id" => 862894085 "company_id" => 35408 "urn" => "urn:li:activity:7267190963897270273" "followers" => null "date" => "1mo" "description" => "Good health allows us to enjoy life, value our loved ones and pursue our passions. We are grateful for the chance to positively impact millions of patients worldwide." "reactions_count" => 200 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-12 08:07:51" "deleted" => 1 ] [ "id" => 862894086 "company_id" => 35408 "urn" => "urn:li:activity:7266873533098561537" "followers" => null "date" => "1mo" "description" => """ The AMS 700™ Inflatable Penile Prosthesis provides a long-term treatment option for erectile dysfunction – and its new TENACIO™ Pump component is designed to help improve ease of use for patients. Learn how this groundbreaking innovation is helping people regain their sexual function.\n \n Visit https://bit.ly/4g5ckt8 for important risk information for the AMS 700 Inflatable Penile Prosthesis.\n \n https://bit.ly/4fUsuFQ """ "reactions_count" => 114 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-12 08:07:51" "deleted" => 1 ] [ "id" => 862894087 "company_id" => 35408 "urn" => "urn:li:activity:7266797821046009856" "followers" => null "date" => "1mo" "description" => "We’re excited to share that we have entered into a definitive agreement to acquire Intera Oncology Inc. , a medical device company that provides a solution to deliver hepatic artery infusion (HAI) therapy to patients with cancerous tumors that have metastasized to the liver. Upon close, we look forward to welcoming the Intera Oncology team to Boston Scientific and Boston Scientific Peripheral Interventions and are excited to add this complementary therapy, which will expand our offerings to treat both primary and metastatic forms of liver cancer. https://bit.ly/3Oq5a70" "reactions_count" => 1879 "comments_count" => 14 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-12 08:07:51" "deleted" => 1 ] [ "id" => 882472904 "company_id" => 35408 "urn" => "urn:li:activity:7282759646359040000" "followers" => null "date" => "3d" "description" => "We’re excited to announce that we’ve entered into a definitive agreement to acquire Bolt Medical, the developer of an innovative, laser-based intravascular lithotripsy (IVL) system. The Bolt IVL™ platform provides a novel application of lithotripsy that uses acoustic pressure waves inside of a balloon catheter to break up hardened masses such as calcium to help restore blood flow. https://bit.ly/3Pv0ehT" "reactions_count" => 3127 "comments_count" => 71 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 1 ] [ "id" => 882472905 "company_id" => 35408 "urn" => "urn:li:activity:7282423903988133889" "followers" => null "date" => "4d" "description" => """ As the new year begins, we remain committed to achieving carbon neutrality in all manufacturing and key distribution sites by 2030 – just one reason we’ve been included for the fifth consecutive year in the latest S&P Dow Jones Indices Sustainability Index for North America. Take a behind-the-scenes look at our facility in Kerkrade, the Netherlands, to see how we’re getting there: https://bit.ly/4gJnViv \n \n #sustainability #DJSI """ "reactions_count" => 360 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 1 ] [ "id" => 882472906 "company_id" => 35408 "urn" => "urn:li:activity:7279511620488183809" "followers" => null "date" => "1w" "description" => "Reflecting on 20+ years of experience, APAC President Stephen Morse shares a key takeaway: Never stop learning. When we stay curious and take advantage of opportunities for collaboration, we keep moving forward. https://bit.ly/3PfjMXc" "reactions_count" => 148 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 1 ] [ "id" => 882472907 "company_id" => 35408 "urn" => "urn:li:activity:7275525914325651457" "followers" => null "date" => "3w" "description" => "We are proud to celebrate a year of remarkable growth and innovation, driven by the winning spirit and dedication of our employees worldwide. Together, we have positively impacted the lives of over 43 million patients globally. As we look ahead to 2025, we remain committed to #AdvancingTogether." "reactions_count" => 1850 "comments_count" => 26 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 1 ] [ "id" => 882472908 "company_id" => 35408 "urn" => "urn:li:activity:7275171217999880192" "followers" => null "date" => "3w" "description" => "We were recently named one of America’s Best Employers for Engineers by Forbes. Hear from software testing engineer Brennan on what it’s like to work in R&D for our electrophysiology business. Explore new career opportunities: https://lnkd.in/da7cwZJE. #LifeSciencesJobs #CardiologyCareers #AdvancingTogether" "reactions_count" => 1019 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 1 ] [ "id" => 882472909 "company_id" => 35408 "urn" => "urn:li:activity:7272264065161306113" "followers" => null "date" => "1mo" "description" => "EP Mapper Celeste shares highlights of her critical role working on our industry-leading FARAPULSE™ Pulsed Field Ablation technology. Join us as we push the boundaries of innovation to solve health care's toughest challenges! https://bit.ly/3BlK86J #LifeSciencesJobs #CardiologyCareers #AdvancingTogether" "reactions_count" => 299 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 1 ] [ "id" => 882472910 "company_id" => 35408 "urn" => "urn:li:activity:7270452192455626753" "followers" => null "date" => "1mo" "description" => "Our unwavering commitment to enhancing the quality of patient care is what guides us. Every success story celebrated at our global Everyone Makes an Impact (EMAI) events begins with our dedicated employees who invest their hearts and hands into making a difference in millions of lives. Thank you to our teams around the world for coming together to celebrate another EMAI. #AdvancingTogether" "reactions_count" => 554 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 1 ] [ "id" => 882472911 "company_id" => 35408 "urn" => "urn:li:activity:7270102519987478529" "followers" => null "date" => "1mo" "description" => "Small steps toward change add up to cover great distances. That is why at Boston Scientific, we are working to reduce waste, one banana peel, candy wrapper and piece of paper at a time. For anyone taking similar steps toward #zerowaste, I am sharing three tactics we have found useful to create lasting shifts toward greater #sustainability." "reactions_count" => 162 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 1 ] [ "id" => 882472912 "company_id" => 35408 "urn" => "urn:li:activity:7269767382452035585" "followers" => null "date" => "1mo" "description" => "In honor of International Day of Persons with Disabilities, we’re illuminating our global sites in purple. Thank you to our LEAD (Leadership, Education and Allies for Disabilities) Employee Resource Group for your dedication and commitment to inclusion. #IDPWD" "reactions_count" => 705 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 1 ] [ "id" => 882472913 "company_id" => 35408 "urn" => "urn:li:activity:7267190963897270273" "followers" => null "date" => "1mo" "description" => "Good health allows us to enjoy life, value our loved ones and pursue our passions. We are grateful for the chance to positively impact millions of patients worldwide." "reactions_count" => 202 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 1 ] [ "id" => 917531144 "company_id" => 35408 "urn" => "urn:li:activity:7290424038160572416" "followers" => null "date" => "5d" "description" => "Our employees work together every day to find innovative solutions to health care’s toughest challenges. It’s because of them that we’ve been named one of Fortune’s World’s Most Admired Companies for the 10th consecutive year. #MostAdmiredCos" "reactions_count" => 465 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 917531145 "company_id" => 35408 "urn" => "urn:li:activity:7288579373794742273" "followers" => null "date" => "1w" "description" => "We have successfully closed the acquisition of Cortex. We look forward to advancing the OptiMap™ System developed by Cortex which complements our electrophysiology portfolio with a differentiated cardiac mapping offering to assist with complex atrial fibrillation cases." "reactions_count" => 1506 "comments_count" => 14 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 917531146 "company_id" => 35408 "urn" => "urn:li:activity:7288209007524126723" "followers" => null "date" => "1w" "description" => "An estimated 30 million U.S. adults suffer from overactive bladder. As Axonics, Inc. officially becomes part of Boston Scientific, Meghan Scanlon, senior vice president and president, Urology, shares how the acquisition stands to help even more people with the condition across the globe. https://bit.ly/4hpIu3p" "reactions_count" => 719 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 917531147 "company_id" => 35408 "urn" => "urn:li:activity:7287511062009065472" "followers" => null "date" => "1w" "description" => "In an interview with CNBC’s Jim Cramer at the J.P. Morgan Healthcare Conference, CEO Mike Mahoney shares how breakthrough products are transforming healthcare and driving strong business performance. "We’re coming off a great 2023, better 2024 and we aim to have a terrific 2025 and beyond," he says." "reactions_count" => 1367 "comments_count" => 20 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 917531148 "company_id" => 35408 "urn" => "urn:li:activity:7285717521674952704" "followers" => null "date" => "2w" "description" => """ As we begin a new year, how will we continue to improve healthcare for patients and grow as a company? Chairman and CEO Mike Mahoney shared what to expect in 2025 at the J.P. Morgan Healthcare Conference. Here are four key takeaways: \n \n 💡 𝗥𝗲𝗹𝗲𝗻𝘁𝗹𝗲𝘀𝘀 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗮𝗻𝗱 𝗱𝗶𝘃𝗲𝗿𝘀𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻: To stay ahead of the curve in a rapidly evolving industry, our R&D and M&A strategies will remain focused on cultivating innovative technologies and diversifying our product portfolio. \n \n 🔬 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹𝗹𝘆 𝗱𝗶𝗳𝗳𝗲𝗿𝗲𝗻𝘁𝗶𝗮𝘁𝗲𝗱 𝗽𝗿𝗼𝗱𝘂𝗰𝘁𝘀: With a diverse portfolio that gives us broad exposure to high-growth opportunities, we’ll continue executing on our strategy of category leadership. As such, we expect our 2025 key growth drivers to come from across our business units.\n \n ❤️ 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗶𝗻𝗴 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁: We are leading a global transformation in atrial fibrillation treatment with rapid, sustained adoption of our FARAPULSE Pulsed Field Ablation system and expect to lead a global LAAC expansion with our WATCHMAN portfolio.\n \n 🚀 𝗜𝗻𝘃𝗲𝘀𝘁𝗶𝗻𝗴 𝗳𝗼𝗿 𝗹𝗼𝗻𝗴-𝘁𝗲𝗿𝗺 𝗴𝗿𝗼𝘄𝘁𝗵: Our differentiated strategy will keep us on track toward our goal to consistently be the highest performing large cap medtech company.\n \n #JPM25 """ "reactions_count" => 1609 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 917531149 "company_id" => 35408 "urn" => "urn:li:activity:7282759646359040000" "followers" => null "date" => "3w" "description" => "We’re excited to announce that we’ve entered into a definitive agreement to acquire Bolt Medical, the developer of an innovative, laser-based intravascular lithotripsy (IVL) system. The Bolt IVL™ platform provides a novel application of lithotripsy that uses acoustic pressure waves inside of a balloon catheter to break up hardened masses such as calcium to help restore blood flow. https://bit.ly/3Pv0ehT" "reactions_count" => 3624 "comments_count" => 83 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 917531150 "company_id" => 35408 "urn" => "urn:li:activity:7282423903988133889" "followers" => null "date" => "3w" "description" => """ As the new year begins, we remain committed to achieving carbon neutrality in all manufacturing and key distribution sites by 2030 – just one reason we’ve been included for the fifth consecutive year in the latest S&P Dow Jones Indices Sustainability Index for North America. Take a behind-the-scenes look at our facility in Kerkrade, the Netherlands, to see how we’re getting there: https://bit.ly/4gJnViv \n \n #sustainability #DJSI """ "reactions_count" => 501 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 917531151 "company_id" => 35408 "urn" => "urn:li:activity:7279511620488183809" "followers" => null "date" => "1mo" "description" => "Reflecting on 20+ years of experience, APAC President Stephen Morse shares a key takeaway: Never stop learning. When we stay curious and take advantage of opportunities for collaboration, we keep moving forward. https://bit.ly/3PfjMXc" "reactions_count" => 181 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 917531152 "company_id" => 35408 "urn" => "urn:li:activity:7275525914325651457" "followers" => null "date" => "1mo" "description" => "We are proud to celebrate a year of remarkable growth and innovation, driven by the winning spirit and dedication of our employees worldwide. Together, we have positively impacted the lives of over 43 million patients globally. As we look ahead to 2025, we remain committed to #AdvancingTogether." "reactions_count" => 1931 "comments_count" => 29 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] [ "id" => 917531153 "company_id" => 35408 "urn" => "urn:li:activity:7275171217999880192" "followers" => null "date" => "1mo" "description" => "We were recently named one of America’s Best Employers for Engineers by Forbes. Hear from software testing engineer Brennan on what it’s like to work in R&D for our electrophysiology business. Explore new career opportunities: https://lnkd.in/da7cwZJE. #LifeSciencesJobs #CardiologyCareers #AdvancingTogether" "reactions_count" => 1074 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-04 21:15:52" "deleted" => 0 ] ] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4599 …} -companyTags: Doctrine\ORM\PersistentCollection {#4601 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4603 …} -users: Doctrine\ORM\PersistentCollection {#4605 …} -logoImageName: "20250226143912-boston-scientific-67bf1980a63cd841900632.png" -coverImageName: "20250227161719-boston-scientific-67c081ff911f3961650864.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4607 …} -tagline: "Leben verändern durch innovative medizinische Lösungen und wissenschaftlichen Fortschritt" -contactEmail: "fabio.laghi@bsci.com" -phone: null -streamUrl: "https://www.youtube.com/watch?v=w_SdC5PE0_U" -streamType: "YOUTUBE" -followers: Doctrine\ORM\PersistentCollection {#4609 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4611 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4613 …} -industry: "Boston Scientific" -size: null -address1: null -address2: null -city: null -postalCode: null -state: null -country: "United States" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4615 …} #createdAt: DateTime @1740048118 {#4576 date: 2025-02-20 10:41:58.0 UTC (+00:00) } #updatedAt: DateTime @1750924639 {#4575 date: 2025-06-26 07:57:19.0 UTC (+00:00) } } App\Entity\Company {#4619 -id: 17 -name: "BRACCO" -website: "https://bracco.com" -description: "" -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4620 …} -companyTags: Doctrine\ORM\PersistentCollection {#4622 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4624 …} -users: Doctrine\ORM\PersistentCollection {#4626 …} -logoImageName: "20250226143942-bracco-logo-67bf199e5e444296154589.png" -coverImageName: "20250227161816-bracco-medical-technologies-cover-67c0823869c41828732198.jpeg" -companyProducts: Doctrine\ORM\PersistentCollection {#4628 …} -tagline: "Pionier in der medizinischen Bildgebung – Innovationen für präzisere Diagnosen und bessere Patientenversorgung" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4630 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4632 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4634 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4636 …} #createdAt: DateTime @1740048384 {#4597 date: 2025-02-20 10:46:24.0 UTC (+00:00) } #updatedAt: DateTime @1750924672 {#4596 date: 2025-06-26 07:57:52.0 UTC (+00:00) } } App\Entity\Company {#4640 -id: 18 -name: "Bristol Myers Squibb" -website: "https://bms.com" -description: """ Bristol-Myers Squibb ist ein globales, BioPharma-Unternehmen, das eine klare Mission verfolgt: Die Erforschung, Entwicklung und Bereitstellung von innovativen Medikamenten, die Patienten helfen, schwere Erkrankungen zu überwinden.\n \n Im Fokus unseres Handelns stehen weltweit Millionen Menschen, denen wir mit unseren Medikamenten in Therapiebereichen wie der Onkologie und Immunologie sowie bei Herz-Kreislauf- und fibrotischen Erkrankungen helfen können. Eine Aufgabe, die uns mit Hingabe, Motivation und Antrieb erfüllt. Durch unsere intensiven Forschungs- und Entwicklungsaktivitäten ist es uns gelungen, eine nachhaltige Entwicklungs-Pipeline für mögliche neue Therapien aufzubauen. Die Zusammenarbeit mit externen Partnern fördert unser Bestreben Innovationen voranzutreiben, unsere Arbeit zu beschleunigen und uns möglichst breit aufzustellen.\n \n Weitere Informationen finden Sie auf unserer Website» """ -externalId: "140537" -details: [ "id" => 140537 "url" => "https://www.linkedin.com/company/bristol-myers-squibb" "hash" => "3815559763c7b91caca96ebc52e7272b" "name" => "Bristol Myers Squibb" "website" => "http://www.bms.com" "size" => "10,001+ employees" "industry" => "Pharmaceutical Manufacturing" "description" => """ At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome.\n \n Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients.\n \n Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do.\n \n Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html """ "followers" => 1544677 "founded" => null "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://media.licdn.com/dms/image/v2/D4E0BAQHPSJGTVwPgvg/company-logo_200_200/company-logo_200_200/0/1719830772393/bristol_myers_squibb_logo?e=2147483647&v=beta&t=vexnjiAyKMLFrYRWi1fqkAw4OH1HOzCNVKS2K9RX8UQ" "created" => "2016-06-17 21:33:03" "last_updated" => "2025-02-09 19:10:40" "last_response_code" => 200 "type" => "Public Company" "headquarters_new_address" => "Lawrence Township, NJ" "employees_count" => null "headquarters_country_restored" => "United States" "headquarters_country_parsed" => "United States" "company_shorthand_name" => "bristol-myers-squibb" "company_shorthand_name_hash" => "23f803c37b4a632092781f22992d11c6" "canonical_url" => "https://www.linkedin.com/company/bristol-myers-squibb" "canonical_hash" => "3815559763c7b91caca96ebc52e7272b" "canonical_shorthand_name" => "bristol-myers-squibb" "canonical_shorthand_name_hash" => "23f803c37b4a632092781f22992d11c6" "deleted" => 0 "last_updated_ux" => 1739128240 "source_id" => 1773 "company_affiliated_collection" => [ [ "id" => 4393028 "company_id" => 140537 "affiliated_company_url" => "https://www.linkedin.com/showcase/advancing-cell-therapy-%E2%80%94-bms-us" "affiliated_company_id" => null "created" => "2021-05-14 06:29:05" "last_updated" => "2022-02-07 10:18:25" "deleted" => 1 ] [ "id" => 8891874 "company_id" => 140537 "affiliated_company_url" => "https://uk.linkedin.com/company/bristol-myers-squibb-uk-ireland" "affiliated_company_id" => 92631738 "created" => "2023-07-03 10:32:05" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] ] "company_also_viewed_collection" => [ [ "id" => 565635 "company_id" => 140537 "viewed_company_url" => "https://www.linkedin.com/company/pfizer" "viewed_company_id" => null "created" => "2016-06-17 21:33:03" "last_updated" => "2019-11-14 02:04:33" "deleted" => 1 ] [ "id" => 565636 "company_id" => 140537 "viewed_company_url" => "https://www.linkedin.com/company/novartis" "viewed_company_id" => null "created" => "2016-06-17 21:33:03" "last_updated" => "2019-11-14 02:04:33" "deleted" => 1 ] [ "id" => 565637 "company_id" => 140537 "viewed_company_url" => "https://www.linkedin.com/company/sanofi-" "viewed_company_id" => null "created" => "2016-06-17 21:33:03" "last_updated" => "2016-12-08 17:29:30" "deleted" => 1 ] [ "id" => 565638 "company_id" => 140537 "viewed_company_url" => "https://www.linkedin.com/company/merck" "viewed_company_id" => null "created" => "2016-06-17 21:33:03" "last_updated" => "2019-11-14 02:04:33" "deleted" => 1 ] [ "id" => 565639 "company_id" => 140537 "viewed_company_url" => "https://www.linkedin.com/company/glaxosmithkline" "viewed_company_id" => null "created" => "2016-06-17 21:33:03" "last_updated" => "2019-01-01 17:33:52" "deleted" => 1 ] [ "id" => 565640 "company_id" => 140537 "viewed_company_url" => "https://www.linkedin.com/company/eli-lilly-and-company" "viewed_company_id" => null "created" => "2016-06-17 21:33:03" "last_updated" => "2016-12-08 17:29:30" "deleted" => 1 ] [ "id" => 38626351 "company_id" => 140537 "viewed_company_url" => "https://www.linkedin.com/company/sanofi" "viewed_company_id" => null "created" => "2016-12-08 17:29:30" "last_updated" => "2019-11-14 02:04:33" "deleted" => 1 ] [ "id" => 38626352 "company_id" => 140537 "viewed_company_url" => "https://www.linkedin.com/company/astrazeneca" "viewed_company_id" => null "created" => "2016-12-08 17:29:30" "last_updated" => "2017-08-28 07:24:06" "deleted" => 1 ] [ "id" => 109795601 "company_id" => 140537 "viewed_company_url" => "https://www.linkedin.com/company/eli-lilly-and-company" "viewed_company_id" => null "created" => "2017-08-28 07:24:05" "last_updated" => "2017-10-11 14:11:55" "deleted" => 1 ] [ "id" => 111794934 "company_id" => 140537 "viewed_company_url" => "https://www.linkedin.com/company/johnson-&-johnson" "viewed_company_id" => null "created" => "2017-10-11 14:11:55" "last_updated" => "2019-11-14 02:04:33" "deleted" => 1 ] [ "id" => 181182682 "company_id" => 140537 "viewed_company_url" => "https://www.linkedin.com/company/amgen" "viewed_company_id" => null "created" => "2019-01-01 17:33:51" "last_updated" => "2019-01-04 01:03:00" "deleted" => 1 ] [ "id" => 182292960 "company_id" => 140537 "viewed_company_url" => "https://www.linkedin.com/company/glaxosmithkline" "viewed_company_id" => null "created" => "2019-01-04 01:03:00" "last_updated" => "2019-02-24 09:45:24" "deleted" => 1 ] [ "id" => 189493785 "company_id" => 140537 "viewed_company_url" => "https://www.linkedin.com/company/eli-lilly-and-company" "viewed_company_id" => null "created" => "2019-02-24 09:45:23" "last_updated" => "2019-08-08 00:20:10" "deleted" => 1 ] [ "id" => 263954360 "company_id" => 140537 "viewed_company_url" => "https://www.linkedin.com/company/amgen" "viewed_company_id" => null "created" => "2019-08-08 00:20:10" "last_updated" => "2019-11-14 02:04:33" "deleted" => 1 ] ] "company_crunchbase_info_collection" => [ [ "id" => 39676 "company_id" => 140537 "cb_url" => "https://www.crunchbase.com/organization/bristol-myers-squibb" "created" => "2020-09-14 15:43:46" "last_updated" => "2021-10-12 10:35:00" "deleted" => 1 ] [ "id" => 139730 "company_id" => 140537 "cb_url" => "https://www.crunchbase.com/organization/bristol-myers-squibb" "created" => "2021-10-12 13:17:01" "last_updated" => "2021-11-22 17:11:34" "deleted" => 1 ] [ "id" => 150506 "company_id" => 140537 "cb_url" => "https://www.crunchbase.com/organization/bristol-myers-squibb" "created" => "2021-11-29 15:55:11" "last_updated" => "2022-07-23 15:09:50" "deleted" => 1 ] [ "id" => 197591 "company_id" => 140537 "cb_url" => "https://www.crunchbase.com/organization/bristol-myers-squibb" "created" => "2022-09-05 10:31:30" "last_updated" => "2022-10-11 11:57:15" "deleted" => 1 ] [ "id" => 255989 "company_id" => 140537 "cb_url" => "https://www.crunchbase.com/organization/bristol-myers-squibb" "created" => "2023-02-06 13:38:51" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] ] "company_featured_employees_collection" => [ [ "id" => 26430085 "company_id" => 140537 "url" => "https://www.linkedin.com/in/kenneth-washington-ii-0b721" "created" => "2019-11-14 02:04:33" "last_updated" => "2020-02-22 13:05:22" "deleted" => 1 ] [ "id" => 26430086 "company_id" => 140537 "url" => "https://www.linkedin.com/in/steve-galatis-54b21" "created" => "2019-11-14 02:04:33" "last_updated" => "2020-02-22 13:05:22" "deleted" => 1 ] [ "id" => 26430087 "company_id" => 140537 "url" => "https://www.linkedin.com/in/julioarodriguez" "created" => "2019-11-14 02:04:33" "last_updated" => "2020-02-22 13:05:22" "deleted" => 1 ] [ "id" => 26430088 "company_id" => 140537 "url" => "https://www.linkedin.com/in/paul-staid-95727" "created" => "2019-11-14 02:04:33" "last_updated" => "2020-02-22 13:05:22" "deleted" => 1 ] [ "id" => 38011767 "company_id" => 140537 "url" => "https://www.linkedin.com/in/chantalveillon" "created" => "2020-02-22 13:05:22" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 38011768 "company_id" => 140537 "url" => "https://www.linkedin.com/in/yerramalla" "created" => "2020-02-22 13:05:22" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 38011769 "company_id" => 140537 "url" => "https://www.linkedin.com/in/doug-rubin-61979" "created" => "2020-02-22 13:05:22" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 38011770 "company_id" => 140537 "url" => "https://www.linkedin.com/in/kenshea" "created" => "2020-02-22 13:05:22" "last_updated" => "2020-05-13 10:28:43" "deleted" => 1 ] [ "id" => 44372846 "company_id" => 140537 "url" => "https://www.linkedin.com/in/anita-geiger-4352b" "created" => "2020-05-13 10:28:43" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 49323564 "company_id" => 140537 "url" => "https://www.linkedin.com/in/anita-geiger-4352b" "created" => "2020-08-06 01:46:02" "last_updated" => "2021-09-05 16:16:07" "deleted" => 1 ] [ "id" => 49323565 "company_id" => 140537 "url" => "https://www.linkedin.com/in/chantalveillon" "created" => "2020-08-06 01:46:02" "last_updated" => "2023-05-09 13:39:19" "deleted" => 1 ] [ "id" => 49323566 "company_id" => 140537 "url" => "https://www.linkedin.com/in/markikaplan" "created" => "2020-08-06 01:46:02" "last_updated" => "2023-07-03 10:32:04" "deleted" => 1 ] [ "id" => 49323567 "company_id" => 140537 "url" => "https://www.linkedin.com/in/yerramalla" "created" => "2020-08-06 01:46:02" "last_updated" => "2020-12-15 09:34:21" "deleted" => 1 ] [ "id" => 57267149 "company_id" => 140537 "url" => "https://www.linkedin.com/in/johnsluddy" "created" => "2020-12-15 09:34:21" "last_updated" => "2021-12-28 09:02:27" "deleted" => 1 ] [ "id" => 72383115 "company_id" => 140537 "url" => "https://www.linkedin.com/in/anita-k%C3%A4lin-geiger-4352b" "created" => "2021-09-05 16:16:07" "last_updated" => "2022-07-23 15:09:50" "deleted" => 1 ] [ "id" => 80895020 "company_id" => 140537 "url" => "https://www.linkedin.com/in/yerramalla" "created" => "2021-12-28 09:02:27" "last_updated" => "2024-04-24 20:11:40" "deleted" => 1 ] [ "id" => 110986550 "company_id" => 140537 "url" => "https://ch.linkedin.com/in/anita-k%C3%A4lin-geiger-4352b" "created" => "2022-07-23 15:09:50" "last_updated" => "2022-09-05 10:31:30" "deleted" => 1 ] [ "id" => 127782722 "company_id" => 140537 "url" => "https://www.linkedin.com/in/anita-k%C3%A4lin-geiger-4352b" "created" => "2022-09-05 10:31:30" "last_updated" => "2022-10-11 11:57:15" "deleted" => 1 ] [ "id" => 146164894 "company_id" => 140537 "url" => "https://ch.linkedin.com/in/anita-k%C3%A4lin-geiger-4352b" "created" => "2022-10-11 11:57:15" "last_updated" => "2022-11-24 01:01:01" "deleted" => 1 ] [ "id" => 155118569 "company_id" => 140537 "url" => "https://www.linkedin.com/in/doug-rubin-61979" "created" => "2022-11-24 01:01:01" "last_updated" => "2023-04-28 18:16:23" "deleted" => 1 ] [ "id" => 163448181 "company_id" => 140537 "url" => "https://www.linkedin.com/in/michael-calluori-66195" "created" => "2023-04-28 18:16:23" "last_updated" => "2023-08-06 12:26:59" "deleted" => 1 ] [ "id" => 163677067 "company_id" => 140537 "url" => "https://www.linkedin.com/in/zenoregas" "created" => "2023-05-09 13:39:19" "last_updated" => "2023-06-08 07:59:28" "deleted" => 1 ] [ "id" => 166258241 "company_id" => 140537 "url" => "https://www.linkedin.com/in/chantalveillon" "created" => "2023-06-08 07:59:28" "last_updated" => "2023-09-01 15:50:23" "deleted" => 1 ] [ "id" => 179290570 "company_id" => 140537 "url" => "https://www.linkedin.com/in/zenoregas" "created" => "2023-07-03 10:32:04" "last_updated" => "2024-02-12 18:24:34" "deleted" => 1 ] [ "id" => 186083739 "company_id" => 140537 "url" => "https://www.linkedin.com/in/markikaplan" "created" => "2023-08-06 12:26:59" "last_updated" => "2024-01-19 07:35:50" "deleted" => 1 ] [ "id" => 198020922 "company_id" => 140537 "url" => "https://www.linkedin.com/in/jennifer-disanto-39b66" "created" => "2023-12-13 15:41:42" "last_updated" => "2024-05-22 05:32:14" "deleted" => 1 ] [ "id" => 201318423 "company_id" => 140537 "url" => "https://www.linkedin.com/in/bill-trebasky-76041" "created" => "2024-02-12 18:24:34" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 201318424 "company_id" => 140537 "url" => "https://www.linkedin.com/in/markikaplan" "created" => "2024-02-12 18:24:34" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 205352372 "company_id" => 140537 "url" => "https://www.linkedin.com/in/filaferro" "created" => "2024-04-24 20:11:40" "last_updated" => "2025-02-09 19:10:40" "deleted" => 1 ] [ "id" => 206427976 "company_id" => 140537 "url" => "https://www.linkedin.com/in/yerramalla" "created" => "2024-05-22 05:32:14" "last_updated" => "2024-08-16 02:28:36" "deleted" => 1 ] [ "id" => 210826173 "company_id" => 140537 "url" => "https://www.linkedin.com/in/lakshmanyerramalla" "created" => "2024-08-16 02:28:36" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] ] "company_featured_investors_collection" => [ [ "id" => 291717 "company_id" => 140537 "investor_id" => 1187 "round_id" => 641660 "created" => "2021-03-17 21:39:27" "last_updated" => "2021-04-25 23:54:26" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 359770 "company_id" => 140537 "investor_id" => 1187 "round_id" => 694673 "created" => "2021-04-25 23:54:26" "last_updated" => "2021-05-14 06:29:05" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 390611 "company_id" => 140537 "investor_id" => 1187 "round_id" => 846985 "created" => "2021-05-14 06:29:05" "last_updated" => "2021-06-09 06:30:08" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 429370 "company_id" => 140537 "investor_id" => 1187 "round_id" => 916182 "created" => "2021-06-09 06:30:08" "last_updated" => "2021-07-14 05:44:53" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 470963 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1002450 "created" => "2021-07-14 05:44:53" "last_updated" => "2021-07-15 18:10:07" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 484496 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1095703 "created" => "2021-07-15 18:10:07" "last_updated" => "2021-08-11 11:16:58" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 539385 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1121358 "created" => "2021-08-11 11:16:58" "last_updated" => "2021-08-17 00:35:39" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 557053 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1241494 "created" => "2021-08-17 00:35:39" "last_updated" => "2021-09-05 16:16:07" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 601209 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1277031 "created" => "2021-09-05 16:16:07" "last_updated" => "2021-09-08 23:53:57" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 615969 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1373534 "created" => "2021-09-08 23:53:57" "last_updated" => "2021-09-14 10:45:50" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 633738 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1402402 "created" => "2021-09-14 10:45:50" "last_updated" => "2021-09-30 12:07:36" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 673759 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1440897 "created" => "2021-09-30 12:07:36" "last_updated" => "2021-10-12 10:35:00" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 706376 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1595838 "created" => "2021-10-12 13:17:01" "last_updated" => "2021-10-25 02:31:35" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 739637 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1595838 "created" => "2021-10-25 02:31:35" "last_updated" => "2021-11-20 08:35:08" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 787814 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1669110 "created" => "2021-11-20 08:35:08" "last_updated" => "2021-11-22 15:45:00" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 802796 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1773531 "created" => "2021-11-22 15:45:00" "last_updated" => "2021-11-22 17:11:34" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 812087 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1821530 "created" => "2021-11-29 15:55:11" "last_updated" => "2021-12-28 09:02:27" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 864732 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1821530 "created" => "2021-12-28 09:02:27" "last_updated" => "2022-01-03 11:05:01" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 912955 "company_id" => 140537 "investor_id" => 1187 "round_id" => 1936229 "created" => "2022-01-03 11:05:01" "last_updated" => "2022-01-19 15:51:36" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 968895 "company_id" => 140537 "investor_id" => 1187 "round_id" => 2041232 "created" => "2022-01-19 15:51:36" "last_updated" => "2022-02-07 10:18:25" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 976731 "company_id" => 140537 "investor_id" => 1187 "round_id" => 2159545 "created" => "2022-02-07 10:18:25" "last_updated" => "2022-02-09 22:45:04" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] [ "id" => 1007895 "company_id" => 140537 "investor_id" => 1187 "round_id" => 2174352 "created" => "2022-02-09 22:45:04" "last_updated" => "2022-03-01 11:01:25" "deleted" => 1 "company_investors_list" => [ "id" => 1187 "name" => "Venrock" "hash" => "3bd166194091738b95db6f106007834b" "cb_url" => "https://www.crunchbase.com/organization/venrock" "created" => "2020-09-07 16:24:08" "last_updated" => "2022-02-07 10:18:26" ] ] ] "company_funding_rounds_collection" => [ [ "id" => 61148 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Private equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => null "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-private-equity--8d6227ad" "created" => "2020-09-14 15:43:46" "last_updated" => "2020-10-05 19:30:05" "deleted" => 1 ] [ "id" => 155068 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Private equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => null "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-private-equity--8d6227ad" "created" => "2020-10-05 19:30:05" "last_updated" => "2020-11-02 15:43:07" "deleted" => 1 ] [ "id" => 248258 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Private equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => null "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-private-equity--8d6227ad" "created" => "2020-11-02 15:43:07" "last_updated" => "2020-12-15 09:34:21" "deleted" => 1 ] [ "id" => 389173 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Private equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => null "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-private-equity--8d6227ad" "created" => "2020-12-15 09:34:21" "last_updated" => "2020-12-16 08:41:10" "deleted" => 1 ] [ "id" => 394901 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Private equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => null "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-private-equity--8d6227ad" "created" => "2020-12-16 08:41:10" "last_updated" => "2021-01-08 06:13:12" "deleted" => 1 ] [ "id" => 468142 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => null "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-01-08 06:13:12" "last_updated" => "2021-01-11 13:53:19" "deleted" => 1 ] [ "id" => 497948 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => null "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-01-11 13:53:19" "last_updated" => "2021-02-03 08:14:58" "deleted" => 1 ] [ "id" => 556425 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => null "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-02-03 08:14:58" "last_updated" => "2021-03-01 17:17:14" "deleted" => 1 ] [ "id" => 641660 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => null "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-03-01 17:17:14" "last_updated" => "2021-03-17 21:39:27" "deleted" => 1 ] [ "id" => 694673 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-03-17 21:39:27" "last_updated" => "2021-04-25 23:54:26" "deleted" => 1 ] [ "id" => 846985 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-04-25 23:54:26" "last_updated" => "2021-05-14 06:29:05" "deleted" => 1 ] [ "id" => 916182 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-05-14 06:29:05" "last_updated" => "2021-06-09 06:30:08" "deleted" => 1 ] [ "id" => 1002450 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-06-09 06:30:08" "last_updated" => "2021-07-14 05:44:53" "deleted" => 1 ] [ "id" => 1095703 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-07-14 05:44:53" "last_updated" => "2021-07-15 18:10:07" "deleted" => 1 ] [ "id" => 1121358 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-07-15 18:10:07" "last_updated" => "2021-08-11 11:16:58" "deleted" => 1 ] [ "id" => 1241494 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-08-11 11:16:58" "last_updated" => "2021-08-17 00:35:39" "deleted" => 1 ] [ "id" => 1277031 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-08-17 00:35:39" "last_updated" => "2021-09-05 16:16:07" "deleted" => 1 ] [ "id" => 1373534 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-09-05 16:16:07" "last_updated" => "2021-09-08 23:53:57" "deleted" => 1 ] [ "id" => 1402402 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-09-08 23:53:57" "last_updated" => "2021-09-14 10:45:50" "deleted" => 1 ] [ "id" => 1440897 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-09-14 10:45:50" "last_updated" => "2021-09-30 12:07:36" "deleted" => 1 ] [ "id" => 1528536 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-09-30 12:07:36" "last_updated" => "2021-10-12 10:35:00" "deleted" => 1 ] [ "id" => 1595838 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-10-12 13:17:01" "last_updated" => "2021-10-25 02:31:35" "deleted" => 1 ] [ "id" => 1669110 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-10-25 02:31:35" "last_updated" => "2021-11-20 08:35:08" "deleted" => 1 ] [ "id" => 1773531 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-11-20 08:35:08" "last_updated" => "2021-11-22 15:45:00" "deleted" => 1 ] [ "id" => 1804042 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-11-22 15:45:00" "last_updated" => "2021-11-22 17:11:34" "deleted" => 1 ] [ "id" => 1821530 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-11-29 15:55:11" "last_updated" => "2021-12-28 09:02:27" "deleted" => 1 ] [ "id" => 1936229 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2021-12-28 09:02:27" "last_updated" => "2022-01-03 11:05:01" "deleted" => 1 ] [ "id" => 2041232 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2022-01-03 11:05:01" "last_updated" => "2022-01-19 15:51:36" "deleted" => 1 ] [ "id" => 2159545 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => "US$ 80.0M" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2022-01-19 15:51:36" "last_updated" => "2022-02-07 10:18:25" "deleted" => 1 ] [ "id" => 2174352 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => """ US$\n 80.0M """ "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2022-02-07 10:18:25" "last_updated" => "2022-02-09 22:45:04" "deleted" => 1 ] [ "id" => 2241111 "last_round_investors_count" => 12 "total_rounds_count" => 1 "last_round_type" => "Post IPO equity" "last_round_date" => "2017-02-21 00:00:00" "last_round_money_raised" => """ US$\n 80.0M """ "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-equity--8d6227ad" "created" => "2022-02-09 22:45:04" "last_updated" => "2022-03-01 11:01:25" "deleted" => 1 ] [ "id" => 2315515 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-02-15 00:00:00" "last_round_money_raised" => """ US$\n 6.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-03-01 11:01:25" "last_updated" => "2022-03-01 22:50:09" "deleted" => 1 ] [ "id" => 2329266 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-02-15 00:00:00" "last_round_money_raised" => """ US$\n 6.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-03-01 22:50:09" "last_updated" => "2022-03-09 03:19:13" "deleted" => 1 ] [ "id" => 2431926 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-02-15 00:00:00" "last_round_money_raised" => """ US$\n 6.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-03-09 03:19:13" "last_updated" => "2022-03-30 08:50:58" "deleted" => 1 ] [ "id" => 2479583 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-02-15 00:00:00" "last_round_money_raised" => """ US$\n 6.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-03-30 08:50:58" "last_updated" => "2022-04-02 06:55:58" "deleted" => 1 ] [ "id" => 2480412 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-02-15 00:00:00" "last_round_money_raised" => """ US$\n 6.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-04-02 06:55:58" "last_updated" => "2022-04-08 09:19:17" "deleted" => 1 ] [ "id" => 2596444 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-02-15 00:00:00" "last_round_money_raised" => """ US$\n 6.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-04-08 09:19:17" "last_updated" => "2022-05-02 11:01:56" "deleted" => 1 ] [ "id" => 2621251 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-02-15 00:00:00" "last_round_money_raised" => """ US$\n 6.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-05-02 11:01:56" "last_updated" => "2022-05-09 21:52:53" "deleted" => 1 ] [ "id" => 2707201 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-02-15 00:00:00" "last_round_money_raised" => """ US$\n 6.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-05-09 21:52:53" "last_updated" => "2022-05-16 12:52:58" "deleted" => 1 ] [ "id" => 2779081 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-02-15 00:00:00" "last_round_money_raised" => """ US$\n 6.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-05-16 12:52:58" "last_updated" => "2022-06-17 17:32:25" "deleted" => 1 ] [ "id" => 2856262 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-02-15 00:00:00" "last_round_money_raised" => """ US$\n 6.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-06-17 17:32:25" "last_updated" => "2022-07-13 09:21:34" "deleted" => 1 ] [ "id" => 2980675 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-02-15 00:00:00" "last_round_money_raised" => """ US$\n 6.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-07-13 09:21:34" "last_updated" => "2022-07-23 15:09:50" "deleted" => 1 ] [ "id" => 3060283 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-07-23 15:09:50" "last_updated" => "2022-08-09 16:29:36" "deleted" => 1 ] [ "id" => 3184010 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-08-09 16:29:36" "last_updated" => "2022-08-12 06:01:00" "deleted" => 1 ] [ "id" => 3218598 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-08-12 06:01:00" "last_updated" => "2022-09-05 10:31:30" "deleted" => 1 ] [ "id" => 3272968 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-02-15 00:00:00" "last_round_money_raised" => """ US$\n 6.0B """ "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-09-05 10:31:30" "last_updated" => "2022-10-11 11:57:15" "deleted" => 1 ] [ "id" => 3452602 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-10-11 11:57:15" "last_updated" => "2022-11-24 01:01:01" "deleted" => 1 ] [ "id" => 3640566 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-11-24 01:01:01" "last_updated" => "2022-12-15 10:16:16" "deleted" => 1 ] [ "id" => 3727905 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2022-12-15 10:16:16" "last_updated" => "2023-01-16 19:30:32" "deleted" => 1 ] [ "id" => 3908018 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2023-01-16 19:30:32" "last_updated" => "2023-01-17 14:15:08" "deleted" => 1 ] [ "id" => 3932450 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2023-01-17 14:15:08" "last_updated" => "2023-02-06 13:38:51" "deleted" => 1 ] [ "id" => 3977237 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2023-02-06 13:38:51" "last_updated" => "2023-02-10 11:05:46" "deleted" => 1 ] [ "id" => 4034375 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2023-02-10 11:05:46" "last_updated" => "2023-03-04 19:25:54" "deleted" => 1 ] [ "id" => 4180558 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2023-03-04 19:25:54" "last_updated" => "2023-04-04 08:44:45" "deleted" => 1 ] [ "id" => 4305957 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2023-04-04 08:44:45" "last_updated" => "2023-04-28 18:16:23" "deleted" => 1 ] [ "id" => 4449593 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2023-04-28 18:16:23" "last_updated" => "2023-05-09 13:39:19" "deleted" => 1 ] [ "id" => 4543922 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2023-05-09 13:39:19" "last_updated" => "2023-06-08 07:59:28" "deleted" => 1 ] [ "id" => 4674084 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2023-06-08 07:59:28" "last_updated" => "2023-07-03 10:32:04" "deleted" => 1 ] [ "id" => 5009719 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2023-07-03 10:32:04" "last_updated" => "2023-08-06 12:26:59" "deleted" => 1 ] [ "id" => 5261497 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2023-08-06 12:26:59" "last_updated" => "2023-09-01 15:50:23" "deleted" => 1 ] [ "id" => 5421701 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2023-09-01 15:50:23" "last_updated" => "2023-10-17 15:55:13" "deleted" => 1 ] [ "id" => 5709479 "last_round_investors_count" => 0 "total_rounds_count" => 2 "last_round_type" => "Post IPO debt" "last_round_date" => "2022-03-15 00:00:00" "last_round_money_raised" => "US$ 6.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--c358dcd7" "created" => "2023-10-17 15:55:13" "last_updated" => "2023-11-09 06:06:53" "deleted" => 1 ] [ "id" => 5854539 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-11-30 00:00:00" "last_round_money_raised" => "US$ 4.5B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--d749fd32" "created" => "2023-11-09 06:06:53" "last_updated" => "2023-12-13 15:41:42" "deleted" => 1 ] [ "id" => 6096975 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-11-30 00:00:00" "last_round_money_raised" => "US$ 4.5B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--d749fd32" "created" => "2023-12-13 15:41:42" "last_updated" => "2024-01-19 07:35:50" "deleted" => 1 ] [ "id" => 6304576 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-11-30 00:00:00" "last_round_money_raised" => "US$ 4.5B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--d749fd32" "created" => "2024-01-19 07:35:50" "last_updated" => "2024-02-12 18:24:34" "deleted" => 1 ] [ "id" => 6422798 "last_round_investors_count" => 0 "total_rounds_count" => 3 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-11-30 00:00:00" "last_round_money_raised" => "US$ 4.5B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--d749fd32" "created" => "2024-02-12 18:24:34" "last_updated" => "2024-03-13 13:55:47" "deleted" => 1 ] [ "id" => 6640576 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2024-03-13 13:55:47" "last_updated" => "2024-04-24 20:11:40" "deleted" => 1 ] [ "id" => 6907109 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2024-04-24 20:11:40" "last_updated" => "2024-05-22 05:32:14" "deleted" => 1 ] [ "id" => 7061271 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2024-05-22 05:32:14" "last_updated" => "2024-06-08 20:28:46" "deleted" => 1 ] [ "id" => 7185754 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2024-06-08 20:28:46" "last_updated" => "2024-07-21 01:20:19" "deleted" => 1 ] [ "id" => 7483969 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2024-07-21 01:20:19" "last_updated" => "2024-08-16 02:28:36" "deleted" => 1 ] [ "id" => 7648070 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2024-08-16 02:28:36" "last_updated" => "2024-08-29 00:21:11" "deleted" => 1 ] [ "id" => 7842459 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2024-08-29 00:21:11" "last_updated" => "2024-09-04 07:59:28" "deleted" => 1 ] [ "id" => 7933426 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2024-09-04 07:59:28" "last_updated" => "2024-10-03 10:14:04" "deleted" => 1 ] [ "id" => 8258412 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2024-10-03 10:14:04" "last_updated" => "2024-10-20 11:08:06" "deleted" => 1 ] [ "id" => 8461268 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2024-10-20 11:08:06" "last_updated" => "2024-11-17 20:05:44" "deleted" => 1 ] [ "id" => 8727788 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2024-11-17 20:05:44" "last_updated" => "2024-11-27 10:43:06" "deleted" => 1 ] [ "id" => 8856964 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2024-11-27 10:43:06" "last_updated" => "2024-11-27 10:59:43" "deleted" => 1 ] [ "id" => 8858124 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2024-11-27 10:59:43" "last_updated" => "2024-12-04 08:49:36" "deleted" => 1 ] [ "id" => 9038347 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2024-12-04 08:49:36" "last_updated" => "2025-01-04 07:10:24" "deleted" => 1 ] [ "id" => 9222743 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2025-01-04 07:10:24" "last_updated" => "2025-01-15 10:17:45" "deleted" => 1 ] [ "id" => 9366024 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2025-01-15 10:17:45" "last_updated" => "2025-02-09 19:10:40" "deleted" => 1 ] [ "id" => 9632252 "last_round_investors_count" => 0 "total_rounds_count" => 4 "last_round_type" => "Post IPO debt" "last_round_date" => "2024-03-14 00:00:00" "last_round_money_raised" => "US$ 13.0B" "cb_url" => "https://www.crunchbase.com/funding_round/bristol-myers-squibb-post-ipo-debt--20e0181e" "created" => "2025-02-09 19:10:40" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] ] "company_locations_collection" => [ [ "id" => 11627523 "company_id" => 140537 "location_address" => "3401 Princeton Pike; Lawrence Township, NJ 08648, US" "is_primary" => 1 "created" => "2019-11-14 02:04:33" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 11627524 "company_id" => 140537 "location_address" => "Arnulfstrasse 29; Munich, BY 80636, DE" "is_primary" => 0 "created" => "2019-11-14 02:04:33" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 11627525 "company_id" => 140537 "location_address" => "Cruiserath Road; Dublin, County Dublin, IE" "is_primary" => 0 "created" => "2019-11-14 02:04:33" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 11627526 "company_id" => 140537 "location_address" => "950 E Paces Ferry Rd NE; Atlanta, GA 30326, US" "is_primary" => 0 "created" => "2019-11-14 02:04:33" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 11627527 "company_id" => 140537 "location_address" => "345 Park Avenue; New York, New York 10154-0037, US" "is_primary" => 0 "created" => "2019-11-14 02:04:33" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 11627528 "company_id" => 140537 "location_address" => "311 Pennington Rocky Hill Rd; Pennington, NJ 08534, US" "is_primary" => 0 "created" => "2019-11-14 02:04:33" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 11627529 "company_id" => 140537 "location_address" => "Avenue de Finlande 4; Braine-l'Alleud, Walloon Region 1420, BE" "is_primary" => 0 "created" => "2019-11-14 02:04:33" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 18364329 "company_id" => 140537 "location_address" => """ \n 3401 Princeton Pike\n ; \n Lawrence Township, NJ 08648, US\n """ "is_primary" => 0 "created" => "2020-07-23 05:26:50" "last_updated" => "2020-08-06 01:46:02" "deleted" => 1 ] [ "id" => 18364331 "company_id" => 140537 "location_address" => """ \n Arnulfstrasse 29\n ; \n Munich, BY 80636, DE\n """ "is_primary" => 0 "created" => "2020-07-23 05:26:50" "last_updated" => "2020-08-06 01:46:02" "deleted" => 1 ] [ "id" => 18364332 "company_id" => 140537 "location_address" => """ \n Cruiserath Road\n ; \n Dublin, County Dublin, IE\n """ "is_primary" => 0 "created" => "2020-07-23 05:26:50" "last_updated" => "2020-08-06 01:46:02" "deleted" => 1 ] [ "id" => 18364333 "company_id" => 140537 "location_address" => """ \n 950 E Paces Ferry Rd NE\n ; \n Atlanta, GA 30326, US\n """ "is_primary" => 0 "created" => "2020-07-23 05:26:50" "last_updated" => "2020-08-06 01:46:02" "deleted" => 1 ] [ "id" => 18364334 "company_id" => 140537 "location_address" => """ \n 345 Park Avenue\n ; \n New York, New York 10154-0037, US\n """ "is_primary" => 0 "created" => "2020-07-23 05:26:50" "last_updated" => "2020-08-06 01:46:02" "deleted" => 1 ] [ "id" => 18364336 "company_id" => 140537 "location_address" => """ \n 311 Pennington Rocky Hill Rd\n ; \n Pennington, NJ 08534, US\n """ "is_primary" => 0 "created" => "2020-07-23 05:26:50" "last_updated" => "2020-08-06 01:46:02" "deleted" => 1 ] [ "id" => 18364337 "company_id" => 140537 "location_address" => """ \n Avenue de Finlande 4\n ; \n Braine-l'Alleud, Walloon Region 1420, BE\n """ "is_primary" => 0 "created" => "2020-07-23 05:26:50" "last_updated" => "2020-08-06 01:46:02" "deleted" => 1 ] [ "id" => 21308871 "company_id" => 140537 "location_address" => "3401 Princeton Pike; Lawrence Township, NJ 08648, US" "is_primary" => 1 "created" => "2020-08-06 01:46:02" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 21308872 "company_id" => 140537 "location_address" => "Arnulfstrasse 29; Munich, BY 80636, DE" "is_primary" => 0 "created" => "2020-08-06 01:46:02" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 21308873 "company_id" => 140537 "location_address" => "Cruiserath Road; Dublin, County Dublin, IE" "is_primary" => 0 "created" => "2020-08-06 01:46:02" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 21308874 "company_id" => 140537 "location_address" => "950 E Paces Ferry Rd NE; Atlanta, GA 30326, US" "is_primary" => 0 "created" => "2020-08-06 01:46:02" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 21308875 "company_id" => 140537 "location_address" => "345 Park Avenue; New York, New York 10154-0037, US" "is_primary" => 0 "created" => "2020-08-06 01:46:02" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 21308876 "company_id" => 140537 "location_address" => "311 Pennington Rocky Hill Rd; Pennington, NJ 08534, US" "is_primary" => 0 "created" => "2020-08-06 01:46:02" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 21308877 "company_id" => 140537 "location_address" => "Avenue de Finlande 4; Braine-l'Alleud, Walloon Region 1420, BE" "is_primary" => 0 "created" => "2020-08-06 01:46:02" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 68031173 "company_id" => 140537 "location_address" => "38 Jackson Road; Devens, MA 01434, US" "is_primary" => 0 "created" => "2022-06-17 17:32:25" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 86909729 "company_id" => 140537 "location_address" => "南京西路1717号; 17楼; 上海, 上海 200040, CN" "is_primary" => 0 "created" => "2022-07-23 15:09:50" "last_updated" => "2022-09-05 10:31:30" "deleted" => 1 ] [ "id" => 109529952 "company_id" => 140537 "location_address" => "南京西路1717号; 17楼; 上海, 上海 200040, CN" "is_primary" => 0 "created" => "2022-10-11 11:57:15" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] ] "company_similar_collection" => [ [ "id" => 45360289 "company_id" => 140537 "url" => "https://www.linkedin.com/company/pfizer" "created" => "2019-11-14 02:04:33" "last_updated" => "2021-07-14 05:44:53" "deleted" => 1 ] [ "id" => 45360290 "company_id" => 140537 "url" => "https://www.linkedin.com/company/merck" "created" => "2019-11-14 02:04:33" "last_updated" => "2021-07-14 05:44:53" "deleted" => 1 ] [ "id" => 45360291 "company_id" => 140537 "url" => "https://www.linkedin.com/company/novartis" "created" => "2019-11-14 02:04:33" "last_updated" => "2020-12-15 09:34:21" "deleted" => 1 ] [ "id" => 45360292 "company_id" => 140537 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2019-11-14 02:04:33" "last_updated" => "2021-07-14 05:44:53" "deleted" => 1 ] [ "id" => 45360293 "company_id" => 140537 "url" => "https://www.linkedin.com/company/amgen" "created" => "2019-11-14 02:04:33" "last_updated" => "2021-07-14 05:44:53" "deleted" => 1 ] [ "id" => 45360294 "company_id" => 140537 "url" => "https://www.linkedin.com/company/sanofi" "created" => "2019-11-14 02:04:33" "last_updated" => "2019-12-23 18:37:06" "deleted" => 1 ] [ "id" => 59887899 "company_id" => 140537 "url" => "https://www.linkedin.com/company/celgene" "created" => "2019-12-23 18:37:06" "last_updated" => "2020-08-18 08:25:59" "deleted" => 1 ] [ "id" => 98177538 "company_id" => 140537 "url" => "https://www.linkedin.com/company/astrazeneca" "created" => "2020-02-22 13:05:22" "last_updated" => "2021-07-14 05:44:53" "deleted" => 1 ] [ "id" => 98177539 "company_id" => 140537 "url" => "https://www.linkedin.com/company/sanofi" "created" => "2020-02-22 13:05:22" "last_updated" => "2020-12-15 09:34:21" "deleted" => 1 ] [ "id" => 98177540 "company_id" => 140537 "url" => "https://www.linkedin.com/company/eli-lilly-and-company" "created" => "2020-02-22 13:05:22" "last_updated" => "2020-10-05 19:30:05" "deleted" => 1 ] [ "id" => 98177541 "company_id" => 140537 "url" => "https://www.linkedin.com/company/glaxosmithkline" "created" => "2020-02-22 13:05:22" "last_updated" => "2021-07-14 05:44:53" "deleted" => 1 ] [ "id" => 208971897 "company_id" => 140537 "url" => "https://www.linkedin.com/company/roche" "created" => "2020-08-18 08:25:59" "last_updated" => "2020-12-15 09:34:21" "deleted" => 1 ] [ "id" => 241915029 "company_id" => 140537 "url" => "https://www.linkedin.com/company/abbvie" "created" => "2020-10-05 19:30:05" "last_updated" => "2021-07-14 05:44:53" "deleted" => 1 ] [ "id" => 325993136 "company_id" => 140537 "url" => "https://ch.linkedin.com/company/novartis" "created" => "2020-12-15 09:34:21" "last_updated" => "2021-07-14 05:44:53" "deleted" => 1 ] [ "id" => 325993137 "company_id" => 140537 "url" => "https://fr.linkedin.com/company/sanofi" "created" => "2020-12-15 09:34:21" "last_updated" => "2021-07-14 05:44:53" "deleted" => 1 ] [ "id" => 325993138 "company_id" => 140537 "url" => "https://ch.linkedin.com/company/roche" "created" => "2020-12-15 09:34:21" "last_updated" => "2021-07-14 05:44:53" "deleted" => 1 ] [ "id" => 462555714 "company_id" => 140537 "url" => "https://www.linkedin.com/company/pfizer" "created" => "2021-09-05 16:16:07" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 462555715 "company_id" => 140537 "url" => "https://www.linkedin.com/company/merck" "created" => "2021-09-05 16:16:07" "last_updated" => "2024-07-21 01:20:19" "deleted" => 1 ] [ "id" => 462555716 "company_id" => 140537 "url" => "https://ch.linkedin.com/company/novartis" "created" => "2021-09-05 16:16:07" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 462555717 "company_id" => 140537 "url" => "https://www.linkedin.com/company/astrazeneca" "created" => "2021-09-05 16:16:07" "last_updated" => "2022-10-11 11:57:15" "deleted" => 1 ] [ "id" => 462555718 "company_id" => 140537 "url" => "https://www.linkedin.com/company/glaxosmithkline" "created" => "2021-09-05 16:16:07" "last_updated" => "2022-10-11 11:57:15" "deleted" => 1 ] [ "id" => 462555719 "company_id" => 140537 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2021-09-05 16:16:07" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 462555720 "company_id" => 140537 "url" => "https://www.linkedin.com/company/abbvie" "created" => "2021-09-05 16:16:07" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 462555721 "company_id" => 140537 "url" => "https://fr.linkedin.com/company/sanofi" "created" => "2021-09-05 16:16:07" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 462555722 "company_id" => 140537 "url" => "https://ch.linkedin.com/company/roche" "created" => "2021-09-05 16:16:07" "last_updated" => "2023-11-09 06:06:53" "deleted" => 1 ] [ "id" => 462555723 "company_id" => 140537 "url" => "https://www.linkedin.com/company/amgen" "created" => "2021-09-05 16:16:07" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 722792971 "company_id" => 140537 "url" => "https://uk.linkedin.com/company/glaxosmithkline" "created" => "2022-10-11 11:57:15" "last_updated" => "2022-11-24 01:01:01" "deleted" => 1 ] [ "id" => 722792972 "company_id" => 140537 "url" => "https://uk.linkedin.com/company/astrazeneca" "created" => "2022-10-11 11:57:15" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 743121060 "company_id" => 140537 "url" => "https://uk.linkedin.com/company/gsk" "created" => "2022-11-24 01:01:01" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 906341103 "company_id" => 140537 "url" => "https://www.linkedin.com/company/eli-lilly-and-company" "created" => "2023-11-09 06:06:53" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 1037003257 "company_id" => 140537 "url" => "https://dk.linkedin.com/company/novo-nordisk" "created" => "2024-07-21 01:20:19" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] ] "company_specialties_collection" => [ [ "id" => 201683 "company_id" => 140537 "specialty" => "Cancer / Oncology" "created" => "2016-06-17 21:33:03" "last_updated" => "2018-08-01 15:11:49" "deleted" => 1 ] [ "id" => 201684 "company_id" => 140537 "specialty" => "HIV/AIDS" "created" => "2016-06-17 21:33:03" "last_updated" => "2016-12-08 17:29:30" "deleted" => 1 ] [ "id" => 201685 "company_id" => 140537 "specialty" => "Cardiovascular Disease" "created" => "2016-06-17 21:33:03" "last_updated" => "2018-08-01 15:11:49" "deleted" => 1 ] [ "id" => 201686 "company_id" => 140537 "specialty" => "Rheumatoid Arthritis" "created" => "2016-06-17 21:33:03" "last_updated" => "2018-08-01 15:11:49" "deleted" => 1 ] [ "id" => 201687 "company_id" => 140537 "specialty" => "Hepatitis" "created" => "2016-06-17 21:33:03" "last_updated" => "2016-12-08 17:29:30" "deleted" => 1 ] [ "id" => 14390640 "company_id" => 140537 "specialty" => "Immunoscience" "created" => "2016-12-08 17:29:30" "last_updated" => "2018-08-01 15:11:49" "deleted" => 1 ] [ "id" => 14390641 "company_id" => 140537 "specialty" => "Fibrosis" "created" => "2016-12-08 17:29:30" "last_updated" => "2018-08-01 15:11:49" "deleted" => 1 ] [ "id" => 22633326 "company_id" => 140537 "specialty" => "biotechnology" "created" => "2018-08-01 15:11:48" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 22633327 "company_id" => 140537 "specialty" => "innovation" "created" => "2018-08-01 15:11:48" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 22633328 "company_id" => 140537 "specialty" => "great place to work" "created" => "2018-08-01 15:11:48" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 22633329 "company_id" => 140537 "specialty" => "pharmaceuticals" "created" => "2018-08-01 15:11:48" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 22633330 "company_id" => 140537 "specialty" => "research and development" "created" => "2018-08-01 15:11:48" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 22633331 "company_id" => 140537 "specialty" => "healthcare" "created" => "2018-08-01 15:11:48" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 54156162 "company_id" => 140537 "specialty" => "biotechnology" "created" => "2020-08-06 01:46:02" "last_updated" => "2022-07-23 15:09:50" "deleted" => 1 ] [ "id" => 54156163 "company_id" => 140537 "specialty" => "innovation" "created" => "2020-08-06 01:46:02" "last_updated" => "2022-07-23 15:09:50" "deleted" => 1 ] [ "id" => 54156164 "company_id" => 140537 "specialty" => "great place to work" "created" => "2020-08-06 01:46:02" "last_updated" => "2022-07-23 15:09:50" "deleted" => 1 ] [ "id" => 54156165 "company_id" => 140537 "specialty" => "pharmaceuticals" "created" => "2020-08-06 01:46:02" "last_updated" => "2022-07-23 15:09:50" "deleted" => 1 ] [ "id" => 54156166 "company_id" => 140537 "specialty" => "research and development" "created" => "2020-08-06 01:46:02" "last_updated" => "2022-07-23 15:09:50" "deleted" => 1 ] [ "id" => 54156167 "company_id" => 140537 "specialty" => "healthcare" "created" => "2020-08-06 01:46:02" "last_updated" => "2022-07-23 15:09:50" "deleted" => 1 ] [ "id" => 101068540 "company_id" => 140537 "specialty" => "biotechnology" "created" => "2022-08-09 16:29:36" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 101068541 "company_id" => 140537 "specialty" => "innovation" "created" => "2022-08-09 16:29:36" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 101068542 "company_id" => 140537 "specialty" => "great place to work" "created" => "2022-08-09 16:29:36" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 101068543 "company_id" => 140537 "specialty" => "pharmaceuticals" "created" => "2022-08-09 16:29:36" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 101068544 "company_id" => 140537 "specialty" => "research and development" "created" => "2022-08-09 16:29:36" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 101068545 "company_id" => 140537 "specialty" => "healthcare" "created" => "2022-08-09 16:29:36" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] ] "company_stock_info_collection" => [ [ "id" => 178 "company_id" => 140537 "ticker" => "BMY" "exchange" => "NYSE" "created" => "2020-04-24 10:30:05" "last_updated" => "2020-07-13 02:14:15" "deleted" => 1 ] [ "id" => 5450 "company_id" => 140537 "ticker" => "BMY" "exchange" => "NYSE" "created" => "2020-07-18 06:03:20" "last_updated" => "2020-07-23 05:26:50" "deleted" => 1 ] [ "id" => 5819 "company_id" => 140537 "ticker" => """ \n BMY\n """ "exchange" => """ \n NYSE\n """ "created" => "2020-07-23 05:26:51" "last_updated" => "2020-08-06 01:46:02" "deleted" => 1 ] [ "id" => 6525 "company_id" => 140537 "ticker" => "BMY" "exchange" => "NYSE" "created" => "2020-08-06 01:46:03" "last_updated" => "2021-03-17 21:39:27" "deleted" => 1 ] [ "id" => 12032 "company_id" => 140537 "ticker" => "BMY" "exchange" => "NYSE" "created" => "2021-04-25 23:54:26" "last_updated" => "2021-08-17 00:35:39" "deleted" => 1 ] [ "id" => 15315 "company_id" => 140537 "ticker" => "BMY" "exchange" => "NYSE" "created" => "2022-01-03 11:05:03" "last_updated" => "2022-01-19 15:51:36" "deleted" => 1 ] [ "id" => 16772 "company_id" => 140537 "ticker" => "BMY" "exchange" => "NYSE" "created" => "2022-02-07 10:18:26" "last_updated" => "2022-03-01 11:01:25" "deleted" => 1 ] [ "id" => 17861 "company_id" => 140537 "ticker" => "BMY" "exchange" => "NYSE" "created" => "2022-03-01 22:50:11" "last_updated" => "2022-03-30 08:50:58" "deleted" => 1 ] [ "id" => 18913 "company_id" => 140537 "ticker" => "BMY" "exchange" => "NYSE" "created" => "2022-04-02 06:55:58" "last_updated" => "2022-07-23 15:09:50" "deleted" => 1 ] [ "id" => 21794 "company_id" => 140537 "ticker" => "BMY" "exchange" => "NYSE" "created" => "2022-09-05 10:31:30" "last_updated" => "2022-10-11 11:57:15" "deleted" => 1 ] [ "id" => 25996 "company_id" => 140537 "ticker" => "BMY" "exchange" => "NYSE" "created" => "2022-12-15 10:16:16" "last_updated" => "2023-02-10 11:05:46" "deleted" => 1 ] [ "id" => 29055 "company_id" => 140537 "ticker" => "BMY" "exchange" => "NYSE" "created" => "2023-03-04 19:25:54" "last_updated" => "2023-04-28 18:16:23" "deleted" => 1 ] [ "id" => 30197 "company_id" => 140537 "ticker" => "BMY" "exchange" => "NYSE" "created" => "2023-05-09 13:39:19" "last_updated" => "2023-06-08 07:59:28" "deleted" => 1 ] [ "id" => 31193 "company_id" => 140537 "ticker" => "BMY" "exchange" => "NYSE" "created" => "2023-07-03 10:32:05" "last_updated" => "2024-08-16 02:28:36" "deleted" => 1 ] [ "id" => 33815 "company_id" => 140537 "ticker" => "BMY" "exchange" => "NYSE" "created" => "2024-09-04 07:59:28" "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] ] "company_updates_collection" => [ [ "id" => 12473015 "company_id" => 140537 "urn" => "urn:li:activity:7008490909977759745" "followers" => 1091681 "date" => "14h" "description" => "Last month, our Chief Digital & Technology Officer Greg Meyers joined HLTH to highlight the positive impact digital technology and data enablement can make in solving some of the world's biggest issues – all in the name of better patient care. #HLTH2022" "reactions_count" => 115 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:30:32" "deleted" => 1 ] [ "id" => 12473016 "company_id" => 140537 "urn" => "urn:li:activity:7008464719942467585" "followers" => 1091681 "date" => "16h" "description" => """ “Unlike Health Tech companies, Bristol Myers Squibb—like other companies in our industry—doesn’t need to see immediate profit directly from digital innovations. We have the flexibility to use digital health technology to bring more medicines to more patients faster, and maximize the benefits patients get once they have those medicines. Our goal is to enhance healthcare for everyone, everywhere.” \n \n Our Chief Digital and Technology Officer Greg Meyers shares his perspective on the role companies like ours must play in determining the future of digital innovation in healthcare. """ "reactions_count" => 64 "comments_count" => 1 "reshared_post_author" => "Greg Meyers" "reshared_post_author_url" => "https://www.linkedin.com/in/greg-meyers-cio" "reshared_post_author_headline" => "EVP, Chief Digital & Technology Officer, Member of Executive Committee at Bristol Myers Squibb" "reshared_post_description" => "As someone who has seen digital "disruption" in many different industries, the two most common questions I get in my nearly year at the helm of the technology function for Bristol Myers Squibb, one of the largest life sciences companies in the world are: "why does it seem so hard to bring technology to healthcare" and "what role should pharma play, if any, in this change." In this blog I explore these questions and why the normal recipe for change out of the silicon valley playbook won't alone change this large and complicated industry. #digitalhealth #IfNotPharmaThenWho" "reshared_post_followers" => null "reshared_post_date" => "18h" "last_updated" => "2023-01-16 19:30:32" "deleted" => 1 ] [ "id" => 12473017 "company_id" => 140537 "urn" => "urn:li:activity:7008128456081235968" "followers" => 1091681 "date" => "1d" "description" => "We’ve invested nearly 20 years in cell therapy research, which has been pivotal in bringing transformative medicines to patients in need. Hear from leaders like Teri Foy on why we’re committed to advancing cell therapy. #ASH22 https://lnkd.in/gK_36DUZ" "reactions_count" => 141 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:30:32" "deleted" => 1 ] [ "id" => 12473018 "company_id" => 140537 "urn" => "urn:li:activity:7008067961953402880" "followers" => 1091681 "date" => "1d" "description" => "At #ASH22, we’re presenting results reflecting our commitment to providing treatment options for diseases associated with anemia, like myelodysplastic syndromes, where patients need options to address debilitating symptoms. Learn more about anemia-associated diseases and our heritage in #MDS research: https://bit.ly/3Y2eu4x" "reactions_count" => 117 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:30:32" "deleted" => 1 ] [ "id" => 12473019 "company_id" => 140537 "urn" => "urn:li:activity:7007735043259342848" "followers" => 1091681 "date" => "2d" "description" => "We’re committed to bringing transformative therapies to patients living with hard-to-treat blood diseases. At this year’s #ASH22 meeting, our results underscore the significant potential and diversity of our innovative research platforms, supporting our focus on delivering the next wave of advances in hematology. Hear more about our commitment from Kristen Hege, senior vice president, Early Clinical Development, Oncology/Hematology and Cell Therapy: https://lnkd.in/gUKA8jpX" "reactions_count" => 160 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:30:32" "deleted" => 1 ] [ "id" => 12473020 "company_id" => 140537 "urn" => "urn:li:activity:7007010984544391168" "followers" => 1091681 "date" => "4d" "description" => "Close collaboration across the scientific community is key to progress. We are excited to debut data at #ASH22 that demonstrate how continued partnerships have helped set the path for advances against diseases, like #multiplemyeloma. https://lnkd.in/gT2tMYFU" "reactions_count" => 188 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:30:32" "deleted" => 1 ] [ "id" => 12473021 "company_id" => 140537 "urn" => "urn:li:activity:7006965704579039234" "followers" => 1091681 "date" => "4d" "description" => """ It was an honor to celebrate this year’s Coast 2 Coast 4 Cancer ride with the V Foundation at the Jimmy V Men’s Classic.\n \n From Cannon Beach, Oregon to Long Branch, New Jersey, 126+ employees went beyond their day-to-day jobs to cycle nearly 3,000 miles in support of #cancer patients. Some of the riders are cancer survivors, while others rode in honor of loved ones affected by the disease. The riders raised more than $1 million and with Bristol Myers Squibb’s $500,000 donation, more than $1.5 million will go to the V Foundation to accelerate the fight against cancer. \n \n We’re grateful to everyone who supported #C2C4C22 and look forward to commemorating the 10th anniversary in 2023! """ "reactions_count" => 535 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:30:32" "deleted" => 1 ] [ "id" => 12473022 "company_id" => 140537 "urn" => "urn:li:activity:7006745321028415488" "followers" => 1091681 "date" => "5d" "description" => "Amadou Diarra, SVP, Global Policy, Advocacy and Govt. Affairs spoke at the OECD - OCDE Forum event, Closing the Cancer Gap: Towards Better Screening and Treatment. Learn how he and other leaders are working to improve access to cancer diagnosis and treatment for patients: https://bit.ly/3HkCslK" "reactions_count" => 178 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:30:32" "deleted" => 1 ] [ "id" => 12473023 "company_id" => 140537 "urn" => "urn:li:activity:7006399469692882944" "followers" => 1091681 "date" => "6d" "description" => "This Crohn’s & Colitis Awareness Week, hear from Michael Braun, SVP, U.S. Immunology, on our commitment to supporting patients with IBD, like ulcerative colitis, through continued research into managing these chronic diseases #CCAwarenessWeek #IBDVisible. Learn more: https://bit.ly/3iMW6wE" "reactions_count" => 392 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:30:32" "deleted" => 1 ] [ "id" => 12473024 "company_id" => 140537 "urn" => "urn:li:activity:7005547432377810944" "followers" => 1091681 "date" => "1w" "description" => "We look forward to #ASH22 where we’ll highlight exciting results from our #multiplemyeloma program, diverse hematologic portfolio and cutting-edge pipeline. Learn how we are collaborating in multiple myeloma: https://lnkd.in/gTjdQMzf" "reactions_count" => 128 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 19:30:32" "deleted" => 1 ] [ "id" => 48501806 "company_id" => 140537 "urn" => "urn:li:activity:7020751654329217024" "followers" => 1100942 "date" => "3h" "description" => "On this year’s #DayofService, watch how our colleagues embody Martin Luther King Jr.’s legacy year-round, like the Black Organization for Leadership and Development’s (BOLD) continued work with Boys & Girls Clubs of America and the Congressional Black Caucus Foundation, our Clinical Trial and Engagement team working to empower female patients, and our colleagues volunteering to make an impact in their communities." "reactions_count" => 77 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-17 14:15:08" "deleted" => 1 ] [ "id" => 48501808 "company_id" => 140537 "urn" => "urn:li:activity:7019356293664575488" "followers" => 1100942 "date" => "3d" "description" => "Catherine Owen, Senior Vice President and General Manager, US Commercial spoke today at Fierce Pharma's #FierceJPMWeek panel about the ways biopharma companies are evolving commercialization strategies to sustain innovation and growth, and continue to deliver on our collective mission for patients. For more on our strategy and cautionary statements: https://bit.ly/3kampxw #JPM23" "reactions_count" => 299 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-17 14:15:08" "deleted" => 1 ] [ "id" => 48501809 "company_id" => 140537 "urn" => "urn:li:activity:7018716108341878784" "followers" => 1100942 "date" => "5d" "description" => "“At BMS, we try to have a depth and breadth of a pipeline that offers the right choices for the right patients." — Kristen Hege, Senior Vice President, Early Clinical Development, Oncology/Hematology and Cell Therapy at Endpoints News' #JPM23 panel on our commitment to developing new and innovative medicines for cancer treatment across solid tumors and blood cancers, and across diverse modalities. Learn more: https://lnkd.in/gq3qEUUy" "reactions_count" => 340 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-17 14:15:08" "deleted" => 1 ] [ "id" => 48501810 "company_id" => 140537 "urn" => "urn:li:activity:7018614992501440512" "followers" => 1100942 "date" => "6d" "description" => "We're unlocking innovative treatments for patients with our robust early-stage pipeline, novel drug discovery platforms and strong network of external partnerships. For more from #JPM23 and cautionary statements: https://bit.ly/3CBtIod" "reactions_count" => 397 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-17 14:15:08" "deleted" => 1 ] [ "id" => 48501811 "company_id" => 140537 "urn" => "urn:li:activity:7018357924972433409" "followers" => 1100942 "date" => "6d" "description" => "Today during Endpoints News #JPM23 panel, Elizabeth Mily, Executive Vice President of Strategy & Business Development, discussed the future of dealmaking in healthcare and the power of collaboration across the innovation ecosystem in bringing transformational medicines to patients. Learn more: https://lnkd.in/gQfPYgZi" "reactions_count" => 204 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-17 14:15:08" "deleted" => 1 ] [ "id" => 48501812 "company_id" => 140537 "urn" => "urn:li:activity:7018331843242463232" "followers" => 1100942 "date" => "6d" "description" => "We’re kicking off a new year, but our focus on transforming patients’ lives through science remains the same. We’re well positioned for the next wave of innovation, delivering a younger, broader and more diversified portfolio while unlocking multiple channels of growth. For more from #JPM23 and cautionary statements: https://bit.ly/3XhGfoJ" "reactions_count" => 372 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-17 14:15:08" "deleted" => 1 ] [ "id" => 48501813 "company_id" => 140537 "urn" => "urn:li:activity:7016870953661972481" "followers" => 1100942 "date" => "1w" "description" => "We’re honored to be recognized as one of the top pharmaceutical companies for inclusiveness in oncology #clinicaltrials, based on Bioethics International's new index for measuring the fair inclusion of underrepresented patients in #clinicalresearch. While we’re excited about the progress we’ve made, we acknowledge there’s more to do to ensure our clinical trials reflect the diverse populations we serve. Learn more: https://prn.to/3jW9Q8U" "reactions_count" => 367 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-17 14:15:08" "deleted" => 1 ] [ "id" => 48501814 "company_id" => 140537 "urn" => "urn:li:activity:7015315794704154624" "followers" => 1100942 "date" => "2w" "description" => "Wishing you and yours a happy and healthy new year! We look forward to another year filled with inspiration and progress as we work together to make a difference for patients around the globe." "reactions_count" => 1973 "comments_count" => 22 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-17 14:15:08" "deleted" => 1 ] [ "id" => 48501815 "company_id" => 140537 "urn" => "urn:li:activity:7011692097640574976" "followers" => 1100942 "date" => "3w" "description" => "In 2022, we transformed more patient lives than ever before. Watch highlights from a year marked by progress, thanks to the passion and dedication put forth by our talented colleagues around the world." "reactions_count" => 703 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-17 14:15:08" "deleted" => 1 ] [ "id" => 48501816 "company_id" => 140537 "urn" => "urn:li:activity:7011078946033197056" "followers" => 1100942 "date" => "3w" "description" => "Japan’s Ministry of Health, Labour and Welfare has approved earlier use of our #CARTcelltherapy. This marks a critical step toward offering patients in Japan with a certain type of blood cancer a personalized treatment option earlier in their care. Learn more about how this milestone underscores the advancements we’re making in cell therapy research: https://lnkd.in/gKdK8iRZ" "reactions_count" => 1306 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-17 14:15:08" "deleted" => 1 ] [ "id" => 49856186 "company_id" => 140537 "urn" => "urn:li:activity:7020751654329217024" "followers" => 1101240 "date" => "1d" "description" => "On this year’s #DayofService, watch how our colleagues embody Martin Luther King Jr.’s legacy year-round, like the Black Organization for Leadership and Development’s (BOLD) continued work with Boys & Girls Clubs of America and the Congressional Black Caucus Foundation, our Clinical Trial and Engagement team working to empower female patients, and our colleagues volunteering to make an impact in their communities." "reactions_count" => 171 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:38:51" "deleted" => 1 ] [ "id" => 49856187 "company_id" => 140537 "urn" => "urn:li:activity:7019356293664575488" "followers" => 1101240 "date" => "4d" "description" => "Catherine Owen, Senior Vice President and General Manager, US Commercial spoke today at Fierce Pharma's #FierceJPMWeek panel about the ways biopharma companies are evolving commercialization strategies to sustain innovation and growth, and continue to deliver on our collective mission for patients. For more on our strategy and cautionary statements: https://bit.ly/3kampxw #JPM23" "reactions_count" => 310 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:38:51" "deleted" => 1 ] [ "id" => 49856188 "company_id" => 140537 "urn" => "urn:li:activity:7018716108341878784" "followers" => 1101240 "date" => "6d" "description" => "“At BMS, we try to have a depth and breadth of a pipeline that offers the right choices for the right patients." — Kristen Hege, Senior Vice President, Early Clinical Development, Oncology/Hematology and Cell Therapy at Endpoints News' #JPM23 panel on our commitment to developing new and innovative medicines for cancer treatment across solid tumors and blood cancers, and across diverse modalities. Learn more: https://lnkd.in/gq3qEUUy" "reactions_count" => 358 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:38:51" "deleted" => 1 ] [ "id" => 49856189 "company_id" => 140537 "urn" => "urn:li:activity:7018614992501440512" "followers" => 1101240 "date" => "6d" "description" => "We're unlocking innovative treatments for patients with our robust early-stage pipeline, novel drug discovery platforms and strong network of external partnerships. For more from #JPM23 and cautionary statements: https://bit.ly/3CBtIod" "reactions_count" => 404 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:38:51" "deleted" => 1 ] [ "id" => 49856190 "company_id" => 140537 "urn" => "urn:li:activity:7018357924972433409" "followers" => 1101240 "date" => "1w" "description" => "Today during Endpoints News #JPM23 panel, Elizabeth Mily, Executive Vice President of Strategy & Business Development, discussed the future of dealmaking in healthcare and the power of collaboration across the innovation ecosystem in bringing transformational medicines to patients. Learn more: https://lnkd.in/gQfPYgZi" "reactions_count" => 207 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:38:51" "deleted" => 1 ] [ "id" => 49856191 "company_id" => 140537 "urn" => "urn:li:activity:7018331843242463232" "followers" => 1101240 "date" => "1w" "description" => "We’re kicking off a new year, but our focus on transforming patients’ lives through science remains the same. We’re well positioned for the next wave of innovation, delivering a younger, broader and more diversified portfolio while unlocking multiple channels of growth. For more from #JPM23 and cautionary statements: https://bit.ly/3XhGfoJ" "reactions_count" => 374 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:38:51" "deleted" => 1 ] [ "id" => 49856192 "company_id" => 140537 "urn" => "urn:li:activity:7016870953661972481" "followers" => 1101240 "date" => "1w" "description" => "We’re honored to be recognized as one of the top pharmaceutical companies for inclusiveness in oncology #clinicaltrials, based on Bioethics International's new index for measuring the fair inclusion of underrepresented patients in #clinicalresearch. While we’re excited about the progress we’ve made, we acknowledge there’s more to do to ensure our clinical trials reflect the diverse populations we serve. Learn more: https://prn.to/3jW9Q8U" "reactions_count" => 368 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:38:51" "deleted" => 1 ] [ "id" => 49856193 "company_id" => 140537 "urn" => "urn:li:activity:7015315794704154624" "followers" => 1101240 "date" => "2w" "description" => "Wishing you and yours a happy and healthy new year! We look forward to another year filled with inspiration and progress as we work together to make a difference for patients around the globe." "reactions_count" => 1975 "comments_count" => 22 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:38:51" "deleted" => 1 ] [ "id" => 49856194 "company_id" => 140537 "urn" => "urn:li:activity:7011692097640574976" "followers" => 1101240 "date" => "3w" "description" => "In 2022, we transformed more patient lives than ever before. Watch highlights from a year marked by progress, thanks to the passion and dedication put forth by our talented colleagues around the world." "reactions_count" => 703 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:38:51" "deleted" => 1 ] [ "id" => 49856195 "company_id" => 140537 "urn" => "urn:li:activity:7011078946033197056" "followers" => 1101240 "date" => "3w" "description" => "Japan’s Ministry of Health, Labour and Welfare has approved earlier use of our #CARTcelltherapy. This marks a critical step toward offering patients in Japan with a certain type of blood cancer a personalized treatment option earlier in their care. Learn more about how this milestone underscores the advancements we’re making in cell therapy research: https://lnkd.in/gKdK8iRZ" "reactions_count" => 1307 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 13:38:51" "deleted" => 1 ] [ "id" => 56068953 "company_id" => 140537 "urn" => "urn:li:activity:7027401149532045312" "followers" => 1108512 "date" => "2d" "description" => "Amadou Diarra, SVP, Global Policy, Advocacy & Government Affairs and new BioNJ Board Chair accepted an Innovator Award on behalf of BMS for our three first-in-class medicines that were launched in 2022. We're excited to help shape the future of the vibrant life sciences community in New Jersey. #PatientsCantWait" "reactions_count" => 158 "comments_count" => 11 "reshared_post_author" => "BioNJ" "reshared_post_author_url" => "https://www.linkedin.com/company/bionj" "reshared_post_author_headline" => null "reshared_post_description" => "A few highlights from last night's #BioNJ Annual Dinner and Innovation Celebration. Congratulations to all of our honorees and award winners! #innovation #celebration #Patientscantwait" "reshared_post_followers" => 5451 "reshared_post_date" => "3d" "last_updated" => "2023-02-10 11:05:46" "deleted" => 1 ] [ "id" => 56068954 "company_id" => 140537 "urn" => "urn:li:activity:7027282209627627520" "followers" => 1108512 "date" => "2d" "description" => "February 4 is #WorldCancerDay, an important opportunity to recognize the power of collaboration in working to #CloseTheCareGap for patients around the globe, and a reminder of what drives us every day." "reactions_count" => 133 "comments_count" => null "reshared_post_author" => "Union for International Cancer Control (UICC)" "reshared_post_author_url" => "https://ch.linkedin.com/company/uicc" "reshared_post_author_headline" => null "reshared_post_description" => """ World Cancer Day would like to thank its partner Bristol Myers Squibb whose financial commitment makes this campaign possible. \n \n Thank you for helping us fight for a world without cancer.\n \n #WorldCancerDay #CloseTheCareGap Estelle Vester-Blokland """ "reshared_post_followers" => 12941 "reshared_post_date" => "1w" "last_updated" => "2023-02-10 11:05:46" "deleted" => 1 ] [ "id" => 56068955 "company_id" => 140537 "urn" => "urn:li:activity:7026904584069550080" "followers" => 1108512 "date" => "3d" "description" => """ 2022 was a successful year for our company, one of significant clinical and regulatory achievements that broadened our product portfolio and advanced our pipeline. We launched three first-in-class medicines that address serious unmet medical needs for patients. This was largely due to our BMS employees whose tireless efforts enable us to introduce innovative treatments and medicines that have a transformational impact on the lives of our patients.\n \n Read more, including important cautionary statements about forward-looking information, here: https://bit.ly/3HOgyqW """ "reactions_count" => 1231 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-10 11:05:46" "deleted" => 1 ] [ "id" => 56068956 "company_id" => 140537 "urn" => "urn:li:activity:7026681687543595008" "followers" => 1108512 "date" => "4d" "description" => "We are honored to be recognized by Fortune once again as one of the World’s #MostAdmiredCos. The recognition is a testament to our commitment to transform patients’ lives through science. Learn about joining our global team: careers.bms.com" "reactions_count" => 1195 "comments_count" => 16 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-10 11:05:46" "deleted" => 1 ] [ "id" => 56068957 "company_id" => 140537 "urn" => "urn:li:activity:7025825019083571200" "followers" => 1108512 "date" => "6d" "description" => """ Despite the availability of effective therapies for #psoriasis, many patients remain untreated or dissatisfied with current treatments.\n \n By building partnerships with researchers, patients and caregivers to deliver innovative treatments, we strive to elevate patient care to new standards and deliver what matters most – the promise of living a better life. https://lnkd.in/g8VRNGHG """ "reactions_count" => 822 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-10 11:05:46" "deleted" => 1 ] [ "id" => 56068958 "company_id" => 140537 "urn" => "urn:li:activity:7024779072530522112" "followers" => 1108512 "date" => "1w" "description" => "World Cancer Day is February 4. Through collaboration with partners like the Union for International Cancer Control (UICC), we are working to overcome systemic barriers and help ensure that every patient has the opportunity to access the highest quality #cancer care. Hear more from our Nick Botwood, SVP and head of WW Medical Affairs Oncology, and Ridwaan Jhetam, SVP and head of WW Medical Affairs, Hematology, on the importance of #WorldCancerDay and how we’re working together to #CloseTheCareGap" "reactions_count" => 277 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-10 11:05:46" "deleted" => 1 ] [ "id" => 56068959 "company_id" => 140537 "urn" => "urn:li:activity:7024737825887592448" "followers" => 1108512 "date" => "1w" "description" => """ Today we received a positive #CHMP opinion from the European Medicines Agency on a new oral treatment for plaque #psoriasis.\n \n “This positive CHMP opinion brings us one step closer to offering a new oral treatment to patients with moderate to severe plaque psoriasis in the EU, where a strong need exists for additional effective and well-tolerated oral therapies,” says Samit Hirawat (he/him), our Chief Medical Officer.\n \n Read more about this #dermatology news. https://lnkd.in/gcRACf3t """ "reactions_count" => 926 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-10 11:05:46" "deleted" => 1 ] [ "id" => 56068960 "company_id" => 140537 "urn" => "urn:li:activity:7024375473967177729" "followers" => 1108512 "date" => "1w" "description" => """ Results show Phase 1/2 trial meets primary endpoint in relapsed or refractory chronic lymphocytic leukemia (#CLL) & small lymphocytic lymphoma (#SLL), one of the most common types of chronic leukemia. \n \n Patients with relapsed or refractory CLL and SLL after prior therapies currently have no standard of care and limited treatment options. These latest results offer an encouraging sign for the prospect of additional treatment options for people living with difficult-to-treat blood cancers. https://bit.ly/3XZ9rkJ """ "reactions_count" => 727 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-10 11:05:46" "deleted" => 1 ] [ "id" => 56068961 "company_id" => 140537 "urn" => "urn:li:activity:7022946604198367232" "followers" => 1108512 "date" => "2w" "description" => "Wishing a happy and healthy Lunar New Year to all who celebrate!" "reactions_count" => 1908 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-10 11:05:46" "deleted" => 1 ] [ "id" => 56068962 "company_id" => 140537 "urn" => "urn:li:activity:7022341638974836736" "followers" => 1108512 "date" => "2w" "description" => """ As a sponsor of Coqual's new study, "Strangers at Home: The Asian and Asian American Professional Experience," join us in amplifying their insights that can help empower companies to support AAPI colleagues and communities. Our Pan-Asian Network colleagues also joined the #CoquealResearch conversation to discuss health equity and social justice initiatives, mentorship for AAPI talent, and more companywide efforts to make our AAPI workforce feel a sense of belonging and supported. \n \n Learn about the study’s important research below. """ "reactions_count" => 58 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-10 11:05:46" "deleted" => 1 ] [ "id" => 64658946 "company_id" => 140537 "urn" => "urn:li:activity:7029562030076416001" "followers" => 1110123 "date" => "5h" "description" => "We are keeping those who’ve been impacted by the Türkiye and Syria earthquakes in our thoughts. The Bristol Myers Squibb Foundation, an independent charitable organization, is donating $1.1 million to longstanding relief partners the International Federation of Red Cross and Red Crescent Societies - IFRC, International Rescue Committee, Americares, and Direct Relief." "reactions_count" => 752 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-04 19:25:54" "deleted" => 1 ] [ "id" => 64658947 "company_id" => 140537 "urn" => "urn:li:activity:7029184996821110784" "followers" => 1110123 "date" => "1d" "description" => "“At BMS, we recognize that our life-saving medicines are critically important to driving outcomes, yet it’s only one of the many variables that determine an individual’s access to health and an equitable health outcome.” – Pamela Fisher, Chief Inclusion & Diversity Officer. Learn about her career journey, how she drives our commitment to patient health equity and how she makes inclusion an organic part of our business. https://bit.ly/3RNbqa4" "reactions_count" => 267 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-04 19:25:54" "deleted" => 1 ] [ "id" => 64658948 "company_id" => 140537 "urn" => "urn:li:activity:7029086570976616448" "followers" => 1110123 "date" => "1d" "description" => "Between 1 in 200 and 1 in 500 people in the U.S. are estimated to be affected by hypertrophic cardiomyopathy (#HCM). This #HCMAwarenessDay, February 22, team up with us and professional basketball player Jared Butler to help advance understanding of HCM signs and symptoms of this disease. https://bit.ly/3Y9OHXS #HeartMonth" "reactions_count" => 167 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-04 19:25:54" "deleted" => 1 ] [ "id" => 64658949 "company_id" => 140537 "urn" => "urn:li:activity:7028817719886041089" "followers" => 1110123 "date" => "2d" "description" => "We're excited to announce our new partnership with Kyoto University, the latest in our Global Expert Centers Initiative to advance cancer treatments by collaborating with research centers across the globe. We look forward to working with the team in Japan and helping to make a difference in patients' lives." "reactions_count" => 356 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-04 19:25:54" "deleted" => 1 ] [ "id" => 64658950 "company_id" => 140537 "urn" => "urn:li:activity:7028467361179439104" "followers" => 1110123 "date" => "3d" "description" => "One way the Black Organization for Leadership and Development (BOLD) at BMS elevates our mission of inclusion is through their Innovators’ podcast, featuring conversations with colleagues like BOLD lead Monique Phillips, PMP, Rondu Vincent, Gaetano Crupi and Thalia Mingo about their career journeys and how they help improve patients’ lives through innovation. Listen below, and follow along this #BlackHistoryMonth as we share more BOLD moments: https://lnkd.in/gDh_KU8i" "reactions_count" => 297 "comments_count" => 14 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-04 19:25:54" "deleted" => 1 ] [ "id" => 64658951 "company_id" => 140537 "urn" => "urn:li:activity:7028424639483678720" "followers" => 1110123 "date" => "3d" "description" => "Building trusted, strategic relationships with diverse businesses that represent the communities where we live and work is vital to our success. We’re honored to be recognized for the ninth consecutive year by the WBENC for our efforts to create more opportunities and growth for women-owned business in our industry." "reactions_count" => 72 "comments_count" => 1 "reshared_post_author" => "WBENC" "reshared_post_author_url" => "https://www.linkedin.com/company/wbenc" "reshared_post_author_headline" => null "reshared_post_description" => "The Women’s Business Enterprise National Council (WBENC) is proud to recognize 66 corporations with the prestigious 2023 WBENC America’s Top Corporations for Women’s Business Enterprises (WBEs) award, the only national award honoring corporations for world-class supplier diversity programs that reduce barriers and drive growth and opportunities for women-owned businesses. Read the press release now: https://lnkd.in/e-P2C3qD" "reshared_post_followers" => 21631 "reshared_post_date" => "1w" "last_updated" => "2023-03-04 19:25:54" "deleted" => 1 ] [ "id" => 64658953 "company_id" => 140537 "urn" => "urn:li:activity:7027401149532045312" "followers" => 1110123 "date" => "6d" "description" => "Amadou Diarra, SVP, Global Policy, Advocacy & Government Affairs and new BioNJ Board Chair accepted an Innovator Award on behalf of BMS for our three first-in-class medicines that were launched in 2022. We're excited to help shape the future of the vibrant life sciences community in New Jersey. #PatientsCantWait" "reactions_count" => 193 "comments_count" => 17 "reshared_post_author" => "BioNJ" "reshared_post_author_url" => "https://www.linkedin.com/company/bionj" "reshared_post_author_headline" => null "reshared_post_description" => "A few highlights from last night's #BioNJ Annual Dinner and Innovation Celebration. Congratulations to all of our honorees and award winners! #innovation #celebration #Patientscantwait" "reshared_post_followers" => 5509 "reshared_post_date" => "6d" "last_updated" => "2023-03-04 19:25:54" "deleted" => 1 ] [ "id" => 64658954 "company_id" => 140537 "urn" => "urn:li:activity:7027282209627627520" "followers" => 1110123 "date" => "6d" "description" => "February 4 is #WorldCancerDay, an important opportunity to recognize the power of collaboration in working to #CloseTheCareGap for patients around the globe, and a reminder of what drives us every day." "reactions_count" => 154 "comments_count" => null "reshared_post_author" => "Union for International Cancer Control (UICC)" "reshared_post_author_url" => "https://ch.linkedin.com/company/uicc" "reshared_post_author_headline" => null "reshared_post_description" => """ World Cancer Day would like to thank its partner Bristol Myers Squibb whose financial commitment makes this campaign possible. \n \n Thank you for helping us fight for a world without cancer.\n \n #WorldCancerDay #CloseTheCareGap Estelle Vester-Blokland """ "reshared_post_followers" => 13037 "reshared_post_date" => "2w" "last_updated" => "2023-03-04 19:25:54" "deleted" => 1 ] [ "id" => 64658955 "company_id" => 140537 "urn" => "urn:li:activity:7026904584069550080" "followers" => 1110123 "date" => "1w" "description" => """ 2022 was a successful year for our company, one of significant clinical and regulatory achievements that broadened our product portfolio and advanced our pipeline. We launched three first-in-class medicines that address serious unmet medical needs for patients. This was largely due to our BMS employees whose tireless efforts enable us to introduce innovative treatments and medicines that have a transformational impact on the lives of our patients.\n \n Read more, including important cautionary statements about forward-looking information, here: https://bit.ly/3HOgyqW """ "reactions_count" => 1370 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-04 19:25:54" "deleted" => 1 ] [ "id" => 64658956 "company_id" => 140537 "urn" => "urn:li:activity:7026681687543595008" "followers" => 1110123 "date" => "1w" "description" => "We are honored to be recognized by Fortune once again as one of the World’s #MostAdmiredCos. The recognition is a testament to our commitment to transform patients’ lives through science. Learn about joining our global team: careers.bms.com" "reactions_count" => 1329 "comments_count" => 17 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-04 19:25:54" "deleted" => 1 ] [ "id" => 95848648 "company_id" => 140537 "urn" => "urn:li:activity:7037421411992276992" "followers" => 1118821 "date" => "22h" "description" => "Our transformative research at #ACC23/#WCCardio continues to showcase our commitment to people living with hypertrophic cardiomyopathy (#HCM), which can affect people regardless of age, gender and ethnicity. Learn more: https://bit.ly/3IOnjJU" "reactions_count" => 108 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 08:44:45" "deleted" => 1 ] [ "id" => 95848649 "company_id" => 140537 "urn" => "urn:li:activity:7037150925693612032" "followers" => 1118821 "date" => "1d" "description" => "It's an honor to be ranked #1 in Medicines and Therapeutics by Fast Company on its list of Most Innovative Companies. We’re focused on accelerating breakthrough science to transform patients’ lives around the world, with an unprecedented number of new medicines across our therapeutic areas. Discover how to join our global team: https://bit.ly/3IKRj89 #FCMostInnovative" "reactions_count" => 688 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 08:44:45" "deleted" => 1 ] [ "id" => 95848650 "company_id" => 140537 "urn" => "urn:li:activity:7037117377511133184" "followers" => 1118821 "date" => "1d" "description" => """ Join our #ECCO2023 sessions to explore our latest data in forms of #IBD like #UlcerativeColitis: \n \n ✔️ 3-year efficacy and safety data with continuous treatment\n ✔️ Efficacy data in biologic-naïve and biologic-experienced patients\n ✔️ Endoscopic and histologic outcomes after temporary treatment discontinuation\n \n Learn more about ECCO: https://bit.ly/3IMMKKs """ "reactions_count" => 90 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 08:44:45" "deleted" => 1 ] [ "id" => 95848651 "company_id" => 140537 "urn" => "urn:li:activity:7037074075483070464" "followers" => 1118821 "date" => "1d" "description" => """ Since the start of her distinguished career, Kristen Hege has been on the forefront of scientific discovery, most recently within the exciting field of cell therapy. Her unwavering commitment to research designed to benefit patients has contributed to several clinical milestones that have made a profound impact on the future of cancer care. \n \n We’re thrilled to see her achievements featured in a recent Healio article. Read more about Kristen's leadership and pioneering spirit here: https://bit.ly/3J3Vr4q\n \n #WomeninScience #CARTcelltherapy """ "reactions_count" => 131 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 08:44:45" "deleted" => 1 ] [ "id" => 95848652 "company_id" => 140537 "urn" => "urn:li:activity:7037051465957330944" "followers" => 1118821 "date" => "1d" "description" => "Ahead of #ACC23, in collaboration with The Janssen Pharmaceutical Companies of Johnson & Johnson, we’re announcing the launch of our pivotal Phase 3 study to evaluate the efficacy and safety of an investigational factor XIa inhibitor, which will enroll nearly 50,000 patients across three studies. https://lnkd.in/gQ788vWh" "reactions_count" => 370 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 08:44:45" "deleted" => 1 ] [ "id" => 95848653 "company_id" => 140537 "urn" => "urn:li:activity:7036810821661798400" "followers" => 1118821 "date" => "2d" "description" => "We’re honored to earn the top spot on Ogilvy Health's latest social media report. By harnessing the power of social media, we aim to ensure patients’ voices are heard and our colleagues feel connected to our mission to do more for patients every day." "reactions_count" => 487 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 08:44:45" "deleted" => 1 ] [ "id" => 95848654 "company_id" => 140537 "urn" => "urn:li:activity:7036473715856916481" "followers" => 1118821 "date" => "3d" "description" => "We're excited to share that two colleagues were honored with Ragan Communications and PR Daily's Top Women in Communications awards today for their global impact and inclusive leadership. Lez Cunningham, senior vice president of Corporate Communications, received the Visionary award, and Jennifer Rasing, global lead for the Pan Asian Network, was recognized as a Diversity, Equity, and Inclusion Champion. Learn more here: https://bit.ly/3maCjsC" "reactions_count" => 233 "comments_count" => 13 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 08:44:45" "deleted" => 1 ] [ "id" => 95848655 "company_id" => 140537 "urn" => "urn:li:activity:7036349669492367360" "followers" => 1118821 "date" => "3d" "description" => """ This #BlackHistoryMonth, Kareem Abdul-Jabbar is sharing his experience with atrial fibrillation (AFib), the most common type of irregular heartbeat. Unfortunately, it’s not just his story. \n \n Despite Black Americans having a disproportionately higher risk for health conditions that put them at greater risk for AFib, and a significantly higher risk of stroke, they are diagnosed at lower rates than White Americans.\n \n We’ve partnered with Kareem to raise awareness of #AFib and encourage those experiencing common symptoms including irregular heartbeat, heart racing, chest pain, shortness of breath, fatigue, and light-headedness to call a doctor – because only a healthcare professional can determine whether common symptoms indicate AFib or another condition. Learn more: NoTimetoWait.com """ "reactions_count" => 395 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 08:44:45" "deleted" => 1 ] [ "id" => 95848656 "company_id" => 140537 "urn" => "urn:li:activity:7036031098082004992" "followers" => 1118821 "date" => "4d" "description" => """ “Equity never ends. It’s 24/7. You have to see your role in the puzzle of justice. If you can see your role in that, you know how you can be accountable in this space and show up in it.” \n \n At this year’s Black Organization for Leadership and Development (BOLD)’s #BlackHistoryMonth keynote, Chris T. Pernell, MD, MPH, FACPM delivered an electrifying speech that amplified our commitment to health equity. Watch memorable moments from the event and join us in celebrating our colleagues whose bold vision for advancing equitable outcomes for patients inspires us year-round. """ "reactions_count" => 224 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-04 08:44:45" "deleted" => 1 ] [ "id" => 95848657 "company_id" => 140537 "urn" => "urn:li:activity:7036003034841124864" "followers" => 1118821 "date" => "4d" "description" => "What an exciting way to celebrate all our efforts from last year’s #C2C4C22 ride. We are so proud of our employee riders who are compelled to go beyond their day jobs to do more for those in the cancer community by cycling to raise money for cancer research with the support of the V Foundation. Together, we can truly help make a difference in patients’ lives!" "reactions_count" => 60 "comments_count" => null "reshared_post_author" => "the V Foundation" "reshared_post_author_url" => "https://www.linkedin.com/company/the-v-foundation" "reshared_post_author_headline" => null "reshared_post_description" => """ We keep the #goodnews rolling! Our partnership with Bristol Myers Squibb for Coast 2 Coast 4 Cancer is a finalist for an Engage for Good’s Halo Award! We couldn’t ask for a better team. \n #CSR #socialimpact #EFG2023 \n 🚲 https://lnkd.in/ejAFrsq """ "reshared_post_followers" => 5619 "reshared_post_date" => "5d" "last_updated" => "2023-04-04 08:44:45" "deleted" => 1 ] [ "id" => 122057800 "company_id" => 140537 "urn" => "urn:li:activity:7047627856490762242" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Greg Meyers" "reshared_post_author_url" => "https://www.linkedin.com/in/greg-meyers-cio" "reshared_post_author_headline" => "EVP, Chief Digital & Technology Officer, Member of Executive Committee at Bristol Myers Squibb" "reshared_post_description" => """ “So much of the work to help women feel like they belong is listening better… and listening differently. We need to permit ourselves to question, push, and show up differently. That’s what needs to change if we want to create workplaces that work for everybody.” –Deepa Purushothaman\n \n Earlier this week, I had the pleasure of kicking off the first town hall of 2023 for the Bristol Myers Squibb Network of Women (B-NOW). During the event, we celebrated some of the outstanding leadership happening within our company to drive gender parity, introduced the resource group’s new lead Carla Daily, and heard from Deepa on various critical topics including the ways we all must evolve to create a truly equitable workforce.\n \n At BMS, we truly believe our people are our greatest strength, which is why we strive for an inclusive and diverse workforce that represents different cultures, backgrounds, and experiences.\n \n And as this year’s Women’s History Month comes to a close, my first as the executive sponsor of B-NOW, it’s clear that while we’ve made massive progress in cementing a culture of inclusion for women, there is still work to be done, no matter the date. I’m excited to continue partnering with Carla and the 7,200-plus members of B-NOW around the world to continue moving our company forward in its efforts to #EmbraceEquity every month. """ "reshared_post_followers" => null "reshared_post_date" => "3d" "last_updated" => "2023-04-28 18:16:23" "deleted" => 1 ] [ "id" => 122057801 "company_id" => 140537 "urn" => "urn:li:activity:7047582095988162560" "followers" => 1130767 "date" => "3d" "description" => """ Transgender patients are at an increased risk of venous thromboembolism (VTE) while receiving gender-affirming therapy or surgery—but there’s little information for clinicians and patients to assess the risk and guide care. \n \n To help bridge this critical information gap, our PRIDE Alliance People & Business Resource Group co-sponsored research—led by the North American Thrombosis Forum (NATF)—to spotlight the risk of VTE in patients undergoing gender-affirming care or surgery, and help providers to ensure best care practices in partnership with their patients. This International #TransgenderDayofVisibility, learn more about the science that’s helping empower transgender patients to live as their authentic selves: https://bit.ly/3U0SpBZ """ "reactions_count" => 222 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-28 18:16:23" "deleted" => 1 ] [ "id" => 122057802 "company_id" => 140537 "urn" => "urn:li:activity:7047560123241639938" "followers" => 1130767 "date" => "3d" "description" => """ Today, the European Medicines Agency issued a positive #CHMP opinion for our #CARTcelltherapy in the treatment of adults with relapsed or refractory diffuse large B-cell #lymphoma (LBCL) after one prior therapy. \n \n This important milestone demonstrates our continued commitment to providing access to effective treatments for patients across the world living with #bloodcancer. Read more about this important news: https://lnkd.in/dxkT44gB """ "reactions_count" => 753 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-28 18:16:23" "deleted" => 1 ] [ "id" => 122057803 "company_id" => 140537 "urn" => "urn:li:activity:7047319044114317313" "followers" => 1130767 "date" => "4d" "description" => "Among several events the BMS Network of Women (B-NOW) hosted in celebration of #WomensHistoryMonth, the group held a thought-provoking panel discussion on prioritizing gender equity in STEM and how our inclusive culture helps drive our colleagues to do more for patients. Watch highlights and learn more about B-NOW: https://lnkd.in/ggTHVFSy" "reactions_count" => 190 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-28 18:16:23" "deleted" => 1 ] [ "id" => 122057805 "company_id" => 140537 "urn" => "urn:li:activity:7047236774061883392" "followers" => 1130767 "date" => "4d" "description" => "#Psoriasis affects approximately 15 million people across Europe and can cause physical and emotional burdens, including plaques, itching and feelings of embarrassment. We’re committed to pathbreaking science to deliver innovative, #dermatology solutions for patients. https://lnkd.in/g_4DyPwi" "reactions_count" => 142 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-28 18:16:23" "deleted" => 1 ] [ "id" => 122057806 "company_id" => 140537 "urn" => "urn:li:activity:7047215659507740673" "followers" => 1130767 "date" => "4d" "description" => """ This week our Lynelle Hoch, senior vice president and lead of our Cell Therapy Franchise, was a featured speaker at the Reuters Pharma USA event. During her presentation, she walked industry peers through our vision to expand the promise of #celltherapy by utilizing key learnings that have come with our pioneering efforts in CAR T and increasing manufacturing capabilities to reach more patients around the world.\n \n Learn more about our commitment to advancing the field of cell therapy by visiting our resource page: https://lnkd.in/gSb8hubm """ "reactions_count" => 380 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-28 18:16:23" "deleted" => 1 ] [ "id" => 122057807 "company_id" => 140537 "urn" => "urn:li:activity:7047145438868606977" "followers" => 1130767 "date" => "4d" "description" => """ A year ago, primary results from CheckMate 816 were the first evidence from Phase 3 trials to support the benefit of #immunotherapy plus chemotherapy given prior to surgery in patients with resectable #NSCLC. Today at #ELCC23, long-term 3-year outcomes from patients in this trial will be presented by Prof. Nicolas Girard and lead author Dr. Patrick Forde. #LCSM \n \n Read the abstract here: https://bit.ly/42SkiQM """ "reactions_count" => 440 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-28 18:16:23" "deleted" => 1 ] [ "id" => 122057808 "company_id" => 140537 "urn" => "urn:li:activity:7046936315967254529" "followers" => 1130767 "date" => "5d" "description" => "Leveraging new technology to accelerate innovation for patients is one reason why our Chief Digital and Technology Officer Greg Meyers was chosen for this year’s Forbes' CIO Next List. Learn more about his vision for the future of digital innovation in healthcare: https://bit.ly/40sobdB" "reactions_count" => 465 "comments_count" => 24 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-28 18:16:23" "deleted" => 1 ] [ "id" => 122057809 "company_id" => 140537 "urn" => "urn:li:activity:7046916658837291008" "followers" => 1130767 "date" => "5d" "description" => """ “You can be a professional, a scientist who’s highly technical and dedicated with expertise in your field, and still have a family, still be a mom.” \n \n Associate Scientific Director – and mom of nine – Tamar Rosenbaum is part of the team that recently launched our protein crystallization experiments into space with potentially groundbreaking innovations for patients and supply chains. In honor of #WomensHistoryMonth, meet Tamar and her colleagues, Christina Cuttitta and Barbra Pagarigan, who are redefining what it means to be a woman in STEM. """ "reactions_count" => 296 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-28 18:16:23" "deleted" => 1 ] [ "id" => 122057810 "company_id" => 140537 "urn" => "urn:li:activity:7046882198758555648" "followers" => 1130767 "date" => "5d" "description" => "We’re pleased to share Women Business Collaborative named Giovanni Caforio as one of its 2023 CEO Excellence in Gender Equity and Diversity honorees in recognition of his leadership in paving the way for gender equity. Learn about our culture of inclusion and our commitment to paving more equitable paths for women in business: https://lnkd.in/gA3ujZwd" "reactions_count" => 702 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-28 18:16:23" "deleted" => 1 ] [ "id" => 154015036 "company_id" => 140537 "urn" => "urn:li:activity:7057729036424269824" "followers" => 1141690 "date" => "38m" "description" => "Meet the next generation of innovators, problem solvers and creative thinkers! This Take Your Child to Work Day, our colleagues’ children got to see their parents in action, get hands-on production experience with our in-house BMS Films video team, attend a science experiment demonstration, and flex their creative muscles by painting a rock to add to our Inspiration Garden. At BMS, we’re committed to creating an environment where working parents, regardless of gender, can advance in their careers while finding the support they need to care for their families, like connecting parents with care services for children and elders, just-in-time sick care, and learning support for school-aged kids." "reactions_count" => 120 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-09 13:39:19" "deleted" => 1 ] [ "id" => 154015037 "company_id" => 140537 "urn" => "urn:li:activity:7057363897711792128" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Giovanni Caforio" "reshared_post_author_url" => "https://www.linkedin.com/in/giovanni-caforiobms" "reshared_post_author_headline" => "Chairman and Chief Executive Officer at Bristol Myers Squibb" "reshared_post_description" => """ It has been the highlight and privilege of my career to lead Bristol Myers Squibb over the past eight years. As I reflect on my tenure, I could not be more proud of the positive impact that we have made on millions of patients’ lives. Together, we advanced the standard of care in each of our core therapeutic areas, launched 12 new medicines and expanded our global presence while building a more diverse and engaged workforce and a more inclusive culture. I will be forever grateful to the entire BMS team for their strong performance, while consistently maintaining our focus on patients. \n \n I am also incredibly excited for Chris Boerner as he steps into his new role as COO on the path to becoming our next CEO when I retire in November. Chris is an exceptional leader and has been integral to our commercial success during his tenure at BMS. His deep knowledge of our strategy and pipeline, and proven execution across all geographies, give the Board confidence that he is the right leader to guide Bristol Myers Squibb through its next stage of growth as we advance our vision to be the world’s leading biopharma company that transforms patients’ lives through science. I look forward to working closely with him to achieve a seamless transition, and I am confident BMS will continue to thrive and write another exciting chapter under Chris’s leadership.\n \n Please join me in congratulating Chris on his new role! """ "reshared_post_followers" => null "reshared_post_date" => "1d" "last_updated" => "2023-05-09 13:39:19" "deleted" => 1 ] [ "id" => 154015038 "company_id" => 140537 "urn" => "urn:li:activity:7057330042455937024" "followers" => 1141690 "date" => "1d" "description" => """ In the first quarter, our strong execution resulted in double-digit revenue growth for our in-line products and new product portfolio. We continue to successfully execute against our key strategic priorities and meaningfully advance our portfolio renewal strategy, achieving important regulatory and clinical milestones that will benefit patients with serious unmet needs. \n \n Read more, including important cautionary statements about forward-looking information, here: https://lnkd.in/gsSjmJQ2 """ "reactions_count" => 528 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-09 13:39:19" "deleted" => 1 ] [ "id" => 154015039 "company_id" => 140537 "urn" => "urn:li:activity:7057143591667679232" "followers" => 1141690 "date" => "1d" "description" => "In recognition for her leadership to advance gender equality and inclusion, we're excited our Ester Banque is a finalist for the WeQual Awards in the Specialist Category. Join us in celebrating this incredible honor." "reactions_count" => 150 "comments_count" => 19 "reshared_post_author" => "WeQual" "reshared_post_author_url" => "https://uk.linkedin.com/company/wequal-awards" "reshared_post_author_headline" => null "reshared_post_description" => """ We have the pleasure of announcing the three finalists for the WeQual Awards, The Americas 2023 - Specialist Category:\n \n - Brenda Dennis, Global Vice President, Client Experience Services at Cisco\n - Natalie Bedford, Senior Vice President, Center Well Specialty Pharmacy at Humana\n - Ester Banque, SVP & GM of U.S. Hematology at Bristol Myers Squibb\n \n A big congratulations to these remarkable leaders who have demonstrated exceptional leadership qualities and accomplishments.\n \n The WeQual Awards were created by Katie Litchfield in 2019 to help address the lack of gender equality at the top of the world’s largest listed companies.\n \n The awards are open to women who report into group executive committees within listed companies. All finalists have spent a minimum of six hours on the WeQual Awards assessment process, which asks for deeply reflective answers relating to their leadership style, approach and impact. To help remove bias, all answers are anonymised and externally scored. To determine the final winner, all finalists are interviewed by a global CEO to determine who is the most ready for a future executive committee role. The announcement of the winners takes place on May 10 2023.\n \n All finalists receive complimentary lifetime membership to WeQual Global, an international community comprising high-level executive women from listed companies. Through WeQual Global, these women create powerful peer-level connections, address the common challenges faced by women in their rise to the top, and engage in forums to share best practice. More information can be found at https://lnkd.in/e46vb36E.\n \n WeQual’s mission is to achieve gender equality at the top of the world's largest companies. We support both individual women and the organisations that employ them. For more information, see wequal.com.\n \n Congratulations to all!\n \n #Csuite #ExecutiveCommittee #GenderEquality """ "reshared_post_followers" => 7590 "reshared_post_date" => "2d" "last_updated" => "2023-05-09 13:39:19" "deleted" => 1 ] [ "id" => 154015040 "company_id" => 140537 "urn" => "urn:li:activity:7057076154326728704" "followers" => 1141690 "date" => "1d" "description" => """ Today we received a positive #CHMP opinion from the European Medicines Agency on a first-in-class treatment for adults living with obstructive hypertrophic cardiomyopathy (#HCM), a debilitating and life-changing heart disease.\n \n Read more about this #cardiology news. https://lnkd.in/dcGHwBfG """ "reactions_count" => 622 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-09 13:39:19" "deleted" => 1 ] [ "id" => 154015041 "company_id" => 140537 "urn" => "urn:li:activity:7056952554395467777" "followers" => 1141690 "date" => "2d" "description" => "As part of advancing our long-term ambitions in cell therapy, we are expanding our global cell therapy manufacturing network to enable in-house viral vector production with the addition of a U.S.-based manufacturing facility and its operations in Libertyville, Illinois. The facility and its operations have capabilities to produce viral vector for both of our CAR T cell therapies and strengthens our long-term cell therapy supply to keep pace with growing demand and ensure that more eligible patients can access these treatments." "reactions_count" => 841 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-09 13:39:19" "deleted" => 1 ] [ "id" => 154015042 "company_id" => 140537 "urn" => "urn:li:activity:7056673218186641408" "followers" => 1141690 "date" => "2d" "description" => """ Our very own Cathryn Shaw-Reid, vice president, Cell Therapy Global Manufacturing, was selected as a 2023 Women MAKE Awards Honoree and Emerging Leader by The Manufacturing Institute - MI for her excellence in manufacturing innovation across the industry. Cathryn has over 20 years of experience in the biopharmaceutical industry, specifically in the global commercialization of products. Her extensive experience and passion for all patients has made her an integral part of this company and our organization. \n \n Cathryn is being honored alongside a prestigious group of 100 women leaders and 30 female stars who exemplify leadership within the manufacturing industry. #MFGWomen """ "reactions_count" => 468 "comments_count" => 56 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-09 13:39:19" "deleted" => 1 ] [ "id" => 154015043 "company_id" => 140537 "urn" => "urn:li:activity:7055601151043403776" "followers" => 1141690 "date" => "5d" "description" => "Will you be attending #AANAM? We’ll share our latest research for #MultipleSclerosis, including safety, preservation of brain volume and cognitive processing." "reactions_count" => 169 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-09 13:39:19" "deleted" => 1 ] [ "id" => 154015044 "company_id" => 140537 "urn" => "urn:li:activity:7055559443853299712" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Karin Shanahan" "reshared_post_author_url" => "https://www.linkedin.com/in/karin-shanahan-9263399" "reshared_post_author_headline" => "EVP, Global Product Development and Supply" "reshared_post_description" => """ At BMS, our mission is to deliver innovative medicines that help patients prevail over serious diseases. As a good corporate citizen, we also have the responsibility to ensure we leave the world a better place for future generations. This is why sustainability is a key component of our purpose and mission in BMS Global Product Development & Supply. To that end, we have a strong track record of sustainability achievements that include helping to reduce greenhouse gas emissions across our global footprint, embracing emerging concepts such as green chemistry and constructing more environmentally friendly manufacturing sites to deliver medicines to patients. \n \n So, as we celebrate Earth Day this year, let's all take a moment to consider the impact we have on the environment and what we can do to make a positive change moving forward. #sustainability #manufacturing #bristolmyerssquibb #environment """ "reshared_post_followers" => null "reshared_post_date" => "6d" "last_updated" => "2023-05-09 13:39:19" "deleted" => 1 ] [ "id" => 154015045 "company_id" => 140537 "urn" => "urn:li:activity:7055523019837886464" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Giovanni Caforio" "reshared_post_author_url" => "https://www.linkedin.com/in/giovanni-caforiobms" "reshared_post_author_headline" => "Chairman and Chief Executive Officer at Bristol Myers Squibb" "reshared_post_description" => "We come together around the world as one Bristol Myers Squibb to celebrate #EarthDay. I'm proud to share our commitment to environmental #sustainability has been one of the foundational elements of our corporate culture alongside our commitment to patients and the communities where we live and work. I want to take a moment today to reflect on the importance of environmental stewardship and share our progress toward ensuring a sustainable future for all." "reshared_post_followers" => null "reshared_post_date" => "6d" "last_updated" => "2023-05-09 13:39:19" "deleted" => 1 ] [ "id" => 170620757 "company_id" => 140537 "urn" => "urn:li:activity:7059544778425716736" "followers" => 1145838 "date" => "5d" "description" => """ Today we announced that the European Commission has approved our #CARTcelltherapy for the treatment of adults living with relapsed or refractory diffuse large B-cell #lymphoma (DLBCL) after one prior therapy. \n \n This approval demonstrates our continued commitment to deliver innovative cancer treatments and the promise of cell therapy to help more patients around the world. \n \n Learn more about the announcement here: https://lnkd.in/gpWKyHxH """ "reactions_count" => 3492 "comments_count" => 25 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 07:59:28" "deleted" => 1 ] [ "id" => 170620758 "company_id" => 140537 "urn" => "urn:li:activity:7059274552526159872" "followers" => 1145838 "date" => "6d" "description" => ""Drug development is a long-term investment. And we’re having to make decisions around those kinds of investments without really knowing what the future looks like, so we’re trying to figure out how we bring innovation into the way we develop drugs, the kinds of trials we do, and how we reach patients and physicians.” – Cathi Ahearn, SVP, Worldwide Commercial Portfolio Strategy on driving healthcare innovation in a tumultuous economy at this year’s Fortune Brainstorm Health. More highlights from her panel discussion here: https://bit.ly/3ANVA77" "reactions_count" => 128 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 07:59:28" "deleted" => 1 ] [ "id" => 170620759 "company_id" => 140537 "urn" => "urn:li:activity:7059190988384186368" "followers" => 1145838 "date" => "6d" "description" => """ Searching for new connections with curiosity. Leading with courage by challenging assumptions. Inviting compassion. These are the key tenets our Pan Asian Network (PAN) is amplifying throughout #AANHPIHeritageMonth in alignment with #MentalHealthAwarenessMonth. Another way PAN is championing the mental health of our AANHPI colleagues and driving our culture of inclusion: hosting a keynote with Amanda Phingbodhipakkiya, a scientist-turned-artist, to explore how combining art and science can empower transformation for our colleagues, patients, and communities. \n \n Follow along this month to see more highlights and learn more about PAN here: https://lnkd.in/grjgAS6M """ "reactions_count" => 336 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 07:59:28" "deleted" => 1 ] [ "id" => 170620760 "company_id" => 140537 "urn" => "urn:li:activity:7058907982968860672" "followers" => 1145838 "date" => "1w" "description" => "This #BladderCancerAwarenessMonth, our team wants to shed light on this devastating disease that impacts over 570,000 patients globally each year. We are committed to raising awareness and exploring potential new treatment options for people living with #bladdercancer." "reactions_count" => 140 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 07:59:28" "deleted" => 1 ] [ "id" => 170620761 "company_id" => 140537 "urn" => "urn:li:activity:7058817342394302464" "followers" => 1145838 "date" => "1w" "description" => "We announced that the U.S. Food and Drug Administration has accepted, and the European Medicines Agency validated, applications for our #anemia therapy as a first-line treatment for very low- to intermediate-risk myelodysplastic syndromes. Learn about our commitment to addressing diseases impacted by anemia." "reactions_count" => 1023 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 07:59:28" "deleted" => 1 ] [ "id" => 170620762 "company_id" => 140537 "urn" => "urn:li:activity:7058789706699837440" "followers" => 1145838 "date" => "1w" "description" => "Today, we announced positive topline results from two studies in patients with specific types of blood cancer. These results underscore our commitment to research to bring the promise of our #CARTcelltherapy to more patients with difficult-to-treat cancers. https://bit.ly/42eMVWW" "reactions_count" => 859 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 07:59:28" "deleted" => 1 ] [ "id" => 170620763 "company_id" => 140537 "urn" => "urn:li:activity:7057830033767194625" "followers" => 1145838 "date" => "1w" "description" => "Food security is just one social determinant of health our Power2Impact initiative aims to address in disproportionately impacted diverse communities. This #NationalMinorityHealthMonth, learn how we work to authentically engage local and global communities at a grassroots level to address health disparities and why for our Sara Ahmad this is especially personal and meaningful work." "reactions_count" => 158 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 07:59:28" "deleted" => 1 ] [ "id" => 170620764 "company_id" => 140537 "urn" => "urn:li:activity:7057775478857691138" "followers" => 1145838 "date" => "1w" "description" => "From our Kayla Garrett's Puget Sound Business Journal’s 40 Under 40 recognition to our Pallavur Sivakumar's moderating role in a Life Science Washington's Innovation Northwest panel, our Seattle-based scientists’ unwavering dedication to advancing #CellTherapy research is part of how we’re transforming the way difficult-to-treat cancers are approached globally. Learn more about our innovation in Washington state: https://lnkd.in/gZnFnhKQ" "reactions_count" => 86 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 07:59:28" "deleted" => 1 ] [ "id" => 170620765 "company_id" => 140537 "urn" => "urn:li:activity:7057729036424269824" "followers" => 1145838 "date" => "1w" "description" => """ Meet the next generation of innovators, problem solvers and creative thinkers! This Take Your Child to Work Day, our colleagues’ children got to see their parents in action, get hands-on production experience with our in-house BMS Films video team, attend a science experiment demonstration, and flex their creative muscles by painting a rock to add to our Inspiration Garden. \n \n At BMS, we’re committed to creating an environment where working parents, regardless of gender, can advance in their careers while finding the support they need to care for their families, like connecting parents with care services for children and elders, just-in-time sick care, and learning support for school-aged kids. """ "reactions_count" => 1340 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 07:59:28" "deleted" => 1 ] [ "id" => 170620766 "company_id" => 140537 "urn" => "urn:li:activity:7057363897711792128" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Giovanni Caforio" "reshared_post_author_url" => "https://www.linkedin.com/in/giovanni-caforiobms" "reshared_post_author_headline" => "Chairman and Chief Executive Officer at Bristol Myers Squibb" "reshared_post_description" => """ It has been the highlight and privilege of my career to lead Bristol Myers Squibb over the past eight years. As I reflect on my tenure, I could not be more proud of the positive impact that we have made on millions of patients’ lives. Together, we advanced the standard of care in each of our core therapeutic areas, launched 12 new medicines and expanded our global presence while building a more diverse and engaged workforce and a more inclusive culture. I will be forever grateful to the entire BMS team for their strong performance, while consistently maintaining our focus on patients. \n \n I am also incredibly excited for Chris Boerner as he steps into his new role as COO on the path to becoming our next CEO when I retire in November. Chris is an exceptional leader and has been integral to our commercial success during his tenure at BMS. His deep knowledge of our strategy and pipeline, and proven execution across all geographies, give the Board confidence that he is the right leader to guide Bristol Myers Squibb through its next stage of growth as we advance our vision to be the world’s leading biopharma company that transforms patients’ lives through science. I look forward to working closely with him to achieve a seamless transition, and I am confident BMS will continue to thrive and write another exciting chapter under Chris’s leadership.\n \n Please join me in congratulating Chris on his new role! """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2023-06-08 07:59:28" "deleted" => 1 ] [ "id" => 195144069 "company_id" => 140537 "urn" => "urn:li:activity:7071832886588399616" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Catherine Owen" "reshared_post_author_url" => "https://www.linkedin.com/in/catherineowen" "reshared_post_author_headline" => "Global P&L Leader, Senior Vice President and General Manager, US Commercial, Bristol Myers Squibb" "reshared_post_description" => """ I am honored and grateful to have been elected to serve on the Biotechnology Innovation Organization (BIO) Board of Directors and Executive Committee representing Bristol Myers Squibb. I look forward to working alongside my fellow board members to promote the life-changing innovations brought forth by the global biotechnology industry. As a passionate advocate for women’s representation on boards, I am excited to continue to drive positive change and collaborate with this dynamic group of industry leaders.\n https://lnkd.in/ezsF7Wbi\n #bms_employee\n #bio2023 """ "reshared_post_followers" => null "reshared_post_date" => "15h" "last_updated" => "2023-07-03 10:32:04" "deleted" => 1 ] [ "id" => 195144070 "company_id" => 140537 "urn" => "urn:li:activity:7071600498516115456" "followers" => 1159358 "date" => "16h" "description" => "The unpredictable nature of cancer calls for creative research strategies to target and help eradicate disease. Harnessing the body`s natural abilities of defense and disease elimination remain of critical interest for our researchers. See how we’re deploying advanced anti-cancer approaches: https://lnkd.in/g8wctpEj #ASCO23" "reactions_count" => 98 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-03 10:32:04" "deleted" => 1 ] [ "id" => 195144071 "company_id" => 140537 "urn" => "urn:li:activity:7071561417501413376" "followers" => 1159358 "date" => "18h" "description" => "Collaboration drives over half our leading medicines—and it’s one way we transform the lives of patients through science. Join us at the Biotechnology Innovation Organization convention this week to hear how we’re partnering with health innovators to accelerate breakthroughs across all our therapeutic areas of focus. If you can't attend #BIO2023, learn about partnering with us to help patients prevail over serious diseases: https://lnkd.in/g_EKPXdn" "reactions_count" => 69 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-03 10:32:04" "deleted" => 1 ] [ "id" => 195144072 "company_id" => 140537 "urn" => "urn:li:activity:7071530496849022976" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "a16z Bio + Health" "reshared_post_author_url" => "https://www.linkedin.com/showcase/a16z-bio-health" "reshared_post_author_headline" => null "reshared_post_description" => """ In our latest Bio Eats World episode, Greg Meyers chats with Jorge Conde about all things AI and biopharma 👇 \n \n - How AI could transform drug discovery and development\n - How companies might have to adapt to harness AI\n - Modalities they’re excited about\n - Greg’s do’s and don’ts for startups looking to partner with a company like BMS\n \n Listen here, or wherever you get podcasts: https://lnkd.in/g2pfr4cW """ "reshared_post_followers" => 4430 "reshared_post_date" => "4d" "last_updated" => "2023-07-03 10:32:04" "deleted" => 1 ] [ "id" => 195144073 "company_id" => 140537 "urn" => "urn:li:activity:7071500924501848064" "followers" => 1159358 "date" => "22h" "description" => """ Join the discussion on the 6th June at ESTS 2023, with our BMS-sponsored Industry Satellite Symposium ‘The Beginning of a New Era: Where are we going with immunotherapies in resectable NSCLC?’ \n \n Our experts Dr Erin Gillaspie and Prof Francesco Grossi will highlight progress in research and the growing impact of #immunotherapy in resectable #NSCLC. Alongside in-depth presentation of the value of an effective multidisciplinary approach to care in this setting, we’ll explore the optimal timing of immunotherapies from a surgical perspective, and consider key learnings drawn from immunotherapy treatment in metastatic NSCLC. A live interactive Q&A will close the session. Attend to discover what the future holds for patients. #LCSM https://bit.ly/3OP3ZzD """ "reactions_count" => 74 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-03 10:32:04" "deleted" => 1 ] [ "id" => 195144074 "company_id" => 140537 "urn" => "urn:li:activity:7071471650084433920" "followers" => 1159358 "date" => "1d" "description" => """ We're honored to be named among Forbes' Net Zero Leaders for creating a positive impact on society while minimizing our company’s environmental footprint. Sustainability touches everything we do, from our facilities to delivering medicines to patients.\n \n “This is excellent recognition of the progress we’re making to face our collective climate and environmental challenges. We will continue to work collaboratively to find new, innovative, science-led solutions that will drive us even further toward achieving our sustainability goals.” — Danielle Menture, Vice President, Environment, Occupational Health, Safety and Sustainability\n \n Learn more: https://bit.ly/3CaGBEX """ "reactions_count" => 149 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-03 10:32:04" "deleted" => 1 ] [ "id" => 195144075 "company_id" => 140537 "urn" => "urn:li:activity:7070866740632584192" "followers" => 1159358 "date" => "2d" "description" => "The potential for tyrosine kinase inhibitors (TKIs) to offer clinical benefit in #lungcancer is being explored. At #ASCO23 we’ll discuss the latest results from the TRIDENT-1 trial. It considers efficacy and safety of a TKI in advanced ROS1+ NSCLC with or without central nervous system metastases. A poster presentation by Jessica Lin will be followed by a discussion and a Q&A session. #LCSM" "reactions_count" => 342 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-03 10:32:04" "deleted" => 1 ] [ "id" => 195144076 "company_id" => 140537 "urn" => "urn:li:activity:7070776142395314177" "followers" => 1159358 "date" => "2d" "description" => """ Rheumatic diseases, like #lupus, can be debilitating, with patients often experiencing chronic pain that can make simple tasks and everyday activities challenging. At #EULAR2023, we showcased our most recent research aimed at developing a new treatment option for patients. \n \n Learn more about our commitment to offering innovative solutions to elevate care for lupus patients in this Q&A with Subhashis Banerjee, MD. """ "reactions_count" => 138 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-03 10:32:04" "deleted" => 1 ] [ "id" => 195144077 "company_id" => 140537 "urn" => "urn:li:activity:7070745946610925569" "followers" => 1159358 "date" => "3d" "description" => """ At #ASCO23 Dr David Carbone will be presenting 4-year data from CheckMate 9LA for first-line dual immunotherapy + chemo versus chemo alone in patients with metastatic NSCLC, including outcomes by tumor histologic subtype, previously reported as a prognostic indicator \n \n We’ll discuss whether dual immunotherapy with chemo can provide durable long-term outcomes. #LCSM """ "reactions_count" => 278 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-03 10:32:04" "deleted" => 1 ] [ "id" => 195144078 "company_id" => 140537 "urn" => "urn:li:activity:7070504352238497792" "followers" => 1159358 "date" => "3d" "description" => """ Our CEO Giovanni Caforio joined CNBC to discuss our innovation and leadership in cancer treatment and research, our commitment to patients, and the key data we are presenting at #ASCO23.\n \n Read more, including important cautionary statements about forward-looking information, here: https://bit.ly/3oI82mv """ "reactions_count" => 989 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-03 10:32:04" "deleted" => 1 ] [ "id" => 228116790 "company_id" => 140537 "urn" => "urn:li:activity:7080597115852189696" "followers" => 1176377 "date" => "2d" "description" => "This #PrideMonth, our PRIDE Alliance brought colleagues together to celebrate the LGBTQIA+ community, honor the progress made to foster inclusion, and recognize the work continues. Watch for a look at a few memorable moments from Pride, including the flag raising kickoff with CEO Giovanni Caforio and PRIDE Alliance lead Paul Shay, the keynote with “All Boys Aren’t Blue” author George M. Johnson, and our third annual Drag Queen Charity Bingo hosted by the incredible Mrs. Kasha Davis to raise funds for Outright International, PFLAG National/Straight for Equality, and The Trevor Project. We’re grateful to our colleagues who helped make our 2023 PRIDE theme, “Stand Up, Stand Supported, Stand Proud” even more impactful." "reactions_count" => 116 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-06 12:26:59" "deleted" => 1 ] [ "id" => 228116791 "company_id" => 140537 "urn" => "urn:li:activity:7080545524549857281" "followers" => 1176377 "date" => "2d" "description" => "Will we see you at #EAN2023? Don’t miss our latest research on the advancement of science for those living with #MultipleSclerosis." "reactions_count" => 80 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-06 12:26:59" "deleted" => 1 ] [ "id" => 228116792 "company_id" => 140537 "urn" => "urn:li:activity:7080198384682201088" "followers" => 1176377 "date" => "3d" "description" => "Our lung cancer development lead, Dr Abderrahim oukessou, MD., discusses the potential to improve outcomes for patients with pre-surgery #immunotherapy options in #lungcancer. #LCSM" "reactions_count" => 192 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-06 12:26:59" "deleted" => 1 ] [ "id" => 228116793 "company_id" => 140537 "urn" => "urn:li:activity:7079851321473802240" "followers" => 1176377 "date" => "4d" "description" => """ We are celebrating a decade of the Coast 2 Coast 4 Cancer ride in the U.S. This tradition began in 2014 when a group of Oncology employees were compelled to do more for those impacted by cancer. Now, in the 10th year of the ride, over 126 employee riders will train for the next five months ahead of participating in the ~3,000-mile trek from the west to east coast. Each rider will be raising funds in support of the V Foundation to advance #cancer research. \n \n Our impact knows no bounds, and this year’s ride will be more inclusive than ever with employees from Canada joining the effort for the first time. With fundraising now open, learn more about #C2C4C23 at https://bit.ly/3BQ6WIz """ "reactions_count" => 616 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-06 12:26:59" "deleted" => 1 ] [ "id" => 228116794 "company_id" => 140537 "urn" => "urn:li:activity:7079816619010469888" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Women Business Collaborative" "reshared_post_author_url" => "https://www.linkedin.com/company/wbcollaborative" "reshared_post_author_headline" => null "reshared_post_description" => """ We proudly celebrate Giovanni Caforio, Chairman of the Board & CEO of Bristol Myers Squibb as one of our 10 Awardees of the 2023 CEO excellence in Gender Equity & Diversity Award. Throughout the years, Bristol Myers Squibb has received a number of awards and recongition for their corporate social responsibility. Thank you for being a champion of opportunities and equality.\n \n Save the date for an insightful event and be inspired by leaders driving positive change! Register here and we hope you will join us September 20 & 21!\n \n https://lnkd.in/ec-ev7q9\n \n #A4ISummit #InclusiveLeadership #EquityMatters #WBCSummit2023\n #WomenInBusiness #WBCA4I #LeadersDrivingChange #A4ISummit #WBCSummit2023 #EquityInclusion #DrivingChange #A4ISummit #TrailblazersInclusion #WBCSummit2023 """ "reshared_post_followers" => 8699 "reshared_post_date" => "5d" "last_updated" => "2023-08-06 12:26:59" "deleted" => 1 ] [ "id" => 228116795 "company_id" => 140537 "urn" => "urn:li:activity:7079443252528979968" "followers" => 1176377 "date" => "5d" "description" => "We’re committed to transforming cardiovascular care for patients worldwide. We support Global Heart Hub's mission to help raise awareness for cardiomyopathy, a group of heart conditions that often runs in families and can lead to serious, sometimes fatal consequences if undetected." "reactions_count" => 131 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-06 12:26:59" "deleted" => 1 ] [ "id" => 228116796 "company_id" => 140537 "urn" => "urn:li:activity:7079189335324925952" "followers" => 1176377 "date" => "6d" "description" => "Today we announced the European Commission approved our first-in-class treatment for symptomatic NYHA class II-III obstructive hypertrophic cardiomyopathy (#HCM), marking an important milestone for patients in the EU who have long awaited a new treatment option." "reactions_count" => 945 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-06 12:26:59" "deleted" => 1 ] [ "id" => 228116797 "company_id" => 140537 "urn" => "urn:li:activity:7079080862771765249" "followers" => 1176377 "date" => "6d" "description" => "Collaboration is vital to address cancer research gaps in Sub-Saharan Africa (SSA). JCO Global Oncology’s recent publication, "Analysis of Cancer Research Projects in Sub-Saharan Africa: A Quantitative Perspective on Unmet Needs and Opportunities," underscores differences between cancer burden and research projects and identifies opportunities for future strategic investments in cancer care in SSA." "reactions_count" => 110 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-06 12:26:59" "deleted" => 1 ] [ "id" => 228116798 "company_id" => 140537 "urn" => "urn:li:activity:7077993711573295104" "followers" => 1176377 "date" => "1w" "description" => """ Just in: the “Bold Innovators” podcast hosted by Bryant Powell, M.B.A., is now streaming on BMS.com, Apple and Spotify. Tune in to season two to meet industry leaders and members of our Black Organization for Leadership and Development (BOLD) like Paul D. Ashley, Wendy Bartie, and more and learn how passion drives them to help patients prevail over serious illnesses. \n \n Listen at the links below: \n • BMS.com: https://bit.ly/3XtdbvS\n • Apple: https://bit.ly/3pnWIMD\n • Spotify: https://lnkd.in/efy4pzR8 """ "reactions_count" => 145 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-06 12:26:59" "deleted" => 1 ] [ "id" => 228116799 "company_id" => 140537 "urn" => "urn:li:activity:7077744561359343616" "followers" => 1176377 "date" => "1w" "description" => """ “Can we together envision a more equitable world in oncology and hematology? How are we going to rise to meet the challenge for ourselves and the professionals and providers who come after us?” \n \n Our Wendy Bartie posed this challenge to industry leaders who gathered for our first Elevating Women in Hematology and Oncology at #ASCO2023. Aimed to celebrate women in cancer care and drive gender parity, the event included inspiring remarks by Dr. Pamela Kunz, of Yale University School of Medicine and Yale Cancer Center who declared that improving equity across every facet of healthcare is an imperative that can lead to improved patient outcomes. """ "reactions_count" => 247 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-06 12:26:59" "deleted" => 1 ] [ "id" => 276065113 "company_id" => 140537 "urn" => "urn:li:activity:7093212609117605889" "followers" => null "date" => null "description" => null "reactions_count" => 303 "comments_count" => 42 "reshared_post_author" => "Karin Shanahan" "reshared_post_author_url" => "https://www.linkedin.com/in/karin-shanahan-9263399" "reshared_post_author_headline" => "EVP, Global Product Development and Supply" "reshared_post_description" => "I am pleased to welcome Thomas Potgieter as Senior Vice President of Cell Therapy Development and Operations. Thomas is a seasoned expert in pharmaceutical manufacturing, and his breadth of expertise will build upon the advances we have made in cell therapy. I look forward to Thomas's perspective as we expand our manufacturing network and deliver for patients through novel approaches. #BMS_Employee" "reshared_post_followers" => null "reshared_post_date" => "19h" "last_updated" => "2023-09-01 15:50:23" "deleted" => 1 ] [ "id" => 276065114 "company_id" => 140537 "urn" => "urn:li:activity:7091857295537496064" "followers" => 1204594 "date" => "4d" "description" => """ We're honored to be named to Disability:IN’s Best Places to Work for Disability Inclusion and receive the top score of 100 on #DEI23’s benchmarking index for the fifth year. \n \n This #DisabilityPrideMonth, learn how we’re fostering an inclusive culture in partnership with DAWN, our Disability Advancement Workplace Network: https://lnkd.in/esbFsR5f """ "reactions_count" => 132 "comments_count" => 3 "reshared_post_author" => "Disability:IN" "reshared_post_author_url" => "https://www.linkedin.com/company/disabilityin" "reshared_post_author_headline" => null "reshared_post_description" => "Disability:IN is proud to announce the 2023 Best Places to Work for Disability Inclusion. Congratulations to the #DEI23 Top Scoring Companies! #AreYouIN?" "reshared_post_followers" => 51215 "reshared_post_date" => "3w" "last_updated" => "2023-09-01 15:50:23" "deleted" => 1 ] [ "id" => 276065116 "company_id" => 140537 "urn" => "urn:li:activity:7091810928043675648" "followers" => 1204594 "date" => "4d" "description" => """ We are the dreamers, thinkers, and doers. Every day, we enter uncharted territory and climb new heights to discover transformational medicines to help patients prevail over serious diseases.\n \n #WeAreBMS and these are Our Stories. Take a look at the milestones we achieved over the past year on global innovation, inclusion and diversity, ESG strategies, and learn more about our mission to transform the lives of patients through science: https://lnkd.in/e6ZQHyKk """ "reactions_count" => 474 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 15:50:23" "deleted" => 1 ] [ "id" => 276065117 "company_id" => 140537 "urn" => "urn:li:activity:7090307357552832513" "followers" => 1204594 "date" => "1w" "description" => """ Bristol Myers Squibb reports second quarter revenues of $11.2 billion, GAAP EPS of $0.99 and non-GAAP EPS of $1.75, which includes a net impact of ($0.05) per share due to Acquired IPRD charges and licensing income. The company is also revising its 2023 outlook and reaffirming its 2020-2025 financial targets. \n \n Read more, including important cautionary statements about forward-looking information, here: https://bit.ly/3YaaXSe """ "reactions_count" => 317 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 15:50:23" "deleted" => 1 ] [ "id" => 276065119 "company_id" => 140537 "urn" => "urn:li:activity:7089635418383507456" "followers" => 1204594 "date" => "1w" "description" => """ “One of the reasons I love coming to work at Bristol Myers Squibb every day is the collaboration with my fellow scientists. We all have the same insatiable drive to dig deep into disease biology to truly understand cancer and battle it from multiple angles,” says Charlie Garnett-Benson, senior scientific director. \n \n Learn more about the work Charlie and her team are doing advance the next generation of #CancerTreatment. """ "reactions_count" => 206 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 15:50:23" "deleted" => 1 ] [ "id" => 276065120 "company_id" => 140537 "urn" => "urn:li:activity:7087415811232948224" "followers" => 1204594 "date" => "2w" "description" => """ Our inclusive research environment creates equal opportunities for all genders at BMS and promotes creativity that allows great ideas to thrive, resulting in transformational science. \n \n Read about these five women who embody what it means to lead in R&D through their work to advance medicines inside and outside the lab. #WomenInSTEM """ "reactions_count" => 306 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 15:50:23" "deleted" => 1 ] [ "id" => 276065122 "company_id" => 140537 "urn" => "urn:li:activity:7087064613426454528" "followers" => 1204594 "date" => "2w" "description" => """ Voorkomen is beter dan genezen.\n \n Dat vinden zowel het Huidfonds als wij bij Bristol Myers Squibb. Daarom hebben we de handen ineen geslagen en loopt er de komende weken een awareness campagne op Weeronline om huidkanker te voorkomen.\n \n Voor meer info ga naar: https://lnkd.in/e_Q8X_5A\n \n #bmsnetherlands #melanomaawareness #partnership """ "reactions_count" => 47 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-01 15:50:23" "deleted" => 1 ] [ "id" => 276065124 "company_id" => 140537 "urn" => "urn:li:activity:7086309027030212608" "followers" => null "date" => null "description" => null "reactions_count" => 91 "comments_count" => 1 "reshared_post_author" => "Bristol Myers Squibb" "reshared_post_author_url" => "https://www.linkedin.com/company/bristol-myers-squibb" "reshared_post_author_headline" => null "reshared_post_description" => """ SOL DEG MED MÅTE! Vær forsiktig når du er ute i sola. Antallet tilfeller av #melanom (hudkreft) øker over hele verden og i Norge er dette en av kreftformene med sterkest økning. Bare i 2022 fikk nesten 3000 nordmenn denne diagnosen. Dessverre ser vi også at dødeligheten har økt over tid her i Norge.\n \n Vi i #BMSNorge ønsker deg en trygg sommer: Nyt gjerne solen – men med forsiktighet. Sjekk ut denne filmen med de viktigste rådene for godt #solvett!\n \n Les gjerne mer om soling og hudkreft hos Kreftforeningen: https://lnkd.in/dUiU-Kyi\n \n #pasientenisentrum #solvett #melanom #hudkreft #solkrem """ "reshared_post_followers" => 1204594 "reshared_post_date" => "1mo" "last_updated" => "2023-09-01 15:50:23" "deleted" => 1 ] [ "id" => 276065125 "company_id" => 140537 "urn" => "urn:li:activity:7085361033556434944" "followers" => null "date" => null "description" => null "reactions_count" => 247 "comments_count" => 2 "reshared_post_author" => "PhRMA Foundation" "reshared_post_author_url" => "https://www.linkedin.com/company/phrma-foundation" "reshared_post_author_headline" => null "reshared_post_description" => """ The PhRMA Foundation is pleased to announce the appointment to its Board of Directors of Dr. Robert Plenge, Executive Vice President, Head of Research at Bristol Myers Squibb.\n https://lnkd.in/gPcfGV5y """ "reshared_post_followers" => 3554 "reshared_post_date" => "3w" "last_updated" => "2023-09-01 15:50:23" "deleted" => 1 ] [ "id" => 276065127 "company_id" => 140537 "urn" => "urn:li:activity:7084938480945917952" "followers" => 1204594 "date" => "3w" "description" => "Sixty percent of transgender and gender-diverse professionals in the U.S. report that gender non-conforming employees experience negative stereotypes and social interactions in the workplace, according to Coqual’s new study, "Challenging Norms: A Global Analysis of Gender at Work.” Together with our Bristol Myers Squibb Network of Women (B-NOW) group, we are honored to share their impactful findings. Read more below." "reactions_count" => 52 "comments_count" => 1 "reshared_post_author" => "Elvie Gee" "reshared_post_author_url" => "https://www.linkedin.com/in/elvie-gee" "reshared_post_author_headline" => "Diversity, Equity & Inclusion Executive" "reshared_post_description" => "We are excited to partner with Coqual as a proud sponsor of "Challenging Norms: A Global Analysis of Gender at Work." Launching today, #Coqual’s new report finds hat the majority of transgender and gender diverse professionals in the U.S. (60%) say that gender non-conforming employees experience negative stereotypes and social interactions in the workplace compared to only 39% of cisgender professionals. Coqual provides data-driven insights that companies and their leaders can use to build inclusive workplaces. Let’s work together to dismantle gender-based discrimination throughout the global workplace. Learn more here: https://lnkd.in/ejQ5mfet #CoqualResearch #CoqualResearch2023 #GenderAtWork" "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2023-09-01 15:50:23" "deleted" => 1 ] [ "id" => 302676788 "company_id" => 140537 "urn" => "urn:li:activity:7100873945075048450" "followers" => null "date" => "6d" "description" => """ What drives our leaders to do more for patients each and every day?\n \n As part of our 9th annual #GlobalPatientWeek celebration, Giovanni Caforio and Chris Boerner will answer this question and more during a #LinkedInLive event moderated by Cari Almo Gallman on Tuesday, September 19 at 9AM ET. """ "reactions_count" => 223 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-17 15:55:13" "deleted" => 1 ] [ "id" => 302676789 "company_id" => 140537 "urn" => "urn:li:activity:7103043785697153024" "followers" => null "date" => "22h" "description" => """ Helping launch the first oncology center in Lesotho. Training partner organizations in other parts of sub-Saharan Africa. Performing clinical research to improve availability of medicines.\n \n These are some of the career opportunities the BMS Foundation and our company offer to PharmD residents. Meet two recent program graduates, Richie Uba and Alejandro Nava, and learn about their incredible experiences that connected them with patients around the globe. """ "reactions_count" => 107 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-17 15:55:13" "deleted" => 1 ] [ "id" => 302676790 "company_id" => 140537 "urn" => "urn:li:activity:7102771989928402944" "followers" => null "date" => "1d" "description" => "The New England Journal of Medicine has published results from the Phase 1/2 CC-92480-MM-001 study of our investigational novel CELMoD™ agent in relapsed and refractory multiple myeloma. Continued partnership with the multiple myeloma community, including through new research, is key to advancing scientific progress #mmsm." "reactions_count" => 194 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-17 15:55:13" "deleted" => 1 ] [ "id" => 302676791 "company_id" => 140537 "urn" => "urn:li:activity:7102756874319486976" "followers" => null "date" => "1d" "description" => "We're committed to delivering scientific information in innovative ways to better meet the educational needs of healthcare providers: Announcing the availability of Inside the Science, a new, on-demand educational capability enabling HCPs to access scientific information in a variety of engaging formats. Launching this month with #Immunology videos in recognition of #PsoriasisAwarenessMonth, and available now at insidethescience.com" "reactions_count" => 178 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-17 15:55:13" "deleted" => 1 ] [ "id" => 302676792 "company_id" => 140537 "urn" => "urn:li:activity:7102726693068447744" "followers" => null "date" => "1d" "description" => "Visiting Lesotho’s first oncology clinic—where a patient received the first chemotherapy infusion in the country just last year—was among the many opportunities our colleague Alexandra Hill experienced volunteering with our Global Initiative for Volunteerism and Engagement (GIVEs) program. She’s one of a half-dozen employees chosen to travel to sub-Saharan Africa with GIVEs in 2022. Learn about our colleagues’ impact on the patients and communities we serve." "reactions_count" => 109 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-17 15:55:13" "deleted" => 1 ] [ "id" => 302676793 "company_id" => 140537 "urn" => "urn:li:activity:7102681401094770689" "followers" => null "date" => "1d" "description" => """ For 10 years, our employees have banded together to demonstrate our long-standing commitment to patients through the C2C4C bike rides. Nearly 350 rider employees from every therapeutic area and 28 different countries will be riding in Europe, the U.S., Japan and Latin America to fundraise and advance cancer research worldwide. \n \n This volunteer initiative serves as a powerful reminder of our company’s mission: to do more for patients and their loved ones who are battling cancer on a daily basis.\n \n Learn more about how you can support our #C2C4C23 riders. """ "reactions_count" => 343 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-17 15:55:13" "deleted" => 1 ] [ "id" => 302676794 "company_id" => 140537 "urn" => "urn:li:activity:7102369935489679361" "followers" => null "date" => null "description" => null "reactions_count" => 92 "comments_count" => 2 "reshared_post_author" => "IFPMA" "reshared_post_author_url" => "https://ch.linkedin.com/company/ifpma" "reshared_post_author_headline" => null "reshared_post_description" => "Globally, almost one in six deaths is due to cancer. Through innovation and partnerships, we’re improving cancer care for people, wherever they live. Amadou Diarra Bristol Myers Squibb explores how we respond to the global cancer burden. #AlwaysInnovating https://lnkd.in/enF2wY6a" "reshared_post_followers" => null "reshared_post_date" => "3d" "last_updated" => "2023-10-17 15:55:13" "deleted" => 1 ] [ "id" => 302676795 "company_id" => 140537 "urn" => "urn:li:activity:7102128418057572353" "followers" => null "date" => "3d" "description" => """ Today we announced that the FDA has approved our first-line #anemia therapy as a treatment for adult patients with very low- to intermediate-risk myelodysplastic syndromes (#MDS). \n \n This approval represents our dedication to expanding the reach of our first-in-class treatment. Thank you to all involved in this milestone for your commitment to bringing this innovative treatment option to patients in need. """ "reactions_count" => 2926 "comments_count" => 29 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-17 15:55:13" "deleted" => 1 ] [ "id" => 302676796 "company_id" => 140537 "urn" => "urn:li:activity:7102003414913425409" "followers" => null "date" => null "description" => null "reactions_count" => 203 "comments_count" => null "reshared_post_author" => "Lynelle Hoch" "reshared_post_author_url" => "https://www.linkedin.com/in/lynelle-hoch-19887994" "reshared_post_author_headline" => "Unlocking the Promise of Cell Therapy as Senior Vice President, Cell Therapy Franchise Lead at Bristol Myers Squibb" "reshared_post_description" => """ To continue advancing the field of #CARTcelltherapy, we must invest in the industry's future to unlock its full potential for patients with cancer and other serious diseases.\n \n With this in mind, BMS invested in a new academic program launching this summer for students enrolled at Drexel University help build a pipeline of talent interested in pursuing careers in cell and gene therapy. \n \n This partnership reinforces BMS’ continued commitment to cell therapy, and I look forward to seeing what the future holds for Drexel students focused on driving innovation in the field. \n \n Read more: bit.ly/45NiDwA\n \n #BMS_Employee """ "reshared_post_followers" => null "reshared_post_date" => "3d" "last_updated" => "2023-10-17 15:55:13" "deleted" => 1 ] [ "id" => 302676797 "company_id" => 140537 "urn" => "urn:li:activity:7101951631461646337" "followers" => null "date" => "3d" "description" => """ #HypertrophicCardiomyopathy (HCM) is the most commonly inherited heart condition and can be a debilitating and life-changing condition if left undiagnosed.\n \n At #ESCCongress we presented long-term data from two phase 3 studies – 56-week data and a 120-week analysis – as a late-breaking and oral presentation.\n \n These findings continue to demonstrate how we’re addressing unmet needs for symptomatic obstructive HCM patients. """ "reactions_count" => 342 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-17 15:55:13" "deleted" => 1 ] [ "id" => 347213029 "company_id" => 140537 "urn" => "urn:li:activity:7119668328591200259" "followers" => null "date" => "1d" "description" => """ Eosinophilic esophagitis (EoE) is becoming more prevalent around the world. That’s why our teams continue to push research forward to identify potential new treatments that relieve symptoms and improve quality of life for patients living with EoE. #EosAware #UEGWeek\n \n Hear more about the disease from Estelle Vester-Blokland, MD, SVP of Global Medical Affairs. """ "reactions_count" => 114 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-09 06:06:53" "deleted" => 1 ] [ "id" => 347213030 "company_id" => 140537 "urn" => "urn:li:activity:7118958650001428480" "followers" => null "date" => "3d" "description" => """ Despite available therapies, many people living with inflammatory bowel disease (#IBD) struggle to manage their disease effectively. \n \n Mark Osterman, our vice president, disease area head, Gastroenterology, explains how our team is actively researching new mechanisms to address IBD, looking beyond the typical immune pathways to further understand and address what is happening in the IBD disease process. #UEGWeek """ "reactions_count" => 150 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-09 06:06:53" "deleted" => 1 ] [ "id" => 347213031 "company_id" => 140537 "urn" => "urn:li:activity:7118732263420284930" "followers" => null "date" => "3d" "description" => "Our CEO Giovanni Caforio issues a statement to BMS colleagues on the tragedies unfolding in Israel and Gaza. Our priority is ensuring the safety and well-being of our people and our patients in the region and we, along with the Bristol Myers Squibb Foundation, are donating to multiple relief organizations in support." "reactions_count" => 692 "comments_count" => 13 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-09 06:06:53" "deleted" => 1 ] [ "id" => 347213032 "company_id" => 140537 "urn" => "urn:li:activity:7118715670980149248" "followers" => null "date" => "4d" "description" => """ This week, I had the pleasure to join a panel at the European Parliament in Brussels, organized by the @TRANSFORM Alliance, that explored the future policy ecosystem for advanced therapy medicinal products in the #EU. \n \n As EU policymakers consider new laws affecting #innovation in medicines through the revised General #Pharma Legislation, we are reminded that a future-proofed #regulatory framework is the way to stretch our science for better patient care. \n \n Cell therapy is a revolution in medicine and cancer #immunotherapy. It paves the way for a promising shift in the future paradigm of cancer care. But cell therapy is uniquely complex and it faces significant challenges, including the development process, scaling manufacturing, adapting supply chains, and updating and aligning regulatory pathways. \n \n These challenges can be tackled through open and constructive dialogue, leading to new ways of working between regulators, payers, industry and others. TRANSFORM Alliance is a successful example of evidence-based cross-stakeholder dialogue. I was energized to be part of a thoughtful discussion. \n \n More collaborations like this one are needed so that more European patients can realize the benefits of innovation. \n \n #BMS_Employee #BMSEUPolicy #MEPsforATMPs """ "reactions_count" => 243 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-09 06:06:53" "deleted" => 1 ] [ "id" => 347213033 "company_id" => 140537 "urn" => "urn:li:activity:7118702929028513792" "followers" => null "date" => "3d" "description" => """ Hear Dr. Tina Cascone introduce a not-to-be-missed BMS-sponsored Industry Satellite Symposium at #ESMO23! Chaired by Professor Jürgen Wolf, our expert faculty will discuss ‘Clinical Perspectives on the Evolution of NSCLC Treatment With I-O and ROS1 TKIs’, with an opportunity for attendees to ‘ask anything’ of the respected speakers. \n \n Explore targeted therapies and immuno-oncology options as the panel highlights recent approvals and potential future options for #NSCLC, alongside detailed analysis of the MDT approach to optimizing treatment decisions. \n \n Join us on Saturday 21 October at 13.00 CEST in the Salamanca Auditorium, Hall 3, IFEMA Madrid, or watch on demand https://bit.ly/3tCVwXr. #LCSM """ "reactions_count" => 99 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-09 06:06:53" "deleted" => 1 ] [ "id" => 347213034 "company_id" => 140537 "urn" => "urn:li:activity:7118655110519431168" "followers" => null "date" => "3d" "description" => """ We’re honored to receive a 5-star rating for Hispanic inclusion in the areas of employment and governance from HACR - Hispanic Association on Corporate Responsibility. One way we’re championing Hispanic inclusion is through our Organization for Latino Achievement’s Network of Executives initiative which aims to shape the next generation of leaders.\n \n As Latinx Hispanic Heritage Month wraps, learn more about this recognition: https://bit.ly/3rP5BjB\n \n #LHMM """ "reactions_count" => 118 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-09 06:06:53" "deleted" => 1 ] [ "id" => 347213035 "company_id" => 140537 "urn" => "urn:li:activity:7118626442967482368" "followers" => null "date" => "3d" "description" => "Millions of atrial fibrillation patients are estimated to be untreated or undertreated due to bleeding concerns, leaving them at risk of stroke. Our Phase 3 Librexia Program in collaboration with The Janssen Pharmaceutical Companies of Johnson & Johnson aims to help close this gap for patients in need. #WTDay23" "reactions_count" => 106 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-09 06:06:53" "deleted" => 1 ] [ "id" => 347213036 "company_id" => 140537 "urn" => "urn:li:activity:7118623529763303424" "followers" => null "date" => "6d" "description" => """ This week in Brussels, I was delighted to join a panel at the #HealthSummit organized by @Friends of Europe, an influential think tank. As a clinician who has spent more than two decades in the #biopharmaceutical industry, I enjoyed sharing some of my learnings and insights about how #digitalization is reshaping healthcare, especially #cancer care. \n \n I was struck at the Health Summit by the engagement from the other panelists, including from the European Commission and the European Parliament, and the audience about the role of digitalization in improving healthcare. With solid and blood cancers causing almost 10 million deaths globally every year, innovation for better care is critical. Digitalization is accelerating discovery and development in #medicines. It is making treatments more targeted and production more efficient. #AI, or artificial intelligence, is reshaping cancer dignosis and treatment, with new opportunities, leveraging large datasets, for improving earlier detection and better care across solid tumour and haematological malignancies.\n \n Digital health records provide the opportunity to optimally map the patient journey and this is enhanced by smartphone integration and moving to cloud-based data capture. Virtual tumor boards are gathering surgeons, oncologists and pathologists to discuss treatment options for cancer patients and provide personalized treatment plans closer to home. Digital tools are enabling the remote review of biopsies and together with teleradiology expediting cancer diagnoses and improving treatment decision making.\n \n The backdrop for all this is the proposed revision to the EU General #Pharma Legislation. It is a chance for EU policymakers to future-proof the scientific ecosystem, including realizing the potential of digital health to help patients with diseases like cancer have better outcomes.\n \n #BMS_Employee """ "reactions_count" => 276 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-09 06:06:53" "deleted" => 1 ] [ "id" => 347213037 "company_id" => 140537 "urn" => "urn:li:activity:7118581162582671361" "followers" => null "date" => "4d" "description" => "Roughly 100 million people are impacted by #psoriasis worldwide. Despite its prevalence, many patients feel dissatisfied with current treatment regimens or find it difficult to reach their treatment goals. Our commitment is to help free patients from the burden of immune-mediated diseases like psoriasis, so that we can change lives for the better." "reactions_count" => 60 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-09 06:06:53" "deleted" => 1 ] [ "id" => 347213038 "company_id" => 140537 "urn" => "urn:li:activity:7117966358000128000" "followers" => null "date" => "5d" "description" => """ “Being authentic is essential. It impacts your personal, professional, and your entire life.” \n \n As the newly appointed Global Lead of our PRIDE Alliance, Frank Sperber is working alongside our leaders and colleagues to foster a culture where the LGBTQ+ community feels welcome, supported and understood. Join us in honoring #NationalComingOutDay and learn about our PRIDE-led initiatives like global Safe Zone workshops, diverse STEM recruitment efforts, and our work addressing health disparities in the LBGTQ+ community: https://lnkd.in/gFZA5a8h """ "reactions_count" => 227 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-09 06:06:53" "deleted" => 1 ] [ "id" => 372094097 "company_id" => 140537 "urn" => "urn:li:activity:7128048559819542528" "followers" => null "date" => "14h" "description" => "Allyson McMillan, senior vice president of U.S. Oncology reflects on our commitment to the lung cancer community. #LungCancerAwarenessMonth" "reactions_count" => 274 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-13 15:41:42" "deleted" => 1 ] [ "id" => 372094098 "company_id" => 140537 "urn" => "urn:li:activity:7128018352182099968" "followers" => null "date" => "16h" "description" => """ On #NationalSTEMDay, we are reminded of our global responsibility to foster the development and engagement of young minds in STEM education and careers. \n \n Learn more about how we’re empowering the next generation to both drive advancement and promote inclusion and diversity within the scientific community. """ "reactions_count" => 200 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-13 15:41:42" "deleted" => 1 ] [ "id" => 372094099 "company_id" => 140537 "urn" => "urn:li:activity:7126568797104193536" "followers" => null "date" => "4d" "description" => "With our deep immunotherapy experience, we strive to create new scientific standards as we work to innovate the advancement of patient outcomes, including the development of T and NK cell engagers to boost immune-mediated killing. #SITC23" "reactions_count" => 750 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-13 15:41:42" "deleted" => 1 ] [ "id" => 372094100 "company_id" => 140537 "urn" => "urn:li:activity:7125872011507089408" "followers" => null "date" => "6d" "description" => "We look forward to joining the #hematology community at the 65th American Society of Hematology Annual Meeting and Exposition. We’ll present data from 73 data disclosures across our diverse portfolio, spanning multiple research platforms and combinations with potential to help more patients with #bloodcancers." "reactions_count" => 239 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-13 15:41:42" "deleted" => 1 ] [ "id" => 372094101 "company_id" => 140537 "urn" => "urn:li:activity:7125481696744939520" "followers" => null "date" => "1w" "description" => "A lung cancer diagnosis is devastating for patients and their loved ones. Hear from two of our leaders about the innovative work we are doing to explore treatment solutions across stages, settings and modalities, driven by our dedication to patients. #LungCancerAwarenessMonth #LCAM #LCSM https://lnkd.in/gT6U2GXM" "reactions_count" => 196 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-13 15:41:42" "deleted" => 1 ] [ "id" => 372094102 "company_id" => 140537 "urn" => "urn:li:activity:7125453706354950144" "followers" => null "date" => "1w" "description" => "Today Chris Boerner begins his new role as our CEO and on April 1, 2024, he’ll succeed Giovanni Caforio as Chair of the Board of Directors. With over eight years’ experience at BMS leading growth and innovation across the company’s key franchises, he ushers in a new era for our global team. Learn more: https://bit.ly/47hfRAr" "reactions_count" => 4075 "comments_count" => 143 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-13 15:41:42" "deleted" => 1 ] [ "id" => 372094103 "company_id" => 140537 "urn" => "urn:li:activity:7125119445219364864" "followers" => null "date" => "1w" "description" => "Thank you, Giovanni Caforio, for your twenty-three years of inclusive and visionary leadership, for always empowering our life-changing work for patients, and for guiding us safely through uncertain times. On his last day as CEO, look back at his enduring legacy, not just for our company but for our millions of patients around the world. We’ll miss you, Giovanni." "reactions_count" => 3665 "comments_count" => 128 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-13 15:41:42" "deleted" => 1 ] [ "id" => 372094104 "company_id" => 140537 "urn" => "urn:li:activity:7124802154527158273" "followers" => null "date" => "1w" "description" => """ Coordinating stem cell transplants and teaching medical students are just two ways Dr. Mahlatse Mankgele is giving hope to multiple myeloma patients through his fellowship supported by the Bristol Myers Squibb Foundation, an independent charitable organization, in South Africa, where clinical hematologists like him are much needed. \n \n Meet him and learn how the BMS Foundation’s commitment to supporting patients, caregivers and the next generation of physicians is making an impact in the region. """ "reactions_count" => 150 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-13 15:41:42" "deleted" => 1 ] [ "id" => 372094105 "company_id" => 140537 "urn" => "urn:li:activity:7123699894028029953" "followers" => null "date" => "1w" "description" => """ Roughly 100 million people are impacted by #psoriasis around the world. To spread awareness about the disease and existing challenges, we’re sharing individual stories from people living with psoriasis about their individual experiences with diagnosis, stigma and more. \n \n Learn more about the world of difference in the psoriasis community through unique, first-hand perspectives. #WorldPsoriasisDay """ "reactions_count" => 162 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-13 15:41:42" "deleted" => 1 ] [ "id" => 412655049 "company_id" => 140537 "urn" => "urn:li:activity:7140452892573937664" "followers" => null "date" => "18h" "description" => "Scientific collaboration is a critical aspect of clinical research aimed at delivering the next wave of advances for patients living with hard-to treat blood diseases. #ASH23 was an opportunity to hear important insights presented from independent research teams, including findings from the EMN Trial Office evaluating our novel agents in early stages of multiple myeloma. https://bit.ly/3RjMUxo" "reactions_count" => 110 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-19 07:35:50" "deleted" => 1 ] [ "id" => 412655050 "company_id" => 140537 "urn" => "urn:li:activity:7140435393446825984" "followers" => null "date" => "19h" "description" => "As #ASH23 comes to a close, we reflect on the breadth of the research presented this year and data we highlighted across our diverse pipeline. These opportunities to connect on the latest hematology advances deepen our partnerships and collaborative efforts across the scientific community. Learn more about our data at ASH 2023: https://bit.ly/3uYjmhi" "reactions_count" => 73 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-19 07:35:50" "deleted" => 1 ] [ "id" => 412655051 "company_id" => 140537 "urn" => "urn:li:activity:7140387860272062464" "followers" => null "date" => "22h" "description" => "Every day, our global R&D teams reimagine the future of science, leading with curiosity and passion. Our 32nd annual R&D Symposium and awards ceremony celebrated the world-class individuals who are building on our legacy of innovation to ensure a brighter future, by bringing transformative medicines to patients faster." "reactions_count" => 383 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-19 07:35:50" "deleted" => 1 ] [ "id" => 412655052 "company_id" => 140537 "urn" => "urn:li:activity:7140088437507854336" "followers" => null "date" => "1d" "description" => """ Today we announced a collaboration with SystImmune to co-develop and co-commercialize a bispecific antibody-drug conjugate with promising potential for the treatment of non-small cell lung cancer and other tumors.\n \n We are enthusiastic about the opportunity to expand our oncology portfolio and continue diversification beyond immuno-oncology so that we can bring more treatment options and make a meaningful difference for people living with cancer. Learn more: https://bit.ly/41pTjvt """ "reactions_count" => 581 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-19 07:35:50" "deleted" => 1 ] [ "id" => 412655053 "company_id" => 140537 "urn" => "urn:li:activity:7140054817367867392" "followers" => null "date" => "1d" "description" => """ “We are a generation that broke stereotypes.” \n \n When oncology product specialist Nadia Estela Diaz Triste began her pharmacology studies in Mexico, STEM careers were discouraged for women in her native country. \n \n Today, she and our colleagues Roberta Cristina Nogueira Corigliano and Diana Zubiri are climbing new heights for women pursuing STEM careers in Latin America. Meet them and hear how they defy cultural and social barriers to fulfill their professional dreams. """ "reactions_count" => 107 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-19 07:35:50" "deleted" => 1 ] [ "id" => 412655054 "company_id" => 140537 "urn" => "urn:li:activity:7139720460786679808" "followers" => null "date" => "2d" "description" => """ We look forward to sharing the latest data on our BET inhibitor in patients with blood cancer today at #ASH23. \n \n This investigational asset represents our efforts to further enhance our industry-leading pipeline and ultimately provide more options for patients with unmet needs. \n \n Learn more about how we’re evaluating the effects of BET inhibitors in blood cancers: https://lnkd.in/gcC7pFu6 """ "reactions_count" => 487 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-19 07:35:50" "deleted" => 1 ] [ "id" => 412655055 "company_id" => 140537 "urn" => "urn:li:activity:7139015607852634112" "followers" => null "date" => "4d" "description" => "I was honored and humbled to be named Executive of the Year by the Intellectual Property Owners Education Foundation this week. As I accepted the award, some sage words from NBA legend Michael Jordan came to mind: “Talent wins games, but teamwork and intelligence win championships.” This award was a true testament to the work of my amazing, dedicated and passionate team at Bristol Myers Squibb. Congratulations to my fellow awardees Audrey Larson, Irwin Mark Jacobs and Prof. Cato Laurencin, true and awesome pioneers!" "reactions_count" => 512 "comments_count" => 87 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-19 07:35:50" "deleted" => 1 ] [ "id" => 412655056 "company_id" => 140537 "urn" => "urn:li:activity:7139014539060146176" "followers" => null "date" => "4d" "description" => "We look forward to joining the thousands of researchers, healthcare professionals, advocacy partners and industry peers coming together for the 65th American Society of Hematology Annual Meeting and Exposition. Learn more about our exciting new data from our hematologic pipeline and portfolio at #ASH23. https://bit.ly/3ThhOsz" "reactions_count" => 186 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-19 07:35:50" "deleted" => 1 ] [ "id" => 412655057 "company_id" => 140537 "urn" => "urn:li:activity:7138980758165049344" "followers" => null "date" => "4d" "description" => """ A hub for #LifeSciences innovation and home to many of our protein degradation discovery and development efforts, San Diego is the perfect location for #ASH23. \n \n We’re excited to present our latest advancements in #ProteinDegradation during the meeting, made possible through the leadership of our teams across the globe. \n \n Hear more from our San Diego site head, Neil Bence, and learn more about our unique approach to this innovative modality: https://lnkd.in/enavS7ex """ "reactions_count" => 147 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-19 07:35:50" "deleted" => 1 ] [ "id" => 412655058 "company_id" => 140537 "urn" => "urn:li:activity:7138938039342419968" "followers" => null "date" => "4d" "description" => "Our research expertise in targeted #proteindegradation fuels our continued commitment to advancing several assets in our pipeline to help meet the needs of more patients, alone or in combination with other therapies." "reactions_count" => 157 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-19 07:35:50" "deleted" => 1 ] [ "id" => 448812228 "company_id" => 140537 "urn" => "urn:li:activity:7153793183414382592" "followers" => null "date" => "9h" "description" => "At this year’s ASCO #GI24, we are presenting key data from our robust development program in gastrointestinal cancers. Our work across forms of esophageal and gastric cancer demonstrates our expertise and commitment to improving outcomes for patients with GI cancers." "reactions_count" => 156 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-12 18:24:34" "deleted" => 1 ] [ "id" => 448812229 "company_id" => 140537 "urn" => "urn:li:activity:7153420603247529985" "followers" => null "date" => "1d" "description" => """ World-class informatics and predictive sciences experts are embedded in our Washington state teams and they play a key role in delivering insights that help accelerate our industry-leading pipeline. \n \n Discover how our local teams unite to advance our pipeline: https://lnkd.in/eWf46B3m """ "reactions_count" => 188 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-12 18:24:34" "deleted" => 1 ] [ "id" => 448812230 "company_id" => 140537 "urn" => "urn:li:activity:7153125434782560256" "followers" => null "date" => "6d" "description" => """ In early 2023, when I took over as the Global Lead of our company's BMS Network of Women (B-NOW) People Business & Resource Group, menopause in the workplace was one of my priorities. With a small yet mighty diverse team, we collaborated with our established UK/Ireland team, launched global guidelines, shared resources, expanded access to training for managers, benefits for employees all while coinciding with World Menopause Day.\n \n Today, I'm honored to announce Bristol Myers Squibb's inclusion in the Harvard Business Review, recognizing our work on menopause awareness, our collaboration with policymakers in the UK & recognition in the US. This journey is a testament to the dedication of our team and our commitment to influencing menopause awareness, acceptance, and support for women in the workplace. Grateful for the opportunity to make a meaningful impact and excited about the continued work ahead! \n \n Kudos to the BMS team including Sundari Pai Luts, Carolyn Brehm, Colleen McDermott-Seiberlich, Lisa Macis. And thank you Bradley Schurman, Tamsen Fadal, Human Change, and Harvard Business Review for acknowledging our efforts. \n \n #WomenEmpowerment #MenopauseAwareness #HarvardBusinessReview #GlobalImpact #bms_employee """ "reactions_count" => 174 "comments_count" => 22 "reshared_post_author" => "Harvard Business Review" "reshared_post_author_url" => "https://www.linkedin.com/company/harvard-business-review" "reshared_post_author_headline" => null "reshared_post_description" => "Nearly two out of every five women reported experiencing menopause symptoms that interfered with their work performance or productivity each week and contributed to burnout." "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2024-02-12 18:24:34" "deleted" => 1 ] [ "id" => 448812231 "company_id" => 140537 "urn" => "urn:li:activity:7153052881242243073" "followers" => null "date" => "2d" "description" => """ I'm pleased to welcome Dr. Tania Small as Senior Vice President, Global Medical Affairs. Tania brings a wealth of experience as a pediatric hematologist and oncologist to our organization and has successfully led medical organizations in advancing access to Oncology, Rare Disease and Hematology patients globally. I look forward Tania’s leadership in expanding access to our medicines and driving impact for patients. \n \n #BMS_Employee """ "reactions_count" => 961 "comments_count" => 62 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-12 18:24:34" "deleted" => 1 ] [ "id" => 448812232 "company_id" => 140537 "urn" => "urn:li:activity:7152660837730586624" "followers" => null "date" => "3d" "description" => """ Mentoring Historically Black Colleges and Universities (HBCU) students through our Tomorrow’s Innovators program is one way our colleagues honor Martin Luther King Jr.’s legacy of giving back. \n \n On this #DayofService, hear Deidra Harper share why volunteering is especially meaningful on the “Black Organization for Leadership and Development (BOLD) Innovators" podcast hosted by Bryant Powell, M.B.A.: https://lnkd.in/eQpQ2be6 """ "reactions_count" => 128 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-12 18:24:34" "deleted" => 1 ] [ "id" => 448812233 "company_id" => 140537 "urn" => "urn:li:activity:7151351705362653184" "followers" => null "date" => "1w" "description" => "Before closing out #JPM24, I want to thank and recognize McKinsey & Company for the privilege to join a panel of several #celltherapy thought leaders to discuss the excellent progress in the field to date. The future for cell therapy is bright, and along with my fellow panelists, I agree the full healthcare ecosystem needs to work together to unlock the full potential of CAR T. #BMS_Employee" "reactions_count" => 371 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-12 18:24:34" "deleted" => 1 ] [ "id" => 448812234 "company_id" => 140537 "urn" => "urn:li:activity:7151248096142794752" "followers" => null "date" => "1w" "description" => """ Explore the latest data from the TRIDENT-1 study, evaluating activity and safety of a next-generation ROS1 tyrosine kinase inhibitor (TKI) in ROS1-fusion positive advanced #NSCLC, now published in the New England Journal of Medicine. \n \n This study included patients naïve to or pretreated with ROS1 TKI, with and without baseline brain metastases or ROS1 resistance mutations. \n \n Research drives our commitment to improve outcomes for people living with #lungcancer. Find the TRIDENT-1 primary manuscript from lead author Dr Alexander Drilon, MD, and other study investigators: https://bit.ly/3tO7RbS """ "reactions_count" => 497 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-12 18:24:34" "deleted" => 1 ] [ "id" => 448812235 "company_id" => 140537 "urn" => "urn:li:activity:7150908945878958080" "followers" => null "date" => "1w" "description" => """ Later today as part of #FierceJPMWeek, I look forward to sharing how at Bristol Myers Squibb, our strategic research framework is helping us meet a challenge felt across the industry – improving R&D productivity for the ultimate benefit of patients. Learn more: bit.ly/48Oa85S. \n \n Our focus on three key principles – harnessing causal human biology, matching therapeutic modality to molecular mechanism of action and focusing on a path to clinical proof-of-concept –will enable us to continue advancing transformative science for patients.\n \n If you’re attending #JPM24 or Fierce JPM Week, what have been your biggest takeaways for R&D so far?\n \n #BMS_Employee """ "reactions_count" => 192 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-12 18:24:34" "deleted" => 1 ] [ "id" => 448812236 "company_id" => 140537 "urn" => "urn:li:activity:7150878670864228353" "followers" => null "date" => "1w" "description" => """ Our CEO Chris Boerner shares what’s ahead for BMS, from our exciting pipeline, innovative science and increasingly diversified portfolio to our recent business development activity. Watch the interview with CNBC’s Jim Cramer: https://cnb.cx/3RRzc58\n \n More from #JPM24 and cautionary statements: https://bit.ly/41QY1T4 """ "reactions_count" => 1214 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-12 18:24:34" "deleted" => 1 ] [ "id" => 448812237 "company_id" => 140537 "urn" => "urn:li:activity:7150530761677254656" "followers" => null "date" => "1w" "description" => "I'm excited to be in San Francisco for this year's JPMorgan Healthcare Conference, where Chris Boerner shared how we are writing the next chapter for Bristol Myers Squibb. With great science and a talented and passionate workforce, we are relentlessly focused on transforming even more patients' lives throughout this decade and beyond. #bmsemployee #jpm2024" "reactions_count" => 638 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-12 18:24:34" "deleted" => 1 ] [ "id" => 469028924 "company_id" => 140537 "urn" => "urn:li:activity:7162445686003724288" "followers" => null "date" => "1d" "description" => """ Seattle-based scientists Ruth Salmon and Kimberly Harrington discovered that their mentor-mentee relationship contributed to their team’s success in discovering, developing and delivering cell therapies to patients around the world. \n \n In recognition of the International Day of Women and Girls in Science, Ruth shares her experience with mentorship at BMS and how it benefits her just as much as Kim, her mentee. #IDWGS #February11 #WomenInScience \n \n Learn more about the importance of female leadership in STEM: https://lnkd.in/ejmp3eEA """ "reactions_count" => 197 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-13 13:55:47" "deleted" => 1 ] [ "id" => 469028925 "company_id" => 140537 "urn" => "urn:li:activity:7161855560877862912" "followers" => null "date" => "2d" "description" => "In recognition of International Day of Women and Girls in Science, I share my thoughts on what it means to be a woman in science. Together, across STEM disciplines, we can uplift women and girls and encourage them to pursue science careers. There’s nothing that brings me more joy than to witness a young mind’s curiosity and passion for science. #IDWGS #WomenInScience #February11" "reactions_count" => 320 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-13 13:55:47" "deleted" => 1 ] [ "id" => 469028926 "company_id" => 140537 "urn" => "urn:li:activity:7161795937504374784" "followers" => null "date" => "2d" "description" => "Happy Lunar New Year to our colleagues and communities we serve around the world! Wishing you prosperity, good health and endless possibilities in the Year of the Dragon." "reactions_count" => 700 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-13 13:55:47" "deleted" => 1 ] [ "id" => 469028927 "company_id" => 140537 "urn" => "urn:li:activity:7161404210003992576" "followers" => null "date" => "4d" "description" => "Our culture of inclusion and diversity helps our teams advance their research by tapping the diverse knowledge and experiences of each individual. This #IDWGS, hear perspectives from our female leaders who share a passion for bringing researchers with different backgrounds and scientific expertise together. #February11" "reactions_count" => 406 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-13 13:55:47" "deleted" => 1 ] [ "id" => 469028928 "company_id" => 140537 "urn" => "urn:li:activity:7160376998467354624" "followers" => null "date" => "6d" "description" => "“The legacy Amadou Diarra leaves at BMS is one to truly inspire generations to come.” Amadou’s groundbreaking work for HIV/AIDS patients in Africa and leading our Global Policy, Patient Advocacy & Government Affairs teams, fully embodies this year’s #BlackHistoryMonth “BOLD Legacy” theme. Our Black Organization for Leadership and Development (BOLD)’s executive sponsor Sandra Leung and head of Corporate Affairs, Cari Almo Gallman, honored Amadou’s storied career and lasting impact ahead of his upcoming retirement." "reactions_count" => 607 "comments_count" => 20 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-13 13:55:47" "deleted" => 1 ] [ "id" => 469028929 "company_id" => 140537 "urn" => "urn:li:activity:7160313970694762497" "followers" => null "date" => "1w" "description" => "We understand the future of our employees, communities, planet and our business are inextricably linked. Being recognized as a leader by JUST 100 reinforces our focused commitment to operating responsibly and sustainably to best serve our patients." "reactions_count" => 179 "comments_count" => null "reshared_post_author" => "Cari Almo Gallman" "reshared_post_author_url" => "https://www.linkedin.com/in/cari-almo-gallman-05015113" "reshared_post_author_headline" => "Executive Vice President, Corporate Affairs, Member Leadership Team" "reshared_post_description" => """ I am proud that Bristol Myers Squibb has been named to the annual JUST 100 list by CNBC and JUST Capital, reinforcing our focus on community impact, employee well-being and ethical practices to best serve our patients. This achievement reflects our collective passion for excellence in what we do – not only by bringing forward innovative medicines, but also by making a positive impact on society.\n \n Congratulations to our incredible team members for this recognition of their dedication to making a difference. Together we are working toward a better, healthier world for generations to come.\n \n #BMS_employee #innovation #equity """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2024-03-13 13:55:47" "deleted" => 1 ] [ "id" => 469028930 "company_id" => 140537 "urn" => "urn:li:activity:7160262484333895681" "followers" => null "date" => "1w" "description" => """ Our San Diego scientists recently hosted the Fleet Science Center's Better Education for Women in Science and Engineering (BE WiSE) group, sharing their personal experiences with #STEM and leading these young women through hands-on activities. It’s community programs like #BEWiSE – and the dedication of Bristol Myers Squibb’s People and Business Resource Groups (PBRGs) like our Network of Women (B-NOW) – that enable our teams to expose local students to STEM, empower the next generation of #WomenInScience and fuel a diverse talent pipeline to advance our collective mission to improve outcomes for patients across the globe. \n \n Discover how my local teams are impacting STEM education in California and beyond: https://lnkd.in/gK-Fgy7R\n \n #BMS_Employee """ "reactions_count" => 148 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-13 13:55:47" "deleted" => 1 ] [ "id" => 469028931 "company_id" => 140537 "urn" => "urn:li:activity:7159968893430603776" "followers" => null "date" => "1w" "description" => """ On #WorldCancerDay, we recognize the scientists who play a critical role in #CancerResearch working to #CloseTheCareGap. Backed by a research framework that focuses on causal human biology, we match therapeutic modality to molecular mechanism of action in our efforts to discover and develop transformative cancer treatments.\n \n Explore our approach to cancer research: https://bit.ly/42m1yJF """ "reactions_count" => 722 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-13 13:55:47" "deleted" => 1 ] [ "id" => 469028932 "company_id" => 140537 "urn" => "urn:li:activity:7159938675898798081" "followers" => null "date" => "1w" "description" => """ Chris Boerner, Chief Executive Officer, shares our desire for a cancer-free world without systemic barriers to potentially life-changing cancer care.\n \n We are dedicated to leveraging our expertise and working with passionate organizations like the Union for International Cancer Control (UICC) to improve outcomes for all patients. Learn how you can help #CloseTheCareGap this #WorldCancerDay. """ "reactions_count" => 560 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-13 13:55:47" "deleted" => 1 ] [ "id" => 505325024 "company_id" => 140537 "urn" => "urn:li:activity:7173301730359635969" "followers" => null "date" => "1d" "description" => "It takes passion and curiosity from experts, like our Cambridge research leader, Mariann Micsinai-Balan, to unlock the transformative power of data. Mariann and many others are using robust datasets in combination with their deep biological knowledge to inform decisions that advance the development of novel therapies. #WomenInScience" "reactions_count" => 116 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-24 20:11:40" "deleted" => 1 ] [ "id" => 505325025 "company_id" => 140537 "urn" => "urn:li:activity:7172984650208792578" "followers" => null "date" => "1d" "description" => "Our team is focused on researching oral options for #psoriasis with the hope of helping those who suffer from this disease. #AAD2024" "reactions_count" => 200 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-24 20:11:40" "deleted" => 1 ] [ "id" => 505325026 "company_id" => 140537 "urn" => "urn:li:activity:7172939340401086464" "followers" => null "date" => "2d" "description" => """ “If I could offer advice to women at any stage in their career it would be: stay curious!” \n \n This #WomensHistoryMonth, we're excited to share SVP Annette Zoe Powers was named to Reuters' list of 20 Trailblazing Women in Pharma for her leadership in expanding access for patients, leading our International Markets Team and helping us reach our ESG goals. Join us in celebrating her recognition—and her wisdom for the next generation of female leaders. Learn more: https://bit.ly/4ciOIjU """ "reactions_count" => 425 "comments_count" => 31 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-24 20:11:40" "deleted" => 1 ] [ "id" => 505325027 "company_id" => 140537 "urn" => "urn:li:activity:7172229664655003648" "followers" => null "date" => "3d" "description" => """ We look forward to joining the American Academy of Dermatology’s Annual Meeting and share more about our dermatology pipeline and ongoing research. Stop by booth #2130 at #AAD2024 to learn more about our efforts to advance dermatology. \n #DermatologyResearch #SkinHealth """ "reactions_count" => 146 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-24 20:11:40" "deleted" => 1 ] [ "id" => 505325028 "company_id" => 140537 "urn" => "urn:li:activity:7171912574916112384" "followers" => null "date" => "4d" "description" => """ Deciding on a disease management plan for #psoriasis is personal. Patients have different preferences and needs, and some may prioritize a treatment approach that best fits their lifestyle. \n \n Learn more about psoriasis and the various types of treatments. #AAD2024 """ "reactions_count" => 241 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-24 20:11:40" "deleted" => 1 ] [ "id" => 505325029 "company_id" => 140537 "urn" => "urn:li:activity:7171867449460527105" "followers" => null "date" => "4d" "description" => "Everyone can #InspireInclusion. Join our colleagues around the world who are creating a more inclusive workplace with equal opportunities for women, led by the BMS Network of Women (B-NOW). #IWD2024" "reactions_count" => 868 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-24 20:11:40" "deleted" => 1 ] [ "id" => 505325030 "company_id" => 140537 "urn" => "urn:li:activity:7170780187473731587" "followers" => null "date" => "1w" "description" => """ This #MyelomaActionMonth we are recognizing the importance of scientific progress to advance treatment options for #multiplemyeloma. \n \n We are continuing to invest in innovative treatment modalities and identifying effective research approaches so that we can work towards progress for patients around the world. \n \n Learn more about how we’re committed to helping patients with this disease: https://bit.ly/3T30DJw """ "reactions_count" => 283 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-24 20:11:40" "deleted" => 1 ] [ "id" => 505325031 "company_id" => 140537 "urn" => "urn:li:activity:7170458318325301248" "followers" => null "date" => "1w" "description" => """ As executive sponsor for our PRIDE Alliance employee resource group, I'm proud to support Bristol Myers Squibb's efforts to empower LGBTQ+ inclusion, awareness and engagement across the organization. My colleague Paul Shay penned this excellent perspective on standardizing the collection of sexual orientation, gender identity and intersex status (SOGIIS) patient demographic data for clinical trials. This is something that BMS is already implementing across therapeutic areas for adults in the U.S. I am hopeful this piece sparks some much-needed industry dialogue to advance equitable health for LGBTQ+ patients.\n \n #BMS_employee #diversityinclinicaltrials #LGBTQhealth """ "reactions_count" => 147 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-24 20:11:40" "deleted" => 1 ] [ "id" => 505325032 "company_id" => 140537 "urn" => "urn:li:activity:7169441377259352065" "followers" => null "date" => "1w" "description" => """ It was great spending part of the day today sharing how Bristol Myers Squibb is using AI to accelerate the discovery, design and development of new medicines at the #bioasia2024 conference in Hyderabad, India. \n \n I also had the chance to cut the ribbon at our new office in Hyderabad. Having gone from an idea to almost 1,000 people in less than a year, BMS has the fastest growing innovation center in the history of State of Telagana. """ "reactions_count" => 477 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-24 20:11:40" "deleted" => 1 ] [ "id" => 551739806 "company_id" => 140537 "urn" => "urn:li:activity:7188174732553322499" "followers" => null "date" => "2d" "description" => """ At every step of our environmental sustainability journey, we're searching for ways to minimize our packaging footprint, transition to more reusable and/or recyclable solutions, and advance energy efficiency. This #EarthDay, we're honored to share that we've received the ENERGY STAR Partner of the Year award, which recognizes our commitment to energy management and our ongoing efforts toward a #CleanEnergyFuture. \n \n Learn more about our progress to advance the health and well-being of our patients and the planet in our 2023 ESG Report: https://lnkd.in/ePxUhd_6 """ "reactions_count" => 166 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-22 05:32:14" "deleted" => 1 ] [ "id" => 551739808 "company_id" => 140537 "urn" => "urn:li:activity:7188130247471509504" "followers" => null "date" => "2d" "description" => "We are pleased to announce a worldwide capacity reservation and supply agreement with Cellares for the manufacture of CAR T cell therapies, giving us access to a next-generation fully automated, end-to-end cell therapy manufacturing platform. As part of the agreement, Cellares will optimize and automate select BMS CAR T cell therapies onto its manufacturing platform, the Cell Shuttle. We look forward to our continued work with Cellares and to the promise this agreement will bring for patients benefiting from CAR T therapies. https://bit.ly/446Wfyx" "reactions_count" => 968 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-22 05:32:14" "deleted" => 1 ] [ "id" => 551739810 "company_id" => 140537 "urn" => "urn:li:activity:7187072518963310592" "followers" => null "date" => "5d" "description" => """ Acute myeloid #leukemia (AML) is one of the most common types of leukemia in adults, however, common symptoms make it difficult to diagnose. \n \n At BMS, with support from our partners, Know AML, Acute Leukemia Advocates Network and others, we work tirelessly towards our goal of broadening the treatment landscape and remain committed to identifying innovative treatments and working toward the potential for improved outcomes for every patient living with this difficult-to-treat blood cancer. \n \n As we approach AML Awareness Day, learn more about AML: https://bit.ly/3Uyb4qR """ "reactions_count" => 390 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-22 05:32:14" "deleted" => 1 ] [ "id" => 551739811 "company_id" => 140537 "urn" => "urn:li:activity:7186687657391869952" "followers" => null "date" => "6d" "description" => """ Thank you to the entire #REPharma2024 team, especially @CharlotteBastiaanse, for welcoming me to Reuters Pharma earlier this week! It was an amazing opportunity to connect with colleagues old and new, and to engage with leaders collectively focused on creating a better environment for patients and for innovation. \n I am a firm believer that science is most relevant when it improves patient lives through access to new medicines. Every patient has the right to get the medicine they need and I am proud to work for an industry that supports this. \n   \n At @BMS, we understand governments’ affordability pressures. But measures to make healthcare more sustainable should be carefully considered to balance competing policy priorities. We believe that properly designed policies can reward innovation, drive value and improve patients’ access to medicines. Together, through constructive dialogue and collaboration, we can work towards solutions for patients, but the starting point must be a common recognition of the value of innovation. Read more on our BMS site dedicated to these important conversations: https://bit.ly/48rgPdB. """ "reactions_count" => 157 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-22 05:32:14" "deleted" => 1 ] [ "id" => 551739812 "company_id" => 140537 "urn" => "urn:li:activity:7186433065278152706" "followers" => null "date" => "1w" "description" => """ Bristol Myers Squibb is proud to be the lead sponsor and collaborate with Coqual on the recently released research study, More than a Monolith: The Advancement of Hispanic and Latino/a Talent. This research shines a light on the persistent challenges faced by Hispanic and Latino/a professionals in the workplace in the United States. \n \n At BMS, we understand that inclusion and diversity are essential elements of our mission and vision. Our partnership with Coqual is evidence of our firm belief that by joining forces, we can bring about significant change and establish a more just future for everyone.\n \n Thank you to Paula Glickenhaus, Nataly Manjarrez Orduño, PhD and Lorena Kuri for representing BMS at last week’s launch event. \n \n I'm incredibly proud to be part of an organization that prioritizes inclusion, diversity, and health equity in everything we do. Let's continue championing these values and leading by example in our industry and beyond. To learn more about our inclusion and diversity progress and aspirational goals, visit ESG.bms.com. \n \n Read about this research here: https://lnkd.in/gAx9TBXi. """ "reactions_count" => 194 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-22 05:32:14" "deleted" => 1 ] [ "id" => 551739813 "company_id" => 140537 "urn" => "urn:li:activity:7186353406863646721" "followers" => null "date" => "1w" "description" => """ As part of our commitment to price transparency, we recently shared in our 2023 ESG Report, that approximately 46 cents of each dollar of our company’s gross sales went back into the healthcare system in the form of discounts, rebates, price concessions and fees in the US. Of this total, approximately half went to Medicare and Medicaid, and 15% went to Veteran Affairs and the U.S. Department of Defense. For more information, please see our 2023 ESG Report at https://www.esg.bms.com.\n \n #BMS_Employee """ "reactions_count" => 147 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-22 05:32:14" "deleted" => 1 ] [ "id" => 551739814 "company_id" => 140537 "urn" => "urn:li:activity:7184253555778691073" "followers" => null "date" => "1w" "description" => """ The story of CAR T #CellTherapy embodies the challenges, perseverance and ingenuity that leads to groundbreaking medical breakthroughs. Hear our scientists reflect on the ways this modality has transformed outcomes for patients today and why it’s only the beginning. \n \n See how CAR T cell therapy research went from hypothesis to reality: https://lnkd.in/evznE8Hp """ "reactions_count" => 921 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-22 05:32:14" "deleted" => 1 ] [ "id" => 551739815 "company_id" => 140537 "urn" => "urn:li:activity:7183886481885679616" "followers" => null "date" => "2w" "description" => """ Our new, state-of-the-art facility will enable us to bring together several of our R&D teams in San Diego under one roof. \n \n With a planned 425,000 square feet of lab and office space and the latest technologies, our new facility is designed to give our scientists the ability to discover and develop the medicines of tomorrow, while also reducing our impact on the environment. """ "reactions_count" => 1083 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-22 05:32:14" "deleted" => 1 ] [ "id" => 551739816 "company_id" => 140537 "urn" => "urn:li:activity:7183845834969485312" "followers" => null "date" => "2w" "description" => """ Yesterday I had the pleasure of co-hosting a panel discussion alongside Michelle Calope Patricia Mae Doykos, PhD Patricia Cornet, MA Nnenna Kalu Florencia Davel Christian Furler O'Brien Jagtar Dhanda Sherell McDearmon and Natanya Candalerio at Bristol Myers Squibb on the topic of “Igniting Commercialization Impact through Health Equity.” To say that I was incredibly inspired by this conversation with my global colleagues is an understatement.\n \n We discussed at length the health disparities facing underrepresented communities and the critical role of embedding strategies within our commercialization processes to close these gaps in care and access across the diseases we treat.\n \n This conversation was a reminder of why BMS is such a special place. I am proud to work for an organization that views health equity as a priority to be threaded through every facet of our business and I feel privileged to work with such highly motivated leaders to bring our scientific innovations to patients in need—no matter where they might be.\n \n #BMS_Employee #healthequity #patientcare """ "reactions_count" => 251 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-22 05:32:14" "deleted" => 1 ] [ "id" => 551739817 "company_id" => 140537 "urn" => "urn:li:activity:7183489140955467776" "followers" => null "date" => "2w" "description" => """ As the only company with two approved #CARTCellTherapy treatments with two distinct targets, we’re leading the charge to bring the promise of this technology to more patients living with serious blood cancers. \n \n CAR T cell therapy remains a key area of focus for our company as we celebrate a recent FDA approval, expanding one of our treatment options to more patients in need. https://bit.ly/49xuhgp """ "reactions_count" => 911 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-22 05:32:14" "deleted" => 1 ] [ "id" => 578852703 "company_id" => 140537 "urn" => "urn:li:activity:7198772939205341187" "followers" => null "date" => "10h" "description" => "Our BMS People and Business Resources Groups (PBRGs) are critical to advancing our inclusion and diversity strategy with key stakeholders internally and externally. We enjoyed having members of our eight PBRGs in Washington, D.C. last week to meet with Congressional offices and highlight the work they are doing to advance health equity, educational support programs and inclusive workforce initiatives. Thanks to the representatives from B-NOW, BOLD, CLIMB, DAWN, OLA, PAN, PRIDE Alliance and VCN who shared their perspectives on Capitol Hill. #bms_employee" "reactions_count" => 138 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:28:46" "deleted" => 1 ] [ "id" => 578852704 "company_id" => 140537 "urn" => "urn:li:activity:7198666133325922304" "followers" => null "date" => "16h" "description" => """ Live Your PosSCZible is our national initiative focused on elevating the voices of those with #schizophrenia and their care partners to drive impactful conversations about the aspirations of the community. \n \n While the symptoms of schizophrenia can have a significant impact on daily functioning and overall quality of life, with appropriately managed symptoms and the right support, people with schizophrenia can achieve their ambitions.\n \n Learn more about Live Your PosSCZible: https://bit.ly/3V7KGEd """ "reactions_count" => 68 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:28:46" "deleted" => 1 ] [ "id" => 578852705 "company_id" => 140537 "urn" => "urn:li:activity:7198336690476695552" "followers" => null "date" => "1d" "description" => """ Bruce Ellsworth, PhD, and Aryeh Fischer, MD, discuss drug discovery and potential new advances in treating #PulmonaryFibrosis in this Q&A. \n \n We understand the challenges faced by individuals living with pulmonary fibrosis, as breathlessness can greatly impact their daily lives. That's why we remain committed to pursuing pathbreaking science that may help patients in need. Read the full article here: https://bit.ly/3ywHlFS\n \n #ATS2024 """ "reactions_count" => 127 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:28:46" "deleted" => 1 ] [ "id" => 578852706 "company_id" => 140537 "urn" => "urn:li:activity:7198306621125447680" "followers" => null "date" => "1d" "description" => """ In order to expand the boundaries of science, we must prioritize enrolling clinical trial populations that are more reflective of broader patient populations. \n \n Discover how we're supporting equitable health outcomes for all and making trials more accessible to underrepresented groups: https://bit.ly/3UJ2ynD \n \n #ClinicalTrialsDay #HealthEquity """ "reactions_count" => 190 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:28:46" "deleted" => 1 ] [ "id" => 578852707 "company_id" => 140537 "urn" => "urn:li:activity:7197959242039877633" "followers" => null "date" => "2d" "description" => "We’re committed to developing transformational therapies that meet the needs of patients living with inflammatory bowel disease (IBD). Our goal is to provide potential treatments that fit into patients’ lives and routines to alleviate the burden and demanding nature of IBD. #WorldIBDDay2024" "reactions_count" => 366 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:28:46" "deleted" => 1 ] [ "id" => 578852708 "company_id" => 140537 "urn" => "urn:li:activity:7197317063235842048" "followers" => null "date" => "4d" "description" => """ With our reentry into psychiatry, #MentalHealthMonth takes on a new meaning for us this year. \n \n We’re committed to addressing the needs of people living with psychiatric conditions like #schizophrenia.\n \n Learn more: https://bit.ly/4apccRZ """ "reactions_count" => 167 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:28:46" "deleted" => 1 ] [ "id" => 578852709 "company_id" => 140537 "urn" => "urn:li:activity:7197285668576722945" "followers" => null "date" => "4d" "description" => "The IDEA Pharma's Pharmaceutical Innovation & Invention Index recognition highlights our ability to create new products for patients that address unmet needs and successfully bring them to market." "reactions_count" => 201 "comments_count" => 1 "reshared_post_author" => "IDEA Pharma \| From R&D to RxD" "reshared_post_author_url" => "https://uk.linkedin.com/company/idea-pharma" "reshared_post_author_headline" => null "reshared_post_description" => """ A big year for Bristol Myers Squibb who secured a prominent position in both innovation and invention, maintaining its 5th place in innovation while ascending three places to claim 4th place for invention.\n \n BMS experienced a substantial increase in net income despite a minimal decrease in R&D spend in the last year. Additionally, BMS boasted an impressive pipeline-to-portfolio ratio of nearly 400%, showcasing its continued dedication to bringing new treatments to patients.\n \n In 2023, BMS achieved several milestones, including 11 approvals in the US, EU, and Japan, 10 Investigational New Drug (IND) applications, and 9 positive readouts in registration and proof-of-concept studies. Notably, the company doubled the number of assets in or entering the registrational stage, reaching a total of 12. The company had over 30 assets in development and the potential for over 40 additional Life Cycle Management (LCM) opportunities across New Molecular Entities (NME) and approved products.\n \n See the full analysis here https://lnkd.in/eM35eRGE\n \n #pharmaceutical\n #innovation\n #PIII2024 """ "reshared_post_followers" => null "reshared_post_date" => "4d" "last_updated" => "2024-06-08 20:28:46" "deleted" => 1 ] [ "id" => 578852710 "company_id" => 140537 "urn" => "urn:li:activity:7197242037018984450" "followers" => null "date" => "5d" "description" => """ At Bristol Myers Squibb, we’re continuing to build upon our legacy of bringing novel cell therapies to market and driving advancements for additional personalized treatments for patients with unmet needs. Our latest accelerated FDA approval of a #CARTcelltherapy for relapsed or refractory (R/R) follicular lymphoma (FL) provides patients a new option for this serious blood cancer. This advancement reaffirms our commitment to delivering innovative therapies that hold potential for improved patient outcomes in challenging-to-treat diseases. Learn more about this FDA approval: https://lnkd.in/eekNVvDp \n \n #BMS_employee """ "reactions_count" => 1089 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:28:46" "deleted" => 1 ] [ "id" => 578852711 "company_id" => 140537 "urn" => "urn:li:activity:7197219330508341252" "followers" => null "date" => "4d" "description" => """ Our pioneering research on the tyrosine kinase 2 (TYK2) pathway aims to change how scientists tackle the challenge of immune-mediated diseases like #psoriasis.\n \n We are committed to helping patients prevail over serious immune-mediated diseases, such as psoriasis. Learn more about our TYK2 research and its role in immunology. \n \n #EADVSymposium """ "reactions_count" => 470 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:28:46" "deleted" => 1 ] [ "id" => 578852712 "company_id" => 140537 "urn" => "urn:li:activity:7196884647463526400" "followers" => null "date" => "5d" "description" => """ Research drives our commitment to improve outcomes for people living with #lungcancer. Find the primary manuscript from the phase 3 CheckMate 77T study published in the NEJM (NEJM Group) from lead author Dr. Tina Cascone, senior author Dr. Mariano Provencio, and co-investigators. Efficacy, safety, surgical outcomes, and HRQoL are comprehensively reported for this perioperative immunotherapy-based treatment in patients with resectable non-small cell lung cancer. \n \n Find the full manuscript here: https://bit.ly/4ajAblz #LCSM """ "reactions_count" => 285 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-08 20:28:46" "deleted" => 1 ] [ "id" => 599834450 "company_id" => 140537 "urn" => "urn:li:activity:7203209226242965504" "followers" => null "date" => "29m" "description" => """ Perioperative #IO based therapy has shown benefits in patients with resectable stages II-III non-metastatic #NSCLC, with results from CheckMate -77T recently being published in the New England Journal of Medicine. \n \n At #ASCO24 Dr Tina Cascone will present an exploratory analysis of this regimen in patients with resectable stage III N2 and non-N2 NSCLC, a subgroup with high unmet need. \n \n Discover why we are committed to improving outcomes for all patients living with #lungcancer. https://bit.ly/3VoHCng """ "reactions_count" => 18 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 01:20:19" "deleted" => 1 ] [ "id" => 599834451 "company_id" => 140537 "urn" => "urn:li:activity:7203017560970199041" "followers" => null "date" => "13h" "description" => "Today at #ASCO24, hear Dr Jonathan Spicer present a four-year survival update from CheckMate -816 of neoadjuvant immunotherapy + chemotherapy in patients with resectable non-metastatic #NSCLC in room S406 at 4:30 pm CDT. #LCSM https://bit.ly/4aIG6AT" "reactions_count" => 223 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 01:20:19" "deleted" => 1 ] [ "id" => 599834452 "company_id" => 140537 "urn" => "urn:li:activity:7202700469163409408" "followers" => null "date" => "1d" "description" => "We are excited to participate in the ASCO Annual Meeting and showcase our advancements in Oncology, Hematology, and Cell Therapy. Visit booth #19061 at #ASCO24 to learn more about our pipeline designed for the future and efforts to drive innovation. Immerse yourself in a Virtual Reality experience on CAR T Manufacturing and CELMoD Cell Therapy edutainment. #Oncology #Hematology #CellTherapy" "reactions_count" => 437 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 01:20:19" "deleted" => 1 ] [ "id" => 599834453 "company_id" => 140537 "urn" => "urn:li:activity:7202402661164302337" "followers" => null "date" => "2d" "description" => """ Join us in Chicago on June 2 for the 5th Annual Conquering Veteran Cancer, Together event where Adam Lenkowsky, Marty Whalen, Catharine Grimes, MBA, Samit Hirawat (he/him), Robert A. McDonald, Manali I. Patel, Lucio N. Gordan, MD, Skip Burris, MD and Michael Kelley will join forces with Conquer Cancer, the ASCO Foundation to focus on Supporting Our Heroes by improving the continuity of care for veteran patients with cancer through improved engagement between the VA, Academic & Community Practice Partners and Patient Caregivers.\n \n Click here to register: https://bit.ly/3V5kSaP """ "reactions_count" => 120 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 01:20:19" "deleted" => 1 ] [ "id" => 599834454 "company_id" => 140537 "urn" => "urn:li:activity:7202388644681187332" "followers" => null "date" => "3d" "description" => """ As I head to #ASCO and look forward to learning about the tremendous strides we’ve made in cancer research this year, I’m also reflecting on the immeasurable impact #oncologists have every day. They contribute to both advancing science and providing hope for patients. \n \n I put pen to paper to extend this note of gratitude to all oncologists for their relentless pursuit in the fight against cancer. \n \n #BMS_Employee """ "reactions_count" => 199 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 01:20:19" "deleted" => 1 ] [ "id" => 599834455 "company_id" => 140537 "urn" => "urn:li:activity:7202375832521031681" "followers" => null "date" => "2d" "description" => "The latest FDA approval marks the fourth indication for our personalized therapy option, treating relapsed or refractory patients across a broader array of lymphomas who often cycle through periods of remission and relapse. Learn more about our scientific innovation and commitment to patients. https://bit.ly/3X5ngRo" "reactions_count" => 150 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 01:20:19" "deleted" => 1 ] [ "id" => 599834456 "company_id" => 140537 "urn" => "urn:li:activity:7202346575463923712" "followers" => null "date" => "2d" "description" => """ We are reflecting on the past decade of innovation in oncology, and on the scientific revelations that have helped bring about progress for the #cancer community. The goal of our transformational research is to give patients the hope of long-term survival.\n \n Read our take on what the past decade has meant for cancer research, and what opportunities are ahead of us. https://lnkd.in/ea-KYREe """ "reactions_count" => 97 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 01:20:19" "deleted" => 1 ] [ "id" => 599834457 "company_id" => 140537 "urn" => "urn:li:activity:7202307858586107905" "followers" => null "date" => "2d" "description" => """ "Together we can create an environment where every individual feels valued, respected, and empowered to unlock their inner dragon."\n \n See memorable moments from our lively #AANHPIHeritageMonth keynote with Pan Asian Network (PAN) Global Lead Jennifer F. Rasing and Asian & Pacific Islander American Health Forum CEO Juliet K. Choi, centered on expanding access to healthcare and opportunities for AANHPI communities. Visit bms.com to learn how we foster inclusion through our commitment to health equity and our colleagues’ professional growth. """ "reactions_count" => 327 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 01:20:19" "deleted" => 1 ] [ "id" => 599834458 "company_id" => 140537 "urn" => "urn:li:activity:7202042414490927104" "followers" => null "date" => "4d" "description" => """ Just one week after the announcement of ASPIRE, our Bristol Myers Squibb roadmap to expanding access in lower- and middle-income countries (LMICs), I had the opportunity to meet with key stakeholders in Geneva during World Health Assembly week to further discuss how BMS is addressing cancer care disparities around the world. \n \n I’m particularly excited about our partnership with the Access to Oncology Medicines (ATOM) Coalition, a multi-stakeholder collaboration spearheaded by the Union for International Cancer Control (UICC), as we continue to strive towards making a meaningful difference in the fight against cancer. \n \n Thank you Dr Cary Adams, Amy Israel, and Melissa Rendler-Garcia for your efforts, and I look forward to the meaningful work we’ll do together. You can read more about the work ATOM is doing here: https://lnkd.in/eNXkG_Yu.\n \n And a big thank you to my colleagues Estelle Vester-Blokland, Sara Martin, Ioana Enache and Vibhooti Ashar – thankful for such an impactful team! \n \n #BMSEmployee #HealthEquity #Collaboration #WHA77 """ "reactions_count" => 268 "comments_count" => 15 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 01:20:19" "deleted" => 1 ] [ "id" => 599834459 "company_id" => 140537 "urn" => "urn:li:activity:7201984335858610176" "followers" => null "date" => "3d" "description" => """ The FDA has approved our #CARTcelltherapy for mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma, offering patients a new treatment option for this disease. \n \n As a result of this approval, our innovative CAR T cell therapy is now able to treat patients across a broader array of B-cell malignancies, addressing significant unmet need. \n \n To those who participated in advancing our cell therapy portfolio to bring our personalized treatment to these patients affected by this disease, thank you for contributing to this monumental milestone. https://bit.ly/4bTUmbH """ "reactions_count" => 3249 "comments_count" => 31 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 01:20:19" "deleted" => 1 ] [ "id" => 650352238 "company_id" => 140537 "urn" => "urn:li:activity:7219755374055170048" "followers" => null "date" => "2d" "description" => """ We’ve achieved major milestones in environmental sustainability, reducing our impacts on the planet and demonstrating progress against our ESG goals: \n \n ✔️ Validation by the Science Based Targets initiative (SBTi) for our near-term and net-zero environment targets\n \n ✔️ Honored with the 2024 ENERGY STAR Partner of the Year: Sustained Excellence award \n \n ✔️ Earned USGBC’s LEED Platinum certification for our state-of-the-art research facility in Cambridge, Massachusetts\n \n ✔️ Named to Dow Jones Sustainability Index North America\n \n Learn more about our progress: bit.ly/3SiXCFx\n \n #Sustainability #EnvironmentalStewardship #SBTi """ "reactions_count" => 123 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-16 02:28:36" "deleted" => 1 ] [ "id" => 650352239 "company_id" => 140537 "urn" => "urn:li:activity:7219392280686641152" "followers" => null "date" => "3d" "description" => """ We’re honored to be recognized as one of the 2024 Best Places to Work for Disability Inclusion, earning 100 on the Disability:IN Disability Equality Index® (DEI). This #DisabilityPrideMonth, learn how our Disability Advancement Workplace Network (DAWN) People Business and Resource Group fosters our culture of inclusion where our colleagues with disabilities are valued and respected: https://bit.ly/4d5yY37 \n #DEI24 """ "reactions_count" => 417 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-16 02:28:36" "deleted" => 1 ] [ "id" => 650352240 "company_id" => 140537 "urn" => "urn:li:activity:7212553201051467776" "followers" => null "date" => "3w" "description" => """ As PRIDE month comes to a close, I’d like to reflect on the incredible sense of community and support I witnessed throughout June. Our journey began with a powerful flag-raising ceremony that set the tone for a month of unity and inclusivity. We marched with joy and solidarity in the PRIDE parade, showcasing our unwavering support for LGBTQ+ rights. Our patient panel provided invaluable insights and fostered deep, meaningful conversations about the experiences and challenges faced by LGBTQ+ individuals. And finally, our delightful Drag Queen Charity Bingo event brought us all together for an afternoon of fun, laughter, and fundraising for vital LGBTQ+ charities. None of this would be possible without the hard work of our Bristol Myers Squibb PRIDE Alliance team, who turns our values into real-life actions that make an impact. Thank you to everyone who participated, supported, and celebrated with us this month. Together, we continue to build a more inclusive and compassionate community, both within our organization and beyond. \n \n #BMSemployee """ "reactions_count" => 325 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-16 02:28:36" "deleted" => 1 ] [ "id" => 650352241 "company_id" => 140537 "urn" => "urn:li:activity:7212538952539406336" "followers" => null "date" => "3w" "description" => """ We have been recognized by S&P Global’s Dow Jones Sustainability Index North America as a corporate sustainability industry leader. \n \n This accomplishment reflects our commitment to continuously improving our environmental, social and governance practices to creating a sustainable around the world. \n \n Learn more about our commitment to operating responsibly: https://bit.ly/3W1c5Ip\n \n #DJSI #sustainability #ESG """ "reactions_count" => 154 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-16 02:28:36" "deleted" => 1 ] [ "id" => 650352242 "company_id" => 140537 "urn" => "urn:li:activity:7212470228084031489" "followers" => null "date" => "3w" "description" => "Sixty of our colleagues in Australia, China, Japan, Korea, Taiwan and the United States begin their #C2C4C Japan fundraising this month, culminating in an epic bike ride this October. Learn about their journey as they raise funds for CancerNet Japan to advance cancer research for patients. See more: https://bit.ly/4cjOw3o" "reactions_count" => 184 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-16 02:28:36" "deleted" => 1 ] [ "id" => 650352243 "company_id" => 140537 "urn" => "urn:li:activity:7212439646771777536" "followers" => null "date" => "3w" "description" => "We’ve advanced LGBTQIA+ inclusion in over a dozen U.S. clinical trials since last year by implementing orientation, gender identity, and intersex status (SOGIIS) data. This #PrideMonth, learn about our efforts to do more across the industry to expand clinical trial diversity while respecting patients’ privacy: https://bit.ly/4cjtkuf" "reactions_count" => 78 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-16 02:28:36" "deleted" => 1 ] [ "id" => 650352244 "company_id" => 140537 "urn" => "urn:li:activity:7212194848303452161" "followers" => null "date" => "3w" "description" => """ The Economist Impact has just released a report commissioned by Bristol Myers Squibb (BMS) on how to address the undertreatment and unmet needs of #psoriasis patients. If you missed the discussion with Prof Jo Lambert, Frida Dunger, Executive Director of IFPA, and Leah Howard, J.D., President and CEO of National Psoriasis Foundation access the online recording from #IFPAConference2024 and read the report here. \n \n https://lnkd.in/d4RJsvsB """ "reactions_count" => 90 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-16 02:28:36" "deleted" => 1 ] [ "id" => 650352245 "company_id" => 140537 "urn" => "urn:li:activity:7212168795203764224" "followers" => null "date" => "3w" "description" => """ We are thrilled to announce that Francisco Ramírez-Valle, MD, PhD, FAAD, our Senior Vice President and Head of the Immunology and Cardiovascular Thematic Research Center, has been recognized in Endpoints News' annual feature on LGBTQ+ leaders in biopharma! Francisco's leadership and dedication to advancing scientific research while fostering an inclusive environment exemplify our core values at Bristol Myers Squibb. His contributions are not only shaping the future of the immunology and cardiovascular treatment landscape but also paving the way for greater LGBTQ+ representation in clinical trials and the biotech industry overall.\n \n “If I can be a mentor to anyone, whether they’re a Latino kid...or from a sexual minority, that they can achieve everything that they want and become a leader if that’s what they want, that would be amazing,” he said.\n \n While we celebrate Francisco and the other incredible honorees, we must acknowledge the challenges the LGBTQ+ community continues to face. Francisco's recognition is a testament to the progress we've made and the work that still needs to be done. Join us in celebrating Francisco and the inspiring work of all the honorees. #LGBTQLeadership #SOGIIS #HealthEquity\n \n Read more: https://bit.ly/3ztX354 """ "reactions_count" => 193 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-16 02:28:36" "deleted" => 1 ] [ "id" => 650352246 "company_id" => 140537 "urn" => "urn:li:activity:7212107790431961088" "followers" => null "date" => "3w" "description" => """ Our team is consistently pursuing innovative research and solutions to help people living with immune-mediated diseases like #UlcerativeColitis find relief. Learn more about an exciting new analysis of our Phase 3 trial evaluating a treatment for adults with moderately-to-severely active ulcerative colitis. \n \n Read more in the journal Clinical Gastroenterology and Hepatology. https://bit.ly/4eA8qIP """ "reactions_count" => 282 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-16 02:28:36" "deleted" => 1 ] [ "id" => 678445889 "company_id" => 140537 "urn" => "urn:li:activity:7229192551960850432" "followers" => null "date" => "2d" "description" => """ We are harnessing the power of the immune system to fight cancer and other diseases, through scientific discovery and efforts to make cell therapy more efficient, scalable and accessible. \n \n Learn more about how we’re approaching the future of healthcare on a cellular level—across our organization and in partnership with a complex ecosystem of stakeholders— to reach patients and their families with transformative treatments they need: https://bit.ly/4dEcgzj\n \n #OnaCellularLevel #CellTherapy """ "reactions_count" => 271 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-04 07:59:28" "deleted" => 1 ] [ "id" => 678445890 "company_id" => 140537 "urn" => "urn:li:activity:7229124803880718337" "followers" => null "date" => "2d" "description" => """ Located in the heart of a robust #LifeSciences hub, our Cambridge Crossing site is designed to support end-to-end drug discovery. Hear site head Emma Lees explain how this epicenter of innovation unites world-class scientists across functions to fuel the future of medicine, ensuring they can rapidly innovate to address patients’ needs. \n \n See how our state-of-the-art research facility – recently LEED Platinum certified – in Boston’s backyard is contributing to our worldwide R&D efforts: https://bit.ly/4dzHBU5 """ "reactions_count" => 612 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-04 07:59:28" "deleted" => 1 ] [ "id" => 678445891 "company_id" => 140537 "urn" => "urn:li:activity:7228848173253836801" "followers" => null "date" => "3d" "description" => """ Los pacientes con #MiocardiopatíaHipertrófica, o #MCH, pueden presentar síntomas como dolor en el pecho, dificultad para respirar, palpitaciones y desmayos. \n \n Estos síntomas pueden interferir con la capacidad del paciente para participar en las actividades diarias. Sus complicaciones pueden incluir fibrilación auricular, accidente cerebrovascular, insuficiencia cardíaca y, en casos raros, muerte súbita. \n \n La MCH puede afectar a las personas de diferentes maneras. Para algunos, los síntomas aparecen y desaparecen, mientras que otros pueden experimentar síntomas que pueden persistir durante mucho tiempo. También es posible que otras personas no experimenten síntomas de inmediato, pero la enfermedad puede continuar progresando. \n \n 👉 Conocer tu historial médico y los signos y síntomas es un primer paso importante para recibir un diagnóstico preciso. \n \n 🔴 Ante cualquier duda, consultá con tu médico. \n \n #BMSArgentina """ "reactions_count" => 64 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-04 07:59:28" "deleted" => 1 ] [ "id" => 678445892 "company_id" => 140537 "urn" => "urn:li:activity:7227327703366979585" "followers" => null "date" => "1w" "description" => """ On the heels of four recent U.S. FDA approvals for our two cell therapies, we continue to grow our treatment center footprint around the country to reach more eligible patients who may benefit.\n \n Eligible patients and healthcare providers can find nearby treatment centers and learn more here: https://bit.ly/3YweD32 """ "reactions_count" => 3059 "comments_count" => 26 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-04 07:59:28" "deleted" => 1 ] [ "id" => 678445893 "company_id" => 140537 "urn" => "urn:li:activity:7226587961230831617" "followers" => null "date" => "1w" "description" => "Our U.S. colleagues are training for the epic #C2C4C cross-country ride right now—and are on their way to their goal of raising $1 million for the V Foundation For Cancer Research! Watch their journey and learn how you can support: https://bit.ly/4fAyFQ8" "reactions_count" => 405 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-04 07:59:28" "deleted" => 1 ] [ "id" => 678445894 "company_id" => 140537 "urn" => "urn:li:activity:7226322815187120129" "followers" => null "date" => "1w" "description" => """ Our work as healthcare leaders is personal. From the patients and families who inspire our pipeline and critical work, to the colleagues and teams who help drive innovation forward, authentic leadership can have a lasting impact. As leaders, prioritizing compassion and leading with empathy allows us to better serve others and keep patients as the priority. \n \n I sat down with Authority Magazine to discuss the impact empathy can have on leadership. Read the full interview here: https://bit.ly/4fuFYbV and tell me, what does empathetic leadership look like to you? \n \n #BMS_employee #HealthcareInnovation #Leadership #Empathy """ "reactions_count" => 430 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-04 07:59:28" "deleted" => 1 ] [ "id" => 678445895 "company_id" => 140537 "urn" => "urn:li:activity:7225190557801680897" "followers" => null "date" => "1w" "description" => "Do you know someone with newly diagnosed multiple myeloma? Listen here to learn more about a clinical trial studying an investigational CAR T medication in newly diagnosed multiple myeloma. Learn more at https://bit.ly/3SAcT4S." "reactions_count" => 432 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-04 07:59:28" "deleted" => 1 ] [ "id" => 678445896 "company_id" => 140537 "urn" => "urn:li:activity:7224844370749882368" "followers" => null "date" => "2w" "description" => "Since its inception in 2020, the BMS PEER Program has been at the forefront of bringing patient advocacy insights to clinical trial protocols. Learn more about how community members play a part in our drug discovery and development process as we work to bring more medicines to patients faster. https://bit.ly/3SACT0e" "reactions_count" => 155 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-04 07:59:28" "deleted" => 1 ] [ "id" => 678445897 "company_id" => 140537 "urn" => "urn:li:activity:7223797056329383937" "followers" => null "date" => "2w" "description" => "Fostering a healthy, inclusive workplace empowers us to do more for patients. We’re pleased to be recognized as one of the “Best Companies to Work For” by U.S. News & World Report for our work/life balance, opportunities for professional development and best-in-class benefits. Learn more: https://bit.ly/3yeMtPn" "reactions_count" => 1124 "comments_count" => 28 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-04 07:59:28" "deleted" => 1 ] [ "id" => 678445898 "company_id" => 140537 "urn" => "urn:li:activity:7223688777347575809" "followers" => null "date" => "2w" "description" => """ We are committed to addressing the needs of people living with neurological conditions like #Alzheimers disease by identifying potential new treatments with the goal of slowing disease progression and addressing symptoms.\n \n Learn more about our ongoing clinical trials: https://bit.ly/3zWTfKb #AAIC24 """ "reactions_count" => 364 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-04 07:59:28" "deleted" => 1 ] [ "id" => 694364324 "company_id" => 140537 "urn" => "urn:li:activity:7236735023016554496" "followers" => null "date" => "17h" "description" => """ Hematologic diseases are diverse, and the nuances of each disease make treating them challenging. \n \n This #BloodCancerAwarenessMonth, Ridwaan Jhetam and Rosanna Ricafort discuss the range of modalities we’re exploring to deliver the next wave of advances in hematology and cell therapy.\n \n #DecodedByBMS #BMSAgainstBloodCancer """ "reactions_count" => 158 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-03 10:14:04" "deleted" => 1 ] [ "id" => 694364325 "company_id" => 140537 "urn" => "urn:li:activity:7236372354564526080" "followers" => null "date" => "1d" "description" => "Visit exposehcm.com to learn more about hypertrophic cardiomyopathy (HCM) and our commitment to advancing research across the HCM disease spectrum. https://bit.ly/4e3Mmpb" "reactions_count" => 97 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-03 10:14:04" "deleted" => 1 ] [ "id" => 694364326 "company_id" => 140537 "urn" => "urn:li:activity:7235964671936065536" "followers" => null "date" => "2d" "description" => """ We shared long-term safety and efficacy data from a Phase 3 study of our treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) at this year’s #ESCCongress. \n \n These results highlight our ongoing dedication to #cardiovascular innovation and our commitment to helping improve the lives of patients in the HCM patient community worldwide. \n \n Learn more: https://bit.ly/3z5yDPF\n \n #HypertrophicCardiomyopathy """ "reactions_count" => 454 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-03 10:14:04" "deleted" => 1 ] [ "id" => 694364327 "company_id" => 140537 "urn" => "urn:li:activity:7235326792260079618" "followers" => null "date" => "4d" "description" => "The Coast 2 Coast 4 Cancer relay kicks off next week in the U.S.! Watch our colleagues train for the 225-mile segment and raise money for cancer research in honor of cancer patients! Learn more about #C2C4C: cancerbikeride.org" "reactions_count" => 553 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-03 10:14:04" "deleted" => 1 ] [ "id" => 694364328 "company_id" => 140537 "urn" => "urn:li:activity:7235270086687617024" "followers" => null "date" => "4d" "description" => "We look forward to sharing how we’re helping to advance cardiovascular research through our Phase 3 Librexia program at the #ESCCongress this weekend, along with our partner Johnson & Johnson Innovative Medicine." "reactions_count" => 228 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-03 10:14:04" "deleted" => 1 ] [ "id" => 694364329 "company_id" => 140537 "urn" => "urn:li:activity:7234605544970305537" "followers" => null "date" => "6d" "description" => "Listen below to the a16z Bio + Health conversation with our Greg Meyers about how we're implementing artificial intelligence in nearly every facet of our business to advance our mission and what we look for in partners." "reactions_count" => 131 "comments_count" => 1 "reshared_post_author" => "a16z Bio + Health" "reshared_post_author_url" => "https://www.linkedin.com/showcase/a16z-bio-health" "reshared_post_author_headline" => null "reshared_post_description" => """ The real magic lies in developing AI to work seamlessly within complex workflows, ultimately leading to faster, more precise therapies.\n \n Recently, Greg Meyers, Executive Vice President and Chief Digital and Technology Officer at Bristol Myers Squibb, joined a16z general partner, Jorge Conde, to discuss how we can move from isolated experiments to truly integrated innovation.\n \n Listen on Raising Health: https://lnkd.in/g7tX6Xiq """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2024-10-03 10:14:04" "deleted" => 1 ] [ "id" => 694364330 "company_id" => 140537 "urn" => "urn:li:activity:7234560365005553665" "followers" => null "date" => "6d" "description" => """ Our scientists are focusing on new ways to advance research in thrombotic conditions, including exploring a new target called Factor XIa. \n \n See how our team is collaborating with Johnson & Johnson Innovative Medicine to explore ways to address the unmet need in stroke, ACS and AFib: https://bit.ly/3X09LRl """ "reactions_count" => 725 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-03 10:14:04" "deleted" => 1 ] [ "id" => 694364331 "company_id" => 140537 "urn" => "urn:li:activity:7234198014817452032" "followers" => null "date" => "1w" "description" => "Healthcare professionals join us at ESC 2024 booth C700 to learn more about our ongoing research in hypertrophic cardiomyopathy." "reactions_count" => 239 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-03 10:14:04" "deleted" => 1 ] [ "id" => 694364332 "company_id" => 140537 "urn" => "urn:li:activity:7232760026178727936" "followers" => null "date" => "1w" "description" => "Diverse career experiences can drive a culture of unity, fuel professional growth, and improve patient outcomes. Read more about my colleague Ann Houseman’s perspective in Life Science Washington magazine on how Bristol Myers Squibb is leveraging Washington’s vibrant growth in this sector to innovate and transform patient care. #BMS_employee" "reactions_count" => 197 "comments_count" => 2 "reshared_post_author" => "Life Science Washington" "reshared_post_author_url" => "https://www.linkedin.com/company/life-science-washington" "reshared_post_author_headline" => null "reshared_post_description" => """ Join Bristol Myers Squibb in harnessing the potential of cell therapy to pioneer state-of-the-art cancer treatments. \n \n Hear from Ann Houseman, vice president at BMS, who recently moved to Washington state to advance biomanufacturing innovations in cell therapies. \n \n Learn more about her story and how you can jump-start your biotech career in Seattle: https://lnkd.in/gr3T7xgY\n \n #FindYourBestLifeinWA #CellTherapies #Biomanufacturing """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-10-03 10:14:04" "deleted" => 1 ] [ "id" => 694364333 "company_id" => 140537 "urn" => "urn:li:activity:7232491498737455104" "followers" => null "date" => "1w" "description" => """ We’re thrilled to unveil the BMS Clinical Trials platform, optimized with AI and patient insights for easier access to trial information. This site helps patients and healthcare providers find the right trials and treatments, supporting our global commitment and ESG goals to clinical trial diversity and advancing the science. \n \n Discover more: https://bit.ly/46ZxANH """ "reactions_count" => 427 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-03 10:14:04" "deleted" => 1 ] [ "id" => 744403207 "company_id" => 140537 "urn" => "urn:li:activity:7244397746080690178" "followers" => null "date" => "1h" "description" => "Patients are at the center of everything we do. See how our colleague Skylar’s brother inspires him to make a difference and why #GlobalPatientWeek is central to our culture: https://bit.ly/3XUnLh1 #OneBMS" "reactions_count" => 39 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 11:08:06" "deleted" => 1 ] [ "id" => 744403208 "company_id" => 140537 "urn" => "urn:li:activity:7244339680803000320" "followers" => null "date" => "5h" "description" => "After a schizophrenia diagnosis in college, Carlos became a psychiatric nurse practitioner to help patients like him on the frontlines, then pivoted to a career in law at University of Michigan Law School and policy at Harvard Kennedy School. Learn how he’s shaping mental health policy and shattering the stigma for patients like him for our 10th #GlobalPatientWeek celebration: https://bit.ly/3Bf2qq1 #OneBMS" "reactions_count" => 77 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 11:08:06" "deleted" => 1 ] [ "id" => 744403209 "company_id" => 140537 "urn" => "urn:li:activity:7244027920900399104" "followers" => null "date" => "1d" "description" => "Overworked from her career and caring for her ailing grandparents, Latarsha knew she needed to prioritize her health after a second stroke in 2016 left her with speech issues. Watch her journey of recovery and resilience and see how she’s become what her friends call “a force of nature:” https://bit.ly/4gsMznE #GlobalPatientWeek #OneBMS" "reactions_count" => 64 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 11:08:06" "deleted" => 1 ] [ "id" => 744403210 "company_id" => 140537 "urn" => "urn:li:activity:7243967443998584832" "followers" => null "date" => "1d" "description" => """ Meet Carlos, Jola, Ale, Christophe and Latarsha. They motivate us to do more for patients every day. \n \n Celebrate our 10th annual #GlobalPatientWeek and learn how they continue to inspire our work to discover, develop and deliver new medicines that can help more patients prevail over serious disease: https://bit.ly/3XSQp27 #OneBMS """ "reactions_count" => 388 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 11:08:06" "deleted" => 1 ] [ "id" => 744403211 "company_id" => 140537 "urn" => "urn:li:activity:7243620100249894913" "followers" => null "date" => "2d" "description" => "We’re looking forward to the EADV 2024 congress. Visit booth A60 for the latest information about the BMS dermatology pipeline and our ongoing clinical trials and visit immunologypathways.com to learn more about TYK2 and other immune signaling pathways. #EADVCongress #OneBMS" "reactions_count" => 143 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 11:08:06" "deleted" => 1 ] [ "id" => 744403212 "company_id" => 140537 "urn" => "urn:li:activity:7243242614555033600" "followers" => null "date" => "3d" "description" => """ We continue to investigate ways to provide a continuum of care in #Alzheimers disease, one that spans from slowing progression to helping patients and families better manage symptoms.\n \n This #WorldAlzheimersDay, we celebrate the resilience of those living with the disease and their caregivers.\n \n Learn more about our ongoing clinical trials: https://bit.ly/4d9VZBO """ "reactions_count" => 220 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 11:08:06" "deleted" => 1 ] [ "id" => 744403213 "company_id" => 140537 "urn" => "urn:li:activity:7242940622481891328" "followers" => null "date" => "4d" "description" => """ Our colleague Eric Champion realized the importance of his work educating healthcare professionals when he became a patient himself. Every year, Eric celebrates #GlobalPatientWeek as an opportunity to reflect on the impact of his—and our—work. \n \n If you’re ready for meaningful work, learn more about our career opportunities: https://bit.ly/3TC8Zcx #OneBMS """ "reactions_count" => 149 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 11:08:06" "deleted" => 1 ] [ "id" => 744403214 "company_id" => 140537 "urn" => "urn:li:activity:7242638789615980544" "followers" => null "date" => "4d" "description" => "For the last decade, our colleagues have connected to our vision of transforming the lives of patients through science in deeply personal ways. Watch our Board Chair and CEO Chris Boerner’s #GlobalPatientWeek message as we celebrate ten years of keeping patients at the heart of everything we do." "reactions_count" => 747 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 11:08:06" "deleted" => 1 ] [ "id" => 744403215 "company_id" => 140537 "urn" => "urn:li:activity:7242578235555725313" "followers" => null "date" => "5d" "description" => "Patients are the “why” behind everything we do. Before our #GlobalPatientWeek kicks off September 23, see who inspires our colleague Renata and learn more about our culture of putting patients first: https://bit.ly/3Xxen1J #OneBMS" "reactions_count" => 104 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 11:08:06" "deleted" => 1 ] [ "id" => 744403216 "company_id" => 140537 "urn" => "urn:li:activity:7242548036302700544" "followers" => null "date" => "5d" "description" => """ Clinical trials help us gain a better understanding of ways we can help reduce the burden of anemia for patients with MDS. \n \n People with MDS who develop anemia often require blood transfusions to increase the number of healthy blood cells in circulation, and these frequent transfusions can lead to a range of complications like iron overload or infection. Learn more about clinical trial opportunities by visiting: https://bit.ly/3BczrTG\n \n #BMSAgainstBloodCancer #BloodCancerAwarenessMonth """ "reactions_count" => 154 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-20 11:08:06" "deleted" => 1 ] [ "id" => 769832876 "company_id" => 140537 "urn" => "urn:li:activity:7248074416461377536" "followers" => null "date" => "1d" "description" => "Our colleagues in Japan are undertaking their epic #C2C4C ride for cancer research, cycling nearly 1,800 kilometers from Tokyo Bay to Otemachi, Tokyo to honor patients with cancer, including their loved ones. Learn how you can support their journey to raise funds for CancerNet Japan: https://bit.ly/4gOJpeb" "reactions_count" => 171 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 20:05:44" "deleted" => 1 ] [ "id" => 769832877 "company_id" => 140537 "urn" => "urn:li:activity:7248044584579002368" "followers" => null "date" => "1d" "description" => """ One year ago, we opened our state-of-the-art facility at Cambridge Crossing, uniting our workforce in the Boston area. From the latest technology to the inspiring culture, hear a few of our scientists share their experiences of how this new site that’s located in a thriving life sciences ecosystem enhances their collaboration. \n \n Explore how our R&D site in Boston’s backyard is leading to increased opportunities for innovation: https://bit.ly/3XW36bc #OneBMS """ "reactions_count" => 99 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 20:05:44" "deleted" => 1 ] [ "id" => 769832878 "company_id" => 140537 "urn" => "urn:li:activity:7248014023290404869" "followers" => null "date" => "1d" "description" => "After riding nearly 3,000 miles across the U.S. through extreme conditions and raising more than $830,000 for cancer research, it was an emotional finish for our #C2C4C riders this week. Join us in celebrating their incredible achievement and support their fundraising efforts for the V Foundation through October 18: cancerbikeride.org" "reactions_count" => 688 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 20:05:44" "deleted" => 1 ] [ "id" => 769832879 "company_id" => 140537 "urn" => "urn:li:activity:7247983854777434112" "followers" => null "date" => "2d" "description" => "The FDA approval of a new treatment for schizophrenia in adults is a proud moment for our company — and a significant step forward for patients. Carlos Dortrait, SVP & General Manager of U.S. Immunology & Neuroscience, offers his perspective on the personal and professional significance of last week’s groundbreaking news: https://bit.ly/4dsNTUU" "reactions_count" => 499 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 20:05:44" "deleted" => 1 ] [ "id" => 769832880 "company_id" => 140537 "urn" => "urn:li:activity:7247953659349594114" "followers" => null "date" => "2d" "description" => """ At its core, the Global Product Development & Supply team (GPS) turns molecules into medicines, raw materials into finished products and is responsible for the delivery of these life-changing medicines to patients across the globe. \n \n Today, we’re celebrating #ManufacturingDay by recognizing the contributions and talent of our award-winning team, who embraces cutting-edge technology and diligently works toward sustainable innovation. \n \n Keep an eye out during this #ManufacturingWeek as we celebrate the power of manufacturing and its impact on patients' lives. """ "reactions_count" => 87 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 20:05:44" "deleted" => 1 ] [ "id" => 769832881 "company_id" => 140537 "urn" => "urn:li:activity:7247689443422158849" "followers" => null "date" => "2d" "description" => "Time is a precious gift for patients. Discover who inspires our colleague Sophia in her #GlobalPatientWeek story below, and learn more about how we come together each year to connect and renew our commitment to supporting patients around the world. https://bit.ly/4eRNpcb #OneBMS" "reactions_count" => 118 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 20:05:44" "deleted" => 1 ] [ "id" => 769832882 "company_id" => 140537 "urn" => "urn:li:activity:7247654306315743234" "followers" => null "date" => "2d" "description" => "When you’re both an employee and a patient, celebrating #GlobalPatientWeek can feel profound. Our colleague Evris Michalopoulos uses this time to pause and reflect on patients’ voices, the impact we’ve had on their lives, and the need for us to keep innovating. If you’re ready to join our life-changing mission, find out more here: https://bit.ly/3Y86i4R #OneBMS" "reactions_count" => 128 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 20:05:44" "deleted" => 1 ] [ "id" => 769832883 "company_id" => 140537 "urn" => "urn:li:activity:7247295096633659394" "followers" => null "date" => "3d" "description" => """ “Each of us is working for someone.” \n \n Our 10th #GlobalPatientWeek united us around inspiring stories that drive our mission to put patients at the center of everything we do. Watch moments from the celebration that give us a renewed sense of purpose, like meeting patients from around the world and hosting health fairs and blood drives. \n \n Learn more: https://bit.ly/3zU0x1n """ "reactions_count" => 265 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 20:05:44" "deleted" => 1 ] [ "id" => 769832884 "company_id" => 140537 "urn" => "urn:li:activity:7246949539960561664" "followers" => null "date" => "4d" "description" => "Every day, our dedicated team members come to work in relentless pursuit to deliver transformative treatment options where there is high unmet need. Adam Lenkowsky, EVP and Chief Commercialization Officer, shares why our recent FDA approval is meaningful to him: https://bit.ly/4dorBUg" "reactions_count" => 347 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 20:05:44" "deleted" => 1 ] [ "id" => 769832885 "company_id" => 140537 "urn" => "urn:li:activity:7246564301413453824" "followers" => null "date" => "5d" "description" => "Our U.S. #C2C4C riders are nearing the end of their journey to raise $1 million for the the V Foundation after enduring extreme temperatures and steep climbs from Oregon to Pennsylvania. See what they’re conquering next and how you can support their mission to honor patients with cancer: cancerbikeride.org" "reactions_count" => 306 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-17 20:05:44" "deleted" => 1 ] [ "id" => 813931581 "company_id" => 140537 "urn" => "urn:li:activity:7263551433378086912" "followers" => null "date" => "5h" "description" => """ Our ambition remains the same today as it was 70 years ago – to address the evolving burden of cardiovascular disease around the globe. \n \n We’re presenting data at the American Heart Association's Annual Scientific Sessions that supports the robust efficacy and safety profile for our treatment of symptomatic obstructive hypertrophic cardiomyopathy (HCM). This brings us a step closer to delivering game-changing and innovative medicines for patients. \n \n #AHA24 Learn more: https://bit.ly/3O6wI19 """ "reactions_count" => 128 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-27 10:43:06" "deleted" => 1 ] [ "id" => 813931582 "company_id" => 140537 "urn" => "urn:li:activity:7263303220590997504" "followers" => null "date" => "1d" "description" => """ Advancing health equity takes a village; we must all use our expertise and come together in collaboration, and genuine partnership is paramount. This week, I joined a discussion at The Milken Future of Health Summit about community-driven efforts and their impact on moving health equity forward. \n \n One of the ways we do this is through engaging and mobilizing community-based health centers in our clinical trial programs. Often left out of the conversation, these health centers are trusted, embedded resources, and by bringing them in to our trials we are able to further ensure that the medicines we develop treat the populations we serve. We take this seriously, holding ourselves accountable to ensure we make a meaningful and measurable impact in the communities where we live and work. \n \n Extending a heartfelt thank you to Nicholas St. Fleur for hosting, and to my fellow panelists Vanessa Garrison, Matthew Tejada, Terris King II, and Muglia Louis for the great conversation.\n \n #healthequity #Milken #BMS_employee """ "reactions_count" => 234 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-27 10:43:06" "deleted" => 1 ] [ "id" => 813931583 "company_id" => 140537 "urn" => "urn:li:activity:7263276156315996161" "followers" => null "date" => "23h" "description" => """ Hear from Francisco Ramírez-Valle, MD, PhD, FAAD, senior vice president and head of our Immunology and Cardiovascular Thematic Research Center, about how our three-step sequential immunotherapy research framework guides our research and development strategy to reset the immune system in patients living with immune-mediated diseases.\n \n Learn more: https://bit.ly/40OXanv #ACR24 #OneBMS """ "reactions_count" => 69 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-27 10:43:06" "deleted" => 1 ] [ "id" => 813931584 "company_id" => 140537 "urn" => "urn:li:activity:7263225818653290500" "followers" => null "date" => "1d" "description" => """ We’re pleased to share that Emma Charles, SVP Intercontinental Markets, was honored with the Gold Globee® Award for Women in Business: Executive of the Year - Healthcare, Medical and BioTech for her leadership in advancing health equity across our 63 Intercontinental markets. The #GlobeeAwards are selected from a rigorous peer-to-peer and industry expert review process. Join us in celebrating the recognition and her dedication to improving access to innovative medicines for patients in need. #OneBMS \n \n Learn more: https://bit.ly/40IozaO \n \n #WomenInBusiness """ "reactions_count" => 323 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-27 10:43:06" "deleted" => 1 ] [ "id" => 813931585 "company_id" => 140537 "urn" => "urn:li:activity:7263189052881879043" "followers" => null "date" => "1d" "description" => "This weekend we’re attending #AHA24, where we’ll be celebrating 100 years of the American Heart Association. We look forward to hearing about the latest updates in cardiovascular research and sharing details on our clinical program, in collaboration with Johnson & Johnson Innovative Medicine. Through this program, we aim to close the gap in unmet needs by improving outcomes in patients with thrombotic diseases, including atrial fibrillation. Learn more: https://bit.ly/3Y7ee6n" "reactions_count" => 80 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-27 10:43:06" "deleted" => 1 ] [ "id" => 813931586 "company_id" => 140537 "urn" => "urn:li:activity:7262912528945491968" "followers" => null "date" => "1d" "description" => """ AI isn't just transforming healthcare—it's revolutionizing how we work at BMS. From AI-powered drug discovery to our career development tools personalizing the employee experience, we're seeing remarkable results across R&D, patient care and talent development. Check out four powerful ways we're leveraging ethical AI today. https://bit.ly/3YMh4Nj\n \n #OneBMS """ "reactions_count" => 103 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-27 10:43:06" "deleted" => 1 ] [ "id" => 813931587 "company_id" => 140537 "urn" => "urn:li:activity:7262854733667659776" "followers" => null "date" => "2d" "description" => """ At #ACR24 we are sharing first results from a Phase 1 study evaluating the potential of our CD19-directed, next-generation (NEX-T) cell therapy asset in patients with severe, refractory autoimmune diseases. \n \n We are honored to have Prof. Georg Schett, an innovator in the field, present results of the study and how they support his hypothesis of the potential of #CARTcelltherapy to “reset” a patient’s immune system. https://bit.ly/4fqufKX """ "reactions_count" => 268 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-27 10:43:06" "deleted" => 1 ] [ "id" => 813931588 "company_id" => 140537 "urn" => "urn:li:activity:7262826656308805632" "followers" => null "date" => "2d" "description" => "We’re looking forward to the AHA 2024 Congress. Visit booth 902 for the latest information about our cardiovascular pipeline and research in obstructive HCM. Follow the link to learn more about the HCM disease spectrum. https://bit.ly/3ABQcHZ #OneBMS #AHA2024" "reactions_count" => 85 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-27 10:43:06" "deleted" => 1 ] [ "id" => 813931589 "company_id" => 140537 "urn" => "urn:li:activity:7262546804662046720" "followers" => null "date" => "1w" "description" => """ National Family Caregivers Month is a time to drive change and inspire action. Throughout the month, our Care @ Work campaign will spotlight senior leaders balancing caregiving and careers. By making these experiences visible, we aim to transform workplace culture to better support America's 32 million employed family caregivers.\n \n Thank you Carlos Dortrait at Bristol Myers Squibb and Teresa Cronin at Eisai US for sharing your stories! We are grateful for your leadership in fostering a culture of care within your workplace.\n \n #careatwork #iCare #NFCM """ "reactions_count" => 55 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-27 10:43:06" "deleted" => 1 ] [ "id" => 825114516 "company_id" => 140537 "urn" => "urn:li:activity:7266828143133396993" "followers" => null "date" => "1d" "description" => "Manufacturing biologics and cell therapies is a complex process. Take a look at our Devens, Massachusetts facility, which supports process development, clinical manufacturing and commercial manufacturing for these medicines. Spanning 89 acres and 1,700 employees, Devens is critical in helping deliver on our vision of transforming patients’ lives through science. Learn more about how BMS has become a leading life sciences presence in Massachusetts. https://bit.ly/3Z15qhF #OneBMS" "reactions_count" => 327 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-04 08:49:36" "deleted" => 1 ] [ "id" => 825114517 "company_id" => 140537 "urn" => "urn:li:activity:7266801598130016258" "followers" => null "date" => "1d" "description" => """ Digital health technology and AI are creating a step change in the way patients are diagnosed and monitored for serious diseases. In line with this progress, we are thrilled to congratulate Viz.AI on receiving the Prix Galien USA 2024 Award for Best Digital Health Solution for their incredible Viz HCM™ module.\n \n As always, we keep patients at the heart of everything we do. By continuing to explore and leverage digital health technologies, we remain committed to redefining what’s possible for patients now and in the future.\n \n #OneBMS """ "reactions_count" => 70 "comments_count" => 2 "reshared_post_author" => "Viz.ai" "reshared_post_author_url" => "https://www.linkedin.com/company/viz-ai" "reshared_post_author_headline" => null "reshared_post_description" => """ 🏅 We're delighted to announce that Viz.ai has been honored with the Prix Galien USA 2024 Award for Best Digital Health Solution for our Viz HCM™ module!\n \n A huge thank you to The Galien Foundation for this incredible recognition and to our dedicated team and partners who made this achievement possible. Together, we are advancing AI-powered solutions to transform healthcare and improve patient outcomes. 🌟 \n \n #Vizai #DigitalHealth #PrixGalienUSA #AIinHealthcare\n \n https://lnkd.in/eTFthCAW """ "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2024-12-04 08:49:36" "deleted" => 1 ] [ "id" => 825114518 "company_id" => 140537 "urn" => "urn:li:activity:7265725762689789952" "followers" => null "date" => "4d" "description" => "Learn more about hypertrophic cardiomyopathy by visiting Inside the Science to register and access medical videos and other educational resources. https://bit.ly/4i21oOM #AHA2024" "reactions_count" => 43 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-04 08:49:36" "deleted" => 1 ] [ "id" => 825114519 "company_id" => 140537 "urn" => "urn:li:activity:7265367863979388928" "followers" => null "date" => "5d" "description" => "We’re honored to share that Greg Meyers, EVP, Chief Digital & Technology Officer has been named to Forbes’ 2024 CIO Next List. As AI and machine learning continue to transform the future of healthcare, Greg has been instrumental in steering how our company leverages these advanced technologies to accelerate our scientific pursuits, empower our employees to do their best work, and deliver for our patients around the world. https://bit.ly/491C47y #OneBMS" "reactions_count" => 308 "comments_count" => 14 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-04 08:49:36" "deleted" => 1 ] [ "id" => 825114520 "company_id" => 140537 "urn" => "urn:li:activity:7265000984538497026" "followers" => null "date" => "6d" "description" => "We are committed to advancing research in cardiovascular diseases. Learn more about our ongoing trials in hypertrophic cardiomyopathy and other cardiovascular conditions on our website, BMS Clinical Trials. https://bit.ly/4fW39v0" "reactions_count" => 94 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-04 08:49:36" "deleted" => 1 ] [ "id" => 825114521 "company_id" => 140537 "urn" => "urn:li:activity:7264729196055220224" "followers" => null "date" => "1w" "description" => "We recently hosted an important discussion about breaking down barriers to healthcare access in low- and middle-income countries, known as LMICs. Together with the Union for International Cancer Control (UICC)’s ATOM Coalition and The Max Foundation, we’re focused on finding sustainable solutions, such as with the ASPIRE initiative, to ensure that every patient gets the care they need. #HealthEquity #GlobalHealth" "reactions_count" => 88 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-04 08:49:36" "deleted" => 1 ] [ "id" => 825114522 "company_id" => 140537 "urn" => "urn:li:activity:7264683873882497024" "followers" => null "date" => "1w" "description" => """ This BMS Veteran and Military Appreciation Month, our Veterans Community Network (VCN) People & Business Resource Group (PBRG) hosted a Veterans Salute and fireside chat with U.S. Marine Sergeant Carlos Evans, his wife, Rosemarie, a nurse and advocate, and Samit Hirawat (he/him), Chief Medical Officer and Head of Development. See highlights from the event—held in partnership with our Disability Advancement Workplace Network and Organization for Latino Achievement PBRGs—and join us in celebrating the history and contributions of those who’ve served. \n \n Learn about VCN Global Lead, Ricardo Sanchez and how our VCN community promotes the success of veteran service members: https://bit.ly/4eCH3wJ #OneBMS """ "reactions_count" => 162 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-04 08:49:36" "deleted" => 1 ] [ "id" => 825114523 "company_id" => 140537 "urn" => "urn:li:activity:7264653695047327744" "followers" => null "date" => "1w" "description" => "We are committed to advancing care for the Rheumatology community. Learn more about our ongoing clinical trials in lupus and Sjogren's disease, and other rheumatologic conditions at BMS Clinical Trials. https://bit.ly/3UUqbdW #OneBMS" "reactions_count" => 93 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-04 08:49:36" "deleted" => 1 ] [ "id" => 825114524 "company_id" => 140537 "urn" => "urn:li:activity:7264613714597752832" "followers" => null "date" => "1w" "description" => """ We’re looking forward to presenting new data at the American Society of Hematology Annual Meeting and Exposition alongside thousands of healthcare professionals, researchers, industry peers and advocacy partners. \n \n Learn more about across our key research platforms, cell therapy and targeted protein degradation, at #ASH24: https://bit.ly/3Zei7Hx """ "reactions_count" => 187 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-04 08:49:36" "deleted" => 1 ] [ "id" => 825114525 "company_id" => 140537 "urn" => "urn:li:activity:7264472500875530240" "followers" => null "date" => "1w" "description" => "Review the data and gain real-world insights from 22 months of a symptomatic obstructive HCM treatment in >6000 adult patients from our risk evaluation and mitigation strategy program. https://bit.ly/4eAKYtN #AHA2024" "reactions_count" => 76 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-04 08:49:36" "deleted" => 1 ] [ "id" => 839601414 "company_id" => 140537 "urn" => "urn:li:activity:7266828143133396993" "followers" => null "date" => "1w" "description" => "Manufacturing biologics and cell therapies is a complex process. Take a look at our Devens, Massachusetts facility, which supports process development, clinical manufacturing and commercial manufacturing for these medicines. Spanning 89 acres and 1,700 employees, Devens is critical in helping deliver on our vision of transforming patients’ lives through science. Learn more about how BMS has become a leading life sciences presence in Massachusetts. https://bit.ly/3Z15qhF #OneBMS" "reactions_count" => 402 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-04 07:10:24" "deleted" => 1 ] [ "id" => 839601415 "company_id" => 140537 "urn" => "urn:li:activity:7266801598130016258" "followers" => null "date" => "1w" "description" => """ Digital health technology and AI are creating a step change in the way patients are diagnosed and monitored for serious diseases. In line with this progress, we are thrilled to congratulate Viz.AI on receiving the Prix Galien USA 2024 Award for Best Digital Health Solution for their incredible Viz HCM™ module.\n \n As always, we keep patients at the heart of everything we do. By continuing to explore and leverage digital health technologies, we remain committed to redefining what’s possible for patients now and in the future.\n \n #OneBMS """ "reactions_count" => 127 "comments_count" => 6 "reshared_post_author" => "Viz.ai" "reshared_post_author_url" => "https://www.linkedin.com/company/viz-ai" "reshared_post_author_headline" => null "reshared_post_description" => """ 🏅 We're delighted to announce that Viz.ai has been honored with the Prix Galien USA 2024 Award for Best Digital Health Solution for our Viz HCM™ module!\n \n A huge thank you to The Galien Foundation for this incredible recognition and to our dedicated team and partners who made this achievement possible. Together, we are advancing AI-powered solutions to transform healthcare and improve patient outcomes. 🌟 \n \n #Vizai #DigitalHealth #PrixGalienUSA #AIinHealthcare\n \n https://lnkd.in/eTFthCAW """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2025-01-04 07:10:24" "deleted" => 1 ] [ "id" => 839601416 "company_id" => 140537 "urn" => "urn:li:activity:7265725762689789952" "followers" => null "date" => "1w" "description" => "Learn more about hypertrophic cardiomyopathy by visiting Inside the Science to register and access medical videos and other educational resources. https://bit.ly/4i21oOM #AHA2024" "reactions_count" => 56 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-04 07:10:24" "deleted" => 1 ] [ "id" => 839601417 "company_id" => 140537 "urn" => "urn:li:activity:7265367863979388928" "followers" => null "date" => "1w" "description" => "We’re honored to share that Greg Meyers, EVP, Chief Digital & Technology Officer has been named to Forbes’ 2024 CIO Next List. As AI and machine learning continue to transform the future of healthcare, Greg has been instrumental in steering how our company leverages these advanced technologies to accelerate our scientific pursuits, empower our employees to do their best work, and deliver for our patients around the world. https://bit.ly/491C47y #OneBMS" "reactions_count" => 344 "comments_count" => 20 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-04 07:10:24" "deleted" => 1 ] [ "id" => 839601418 "company_id" => 140537 "urn" => "urn:li:activity:7265000984538497026" "followers" => null "date" => "1w" "description" => "We are committed to advancing research in cardiovascular diseases. Learn more about our ongoing trials in hypertrophic cardiomyopathy and other cardiovascular conditions on our website, BMS Clinical Trials. https://bit.ly/4fW39v0" "reactions_count" => 99 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-04 07:10:24" "deleted" => 1 ] [ "id" => 839601419 "company_id" => 140537 "urn" => "urn:li:activity:7264729196055220224" "followers" => null "date" => "2w" "description" => "We recently hosted an important discussion about breaking down barriers to healthcare access in low- and middle-income countries, known as LMICs. Together with the Union for International Cancer Control (UICC)’s ATOM Coalition and The Max Foundation, we’re focused on finding sustainable solutions, such as with the ASPIRE initiative, to ensure that every patient gets the care they need. #HealthEquity #GlobalHealth" "reactions_count" => 93 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-04 07:10:24" "deleted" => 1 ] [ "id" => 839601420 "company_id" => 140537 "urn" => "urn:li:activity:7264683873882497024" "followers" => null "date" => "2w" "description" => """ This BMS Veteran and Military Appreciation Month, our Veterans Community Network (VCN) People & Business Resource Group (PBRG) hosted a Veterans Salute and fireside chat with U.S. Marine Sergeant Carlos Evans, his wife, Rosemarie, a nurse and advocate, and Samit Hirawat (he/him), Chief Medical Officer and Head of Development. See highlights from the event—held in partnership with our Disability Advancement Workplace Network and Organization for Latino Achievement PBRGs—and join us in celebrating the history and contributions of those who’ve served. \n \n Learn about VCN Global Lead, Ricardo Sanchez and how our VCN community promotes the success of veteran service members: https://bit.ly/4eCH3wJ #OneBMS """ "reactions_count" => 174 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-04 07:10:24" "deleted" => 1 ] [ "id" => 839601421 "company_id" => 140537 "urn" => "urn:li:activity:7264653695047327744" "followers" => null "date" => "2w" "description" => "We are committed to advancing care for the Rheumatology community. Learn more about our ongoing clinical trials in lupus and Sjogren's disease, and other rheumatologic conditions at BMS Clinical Trials. https://bit.ly/3UUqbdW #OneBMS" "reactions_count" => 95 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-04 07:10:24" "deleted" => 1 ] [ "id" => 839601422 "company_id" => 140537 "urn" => "urn:li:activity:7264613714597752832" "followers" => null "date" => "2w" "description" => """ We’re looking forward to presenting new data at the American Society of Hematology Annual Meeting and Exposition alongside thousands of healthcare professionals, researchers, industry peers and advocacy partners. \n \n Learn more about across our key research platforms, cell therapy and targeted protein degradation, at #ASH24: https://bit.ly/3Zei7Hx """ "reactions_count" => 200 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-04 07:10:24" "deleted" => 1 ] [ "id" => 839601423 "company_id" => 140537 "urn" => "urn:li:activity:7264472500875530240" "followers" => null "date" => "2w" "description" => "Review the data and gain real-world insights from 22 months of a symptomatic obstructive HCM treatment in >6000 adult patients from our risk evaluation and mitigation strategy program. https://bit.ly/4eAKYtN #AHA2024" "reactions_count" => 83 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-04 07:10:24" "deleted" => 1 ] [ "id" => 867057198 "company_id" => 140537 "urn" => "urn:li:activity:7280221335388057600" "followers" => null "date" => "2d" "description" => "Wishing everyone a healthy and happy New Year! We look forward to another year of inspiration and innovation as we work together as #OneBMS to transform patients' lives through science." "reactions_count" => 1417 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 10:17:45" "deleted" => 1 ] [ "id" => 867057199 "company_id" => 140537 "urn" => "urn:li:activity:7278547396123406336" "followers" => null "date" => "6d" "description" => """ Our new FDA-approved immunotherapy treatment option for use by subcutaneous injection builds on our legacy of delivering transformational medicines. \n \n Learn more: https://bit.ly/3DKfxjV """ "reactions_count" => 911 "comments_count" => 21 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 10:17:45" "deleted" => 1 ] [ "id" => 867057200 "company_id" => 140537 "urn" => "urn:li:activity:7277015043618004993" "followers" => null "date" => "1w" "description" => """ I had the pleasure of taking part in the 2024 #HispanicLeadershipSummit at the United Nation in NYC through The Hispanic Star and the We Are All Human Foundation Claudia Romo Edelman. This multi-day Leadership Forum provided a platform to both celebrate the achievements of the Hispanic and Latino communities and to convene on the work still needed to elevate our voices. Among those in attendance were several of my Bristol Myers Squibb colleagues, including Lorena Kuri, global lead of the Organization for Latino Achievement (OLA) People & Business Resource Group and other OLA members. To be in the presence of fellow Hispanic and Latino leaders and allies with a centralized focus on unity, representation and goal setting has left me feeling grateful and energized for the new year. \n During the summit, I was honored to be on a panel to discuss the importance of authentic allyship and fostering partnerships with those who can use their influence to advocate on behalf of the Hispanic and Latino communities. This work is personal and enduring for me. I am deeply committed to advocating for those in need and driving progress through impactful actions for all underrepresented groups.\n I am so thankful for community spaces like the #HispanicLeadershipSummit. The work we do today is what will help ensure an even brighter, shiner and more unified future. \n Thank you for having us. \n #HLS2024 #TogetherWeShine #HispanicProgress #Allyship #WeAreAllHuman #BMS_Employee #BuildingtheFutureTogether """ "reactions_count" => 260 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 10:17:45" "deleted" => 1 ] [ "id" => 867057201 "company_id" => 140537 "urn" => "urn:li:activity:7276939981481291776" "followers" => null "date" => "1w" "description" => """ Today, we announced topline results from two pivotal Phase 3 trials for an investigational medicine in adults with #PsoriaticArthritis.\n \n Our research underscores our commitment to following the science to help more patients with immune-mediated rheumatic diseases potentially achieve their treatment goals. Learn more about the topline results: https://bit.ly/4iHxO1o """ "reactions_count" => 594 "comments_count" => 19 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 10:17:45" "deleted" => 1 ] [ "id" => 867057202 "company_id" => 140537 "urn" => "urn:li:activity:7275917956688097281" "followers" => null "date" => "2w" "description" => """ We’re celebrating 10 years since bringing an important immunotherapy treatment option to cancer patients. As we look to the future in #Oncology, we remain committed to advancing cancer treatment through research and innovation.\n \n Thank you to those who have been instrumental in helping to make a meaningful difference in the lives of patients worldwide. """ "reactions_count" => 342 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 10:17:45" "deleted" => 1 ] [ "id" => 867057203 "company_id" => 140537 "urn" => "urn:li:activity:7275872788517666817" "followers" => null "date" => "2w" "description" => "In 2024, our dedicated colleagues and partners around the world helped us reach new milestones for our patients. Watch highlights from the year and join in celebrating our achievements, from pursuing bold science and digital innovations to our #C2C4C riders who raised millions for cancer research. We look forward to the new year and giving more hope to more patients, together. #OneBMS" "reactions_count" => 278 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 10:17:45" "deleted" => 1 ] [ "id" => 867057204 "company_id" => 140537 "urn" => "urn:li:activity:7275569771490729985" "followers" => null "date" => "2w" "description" => """ We are nearing the end of another transformative year, and I am proud to share our latest Climate Change Report, which highlights our ongoing commitment to sustainability and responsible innovation. 🌍\n \n At Bristol Myers Squibb we recognize the critical role we play in addressing climate change and are dedicated to minimizing our environmental impact while advancing our mission to improve patient outcomes. This report underscores our strategic initiatives and achievements in reducing carbon emissions, enhancing energy efficiency, and fostering sustainable practices across our global operations to support climate resiliency.\n \n I invite you to explore our Climate Change Report to learn more. Together, let’s continue to drive positive change and make a lasting impact.\n \n Read the full report here: BMS Climate Change Report (https://lnkd.in/edhH3aGx)\n \n #Sustainability #ClimateChange #ResponsibleBusiness #BMS_Employee """ "reactions_count" => 154 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 10:17:45" "deleted" => 1 ] [ "id" => 867057205 "company_id" => 140537 "urn" => "urn:li:activity:7275190767764049920" "followers" => null "date" => "2w" "description" => """ Last week, our Targeted Protein Degradation Forum in San Diego provided a valuable opportunity to engage with thought leaders on the latest advancements in #hematology. \n \n We are committed to transforming the treatment landscape for patients living with a broad range of hematological diseases, including multiple myeloma and lymphoma, as we continue to expand our discovery and development of novel protein degraders, and target disease-causing proteins previously considered “undruggable." Discover more about targeted protein degradation: https://bit.ly/3P3fF0w #ASH24 #TargetedProteinDegradation """ "reactions_count" => 195 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 10:17:45" "deleted" => 1 ] [ "id" => 867057206 "company_id" => 140537 "urn" => "urn:li:activity:7275147848160096259" "followers" => null "date" => "2w" "description" => "How are we applying precision medicine to advance new #CardiovascularDisease (CVD) therapies? In a recent Q&A with Francisco Ramírez-Valle, MD, PhD, FAAD, he discusses how we’re drawing on decades of insights in genetics and causal human biology to discover and develop more individualized and effective options for people with living CVD. Learn more: https://bit.ly/3VFPHUx #OneBMS" "reactions_count" => 218 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 10:17:45" "deleted" => 1 ] [ "id" => 867057207 "company_id" => 140537 "urn" => "urn:li:activity:7274423196513099776" "followers" => null "date" => "2w" "description" => """ Computational scientists like Ivy thrive as members of our Research teams, working alongside lab scientists to approach scientific questions with a wide range of lived experiences and expertise, to help discover and develop transformative medicines for patients. \n \n See how our collaborative culture advances our approach to science: https://bit.ly/4gdlILX #OneBMS """ "reactions_count" => 117 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 10:17:45" "deleted" => 1 ] [ "id" => 886591329 "company_id" => 140537 "urn" => "urn:li:activity:7284660642492350465" "followers" => null "date" => "1d" "description" => "Since pioneering a dual immunotherapy combination more than ten years ago, we have significantly improved outcomes for advanced #melanoma patients and applied learnings to many other cancers. Over a decade later, we continue to strive to bring innovative medicines to as many cancer patients as possible. #OneBMS" "reactions_count" => 238 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 1 ] [ "id" => 886591330 "company_id" => 140537 "urn" => "urn:li:activity:7284644717634412544" "followers" => null "date" => "1d" "description" => """ We’re honored to be recognized for the second consecutive year as a corporate sustainability leader by S&P Global in the prestigious Dow Jones Sustainability Index for 2024-2025. This achievement highlights our dedication to leveraging our capabilities and resources to advance patient health, foster a diverse and high-performing workforce, and expand the boundaries of science, while minimizing our environmental impact.\n \n Learn more: https://bit.ly/4fVUb0B\n \n #DJSI #ESG #Sustainability """ "reactions_count" => 110 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 1 ] [ "id" => 886591331 "company_id" => 140537 "urn" => "urn:li:activity:7283577332919894018" "followers" => null "date" => "4d" "description" => """ Life sciences and healthcare is touted as AI's biggest opportunity to benefit humanity. But why is transforming this industry so challenging? As someone driving this change day in and day out at Bristol Myers Squibb, I can say firsthand—it's complicated.\n \n As industry leaders prepare for #JPMorganHealth, AI will be high on the agenda. I'm pleased to share my perspective on this critical topic published in STAT today.\n #Healthcare #AI #Innovation #LifeSciences #JPM24 #OneBMS\n \n https://lnkd.in/eDVV-Q-z """ "reactions_count" => 386 "comments_count" => 15 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 1 ] [ "id" => 886591332 "company_id" => 140537 "urn" => "urn:li:activity:7283120379823308802" "followers" => null "date" => "5d" "description" => "We are committed to advancing research in cardiovascular diseases. Learn more about an ongoing trial in adolescents with obstructive hypertrophic cardiomyopathy at BMS Clinical Trials. https://bit.ly/4a7SyM0" "reactions_count" => 89 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 1 ] [ "id" => 886591333 "company_id" => 140537 "urn" => "urn:li:activity:7282456002036207619" "followers" => null "date" => "1w" "description" => """ Mecide Gharibo, vice president, US Medical Hematology and Oncology, discusses subcutaneous treatments in general and their potential for faster treatment delivery. \n \n Learn more: https://bit.ly/4fTt3iG """ "reactions_count" => 316 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 1 ] [ "id" => 886591334 "company_id" => 140537 "urn" => "urn:li:activity:7280221335388057600" "followers" => null "date" => "1w" "description" => "Wishing everyone a healthy and happy New Year! We look forward to another year of inspiration and innovation as we work together as #OneBMS to transform patients' lives through science." "reactions_count" => 1838 "comments_count" => 14 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 1 ] [ "id" => 886591335 "company_id" => 140537 "urn" => "urn:li:activity:7278547396123406336" "followers" => null "date" => "2w" "description" => """ Our new FDA-approved immunotherapy treatment option for use by subcutaneous injection builds on our legacy of delivering transformational medicines. \n \n Learn more: https://bit.ly/3DKfxjV """ "reactions_count" => 1265 "comments_count" => 27 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 1 ] [ "id" => 886591336 "company_id" => 140537 "urn" => "urn:li:activity:7277015043618004993" "followers" => null "date" => "3w" "description" => """ I had the pleasure of taking part in the 2024 #HispanicLeadershipSummit at the United Nation in NYC through The Hispanic Star and the We Are All Human Foundation Claudia Romo Edelman. This multi-day Leadership Forum provided a platform to both celebrate the achievements of the Hispanic and Latino communities and to convene on the work still needed to elevate our voices. Among those in attendance were several of my Bristol Myers Squibb colleagues, including Lorena Kuri, global lead of the Organization for Latino Achievement (OLA) People & Business Resource Group and other OLA members. To be in the presence of fellow Hispanic and Latino leaders and allies with a centralized focus on unity, representation and goal setting has left me feeling grateful and energized for the new year. \n During the summit, I was honored to be on a panel to discuss the importance of authentic allyship and fostering partnerships with those who can use their influence to advocate on behalf of the Hispanic and Latino communities. This work is personal and enduring for me. I am deeply committed to advocating for those in need and driving progress through impactful actions for all underrepresented groups.\n I am so thankful for community spaces like the #HispanicLeadershipSummit. The work we do today is what will help ensure an even brighter, shiner and more unified future. \n Thank you for having us. \n #HLS2024 #TogetherWeShine #HispanicProgress #Allyship #WeAreAllHuman #BMS_Employee #BuildingtheFutureTogether """ "reactions_count" => 303 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 1 ] [ "id" => 886591337 "company_id" => 140537 "urn" => "urn:li:activity:7276939981481291776" "followers" => null "date" => "3w" "description" => """ Today, we announced topline results from two pivotal Phase 3 trials for an investigational medicine in adults with #PsoriaticArthritis.\n \n Our research underscores our commitment to following the science to help more patients with immune-mediated rheumatic diseases potentially achieve their treatment goals. Learn more about the topline results: https://bit.ly/4iHxO1o """ "reactions_count" => 690 "comments_count" => 21 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 1 ] [ "id" => 886591338 "company_id" => 140537 "urn" => "urn:li:activity:7275917956688097281" "followers" => null "date" => "3w" "description" => """ We’re celebrating 10 years since bringing an important immunotherapy treatment option to cancer patients. As we look to the future in #Oncology, we remain committed to advancing cancer treatment through research and innovation.\n \n Thank you to those who have been instrumental in helping to make a meaningful difference in the lives of patients worldwide. """ "reactions_count" => 410 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 1 ] [ "id" => 927254130 "company_id" => 140537 "urn" => "urn:li:activity:7293289929919348737" "followers" => null "date" => "1d" "description" => """ Today, we reported our 2024 Fourth Quarter and Full-Year Financial Results, reflecting progress toward delivering sustainable top-tier growth. \n \n We made good progress in 2024 and finished the year with a fourth quarter of important pipeline advancements and strong growth in key products. The fourth quarter also marked the launch of a new treatment for schizophrenia in adults, which we expect to have a meaningful impact on patients and the company. In 2025, we’re building on the foundation we created last year and remain focused on executing our strategy and delivering more innovative medicines to more patients faster. \n \n Read more, including important cautionary statements about forward-looking information, here: https://bit.ly/3QrSopT """ "reactions_count" => 228 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 927254131 "company_id" => 140537 "urn" => "urn:li:activity:7292610508011040769" "followers" => null "date" => "3d" "description" => """ I'm excited to celebrate Black History Month with my BMS colleagues!\n \n This year's theme, "Amplifying Our Voices," resonates deeply with me. As the leader of the Black Organization for Leadership and Development People & Business Resource Group at BMS, I've seen firsthand the impact of amplifying underrepresented voices. Doing so allows us to not only elevate individual perspectives but also create a more inclusive environment that can drive innovation, collaboration and patient-centered solutions. This, in turn, enables us to better serve our patients and communities.\n \n I am looking forward to the meaningful discussions, learning opportunities and celebration of culture this month will bring. Let's recommit to creating a workplace culture where everyone feels heard, valued and empowered.\n \n #BlackHistoryMonth #AmplifyingVoices #Inclusion #ProudToBeBMS """ "reactions_count" => 174 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 927254132 "company_id" => 140537 "urn" => "urn:li:activity:7292587785213935618" "followers" => null "date" => "3d" "description" => """ When it comes to #CancerResearch, we’re leveraging our deep understanding of causal human biology and matching modality to mechanism to continue to develop innovative, transformational treatments for those living with cancer. \n \n Explore how we aim to continue advancing the next generation of cancer treatments: https://bit.ly/3PYFGhY #WorldCancerDay #OneBMS """ "reactions_count" => 114 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 927254133 "company_id" => 140537 "urn" => "urn:li:activity:7292542487393435648" "followers" => null "date" => "3d" "description" => """ Tremendous progress has been made by the scientific, advocacy and patient communities in oncologic and hematologic research over the past decade, and we know there is still work left to do as we continue to strive towards a cure. \n \n We are privileged and grateful to be able to learn from our peers and collaborate on novel treatment options resulting in better outcomes for patients. https://bit.ly/3WEcuRd\n \n #WorldCancerDay #OneBMS """ "reactions_count" => 238 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 927254134 "company_id" => 140537 "urn" => "urn:li:activity:7291085373043081217" "followers" => null "date" => "1w" "description" => """ The European Medicines Agency (EMA) #CHMP issued a positive opinion for our #CARTcelltherapy for patients living with relapsed or refractory follicular lymphoma (FL). \n \n This recommendation brings us closer to expanding access to the innovative potential of cell therapy and addressing ongoing unmet need for patients living with serious blood cancers. \n \n Learn more: https://bit.ly/40WQ8g0 """ "reactions_count" => 330 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 927254135 "company_id" => 140537 "urn" => "urn:li:activity:7290773541367472128" "followers" => null "date" => "1w" "description" => "Happy Lunar New Year! As we begin the Year of the Snake, we wish our colleagues, partners and communities around the world prosperity and good health." "reactions_count" => 1120 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 927254136 "company_id" => 140537 "urn" => "urn:li:activity:7290406917678530560" "followers" => null "date" => "1w" "description" => "We’re excited to announce that VP Neil Bence was honored as a 2024 PhRMA Working for Cures Champion for his role in advancing science for patients, including raising awareness about their conditions and leading site tours with lawmakers. Join us in celebrating his achievement and learn more about the honor: https://bit.ly/3PU5yeQ" "reactions_count" => 240 "comments_count" => 30 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 927254137 "company_id" => 140537 "urn" => "urn:li:activity:7290093120145223680" "followers" => null "date" => "1w" "description" => """ At Bristol Myers Squibb, we celebrate the achievements that shape healthcare and innovation.\n We are proud to announce that Juan Ignacio Diddi , General Manager in Puerto Rico, has been elected President of the Pharmaceutical Industry Association of Puerto Rico (PIA).\n \n Another opportunity to drive progress and action. As Juan shared: "The pharmaceutical industry is essential for enhancing health and improving the quality of life for individuals. Additionally, it is a critical component of the global economy, driving growth and innovation."\n \n We are confident that Juan’s leadership will inspire transformative change and further strengthen the biopharmaceutical industry’s contributions to Puerto Rico’s communities and beyond.\n \n Congratulations, Juan Ignacio Diddi ! 👏🌟\n \n Learn more about PIA's new board members 👉 : https://lnkd.in/dkndFK93\n \n #BMSLATAM #BMSPuertoRico #Leadership #Innovation #PharmaceuticalIndustry """ "reactions_count" => 106 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 927254138 "company_id" => 140537 "urn" => "urn:li:activity:7288269308390981634" "followers" => null "date" => "2w" "description" => "Transforming patients’ lives is at the heart of what we do. By focusing on breakthrough science in key therapeutic areas, we’re accelerating delivery of novel medicines to reach more patients, faster. Learn more: https://bit.ly/4h2Xrsn" "reactions_count" => 140 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] [ "id" => 927254139 "company_id" => 140537 "urn" => "urn:li:activity:7287934002529759233" "followers" => null "date" => "2w" "description" => "Through business development, we pursue breakthrough science across all stages of development to accelerate innovation for patients. Learn more: https://bit.ly/40GUkk5" "reactions_count" => 92 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-09 19:10:40" "deleted" => 0 ] ] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4641 …} -companyTags: Doctrine\ORM\PersistentCollection {#4643 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4645 …} -users: Doctrine\ORM\PersistentCollection {#4647 …} -logoImageName: "20250226144019-bms-bristol-myers-squibb-emblem-67bf19c390259124624791.png" -coverImageName: "20250227161852-bmy-03bb5df8-67c0825c6e1a2410816151.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4649 …} -tagline: "Innovative BioPharma-Lösungen für Onkologie, Immunologie und schwerwiegende Erkrankunge" -contactEmail: "immunology-ch@bms.com" -phone: "41417677200" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4651 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4653 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4655 …} -industry: "" -size: null -address1: "Hinterbergstrasse 16" -address2: null -city: "Steinhausen" -postalCode: "6312" -state: null -country: "United States" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4657 …} #createdAt: DateTime @1740048727 {#4618 date: 2025-02-20 10:52:07.0 UTC (+00:00) } #updatedAt: DateTime @1750924692 {#4617 date: 2025-06-26 07:58:12.0 UTC (+00:00) } } App\Entity\Company {#4661 -id: 19 -name: "Pfizer" -website: "https://pfizer.com" -description: """ Pfizer steht für die erfolgreiche Erforschung und Entwicklung von innovativen Arzneimitteln – und das schon seit über 160 Jahren. Damals wie heute gilt, dass die grossen medizinischen Herausforderungen keinen Aufschub dulden. Ob Krebs oder Herz-Kreislauf-Erkrankungen – mit pharmazeutischen Innovationen leistet Pfizer einen wichtigen Beitrag zur Prävention und zur Behandlung von weit verbreiteten, aber auch von seltenen Erkrankungen. Als weltweit führendes forschendes Pharmaunternehmen setzen wir bei Pfizer unsere wissenschaftliche Kompetenz und unsere weltweiten Möglichkeiten ein, um die Lebensqualität und Gesundheit in jedem Lebensabschnitt zu verbessern. Wir alle bei Pfizer haben ein gemeinsames Ziel: Ihre Gesundheit. Deshalb entwickeln wir innovative Medikamente, die helfen, Krankheiten zu verhindern, zu heilen oder erträglicher zu machen. Wir wollen, dass alle, denen unsere Therapien von Nutzen sind, diese auch erhalten. Wir glauben, dass durch Fortschritt Hoffnung entsteht und die begründete Aussicht auf eine gesündere Welt.\n \n Weitere Informationen finden Sie auf unserer Website» """ -externalId: "1258906" -details: [ "id" => 1258906 "url" => "https://www.linkedin.com/company/pfizer" "hash" => "a33e5dc232ee4017c97fbc2d36caa52d" "name" => "Pfizer" "website" => "http://www.pfizer.com" "size" => "10,001+ employees" "industry" => "Pharmaceutical Manufacturing" "description" => """ We’re celebrating over 175 years of daring scientific innovation—and we’re not done yet. Let’s outdo yesterday. Protect your health at PfizerForAll.com\n \n For additional information on our guidelines, please visit http://www.pfizer.com/community-guidelines """ "followers" => 6151302 "founded" => null "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://media.licdn.com/dms/image/v2/D4D0BAQGUWkaCJOWLdA/company-logo_200_200/company-logo_200_200/0/1720685515776/pfizer_logo?e=2147483647&v=beta&t=MOyriMjHIQ-TAvOb5XOhpBZVLEwEf8CG1YDVMlWOrMs" "created" => "2016-06-20 04:04:18" "last_updated" => "2025-02-15 05:09:13" "last_response_code" => 200 "type" => "Public Company" "headquarters_new_address" => "New York, New York" "employees_count" => 102615 "headquarters_country_restored" => "United States" "headquarters_country_parsed" => "United States" "company_shorthand_name" => "pfizer" "company_shorthand_name_hash" => "05a203d85ee01909eaf728dc16f0f6cb" "canonical_url" => "https://www.linkedin.com/company/pfizer" "canonical_hash" => "a33e5dc232ee4017c97fbc2d36caa52d" "canonical_shorthand_name" => "pfizer" "canonical_shorthand_name_hash" => "05a203d85ee01909eaf728dc16f0f6cb" "deleted" => 0 "last_updated_ux" => 1739596152 "source_id" => 1185 "company_affiliated_collection" => [ [ "id" => 38702 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/company/medivation" "affiliated_company_id" => null "created" => "2016-12-08 17:40:09" "last_updated" => "2017-02-23 07:53:00" "deleted" => 1 ] [ "id" => 38703 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/company/anacor-pharmaceuticals" "affiliated_company_id" => null "created" => "2016-12-08 17:40:09" "last_updated" => "2019-08-05 23:54:41" "deleted" => 1 ] [ "id" => 38704 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/company/pfizer-italia" "affiliated_company_id" => null "created" => "2016-12-08 17:40:09" "last_updated" => "2019-08-05 23:54:41" "deleted" => 1 ] [ "id" => 38705 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/company/bamboo-therapeutics" "affiliated_company_id" => null "created" => "2016-12-08 17:40:09" "last_updated" => "2019-08-05 23:54:41" "deleted" => 1 ] [ "id" => 180665 "company_id" => 1258906 "affiliated_company_url" => "https://ca.linkedin.com/company/bamboo-therapeutics" "affiliated_company_id" => null "created" => "2019-08-05 23:54:42" "last_updated" => "2019-10-16 15:52:49" "deleted" => 1 ] [ "id" => 180666 "company_id" => 1258906 "affiliated_company_url" => "https://ca.linkedin.com/company/pfizer-italia" "affiliated_company_id" => null "created" => "2019-08-05 23:54:42" "last_updated" => "2019-10-16 15:52:49" "deleted" => 1 ] [ "id" => 180667 "company_id" => 1258906 "affiliated_company_url" => "https://ca.linkedin.com/company/anacor-pharmaceuticals" "affiliated_company_id" => null "created" => "2019-08-05 23:54:42" "last_updated" => "2019-10-16 15:52:49" "deleted" => 1 ] [ "id" => 275580 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/company/pfizer-italia" "affiliated_company_id" => null "created" => "2019-10-16 15:52:49" "last_updated" => "2020-02-04 09:20:59" "deleted" => 1 ] [ "id" => 275581 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/company/anacor-pharmaceuticals" "affiliated_company_id" => null "created" => "2019-10-16 15:52:49" "last_updated" => "2020-02-04 09:20:59" "deleted" => 1 ] [ "id" => 275582 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/company/bamboo-therapeutics" "affiliated_company_id" => null "created" => "2019-10-16 15:52:49" "last_updated" => "2020-02-04 09:20:59" "deleted" => 1 ] [ "id" => 275583 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/company/pfizer-centreone" "affiliated_company_id" => null "created" => "2019-10-16 15:52:49" "last_updated" => "2020-04-15 01:47:44" "deleted" => 1 ] [ "id" => 738673 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/company/pfizer-italia" "affiliated_company_id" => 10678200 "created" => "2020-02-04 09:20:59" "last_updated" => "2020-11-20 21:57:24" "deleted" => 1 ] [ "id" => 738674 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/company/anacor-pharmaceuticals" "affiliated_company_id" => 9071994 "created" => "2020-02-04 09:20:59" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 738675 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/company/bamboo-therapeutics" "affiliated_company_id" => 384237 "created" => "2020-02-04 09:20:59" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 2559633 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/showcase/pfizer-centreone" "affiliated_company_id" => 25980521 "created" => "2020-04-15 01:47:44" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 3814300 "company_id" => 1258906 "affiliated_company_url" => "https://it.linkedin.com/company/pfizer-italia" "affiliated_company_id" => 10678200 "created" => "2020-11-20 21:57:24" "last_updated" => "2021-03-15 02:09:15" "deleted" => 1 ] [ "id" => 6383026 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/showcase/pfizer-centreone" "affiliated_company_id" => 25980521 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 6383027 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/company/anacor-pharmaceuticals" "affiliated_company_id" => 9071994 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 6383028 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/company/bamboo-therapeutics" "affiliated_company_id" => 384237 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 8093766 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/showcase/pfizer-medical" "affiliated_company_id" => null "created" => "2023-02-08 08:59:27" "last_updated" => "2023-03-10 16:13:16" "deleted" => 1 ] [ "id" => 8356277 "company_id" => 1258906 "affiliated_company_url" => "https://www.linkedin.com/showcase/pfizer-medical" "affiliated_company_id" => 90074370 "created" => "2023-03-10 16:13:16" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] ] "company_also_viewed_collection" => [ [ "id" => 5061968 "company_id" => 1258906 "viewed_company_url" => "https://www.linkedin.com/company/novartis" "viewed_company_id" => null "created" => "2016-06-20 04:04:18" "last_updated" => "2019-08-05 23:54:41" "deleted" => 1 ] [ "id" => 5061969 "company_id" => 1258906 "viewed_company_url" => "https://www.linkedin.com/company/johnson-&-johnson" "viewed_company_id" => null "created" => "2016-06-20 04:04:18" "last_updated" => "2019-08-05 23:54:41" "deleted" => 1 ] [ "id" => 5061970 "company_id" => 1258906 "viewed_company_url" => "https://www.linkedin.com/company/glaxosmithkline" "viewed_company_id" => null "created" => "2016-06-20 04:04:18" "last_updated" => "2019-08-05 23:54:41" "deleted" => 1 ] [ "id" => 5061971 "company_id" => 1258906 "viewed_company_url" => "https://www.linkedin.com/company/sanofi-" "viewed_company_id" => null "created" => "2016-06-20 04:04:18" "last_updated" => "2016-12-08 17:40:10" "deleted" => 1 ] [ "id" => 5061972 "company_id" => 1258906 "viewed_company_url" => "https://www.linkedin.com/company/procter-&-gamble" "viewed_company_id" => null "created" => "2016-06-20 04:04:18" "last_updated" => "2016-12-08 17:40:10" "deleted" => 1 ] [ "id" => 5061973 "company_id" => 1258906 "viewed_company_url" => "https://www.linkedin.com/company/merck" "viewed_company_id" => null "created" => "2016-06-20 04:04:18" "last_updated" => "2018-07-10 08:55:14" "deleted" => 1 ] [ "id" => 38643121 "company_id" => 1258906 "viewed_company_url" => "https://www.linkedin.com/company/sanofi" "viewed_company_id" => null "created" => "2016-12-08 17:40:09" "last_updated" => "2019-08-05 23:54:41" "deleted" => 1 ] [ "id" => 38643122 "company_id" => 1258906 "viewed_company_url" => "https://www.linkedin.com/company/astrazeneca" "viewed_company_id" => null "created" => "2016-12-08 17:40:09" "last_updated" => "2017-02-23 07:53:00" "deleted" => 1 ] [ "id" => 85878699 "company_id" => 1258906 "viewed_company_url" => "https://www.linkedin.com/company/bayer" "viewed_company_id" => null "created" => "2017-02-23 07:52:59" "last_updated" => "2018-07-10 08:55:14" "deleted" => 1 ] [ "id" => 139870620 "company_id" => 1258906 "viewed_company_url" => "https://www.linkedin.com/company/procter-and-gamble" "viewed_company_id" => null "created" => "2018-07-10 08:55:14" "last_updated" => "2019-08-05 23:54:41" "deleted" => 1 ] [ "id" => 139870621 "company_id" => 1258906 "viewed_company_url" => "https://www.linkedin.com/company/abbott-" "viewed_company_id" => null "created" => "2018-07-10 08:55:14" "last_updated" => "2019-03-09 08:40:03" "deleted" => 1 ] [ "id" => 194547293 "company_id" => 1258906 "viewed_company_url" => "https://www.linkedin.com/company/merck" "viewed_company_id" => null "created" => "2019-03-09 08:40:03" "last_updated" => "2019-08-05 23:54:41" "deleted" => 1 ] [ "id" => 260665608 "company_id" => 1258906 "viewed_company_url" => "https://ca.linkedin.com/company/johnson-&-johnson" "viewed_company_id" => null "created" => "2019-08-05 23:54:41" "last_updated" => "2019-10-16 15:52:49" "deleted" => 1 ] [ "id" => 260665613 "company_id" => 1258906 "viewed_company_url" => "https://ca.linkedin.com/company/novartis" "viewed_company_id" => null "created" => "2019-08-05 23:54:41" "last_updated" => "2019-10-16 15:52:49" "deleted" => 1 ] [ "id" => 260665619 "company_id" => 1258906 "viewed_company_url" => "https://ca.linkedin.com/company/sanofi" "viewed_company_id" => null "created" => "2019-08-05 23:54:41" "last_updated" => "2019-10-16 15:52:49" "deleted" => 1 ] [ "id" => 260665625 "company_id" => 1258906 "viewed_company_url" => "https://ca.linkedin.com/company/glaxosmithkline" "viewed_company_id" => null "created" => "2019-08-05 23:54:41" "last_updated" => "2019-10-16 15:52:49" "deleted" => 1 ] [ "id" => 260665630 "company_id" => 1258906 "viewed_company_url" => "https://ca.linkedin.com/company/procter-and-gamble" "viewed_company_id" => null "created" => "2019-08-05 23:54:41" "last_updated" => "2019-10-16 15:52:49" "deleted" => 1 ] [ "id" => 260665633 "company_id" => 1258906 "viewed_company_url" => "https://ca.linkedin.com/company/merck" "viewed_company_id" => null "created" => "2019-08-05 23:54:41" "last_updated" => "2019-10-16 15:52:49" "deleted" => 1 ] ] "company_crunchbase_info_collection" => [ [ "id" => 402053 "company_id" => 1258906 "cb_url" => "https://www.crunchbase.com/organization/pfizer" "created" => "2023-06-17 13:41:27" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] ] "company_featured_employees_collection" => [ [ "id" => 1799863 "company_id" => 1258906 "url" => "https://www.linkedin.com/in/robin-cerrito-7412" "created" => "2019-10-16 15:52:49" "last_updated" => "2020-01-31 06:16:26" "deleted" => 1 ] [ "id" => 1799865 "company_id" => 1258906 "url" => "https://www.linkedin.com/in/keli-arnold-b633" "created" => "2019-10-16 15:52:49" "last_updated" => "2020-01-31 06:16:26" "deleted" => 1 ] [ "id" => 1799868 "company_id" => 1258906 "url" => "https://www.linkedin.com/in/jason-kim-8015" "created" => "2019-10-16 15:52:49" "last_updated" => "2020-01-31 06:16:26" "deleted" => 1 ] [ "id" => 1799870 "company_id" => 1258906 "url" => "https://www.linkedin.com/in/jmsaunders" "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 34949547 "company_id" => 1258906 "url" => "https://www.linkedin.com/in/timothylanderson" "created" => "2020-01-31 06:16:26" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 63974742 "company_id" => 1258906 "url" => "https://www.linkedin.com/in/anthonythorp" "created" => "2021-04-15 02:26:40" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 66821154 "company_id" => 1258906 "url" => "https://www.linkedin.com/in/aribackman" "created" => "2021-06-20 17:17:27" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 99322352 "company_id" => 1258906 "url" => "https://www.linkedin.com/in/jmsaunders" "created" => "2022-07-17 08:29:50" "last_updated" => "2024-01-07 05:54:35" "deleted" => 1 ] [ "id" => 99322353 "company_id" => 1258906 "url" => "https://www.linkedin.com/in/aribackman" "created" => "2022-07-17 08:29:50" "last_updated" => "2024-01-07 05:54:35" "deleted" => 1 ] [ "id" => 99322354 "company_id" => 1258906 "url" => "https://www.linkedin.com/in/timothylanderson" "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 199017642 "company_id" => 1258906 "url" => "https://www.linkedin.com/in/karenosofskymichelson" "created" => "2024-01-07 05:54:35" "last_updated" => "2025-02-15 05:09:12" "deleted" => 1 ] [ "id" => 200979801 "company_id" => 1258906 "url" => "https://www.linkedin.com/in/clarkted" "created" => "2024-02-02 00:56:22" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 220562151 "company_id" => 1258906 "url" => "https://www.linkedin.com/in/mack-mackenzie-4193a" "created" => "2025-02-15 05:09:12" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] ] "company_featured_investors_collection" => [ [ "id" => 4047665 "company_id" => 1258906 "investor_id" => 4071 "round_id" => 8350662 "created" => "2024-11-09 16:57:05" "last_updated" => "2024-12-08 18:55:07" "deleted" => 1 "company_investors_list" => [ "id" => 4071 "name" => "Starboard Value" "hash" => "0e56042e530d751fd18b09f4a1783af1" "cb_url" => "https://www.crunchbase.com/organization/starboard-value" "created" => "2020-09-09 15:55:51" "last_updated" => "2022-02-07 10:21:02" ] ] [ "id" => 4282642 "company_id" => 1258906 "investor_id" => 4071 "round_id" => 8656078 "created" => "2024-12-08 18:55:07" "last_updated" => "2025-01-18 21:21:12" "deleted" => 1 "company_investors_list" => [ "id" => 4071 "name" => "Starboard Value" "hash" => "0e56042e530d751fd18b09f4a1783af1" "cb_url" => "https://www.crunchbase.com/organization/starboard-value" "created" => "2020-09-09 15:55:51" "last_updated" => "2022-02-07 10:21:02" ] ] [ "id" => 4439400 "company_id" => 1258906 "investor_id" => 4071 "round_id" => 9107315 "created" => "2025-01-18 21:21:12" "last_updated" => "2025-02-15 05:09:12" "deleted" => 1 "company_investors_list" => [ "id" => 4071 "name" => "Starboard Value" "hash" => "0e56042e530d751fd18b09f4a1783af1" "cb_url" => "https://www.crunchbase.com/organization/starboard-value" "created" => "2020-09-09 15:55:51" "last_updated" => "2022-02-07 10:21:02" ] ] [ "id" => 4583942 "company_id" => 1258906 "investor_id" => 4071 "round_id" => 9416881 "created" => "2025-02-15 05:09:12" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 "company_investors_list" => [ "id" => 4071 "name" => "Starboard Value" "hash" => "0e56042e530d751fd18b09f4a1783af1" "cb_url" => "https://www.crunchbase.com/organization/starboard-value" "created" => "2020-09-09 15:55:51" "last_updated" => "2022-02-07 10:21:02" ] ] ] "company_funding_rounds_collection" => [ [ "id" => 131316 "last_round_investors_count" => 0 "total_rounds_count" => 0 "last_round_type" => null "last_round_date" => null "last_round_money_raised" => null "cb_url" => null "created" => "2020-09-22 20:26:21" "last_updated" => "2020-10-08 03:22:48" "deleted" => 1 ] [ "id" => 4830057 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2023-06-17 13:41:27" "last_updated" => "2023-07-13 23:17:18" "deleted" => 1 ] [ "id" => 5070141 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2023-07-13 23:17:18" "last_updated" => "2023-08-15 04:14:54" "deleted" => 1 ] [ "id" => 5360416 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2023-08-15 04:14:54" "last_updated" => "2023-09-11 21:09:31" "deleted" => 1 ] [ "id" => 5507439 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2023-09-11 21:09:31" "last_updated" => "2023-10-17 18:00:12" "deleted" => 1 ] [ "id" => 5710091 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2023-10-17 18:00:12" "last_updated" => "2023-11-26 05:54:43" "deleted" => 1 ] [ "id" => 5964752 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2023-11-26 05:54:43" "last_updated" => "2023-12-08 02:29:38" "deleted" => 1 ] [ "id" => 6055351 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2023-12-08 02:29:38" "last_updated" => "2024-01-07 05:54:35" "deleted" => 1 ] [ "id" => 6217230 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2024-01-07 05:54:35" "last_updated" => "2024-02-02 00:56:22" "deleted" => 1 ] [ "id" => 6369942 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2024-02-02 00:56:22" "last_updated" => "2024-03-08 17:45:58" "deleted" => 1 ] [ "id" => 6604357 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2024-03-08 17:45:58" "last_updated" => "2024-04-15 16:21:30" "deleted" => 1 ] [ "id" => 6855377 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2024-04-15 16:21:30" "last_updated" => "2024-05-26 01:15:26" "deleted" => 1 ] [ "id" => 7104749 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2024-05-26 01:15:26" "last_updated" => "2024-06-17 16:38:55" "deleted" => 1 ] [ "id" => 7278598 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2024-06-17 16:38:55" "last_updated" => "2024-07-18 02:11:25" "deleted" => 1 ] [ "id" => 7461329 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2024-07-18 02:11:25" "last_updated" => "2024-08-18 03:55:51" "deleted" => 1 ] [ "id" => 7686038 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2024-08-18 03:55:51" "last_updated" => "2024-08-31 15:23:13" "deleted" => 1 ] [ "id" => 7889157 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2024-08-31 15:23:13" "last_updated" => "2024-09-11 00:10:24" "deleted" => 1 ] [ "id" => 8045779 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2024-09-11 00:10:24" "last_updated" => "2024-10-09 03:37:03" "deleted" => 1 ] [ "id" => 8317858 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2024-10-09 03:37:03" "last_updated" => "2024-10-11 23:57:33" "deleted" => 1 ] [ "id" => 8350662 "last_round_investors_count" => 0 "total_rounds_count" => 1 "last_round_type" => "Post IPO debt" "last_round_date" => "2023-06-16 00:00:00" "last_round_money_raised" => "US$ 31.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-debt--b311f75b" "created" => "2024-10-11 23:57:33" "last_updated" => "2024-11-09 16:57:05" "deleted" => 1 ] [ "id" => 8656078 "last_round_investors_count" => 1 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2024-11-07 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-equity--8d2d0359" "created" => "2024-11-09 16:57:05" "last_updated" => "2024-12-08 18:55:07" "deleted" => 1 ] [ "id" => 9107315 "last_round_investors_count" => 1 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2024-11-07 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-equity--8d2d0359" "created" => "2024-12-08 18:55:07" "last_updated" => "2025-01-18 21:21:12" "deleted" => 1 ] [ "id" => 9416881 "last_round_investors_count" => 1 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2024-11-07 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-equity--8d2d0359" "created" => "2025-01-18 21:21:12" "last_updated" => "2025-02-15 05:09:12" "deleted" => 1 ] [ "id" => 9701330 "last_round_investors_count" => 1 "total_rounds_count" => 2 "last_round_type" => "Post IPO equity" "last_round_date" => "2024-11-07 00:00:00" "last_round_money_raised" => "US$ 1.0B" "cb_url" => "https://www.crunchbase.com/funding_round/pfizer-post-ipo-equity--8d2d0359" "created" => "2025-02-15 05:09:12" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] ] "company_locations_collection" => [ [ "id" => 696173 "company_id" => 1258906 "location_address" => "New York; New York, New York 10017, US" "is_primary" => 1 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696174 "company_id" => 1258906 "location_address" => "Abilay han dangili 141; Almaty, Almaty Oblysy 050000, KZ" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696175 "company_id" => 1258906 "location_address" => "Littleconnell; Newbridge, County Kildare, IE" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696176 "company_id" => 1258906 "location_address" => "280 Shennecossett Rd; Groton, CT 06340, US" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696178 "company_id" => 1258906 "location_address" => "Rijksweg 12; Puurs, Flemish Region 2870, BE" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2020-02-04 09:20:59" "deleted" => 1 ] [ "id" => 696181 "company_id" => 1258906 "location_address" => "85 Bute Ln; Sandton, Gauteng 2196, ZA" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696182 "company_id" => 1258906 "location_address" => "Via Isonzo, 71; Latina, Laz. 04100, IT" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696184 "company_id" => 1258906 "location_address" => "1 Burtt Rd; Andover, MA 01810, US" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696186 "company_id" => 1258906 "location_address" => "Mumbai; Mumbai, Maharastra 400102, IN" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696188 "company_id" => 1258906 "location_address" => "1200 Parkdale Rd; Rochester, MI 48307, US" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696189 "company_id" => 1258906 "location_address" => "1040 Swabia Ct; Durham, NC 27703, US" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696190 "company_id" => 1258906 "location_address" => "No. 177, Sec 2, Zhong Zheng E. Rd.; New Taipei City, New Taipei City 251, TW" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696191 "company_id" => 1258906 "location_address" => "1 Giralda Farms; Madison, NJ 07940, US" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696193 "company_id" => 1258906 "location_address" => "38-42 Wharf Rd; Sydney, NSW 2114, AU" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696194 "company_id" => 1258906 "location_address" => "500 Arcola Rd; Collegeville, PA 19426, US" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696196 "company_id" => 1258906 "location_address" => "1025 Boulevard Marcel-Laurin; Montreal, QC H4R 1J6, CA" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696197 "company_id" => 1258906 "location_address" => "31 Tuas South Ave 6; Singapore, Singapore 637578, SG" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 696200 "company_id" => 1258906 "location_address" => "Arye Shenkar 9; Herzliya, Tel Aviv 46725, IL" "is_primary" => 0 "created" => "2019-10-16 15:52:49" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 13472061 "company_id" => 1258906 "location_address" => "110; JUNGGU, Seoul, KR" "is_primary" => 0 "created" => "2020-01-31 06:16:26" "last_updated" => "2020-02-04 09:20:59" "deleted" => 1 ] [ "id" => 13746684 "company_id" => 1258906 "location_address" => "Rijksweg 12; Puurs, Flemish Region 2870, BE" "is_primary" => 0 "created" => "2020-03-12 17:10:03" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 13746685 "company_id" => 1258906 "location_address" => "110; JUNGGU, Seoul, KR" "is_primary" => 0 "created" => "2020-03-12 17:10:03" "last_updated" => "2020-12-20 19:57:19" "deleted" => 1 ] [ "id" => 75239293 "company_id" => 1258906 "location_address" => "New York; New York, New York 10017, US" "is_primary" => 1 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239294 "company_id" => 1258906 "location_address" => "Abilay han dangili 141; Almaty, Almaty Oblysy 050000, KZ" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239295 "company_id" => 1258906 "location_address" => "Littleconnell; Newbridge, County Kildare, IE" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239296 "company_id" => 1258906 "location_address" => "280 Shennecossett Rd; Groton, CT 06340, US" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239297 "company_id" => 1258906 "location_address" => "Rijksweg 12; Puurs, Flemish Region 2870, BE" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239298 "company_id" => 1258906 "location_address" => "85 Bute Ln; Sandton, Gauteng 2196, ZA" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239299 "company_id" => 1258906 "location_address" => "Via Isonzo, 71; Latina, Laz. 04100, IT" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239300 "company_id" => 1258906 "location_address" => "1 Burtt Rd; Andover, MA 01810, US" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239301 "company_id" => 1258906 "location_address" => "Mumbai; Mumbai, Maharastra 400102, IN" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239302 "company_id" => 1258906 "location_address" => "1200 Parkdale Rd; Rochester, MI 48307, US" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239303 "company_id" => 1258906 "location_address" => "1040 Swabia Ct; Durham, NC 27703, US" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239304 "company_id" => 1258906 "location_address" => "No. 177, Sec 2, Zhong Zheng E. Rd.; New Taipei City, New Taipei City 251, TW" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239305 "company_id" => 1258906 "location_address" => "1 Giralda Farms; Madison, NJ 07940, US" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239306 "company_id" => 1258906 "location_address" => "38-42 Wharf Rd; Sydney, NSW 2114, AU" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239307 "company_id" => 1258906 "location_address" => "500 Arcola Rd; Collegeville, PA 19426, US" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239308 "company_id" => 1258906 "location_address" => "1025 Boulevard Marcel-Laurin; Montreal, QC H4R 1J6, CA" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239309 "company_id" => 1258906 "location_address" => "31 Tuas South Ave 6; Singapore, Singapore 637578, SG" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 75239310 "company_id" => 1258906 "location_address" => "Arye Shenkar 9; Herzliya, Tel Aviv 46725, IL" "is_primary" => 0 "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 98072050 "company_id" => 1258906 "location_address" => "110; JUNGGU, Seoul, KR" "is_primary" => 0 "created" => "2022-08-09 20:43:39" "last_updated" => "2022-10-12 13:29:32" "deleted" => 1 ] [ "id" => 113957572 "company_id" => 1258906 "location_address" => "110; JUNGGU, Seoul, KR" "is_primary" => 0 "created" => "2022-11-23 05:21:13" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] ] "company_similar_collection" => [ [ "id" => 2404911 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2019-10-16 15:52:49" "last_updated" => "2021-06-20 17:17:27" "deleted" => 1 ] [ "id" => 2404913 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/novartis" "created" => "2019-10-16 15:52:49" "last_updated" => "2020-11-20 21:57:24" "deleted" => 1 ] [ "id" => 2404916 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/sanofi" "created" => "2019-10-16 15:52:49" "last_updated" => "2020-11-20 21:57:24" "deleted" => 1 ] [ "id" => 2404918 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/glaxosmithkline" "created" => "2019-10-16 15:52:49" "last_updated" => "2021-06-20 17:17:27" "deleted" => 1 ] [ "id" => 2404922 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/procter-and-gamble" "created" => "2019-10-16 15:52:49" "last_updated" => "2021-06-20 17:17:27" "deleted" => 1 ] [ "id" => 2404924 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/roche" "created" => "2019-10-16 15:52:49" "last_updated" => "2020-11-20 21:57:24" "deleted" => 1 ] [ "id" => 81421218 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/bayer" "created" => "2020-01-31 06:16:26" "last_updated" => "2020-11-20 21:57:24" "deleted" => 1 ] [ "id" => 81421219 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/merck" "created" => "2020-01-31 06:16:26" "last_updated" => "2021-06-20 17:17:27" "deleted" => 1 ] [ "id" => 81421220 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/abbott-" "created" => "2020-01-31 06:16:26" "last_updated" => "2021-06-20 17:17:27" "deleted" => 1 ] [ "id" => 81421221 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/astrazeneca" "created" => "2020-01-31 06:16:26" "last_updated" => "2021-06-20 17:17:27" "deleted" => 1 ] [ "id" => 286884225 "company_id" => 1258906 "url" => "https://ch.linkedin.com/company/novartis" "created" => "2020-11-20 21:57:24" "last_updated" => "2021-06-20 17:17:27" "deleted" => 1 ] [ "id" => 286884226 "company_id" => 1258906 "url" => "https://fr.linkedin.com/company/sanofi" "created" => "2020-11-20 21:57:24" "last_updated" => "2021-06-20 17:17:27" "deleted" => 1 ] [ "id" => 286884227 "company_id" => 1258906 "url" => "https://de.linkedin.com/company/bayer" "created" => "2020-11-20 21:57:24" "last_updated" => "2021-06-20 17:17:27" "deleted" => 1 ] [ "id" => 286884228 "company_id" => 1258906 "url" => "https://ch.linkedin.com/company/roche" "created" => "2020-11-20 21:57:24" "last_updated" => "2021-06-20 17:17:27" "deleted" => 1 ] [ "id" => 475868491 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2021-09-08 22:17:04" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 475868492 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/glaxosmithkline" "created" => "2021-09-08 22:17:04" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 475868493 "company_id" => 1258906 "url" => "https://ch.linkedin.com/company/novartis" "created" => "2021-09-08 22:17:04" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 475868494 "company_id" => 1258906 "url" => "https://fr.linkedin.com/company/sanofi" "created" => "2021-09-08 22:17:04" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 475868495 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/astrazeneca" "created" => "2021-09-08 22:17:04" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 475868496 "company_id" => 1258906 "url" => "https://de.linkedin.com/company/bayer" "created" => "2021-09-08 22:17:04" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 475868497 "company_id" => 1258906 "url" => "https://ch.linkedin.com/company/roche" "created" => "2021-09-08 22:17:04" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 475868498 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/merck" "created" => "2021-09-08 22:17:04" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 475868499 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/abbott-" "created" => "2021-09-08 22:17:04" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 475868500 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/procter-and-gamble" "created" => "2021-09-08 22:17:04" "last_updated" => "2022-02-28 11:29:45" "deleted" => 1 ] [ "id" => 555816872 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/unilever" "created" => "2022-02-28 11:29:45" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 667129185 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/glaxosmithkline" "created" => "2022-07-17 08:29:50" "last_updated" => "2022-10-12 13:29:32" "deleted" => 1 ] [ "id" => 667129186 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 667129187 "company_id" => 1258906 "url" => "https://ch.linkedin.com/company/novartis" "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 667129188 "company_id" => 1258906 "url" => "https://fr.linkedin.com/company/sanofi" "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 667129189 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/astrazeneca" "created" => "2022-07-17 08:29:50" "last_updated" => "2022-10-12 13:29:32" "deleted" => 1 ] [ "id" => 667129190 "company_id" => 1258906 "url" => "https://de.linkedin.com/company/bayer" "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 667129191 "company_id" => 1258906 "url" => "https://ch.linkedin.com/company/roche" "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 667129192 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/abbott-" "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 667129193 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/merck" "created" => "2022-07-17 08:29:50" "last_updated" => "2024-07-18 02:11:25" "deleted" => 1 ] [ "id" => 667129194 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/unilever" "created" => "2022-07-17 08:29:50" "last_updated" => "2022-10-12 13:29:32" "deleted" => 1 ] [ "id" => 724269000 "company_id" => 1258906 "url" => "https://uk.linkedin.com/company/glaxosmithkline" "created" => "2022-10-12 13:29:32" "last_updated" => "2022-11-23 05:21:13" "deleted" => 1 ] [ "id" => 724269001 "company_id" => 1258906 "url" => "https://uk.linkedin.com/company/astrazeneca" "created" => "2022-10-12 13:29:32" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 724269002 "company_id" => 1258906 "url" => "https://uk.linkedin.com/company/unilever" "created" => "2022-10-12 13:29:32" "last_updated" => "2023-06-17 13:41:27" "deleted" => 1 ] [ "id" => 742527714 "company_id" => 1258906 "url" => "https://uk.linkedin.com/company/gsk" "created" => "2022-11-23 05:21:13" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 837858290 "company_id" => 1258906 "url" => "https://www.linkedin.com/company/eli-lilly-and-company" "created" => "2023-06-17 13:41:27" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 1034884166 "company_id" => 1258906 "url" => "https://dk.linkedin.com/company/novo-nordisk" "created" => "2024-07-18 02:11:25" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] ] "company_specialties_collection" => [ [ "id" => 1848085 "company_id" => 1258906 "specialty" => "To apply science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe" "created" => "2016-06-20 04:04:18" "last_updated" => "2020-07-31 11:42:08" "deleted" => 1 ] [ "id" => 1848086 "company_id" => 1258906 "specialty" => "effective and affordable medicines and health care services to the people who need them." "created" => "2016-06-20 04:04:18" "last_updated" => "2020-07-31 11:42:08" "deleted" => 1 ] [ "id" => 53390954 "company_id" => 1258906 "specialty" => "To apply science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe and effective and affordable medicines and health care services to the people who need them." "created" => "2020-07-31 11:42:08" "last_updated" => "2022-06-24 21:15:44" "deleted" => 1 ] [ "id" => 77418095 "company_id" => 1258906 "specialty" => "To apply science and our global resources to improve health and well-being at every stage of life. We strive to provide access to safe and effective and affordable medicines and health care services to the people who need them." "created" => "2022-07-17 08:29:50" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] ] "company_stock_info_collection" => [] "company_updates_collection" => [ [ "id" => 26592388 "company_id" => 1258906 "urn" => "urn:li:activity:7010650674619195392" "followers" => 5091386 "date" => "1w" "description" => """ Thank you Save the Children US for your partnership and commitment to helping advance equitable access to routine immunizations for children in Kenya. Because no child should die from an infection that could be prevented with access to basic healthcare.\n \n Watch this video to learn more about how Save the Children is working with community health workers and volunteers to reach those in need with essential health services 👇\n \n #Partnership #InfectiousDiseases #HealthEquity """ "reactions_count" => 269 "comments_count" => 3 "reshared_post_author" => "Save the Children US" "reshared_post_author_url" => "https://www.linkedin.com/company/save-the-children-us" "reshared_post_author_headline" => null "reshared_post_description" => """ Since 2020, we have worked with the Pfizer Foundation in Kenya to ensure children receive life-saving vaccines. \n \n Save the Children staff work with volunteers and health workers to increase immunization coverage in urban Nairobi and remote communities in the northeast, helping more children grow up healthy and strong so they can reach their full potential! """ "reshared_post_followers" => 112102 "reshared_post_date" => "2w" "last_updated" => "2023-01-11 19:51:55" "deleted" => 1 ] [ "id" => 26592389 "company_id" => 1258906 "urn" => "urn:li:activity:7009177610316357633" "followers" => 5091386 "date" => "2w" "description" => "Pfizer is proud of this research agreement with Anumana to develop an AI-ECG algorithm for earlier suspicion of cardiac amyloidosis. Learn more about the research agreement: on.pfizer.com/3uUY2WI" "reactions_count" => 660 "comments_count" => 10 "reshared_post_author" => "Anumana" "reshared_post_author_url" => "https://www.linkedin.com/company/anumana-inc" "reshared_post_author_headline" => null "reshared_post_description" => """ #NEW: Anumana is thrilled to announce the initiation of a research agreement from Pfizer to develop an AI-ECG algorithm to aid in early detection of patients who may be at risk of cardiac #amyloidosis. While there is no known cure for this disease, earlier suspicion may be crucial to improve time to diagnosis and care.\n \n Under the research agreement, Anumana will conduct clinical validation and prepare for FDA De Novo classification for the AI-ECG algorithm for early suspicion of cardiac amyloidosis as a #SaMD. In addition, Anumana aims to gain regulatory approval in the E.U. and Japan.\n \n “We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.” said David McMullin, Chief Business Officer at Anumana.\n \n The research agreement with Pfizer will deepen Anumana’s efforts to implement AI-enabled software that can uncover ECG signals unrecognizable to the human eye. AI-ECG algorithms have the potential to provide an early warning in #cardiology, enabling patients to receive earlier intervention. \n \n Congratulations to the leaders at Anumana & Pfizer for initiating a research agreement supporting development of innovative AI software solutions for cardiology to address the unmet medical need for early suspicion of occult #heartdisease. #epeeps\n \n Learn more about the collaboration 👉🏽 https://lnkd.in/e_-TDzrM\n \n Murali Aravamudan, Venky Soundararajan, Paul Friedman, Francisco Lopez-Jimenez, Martha Grogan, Zachi Attia, Angela Dispenzieri """ "reshared_post_followers" => 2606 "reshared_post_date" => "2w" "last_updated" => "2023-01-11 19:51:55" "deleted" => 1 ] [ "id" => 26592390 "company_id" => 1258906 "urn" => "urn:li:activity:7008474835232153600" "followers" => 5091386 "date" => "2w" "description" => """ No one’s skin is exactly the same. Ensuring patients of every skin color suffering from dermatological diseases feel seen and understood is critical to advancing the field of medical dermatology. \n \n While progress has been made, there is still work to be done. In partnership with Bloomberg Live, our very own Leslie Koby sat down with Seemal R. Desai, MD, FAAD to discuss health equity in medical dermatology, the disparate challenges patients of color face, and efforts like the Every Color is Primary initiative to help address them. \n \n Watch the discussion to hear more. """ "reactions_count" => 476 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-11 19:51:55" "deleted" => 1 ] [ "id" => 26592391 "company_id" => 1258906 "urn" => "urn:li:activity:7006981733384417280" "followers" => 5091386 "date" => "2w" "description" => "Pfizer is offering a new grant seeking to advance #equity amongst people living with hemophilia (PLwH) to support their evidence-informed decisions about their #hemophilia treatment. Eligible applicants include Patient Advocacy Groups or other non-profit organizations of all sizes and from all countries that provide therapeutic #education to PLwH. The application submission deadline is Feb 16, 2023: https://lnkd.in/eEwmrAvM" "reactions_count" => 418 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-11 19:51:55" "deleted" => 1 ] [ "id" => 26592392 "company_id" => 1258906 "urn" => "urn:li:activity:7006663228265033728" "followers" => 5091386 "date" => "2w" "description" => """ BREAKING: Along with our partner BioNTech SE, we received Emergency Use Authorization from the FDA for our Omicron-adapted #COVID19 vaccine as the third dose in the three-dose primary series in children 6 months through 4 years. Doses will be shipped immediately upon recommendation by CDC.\n \n Learn more about this announcement: https://lnkd.in/gFE6zupr \n \n _ _ _\n Emergency uses of the bivalent vaccine have not been approved or licensed by FDA, but have been authorized under an Emergency Use Authorization (EUA) to prevent COVID-19 in individuals 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use, unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at www.cvdvaccine-us.com """ "reactions_count" => 4645 "comments_count" => 30 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-11 19:51:55" "deleted" => 1 ] [ "id" => 26592393 "company_id" => 1258906 "urn" => "urn:li:activity:7004104900158574593" "followers" => 5091386 "date" => "4w" "description" => """ We’re hiring Engineers, Maintenance, Supervisors, Quality, Lab, and Technicians. Pfizer Rocky Mount will be hosting an Engineering & Technical Career Fair on December 6 at the Rocky Mount Event Center! This is a unique opportunity to meet the team, apply, and interview during the event! If you’ve ever been curious about a career at Pfizer, now is the time to come out and learn more. Pre-register using this link: https://lnkd.in/eu3FuDbg\n #hiringnow """ "reactions_count" => 498 "comments_count" => 56 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-11 19:51:55" "deleted" => 1 ] [ "id" => 26592394 "company_id" => 1258906 "urn" => "urn:li:activity:7003840485647663104" "followers" => 5091386 "date" => "4w" "description" => "We are proud to be awarded “Supply Chain Breakthrough of the Year” by Gartner for building an entirely new ultra-cold supply chain, in record time, which brought our #COVID19 vaccine co-developed with BioNTech to the world. Additionally, Pfizer was ranked #6 in Gartner’s Global Supply Chain Top 25 for 2022: https://lnkd.in/d3wGUT3F. This is a testament to the innovations and breakthrough solutions of our incredible Pfizer Global Supply colleagues who continue to make the impossible possible." "reactions_count" => 1838 "comments_count" => 22 "reshared_post_author" => "Gartner for Supply Chain" "reshared_post_author_url" => "https://www.linkedin.com/showcase/gartner-for-supply-chain" "reshared_post_author_headline" => null "reshared_post_description" => """ Pfizer's 2022 innovation for deep-freezing the supply chain to bring the #COVID19 vaccine to the world earned them the title Breakthrough of the Year 🎉 \n \n Learn how they got there in our report: https://gtnr.it/3LIxL5k\n \n #GartnerSC #SupplyChainManagement #SupplyChainExcellence """ "reshared_post_followers" => 47720 "reshared_post_date" => "2mo" "last_updated" => "2023-01-11 19:51:55" "deleted" => 1 ] [ "id" => 26592395 "company_id" => 1258906 "urn" => "urn:li:activity:7000887873432367104" "followers" => 5091386 "date" => "1mo" "description" => """ Are you an experienced engineer, technician, or supervisor? Or do you have maintenance, technician, supervisor, quality, or lab experience?\n \n Register for our Pfizer’s Engineering and Technical Career Fair in Rocky Mount on December 6. You’ll have a chance to meet the team.\n \n Apply for jobs and interview! Apply now: https://lnkd.in/dcCEtUHg """ "reactions_count" => 382 "comments_count" => 30 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-11 19:51:55" "deleted" => 1 ] [ "id" => 26592396 "company_id" => 1258906 "urn" => "urn:li:activity:6999400949043654656" "followers" => 5091386 "date" => "1mo" "description" => "We are proud to join forces with the British Society for Antimicrobial Chemotherapy (BSAC) and EBRD to improve understanding amongst the financial community of the value of antimicrobial stewardship programs, and the need for investment in future pandemic preparedness. Read more about how this alliance will help address the global threat of antimicrobial resistance below. #AntimicrobialResistance #AMR" "reactions_count" => 257 "comments_count" => 2 "reshared_post_author" => "EBRD" "reshared_post_author_url" => "https://uk.linkedin.com/company/ebrd" "reshared_post_author_headline" => null "reshared_post_description" => """ Proud to have formed an alliance with British Society for Antimicrobial Chemotherapy (BSAC) and Pfizer to tackle antimicrobial resistance. A global public health threat that leads to more deaths than either HIV/AIDS or malaria.\n \n Together, we will encourage cooperation between commerce and investment companies to reduce the risks of AMR to society, saving lives while protecting the global economy.\n \n We are launching this alliance in anticipation of this year's World Antimicrobial Awareness Week.\n \n https://lnkd.in/eFuRZRkX\n \n #AntimicrobialResistance, #WAAW, #BSAC, #Pfizer """ "reshared_post_followers" => 196676 "reshared_post_date" => "1mo" "last_updated" => "2023-01-11 19:51:55" "deleted" => 1 ] [ "id" => 26592397 "company_id" => 1258906 "urn" => "urn:li:activity:6999392028824395776" "followers" => 5091386 "date" => "1mo" "description" => "Last week, our CEO Albert Bourla was presented with the “Courage Against Hate” award from the Anti-Defamation League. Albert used the opportunity to deliver a powerful speech on challenging anti-Semitism, racism, and all other forms of bigotry, especially when disinformation is used as a tool to sow hatred. Below are his remarks." "reactions_count" => 959 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-11 19:51:55" "deleted" => 1 ] [ "id" => 40187611 "company_id" => 1258906 "urn" => "urn:li:activity:7010650674619195392" "followers" => 5110922 "date" => "3w" "description" => """ Thank you Save the Children US for your partnership and commitment to helping advance equitable access to routine immunizations for children in Kenya. Because no child should die from an infection that could be prevented with access to basic healthcare.\n \n Watch this video to learn more about how Save the Children is working with community health workers and volunteers to reach those in need with essential health services 👇\n \n #Partnership #InfectiousDiseases #HealthEquity """ "reactions_count" => 298 "comments_count" => 3 "reshared_post_author" => "Save the Children US" "reshared_post_author_url" => "https://www.linkedin.com/company/save-the-children-us" "reshared_post_author_headline" => null "reshared_post_description" => """ Since 2020, we have worked with the Pfizer Foundation in Kenya to ensure children receive life-saving vaccines. \n \n Save the Children staff work with volunteers and health workers to increase immunization coverage in urban Nairobi and remote communities in the northeast, helping more children grow up healthy and strong so they can reach their full potential! """ "reshared_post_followers" => 114105 "reshared_post_date" => "4w" "last_updated" => "2023-01-16 22:49:30" "deleted" => 1 ] [ "id" => 40187612 "company_id" => 1258906 "urn" => "urn:li:activity:7009177610316357633" "followers" => 5110922 "date" => "3w" "description" => "Pfizer is proud of this research agreement with Anumana to develop an AI-ECG algorithm for earlier suspicion of cardiac amyloidosis. Learn more about the research agreement: on.pfizer.com/3uUY2WI" "reactions_count" => 659 "comments_count" => 10 "reshared_post_author" => "Anumana" "reshared_post_author_url" => "https://www.linkedin.com/company/anumana-inc" "reshared_post_author_headline" => null "reshared_post_description" => """ #NEW: Anumana is thrilled to announce the initiation of a research agreement from Pfizer to develop an AI-ECG algorithm to aid in early detection of patients who may be at risk of cardiac #amyloidosis. While there is no known cure for this disease, earlier suspicion may be crucial to improve time to diagnosis and care.\n \n Under the research agreement, Anumana will conduct clinical validation and prepare for FDA De Novo classification for the AI-ECG algorithm for early suspicion of cardiac amyloidosis as a #SaMD. In addition, Anumana aims to gain regulatory approval in the E.U. and Japan.\n \n “We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.” said David McMullin, Chief Business Officer at Anumana.\n \n The research agreement with Pfizer will deepen Anumana’s efforts to implement AI-enabled software that can uncover ECG signals unrecognizable to the human eye. AI-ECG algorithms have the potential to provide an early warning in #cardiology, enabling patients to receive earlier intervention. \n \n Congratulations to the leaders at Anumana & Pfizer for initiating a research agreement supporting development of innovative AI software solutions for cardiology to address the unmet medical need for early suspicion of occult #heartdisease. #epeeps\n \n Learn more about the collaboration 👉🏽 https://lnkd.in/e_-TDzrM\n \n Murali Aravamudan, Venky Soundararajan, Paul Friedman, Francisco Lopez-Jimenez, Martha Grogan, Zachi Attia, Angela Dispenzieri """ "reshared_post_followers" => 2655 "reshared_post_date" => "3w" "last_updated" => "2023-01-16 22:49:30" "deleted" => 1 ] [ "id" => 40187613 "company_id" => 1258906 "urn" => "urn:li:activity:7008474835232153600" "followers" => 5110922 "date" => "4w" "description" => """ No one’s skin is exactly the same. Ensuring patients of every skin color suffering from dermatological diseases feel seen and understood is critical to advancing the field of medical dermatology. \n \n While progress has been made, there is still work to be done. In partnership with Bloomberg Live, our very own Leslie Koby sat down with Seemal R. Desai, MD, FAAD to discuss health equity in medical dermatology, the disparate challenges patients of color face, and efforts like the Every Color is Primary initiative to help address them. \n \n Watch the discussion to hear more. """ "reactions_count" => 486 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 22:49:30" "deleted" => 1 ] [ "id" => 40187614 "company_id" => 1258906 "urn" => "urn:li:activity:7006981733384417280" "followers" => 5110922 "date" => "1mo" "description" => "Pfizer is offering a new grant seeking to advance #equity amongst people living with hemophilia (PLwH) to support their evidence-informed decisions about their #hemophilia treatment. Eligible applicants include Patient Advocacy Groups or other non-profit organizations of all sizes and from all countries that provide therapeutic #education to PLwH. The application submission deadline is Feb 16, 2023: https://lnkd.in/eEwmrAvM" "reactions_count" => 426 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 22:49:30" "deleted" => 1 ] [ "id" => 40187615 "company_id" => 1258906 "urn" => "urn:li:activity:7006663228265033728" "followers" => 5110922 "date" => "1mo" "description" => """ BREAKING: Along with our partner BioNTech SE, we received Emergency Use Authorization from the FDA for our Omicron-adapted #COVID19 vaccine as the third dose in the three-dose primary series in children 6 months through 4 years. Doses will be shipped immediately upon recommendation by CDC.\n \n Learn more about this announcement: https://lnkd.in/gFE6zupr \n \n _ _ _\n Emergency uses of the bivalent vaccine have not been approved or licensed by FDA, but have been authorized under an Emergency Use Authorization (EUA) to prevent COVID-19 in individuals 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use, unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at www.cvdvaccine-us.com """ "reactions_count" => 4661 "comments_count" => 30 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 22:49:30" "deleted" => 1 ] [ "id" => 40187616 "company_id" => 1258906 "urn" => "urn:li:activity:7004104900158574593" "followers" => 5110922 "date" => "1mo" "description" => """ We’re hiring Engineers, Maintenance, Supervisors, Quality, Lab, and Technicians. Pfizer Rocky Mount will be hosting an Engineering & Technical Career Fair on December 6 at the Rocky Mount Event Center! This is a unique opportunity to meet the team, apply, and interview during the event! If you’ve ever been curious about a career at Pfizer, now is the time to come out and learn more. Pre-register using this link: https://lnkd.in/eu3FuDbg\n #hiringnow """ "reactions_count" => 496 "comments_count" => 56 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 22:49:30" "deleted" => 1 ] [ "id" => 40187617 "company_id" => 1258906 "urn" => "urn:li:activity:7003840485647663104" "followers" => 5110922 "date" => "1mo" "description" => "We are proud to be awarded “Supply Chain Breakthrough of the Year” by Gartner for building an entirely new ultra-cold supply chain, in record time, which brought our #COVID19 vaccine co-developed with BioNTech to the world. Additionally, Pfizer was ranked #6 in Gartner’s Global Supply Chain Top 25 for 2022: https://lnkd.in/d3wGUT3F. This is a testament to the innovations and breakthrough solutions of our incredible Pfizer Global Supply colleagues who continue to make the impossible possible." "reactions_count" => 1836 "comments_count" => 22 "reshared_post_author" => "Gartner for Supply Chain" "reshared_post_author_url" => "https://www.linkedin.com/showcase/gartner-for-supply-chain" "reshared_post_author_headline" => null "reshared_post_description" => """ Pfizer's 2022 innovation for deep-freezing the supply chain to bring the #COVID19 vaccine to the world earned them the title Breakthrough of the Year 🎉 \n \n Learn how they got there in our report: https://gtnr.it/3LIxL5k\n \n #GartnerSC #SupplyChainManagement #SupplyChainExcellence """ "reshared_post_followers" => 48531 "reshared_post_date" => "3mo" "last_updated" => "2023-01-16 22:49:30" "deleted" => 1 ] [ "id" => 40187618 "company_id" => 1258906 "urn" => "urn:li:activity:7000887873432367104" "followers" => 5110922 "date" => "1mo" "description" => """ Are you an experienced engineer, technician, or supervisor? Or do you have maintenance, technician, supervisor, quality, or lab experience?\n \n Register for our Pfizer’s Engineering and Technical Career Fair in Rocky Mount on December 6. You’ll have a chance to meet the team.\n \n Apply for jobs and interview! Apply now: https://lnkd.in/dcCEtUHg """ "reactions_count" => 381 "comments_count" => 29 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 22:49:30" "deleted" => 1 ] [ "id" => 40187619 "company_id" => 1258906 "urn" => "urn:li:activity:6999400949043654656" "followers" => 5110922 "date" => "1mo" "description" => "We are proud to join forces with the British Society for Antimicrobial Chemotherapy (BSAC) and EBRD to improve understanding amongst the financial community of the value of antimicrobial stewardship programs, and the need for investment in future pandemic preparedness. Read more about how this alliance will help address the global threat of antimicrobial resistance below. #AntimicrobialResistance #AMR" "reactions_count" => 256 "comments_count" => 2 "reshared_post_author" => "EBRD" "reshared_post_author_url" => "https://uk.linkedin.com/company/ebrd" "reshared_post_author_headline" => null "reshared_post_description" => """ Proud to have formed an alliance with British Society for Antimicrobial Chemotherapy (BSAC) and Pfizer to tackle antimicrobial resistance. A global public health threat that leads to more deaths than either HIV/AIDS or malaria.\n \n Together, we will encourage cooperation between commerce and investment companies to reduce the risks of AMR to society, saving lives while protecting the global economy.\n \n We are launching this alliance in anticipation of this year's World Antimicrobial Awareness Week.\n \n https://lnkd.in/eFuRZRkX\n \n #AntimicrobialResistance, #WAAW, #BSAC, #Pfizer """ "reshared_post_followers" => 197513 "reshared_post_date" => "2mo" "last_updated" => "2023-01-16 22:49:30" "deleted" => 1 ] [ "id" => 40187620 "company_id" => 1258906 "urn" => "urn:li:activity:6999392028824395776" "followers" => 5110922 "date" => "1mo" "description" => "Last week, our CEO Albert Bourla was presented with the “Courage Against Hate” award from the Anti-Defamation League. Albert used the opportunity to deliver a powerful speech on challenging anti-Semitism, racism, and all other forms of bigotry, especially when disinformation is used as a tool to sow hatred. Below are his remarks." "reactions_count" => 956 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 22:49:30" "deleted" => 1 ] [ "id" => 48977873 "company_id" => 1258906 "urn" => "urn:li:activity:7010650674619195392" "followers" => 5119360 "date" => "4w" "description" => """ Thank you Save the Children US for your partnership and commitment to helping advance equitable access to routine immunizations for children in Kenya. Because no child should die from an infection that could be prevented with access to basic healthcare.\n \n Watch this video to learn more about how Save the Children is working with community health workers and volunteers to reach those in need with essential health services 👇\n \n #Partnership #InfectiousDiseases #HealthEquity """ "reactions_count" => 294 "comments_count" => 3 "reshared_post_author" => "Save the Children US" "reshared_post_author_url" => "https://www.linkedin.com/company/save-the-children-us" "reshared_post_author_headline" => null "reshared_post_description" => """ Since 2020, we have worked with the Pfizer Foundation in Kenya to ensure children receive life-saving vaccines. \n \n Save the Children staff work with volunteers and health workers to increase immunization coverage in urban Nairobi and remote communities in the northeast, helping more children grow up healthy and strong so they can reach their full potential! """ "reshared_post_followers" => 115000 "reshared_post_date" => "1mo" "last_updated" => "2023-01-16 22:49:39" "deleted" => 1 ] [ "id" => 48977874 "company_id" => 1258906 "urn" => "urn:li:activity:7009177610316357633" "followers" => 5119360 "date" => "1mo" "description" => "Pfizer is proud of this research agreement with Anumana to develop an AI-ECG algorithm for earlier suspicion of cardiac amyloidosis. Learn more about the research agreement: on.pfizer.com/3uUY2WI" "reactions_count" => 659 "comments_count" => 10 "reshared_post_author" => "Anumana" "reshared_post_author_url" => "https://www.linkedin.com/company/anumana-inc" "reshared_post_author_headline" => null "reshared_post_description" => """ #NEW: Anumana is thrilled to announce the initiation of a research agreement from Pfizer to develop an AI-ECG algorithm to aid in early detection of patients who may be at risk of cardiac #amyloidosis. While there is no known cure for this disease, earlier suspicion may be crucial to improve time to diagnosis and care.\n \n Under the research agreement, Anumana will conduct clinical validation and prepare for FDA De Novo classification for the AI-ECG algorithm for early suspicion of cardiac amyloidosis as a #SaMD. In addition, Anumana aims to gain regulatory approval in the E.U. and Japan.\n \n “We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.” said David McMullin, Chief Business Officer at Anumana.\n \n The research agreement with Pfizer will deepen Anumana’s efforts to implement AI-enabled software that can uncover ECG signals unrecognizable to the human eye. AI-ECG algorithms have the potential to provide an early warning in #cardiology, enabling patients to receive earlier intervention. \n \n Congratulations to the leaders at Anumana & Pfizer for initiating a research agreement supporting development of innovative AI software solutions for cardiology to address the unmet medical need for early suspicion of occult #heartdisease. #epeeps\n \n Learn more about the collaboration 👉🏽 https://lnkd.in/e_-TDzrM\n \n Murali Aravamudan, Venky Soundararajan, Paul Friedman, Francisco Lopez-Jimenez, Martha Grogan, Zachi Attia, Angela Dispenzieri """ "reshared_post_followers" => 2687 "reshared_post_date" => "1mo" "last_updated" => "2023-01-16 22:49:39" "deleted" => 1 ] [ "id" => 48977875 "company_id" => 1258906 "urn" => "urn:li:activity:7008474835232153600" "followers" => 5119360 "date" => "1mo" "description" => """ No one’s skin is exactly the same. Ensuring patients of every skin color suffering from dermatological diseases feel seen and understood is critical to advancing the field of medical dermatology. \n \n While progress has been made, there is still work to be done. In partnership with Bloomberg Live, our very own Leslie Koby sat down with Seemal R. Desai, MD, FAAD to discuss health equity in medical dermatology, the disparate challenges patients of color face, and efforts like the Every Color is Primary initiative to help address them. \n \n Watch the discussion to hear more. """ "reactions_count" => 495 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 22:49:39" "deleted" => 1 ] [ "id" => 48977876 "company_id" => 1258906 "urn" => "urn:li:activity:7006981733384417280" "followers" => 5119360 "date" => "1mo" "description" => "Pfizer is offering a new grant seeking to advance #equity amongst people living with hemophilia (PLwH) to support their evidence-informed decisions about their #hemophilia treatment. Eligible applicants include Patient Advocacy Groups or other non-profit organizations of all sizes and from all countries that provide therapeutic #education to PLwH. The application submission deadline is Feb 16, 2023: https://lnkd.in/eEwmrAvM" "reactions_count" => 432 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 22:49:39" "deleted" => 1 ] [ "id" => 48977877 "company_id" => 1258906 "urn" => "urn:li:activity:7006663228265033728" "followers" => 5119360 "date" => "1mo" "description" => """ BREAKING: Along with our partner BioNTech SE, we received Emergency Use Authorization from the FDA for our Omicron-adapted #COVID19 vaccine as the third dose in the three-dose primary series in children 6 months through 4 years. Doses will be shipped immediately upon recommendation by CDC.\n \n Learn more about this announcement: https://lnkd.in/gFE6zupr \n \n _ _ _\n Emergency uses of the bivalent vaccine have not been approved or licensed by FDA, but have been authorized under an Emergency Use Authorization (EUA) to prevent COVID-19 in individuals 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use, unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at www.cvdvaccine-us.com """ "reactions_count" => 4658 "comments_count" => 30 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 22:49:39" "deleted" => 1 ] [ "id" => 48977878 "company_id" => 1258906 "urn" => "urn:li:activity:7004104900158574593" "followers" => 5119360 "date" => "1mo" "description" => """ We’re hiring Engineers, Maintenance, Supervisors, Quality, Lab, and Technicians. Pfizer Rocky Mount will be hosting an Engineering & Technical Career Fair on December 6 at the Rocky Mount Event Center! This is a unique opportunity to meet the team, apply, and interview during the event! If you’ve ever been curious about a career at Pfizer, now is the time to come out and learn more. Pre-register using this link: https://lnkd.in/eu3FuDbg\n #hiringnow """ "reactions_count" => 499 "comments_count" => 56 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 22:49:39" "deleted" => 1 ] [ "id" => 48977879 "company_id" => 1258906 "urn" => "urn:li:activity:7003840485647663104" "followers" => 5119360 "date" => "1mo" "description" => "We are proud to be awarded “Supply Chain Breakthrough of the Year” by Gartner for building an entirely new ultra-cold supply chain, in record time, which brought our #COVID19 vaccine co-developed with BioNTech to the world. Additionally, Pfizer was ranked #6 in Gartner’s Global Supply Chain Top 25 for 2022: https://lnkd.in/d3wGUT3F. This is a testament to the innovations and breakthrough solutions of our incredible Pfizer Global Supply colleagues who continue to make the impossible possible." "reactions_count" => 1837 "comments_count" => 22 "reshared_post_author" => "Gartner for Supply Chain" "reshared_post_author_url" => "https://www.linkedin.com/showcase/gartner-for-supply-chain" "reshared_post_author_headline" => null "reshared_post_description" => """ Pfizer's 2022 innovation for deep-freezing the supply chain to bring the #COVID19 vaccine to the world earned them the title Breakthrough of the Year 🎉 \n \n Learn how they got there in our report: https://gtnr.it/3LIxL5k\n \n #GartnerSC #SupplyChainManagement #SupplyChainExcellence """ "reshared_post_followers" => 48775 "reshared_post_date" => "3mo" "last_updated" => "2023-01-16 22:49:39" "deleted" => 1 ] [ "id" => 48977880 "company_id" => 1258906 "urn" => "urn:li:activity:7000887873432367104" "followers" => 5119360 "date" => "1mo" "description" => """ Are you an experienced engineer, technician, or supervisor? Or do you have maintenance, technician, supervisor, quality, or lab experience?\n \n Register for our Pfizer’s Engineering and Technical Career Fair in Rocky Mount on December 6. You’ll have a chance to meet the team.\n \n Apply for jobs and interview! Apply now: https://lnkd.in/dcCEtUHg """ "reactions_count" => 381 "comments_count" => 32 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 22:49:39" "deleted" => 1 ] [ "id" => 48977881 "company_id" => 1258906 "urn" => "urn:li:activity:6999400949043654656" "followers" => 5119360 "date" => "1mo" "description" => "We are proud to join forces with the British Society for Antimicrobial Chemotherapy (BSAC) and EBRD to improve understanding amongst the financial community of the value of antimicrobial stewardship programs, and the need for investment in future pandemic preparedness. Read more about how this alliance will help address the global threat of antimicrobial resistance below. #AntimicrobialResistance #AMR" "reactions_count" => 251 "comments_count" => 2 "reshared_post_author" => "EBRD" "reshared_post_author_url" => "https://uk.linkedin.com/company/ebrd" "reshared_post_author_headline" => null "reshared_post_description" => """ Proud to have formed an alliance with British Society for Antimicrobial Chemotherapy (BSAC) and Pfizer to tackle antimicrobial resistance. A global public health threat that leads to more deaths than either HIV/AIDS or malaria.\n \n Together, we will encourage cooperation between commerce and investment companies to reduce the risks of AMR to society, saving lives while protecting the global economy.\n \n We are launching this alliance in anticipation of this year's World Antimicrobial Awareness Week.\n \n https://lnkd.in/eFuRZRkX\n \n #AntimicrobialResistance, #WAAW, #BSAC, #Pfizer """ "reshared_post_followers" => 197852 "reshared_post_date" => "2mo" "last_updated" => "2023-01-16 22:49:39" "deleted" => 1 ] [ "id" => 48977882 "company_id" => 1258906 "urn" => "urn:li:activity:6999392028824395776" "followers" => 5119360 "date" => "1mo" "description" => "Last week, our CEO Albert Bourla was presented with the “Courage Against Hate” award from the Anti-Defamation League. Albert used the opportunity to deliver a powerful speech on challenging anti-Semitism, racism, and all other forms of bigotry, especially when disinformation is used as a tool to sow hatred. Below are his remarks." "reactions_count" => 952 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-16 22:49:39" "deleted" => 1 ] [ "id" => 48978194 "company_id" => 1258906 "urn" => "urn:li:activity:7010650674619195392" "followers" => 5119361 "date" => "4w" "description" => """ Thank you Save the Children US for your partnership and commitment to helping advance equitable access to routine immunizations for children in Kenya. Because no child should die from an infection that could be prevented with access to basic healthcare.\n \n Watch this video to learn more about how Save the Children is working with community health workers and volunteers to reach those in need with essential health services 👇\n \n #Partnership #InfectiousDiseases #HealthEquity """ "reactions_count" => 294 "comments_count" => 3 "reshared_post_author" => "Save the Children US" "reshared_post_author_url" => "https://www.linkedin.com/company/save-the-children-us" "reshared_post_author_headline" => null "reshared_post_description" => """ Since 2020, we have worked with the Pfizer Foundation in Kenya to ensure children receive life-saving vaccines. \n \n Save the Children staff work with volunteers and health workers to increase immunization coverage in urban Nairobi and remote communities in the northeast, helping more children grow up healthy and strong so they can reach their full potential! """ "reshared_post_followers" => 115000 "reshared_post_date" => "1mo" "last_updated" => "2023-02-06 14:43:33" "deleted" => 1 ] [ "id" => 48978195 "company_id" => 1258906 "urn" => "urn:li:activity:7009177610316357633" "followers" => 5119361 "date" => "1mo" "description" => "Pfizer is proud of this research agreement with Anumana to develop an AI-ECG algorithm for earlier suspicion of cardiac amyloidosis. Learn more about the research agreement: on.pfizer.com/3uUY2WI" "reactions_count" => 659 "comments_count" => 10 "reshared_post_author" => "Anumana" "reshared_post_author_url" => "https://www.linkedin.com/company/anumana-inc" "reshared_post_author_headline" => null "reshared_post_description" => """ #NEW: Anumana is thrilled to announce the initiation of a research agreement from Pfizer to develop an AI-ECG algorithm to aid in early detection of patients who may be at risk of cardiac #amyloidosis. While there is no known cure for this disease, earlier suspicion may be crucial to improve time to diagnosis and care.\n \n Under the research agreement, Anumana will conduct clinical validation and prepare for FDA De Novo classification for the AI-ECG algorithm for early suspicion of cardiac amyloidosis as a #SaMD. In addition, Anumana aims to gain regulatory approval in the E.U. and Japan.\n \n “We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.” said David McMullin, Chief Business Officer at Anumana.\n \n The research agreement with Pfizer will deepen Anumana’s efforts to implement AI-enabled software that can uncover ECG signals unrecognizable to the human eye. AI-ECG algorithms have the potential to provide an early warning in #cardiology, enabling patients to receive earlier intervention. \n \n Congratulations to the leaders at Anumana & Pfizer for initiating a research agreement supporting development of innovative AI software solutions for cardiology to address the unmet medical need for early suspicion of occult #heartdisease. #epeeps\n \n Learn more about the collaboration 👉🏽 https://lnkd.in/e_-TDzrM\n \n Murali Aravamudan, Venky Soundararajan, Paul Friedman, Francisco Lopez-Jimenez, Martha Grogan, Zachi Attia, Angela Dispenzieri """ "reshared_post_followers" => 2687 "reshared_post_date" => "1mo" "last_updated" => "2023-02-06 14:43:33" "deleted" => 1 ] [ "id" => 48978196 "company_id" => 1258906 "urn" => "urn:li:activity:7008474835232153600" "followers" => 5119361 "date" => "1mo" "description" => """ No one’s skin is exactly the same. Ensuring patients of every skin color suffering from dermatological diseases feel seen and understood is critical to advancing the field of medical dermatology. \n \n While progress has been made, there is still work to be done. In partnership with Bloomberg Live, our very own Leslie Koby sat down with Seemal R. Desai, MD, FAAD to discuss health equity in medical dermatology, the disparate challenges patients of color face, and efforts like the Every Color is Primary initiative to help address them. \n \n Watch the discussion to hear more. """ "reactions_count" => 495 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:43:33" "deleted" => 1 ] [ "id" => 48978197 "company_id" => 1258906 "urn" => "urn:li:activity:7006981733384417280" "followers" => 5119361 "date" => "1mo" "description" => "Pfizer is offering a new grant seeking to advance #equity amongst people living with hemophilia (PLwH) to support their evidence-informed decisions about their #hemophilia treatment. Eligible applicants include Patient Advocacy Groups or other non-profit organizations of all sizes and from all countries that provide therapeutic #education to PLwH. The application submission deadline is Feb 16, 2023: https://lnkd.in/eEwmrAvM" "reactions_count" => 432 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:43:33" "deleted" => 1 ] [ "id" => 48978198 "company_id" => 1258906 "urn" => "urn:li:activity:7006663228265033728" "followers" => 5119361 "date" => "1mo" "description" => """ BREAKING: Along with our partner BioNTech SE, we received Emergency Use Authorization from the FDA for our Omicron-adapted #COVID19 vaccine as the third dose in the three-dose primary series in children 6 months through 4 years. Doses will be shipped immediately upon recommendation by CDC.\n \n Learn more about this announcement: https://lnkd.in/gFE6zupr \n \n _ _ _\n Emergency uses of the bivalent vaccine have not been approved or licensed by FDA, but have been authorized under an Emergency Use Authorization (EUA) to prevent COVID-19 in individuals 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use, unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at www.cvdvaccine-us.com """ "reactions_count" => 4658 "comments_count" => 30 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:43:33" "deleted" => 1 ] [ "id" => 48978199 "company_id" => 1258906 "urn" => "urn:li:activity:7004104900158574593" "followers" => 5119361 "date" => "1mo" "description" => """ We’re hiring Engineers, Maintenance, Supervisors, Quality, Lab, and Technicians. Pfizer Rocky Mount will be hosting an Engineering & Technical Career Fair on December 6 at the Rocky Mount Event Center! This is a unique opportunity to meet the team, apply, and interview during the event! If you’ve ever been curious about a career at Pfizer, now is the time to come out and learn more. Pre-register using this link: https://lnkd.in/eu3FuDbg\n #hiringnow """ "reactions_count" => 499 "comments_count" => 56 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:43:33" "deleted" => 1 ] [ "id" => 48978200 "company_id" => 1258906 "urn" => "urn:li:activity:7003840485647663104" "followers" => 5119361 "date" => "1mo" "description" => "We are proud to be awarded “Supply Chain Breakthrough of the Year” by Gartner for building an entirely new ultra-cold supply chain, in record time, which brought our #COVID19 vaccine co-developed with BioNTech to the world. Additionally, Pfizer was ranked #6 in Gartner’s Global Supply Chain Top 25 for 2022: https://lnkd.in/d3wGUT3F. This is a testament to the innovations and breakthrough solutions of our incredible Pfizer Global Supply colleagues who continue to make the impossible possible." "reactions_count" => 1837 "comments_count" => 22 "reshared_post_author" => "Gartner for Supply Chain" "reshared_post_author_url" => "https://www.linkedin.com/showcase/gartner-for-supply-chain" "reshared_post_author_headline" => null "reshared_post_description" => """ Pfizer's 2022 innovation for deep-freezing the supply chain to bring the #COVID19 vaccine to the world earned them the title Breakthrough of the Year 🎉 \n \n Learn how they got there in our report: https://gtnr.it/3LIxL5k\n \n #GartnerSC #SupplyChainManagement #SupplyChainExcellence """ "reshared_post_followers" => 48775 "reshared_post_date" => "3mo" "last_updated" => "2023-02-06 14:43:33" "deleted" => 1 ] [ "id" => 48978201 "company_id" => 1258906 "urn" => "urn:li:activity:7000887873432367104" "followers" => 5119361 "date" => "1mo" "description" => """ Are you an experienced engineer, technician, or supervisor? Or do you have maintenance, technician, supervisor, quality, or lab experience?\n \n Register for our Pfizer’s Engineering and Technical Career Fair in Rocky Mount on December 6. You’ll have a chance to meet the team.\n \n Apply for jobs and interview! Apply now: https://lnkd.in/dcCEtUHg """ "reactions_count" => 381 "comments_count" => 32 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:43:33" "deleted" => 1 ] [ "id" => 48978202 "company_id" => 1258906 "urn" => "urn:li:activity:6999400949043654656" "followers" => 5119361 "date" => "1mo" "description" => "We are proud to join forces with the British Society for Antimicrobial Chemotherapy (BSAC) and EBRD to improve understanding amongst the financial community of the value of antimicrobial stewardship programs, and the need for investment in future pandemic preparedness. Read more about how this alliance will help address the global threat of antimicrobial resistance below. #AntimicrobialResistance #AMR" "reactions_count" => 251 "comments_count" => 2 "reshared_post_author" => "EBRD" "reshared_post_author_url" => "https://uk.linkedin.com/company/ebrd" "reshared_post_author_headline" => null "reshared_post_description" => """ Proud to have formed an alliance with British Society for Antimicrobial Chemotherapy (BSAC) and Pfizer to tackle antimicrobial resistance. A global public health threat that leads to more deaths than either HIV/AIDS or malaria.\n \n Together, we will encourage cooperation between commerce and investment companies to reduce the risks of AMR to society, saving lives while protecting the global economy.\n \n We are launching this alliance in anticipation of this year's World Antimicrobial Awareness Week.\n \n https://lnkd.in/eFuRZRkX\n \n #AntimicrobialResistance, #WAAW, #BSAC, #Pfizer """ "reshared_post_followers" => 197852 "reshared_post_date" => "2mo" "last_updated" => "2023-02-06 14:43:33" "deleted" => 1 ] [ "id" => 48978203 "company_id" => 1258906 "urn" => "urn:li:activity:6999392028824395776" "followers" => 5119361 "date" => "1mo" "description" => "Last week, our CEO Albert Bourla was presented with the “Courage Against Hate” award from the Anti-Defamation League. Albert used the opportunity to deliver a powerful speech on challenging anti-Semitism, racism, and all other forms of bigotry, especially when disinformation is used as a tool to sow hatred. Below are his remarks." "reactions_count" => 952 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 14:43:33" "deleted" => 1 ] [ "id" => 56270547 "company_id" => 1258906 "urn" => "urn:li:activity:7026574747689783297" "followers" => 5154663 "date" => "4d" "description" => """ To build inclusive and diverse colleague communities there must be intentional action. At Pfizer, we are proud of our efforts to create a culture where we support our colleagues and create opportunities for growth. This #BlackHistoryMonth, join us #LIVE as our colleagues Sherry Cassano, Sean Hudson and Ebony Arrington discuss how diverse voices create breakthroughs for our patients.\n \n 🗓️ Monday, February 13 at 11 am, ET """ "reactions_count" => 163 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-08 08:59:27" "deleted" => 1 ] [ "id" => 56270548 "company_id" => 1258906 "urn" => "urn:li:activity:7026233275023060992" "followers" => 5154663 "date" => "5d" "description" => """ Pfizer Ventures, our #VentureCapital arm, had another impactful year in 2022, with 10 new investments in emerging #biotech companies working in Pfizer’s core therapeutic areas or on transformative technologies—supporting our goal of enabling cutting-edge science with the potential to enhance our pipeline, shape the future of our industry and change patients’ lives.\n \n Check out the full Pfizer Ventures “2022 in Review” report to read about the year’s portfolio highlights, and visit https://lnkd.in/gHBDkS7X to learn more. """ "reactions_count" => 405 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-08 08:59:27" "deleted" => 1 ] [ "id" => 56270549 "company_id" => 1258906 "urn" => "urn:li:activity:7026212415067357184" "followers" => 5154663 "date" => "5d" "description" => "Here are a few of the highlights from our Q4 & Full Year 2022 earnings report. See the full details from our presentation today: https://lnkd.in/gQBPCaxN" "reactions_count" => 1285 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-08 08:59:27" "deleted" => 1 ] [ "id" => 56270550 "company_id" => 1258906 "urn" => "urn:li:activity:7025870470419730433" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Albert Bourla" "reshared_post_author_url" => "https://www.linkedin.com/in/albert-bourla" "reshared_post_author_headline" => "Chairman and Chief Executive Officer, Pfizer" "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => "6d" "last_updated" => "2023-02-08 08:59:27" "deleted" => 1 ] [ "id" => 56270551 "company_id" => 1258906 "urn" => "urn:li:activity:7010650674619195392" "followers" => 5154663 "date" => "1mo" "description" => """ Thank you Save the Children US for your partnership and commitment to helping advance equitable access to routine immunizations for children in Kenya. Because no child should die from an infection that could be prevented with access to basic healthcare.\n \n Watch this video to learn more about how Save the Children is working with community health workers and volunteers to reach those in need with essential health services 👇\n \n #Partnership #InfectiousDiseases #HealthEquity """ "reactions_count" => 297 "comments_count" => 3 "reshared_post_author" => "Save the Children US" "reshared_post_author_url" => "https://www.linkedin.com/company/save-the-children-us" "reshared_post_author_headline" => null "reshared_post_description" => """ Since 2020, we have worked with the Pfizer Foundation in Kenya to ensure children receive life-saving vaccines. \n \n Save the Children staff work with volunteers and health workers to increase immunization coverage in urban Nairobi and remote communities in the northeast, helping more children grow up healthy and strong so they can reach their full potential! """ "reshared_post_followers" => 119364 "reshared_post_date" => "1mo" "last_updated" => "2023-02-08 08:59:27" "deleted" => 1 ] [ "id" => 56270552 "company_id" => 1258906 "urn" => "urn:li:activity:7009177610316357633" "followers" => 5154663 "date" => "1mo" "description" => "Pfizer is proud of this research agreement with Anumana to develop an AI-ECG algorithm for earlier suspicion of cardiac amyloidosis. Learn more about the research agreement: on.pfizer.com/3uUY2WI" "reactions_count" => 659 "comments_count" => 10 "reshared_post_author" => "Anumana" "reshared_post_author_url" => "https://www.linkedin.com/company/anumana-inc" "reshared_post_author_headline" => null "reshared_post_description" => """ #NEW: Anumana is thrilled to announce the initiation of a research agreement from Pfizer to develop an AI-ECG algorithm to aid in early detection of patients who may be at risk of cardiac #amyloidosis. While there is no known cure for this disease, earlier suspicion may be crucial to improve time to diagnosis and care.\n \n Under the research agreement, Anumana will conduct clinical validation and prepare for FDA De Novo classification for the AI-ECG algorithm for early suspicion of cardiac amyloidosis as a #SaMD. In addition, Anumana aims to gain regulatory approval in the E.U. and Japan.\n \n “We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.” said David McMullin, Chief Business Officer at Anumana.\n \n The research agreement with Pfizer will deepen Anumana’s efforts to implement AI-enabled software that can uncover ECG signals unrecognizable to the human eye. AI-ECG algorithms have the potential to provide an early warning in #cardiology, enabling patients to receive earlier intervention. \n \n Congratulations to the leaders at Anumana & Pfizer for initiating a research agreement supporting development of innovative AI software solutions for cardiology to address the unmet medical need for early suspicion of occult #heartdisease. #epeeps\n \n Learn more about the collaboration 👉🏽 https://lnkd.in/e_-TDzrM\n \n Murali Aravamudan, Venky Soundararajan, Paul Friedman, Francisco Lopez-Jimenez, Martha Grogan, Zachi Attia, Angela Dispenzieri """ "reshared_post_followers" => 2769 "reshared_post_date" => "1mo" "last_updated" => "2023-02-08 08:59:27" "deleted" => 1 ] [ "id" => 56270553 "company_id" => 1258906 "urn" => "urn:li:activity:7008474835232153600" "followers" => 5154663 "date" => "1mo" "description" => """ No one’s skin is exactly the same. Ensuring patients of every skin color suffering from dermatological diseases feel seen and understood is critical to advancing the field of medical dermatology. \n \n While progress has been made, there is still work to be done. In partnership with Bloomberg Live, our very own Leslie Koby sat down with Seemal R. Desai, MD, FAAD to discuss health equity in medical dermatology, the disparate challenges patients of color face, and efforts like the Every Color is Primary initiative to help address them. \n \n Watch the discussion to hear more. """ "reactions_count" => 510 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-08 08:59:27" "deleted" => 1 ] [ "id" => 56270554 "company_id" => 1258906 "urn" => "urn:li:activity:7006981733384417280" "followers" => 5154663 "date" => "1mo" "description" => "Pfizer is offering a new grant seeking to advance #equity amongst people living with hemophilia (PLwH) to support their evidence-informed decisions about their #hemophilia treatment. Eligible applicants include Patient Advocacy Groups or other non-profit organizations of all sizes and from all countries that provide therapeutic #education to PLwH. The application submission deadline is Feb 16, 2023: https://lnkd.in/eEwmrAvM" "reactions_count" => 431 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-08 08:59:27" "deleted" => 1 ] [ "id" => 56270555 "company_id" => 1258906 "urn" => "urn:li:activity:7006663228265033728" "followers" => 5154663 "date" => "1mo" "description" => """ BREAKING: Along with our partner BioNTech SE, we received Emergency Use Authorization from the FDA for our Omicron-adapted #COVID19 vaccine as the third dose in the three-dose primary series in children 6 months through 4 years. Doses will be shipped immediately upon recommendation by CDC.\n \n Learn more about this announcement: https://lnkd.in/gFE6zupr \n \n _ _ _\n Emergency uses of the bivalent vaccine have not been approved or licensed by FDA, but have been authorized under an Emergency Use Authorization (EUA) to prevent COVID-19 in individuals 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use, unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at www.cvdvaccine-us.com """ "reactions_count" => 4655 "comments_count" => 32 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-08 08:59:27" "deleted" => 1 ] [ "id" => 60396531 "company_id" => 1258906 "urn" => "urn:li:activity:7026574747689783297" "followers" => 5158192 "date" => "6d" "description" => """ To build inclusive and diverse colleague communities there must be intentional action. At Pfizer, we are proud of our efforts to create a culture where we support our colleagues and create opportunities for growth. This #BlackHistoryMonth, join us #LIVE as our colleagues Sherry Cassano, Sean Hudson and Ebony Arrington discuss how diverse voices create breakthroughs for our patients.\n \n 🗓️ Monday, February 13 at 11 am, ET """ "reactions_count" => 179 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-10 16:13:16" "deleted" => 1 ] [ "id" => 60396532 "company_id" => 1258906 "urn" => "urn:li:activity:7028825876733562880" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Albert Bourla" "reshared_post_author_url" => "https://www.linkedin.com/in/albert-bourla" "reshared_post_author_headline" => "Chairman and Chief Executive Officer, Pfizer" "reshared_post_description" => """ Our hearts go out to everyone who has been affected by the devastating earthquake in Turkey and Syria. The images of destruction and the loss of life are unimaginable, and the stories of lives disrupted are heartbreaking. \n \n We are closely monitoring the situation and ready to provide support to our colleagues and their families who are in the region. Additionally, we will match all donations made through The Pfizer Foundation to any of our five disaster relief partners who are already responding to the affected areas. As more response efforts are launched, we will continue to assess ways in which Pfizer can help, including any requests for donated medicines or vaccines. """ "reshared_post_followers" => null "reshared_post_date" => "9h" "last_updated" => "2023-03-10 16:13:16" "deleted" => 1 ] [ "id" => 60396533 "company_id" => 1258906 "urn" => "urn:li:activity:7026233275023060992" "followers" => 5158192 "date" => "1w" "description" => """ Pfizer Ventures, our #VentureCapital arm, had another impactful year in 2022, with 10 new investments in emerging #biotech companies working in Pfizer’s core therapeutic areas or on transformative technologies—supporting our goal of enabling cutting-edge science with the potential to enhance our pipeline, shape the future of our industry and change patients’ lives.\n \n Check out the full Pfizer Ventures “2022 in Review” report to read about the year’s portfolio highlights, and visit https://lnkd.in/gHBDkS7X to learn more. """ "reactions_count" => 407 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-10 16:13:16" "deleted" => 1 ] [ "id" => 60396534 "company_id" => 1258906 "urn" => "urn:li:activity:7026212415067357184" "followers" => 5158192 "date" => "1w" "description" => "Here are a few of the highlights from our Q4 & Full Year 2022 earnings report. See the full details from our presentation today: https://lnkd.in/gQBPCaxN" "reactions_count" => 1300 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-10 16:13:16" "deleted" => 1 ] [ "id" => 60396535 "company_id" => 1258906 "urn" => "urn:li:activity:7025870470419730433" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Albert Bourla" "reshared_post_author_url" => "https://www.linkedin.com/in/albert-bourla" "reshared_post_author_headline" => "Chairman and Chief Executive Officer, Pfizer" "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2023-03-10 16:13:16" "deleted" => 1 ] [ "id" => 60396536 "company_id" => 1258906 "urn" => "urn:li:activity:7010650674619195392" "followers" => 5158192 "date" => "1mo" "description" => """ Thank you Save the Children US for your partnership and commitment to helping advance equitable access to routine immunizations for children in Kenya. Because no child should die from an infection that could be prevented with access to basic healthcare.\n \n Watch this video to learn more about how Save the Children is working with community health workers and volunteers to reach those in need with essential health services 👇\n \n #Partnership #InfectiousDiseases #HealthEquity """ "reactions_count" => 297 "comments_count" => 3 "reshared_post_author" => "Save the Children US" "reshared_post_author_url" => "https://www.linkedin.com/company/save-the-children-us" "reshared_post_author_headline" => null "reshared_post_description" => """ Since 2020, we have worked with the Pfizer Foundation in Kenya to ensure children receive life-saving vaccines. \n \n Save the Children staff work with volunteers and health workers to increase immunization coverage in urban Nairobi and remote communities in the northeast, helping more children grow up healthy and strong so they can reach their full potential! """ "reshared_post_followers" => 119683 "reshared_post_date" => "1mo" "last_updated" => "2023-03-10 16:13:16" "deleted" => 1 ] [ "id" => 60396537 "company_id" => 1258906 "urn" => "urn:li:activity:7009177610316357633" "followers" => 5158192 "date" => "1mo" "description" => "Pfizer is proud of this research agreement with Anumana to develop an AI-ECG algorithm for earlier suspicion of cardiac amyloidosis. Learn more about the research agreement: on.pfizer.com/3uUY2WI" "reactions_count" => 659 "comments_count" => 10 "reshared_post_author" => "Anumana" "reshared_post_author_url" => "https://www.linkedin.com/company/anumana-inc" "reshared_post_author_headline" => null "reshared_post_description" => """ #NEW: Anumana is thrilled to announce the initiation of a research agreement from Pfizer to develop an AI-ECG algorithm to aid in early detection of patients who may be at risk of cardiac #amyloidosis. While there is no known cure for this disease, earlier suspicion may be crucial to improve time to diagnosis and care.\n \n Under the research agreement, Anumana will conduct clinical validation and prepare for FDA De Novo classification for the AI-ECG algorithm for early suspicion of cardiac amyloidosis as a #SaMD. In addition, Anumana aims to gain regulatory approval in the E.U. and Japan.\n \n “We believe this collaboration will demonstrate the power of Anumana’s AI-ECG algorithms to help clinicians intervene earlier, giving them greater ability to improve patient outcomes and prolong lives.” said David McMullin, Chief Business Officer at Anumana.\n \n The research agreement with Pfizer will deepen Anumana’s efforts to implement AI-enabled software that can uncover ECG signals unrecognizable to the human eye. AI-ECG algorithms have the potential to provide an early warning in #cardiology, enabling patients to receive earlier intervention. \n \n Congratulations to the leaders at Anumana & Pfizer for initiating a research agreement supporting development of innovative AI software solutions for cardiology to address the unmet medical need for early suspicion of occult #heartdisease. #epeeps\n \n Learn more about the collaboration 👉🏽 https://lnkd.in/e_-TDzrM\n \n Murali Aravamudan, Venky Soundararajan, Paul Friedman, Francisco Lopez-Jimenez, Martha Grogan, Zachi Attia, Angela Dispenzieri """ "reshared_post_followers" => 2774 "reshared_post_date" => "1mo" "last_updated" => "2023-03-10 16:13:16" "deleted" => 1 ] [ "id" => 60396538 "company_id" => 1258906 "urn" => "urn:li:activity:7008474835232153600" "followers" => 5158192 "date" => "1mo" "description" => """ No one’s skin is exactly the same. Ensuring patients of every skin color suffering from dermatological diseases feel seen and understood is critical to advancing the field of medical dermatology. \n \n While progress has been made, there is still work to be done. In partnership with Bloomberg Live, our very own Leslie Koby sat down with Seemal R. Desai, MD, FAAD to discuss health equity in medical dermatology, the disparate challenges patients of color face, and efforts like the Every Color is Primary initiative to help address them. \n \n Watch the discussion to hear more. """ "reactions_count" => 510 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-10 16:13:16" "deleted" => 1 ] [ "id" => 60396539 "company_id" => 1258906 "urn" => "urn:li:activity:7006981733384417280" "followers" => 5158192 "date" => "2mo" "description" => "Pfizer is offering a new grant seeking to advance #equity amongst people living with hemophilia (PLwH) to support their evidence-informed decisions about their #hemophilia treatment. Eligible applicants include Patient Advocacy Groups or other non-profit organizations of all sizes and from all countries that provide therapeutic #education to PLwH. The application submission deadline is Feb 16, 2023: https://lnkd.in/eEwmrAvM" "reactions_count" => 431 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-10 16:13:16" "deleted" => 1 ] [ "id" => 105149375 "company_id" => 1258906 "urn" => "urn:li:activity:7034966149243006976" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Albert Bourla" "reshared_post_author_url" => "https://www.linkedin.com/in/albert-bourla" "reshared_post_author_headline" => "Chairman and Chief Executive Officer, Pfizer" "reshared_post_description" => """ Today, February 24, 2023, marks a somber milestone. Russian forces invaded Ukraine on this day one year ago, triggering a humanitarian crisis that has created ripples of fear, despair and devastation worldwide. We’ve lost many innocent people, and we’ve watched global geopolitical tension escalate. \n \n When the international community made the decision to implement unprecedented sanctions against Russia, most sanctions and export control restrictions contained exclusions for the provision of medicine. In addition, Pfizer recognized that halting the delivery of medicine, including cancer or cardiovascular therapies, to Russia would cause significant patient suffering and potential loss of life. Ending Pfizer operations in Russia would run counter to our guiding principle of putting patients first. \n \n Yet business in Russia could not then, and cannot now, continue as usual. Last year, on March 14, we announced that Pfizer would donate the equivalent of all profits from our sales in Russia to causes that provide direct humanitarian support to the people of Ukraine. Since announcing that commitment, we have committed more than $30 million to 15 unique organizations, each of which provides on-the-ground humanitarian support to the people of Ukraine. \n \n As the war continues, the global community has a responsibility to ensure support to Ukraine continues unabated. We remain hopeful that a peaceful outcome is possible. Our support remains steadfast and consistent with Pfizer’s core values, particularly those of courage, excellence and equity.\n \n \n To learn more about how Pfizer is responding to the crisis in Ukraine, visit: https://lnkd.in/epH_Zp9A """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2023-04-06 23:49:47" "deleted" => 1 ] [ "id" => 105149376 "company_id" => 1258906 "urn" => "urn:li:activity:7032040345374769153" "followers" => 5212550 "date" => "3w" "description" => null "reactions_count" => 996 "comments_count" => 8 "reshared_post_author" => "Pfizer Medical" "reshared_post_author_url" => "https://www.linkedin.com/showcase/pfizer-medical" "reshared_post_author_headline" => null "reshared_post_description" => """ Announcing our new Global Medical LinkedIn channel! \n \n Follow our channel to access the latest scientific information, opportunities, disease education and a variety of content resources in therapeutic areas important to our Global Health Care Professional (HCP) community. \n Our posts and resources are intended and tailored to the country of the HCP audience. """ "reshared_post_followers" => 7010 "reshared_post_date" => "3w" "last_updated" => "2023-04-06 23:49:47" "deleted" => 1 ] [ "id" => 105149377 "company_id" => 1258906 "urn" => "urn:li:activity:7026574747689783297" "followers" => 5212550 "date" => "1mo" "description" => """ To build inclusive and diverse colleague communities there must be intentional action. At Pfizer, we are proud of our efforts to create a culture where we support our colleagues and create opportunities for growth. This #BlackHistoryMonth, join us #LIVE as our colleagues Sherry Cassano, Sean Hudson and Ebony Arrington discuss how diverse voices create breakthroughs for our patients.\n \n 🗓️ Monday, February 13 at 11 am, ET """ "reactions_count" => 477 "comments_count" => 186 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-06 23:49:47" "deleted" => 1 ] [ "id" => 105149378 "company_id" => 1258906 "urn" => "urn:li:activity:7029781382079905792" "followers" => 5212550 "date" => "3w" "description" => """ One in three people in the US will develop herpes zoster, more commonly known as #shingles, in their lifetime, with the elderly and immunocompromised at highest risk. Yet, only about one-third of people age 60+ are vaccinated.\n \n This is one of the many reasons that we, along with BioNTech SE, are initiating a study of the first #mRNA-based shingles vaccine in clinical studies. We believe that by utilizing mRNA technology, we can potentially develop a shingles vaccine that shows high efficacy, is well tolerated, and could be efficiently produced. \n \n Learn more about the trial: https://lnkd.in/eHja3VZ3 """ "reactions_count" => 933 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-06 23:49:47" "deleted" => 1 ] [ "id" => 105149379 "company_id" => 1258906 "urn" => "urn:li:activity:7029139355877183489" "followers" => 5212550 "date" => "4w" "description" => """ European nations are experiencing some of the lowest rates of #vaccine confidence in the world.\n \n A new survey fielded with Excellence in Pediatrics Institute uncovered top challenges and potential solutions to address pediatric vaccination rates in Europe.\n \n Social media emerged as the best channel to share compelling messages about vaccine safety, effectiveness and burden of disease, to help combat barriers like misinformation about vaccines or a belief that vaccines aren’t necessary.\n \n Click through to check out more of our top findings from the survey and find resources and tools here: https://lnkd.in/gnR4rD5m """ "reactions_count" => 317 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-06 23:49:47" "deleted" => 1 ] [ "id" => 105149380 "company_id" => 1258906 "urn" => "urn:li:activity:7028825876733562880" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Albert Bourla" "reshared_post_author_url" => "https://www.linkedin.com/in/albert-bourla" "reshared_post_author_headline" => "Chairman and Chief Executive Officer, Pfizer" "reshared_post_description" => """ Our hearts go out to everyone who has been affected by the devastating earthquake in Turkey and Syria. The images of destruction and the loss of life are unimaginable, and the stories of lives disrupted are heartbreaking. \n \n We are closely monitoring the situation and ready to provide support to our colleagues and their families who are in the region. Additionally, we will match all donations made through The Pfizer Foundation to any of our five disaster relief partners who are already responding to the affected areas. As more response efforts are launched, we will continue to assess ways in which Pfizer can help, including any requests for donated medicines or vaccines. """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-04-06 23:49:47" "deleted" => 1 ] [ "id" => 105149381 "company_id" => 1258906 "urn" => "urn:li:activity:7026233275023060992" "followers" => 5212550 "date" => "1mo" "description" => """ Pfizer Ventures, our #VentureCapital arm, had another impactful year in 2022, with 10 new investments in emerging #biotech companies working in Pfizer’s core therapeutic areas or on transformative technologies—supporting our goal of enabling cutting-edge science with the potential to enhance our pipeline, shape the future of our industry and change patients’ lives.\n \n Check out the full Pfizer Ventures “2022 in Review” report to read about the year’s portfolio highlights, and visit https://lnkd.in/gHBDkS7X to learn more. """ "reactions_count" => 421 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-06 23:49:47" "deleted" => 1 ] [ "id" => 105149382 "company_id" => 1258906 "urn" => "urn:li:activity:7026212415067357184" "followers" => 5212550 "date" => "1mo" "description" => "Here are a few of the highlights from our Q4 & Full Year 2022 earnings report. See the full details from our presentation today: https://lnkd.in/gQBPCaxN" "reactions_count" => 1337 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-06 23:49:47" "deleted" => 1 ] [ "id" => 105149383 "company_id" => 1258906 "urn" => "urn:li:activity:7025870470419730433" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Albert Bourla" "reshared_post_author_url" => "https://www.linkedin.com/in/albert-bourla" "reshared_post_author_headline" => "Chairman and Chief Executive Officer, Pfizer" "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-04-06 23:49:47" "deleted" => 1 ] [ "id" => 123743432 "company_id" => 1258906 "urn" => "urn:li:activity:7048727051096264704" "followers" => 5267216 "date" => "2d" "description" => "In 2022, we delivered life-changing innovations to an estimated 1.3+ billion patients around the world. CEO Albert Bourla reflects on our 2022 highlights in our new #AnnualReview: https://lnkd.in/g7T2ndgx" "reactions_count" => 1500 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-01 05:09:20" "deleted" => 1 ] [ "id" => 123743433 "company_id" => 1258906 "urn" => "urn:li:activity:7044667407197437952" "followers" => 5267216 "date" => "2w" "description" => """ Our Chief Medical Officer Aida Habtezion recently sat down for the #MikaStraightUp podcast with host Mika Brzezinski. Listen now: https://lnkd.in/e3vGZdCH\n \n On the podcast Mika and Aida discuss topics ranging from Aida’s career journey from practicing physician and scientist to industry executive, her passion for health equity, and her advice for advancing women in the life sciences through #mentorship, #allyship, and self-advocacy.\n \n #WomensHistoryMonth #Leadership """ "reactions_count" => 226 "comments_count" => 4 "reshared_post_author" => "Aida Habtezion" "reshared_post_author_url" => "https://www.linkedin.com/in/aida-habtezion-2862657" "reshared_post_author_headline" => "SVP, Chief Medical Officer and Head of Worldwide Medical and Safety, Pfizer Inc" "reshared_post_description" => """ I recently joined Mika Brzezinski on the #MikaStraightUp podcast to discuss several aspects of personal importance to me, and to many female leaders across the healthcare ecosystem. We discussed the career journey that led me to Pfizer, my passion for health equity, and how we can support and advance more women on the path to #leadership in the #lifesciences.\n \n It is important that we continue this dialogue, particularly during Women’s History Month. I hope that our conversation inspires listeners to reach out to each other as #mentors and #allies, and be strong advocates. Take a listen here: https://lnkd.in/eq93WQgm\n \n #WomensHistoryMonth #HealthEquity """ "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2023-05-01 05:09:20" "deleted" => 1 ] [ "id" => 123743434 "company_id" => 1258906 "urn" => "urn:li:activity:7041803273535660033" "followers" => 5267216 "date" => "3w" "description" => """ We’re #LIVE celebrating the stories of resilient women for #WomensHistoryMonth. We know that delivering on our purpose of breakthroughs that change patients’ lives is dependent on our people—all of our people.\n \n Join us now as we hear from three colleagues, Mona Babury, CDP, PMP, Baheshta Abed Rahimi, and Najlla Habibyar—who are intricately involved with the Pfizer Refugee Leadership Initiative as they discuss the importance of empowering women around the world. \n \n Read more about these inspiring women and their work with the Pfizer Refugee Leadership Initiative in our 2022 #AnnualReview: https://lnkd.in/eK7Re48h """ "reactions_count" => 918 "comments_count" => 450 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-01 05:09:20" "deleted" => 1 ] [ "id" => 123743435 "company_id" => 1258906 "urn" => "urn:li:activity:7042280230866079744" "followers" => 5267216 "date" => "2w" "description" => "Today, we’re sharing our latest #ProstateCancer update: top-line results from our Phase 3 trial in partnership with Astellas Pharma US. See the details from the trial evaluating our novel hormone therapy in adult males with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence." "reactions_count" => 2292 "comments_count" => 15 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-01 05:09:20" "deleted" => 1 ] [ "id" => 123743436 "company_id" => 1258906 "urn" => "urn:li:activity:7041541222183653376" "followers" => 5267216 "date" => "3w" "description" => """ BREAKING: Today, we announced with BioNTech SE that the FDA granted Emergency Use Authorization of our Omicron-adapted #COVID19 booster (fourth dose) in children 6 months through 4 years – the final age group to have access to the bivalent vaccine. This age group is eligible to receive the booster at least 2 months after completing the three-dose primary vaccination series with our original COVID-19 vaccine.\n \n Learn more about this announcement: https://lnkd.in/eQyf3qjf\n \n ___\n Emergency uses of the bivalent vaccine have not been approved or licensed by FDA but have been authorized under an Emergency Use Authorization (EUA) to prevent COVID-19 in individuals 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use, unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at www.cvdvaccine-us.com """ "reactions_count" => 2029 "comments_count" => 24 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-01 05:09:20" "deleted" => 1 ] [ "id" => 123743437 "company_id" => 1258906 "urn" => "urn:li:activity:7034966149243006976" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Albert Bourla" "reshared_post_author_url" => "https://www.linkedin.com/in/albert-bourla" "reshared_post_author_headline" => "Chairman and Chief Executive Officer, Pfizer" "reshared_post_description" => """ Today, February 24, 2023, marks a somber milestone. Russian forces invaded Ukraine on this day one year ago, triggering a humanitarian crisis that has created ripples of fear, despair and devastation worldwide. We’ve lost many innocent people, and we’ve watched global geopolitical tension escalate. \n \n When the international community made the decision to implement unprecedented sanctions against Russia, most sanctions and export control restrictions contained exclusions for the provision of medicine. In addition, Pfizer recognized that halting the delivery of medicine, including cancer or cardiovascular therapies, to Russia would cause significant patient suffering and potential loss of life. Ending Pfizer operations in Russia would run counter to our guiding principle of putting patients first. \n \n Yet business in Russia could not then, and cannot now, continue as usual. Last year, on March 14, we announced that Pfizer would donate the equivalent of all profits from our sales in Russia to causes that provide direct humanitarian support to the people of Ukraine. Since announcing that commitment, we have committed more than $30 million to 15 unique organizations, each of which provides on-the-ground humanitarian support to the people of Ukraine. \n \n As the war continues, the global community has a responsibility to ensure support to Ukraine continues unabated. We remain hopeful that a peaceful outcome is possible. Our support remains steadfast and consistent with Pfizer’s core values, particularly those of courage, excellence and equity.\n \n \n To learn more about how Pfizer is responding to the crisis in Ukraine, visit: https://lnkd.in/epH_Zp9A """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-05-01 05:09:20" "deleted" => 1 ] [ "id" => 123743438 "company_id" => 1258906 "urn" => "urn:li:activity:7032040345374769153" "followers" => 5267216 "date" => "1mo" "description" => null "reactions_count" => 990 "comments_count" => 7 "reshared_post_author" => "Pfizer Medical" "reshared_post_author_url" => "https://www.linkedin.com/showcase/pfizer-medical" "reshared_post_author_headline" => null "reshared_post_description" => """ Announcing our new Global Medical LinkedIn channel! \n \n Follow our channel to access the latest scientific information, opportunities, disease education and a variety of content resources in therapeutic areas important to our Global Health Care Professional (HCP) community. \n Our posts and resources are intended and tailored to the country of the HCP audience. """ "reshared_post_followers" => 7855 "reshared_post_date" => "1mo" "last_updated" => "2023-05-01 05:09:20" "deleted" => 1 ] [ "id" => 123743439 "company_id" => 1258906 "urn" => "urn:li:activity:7026574747689783297" "followers" => 5267216 "date" => "2mo" "description" => """ To build inclusive and diverse colleague communities there must be intentional action. At Pfizer, we are proud of our efforts to create a culture where we support our colleagues and create opportunities for growth. This #BlackHistoryMonth, join us #LIVE as our colleagues Sherry Cassano, Sean Hudson and Ebony Arrington discuss how diverse voices create breakthroughs for our patients.\n \n 🗓️ Monday, February 13 at 11 am, ET """ "reactions_count" => 479 "comments_count" => 187 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-01 05:09:20" "deleted" => 1 ] [ "id" => 123743440 "company_id" => 1258906 "urn" => "urn:li:activity:7029781382079905792" "followers" => 5267216 "date" => "1mo" "description" => """ One in three people in the US will develop herpes zoster, more commonly known as #shingles, in their lifetime, with the elderly and immunocompromised at highest risk. Yet, only about one-third of people age 60+ are vaccinated.\n \n This is one of the many reasons that we, along with BioNTech SE, are initiating a study of the first #mRNA-based shingles vaccine in clinical studies. We believe that by utilizing mRNA technology, we can potentially develop a shingles vaccine that shows high efficacy, is well tolerated, and could be efficiently produced. \n \n Learn more about the trial: https://lnkd.in/eHja3VZ3 """ "reactions_count" => 928 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-01 05:09:20" "deleted" => 1 ] [ "id" => 123743441 "company_id" => 1258906 "urn" => "urn:li:activity:7029139355877183489" "followers" => 5267216 "date" => "1mo" "description" => """ European nations are experiencing some of the lowest rates of #vaccine confidence in the world.\n \n A new survey fielded with Excellence in Pediatrics Institute uncovered top challenges and potential solutions to address pediatric vaccination rates in Europe.\n \n Social media emerged as the best channel to share compelling messages about vaccine safety, effectiveness and burden of disease, to help combat barriers like misinformation about vaccines or a belief that vaccines aren’t necessary.\n \n Click through to check out more of our top findings from the survey and find resources and tools here: https://lnkd.in/gnR4rD5m """ "reactions_count" => 320 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-01 05:09:20" "deleted" => 1 ] [ "id" => 157518053 "company_id" => 1258906 "urn" => "urn:li:activity:7054113229798576128" "followers" => 5307931 "date" => "1w" "description" => """ #EarthDay was first celebrated more than 50 years ago, and it has become a basis of our modern sustainability work. Watch as our colleagues Caroline Roan and Louise Proud discuss Pfizer’s climate action ambitions. \n To learn more, visit Pfizer.com/ESG_Report. \n \n \n —\n https://lnkd.in/d4YrTfX2\n https://lnkd.in/eQRpmbQq """ "reactions_count" => 864 "comments_count" => 301 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-17 13:41:27" "deleted" => 1 ] [ "id" => 157518054 "company_id" => 1258906 "urn" => "urn:li:activity:7056531913129218048" "followers" => 5307931 "date" => "5d" "description" => "Impfungen schützen vor Erkrankungen. Sie können aber noch viel mehr, wenn sich viele Menschen impfen lassen. Mehr dazu im Video! #Impfwoche #ImpfenSchützt" "reactions_count" => 184 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-17 13:41:27" "deleted" => 1 ] [ "id" => 157518055 "company_id" => 1258906 "urn" => "urn:li:activity:7054106997612310529" "followers" => 5307931 "date" => "1w" "description" => """ Climate change is considered the single biggest health threat facing humanity by the WHO. At Pfizer, we’re taking bold action to help keep our planet livable, so that everyone, everywhere can lead healthy lives. \n \n The environmental consequences of climate change like extreme floods, heat, and fires put human health at risk, which is why we’re taking action to help protect our world and global health as part of Pfizer’s #ESG commitments.\n \n Since 2000, Pfizer has reduced our company greenhouse gas emissions by more than 60%. \n \n Here’s how we’re continuing to help address climate impact: \n 🌎 Aiming to achieve Net-Zero Standard by 2040 \n 🌱 Accelerating the transition away from fossil fuels\n 🤝 Collaborating with suppliers to make a bigger impact\n …And more\n \n Learn more about what we’re doing and how the healthcare sector can help address the impact of climate change The Guardian: https://lnkd.in/gC8_c7hh \n \n #EarthDay #EnvironmentalHealth #HealthEquity #GlobalHealth #ESG #ClimateAction """ "reactions_count" => 793 "comments_count" => 13 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-17 13:41:27" "deleted" => 1 ] [ "id" => 157518056 "company_id" => 1258906 "urn" => "urn:li:activity:7048727051096264704" "followers" => 5307931 "date" => "3w" "description" => "In 2022, we delivered life-changing innovations to an estimated 1.3+ billion patients around the world. CEO Albert Bourla reflects on our 2022 highlights in our new #AnnualReview: https://lnkd.in/g7T2ndgx" "reactions_count" => 1984 "comments_count" => 19 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-17 13:41:27" "deleted" => 1 ] [ "id" => 157518057 "company_id" => 1258906 "urn" => "urn:li:activity:7044667407197437952" "followers" => 5307931 "date" => "1mo" "description" => """ Our Chief Medical Officer Aida Habtezion recently sat down for the #MikaStraightUp podcast with host Mika Brzezinski. Listen now: https://lnkd.in/e3vGZdCH\n \n On the podcast Mika and Aida discuss topics ranging from Aida’s career journey from practicing physician and scientist to industry executive, her passion for health equity, and her advice for advancing women in the life sciences through #mentorship, #allyship, and self-advocacy.\n \n #WomensHistoryMonth #Leadership """ "reactions_count" => 229 "comments_count" => 4 "reshared_post_author" => "Aida Habtezion" "reshared_post_author_url" => "https://www.linkedin.com/in/aida-habtezion-2862657" "reshared_post_author_headline" => "SVP, Chief Medical Officer and Head of Worldwide Medical and Safety, Pfizer Inc" "reshared_post_description" => """ I recently joined Mika Brzezinski on the #MikaStraightUp podcast to discuss several aspects of personal importance to me, and to many female leaders across the healthcare ecosystem. We discussed the career journey that led me to Pfizer, my passion for health equity, and how we can support and advance more women on the path to #leadership in the #lifesciences.\n \n It is important that we continue this dialogue, particularly during Women’s History Month. I hope that our conversation inspires listeners to reach out to each other as #mentors and #allies, and be strong advocates. Take a listen here: https://lnkd.in/eq93WQgm\n \n #WomensHistoryMonth #HealthEquity """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-06-17 13:41:27" "deleted" => 1 ] [ "id" => 157518058 "company_id" => 1258906 "urn" => "urn:li:activity:7041803273535660033" "followers" => 5307931 "date" => "1mo" "description" => """ We’re #LIVE celebrating the stories of resilient women for #WomensHistoryMonth. We know that delivering on our purpose of breakthroughs that change patients’ lives is dependent on our people—all of our people.\n \n Join us now as we hear from three colleagues, Mona Babury, CDP, PMP, Baheshta Abed Rahimi, and Najlla Habibyar—who are intricately involved with the Pfizer Refugee Leadership Initiative as they discuss the importance of empowering women around the world. \n \n Read more about these inspiring women and their work with the Pfizer Refugee Leadership Initiative in our 2022 #AnnualReview: https://lnkd.in/eK7Re48h """ "reactions_count" => 933 "comments_count" => 447 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-17 13:41:27" "deleted" => 1 ] [ "id" => 157518059 "company_id" => 1258906 "urn" => "urn:li:activity:7042280230866079744" "followers" => 5307931 "date" => "1mo" "description" => "Today, we’re sharing our latest #ProstateCancer update: top-line results from our Phase 3 trial in partnership with Astellas Pharma US. See the details from the trial evaluating our novel hormone therapy in adult males with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence." "reactions_count" => 2282 "comments_count" => 15 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-17 13:41:27" "deleted" => 1 ] [ "id" => 157518060 "company_id" => 1258906 "urn" => "urn:li:activity:7041541222183653376" "followers" => 5307931 "date" => "1mo" "description" => """ BREAKING: Today, we announced with BioNTech SE that the FDA granted Emergency Use Authorization of our Omicron-adapted #COVID19 booster (fourth dose) in children 6 months through 4 years – the final age group to have access to the bivalent vaccine. This age group is eligible to receive the booster at least 2 months after completing the three-dose primary vaccination series with our original COVID-19 vaccine.\n \n Learn more about this announcement: https://lnkd.in/eQyf3qjf\n \n ___\n Emergency uses of the bivalent vaccine have not been approved or licensed by FDA but have been authorized under an Emergency Use Authorization (EUA) to prevent COVID-19 in individuals 6 months of age and older. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use, unless the declaration is terminated or authorization revoked sooner. Please see EUA Fact Sheets at www.cvdvaccine-us.com """ "reactions_count" => 2048 "comments_count" => 24 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-17 13:41:27" "deleted" => 1 ] [ "id" => 157518061 "company_id" => 1258906 "urn" => "urn:li:activity:7034966149243006976" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Albert Bourla" "reshared_post_author_url" => "https://www.linkedin.com/in/albert-bourla" "reshared_post_author_headline" => "Chairman and Chief Executive Officer, Pfizer" "reshared_post_description" => """ Today, February 24, 2023, marks a somber milestone. Russian forces invaded Ukraine on this day one year ago, triggering a humanitarian crisis that has created ripples of fear, despair and devastation worldwide. We’ve lost many innocent people, and we’ve watched global geopolitical tension escalate. \n \n When the international community made the decision to implement unprecedented sanctions against Russia, most sanctions and export control restrictions contained exclusions for the provision of medicine. In addition, Pfizer recognized that halting the delivery of medicine, including cancer or cardiovascular therapies, to Russia would cause significant patient suffering and potential loss of life. Ending Pfizer operations in Russia would run counter to our guiding principle of putting patients first. \n \n Yet business in Russia could not then, and cannot now, continue as usual. Last year, on March 14, we announced that Pfizer would donate the equivalent of all profits from our sales in Russia to causes that provide direct humanitarian support to the people of Ukraine. Since announcing that commitment, we have committed more than $30 million to 15 unique organizations, each of which provides on-the-ground humanitarian support to the people of Ukraine. \n \n As the war continues, the global community has a responsibility to ensure support to Ukraine continues unabated. We remain hopeful that a peaceful outcome is possible. Our support remains steadfast and consistent with Pfizer’s core values, particularly those of courage, excellence and equity.\n \n \n To learn more about how Pfizer is responding to the crisis in Ukraine, visit: https://lnkd.in/epH_Zp9A """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2023-06-17 13:41:27" "deleted" => 1 ] [ "id" => 157518062 "company_id" => 1258906 "urn" => "urn:li:activity:7032040345374769153" "followers" => 5307931 "date" => "2mo" "description" => null "reactions_count" => 979 "comments_count" => 7 "reshared_post_author" => "Pfizer Medical" "reshared_post_author_url" => "https://www.linkedin.com/showcase/pfizer-medical" "reshared_post_author_headline" => null "reshared_post_description" => """ Announcing our new Global Medical LinkedIn channel! \n \n Follow our channel to access the latest scientific information, opportunities, disease education and a variety of content resources in therapeutic areas important to our Global Health Care Professional (HCP) community. \n Our posts and resources are intended and tailored to the country of the HCP audience. """ "reshared_post_followers" => 8510 "reshared_post_date" => "2mo" "last_updated" => "2023-06-17 13:41:27" "deleted" => 1 ] [ "id" => 211550509 "company_id" => 1258906 "urn" => "urn:li:activity:7074089578239774720" "followers" => 5396938 "date" => "4d" "description" => """ Bonjour! Join us next week at the Cannes Lions International Festival of Creativity for an incredible session on "How to Use Creative Transformation to Disrupt Your Business". \n \n 📅 Date: June 19, 2023 \n ⏰ Time: 3:45PM CET \n 📍 Location: Palais des Festivals \n \n This thought-provoking session will feature our very own CCO Angela Hwang and CMO Drew P., along with Thrive Global Founder & CEO Arianna Huffington, and performance by renowned poet IN-Q. Together, they’ll take you on a journey of creative transformation, showcase some innovative marketing campaigns, and share their insights and experiences on igniting transformative change within their organizations. #CannesLions2023 \n \n We hope to see you there: https://lnkd.in/esej9zhc """ "reactions_count" => 263 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:17:18" "deleted" => 1 ] [ "id" => 211550510 "company_id" => 1258906 "urn" => "urn:li:activity:7074030032892923904" "followers" => 5396938 "date" => "4d" "description" => """ Here at Pfizer, our dedication to creating breakthrough medicines for diseases that represent significant areas of need also manifests in our partnerships with the scientific community.\n \n That’s why we are proud to be part of this important and unique research initiative with the HARMONY Alliance \| Public-Private Partnership for Big Data in Hematology as we work collectively with other partners to improve the lives of those living with hematologic malignancies. """ "reactions_count" => 329 "comments_count" => 4 "reshared_post_author" => "HARMONY Alliance \| Public-Private Partnership for Big Data in Hematology" "reshared_post_author_url" => "https://nl.linkedin.com/company/harmony-alliance" "reshared_post_author_headline" => null "reshared_post_description" => """ Press release \| The HARMONY Alliance is set to become a research foundation\n \n We have revolutionized the use of big data in Hematologic Malignancies research. Now we have the unique opportunity to become a non-profit research foundation and bring hematology research and patient care to the next level.\n \n >> Read the press release here: https://bit.ly/3NiLYZo\n \n Over the past six years, the HARMONY Alliance (IMI-HARMONY and IMI-HARMONY PLUS) we have built a robust, open, collaborative research community that leverages big data to improve patient care. The EU grant phase (European Commission’s Innovative Health Initiative, IHI, formerly known as IMI) that made this possible ends this year. \n Thanks to the strong commitment and drive of our multi-stakeholder partners and members, we have the unique opportunity to continue our work as a non-profit, collaborative research foundation. \n \n #bigdataforbloodcancer #research #bigdata #datascience #dataanalytics\n \n Innovative Health Initiative (IHI) EFPIA - European Federation of Pharmaceutical Industries and Associations European Commission """ "reshared_post_followers" => 1008 "reshared_post_date" => "1w" "last_updated" => "2023-07-13 23:17:18" "deleted" => 1 ] [ "id" => 211550511 "company_id" => 1258906 "urn" => "urn:li:activity:7070068894362734592" "followers" => 5396938 "date" => "2w" "description" => """ Exciting Opportunity to Apply! 🚀\n \n Join the Pfizer Breakthrough Change Accelerator team by participating in the Global Product Development (GPD) CSR.Gen Challenge! Are you ready to showcase your expertise in Machine Learning/Data Science and make a meaningful impact? Click here to get started: https://lnkd.in/ghNQnnqd\n \n Pfizer’s GPD is hosting an innovation challenge, seeking innovative solutions based on AI/ML solution to address relevant business challenges. This time, we’re focusing on automating Clinical Study Report (CSR) generation using Generative AI.\n \n To dive into the details of the challenge and apply, visit the Challenge overview on the Breakthrough Change Accelerator website. Don’t miss this opportunity to collaborate with Pfizer and drive innovation in the healthcare industry!\n \n \n \n \n \n \n #Pfizer #BreakthroughChangeAccelerator #InnovationChallenge #GenerativeAI #MachineLearning #DataScience #HealthcareInnovation #ClinicalTrial """ "reactions_count" => 516 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:17:18" "deleted" => 1 ] [ "id" => 211550512 "company_id" => 1258906 "urn" => "urn:li:activity:7069326650550726656" "followers" => 5396938 "date" => "2w" "description" => "Join us #LIVE as our colleagues Jamie Chan, Sadeq Islam, and Desiree V. reflect on this year’s Global Asian Alliance’s theme of Advancing Leaders Through Opportunity." "reactions_count" => 1338 "comments_count" => 763 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:17:18" "deleted" => 1 ] [ "id" => 211550513 "company_id" => 1258906 "urn" => "urn:li:activity:7064286683529125888" "followers" => 5396938 "date" => "1mo" "description" => "Cancer-related outcomes can vary significantly depending on factors such as race and ethnicity. At Pfizer, we are committed to addressing these disparities and are proud to support the work of Cancer Support Community as they highlight the importance of diversity in clinical trials for both individual patients and their broader communities." "reactions_count" => 226 "comments_count" => 4 "reshared_post_author" => "Cancer Support Community" "reshared_post_author_url" => "https://www.linkedin.com/company/cancer-support-community" "reshared_post_author_headline" => null "reshared_post_description" => """ “The Black community has the most to benefit from clinical trials because we historically have been the most excluded.” In the powerful new short documentary, How Does a Clinical Trial Benefit Me, cancer patients and renowned oncology professionals talk openly about historical human rights violations and present-day benefits of clinical trials. \n \n #JustifiedMedicalMistrust #EmpoweringPatients #ClinicalTrials #healthequity\n \n Watch full documentary here: https://lnkd.in/e9KE7P_B """ "reshared_post_followers" => 5470 "reshared_post_date" => "1mo" "last_updated" => "2023-07-13 23:17:18" "deleted" => 1 ] [ "id" => 211550514 "company_id" => 1258906 "urn" => "urn:li:activity:7063951627652644864" "followers" => 5396938 "date" => "1mo" "description" => """ Today we proudly launch Activate – a collaborative program to help decarbonize shared API supply chains with our peers. Combining our expertise with AstraZeneca, Bristol Myers Squibb, GSK, Johnson & Johnson, and Sanofi, and facilitated by Manufacture 2030, Activate will utilize supplier engagement to help address this carbon-intense area across the sector.\n \n In addition to emissions reductions, Activate aims to bring numerous benefits for participating suppliers, including cost savings and resource efficiency gains. #ActivateM2030 #ActivateAPIs """ "reactions_count" => 273 "comments_count" => 5 "reshared_post_author" => "Manufacture 2030 \| M2030" "reshared_post_author_url" => "https://uk.linkedin.com/company/manufacture-2030" "reshared_post_author_headline" => null "reshared_post_description" => """ Today marks the start of a new program where global pharmaceutical companies are coming together to collaborate... but why? Let’s take a closer look ⬇️\n \n https://lnkd.in/e-sG7qEw\n \n AstraZeneca \| Bristol Myers Squibb \| GSK \| Johnson & Johnson \| Pfizer \| Sanofi """ "reshared_post_followers" => 9291 "reshared_post_date" => "1mo" "last_updated" => "2023-07-13 23:17:18" "deleted" => 1 ] [ "id" => 211550515 "company_id" => 1258906 "urn" => "urn:li:activity:7063945796244627456" "followers" => 5396938 "date" => "1mo" "description" => """ Millions of moms and babies are behind on their immunizations, creating greater risk for adverse health outcomes. March of Dimes hosted a panel of experts to discuss how to increase access to maternal #vaccines for vulnerable communities that these health providers, community leaders and health advocates work within. You can watch this important conversation here: \n \n Funding for this webinar was provided by Pfizer. """ "reactions_count" => 303 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:17:18" "deleted" => 1 ] [ "id" => 211550516 "company_id" => 1258906 "urn" => "urn:li:activity:7062510118663286784" "followers" => 5396938 "date" => "1mo" "description" => """ Delighted to share that our own Sherry Cassano, Chief Talent Officer, Senior Vice President, People Experience has been named the winner of the People category at the WeQual Awards, The Americas 2023. \n \n The WeQual Awards identifies and showcases women as part of WeQual’s mission to increase #genderequality at the top of the world’s largest companies. We are honored to be included in the WeQual Awards as a reflection of our commitment to fostering a culture of equity and innovation within our organization.\n \n #pfizerproud #leadership #equity """ "reactions_count" => 329 "comments_count" => 21 "reshared_post_author" => "Sherry Cassano" "reshared_post_author_url" => "https://www.linkedin.com/in/sherry-cassano" "reshared_post_author_headline" => null "reshared_post_description" => """ I am so excited to share that I have been named the winner of the People category in the WeQual Awards, The Americas 2023. The WeQual Awards identify and showcase women leaders ready for a future C-suite position. See the announcement video in the link below.\n \n https://lnkd.in/e39nhmBP\n \n I am now officially a WeQual Alumni. I am really looking forward to getting to know and learn from the many other talented, executive women on the WeQual Global platform. Congratulations to my fellow People category nominees: Tracy Herbert and Jennifer Walker.\n \n WeQual exists to drive gender equality at the top of the world’s largest companies. I’m very proud to be a part of this mission.\n \n #genderequality #womeninbusiness #awards """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-07-13 23:17:18" "deleted" => 1 ] [ "id" => 211550517 "company_id" => 1258906 "urn" => "urn:li:activity:7059884869392232448" "followers" => 5396938 "date" => "1mo" "description" => "https://lnkd.in/gu2Jpg_d" "reactions_count" => 393 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:17:18" "deleted" => 1 ] [ "id" => 211550518 "company_id" => 1258906 "urn" => "urn:li:activity:7059197400401252352" "followers" => 5396938 "date" => "1mo" "description" => "Below are some highlights from our Q1 2023 earnings report. Check out the full details from today’s presentation here: https://lnkd.in/g46ruaZi" "reactions_count" => 1549 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-13 23:17:18" "deleted" => 1 ] [ "id" => 240144572 "company_id" => 1258906 "urn" => "urn:li:activity:7084587831557267456" "followers" => 5455706 "date" => "2d" "description" => "Congratulations to Rady Johnson on being named the 2023 Executive Sponsor of the Year by Disability:IN! This prestigious award recognizes Rady's commitment to inclusivity and support for individuals with disabilities. Well-deserved, Rady!" "reactions_count" => 83 "comments_count" => 1 "reshared_post_author" => "Disability:IN" "reshared_post_author_url" => "https://www.linkedin.com/company/disabilityin" "reshared_post_author_headline" => null "reshared_post_description" => """ Please help us congratulate the Disability:IN Inclusion Award Winners that were announced during today's Opening Plenary!\n \n - 2023 Affiliate of the Year: Disability:IN Utah (Affiliate)\n - 2023 Executive Sponsor of the Year: Rady Johnson of Pfizer\n - 2023 Employer of the Year: Walgreens Boots Alliance\n \n #AreYouIN? """ "reshared_post_followers" => 49386 "reshared_post_date" => "2d" "last_updated" => "2023-08-15 04:14:54" "deleted" => 1 ] [ "id" => 240144573 "company_id" => 1258906 "urn" => "urn:li:activity:7083120859409780737" "followers" => 5455706 "date" => "6d" "description" => """ Antimicrobial resistance can impact people of any age, in any country, and urgently needs to be addressed. We're proud to be part of the upcoming #RaceAgainstResistance film produced for Pfizer by BBC StoryWorks Commercial Productions. Watch the trailer below. \n \n #AMR #StopSuperbugs """ "reactions_count" => 468 "comments_count" => 4 "reshared_post_author" => "BBC StoryWorks" "reshared_post_author_url" => "https://uk.linkedin.com/showcase/bbc-storyworks" "reshared_post_author_headline" => null "reshared_post_description" => """ #Advertisement feature presented by Biotechnology Innovation Organization. 💊 Antibiotics are vital to fighting infection – can you imagine a world where they stopped working? \n Race Against Resistance is a film which dives into one of humanity’s biggest existential threats 🦠 - and the people determined to save us. \n \n 📽️ 🎬 Race Against Resistance launches on September 5 – see you then. \n \n #RaceAgainstResistance \n #NaturesBuildingBlocks """ "reshared_post_followers" => 5798 "reshared_post_date" => "1mo" "last_updated" => "2023-08-15 04:14:54" "deleted" => 1 ] [ "id" => 240144574 "company_id" => 1258906 "urn" => "urn:li:activity:7079830029567721472" "followers" => 5455706 "date" => "2w" "description" => """ We are honored to share the 17th anniversary edition of the Pfizer Pride Journal, a cherished platform that amplifies the voices of our LGBTQ+ colleagues and allies, offering a space to share personal stories of resilience, triumph, and aspirations during #PrideMonth.\n \n At Pfizer, we aim to foster an inclusive environment that embraces diversity, equity, and empowers everyone to live authentically. That is why we take immense pride in publishing this journal annually so that these stories can be shared and joyously celebrated. Each story is a testament to the strength and determination within our vibrant LGBTQ+ community of colleagues.\n \n Explore these captivating voices that have inspired countless individuals by visiting: https://lnkd.in/gJvwzVvy """ "reactions_count" => 458 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 04:14:54" "deleted" => 1 ] [ "id" => 240144575 "company_id" => 1258906 "urn" => "urn:li:activity:7078130956682850305" "followers" => 5455706 "date" => "2w" "description" => """ NEWS: Pfizer is proud to bring the first and only FDA-approved treatment for both adults and teens 12 and older living with severe #alopecia areata. \n \n 🔹: Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, causing hair to fall out. \n \n 🔹: This disease affects nearly 7M people in the U.S. and approximately 147M people globally. \n \n Read more in our press release: https://lnkd.in/ew4E_SGU """ "reactions_count" => 4867 "comments_count" => 73 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 04:14:54" "deleted" => 1 ] [ "id" => 240144576 "company_id" => 1258906 "urn" => "urn:li:activity:7078037008446578688" "followers" => 5455706 "date" => "2w" "description" => """ We are excited to announce our 4th Annual Pfizer Chemistry Connect event is now accepting applications! A Virtual Symposium for Organic Chemists, Analytical Chemists, and Chemical Engineers on November 14, 2023. \n \n Apply for the opportunity to present your postdoctoral, graduate, or undergraduate research and network with Pfizer colleagues. 🧬\n \n For additional details and application, please visit: https://lnkd.in/eqvHZJJK. The application deadline is Thursday, October 12, 2023. """ "reactions_count" => 692 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 04:14:54" "deleted" => 1 ] [ "id" => 240144577 "company_id" => 1258906 "urn" => "urn:li:activity:7077332534744768513" "followers" => 5455706 "date" => "3w" "description" => """ In honor of #WorldRefugeeDay, Albert Bourla and Pfizer are proud to support the International Rescue Committee and call on the private sector to address the growing refugee crisis.\n \n We are dedicated to the economic inclusion of refugees and will continue to improve our Refugee Leadership Initiative in support of #equity and education.\n \n https://lnkd.in/ey_uQpzC """ "reactions_count" => 278 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 04:14:54" "deleted" => 1 ] [ "id" => 240144578 "company_id" => 1258906 "urn" => "urn:li:activity:7077316062769258497" "followers" => 5455706 "date" => "3w" "description" => """ Congratulations to the Anumana team for having received Breakthrough Device Designation from the FDA. This designation recognizes the potential of their ECG-AI algorithm to aid early detection of #CardiacAmyloidosis, a rare and underdiagnosed cause of heart failure. \n \n Learn more about this news: https://lnkd.in/d4wS5B5J """ "reactions_count" => 312 "comments_count" => 5 "reshared_post_author" => "Anumana" "reshared_post_author_url" => "https://www.linkedin.com/company/anumana-inc" "reshared_post_author_headline" => null "reshared_post_description" => """ 📣#NEW: We’re thrilled to announce that Anumana has received FDA Breakthrough Device Designation for our ECG-AI algorithm designed to aid early identification of cardiac #amyloidosis.\n \n Anumana advisor, Dr. Paul Friedman, Chair of the Department of Cardiology at Mayo Clinic (MN) highlights that “this [BDD] recognizes the importance of having new tools to detect rare cardiac diseases [like #cardiacamyloidosis] in ways never before possible.” \n \n “The use of #AI algorithms to identify subtle signals in ECGs that are imperceptible to humans, stands to transform #cardiovascular medicine by aiding #earlydetection,” said Dr. Friedman.\n \n Anumana is grateful for the collaboration with Mayo Clinic, and support from Pfizer, to further develop and validate this algorithm. Our team is committed to bringing these AI solutions into clinical workflows and empowering clinicians to detect disease early, in more easily treated stages.\n \n #breakthroughdevice #AIforhealth\n \n Congratulations to Murali Aravamudan, Venky Soundararajan and the nference team, David McMullin and the Anumana team, Paul Friedman, Francisco Lopez-Jimenez, Zachi Attia, Martha Grogan, and the Mayo Clinic Cardiovascular Services research team, and thank you to Pfizer for their support.\n \n Learn more about the update 👇🏼\n https://lnkd.in/eMgfuFuZ """ "reshared_post_followers" => 3372 "reshared_post_date" => "3w" "last_updated" => "2023-08-15 04:14:54" "deleted" => 1 ] [ "id" => 240144579 "company_id" => 1258906 "urn" => "urn:li:activity:7076653171439194112" "followers" => 5455706 "date" => "3w" "description" => "I’m so excited to hear from my colleagues about what #juneteenth means to them. Listen and learn, listen and learn." "reactions_count" => 61 "comments_count" => 2 "reshared_post_author" => "Pfizer" "reshared_post_author_url" => "https://www.linkedin.com/company/pfizer" "reshared_post_author_headline" => null "reshared_post_description" => """ We're on a journey to bring more equity to health. As we commemorate #Juneteenth, Pfizer proudly stands with the Black community in honoring the spirit of freedom, resilience, and progress. Juneteenth marks a powerful reminder of the ongoing struggle for equality and justice, and a call to action to create a more inclusive and equitable world. \n \n We actively foster diversity, equity, and inclusion by building and nurturing programs and partnerships that extend beyond our company.\n \n We recognize that #healthequity is only achieved when breakthroughs are made accessible to all. We firmly believe that everyone, regardless of their background or circumstances, deserves access to quality healthcare and the opportunity to lead a healthier life. \n \n Join us on this journey as we work towards a future where not only racial disparities are eliminated, but also health inequalities are eliminated, and health equity is a reality for all. Learn more by visiting on.pfizer.com/HealthEquity """ "reshared_post_followers" => 5455706 "reshared_post_date" => "3w" "last_updated" => "2023-08-15 04:14:54" "deleted" => 1 ] [ "id" => 240144580 "company_id" => 1258906 "urn" => "urn:li:activity:7076541604819263488" "followers" => 5455706 "date" => "3w" "description" => """ We're on a journey to bring more equity to health. As we commemorate #Juneteenth, Pfizer proudly stands with the Black community in honoring the spirit of freedom, resilience, and progress. Juneteenth marks a powerful reminder of the ongoing struggle for equality and justice, and a call to action to create a more inclusive and equitable world. \n \n We actively foster diversity, equity, and inclusion by building and nurturing programs and partnerships that extend beyond our company.\n \n We recognize that #healthequity is only achieved when breakthroughs are made accessible to all. We firmly believe that everyone, regardless of their background or circumstances, deserves access to quality healthcare and the opportunity to lead a healthier life. \n \n Join us on this journey as we work towards a future where not only racial disparities are eliminated, but also health inequalities are eliminated, and health equity is a reality for all. Learn more by visiting on.pfizer.com/HealthEquity """ "reactions_count" => 515 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 04:14:54" "deleted" => 1 ] [ "id" => 240144581 "company_id" => 1258906 "urn" => "urn:li:activity:7074089578239774720" "followers" => 5455706 "date" => "1mo" "description" => """ Bonjour! Join us next week at the Cannes Lions International Festival of Creativity for an incredible session on "How to Use Creative Transformation to Disrupt Your Business". \n \n 📅 Date: June 19, 2023 \n ⏰ Time: 3:45PM CET \n 📍 Location: Palais des Festivals \n \n This thought-provoking session will feature our very own CCO Angela Hwang and CMO Drew P., along with Thrive Global Founder & CEO Arianna Huffington, and performance by renowned poet IN-Q. Together, they’ll take you on a journey of creative transformation, showcase some innovative marketing campaigns, and share their insights and experiences on igniting transformative change within their organizations. #CannesLions2023 \n \n We hope to see you there: https://lnkd.in/esej9zhc """ "reactions_count" => 305 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 04:14:54" "deleted" => 1 ] [ "id" => 294301209 "company_id" => 1258906 "urn" => "urn:li:activity:7096925667551768577" "followers" => null "date" => "9h" "description" => """ BREAKING: We are proud to announce the U.S. FDA has approved our bispecific antibody treatment, under the accelerated approval program, for certain adults living with relapsed or refractory multiple myeloma (RRMM).\n \n RRMM is currently incurable, and patients will generally relapse.\n \n This approval represents a significant moment for people living with RRMM, offering access to a new treatment option. Learn more about this announcement: https://lnkd.in/eUFJYxrS """ "reactions_count" => 2463 "comments_count" => 26 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-11 21:09:31" "deleted" => 1 ] [ "id" => 294301210 "company_id" => 1258906 "urn" => "urn:li:activity:7092188498048229376" "followers" => null "date" => "1w" "description" => "Below are some highlights from our Q2 2023 earnings report. Check out the full details from today’s presentation here: https://lnkd.in/ePEqBqVm" "reactions_count" => 1396 "comments_count" => 13 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-11 21:09:31" "deleted" => 1 ] [ "id" => 294301211 "company_id" => 1258906 "urn" => "urn:li:activity:7090662175022698496" "followers" => null "date" => "3w" "description" => """ 📣 Pfizer Puurs werft aan! Wil jij meewerken aan de gezondheid van miljoenen mensen? Ben je in staat om complexe problemen of storingen te analyseren en op te lossen? Doet onze hoogtechnologische omgeving jou watertanden?\n \n Dan ben jij misschien wel de technieker die wij zoeken! Interesse? Solliciteren kan via: https://lnkd.in/eR4MDH8m\n \n #PfizerPuurs #jobs """ "reactions_count" => 182 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-11 21:09:31" "deleted" => 1 ] [ "id" => 294301212 "company_id" => 1258906 "urn" => "urn:li:activity:7088240922529816578" "followers" => null "date" => "3w" "description" => """ Members of Pfizer’s Executive Leadership team traveled to our manufacturing facility in Rocky Mount, N.C. today, following the devastating tornado that hit the community on Wednesday, July 19. \n \n “Clearly nature is strong. So too is ingenuity and the human spirit. A great deal of work needs to be done, but I assure everyone, most importantly the people of the Rocky Mount community, that we will put Pfizer’s full power behind this effort,” said Dr. Albert Bourla, Chairman and CEO, Pfizer Inc. “We will work in lockstep with our partners and local authorities to restore and rebuild the site and the community.”\n \n We are committed to restoring full function to the site, which is a key producer for sterile injectables. See how we are working to restore the facility and the community: \n \n https://lnkd.in/esEbFDZU """ "reactions_count" => 3018 "comments_count" => 50 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-11 21:09:31" "deleted" => 1 ] [ "id" => 294301213 "company_id" => 1258906 "urn" => "urn:li:activity:7088156029091254272" "followers" => null "date" => "3w" "description" => """ This week, NEJM Group published data on our maternal vaccine candidate for Group B streptococcus (GBS). The data suggest that maternal vaccination may help protect newborns and young infants against invasive GBS, a common cause of sepsis, pneumonia, and meningitis in newborns.\n \n We are excited to continue progressing our GBS vaccine candidate to help prevent these potentially devastating illnesses in infants.\n \n Read more here: https://lnkd.in/gGJEMxXJ """ "reactions_count" => 822 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-11 21:09:31" "deleted" => 1 ] [ "id" => 294301214 "company_id" => 1258906 "urn" => "urn:li:activity:7087842331617304577" "followers" => null "date" => null "description" => null "reactions_count" => 437 "comments_count" => 4 "reshared_post_author" => "Biotechnology Innovation Organization" "reshared_post_author_url" => "https://www.linkedin.com/company/biotechnology-innovation-organization" "reshared_post_author_headline" => null "reshared_post_description" => """ #Vaccines help children grow and develop free from preventable diseases. Among U.S. children born between 1994 and 2021 #vaccinations will prevent: \n 🤒 472 million illnesses \n 🏥 29.8 million hospitalizations \n ☠️ 1,052,000 deaths \n 💰 Nearly $2.2 TRILLION in societal costs #StandUpForScience https://lnkd.in/gThD9_iH """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2023-09-11 21:09:31" "deleted" => 1 ] [ "id" => 294301215 "company_id" => 1258906 "urn" => "urn:li:activity:7087039968350457856" "followers" => null "date" => null "description" => null "reactions_count" => 713 "comments_count" => 6 "reshared_post_author" => "Flagship Pioneering" "reshared_post_author_url" => "https://www.linkedin.com/company/flagship-pioneering" "reshared_post_author_headline" => null "reshared_post_description" => """ Flagship Pioneering and Pfizer partner to create a new pipeline of innovative medicines targeting unmet needs and leveraging Flagship’s ecosystem of pioneering bioplatforms. Flagship’s Pioneering Medicines, working in collaboration with Pfizer’s R&D leadership, will lead the exploration process. \n \n For more: bit.ly/3pVMbsv """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2023-09-11 21:09:31" "deleted" => 1 ] [ "id" => 294301216 "company_id" => 1258906 "urn" => "urn:li:activity:7084587831557267456" "followers" => null "date" => "1mo" "description" => "Congratulations to Rady Johnson on being named the 2023 Executive Sponsor of the Year by Disability:IN! This prestigious award recognizes Rady's commitment to inclusivity and support for individuals with disabilities. Well-deserved, Rady!" "reactions_count" => 129 "comments_count" => 4 "reshared_post_author" => "Disability:IN" "reshared_post_author_url" => "https://www.linkedin.com/company/disabilityin" "reshared_post_author_headline" => null "reshared_post_description" => """ Please help us congratulate the Disability:IN Inclusion Award Winners that were announced during today's Opening Plenary!\n \n - 2023 Affiliate of the Year: Disability:IN Utah (Affiliate)\n - 2023 Executive Sponsor of the Year: Rady Johnson of Pfizer\n - 2023 Employer of the Year: Walgreens Boots Alliance\n \n #AreYouIN? """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-09-11 21:09:31" "deleted" => 1 ] [ "id" => 294301217 "company_id" => 1258906 "urn" => "urn:li:activity:7083120859409780737" "followers" => null "date" => "1mo" "description" => """ Antimicrobial resistance can impact people of any age, in any country, and urgently needs to be addressed. We're proud to be part of the upcoming #RaceAgainstResistance film produced for Pfizer by BBC StoryWorks Commercial Productions. Watch the trailer below. \n \n #AMR #StopSuperbugs """ "reactions_count" => 477 "comments_count" => 6 "reshared_post_author" => "BBC StoryWorks" "reshared_post_author_url" => "https://uk.linkedin.com/showcase/bbc-storyworks" "reshared_post_author_headline" => null "reshared_post_description" => """ #Advertisement feature presented by Biotechnology Innovation Organization. 💊 Antibiotics are vital to fighting infection – can you imagine a world where they stopped working? \n Race Against Resistance is a film which dives into one of humanity’s biggest existential threats 🦠 - and the people determined to save us. \n \n 📽️ 🎬 Race Against Resistance launches on September 5 – see you then. \n \n #RaceAgainstResistance \n #NaturesBuildingBlocks """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2023-09-11 21:09:31" "deleted" => 1 ] [ "id" => 294301218 "company_id" => 1258906 "urn" => "urn:li:activity:7079830029567721472" "followers" => null "date" => "1mo" "description" => """ We are honored to share the 17th anniversary edition of the Pfizer Pride Journal, a cherished platform that amplifies the voices of our LGBTQ+ colleagues and allies, offering a space to share personal stories of resilience, triumph, and aspirations during #PrideMonth.\n \n At Pfizer, we aim to foster an inclusive environment that embraces diversity, equity, and empowers everyone to live authentically. That is why we take immense pride in publishing this journal annually so that these stories can be shared and joyously celebrated. Each story is a testament to the strength and determination within our vibrant LGBTQ+ community of colleagues.\n \n Explore these captivating voices that have inspired countless individuals by visiting: https://lnkd.in/gJvwzVvy """ "reactions_count" => 460 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-11 21:09:31" "deleted" => 1 ] [ "id" => 347334523 "company_id" => 1258906 "urn" => "urn:li:activity:7118586571963920384" "followers" => null "date" => "4d" "description" => """ BREAKING: We’re proud to announce the U.S. FDA has approved Pfizer’s oral treatment option for adults with moderate to severe #UlcerativeColitis (UC). \n \n This approval is a meaningful milestone for the 1.25M people in the U.S. living with this chronic condition, offering them a new treatment option. \n \n Learn more about this breakthrough at https://lnkd.in/eNSit2TD """ "reactions_count" => 3122 "comments_count" => 20 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 05:54:43" "deleted" => 1 ] [ "id" => 347334524 "company_id" => 1258906 "urn" => "urn:li:activity:7118581282032246784" "followers" => null "date" => "4d" "description" => """ BREAKING NEWS: Today, we announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the approval of our BCMA bispecific antibody treatment for certain people living with #MultipleMyeloma (MM).\n \n Over 176,000 people are diagnosed with MM globally each year. We are committed to addressing the unmet needs of patients and their families.\n \n Read more: https://lnkd.in/efgEVrK7 """ "reactions_count" => 1108 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 05:54:43" "deleted" => 1 ] [ "id" => 347334525 "company_id" => 1258906 "urn" => "urn:li:activity:7118251941557624833" "followers" => null "date" => "5d" "description" => """ Over the past few days, the scope of the atrocities carried out against Israel and its citizens have become clearer and more horrific. I know I am not alone when I express my shock and grief about the ongoing situation. I can scarcely imagine the full magnitude of what people are experiencing there: civilians of all ages targeted and killed in cold blood, hostages taken and tortured, victims paraded through the streets, and so much more. It is not enough to condemn these actions—we ourselves must take action.\n \n To help support urgent and humanitarian health needs in the region, The Pfizer Foundation has launched a donation campaign to support several key organizations that are working to provide critical emergency assistance in the region, and Pfizer will match all colleague donations made through this campaign. The Pfizer Foundation is also in active discussions with our partner NGOs on the ground to determine if additional financial support is required. And we continue to work with our global network of humanitarian and logistics partners to assess the need for medicines and vaccines, and are ready to provide support where needed.\n \n Personally, I am heartbroken by the atrocities we have witnessed, and over the last few days, I have been on the phone constantly with friends and relatives in Israel. My prayers continue to be with them and with the people of Israel.\n \n Yesterday, I shared this letter with all Pfizer colleagues: """ "reactions_count" => 1142 "comments_count" => 358 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 05:54:43" "deleted" => 1 ] [ "id" => 347334526 "company_id" => 1258906 "urn" => "urn:li:activity:7117506876941942785" "followers" => null "date" => "1w" "description" => "We are deeply committed to all of our colleagues who contribute in the relentless pursuit of breakthroughs that change patients’ lives. We are proud to be recognized by Forbes World’s Best Employers list for 2023: https://lnkd.in/enE4ahwt" "reactions_count" => 1967 "comments_count" => 29 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 05:54:43" "deleted" => 1 ] [ "id" => 347334527 "company_id" => 1258906 "urn" => "urn:li:activity:7116063675198709760" "followers" => null "date" => "1w" "description" => """ Create your legacy! That was the theme at our event celebrating #HispanicHeritageMonth. Every year, Pfizer’s Latino Community Colleague Resource Group hosts a summit that brings together Pfizer colleagues from all over the world as well as professionals from different industries to celebrate their heritage, and share their stories and experiences as Latino professionals. Special thanks to my colleagues Mia Ortiz and Melissa Barreto for organizing this incredible event.\n \n This year’s theme really got me thinking about what that word—“legacy”—means. To me, legacy is about blazing a positive and hopefully transformative path that can inspire others to succeed. Pfizer has a legacy: We have a 175-year history of innovating for patients—from helping to pioneer large-scale penicillin manufacturing during World War II, to developing vaccines that have helped eradicate devastating diseases. Our legacy has changed the lives of billions of people.\n \n Hispanic Heritage Month is a special time in the US that celebrates the historic independence of several Latin American countries. The many men and women who fought for their countries’ independence left a legacy that continues to inspire to this day. I hope to build a legacy as well, one that embodies the four values we hold dear at Pfizer: courage, excellence, equity, and joy. \n \n What legacy do you want to create? """ "reactions_count" => 660 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 05:54:43" "deleted" => 1 ] [ "id" => 347334528 "company_id" => 1258906 "urn" => "urn:li:activity:7112866928313937920" "followers" => null "date" => "2w" "description" => """ Pfizer’s new Chief Investor Relations Officer brings a wealth of experience in our commitment to drive shareholder value.\n \n Read more about Francesca DeMartino: https://lnkd.in/epPYf49y """ "reactions_count" => 699 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 05:54:43" "deleted" => 1 ] [ "id" => 347334529 "company_id" => 1258906 "urn" => "urn:li:activity:7110608630634225664" "followers" => null "date" => "3w" "description" => """ Together with Research!America: Discovery. Innovation. Health., we’re honored to announce the recipient of the 2023 Discovery \| Innovation \| Health Prize as Dr. Nevan Krogan. \n \n Pfizer was proud to support this prize, which aims to recognize and provide funding for a researcher with a bold vision for progress against pandemic threats. In the early stages of the COVID-19 pandemic, Dr. Krogan came together with scientists from around the world to map SARS-CoV-2 which helped facilitate the rapid discovery of potential antiviral compounds. Now, he is establishing a center for excellence, a global network with cross-sector, cross-disciplinary, international collaboration that will better prepare us to take unified action and save more lives if faced with another pandemic. \n \n Pfizer’s Annaliesa A., head of Vaccine Research and Development, presented Dr. Krogan with the award at the Research!America National Health Research Forum in Washington, DC. \n \n #RAForum #Innovation #PublicHealth """ "reactions_count" => 314 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 05:54:43" "deleted" => 1 ] [ "id" => 347334530 "company_id" => 1258906 "urn" => "urn:li:activity:7108483653986344960" "followers" => null "date" => "1mo" "description" => """ #COVID19 vaccines for the 2023-2024 fall and winter season are now available across the U.S. So, what does this mean for your patients? We have answers to some common questions.\n \n Learn more: https://lnkd.in/egnq6tay """ "reactions_count" => 561 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 05:54:43" "deleted" => 1 ] [ "id" => 347334531 "company_id" => 1258906 "urn" => "urn:li:activity:7108152587190738944" "followers" => null "date" => "1mo" "description" => """ #IfYouOnlyKnew the silent struggles children with eczema face, you’d see that every day brings challenges that run more than skin deep. \n \n This #WorldAtopicEczemaDay, hear from patient advocates who have lived it and share your childhood eczema stories using #IfYouOnlyKnew to help others feel more comfortable in their own skin.\n \n Learn more about atopic eczema: https://lnkd.in/dAyFWaX7 """ "reactions_count" => 441 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 05:54:43" "deleted" => 1 ] [ "id" => 347334532 "company_id" => 1258906 "urn" => "urn:li:activity:7107793084700061696" "followers" => null "date" => "1mo" "description" => """ We are proud to stand at #6 among TIME World’s Best Companies 2023 and #1 on the Chemicals, Drugs & Biotechnology industry list. This ranking was based on a comprehensive research study conducted to identify the top performing global companies, measuring revenue growth, employee-satisfaction surveys, and rigorous environmental, social, and corporate governance data to compile the final list. \n \n At Pfizer, our purpose is clear: to deliver breakthroughs that change patients' lives. We are driven by a shared commitment to improving global health and having a positive impact on the people and communities who rely on us. This recognition by TIME affirms that our efforts are making a difference. \n \n https://ti.me/44Jnfmo """ "reactions_count" => 4294 "comments_count" => 56 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 05:54:43" "deleted" => 1 ] [ "id" => 392432493 "company_id" => 1258906 "urn" => "urn:li:activity:7128069979517681665" "followers" => null "date" => "2w" "description" => """ Finding innovative ways to make clinical trials accessible and accelerating breakthroughs to patients is how we continue to push science forward. We are proud to introduce the first industry-sponsored research registry called PfizerLink.\n \n PfizerLink aims to make it easier for interested individuals to find Pfizer clinical trials, including for those who have been historically underrepresented, and address the long-standing challenges associated with clinical trial recruitment. This novel online approach will allow people who are interested – either healthy volunteers or those with medical conditions – to be rapidly pre-screened and connected to a trial navigator that will connect them to an available Pfizer clinical trial nearby or notify them if one becomes available.\n \n The registry helps address the frustrations some people feel in searching for and learning about new trials. In fact, the most recent CISCRP study on the public’s attitudes towards clinical research found that despite higher levels of awareness, a quarter of respondents are not confident in their ability to find a clinical research study that is right for them.\n \n Industrywide, approximately 80% of clinical trials fail to meet enrollment deadlines, while 30% of Phase 3 studies last longer than expected due to challenges in recruitment. Because potentially eligible participants would already be identified and pre-screened through PfizerLink, enrollment in newly launched Pfizer trials can be significantly accelerated. \n \n PfizerLink aims to make it easier for potential participants to get involved in the research that matters to them.\n \n To learn more about PfizerLink, please visit https://www.pfi.sr/SkM. """ "reactions_count" => 523 "comments_count" => 39 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-08 02:29:38" "deleted" => 1 ] [ "id" => 392432494 "company_id" => 1258906 "urn" => "urn:li:activity:7125194364632330240" "followers" => null "date" => "3w" "description" => "Below are some highlights from our Q3 2023 earnings report. Check out the full details from today’s presentation here: https://lnkd.in/eKE6B9qW" "reactions_count" => 781 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-08 02:29:38" "deleted" => 1 ] [ "id" => 392432495 "company_id" => 1258906 "urn" => "urn:li:activity:7118586571963920384" "followers" => null "date" => "1mo" "description" => """ BREAKING: We’re proud to announce the U.S. FDA has approved Pfizer’s oral treatment option for adults with moderate to severe #UlcerativeColitis (UC). \n \n This approval is a meaningful milestone for the 1.25M people in the U.S. living with this chronic condition, offering them a new treatment option. \n \n Learn more about this breakthrough at https://lnkd.in/eNSit2TD """ "reactions_count" => 3498 "comments_count" => 31 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-08 02:29:38" "deleted" => 1 ] [ "id" => 392432496 "company_id" => 1258906 "urn" => "urn:li:activity:7118581282032246784" "followers" => null "date" => "1mo" "description" => """ BREAKING NEWS: Today, we announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the approval of our BCMA bispecific antibody treatment for certain people living with #MultipleMyeloma (MM).\n \n Over 176,000 people are diagnosed with MM globally each year. We are committed to addressing the unmet needs of patients and their families.\n \n Read more: https://lnkd.in/efgEVrK7 """ "reactions_count" => 1265 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-08 02:29:38" "deleted" => 1 ] [ "id" => 392432497 "company_id" => 1258906 "urn" => "urn:li:activity:7118251941557624833" "followers" => null "date" => "1mo" "description" => """ Over the past few days, the scope of the atrocities carried out against Israel and its citizens have become clearer and more horrific. I know I am not alone when I express my shock and grief about the ongoing situation. I can scarcely imagine the full magnitude of what people are experiencing there: civilians of all ages targeted and killed in cold blood, hostages taken and tortured, victims paraded through the streets, and so much more. It is not enough to condemn these actions—we ourselves must take action.\n \n To help support urgent and humanitarian health needs in the region, The Pfizer Foundation has launched a donation campaign to support several key organizations that are working to provide critical emergency assistance in the region, and Pfizer will match all colleague donations made through this campaign. The Pfizer Foundation is also in active discussions with our partner NGOs on the ground to determine if additional financial support is required. And we continue to work with our global network of humanitarian and logistics partners to assess the need for medicines and vaccines, and are ready to provide support where needed.\n \n Personally, I am heartbroken by the atrocities we have witnessed, and over the last few days, I have been on the phone constantly with friends and relatives in Israel. My prayers continue to be with them and with the people of Israel.\n \n Yesterday, I shared this letter with all Pfizer colleagues: """ "reactions_count" => 1398 "comments_count" => 551 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-08 02:29:38" "deleted" => 1 ] [ "id" => 392432498 "company_id" => 1258906 "urn" => "urn:li:activity:7117506876941942785" "followers" => null "date" => "1mo" "description" => "We are deeply committed to all of our colleagues who contribute in the relentless pursuit of breakthroughs that change patients’ lives. We are proud to be recognized by Forbes World’s Best Employers list for 2023: https://lnkd.in/enE4ahwt" "reactions_count" => 2080 "comments_count" => 39 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-08 02:29:38" "deleted" => 1 ] [ "id" => 392432499 "company_id" => 1258906 "urn" => "urn:li:activity:7116063675198709760" "followers" => null "date" => "1mo" "description" => """ Create your legacy! That was the theme at our event celebrating #HispanicHeritageMonth. Every year, Pfizer’s Latino Community Colleague Resource Group hosts a summit that brings together Pfizer colleagues from all over the world as well as professionals from different industries to celebrate their heritage, and share their stories and experiences as Latino professionals. Special thanks to my colleagues Mia Ortiz and Melissa Barreto for organizing this incredible event.\n \n This year’s theme really got me thinking about what that word—“legacy”—means. To me, legacy is about blazing a positive and hopefully transformative path that can inspire others to succeed. Pfizer has a legacy: We have a 175-year history of innovating for patients—from helping to pioneer large-scale penicillin manufacturing during World War II, to developing vaccines that have helped eradicate devastating diseases. Our legacy has changed the lives of billions of people.\n \n Hispanic Heritage Month is a special time in the US that celebrates the historic independence of several Latin American countries. The many men and women who fought for their countries’ independence left a legacy that continues to inspire to this day. I hope to build a legacy as well, one that embodies the four values we hold dear at Pfizer: courage, excellence, equity, and joy. \n \n What legacy do you want to create? """ "reactions_count" => 712 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-08 02:29:38" "deleted" => 1 ] [ "id" => 392432500 "company_id" => 1258906 "urn" => "urn:li:activity:7112866928313937920" "followers" => null "date" => "1mo" "description" => """ Pfizer’s new Chief Investor Relations Officer brings a wealth of experience in our commitment to drive shareholder value.\n \n Read more about Francesca DeMartino: https://lnkd.in/epPYf49y """ "reactions_count" => 698 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-08 02:29:38" "deleted" => 1 ] [ "id" => 392432501 "company_id" => 1258906 "urn" => "urn:li:activity:7110608630634225664" "followers" => null "date" => "2mo" "description" => """ Together with Research!America: Discovery. Innovation. Health., we’re honored to announce the recipient of the 2023 Discovery \| Innovation \| Health Prize as Dr. Nevan Krogan. \n \n Pfizer was proud to support this prize, which aims to recognize and provide funding for a researcher with a bold vision for progress against pandemic threats. In the early stages of the COVID-19 pandemic, Dr. Krogan came together with scientists from around the world to map SARS-CoV-2 which helped facilitate the rapid discovery of potential antiviral compounds. Now, he is establishing a center for excellence, a global network with cross-sector, cross-disciplinary, international collaboration that will better prepare us to take unified action and save more lives if faced with another pandemic. \n \n Pfizer’s Annaliesa A., head of Vaccine Research and Development, presented Dr. Krogan with the award at the Research!America National Health Research Forum in Washington, DC. \n \n #RAForum #Innovation #PublicHealth """ "reactions_count" => 318 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-08 02:29:38" "deleted" => 1 ] [ "id" => 392432502 "company_id" => 1258906 "urn" => "urn:li:activity:7108483653986344960" "followers" => null "date" => "2mo" "description" => """ #COVID19 vaccines for the 2023-2024 fall and winter season are now available across the U.S. So, what does this mean for your patients? We have answers to some common questions.\n \n Learn more: https://lnkd.in/egnq6tay """ "reactions_count" => 561 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-08 02:29:38" "deleted" => 1 ] [ "id" => 405903378 "company_id" => 1258906 "urn" => "urn:li:activity:7136374518087892992" "followers" => null "date" => "6d" "description" => """ Learn about tangible solutions to disrupt structural inequities in healthcare facilities and delivery in our final ‘Health Equity in Action’ Health Affairs Forefront series post, co-authored by Walter D. Conwell, MD, MBA, Chief Diversity and Inclusion Officer at Morehouse School of Medicine, and Niesha Foster, our VP of Global Health and Social Impact: https://bit.ly/3T5ZrH9\n \n In this piece, they share practical insights and underscore the need to:\n ✔️ promote patient-centric care\n ✔️ address the social determinants of health as part of care plans\n ✔️ invest in the training and wellness of healthcare providers, among other priorities.\n \n #EquityInAction #PublicHealth #HealthEquity #Partnership """ "reactions_count" => 209 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 05:54:35" "deleted" => 1 ] [ "id" => 405903379 "company_id" => 1258906 "urn" => "urn:li:activity:7128069979517681665" "followers" => null "date" => "4w" "description" => """ Finding innovative ways to make clinical trials accessible and accelerating breakthroughs to patients is how we continue to push science forward. We are proud to introduce the first industry-sponsored research registry called PfizerLink.\n \n PfizerLink aims to make it easier for interested individuals to find Pfizer clinical trials, including for those who have been historically underrepresented, and address the long-standing challenges associated with clinical trial recruitment. This novel online approach will allow people who are interested – either healthy volunteers or those with medical conditions – to be rapidly pre-screened and connected to a trial navigator that will connect them to an available Pfizer clinical trial nearby or notify them if one becomes available.\n \n The registry helps address the frustrations some people feel in searching for and learning about new trials. In fact, the most recent CISCRP study on the public’s attitudes towards clinical research found that despite higher levels of awareness, a quarter of respondents are not confident in their ability to find a clinical research study that is right for them.\n \n Industrywide, approximately 80% of clinical trials fail to meet enrollment deadlines, while 30% of Phase 3 studies last longer than expected due to challenges in recruitment. Because potentially eligible participants would already be identified and pre-screened through PfizerLink, enrollment in newly launched Pfizer trials can be significantly accelerated. \n \n PfizerLink aims to make it easier for potential participants to get involved in the research that matters to them.\n \n To learn more about PfizerLink, please visit https://www.pfi.sr/SkM. """ "reactions_count" => 535 "comments_count" => 40 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 05:54:35" "deleted" => 1 ] [ "id" => 405903380 "company_id" => 1258906 "urn" => "urn:li:activity:7125194364632330240" "followers" => null "date" => "1mo" "description" => "Below are some highlights from our Q3 2023 earnings report. Check out the full details from today’s presentation here: https://lnkd.in/eKE6B9qW" "reactions_count" => 792 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 05:54:35" "deleted" => 1 ] [ "id" => 405903381 "company_id" => 1258906 "urn" => "urn:li:activity:7118586571963920384" "followers" => null "date" => "1mo" "description" => """ BREAKING: We’re proud to announce the U.S. FDA has approved Pfizer’s oral treatment option for adults with moderate to severe #UlcerativeColitis (UC). \n \n This approval is a meaningful milestone for the 1.25M people in the U.S. living with this chronic condition, offering them a new treatment option. \n \n Learn more about this breakthrough at https://lnkd.in/eNSit2TD """ "reactions_count" => 3501 "comments_count" => 32 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 05:54:35" "deleted" => 1 ] [ "id" => 405903382 "company_id" => 1258906 "urn" => "urn:li:activity:7118581282032246784" "followers" => null "date" => "1mo" "description" => """ BREAKING NEWS: Today, we announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the approval of our BCMA bispecific antibody treatment for certain people living with #MultipleMyeloma (MM).\n \n Over 176,000 people are diagnosed with MM globally each year. We are committed to addressing the unmet needs of patients and their families.\n \n Read more: https://lnkd.in/efgEVrK7 """ "reactions_count" => 1270 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 05:54:35" "deleted" => 1 ] [ "id" => 405903383 "company_id" => 1258906 "urn" => "urn:li:activity:7118251941557624833" "followers" => null "date" => "1mo" "description" => """ Over the past few days, the scope of the atrocities carried out against Israel and its citizens have become clearer and more horrific. I know I am not alone when I express my shock and grief about the ongoing situation. I can scarcely imagine the full magnitude of what people are experiencing there: civilians of all ages targeted and killed in cold blood, hostages taken and tortured, victims paraded through the streets, and so much more. It is not enough to condemn these actions—we ourselves must take action.\n \n To help support urgent and humanitarian health needs in the region, The Pfizer Foundation has launched a donation campaign to support several key organizations that are working to provide critical emergency assistance in the region, and Pfizer will match all colleague donations made through this campaign. The Pfizer Foundation is also in active discussions with our partner NGOs on the ground to determine if additional financial support is required. And we continue to work with our global network of humanitarian and logistics partners to assess the need for medicines and vaccines, and are ready to provide support where needed.\n \n Personally, I am heartbroken by the atrocities we have witnessed, and over the last few days, I have been on the phone constantly with friends and relatives in Israel. My prayers continue to be with them and with the people of Israel.\n \n Yesterday, I shared this letter with all Pfizer colleagues: """ "reactions_count" => 1401 "comments_count" => 555 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 05:54:35" "deleted" => 1 ] [ "id" => 405903384 "company_id" => 1258906 "urn" => "urn:li:activity:7117506876941942785" "followers" => null "date" => "1mo" "description" => "We are deeply committed to all of our colleagues who contribute in the relentless pursuit of breakthroughs that change patients’ lives. We are proud to be recognized by Forbes World’s Best Employers list for 2023: https://lnkd.in/enE4ahwt" "reactions_count" => 2087 "comments_count" => 41 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 05:54:35" "deleted" => 1 ] [ "id" => 405903385 "company_id" => 1258906 "urn" => "urn:li:activity:7116063675198709760" "followers" => null "date" => "2mo" "description" => """ Create your legacy! That was the theme at our event celebrating #HispanicHeritageMonth. Every year, Pfizer’s Latino Community Colleague Resource Group hosts a summit that brings together Pfizer colleagues from all over the world as well as professionals from different industries to celebrate their heritage, and share their stories and experiences as Latino professionals. Special thanks to my colleagues Mia Ortiz and Melissa Barreto for organizing this incredible event.\n \n This year’s theme really got me thinking about what that word—“legacy”—means. To me, legacy is about blazing a positive and hopefully transformative path that can inspire others to succeed. Pfizer has a legacy: We have a 175-year history of innovating for patients—from helping to pioneer large-scale penicillin manufacturing during World War II, to developing vaccines that have helped eradicate devastating diseases. Our legacy has changed the lives of billions of people.\n \n Hispanic Heritage Month is a special time in the US that celebrates the historic independence of several Latin American countries. The many men and women who fought for their countries’ independence left a legacy that continues to inspire to this day. I hope to build a legacy as well, one that embodies the four values we hold dear at Pfizer: courage, excellence, equity, and joy. \n \n What legacy do you want to create? """ "reactions_count" => 713 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 05:54:35" "deleted" => 1 ] [ "id" => 405903386 "company_id" => 1258906 "urn" => "urn:li:activity:7112866928313937920" "followers" => null "date" => "2mo" "description" => """ Pfizer’s new Chief Investor Relations Officer brings a wealth of experience in our commitment to drive shareholder value.\n \n Read more about Francesca DeMartino: https://lnkd.in/epPYf49y """ "reactions_count" => 699 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 05:54:35" "deleted" => 1 ] [ "id" => 405903387 "company_id" => 1258906 "urn" => "urn:li:activity:7110608630634225664" "followers" => null "date" => "2mo" "description" => """ Together with Research!America: Discovery. Innovation. Health., we’re honored to announce the recipient of the 2023 Discovery \| Innovation \| Health Prize as Dr. Nevan Krogan. \n \n Pfizer was proud to support this prize, which aims to recognize and provide funding for a researcher with a bold vision for progress against pandemic threats. In the early stages of the COVID-19 pandemic, Dr. Krogan came together with scientists from around the world to map SARS-CoV-2 which helped facilitate the rapid discovery of potential antiviral compounds. Now, he is establishing a center for excellence, a global network with cross-sector, cross-disciplinary, international collaboration that will better prepare us to take unified action and save more lives if faced with another pandemic. \n \n Pfizer’s Annaliesa A., head of Vaccine Research and Development, presented Dr. Krogan with the award at the Research!America National Health Research Forum in Washington, DC. \n \n #RAForum #Innovation #PublicHealth """ "reactions_count" => 319 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 05:54:35" "deleted" => 1 ] [ "id" => 432998504 "company_id" => 1258906 "urn" => "urn:li:activity:7141780978330472448" "followers" => null "date" => "3w" "description" => "We are excited to announce that the U.S. FDA granted approval to our combination therapy from Seagen for locally advanced/metastatic urothelial cancer, developed with Astellas Pharma US and Merck. We look forward to the potential of this therapy to become a new standard of care for these patients. Read more here: https://lnkd.in/ev4uTdYe" "reactions_count" => 2830 "comments_count" => 15 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-02 00:56:22" "deleted" => 1 ] [ "id" => 432998505 "company_id" => 1258906 "urn" => "urn:li:activity:7141157548505628673" "followers" => null "date" => "3w" "description" => """ Pfizer is proud to provide an unrestricted donation to the American Association for Cancer Research (AACR), the first and largest cancer research organization formed in the world. This donation will directly support AACR in its mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, and funding for cancer research. \n \n Thank you to the AACR for your partnership in accelerating the discovery of new breakthroughs in order to bring new hope to people living with cancer around the world. """ "reactions_count" => 452 "comments_count" => 6 "reshared_post_author" => "American Association for Cancer Research" "reshared_post_author_url" => "https://www.linkedin.com/company/american-association-for-cancer-research" "reshared_post_author_headline" => null "reshared_post_description" => "We are grateful that Pfizer Inc. has chosen to donate the rights of its royalties from the sale of Bavencio® (avelumab) in the United States to AACR. This unrestricted donation will advance our mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, and funding for cancer research. https://bit.ly/470hgLd" "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2024-02-02 00:56:22" "deleted" => 1 ] [ "id" => 432998506 "company_id" => 1258906 "urn" => "urn:li:activity:7136374518087892992" "followers" => null "date" => "1mo" "description" => """ Learn about tangible solutions to disrupt structural inequities in healthcare facilities and delivery in our final ‘Health Equity in Action’ Health Affairs Forefront series post, co-authored by Walter D. Conwell, MD, MBA, Chief Diversity and Inclusion Officer at Morehouse School of Medicine, and Niesha Foster, our VP of Global Health and Social Impact: https://bit.ly/3T5ZrH9\n \n In this piece, they share practical insights and underscore the need to:\n ✔️ promote patient-centric care\n ✔️ address the social determinants of health as part of care plans\n ✔️ invest in the training and wellness of healthcare providers, among other priorities.\n \n #EquityInAction #PublicHealth #HealthEquity #Partnership """ "reactions_count" => 242 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-02 00:56:22" "deleted" => 1 ] [ "id" => 432998507 "company_id" => 1258906 "urn" => "urn:li:activity:7128069979517681665" "followers" => null "date" => "1mo" "description" => """ Finding innovative ways to make clinical trials accessible and accelerating breakthroughs to patients is how we continue to push science forward. We are proud to introduce the first industry-sponsored research registry called PfizerLink.\n \n PfizerLink aims to make it easier for interested individuals to find Pfizer clinical trials, including for those who have been historically underrepresented, and address the long-standing challenges associated with clinical trial recruitment. This novel online approach will allow people who are interested – either healthy volunteers or those with medical conditions – to be rapidly pre-screened and connected to a trial navigator that will connect them to an available Pfizer clinical trial nearby or notify them if one becomes available.\n \n The registry helps address the frustrations some people feel in searching for and learning about new trials. In fact, the most recent CISCRP study on the public’s attitudes towards clinical research found that despite higher levels of awareness, a quarter of respondents are not confident in their ability to find a clinical research study that is right for them.\n \n Industrywide, approximately 80% of clinical trials fail to meet enrollment deadlines, while 30% of Phase 3 studies last longer than expected due to challenges in recruitment. Because potentially eligible participants would already be identified and pre-screened through PfizerLink, enrollment in newly launched Pfizer trials can be significantly accelerated. \n \n PfizerLink aims to make it easier for potential participants to get involved in the research that matters to them.\n \n To learn more about PfizerLink, please visit https://www.pfi.sr/SkM. """ "reactions_count" => 555 "comments_count" => 40 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-02 00:56:22" "deleted" => 1 ] [ "id" => 432998508 "company_id" => 1258906 "urn" => "urn:li:activity:7125194364632330240" "followers" => null "date" => "2mo" "description" => "Below are some highlights from our Q3 2023 earnings report. Check out the full details from today’s presentation here: https://lnkd.in/eKE6B9qW" "reactions_count" => 808 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-02 00:56:22" "deleted" => 1 ] [ "id" => 432998509 "company_id" => 1258906 "urn" => "urn:li:activity:7118586571963920384" "followers" => null "date" => "2mo" "description" => """ BREAKING: We’re proud to announce the U.S. FDA has approved Pfizer’s oral treatment option for adults with moderate to severe #UlcerativeColitis (UC). \n \n This approval is a meaningful milestone for the 1.25M people in the U.S. living with this chronic condition, offering them a new treatment option. \n \n Learn more about this breakthrough at https://lnkd.in/eNSit2TD """ "reactions_count" => 3513 "comments_count" => 32 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-02 00:56:22" "deleted" => 1 ] [ "id" => 432998510 "company_id" => 1258906 "urn" => "urn:li:activity:7118581282032246784" "followers" => null "date" => "2mo" "description" => """ BREAKING NEWS: Today, we announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the approval of our BCMA bispecific antibody treatment for certain people living with #MultipleMyeloma (MM).\n \n Over 176,000 people are diagnosed with MM globally each year. We are committed to addressing the unmet needs of patients and their families.\n \n Read more: https://lnkd.in/efgEVrK7 """ "reactions_count" => 1277 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-02 00:56:22" "deleted" => 1 ] [ "id" => 432998511 "company_id" => 1258906 "urn" => "urn:li:activity:7118251941557624833" "followers" => null "date" => "2mo" "description" => """ Over the past few days, the scope of the atrocities carried out against Israel and its citizens have become clearer and more horrific. I know I am not alone when I express my shock and grief about the ongoing situation. I can scarcely imagine the full magnitude of what people are experiencing there: civilians of all ages targeted and killed in cold blood, hostages taken and tortured, victims paraded through the streets, and so much more. It is not enough to condemn these actions—we ourselves must take action.\n \n To help support urgent and humanitarian health needs in the region, The Pfizer Foundation has launched a donation campaign to support several key organizations that are working to provide critical emergency assistance in the region, and Pfizer will match all colleague donations made through this campaign. The Pfizer Foundation is also in active discussions with our partner NGOs on the ground to determine if additional financial support is required. And we continue to work with our global network of humanitarian and logistics partners to assess the need for medicines and vaccines, and are ready to provide support where needed.\n \n Personally, I am heartbroken by the atrocities we have witnessed, and over the last few days, I have been on the phone constantly with friends and relatives in Israel. My prayers continue to be with them and with the people of Israel.\n \n Yesterday, I shared this letter with all Pfizer colleagues: """ "reactions_count" => 1412 "comments_count" => 560 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-02 00:56:22" "deleted" => 1 ] [ "id" => 432998512 "company_id" => 1258906 "urn" => "urn:li:activity:7117506876941942785" "followers" => null "date" => "2mo" "description" => "We are deeply committed to all of our colleagues who contribute in the relentless pursuit of breakthroughs that change patients’ lives. We are proud to be recognized by Forbes World’s Best Employers list for 2023: https://lnkd.in/enE4ahwt" "reactions_count" => 2105 "comments_count" => 45 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-02 00:56:22" "deleted" => 1 ] [ "id" => 432998513 "company_id" => 1258906 "urn" => "urn:li:activity:7116063675198709760" "followers" => null "date" => "3mo" "description" => """ Create your legacy! That was the theme at our event celebrating #HispanicHeritageMonth. Every year, Pfizer’s Latino Community Colleague Resource Group hosts a summit that brings together Pfizer colleagues from all over the world as well as professionals from different industries to celebrate their heritage, and share their stories and experiences as Latino professionals. Special thanks to my colleagues Mia Ortiz and Melissa Barreto for organizing this incredible event.\n \n This year’s theme really got me thinking about what that word—“legacy”—means. To me, legacy is about blazing a positive and hopefully transformative path that can inspire others to succeed. Pfizer has a legacy: We have a 175-year history of innovating for patients—from helping to pioneer large-scale penicillin manufacturing during World War II, to developing vaccines that have helped eradicate devastating diseases. Our legacy has changed the lives of billions of people.\n \n Hispanic Heritage Month is a special time in the US that celebrates the historic independence of several Latin American countries. The many men and women who fought for their countries’ independence left a legacy that continues to inspire to this day. I hope to build a legacy as well, one that embodies the four values we hold dear at Pfizer: courage, excellence, equity, and joy. \n \n What legacy do you want to create? """ "reactions_count" => 715 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-02 00:56:22" "deleted" => 1 ] [ "id" => 460721489 "company_id" => 1258906 "urn" => "urn:li:activity:7157888648477073408" "followers" => null "date" => "3d" "description" => """ As the Enterprise Chair of Pfizer’s Global Black Community colleague resource group, my leadership team and I outlined four priorities for 2024 that are aimed at helping Pfizer attract and retain Black talent at all levels within the company. \n \n One of these priorities, which I am proud to share here, is our expanded engagement with historically Black colleges and universities (HBCUs) and the students they serve. Last week, in honor of the MLK Holiday in the United States, we held a program titled, “Preserving the Dream: Advancing Education and Equity for MLK’s Legacy” with special guests, Dr. Roslyn Clark Artis, President, Benedict College (SC), Dr. Paulette Dillard, President, Shaw University (NC), and Dr. Tashni-Ann Dubroy, Executive Vice President & Chief Operating Officer, Howard University (DC). \n \n We were excited to introduce not only these outstanding women to our diverse population of colleagues at Pfizer but also the value of an HBCU education. \n \n In the words of Dr. King, a Morehouse College graduate, “I have the audacity to believe that peoples everywhere can have three meals a day for their bodies, education and culture for their minds, and dignity, equality, and freedom for their spirits." Like Dr. King, we can all empower change. """ "reactions_count" => 351 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-08 17:45:58" "deleted" => 1 ] [ "id" => 460721490 "company_id" => 1258906 "urn" => "urn:li:activity:7157736536833232896" "followers" => null "date" => "3d" "description" => """ #CervicalCancer is the fourth most common cancer among women globally. Join us in supporting those living with the disease and ensuring their voices are seen and heard by watching stories, like Kristine’s, on the #CeMe YouTube channel.\n \n Together with our partner, Genmab, we are dedicated to supporting the cervical cancer community this #CervicalCancerAwarenessMonth, and year-round.\n \n https://lnkd.in/e2kgTGNp """ "reactions_count" => 237 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-08 17:45:58" "deleted" => 1 ] [ "id" => 460721491 "company_id" => 1258906 "urn" => "urn:li:activity:7150874402610450432" "followers" => null "date" => "3w" "description" => "Wishing Ultromics success with their development of EchoGo® Amyloidosis. This exciting tech uses AI to analyze routine ultrasound scans of the heart, known as an echocardiogram or echo. Our hope is that AI will offer an early warning to help physicians suspect and detect cardiac amyloidosis earlier🤞. Find out more below." "reactions_count" => 1098 "comments_count" => 23 "reshared_post_author" => "Ultromics" "reshared_post_author_url" => "https://uk.linkedin.com/company/ultromics" "reshared_post_author_headline" => null "reshared_post_description" => """ Ultromics is excited to announce a new partnership with Pfizer to expedite the development of an Echo AI algorithm for the early detection of Cardiac Amyloidosis—an underdiagnosed, life-threatening disease that can cause Heart Failure.\n \n Under the partnership, Ultromics will research and pursue FDA clearance for its Amyloidosis algorithm that has received Breakthrough Device Designation.\n \n “𝐄𝐜𝐡𝐨𝐜𝐚𝐫𝐝𝐢𝐨𝐠𝐫𝐚𝐩𝐡𝐲, 𝐰𝐡𝐢𝐥𝐞 𝐟𝐮𝐧𝐝𝐚𝐦𝐞𝐧𝐭𝐚𝐥 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐞𝐚𝐫𝐥𝐲 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐦𝐚𝐧𝐲 𝐡𝐞𝐚𝐫𝐭 𝐜𝐨𝐧𝐝𝐢𝐭𝐢𝐨𝐧𝐬, 𝐢𝐬 𝐡𝐢𝐧𝐝𝐞𝐫𝐞𝐝 𝐛𝐲 𝐬𝐮𝐛𝐣𝐞𝐜𝐭𝐢𝐯𝐢𝐭𝐲 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐝𝐞𝐦𝐚𝐧𝐝 𝐟𝐨𝐫 𝐬𝐜𝐚𝐫𝐜𝐞 𝐞𝐱𝐩𝐞𝐫𝐭𝐢𝐬𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐚𝐜𝐜𝐮𝐫𝐚𝐭𝐞 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐜𝐚𝐫𝐝𝐢𝐚𝐜 𝐚𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬. 𝐀𝐈-𝐚𝐮𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐜𝐚𝐫𝐝𝐢𝐚𝐜 𝐚𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬 𝐦𝐚𝐲 𝐛𝐞 𝐞𝐬𝐩𝐞𝐜𝐢𝐚𝐥𝐥𝐲 𝐮𝐬𝐞𝐟𝐮𝐥 𝐢𝐧 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐟𝐚𝐜𝐢𝐥𝐢𝐭𝐢𝐞𝐬 𝐥𝐚𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐭𝐢𝐦𝐞 𝐚𝐧𝐝 𝐫𝐞𝐬𝐨𝐮𝐫𝐜𝐞𝐬 𝐧𝐞𝐞𝐝𝐞𝐝 𝐟𝐨𝐫 𝐜𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐚𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭.”\n \n - 𝑃𝑟𝑜𝑓. 𝑆𝑎𝑛𝑗𝑖𝑣 𝐽. 𝑆ℎ𝑎ℎ, 𝑀𝐷, 𝑡ℎ𝑒 𝐷𝑖𝑟𝑒𝑐𝑡𝑜𝑟 𝑜𝑓 𝑅𝑒𝑠𝑒𝑎𝑟𝑐ℎ 𝑓𝑜𝑟 𝑡ℎ𝑒 𝐵𝑙𝑢ℎ𝑚 𝐶𝑎𝑟𝑑𝑖𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝐼𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑒 𝑎𝑛𝑑 𝐷𝑖𝑟𝑒𝑐𝑡𝑜𝑟, 𝐶𝑒𝑛𝑡𝑒𝑟 𝑓𝑜𝑟 𝐷𝑒𝑒𝑝 𝑃ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑖𝑛𝑔 𝑎𝑛𝑑 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑀𝑒𝑑𝑖𝑐𝑖𝑛𝑒 𝑖𝑛 𝑡ℎ𝑒 𝐼𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑒 𝑓𝑜𝑟 𝐴𝑢𝑔𝑚𝑒𝑛𝑡𝑒𝑑 𝐼𝑛𝑡𝑒𝑙𝑙𝑖𝑔𝑒𝑛𝑐𝑒 𝑖𝑛 𝑀𝑒𝑑𝑖𝑐𝑖𝑛𝑒 𝑎𝑡 𝑁𝑜𝑟𝑡ℎ𝑤𝑒𝑠𝑡𝑒𝑟𝑛 𝑈𝑛𝑖𝑣𝑒𝑟𝑠𝑖𝑡𝑦 𝐹𝑒𝑖𝑛𝑏𝑒𝑟𝑔 𝑆𝑐ℎ𝑜𝑜𝑙 𝑜𝑓 𝑀𝑒𝑑𝑖𝑐𝑖𝑛𝑒. \n \n Press release: https://lnkd.in/e3C28Yhf\n \n #Ultromics #EchoGo #Pfizer #CardiacAmyloidosis #EarlyDetection #HealthcareInnovation """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2024-03-08 17:45:58" "deleted" => 1 ] [ "id" => 460721492 "company_id" => 1258906 "urn" => "urn:li:activity:7141780978330472448" "followers" => null "date" => "1mo" "description" => "We are excited to announce that the U.S. FDA granted approval to our combination therapy from Seagen for locally advanced/metastatic urothelial cancer, developed with Astellas Pharma US and Merck. We look forward to the potential of this therapy to become a new standard of care for these patients. Read more here: https://lnkd.in/ev4uTdYe" "reactions_count" => 2893 "comments_count" => 17 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-08 17:45:58" "deleted" => 1 ] [ "id" => 460721493 "company_id" => 1258906 "urn" => "urn:li:activity:7141157548505628673" "followers" => null "date" => "1mo" "description" => """ Pfizer is proud to provide an unrestricted donation to the American Association for Cancer Research (AACR), the first and largest cancer research organization formed in the world. This donation will directly support AACR in its mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, and funding for cancer research. \n \n Thank you to the AACR for your partnership in accelerating the discovery of new breakthroughs in order to bring new hope to people living with cancer around the world. """ "reactions_count" => 463 "comments_count" => 3 "reshared_post_author" => "American Association for Cancer Research" "reshared_post_author_url" => "https://www.linkedin.com/company/american-association-for-cancer-research" "reshared_post_author_headline" => null "reshared_post_description" => "We are grateful that Pfizer Inc. has chosen to donate the rights of its royalties from the sale of Bavencio® (avelumab) in the United States to AACR. This unrestricted donation will advance our mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, and funding for cancer research. https://bit.ly/470hgLd" "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-03-08 17:45:58" "deleted" => 1 ] [ "id" => 460721494 "company_id" => 1258906 "urn" => "urn:li:activity:7136374518087892992" "followers" => null "date" => "2mo" "description" => """ Learn about tangible solutions to disrupt structural inequities in healthcare facilities and delivery in our final ‘Health Equity in Action’ Health Affairs Forefront series post, co-authored by Walter D. Conwell, MD, MBA, Chief Diversity and Inclusion Officer at Morehouse School of Medicine, and Niesha Foster, our VP of Global Health and Social Impact: https://bit.ly/3T5ZrH9\n \n In this piece, they share practical insights and underscore the need to:\n ✔️ promote patient-centric care\n ✔️ address the social determinants of health as part of care plans\n ✔️ invest in the training and wellness of healthcare providers, among other priorities.\n \n #EquityInAction #PublicHealth #HealthEquity #Partnership """ "reactions_count" => 250 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-08 17:45:58" "deleted" => 1 ] [ "id" => 460721495 "company_id" => 1258906 "urn" => "urn:li:activity:7128069979517681665" "followers" => null "date" => "2mo" "description" => """ Finding innovative ways to make clinical trials accessible and accelerating breakthroughs to patients is how we continue to push science forward. We are proud to introduce the first industry-sponsored research registry called PfizerLink.\n \n PfizerLink aims to make it easier for interested individuals to find Pfizer clinical trials, including for those who have been historically underrepresented, and address the long-standing challenges associated with clinical trial recruitment. This novel online approach will allow people who are interested – either healthy volunteers or those with medical conditions – to be rapidly pre-screened and connected to a trial navigator that will connect them to an available Pfizer clinical trial nearby or notify them if one becomes available.\n \n The registry helps address the frustrations some people feel in searching for and learning about new trials. In fact, the most recent CISCRP study on the public’s attitudes towards clinical research found that despite higher levels of awareness, a quarter of respondents are not confident in their ability to find a clinical research study that is right for them.\n \n Industrywide, approximately 80% of clinical trials fail to meet enrollment deadlines, while 30% of Phase 3 studies last longer than expected due to challenges in recruitment. Because potentially eligible participants would already be identified and pre-screened through PfizerLink, enrollment in newly launched Pfizer trials can be significantly accelerated. \n \n PfizerLink aims to make it easier for potential participants to get involved in the research that matters to them.\n \n To learn more about PfizerLink, please visit https://www.pfi.sr/SkM. """ "reactions_count" => 561 "comments_count" => 40 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-08 17:45:58" "deleted" => 1 ] [ "id" => 460721496 "company_id" => 1258906 "urn" => "urn:li:activity:7125194364632330240" "followers" => null "date" => "3mo" "description" => "Below are some highlights from our Q3 2023 earnings report. Check out the full details from today’s presentation here: https://lnkd.in/eKE6B9qW" "reactions_count" => 815 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-08 17:45:58" "deleted" => 1 ] [ "id" => 460721497 "company_id" => 1258906 "urn" => "urn:li:activity:7118586571963920384" "followers" => null "date" => "3mo" "description" => """ BREAKING: We’re proud to announce the U.S. FDA has approved Pfizer’s oral treatment option for adults with moderate to severe #UlcerativeColitis (UC). \n \n This approval is a meaningful milestone for the 1.25M people in the U.S. living with this chronic condition, offering them a new treatment option. \n \n Learn more about this breakthrough at https://lnkd.in/eNSit2TD """ "reactions_count" => 3516 "comments_count" => 32 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-08 17:45:58" "deleted" => 1 ] [ "id" => 460721498 "company_id" => 1258906 "urn" => "urn:li:activity:7118581282032246784" "followers" => null "date" => "3mo" "description" => """ BREAKING NEWS: Today, we announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the approval of our BCMA bispecific antibody treatment for certain people living with #MultipleMyeloma (MM).\n \n Over 176,000 people are diagnosed with MM globally each year. We are committed to addressing the unmet needs of patients and their families.\n \n Read more: https://lnkd.in/efgEVrK7 """ "reactions_count" => 1282 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-08 17:45:58" "deleted" => 1 ] [ "id" => 499741143 "company_id" => 1258906 "urn" => "urn:li:activity:7169337533321973760" "followers" => null "date" => "1w" "description" => """ At Pfizer Oncology, we have a bold vision: To accelerate breakthroughs that help people with cancer globally live longer and better lives. This vision drives everything we do and reflects our colleagues’ personal mission to improve the lives of people with cancer.\n \n In a meeting with the investment community, we outlined strategic priorities for our newly formed Oncology organization, and how our deep and diverse pipeline, industry-leading Oncology expertise, and anticipated near- and mid-term catalysts are expected to position the company to deliver strong growth and shareholder value.\n \n Below are some highlights from the event, and you can view the presentation and other details here: www.pfizer.com/investors.\n \n #LetsOutdoCancer """ "reactions_count" => 1101 "comments_count" => 16 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 16:21:30" "deleted" => 1 ] [ "id" => 499741144 "company_id" => 1258906 "urn" => "urn:li:activity:7168666598973632513" "followers" => null "date" => "1w" "description" => """ Pfizer’s Chief Global Supply Officer, Mike McDermott, will be speaking at the TechOps Leadership Accelerator Program in NYC. We are proud of Mike’s unwavering commitment to helping shape the next generation of innovators and leaders in the biotech industry. Bringing more than 30 years of industry experience, Mike has been at the forefront of developing Pfizer’s world-class supply chain and “lightspeed” culture.\n \n To attend Mike’s session register here: https://lnkd.in/eNJ8SUSu """ "reactions_count" => 250 "comments_count" => 2 "reshared_post_author" => "Pascal Bécotte" "reshared_post_author_url" => "https://www.linkedin.com/in/pascal-b%C3%A9cotte-9435134" "reshared_post_author_headline" => "Hub Leader - New York City, Stamford & Canada at Russell Reynolds Associates" "reshared_post_description" => "We look forward to welcoming @MikeMcDermott as a faculty member at our inaugural TechOps Leadership Accelerator Program in June in NYC to teach participants about Authentic Leadership. The purpose of this program is to accelerate leadership development for a select cohort of functional VP-Level industry participants (Manufacturing, Supply Chain, Quality, Process Development, MSAT, HRBP) or smaller biotech CTOs to prepare them for the #1 roles in larger companies in the industry. Five "rarely taught" modules will be delivered by a combination of global leading topic matter experts AND renowned and proven industry leaders. Secure your spot today to learn from him and other industry experts: https://lnkd.in/eNJ8SUSu #biotech #manufacturing #leadership" "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2024-04-15 16:21:30" "deleted" => 1 ] [ "id" => 499741145 "company_id" => 1258906 "urn" => "urn:li:activity:7166724230489845760" "followers" => null "date" => "2w" "description" => """ The Pfizer Rare disease team was very happy to welcome in its Brussels headquarters Christina Verhofstadt and Denis Wolfs from the recently founded AMYBEL patient association. Under the motto “Bring Amyloidosis into the light,” the purpose of Amybel is to inform, guide and support patients with Amyloidosis. \n \n The two board members of Amybel shared with us their personal story and how they got diagnosed, which even reinforced our commitment to support them and raise awareness around this rare and often underdiagnosed condition. \n Amyloidosis causes an abnormal accumulation of parts of proteins and can affect different tissues and organs, such as the heart for instance. An early diagnose can make a real difference in the evolution of the disease. \n For more information on the disease check today www.amyloidose.be and very soon www.amybel.be as well.\n \n #Amyloidosis #RareDisease #RadiOrg #PfizerBelgium \n \n Maura Verdoliva Stefaan Osaer Quentin Vander Stricht Dave Ceyssens Marie-Lise Verschelden Arnoud den Ouden Ruben Weckx Michiel Vanmeert, PhD, PharmD Ingrid Van Steenberge Mieke Vandenberghe, MD Bharati Shivalkar Arturo Prieto Rodríguez """ "reactions_count" => 709 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 16:21:30" "deleted" => 1 ] [ "id" => 499741146 "company_id" => 1258906 "urn" => "urn:li:activity:7166476720739459073" "followers" => null "date" => "2w" "description" => """ 📅 Save the Date : 14 mars 2024\n 🆕 Nouvelle édition du Choix de la Science\n 📍 + d'infos sur le programme & les intervenants➡️ https://lnkd.in/ez4Av2rQ\n \n #LeChoixDeLaScience #ScienceWillWin #LaScienceVaincra """ "reactions_count" => 315 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 16:21:30" "deleted" => 1 ] [ "id" => 499741147 "company_id" => 1258906 "urn" => "urn:li:activity:7162852839277469696" "followers" => null "date" => "3w" "description" => """ Dr. Kathleen strives to outpace, outsmart and outmaneuver cancer at every turn. While she once dreamed of being a practicing medical doctor, she realized a career as a researcher could help her bring impact to patients' lives. Dr. Kathleen is helping spearhead our vision to Outdo Cancer - leading world-class scientists who are paving the way for the next generation of cancer therapies. \n \n Meet Kathleen at LetsOutdoCancer.com. \n \n #Cancer #CancerResearch #Oncology """ "reactions_count" => 625 "comments_count" => 15 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 16:21:30" "deleted" => 1 ] [ "id" => 499741148 "company_id" => 1258906 "urn" => "urn:li:activity:7162587354111668224" "followers" => null "date" => "3w" "description" => """ Today is a big day, and not just for the reasons you think. Here's to the women and girls whose brilliance has inspired us for 175 years. \n \n #womeninstem """ "reactions_count" => 3730 "comments_count" => 42 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 16:21:30" "deleted" => 1 ] [ "id" => 499741149 "company_id" => 1258906 "urn" => "urn:li:activity:7157888648477073408" "followers" => null "date" => "1mo" "description" => """ As the Enterprise Chair of Pfizer’s Global Black Community colleague resource group, my leadership team and I outlined four priorities for 2024 that are aimed at helping Pfizer attract and retain Black talent at all levels within the company. \n \n One of these priorities, which I am proud to share here, is our expanded engagement with historically Black colleges and universities (HBCUs) and the students they serve. Last week, in honor of the MLK Holiday in the United States, we held a program titled, “Preserving the Dream: Advancing Education and Equity for MLK’s Legacy” with special guests, Dr. Roslyn Clark Artis, President, Benedict College (SC), Dr. Paulette Dillard, President, Shaw University (NC), and Dr. Tashni-Ann Dubroy, Executive Vice President & Chief Operating Officer, Howard University (DC). \n \n We were excited to introduce not only these outstanding women to our diverse population of colleagues at Pfizer but also the value of an HBCU education. \n \n In the words of Dr. King, a Morehouse College graduate, “I have the audacity to believe that peoples everywhere can have three meals a day for their bodies, education and culture for their minds, and dignity, equality, and freedom for their spirits." Like Dr. King, we can all empower change. """ "reactions_count" => 396 "comments_count" => 17 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 16:21:30" "deleted" => 1 ] [ "id" => 499741150 "company_id" => 1258906 "urn" => "urn:li:activity:7157736536833232896" "followers" => null "date" => "1mo" "description" => """ #CervicalCancer is the fourth most common cancer among women globally. Join us in supporting those living with the disease and ensuring their voices are seen and heard by watching stories, like Kristine’s, on the #CeMe YouTube channel.\n \n Together with our partner, Genmab, we are dedicated to supporting the cervical cancer community this #CervicalCancerAwarenessMonth, and year-round.\n \n https://lnkd.in/e2kgTGNp """ "reactions_count" => 279 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 16:21:30" "deleted" => 1 ] [ "id" => 499741151 "company_id" => 1258906 "urn" => "urn:li:activity:7150874402610450432" "followers" => null "date" => "1mo" "description" => "Wishing Ultromics success with their development of EchoGo® Amyloidosis. This exciting tech uses AI to analyze routine ultrasound scans of the heart, known as an echocardiogram or echo. Our hope is that AI will offer an early warning to help physicians suspect and detect cardiac amyloidosis earlier🤞. Find out more below." "reactions_count" => 1111 "comments_count" => 23 "reshared_post_author" => "Ultromics" "reshared_post_author_url" => "https://uk.linkedin.com/company/ultromics" "reshared_post_author_headline" => null "reshared_post_description" => """ Ultromics is excited to announce a new partnership with Pfizer to expedite the development of an Echo AI algorithm for the early detection of Cardiac Amyloidosis—an underdiagnosed, life-threatening disease that can cause Heart Failure.\n \n Under the partnership, Ultromics will research and pursue FDA clearance for its Amyloidosis algorithm that has received Breakthrough Device Designation.\n \n “𝐄𝐜𝐡𝐨𝐜𝐚𝐫𝐝𝐢𝐨𝐠𝐫𝐚𝐩𝐡𝐲, 𝐰𝐡𝐢𝐥𝐞 𝐟𝐮𝐧𝐝𝐚𝐦𝐞𝐧𝐭𝐚𝐥 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐞𝐚𝐫𝐥𝐲 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐦𝐚𝐧𝐲 𝐡𝐞𝐚𝐫𝐭 𝐜𝐨𝐧𝐝𝐢𝐭𝐢𝐨𝐧𝐬, 𝐢𝐬 𝐡𝐢𝐧𝐝𝐞𝐫𝐞𝐝 𝐛𝐲 𝐬𝐮𝐛𝐣𝐞𝐜𝐭𝐢𝐯𝐢𝐭𝐲 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐝𝐞𝐦𝐚𝐧𝐝 𝐟𝐨𝐫 𝐬𝐜𝐚𝐫𝐜𝐞 𝐞𝐱𝐩𝐞𝐫𝐭𝐢𝐬𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐚𝐜𝐜𝐮𝐫𝐚𝐭𝐞 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐜𝐚𝐫𝐝𝐢𝐚𝐜 𝐚𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬. 𝐀𝐈-𝐚𝐮𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐜𝐚𝐫𝐝𝐢𝐚𝐜 𝐚𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬 𝐦𝐚𝐲 𝐛𝐞 𝐞𝐬𝐩𝐞𝐜𝐢𝐚𝐥𝐥𝐲 𝐮𝐬𝐞𝐟𝐮𝐥 𝐢𝐧 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐟𝐚𝐜𝐢𝐥𝐢𝐭𝐢𝐞𝐬 𝐥𝐚𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐭𝐢𝐦𝐞 𝐚𝐧𝐝 𝐫𝐞𝐬𝐨𝐮𝐫𝐜𝐞𝐬 𝐧𝐞𝐞𝐝𝐞𝐝 𝐟𝐨𝐫 𝐜𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐚𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭.”\n \n - 𝑃𝑟𝑜𝑓. 𝑆𝑎𝑛𝑗𝑖𝑣 𝐽. 𝑆ℎ𝑎ℎ, 𝑀𝐷, 𝑡ℎ𝑒 𝐷𝑖𝑟𝑒𝑐𝑡𝑜𝑟 𝑜𝑓 𝑅𝑒𝑠𝑒𝑎𝑟𝑐ℎ 𝑓𝑜𝑟 𝑡ℎ𝑒 𝐵𝑙𝑢ℎ𝑚 𝐶𝑎𝑟𝑑𝑖𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝐼𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑒 𝑎𝑛𝑑 𝐷𝑖𝑟𝑒𝑐𝑡𝑜𝑟, 𝐶𝑒𝑛𝑡𝑒𝑟 𝑓𝑜𝑟 𝐷𝑒𝑒𝑝 𝑃ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑖𝑛𝑔 𝑎𝑛𝑑 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑀𝑒𝑑𝑖𝑐𝑖𝑛𝑒 𝑖𝑛 𝑡ℎ𝑒 𝐼𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑒 𝑓𝑜𝑟 𝐴𝑢𝑔𝑚𝑒𝑛𝑡𝑒𝑑 𝐼𝑛𝑡𝑒𝑙𝑙𝑖𝑔𝑒𝑛𝑐𝑒 𝑖𝑛 𝑀𝑒𝑑𝑖𝑐𝑖𝑛𝑒 𝑎𝑡 𝑁𝑜𝑟𝑡ℎ𝑤𝑒𝑠𝑡𝑒𝑟𝑛 𝑈𝑛𝑖𝑣𝑒𝑟𝑠𝑖𝑡𝑦 𝐹𝑒𝑖𝑛𝑏𝑒𝑟𝑔 𝑆𝑐ℎ𝑜𝑜𝑙 𝑜𝑓 𝑀𝑒𝑑𝑖𝑐𝑖𝑛𝑒. \n \n Press release: https://lnkd.in/e3C28Yhf\n \n #Ultromics #EchoGo #Pfizer #CardiacAmyloidosis #EarlyDetection #HealthcareInnovation """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-04-15 16:21:30" "deleted" => 1 ] [ "id" => 499741152 "company_id" => 1258906 "urn" => "urn:li:activity:7141780978330472448" "followers" => null "date" => "2mo" "description" => "We are excited to announce that the U.S. FDA granted approval to our combination therapy from Seagen for locally advanced/metastatic urothelial cancer, developed with Astellas Pharma US and Merck. We look forward to the potential of this therapy to become a new standard of care for these patients. Read more here: https://lnkd.in/ev4uTdYe" "reactions_count" => 2913 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-15 16:21:30" "deleted" => 1 ] [ "id" => 541827930 "company_id" => 1258906 "urn" => "urn:li:activity:7178390309343526917" "followers" => null "date" => "2w" "description" => "Our dedication to breakthrough innovation is grounded in our values of courage, excellence, equity, and joy, which drive us day in and day out. Our CEO Albert Bourla shares more on our progress in our 2023 #AnnualReview: https://Pfizer.com/Annual" "reactions_count" => 996 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-26 01:15:26" "deleted" => 1 ] [ "id" => 541827931 "company_id" => 1258906 "urn" => "urn:li:activity:7169337533321973760" "followers" => null "date" => "1mo" "description" => """ At Pfizer Oncology, we have a bold vision: To accelerate breakthroughs that help people with cancer globally live longer and better lives. This vision drives everything we do and reflects our colleagues’ personal mission to improve the lives of people with cancer.\n \n In a meeting with the investment community, we outlined strategic priorities for our newly formed Oncology organization, and how our deep and diverse pipeline, industry-leading Oncology expertise, and anticipated near- and mid-term catalysts are expected to position the company to deliver strong growth and shareholder value.\n \n Below are some highlights from the event, and you can view the presentation and other details here: www.pfizer.com/investors.\n \n #LetsOutdoCancer """ "reactions_count" => 1171 "comments_count" => 19 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-26 01:15:26" "deleted" => 1 ] [ "id" => 541827932 "company_id" => 1258906 "urn" => "urn:li:activity:7168666598973632513" "followers" => null "date" => "1mo" "description" => """ Pfizer’s Chief Global Supply Officer, Mike McDermott, will be speaking at the TechOps Leadership Accelerator Program in NYC. We are proud of Mike’s unwavering commitment to helping shape the next generation of innovators and leaders in the biotech industry. Bringing more than 30 years of industry experience, Mike has been at the forefront of developing Pfizer’s world-class supply chain and “lightspeed” culture.\n \n To attend Mike’s session register here: https://lnkd.in/eNJ8SUSu """ "reactions_count" => 256 "comments_count" => 2 "reshared_post_author" => "Pascal Bécotte" "reshared_post_author_url" => "https://www.linkedin.com/in/pascal-b%C3%A9cotte-9435134" "reshared_post_author_headline" => "Hub Leader - New York City, Stamford & Canada at Russell Reynolds Associates" "reshared_post_description" => "We look forward to welcoming @MikeMcDermott as a faculty member at our inaugural TechOps Leadership Accelerator Program in June in NYC to teach participants about Authentic Leadership. The purpose of this program is to accelerate leadership development for a select cohort of functional VP-Level industry participants (Manufacturing, Supply Chain, Quality, Process Development, MSAT, HRBP) or smaller biotech CTOs to prepare them for the #1 roles in larger companies in the industry. Five "rarely taught" modules will be delivered by a combination of global leading topic matter experts AND renowned and proven industry leaders. Secure your spot today to learn from him and other industry experts: https://lnkd.in/eNJ8SUSu #biotech #manufacturing #leadership" "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-05-26 01:15:26" "deleted" => 1 ] [ "id" => 541827933 "company_id" => 1258906 "urn" => "urn:li:activity:7166724230489845760" "followers" => null "date" => "1mo" "description" => """ The Pfizer Rare disease team was very happy to welcome in its Brussels headquarters Christina Verhofstadt and Denis Wolfs from the recently founded AMYBEL patient association. Under the motto “Bring Amyloidosis into the light,” the purpose of Amybel is to inform, guide and support patients with Amyloidosis. \n \n The two board members of Amybel shared with us their personal story and how they got diagnosed, which even reinforced our commitment to support them and raise awareness around this rare and often underdiagnosed condition. \n Amyloidosis causes an abnormal accumulation of parts of proteins and can affect different tissues and organs, such as the heart for instance. An early diagnose can make a real difference in the evolution of the disease. \n For more information on the disease check today www.amyloidose.be and very soon www.amybel.be as well.\n \n #Amyloidosis #RareDisease #RadiOrg #PfizerBelgium \n \n Maura Verdoliva Stefaan Osaer Quentin Vander Stricht Dave Ceyssens Marie-Lise Verschelden Arnoud den Ouden Ruben Weckx Michiel Vanmeert, PhD, PharmD Ingrid Van Steenberge Mieke Vandenberghe, MD Bharati Shivalkar Arturo Prieto Rodríguez """ "reactions_count" => 736 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-26 01:15:26" "deleted" => 1 ] [ "id" => 541827934 "company_id" => 1258906 "urn" => "urn:li:activity:7166476720739459073" "followers" => null "date" => "1mo" "description" => """ 📅 Save the Date : 14 mars 2024\n 🆕 Nouvelle édition du Choix de la Science\n 📍 + d'infos sur le programme & les intervenants➡️ https://lnkd.in/ez4Av2rQ\n \n #LeChoixDeLaScience #ScienceWillWin #LaScienceVaincra """ "reactions_count" => 323 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-26 01:15:26" "deleted" => 1 ] [ "id" => 541827935 "company_id" => 1258906 "urn" => "urn:li:activity:7162852839277469696" "followers" => null "date" => "2mo" "description" => """ Dr. Kathleen strives to outpace, outsmart and outmaneuver cancer at every turn. While she once dreamed of being a practicing medical doctor, she realized a career as a researcher could help her bring impact to patients' lives. Dr. Kathleen is helping spearhead our vision to Outdo Cancer - leading world-class scientists who are paving the way for the next generation of cancer therapies. \n \n Meet Kathleen at LetsOutdoCancer.com. \n \n #Cancer #CancerResearch #Oncology """ "reactions_count" => 631 "comments_count" => 17 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-26 01:15:26" "deleted" => 1 ] [ "id" => 541827936 "company_id" => 1258906 "urn" => "urn:li:activity:7162587354111668224" "followers" => null "date" => "2mo" "description" => """ Today is a big day, and not just for the reasons you think. Here's to the women and girls whose brilliance has inspired us for 175 years. \n \n #womeninstem """ "reactions_count" => 3753 "comments_count" => 42 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-26 01:15:26" "deleted" => 1 ] [ "id" => 541827937 "company_id" => 1258906 "urn" => "urn:li:activity:7157888648477073408" "followers" => null "date" => "2mo" "description" => """ As the Enterprise Chair of Pfizer’s Global Black Community colleague resource group, my leadership team and I outlined four priorities for 2024 that are aimed at helping Pfizer attract and retain Black talent at all levels within the company. \n \n One of these priorities, which I am proud to share here, is our expanded engagement with historically Black colleges and universities (HBCUs) and the students they serve. Last week, in honor of the MLK Holiday in the United States, we held a program titled, “Preserving the Dream: Advancing Education and Equity for MLK’s Legacy” with special guests, Dr. Roslyn Clark Artis, President, Benedict College (SC), Dr. Paulette Dillard, President, Shaw University (NC), and Dr. Tashni-Ann Dubroy, Executive Vice President & Chief Operating Officer, Howard University (DC). \n \n We were excited to introduce not only these outstanding women to our diverse population of colleagues at Pfizer but also the value of an HBCU education. \n \n In the words of Dr. King, a Morehouse College graduate, “I have the audacity to believe that peoples everywhere can have three meals a day for their bodies, education and culture for their minds, and dignity, equality, and freedom for their spirits." Like Dr. King, we can all empower change. """ "reactions_count" => 399 "comments_count" => 17 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-26 01:15:26" "deleted" => 1 ] [ "id" => 541827938 "company_id" => 1258906 "urn" => "urn:li:activity:7157736536833232896" "followers" => null "date" => "2mo" "description" => """ #CervicalCancer is the fourth most common cancer among women globally. Join us in supporting those living with the disease and ensuring their voices are seen and heard by watching stories, like Kristine’s, on the #CeMe YouTube channel.\n \n Together with our partner, Genmab, we are dedicated to supporting the cervical cancer community this #CervicalCancerAwarenessMonth, and year-round.\n \n https://lnkd.in/e2kgTGNp """ "reactions_count" => 286 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-26 01:15:26" "deleted" => 1 ] [ "id" => 541827939 "company_id" => 1258906 "urn" => "urn:li:activity:7150874402610450432" "followers" => null "date" => "3mo" "description" => "Wishing Ultromics success with their development of EchoGo® Amyloidosis. This exciting tech uses AI to analyze routine ultrasound scans of the heart, known as an echocardiogram or echo. Our hope is that AI will offer an early warning to help physicians suspect and detect cardiac amyloidosis earlier🤞. Find out more below." "reactions_count" => 1114 "comments_count" => 23 "reshared_post_author" => "Ultromics" "reshared_post_author_url" => "https://uk.linkedin.com/company/ultromics" "reshared_post_author_headline" => null "reshared_post_description" => """ Ultromics is excited to announce a new partnership with Pfizer to expedite the development of an Echo AI algorithm for the early detection of Cardiac Amyloidosis—an underdiagnosed, life-threatening disease that can cause Heart Failure.\n \n Under the partnership, Ultromics will research and pursue FDA clearance for its Amyloidosis algorithm that has received Breakthrough Device Designation.\n \n “𝐄𝐜𝐡𝐨𝐜𝐚𝐫𝐝𝐢𝐨𝐠𝐫𝐚𝐩𝐡𝐲, 𝐰𝐡𝐢𝐥𝐞 𝐟𝐮𝐧𝐝𝐚𝐦𝐞𝐧𝐭𝐚𝐥 𝐟𝐨𝐫 𝐭𝐡𝐞 𝐞𝐚𝐫𝐥𝐲 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐦𝐚𝐧𝐲 𝐡𝐞𝐚𝐫𝐭 𝐜𝐨𝐧𝐝𝐢𝐭𝐢𝐨𝐧𝐬, 𝐢𝐬 𝐡𝐢𝐧𝐝𝐞𝐫𝐞𝐝 𝐛𝐲 𝐬𝐮𝐛𝐣𝐞𝐜𝐭𝐢𝐯𝐢𝐭𝐲 𝐚𝐧𝐝 𝐭𝐡𝐞 𝐝𝐞𝐦𝐚𝐧𝐝 𝐟𝐨𝐫 𝐬𝐜𝐚𝐫𝐜𝐞 𝐞𝐱𝐩𝐞𝐫𝐭𝐢𝐬𝐞 𝐢𝐧 𝐭𝐡𝐞 𝐚𝐜𝐜𝐮𝐫𝐚𝐭𝐞 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐨𝐟 𝐜𝐚𝐫𝐝𝐢𝐚𝐜 𝐚𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬. 𝐀𝐈-𝐚𝐮𝐠𝐦𝐞𝐧𝐭𝐞𝐝 𝐝𝐞𝐭𝐞𝐜𝐭𝐢𝐨𝐧 𝐨𝐟 𝐜𝐚𝐫𝐝𝐢𝐚𝐜 𝐚𝐦𝐲𝐥𝐨𝐢𝐝𝐨𝐬𝐢𝐬 𝐦𝐚𝐲 𝐛𝐞 𝐞𝐬𝐩𝐞𝐜𝐢𝐚𝐥𝐥𝐲 𝐮𝐬𝐞𝐟𝐮𝐥 𝐢𝐧 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐟𝐚𝐜𝐢𝐥𝐢𝐭𝐢𝐞𝐬 𝐥𝐚𝐜𝐤𝐢𝐧𝐠 𝐭𝐡𝐞 𝐭𝐢𝐦𝐞 𝐚𝐧𝐝 𝐫𝐞𝐬𝐨𝐮𝐫𝐜𝐞𝐬 𝐧𝐞𝐞𝐝𝐞𝐝 𝐟𝐨𝐫 𝐜𝐨𝐦𝐩𝐫𝐞𝐡𝐞𝐧𝐬𝐢𝐯𝐞 𝐚𝐬𝐬𝐞𝐬𝐬𝐦𝐞𝐧𝐭.”\n \n - 𝑃𝑟𝑜𝑓. 𝑆𝑎𝑛𝑗𝑖𝑣 𝐽. 𝑆ℎ𝑎ℎ, 𝑀𝐷, 𝑡ℎ𝑒 𝐷𝑖𝑟𝑒𝑐𝑡𝑜𝑟 𝑜𝑓 𝑅𝑒𝑠𝑒𝑎𝑟𝑐ℎ 𝑓𝑜𝑟 𝑡ℎ𝑒 𝐵𝑙𝑢ℎ𝑚 𝐶𝑎𝑟𝑑𝑖𝑜𝑣𝑎𝑠𝑐𝑢𝑙𝑎𝑟 𝐼𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑒 𝑎𝑛𝑑 𝐷𝑖𝑟𝑒𝑐𝑡𝑜𝑟, 𝐶𝑒𝑛𝑡𝑒𝑟 𝑓𝑜𝑟 𝐷𝑒𝑒𝑝 𝑃ℎ𝑒𝑛𝑜𝑡𝑦𝑝𝑖𝑛𝑔 𝑎𝑛𝑑 𝑃𝑟𝑒𝑐𝑖𝑠𝑖𝑜𝑛 𝑀𝑒𝑑𝑖𝑐𝑖𝑛𝑒 𝑖𝑛 𝑡ℎ𝑒 𝐼𝑛𝑠𝑡𝑖𝑡𝑢𝑡𝑒 𝑓𝑜𝑟 𝐴𝑢𝑔𝑚𝑒𝑛𝑡𝑒𝑑 𝐼𝑛𝑡𝑒𝑙𝑙𝑖𝑔𝑒𝑛𝑐𝑒 𝑖𝑛 𝑀𝑒𝑑𝑖𝑐𝑖𝑛𝑒 𝑎𝑡 𝑁𝑜𝑟𝑡ℎ𝑤𝑒𝑠𝑡𝑒𝑟𝑛 𝑈𝑛𝑖𝑣𝑒𝑟𝑠𝑖𝑡𝑦 𝐹𝑒𝑖𝑛𝑏𝑒𝑟𝑔 𝑆𝑐ℎ𝑜𝑜𝑙 𝑜𝑓 𝑀𝑒𝑑𝑖𝑐𝑖𝑛𝑒. \n \n Press release: https://lnkd.in/e3C28Yhf\n \n #Ultromics #EchoGo #Pfizer #CardiacAmyloidosis #EarlyDetection #HealthcareInnovation """ "reshared_post_followers" => null "reshared_post_date" => "3mo" "last_updated" => "2024-05-26 01:15:26" "deleted" => 1 ] [ "id" => 586867675 "company_id" => 1258906 "urn" => "urn:li:activity:7198344733834756096" "followers" => null "date" => "4d" "description" => """ Behind every innovative breakthrough are scientists, doctors, nurses, participant volunteers, and many others who work with us to advance science and medicine.\n \n They continue to inspire us with their ambition, passion, and commitment to finding new treatments, vaccines, and potential cures for diseases that affect millions of people around the world. They are the #TrailblazersAmongUs.\n \n Today, on #ClinicalTrialsDay, we celebrate all those who help make the impossible possible. Thank you.\n \n #CTD2024 """ "reactions_count" => 911 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-17 16:38:55" "deleted" => 1 ] [ "id" => 586867676 "company_id" => 1258906 "urn" => "urn:li:activity:7178390309343526917" "followers" => null "date" => "1mo" "description" => "Our dedication to breakthrough innovation is grounded in our values of courage, excellence, equity, and joy, which drive us day in and day out. Our CEO Albert Bourla shares more on our progress in our 2023 #AnnualReview: https://Pfizer.com/Annual" "reactions_count" => 1054 "comments_count" => 16 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-17 16:38:55" "deleted" => 1 ] [ "id" => 586867677 "company_id" => 1258906 "urn" => "urn:li:activity:7169337533321973760" "followers" => null "date" => "2mo" "description" => """ At Pfizer Oncology, we have a bold vision: To accelerate breakthroughs that help people with cancer globally live longer and better lives. This vision drives everything we do and reflects our colleagues’ personal mission to improve the lives of people with cancer.\n \n In a meeting with the investment community, we outlined strategic priorities for our newly formed Oncology organization, and how our deep and diverse pipeline, industry-leading Oncology expertise, and anticipated near- and mid-term catalysts are expected to position the company to deliver strong growth and shareholder value.\n \n Below are some highlights from the event, and you can view the presentation and other details here: www.pfizer.com/investors.\n \n #LetsOutdoCancer """ "reactions_count" => 1194 "comments_count" => 16 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-17 16:38:55" "deleted" => 1 ] [ "id" => 586867678 "company_id" => 1258906 "urn" => "urn:li:activity:7168666598973632513" "followers" => null "date" => "2mo" "description" => """ Pfizer’s Chief Global Supply Officer, Mike McDermott, will be speaking at the TechOps Leadership Accelerator Program in NYC. We are proud of Mike’s unwavering commitment to helping shape the next generation of innovators and leaders in the biotech industry. Bringing more than 30 years of industry experience, Mike has been at the forefront of developing Pfizer’s world-class supply chain and “lightspeed” culture.\n \n To attend Mike’s session register here: https://lnkd.in/eNJ8SUSu """ "reactions_count" => 260 "comments_count" => 2 "reshared_post_author" => "Pascal Bécotte" "reshared_post_author_url" => "https://www.linkedin.com/in/pascal-b%C3%A9cotte-9435134" "reshared_post_author_headline" => "Hub Leader - New York City, Stamford & Canada at Russell Reynolds Associates" "reshared_post_description" => "We look forward to welcoming @MikeMcDermott as a faculty member at our inaugural TechOps Leadership Accelerator Program in June in NYC to teach participants about Authentic Leadership. The purpose of this program is to accelerate leadership development for a select cohort of functional VP-Level industry participants (Manufacturing, Supply Chain, Quality, Process Development, MSAT, HRBP) or smaller biotech CTOs to prepare them for the #1 roles in larger companies in the industry. Five "rarely taught" modules will be delivered by a combination of global leading topic matter experts AND renowned and proven industry leaders. Secure your spot today to learn from him and other industry experts: https://lnkd.in/eNJ8SUSu #biotech #manufacturing #leadership" "reshared_post_followers" => null "reshared_post_date" => "3mo" "last_updated" => "2024-06-17 16:38:55" "deleted" => 1 ] [ "id" => 586867679 "company_id" => 1258906 "urn" => "urn:li:activity:7166724230489845760" "followers" => null "date" => "3mo" "description" => """ The Pfizer Rare disease team was very happy to welcome in its Brussels headquarters Christina Verhofstadt and Denis Wolfs from the recently founded AMYBEL patient association. Under the motto “Bring Amyloidosis into the light,” the purpose of Amybel is to inform, guide and support patients with Amyloidosis. \n \n The two board members of Amybel shared with us their personal story and how they got diagnosed, which even reinforced our commitment to support them and raise awareness around this rare and often underdiagnosed condition. \n Amyloidosis causes an abnormal accumulation of parts of proteins and can affect different tissues and organs, such as the heart for instance. An early diagnose can make a real difference in the evolution of the disease. \n For more information on the disease check today www.amyloidose.be and very soon www.amybel.be as well.\n \n #Amyloidosis #RareDisease #RadiOrg #PfizerBelgium \n \n Maura Verdoliva Stefaan Osaer Quentin Vander Stricht Dave Ceyssens Marie-Lise Verschelden Arnoud den Ouden Ruben Weckx Michiel Vanmeert, PhD, PharmD Ingrid Van Steenberge Mieke Vandenberghe, MD Bharati Shivalkar Arturo Prieto Rodríguez """ "reactions_count" => 751 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-17 16:38:55" "deleted" => 1 ] [ "id" => 586867680 "company_id" => 1258906 "urn" => "urn:li:activity:7166476720739459073" "followers" => null "date" => "3mo" "description" => """ 📅 Save the Date : 14 mars 2024\n 🆕 Nouvelle édition du Choix de la Science\n 📍 + d'infos sur le programme & les intervenants➡️ https://lnkd.in/ez4Av2rQ\n \n #LeChoixDeLaScience #ScienceWillWin #LaScienceVaincra """ "reactions_count" => 329 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-17 16:38:55" "deleted" => 1 ] [ "id" => 586867681 "company_id" => 1258906 "urn" => "urn:li:activity:7162852839277469696" "followers" => null "date" => "3mo" "description" => """ Dr. Kathleen strives to outpace, outsmart and outmaneuver cancer at every turn. While she once dreamed of being a practicing medical doctor, she realized a career as a researcher could help her bring impact to patients' lives. Dr. Kathleen is helping spearhead our vision to Outdo Cancer - leading world-class scientists who are paving the way for the next generation of cancer therapies. \n \n Meet Kathleen at LetsOutdoCancer.com. \n \n #Cancer #CancerResearch #Oncology """ "reactions_count" => 639 "comments_count" => 17 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-17 16:38:55" "deleted" => 1 ] [ "id" => 586867682 "company_id" => 1258906 "urn" => "urn:li:activity:7162587354111668224" "followers" => null "date" => "3mo" "description" => """ Today is a big day, and not just for the reasons you think. Here's to the women and girls whose brilliance has inspired us for 175 years. \n \n #womeninstem """ "reactions_count" => 3755 "comments_count" => 42 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-17 16:38:55" "deleted" => 1 ] [ "id" => 586867683 "company_id" => 1258906 "urn" => "urn:li:activity:7157888648477073408" "followers" => null "date" => "3mo" "description" => """ As the Enterprise Chair of Pfizer’s Global Black Community colleague resource group, my leadership team and I outlined four priorities for 2024 that are aimed at helping Pfizer attract and retain Black talent at all levels within the company. \n \n One of these priorities, which I am proud to share here, is our expanded engagement with historically Black colleges and universities (HBCUs) and the students they serve. Last week, in honor of the MLK Holiday in the United States, we held a program titled, “Preserving the Dream: Advancing Education and Equity for MLK’s Legacy” with special guests, Dr. Roslyn Clark Artis, President, Benedict College (SC), Dr. Paulette Dillard, President, Shaw University (NC), and Dr. Tashni-Ann Dubroy, Executive Vice President & Chief Operating Officer, Howard University (DC). \n \n We were excited to introduce not only these outstanding women to our diverse population of colleagues at Pfizer but also the value of an HBCU education. \n \n In the words of Dr. King, a Morehouse College graduate, “I have the audacity to believe that peoples everywhere can have three meals a day for their bodies, education and culture for their minds, and dignity, equality, and freedom for their spirits." Like Dr. King, we can all empower change. """ "reactions_count" => 399 "comments_count" => 17 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-17 16:38:55" "deleted" => 1 ] [ "id" => 586867684 "company_id" => 1258906 "urn" => "urn:li:activity:7157736536833232896" "followers" => null "date" => "3mo" "description" => """ #CervicalCancer is the fourth most common cancer among women globally. Join us in supporting those living with the disease and ensuring their voices are seen and heard by watching stories, like Kristine’s, on the #CeMe YouTube channel.\n \n Together with our partner, Genmab, we are dedicated to supporting the cervical cancer community this #CervicalCancerAwarenessMonth, and year-round.\n \n https://lnkd.in/e2kgTGNp """ "reactions_count" => 288 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-17 16:38:55" "deleted" => 1 ] [ "id" => 614132864 "company_id" => 1258906 "urn" => "urn:li:activity:7198344733834756096" "followers" => null "date" => "3w" "description" => """ Behind every innovative breakthrough are scientists, doctors, nurses, participant volunteers, and many others who work with us to advance science and medicine.\n \n They continue to inspire us with their ambition, passion, and commitment to finding new treatments, vaccines, and potential cures for diseases that affect millions of people around the world. They are the #TrailblazersAmongUs.\n \n Today, on #ClinicalTrialsDay, we celebrate all those who help make the impossible possible. Thank you.\n \n #CTD2024 """ "reactions_count" => 1014 "comments_count" => 14 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-18 02:11:25" "deleted" => 1 ] [ "id" => 614132865 "company_id" => 1258906 "urn" => "urn:li:activity:7178390309343526917" "followers" => null "date" => "2mo" "description" => "Our dedication to breakthrough innovation is grounded in our values of courage, excellence, equity, and joy, which drive us day in and day out. Our CEO Albert Bourla shares more on our progress in our 2023 #AnnualReview: https://Pfizer.com/Annual" "reactions_count" => 1063 "comments_count" => 16 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-18 02:11:25" "deleted" => 1 ] [ "id" => 614132866 "company_id" => 1258906 "urn" => "urn:li:activity:7169337533321973760" "followers" => null "date" => "3mo" "description" => """ At Pfizer Oncology, we have a bold vision: To accelerate breakthroughs that help people with cancer globally live longer and better lives. This vision drives everything we do and reflects our colleagues’ personal mission to improve the lives of people with cancer.\n \n In a meeting with the investment community, we outlined strategic priorities for our newly formed Oncology organization, and how our deep and diverse pipeline, industry-leading Oncology expertise, and anticipated near- and mid-term catalysts are expected to position the company to deliver strong growth and shareholder value.\n \n Below are some highlights from the event, and you can view the presentation and other details here: www.pfizer.com/investors.\n \n #LetsOutdoCancer """ "reactions_count" => 1199 "comments_count" => 17 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-18 02:11:25" "deleted" => 1 ] [ "id" => 614132867 "company_id" => 1258906 "urn" => "urn:li:activity:7168666598973632513" "followers" => null "date" => "3mo" "description" => """ Pfizer’s Chief Global Supply Officer, Mike McDermott, will be speaking at the TechOps Leadership Accelerator Program in NYC. We are proud of Mike’s unwavering commitment to helping shape the next generation of innovators and leaders in the biotech industry. Bringing more than 30 years of industry experience, Mike has been at the forefront of developing Pfizer’s world-class supply chain and “lightspeed” culture.\n \n To attend Mike’s session register here: https://lnkd.in/eNJ8SUSu """ "reactions_count" => 262 "comments_count" => 2 "reshared_post_author" => "Pascal Bécotte" "reshared_post_author_url" => "https://www.linkedin.com/in/pascal-b%C3%A9cotte-9435134" "reshared_post_author_headline" => "Hub Leader - New York City, Stamford & Canada at Russell Reynolds Associates" "reshared_post_description" => "We look forward to welcoming @MikeMcDermott as a faculty member at our inaugural TechOps Leadership Accelerator Program in June in NYC to teach participants about Authentic Leadership. The purpose of this program is to accelerate leadership development for a select cohort of functional VP-Level industry participants (Manufacturing, Supply Chain, Quality, Process Development, MSAT, HRBP) or smaller biotech CTOs to prepare them for the #1 roles in larger companies in the industry. Five "rarely taught" modules will be delivered by a combination of global leading topic matter experts AND renowned and proven industry leaders. Secure your spot today to learn from him and other industry experts: https://lnkd.in/eNJ8SUSu #biotech #manufacturing #leadership" "reshared_post_followers" => null "reshared_post_date" => "3mo" "last_updated" => "2024-07-18 02:11:25" "deleted" => 1 ] [ "id" => 614132868 "company_id" => 1258906 "urn" => "urn:li:activity:7166724230489845760" "followers" => null "date" => "3mo" "description" => """ The Pfizer Rare disease team was very happy to welcome in its Brussels headquarters Christina Verhofstadt and Denis Wolfs from the recently founded AMYBEL patient association. Under the motto “Bring Amyloidosis into the light,” the purpose of Amybel is to inform, guide and support patients with Amyloidosis. \n \n The two board members of Amybel shared with us their personal story and how they got diagnosed, which even reinforced our commitment to support them and raise awareness around this rare and often underdiagnosed condition. \n Amyloidosis causes an abnormal accumulation of parts of proteins and can affect different tissues and organs, such as the heart for instance. An early diagnose can make a real difference in the evolution of the disease. \n For more information on the disease check today www.amyloidose.be and very soon www.amybel.be as well.\n \n #Amyloidosis #RareDisease #RadiOrg #PfizerBelgium \n \n Maura Verdoliva Stefaan Osaer Quentin Vander Stricht Dave Ceyssens Marie-Lise Verschelden Arnoud den Ouden Ruben Weckx Michiel Vanmeert, PhD, PharmD Ingrid Van Steenberge Mieke Vandenberghe, MD Bharati Shivalkar Arturo Prieto Rodríguez """ "reactions_count" => 754 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-18 02:11:25" "deleted" => 1 ] [ "id" => 614132869 "company_id" => 1258906 "urn" => "urn:li:activity:7166476720739459073" "followers" => null "date" => "3mo" "description" => """ 📅 Save the Date : 14 mars 2024\n 🆕 Nouvelle édition du Choix de la Science\n 📍 + d'infos sur le programme & les intervenants➡️ https://lnkd.in/ez4Av2rQ\n \n #LeChoixDeLaScience #ScienceWillWin #LaScienceVaincra """ "reactions_count" => 328 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-18 02:11:25" "deleted" => 1 ] [ "id" => 614132870 "company_id" => 1258906 "urn" => "urn:li:activity:7162852839277469696" "followers" => null "date" => "4mo" "description" => """ Dr. Kathleen strives to outpace, outsmart and outmaneuver cancer at every turn. While she once dreamed of being a practicing medical doctor, she realized a career as a researcher could help her bring impact to patients' lives. Dr. Kathleen is helping spearhead our vision to Outdo Cancer - leading world-class scientists who are paving the way for the next generation of cancer therapies. \n \n Meet Kathleen at LetsOutdoCancer.com. \n \n #Cancer #CancerResearch #Oncology """ "reactions_count" => 640 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-18 02:11:25" "deleted" => 1 ] [ "id" => 614132871 "company_id" => 1258906 "urn" => "urn:li:activity:7162587354111668224" "followers" => null "date" => "4mo" "description" => """ Today is a big day, and not just for the reasons you think. Here's to the women and girls whose brilliance has inspired us for 175 years. \n \n #womeninstem """ "reactions_count" => 3757 "comments_count" => 42 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-18 02:11:25" "deleted" => 1 ] [ "id" => 614132872 "company_id" => 1258906 "urn" => "urn:li:activity:7157888648477073408" "followers" => null "date" => "4mo" "description" => """ As the Enterprise Chair of Pfizer’s Global Black Community colleague resource group, my leadership team and I outlined four priorities for 2024 that are aimed at helping Pfizer attract and retain Black talent at all levels within the company. \n \n One of these priorities, which I am proud to share here, is our expanded engagement with historically Black colleges and universities (HBCUs) and the students they serve. Last week, in honor of the MLK Holiday in the United States, we held a program titled, “Preserving the Dream: Advancing Education and Equity for MLK’s Legacy” with special guests, Dr. Roslyn Clark Artis, President, Benedict College (SC), Dr. Paulette Dillard, President, Shaw University (NC), and Dr. Tashni-Ann Dubroy, Executive Vice President & Chief Operating Officer, Howard University (DC). \n \n We were excited to introduce not only these outstanding women to our diverse population of colleagues at Pfizer but also the value of an HBCU education. \n \n In the words of Dr. King, a Morehouse College graduate, “I have the audacity to believe that peoples everywhere can have three meals a day for their bodies, education and culture for their minds, and dignity, equality, and freedom for their spirits." Like Dr. King, we can all empower change. """ "reactions_count" => 400 "comments_count" => 17 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-18 02:11:25" "deleted" => 1 ] [ "id" => 614132873 "company_id" => 1258906 "urn" => "urn:li:activity:7157736536833232896" "followers" => null "date" => "4mo" "description" => """ #CervicalCancer is the fourth most common cancer among women globally. Join us in supporting those living with the disease and ensuring their voices are seen and heard by watching stories, like Kristine’s, on the #CeMe YouTube channel.\n \n Together with our partner, Genmab, we are dedicated to supporting the cervical cancer community this #CervicalCancerAwarenessMonth, and year-round.\n \n https://lnkd.in/e2kgTGNp """ "reactions_count" => 291 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-18 02:11:25" "deleted" => 1 ] [ "id" => 646225750 "company_id" => 1258906 "urn" => "urn:li:activity:7207083813418496001" "followers" => null "date" => "1mo" "description" => "Really great event today in our NYC office celebrating Pride month." "reactions_count" => 383 "comments_count" => 7 "reshared_post_author" => "Pfizer" "reshared_post_author_url" => "https://www.linkedin.com/company/pfizer" "reshared_post_author_headline" => null "reshared_post_description" => "To continue the celebration of Pride Month, our Colleague Resource Group, Out Pfizer Employee Network (OPEN), held an event at our New York headquarters to talk about the importance of allyship. The panel reflected on their own personal experiences and stories they have encountered with their personal allies and being allies to the LGBTQ+ community. The conversation wrapped up where everyone voiced how they feel supported and safe working at Pfizer." "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-08-18 03:55:51" "deleted" => 1 ] [ "id" => 646225751 "company_id" => 1258906 "urn" => "urn:li:activity:7198344733834756096" "followers" => null "date" => "1mo" "description" => """ Behind every innovative breakthrough are scientists, doctors, nurses, participant volunteers, and many others who work with us to advance science and medicine.\n \n They continue to inspire us with their ambition, passion, and commitment to finding new treatments, vaccines, and potential cures for diseases that affect millions of people around the world. They are the #TrailblazersAmongUs.\n \n Today, on #ClinicalTrialsDay, we celebrate all those who help make the impossible possible. Thank you.\n \n #CTD2024 """ "reactions_count" => 1058 "comments_count" => 19 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-18 03:55:51" "deleted" => 1 ] [ "id" => 646225752 "company_id" => 1258906 "urn" => "urn:li:activity:7178390309343526917" "followers" => null "date" => "3mo" "description" => "Our dedication to breakthrough innovation is grounded in our values of courage, excellence, equity, and joy, which drive us day in and day out. Our CEO Albert Bourla shares more on our progress in our 2023 #AnnualReview: https://Pfizer.com/Annual" "reactions_count" => 1075 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-18 03:55:51" "deleted" => 1 ] [ "id" => 646225753 "company_id" => 1258906 "urn" => "urn:li:activity:7169337533321973760" "followers" => null "date" => "4mo" "description" => """ At Pfizer Oncology, we have a bold vision: To accelerate breakthroughs that help people with cancer globally live longer and better lives. This vision drives everything we do and reflects our colleagues’ personal mission to improve the lives of people with cancer.\n \n In a meeting with the investment community, we outlined strategic priorities for our newly formed Oncology organization, and how our deep and diverse pipeline, industry-leading Oncology expertise, and anticipated near- and mid-term catalysts are expected to position the company to deliver strong growth and shareholder value.\n \n Below are some highlights from the event, and you can view the presentation and other details here: www.pfizer.com/investors.\n \n #LetsOutdoCancer """ "reactions_count" => 1219 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-18 03:55:51" "deleted" => 1 ] [ "id" => 646225754 "company_id" => 1258906 "urn" => "urn:li:activity:7168666598973632513" "followers" => null "date" => "4mo" "description" => """ Pfizer’s Chief Global Supply Officer, Mike McDermott, will be speaking at the TechOps Leadership Accelerator Program in NYC. We are proud of Mike’s unwavering commitment to helping shape the next generation of innovators and leaders in the biotech industry. Bringing more than 30 years of industry experience, Mike has been at the forefront of developing Pfizer’s world-class supply chain and “lightspeed” culture.\n \n To attend Mike’s session register here: https://lnkd.in/eNJ8SUSu """ "reactions_count" => 269 "comments_count" => 2 "reshared_post_author" => "Pascal Bécotte" "reshared_post_author_url" => "https://www.linkedin.com/in/pascal-b%C3%A9cotte-9435134" "reshared_post_author_headline" => "Hub Leader - New York City, Stamford & Canada at Russell Reynolds Associates" "reshared_post_description" => "We look forward to welcoming @MikeMcDermott as a faculty member at our inaugural TechOps Leadership Accelerator Program in June in NYC to teach participants about Authentic Leadership. The purpose of this program is to accelerate leadership development for a select cohort of functional VP-Level industry participants (Manufacturing, Supply Chain, Quality, Process Development, MSAT, HRBP) or smaller biotech CTOs to prepare them for the #1 roles in larger companies in the industry. Five "rarely taught" modules will be delivered by a combination of global leading topic matter experts AND renowned and proven industry leaders. Secure your spot today to learn from him and other industry experts: https://lnkd.in/eNJ8SUSu #biotech #manufacturing #leadership" "reshared_post_followers" => null "reshared_post_date" => "4mo" "last_updated" => "2024-08-18 03:55:51" "deleted" => 1 ] [ "id" => 646225755 "company_id" => 1258906 "urn" => "urn:li:activity:7166724230489845760" "followers" => null "date" => "4mo" "description" => """ The Pfizer Rare disease team was very happy to welcome in its Brussels headquarters Christina Verhofstadt and Denis Wolfs from the recently founded AMYBEL patient association. Under the motto “Bring Amyloidosis into the light,” the purpose of Amybel is to inform, guide and support patients with Amyloidosis. \n \n The two board members of Amybel shared with us their personal story and how they got diagnosed, which even reinforced our commitment to support them and raise awareness around this rare and often underdiagnosed condition. \n Amyloidosis causes an abnormal accumulation of parts of proteins and can affect different tissues and organs, such as the heart for instance. An early diagnose can make a real difference in the evolution of the disease. \n For more information on the disease check today www.amyloidose.be and very soon www.amybel.be as well.\n \n #Amyloidosis #RareDisease #RadiOrg #PfizerBelgium \n \n Maura Verdoliva Stefaan Osaer Quentin Vander Stricht Dave Ceyssens Marie-Lise Verschelden Arnoud den Ouden Ruben Weckx Michiel Vanmeert, PhD, PharmD Ingrid Van Steenberge Mieke Vandenberghe, MD Bharati Shivalkar Arturo Prieto Rodríguez """ "reactions_count" => 762 "comments_count" => 11 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-18 03:55:51" "deleted" => 1 ] [ "id" => 646225756 "company_id" => 1258906 "urn" => "urn:li:activity:7166476720739459073" "followers" => null "date" => "4mo" "description" => """ 📅 Save the Date : 14 mars 2024\n 🆕 Nouvelle édition du Choix de la Science\n 📍 + d'infos sur le programme & les intervenants➡️ https://lnkd.in/ez4Av2rQ\n \n #LeChoixDeLaScience #ScienceWillWin #LaScienceVaincra """ "reactions_count" => 335 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-18 03:55:51" "deleted" => 1 ] [ "id" => 646225757 "company_id" => 1258906 "urn" => "urn:li:activity:7162852839277469696" "followers" => null "date" => "5mo" "description" => """ Dr. Kathleen strives to outpace, outsmart and outmaneuver cancer at every turn. While she once dreamed of being a practicing medical doctor, she realized a career as a researcher could help her bring impact to patients' lives. Dr. Kathleen is helping spearhead our vision to Outdo Cancer - leading world-class scientists who are paving the way for the next generation of cancer therapies. \n \n Meet Kathleen at LetsOutdoCancer.com. \n \n #Cancer #CancerResearch #Oncology """ "reactions_count" => 646 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-18 03:55:51" "deleted" => 1 ] [ "id" => 646225758 "company_id" => 1258906 "urn" => "urn:li:activity:7162587354111668224" "followers" => null "date" => "5mo" "description" => """ Today is a big day, and not just for the reasons you think. Here's to the women and girls whose brilliance has inspired us for 175 years. \n \n #womeninstem """ "reactions_count" => 3761 "comments_count" => 42 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-18 03:55:51" "deleted" => 1 ] [ "id" => 646225759 "company_id" => 1258906 "urn" => "urn:li:activity:7157888648477073408" "followers" => null "date" => "5mo" "description" => """ As the Enterprise Chair of Pfizer’s Global Black Community colleague resource group, my leadership team and I outlined four priorities for 2024 that are aimed at helping Pfizer attract and retain Black talent at all levels within the company. \n \n One of these priorities, which I am proud to share here, is our expanded engagement with historically Black colleges and universities (HBCUs) and the students they serve. Last week, in honor of the MLK Holiday in the United States, we held a program titled, “Preserving the Dream: Advancing Education and Equity for MLK’s Legacy” with special guests, Dr. Roslyn Clark Artis, President, Benedict College (SC), Dr. Paulette Dillard, President, Shaw University (NC), and Dr. Tashni-Ann Dubroy, Executive Vice President & Chief Operating Officer, Howard University (DC). \n \n We were excited to introduce not only these outstanding women to our diverse population of colleagues at Pfizer but also the value of an HBCU education. \n \n In the words of Dr. King, a Morehouse College graduate, “I have the audacity to believe that peoples everywhere can have three meals a day for their bodies, education and culture for their minds, and dignity, equality, and freedom for their spirits." Like Dr. King, we can all empower change. """ "reactions_count" => 404 "comments_count" => 17 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-18 03:55:51" "deleted" => 1 ] [ "id" => 685258907 "company_id" => 1258906 "urn" => "urn:li:activity:7225138414537379841" "followers" => null "date" => "2w" "description" => "As part of Pfizer’s ambition to achieve the Net Zero Standard and RE100, we’re proud to partner with Vesper Energy and others to help generate new solar energy. Learn more below 👇" "reactions_count" => 407 "comments_count" => 17 "reshared_post_author" => "Vesper Energy" "reshared_post_author_url" => "https://www.linkedin.com/company/vesper-energy" "reshared_post_author_headline" => null "reshared_post_description" => """ Solar projects do more than benefit their local communities—they advance the sustainability goals of some of the world's leading companies. Through power purchase agreements, companies can contribute to a cleaner, more stable grid for everyone. \n \n We are thrilled to collaborate with Pfizer, Zoetis, Brunswick Corporation on our Hornet Solar project. This initiative will generate enough clean energy to power approximately 160,000 homes annually, supporting renewable energy infrastructure and has the potential to benefit communities for decades to come. By bolstering reliable and clean energy options, we are enhancing grid stability and environmental sustainability. \n \n Together, we are paving the way for a brighter, cleaner, and more sustainable world! \n \n Learn more: https://lnkd.in/guyJV6wc """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-09-11 00:10:24" "deleted" => 1 ] [ "id" => 685258908 "company_id" => 1258906 "urn" => "urn:li:activity:7207083813418496001" "followers" => null "date" => "2mo" "description" => "Really great event today in our NYC office celebrating Pride month." "reactions_count" => 420 "comments_count" => 10 "reshared_post_author" => "Pfizer" "reshared_post_author_url" => "https://www.linkedin.com/company/pfizer" "reshared_post_author_headline" => null "reshared_post_description" => "To continue the celebration of Pride Month, our Colleague Resource Group, Out Pfizer Employee Network (OPEN), held an event at our New York headquarters to talk about the importance of allyship. The panel reflected on their own personal experiences and stories they have encountered with their personal allies and being allies to the LGBTQ+ community. The conversation wrapped up where everyone voiced how they feel supported and safe working at Pfizer." "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2024-09-11 00:10:24" "deleted" => 1 ] [ "id" => 685258909 "company_id" => 1258906 "urn" => "urn:li:activity:7198344733834756096" "followers" => null "date" => "2mo" "description" => """ Behind every innovative breakthrough are scientists, doctors, nurses, participant volunteers, and many others who work with us to advance science and medicine.\n \n They continue to inspire us with their ambition, passion, and commitment to finding new treatments, vaccines, and potential cures for diseases that affect millions of people around the world. They are the #TrailblazersAmongUs.\n \n Today, on #ClinicalTrialsDay, we celebrate all those who help make the impossible possible. Thank you.\n \n #CTD2024 """ "reactions_count" => 1103 "comments_count" => 21 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 00:10:24" "deleted" => 1 ] [ "id" => 685258910 "company_id" => 1258906 "urn" => "urn:li:activity:7178390309343526917" "followers" => null "date" => "4mo" "description" => "Our dedication to breakthrough innovation is grounded in our values of courage, excellence, equity, and joy, which drive us day in and day out. Our CEO Albert Bourla shares more on our progress in our 2023 #AnnualReview: https://Pfizer.com/Annual" "reactions_count" => 1101 "comments_count" => 20 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 00:10:24" "deleted" => 1 ] [ "id" => 685258911 "company_id" => 1258906 "urn" => "urn:li:activity:7169337533321973760" "followers" => null "date" => "5mo" "description" => """ At Pfizer Oncology, we have a bold vision: To accelerate breakthroughs that help people with cancer globally live longer and better lives. This vision drives everything we do and reflects our colleagues’ personal mission to improve the lives of people with cancer.\n \n In a meeting with the investment community, we outlined strategic priorities for our newly formed Oncology organization, and how our deep and diverse pipeline, industry-leading Oncology expertise, and anticipated near- and mid-term catalysts are expected to position the company to deliver strong growth and shareholder value.\n \n Below are some highlights from the event, and you can view the presentation and other details here: www.pfizer.com/investors.\n \n #LetsOutdoCancer """ "reactions_count" => 1242 "comments_count" => 19 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 00:10:24" "deleted" => 1 ] [ "id" => 685258912 "company_id" => 1258906 "urn" => "urn:li:activity:7168666598973632513" "followers" => null "date" => "5mo" "description" => """ Pfizer’s Chief Global Supply Officer, Mike McDermott, will be speaking at the TechOps Leadership Accelerator Program in NYC. We are proud of Mike’s unwavering commitment to helping shape the next generation of innovators and leaders in the biotech industry. Bringing more than 30 years of industry experience, Mike has been at the forefront of developing Pfizer’s world-class supply chain and “lightspeed” culture.\n \n To attend Mike’s session register here: https://lnkd.in/eNJ8SUSu """ "reactions_count" => 277 "comments_count" => 2 "reshared_post_author" => "Pascal Bécotte" "reshared_post_author_url" => "https://www.linkedin.com/in/pascal-b%C3%A9cotte-9435134" "reshared_post_author_headline" => "Hub Leader - New York City, Stamford & Canada at Russell Reynolds Associates" "reshared_post_description" => "We look forward to welcoming @MikeMcDermott as a faculty member at our inaugural TechOps Leadership Accelerator Program in June in NYC to teach participants about Authentic Leadership. The purpose of this program is to accelerate leadership development for a select cohort of functional VP-Level industry participants (Manufacturing, Supply Chain, Quality, Process Development, MSAT, HRBP) or smaller biotech CTOs to prepare them for the #1 roles in larger companies in the industry. Five "rarely taught" modules will be delivered by a combination of global leading topic matter experts AND renowned and proven industry leaders. Secure your spot today to learn from him and other industry experts: https://lnkd.in/eNJ8SUSu #biotech #manufacturing #leadership" "reshared_post_followers" => null "reshared_post_date" => "5mo" "last_updated" => "2024-09-11 00:10:24" "deleted" => 1 ] [ "id" => 685258913 "company_id" => 1258906 "urn" => "urn:li:activity:7166724230489845760" "followers" => null "date" => "5mo" "description" => """ The Pfizer Rare disease team was very happy to welcome in its Brussels headquarters Christina Verhofstadt and Denis Wolfs from the recently founded AMYBEL patient association. Under the motto “Bring Amyloidosis into the light,” the purpose of Amybel is to inform, guide and support patients with Amyloidosis. \n \n The two board members of Amybel shared with us their personal story and how they got diagnosed, which even reinforced our commitment to support them and raise awareness around this rare and often underdiagnosed condition. \n Amyloidosis causes an abnormal accumulation of parts of proteins and can affect different tissues and organs, such as the heart for instance. An early diagnose can make a real difference in the evolution of the disease. \n For more information on the disease check today www.amyloidose.be and very soon www.amybel.be as well.\n \n #Amyloidosis #RareDisease #RadiOrg #PfizerBelgium \n \n Maura Verdoliva Stefaan Osaer Quentin Vander Stricht Dave Ceyssens Marie-Lise Verschelden Arnoud den Ouden Ruben Weckx Michiel Vanmeert, PhD, PharmD Ingrid Van Steenberge Mieke Vandenberghe, MD Bharati Shivalkar Arturo Prieto Rodríguez """ "reactions_count" => 773 "comments_count" => 13 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 00:10:24" "deleted" => 1 ] [ "id" => 685258914 "company_id" => 1258906 "urn" => "urn:li:activity:7166476720739459073" "followers" => null "date" => "5mo" "description" => """ 📅 Save the Date : 14 mars 2024\n 🆕 Nouvelle édition du Choix de la Science\n 📍 + d'infos sur le programme & les intervenants➡️ https://lnkd.in/ez4Av2rQ\n \n #LeChoixDeLaScience #ScienceWillWin #LaScienceVaincra """ "reactions_count" => 339 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 00:10:24" "deleted" => 1 ] [ "id" => 685258915 "company_id" => 1258906 "urn" => "urn:li:activity:7162852839277469696" "followers" => null "date" => "6mo" "description" => """ Dr. Kathleen strives to outpace, outsmart and outmaneuver cancer at every turn. While she once dreamed of being a practicing medical doctor, she realized a career as a researcher could help her bring impact to patients' lives. Dr. Kathleen is helping spearhead our vision to Outdo Cancer - leading world-class scientists who are paving the way for the next generation of cancer therapies. \n \n Meet Kathleen at LetsOutdoCancer.com. \n \n #Cancer #CancerResearch #Oncology """ "reactions_count" => 652 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 00:10:24" "deleted" => 1 ] [ "id" => 685258916 "company_id" => 1258906 "urn" => "urn:li:activity:7162587354111668224" "followers" => null "date" => "6mo" "description" => """ Today is a big day, and not just for the reasons you think. Here's to the women and girls whose brilliance has inspired us for 175 years. \n \n #womeninstem """ "reactions_count" => 3767 "comments_count" => 42 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-11 00:10:24" "deleted" => 1 ] [ "id" => 713489240 "company_id" => 1258906 "urn" => "urn:li:activity:7238928429885128704" "followers" => null "date" => "1d" "description" => """ We're proud to partner with multidisciplinary stakeholders to support the IHI-SYNTHIA project – an initiative led by the Innovative Health Initiative aiming to revolutionize the field of personalized medicine by harnessing the power of synthetic data to improve health outcomes, including in cancer and #Hematology.\n \n #SYNTHIA """ "reactions_count" => 192 "comments_count" => 9 "reshared_post_author" => "IHI-SYNTHIA" "reshared_post_author_url" => "https://www.linkedin.com/company/ihi-synthia" "reshared_post_author_headline" => null "reshared_post_description" => "SYNTHIA is a pioneering collaboration of 32 partners from Medtech, Pharma, Academia, Medical Research, and Healthcare institutions - uniting SDG developers, FAIR data experts, clinical researchers, developers of therapies and data-based tools, legal experts, socio-economic analysts, regulatory, policy advocacy, and communication -> all dedicated to advancing #SyntheticData in healthcare! #DataGeneration #PrecisionMedicine -> funded by Innovative Health Initiative (IHI)" "reshared_post_followers" => null "reshared_post_date" => "5d" "last_updated" => "2024-10-09 03:37:03" "deleted" => 1 ] [ "id" => 713489241 "company_id" => 1258906 "urn" => "urn:li:activity:7231400089552900096" "followers" => null "date" => "3w" "description" => """ “You can’t do anything if you don’t have colleagues that are talented, that are motivated, that are driven by purpose.”\n \n A great message from my colleague Chris Boshoff, MD, PhD, FMedSci, and one with which I completely agree. Our Pfizer Oncology team exemplifies hard work, dedication, and above all, passion. We’re working tirelessly to develop a new generation of potential breakthroughs across cancers and tumor types that brings new hope to patients—because we’re united by the shared vision of a world where people with cancer live better and longer lives. """ "reactions_count" => 1291 "comments_count" => 39 "reshared_post_author" => "The Wall Street Journal" "reshared_post_author_url" => "https://www.linkedin.com/company/the-wall-street-journal" "reshared_post_author_headline" => null "reshared_post_description" => "Pfizer is betting that cancer drugs can lead a turnaround. That’s why its new cancer boss is handing out sunglasses and mingling with the staff of a recently acquired biotech." "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2024-10-09 03:37:03" "deleted" => 1 ] [ "id" => 713489242 "company_id" => 1258906 "urn" => "urn:li:activity:7225138414537379841" "followers" => null "date" => "1mo" "description" => "As part of Pfizer’s ambition to achieve the Net Zero Standard and RE100, we’re proud to partner with Vesper Energy and others to help generate new solar energy. Learn more below 👇" "reactions_count" => 438 "comments_count" => 13 "reshared_post_author" => "Vesper Energy" "reshared_post_author_url" => "https://www.linkedin.com/company/vesper-energy" "reshared_post_author_headline" => null "reshared_post_description" => """ Solar projects do more than benefit their local communities—they advance the sustainability goals of some of the world's leading companies. Through power purchase agreements, companies can contribute to a cleaner, more stable grid for everyone. \n \n We are thrilled to collaborate with Pfizer, Zoetis, Brunswick Corporation on our Hornet Solar project. This initiative will generate enough clean energy to power approximately 160,000 homes annually, supporting renewable energy infrastructure and has the potential to benefit communities for decades to come. By bolstering reliable and clean energy options, we are enhancing grid stability and environmental sustainability. \n \n Together, we are paving the way for a brighter, cleaner, and more sustainable world! \n \n Learn more: https://lnkd.in/guyJV6wc """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2024-10-09 03:37:03" "deleted" => 1 ] [ "id" => 713489243 "company_id" => 1258906 "urn" => "urn:li:activity:7207083813418496001" "followers" => null "date" => "2mo" "description" => "Really great event today in our NYC office celebrating Pride month." "reactions_count" => 429 "comments_count" => 10 "reshared_post_author" => "Pfizer" "reshared_post_author_url" => "https://www.linkedin.com/company/pfizer" "reshared_post_author_headline" => null "reshared_post_description" => "To continue the celebration of Pride Month, our Colleague Resource Group, Out Pfizer Employee Network (OPEN), held an event at our New York headquarters to talk about the importance of allyship. The panel reflected on their own personal experiences and stories they have encountered with their personal allies and being allies to the LGBTQ+ community. The conversation wrapped up where everyone voiced how they feel supported and safe working at Pfizer." "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2024-10-09 03:37:03" "deleted" => 1 ] [ "id" => 713489244 "company_id" => 1258906 "urn" => "urn:li:activity:7198344733834756096" "followers" => null "date" => "3mo" "description" => """ Behind every innovative breakthrough are scientists, doctors, nurses, participant volunteers, and many others who work with us to advance science and medicine.\n \n They continue to inspire us with their ambition, passion, and commitment to finding new treatments, vaccines, and potential cures for diseases that affect millions of people around the world. They are the #TrailblazersAmongUs.\n \n Today, on #ClinicalTrialsDay, we celebrate all those who help make the impossible possible. Thank you.\n \n #CTD2024 """ "reactions_count" => 1118 "comments_count" => 22 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-09 03:37:03" "deleted" => 1 ] [ "id" => 713489245 "company_id" => 1258906 "urn" => "urn:li:activity:7178390309343526917" "followers" => null "date" => "5mo" "description" => "Our dedication to breakthrough innovation is grounded in our values of courage, excellence, equity, and joy, which drive us day in and day out. Our CEO Albert Bourla shares more on our progress in our 2023 #AnnualReview: https://Pfizer.com/Annual" "reactions_count" => 1113 "comments_count" => 19 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-09 03:37:03" "deleted" => 1 ] [ "id" => 713489246 "company_id" => 1258906 "urn" => "urn:li:activity:7169337533321973760" "followers" => null "date" => "6mo" "description" => """ At Pfizer Oncology, we have a bold vision: To accelerate breakthroughs that help people with cancer globally live longer and better lives. This vision drives everything we do and reflects our colleagues’ personal mission to improve the lives of people with cancer.\n \n In a meeting with the investment community, we outlined strategic priorities for our newly formed Oncology organization, and how our deep and diverse pipeline, industry-leading Oncology expertise, and anticipated near- and mid-term catalysts are expected to position the company to deliver strong growth and shareholder value.\n \n Below are some highlights from the event, and you can view the presentation and other details here: www.pfizer.com/investors.\n \n #LetsOutdoCancer """ "reactions_count" => 1251 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-09 03:37:03" "deleted" => 1 ] [ "id" => 713489247 "company_id" => 1258906 "urn" => "urn:li:activity:7168666598973632513" "followers" => null "date" => "6mo" "description" => """ Pfizer’s Chief Global Supply Officer, Mike McDermott, will be speaking at the TechOps Leadership Accelerator Program in NYC. We are proud of Mike’s unwavering commitment to helping shape the next generation of innovators and leaders in the biotech industry. Bringing more than 30 years of industry experience, Mike has been at the forefront of developing Pfizer’s world-class supply chain and “lightspeed” culture.\n \n To attend Mike’s session register here: https://lnkd.in/eNJ8SUSu """ "reactions_count" => 284 "comments_count" => 2 "reshared_post_author" => "Pascal Bécotte" "reshared_post_author_url" => "https://www.linkedin.com/in/pascal-b%C3%A9cotte-9435134" "reshared_post_author_headline" => "Hub Leader - New York City, Stamford & Canada at Russell Reynolds Associates" "reshared_post_description" => "We look forward to welcoming @MikeMcDermott as a faculty member at our inaugural TechOps Leadership Accelerator Program in June in NYC to teach participants about Authentic Leadership. The purpose of this program is to accelerate leadership development for a select cohort of functional VP-Level industry participants (Manufacturing, Supply Chain, Quality, Process Development, MSAT, HRBP) or smaller biotech CTOs to prepare them for the #1 roles in larger companies in the industry. Five "rarely taught" modules will be delivered by a combination of global leading topic matter experts AND renowned and proven industry leaders. Secure your spot today to learn from him and other industry experts: https://lnkd.in/eNJ8SUSu #biotech #manufacturing #leadership" "reshared_post_followers" => null "reshared_post_date" => "6mo" "last_updated" => "2024-10-09 03:37:03" "deleted" => 1 ] [ "id" => 713489248 "company_id" => 1258906 "urn" => "urn:li:activity:7166724230489845760" "followers" => null "date" => "6mo" "description" => """ The Pfizer Rare disease team was very happy to welcome in its Brussels headquarters Christina Verhofstadt and Denis Wolfs from the recently founded AMYBEL patient association. Under the motto “Bring Amyloidosis into the light,” the purpose of Amybel is to inform, guide and support patients with Amyloidosis. \n \n The two board members of Amybel shared with us their personal story and how they got diagnosed, which even reinforced our commitment to support them and raise awareness around this rare and often underdiagnosed condition. \n Amyloidosis causes an abnormal accumulation of parts of proteins and can affect different tissues and organs, such as the heart for instance. An early diagnose can make a real difference in the evolution of the disease. \n For more information on the disease check today www.amyloidose.be and very soon www.amybel.be as well.\n \n #Amyloidosis #RareDisease #RadiOrg #PfizerBelgium \n \n Maura Verdoliva Stefaan Osaer Quentin Vander Stricht Dave Ceyssens Marie-Lise Verschelden Arnoud den Ouden Ruben Weckx Michiel Vanmeert, PhD, PharmD Ingrid Van Steenberge Mieke Vandenberghe, MD Bharati Shivalkar Arturo Prieto Rodríguez """ "reactions_count" => 780 "comments_count" => 13 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-09 03:37:03" "deleted" => 1 ] [ "id" => 713489249 "company_id" => 1258906 "urn" => "urn:li:activity:7166476720739459073" "followers" => null "date" => "6mo" "description" => """ 📅 Save the Date : 14 mars 2024\n 🆕 Nouvelle édition du Choix de la Science\n 📍 + d'infos sur le programme & les intervenants➡️ https://lnkd.in/ez4Av2rQ\n \n #LeChoixDeLaScience #ScienceWillWin #LaScienceVaincra """ "reactions_count" => 345 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-09 03:37:03" "deleted" => 1 ] [ "id" => 752013770 "company_id" => 1258906 "urn" => "urn:li:activity:7244338172892000257" "followers" => null "date" => "3d" "description" => """ Understanding proteins helps unlock new insights, develop innovative treatments, and drive scientific progress. To introduce our new #explainer series, which breaks down some of the scientific concepts central to our work at Pfizer, we’re exploring what proteins are and how they play a vital role in countless daily processes within our bodies.\n \n #Proteins #Innovation """ "reactions_count" => 419 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-11 23:57:33" "deleted" => 1 ] [ "id" => 752013771 "company_id" => 1258906 "urn" => "urn:li:activity:7242531570228559872" "followers" => null "date" => "1w" "description" => "Pfizer has been recognized in the top 25% of Forbes' inaugural list of America's Best Employers for Tech Workers, where we are one of just four companies spotlighted in the Drug and Biotechnology category. Pfizer’s inclusion on this prestigious list is a testament to our dynamic and supportive culture, where every colleague has the opportunity to grow, excel, and make a meaningful impact. https://lnkd.in/gjmBJCbd" "reactions_count" => 704 "comments_count" => 20 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-11 23:57:33" "deleted" => 1 ] [ "id" => 752013772 "company_id" => 1258906 "urn" => "urn:li:activity:7241521440259289088" "followers" => null "date" => "1w" "description" => """ We’re supporting The Leukemia & Lymphoma Society as they work to define #BloodCancer and redefine what’s possible after diagnosis.\n \n Together, in partnership with the blood cancer community, we remain dedicated to making meaningful change to create a world where people with blood cancer live longer and better lives. """ "reactions_count" => 370 "comments_count" => 5 "reshared_post_author" => "The Leukemia & Lymphoma Society" "reshared_post_author_url" => "https://www.linkedin.com/company/llsusa" "reshared_post_author_headline" => null "reshared_post_description" => """ Every 180 seconds, someone in the U.S. hears the words “You have blood cancer.” ❤️ With 100+ types of blood cancer affecting millions of lives, we need to bring more awareness to this disease.\n \n #BloodCancerAwarenessMonth is our chance to define blood cancer and redefine what’s possible after diagnosis thanks to the progress we’ve made in funding innovative research, offering free education, support, and driving healthcare advocacy. Blood is life. Support is too. 🔥 Give today and your donation will be doubled 👉 https://bit.ly/3TwybAO """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2024-10-11 23:57:33" "deleted" => 1 ] [ "id" => 752013773 "company_id" => 1258906 "urn" => "urn:li:activity:7240702920025944064" "followers" => null "date" => "1w" "description" => """ Today in a late-breaking presentation at ESMO - European Society for Medical Oncology 2024, we unveil new Phase 2 data in cancer cachexia, a life-threatening wasting condition with no FDA-approved treatments. Learn more about our #cachexia research: https://lnkd.in/eNS2kcB3\n \n #Cachexia #ESMO24 """ "reactions_count" => 1162 "comments_count" => 26 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-11 23:57:33" "deleted" => 1 ] [ "id" => 752013774 "company_id" => 1258906 "urn" => "urn:li:activity:7240445341181890561" "followers" => null "date" => "2w" "description" => """ We’re pleased to partner with the International Myeloma Foundation to raise awareness of the impact of #MultipleMyeloma.\n \n Our long-standing relationships with the community are imperative in understanding and supporting the unique needs of patients as we work to deliver breakthroughs in #BloodCancer and #kNOwMyeloma. """ "reactions_count" => 818 "comments_count" => 9 "reshared_post_author" => "International Myeloma Foundation" "reshared_post_author_url" => "https://www.linkedin.com/company/international-myeloma-foundation" "reshared_post_author_headline" => null "reshared_post_description" => "Did you know that September is Blood Cancer Awareness Month? Myeloma, a cancer of plasma cells in your bone marrow, is the 2nd most common blood cancer in the world. How well do you #kNOwMyeloma? Thank you,Pfizer, for helping raise myeloma awareness." "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2024-10-11 23:57:33" "deleted" => 1 ] [ "id" => 752013775 "company_id" => 1258906 "urn" => "urn:li:activity:7238928429885128704" "followers" => null "date" => "2w" "description" => """ We're proud to partner with multidisciplinary stakeholders to support the IHI-SYNTHIA project – an initiative led by the Innovative Health Initiative aiming to revolutionize the field of personalized medicine by harnessing the power of synthetic data to improve health outcomes, including in cancer and #Hematology.\n \n #SYNTHIA """ "reactions_count" => 255 "comments_count" => 15 "reshared_post_author" => "IHI-SYNTHIA" "reshared_post_author_url" => "https://www.linkedin.com/company/ihi-synthia" "reshared_post_author_headline" => null "reshared_post_description" => "SYNTHIA is a pioneering collaboration of 32 partners from Medtech, Pharma, Academia, Medical Research, and Healthcare institutions - uniting SDG developers, FAIR data experts, clinical researchers, developers of therapies and data-based tools, legal experts, socio-economic analysts, regulatory, policy advocacy, and communication -> all dedicated to advancing #SyntheticData in healthcare! #DataGeneration #PrecisionMedicine -> funded by Innovative Health Initiative (IHI)" "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2024-10-11 23:57:33" "deleted" => 1 ] [ "id" => 752013776 "company_id" => 1258906 "urn" => "urn:li:activity:7231400089552900096" "followers" => null "date" => "1mo" "description" => """ “You can’t do anything if you don’t have colleagues that are talented, that are motivated, that are driven by purpose.”\n \n A great message from my colleague Chris Boshoff, MD, PhD, FMedSci, and one with which I completely agree. Our Pfizer Oncology team exemplifies hard work, dedication, and above all, passion. We’re working tirelessly to develop a new generation of potential breakthroughs across cancers and tumor types that brings new hope to patients—because we’re united by the shared vision of a world where people with cancer live better and longer lives. """ "reactions_count" => 1308 "comments_count" => 39 "reshared_post_author" => "The Wall Street Journal" "reshared_post_author_url" => "https://www.linkedin.com/company/the-wall-street-journal" "reshared_post_author_headline" => null "reshared_post_description" => "Pfizer is betting that cancer drugs can lead a turnaround. That’s why its new cancer boss is handing out sunglasses and mingling with the staff of a recently acquired biotech." "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-10-11 23:57:33" "deleted" => 1 ] [ "id" => 752013777 "company_id" => 1258906 "urn" => "urn:li:activity:7225138414537379841" "followers" => null "date" => "1mo" "description" => "As part of Pfizer’s ambition to achieve the Net Zero Standard and RE100, we’re proud to partner with Vesper Energy and others to help generate new solar energy. Learn more below 👇" "reactions_count" => 442 "comments_count" => 13 "reshared_post_author" => "Vesper Energy" "reshared_post_author_url" => "https://www.linkedin.com/company/vesper-energy" "reshared_post_author_headline" => null "reshared_post_description" => """ Solar projects do more than benefit their local communities—they advance the sustainability goals of some of the world's leading companies. Through power purchase agreements, companies can contribute to a cleaner, more stable grid for everyone. \n \n We are thrilled to collaborate with Pfizer, Zoetis, Brunswick Corporation on our Hornet Solar project. This initiative will generate enough clean energy to power approximately 160,000 homes annually, supporting renewable energy infrastructure and has the potential to benefit communities for decades to come. By bolstering reliable and clean energy options, we are enhancing grid stability and environmental sustainability. \n \n Together, we are paving the way for a brighter, cleaner, and more sustainable world! \n \n Learn more: https://lnkd.in/guyJV6wc """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2024-10-11 23:57:33" "deleted" => 1 ] [ "id" => 752013778 "company_id" => 1258906 "urn" => "urn:li:activity:7207083813418496001" "followers" => null "date" => "3mo" "description" => "Really great event today in our NYC office celebrating Pride month." "reactions_count" => 430 "comments_count" => 10 "reshared_post_author" => "Pfizer" "reshared_post_author_url" => "https://www.linkedin.com/company/pfizer" "reshared_post_author_headline" => null "reshared_post_description" => "To continue the celebration of Pride Month, our Colleague Resource Group, Out Pfizer Employee Network (OPEN), held an event at our New York headquarters to talk about the importance of allyship. The panel reflected on their own personal experiences and stories they have encountered with their personal allies and being allies to the LGBTQ+ community. The conversation wrapped up where everyone voiced how they feel supported and safe working at Pfizer." "reshared_post_followers" => null "reshared_post_date" => "3mo" "last_updated" => "2024-10-11 23:57:33" "deleted" => 1 ] [ "id" => 752013779 "company_id" => 1258906 "urn" => "urn:li:activity:7198344733834756096" "followers" => null "date" => "4mo" "description" => """ Behind every innovative breakthrough are scientists, doctors, nurses, participant volunteers, and many others who work with us to advance science and medicine.\n \n They continue to inspire us with their ambition, passion, and commitment to finding new treatments, vaccines, and potential cures for diseases that affect millions of people around the world. They are the #TrailblazersAmongUs.\n \n Today, on #ClinicalTrialsDay, we celebrate all those who help make the impossible possible. Thank you.\n \n #CTD2024 """ "reactions_count" => 1123 "comments_count" => 21 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-11 23:57:33" "deleted" => 1 ] [ "id" => 756200062 "company_id" => 1258906 "urn" => "urn:li:activity:7244338172892000257" "followers" => null "date" => "2w" "description" => """ Understanding proteins helps unlock new insights, develop innovative treatments, and drive scientific progress. To introduce our new #explainer series, which breaks down some of the scientific concepts central to our work at Pfizer, we’re exploring what proteins are and how they play a vital role in countless daily processes within our bodies.\n \n #Proteins #Innovation """ "reactions_count" => 571 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-09 16:57:05" "deleted" => 1 ] [ "id" => 756200063 "company_id" => 1258906 "urn" => "urn:li:activity:7242531570228559872" "followers" => null "date" => "2w" "description" => "Pfizer has been recognized in the top 25% of Forbes' inaugural list of America's Best Employers for Tech Workers, where we are one of just four companies spotlighted in the Drug and Biotechnology category. Pfizer’s inclusion on this prestigious list is a testament to our dynamic and supportive culture, where every colleague has the opportunity to grow, excel, and make a meaningful impact. https://lnkd.in/gjmBJCbd" "reactions_count" => 743 "comments_count" => 18 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-09 16:57:05" "deleted" => 1 ] [ "id" => 756200064 "company_id" => 1258906 "urn" => "urn:li:activity:7241521440259289088" "followers" => null "date" => "3w" "description" => """ We’re supporting The Leukemia & Lymphoma Society as they work to define #BloodCancer and redefine what’s possible after diagnosis.\n \n Together, in partnership with the blood cancer community, we remain dedicated to making meaningful change to create a world where people with blood cancer live longer and better lives. """ "reactions_count" => 380 "comments_count" => 5 "reshared_post_author" => "The Leukemia & Lymphoma Society" "reshared_post_author_url" => "https://www.linkedin.com/company/llsusa" "reshared_post_author_headline" => null "reshared_post_description" => """ Every 180 seconds, someone in the U.S. hears the words “You have blood cancer.” ❤️ With 100+ types of blood cancer affecting millions of lives, we need to bring more awareness to this disease.\n \n #BloodCancerAwarenessMonth is our chance to define blood cancer and redefine what’s possible after diagnosis thanks to the progress we’ve made in funding innovative research, offering free education, support, and driving healthcare advocacy. Blood is life. Support is too. 🔥 Give today and your donation will be doubled 👉 https://bit.ly/3TwybAO """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2024-11-09 16:57:05" "deleted" => 1 ] [ "id" => 756200065 "company_id" => 1258906 "urn" => "urn:li:activity:7240702920025944064" "followers" => null "date" => "3w" "description" => """ Today in a late-breaking presentation at ESMO - European Society for Medical Oncology 2024, we unveil new Phase 2 data in cancer cachexia, a life-threatening wasting condition with no FDA-approved treatments. Learn more about our #cachexia research: https://lnkd.in/eNS2kcB3\n \n #Cachexia #ESMO24 """ "reactions_count" => 1196 "comments_count" => 25 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-09 16:57:05" "deleted" => 1 ] [ "id" => 756200066 "company_id" => 1258906 "urn" => "urn:li:activity:7240445341181890561" "followers" => null "date" => "3w" "description" => """ We’re pleased to partner with the International Myeloma Foundation to raise awareness of the impact of #MultipleMyeloma.\n \n Our long-standing relationships with the community are imperative in understanding and supporting the unique needs of patients as we work to deliver breakthroughs in #BloodCancer and #kNOwMyeloma. """ "reactions_count" => 841 "comments_count" => 10 "reshared_post_author" => "International Myeloma Foundation" "reshared_post_author_url" => "https://www.linkedin.com/company/international-myeloma-foundation" "reshared_post_author_headline" => null "reshared_post_description" => "Did you know that September is Blood Cancer Awareness Month? Myeloma, a cancer of plasma cells in your bone marrow, is the 2nd most common blood cancer in the world. How well do you #kNOwMyeloma? Thank you,Pfizer, for helping raise myeloma awareness." "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2024-11-09 16:57:05" "deleted" => 1 ] [ "id" => 756200067 "company_id" => 1258906 "urn" => "urn:li:activity:7238928429885128704" "followers" => null "date" => "4w" "description" => """ We're proud to partner with multidisciplinary stakeholders to support the IHI-SYNTHIA project – an initiative led by the Innovative Health Initiative aiming to revolutionize the field of personalized medicine by harnessing the power of synthetic data to improve health outcomes, including in cancer and #Hematology.\n \n #SYNTHIA """ "reactions_count" => 261 "comments_count" => 15 "reshared_post_author" => "IHI-SYNTHIA" "reshared_post_author_url" => "https://www.linkedin.com/company/ihi-synthia" "reshared_post_author_headline" => null "reshared_post_description" => "SYNTHIA is a pioneering collaboration of 32 partners from Medtech, Pharma, Academia, Medical Research, and Healthcare institutions - uniting SDG developers, FAIR data experts, clinical researchers, developers of therapies and data-based tools, legal experts, socio-economic analysts, regulatory, policy advocacy, and communication -> all dedicated to advancing #SyntheticData in healthcare! #DataGeneration #PrecisionMedicine -> funded by Innovative Health Initiative (IHI)" "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-11-09 16:57:05" "deleted" => 1 ] [ "id" => 756200068 "company_id" => 1258906 "urn" => "urn:li:activity:7231400089552900096" "followers" => null "date" => "1mo" "description" => """ “You can’t do anything if you don’t have colleagues that are talented, that are motivated, that are driven by purpose.”\n \n A great message from my colleague Chris Boshoff, MD, PhD, FMedSci, and one with which I completely agree. Our Pfizer Oncology team exemplifies hard work, dedication, and above all, passion. We’re working tirelessly to develop a new generation of potential breakthroughs across cancers and tumor types that brings new hope to patients—because we’re united by the shared vision of a world where people with cancer live better and longer lives. """ "reactions_count" => 1306 "comments_count" => 39 "reshared_post_author" => "The Wall Street Journal" "reshared_post_author_url" => "https://www.linkedin.com/company/the-wall-street-journal" "reshared_post_author_headline" => null "reshared_post_description" => "Pfizer is betting that cancer drugs can lead a turnaround. That’s why its new cancer boss is handing out sunglasses and mingling with the staff of a recently acquired biotech." "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-11-09 16:57:05" "deleted" => 1 ] [ "id" => 756200069 "company_id" => 1258906 "urn" => "urn:li:activity:7225138414537379841" "followers" => null "date" => "2mo" "description" => "As part of Pfizer’s ambition to achieve the Net Zero Standard and RE100, we’re proud to partner with Vesper Energy and others to help generate new solar energy. Learn more below 👇" "reactions_count" => 437 "comments_count" => 13 "reshared_post_author" => "Vesper Energy" "reshared_post_author_url" => "https://www.linkedin.com/company/vesper-energy" "reshared_post_author_headline" => null "reshared_post_description" => """ Solar projects do more than benefit their local communities—they advance the sustainability goals of some of the world's leading companies. Through power purchase agreements, companies can contribute to a cleaner, more stable grid for everyone. \n \n We are thrilled to collaborate with Pfizer, Zoetis, Brunswick Corporation on our Hornet Solar project. This initiative will generate enough clean energy to power approximately 160,000 homes annually, supporting renewable energy infrastructure and has the potential to benefit communities for decades to come. By bolstering reliable and clean energy options, we are enhancing grid stability and environmental sustainability. \n \n Together, we are paving the way for a brighter, cleaner, and more sustainable world! \n \n Learn more: https://lnkd.in/guyJV6wc """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2024-11-09 16:57:05" "deleted" => 1 ] [ "id" => 756200070 "company_id" => 1258906 "urn" => "urn:li:activity:7207083813418496001" "followers" => null "date" => "3mo" "description" => "Really great event today in our NYC office celebrating Pride month." "reactions_count" => 431 "comments_count" => 10 "reshared_post_author" => "Pfizer" "reshared_post_author_url" => "https://www.linkedin.com/company/pfizer" "reshared_post_author_headline" => null "reshared_post_description" => "To continue the celebration of Pride Month, our Colleague Resource Group, Out Pfizer Employee Network (OPEN), held an event at our New York headquarters to talk about the importance of allyship. The panel reflected on their own personal experiences and stories they have encountered with their personal allies and being allies to the LGBTQ+ community. The conversation wrapped up where everyone voiced how they feel supported and safe working at Pfizer." "reshared_post_followers" => null "reshared_post_date" => "3mo" "last_updated" => "2024-11-09 16:57:05" "deleted" => 1 ] [ "id" => 756200071 "company_id" => 1258906 "urn" => "urn:li:activity:7198344733834756096" "followers" => null "date" => "4mo" "description" => """ Behind every innovative breakthrough are scientists, doctors, nurses, participant volunteers, and many others who work with us to advance science and medicine.\n \n They continue to inspire us with their ambition, passion, and commitment to finding new treatments, vaccines, and potential cures for diseases that affect millions of people around the world. They are the #TrailblazersAmongUs.\n \n Today, on #ClinicalTrialsDay, we celebrate all those who help make the impossible possible. Thank you.\n \n #CTD2024 """ "reactions_count" => 1121 "comments_count" => 21 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-09 16:57:05" "deleted" => 1 ] [ "id" => 801122584 "company_id" => 1258906 "urn" => "urn:li:activity:7256702117749362688" "followers" => null "date" => "1w" "description" => "Is the Medicine in Your Medicine Cabinet Safe? Unfortunately, there is a troubling lack of knowledge about counterfeits among U.S. healthcare providers. Therein lies opportunity in empowering health care providers and patients" "reactions_count" => 325 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-08 18:55:07" "deleted" => 1 ] [ "id" => 801122585 "company_id" => 1258906 "urn" => "urn:li:activity:7244338172892000257" "followers" => null "date" => "1mo" "description" => """ Understanding proteins helps unlock new insights, develop innovative treatments, and drive scientific progress. To introduce our new #explainer series, which breaks down some of the scientific concepts central to our work at Pfizer, we’re exploring what proteins are and how they play a vital role in countless daily processes within our bodies.\n \n #Proteins #Innovation """ "reactions_count" => 659 "comments_count" => 12 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-08 18:55:07" "deleted" => 1 ] [ "id" => 801122586 "company_id" => 1258906 "urn" => "urn:li:activity:7242531570228559872" "followers" => null "date" => "1mo" "description" => "Pfizer has been recognized in the top 25% of Forbes' inaugural list of America's Best Employers for Tech Workers, where we are one of just four companies spotlighted in the Drug and Biotechnology category. Pfizer’s inclusion on this prestigious list is a testament to our dynamic and supportive culture, where every colleague has the opportunity to grow, excel, and make a meaningful impact. https://lnkd.in/gjmBJCbd" "reactions_count" => 800 "comments_count" => 20 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-08 18:55:07" "deleted" => 1 ] [ "id" => 801122587 "company_id" => 1258906 "urn" => "urn:li:activity:7241521440259289088" "followers" => null "date" => "1mo" "description" => """ We’re supporting The Leukemia & Lymphoma Society as they work to define #BloodCancer and redefine what’s possible after diagnosis.\n \n Together, in partnership with the blood cancer community, we remain dedicated to making meaningful change to create a world where people with blood cancer live longer and better lives. """ "reactions_count" => 400 "comments_count" => 5 "reshared_post_author" => "The Leukemia & Lymphoma Society" "reshared_post_author_url" => "https://www.linkedin.com/company/llsusa" "reshared_post_author_headline" => null "reshared_post_description" => """ Every 180 seconds, someone in the U.S. hears the words “You have blood cancer.” ❤️ With 100+ types of blood cancer affecting millions of lives, we need to bring more awareness to this disease.\n \n #BloodCancerAwarenessMonth is our chance to define blood cancer and redefine what’s possible after diagnosis thanks to the progress we’ve made in funding innovative research, offering free education, support, and driving healthcare advocacy. Blood is life. Support is too. 🔥 Give today and your donation will be doubled 👉 https://bit.ly/3TwybAO """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-12-08 18:55:07" "deleted" => 1 ] [ "id" => 801122588 "company_id" => 1258906 "urn" => "urn:li:activity:7240702920025944064" "followers" => null "date" => "1mo" "description" => """ Today in a late-breaking presentation at ESMO - European Society for Medical Oncology 2024, we unveil new Phase 2 data in cancer cachexia, a life-threatening wasting condition with no FDA-approved treatments. Learn more about our #cachexia research: https://lnkd.in/eNS2kcB3\n \n #Cachexia #ESMO24 """ "reactions_count" => 1224 "comments_count" => 27 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-08 18:55:07" "deleted" => 1 ] [ "id" => 801122589 "company_id" => 1258906 "urn" => "urn:li:activity:7240445341181890561" "followers" => null "date" => "1mo" "description" => """ We’re pleased to partner with the International Myeloma Foundation to raise awareness of the impact of #MultipleMyeloma.\n \n Our long-standing relationships with the community are imperative in understanding and supporting the unique needs of patients as we work to deliver breakthroughs in #BloodCancer and #kNOwMyeloma. """ "reactions_count" => 865 "comments_count" => 11 "reshared_post_author" => "International Myeloma Foundation" "reshared_post_author_url" => "https://www.linkedin.com/company/international-myeloma-foundation" "reshared_post_author_headline" => null "reshared_post_description" => "Did you know that September is Blood Cancer Awareness Month? Myeloma, a cancer of plasma cells in your bone marrow, is the 2nd most common blood cancer in the world. How well do you #kNOwMyeloma? Thank you,Pfizer, for helping raise myeloma awareness." "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-12-08 18:55:07" "deleted" => 1 ] [ "id" => 801122590 "company_id" => 1258906 "urn" => "urn:li:activity:7238928429885128704" "followers" => null "date" => "2mo" "description" => """ We're proud to partner with multidisciplinary stakeholders to support the IHI-SYNTHIA project – an initiative led by the Innovative Health Initiative aiming to revolutionize the field of personalized medicine by harnessing the power of synthetic data to improve health outcomes, including in cancer and #Hematology.\n \n #SYNTHIA """ "reactions_count" => 280 "comments_count" => 14 "reshared_post_author" => "IHI-SYNTHIA" "reshared_post_author_url" => "https://www.linkedin.com/company/ihi-synthia" "reshared_post_author_headline" => null "reshared_post_description" => "SYNTHIA is a pioneering collaboration of 32 partners from Medtech, Pharma, Academia, Medical Research, and Healthcare institutions - uniting SDG developers, FAIR data experts, clinical researchers, developers of therapies and data-based tools, legal experts, socio-economic analysts, regulatory, policy advocacy, and communication -> all dedicated to advancing #SyntheticData in healthcare! #DataGeneration #PrecisionMedicine -> funded by Innovative Health Initiative (IHI)" "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2024-12-08 18:55:07" "deleted" => 1 ] [ "id" => 801122591 "company_id" => 1258906 "urn" => "urn:li:activity:7231400089552900096" "followers" => null "date" => "2mo" "description" => """ “You can’t do anything if you don’t have colleagues that are talented, that are motivated, that are driven by purpose.”\n \n A great message from my colleague Chris Boshoff, MD, PhD, FMedSci, and one with which I completely agree. Our Pfizer Oncology team exemplifies hard work, dedication, and above all, passion. We’re working tirelessly to develop a new generation of potential breakthroughs across cancers and tumor types that brings new hope to patients—because we’re united by the shared vision of a world where people with cancer live better and longer lives. """ "reactions_count" => 1317 "comments_count" => 42 "reshared_post_author" => "The Wall Street Journal" "reshared_post_author_url" => "https://www.linkedin.com/company/the-wall-street-journal" "reshared_post_author_headline" => null "reshared_post_description" => "Pfizer is betting that cancer drugs can lead a turnaround. That’s why its new cancer boss is handing out sunglasses and mingling with the staff of a recently acquired biotech." "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2024-12-08 18:55:07" "deleted" => 1 ] [ "id" => 801122592 "company_id" => 1258906 "urn" => "urn:li:activity:7225138414537379841" "followers" => null "date" => "3mo" "description" => "As part of Pfizer’s ambition to achieve the Net Zero Standard and RE100, we’re proud to partner with Vesper Energy and others to help generate new solar energy. Learn more below 👇" "reactions_count" => 450 "comments_count" => 13 "reshared_post_author" => "Vesper Energy" "reshared_post_author_url" => "https://www.linkedin.com/company/vesper-energy" "reshared_post_author_headline" => null "reshared_post_description" => """ Solar projects do more than benefit their local communities—they advance the sustainability goals of some of the world's leading companies. Through power purchase agreements, companies can contribute to a cleaner, more stable grid for everyone. \n \n We are thrilled to collaborate with Pfizer, Zoetis, Brunswick Corporation on our Hornet Solar project. This initiative will generate enough clean energy to power approximately 160,000 homes annually, supporting renewable energy infrastructure and has the potential to benefit communities for decades to come. By bolstering reliable and clean energy options, we are enhancing grid stability and environmental sustainability. \n \n Together, we are paving the way for a brighter, cleaner, and more sustainable world! \n \n Learn more: https://lnkd.in/guyJV6wc """ "reshared_post_followers" => null "reshared_post_date" => "4mo" "last_updated" => "2024-12-08 18:55:07" "deleted" => 1 ] [ "id" => 801122593 "company_id" => 1258906 "urn" => "urn:li:activity:7207083813418496001" "followers" => null "date" => "4mo" "description" => "Really great event today in our NYC office celebrating Pride month." "reactions_count" => 436 "comments_count" => 10 "reshared_post_author" => "Pfizer" "reshared_post_author_url" => "https://www.linkedin.com/company/pfizer" "reshared_post_author_headline" => null "reshared_post_description" => "To continue the celebration of Pride Month, our Colleague Resource Group, Out Pfizer Employee Network (OPEN), held an event at our New York headquarters to talk about the importance of allyship. The panel reflected on their own personal experiences and stories they have encountered with their personal allies and being allies to the LGBTQ+ community. The conversation wrapped up where everyone voiced how they feel supported and safe working at Pfizer." "reshared_post_followers" => null "reshared_post_date" => "4mo" "last_updated" => "2024-12-08 18:55:07" "deleted" => 1 ] [ "id" => 848981812 "company_id" => 1258906 "urn" => "urn:li:activity:7269401068944429056" "followers" => null "date" => "5d" "description" => """ Healthcare isn’t one-size-fits-all. That’s why we created PfizerForAll. \n \n In a recent article, Aamir Malik, our Chief U.S. Commercial Officer, explains how our new digital platform is a resource for people with #migraine, #COVID19, and #flu. He also shares the challenges faced by two women managing migraine and COVID-19 and the ways that PfizerForAll is showing up for people in times of need. Read here to learn how PfizerForAll can help you: """ "reactions_count" => 236 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-18 21:21:12" "deleted" => 1 ] [ "id" => 848981813 "company_id" => 1258906 "urn" => "urn:li:activity:7265111349595181057" "followers" => null "date" => "2w" "description" => """ On November 20th, we join in observing Trans Day of Remembrance, a day dedicated to honoring the memory of transgender individuals whose lives were tragically lost due to anti-transgender violence. This day serves as a poignant reminder of the ongoing challenges faced by the transgender community and underscores the importance of our collective efforts to foster a safe and inclusive environment for all.\n \n To mark this day and Transgender Awareness Week, members of OPEN (Out Pfizer Employee Network) gathered to writer letters of support to those in the transgender community. Their heartfelt messages aim to provide encouragement and solidarity to individuals who often face significant challenges. """ "reactions_count" => 342 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-18 21:21:12" "deleted" => 1 ] [ "id" => 848981814 "company_id" => 1258906 "urn" => "urn:li:activity:7265083939134791681" "followers" => null "date" => "2w" "description" => "Congratulations to the team at Ultromics on receiving FDA Clearance for EchoGo Amyloidosis – their innovative AI tech to help improve earlier detection of both light chain and transthyretin cardiac amyloidosis from a single 4 chamber echo scan. Great to see innovation in action for this serious and underdiagnosed cause of heart failure." "reactions_count" => 503 "comments_count" => 15 "reshared_post_author" => "Ultromics" "reshared_post_author_url" => "https://uk.linkedin.com/company/ultromics" "reshared_post_author_headline" => null "reshared_post_description" => """ We are excited to announce that EchoGo® Amyloidosis has received Breakthrough Device FDA clearance! Developed in collaboration with Johnson & Johnson Innovative Medicine and with support from Pfizer, EchoGo® Amyloidosis is the first FDA-cleared AI screening tool designed to help detect amyloidosis from an echocardiogram.\n \n The clearance was achieved as part of Ultromics' participation in the pilot of the FDA’s Total Product Lifecycle Advisory Program (TAP) and is the first device enrolled in TAP to receive FDA marketing authorization. \n \n EchoGo® Amyloidosis is part of Ultromics’ EchoGo® platform, complementing our reimbursable EchoGo® Heart Failure device to provide a robust solution for diagnosing heart failure and its underlying causes.\n \n Cardiac Amyloidosis is a rare and underdiagnosed cause of heart failure, with up to two-thirds of cases missed. The consequences are severe, but this breakthrough technology can facilitate detection:\n \n “𝗥𝗲𝗾𝘂𝗶𝗿𝗶𝗻𝗴 𝗼𝗻𝗹𝘆 𝗮 𝘀𝗶𝗻𝗴𝗹𝗲 𝗮𝗽𝗶𝗰𝗮𝗹 𝟰 𝗰𝗵𝗮𝗺𝗯𝗲𝗿 𝗶𝗺𝗮𝗴𝗲, 𝗘𝗰𝗵𝗼𝗚𝗼® 𝗔𝗺𝘆𝗹𝗼𝗶𝗱𝗼𝘀𝗶𝘀 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝘀 𝗖𝗮𝗿𝗱𝗶𝗮𝗰 𝗔𝗺𝘆𝗹𝗼𝗶𝗱𝗼𝘀𝗶𝘀, 𝗮𝗻𝗱 𝘄𝗶𝗹𝗹 𝗵𝗲𝗹𝗽 𝗱𝗿𝗶𝘃𝗲 𝗲𝗮𝗿𝗹𝗶𝗲𝗿 𝗮𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗮𝗽𝗽𝗿𝗼𝗽𝗿𝗶𝗮𝘁𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗰𝗮𝗿𝗲 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗶𝘀 𝘂𝗻𝗱𝗲𝗿𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗲𝗱 𝗱𝗶𝘀𝗲𝗮𝘀𝗲."\n \n - 𝗥𝗼𝘀𝘀 𝗨𝗽𝘁𝗼𝗻, 𝗣𝗵𝗗, 𝗙𝗼𝘂𝗻𝗱𝗲𝗿, 𝗖𝗘𝗢 𝗮𝗻𝗱 𝗖𝗵𝗶𝗲𝗳 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗢𝗳𝗳𝗶𝗰𝗲𝗿, 𝗨𝗹𝘁𝗿𝗼𝗺𝗶𝗰𝘀, 𝗮𝗻𝗱 𝗔𝗜 𝗖𝗼-𝗖𝗵𝗮𝗶𝗿, 𝗛𝗲𝗮𝗿𝘁𝗦𝗵𝗮𝗿𝗲, 𝗙𝗡𝗜𝗛.\n \n Learn more: https://lnkd.in/eDFf-pA4\n \n #Ultromics #EchoGo #JNJ #Pfizer #MayoClinic #PrecisionDetection #CardiacAmyloidosis #Amyloidosis #AL #ATTR #EchoFirst #Echocardiography #Cardiovascular #Cardiology #AIinHealthcare #HealthTech #Innovation """ "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2025-01-18 21:21:12" "deleted" => 1 ] [ "id" => 848981815 "company_id" => 1258906 "urn" => "urn:li:activity:7264978138441379840" "followers" => null "date" => "2w" "description" => """ Today I have the privilege of announcing that Dr. Chris Boshoff, MD, PhD, FMedSci has been appointed to lead our pipeline of potential new medicines and vaccines—work that is at the very heart of Pfizer's ability to change patients' lives. Effective January 1, 2025, Chris will become Pfizer’s new Chief Scientific Officer and President, Research & Development, overseeing all functions of Pfizer’s R&D across all therapeutic areas.\n \n In his current role as our Chief Oncology Officer, Chris has shaped Pfizer Oncology into one of our most productive divisions. In his 11 years at Pfizer, he has delivered an impressive 24 approved innovative medicines and biosimilars in more than 30 indications, and I am confident that he will accomplish great things across our entire portfolio. He is an extraordinary scientist and leader with a passion for helping patients. Throughout our comprehensive selection process, Chris stood out as a proven leader with a compelling vision for the future of Pfizer R&D. \n \n Chris will succeed Dr. Mikael Dolsten, who is retiring at the end of the year. I want to thank Mikael for his dedication and all that he has contributed during his long tenure at Pfizer. \n \n I’m also thrilled to announce Dr. Roger Dansey will serve as Interim Chief Oncology Officer and to welcome Dr. Johanna Bendell to Pfizer as our new Chief Development Officer, Oncology. Roger will work with Chris in selecting a permanent candidate for the role. \n \n I look forward to working with these talented leaders and their teams to continue advancing scientific breakthroughs that help patients everywhere. \n \n https://lnkd.in/eXT2ekYa """ "reactions_count" => 2136 "comments_count" => 93 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-18 21:21:12" "deleted" => 1 ] [ "id" => 848981816 "company_id" => 1258906 "urn" => "urn:li:activity:7256702117749362688" "followers" => null "date" => "1mo" "description" => "Is the Medicine in Your Medicine Cabinet Safe? Unfortunately, there is a troubling lack of knowledge about counterfeits among U.S. healthcare providers. Therein lies opportunity in empowering health care providers and patients" "reactions_count" => 366 "comments_count" => 23 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-18 21:21:12" "deleted" => 1 ] [ "id" => 848981817 "company_id" => 1258906 "urn" => "urn:li:activity:7244338172892000257" "followers" => null "date" => "2mo" "description" => """ Understanding proteins helps unlock new insights, develop innovative treatments, and drive scientific progress. To introduce our new #explainer series, which breaks down some of the scientific concepts central to our work at Pfizer, we’re exploring what proteins are and how they play a vital role in countless daily processes within our bodies.\n \n #Proteins #Innovation """ "reactions_count" => 684 "comments_count" => 13 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-18 21:21:12" "deleted" => 1 ] [ "id" => 848981818 "company_id" => 1258906 "urn" => "urn:li:activity:7242531570228559872" "followers" => null "date" => "2mo" "description" => "Pfizer has been recognized in the top 25% of Forbes' inaugural list of America's Best Employers for Tech Workers, where we are one of just four companies spotlighted in the Drug and Biotechnology category. Pfizer’s inclusion on this prestigious list is a testament to our dynamic and supportive culture, where every colleague has the opportunity to grow, excel, and make a meaningful impact. https://lnkd.in/gjmBJCbd" "reactions_count" => 807 "comments_count" => 22 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-18 21:21:12" "deleted" => 1 ] [ "id" => 848981819 "company_id" => 1258906 "urn" => "urn:li:activity:7241521440259289088" "followers" => null "date" => "2mo" "description" => """ We’re supporting The Leukemia & Lymphoma Society as they work to define #BloodCancer and redefine what’s possible after diagnosis.\n \n Together, in partnership with the blood cancer community, we remain dedicated to making meaningful change to create a world where people with blood cancer live longer and better lives. """ "reactions_count" => 399 "comments_count" => 6 "reshared_post_author" => "The Leukemia & Lymphoma Society" "reshared_post_author_url" => "https://www.linkedin.com/company/llsusa" "reshared_post_author_headline" => null "reshared_post_description" => """ Every 180 seconds, someone in the U.S. hears the words “You have blood cancer.” ❤️ With 100+ types of blood cancer affecting millions of lives, we need to bring more awareness to this disease.\n \n #BloodCancerAwarenessMonth is our chance to define blood cancer and redefine what’s possible after diagnosis thanks to the progress we’ve made in funding innovative research, offering free education, support, and driving healthcare advocacy. Blood is life. Support is too. 🔥 Give today and your donation will be doubled 👉 https://bit.ly/3TwybAO """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2025-01-18 21:21:12" "deleted" => 1 ] [ "id" => 848981820 "company_id" => 1258906 "urn" => "urn:li:activity:7240702920025944064" "followers" => null "date" => "2mo" "description" => """ Today in a late-breaking presentation at ESMO - European Society for Medical Oncology 2024, we unveil new Phase 2 data in cancer cachexia, a life-threatening wasting condition with no FDA-approved treatments. Learn more about our #cachexia research: https://lnkd.in/eNS2kcB3\n \n #Cachexia #ESMO24 """ "reactions_count" => 1228 "comments_count" => 28 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-18 21:21:12" "deleted" => 1 ] [ "id" => 848981821 "company_id" => 1258906 "urn" => "urn:li:activity:7240445341181890561" "followers" => null "date" => "2mo" "description" => """ We’re pleased to partner with the International Myeloma Foundation to raise awareness of the impact of #MultipleMyeloma.\n \n Our long-standing relationships with the community are imperative in understanding and supporting the unique needs of patients as we work to deliver breakthroughs in #BloodCancer and #kNOwMyeloma. """ "reactions_count" => 878 "comments_count" => 13 "reshared_post_author" => "International Myeloma Foundation" "reshared_post_author_url" => "https://www.linkedin.com/company/international-myeloma-foundation" "reshared_post_author_headline" => null "reshared_post_description" => "Did you know that September is Blood Cancer Awareness Month? Myeloma, a cancer of plasma cells in your bone marrow, is the 2nd most common blood cancer in the world. How well do you #kNOwMyeloma? Thank you,Pfizer, for helping raise myeloma awareness." "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2025-01-18 21:21:12" "deleted" => 1 ] [ "id" => 895558115 "company_id" => 1258906 "urn" => "urn:li:activity:7272666984452952064" "followers" => null "date" => "1mo" "description" => "Pfizer has been named an honoree in the Enduring Impact: 15+ Years in Business category of Fast Company's 2024 Brands That Matter Awards. This recognition highlights our brand's ability to effectively and authentically connect with our target consumers. https://lnkd.in/eNk9cBeH" "reactions_count" => 223 "comments_count" => 14 "reshared_post_author" => "Fast Company" "reshared_post_author_url" => "https://www.linkedin.com/company/fast-company" "reshared_post_author_headline" => null "reshared_post_description" => """ Fast Company’s 2024 Brands that Matter honorees have found ways to establish broader cultural relevance while authentically connecting with consumers.\n ⁠\n It’s never been easy—and maintaining that connection gets even harder when constant messaging makes audiences want to tune out. But the 129 Brands That Matter honorees have cut through the din to deliver their message.⁠\n ⁠\n This Brands That Matter list includes 66 benchmark brands and 63 honorees in eight categories. And new in 2024, Brands That Matter is also honoring its inaugural CMOs of the Year—10 marketing professionals whose work has helped cement their brands as cultural forces and demonstrates brands at their best. ⁠\n ⁠\n Read more about the Brands That Matter winners: https://bit.ly/3thGYfY\n \n #FCBrandAwards ⁠[Illustration: Patrik Mollwing]⁠ """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2025-02-15 05:09:12" "deleted" => 1 ] [ "id" => 895558116 "company_id" => 1258906 "urn" => "urn:li:activity:7269401068944429056" "followers" => null "date" => "1mo" "description" => """ Healthcare isn’t one-size-fits-all. That’s why we created PfizerForAll. \n \n In a recent article, Aamir Malik, our Chief U.S. Commercial Officer, explains how our new digital platform is a resource for people with #migraine, #COVID19, and #flu. He also shares the challenges faced by two women managing migraine and COVID-19 and the ways that PfizerForAll is showing up for people in times of need. Read here to learn how PfizerForAll can help you: """ "reactions_count" => 301 "comments_count" => 14 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 1 ] [ "id" => 895558117 "company_id" => 1258906 "urn" => "urn:li:activity:7265111349595181057" "followers" => null "date" => "1mo" "description" => """ On November 20th, we join in observing Trans Day of Remembrance, a day dedicated to honoring the memory of transgender individuals whose lives were tragically lost due to anti-transgender violence. This day serves as a poignant reminder of the ongoing challenges faced by the transgender community and underscores the importance of our collective efforts to foster a safe and inclusive environment for all.\n \n To mark this day and Transgender Awareness Week, members of OPEN (Out Pfizer Employee Network) gathered to write letters of support to those in the transgender community. Their heartfelt messages aim to provide encouragement and solidarity to individuals who often face significant challenges. """ "reactions_count" => 368 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 1 ] [ "id" => 895558118 "company_id" => 1258906 "urn" => "urn:li:activity:7265083939134791681" "followers" => null "date" => "1mo" "description" => "Congratulations to the team at Ultromics on receiving FDA Clearance for EchoGo Amyloidosis – their innovative AI tech to help improve earlier detection of both light chain and transthyretin cardiac amyloidosis from a single 4 chamber echo scan. Great to see innovation in action for this serious and underdiagnosed cause of heart failure." "reactions_count" => 533 "comments_count" => 16 "reshared_post_author" => "Ultromics" "reshared_post_author_url" => "https://uk.linkedin.com/company/ultromics" "reshared_post_author_headline" => null "reshared_post_description" => """ We are excited to announce that EchoGo® Amyloidosis has received Breakthrough Device FDA clearance! Developed in collaboration with Johnson & Johnson Innovative Medicine and with support from Pfizer, EchoGo® Amyloidosis is the first FDA-cleared AI screening tool designed to help detect amyloidosis from an echocardiogram.\n \n The clearance was achieved as part of Ultromics' participation in the pilot of the FDA’s Total Product Lifecycle Advisory Program (TAP) and is the first device enrolled in TAP to receive FDA marketing authorization. \n \n EchoGo® Amyloidosis is part of Ultromics’ EchoGo® platform, complementing our reimbursable EchoGo® Heart Failure device to provide a robust solution for diagnosing heart failure and its underlying causes.\n \n Cardiac Amyloidosis is a rare and underdiagnosed cause of heart failure, with up to two-thirds of cases missed. The consequences are severe, but this breakthrough technology can facilitate detection:\n \n “𝗥𝗲𝗾𝘂𝗶𝗿𝗶𝗻𝗴 𝗼𝗻𝗹𝘆 𝗮 𝘀𝗶𝗻𝗴𝗹𝗲 𝗮𝗽𝗶𝗰𝗮𝗹 𝟰 𝗰𝗵𝗮𝗺𝗯𝗲𝗿 𝗶𝗺𝗮𝗴𝗲, 𝗘𝗰𝗵𝗼𝗚𝗼® 𝗔𝗺𝘆𝗹𝗼𝗶𝗱𝗼𝘀𝗶𝘀 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝘀 𝗖𝗮𝗿𝗱𝗶𝗮𝗰 𝗔𝗺𝘆𝗹𝗼𝗶𝗱𝗼𝘀𝗶𝘀, 𝗮𝗻𝗱 𝘄𝗶𝗹𝗹 𝗵𝗲𝗹𝗽 𝗱𝗿𝗶𝘃𝗲 𝗲𝗮𝗿𝗹𝗶𝗲𝗿 𝗮𝗰𝗰𝗲𝘀𝘀 𝘁𝗼 𝗮𝗽𝗽𝗿𝗼𝗽𝗿𝗶𝗮𝘁𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗮𝗻𝗱 𝗰𝗮𝗿𝗲 𝗳𝗼𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝘄𝗶𝘁𝗵 𝘁𝗵𝗶𝘀 𝘂𝗻𝗱𝗲𝗿𝗱𝗶𝗮𝗴𝗻𝗼𝘀𝗲𝗱 𝗱𝗶𝘀𝗲𝗮𝘀𝗲."\n \n - 𝗥𝗼𝘀𝘀 𝗨𝗽𝘁𝗼𝗻, 𝗣𝗵𝗗, 𝗙𝗼𝘂𝗻𝗱𝗲𝗿, 𝗖𝗘𝗢 𝗮𝗻𝗱 𝗖𝗵𝗶𝗲𝗳 𝗦𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗢𝗳𝗳𝗶𝗰𝗲𝗿, 𝗨𝗹𝘁𝗿𝗼𝗺𝗶𝗰𝘀, 𝗮𝗻𝗱 𝗔𝗜 𝗖𝗼-𝗖𝗵𝗮𝗶𝗿, 𝗛𝗲𝗮𝗿𝘁𝗦𝗵𝗮𝗿𝗲, 𝗙𝗡𝗜𝗛.\n \n Learn more: https://lnkd.in/eDFf-pA4\n \n #Ultromics #EchoGo #JNJ #Pfizer #MayoClinic #PrecisionDetection #CardiacAmyloidosis #Amyloidosis #AL #ATTR #EchoFirst #Echocardiography #Cardiovascular #Cardiology #AIinHealthcare #HealthTech #Innovation """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2025-02-15 05:09:12" "deleted" => 1 ] [ "id" => 895558119 "company_id" => 1258906 "urn" => "urn:li:activity:7264978138441379840" "followers" => null "date" => "1mo" "description" => """ Today I have the privilege of announcing that Dr. Chris Boshoff, MD, PhD, FMedSci has been appointed to lead our pipeline of potential new medicines and vaccines—work that is at the very heart of Pfizer's ability to change patients' lives. Effective January 1, 2025, Chris will become Pfizer’s new Chief Scientific Officer and President, Research & Development, overseeing all functions of Pfizer’s R&D across all therapeutic areas.\n \n In his current role as our Chief Oncology Officer, Chris has shaped Pfizer Oncology into one of our most productive divisions. In his 11 years at Pfizer, he has delivered an impressive 24 approved innovative medicines and biosimilars in more than 30 indications, and I am confident that he will accomplish great things across our entire portfolio. He is an extraordinary scientist and leader with a passion for helping patients. Throughout our comprehensive selection process, Chris stood out as a proven leader with a compelling vision for the future of Pfizer R&D. \n \n Chris will succeed Dr. Mikael Dolsten, who is retiring at the end of the year. I want to thank Mikael for his dedication and all that he has contributed during his long tenure at Pfizer. \n \n I’m also thrilled to announce Dr. Roger Dansey will serve as Interim Chief Oncology Officer and to welcome Dr. Johanna Bendell to Pfizer as our new Chief Development Officer, Oncology. Roger will work with Chris in selecting a permanent candidate for the role. \n \n I look forward to working with these talented leaders and their teams to continue advancing scientific breakthroughs that help patients everywhere. \n \n https://lnkd.in/eXT2ekYa """ "reactions_count" => 2286 "comments_count" => 99 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 1 ] [ "id" => 895558120 "company_id" => 1258906 "urn" => "urn:li:activity:7256702117749362688" "followers" => null "date" => "2mo" "description" => "Is the Medicine in Your Medicine Cabinet Safe? Unfortunately, there is a troubling lack of knowledge about counterfeits among U.S. healthcare providers. Therein lies opportunity in empowering health care providers and patients" "reactions_count" => 375 "comments_count" => 23 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 1 ] [ "id" => 895558121 "company_id" => 1258906 "urn" => "urn:li:activity:7244338172892000257" "followers" => null "date" => "3mo" "description" => """ Understanding proteins helps unlock new insights, develop innovative treatments, and drive scientific progress. To introduce our new #explainer series, which breaks down some of the scientific concepts central to our work at Pfizer, we’re exploring what proteins are and how they play a vital role in countless daily processes within our bodies.\n \n #Proteins #Innovation """ "reactions_count" => 699 "comments_count" => 13 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 1 ] [ "id" => 895558122 "company_id" => 1258906 "urn" => "urn:li:activity:7242531570228559872" "followers" => null "date" => "4mo" "description" => "Pfizer has been recognized in the top 25% of Forbes' inaugural list of America's Best Employers for Tech Workers, where we are one of just four companies spotlighted in the Drug and Biotechnology category. Pfizer’s inclusion on this prestigious list is a testament to our dynamic and supportive culture, where every colleague has the opportunity to grow, excel, and make a meaningful impact. https://lnkd.in/gjmBJCbd" "reactions_count" => 809 "comments_count" => 22 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 1 ] [ "id" => 895558123 "company_id" => 1258906 "urn" => "urn:li:activity:7241521440259289088" "followers" => null "date" => "4mo" "description" => """ We’re supporting The Leukemia & Lymphoma Society as they work to define #BloodCancer and redefine what’s possible after diagnosis.\n \n Together, in partnership with the blood cancer community, we remain dedicated to making meaningful change to create a world where people with blood cancer live longer and better lives. """ "reactions_count" => 401 "comments_count" => 6 "reshared_post_author" => "The Leukemia & Lymphoma Society" "reshared_post_author_url" => "https://www.linkedin.com/company/llsusa" "reshared_post_author_headline" => null "reshared_post_description" => """ Every 180 seconds, someone in the U.S. hears the words “You have blood cancer.” ❤️ With 100+ types of blood cancer affecting millions of lives, we need to bring more awareness to this disease.\n \n #BloodCancerAwarenessMonth is our chance to define blood cancer and redefine what’s possible after diagnosis thanks to the progress we’ve made in funding innovative research, offering free education, support, and driving healthcare advocacy. Blood is life. Support is too. 🔥 Give today and your donation will be doubled 👉 https://bit.ly/3TwybAO """ "reshared_post_followers" => null "reshared_post_date" => "4mo" "last_updated" => "2025-02-15 05:09:12" "deleted" => 1 ] [ "id" => 895558124 "company_id" => 1258906 "urn" => "urn:li:activity:7240702920025944064" "followers" => null "date" => "4mo" "description" => """ Today in a late-breaking presentation at ESMO - European Society for Medical Oncology 2024, we unveil new Phase 2 data in cancer cachexia, a life-threatening wasting condition with no FDA-approved treatments. Learn more about our #cachexia research: https://lnkd.in/eNS2kcB3\n \n #Cachexia #ESMO24 """ "reactions_count" => 1230 "comments_count" => 28 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 1 ] [ "id" => 937983027 "company_id" => 1258906 "urn" => "urn:li:activity:7295124392294973441" "followers" => null "date" => "1d" "description" => """ Introducing Health Answers by Pfizer (healthanswers.pfizer.com), a new consumer digital experience powered by generative AI that provides up to date, relevant answers to any health & wellness question. It summarizes information from trusted and credible organizations that have high standards for maintaining a science-based approach and editorial independence.\n \n Health Answers by Pfizer is designed to be easy to use. Just ask a health or wellness question and get a clear answer. You can ask follow-up questions or choose from suggested ones, and it will retain the context of your prior question. If you want to dive deeper on a particular topic, you can scroll down for relevant articles, videos, and things you can try at home. You can also easily connect with an expert when needed.\n \n Importantly, Health Answers by Pfizer is objective and unbiased and does not promote Pfizer’s medicines or position on any health topic.\n We are passionate about helping people live healthier lives. And now with Health Answers by Pfizer, we’re taking it one step further.\n \n Visit HealthAnswers.Pfizer.com (available in the U.S. only) or click on the link from PfizerForAll. """ "reactions_count" => 373 "comments_count" => 9 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 937983028 "company_id" => 1258906 "urn" => "urn:li:activity:7294504108172951552" "followers" => null "date" => "3d" "description" => """ We’re working to deliver eight cancer breakthroughs by 2030. And while we pursue the science that will shape tomorrow, we're also supporting millions of Americans on their health journey today, through PfizerForAll. We’re proud to bring this mission to the Big Game tonight. 💙 \n \n Visit PfizerForAll.com to take the first step and learn how to better understand your cancer risks. """ "reactions_count" => 2883 "comments_count" => 91 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 937983029 "company_id" => 1258906 "urn" => "urn:li:activity:7293272651651796994" "followers" => null "date" => "1w" "description" => """ “What sets us apart from traditional private, private practices is we see patients regardless of their ability to pay. We do have a sliding fee scale. It's based on a patient's income as well as their family size. We look for ways outside of the exam room that we can address health and help remove barriers for our patients to get to good health outcomes.”\n \n Navigating health challenges in rural communities can be hard. Our partner Delta Health Center is pushing for better health outcomes in the Mississippi Delta by building trusted relationships with patients.\n \n Learn more in this video created in partnership with Direct Relief: https://lnkd.in/eNdDvH7Y """ "reactions_count" => 208 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 937983030 "company_id" => 1258906 "urn" => "urn:li:activity:7290787494948683779" "followers" => null "date" => "1w" "description" => """ We are honored to be named the American Cancer Society’s 2024 Corporate Partner of the Year.\n \n This award recognizes Pfizer’s longstanding commitment to addressing unmet needs and tackling inequities in #cancer, including through our support of the American Cancer Society #ChangeTheOdds initiative, which aims to improve access and awareness of cancer screening, clinical trial opportunities and patient support and navigation in underserved communities across the U.S.\n \n Pfizer’s vision is a world where people with cancer live better and longer lives, and we’re proud to partner with organizations like the American Cancer Society on impactful initiatives that make a meaningful difference for patients.\n \n https://lnkd.in/eujnYbN4 """ "reactions_count" => 783 "comments_count" => 26 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 937983031 "company_id" => 1258906 "urn" => "urn:li:activity:7290298137099870210" "followers" => null "date" => "2w" "description" => """ Die Pfizer #Manufacturing im Klassenzimmer 📚 \n \n Vor kurzem hatten drei unserer Kolleginnen aus #Orth das Vergnügen, Schülerinnen des BG BRG Groß-Enzersdorf kennenzulernen und ihnen einen Einblick in unsere Arbeitswelt zu geben. 🧪\n \n Es ist uns immer wieder eine Freude, die Arbeitsbereiche einer #Impfstoffproduktion und #Qualitätskontrolle 🔬 vorzustellen und so\n \n … Zukunftsperspektiven aufzuzeigen 🚀\n … und die #Berufsorientierung junger Menschen zu fördern. 👩🔬👨🔬\n \n Bei so engagierten und interessierten Schülerinnen kommen wir auch jederzeit gerne wieder! \n \n #VorOrtInOrth #MeetingYoungTalents """ "reactions_count" => 243 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 937983032 "company_id" => 1258906 "urn" => "urn:li:activity:7290296089834913792" "followers" => null "date" => "2w" "description" => """ 👩🏻 🪞 La piel de las pacientes de #cáncerdemama se puede ver afectada durante el tratamiento oncológico. Hoy en ‘Charlas más allá del espejo’ conocemos las recomendaciones dermatológicas de la dra. Elena Galve, oncóloga médica en el Hospital Universitario Basurto (Bilbao).\n \n 🎥 ‘Charlas más allá del espejo’ es una serie de vídeos conducidos por la periodista Emma García en los que abordamos temas relacionados con el cuidado integral de las pacientes de cáncer de mama y cáncer de mama metastásico.\n \n Encuentra más recursos en nuestra web contigoenelcancerdemamametastasico\n \n #Oncología #PfizerEspaña #Cáncer #pacientes """ "reactions_count" => 179 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 937983033 "company_id" => 1258906 "urn" => "urn:li:activity:7290089475332816897" "followers" => null "date" => "2w" "description" => """ Na Pfizer, temos o compromisso de fazer a diferença nas comunidades onde estamos inseridos. Através de parcerias com ONGs e projetos sociais, nos esforçamos para apoiar populações em situação de vulnerabilidade e melhorar o acesso à saúde para todos. \n \n Saiba mais em: https://lnkd.in/eXgC32uq \n \n #ResponsabilidadeSocial #PfizerBrasil #PorUmMundoMelhor \n #PraTodosVerem: este conteúdo possui recurso de texto alternativo. """ "reactions_count" => 109 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 937983034 "company_id" => 1258906 "urn" => "urn:li:activity:7272666984452952064" "followers" => null "date" => "2mo" "description" => "Pfizer has been named an honoree in the Enduring Impact: 15+ Years in Business category of Fast Company's 2024 Brands That Matter Awards. This recognition highlights our brand's ability to effectively and authentically connect with our target consumers. https://lnkd.in/eNk9cBeH" "reactions_count" => 241 "comments_count" => 15 "reshared_post_author" => "Fast Company" "reshared_post_author_url" => "https://www.linkedin.com/company/fast-company" "reshared_post_author_headline" => null "reshared_post_description" => """ Fast Company’s 2024 Brands that Matter honorees have found ways to establish broader cultural relevance while authentically connecting with consumers.\n ⁠\n It’s never been easy—and maintaining that connection gets even harder when constant messaging makes audiences want to tune out. But the 129 Brands That Matter honorees have cut through the din to deliver their message.⁠\n ⁠\n This Brands That Matter list includes 66 benchmark brands and 63 honorees in eight categories. And new in 2024, Brands That Matter is also honoring its inaugural CMOs of the Year—10 marketing professionals whose work has helped cement their brands as cultural forces and demonstrates brands at their best. ⁠\n ⁠\n Read more about the Brands That Matter winners: https://bit.ly/3thGYfY\n \n #FCBrandAwards ⁠[Illustration: Patrik Mollwing]⁠ """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 937983035 "company_id" => 1258906 "urn" => "urn:li:activity:7269401068944429056" "followers" => null "date" => "2mo" "description" => """ Healthcare isn’t one-size-fits-all. That’s why we created PfizerForAll. \n \n In a recent article, Aamir Malik, our Chief U.S. Commercial Officer, explains how our new digital platform is a resource for people with #migraine, #COVID19, and #flu. He also shares the challenges faced by two women managing migraine and COVID-19 and the ways that PfizerForAll is showing up for people in times of need. Read here to learn how PfizerForAll can help you: """ "reactions_count" => 313 "comments_count" => 17 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] [ "id" => 937983036 "company_id" => 1258906 "urn" => "urn:li:activity:7265111349595181057" "followers" => null "date" => "2mo" "description" => """ On November 20th, we join in observing Trans Day of Remembrance, a day dedicated to honoring the memory of transgender individuals whose lives were tragically lost due to anti-transgender violence. This day serves as a poignant reminder of the ongoing challenges faced by the transgender community and underscores the importance of our collective efforts to foster a safe and inclusive environment for all.\n \n To mark this day and Transgender Awareness Week, members of OPEN (Out Pfizer Employee Network) gathered to write letters of support to those in the transgender community. Their heartfelt messages aim to provide encouragement and solidarity to individuals who often face significant challenges. """ "reactions_count" => 378 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-15 05:09:12" "deleted" => 0 ] ] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4662 …} -companyTags: Doctrine\ORM\PersistentCollection {#4664 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4666 …} -users: Doctrine\ORM\PersistentCollection {#4668 …} -logoImageName: "20250226145702-03-pfizer-logo-67bf1dae346cf093699165.png" -coverImageName: "20250227162455-5968374-67c083c743059162748640.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4670 …} -tagline: "Über 160 Jahre Innovation in der Arzneimittelforschung für eine gesündere Welt" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4672 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4674 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4676 …} -industry: "Pfizer" -size: "102615" -address1: null -address2: null -city: null -postalCode: null -state: null -country: "United States" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4678 …} #createdAt: DateTime @1740049033 {#4639 date: 2025-02-20 10:57:13.0 UTC (+00:00) } #updatedAt: DateTime @1750925443 {#4638 date: 2025-06-26 08:10:43.0 UTC (+00:00) } } App\Entity\Company {#4682 -id: 20 -name: "CSL Behring" -website: "https://cslbehring.ch" -description: """ Driven by Our Promise\n \n Alles begann mit einem Versprechen. Vor über 100 Jahren wurde CSL gegründet, um mit modernen Technologien Leben zu retten. In den 100 Jahren seither wuchs CSL Behring zu einem führenden Unternehmen im Biotechnologiebereich und hält sich weiterhin an das Versprechen, Leben zu retten und zu verbessern. Wir bieten die breiteste Palette an aus Plasma gewonnenen und rekombinanten Therapien in unserer Branche. Unsere Möglichkeiten für Innovationen und die weltweite Bereitstellung lebensrettender Medikamente für Patienten mit ungedeckten medizinischen Bedürfnissen verhalfen uns zum Ruf eines Unternehmens, bei dem der Patient immer an erster Stelle steht. Wir sind CSL Behring und wir sind unserem Versprechen verpflichtet.\n \n Weitere Informationen finden Sie in unserem Fachpublikumsbereich oder unserer LinkedIn Gruppe.\n \n Wir freuen uns auf Ihren Besuch! """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4683 …} -companyTags: Doctrine\ORM\PersistentCollection {#4685 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4687 …} -users: Doctrine\ORM\PersistentCollection {#4689 …} -logoImageName: "20250226144044-csl-behring-logo-67bf19dcce2b7523039147.png" -coverImageName: "20250227162356-csl-ax-4bd79cf1-67c0838c18c45278576294.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4691 …} -tagline: "Über 100 Jahre Innovation für lebensrettende Therapien und die Verbesserung der Patientenversorgung" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4693 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4695 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4697 …} -industry: "" -size: "" -address1: "Wankdorfstrasse 10" -address2: "" -city: "Bern" -postalCode: "3014" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4699 …} #createdAt: DateTime @1740049575 {#4660 date: 2025-02-20 11:06:15.0 UTC (+00:00) } #updatedAt: DateTime @1750924723 {#4659 date: 2025-06-26 07:58:43.0 UTC (+00:00) } } App\Entity\Company {#4703 -id: 21 -name: "Daiichi Sankyo (Switzerland)" -website: "https://daiichi-sankyo.ch" -description: """ Herzlich willkommen am virtuellen Stand der Daiichi Sankyo (Schweiz) AG\n \n Wir engagieren uns seit vielen Jahren im Bereich der kardiovaskulären Gesundheit.\n \n Nebst lang etablierten Produkten wie Lixiana für Ihren alternden Patienten mit nicht valvulärem Vorhofflimmern sind seit dem 1. April 2022 Nilemdo und Nustendi als ADD-On zur Lipidbehandlung auf die SL aufgenommen worden.+\n \n Wir freuen uns über Ihren Besuch.\n \n Sie erreichen uns für alle Anliegen unter info@daiichi-sankyo.ch oder via 043 433 33 00. """ -externalId: "6832192" -details: [ "id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo-schweiz-ag" "hash" => "302133fa01828678b363e0e980b09bb8" "name" => "Daiichi Sankyo (Switzerland)" "website" => "http://www.daiichi-sankyo.ch" "size" => "11-50 employees" "industry" => "Pharmaceutical Manufacturing" "description" => """ Daiichi Sankyo is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. \n \n While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia and bacterial infections, Daiichi Sankyo is also engaged in the development of treatments for thrombotic disorders and focuses on the discovery of novel oncology and cardiovascular-metabolic therapies. \n \n The company's roots extend back to 1899 and the early days of industrialisation of the pharmaceutical sector. The company was created in 2005 through the merger of two traditional Japanese enterprises, Daiichi and Sankyo. Daiichi Sankyo's world headquarters are in Tokyo, Japan, and its European base is located in Munich, Germany. \n \n The company does business in nearly 60 countries around the world, including 12 European countries. Daiichi Sankyo has been one of the strongest Japanese pharmaceutical companies located in Europe since it set up its European production facilities and marketing offices in 1990. """ "followers" => null "founded" => null "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://media.licdn.com/dms/image/v2/C4D0BAQHfgf63MN_dvA/company-logo_200_200/company-logo_200_200/0/1630569448952/daiichi_sankyo_schweiz_ag_logo?e=2147483647&v=beta&t=ykU-HV1mqeE2zMB5y-auoAQMteV2TvemR73pgijsRJY" "created" => "2016-06-24 13:15:15" "last_updated" => "2025-02-02 16:08:13" "last_response_code" => 200 "type" => "Public Company" "headquarters_new_address" => "Zürich" "employees_count" => null "headquarters_country_restored" => "Switzerland" "headquarters_country_parsed" => "Switzerland" "company_shorthand_name" => "daiichi-sankyo-schweiz-ag" "company_shorthand_name_hash" => "581fd1c83848af755925c6c1ecbc0fac" "canonical_url" => "https://ch.linkedin.com/company/daiichi-sankyo-schweiz-ag" "canonical_hash" => "860f316bf946b0b731fea315630d8469" "canonical_shorthand_name" => "daiichi-sankyo-schweiz-ag" "canonical_shorthand_name_hash" => "581fd1c83848af755925c6c1ecbc0fac" "deleted" => 0 "last_updated_ux" => 1738512493 "source_id" => 5391673 "company_affiliated_collection" => [] "company_also_viewed_collection" => [ [ "id" => 26413403 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/scire-brigitte-gansen" "viewed_company_id" => null "created" => "2016-06-24 13:15:15" "last_updated" => "2017-08-06 12:39:44" "deleted" => 1 ] [ "id" => 26413404 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/cemio-switzerland-ag" "viewed_company_id" => null "created" => "2016-06-24 13:15:15" "last_updated" => "2017-01-26 10:55:32" "deleted" => 1 ] [ "id" => 26413405 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/ig-instrumenten-gesellschaft-ag" "viewed_company_id" => null "created" => "2016-06-24 13:15:15" "last_updated" => "2016-12-12 10:00:25" "deleted" => 1 ] [ "id" => 26413406 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/effrx-pharmaceuticals-sa" "viewed_company_id" => null "created" => "2016-06-24 13:15:15" "last_updated" => "2017-08-06 12:39:44" "deleted" => 1 ] [ "id" => 26413407 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/pharminsight" "viewed_company_id" => null "created" => "2016-06-24 13:15:15" "last_updated" => "2016-12-12 10:00:25" "deleted" => 1 ] [ "id" => 26413408 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/metriopharm" "viewed_company_id" => null "created" => "2016-06-24 13:15:15" "last_updated" => "2016-12-12 10:00:25" "deleted" => 1 ] [ "id" => 46890621 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/auron-healthcare-ag" "viewed_company_id" => null "created" => "2016-12-12 10:00:24" "last_updated" => "2017-08-06 12:39:44" "deleted" => 1 ] [ "id" => 46890622 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/azad-armenia" "viewed_company_id" => null "created" => "2016-12-12 10:00:24" "last_updated" => "2017-08-06 12:39:44" "deleted" => 1 ] [ "id" => 46890623 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/daiichi-sankyo-europe-gmbh" "viewed_company_id" => null "created" => "2016-12-12 10:00:24" "last_updated" => "2017-01-26 10:55:32" "deleted" => 1 ] [ "id" => 75771066 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/daiichi-sankyo-deutschland-gmbh" "viewed_company_id" => null "created" => "2017-01-26 10:55:31" "last_updated" => "2019-02-23 01:06:01" "deleted" => 1 ] [ "id" => 75771067 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/daiichi-sankyo" "viewed_company_id" => null "created" => "2017-01-26 10:55:31" "last_updated" => "2019-08-01 20:47:47" "deleted" => 1 ] [ "id" => 97926360 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/daiichi-sankyo-europe-gmbh" "viewed_company_id" => null "created" => "2017-08-06 12:39:43" "last_updated" => "2018-03-11 21:47:53" "deleted" => 1 ] [ "id" => 97926361 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/daiichi-sankyo-co-ltd-" "viewed_company_id" => null "created" => "2017-08-06 12:39:43" "last_updated" => "2018-03-11 21:47:53" "deleted" => 1 ] [ "id" => 97926362 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/medicom-pharma-ag" "viewed_company_id" => null "created" => "2017-08-06 12:39:43" "last_updated" => "2017-10-26 10:05:34" "deleted" => 1 ] [ "id" => 97926363 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/polyneuron-pharmaceuticals" "viewed_company_id" => null "created" => "2017-08-06 12:39:43" "last_updated" => "2017-10-26 10:05:34" "deleted" => 1 ] [ "id" => 114052219 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/bluenovius-b-v-" "viewed_company_id" => null "created" => "2017-10-26 10:05:33" "last_updated" => "2018-03-11 21:47:53" "deleted" => 1 ] [ "id" => 114052220 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/create-uk" "viewed_company_id" => null "created" => "2017-10-26 10:05:33" "last_updated" => "2018-03-11 21:47:53" "deleted" => 1 ] [ "id" => 127446159 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/daiichi-sankyo-brasil-ltda" "viewed_company_id" => null "created" => "2018-03-11 21:47:52" "last_updated" => "2018-08-07 18:12:37" "deleted" => 1 ] [ "id" => 127446160 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/daiichi-sankyo-austria-gmbh" "viewed_company_id" => null "created" => "2018-03-11 21:47:52" "last_updated" => "2018-12-09 03:35:07" "deleted" => 1 ] [ "id" => 127446161 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/sanofigenzyme" "viewed_company_id" => null "created" => "2018-03-11 21:47:52" "last_updated" => "2018-08-07 18:12:37" "deleted" => 1 ] [ "id" => 127446162 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/kyona" "viewed_company_id" => null "created" => "2018-03-11 21:47:52" "last_updated" => "2018-08-07 18:12:37" "deleted" => 1 ] [ "id" => 152377475 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/daiichi-sankyo-europe-gmbh" "viewed_company_id" => null "created" => "2018-08-07 18:12:37" "last_updated" => "2019-08-01 20:47:47" "deleted" => 1 ] [ "id" => 152377476 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/baxter-deutschland-gmbh" "viewed_company_id" => null "created" => "2018-08-07 18:12:37" "last_updated" => "2018-12-09 03:35:07" "deleted" => 1 ] [ "id" => 152377477 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/novartis" "viewed_company_id" => null "created" => "2018-08-07 18:12:37" "last_updated" => "2019-02-23 01:06:01" "deleted" => 1 ] [ "id" => 175484348 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/pfizer" "viewed_company_id" => null "created" => "2018-12-09 03:35:06" "last_updated" => "2019-02-23 01:06:01" "deleted" => 1 ] [ "id" => 175484349 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/clovis-oncology" "viewed_company_id" => null "created" => "2018-12-09 03:35:06" "last_updated" => "2019-02-23 01:06:01" "deleted" => 1 ] [ "id" => 188947757 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/sabine-burg" "viewed_company_id" => null "created" => "2019-02-23 01:06:01" "last_updated" => "2019-08-01 20:47:47" "deleted" => 1 ] [ "id" => 188947758 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/oratek" "viewed_company_id" => null "created" => "2019-02-23 01:06:01" "last_updated" => "2019-05-28 02:03:31" "deleted" => 1 ] [ "id" => 188947759 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/swiss-professional-media-ag" "viewed_company_id" => null "created" => "2019-02-23 01:06:01" "last_updated" => "2019-05-28 02:03:31" "deleted" => 1 ] [ "id" => 188947760 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/louis-widmer-sa" "viewed_company_id" => null "created" => "2019-02-23 01:06:01" "last_updated" => "2019-03-17 20:59:32" "deleted" => 1 ] [ "id" => 196434244 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/abbott-" "viewed_company_id" => null "created" => "2019-03-17 20:59:31" "last_updated" => "2019-05-28 02:03:31" "deleted" => 1 ] [ "id" => 222382344 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/daiichi-sankyo-deutschland-gmbh" "viewed_company_id" => null "created" => "2019-05-28 02:03:31" "last_updated" => "2019-08-01 20:47:47" "deleted" => 1 ] [ "id" => 222382349 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/otpsuisseromande" "viewed_company_id" => null "created" => "2019-05-28 02:03:31" "last_updated" => "2019-08-01 20:47:47" "deleted" => 1 ] [ "id" => 222382352 "company_id" => 6832192 "viewed_company_url" => "https://www.linkedin.com/company/adep-assistance" "viewed_company_id" => null "created" => "2019-05-28 02:03:31" "last_updated" => "2019-08-01 20:47:47" "deleted" => 1 ] [ "id" => 255309498 "company_id" => 6832192 "viewed_company_url" => "https://es.linkedin.com/company/daiichi-sankyo" "viewed_company_id" => null "created" => "2019-08-01 20:47:47" "last_updated" => "2019-10-17 00:53:14" "deleted" => 1 ] [ "id" => 255309500 "company_id" => 6832192 "viewed_company_url" => "https://es.linkedin.com/company/daiichi-sankyo-europe-gmbh" "viewed_company_id" => null "created" => "2019-08-01 20:47:47" "last_updated" => "2019-10-17 00:53:14" "deleted" => 1 ] [ "id" => 255309501 "company_id" => 6832192 "viewed_company_url" => "https://es.linkedin.com/company/kjc-limited" "viewed_company_id" => null "created" => "2019-08-01 20:47:47" "last_updated" => "2019-10-17 00:53:14" "deleted" => 1 ] [ "id" => 255309502 "company_id" => 6832192 "viewed_company_url" => "https://es.linkedin.com/company/sabine-burg" "viewed_company_id" => null "created" => "2019-08-01 20:47:47" "last_updated" => "2019-10-17 00:53:14" "deleted" => 1 ] [ "id" => 255309503 "company_id" => 6832192 "viewed_company_url" => "https://es.linkedin.com/company/propelperform" "viewed_company_id" => null "created" => "2019-08-01 20:47:47" "last_updated" => "2019-10-17 00:53:14" "deleted" => 1 ] [ "id" => 255309504 "company_id" => 6832192 "viewed_company_url" => "https://es.linkedin.com/company/sellxpert-ag" "viewed_company_id" => null "created" => "2019-08-01 20:47:47" "last_updated" => "2019-10-17 00:53:14" "deleted" => 1 ] ] "company_crunchbase_info_collection" => [] "company_featured_employees_collection" => [ [ "id" => 7198687 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/sven-krause-673936a" "created" => "2019-10-17 00:53:14" "last_updated" => "2020-01-19 14:55:49" "deleted" => 1 ] [ "id" => 7198689 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/lucasschalch" "created" => "2019-10-17 00:53:14" "last_updated" => "2020-01-19 14:55:49" "deleted" => 1 ] [ "id" => 7198691 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/myriam-vincent-18679012" "created" => "2019-10-17 00:53:14" "last_updated" => "2020-07-26 18:58:37" "deleted" => 1 ] [ "id" => 7198693 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/tomoko-yoshimura-b7071038" "created" => "2019-10-17 00:53:14" "last_updated" => "2019-12-17 16:28:11" "deleted" => 1 ] [ "id" => 29181406 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/urs-ruetz" "created" => "2019-12-17 16:28:11" "last_updated" => "2020-01-19 14:55:49" "deleted" => 1 ] [ "id" => 32524180 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/maria-rohner-50808850" "created" => "2020-01-19 14:55:49" "last_updated" => "2020-07-26 18:58:37" "deleted" => 1 ] [ "id" => 32524181 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/ralph-ulrich-z%C3%BCrcher-0a218851" "created" => "2020-01-19 14:55:49" "last_updated" => "2020-07-26 18:58:37" "deleted" => 1 ] [ "id" => 32524182 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/vanessa-heller-12a0a853" "created" => "2020-01-19 14:55:49" "last_updated" => "2020-07-26 18:58:37" "deleted" => 1 ] [ "id" => 50994629 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/maria-rohner-50808850" "created" => "2020-08-17 23:35:24" "last_updated" => "2022-07-25 16:55:44" "deleted" => 1 ] [ "id" => 50994630 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/vanessa-heller-12a0a853" "created" => "2020-08-17 23:35:24" "last_updated" => "2022-05-16 02:58:55" "deleted" => 1 ] [ "id" => 50994631 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/vincent-tchang-phd-17a41958" "created" => "2020-08-17 23:35:24" "last_updated" => "2020-12-22 12:26:29" "deleted" => 1 ] [ "id" => 50994632 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/selim-kenber-3a5a1b8b" "created" => "2020-08-17 23:35:24" "last_updated" => "2020-11-01 01:54:42" "deleted" => 1 ] [ "id" => 55430642 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/mazin-soubt" "created" => "2020-11-01 01:54:42" "last_updated" => "2022-07-25 16:55:44" "deleted" => 1 ] [ "id" => 58248014 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/arnaud-sestier-97932228" "created" => "2020-12-22 12:26:29" "last_updated" => "2022-02-08 20:29:48" "deleted" => 1 ] [ "id" => 85403279 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/sgisler" "created" => "2022-02-08 20:29:48" "last_updated" => "2022-07-25 16:55:44" "deleted" => 1 ] [ "id" => 90931008 "company_id" => 6832192 "url" => "https://www.linkedin.com/in/nicole-wenisch-073a7529" "created" => "2022-05-16 02:58:55" "last_updated" => "2022-07-25 16:55:44" "deleted" => 1 ] [ "id" => 117254593 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/mazin-soubt" "created" => "2022-07-25 16:55:44" "last_updated" => "2024-04-17 04:46:07" "deleted" => 1 ] [ "id" => 117254594 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/sgisler/en" "created" => "2022-07-25 16:55:44" "last_updated" => "2022-10-08 11:54:54" "deleted" => 1 ] [ "id" => 117254595 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/nicole-wenisch-073a7529/en" "created" => "2022-07-25 16:55:44" "last_updated" => "2023-06-11 07:08:20" "deleted" => 1 ] [ "id" => 117254596 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/maria-rohner-50808850/en" "created" => "2022-07-25 16:55:44" "last_updated" => "2023-06-11 07:08:20" "deleted" => 1 ] [ "id" => 144699032 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/vincent-tchang-phd-17a41958/en" "created" => "2022-10-08 11:54:54" "last_updated" => "2022-11-15 01:34:53" "deleted" => 1 ] [ "id" => 153660877 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/sgisler/en" "created" => "2022-11-15 01:34:53" "last_updated" => "2023-06-11 07:08:20" "deleted" => 1 ] [ "id" => 168914495 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/sgisler" "created" => "2023-06-11 07:08:20" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 168914496 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/nicole-wenisch-073a7529" "created" => "2023-06-11 07:08:20" "last_updated" => "2024-04-17 04:46:07" "deleted" => 1 ] [ "id" => 168914497 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/dominic-p-zahn-33367b2b" "created" => "2023-06-11 07:08:20" "last_updated" => "2023-09-17 23:08:07" "deleted" => 1 ] [ "id" => 189783473 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/erkanuenal" "created" => "2023-09-17 23:08:07" "last_updated" => "2023-11-21 02:36:00" "deleted" => 1 ] [ "id" => 195878802 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/berrinschwenk/en" "created" => "2023-11-21 02:36:00" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 205036979 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/erkanuenal" "created" => "2024-04-17 04:46:07" "last_updated" => "2024-11-26 12:23:53" "deleted" => 1 ] [ "id" => 205036980 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/dominic-p-zahn-33367b2b" "created" => "2024-04-17 04:46:07" "last_updated" => "2024-07-15 03:39:21" "deleted" => 1 ] [ "id" => 209180675 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/dr-jennifer-ridyard-phd-76776817" "created" => "2024-07-15 03:39:21" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 216305177 "company_id" => 6832192 "url" => "https://ch.linkedin.com/in/alexander-fuchs-compliance" "created" => "2024-11-26 12:23:53" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] ] "company_featured_investors_collection" => [] "company_funding_rounds_collection" => [] "company_locations_collection" => [ [ "id" => 2946516 "company_id" => 6832192 "location_address" => "Gewerbestrasse 16; Postfach 123; Thalwil, CH" "is_primary" => 1 "created" => "2019-10-17 00:53:14" "last_updated" => "2020-07-26 18:58:37" "deleted" => 1 ] [ "id" => 18990953 "company_id" => 6832192 "location_address" => """ \n Gewerbestrasse 16\n ; \n Postfach 123\n ; \n Thalwil, CH\n """ "is_primary" => 0 "created" => "2020-07-26 18:58:37" "last_updated" => "2020-08-17 23:35:24" "deleted" => 1 ] [ "id" => 22498643 "company_id" => 6832192 "location_address" => "Vulkanstrasse 106; Postfach; Zürich, CH" "is_primary" => 1 "created" => "2020-08-17 23:35:24" "last_updated" => "2023-09-17 23:08:07" "deleted" => 1 ] [ "id" => 136189229 "company_id" => 6832192 "location_address" => "Vulkanstrasse 106; Postfach; Zürich, 8010, CH" "is_primary" => 1 "created" => "2023-09-17 23:08:07" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] ] "company_similar_collection" => [ [ "id" => 11004884 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo-europe-gmbh" "created" => "2019-10-17 00:53:14" "last_updated" => "2020-11-11 18:07:52" "deleted" => 1 ] [ "id" => 11004885 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo" "created" => "2019-10-17 00:53:14" "last_updated" => "2021-07-24 10:17:14" "deleted" => 1 ] [ "id" => 11004886 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo-deutschland-gmbh" "created" => "2019-10-17 00:53:14" "last_updated" => "2020-01-19 14:55:49" "deleted" => 1 ] [ "id" => 11004887 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/innomedica-holding-ag" "created" => "2019-10-17 00:53:14" "last_updated" => "2019-12-17 16:28:11" "deleted" => 1 ] [ "id" => 11004889 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/sichh---swiss-integrative-center-for-human-health" "created" => "2019-10-17 00:53:14" "last_updated" => "2019-11-21 07:01:10" "deleted" => 1 ] [ "id" => 11004891 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/sakk-schweizerische-arbeitsgemeinschaft-f%C3%BCr-klinische-krebsforschung" "created" => "2019-10-17 00:53:14" "last_updated" => "2019-11-21 07:01:10" "deleted" => 1 ] [ "id" => 48604224 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/anteris-medical-gmbh" "created" => "2019-11-21 07:01:10" "last_updated" => "2020-02-12 07:58:50" "deleted" => 1 ] [ "id" => 48604225 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/divaris-real-estate" "created" => "2019-11-21 07:01:10" "last_updated" => "2020-02-12 07:58:50" "deleted" => 1 ] [ "id" => 58076828 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/luzerner-kantonsspital" "created" => "2019-12-17 16:28:11" "last_updated" => "2020-02-12 07:58:50" "deleted" => 1 ] [ "id" => 70441593 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/sakk-schweizerische-arbeitsgemeinschaft-f%C3%BCr-klinische-krebsforschung" "created" => "2020-01-19 14:55:49" "last_updated" => "2020-05-22 20:04:22" "deleted" => 1 ] [ "id" => 70441594 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/hospitec-ag" "created" => "2020-01-19 14:55:49" "last_updated" => "2020-04-27 15:19:32" "deleted" => 1 ] [ "id" => 70441595 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/le-mirador-resort-&-spa" "created" => "2020-01-19 14:55:49" "last_updated" => "2020-03-21 15:05:36" "deleted" => 1 ] [ "id" => 70441596 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/von-rundstedt-switzerland" "created" => "2020-01-19 14:55:49" "last_updated" => "2020-02-12 07:58:50" "deleted" => 1 ] [ "id" => 70441597 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo-brasil-ltda" "created" => "2020-01-19 14:55:49" "last_updated" => "2020-02-12 07:58:50" "deleted" => 1 ] [ "id" => 88794340 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/spiez-laboratory" "created" => "2020-02-12 07:58:50" "last_updated" => "2020-05-22 20:04:22" "deleted" => 1 ] [ "id" => 88794341 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/vbg-verkehrsbetriebe-glattal-ag" "created" => "2020-02-12 07:58:50" "last_updated" => "2020-05-22 20:04:22" "deleted" => 1 ] [ "id" => 88794342 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/jobtalente-gmbh" "created" => "2020-02-12 07:58:50" "last_updated" => "2020-05-22 20:04:22" "deleted" => 1 ] [ "id" => 88794343 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/i-believe-in-you" "created" => "2020-02-12 07:58:50" "last_updated" => "2020-04-27 15:19:32" "deleted" => 1 ] [ "id" => 88794344 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/kuraray-europe-gmbh" "created" => "2020-02-12 07:58:50" "last_updated" => "2020-04-27 15:19:32" "deleted" => 1 ] [ "id" => 115114029 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/varanahventures" "created" => "2020-03-21 15:05:36" "last_updated" => "2020-05-22 20:04:22" "deleted" => 1 ] [ "id" => 139041171 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/zoll-medical-corporation" "created" => "2020-04-27 15:19:32" "last_updated" => "2020-05-22 20:04:22" "deleted" => 1 ] [ "id" => 139041172 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/cashgate-ag" "created" => "2020-04-27 15:19:32" "last_updated" => "2020-05-22 20:04:22" "deleted" => 1 ] [ "id" => 139041173 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/incyte" "created" => "2020-04-27 15:19:32" "last_updated" => "2020-05-22 20:04:22" "deleted" => 1 ] [ "id" => 155455018 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo-china-holdings-co.-ltd." "created" => "2020-05-22 20:04:22" "last_updated" => "2020-07-26 18:58:37" "deleted" => 1 ] [ "id" => 155455019 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/%e7%ac%ac%e4%b8%80%e4%b8%89%e5%85%b1%e3%82%a8%e3%82%b9%e3%83%95%e3%82%a1%e6%a0%aa%e5%bc%8f%e4%bc%9a%e7%a4%be" "created" => "2020-05-22 20:04:22" "last_updated" => "2020-07-26 18:58:37" "deleted" => 1 ] [ "id" => 155455020 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo-ireland-ltd" "created" => "2020-05-22 20:04:22" "last_updated" => "2020-07-26 18:58:37" "deleted" => 1 ] [ "id" => 155455021 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo-co-ltd" "created" => "2020-05-22 20:04:22" "last_updated" => "2020-07-26 18:58:37" "deleted" => 1 ] [ "id" => 155455022 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo-austria-gmbh" "created" => "2020-05-22 20:04:22" "last_updated" => "2020-07-26 18:58:37" "deleted" => 1 ] [ "id" => 155455023 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo-deutschland-gmbh" "created" => "2020-05-22 20:04:22" "last_updated" => "2020-07-26 18:58:37" "deleted" => 1 ] [ "id" => 155455026 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/granovit" "created" => "2020-05-22 20:04:22" "last_updated" => "2020-06-09 11:30:04" "deleted" => 1 ] [ "id" => 155455028 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo-ireland" "created" => "2020-05-22 20:04:22" "last_updated" => "2020-06-09 11:30:04" "deleted" => 1 ] [ "id" => 165938680 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/iqone" "created" => "2020-06-09 11:30:04" "last_updated" => "2020-08-17 23:35:24" "deleted" => 1 ] [ "id" => 165938681 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/pakka-ag" "created" => "2020-06-09 11:30:04" "last_updated" => "2020-07-26 18:58:37" "deleted" => 1 ] [ "id" => 191922821 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/novartis" "created" => "2020-07-26 18:58:37" "last_updated" => "2020-11-01 01:54:42" "deleted" => 1 ] [ "id" => 191922822 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/endago" "created" => "2020-07-26 18:58:37" "last_updated" => "2020-11-01 01:54:42" "deleted" => 1 ] [ "id" => 191922823 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/bedag" "created" => "2020-07-26 18:58:37" "last_updated" => "2020-09-15 16:47:33" "deleted" => 1 ] [ "id" => 191922824 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/shqa-swiss-health-quality-association" "created" => "2020-07-26 18:58:37" "last_updated" => "2020-09-15 16:47:33" "deleted" => 1 ] [ "id" => 191922825 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/carify-me" "created" => "2020-07-26 18:58:37" "last_updated" => "2020-09-15 16:47:33" "deleted" => 1 ] [ "id" => 191922826 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/biokemasa" "created" => "2020-07-26 18:58:37" "last_updated" => "2020-09-15 16:47:33" "deleted" => 1 ] [ "id" => 191922827 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2020-07-26 18:58:37" "last_updated" => "2020-08-17 23:35:24" "deleted" => 1 ] [ "id" => 208628871 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daichi" "created" => "2020-08-17 23:35:24" "last_updated" => "2020-12-22 12:26:29" "deleted" => 1 ] [ "id" => 208628872 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/groupe-e" "created" => "2020-08-17 23:35:24" "last_updated" => "2020-11-01 01:54:42" "deleted" => 1 ] [ "id" => 230193506 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/toppharm" "created" => "2020-09-15 16:47:33" "last_updated" => "2020-11-11 18:07:52" "deleted" => 1 ] [ "id" => 230193507 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/neusta-consulting" "created" => "2020-09-15 16:47:33" "last_updated" => "2020-11-11 18:07:52" "deleted" => 1 ] [ "id" => 230193508 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/enrival-ab" "created" => "2020-09-15 16:47:33" "last_updated" => "2020-11-11 18:07:52" "deleted" => 1 ] [ "id" => 230193509 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/swissmedic" "created" => "2020-09-15 16:47:33" "last_updated" => "2020-11-11 18:07:52" "deleted" => 1 ] [ "id" => 260290064 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo-deutschland-gmbh" "created" => "2020-11-01 01:54:42" "last_updated" => "2020-11-11 18:07:52" "deleted" => 1 ] [ "id" => 260290065 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/wavetech-ag" "created" => "2020-11-01 01:54:42" "last_updated" => "2020-11-11 18:07:52" "deleted" => 1 ] [ "id" => 260290066 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/cellebrite" "created" => "2020-11-01 01:54:42" "last_updated" => "2020-11-11 18:07:52" "deleted" => 1 ] [ "id" => 267140820 "company_id" => 6832192 "url" => "https://de.linkedin.com/company/daiichi-sankyo-europe-gmbh" "created" => "2020-11-11 18:07:52" "last_updated" => "2021-07-24 10:17:14" "deleted" => 1 ] [ "id" => 267140821 "company_id" => 6832192 "url" => "https://de.linkedin.com/company/daiichi-sankyo-deutschland-gmbh" "created" => "2020-11-11 18:07:52" "last_updated" => "2021-01-28 19:27:26" "deleted" => 1 ] [ "id" => 267140822 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/wavetech-ag" "created" => "2020-11-11 18:07:52" "last_updated" => "2020-12-22 12:26:29" "deleted" => 1 ] [ "id" => 267140823 "company_id" => 6832192 "url" => "https://de.linkedin.com/company/neusta-consulting" "created" => "2020-11-11 18:07:52" "last_updated" => "2020-12-22 12:26:29" "deleted" => 1 ] [ "id" => 267140824 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/toppharm" "created" => "2020-11-11 18:07:52" "last_updated" => "2020-12-22 12:26:29" "deleted" => 1 ] [ "id" => 267140825 "company_id" => 6832192 "url" => "https://se.linkedin.com/company/enrival-ab" "created" => "2020-11-11 18:07:52" "last_updated" => "2020-12-22 12:26:29" "deleted" => 1 ] [ "id" => 267140826 "company_id" => 6832192 "url" => "https://il.linkedin.com/company/cellebrite" "created" => "2020-11-11 18:07:52" "last_updated" => "2020-12-22 12:26:29" "deleted" => 1 ] [ "id" => 267140827 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/bbc" "created" => "2020-11-11 18:07:52" "last_updated" => "2020-12-22 12:26:29" "deleted" => 1 ] [ "id" => 342534231 "company_id" => 6832192 "url" => "https://de.linkedin.com/company/sandoz" "created" => "2020-12-22 12:26:29" "last_updated" => "2021-04-13 18:15:06" "deleted" => 1 ] [ "id" => 342534232 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/hofer-corp" "created" => "2020-12-22 12:26:29" "last_updated" => "2021-02-13 23:45:08" "deleted" => 1 ] [ "id" => 342534233 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/roche" "created" => "2020-12-22 12:26:29" "last_updated" => "2021-02-13 23:45:08" "deleted" => 1 ] [ "id" => 342534234 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/joineer" "created" => "2020-12-22 12:26:29" "last_updated" => "2021-02-13 23:45:08" "deleted" => 1 ] [ "id" => 342534235 "company_id" => 6832192 "url" => "https://jp.linkedin.com/company/takeda-pharmaceuticals" "created" => "2020-12-22 12:26:29" "last_updated" => "2021-01-28 19:27:26" "deleted" => 1 ] [ "id" => 342534236 "company_id" => 6832192 "url" => "https://fr.linkedin.com/company/group-cva" "created" => "2020-12-22 12:26:29" "last_updated" => "2021-01-28 19:27:26" "deleted" => 1 ] [ "id" => 342534237 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/nuventra" "created" => "2020-12-22 12:26:29" "last_updated" => "2021-01-28 19:27:26" "deleted" => 1 ] [ "id" => 362048137 "company_id" => 6832192 "url" => "https://ca.linkedin.com/company/janssencanada" "created" => "2021-01-28 19:27:26" "last_updated" => "2021-07-24 10:17:14" "deleted" => 1 ] [ "id" => 362048138 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/pfizer" "created" => "2021-01-28 19:27:26" "last_updated" => "2021-04-13 18:15:06" "deleted" => 1 ] [ "id" => 362048139 "company_id" => 6832192 "url" => "https://cz.linkedin.com/company/exceed-orphan" "created" => "2021-01-28 19:27:26" "last_updated" => "2021-02-13 23:45:08" "deleted" => 1 ] [ "id" => 362048140 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/incyte" "created" => "2021-01-28 19:27:26" "last_updated" => "2021-02-13 23:45:08" "deleted" => 1 ] [ "id" => 372081757 "company_id" => 6832192 "url" => "https://de.linkedin.com/company/daiichi-sankyo-deutschland-gmbh" "created" => "2021-02-13 23:45:08" "last_updated" => "2021-07-24 10:17:14" "deleted" => 1 ] [ "id" => 372081758 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/shqa-swiss-health-quality-association" "created" => "2021-02-13 23:45:08" "last_updated" => "2021-07-24 10:17:14" "deleted" => 1 ] [ "id" => 372081759 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/clavisit-ag" "created" => "2021-02-13 23:45:08" "last_updated" => "2021-04-13 18:15:06" "deleted" => 1 ] [ "id" => 372081760 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/allchemet-ag" "created" => "2021-02-13 23:45:08" "last_updated" => "2021-04-13 18:15:06" "deleted" => 1 ] [ "id" => 372081761 "company_id" => 6832192 "url" => "https://es.linkedin.com/company/asociaci%C3%B3n-mundus" "created" => "2021-02-13 23:45:08" "last_updated" => "2021-04-13 18:15:06" "deleted" => 1 ] [ "id" => 393938806 "company_id" => 6832192 "url" => "https://de.linkedin.com/company/der-erfolgreiche-pharmareferent" "created" => "2021-04-13 18:15:06" "last_updated" => "2021-07-24 10:17:14" "deleted" => 1 ] [ "id" => 393938807 "company_id" => 6832192 "url" => "https://de.linkedin.com/company/jurebus" "created" => "2021-04-13 18:15:06" "last_updated" => "2021-07-24 10:17:14" "deleted" => 1 ] [ "id" => 393938808 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/bcp-business-consulting-partner-ag" "created" => "2021-04-13 18:15:06" "last_updated" => "2021-07-24 10:17:14" "deleted" => 1 ] [ "id" => 393938809 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/orthosan-ag" "created" => "2021-04-13 18:15:06" "last_updated" => "2021-07-24 10:17:14" "deleted" => 1 ] [ "id" => 393938810 "company_id" => 6832192 "url" => "https://de.linkedin.com/company/bayer" "created" => "2021-04-13 18:15:06" "last_updated" => "2021-07-24 10:17:14" "deleted" => 1 ] [ "id" => 505242173 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo" "created" => "2021-09-14 21:19:39" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 505242174 "company_id" => 6832192 "url" => "https://de.linkedin.com/company/daiichi-sankyo-deutschland-gmbh" "created" => "2021-09-14 21:19:39" "last_updated" => "2025-01-03 15:55:41" "deleted" => 1 ] [ "id" => 505242175 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/shqa-swiss-health-quality-association" "created" => "2021-09-14 21:19:39" "last_updated" => "2023-03-13 20:18:06" "deleted" => 1 ] [ "id" => 505242176 "company_id" => 6832192 "url" => "https://ca.linkedin.com/company/janssencanada" "created" => "2021-09-14 21:19:39" "last_updated" => "2022-02-28 19:39:05" "deleted" => 1 ] [ "id" => 505242177 "company_id" => 6832192 "url" => "https://de.linkedin.com/company/daiichi-sankyo-europe-gmbh" "created" => "2021-09-14 21:19:39" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 505242178 "company_id" => 6832192 "url" => "https://de.linkedin.com/company/der-erfolgreiche-pharmareferent" "created" => "2021-09-14 21:19:39" "last_updated" => "2022-02-28 19:39:05" "deleted" => 1 ] [ "id" => 505242179 "company_id" => 6832192 "url" => "https://de.linkedin.com/company/jurebus" "created" => "2021-09-14 21:19:39" "last_updated" => "2022-02-28 19:39:05" "deleted" => 1 ] [ "id" => 505242180 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/bcp-business-consulting-partner-ag" "created" => "2021-09-14 21:19:39" "last_updated" => "2022-02-28 19:39:05" "deleted" => 1 ] [ "id" => 505242181 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/orthosan-ag" "created" => "2021-09-14 21:19:39" "last_updated" => "2022-02-28 19:39:05" "deleted" => 1 ] [ "id" => 505242182 "company_id" => 6832192 "url" => "https://de.linkedin.com/company/bayer" "created" => "2021-09-14 21:19:39" "last_updated" => "2022-02-28 19:39:05" "deleted" => 1 ] [ "id" => 556503174 "company_id" => 6832192 "url" => "https://jp.linkedin.com/company/daiichi-sankyo-co-ltd-" "created" => "2022-02-28 19:39:05" "last_updated" => "2023-05-07 18:18:30" "deleted" => 1 ] [ "id" => 556503175 "company_id" => 6832192 "url" => "https://ie.linkedin.com/company/daiichi-sankyo-ireland" "created" => "2022-02-28 19:39:05" "last_updated" => "2022-07-25 16:55:44" "deleted" => 1 ] [ "id" => 556503176 "company_id" => 6832192 "url" => "https://be.linkedin.com/company/daiichi-sankyo-belgium" "created" => "2022-02-28 19:39:05" "last_updated" => "2022-06-17 11:33:20" "deleted" => 1 ] [ "id" => 556503177 "company_id" => 6832192 "url" => "https://nl.linkedin.com/company/daiichi-sankyo-nederland" "created" => "2022-02-28 19:39:05" "last_updated" => "2022-10-08 11:54:54" "deleted" => 1 ] [ "id" => 556503178 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/astrazeneca" "created" => "2022-02-28 19:39:05" "last_updated" => "2022-06-17 11:33:20" "deleted" => 1 ] [ "id" => 556503179 "company_id" => 6832192 "url" => "https://nl.linkedin.com/company/daiichi-sankyo-nederland-b.v." "created" => "2022-02-28 19:39:05" "last_updated" => "2022-06-17 11:33:20" "deleted" => 1 ] [ "id" => 629840244 "company_id" => 6832192 "url" => "https://tr.linkedin.com/company/daiichi-sankyo-t%C3%BCrkiye" "created" => "2022-06-17 11:33:20" "last_updated" => "2022-12-19 06:38:46" "deleted" => 1 ] [ "id" => 629840245 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/biomed-ag" "created" => "2022-06-17 11:33:20" "last_updated" => "2022-09-14 15:00:49" "deleted" => 1 ] [ "id" => 629840246 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/swisscom" "created" => "2022-06-17 11:33:20" "last_updated" => "2022-07-25 16:55:44" "deleted" => 1 ] [ "id" => 689211991 "company_id" => 6832192 "url" => "https://dk.linkedin.com/company/novo-nordisk" "created" => "2022-07-25 16:55:44" "last_updated" => "2023-07-04 06:58:22" "deleted" => 1 ] [ "id" => 689211992 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/msdswitzerland" "created" => "2022-07-25 16:55:44" "last_updated" => "2022-10-08 11:54:54" "deleted" => 1 ] [ "id" => 707153997 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2022-09-14 15:00:49" "last_updated" => "2022-10-08 11:54:54" "deleted" => 1 ] [ "id" => 720946433 "company_id" => 6832192 "url" => "https://nl.linkedin.com/company/daiichi-sankyo-nederland-b.v." "created" => "2022-10-08 11:54:54" "last_updated" => "2023-02-15 06:00:48" "deleted" => 1 ] [ "id" => 720946434 "company_id" => 6832192 "url" => "https://uk.linkedin.com/company/astrazeneca" "created" => "2022-10-08 11:54:54" "last_updated" => "2022-12-19 06:38:46" "deleted" => 1 ] [ "id" => 720946435 "company_id" => 6832192 "url" => "https://ie.linkedin.com/company/daiichi-sankyo-ireland" "created" => "2022-10-08 11:54:54" "last_updated" => "2023-02-15 06:00:48" "deleted" => 1 ] [ "id" => 752032773 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/novartis" "created" => "2022-12-19 06:38:46" "last_updated" => "2023-07-04 06:58:22" "deleted" => 1 ] [ "id" => 752032774 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo-austria-gmbh" "created" => "2022-12-19 06:38:46" "last_updated" => "2023-02-15 06:00:48" "deleted" => 1 ] [ "id" => 777275988 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/msdswitzerland" "created" => "2023-02-15 06:00:48" "last_updated" => "2024-03-16 15:44:05" "deleted" => 1 ] [ "id" => 777275989 "company_id" => 6832192 "url" => "https://jp.linkedin.com/company/takeda-pharmaceuticals" "created" => "2023-02-15 06:00:48" "last_updated" => "2024-03-16 15:44:05" "deleted" => 1 ] [ "id" => 777275990 "company_id" => 6832192 "url" => "https://sg.linkedin.com/company/astellas-pharma-singapore" "created" => "2023-02-15 06:00:48" "last_updated" => "2023-04-12 00:30:51" "deleted" => 1 ] [ "id" => 793699819 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/octapharma" "created" => "2023-03-13 20:18:06" "last_updated" => "2023-04-12 00:30:51" "deleted" => 1 ] [ "id" => 800465604 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/roche" "created" => "2023-04-12 00:30:51" "last_updated" => "2023-06-11 07:08:20" "deleted" => 1 ] [ "id" => 800465605 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/abbvie" "created" => "2023-04-12 00:30:51" "last_updated" => "2023-05-07 18:18:30" "deleted" => 1 ] [ "id" => 819618514 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/daiichi-sankyo-austria-gmbh" "created" => "2023-05-07 18:18:30" "last_updated" => "2024-11-26 12:23:53" "deleted" => 1 ] [ "id" => 819618515 "company_id" => 6832192 "url" => "https://ie.linkedin.com/company/daiichi-sankyo-ireland" "created" => "2023-05-07 18:18:30" "last_updated" => "2023-10-16 05:44:21" "deleted" => 1 ] [ "id" => 832720289 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/beigene" "created" => "2023-06-11 07:08:20" "last_updated" => "2023-07-04 06:58:22" "deleted" => 1 ] [ "id" => 845270802 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/bristol-myers-squibb" "created" => "2023-07-04 06:58:22" "last_updated" => "2023-10-16 05:44:21" "deleted" => 1 ] [ "id" => 845270803 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/abbvie" "created" => "2023-07-04 06:58:22" "last_updated" => "2023-11-21 02:36:00" "deleted" => 1 ] [ "id" => 845270804 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/roche" "created" => "2023-07-04 06:58:22" "last_updated" => "2024-11-02 02:07:28" "deleted" => 1 ] [ "id" => 893553352 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/sandoz" "created" => "2023-10-16 05:44:21" "last_updated" => "2024-01-06 23:07:57" "deleted" => 1 ] [ "id" => 893553353 "company_id" => 6832192 "url" => "https://fr.linkedin.com/company/daiichi-sankyo-france" "created" => "2023-10-16 05:44:21" "last_updated" => "2023-11-21 02:36:00" "deleted" => 1 ] [ "id" => 910732673 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/om-pharma" "created" => "2023-11-21 02:36:00" "last_updated" => "2024-05-21 00:06:44" "deleted" => 1 ] [ "id" => 910732674 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/bristol-myers-squibb" "created" => "2023-11-21 02:36:00" "last_updated" => "2023-12-01 12:47:54" "deleted" => 1 ] [ "id" => 918106985 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/labatec-pharma-sa" "created" => "2023-12-01 12:47:54" "last_updated" => "2024-01-06 23:07:57" "deleted" => 1 ] [ "id" => 932490309 "company_id" => 6832192 "url" => "https://jp.linkedin.com/company/daiichi-sankyo-co-ltd-" "created" => "2024-01-06 23:07:57" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 932490310 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/eli-lilly-and-company" "created" => "2024-01-06 23:07:57" "last_updated" => "2024-02-21 08:18:49" "deleted" => 1 ] [ "id" => 953198975 "company_id" => 6832192 "url" => "https://ie.linkedin.com/company/daiichi-sankyo-ireland" "created" => "2024-02-21 08:18:49" "last_updated" => "2024-04-17 04:46:07" "deleted" => 1 ] [ "id" => 969000080 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/bwrtswitzerland" "created" => "2024-03-16 15:44:05" "last_updated" => "2024-04-17 04:46:07" "deleted" => 1 ] [ "id" => 969000081 "company_id" => 6832192 "url" => "https://uk.linkedin.com/company/astrazeneca" "created" => "2024-03-16 15:44:05" "last_updated" => "2024-04-17 04:46:07" "deleted" => 1 ] [ "id" => 987646315 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/eli-lilly-and-company" "created" => "2024-04-17 04:46:07" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 987646316 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/msdswitzerland" "created" => "2024-04-17 04:46:07" "last_updated" => "2024-05-21 00:06:44" "deleted" => 1 ] [ "id" => 987646317 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2024-04-17 04:46:07" "last_updated" => "2024-09-21 05:40:06" "deleted" => 1 ] [ "id" => 1002835130 "company_id" => 6832192 "url" => "https://uk.linkedin.com/company/astrazeneca" "created" => "2024-05-21 00:06:44" "last_updated" => "2024-07-15 03:39:21" "deleted" => 1 ] [ "id" => 1002835131 "company_id" => 6832192 "url" => "https://it.linkedin.com/company/daiichi-sankyo-italia" "created" => "2024-05-21 00:06:44" "last_updated" => "2024-06-05 17:28:32" "deleted" => 1 ] [ "id" => 1012459503 "company_id" => 6832192 "url" => "https://uk.linkedin.com/company/gsk" "created" => "2024-06-05 17:28:32" "last_updated" => "2025-02-02 16:08:13" "deleted" => 1 ] [ "id" => 1032911779 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/msdswitzerland" "created" => "2024-07-15 03:39:21" "last_updated" => "2024-08-01 08:25:01" "deleted" => 1 ] [ "id" => 1042400306 "company_id" => 6832192 "url" => "https://uk.linkedin.com/company/astrazeneca" "created" => "2024-08-01 08:25:01" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 1073642941 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/msdswitzerland" "created" => "2024-09-21 05:40:06" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 1093204423 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/pfizer" "created" => "2024-11-02 02:07:28" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 1109749054 "company_id" => 6832192 "url" => "https://au.linkedin.com/company/csl" "created" => "2024-11-26 12:23:53" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 1126374555 "company_id" => 6832192 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2025-01-03 15:55:41" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 1146007247 "company_id" => 6832192 "url" => "https://ch.linkedin.com/company/roche" "created" => "2025-02-02 16:08:13" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] ] "company_specialties_collection" => [ [ "id" => 66414647 "company_id" => 6832192 "specialty" => "Cardiovaskuläre Produkte and Onkologieprodukte" "created" => "2021-09-14 21:19:39" "last_updated" => "2022-07-25 16:55:44" "deleted" => 1 ] [ "id" => 96834200 "company_id" => 6832192 "specialty" => "Cardiovaskuläre Produkte and Onkologieprodukte" "created" => "2022-08-08 03:59:16" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] ] "company_stock_info_collection" => [] "company_updates_collection" => [ [ "id" => 18070580 "company_id" => 6832192 "urn" => "urn:li:activity:7001547398321688577" "followers" => 402 "date" => "3w" "description" => """ Are you looking for a new exciting professional challenge as MSL – Medical Scientific Liaison Oncology?\n \n Then start your application now:\n https://lnkd.in/ezGrW69W\n \n #newjob #pharma #oncology #medical #zürich #medicine #lifesciences #naturalsciences #hiring #msl """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => "Andrea Nienaber-Grundlehner" "reshared_post_author_url" => "https://ch.linkedin.com/in/andrea-nienaber-grundlehner-367a013" "reshared_post_author_headline" => "Managing Partner at DE BORD INTERNATIONAL" "reshared_post_description" => """ You feel attracted by pioneering work?\n Please watch out this OPPORTUNITY for an experienced \n Medical Scientific Liaison Oncology\n In this role, you are the field-based contact for medical and clinical inquiries and contribute to positioning innovative treatment options for patients in Switzerland. As MSL you are responsible for pre-launch and partnering activities and develop expert knowledge about antibody-drug conjugates that are currently in the clinical development. Link to the job ad\n https://lnkd.in/ey-b-Y-f\n \n #msl #medicalscienceliaison #oncology #biologics #innovation #collaboration #teamwork Daiichi Sankyo (Switzerland) """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-01-23 19:04:48" "deleted" => 1 ] [ "id" => 18070581 "company_id" => 6832192 "urn" => "urn:li:activity:6993494976844165120" "followers" => 402 "date" => "1mo" "description" => """ Are you looking for a new exciting professional challenge as Senior Medical Advisor Oncology ADCs (Antibody-Drug-Conjugate)?\n \n Then start your application now:\n https://lnkd.in/dTpdNgt6\n \n #newjob #pharma #medicaladvisor #oncology #medical #zürich #medicine #lifesciences #naturalsciences #hiring """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-23 19:04:48" "deleted" => 1 ] [ "id" => 18070582 "company_id" => 6832192 "urn" => "urn:li:activity:6977558334186921984" "followers" => 402 "date" => "3mo" "description" => """ Wir sind stolz darauf, von Pharma Intelligence als Pharmaunternehmen des Jahres 2022 ausgezeichnet worden zu sein. Die #PharmaIntelligenceAwards Japan würdigen herausragende Fortschritte und Innovationen in der japanischen Pharma- und Biotech-Industrie.\n \n #pharma #proud #Schweiz\n \n \n https://lnkd.in/e7gDiUG2 """ "reactions_count" => 2 "comments_count" => 1 "reshared_post_author" => "Pharma Intelligence, now Citeline" "reshared_post_author_url" => "https://uk.linkedin.com/company/pharma-intelligence-" "reshared_post_author_headline" => null "reshared_post_description" => """ Our penultimate award to for Pharma Company of the Year. \n \n This has been awarded to Daiichi Sankyo - well done for your deserved win! \n #PharmaIntelligenceAwards """ "reshared_post_followers" => 15043 "reshared_post_date" => "3mo" "last_updated" => "2023-01-23 19:04:48" "deleted" => 1 ] [ "id" => 18070583 "company_id" => 6832192 "urn" => "urn:li:activity:6973615147319762944" "followers" => 402 "date" => "3mo" "description" => """ Are you looking for a new exciting professional challenge as Senior Specialist TMF (Trial Master File) Operations?\n \n Then start your application now:\n https://lnkd.in/d582ye8k\n \n Note: This role can be filled in US or Europe - in one of Daiichi Sankyo's affiliate countries.\n \n #newjob #pharma #TMF #TrialMasterFile #US #Europe #hiring """ "reactions_count" => 3 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-23 19:04:48" "deleted" => 1 ] [ "id" => 18070584 "company_id" => 6832192 "urn" => "urn:li:activity:6970053668817489920" "followers" => 402 "date" => "3mo" "description" => """ Daiichi Sankyo Switzerland are currently hiring for the position of Commercial Excellence Manager.\n \n At Daiichi Sankyo in Europe, we offer a workplace where your voice is heard. Everything we do, we do with a high level of commitment and a clear focus on patients’ needs. We know that our bold ambition to change patients’ lives for the better can only be achieved through the power of collaboration and the exploration of new approaches. Thus, we encourage our colleagues across Europe to be courageous, to bring their ideas to the table and to embrace opportunities to grow. When you join our European family, you will be a part of a dynamic company where everyone, no matter their role, rolls up their sleeves and gets things done.\n \n For full details on the role of Commercial Excellence Manager and to apply please click on the link below:\n \n https://lnkd.in/eUjEU_Fm\n \n #hiring #opportunities #europe """ "reactions_count" => 1 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-23 19:04:48" "deleted" => 1 ] [ "id" => 18070585 "company_id" => 6832192 "urn" => "urn:li:activity:6970009537923661825" "followers" => 402 "date" => "3mo" "description" => """ Daiichi Sankyo Switzerland are currently hiring for the position of Head of Market Access.\n \n At Daiichi Sankyo in Europe, we offer a workplace where your voice is heard. Everything we do, we do with a high level of commitment and a clear focus on patients’ needs. We know that our bold ambition to change patients’ lives for the better can only be achieved through the power of collaboration and the exploration of new approaches. Thus, we encourage our colleagues across Europe to be courageous, to bring their ideas to the table and to embrace opportunities to grow. When you join our European family, you will be a part of a dynamic company where everyone, no matter their role, rolls up their sleeves and gets things done.\n \n For full details on the role of Head of Market Access and to apply please click on the link below:\n \n https://lnkd.in/egAmTV-2\n \n #hiring #opportunities #collaboration """ "reactions_count" => 15 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-23 19:04:48" "deleted" => 1 ] [ "id" => 52995437 "company_id" => 6832192 "urn" => "urn:li:activity:7001547398321688577" "followers" => 410 "date" => "2mo" "description" => """ Are you looking for a new exciting professional challenge as MSL – Medical Scientific Liaison Oncology?\n \n Then start your application now:\n https://lnkd.in/ezGrW69W\n \n #newjob #pharma #oncology #medical #zürich #medicine #lifesciences #naturalsciences #hiring #msl """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => "Andrea Nienaber-Grundlehner" "reshared_post_author_url" => "https://ch.linkedin.com/in/andrea-nienaber-grundlehner-367a013" "reshared_post_author_headline" => "Executive Search + HR Consulting - Life Sciences + Medical Device + Pharma" "reshared_post_description" => """ You feel attracted by pioneering work?\n Please watch out this OPPORTUNITY for an experienced \n Medical Scientific Liaison Oncology\n In this role, you are the field-based contact for medical and clinical inquiries and contribute to positioning innovative treatment options for patients in Switzerland. As MSL you are responsible for pre-launch and partnering activities and develop expert knowledge about antibody-drug conjugates that are currently in the clinical development. Link to the job ad\n https://lnkd.in/ey-b-Y-f\n \n #msl #medicalscienceliaison #oncology #biologics #innovation #collaboration #teamwork Daiichi Sankyo (Switzerland) """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2023-02-15 06:00:48" "deleted" => 1 ] [ "id" => 52995438 "company_id" => 6832192 "urn" => "urn:li:activity:6993494976844165120" "followers" => 410 "date" => "2mo" "description" => """ Are you looking for a new exciting professional challenge as Senior Medical Advisor Oncology ADCs (Antibody-Drug-Conjugate)?\n \n Then start your application now:\n https://lnkd.in/dTpdNgt6\n \n #newjob #pharma #medicaladvisor #oncology #medical #zürich #medicine #lifesciences #naturalsciences #hiring """ "reactions_count" => 9 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-15 06:00:48" "deleted" => 1 ] [ "id" => 52995439 "company_id" => 6832192 "urn" => "urn:li:activity:6977558334186921984" "followers" => 410 "date" => "4mo" "description" => """ Wir sind stolz darauf, von Pharma Intelligence als Pharmaunternehmen des Jahres 2022 ausgezeichnet worden zu sein. Die #PharmaIntelligenceAwards Japan würdigen herausragende Fortschritte und Innovationen in der japanischen Pharma- und Biotech-Industrie.\n \n #pharma #proud #Schweiz\n \n \n https://lnkd.in/e7gDiUG2 """ "reactions_count" => 2 "comments_count" => 1 "reshared_post_author" => "Pharma Intelligence, now Citeline" "reshared_post_author_url" => "https://uk.linkedin.com/company/pharma-intelligence-" "reshared_post_author_headline" => null "reshared_post_description" => """ Our penultimate award to for Pharma Company of the Year. \n \n This has been awarded to Daiichi Sankyo - well done for your deserved win! \n #PharmaIntelligenceAwards """ "reshared_post_followers" => 15160 "reshared_post_date" => "4mo" "last_updated" => "2023-02-15 06:00:48" "deleted" => 1 ] [ "id" => 52995440 "company_id" => 6832192 "urn" => "urn:li:activity:6973615147319762944" "followers" => 410 "date" => "4mo" "description" => """ Are you looking for a new exciting professional challenge as Senior Specialist TMF (Trial Master File) Operations?\n \n Then start your application now:\n https://lnkd.in/d582ye8k\n \n Note: This role can be filled in US or Europe - in one of Daiichi Sankyo's affiliate countries.\n \n #newjob #pharma #TMF #TrialMasterFile #US #Europe #hiring """ "reactions_count" => 3 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-15 06:00:48" "deleted" => 1 ] [ "id" => 52995442 "company_id" => 6832192 "urn" => "urn:li:activity:6970053668817489920" "followers" => 410 "date" => "4mo" "description" => """ Daiichi Sankyo Switzerland are currently hiring for the position of Commercial Excellence Manager.\n \n At Daiichi Sankyo in Europe, we offer a workplace where your voice is heard. Everything we do, we do with a high level of commitment and a clear focus on patients’ needs. We know that our bold ambition to change patients’ lives for the better can only be achieved through the power of collaboration and the exploration of new approaches. Thus, we encourage our colleagues across Europe to be courageous, to bring their ideas to the table and to embrace opportunities to grow. When you join our European family, you will be a part of a dynamic company where everyone, no matter their role, rolls up their sleeves and gets things done.\n \n For full details on the role of Commercial Excellence Manager and to apply please click on the link below:\n \n https://lnkd.in/eUjEU_Fm\n \n #hiring #opportunities #europe """ "reactions_count" => 1 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-15 06:00:48" "deleted" => 1 ] [ "id" => 52995443 "company_id" => 6832192 "urn" => "urn:li:activity:6970009537923661825" "followers" => 410 "date" => "4mo" "description" => """ Daiichi Sankyo Switzerland are currently hiring for the position of Head of Market Access.\n \n At Daiichi Sankyo in Europe, we offer a workplace where your voice is heard. Everything we do, we do with a high level of commitment and a clear focus on patients’ needs. We know that our bold ambition to change patients’ lives for the better can only be achieved through the power of collaboration and the exploration of new approaches. Thus, we encourage our colleagues across Europe to be courageous, to bring their ideas to the table and to embrace opportunities to grow. When you join our European family, you will be a part of a dynamic company where everyone, no matter their role, rolls up their sleeves and gets things done.\n \n For full details on the role of Head of Market Access and to apply please click on the link below:\n \n https://lnkd.in/egAmTV-2\n \n #hiring #opportunities #collaboration """ "reactions_count" => 15 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-15 06:00:48" "deleted" => 1 ] [ "id" => 74749491 "company_id" => 6832192 "urn" => "urn:li:activity:6977558334186921984" "followers" => 419 "date" => "4mo" "description" => """ Wir sind stolz darauf, von Pharma Intelligence als Pharmaunternehmen des Jahres 2022 ausgezeichnet worden zu sein. Die #PharmaIntelligenceAwards Japan würdigen herausragende Fortschritte und Innovationen in der japanischen Pharma- und Biotech-Industrie.\n \n #pharma #proud #Schweiz\n \n \n https://lnkd.in/e7gDiUG2 """ "reactions_count" => 2 "comments_count" => 1 "reshared_post_author" => "Pharma Intelligence, now Citeline" "reshared_post_author_url" => "https://uk.linkedin.com/company/pharma-intelligence-" "reshared_post_author_headline" => null "reshared_post_description" => """ Our penultimate award to for Pharma Company of the Year. \n \n This has been awarded to Daiichi Sankyo - well done for your deserved win! \n #PharmaIntelligenceAwards """ "reshared_post_followers" => 15230 "reshared_post_date" => "5mo" "last_updated" => "2023-03-13 20:18:06" "deleted" => 1 ] [ "id" => 74749492 "company_id" => 6832192 "urn" => "urn:li:activity:6970053668817489920" "followers" => 419 "date" => "5mo" "description" => """ Daiichi Sankyo Switzerland are currently hiring for the position of Commercial Excellence Manager.\n \n At Daiichi Sankyo in Europe, we offer a workplace where your voice is heard. Everything we do, we do with a high level of commitment and a clear focus on patients’ needs. We know that our bold ambition to change patients’ lives for the better can only be achieved through the power of collaboration and the exploration of new approaches. Thus, we encourage our colleagues across Europe to be courageous, to bring their ideas to the table and to embrace opportunities to grow. When you join our European family, you will be a part of a dynamic company where everyone, no matter their role, rolls up their sleeves and gets things done.\n \n For full details on the role of Commercial Excellence Manager and to apply please click on the link below:\n \n https://lnkd.in/eUjEU_Fm\n \n #hiring #opportunities #europe """ "reactions_count" => 1 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-13 20:18:06" "deleted" => 1 ] [ "id" => 74749493 "company_id" => 6832192 "urn" => "urn:li:activity:6970009537923661825" "followers" => 419 "date" => "5mo" "description" => """ Daiichi Sankyo Switzerland are currently hiring for the position of Head of Market Access.\n \n At Daiichi Sankyo in Europe, we offer a workplace where your voice is heard. Everything we do, we do with a high level of commitment and a clear focus on patients’ needs. We know that our bold ambition to change patients’ lives for the better can only be achieved through the power of collaboration and the exploration of new approaches. Thus, we encourage our colleagues across Europe to be courageous, to bring their ideas to the table and to embrace opportunities to grow. When you join our European family, you will be a part of a dynamic company where everyone, no matter their role, rolls up their sleeves and gets things done.\n \n For full details on the role of Head of Market Access and to apply please click on the link below:\n \n https://lnkd.in/egAmTV-2\n \n #hiring #opportunities #collaboration """ "reactions_count" => 15 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-13 20:18:06" "deleted" => 1 ] [ "id" => 112061770 "company_id" => 6832192 "urn" => "urn:li:activity:7032018134249168896" "followers" => 426 "date" => "3w" "description" => """ Cardivity - \n Ready for an extraordinary cardiology challenge as a team located in Switzerland?\n It's your turn as cardiology residents to test your knowledge. \n \n \n #Cardiology #Residents #Quiz #Schweiz #Teamwork #Competition #WeCareForEveryHeartbeat """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 00:30:51" "deleted" => 1 ] [ "id" => 112061771 "company_id" => 6832192 "urn" => "urn:li:activity:6977558334186921984" "followers" => 426 "date" => "5mo" "description" => """ Wir sind stolz darauf, von Pharma Intelligence als Pharmaunternehmen des Jahres 2022 ausgezeichnet worden zu sein. Die #PharmaIntelligenceAwards Japan würdigen herausragende Fortschritte und Innovationen in der japanischen Pharma- und Biotech-Industrie.\n \n #pharma #proud #Schweiz\n \n \n https://lnkd.in/e7gDiUG2 """ "reactions_count" => 3 "comments_count" => 1 "reshared_post_author" => "Pharma Intelligence, now Citeline" "reshared_post_author_url" => "https://uk.linkedin.com/company/pharma-intelligence-" "reshared_post_author_headline" => null "reshared_post_description" => """ Our penultimate award to for Pharma Company of the Year. \n \n This has been awarded to Daiichi Sankyo - well done for your deserved win! \n #PharmaIntelligenceAwards """ "reshared_post_followers" => 15308 "reshared_post_date" => "6mo" "last_updated" => "2023-04-12 00:30:51" "deleted" => 1 ] [ "id" => 127692263 "company_id" => 6832192 "urn" => "urn:li:activity:7032018134249168896" "followers" => 443 "date" => "1mo" "description" => """ Cardivity - \n Ready for an extraordinary cardiology challenge as a team located in Switzerland?\n It's your turn as cardiology residents to test your knowledge. \n \n \n #Cardiology #Residents #Quiz #Schweiz #Teamwork #Competition #WeCareForEveryHeartbeat """ "reactions_count" => 19 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-07 18:18:30" "deleted" => 1 ] [ "id" => 127692264 "company_id" => 6832192 "urn" => "urn:li:activity:6977558334186921984" "followers" => 443 "date" => "6mo" "description" => """ Wir sind stolz darauf, von Pharma Intelligence als Pharmaunternehmen des Jahres 2022 ausgezeichnet worden zu sein. Die #PharmaIntelligenceAwards Japan würdigen herausragende Fortschritte und Innovationen in der japanischen Pharma- und Biotech-Industrie.\n \n #pharma #proud #Schweiz\n \n \n https://lnkd.in/e7gDiUG2 """ "reactions_count" => 3 "comments_count" => 1 "reshared_post_author" => "Pharma Intelligence, now Citeline" "reshared_post_author_url" => "https://uk.linkedin.com/company/pharma-intelligence-" "reshared_post_author_headline" => null "reshared_post_description" => """ Our penultimate award to for Pharma Company of the Year. \n \n This has been awarded to Daiichi Sankyo - well done for your deserved win! \n #PharmaIntelligenceAwards """ "reshared_post_followers" => 15376 "reshared_post_date" => "7mo" "last_updated" => "2023-05-07 18:18:30" "deleted" => 1 ] [ "id" => 168027212 "company_id" => 6832192 "urn" => "urn:li:activity:7059428456714928128" "followers" => 463 "date" => "4d" "description" => """ 📢 Bist du bereit für eine neue spannende Herausforderung als Customer Experience Specialist (m/w/d) in unserem Team? Dann bewirb dich noch heute. Wir freuen uns auf dich!\n \n #team #neuerjob #customerexperience #sales #verkauf #salesrepresentative #kardiologie #wecareforeveryheartbeat #schweiz #aargau """ "reactions_count" => 4 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-11 07:08:20" "deleted" => 1 ] [ "id" => 168027213 "company_id" => 6832192 "urn" => "urn:li:activity:7052642175418798080" "followers" => 463 "date" => "3w" "description" => """ Are you ready for a new exciting challenge as Market Access Manager (m/f/x) in our team? Then apply today. We are looking forward to it!\n \n https://lnkd.in/e6bCtpwq\n \n #team #newjob #marketaccessmanager #zürich #oncology #wecareforeveryheartbeat #schweiz """ "reactions_count" => 13 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-11 07:08:20" "deleted" => 1 ] [ "id" => 168027214 "company_id" => 6832192 "urn" => "urn:li:activity:7032018134249168896" "followers" => 463 "date" => "2mo" "description" => """ Cardivity - \n Ready for an extraordinary cardiology challenge as a team located in Switzerland?\n It's your turn as cardiology residents to test your knowledge. \n \n \n #Cardiology #Residents #Quiz #Schweiz #Teamwork #Competition #WeCareForEveryHeartbeat """ "reactions_count" => 19 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-11 07:08:20" "deleted" => 1 ] [ "id" => 168027215 "company_id" => 6832192 "urn" => "urn:li:activity:6977558334186921984" "followers" => 463 "date" => "7mo" "description" => """ Wir sind stolz darauf, von Pharma Intelligence als Pharmaunternehmen des Jahres 2022 ausgezeichnet worden zu sein. Die #PharmaIntelligenceAwards Japan würdigen herausragende Fortschritte und Innovationen in der japanischen Pharma- und Biotech-Industrie.\n \n #pharma #proud #Schweiz\n \n \n https://lnkd.in/e7gDiUG2 """ "reactions_count" => 3 "comments_count" => 1 "reshared_post_author" => "Pharma Intelligence, now Citeline" "reshared_post_author_url" => "https://uk.linkedin.com/company/pharma-intelligence-" "reshared_post_author_headline" => null "reshared_post_description" => """ Our penultimate award to for Pharma Company of the Year. \n \n This has been awarded to Daiichi Sankyo - well done for your deserved win! \n #PharmaIntelligenceAwards """ "reshared_post_followers" => 15458 "reshared_post_date" => "8mo" "last_updated" => "2023-06-11 07:08:20" "deleted" => 1 ] [ "id" => 200362008 "company_id" => 6832192 "urn" => "urn:li:activity:7067864877238738944" "followers" => 479 "date" => "2w" "description" => """ 📢 Are you ready for a new exciting challenge as Market Access Manager (m/f/x) in our team? Then apply today. We are looking forward to it!\n \n #team #newjob #marketaccessmanager #zürich #oncology #wecareforeveryheartbeat #schweiz """ "reactions_count" => 4 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-04 06:58:22" "deleted" => 1 ] [ "id" => 200362009 "company_id" => 6832192 "urn" => "urn:li:activity:7059428456714928128" "followers" => 479 "date" => "1mo" "description" => """ 📢 Bist du bereit für eine neue spannende Herausforderung als Customer Experience Specialist (m/w/d) in unserem Team? Dann bewirb dich noch heute. Wir freuen uns auf dich!\n \n #team #neuerjob #customerexperience #sales #verkauf #salesrepresentative #kardiologie #wecareforeveryheartbeat #schweiz #aargau """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-04 06:58:22" "deleted" => 1 ] [ "id" => 200362010 "company_id" => 6832192 "urn" => "urn:li:activity:7032018134249168896" "followers" => 479 "date" => "3mo" "description" => """ Cardivity - \n Ready for an extraordinary cardiology challenge as a team located in Switzerland?\n It's your turn as cardiology residents to test your knowledge. \n \n \n #Cardiology #Residents #Quiz #Schweiz #Teamwork #Competition #WeCareForEveryHeartbeat """ "reactions_count" => 19 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-04 06:58:22" "deleted" => 1 ] [ "id" => 200362011 "company_id" => 6832192 "urn" => "urn:li:activity:6977558334186921984" "followers" => 479 "date" => "8mo" "description" => """ Wir sind stolz darauf, von Pharma Intelligence als Pharmaunternehmen des Jahres 2022 ausgezeichnet worden zu sein. Die #PharmaIntelligenceAwards Japan würdigen herausragende Fortschritte und Innovationen in der japanischen Pharma- und Biotech-Industrie.\n \n #pharma #proud #Schweiz\n \n \n https://lnkd.in/e7gDiUG2 """ "reactions_count" => 3 "comments_count" => 1 "reshared_post_author" => "Pharma Intelligence, now Citeline" "reshared_post_author_url" => "https://uk.linkedin.com/company/pharma-intelligence-" "reshared_post_author_headline" => null "reshared_post_description" => """ Our penultimate award to for Pharma Company of the Year. \n \n This has been awarded to Daiichi Sankyo - well done for your deserved win! \n #PharmaIntelligenceAwards """ "reshared_post_followers" => 15555 "reshared_post_date" => "9mo" "last_updated" => "2023-07-04 06:58:22" "deleted" => 1 ] [ "id" => 229569405 "company_id" => 6832192 "urn" => "urn:li:activity:7067864877238738944" "followers" => 482 "date" => "1mo" "description" => """ 📢 Are you ready for a new exciting challenge as Market Access Manager (m/f/x) in our team? Then apply today. We are looking forward to it!\n \n #team #newjob #marketaccessmanager #zürich #oncology #wecareforeveryheartbeat #schweiz """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-04 20:00:31" "deleted" => 1 ] [ "id" => 229569406 "company_id" => 6832192 "urn" => "urn:li:activity:7059428456714928128" "followers" => 482 "date" => "2mo" "description" => """ 📢 Bist du bereit für eine neue spannende Herausforderung als Customer Experience Specialist (m/w/d) in unserem Team? Dann bewirb dich noch heute. Wir freuen uns auf dich!\n \n #team #neuerjob #customerexperience #sales #verkauf #salesrepresentative #kardiologie #wecareforeveryheartbeat #schweiz #aargau """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-04 20:00:31" "deleted" => 1 ] [ "id" => 229569407 "company_id" => 6832192 "urn" => "urn:li:activity:7032018134249168896" "followers" => 482 "date" => "4mo" "description" => """ Cardivity - \n Ready for an extraordinary cardiology challenge as a team located in Switzerland?\n It's your turn as cardiology residents to test your knowledge. \n \n \n #Cardiology #Residents #Quiz #Schweiz #Teamwork #Competition #WeCareForEveryHeartbeat """ "reactions_count" => 19 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-04 20:00:31" "deleted" => 1 ] [ "id" => 229569408 "company_id" => 6832192 "urn" => "urn:li:activity:6977558334186921984" "followers" => 482 "date" => "9mo" "description" => """ Wir sind stolz darauf, von Pharma Intelligence als Pharmaunternehmen des Jahres 2022 ausgezeichnet worden zu sein. Die #PharmaIntelligenceAwards Japan würdigen herausragende Fortschritte und Innovationen in der japanischen Pharma- und Biotech-Industrie.\n \n #pharma #proud #Schweiz\n \n \n https://lnkd.in/e7gDiUG2 """ "reactions_count" => 3 "comments_count" => 1 "reshared_post_author" => "Pharma Intelligence, now Citeline" "reshared_post_author_url" => "https://uk.linkedin.com/company/pharma-intelligence-" "reshared_post_author_headline" => null "reshared_post_description" => """ Our penultimate award to for Pharma Company of the Year. \n \n This has been awarded to Daiichi Sankyo - well done for your deserved win! \n #PharmaIntelligenceAwards """ "reshared_post_followers" => 15617 "reshared_post_date" => "10mo" "last_updated" => "2023-08-04 20:00:31" "deleted" => 1 ] [ "id" => 271998244 "company_id" => 6832192 "urn" => "urn:li:activity:6977558334186921984" "followers" => 489 "date" => "10mo" "description" => """ Wir sind stolz darauf, von Pharma Intelligence als Pharmaunternehmen des Jahres 2022 ausgezeichnet worden zu sein. Die #PharmaIntelligenceAwards Japan würdigen herausragende Fortschritte und Innovationen in der japanischen Pharma- und Biotech-Industrie.\n \n #pharma #proud #Schweiz\n \n \n https://lnkd.in/e7gDiUG2 """ "reactions_count" => 3 "comments_count" => 1 "reshared_post_author" => "Pharma Intelligence, now Citeline" "reshared_post_author_url" => "https://uk.linkedin.com/company/pharma-intelligence-" "reshared_post_author_headline" => null "reshared_post_description" => """ Our penultimate award to for Pharma Company of the Year. \n \n This has been awarded to Daiichi Sankyo - well done for your deserved win! \n #PharmaIntelligenceAwards """ "reshared_post_followers" => 15712 "reshared_post_date" => "11mo" "last_updated" => "2023-09-17 23:08:07" "deleted" => 1 ] [ "id" => 322656706 "company_id" => 6832192 "urn" => "urn:li:activity:6977558334186921984" "followers" => null "date" => "12mo" "description" => """ Wir sind stolz darauf, von Pharma Intelligence als Pharmaunternehmen des Jahres 2022 ausgezeichnet worden zu sein. Die #PharmaIntelligenceAwards Japan würdigen herausragende Fortschritte und Innovationen in der japanischen Pharma- und Biotech-Industrie.\n \n #pharma #proud #Schweiz\n \n \n https://lnkd.in/e7gDiUG2 """ "reactions_count" => 3 "comments_count" => 1 "reshared_post_author" => "Pharma Intelligence, now Citeline" "reshared_post_author_url" => "https://uk.linkedin.com/company/pharma-intelligence-" "reshared_post_author_headline" => null "reshared_post_description" => """ Our penultimate award to for Pharma Company of the Year. \n \n This has been awarded to Daiichi Sankyo - well done for your deserved win! \n #PharmaIntelligenceAwards """ "reshared_post_followers" => null "reshared_post_date" => "1y" "last_updated" => "2023-10-16 05:44:21" "deleted" => 1 ] [ "id" => 544346286 "company_id" => 6832192 "urn" => "urn:li:activity:7179154587134623744" "followers" => null "date" => "2w" "description" => """ “Culture eats strategy for breakfast” (Peter Drucker) 💡 \n With this motto, in March 2023, all employees of Daiichi Sankyo (Schweiz) AG) engaged in a co-creation effort to build our joint mission, vision and core behaviors.\n This journey was fascinating! It was filled with fruitful exchanges, passionate debates, commitment to get to a result that would have captured our hearts and stimulated our minds.\n As for every global company, mission, vision and core behaviors are harmonized at global level. Hence, a part of the journey was aimed at addressing the following key question: How do we build on our global legacy and add the local twist to make sure we can perceive our corporate culture as fully ours?\n We believe in a culture of collaboration, respect and support. Every member of our team is valuable and contributes to the success of the company. By aligning ourselves with these values, we strive to grow together as a team and move our company forward to make a positive impact. This is true in Daiichi Sankyo, regardless of which country we operate.\n Images might be the best way to express a concept and memorize it, hence, together with a very talented visual artist helge windisch, we have decorated our office to show an image of how our global behaviors meet with the Swiss mountaineering and adventurous spirit which animates all of us!\n \n #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Teamwork #Wallprint #Companymission #Companyvision #Pharma """ "reactions_count" => 62 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-21 00:06:44" "deleted" => 1 ] [ "id" => 577241406 "company_id" => 6832192 "urn" => "urn:li:activity:7179154587134623744" "followers" => null "date" => "1mo" "description" => """ “Culture eats strategy for breakfast” (Peter Drucker) 💡 \n With this motto, in March 2023, all employees of Daiichi Sankyo (Schweiz) AG) engaged in a co-creation effort to build our joint mission, vision and core behaviors.\n This journey was fascinating! It was filled with fruitful exchanges, passionate debates, commitment to get to a result that would have captured our hearts and stimulated our minds.\n As for every global company, mission, vision and core behaviors are harmonized at global level. Hence, a part of the journey was aimed at addressing the following key question: How do we build on our global legacy and add the local twist to make sure we can perceive our corporate culture as fully ours?\n We believe in a culture of collaboration, respect and support. Every member of our team is valuable and contributes to the success of the company. By aligning ourselves with these values, we strive to grow together as a team and move our company forward to make a positive impact. This is true in Daiichi Sankyo, regardless of which country we operate.\n Images might be the best way to express a concept and memorize it, hence, together with a very talented visual artist helge windisch, we have decorated our office to show an image of how our global behaviors meet with the Swiss mountaineering and adventurous spirit which animates all of us!\n \n #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Teamwork #Wallprint #Companymission #Companyvision #Pharma """ "reactions_count" => 64 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-05 17:28:32" "deleted" => 1 ] [ "id" => 594464716 "company_id" => 6832192 "urn" => "urn:li:activity:7199676213471100928" "followers" => null "date" => "1w" "description" => """ We are excited to announce the launch of DSPACE!\n \n #DSPACE is the Digital Innovation Hub at #DaiichiSankyoEurope, where we leverage digital technologies to support patients and healthcare professionals across Europe. \n \n Through understanding the needs of people living with #CardiovascularDisease and cancer, and the challenges healthcare professionals face, we aim to utilise the latest technologies to support people more effectively in their care journey 👩⚕️\n \n Learn more about #DSPACE here https://lnkd.in/dgkJsPCg """ "reactions_count" => 137 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-15 03:39:21" "deleted" => 1 ] [ "id" => 594464717 "company_id" => 6832192 "urn" => "urn:li:activity:7179154587134623744" "followers" => null "date" => "2mo" "description" => """ “Culture eats strategy for breakfast” (Peter Drucker) 💡 \n With this motto, in March 2023, all employees of Daiichi Sankyo (Schweiz) AG) engaged in a co-creation effort to build our joint mission, vision and core behaviors.\n This journey was fascinating! It was filled with fruitful exchanges, passionate debates, commitment to get to a result that would have captured our hearts and stimulated our minds.\n As for every global company, mission, vision and core behaviors are harmonized at global level. Hence, a part of the journey was aimed at addressing the following key question: How do we build on our global legacy and add the local twist to make sure we can perceive our corporate culture as fully ours?\n We believe in a culture of collaboration, respect and support. Every member of our team is valuable and contributes to the success of the company. By aligning ourselves with these values, we strive to grow together as a team and move our company forward to make a positive impact. This is true in Daiichi Sankyo, regardless of which country we operate.\n Images might be the best way to express a concept and memorize it, hence, together with a very talented visual artist helge windisch, we have decorated our office to show an image of how our global behaviors meet with the Swiss mountaineering and adventurous spirit which animates all of us!\n \n #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Teamwork #Wallprint #Companymission #Companyvision #Pharma """ "reactions_count" => 67 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-15 03:39:21" "deleted" => 1 ] [ "id" => 642149691 "company_id" => 6832192 "urn" => "urn:li:activity:7199676213471100928" "followers" => null "date" => "1mo" "description" => """ We are excited to announce the launch of DSPACE!\n \n #DSPACE is the Digital Innovation Hub at #DaiichiSankyoEurope, where we leverage digital technologies to support patients and healthcare professionals across Europe. \n \n Through understanding the needs of people living with #CardiovascularDisease and cancer, and the challenges healthcare professionals face, we aim to utilise the latest technologies to support people more effectively in their care journey 👩⚕️\n \n Learn more about #DSPACE here https://lnkd.in/dgkJsPCg """ "reactions_count" => 151 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-01 08:25:01" "deleted" => 1 ] [ "id" => 642149692 "company_id" => 6832192 "urn" => "urn:li:activity:7179154587134623744" "followers" => null "date" => "3mo" "description" => """ “Culture eats strategy for breakfast” (Peter Drucker) 💡 \n With this motto, in March 2023, all employees of Daiichi Sankyo (Schweiz) AG) engaged in a co-creation effort to build our joint mission, vision and core behaviors.\n This journey was fascinating! It was filled with fruitful exchanges, passionate debates, commitment to get to a result that would have captured our hearts and stimulated our minds.\n As for every global company, mission, vision and core behaviors are harmonized at global level. Hence, a part of the journey was aimed at addressing the following key question: How do we build on our global legacy and add the local twist to make sure we can perceive our corporate culture as fully ours?\n We believe in a culture of collaboration, respect and support. Every member of our team is valuable and contributes to the success of the company. By aligning ourselves with these values, we strive to grow together as a team and move our company forward to make a positive impact. This is true in Daiichi Sankyo, regardless of which country we operate.\n Images might be the best way to express a concept and memorize it, hence, together with a very talented visual artist helge windisch, we have decorated our office to show an image of how our global behaviors meet with the Swiss mountaineering and adventurous spirit which animates all of us!\n \n #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Teamwork #Wallprint #Companymission #Companyvision #Pharma """ "reactions_count" => 69 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-01 08:25:01" "deleted" => 1 ] [ "id" => 659718763 "company_id" => 6832192 "urn" => "urn:li:activity:7199676213471100928" "followers" => null "date" => "2mo" "description" => """ We are excited to announce the launch of DSPACE!\n \n #DSPACE is the Digital Innovation Hub at #DaiichiSankyoEurope, where we leverage digital technologies to support patients and healthcare professionals across Europe. \n \n Through understanding the needs of people living with #CardiovascularDisease and cancer, and the challenges healthcare professionals face, we aim to utilise the latest technologies to support people more effectively in their care journey 👩⚕️\n \n Learn more about #DSPACE here https://lnkd.in/dgkJsPCg """ "reactions_count" => 151 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-06 00:06:20" "deleted" => 1 ] [ "id" => 659718764 "company_id" => 6832192 "urn" => "urn:li:activity:7179154587134623744" "followers" => null "date" => "4mo" "description" => """ “Culture eats strategy for breakfast” (Peter Drucker) 💡 \n With this motto, in March 2023, all employees of Daiichi Sankyo (Schweiz) AG) engaged in a co-creation effort to build our joint mission, vision and core behaviors.\n This journey was fascinating! It was filled with fruitful exchanges, passionate debates, commitment to get to a result that would have captured our hearts and stimulated our minds.\n As for every global company, mission, vision and core behaviors are harmonized at global level. Hence, a part of the journey was aimed at addressing the following key question: How do we build on our global legacy and add the local twist to make sure we can perceive our corporate culture as fully ours?\n We believe in a culture of collaboration, respect and support. Every member of our team is valuable and contributes to the success of the company. By aligning ourselves with these values, we strive to grow together as a team and move our company forward to make a positive impact. This is true in Daiichi Sankyo, regardless of which country we operate.\n Images might be the best way to express a concept and memorize it, hence, together with a very talented visual artist helge windisch, we have decorated our office to show an image of how our global behaviors meet with the Swiss mountaineering and adventurous spirit which animates all of us!\n \n #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Teamwork #Wallprint #Companymission #Companyvision #Pharma """ "reactions_count" => 69 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-06 00:06:20" "deleted" => 1 ] [ "id" => 699069682 "company_id" => 6832192 "urn" => "urn:li:activity:7235317109096931328" "followers" => null "date" => "6d" "description" => "Proud to have been part of the initiative, even prouder of being part of Daiichi Sankyo (Schweiz) AG ! 🙏👏" "reactions_count" => 1 "comments_count" => null "reshared_post_author" => "Daiichi Sankyo (Switzerland)" "reshared_post_author_url" => "https://ch.linkedin.com/company/daiichi-sankyo-schweiz-ag" "reshared_post_author_headline" => null "reshared_post_description" => """ 👉 Successful Clean-Up Day: A Step Towards a Cleaner Planet 💚🌍 \n \n We are proud to announce the successful completion of our Clean-Up Day last Friday, 23rd August, a heartfelt initiative dedicated to making our environment cleaner. This event saw enthusiastic participation from our team members in Switzerland who came together with a shared commitment to environmental sustainability and community well-being.\n \n As part of the European initiative, the Clean-Up Day, our DSCH team worked hard to collect and properly dispose of waste in our local area, demonstrating the power of collective action. The dedication and hard work of our volunteers not only made a significant impact on our environment but also raised awareness about the importance of reducing waste and promoting sustainable practices.\n \n Together, we have taken a crucial step towards a cleaner and more sustainable future. Let's continue to support and participate in such initiatives, ensuring that our efforts contribute to a healthier planet. Thank you to everyone who participated and made this Clean-Up Day a resounding success!\n \n \n #CleanupDay #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Companymission #Companyvision #Pharma #Zürich #Cleanerplanet\n \n CH/DSC/08/24/0001 """ "reshared_post_followers" => null "reshared_post_date" => "6d" "last_updated" => "2024-09-21 05:40:06" "deleted" => 1 ] [ "id" => 699069683 "company_id" => 6832192 "urn" => "urn:li:activity:7235184574580822018" "followers" => null "date" => "6d" "description" => """ 👉 Successful Clean-Up Day: A Step Towards a Cleaner Planet 💚🌍 \n \n We are proud to announce the successful completion of our Clean-Up Day last Friday, 23rd August, a heartfelt initiative dedicated to making our environment cleaner. This event saw enthusiastic participation from our team members in Switzerland who came together with a shared commitment to environmental sustainability and community well-being.\n \n As part of the European initiative, the Clean-Up Day, our DSCH team worked hard to collect and properly dispose of waste in our local area, demonstrating the power of collective action. The dedication and hard work of our volunteers not only made a significant impact on our environment but also raised awareness about the importance of reducing waste and promoting sustainable practices.\n \n Together, we have taken a crucial step towards a cleaner and more sustainable future. Let's continue to support and participate in such initiatives, ensuring that our efforts contribute to a healthier planet. Thank you to everyone who participated and made this Clean-Up Day a resounding success!\n \n \n #CleanupDay #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Companymission #Companyvision #Pharma #Zürich #Cleanerplanet\n \n CH/DSC/08/24/0001 """ "reactions_count" => 27 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-21 05:40:06" "deleted" => 1 ] [ "id" => 699069684 "company_id" => 6832192 "urn" => "urn:li:activity:7199676213471100928" "followers" => null "date" => "3mo" "description" => """ We are excited to announce the launch of DSPACE!\n \n #DSPACE is the Digital Innovation Hub at #DaiichiSankyoEurope, where we leverage digital technologies to support patients and healthcare professionals across Europe. \n \n Through understanding the needs of people living with #CardiovascularDisease and cancer, and the challenges healthcare professionals face, we aim to utilise the latest technologies to support people more effectively in their care journey 👩⚕️\n \n Learn more about #DSPACE here https://lnkd.in/dgkJsPCg """ "reactions_count" => 152 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-21 05:40:06" "deleted" => 1 ] [ "id" => 699069685 "company_id" => 6832192 "urn" => "urn:li:activity:7179154587134623744" "followers" => null "date" => "5mo" "description" => """ “Culture eats strategy for breakfast” (Peter Drucker) 💡 \n With this motto, in March 2023, all employees of Daiichi Sankyo (Schweiz) AG) engaged in a co-creation effort to build our joint mission, vision and core behaviors.\n This journey was fascinating! It was filled with fruitful exchanges, passionate debates, commitment to get to a result that would have captured our hearts and stimulated our minds.\n As for every global company, mission, vision and core behaviors are harmonized at global level. Hence, a part of the journey was aimed at addressing the following key question: How do we build on our global legacy and add the local twist to make sure we can perceive our corporate culture as fully ours?\n We believe in a culture of collaboration, respect and support. Every member of our team is valuable and contributes to the success of the company. By aligning ourselves with these values, we strive to grow together as a team and move our company forward to make a positive impact. This is true in Daiichi Sankyo, regardless of which country we operate.\n Images might be the best way to express a concept and memorize it, hence, together with a very talented visual artist helge windisch, we have decorated our office to show an image of how our global behaviors meet with the Swiss mountaineering and adventurous spirit which animates all of us!\n \n #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Teamwork #Wallprint #Companymission #Companyvision #Pharma """ "reactions_count" => 70 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-26 20:26:52" "deleted" => 1 ] [ "id" => 732567454 "company_id" => 6832192 "urn" => "urn:li:activity:7235317109096931328" "followers" => null "date" => "2w" "description" => "Proud to have been part of the initiative, even prouder of being part of Daiichi Sankyo (Schweiz) AG ! 🙏👏" "reactions_count" => 3 "comments_count" => null "reshared_post_author" => "Daiichi Sankyo (Switzerland)" "reshared_post_author_url" => "https://ch.linkedin.com/company/daiichi-sankyo-schweiz-ag" "reshared_post_author_headline" => null "reshared_post_description" => """ 👉 Successful Clean-Up Day: A Step Towards a Cleaner Planet 💚🌍 \n \n We are proud to announce the successful completion of our Clean-Up Day last Friday, 23rd August, a heartfelt initiative dedicated to making our environment cleaner. This event saw enthusiastic participation from our team members in Switzerland who came together with a shared commitment to environmental sustainability and community well-being.\n \n As part of the European initiative, the Clean-Up Day, our DSCH team worked hard to collect and properly dispose of waste in our local area, demonstrating the power of collective action. The dedication and hard work of our volunteers not only made a significant impact on our environment but also raised awareness about the importance of reducing waste and promoting sustainable practices.\n \n Together, we have taken a crucial step towards a cleaner and more sustainable future. Let's continue to support and participate in such initiatives, ensuring that our efforts contribute to a healthier planet. Thank you to everyone who participated and made this Clean-Up Day a resounding success!\n \n \n #CleanupDay #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Companymission #Companyvision #Pharma #Zürich #Cleanerplanet\n \n CH/DSC/08/24/0001 """ "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2024-10-26 20:26:52" "deleted" => 1 ] [ "id" => 732567455 "company_id" => 6832192 "urn" => "urn:li:activity:7235184574580822018" "followers" => null "date" => "2w" "description" => """ 👉 Successful Clean-Up Day: A Step Towards a Cleaner Planet 💚🌍 \n \n We are proud to announce the successful completion of our Clean-Up Day last Friday, 23rd August, a heartfelt initiative dedicated to making our environment cleaner. This event saw enthusiastic participation from our team members in Switzerland who came together with a shared commitment to environmental sustainability and community well-being.\n \n As part of the European initiative, the Clean-Up Day, our DSCH team worked hard to collect and properly dispose of waste in our local area, demonstrating the power of collective action. The dedication and hard work of our volunteers not only made a significant impact on our environment but also raised awareness about the importance of reducing waste and promoting sustainable practices.\n \n Together, we have taken a crucial step towards a cleaner and more sustainable future. Let's continue to support and participate in such initiatives, ensuring that our efforts contribute to a healthier planet. Thank you to everyone who participated and made this Clean-Up Day a resounding success!\n \n \n #CleanupDay #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Companymission #Companyvision #Pharma #Zürich #Cleanerplanet\n \n CH/DSC/08/24/0001 """ "reactions_count" => 29 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-26 20:26:52" "deleted" => 1 ] [ "id" => 732567456 "company_id" => 6832192 "urn" => "urn:li:activity:7199676213471100928" "followers" => null "date" => "4mo" "description" => """ We are excited to announce the launch of DSPACE!\n \n #DSPACE is the Digital Innovation Hub at #DaiichiSankyoEurope, where we leverage digital technologies to support patients and healthcare professionals across Europe. \n \n Through understanding the needs of people living with #CardiovascularDisease and cancer, and the challenges healthcare professionals face, we aim to utilise the latest technologies to support people more effectively in their care journey 👩⚕️\n \n Learn more about #DSPACE here https://lnkd.in/dgkJsPCg """ "reactions_count" => 152 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-02 02:07:28" "deleted" => 1 ] [ "id" => 778976549 "company_id" => 6832192 "urn" => "urn:li:activity:7235317109096931328" "followers" => null "date" => "1mo" "description" => "Proud to have been part of the initiative, even prouder of being part of Daiichi Sankyo (Schweiz) AG ! 🙏👏" "reactions_count" => 4 "comments_count" => null "reshared_post_author" => "Daiichi Sankyo (Switzerland)" "reshared_post_author_url" => "https://ch.linkedin.com/company/daiichi-sankyo-schweiz-ag" "reshared_post_author_headline" => null "reshared_post_description" => """ 👉 Successful Clean-Up Day: A Step Towards a Cleaner Planet 💚🌍 \n \n We are proud to announce the successful completion of our Clean-Up Day last Friday, 23rd August, a heartfelt initiative dedicated to making our environment cleaner. This event saw enthusiastic participation from our team members in Switzerland who came together with a shared commitment to environmental sustainability and community well-being.\n \n As part of the European initiative, the Clean-Up Day, our DSCH team worked hard to collect and properly dispose of waste in our local area, demonstrating the power of collective action. The dedication and hard work of our volunteers not only made a significant impact on our environment but also raised awareness about the importance of reducing waste and promoting sustainable practices.\n \n Together, we have taken a crucial step towards a cleaner and more sustainable future. Let's continue to support and participate in such initiatives, ensuring that our efforts contribute to a healthier planet. Thank you to everyone who participated and made this Clean-Up Day a resounding success!\n \n \n #CleanupDay #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Companymission #Companyvision #Pharma #Zürich #Cleanerplanet\n \n CH/DSC/08/24/0001 """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-11-02 02:07:28" "deleted" => 1 ] [ "id" => 778976550 "company_id" => 6832192 "urn" => "urn:li:activity:7235184574580822018" "followers" => null "date" => "1mo" "description" => """ 👉 Successful Clean-Up Day: A Step Towards a Cleaner Planet 💚🌍 \n \n We are proud to announce the successful completion of our Clean-Up Day last Friday, 23rd August, a heartfelt initiative dedicated to making our environment cleaner. This event saw enthusiastic participation from our team members in Switzerland who came together with a shared commitment to environmental sustainability and community well-being.\n \n As part of the European initiative, the Clean-Up Day, our DSCH team worked hard to collect and properly dispose of waste in our local area, demonstrating the power of collective action. The dedication and hard work of our volunteers not only made a significant impact on our environment but also raised awareness about the importance of reducing waste and promoting sustainable practices.\n \n Together, we have taken a crucial step towards a cleaner and more sustainable future. Let's continue to support and participate in such initiatives, ensuring that our efforts contribute to a healthier planet. Thank you to everyone who participated and made this Clean-Up Day a resounding success!\n \n \n #CleanupDay #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Companymission #Companyvision #Pharma #Zürich #Cleanerplanet\n \n CH/DSC/08/24/0001 """ "reactions_count" => 29 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-02 02:07:28" "deleted" => 1 ] [ "id" => 778976551 "company_id" => 6832192 "urn" => "urn:li:activity:7179154587134623744" "followers" => null "date" => "6mo" "description" => """ “Culture eats strategy for breakfast” (Peter Drucker) 💡 \n With this motto, in March 2023, all employees of Daiichi Sankyo (Schweiz) AG) engaged in a co-creation effort to build our joint mission, vision and core behaviors.\n This journey was fascinating! It was filled with fruitful exchanges, passionate debates, commitment to get to a result that would have captured our hearts and stimulated our minds.\n As for every global company, mission, vision and core behaviors are harmonized at global level. Hence, a part of the journey was aimed at addressing the following key question: How do we build on our global legacy and add the local twist to make sure we can perceive our corporate culture as fully ours?\n We believe in a culture of collaboration, respect and support. Every member of our team is valuable and contributes to the success of the company. By aligning ourselves with these values, we strive to grow together as a team and move our company forward to make a positive impact. This is true in Daiichi Sankyo, regardless of which country we operate.\n Images might be the best way to express a concept and memorize it, hence, together with a very talented visual artist helge windisch, we have decorated our office to show an image of how our global behaviors meet with the Swiss mountaineering and adventurous spirit which animates all of us!\n \n #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Teamwork #Wallprint #Companymission #Companyvision #Pharma """ "reactions_count" => 70 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-02 02:07:28" "deleted" => 1 ] [ "id" => 782811603 "company_id" => 6832192 "urn" => "urn:li:activity:7257678788648427520" "followers" => null "date" => "1d" "description" => """ 👉 "Our journey to build the Daiichi Sankyo CH ONE identity"\n \n Organizations, especially growing ones, go through different evolution phases. In the last three years, Daiichi Sankyo Switzerland has substantially grown from a business perspective and added many new colleagues, coming from different companies with very distinct corporate culture. While this is a situation many companies aspire to have, sustainable growth is generally based on strong purpose and identity. The creation of ONE common identity and sense of belonging was a key business objective and the trigger of an unforgettable journey.\n \n The first milestone dates back to March 2023, as the team embarked on the pivotal mission to define the local vision and the core behaviors to realized it. The resulting bottom-up, inclusive approach fostered belonging and a common sense of purpose which serves as foundation of our business strategies and people interactions.\n \n In the following 18 months, we have combined our efforts various times, we have invested time to build our ONE identity and assign a visual to it to decorate our Zurich office, to remind us of our collective effort. We went beyond, by engaging each and every employee to discuss tangible actions to advance on key topics like processes optimization, communication and collaboration, trust and empowerment, we identify key areas of action which are guiding our execution to date.\n \n It is with great pride that we look back end of the first phase of this journey, which we recently celebrated in the beautiful Swiss town of Solothurn. In that context, we acknowledged our progress and through workshops and discussions, we developed a roadmap with clear objectives and tangible actions. We also took the time to do a personal appreciation exercise, to share with one another, in an engaging way, how much we value the contribution each team member is making to achieve our goal while maintaining a positive working environment. Finally, as every special moment deserves, we had a souvenir to bring home, an own handmade wine glass to remind us all of the path we walked together, ready to write the next chapter.\n Grateful to all the DSCH employees and special mention to our external partners who made the journey possible; Anna Inama, MSc, ICF MCC and Andy Fryer as leadership coaches and helge windisch for creating a visual impression image of what Daiichi Sankyo (Schweiz) AG aspires to be! \n \n #OneIdentity #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #CompanyCulture #CompanyMission #CompanyVision #Pharma #Zürich\n \n CH/DSC/10/24/0001_EN """ "reactions_count" => 53 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-26 12:23:53" "deleted" => 1 ] [ "id" => 782811604 "company_id" => 6832192 "urn" => "urn:li:activity:7235317109096931328" "followers" => null "date" => "2mo" "description" => "Proud to have been part of the initiative, even prouder of being part of Daiichi Sankyo (Schweiz) AG ! 🙏👏" "reactions_count" => 4 "comments_count" => null "reshared_post_author" => "Daiichi Sankyo (Switzerland)" "reshared_post_author_url" => "https://ch.linkedin.com/company/daiichi-sankyo-schweiz-ag" "reshared_post_author_headline" => null "reshared_post_description" => """ 👉 Successful Clean-Up Day: A Step Towards a Cleaner Planet 💚🌍 \n \n We are proud to announce the successful completion of our Clean-Up Day last Friday, 23rd August, a heartfelt initiative dedicated to making our environment cleaner. This event saw enthusiastic participation from our team members in Switzerland who came together with a shared commitment to environmental sustainability and community well-being.\n \n As part of the European initiative, the Clean-Up Day, our DSCH team worked hard to collect and properly dispose of waste in our local area, demonstrating the power of collective action. The dedication and hard work of our volunteers not only made a significant impact on our environment but also raised awareness about the importance of reducing waste and promoting sustainable practices.\n \n Together, we have taken a crucial step towards a cleaner and more sustainable future. Let's continue to support and participate in such initiatives, ensuring that our efforts contribute to a healthier planet. Thank you to everyone who participated and made this Clean-Up Day a resounding success!\n \n \n #CleanupDay #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Companymission #Companyvision #Pharma #Zürich #Cleanerplanet\n \n CH/DSC/08/24/0001 """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2024-12-01 15:14:18" "deleted" => 1 ] [ "id" => 782811605 "company_id" => 6832192 "urn" => "urn:li:activity:7235184574580822018" "followers" => null "date" => "2mo" "description" => """ 👉 Successful Clean-Up Day: A Step Towards a Cleaner Planet 💚🌍 \n \n We are proud to announce the successful completion of our Clean-Up Day last Friday, 23rd August, a heartfelt initiative dedicated to making our environment cleaner. This event saw enthusiastic participation from our team members in Switzerland who came together with a shared commitment to environmental sustainability and community well-being.\n \n As part of the European initiative, the Clean-Up Day, our DSCH team worked hard to collect and properly dispose of waste in our local area, demonstrating the power of collective action. The dedication and hard work of our volunteers not only made a significant impact on our environment but also raised awareness about the importance of reducing waste and promoting sustainable practices.\n \n Together, we have taken a crucial step towards a cleaner and more sustainable future. Let's continue to support and participate in such initiatives, ensuring that our efforts contribute to a healthier planet. Thank you to everyone who participated and made this Clean-Up Day a resounding success!\n \n \n #CleanupDay #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Companymission #Companyvision #Pharma #Zürich #Cleanerplanet\n \n CH/DSC/08/24/0001 """ "reactions_count" => 30 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-01 15:14:18" "deleted" => 1 ] [ "id" => 782811606 "company_id" => 6832192 "urn" => "urn:li:activity:7199676213471100928" "followers" => null "date" => "5mo" "description" => """ We are excited to announce the launch of DSPACE!\n \n #DSPACE is the Digital Innovation Hub at #DaiichiSankyoEurope, where we leverage digital technologies to support patients and healthcare professionals across Europe. \n \n Through understanding the needs of people living with #CardiovascularDisease and cancer, and the challenges healthcare professionals face, we aim to utilise the latest technologies to support people more effectively in their care journey 👩⚕️\n \n Learn more about #DSPACE here https://lnkd.in/dgkJsPCg """ "reactions_count" => 152 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-26 12:23:53" "deleted" => 1 ] [ "id" => 782811607 "company_id" => 6832192 "urn" => "urn:li:activity:7179154587134623744" "followers" => null "date" => "7mo" "description" => """ “Culture eats strategy for breakfast” (Peter Drucker) 💡 \n With this motto, in March 2023, all employees of Daiichi Sankyo (Schweiz) AG) engaged in a co-creation effort to build our joint mission, vision and core behaviors.\n This journey was fascinating! It was filled with fruitful exchanges, passionate debates, commitment to get to a result that would have captured our hearts and stimulated our minds.\n As for every global company, mission, vision and core behaviors are harmonized at global level. Hence, a part of the journey was aimed at addressing the following key question: How do we build on our global legacy and add the local twist to make sure we can perceive our corporate culture as fully ours?\n We believe in a culture of collaboration, respect and support. Every member of our team is valuable and contributes to the success of the company. By aligning ourselves with these values, we strive to grow together as a team and move our company forward to make a positive impact. This is true in Daiichi Sankyo, regardless of which country we operate.\n Images might be the best way to express a concept and memorize it, hence, together with a very talented visual artist helge windisch, we have decorated our office to show an image of how our global behaviors meet with the Swiss mountaineering and adventurous spirit which animates all of us!\n \n #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Teamwork #Wallprint #Companymission #Companyvision #Pharma """ "reactions_count" => 71 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-26 12:23:53" "deleted" => 1 ] [ "id" => 818110955 "company_id" => 6832192 "urn" => "urn:li:activity:7265657136913797121" "followers" => null "date" => "4d" "description" => """ Very grateful to PharmaBoardroom for giving us a space to present Daiichi Sankyo (Switzerland) to its readers.\n In the interview you will find details of Daiichi Sankyo history, insights on our recent business trajectory in Switzerland, details of our ambition to improve outcomes for Swiss patients affected by cardiovascular and oncology diseases.\n \n Special thanks to Roxane Höck for selecting us and for guiding a very stimulating conversation.\n \n I hope you will find the content enjoyable, happy reading!\n \n https://lnkd.in/ePs4GYwq\n \n #ProudtobeDSCH """ "reactions_count" => 83 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-01 15:14:18" "deleted" => 1 ] [ "id" => 818110956 "company_id" => 6832192 "urn" => "urn:li:activity:7257678788648427520" "followers" => null "date" => "3w" "description" => """ 👉 "Our journey to build the Daiichi Sankyo CH ONE identity"\n \n Organizations, especially growing ones, go through different evolution phases. In the last three years, Daiichi Sankyo Switzerland has substantially grown from a business perspective and added many new colleagues, coming from different companies with very distinct corporate culture. While this is a situation many companies aspire to have, sustainable growth is generally based on strong purpose and identity. The creation of ONE common identity and sense of belonging was a key business objective and the trigger of an unforgettable journey.\n \n The first milestone dates back to March 2023, as the team embarked on the pivotal mission to define the local vision and the core behaviors to realized it. The resulting bottom-up, inclusive approach fostered belonging and a common sense of purpose which serves as foundation of our business strategies and people interactions.\n \n In the following 18 months, we have combined our efforts various times, we have invested time to build our ONE identity and assign a visual to it to decorate our Zurich office, to remind us of our collective effort. We went beyond, by engaging each and every employee to discuss tangible actions to advance on key topics like processes optimization, communication and collaboration, trust and empowerment, we identify key areas of action which are guiding our execution to date.\n \n It is with great pride that we look back end of the first phase of this journey, which we recently celebrated in the beautiful Swiss town of Solothurn. In that context, we acknowledged our progress and through workshops and discussions, we developed a roadmap with clear objectives and tangible actions. We also took the time to do a personal appreciation exercise, to share with one another, in an engaging way, how much we value the contribution each team member is making to achieve our goal while maintaining a positive working environment. Finally, as every special moment deserves, we had a souvenir to bring home, an own handmade wine glass to remind us all of the path we walked together, ready to write the next chapter.\n Grateful to all the DSCH employees and special mention to our external partners who made the journey possible; Anna Inama, MSc, ICF MCC and Andy Fryer as leadership coaches and helge windisch for creating a visual impression image of what Daiichi Sankyo (Schweiz) AG aspires to be! \n \n #OneIdentity #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #CompanyCulture #CompanyMission #CompanyVision #Pharma #Zürich\n \n CH/DSC/10/24/0001_EN """ "reactions_count" => 79 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-01 15:14:18" "deleted" => 1 ] [ "id" => 818110957 "company_id" => 6832192 "urn" => "urn:li:activity:7199676213471100928" "followers" => null "date" => "6mo" "description" => """ We are excited to announce the launch of DSPACE!\n \n #DSPACE is the Digital Innovation Hub at #DaiichiSankyoEurope, where we leverage digital technologies to support patients and healthcare professionals across Europe. \n \n Through understanding the needs of people living with #CardiovascularDisease and cancer, and the challenges healthcare professionals face, we aim to utilise the latest technologies to support people more effectively in their care journey 👩⚕️\n \n Learn more about #DSPACE here https://lnkd.in/dgkJsPCg """ "reactions_count" => 152 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-03 15:55:41" "deleted" => 1 ] [ "id" => 818110958 "company_id" => 6832192 "urn" => "urn:li:activity:7179154587134623744" "followers" => null "date" => "8mo" "description" => """ “Culture eats strategy for breakfast” (Peter Drucker) 💡 \n With this motto, in March 2023, all employees of Daiichi Sankyo (Schweiz) AG) engaged in a co-creation effort to build our joint mission, vision and core behaviors.\n This journey was fascinating! It was filled with fruitful exchanges, passionate debates, commitment to get to a result that would have captured our hearts and stimulated our minds.\n As for every global company, mission, vision and core behaviors are harmonized at global level. Hence, a part of the journey was aimed at addressing the following key question: How do we build on our global legacy and add the local twist to make sure we can perceive our corporate culture as fully ours?\n We believe in a culture of collaboration, respect and support. Every member of our team is valuable and contributes to the success of the company. By aligning ourselves with these values, we strive to grow together as a team and move our company forward to make a positive impact. This is true in Daiichi Sankyo, regardless of which country we operate.\n Images might be the best way to express a concept and memorize it, hence, together with a very talented visual artist helge windisch, we have decorated our office to show an image of how our global behaviors meet with the Swiss mountaineering and adventurous spirit which animates all of us!\n \n #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Teamwork #Wallprint #Companymission #Companyvision #Pharma """ "reactions_count" => 71 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-03 15:55:41" "deleted" => 1 ] [ "id" => 833577172 "company_id" => 6832192 "urn" => "urn:li:activity:7265657136913797121" "followers" => null "date" => "1w" "description" => """ Very grateful to PharmaBoardroom for giving us a space to present Daiichi Sankyo (Switzerland) to its readers.\n In the interview you will find details of Daiichi Sankyo history, insights on our recent business trajectory in Switzerland, details of our ambition to improve outcomes for Swiss patients affected by cardiovascular and oncology diseases.\n \n Special thanks to Roxane Höck for selecting us and for guiding a very stimulating conversation.\n \n I hope you will find the content enjoyable, happy reading!\n \n https://lnkd.in/ePs4GYwq\n \n #ProudtobeDSCH """ "reactions_count" => 103 "comments_count" => 6 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-03 15:55:41" "deleted" => 1 ] [ "id" => 833577173 "company_id" => 6832192 "urn" => "urn:li:activity:7257678788648427520" "followers" => null "date" => "1mo" "description" => """ 👉 "Our journey to build the Daiichi Sankyo CH ONE identity"\n \n Organizations, especially growing ones, go through different evolution phases. In the last three years, Daiichi Sankyo Switzerland has substantially grown from a business perspective and added many new colleagues, coming from different companies with very distinct corporate culture. While this is a situation many companies aspire to have, sustainable growth is generally based on strong purpose and identity. The creation of ONE common identity and sense of belonging was a key business objective and the trigger of an unforgettable journey.\n \n The first milestone dates back to March 2023, as the team embarked on the pivotal mission to define the local vision and the core behaviors to realized it. The resulting bottom-up, inclusive approach fostered belonging and a common sense of purpose which serves as foundation of our business strategies and people interactions.\n \n In the following 18 months, we have combined our efforts various times, we have invested time to build our ONE identity and assign a visual to it to decorate our Zurich office, to remind us of our collective effort. We went beyond, by engaging each and every employee to discuss tangible actions to advance on key topics like processes optimization, communication and collaboration, trust and empowerment, we identify key areas of action which are guiding our execution to date.\n \n It is with great pride that we look back end of the first phase of this journey, which we recently celebrated in the beautiful Swiss town of Solothurn. In that context, we acknowledged our progress and through workshops and discussions, we developed a roadmap with clear objectives and tangible actions. We also took the time to do a personal appreciation exercise, to share with one another, in an engaging way, how much we value the contribution each team member is making to achieve our goal while maintaining a positive working environment. Finally, as every special moment deserves, we had a souvenir to bring home, an own handmade wine glass to remind us all of the path we walked together, ready to write the next chapter.\n Grateful to all the DSCH employees and special mention to our external partners who made the journey possible; Anna Inama, MSc, ICF MCC and Andy Fryer as leadership coaches and helge windisch for creating a visual impression image of what Daiichi Sankyo (Schweiz) AG aspires to be! \n \n #OneIdentity #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #CompanyCulture #CompanyMission #CompanyVision #Pharma #Zürich\n \n CH/DSC/10/24/0001_EN """ "reactions_count" => 79 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-03 15:55:41" "deleted" => 1 ] [ "id" => 833577174 "company_id" => 6832192 "urn" => "urn:li:activity:7235317109096931328" "followers" => null "date" => "3mo" "description" => "Proud to have been part of the initiative, even prouder of being part of Daiichi Sankyo (Schweiz) AG ! 🙏👏" "reactions_count" => 4 "comments_count" => null "reshared_post_author" => "Daiichi Sankyo (Switzerland)" "reshared_post_author_url" => "https://ch.linkedin.com/company/daiichi-sankyo-schweiz-ag" "reshared_post_author_headline" => null "reshared_post_description" => """ 👉 Successful Clean-Up Day: A Step Towards a Cleaner Planet 💚🌍 \n \n We are proud to announce the successful completion of our Clean-Up Day last Friday, 23rd August, a heartfelt initiative dedicated to making our environment cleaner. This event saw enthusiastic participation from our team members in Switzerland who came together with a shared commitment to environmental sustainability and community well-being.\n \n As part of the European initiative, the Clean-Up Day, our DSCH team worked hard to collect and properly dispose of waste in our local area, demonstrating the power of collective action. The dedication and hard work of our volunteers not only made a significant impact on our environment but also raised awareness about the importance of reducing waste and promoting sustainable practices.\n \n Together, we have taken a crucial step towards a cleaner and more sustainable future. Let's continue to support and participate in such initiatives, ensuring that our efforts contribute to a healthier planet. Thank you to everyone who participated and made this Clean-Up Day a resounding success!\n \n \n #CleanupDay #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Companymission #Companyvision #Pharma #Zürich #Cleanerplanet\n \n CH/DSC/08/24/0001 """ "reshared_post_followers" => null "reshared_post_date" => "3mo" "last_updated" => "2025-01-03 15:55:41" "deleted" => 1 ] [ "id" => 833577175 "company_id" => 6832192 "urn" => "urn:li:activity:7235184574580822018" "followers" => null "date" => "3mo" "description" => """ 👉 Successful Clean-Up Day: A Step Towards a Cleaner Planet 💚🌍 \n \n We are proud to announce the successful completion of our Clean-Up Day last Friday, 23rd August, a heartfelt initiative dedicated to making our environment cleaner. This event saw enthusiastic participation from our team members in Switzerland who came together with a shared commitment to environmental sustainability and community well-being.\n \n As part of the European initiative, the Clean-Up Day, our DSCH team worked hard to collect and properly dispose of waste in our local area, demonstrating the power of collective action. The dedication and hard work of our volunteers not only made a significant impact on our environment but also raised awareness about the importance of reducing waste and promoting sustainable practices.\n \n Together, we have taken a crucial step towards a cleaner and more sustainable future. Let's continue to support and participate in such initiatives, ensuring that our efforts contribute to a healthier planet. Thank you to everyone who participated and made this Clean-Up Day a resounding success!\n \n \n #CleanupDay #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Companymission #Companyvision #Pharma #Zürich #Cleanerplanet\n \n CH/DSC/08/24/0001 """ "reactions_count" => 30 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-03 15:55:41" "deleted" => 1 ] [ "id" => 865486680 "company_id" => 6832192 "urn" => "urn:li:activity:7265657136913797121" "followers" => null "date" => "1mo" "description" => """ Very grateful to PharmaBoardroom for giving us a space to present Daiichi Sankyo (Switzerland) to its readers.\n In the interview you will find details of Daiichi Sankyo history, insights on our recent business trajectory in Switzerland, details of our ambition to improve outcomes for Swiss patients affected by cardiovascular and oncology diseases.\n \n Special thanks to Roxane Höck for selecting us and for guiding a very stimulating conversation.\n \n I hope you will find the content enjoyable, happy reading!\n \n https://lnkd.in/ePs4GYwq\n \n #ProudtobeDSCH """ "reactions_count" => 127 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-22 13:10:12" "deleted" => 1 ] [ "id" => 865486681 "company_id" => 6832192 "urn" => "urn:li:activity:7257678788648427520" "followers" => null "date" => "2mo" "description" => """ 👉 "Our journey to build the Daiichi Sankyo CH ONE identity"\n \n Organizations, especially growing ones, go through different evolution phases. In the last three years, Daiichi Sankyo Switzerland has substantially grown from a business perspective and added many new colleagues, coming from different companies with very distinct corporate culture. While this is a situation many companies aspire to have, sustainable growth is generally based on strong purpose and identity. The creation of ONE common identity and sense of belonging was a key business objective and the trigger of an unforgettable journey.\n \n The first milestone dates back to March 2023, as the team embarked on the pivotal mission to define the local vision and the core behaviors to realized it. The resulting bottom-up, inclusive approach fostered belonging and a common sense of purpose which serves as foundation of our business strategies and people interactions.\n \n In the following 18 months, we have combined our efforts various times, we have invested time to build our ONE identity and assign a visual to it to decorate our Zurich office, to remind us of our collective effort. We went beyond, by engaging each and every employee to discuss tangible actions to advance on key topics like processes optimization, communication and collaboration, trust and empowerment, we identify key areas of action which are guiding our execution to date.\n \n It is with great pride that we look back end of the first phase of this journey, which we recently celebrated in the beautiful Swiss town of Solothurn. In that context, we acknowledged our progress and through workshops and discussions, we developed a roadmap with clear objectives and tangible actions. We also took the time to do a personal appreciation exercise, to share with one another, in an engaging way, how much we value the contribution each team member is making to achieve our goal while maintaining a positive working environment. Finally, as every special moment deserves, we had a souvenir to bring home, an own handmade wine glass to remind us all of the path we walked together, ready to write the next chapter.\n Grateful to all the DSCH employees and special mention to our external partners who made the journey possible; Anna Inama, MSc, ICF MCC and Andy Fryer as leadership coaches and helge windisch for creating a visual impression image of what Daiichi Sankyo (Schweiz) AG aspires to be! \n \n #OneIdentity #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #CompanyCulture #CompanyMission #CompanyVision #Pharma #Zürich\n \n CH/DSC/10/24/0001_EN """ "reactions_count" => 79 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-02 16:08:13" "deleted" => 1 ] [ "id" => 865486682 "company_id" => 6832192 "urn" => "urn:li:activity:7235317109096931328" "followers" => null "date" => "4mo" "description" => "Proud to have been part of the initiative, even prouder of being part of Daiichi Sankyo (Schweiz) AG ! 🙏👏" "reactions_count" => 4 "comments_count" => null "reshared_post_author" => "Daiichi Sankyo (Switzerland)" "reshared_post_author_url" => "https://ch.linkedin.com/company/daiichi-sankyo-schweiz-ag" "reshared_post_author_headline" => null "reshared_post_description" => """ 👉 Successful Clean-Up Day: A Step Towards a Cleaner Planet 💚🌍 \n \n We are proud to announce the successful completion of our Clean-Up Day last Friday, 23rd August, a heartfelt initiative dedicated to making our environment cleaner. This event saw enthusiastic participation from our team members in Switzerland who came together with a shared commitment to environmental sustainability and community well-being.\n \n As part of the European initiative, the Clean-Up Day, our DSCH team worked hard to collect and properly dispose of waste in our local area, demonstrating the power of collective action. The dedication and hard work of our volunteers not only made a significant impact on our environment but also raised awareness about the importance of reducing waste and promoting sustainable practices.\n \n Together, we have taken a crucial step towards a cleaner and more sustainable future. Let's continue to support and participate in such initiatives, ensuring that our efforts contribute to a healthier planet. Thank you to everyone who participated and made this Clean-Up Day a resounding success!\n \n \n #CleanupDay #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Companymission #Companyvision #Pharma #Zürich #Cleanerplanet\n \n CH/DSC/08/24/0001 """ "reshared_post_followers" => null "reshared_post_date" => "4mo" "last_updated" => "2025-02-02 16:08:13" "deleted" => 1 ] [ "id" => 865486683 "company_id" => 6832192 "urn" => "urn:li:activity:7235184574580822018" "followers" => null "date" => "4mo" "description" => """ 👉 Successful Clean-Up Day: A Step Towards a Cleaner Planet 💚🌍 \n \n We are proud to announce the successful completion of our Clean-Up Day last Friday, 23rd August, a heartfelt initiative dedicated to making our environment cleaner. This event saw enthusiastic participation from our team members in Switzerland who came together with a shared commitment to environmental sustainability and community well-being.\n \n As part of the European initiative, the Clean-Up Day, our DSCH team worked hard to collect and properly dispose of waste in our local area, demonstrating the power of collective action. The dedication and hard work of our volunteers not only made a significant impact on our environment but also raised awareness about the importance of reducing waste and promoting sustainable practices.\n \n Together, we have taken a crucial step towards a cleaner and more sustainable future. Let's continue to support and participate in such initiatives, ensuring that our efforts contribute to a healthier planet. Thank you to everyone who participated and made this Clean-Up Day a resounding success!\n \n \n #CleanupDay #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Companymission #Companyvision #Pharma #Zürich #Cleanerplanet\n \n CH/DSC/08/24/0001 """ "reactions_count" => 30 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-02 16:08:13" "deleted" => 1 ] [ "id" => 865486684 "company_id" => 6832192 "urn" => "urn:li:activity:7199676213471100928" "followers" => null "date" => "7mo" "description" => """ We are excited to announce the launch of DSPACE!\n \n #DSPACE is the Digital Innovation Hub at #DaiichiSankyoEurope, where we leverage digital technologies to support patients and healthcare professionals across Europe. \n \n Through understanding the needs of people living with #CardiovascularDisease and cancer, and the challenges healthcare professionals face, we aim to utilise the latest technologies to support people more effectively in their care journey 👩⚕️\n \n Learn more about #DSPACE here https://lnkd.in/dgkJsPCg """ "reactions_count" => 152 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-22 13:10:12" "deleted" => 1 ] [ "id" => 865486685 "company_id" => 6832192 "urn" => "urn:li:activity:7179154587134623744" "followers" => null "date" => "9mo" "description" => """ “Culture eats strategy for breakfast” (Peter Drucker) 💡 \n With this motto, in March 2023, all employees of Daiichi Sankyo (Schweiz) AG) engaged in a co-creation effort to build our joint mission, vision and core behaviors.\n This journey was fascinating! It was filled with fruitful exchanges, passionate debates, commitment to get to a result that would have captured our hearts and stimulated our minds.\n As for every global company, mission, vision and core behaviors are harmonized at global level. Hence, a part of the journey was aimed at addressing the following key question: How do we build on our global legacy and add the local twist to make sure we can perceive our corporate culture as fully ours?\n We believe in a culture of collaboration, respect and support. Every member of our team is valuable and contributes to the success of the company. By aligning ourselves with these values, we strive to grow together as a team and move our company forward to make a positive impact. This is true in Daiichi Sankyo, regardless of which country we operate.\n Images might be the best way to express a concept and memorize it, hence, together with a very talented visual artist helge windisch, we have decorated our office to show an image of how our global behaviors meet with the Swiss mountaineering and adventurous spirit which animates all of us!\n \n #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Teamwork #Wallprint #Companymission #Companyvision #Pharma """ "reactions_count" => 71 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-02 16:08:13" "deleted" => 1 ] [ "id" => 905093148 "company_id" => 6832192 "urn" => "urn:li:activity:7265657136913797121" "followers" => null "date" => "2mo" "description" => """ Very grateful to PharmaBoardroom for giving us a space to present Daiichi Sankyo (Switzerland) to its readers.\n In the interview you will find details of Daiichi Sankyo history, insights on our recent business trajectory in Switzerland, details of our ambition to improve outcomes for Swiss patients affected by cardiovascular and oncology diseases.\n \n Special thanks to Roxane Höck for selecting us and for guiding a very stimulating conversation.\n \n I hope you will find the content enjoyable, happy reading!\n \n https://lnkd.in/ePs4GYwq\n \n #ProudtobeDSCH """ "reactions_count" => 127 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-02 16:08:13" "deleted" => 1 ] [ "id" => 905093149 "company_id" => 6832192 "urn" => "urn:li:activity:7199676213471100928" "followers" => null "date" => "8mo" "description" => """ We are excited to announce the launch of DSPACE!\n \n #DSPACE is the Digital Innovation Hub at #DaiichiSankyoEurope, where we leverage digital technologies to support patients and healthcare professionals across Europe. \n \n Through understanding the needs of people living with #CardiovascularDisease and cancer, and the challenges healthcare professionals face, we aim to utilise the latest technologies to support people more effectively in their care journey 👩⚕️\n \n Learn more about #DSPACE here https://lnkd.in/dgkJsPCg """ "reactions_count" => 152 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 913556890 "company_id" => 6832192 "urn" => "urn:li:activity:7290997813759414273" "followers" => null "date" => "1d" "description" => """ 🌟 Daiichi Sankyo Switzerland is officially a Great Place to Work™! 🌟\n \n We are incredibly proud to receive this certification, which celebrates the culture we’ve built together—one rooted in trust, collaboration, and purpose.\n This milestone is a testament to our incredible team, whose passion and dedication make Daiichi Sankyo (Schweiz) AG a place where innovation thrives, careers grow, and lives are changed.\n \n ➡️ Discover what makes us a Great Place to Work™ and explore opportunities to join our team here: \n https://lnkd.in/dTX7nwgZ\n \n \n #GreatPlaceToWork #ProudtobeDSCH #DaiichiSankyo #Teamwork #Innovation #Healthcare\n \n \n \n CH/DSC/01/25/0002_EN """ "reactions_count" => 68 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 913556891 "company_id" => 6832192 "urn" => "urn:li:activity:7265657136913797121" "followers" => null "date" => "2mo" "description" => """ Very grateful to PharmaBoardroom for giving us a space to present Daiichi Sankyo (Switzerland) to its readers.\n In the interview you will find details of Daiichi Sankyo history, insights on our recent business trajectory in Switzerland, details of our ambition to improve outcomes for Swiss patients affected by cardiovascular and oncology diseases.\n \n Special thanks to Roxane Höck for selecting us and for guiding a very stimulating conversation.\n \n I hope you will find the content enjoyable, happy reading!\n \n https://lnkd.in/ePs4GYwq\n \n #ProudtobeDSCH """ "reactions_count" => 128 "comments_count" => 7 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 913556892 "company_id" => 6832192 "urn" => "urn:li:activity:7257678788648427520" "followers" => null "date" => "3mo" "description" => """ 👉 "Our journey to build the Daiichi Sankyo CH ONE identity"\n \n Organizations, especially growing ones, go through different evolution phases. In the last three years, Daiichi Sankyo Switzerland has substantially grown from a business perspective and added many new colleagues, coming from different companies with very distinct corporate culture. While this is a situation many companies aspire to have, sustainable growth is generally based on strong purpose and identity. The creation of ONE common identity and sense of belonging was a key business objective and the trigger of an unforgettable journey.\n \n The first milestone dates back to March 2023, as the team embarked on the pivotal mission to define the local vision and the core behaviors to realized it. The resulting bottom-up, inclusive approach fostered belonging and a common sense of purpose which serves as foundation of our business strategies and people interactions.\n \n In the following 18 months, we have combined our efforts various times, we have invested time to build our ONE identity and assign a visual to it to decorate our Zurich office, to remind us of our collective effort. We went beyond, by engaging each and every employee to discuss tangible actions to advance on key topics like processes optimization, communication and collaboration, trust and empowerment, we identify key areas of action which are guiding our execution to date.\n \n It is with great pride that we look back end of the first phase of this journey, which we recently celebrated in the beautiful Swiss town of Solothurn. In that context, we acknowledged our progress and through workshops and discussions, we developed a roadmap with clear objectives and tangible actions. We also took the time to do a personal appreciation exercise, to share with one another, in an engaging way, how much we value the contribution each team member is making to achieve our goal while maintaining a positive working environment. Finally, as every special moment deserves, we had a souvenir to bring home, an own handmade wine glass to remind us all of the path we walked together, ready to write the next chapter.\n Grateful to all the DSCH employees and special mention to our external partners who made the journey possible; Anna Inama, MSc, ICF MCC and Andy Fryer as leadership coaches and helge windisch for creating a visual impression image of what Daiichi Sankyo (Schweiz) AG aspires to be! \n \n #OneIdentity #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #CompanyCulture #CompanyMission #CompanyVision #Pharma #Zürich\n \n CH/DSC/10/24/0001_EN """ "reactions_count" => 79 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 913556893 "company_id" => 6832192 "urn" => "urn:li:activity:7235317109096931328" "followers" => null "date" => "5mo" "description" => "Proud to have been part of the initiative, even prouder of being part of Daiichi Sankyo (Schweiz) AG ! 🙏👏" "reactions_count" => 4 "comments_count" => null "reshared_post_author" => "Daiichi Sankyo (Switzerland)" "reshared_post_author_url" => "https://ch.linkedin.com/company/daiichi-sankyo-schweiz-ag" "reshared_post_author_headline" => null "reshared_post_description" => """ 👉 Successful Clean-Up Day: A Step Towards a Cleaner Planet 💚🌍 \n \n We are proud to announce the successful completion of our Clean-Up Day last Friday, 23rd August, a heartfelt initiative dedicated to making our environment cleaner. This event saw enthusiastic participation from our team members in Switzerland who came together with a shared commitment to environmental sustainability and community well-being.\n \n As part of the European initiative, the Clean-Up Day, our DSCH team worked hard to collect and properly dispose of waste in our local area, demonstrating the power of collective action. The dedication and hard work of our volunteers not only made a significant impact on our environment but also raised awareness about the importance of reducing waste and promoting sustainable practices.\n \n Together, we have taken a crucial step towards a cleaner and more sustainable future. Let's continue to support and participate in such initiatives, ensuring that our efforts contribute to a healthier planet. Thank you to everyone who participated and made this Clean-Up Day a resounding success!\n \n \n #CleanupDay #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Companymission #Companyvision #Pharma #Zürich #Cleanerplanet\n \n CH/DSC/08/24/0001 """ "reshared_post_followers" => null "reshared_post_date" => "5mo" "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 913556894 "company_id" => 6832192 "urn" => "urn:li:activity:7235184574580822018" "followers" => null "date" => "5mo" "description" => """ 👉 Successful Clean-Up Day: A Step Towards a Cleaner Planet 💚🌍 \n \n We are proud to announce the successful completion of our Clean-Up Day last Friday, 23rd August, a heartfelt initiative dedicated to making our environment cleaner. This event saw enthusiastic participation from our team members in Switzerland who came together with a shared commitment to environmental sustainability and community well-being.\n \n As part of the European initiative, the Clean-Up Day, our DSCH team worked hard to collect and properly dispose of waste in our local area, demonstrating the power of collective action. The dedication and hard work of our volunteers not only made a significant impact on our environment but also raised awareness about the importance of reducing waste and promoting sustainable practices.\n \n Together, we have taken a crucial step towards a cleaner and more sustainable future. Let's continue to support and participate in such initiatives, ensuring that our efforts contribute to a healthier planet. Thank you to everyone who participated and made this Clean-Up Day a resounding success!\n \n \n #CleanupDay #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Companymission #Companyvision #Pharma #Zürich #Cleanerplanet\n \n CH/DSC/08/24/0001 """ "reactions_count" => 30 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] [ "id" => 913556895 "company_id" => 6832192 "urn" => "urn:li:activity:7179154587134623744" "followers" => null "date" => "10mo" "description" => """ “Culture eats strategy for breakfast” (Peter Drucker) 💡 \n With this motto, in March 2023, all employees of Daiichi Sankyo (Schweiz) AG) engaged in a co-creation effort to build our joint mission, vision and core behaviors.\n This journey was fascinating! It was filled with fruitful exchanges, passionate debates, commitment to get to a result that would have captured our hearts and stimulated our minds.\n As for every global company, mission, vision and core behaviors are harmonized at global level. Hence, a part of the journey was aimed at addressing the following key question: How do we build on our global legacy and add the local twist to make sure we can perceive our corporate culture as fully ours?\n We believe in a culture of collaboration, respect and support. Every member of our team is valuable and contributes to the success of the company. By aligning ourselves with these values, we strive to grow together as a team and move our company forward to make a positive impact. This is true in Daiichi Sankyo, regardless of which country we operate.\n Images might be the best way to express a concept and memorize it, hence, together with a very talented visual artist helge windisch, we have decorated our office to show an image of how our global behaviors meet with the Swiss mountaineering and adventurous spirit which animates all of us!\n \n #DaiichiSankyo #Teamwork #Wecareforeveryheartbeat #Companyvalues #Cardiology #Oncology #Companyculture #Teamwork #Wallprint #Companymission #Companyvision #Pharma """ "reactions_count" => 71 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-02 16:08:13" "deleted" => 0 ] ] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4704 …} -companyTags: Doctrine\ORM\PersistentCollection {#4706 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4708 …} -users: Doctrine\ORM\PersistentCollection {#4710 …} -logoImageName: "20250226144142-csm-reference-daiichi-sankyo-logo-70f5ca5e37-67bf1a1643137003090124.png" -coverImageName: "20250227162524-4568-t-819061e7-67c083e484a86750353772.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4712 …} -tagline: "Innovationen für die kardiovaskuläre Gesundheit – Fortschritte in der Lipidbehandlung und Vorhofflimmern" -contactEmail: "info@daiichi-sankyo.ch" -phone: "41434333300" -streamUrl: "https://vimeo.com/586746879" -streamType: "VIMEO" -followers: Doctrine\ORM\PersistentCollection {#4714 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4716 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4718 …} -industry: "" -size: null -address1: "Vulkanstrasse 106" -address2: null -city: "Zürich" -postalCode: "8048" -state: null -country: "Switzerland" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4720 …} #createdAt: DateTime @1740049804 {#4681 date: 2025-02-20 11:10:04.0 UTC (+00:00) } #updatedAt: DateTime @1750924740 {#4680 date: 2025-06-26 07:59:00.0 UTC (+00:00) } } App\Entity\Company {#4724 -id: 22 -name: "Desitin Pharma GmbH" -website: "https://desitin.ch" -description: """ Desitin Pharma GmbH in Liestal in die schweizerische Tochterfirma der Desitin Arzneimittel GmbH, eines 1919 in Berlin gegründeten und seit 1945 in Hamburg ansässigen pharmazeutischen Familienunternehmens. \n \n In der Schweiz ist Desitin die Spezialistin im Therapiegebiet Epilepsie. Mit neun Präparaten bietet Desitin das breiteste Sortiment oraler und parenteraler Antiepileptika in der Schweiz an. Es ist unser Ziel, mit innovativen Medikamenten und Serviceangeboten Fachpersonen und Patienten zu unterstützen, um einen optimalen therapeutischen Erfolg zu erzielen. Desitin hat sich darauf spezialisiert, die Galenik von Medikamenten weiterzuentwickeln und Darreichungsformen anzubieten, die die Einnahme erleichtern und somit die Compliance erhöhen. Solche galenischen Weiterentwicklungen sind z.B. viertelbare Tabletten, die ein Aufdosieren vereinfachen können oder Minitabletten, die bei eingeschränkter Schluckfunktion besser eingenommen werden. """ -externalId: "94060592" -details: [ "id" => 94060592 "url" => "https://www.linkedin.com/company/desitin-ch" "hash" => "d7a4f5d617fcbfc12a0a8b56d3945efc" "name" => "Desitin Pharma GmbH" "website" => "https://www.desitin.ch/" "size" => "2-10 employees" "industry" => "Pharmaceutical Manufacturing" "description" => """ In der Schweiz ist Desitin die Spezialistin im Therapiegebiet Epilepsie. Mit zehn Präparaten bietet Desitin das breiteste Sortiment oraler und parenteraler Antiepileptika in der Schweiz an. \n Es ist unser Ziel, mit innovativen Medikamenten und Serviceangeboten Fachpersonen und Patienten zu unterstützen, um einen optimalen therapeutischen Erfolg zu erzielen. \n \n Desitin hat sich darauf spezialisiert, die Galenik von Medikamenten weiterzuentwickeln und Darreichungsformen anzubieten, die die Einnahme erleichtern und somit die Compliance erhöhen. \n Solche galenischen Weiterentwicklungen sind z.B. viertelbare Tabletten, die ein Aufdosieren vereinfachen können oder Minitabletten, die bei eingeschränkter Schluckfunktion besser eingenommen werden. """ "followers" => 170 "founded" => null "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://media.licdn.com/dms/image/v2/D4D0BAQGXspCRxnxSCA/company-logo_200_200/company-logo_200_200/0/1682579347705/desitin_ch_logo?e=2147483647&v=beta&t=7AvmEr8frLYXdjwmvada3_1SiYfjKf5ON21LkEpqIvY" "created" => "2023-10-18 07:58:55" "last_updated" => "2025-02-08 17:42:10" "last_response_code" => 200 "type" => "Public Company" "headquarters_new_address" => "Liestal, BL" "employees_count" => null "headquarters_country_restored" => null "headquarters_country_parsed" => "Switzerland" "company_shorthand_name" => "desitin-ch" "company_shorthand_name_hash" => "8ffea4272c62eb51da09e7bc86cc59e8" "canonical_url" => "https://ch.linkedin.com/company/desitin-ch" "canonical_hash" => "fb490cc2c9a513fb02385d3d29bcfd3b" "canonical_shorthand_name" => "desitin-ch" "canonical_shorthand_name_hash" => "8ffea4272c62eb51da09e7bc86cc59e8" "deleted" => 0 "last_updated_ux" => 1739036530 "source_id" => 93213286 "company_affiliated_collection" => [] "company_also_viewed_collection" => [] "company_crunchbase_info_collection" => [] "company_featured_employees_collection" => [ [ "id" => 192289616 "company_id" => 94060592 "url" => "https://no.linkedin.com/in/ann-karin-skogen-b7636544" "created" => "2023-10-18 07:58:54" "last_updated" => "2024-04-24 08:05:53" "deleted" => 1 ] [ "id" => 192289617 "company_id" => 94060592 "url" => "https://ch.linkedin.com/in/jan-oliver-lorenz-97b74a88" "created" => "2023-10-18 07:58:54" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 192289618 "company_id" => 94060592 "url" => "https://de.linkedin.com/in/kathrin-haase-764371127" "created" => "2023-10-18 07:58:54" "last_updated" => "2023-11-26 16:28:15" "deleted" => 1 ] [ "id" => 197309971 "company_id" => 94060592 "url" => "https://ch.linkedin.com/in/victoria-blaha-6a5baa66" "created" => "2023-11-26 16:28:15" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 197309972 "company_id" => 94060592 "url" => "https://ch.linkedin.com/in/renata-voegeli-855a9496" "created" => "2023-11-26 16:28:15" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 205264803 "company_id" => 94060592 "url" => "https://de.linkedin.com/in/kathrin-haase-764371127" "created" => "2024-04-24 08:05:53" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] ] "company_featured_investors_collection" => [] "company_funding_rounds_collection" => [] "company_locations_collection" => [ [ "id" => 140057220 "company_id" => 94060592 "location_address" => "Hammerstrasse 47; Liestal, BL CH-4410, CH" "is_primary" => 1 "created" => "2023-10-18 07:58:54" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] ] "company_similar_collection" => [ [ "id" => 894855696 "company_id" => 94060592 "url" => "https://de.linkedin.com/company/desitin-arzneimittel-gmbh" "created" => "2023-10-18 07:58:54" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 894855697 "company_id" => 94060592 "url" => "https://cz.linkedin.com/company/medicon-a-s-" "created" => "2023-10-18 07:58:54" "last_updated" => "2024-01-05 19:21:32" "deleted" => 1 ] [ "id" => 894855698 "company_id" => 94060592 "url" => "https://cz.linkedin.com/company/benu-ceska-republika" "created" => "2023-10-18 07:58:54" "last_updated" => "2024-01-05 19:21:32" "deleted" => 1 ] [ "id" => 894855699 "company_id" => 94060592 "url" => "https://de.linkedin.com/company/merz-therapeutics" "created" => "2023-10-18 07:58:54" "last_updated" => "2024-01-05 19:21:32" "deleted" => 1 ] [ "id" => 894855700 "company_id" => 94060592 "url" => "https://de.linkedin.com/company/bayer" "created" => "2023-10-18 07:58:54" "last_updated" => "2023-12-13 16:04:31" "deleted" => 1 ] [ "id" => 917096838 "company_id" => 94060592 "url" => "https://ae.linkedin.com/company/ms-pharma-uae" "created" => "2023-11-26 16:28:15" "last_updated" => "2024-01-05 19:21:32" "deleted" => 1 ] [ "id" => 917096839 "company_id" => 94060592 "url" => "https://ch.linkedin.com/company/bioeq-ag" "created" => "2023-11-26 16:28:15" "last_updated" => "2024-01-05 19:21:32" "deleted" => 1 ] [ "id" => 917096840 "company_id" => 94060592 "url" => "https://in.linkedin.com/company/gmp-technical-solutions-pvt-ltd" "created" => "2023-11-26 16:28:15" "last_updated" => "2024-01-05 19:21:32" "deleted" => 1 ] [ "id" => 917096841 "company_id" => 94060592 "url" => "https://www.linkedin.com/company/bd1" "created" => "2023-11-26 16:28:15" "last_updated" => "2023-12-13 16:04:31" "deleted" => 1 ] [ "id" => 924241889 "company_id" => 94060592 "url" => "https://be.linkedin.com/company/neuropsychology-lab-leuven" "created" => "2023-12-13 16:04:31" "last_updated" => "2024-04-24 08:05:53" "deleted" => 1 ] [ "id" => 924241890 "company_id" => 94060592 "url" => "https://be.linkedin.com/company/homestartvlaanderen" "created" => "2023-12-13 16:04:31" "last_updated" => "2024-05-19 04:25:51" "deleted" => 1 ] [ "id" => 924241891 "company_id" => 94060592 "url" => "https://www.linkedin.com/company/absci" "created" => "2023-12-13 16:04:31" "last_updated" => "2024-01-05 19:21:32" "deleted" => 1 ] [ "id" => 931983308 "company_id" => 94060592 "url" => "https://uk.linkedin.com/company/desitin" "created" => "2024-01-05 19:21:32" "last_updated" => "2025-02-08 17:42:10" "deleted" => 1 ] [ "id" => 931983309 "company_id" => 94060592 "url" => "https://ch.linkedin.com/company/marketeersbern" "created" => "2024-01-05 19:21:32" "last_updated" => "2024-05-19 04:25:51" "deleted" => 1 ] [ "id" => 931983310 "company_id" => 94060592 "url" => "https://ch.linkedin.com/company/baumer-ag" "created" => "2024-01-05 19:21:32" "last_updated" => "2024-04-24 08:05:53" "deleted" => 1 ] [ "id" => 931983311 "company_id" => 94060592 "url" => "https://www.linkedin.com/company/intervexion-therapeutics-llc" "created" => "2024-01-05 19:21:32" "last_updated" => "2024-04-24 08:05:53" "deleted" => 1 ] [ "id" => 931983312 "company_id" => 94060592 "url" => "https://www.linkedin.com/company/aphrodite-health" "created" => "2024-01-05 19:21:32" "last_updated" => "2024-04-24 08:05:53" "deleted" => 1 ] [ "id" => 931983313 "company_id" => 94060592 "url" => "https://www.linkedin.com/company/felicity-pharma" "created" => "2024-01-05 19:21:32" "last_updated" => "2024-02-28 13:23:23" "deleted" => 1 ] [ "id" => 931983314 "company_id" => 94060592 "url" => "https://tw.linkedin.com/company/annji-pharmaceutical-co-ltd" "created" => "2024-01-05 19:21:32" "last_updated" => "2024-02-28 13:23:23" "deleted" => 1 ] [ "id" => 960626601 "company_id" => 94060592 "url" => "https://sg.linkedin.com/company/r-a-corder-consulting-pte-ltd" "created" => "2024-02-28 13:23:23" "last_updated" => "2024-06-13 20:50:35" "deleted" => 1 ] [ "id" => 960626602 "company_id" => 94060592 "url" => "https://ch.linkedin.com/company/roche" "created" => "2024-02-28 13:23:23" "last_updated" => "2024-05-19 04:25:51" "deleted" => 1 ] [ "id" => 990558839 "company_id" => 94060592 "url" => "https://uk.linkedin.com/company/namipharma" "created" => "2024-04-24 08:05:53" "last_updated" => "2024-06-13 20:50:35" "deleted" => 1 ] [ "id" => 990558840 "company_id" => 94060592 "url" => "https://ch.linkedin.com/company/soul-sense-akademie-f%C3%BCr-integrales-bewusstsein" "created" => "2024-04-24 08:05:53" "last_updated" => "2024-06-13 20:50:35" "deleted" => 1 ] [ "id" => 990558841 "company_id" => 94060592 "url" => "https://ch.linkedin.com/company/effik-suisse" "created" => "2024-04-24 08:05:53" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 990558842 "company_id" => 94060592 "url" => "https://de.linkedin.com/company/pharmarecht-marburg" "created" => "2024-04-24 08:05:53" "last_updated" => "2024-05-19 04:25:51" "deleted" => 1 ] [ "id" => 1001557281 "company_id" => 94060592 "url" => "https://ch.linkedin.com/company/dr-falk-pharma-ag" "created" => "2024-05-19 04:25:51" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 1001557282 "company_id" => 94060592 "url" => "https://cz.linkedin.com/company/medicon-a-s-" "created" => "2024-05-19 04:25:51" "last_updated" => "2024-10-21 13:29:42" "deleted" => 1 ] [ "id" => 1001557283 "company_id" => 94060592 "url" => "https://in.linkedin.com/company/gmp-technical-solutions-pvt-ltd" "created" => "2024-05-19 04:25:51" "last_updated" => "2024-11-27 18:19:28" "deleted" => 1 ] [ "id" => 1001557284 "company_id" => 94060592 "url" => "https://de.linkedin.com/company/infectopharm-arzneimittel-und-consilium-gmbh" "created" => "2024-05-19 04:25:51" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 1018183757 "company_id" => 94060592 "url" => "https://ch.linkedin.com/company/kaper-pharma" "created" => "2024-06-13 20:50:35" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 1018183758 "company_id" => 94060592 "url" => "https://de.linkedin.com/company/pohl-boskamp" "created" => "2024-06-13 20:50:35" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 1018183759 "company_id" => 94060592 "url" => "https://de.linkedin.com/company/nordmark-pharma" "created" => "2024-06-13 20:50:35" "last_updated" => "2025-01-17 22:19:43" "deleted" => 1 ] [ "id" => 1088667883 "company_id" => 94060592 "url" => "https://ch.linkedin.com/company/medicus-aerztezentrum" "created" => "2024-10-21 13:29:42" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 1112883322 "company_id" => 94060592 "url" => "https://de.linkedin.com/company/alfred-e.-tiefenbacher-gmbh-&-co.-kg-" "created" => "2024-11-27 18:19:28" "last_updated" => "2025-01-17 22:19:43" "deleted" => 1 ] [ "id" => 1137134931 "company_id" => 94060592 "url" => "https://ch.linkedin.com/company/aphaia-pharma" "created" => "2025-01-17 22:19:43" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 1137134932 "company_id" => 94060592 "url" => "https://ch.linkedin.com/company/sigma-pharma-tools" "created" => "2025-01-17 22:19:43" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 1150891702 "company_id" => 94060592 "url" => "https://de.linkedin.com/company/nordmark-pharma" "created" => "2025-02-08 17:42:10" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] ] "company_specialties_collection" => [ [ "id" => 125943870 "company_id" => 94060592 "specialty" => "Epilepsie and Generika" "created" => "2023-10-18 07:58:54" "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] ] "company_stock_info_collection" => [] "company_updates_collection" => [ [ "id" => 393278818 "company_id" => 94060592 "urn" => "urn:li:activity:7132283393181933568" "followers" => null "date" => "6d" "description" => "Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“, vom 23. - 24.November 2023 im Kongresshaus Zürich, am Stand Nr. 6 und erfahren Sie mehr über unser umfangreiches Service-Angebot." "reactions_count" => 6 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-13 16:04:31" "deleted" => 1 ] [ "id" => 393278819 "company_id" => 94060592 "urn" => "urn:li:activity:7128312802674401280" "followers" => null "date" => "2w" "description" => """ Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“ \n vom 23. - 24.11.2023 im Kongresshaus Zürich am Stand Nr. 6 \n und erfahren Sie mehr über unser umfangreiches Service-Angebot. """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-13 16:04:31" "deleted" => 1 ] [ "id" => 412683737 "company_id" => 94060592 "urn" => "urn:li:activity:7132283393181933568" "followers" => null "date" => "3w" "description" => "Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“, vom 23. - 24.November 2023 im Kongresshaus Zürich, am Stand Nr. 6 und erfahren Sie mehr über unser umfangreiches Service-Angebot." "reactions_count" => 9 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-05 19:21:32" "deleted" => 1 ] [ "id" => 412683739 "company_id" => 94060592 "urn" => "urn:li:activity:7128312802674401280" "followers" => null "date" => "1mo" "description" => """ Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“ \n vom 23. - 24.11.2023 im Kongresshaus Zürich am Stand Nr. 6 \n und erfahren Sie mehr über unser umfangreiches Service-Angebot. """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-28 13:23:23" "deleted" => 1 ] [ "id" => 431213243 "company_id" => 94060592 "urn" => "urn:li:activity:7132283393181933568" "followers" => null "date" => "1mo" "description" => "Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“, vom 23. - 24.November 2023 im Kongresshaus Zürich, am Stand Nr. 6 und erfahren Sie mehr über unser umfangreiches Service-Angebot." "reactions_count" => 10 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-28 13:23:23" "deleted" => 1 ] [ "id" => 490465878 "company_id" => 94060592 "urn" => "urn:li:activity:7132283393181933568" "followers" => null "date" => "3mo" "description" => "Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“, vom 23. - 24.November 2023 im Kongresshaus Zürich, am Stand Nr. 6 und erfahren Sie mehr über unser umfangreiches Service-Angebot." "reactions_count" => 10 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-24 08:05:53" "deleted" => 1 ] [ "id" => 490465879 "company_id" => 94060592 "urn" => "urn:li:activity:7128312802674401280" "followers" => null "date" => "3mo" "description" => """ Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“ \n vom 23. - 24.11.2023 im Kongresshaus Zürich am Stand Nr. 6 \n und erfahren Sie mehr über unser umfangreiches Service-Angebot. """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-24 08:05:53" "deleted" => 1 ] [ "id" => 549773482 "company_id" => 94060592 "urn" => "urn:li:activity:7185563875830865920" "followers" => null "date" => "5d" "description" => """ Mit zehn Präparaten bietet Desitin das breiteste Sortiment oraler und parenteraler Antiepileptika in der Schweiz. Die bestmögliche Therapie der Patienten steht für uns im Vordergrund der Aktivitäten. \n Dies bedingt eine stetige Weiterentwicklung der Medikamente und deren Darreichungsformen, um die Einnahme zu erleichtern und die Compliance zu erhöhen. \n \n Unsere Antiepileptika auf einen Blick: www.desitin.ch/produkte\n \n #desitin #epilepsie #epilepsy #generika #antiepilepticum #galenik """ "reactions_count" => 42 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-19 04:25:51" "deleted" => 1 ] [ "id" => 549773483 "company_id" => 94060592 "urn" => "urn:li:activity:7173685533494251520" "followers" => null "date" => "1mo" "description" => """ Vielversprechende positive Studienresultate mit 298 Patienten, welche an obstruktiver Schlafapnoe leiden.\n \n Résultats positifs et prometteurs d'une étude portant sur 298 patients souffrant d'apnée obstructive du sommeil !\n \n Pour plus d'informations, cliquez ici (en anglais/english) : \n https://lnkd.in/emmxvKAa\n \n #schlafapnoe #osa #sleephealth #desitin #epilepsie #epilepsy #generika #antiepilepticum #apnee #sleephealth """ "reactions_count" => 27 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-19 04:25:51" "deleted" => 1 ] [ "id" => 549773484 "company_id" => 94060592 "urn" => "urn:li:activity:7132283393181933568" "followers" => null "date" => "5mo" "description" => "Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“, vom 23. - 24.November 2023 im Kongresshaus Zürich, am Stand Nr. 6 und erfahren Sie mehr über unser umfangreiches Service-Angebot." "reactions_count" => 11 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-19 04:25:51" "deleted" => 1 ] [ "id" => 549773485 "company_id" => 94060592 "urn" => "urn:li:activity:7128312802674401280" "followers" => null "date" => "5mo" "description" => """ Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“ \n vom 23. - 24.11.2023 im Kongresshaus Zürich am Stand Nr. 6 \n und erfahren Sie mehr über unser umfangreiches Service-Angebot. """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-19 04:25:51" "deleted" => 1 ] [ "id" => 574726111 "company_id" => 94060592 "urn" => "urn:li:activity:7185563875830865920" "followers" => null "date" => "1mo" "description" => """ Mit zehn Präparaten bietet Desitin das breiteste Sortiment oraler und parenteraler Antiepileptika in der Schweiz. Die bestmögliche Therapie der Patienten steht für uns im Vordergrund der Aktivitäten. \n Dies bedingt eine stetige Weiterentwicklung der Medikamente und deren Darreichungsformen, um die Einnahme zu erleichtern und die Compliance zu erhöhen. \n \n Unsere Antiepileptika auf einen Blick: www.desitin.ch/produkte\n \n #desitin #epilepsie #epilepsy #generika #antiepilepticum #galenik """ "reactions_count" => 52 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-13 20:50:35" "deleted" => 1 ] [ "id" => 574726112 "company_id" => 94060592 "urn" => "urn:li:activity:7173685533494251520" "followers" => null "date" => "2mo" "description" => """ Vielversprechende positive Studienresultate mit 298 Patienten, welche an obstruktiver Schlafapnoe leiden.\n \n Résultats positifs et prometteurs d'une étude portant sur 298 patients souffrant d'apnée obstructive du sommeil !\n \n Pour plus d'informations, cliquez ici (en anglais/english) : \n https://lnkd.in/emmxvKAa\n \n #schlafapnoe #osa #sleephealth #desitin #epilepsie #epilepsy #generika #antiepilepticum #apnee #sleephealth """ "reactions_count" => 28 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 22:43:35" "deleted" => 1 ] [ "id" => 574726113 "company_id" => 94060592 "urn" => "urn:li:activity:7132283393181933568" "followers" => null "date" => "6mo" "description" => "Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“, vom 23. - 24.November 2023 im Kongresshaus Zürich, am Stand Nr. 6 und erfahren Sie mehr über unser umfangreiches Service-Angebot." "reactions_count" => 11 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 22:43:35" "deleted" => 1 ] [ "id" => 574726114 "company_id" => 94060592 "urn" => "urn:li:activity:7128312802674401280" "followers" => null "date" => "6mo" "description" => """ Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“ \n vom 23. - 24.11.2023 im Kongresshaus Zürich am Stand Nr. 6 \n und erfahren Sie mehr über unser umfangreiches Service-Angebot. """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-13 20:50:35" "deleted" => 1 ] [ "id" => 608297334 "company_id" => 94060592 "urn" => "urn:li:activity:7201189871967707137" "followers" => null "date" => "1w" "description" => """ Es ist endlich wieder soweit :\n am 6.-7. Juni 2024 findet das\n ▶ «Annual Meeting 2024» der Swiss Neurological Society SNS\n im Congress Center Basel statt!\n \n Besuchen Sie uns am ⚡Stand 25 in der Halle 4.1 (Congress Center Basel) und erfahren Sie mehr über unser umfangreiches Service-Angebot.\n Wir freuen uns auf Sie! \n \n https://www.desitin.ch/\n \n #swissneurological #neurology #sngkongress #desitin #epilepsie #epilepsy #generika #antiepilepiticum #galenik """ "reactions_count" => 22 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 22:43:35" "deleted" => 1 ] [ "id" => 608297335 "company_id" => 94060592 "urn" => "urn:li:activity:7185563875830865920" "followers" => null "date" => "1mo" "description" => """ Mit zehn Präparaten bietet Desitin das breiteste Sortiment oraler und parenteraler Antiepileptika in der Schweiz. Die bestmögliche Therapie der Patienten steht für uns im Vordergrund der Aktivitäten. \n Dies bedingt eine stetige Weiterentwicklung der Medikamente und deren Darreichungsformen, um die Einnahme zu erleichtern und die Compliance zu erhöhen. \n \n Unsere Antiepileptika auf einen Blick: www.desitin.ch/produkte\n \n #desitin #epilepsie #epilepsy #generika #antiepilepticum #galenik """ "reactions_count" => 56 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 22:43:35" "deleted" => 1 ] [ "id" => 608297336 "company_id" => 94060592 "urn" => "urn:li:activity:7128312802674401280" "followers" => null "date" => "7mo" "description" => """ Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“ \n vom 23. - 24.11.2023 im Kongresshaus Zürich am Stand Nr. 6 \n und erfahren Sie mehr über unser umfangreiches Service-Angebot. """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-21 22:43:35" "deleted" => 1 ] [ "id" => 651583740 "company_id" => 94060592 "urn" => "urn:li:activity:7201189871967707137" "followers" => null "date" => "1mo" "description" => """ Es ist endlich wieder soweit :\n am 6.-7. Juni 2024 findet das\n ▶ «Annual Meeting 2024» der Swiss Neurological Society SNS\n im Congress Center Basel statt!\n \n Besuchen Sie uns am ⚡Stand 25 in der Halle 4.1 (Congress Center Basel) und erfahren Sie mehr über unser umfangreiches Service-Angebot.\n Wir freuen uns auf Sie! \n \n https://www.desitin.ch/\n \n #swissneurological #neurology #sngkongress #desitin #epilepsie #epilepsy #generika #antiepilepiticum #galenik """ "reactions_count" => 25 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-17 04:20:44" "deleted" => 1 ] [ "id" => 651583741 "company_id" => 94060592 "urn" => "urn:li:activity:7185563875830865920" "followers" => null "date" => "3mo" "description" => """ Mit zehn Präparaten bietet Desitin das breiteste Sortiment oraler und parenteraler Antiepileptika in der Schweiz. Die bestmögliche Therapie der Patienten steht für uns im Vordergrund der Aktivitäten. \n Dies bedingt eine stetige Weiterentwicklung der Medikamente und deren Darreichungsformen, um die Einnahme zu erleichtern und die Compliance zu erhöhen. \n \n Unsere Antiepileptika auf einen Blick: www.desitin.ch/produkte\n \n #desitin #epilepsie #epilepsy #generika #antiepilepticum #galenik """ "reactions_count" => 56 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-17 04:20:44" "deleted" => 1 ] [ "id" => 651583742 "company_id" => 94060592 "urn" => "urn:li:activity:7173685533494251520" "followers" => null "date" => "4mo" "description" => """ Vielversprechende positive Studienresultate mit 298 Patienten, welche an obstruktiver Schlafapnoe leiden.\n \n Résultats positifs et prometteurs d'une étude portant sur 298 patients souffrant d'apnée obstructive du sommeil !\n \n Pour plus d'informations, cliquez ici (en anglais/english) : \n https://lnkd.in/emmxvKAa\n \n #schlafapnoe #osa #sleephealth #desitin #epilepsie #epilepsy #generika #antiepilepticum #apnee #sleephealth """ "reactions_count" => 28 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-17 04:20:44" "deleted" => 1 ] [ "id" => 651583743 "company_id" => 94060592 "urn" => "urn:li:activity:7132283393181933568" "followers" => null "date" => "8mo" "description" => "Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“, vom 23. - 24.November 2023 im Kongresshaus Zürich, am Stand Nr. 6 und erfahren Sie mehr über unser umfangreiches Service-Angebot." "reactions_count" => 11 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-17 04:20:44" "deleted" => 1 ] [ "id" => 651583744 "company_id" => 94060592 "urn" => "urn:li:activity:7128312802674401280" "followers" => null "date" => "8mo" "description" => """ Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“ \n vom 23. - 24.11.2023 im Kongresshaus Zürich am Stand Nr. 6 \n und erfahren Sie mehr über unser umfangreiches Service-Angebot. """ "reactions_count" => 16 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-17 04:20:44" "deleted" => 1 ] [ "id" => 682006519 "company_id" => 94060592 "urn" => "urn:li:activity:7226149940723396608" "followers" => null "date" => "1w" "description" => """ Besuchen Sie unsere Website und profitieren Sie im geschützten Fachkreis-Bereich von Informationen und hilfreichen Dienstleistungen auf Deutsch und Französisch. \n \n Visitez notre site Internet et profitez, dans l'espace protégé réservé aux professionnels, d'informations et de services utiles en allemand et en français. \n #desitin #epilepsie #epilepsy #generika #generique #generic #antiepilepticum #antiepileptique #antiepileptic #innovation """ "reactions_count" => 14 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-16 17:55:25" "deleted" => 1 ] [ "id" => 682006520 "company_id" => 94060592 "urn" => "urn:li:activity:7201189871967707137" "followers" => null "date" => "2mo" "description" => """ Es ist endlich wieder soweit :\n am 6.-7. Juni 2024 findet das\n ▶ «Annual Meeting 2024» der Swiss Neurological Society SNS\n im Congress Center Basel statt!\n \n Besuchen Sie uns am ⚡Stand 25 in der Halle 4.1 (Congress Center Basel) und erfahren Sie mehr über unser umfangreiches Service-Angebot.\n Wir freuen uns auf Sie! \n \n https://www.desitin.ch/\n \n #swissneurological #neurology #sngkongress #desitin #epilepsie #epilepsy #generika #antiepilepiticum #galenik """ "reactions_count" => 26 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-16 17:55:25" "deleted" => 1 ] [ "id" => 682006521 "company_id" => 94060592 "urn" => "urn:li:activity:7185563875830865920" "followers" => null "date" => "4mo" "description" => """ Mit zehn Präparaten bietet Desitin das breiteste Sortiment oraler und parenteraler Antiepileptika in der Schweiz. Die bestmögliche Therapie der Patienten steht für uns im Vordergrund der Aktivitäten. \n Dies bedingt eine stetige Weiterentwicklung der Medikamente und deren Darreichungsformen, um die Einnahme zu erleichtern und die Compliance zu erhöhen. \n \n Unsere Antiepileptika auf einen Blick: www.desitin.ch/produkte\n \n #desitin #epilepsie #epilepsy #generika #antiepilepticum #galenik """ "reactions_count" => 57 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-16 17:55:25" "deleted" => 1 ] [ "id" => 682006522 "company_id" => 94060592 "urn" => "urn:li:activity:7173685533494251520" "followers" => null "date" => "5mo" "description" => """ Vielversprechende positive Studienresultate mit 298 Patienten, welche an obstruktiver Schlafapnoe leiden.\n \n Résultats positifs et prometteurs d'une étude portant sur 298 patients souffrant d'apnée obstructive du sommeil !\n \n Pour plus d'informations, cliquez ici (en anglais/english) : \n https://lnkd.in/emmxvKAa\n \n #schlafapnoe #osa #sleephealth #desitin #epilepsie #epilepsy #generika #antiepilepticum #apnee #sleephealth """ "reactions_count" => 28 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-16 17:55:25" "deleted" => 1 ] [ "id" => 682006523 "company_id" => 94060592 "urn" => "urn:li:activity:7132283393181933568" "followers" => null "date" => "9mo" "description" => "Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“, vom 23. - 24.November 2023 im Kongresshaus Zürich, am Stand Nr. 6 und erfahren Sie mehr über unser umfangreiches Service-Angebot." "reactions_count" => 11 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-16 17:55:25" "deleted" => 1 ] [ "id" => 682006524 "company_id" => 94060592 "urn" => "urn:li:activity:7128312802674401280" "followers" => null "date" => "9mo" "description" => """ Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“ \n vom 23. - 24.11.2023 im Kongresshaus Zürich am Stand Nr. 6 \n und erfahren Sie mehr über unser umfangreiches Service-Angebot. """ "reactions_count" => 16 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-16 17:55:25" "deleted" => 1 ] [ "id" => 729246204 "company_id" => 94060592 "urn" => "urn:li:activity:7226149940723396608" "followers" => null "date" => "1mo" "description" => """ Besuchen Sie unsere Website und profitieren Sie im geschützten Fachkreis-Bereich von Informationen und hilfreichen Dienstleistungen auf Deutsch und Französisch. \n \n Visitez notre site Internet et profitez, dans l'espace protégé réservé aux professionnels, d'informations et de services utiles en allemand et en français. \n #desitin #epilepsie #epilepsy #generika #generique #generic #antiepilepticum #antiepileptique #antiepileptic #innovation """ "reactions_count" => 16 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-21 13:29:42" "deleted" => 1 ] [ "id" => 729246205 "company_id" => 94060592 "urn" => "urn:li:activity:7201189871967707137" "followers" => null "date" => "3mo" "description" => """ Es ist endlich wieder soweit :\n am 6.-7. Juni 2024 findet das\n ▶ «Annual Meeting 2024» der Swiss Neurological Society SNS\n im Congress Center Basel statt!\n \n Besuchen Sie uns am ⚡Stand 25 in der Halle 4.1 (Congress Center Basel) und erfahren Sie mehr über unser umfangreiches Service-Angebot.\n Wir freuen uns auf Sie! \n \n https://www.desitin.ch/\n \n #swissneurological #neurology #sngkongress #desitin #epilepsie #epilepsy #generika #antiepilepiticum #galenik """ "reactions_count" => 26 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-05 04:21:59" "deleted" => 1 ] [ "id" => 729246206 "company_id" => 94060592 "urn" => "urn:li:activity:7185563875830865920" "followers" => null "date" => "5mo" "description" => """ Mit zehn Präparaten bietet Desitin das breiteste Sortiment oraler und parenteraler Antiepileptika in der Schweiz. Die bestmögliche Therapie der Patienten steht für uns im Vordergrund der Aktivitäten. \n Dies bedingt eine stetige Weiterentwicklung der Medikamente und deren Darreichungsformen, um die Einnahme zu erleichtern und die Compliance zu erhöhen. \n \n Unsere Antiepileptika auf einen Blick: www.desitin.ch/produkte\n \n #desitin #epilepsie #epilepsy #generika #antiepilepticum #galenik """ "reactions_count" => 57 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-10 10:29:41" "deleted" => 1 ] [ "id" => 729246207 "company_id" => 94060592 "urn" => "urn:li:activity:7173685533494251520" "followers" => null "date" => "6mo" "description" => """ Vielversprechende positive Studienresultate mit 298 Patienten, welche an obstruktiver Schlafapnoe leiden.\n \n Résultats positifs et prometteurs d'une étude portant sur 298 patients souffrant d'apnée obstructive du sommeil !\n \n Pour plus d'informations, cliquez ici (en anglais/english) : \n https://lnkd.in/emmxvKAa\n \n #schlafapnoe #osa #sleephealth #desitin #epilepsie #epilepsy #generika #antiepilepticum #apnee #sleephealth """ "reactions_count" => 28 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-10 10:29:41" "deleted" => 1 ] [ "id" => 729246208 "company_id" => 94060592 "urn" => "urn:li:activity:7132283393181933568" "followers" => null "date" => "10mo" "description" => "Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“, vom 23. - 24.November 2023 im Kongresshaus Zürich, am Stand Nr. 6 und erfahren Sie mehr über unser umfangreiches Service-Angebot." "reactions_count" => 11 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-10 10:29:41" "deleted" => 1 ] [ "id" => 729246209 "company_id" => 94060592 "urn" => "urn:li:activity:7128312802674401280" "followers" => null "date" => "10mo" "description" => """ Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“ \n vom 23. - 24.11.2023 im Kongresshaus Zürich am Stand Nr. 6 \n und erfahren Sie mehr über unser umfangreiches Service-Angebot. """ "reactions_count" => 16 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-21 13:29:42" "deleted" => 1 ] [ "id" => 746640797 "company_id" => 94060592 "urn" => "urn:li:activity:7201189871967707137" "followers" => null "date" => "4mo" "description" => """ Es ist endlich wieder soweit :\n am 6.-7. Juni 2024 findet das\n ▶ «Annual Meeting 2024» der Swiss Neurological Society SNS\n im Congress Center Basel statt!\n \n Besuchen Sie uns am ⚡Stand 25 in der Halle 4.1 (Congress Center Basel) und erfahren Sie mehr über unser umfangreiches Service-Angebot.\n Wir freuen uns auf Sie! \n \n https://www.desitin.ch/\n \n #swissneurological #neurology #sngkongress #desitin #epilepsie #epilepsy #generika #antiepilepiticum #galenik """ "reactions_count" => 26 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-10 10:29:41" "deleted" => 1 ] [ "id" => 771794051 "company_id" => 94060592 "urn" => "urn:li:activity:7226149940723396608" "followers" => null "date" => "2mo" "description" => """ Besuchen Sie unsere Website und profitieren Sie im geschützten Fachkreis-Bereich von Informationen und hilfreichen Dienstleistungen auf Deutsch und Französisch. \n \n Visitez notre site Internet et profitez, dans l'espace protégé réservé aux professionnels, d'informations et de services utiles en allemand et en français. \n #desitin #epilepsie #epilepsy #generika #generique #generic #antiepilepticum #antiepileptique #antiepileptic #innovation """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-10 10:29:41" "deleted" => 1 ] [ "id" => 771794052 "company_id" => 94060592 "urn" => "urn:li:activity:7128312802674401280" "followers" => null "date" => "11mo" "description" => """ Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“ \n vom 23. - 24.11.2023 im Kongresshaus Zürich am Stand Nr. 6 \n und erfahren Sie mehr über unser umfangreiches Service-Angebot. """ "reactions_count" => 16 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-10 10:29:41" "deleted" => 1 ] [ "id" => 801874628 "company_id" => 94060592 "urn" => "urn:li:activity:7226149940723396608" "followers" => null "date" => "3mo" "description" => """ Besuchen Sie unsere Website und profitieren Sie im geschützten Fachkreis-Bereich von Informationen und hilfreichen Dienstleistungen auf Deutsch und Französisch. \n \n Visitez notre site Internet et profitez, dans l'espace protégé réservé aux professionnels, d'informations et de services utiles en allemand et en français. \n #desitin #epilepsie #epilepsy #generika #generique #generic #antiepilepticum #antiepileptique #antiepileptic #innovation """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-09 04:40:05" "deleted" => 1 ] [ "id" => 801874630 "company_id" => 94060592 "urn" => "urn:li:activity:7201189871967707137" "followers" => null "date" => "5mo" "description" => """ Es ist endlich wieder soweit :\n am 6.-7. Juni 2024 findet das\n ▶ «Annual Meeting 2024» der Swiss Neurological Society SNS\n im Congress Center Basel statt!\n \n Besuchen Sie uns am ⚡Stand 25 in der Halle 4.1 (Congress Center Basel) und erfahren Sie mehr über unser umfangreiches Service-Angebot.\n Wir freuen uns auf Sie! \n \n https://www.desitin.ch/\n \n #swissneurological #neurology #sngkongress #desitin #epilepsie #epilepsy #generika #antiepilepiticum #galenik """ "reactions_count" => 26 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-27 18:19:28" "deleted" => 1 ] [ "id" => 801874633 "company_id" => 94060592 "urn" => "urn:li:activity:7185563875830865920" "followers" => null "date" => "6mo" "description" => """ Mit zehn Präparaten bietet Desitin das breiteste Sortiment oraler und parenteraler Antiepileptika in der Schweiz. Die bestmögliche Therapie der Patienten steht für uns im Vordergrund der Aktivitäten. \n Dies bedingt eine stetige Weiterentwicklung der Medikamente und deren Darreichungsformen, um die Einnahme zu erleichtern und die Compliance zu erhöhen. \n \n Unsere Antiepileptika auf einen Blick: www.desitin.ch/produkte\n \n #desitin #epilepsie #epilepsy #generika #antiepilepticum #galenik """ "reactions_count" => 57 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-27 18:19:28" "deleted" => 1 ] [ "id" => 801874635 "company_id" => 94060592 "urn" => "urn:li:activity:7173685533494251520" "followers" => null "date" => "8mo" "description" => """ Vielversprechende positive Studienresultate mit 298 Patienten, welche an obstruktiver Schlafapnoe leiden.\n \n Résultats positifs et prometteurs d'une étude portant sur 298 patients souffrant d'apnée obstructive du sommeil !\n \n Pour plus d'informations, cliquez ici (en anglais/english) : \n https://lnkd.in/emmxvKAa\n \n #schlafapnoe #osa #sleephealth #desitin #epilepsie #epilepsy #generika #antiepilepticum #apnee #sleephealth """ "reactions_count" => 30 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-27 18:19:28" "deleted" => 1 ] [ "id" => 801874637 "company_id" => 94060592 "urn" => "urn:li:activity:7132283393181933568" "followers" => null "date" => "11mo" "description" => "Besuchen Sie uns an der „Gemeinsamen Jahrestagung 2023 der SNG“, vom 23. - 24.November 2023 im Kongresshaus Zürich, am Stand Nr. 6 und erfahren Sie mehr über unser umfangreiches Service-Angebot." "reactions_count" => 11 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-27 18:19:28" "deleted" => 1 ] [ "id" => 827342748 "company_id" => 94060592 "urn" => "urn:li:activity:7262011332550389760" "followers" => null "date" => "2w" "description" => """ Full article only for subscribers, but the abstract is already useful. For example: Universal screening for anxiety and depression is recommended.\n \n https://lnkd.in/edZa8USz """ "reactions_count" => 3 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-09 04:40:05" "deleted" => 1 ] [ "id" => 827342749 "company_id" => 94060592 "urn" => "urn:li:activity:7201189871967707137" "followers" => null "date" => "6mo" "description" => """ Es ist endlich wieder soweit :\n am 6.-7. Juni 2024 findet das\n ▶ «Annual Meeting 2024» der Swiss Neurological Society SNS\n im Congress Center Basel statt!\n \n Besuchen Sie uns am ⚡Stand 25 in der Halle 4.1 (Congress Center Basel) und erfahren Sie mehr über unser umfangreiches Service-Angebot.\n Wir freuen uns auf Sie! \n \n https://www.desitin.ch/\n \n #swissneurological #neurology #sngkongress #desitin #epilepsie #epilepsy #generika #antiepilepiticum #galenik """ "reactions_count" => 26 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-17 22:19:43" "deleted" => 1 ] [ "id" => 827342750 "company_id" => 94060592 "urn" => "urn:li:activity:7185563875830865920" "followers" => null "date" => "7mo" "description" => """ Mit zehn Präparaten bietet Desitin das breiteste Sortiment oraler und parenteraler Antiepileptika in der Schweiz. Die bestmögliche Therapie der Patienten steht für uns im Vordergrund der Aktivitäten. \n Dies bedingt eine stetige Weiterentwicklung der Medikamente und deren Darreichungsformen, um die Einnahme zu erleichtern und die Compliance zu erhöhen. \n \n Unsere Antiepileptika auf einen Blick: www.desitin.ch/produkte\n \n #desitin #epilepsie #epilepsy #generika #antiepilepticum #galenik """ "reactions_count" => 57 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-17 22:19:43" "deleted" => 1 ] [ "id" => 827342751 "company_id" => 94060592 "urn" => "urn:li:activity:7173685533494251520" "followers" => null "date" => "8mo" "description" => """ Vielversprechende positive Studienresultate mit 298 Patienten, welche an obstruktiver Schlafapnoe leiden.\n \n Résultats positifs et prometteurs d'une étude portant sur 298 patients souffrant d'apnée obstructive du sommeil !\n \n Pour plus d'informations, cliquez ici (en anglais/english) : \n https://lnkd.in/emmxvKAa\n \n #schlafapnoe #osa #sleephealth #desitin #epilepsie #epilepsy #generika #antiepilepticum #apnee #sleephealth """ "reactions_count" => 31 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-17 22:19:43" "deleted" => 1 ] [ "id" => 850028222 "company_id" => 94060592 "urn" => "urn:li:activity:7262011332550389760" "followers" => null "date" => "3w" "description" => """ Full article only for subscribers, but the abstract is already useful. For example: Universal screening for anxiety and depression is recommended.\n \n https://lnkd.in/edZa8USz """ "reactions_count" => 4 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-17 22:19:43" "deleted" => 1 ] [ "id" => 850028223 "company_id" => 94060592 "urn" => "urn:li:activity:7226149940723396608" "followers" => null "date" => "4mo" "description" => """ Besuchen Sie unsere Website und profitieren Sie im geschützten Fachkreis-Bereich von Informationen und hilfreichen Dienstleistungen auf Deutsch und Französisch. \n \n Visitez notre site Internet et profitez, dans l'espace protégé réservé aux professionnels, d'informations et de services utiles en allemand et en français. \n #desitin #epilepsie #epilepsy #generika #generique #generic #antiepilepticum #antiepileptique #antiepileptic #innovation """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-17 22:19:43" "deleted" => 1 ] [ "id" => 892905989 "company_id" => 94060592 "urn" => "urn:li:activity:7262011332550389760" "followers" => null "date" => "2mo" "description" => """ Full article only for subscribers, but the abstract is already useful. For example: Universal screening for anxiety and depression is recommended.\n \n https://lnkd.in/edZa8USz """ "reactions_count" => 4 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 892905990 "company_id" => 94060592 "urn" => "urn:li:activity:7226149940723396608" "followers" => null "date" => "5mo" "description" => """ Besuchen Sie unsere Website und profitieren Sie im geschützten Fachkreis-Bereich von Informationen und hilfreichen Dienstleistungen auf Deutsch und Französisch. \n \n Visitez notre site Internet et profitez, dans l'espace protégé réservé aux professionnels, d'informations et de services utiles en allemand et en français. \n #desitin #epilepsie #epilepsy #generika #generique #generic #antiepilepticum #antiepileptique #antiepileptic #innovation """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-08 17:42:10" "deleted" => 1 ] [ "id" => 892905991 "company_id" => 94060592 "urn" => "urn:li:activity:7201189871967707137" "followers" => null "date" => "7mo" "description" => """ Es ist endlich wieder soweit :\n am 6.-7. Juni 2024 findet das\n ▶ «Annual Meeting 2024» der Swiss Neurological Society SNS\n im Congress Center Basel statt!\n \n Besuchen Sie uns am ⚡Stand 25 in der Halle 4.1 (Congress Center Basel) und erfahren Sie mehr über unser umfangreiches Service-Angebot.\n Wir freuen uns auf Sie! \n \n https://www.desitin.ch/\n \n #swissneurological #neurology #sngkongress #desitin #epilepsie #epilepsy #generika #antiepilepiticum #galenik """ "reactions_count" => 26 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-08 17:42:10" "deleted" => 1 ] [ "id" => 892905992 "company_id" => 94060592 "urn" => "urn:li:activity:7185563875830865920" "followers" => null "date" => "9mo" "description" => """ Mit zehn Präparaten bietet Desitin das breiteste Sortiment oraler und parenteraler Antiepileptika in der Schweiz. Die bestmögliche Therapie der Patienten steht für uns im Vordergrund der Aktivitäten. \n Dies bedingt eine stetige Weiterentwicklung der Medikamente und deren Darreichungsformen, um die Einnahme zu erleichtern und die Compliance zu erhöhen. \n \n Unsere Antiepileptika auf einen Blick: www.desitin.ch/produkte\n \n #desitin #epilepsie #epilepsy #generika #antiepilepticum #galenik """ "reactions_count" => 57 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 892905993 "company_id" => 94060592 "urn" => "urn:li:activity:7173685533494251520" "followers" => null "date" => "10mo" "description" => """ Vielversprechende positive Studienresultate mit 298 Patienten, welche an obstruktiver Schlafapnoe leiden.\n \n Résultats positifs et prometteurs d'une étude portant sur 298 patients souffrant d'apnée obstructive du sommeil !\n \n Pour plus d'informations, cliquez ici (en anglais/english) : \n https://lnkd.in/emmxvKAa\n \n #schlafapnoe #osa #sleephealth #desitin #epilepsie #epilepsy #generika #antiepilepticum #apnee #sleephealth """ "reactions_count" => 31 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-08 17:42:10" "deleted" => 1 ] [ "id" => 925390254 "company_id" => 94060592 "urn" => "urn:li:activity:7226149940723396608" "followers" => null "date" => "6mo" "description" => """ Besuchen Sie unsere Website und profitieren Sie im geschützten Fachkreis-Bereich von Informationen und hilfreichen Dienstleistungen auf Deutsch und Französisch. \n \n Visitez notre site Internet et profitez, dans l'espace protégé réservé aux professionnels, d'informations et de services utiles en allemand et en français. \n #desitin #epilepsie #epilepsy #generika #generique #generic #antiepilepticum #antiepileptique #antiepileptic #innovation """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 925390255 "company_id" => 94060592 "urn" => "urn:li:activity:7201189871967707137" "followers" => null "date" => "8mo" "description" => """ Es ist endlich wieder soweit :\n am 6.-7. Juni 2024 findet das\n ▶ «Annual Meeting 2024» der Swiss Neurological Society SNS\n im Congress Center Basel statt!\n \n Besuchen Sie uns am ⚡Stand 25 in der Halle 4.1 (Congress Center Basel) und erfahren Sie mehr über unser umfangreiches Service-Angebot.\n Wir freuen uns auf Sie! \n \n https://www.desitin.ch/\n \n #swissneurological #neurology #sngkongress #desitin #epilepsie #epilepsy #generika #antiepilepiticum #galenik """ "reactions_count" => 26 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] [ "id" => 925390256 "company_id" => 94060592 "urn" => "urn:li:activity:7173685533494251520" "followers" => null "date" => "11mo" "description" => """ Vielversprechende positive Studienresultate mit 298 Patienten, welche an obstruktiver Schlafapnoe leiden.\n \n Résultats positifs et prometteurs d'une étude portant sur 298 patients souffrant d'apnée obstructive du sommeil !\n \n Pour plus d'informations, cliquez ici (en anglais/english) : \n https://lnkd.in/emmxvKAa\n \n #schlafapnoe #osa #sleephealth #desitin #epilepsie #epilepsy #generika #antiepilepticum #apnee #sleephealth """ "reactions_count" => 31 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-08 17:42:10" "deleted" => 0 ] ] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4725 …} -companyTags: Doctrine\ORM\PersistentCollection {#4727 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4729 …} -users: Doctrine\ORM\PersistentCollection {#4731 …} -logoImageName: "20250226144209-desitin-logo-67bf1a318e6b6926229387.png" -coverImageName: "20250227162559-cropped-cropped-desitin-icon-1-1-32x32-67c0840744994957004425.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4733 …} -tagline: "Spezialist für Epilepsie-Therapien – Innovative Medikamente und Serviceangebote für besseren therapeutischen Erfolg" -contactEmail: "info@desitin.ch" -phone: "41619266010" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4735 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4737 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4739 …} -industry: "" -size: null -address1: "Hammerstrasse 47" -address2: null -city: "Liestal" -postalCode: "4410" -state: null -country: "Switzerland" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4741 …} #createdAt: DateTime @1740050247 {#4702 date: 2025-02-20 11:17:27.0 UTC (+00:00) } #updatedAt: DateTime @1750924770 {#4701 date: 2025-06-26 07:59:30.0 UTC (+00:00) } } App\Entity\Company {#4745 -id: 24 -name: "Effik SA" -website: "https://effik.ch" -description: null -externalId: "6102149" -details: [ "id" => 6102149 "url" => "https://www.linkedin.com/company/effik-sa" "hash" => "ee1ed2e07a564c608f1fd3b4f0d52f54" "name" => "Effik SA" "website" => "http://www.effik.ch" "size" => null "industry" => "Financial Services" "description" => null "followers" => null "founded" => null "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://static.licdn.com/aero-v1/sc/h/cs8pjfgyw96g44ln9r7tct85f" "created" => "2016-06-24 04:33:25" "last_updated" => "2025-02-02 06:33:52" "last_response_code" => 200 "type" => null "headquarters_new_address" => null "employees_count" => 2 "headquarters_country_restored" => null "headquarters_country_parsed" => null "company_shorthand_name" => "effik-sa" "company_shorthand_name_hash" => "3ec71ba9a3f8f2a2b4864ae54ac9516a" "canonical_url" => "https://ch.linkedin.com/company/effik-sa" "canonical_hash" => "a5f76ae1a7687dea235e8395be190397" "canonical_shorthand_name" => "effik-sa" "canonical_shorthand_name_hash" => "3ec71ba9a3f8f2a2b4864ae54ac9516a" "deleted" => 0 "last_updated_ux" => 1738478032 "source_id" => 1610210 "company_affiliated_collection" => [] "company_also_viewed_collection" => [ [ "id" => 23490905 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/effik" "viewed_company_id" => null "created" => "2016-06-24 04:33:25" "last_updated" => "2019-10-16 23:01:09" "deleted" => 1 ] [ "id" => 23490906 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/horphag-research" "viewed_company_id" => null "created" => "2016-06-24 04:33:25" "last_updated" => "2016-12-10 04:41:48" "deleted" => 1 ] [ "id" => 23490907 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/la-farmochimica-s-r-l-" "viewed_company_id" => null "created" => "2016-06-24 04:33:25" "last_updated" => "2016-12-10 04:41:48" "deleted" => 1 ] [ "id" => 23490908 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/essex-italia-srl" "viewed_company_id" => null "created" => "2016-06-24 04:33:25" "last_updated" => "2016-12-10 04:41:48" "deleted" => 1 ] [ "id" => 23490909 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/athena-pharma-italia" "viewed_company_id" => null "created" => "2016-06-24 04:33:25" "last_updated" => "2016-12-10 04:41:48" "deleted" => 1 ] [ "id" => 23490910 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/laboratori-baldacci-spa" "viewed_company_id" => null "created" => "2016-06-24 04:33:25" "last_updated" => "2016-12-10 04:41:48" "deleted" => 1 ] [ "id" => 41071082 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/effik-italia-s.p.a." "viewed_company_id" => null "created" => "2016-12-10 04:41:48" "last_updated" => "2019-10-16 23:01:09" "deleted" => 1 ] [ "id" => 41071083 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/italfarmaco" "viewed_company_id" => null "created" => "2016-12-10 04:41:48" "last_updated" => "2019-10-16 23:01:09" "deleted" => 1 ] [ "id" => 41071084 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/effikas" "viewed_company_id" => null "created" => "2016-12-10 04:41:48" "last_updated" => "2017-01-17 15:41:46" "deleted" => 1 ] [ "id" => 41071085 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/piramal-lifesciences-limited" "viewed_company_id" => null "created" => "2016-12-10 04:41:48" "last_updated" => "2017-01-17 15:41:46" "deleted" => 1 ] [ "id" => 41071086 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/www.theengagementoutlet.com" "viewed_company_id" => null "created" => "2016-12-10 04:41:48" "last_updated" => "2017-01-17 15:41:46" "deleted" => 1 ] [ "id" => 72561414 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/recordati" "viewed_company_id" => null "created" => "2017-01-17 15:41:45" "last_updated" => "2017-02-27 02:36:30" "deleted" => 1 ] [ "id" => 72561415 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/teva-pharmaceuticals" "viewed_company_id" => null "created" => "2017-01-17 15:41:45" "last_updated" => "2017-02-27 02:36:30" "deleted" => 1 ] [ "id" => 72561416 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/novartis" "viewed_company_id" => null "created" => "2017-01-17 15:41:45" "last_updated" => "2017-02-27 02:36:30" "deleted" => 1 ] [ "id" => 86715071 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/keyplace-outplacement-&-inplacement" "viewed_company_id" => null "created" => "2017-02-27 02:36:29" "last_updated" => "2017-07-31 06:01:41" "deleted" => 1 ] [ "id" => 86715072 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/gobbi-novag" "viewed_company_id" => null "created" => "2017-02-27 02:36:29" "last_updated" => "2017-07-31 06:01:41" "deleted" => 1 ] [ "id" => 86715073 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/laboratorios-senosiain-sa-de-cv" "viewed_company_id" => null "created" => "2017-02-27 02:36:29" "last_updated" => "2017-07-31 06:01:41" "deleted" => 1 ] [ "id" => 94612480 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/sofar-s.p.a." "viewed_company_id" => null "created" => "2017-07-31 06:01:40" "last_updated" => "2018-03-12 19:42:30" "deleted" => 1 ] [ "id" => 94612481 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/menarini" "viewed_company_id" => null "created" => "2017-07-31 06:01:40" "last_updated" => "2017-11-21 08:34:40" "deleted" => 1 ] [ "id" => 94612482 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/pharmartel-limited" "viewed_company_id" => null "created" => "2017-07-31 06:01:40" "last_updated" => "2017-11-21 08:34:40" "deleted" => 1 ] [ "id" => 117613618 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/pharmanutra-srl" "viewed_company_id" => null "created" => "2017-11-21 08:34:39" "last_updated" => "2018-03-12 19:42:30" "deleted" => 1 ] [ "id" => 117613619 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/precognition-limited" "viewed_company_id" => null "created" => "2017-11-21 08:34:39" "last_updated" => "2018-03-12 19:42:30" "deleted" => 1 ] [ "id" => 133565612 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/laboratoires-genevrier" "viewed_company_id" => null "created" => "2018-03-12 19:42:30" "last_updated" => "2019-10-16 23:01:09" "deleted" => 1 ] [ "id" => 133565614 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/effik-benelux" "viewed_company_id" => null "created" => "2018-03-12 19:42:30" "last_updated" => "2018-09-21 07:50:52" "deleted" => 1 ] [ "id" => 133565616 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/effik-international" "viewed_company_id" => null "created" => "2018-03-12 19:42:30" "last_updated" => "2018-09-21 07:50:52" "deleted" => 1 ] [ "id" => 161426267 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/italfarmacia-srl" "viewed_company_id" => null "created" => "2018-09-21 07:50:52" "last_updated" => "2019-03-17 11:10:20" "deleted" => 1 ] [ "id" => 161426268 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/menarini" "viewed_company_id" => null "created" => "2018-09-21 07:50:52" "last_updated" => "2019-05-28 01:45:27" "deleted" => 1 ] [ "id" => 196334723 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/e-medicus" "viewed_company_id" => null "created" => "2019-03-17 11:10:20" "last_updated" => "2019-05-28 01:45:27" "deleted" => 1 ] [ "id" => 222219835 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/angelini" "viewed_company_id" => null "created" => "2019-05-28 01:45:27" "last_updated" => "2019-10-16 23:01:09" "deleted" => 1 ] [ "id" => 222219842 "company_id" => 6102149 "viewed_company_url" => "https://www.linkedin.com/company/ferring-pharmaceuticals" "viewed_company_id" => null "created" => "2019-05-28 01:45:27" "last_updated" => "2019-10-16 23:01:09" "deleted" => 1 ] ] "company_crunchbase_info_collection" => [] "company_featured_employees_collection" => [ [ "id" => 6075358 "company_id" => 6102149 "url" => "https://www.linkedin.com/in/edgard-bertrand-6897222a" "created" => "2019-10-16 23:01:09" "last_updated" => "2021-03-01 15:22:06" "deleted" => 1 ] [ "id" => 6075362 "company_id" => 6102149 "url" => "https://www.linkedin.com/in/monay-liliane-72604741" "created" => "2019-10-16 23:01:09" "last_updated" => "2022-07-23 15:47:14" "deleted" => 1 ] [ "id" => 6075368 "company_id" => 6102149 "url" => "https://www.linkedin.com/in/cansel-eldeniz-75b95141" "created" => "2019-10-16 23:01:09" "last_updated" => "2020-01-18 13:06:54" "deleted" => 1 ] [ "id" => 111028872 "company_id" => 6102149 "url" => "https://ch.linkedin.com/in/monay-liliane-72604741/en" "created" => "2022-07-23 15:47:14" "last_updated" => "2023-07-07 12:52:35" "deleted" => 1 ] [ "id" => 180569779 "company_id" => 6102149 "url" => "https://ch.linkedin.com/in/monay-liliane-72604741" "created" => "2023-07-07 12:52:35" "last_updated" => "2025-02-02 06:33:52" "deleted" => 0 ] ] "company_featured_investors_collection" => [] "company_funding_rounds_collection" => [] "company_locations_collection" => [] "company_similar_collection" => [ [ "id" => 9479367 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/effik" "created" => "2019-10-16 23:01:09" "last_updated" => "2020-11-21 03:54:55" "deleted" => 1 ] [ "id" => 9479371 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/effik-italia-s.p.a." "created" => "2019-10-16 23:01:09" "last_updated" => "2020-11-21 03:54:55" "deleted" => 1 ] [ "id" => 9479375 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/thea-pharma-ila%C3%A7-tic--ltd--%C5%9Fti-" "created" => "2019-10-16 23:01:09" "last_updated" => "2019-11-20 10:51:48" "deleted" => 1 ] [ "id" => 9479378 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/italfarmaco" "created" => "2019-10-16 23:01:09" "last_updated" => "2020-08-18 14:42:47" "deleted" => 1 ] [ "id" => 9479381 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/angelini" "created" => "2019-10-16 23:01:09" "last_updated" => "2019-11-20 10:51:48" "deleted" => 1 ] [ "id" => 9479386 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/ferring-pharmaceuticals" "created" => "2019-10-16 23:01:09" "last_updated" => "2019-11-20 10:51:48" "deleted" => 1 ] [ "id" => 48298010 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/itf-research-pharma-sl" "created" => "2019-11-20 10:51:48" "last_updated" => "2020-03-15 10:58:23" "deleted" => 1 ] [ "id" => 48298011 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/laboratorios-effik-sa" "created" => "2019-11-20 10:51:48" "last_updated" => "2020-03-15 10:58:23" "deleted" => 1 ] [ "id" => 48298013 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/lifepharma-italfarmaco-vietnam" "created" => "2019-11-20 10:51:48" "last_updated" => "2020-03-15 10:58:23" "deleted" => 1 ] [ "id" => 69419967 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/italfarmaco-s.p.a." "created" => "2020-01-18 13:06:54" "last_updated" => "2020-03-15 10:58:23" "deleted" => 1 ] [ "id" => 69419969 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/thea-pharma-ila%C3%A7-tic--ltd--%C5%9Fti-" "created" => "2020-01-18 13:06:54" "last_updated" => "2020-03-15 10:58:23" "deleted" => 1 ] [ "id" => 69419970 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/angelini" "created" => "2020-01-18 13:06:54" "last_updated" => "2020-03-15 10:58:23" "deleted" => 1 ] [ "id" => 69419971 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/ferring-pharmaceuticals" "created" => "2020-01-18 13:06:54" "last_updated" => "2020-03-15 10:58:23" "deleted" => 1 ] [ "id" => 110130873 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/la-savonnerie-de-romu" "created" => "2020-03-15 10:58:23" "last_updated" => "2020-08-18 14:42:47" "deleted" => 1 ] [ "id" => 110130874 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/wildcat-echo" "created" => "2020-03-15 10:58:23" "last_updated" => "2020-08-18 14:42:47" "deleted" => 1 ] [ "id" => 110130875 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/dorganics" "created" => "2020-03-15 10:58:23" "last_updated" => "2020-08-18 14:42:47" "deleted" => 1 ] [ "id" => 110130876 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/maison-berthe-guilhem" "created" => "2020-03-15 10:58:23" "last_updated" => "2020-07-05 21:21:17" "deleted" => 1 ] [ "id" => 110130877 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/societe-francaise-rhumatologie" "created" => "2020-03-15 10:58:23" "last_updated" => "2020-05-23 10:17:25" "deleted" => 1 ] [ "id" => 110130878 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/cpcad" "created" => "2020-03-15 10:58:23" "last_updated" => "2020-05-23 10:17:25" "deleted" => 1 ] [ "id" => 110130879 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/ceano-cosmetics" "created" => "2020-03-15 10:58:23" "last_updated" => "2020-04-15 16:40:36" "deleted" => 1 ] [ "id" => 132293757 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/crazy-rumors" "created" => "2020-04-15 16:40:36" "last_updated" => "2020-06-06 03:12:41" "deleted" => 1 ] [ "id" => 155658629 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/exeltis" "created" => "2020-05-23 10:17:25" "last_updated" => "2020-11-21 03:54:55" "deleted" => 1 ] [ "id" => 155658631 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/ceano-cosmetics" "created" => "2020-05-23 10:17:25" "last_updated" => "2020-06-06 03:12:41" "deleted" => 1 ] [ "id" => 163375986 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/heather-hills-farm-limited" "created" => "2020-06-06 03:12:41" "last_updated" => "2020-07-05 21:21:17" "deleted" => 1 ] [ "id" => 163375987 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/es-cosmetic-laboratories" "created" => "2020-06-06 03:12:41" "last_updated" => "2020-07-05 21:21:17" "deleted" => 1 ] [ "id" => 177417970 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/bendalis-gmbh" "created" => "2020-07-05 21:21:17" "last_updated" => "2020-09-17 13:03:58" "deleted" => 1 ] [ "id" => 177417971 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/campuspharma" "created" => "2020-07-05 21:21:17" "last_updated" => "2020-09-17 13:03:58" "deleted" => 1 ] [ "id" => 177417972 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/sophiagenetics" "created" => "2020-07-05 21:21:17" "last_updated" => "2020-09-17 13:03:58" "deleted" => 1 ] [ "id" => 209575262 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/cotovio-pinto-helio-sergio" "created" => "2020-08-18 14:42:47" "last_updated" => "2020-11-21 03:54:55" "deleted" => 1 ] [ "id" => 209575263 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/lifewell-pharmaceutical-&-healthcare" "created" => "2020-08-18 14:42:47" "last_updated" => "2020-10-14 10:13:43" "deleted" => 1 ] [ "id" => 209575264 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/angelinipharma" "created" => "2020-08-18 14:42:47" "last_updated" => "2020-09-17 13:03:58" "deleted" => 1 ] [ "id" => 209575265 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/omega-pharma" "created" => "2020-08-18 14:42:47" "last_updated" => "2020-09-17 13:03:58" "deleted" => 1 ] [ "id" => 231942562 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/effik-international" "created" => "2020-09-17 13:03:58" "last_updated" => "2020-11-21 03:54:55" "deleted" => 1 ] [ "id" => 231942563 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/italfarmaco" "created" => "2020-09-17 13:03:58" "last_updated" => "2020-11-21 03:54:55" "deleted" => 1 ] [ "id" => 231942564 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/lifepharm-global-network---independent-business-owner" "created" => "2020-09-17 13:03:58" "last_updated" => "2021-05-13 20:40:06" "deleted" => 1 ] [ "id" => 231942565 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/lifepharma-italfarmaco-vietnam" "created" => "2020-09-17 13:03:58" "last_updated" => "2020-10-14 10:13:43" "deleted" => 1 ] [ "id" => 231942566 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/chemi-nutra" "created" => "2020-09-17 13:03:58" "last_updated" => "2020-10-14 10:13:43" "deleted" => 1 ] [ "id" => 249687925 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/laboratorios-effik-sa" "created" => "2020-10-14 10:13:43" "last_updated" => "2020-11-21 03:54:55" "deleted" => 1 ] [ "id" => 249687926 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/seegpharm-sa" "created" => "2020-10-14 10:13:43" "last_updated" => "2020-11-21 03:54:55" "deleted" => 1 ] [ "id" => 249687927 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/merkel" "created" => "2020-10-14 10:13:43" "last_updated" => "2020-11-21 03:54:55" "deleted" => 1 ] [ "id" => 288493203 "company_id" => 6102149 "url" => "https://fr.linkedin.com/company/effik" "created" => "2020-11-21 03:54:55" "last_updated" => "2021-07-16 17:51:46" "deleted" => 1 ] [ "id" => 288493204 "company_id" => 6102149 "url" => "https://it.linkedin.com/company/effik-italia-s.p.a." "created" => "2020-11-21 03:54:55" "last_updated" => "2021-05-13 20:40:06" "deleted" => 1 ] [ "id" => 288493205 "company_id" => 6102149 "url" => "https://es.linkedin.com/company/laboratorios-effik-sa" "created" => "2020-11-21 03:54:55" "last_updated" => "2021-07-16 17:51:46" "deleted" => 1 ] [ "id" => 288493206 "company_id" => 6102149 "url" => "https://ch.linkedin.com/company/seegpharm-sa" "created" => "2020-11-21 03:54:55" "last_updated" => "2021-07-16 17:51:46" "deleted" => 1 ] [ "id" => 288493207 "company_id" => 6102149 "url" => "https://be.linkedin.com/company/effik-international" "created" => "2020-11-21 03:54:55" "last_updated" => "2021-05-13 20:40:06" "deleted" => 1 ] [ "id" => 288493208 "company_id" => 6102149 "url" => "https://es.linkedin.com/company/exeltis" "created" => "2020-11-21 03:54:55" "last_updated" => "2021-02-04 08:06:04" "deleted" => 1 ] [ "id" => 288493209 "company_id" => 6102149 "url" => "https://fr.linkedin.com/company/cotovio-pinto-helio-sergio" "created" => "2020-11-21 03:54:55" "last_updated" => "2021-04-12 18:29:36" "deleted" => 1 ] [ "id" => 288493210 "company_id" => 6102149 "url" => "https://ch.linkedin.com/company/elpro-buchs-ag" "created" => "2020-11-21 03:54:55" "last_updated" => "2021-07-16 17:51:46" "deleted" => 1 ] [ "id" => 288493211 "company_id" => 6102149 "url" => "https://de.linkedin.com/company/merkel" "created" => "2020-11-21 03:54:55" "last_updated" => "2021-07-16 17:51:46" "deleted" => 1 ] [ "id" => 364302006 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/chemi-nutra" "created" => "2021-02-04 08:06:04" "last_updated" => "2021-03-01 15:22:06" "deleted" => 1 ] [ "id" => 380607753 "company_id" => 6102149 "url" => "https://ma.linkedin.com/company/laboratoires-pharmaceutiques-galenica" "created" => "2021-03-01 15:22:06" "last_updated" => "2021-07-16 17:51:46" "deleted" => 1 ] [ "id" => 392836470 "company_id" => 6102149 "url" => "https://fr.linkedin.com/company/altran" "created" => "2021-04-12 18:29:36" "last_updated" => "2021-07-16 17:51:46" "deleted" => 1 ] [ "id" => 412726516 "company_id" => 6102149 "url" => "https://fr.linkedin.com/company/cotovio-pinto-helio-sergio" "created" => "2021-05-13 20:40:06" "last_updated" => "2021-07-16 17:51:46" "deleted" => 1 ] [ "id" => 412726517 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/chemi-nutra" "created" => "2021-05-13 20:40:06" "last_updated" => "2021-07-16 17:51:46" "deleted" => 1 ] [ "id" => 412726518 "company_id" => 6102149 "url" => "https://vn.linkedin.com/company/lifepharma-italfarmaco-vietnam" "created" => "2021-05-13 20:40:06" "last_updated" => "2021-07-16 17:51:46" "deleted" => 1 ] [ "id" => 478528020 "company_id" => 6102149 "url" => "https://fr.linkedin.com/company/effik" "created" => "2021-09-09 09:47:13" "last_updated" => "2025-02-02 06:33:52" "deleted" => 0 ] [ "id" => 478528021 "company_id" => 6102149 "url" => "https://es.linkedin.com/company/laboratorios-effik-sa" "created" => "2021-09-09 09:47:13" "last_updated" => "2022-03-02 22:18:54" "deleted" => 1 ] [ "id" => 478528022 "company_id" => 6102149 "url" => "https://ma.linkedin.com/company/laboratoires-pharmaceutiques-galenica" "created" => "2021-09-09 09:47:13" "last_updated" => "2022-03-02 22:18:54" "deleted" => 1 ] [ "id" => 478528023 "company_id" => 6102149 "url" => "https://fr.linkedin.com/company/altran" "created" => "2021-09-09 09:47:13" "last_updated" => "2022-06-15 16:26:20" "deleted" => 1 ] [ "id" => 478528024 "company_id" => 6102149 "url" => "https://ch.linkedin.com/company/seegpharm-sa" "created" => "2021-09-09 09:47:13" "last_updated" => "2022-03-02 22:18:54" "deleted" => 1 ] [ "id" => 478528025 "company_id" => 6102149 "url" => "https://ch.linkedin.com/company/elpro-buchs-ag" "created" => "2021-09-09 09:47:13" "last_updated" => "2022-03-02 22:18:54" "deleted" => 1 ] [ "id" => 478528026 "company_id" => 6102149 "url" => "https://de.linkedin.com/company/merkel" "created" => "2021-09-09 09:47:13" "last_updated" => "2022-03-02 22:18:54" "deleted" => 1 ] [ "id" => 478528027 "company_id" => 6102149 "url" => "https://fr.linkedin.com/company/cotovio-pinto-helio-sergio" "created" => "2021-09-09 09:47:13" "last_updated" => "2022-03-02 22:18:54" "deleted" => 1 ] [ "id" => 478528028 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/chemi-nutra" "created" => "2021-09-09 09:47:13" "last_updated" => "2022-03-02 22:18:54" "deleted" => 1 ] [ "id" => 478528029 "company_id" => 6102149 "url" => "https://vn.linkedin.com/company/lifepharma-italfarmaco-vietnam" "created" => "2021-09-09 09:47:13" "last_updated" => "2022-03-02 22:18:54" "deleted" => 1 ] [ "id" => 625761546 "company_id" => 6102149 "url" => "https://pt.linkedin.com/company/tw-wellness" "created" => "2022-06-15 16:26:20" "last_updated" => "2023-05-01 06:34:48" "deleted" => 1 ] [ "id" => 873553782 "company_id" => 6102149 "url" => "https://br.linkedin.com/company/effika-investimentos" "created" => "2023-09-03 16:45:34" "last_updated" => "2024-09-09 03:05:03" "deleted" => 1 ] [ "id" => 1040780318 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/rexcer" "created" => "2024-07-24 18:56:37" "last_updated" => "2025-02-02 06:33:52" "deleted" => 0 ] [ "id" => 1040780319 "company_id" => 6102149 "url" => "https://eg.linkedin.com/company/sakura-egypt" "created" => "2024-07-24 18:56:37" "last_updated" => "2025-02-02 06:33:52" "deleted" => 0 ] [ "id" => 1040780320 "company_id" => 6102149 "url" => "https://ae.linkedin.com/company/scientific-pharmacy-a-member-of-planet-pharmacy" "created" => "2024-07-24 18:56:37" "last_updated" => "2025-02-02 06:33:52" "deleted" => 0 ] [ "id" => 1040780321 "company_id" => 6102149 "url" => "https://www.linkedin.com/company/kedrion-usa" "created" => "2024-07-24 18:56:37" "last_updated" => "2025-02-02 06:33:52" "deleted" => 0 ] [ "id" => 1040780322 "company_id" => 6102149 "url" => "https://eg.linkedin.com/company/integra-pharm" "created" => "2024-07-24 18:56:37" "last_updated" => "2025-02-02 06:33:52" "deleted" => 0 ] ] "company_specialties_collection" => [] "company_stock_info_collection" => [] "company_updates_collection" => [] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4746 …} -companyTags: Doctrine\ORM\PersistentCollection {#4748 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4750 …} -users: Doctrine\ORM\PersistentCollection {#4752 …} -logoImageName: "20250226144247-effik-italfarmaco-logo-67bf1a57b4c91330659727.png" -coverImageName: "20250227162639-effik-italfarmaco-logo-67c0842fd26bb723685859.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4754 …} -tagline: "Innovationen in der Frauengesundheit – Fortschrittliche Lösungen für eine bessere Lebensqualität" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4756 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4758 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4760 …} -industry: "" -size: "" -address1: "Rue du Marché 10" -address2: null -city: "Nyon" -postalCode: "1260" -state: null -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4762 …} #createdAt: DateTime @1740055282 {#4723 date: 2025-02-20 12:41:22.0 UTC (+00:00) } #updatedAt: DateTime @1759132389 {#4722 date: 2025-09-29 07:53:09.0 UTC (+00:00) } } App\Entity\Company {#4766 -id: 25 -name: "Eisai Pharma AG" -website: "https://eisai.ch" -description: """ Die Eisai Pharma AG ist die Schweizer Niederlassung der Eisai Group, einem forschenden Pharmaunternehmen mit Hauptsitz in Tokio, Japan. Seit 2005 vermarktet und vertreibt Eisai seine Medikamente für den Schweizer Markt von Zürich aus. Unsere Mitarbeitenden sind in den Bereichen Vertrieb & Marketing, Medizin, Zulassung, Finanzen und pharmazeutische Dienstleistungen tätig.\n \n Die Schwerpunkte liegen in den Bereichen Neurologie und Onkologie.\n \n Für unsere Mitarbeitenden ist ihre Arbeit nicht nur ein „Job“: Wir fühlen uns unserer Unternehmensphilosophie verpflichtet und setzen uns dafür ein, dass Menschen mit schwerwiegenden Erkrankungen Zugang zu den für sie notwendigen Medikamenten erhalten.\n \n Weitere Informationen finden Sie unter eisai.ch """ -externalId: "95325813" -details: [ "id" => 95325813 "url" => "https://www.linkedin.com/company/eisai-pharma-ag" "hash" => "f63abdcba718a92da27392713cd57414" "name" => "EISAI PHARMA AG" "website" => "http://www.eisai.ch" "size" => null "industry" => null "description" => null "followers" => 2 "founded" => null "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://static.licdn.com/aero-v1/sc/h/cs8pjfgyw96g44ln9r7tct85f" "created" => "2024-04-16 08:04:28" "last_updated" => "2025-02-09 17:04:17" "last_response_code" => 200 "type" => null "headquarters_new_address" => "Zurich, Zurich" "employees_count" => null "headquarters_country_restored" => null "headquarters_country_parsed" => "Switzerland" "company_shorthand_name" => "eisai-pharma-ag" "company_shorthand_name_hash" => "f2911e8e813f130b107eada5260f7fec" "canonical_url" => "https://ch.linkedin.com/company/eisai-pharma-ag" "canonical_hash" => "446849855cc98b533d4b1c0dde8c1e7f" "canonical_shorthand_name" => "eisai-pharma-ag" "canonical_shorthand_name_hash" => "f2911e8e813f130b107eada5260f7fec" "deleted" => 0 "last_updated_ux" => 1739120656 "source_id" => 94769403 "company_affiliated_collection" => [] "company_also_viewed_collection" => [] "company_crunchbase_info_collection" => [] "company_featured_employees_collection" => [ [ "id" => 204803742 "company_id" => 95325813 "url" => "https://ch.linkedin.com/in/juan-gomez-72b66553" "created" => "2024-04-16 08:04:28" "last_updated" => "2024-08-14 22:12:43" "deleted" => 1 ] ] "company_featured_investors_collection" => [] "company_funding_rounds_collection" => [] "company_locations_collection" => [ [ "id" => 141920883 "company_id" => 95325813 "location_address" => "Zurich, Zurich 8050, CH" "is_primary" => 0 "created" => "2024-04-16 08:04:28" "last_updated" => "2025-02-09 17:04:16" "deleted" => 0 ] ] "company_similar_collection" => [ [ "id" => 986386764 "company_id" => 95325813 "url" => "https://uk.linkedin.com/company/eisai-emea" "created" => "2024-04-16 08:04:28" "last_updated" => "2025-02-09 17:04:16" "deleted" => 0 ] [ "id" => 986386765 "company_id" => 95325813 "url" => "https://in.linkedin.com/company/samarth-life-sciences-private-limited" "created" => "2024-04-16 08:04:28" "last_updated" => "2024-09-08 20:04:27" "deleted" => 1 ] [ "id" => 986386766 "company_id" => 95325813 "url" => "https://www.linkedin.com/company/aimmune-therapeutics" "created" => "2024-04-16 08:04:28" "last_updated" => "2024-12-08 06:07:41" "deleted" => 1 ] [ "id" => 986386767 "company_id" => 95325813 "url" => "https://www.linkedin.com/company/eisai" "created" => "2024-04-16 08:04:28" "last_updated" => "2025-02-09 17:04:16" "deleted" => 0 ] [ "id" => 986386768 "company_id" => 95325813 "url" => "https://in.linkedin.com/company/cadila-pharmaceuticals" "created" => "2024-04-16 08:04:28" "last_updated" => "2024-09-08 20:04:27" "deleted" => 1 ] [ "id" => 986386769 "company_id" => 95325813 "url" => "https://ie.linkedin.com/company/allergan" "created" => "2024-04-16 08:04:28" "last_updated" => "2024-09-08 20:04:27" "deleted" => 1 ] [ "id" => 986386770 "company_id" => 95325813 "url" => "https://www.linkedin.com/company/gilead-sciences" "created" => "2024-04-16 08:04:28" "last_updated" => "2024-06-10 18:18:27" "deleted" => 1 ] [ "id" => 986386771 "company_id" => 95325813 "url" => "https://in.linkedin.com/company/sun-pharma" "created" => "2024-04-16 08:04:28" "last_updated" => "2024-06-10 18:18:27" "deleted" => 1 ] [ "id" => 986386772 "company_id" => 95325813 "url" => "https://jp.linkedin.com/company/takeda-pharmaceuticals" "created" => "2024-04-16 08:04:28" "last_updated" => "2024-05-18 21:03:30" "deleted" => 1 ] [ "id" => 986386773 "company_id" => 95325813 "url" => "https://www.linkedin.com/company/eli-lilly-and-company" "created" => "2024-04-16 08:04:28" "last_updated" => "2024-05-18 21:03:30" "deleted" => 1 ] [ "id" => 1001357248 "company_id" => 95325813 "url" => "https://fr.linkedin.com/company/ipsen" "created" => "2024-05-18 21:03:30" "last_updated" => "2024-08-14 22:12:43" "deleted" => 1 ] [ "id" => 1001357249 "company_id" => 95325813 "url" => "https://www.linkedin.com/company/regeneron-pharmaceuticals" "created" => "2024-05-18 21:03:30" "last_updated" => "2024-08-14 22:12:43" "deleted" => 1 ] [ "id" => 1016102898 "company_id" => 95325813 "url" => "https://www.linkedin.com/company/esaitoolkit" "created" => "2024-06-10 18:18:27" "last_updated" => "2024-09-05 19:14:02" "deleted" => 1 ] [ "id" => 1016102899 "company_id" => 95325813 "url" => "https://jp.linkedin.com/company/eisaiglobal" "created" => "2024-06-10 18:18:27" "last_updated" => "2025-02-09 17:04:16" "deleted" => 0 ] [ "id" => 1049114208 "company_id" => 95325813 "url" => "https://in.linkedin.com/company/eisaiindia" "created" => "2024-08-14 22:12:43" "last_updated" => "2025-02-09 17:04:16" "deleted" => 0 ] [ "id" => 1049114209 "company_id" => 95325813 "url" => "https://www.linkedin.com/company/2seventybio" "created" => "2024-08-14 22:12:43" "last_updated" => "2025-02-09 17:04:16" "deleted" => 0 ] [ "id" => 1059864556 "company_id" => 95325813 "url" => "https://www.linkedin.com/company/esai-toolkit" "created" => "2024-09-05 19:14:02" "last_updated" => "2025-02-09 17:04:16" "deleted" => 0 ] [ "id" => 1063698129 "company_id" => 95325813 "url" => "https://www.linkedin.com/company/organon" "created" => "2024-09-08 20:04:27" "last_updated" => "2024-10-18 08:07:13" "deleted" => 1 ] [ "id" => 1063698130 "company_id" => 95325813 "url" => "https://fr.linkedin.com/company/ipsen" "created" => "2024-09-08 20:04:27" "last_updated" => "2024-10-18 08:07:13" "deleted" => 1 ] [ "id" => 1063698131 "company_id" => 95325813 "url" => "https://www.linkedin.com/company/regeneron-pharmaceuticals" "created" => "2024-09-08 20:04:27" "last_updated" => "2024-10-18 08:07:13" "deleted" => 1 ] [ "id" => 1086534738 "company_id" => 95325813 "url" => "https://pk.linkedin.com/company/irza-pharma" "created" => "2024-10-18 08:07:13" "last_updated" => "2025-02-09 17:04:16" "deleted" => 0 ] [ "id" => 1086534739 "company_id" => 95325813 "url" => "https://in.linkedin.com/company/reneev-developers" "created" => "2024-10-18 08:07:13" "last_updated" => "2025-02-09 17:04:16" "deleted" => 0 ] [ "id" => 1086534740 "company_id" => 95325813 "url" => "https://in.linkedin.com/company/proclink-consulting" "created" => "2024-10-18 08:07:13" "last_updated" => "2025-02-09 17:04:16" "deleted" => 0 ] [ "id" => 1119528394 "company_id" => 95325813 "url" => "https://www.linkedin.com/company/organon" "created" => "2024-12-08 06:07:41" "last_updated" => "2025-01-09 06:34:55" "deleted" => 1 ] [ "id" => 1131061684 "company_id" => 95325813 "url" => "https://in.linkedin.com/company/torrent-pharmaceuticals-ltd" "created" => "2025-01-09 06:34:55" "last_updated" => "2025-02-09 17:04:16" "deleted" => 0 ] ] "company_specialties_collection" => [] "company_stock_info_collection" => [] "company_updates_collection" => [] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4767 …} -companyTags: Doctrine\ORM\PersistentCollection {#4769 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4771 …} -users: Doctrine\ORM\PersistentCollection {#4773 …} -logoImageName: "20250226144311-eisai-logo-svg-67bf1a6f4255c334672300.png" -coverImageName: "20250227162655-eisai-logo-svg-67c0843f10809892232327.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4775 …} -tagline: "Forschung und Innovation in Neurologie und Onkologie für besseren Patienten-Zugang zu lebenswichtigen Medikamenten" -contactEmail: "yannick_rieger@eisai.net" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4777 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4779 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4781 …} -industry: "" -size: null -address1: null -address2: null -city: null -postalCode: null -state: null -country: "Switzerland" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4783 …} #createdAt: DateTime @1740055727 {#4744 date: 2025-02-20 12:48:47.0 UTC (+00:00) } #updatedAt: DateTime @1750924869 {#4743 date: 2025-06-26 08:01:09.0 UTC (+00:00) } } App\Entity\Company {#4787 -id: 26 -name: "Eli Lilly (Suisse) SA" -website: "https://lilly.ch" -description: "" -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4788 …} -companyTags: Doctrine\ORM\PersistentCollection {#4790 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4792 …} -users: Doctrine\ORM\PersistentCollection {#4794 …} -logoImageName: "20250226144333-lilly-logo-svg-67bf1a857c8f4661220483.png" -coverImageName: "20250227162711-lilly-favicon-67c0844f271c1177493148.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4796 …} -tagline: "Innovationen in der Onkologie, Diabetes und Immunologie für eine bessere Patientenversorgung" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4798 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4800 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4802 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4804 …} #createdAt: DateTime @1740060856 {#4765 date: 2025-02-20 14:14:16.0 UTC (+00:00) } #updatedAt: DateTime @1750924919 {#4764 date: 2025-06-26 08:01:59.0 UTC (+00:00) } } App\Entity\Company {#4808 -id: 27 -name: "EVER Pharma Schweiz GmbH" -website: "https://d-minecare.com" -description: """ Wir ─ die EVER Pharma GmbH ─ sind ein inhabergeführtes Unternehmen in den Bereichen Neurologie, Intensivmedizin, Anästhesie und Onkologie.\n \n Als Pharmaspezialist widmen wir uns der Herstellung und ebenso der Forschung und Weiterentwicklung unserer Therapiefelder. U.a. fokussieren wir dabei die Apomorphin-, Pen- und Pumpen-Technologie im Rahmen einer patienten-orientierten Parkinson-Therapie.\n \n Seit 2021 können wir Ärzte und Pflegekräfte direkt bei der subkutanen Apomorphin-Therapie unterstützen und so die „Therapie-Brücke zu den Patienten“ mit Leben füllen.\n \n Das gesamtheitliche D-mine® Care Parkinson Therapie-Konzept steht hierbei mit dem \n \n D-mine® Pen, der D-mine® Pumpe, dem D-mine® Infset und Dacepton® sowie der individuellen Patienten-Versorgung im Mittelpunkt.\n \n Weitere Informationen zum D-mine® Care Programm und den dazugehörigen Arzneimitteln finden Sie unter www.d-minecare.com. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4809 …} -companyTags: Doctrine\ORM\PersistentCollection {#4811 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4813 …} -users: Doctrine\ORM\PersistentCollection {#4815 …} -logoImageName: "20250226144357-everpharma-logo-67bf1a9dbad67342272607.png" -coverImageName: "20250227162750-images-67c0847654c4c570140788.jpeg" -companyProducts: Doctrine\ORM\PersistentCollection {#4817 …} -tagline: "Innovative Parkinson-Therapien mit D-mine® Care für eine patientenorientierte Versorgung" -contactEmail: "daniel.stengel@everpharma.com" -phone: "41798863389" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4819 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4821 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4823 …} -industry: "" -size: "" -address1: "Sägeweg 11" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "https://www.linkedin.com/company/d-mine-care/" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4825 …} #createdAt: DateTime @1740061344 {#4786 date: 2025-02-20 14:22:24.0 UTC (+00:00) } #updatedAt: DateTime @1750924942 {#4785 date: 2025-06-26 08:02:22.0 UTC (+00:00) } } App\Entity\Company {#4829 -id: 28 -name: "Fujirebio" -website: "https://fujirebio.com" -description: """ Fujirebio is is a global leader in the field of high-quality in vitro diagnostics (IVD) and an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care.\n \n Our global teams located in Japan, Asia, Europe and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. Through this business model, we ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time.\n \n Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions. \n \n Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network.\n \n Fujirebio is today a consolidated subsidiary of H.U. Group Holdings, Inc. (listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America. """ -externalId: "3731879" -details: [ "id" => 3731879 "url" => "https://www.linkedin.com/company/fujirebioeurope" "hash" => "9e338da5b72f3cd5155c488abc6af345" "name" => "Fujirebio" "website" => "http://www.fujirebio.com" "size" => "1,001-5,000 employees" "industry" => "Biotechnology Research" "description" => """ Fujirebio is is a global leader in the field of high-quality in vitro diagnostics (IVD) and an R&D-driven company constantly developing new technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care.\n \n Our global teams located in Japan, Asia, Europe and the US focus on delivering products with the highest quality standards to our customers and partners. We value partnerships with other leading companies in the industry, sharing knowledge, capabilities, and critical materials in order to supply, develop or manufacture diagnostic solutions on a wide variety of platforms. Through this business model, we ensure that the potentially life-changing diagnostic markers meet the largest global need in the shortest possible time.\n \n Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions. \n \n Founded in 1950 in Tokyo, Japan, Fujirebio has over the years concluded a number of successful acquisitions of best-in-class IVD companies. Examples include Centocor Diagnostics in 1998, CanAg Diagnostics in 2006 and Innogenetics in 2010. Today, Fujirebio’s global presence includes offices in the United States, Latin America, Europe and Asia as well as a vast international distribution network.\n \n Fujirebio is today a consolidated subsidiary of H.U. Group Holdings, Inc. (listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America. """ "followers" => null "founded" => null "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://media.licdn.com/dms/image/v2/D4D0BAQFNqLOqZsaGjQ/company-logo_200_200/company-logo_200_200/0/1725455913766/fujirebioeurope_logo?e=2147483647&v=beta&t=TfJLBK-WMP4pkriC41rbnGhLy4Fn-qkb-hotzzEZheU" "created" => "2016-06-22 23:38:37" "last_updated" => "2024-09-09 23:22:26" "last_response_code" => 200 "type" => "Public Company" "headquarters_new_address" => "Gent" "employees_count" => 250 "headquarters_country_restored" => "Belgium" "headquarters_country_parsed" => "Belgium" "company_shorthand_name" => "fujirebioeurope" "company_shorthand_name_hash" => "b559a6f3db86e09fc5c1924eda64d93c" "canonical_url" => "https://www.linkedin.com/company/fujirebioeurope" "canonical_hash" => "9e338da5b72f3cd5155c488abc6af345" "canonical_shorthand_name" => "fujirebioeurope" "canonical_shorthand_name_hash" => "b559a6f3db86e09fc5c1924eda64d93c" "deleted" => 0 "last_updated_ux" => 1725924145 "source_id" => 17068 "company_affiliated_collection" => [] "company_also_viewed_collection" => [ [ "id" => 14052801 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/fujirebio-diagnostics-inc." "viewed_company_id" => null "created" => "2016-06-22 23:38:37" "last_updated" => "2019-10-25 16:24:16" "deleted" => 1 ] [ "id" => 14052802 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/ablynx" "viewed_company_id" => null "created" => "2016-06-22 23:38:37" "last_updated" => "2018-03-13 06:57:14" "deleted" => 1 ] [ "id" => 14052803 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/argen-x" "viewed_company_id" => null "created" => "2016-06-22 23:38:37" "last_updated" => "2018-03-13 06:57:14" "deleted" => 1 ] [ "id" => 14052804 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/thrombogenics" "viewed_company_id" => null "created" => "2016-06-22 23:38:37" "last_updated" => "2017-01-17 10:55:25" "deleted" => 1 ] [ "id" => 14052805 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/actogenix-n.v." "viewed_company_id" => null "created" => "2016-06-22 23:38:37" "last_updated" => "2016-12-08 21:14:09" "deleted" => 1 ] [ "id" => 14052806 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/celyad" "viewed_company_id" => null "created" => "2016-06-22 23:38:37" "last_updated" => "2016-12-08 21:14:09" "deleted" => 1 ] [ "id" => 38876879 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/fujirebio-diagnostics-ab" "viewed_company_id" => null "created" => "2016-12-08 21:14:09" "last_updated" => "2019-10-25 16:24:16" "deleted" => 1 ] [ "id" => 38876880 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/eurogentec" "viewed_company_id" => null "created" => "2016-12-08 21:14:09" "last_updated" => "2017-10-11 17:46:09" "deleted" => 1 ] [ "id" => 71375272 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/actogenix-n.v." "viewed_company_id" => null "created" => "2017-01-17 10:55:25" "last_updated" => "2017-02-23 18:49:43" "deleted" => 1 ] [ "id" => 85964146 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/thrombogenics" "viewed_company_id" => null "created" => "2017-02-23 18:49:43" "last_updated" => "2017-07-28 16:19:12" "deleted" => 1 ] [ "id" => 93245089 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/diasorin" "viewed_company_id" => null "created" => "2017-07-28 16:19:12" "last_updated" => "2017-10-11 17:46:09" "deleted" => 1 ] [ "id" => 111911964 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/diagnostica-stago" "viewed_company_id" => null "created" => "2017-10-11 17:46:09" "last_updated" => "2018-03-13 06:57:14" "deleted" => 1 ] [ "id" => 111911965 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/biomerieux" "viewed_company_id" => null "created" => "2017-10-11 17:46:09" "last_updated" => "2018-03-13 06:57:14" "deleted" => 1 ] [ "id" => 137918068 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/innogenetics-s-r-l-" "viewed_company_id" => null "created" => "2018-03-13 06:57:14" "last_updated" => "2019-07-31 17:51:42" "deleted" => 1 ] [ "id" => 137918069 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/roche" "viewed_company_id" => null "created" => "2018-03-13 06:57:14" "last_updated" => "2019-08-31 01:09:37" "deleted" => 1 ] [ "id" => 137918070 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/beckman-coulter" "viewed_company_id" => null "created" => "2018-03-13 06:57:14" "last_updated" => "2018-07-13 07:50:11" "deleted" => 1 ] [ "id" => 137918071 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/bio-rad" "viewed_company_id" => null "created" => "2018-03-13 06:57:14" "last_updated" => "2019-10-25 16:24:16" "deleted" => 1 ] [ "id" => 144759302 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/abbott-" "viewed_company_id" => null "created" => "2018-07-13 07:50:11" "last_updated" => "2018-08-01 22:45:42" "deleted" => 1 ] [ "id" => 149643678 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/beckman-coulter" "viewed_company_id" => null "created" => "2018-08-01 22:45:41" "last_updated" => "2018-08-11 08:42:42" "deleted" => 1 ] [ "id" => 154124199 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/abbott-" "viewed_company_id" => null "created" => "2018-08-11 08:42:42" "last_updated" => "2019-05-28 05:39:59" "deleted" => 1 ] [ "id" => 224335014 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/biomerieux" "viewed_company_id" => null "created" => "2019-05-28 05:39:59" "last_updated" => "2019-10-04 22:42:48" "deleted" => 1 ] [ "id" => 251110417 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/siemens-healthineers" "viewed_company_id" => null "created" => "2019-07-31 17:51:42" "last_updated" => "2019-10-25 16:24:16" "deleted" => 1 ] [ "id" => 272175149 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/abbott-" "viewed_company_id" => null "created" => "2019-08-31 01:09:37" "last_updated" => "2019-10-25 16:24:16" "deleted" => 1 ] [ "id" => 284997587 "company_id" => 3731879 "viewed_company_url" => "https://www.linkedin.com/company/fujirebio-holdings" "viewed_company_id" => null "created" => "2019-10-04 22:42:48" "last_updated" => "2019-10-25 16:24:16" "deleted" => 1 ] ] "company_crunchbase_info_collection" => [] "company_featured_employees_collection" => [ [ "id" => 16862339 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/toon-de-kesel-3b3310" "created" => "2019-10-25 16:24:16" "last_updated" => "2020-01-26 11:34:33" "deleted" => 1 ] [ "id" => 16862340 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/luc-van-dijck-b57378" "created" => "2019-10-25 16:24:16" "last_updated" => "2020-01-26 11:34:33" "deleted" => 1 ] [ "id" => 16862341 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/wim-ottevaere-1383b5" "created" => "2019-10-25 16:24:16" "last_updated" => "2020-01-26 11:34:33" "deleted" => 1 ] [ "id" => 16862342 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/ray-hayduk-77a47b" "created" => "2019-10-25 16:24:16" "last_updated" => "2020-01-26 11:34:33" "deleted" => 1 ] [ "id" => 33731635 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/richard-van-maanen-037b48" "created" => "2020-01-26 11:34:33" "last_updated" => "2020-04-06 17:40:23" "deleted" => 1 ] [ "id" => 33731637 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/ronald-tuntelder-61a2061" "created" => "2020-01-26 11:34:33" "last_updated" => "2021-04-26 05:37:46" "deleted" => 1 ] [ "id" => 33731638 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/peter-hermans-22039a2" "created" => "2020-01-26 11:34:33" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 33731639 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/kurt-troch-7368b02" "created" => "2020-01-26 11:34:33" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 56499795 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/rob-de-raaij-a647512" "created" => "2020-12-03 17:40:09" "last_updated" => "2021-08-21 09:37:49" "deleted" => 1 ] [ "id" => 68821142 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/sagit-cantker-a8290b" "created" => "2021-07-15 05:52:04" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 80895746 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/manu-vandijck-9321071" "created" => "2021-12-28 09:06:14" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 95651644 "company_id" => 3731879 "url" => "https://de.linkedin.com/in/sagit-cantker-a8290b" "created" => "2022-07-15 06:37:30" "last_updated" => "2022-09-16 08:13:55" "deleted" => 1 ] [ "id" => 95651645 "company_id" => 3731879 "url" => "https://be.linkedin.com/in/manu-vandijck-9321071" "created" => "2022-07-15 06:37:30" "last_updated" => "2022-09-16 08:13:55" "deleted" => 1 ] [ "id" => 95651646 "company_id" => 3731879 "url" => "https://be.linkedin.com/in/peter-hermans-22039a2" "created" => "2022-07-15 06:37:30" "last_updated" => "2022-09-16 08:13:55" "deleted" => 1 ] [ "id" => 95651647 "company_id" => 3731879 "url" => "https://be.linkedin.com/in/kurt-troch-7368b02" "created" => "2022-07-15 06:37:30" "last_updated" => "2022-09-16 08:13:55" "deleted" => 1 ] [ "id" => 132701981 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/sagit-cantker-a8290b" "created" => "2022-09-16 08:13:55" "last_updated" => "2022-10-16 10:19:51" "deleted" => 1 ] [ "id" => 132701982 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/manu-vandijck-9321071" "created" => "2022-09-16 08:13:55" "last_updated" => "2022-10-16 10:19:51" "deleted" => 1 ] [ "id" => 132701983 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/peter-hermans-22039a2" "created" => "2022-09-16 08:13:55" "last_updated" => "2022-10-16 10:19:51" "deleted" => 1 ] [ "id" => 132701984 "company_id" => 3731879 "url" => "https://www.linkedin.com/in/kurt-troch-7368b02" "created" => "2022-09-16 08:13:55" "last_updated" => "2022-10-16 10:19:51" "deleted" => 1 ] [ "id" => 150407928 "company_id" => 3731879 "url" => "https://de.linkedin.com/in/sagit-cantker-a8290b" "created" => "2022-10-16 10:19:51" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 150407929 "company_id" => 3731879 "url" => "https://be.linkedin.com/in/manu-vandijck-9321071" "created" => "2022-10-16 10:19:51" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 150407930 "company_id" => 3731879 "url" => "https://be.linkedin.com/in/peter-hermans-22039a2" "created" => "2022-10-16 10:19:51" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 150407931 "company_id" => 3731879 "url" => "https://be.linkedin.com/in/kurt-troch-7368b02" "created" => "2022-10-16 10:19:51" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] ] "company_featured_investors_collection" => [] "company_funding_rounds_collection" => [] "company_locations_collection" => [ [ "id" => 6929336 "company_id" => 3731879 "location_address" => "Technologiepark 6; Gent, BE" "is_primary" => 1 "created" => "2019-10-25 16:24:16" "last_updated" => "2021-08-21 09:37:49" "deleted" => 1 ] [ "id" => 6929337 "company_id" => 3731879 "location_address" => "Via Pontina, Km 29; Pomezia RM, Roma 00040, IT" "is_primary" => 0 "created" => "2019-10-25 16:24:16" "last_updated" => "2021-08-21 09:37:49" "deleted" => 1 ] [ "id" => 6929338 "company_id" => 3731879 "location_address" => "Alameda Rio Negro 585; Alphaville; Barueri, São Paulo 06454-000, BR" "is_primary" => 0 "created" => "2019-10-25 16:24:16" "last_updated" => "2021-08-21 09:37:49" "deleted" => 1 ] [ "id" => 6929339 "company_id" => 3731879 "location_address" => "1 Avenue de l'Atlantique; Les Ulis, Île-de-France 91940, FR" "is_primary" => 0 "created" => "2019-10-25 16:24:16" "last_updated" => "2021-08-21 09:37:49" "deleted" => 1 ] [ "id" => 6929340 "company_id" => 3731879 "location_address" => "Calle Tarragona 161, Planta 14; Barcelona, ES" "is_primary" => 0 "created" => "2019-10-25 16:24:16" "last_updated" => "2021-08-21 09:37:49" "deleted" => 1 ] [ "id" => 6929341 "company_id" => 3731879 "location_address" => "Hans-Böckler-Allee 20; Hannover, DE" "is_primary" => 0 "created" => "2019-10-25 16:24:16" "last_updated" => "2021-08-21 09:37:49" "deleted" => 1 ] [ "id" => 29135947 "company_id" => 3731879 "location_address" => "Technologiepark 6; Gent, BE" "is_primary" => 1 "created" => "2021-08-26 21:44:05" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 29135948 "company_id" => 3731879 "location_address" => "Via Pontina, Km 29; Pomezia RM, Roma 00040, IT" "is_primary" => 0 "created" => "2021-08-26 21:44:05" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 29135949 "company_id" => 3731879 "location_address" => "Alameda Rio Negro 585; Alphaville; Barueri, São Paulo 06454-000, BR" "is_primary" => 0 "created" => "2021-08-26 21:44:05" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 29135950 "company_id" => 3731879 "location_address" => "1 Avenue de l'Atlantique; Les Ulis, Île-de-France 91940, FR" "is_primary" => 0 "created" => "2021-08-26 21:44:05" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 29135951 "company_id" => 3731879 "location_address" => "Calle Tarragona 161, Planta 14; Barcelona, ES" "is_primary" => 0 "created" => "2021-08-26 21:44:05" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 29135952 "company_id" => 3731879 "location_address" => "Hans-Böckler-Allee 20; Hannover, DE" "is_primary" => 0 "created" => "2021-08-26 21:44:05" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 71389844 "company_id" => 3731879 "location_address" => "Technologiepark 6; Gent, BE" "is_primary" => 1 "created" => "2022-07-15 06:37:30" "last_updated" => "2023-09-11 14:34:53" "deleted" => 1 ] [ "id" => 71389845 "company_id" => 3731879 "location_address" => "Hans-Böckler-Allee 20; Hannover, DE" "is_primary" => 0 "created" => "2022-07-15 06:37:30" "last_updated" => "2023-09-11 14:34:53" "deleted" => 1 ] [ "id" => 71389846 "company_id" => 3731879 "location_address" => "Calle Tarragona 161, Planta 14; Barcelona, ES" "is_primary" => 0 "created" => "2022-07-15 06:37:30" "last_updated" => "2023-09-11 14:34:53" "deleted" => 1 ] [ "id" => 71389847 "company_id" => 3731879 "location_address" => "Via Pontina, Km 29; Pomezia RM, Roma 00040, IT" "is_primary" => 0 "created" => "2022-07-15 06:37:30" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 71389848 "company_id" => 3731879 "location_address" => "1 Avenue de l'Atlantique; Les Ulis, Île-de-France 91940, FR" "is_primary" => 0 "created" => "2022-07-15 06:37:30" "last_updated" => "2024-07-16 04:58:42" "deleted" => 1 ] [ "id" => 71389849 "company_id" => 3731879 "location_address" => "Alameda Rio Negro 585; Alphaville; Barueri, São Paulo 06454-000, BR" "is_primary" => 0 "created" => "2022-07-15 06:37:30" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 132614055 "company_id" => 3731879 "location_address" => "Technologiepark 6; Gent, 9052, BE" "is_primary" => 1 "created" => "2023-09-11 14:34:53" "last_updated" => "2024-07-16 04:58:42" "deleted" => 1 ] [ "id" => 132614056 "company_id" => 3731879 "location_address" => "Hans-Böckler-Allee 20; Hannover, 30173, DE" "is_primary" => 0 "created" => "2023-09-11 14:34:53" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 132614057 "company_id" => 3731879 "location_address" => "Calle Tarragona 161, Planta 14; Barcelona, 08014, ES" "is_primary" => 0 "created" => "2023-09-11 14:34:53" "last_updated" => "2024-07-16 04:58:42" "deleted" => 1 ] [ "id" => 142596258 "company_id" => 3731879 "location_address" => "Akasaka Intercity AIR, 1-8-1, Akasaka; Minato-ku, Tokyo, 107-0052, JP" "is_primary" => 1 "created" => "2024-07-16 04:58:42" "last_updated" => "2024-08-12 23:47:38" "deleted" => 1 ] [ "id" => 142596259 "company_id" => 3731879 "location_address" => "201 Great Valley Pkwy; Malvern, Pennsylvania 19355, US" "is_primary" => 0 "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 142596260 "company_id" => 3731879 "location_address" => "Technologiepark 6; Gent, 9052, BE" "is_primary" => 0 "created" => "2024-07-16 04:58:42" "last_updated" => "2024-08-12 23:47:38" "deleted" => 1 ] [ "id" => 142596261 "company_id" => 3731879 "location_address" => "Citypark Cornellà, Ctra. l’Hospitalet 147-149; Edificio Atenas, PB 3-4; Cornellà de Llobregat, Barcelona, 08940, ES" "is_primary" => 0 "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 142596262 "company_id" => 3731879 "location_address" => "1 Avenue de l'Atlantique; Les Conquérants; ZA COURTABOEUF, Île-de-France 91976, FR" "is_primary" => 0 "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 142596263 "company_id" => 3731879 "location_address" => "Akasaka Intercity AIR, 1-8-1, Akasaka; Minato-ku, Tokyo, 107-0052, JP" "is_primary" => 0 "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 142596264 "company_id" => 3731879 "location_address" => "153 Komiya-machi; Hachioji-city, Tokyo, 192-0031, JP" "is_primary" => 0 "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 142596265 "company_id" => 3731879 "location_address" => "935 Ishikawa-cho, Hachioji-city; Tokyo, 192-0032, JP" "is_primary" => 0 "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 142596266 "company_id" => 3731879 "location_address" => "188 HongBaoShi Road; Room3302, Building A, GUBEI SOHO; Shanghai, 201103, CN" "is_primary" => 0 "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 142596267 "company_id" => 3731879 "location_address" => "Southern Road Capital Gym Haidian District; Room 1151, Hotel Nikko New Century Beijing Office Tower Building, No.6; Beijing, 100044, CN" "is_primary" => 0 "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 142596268 "company_id" => 3731879 "location_address" => "1175 Sonora Ct; Sunnyvale, California 94086, US" "is_primary" => 0 "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 142818442 "company_id" => 3731879 "location_address" => "Technologiepark 6; Gent, 9052, BE" "is_primary" => 1 "created" => "2024-08-12 23:47:38" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 142818443 "company_id" => 3731879 "location_address" => "Akasaka Intercity AIR, 1-8-1, Akasaka; Minato-ku, Tokyo, 107-0052, JP" "is_primary" => 0 "created" => "2024-08-12 23:47:38" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] ] "company_similar_collection" => [ [ "id" => 26180246 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/fujirebio-diagnostics-ab" "created" => "2019-10-25 16:24:16" "last_updated" => "2020-12-03 17:40:09" "deleted" => 1 ] [ "id" => 26180247 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/fujirebio-diagnostics-inc." "created" => "2019-10-25 16:24:16" "last_updated" => "2019-11-01 00:26:55" "deleted" => 1 ] [ "id" => 26180248 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/bio-rad" "created" => "2019-10-25 16:24:16" "last_updated" => "2020-05-29 08:33:48" "deleted" => 1 ] [ "id" => 26180249 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/abbott-" "created" => "2019-10-25 16:24:16" "last_updated" => "2021-06-21 01:35:30" "deleted" => 1 ] [ "id" => 26180250 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/roche" "created" => "2019-10-25 16:24:16" "last_updated" => "2020-12-03 17:40:09" "deleted" => 1 ] [ "id" => 26180251 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/siemens-healthineers" "created" => "2019-10-25 16:24:16" "last_updated" => "2019-11-25 06:24:33" "deleted" => 1 ] [ "id" => 27631258 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/fujirebio-us" "created" => "2019-11-01 00:26:55" "last_updated" => "2021-06-21 01:35:30" "deleted" => 1 ] [ "id" => 50132461 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/fujirebio-holdings" "created" => "2019-11-25 06:24:33" "last_updated" => "2020-04-06 17:40:23" "deleted" => 1 ] [ "id" => 75703497 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/diasorin" "created" => "2020-01-26 11:34:33" "last_updated" => "2020-05-02 12:54:44" "deleted" => 1 ] [ "id" => 75703499 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/prodigest" "created" => "2020-01-26 11:34:33" "last_updated" => "2020-02-05 14:48:09" "deleted" => 1 ] [ "id" => 75703503 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/siemens-healthineers" "created" => "2020-01-26 11:34:33" "last_updated" => "2020-01-30 12:54:51" "deleted" => 1 ] [ "id" => 75703509 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/inbiose-n-v" "created" => "2020-01-26 11:34:33" "last_updated" => "2020-01-30 12:54:51" "deleted" => 1 ] [ "id" => 80892430 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/ortho-clinical-diagnostics" "created" => "2020-01-30 12:54:51" "last_updated" => "2020-11-05 09:59:31" "deleted" => 1 ] [ "id" => 80892431 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/biomerieux" "created" => "2020-01-30 12:54:51" "last_updated" => "2020-05-02 12:54:44" "deleted" => 1 ] [ "id" => 84689829 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/siemens-healthineers" "created" => "2020-02-05 14:48:09" "last_updated" => "2020-07-30 20:22:01" "deleted" => 1 ] [ "id" => 127567979 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/miraca" "created" => "2020-04-06 17:40:23" "last_updated" => "2020-12-03 17:40:09" "deleted" => 1 ] [ "id" => 142055213 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/innogenetics-s-r-l-" "created" => "2020-05-02 12:54:44" "last_updated" => "2020-09-21 10:01:49" "deleted" => 1 ] [ "id" => 142055214 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/fujirebio-italia-s.r.l." "created" => "2020-05-02 12:54:44" "last_updated" => "2020-06-01 18:42:08" "deleted" => 1 ] [ "id" => 160017405 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/diasorin" "created" => "2020-05-29 08:33:48" "last_updated" => "2020-12-03 17:40:09" "deleted" => 1 ] [ "id" => 160810005 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/thermo-fisher-scientific" "created" => "2020-06-01 18:42:08" "last_updated" => "2020-07-30 20:22:01" "deleted" => 1 ] [ "id" => 197412203 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/miraca-life-sciences" "created" => "2020-07-30 20:22:01" "last_updated" => "2020-08-23 16:40:32" "deleted" => 1 ] [ "id" => 197412204 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/biomerieux" "created" => "2020-07-30 20:22:01" "last_updated" => "2020-09-29 01:26:45" "deleted" => 1 ] [ "id" => 213854996 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/fujirebio-holdings" "created" => "2020-08-23 16:40:32" "last_updated" => "2020-12-03 17:40:09" "deleted" => 1 ] [ "id" => 235604587 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/siemens-healthineers" "created" => "2020-09-21 10:01:49" "last_updated" => "2020-09-29 01:26:45" "deleted" => 1 ] [ "id" => 239448768 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/novosanis" "created" => "2020-09-29 01:26:45" "last_updated" => "2020-11-05 09:59:31" "deleted" => 1 ] [ "id" => 239448769 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/ablynx" "created" => "2020-09-29 01:26:45" "last_updated" => "2020-12-03 17:40:09" "deleted" => 1 ] [ "id" => 262635704 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/fujirebio-italia-s.r.l." "created" => "2020-11-05 09:59:31" "last_updated" => "2020-12-03 17:40:09" "deleted" => 1 ] [ "id" => 262635705 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/glpg" "created" => "2020-11-05 09:59:31" "last_updated" => "2020-12-03 17:40:09" "deleted" => 1 ] [ "id" => 304202572 "company_id" => 3731879 "url" => "https://se.linkedin.com/company/fujirebio-diagnostics-ab" "created" => "2020-12-03 17:40:09" "last_updated" => "2021-06-21 01:35:30" "deleted" => 1 ] [ "id" => 304202573 "company_id" => 3731879 "url" => "https://jp.linkedin.com/company/miraca" "created" => "2020-12-03 17:40:09" "last_updated" => "2021-06-21 01:35:30" "deleted" => 1 ] [ "id" => 304202574 "company_id" => 3731879 "url" => "https://ch.linkedin.com/company/roche" "created" => "2020-12-03 17:40:09" "last_updated" => "2021-06-21 01:35:30" "deleted" => 1 ] [ "id" => 304202575 "company_id" => 3731879 "url" => "https://it.linkedin.com/company/fujirebio-italia-s.r.l." "created" => "2020-12-03 17:40:09" "last_updated" => "2021-04-26 05:37:46" "deleted" => 1 ] [ "id" => 304202576 "company_id" => 3731879 "url" => "https://be.linkedin.com/company/ablynx" "created" => "2020-12-03 17:40:09" "last_updated" => "2021-02-12 17:31:54" "deleted" => 1 ] [ "id" => 304202577 "company_id" => 3731879 "url" => "https://jp.linkedin.com/company/fujirebio-holdings" "created" => "2020-12-03 17:40:09" "last_updated" => "2021-01-18 16:27:10" "deleted" => 1 ] [ "id" => 304202578 "company_id" => 3731879 "url" => "https://it.linkedin.com/company/diasorin" "created" => "2020-12-03 17:40:09" "last_updated" => "2021-01-18 16:27:10" "deleted" => 1 ] [ "id" => 304202579 "company_id" => 3731879 "url" => "https://fr.linkedin.com/company/biomerieux" "created" => "2020-12-03 17:40:09" "last_updated" => "2021-04-26 05:37:46" "deleted" => 1 ] [ "id" => 356642764 "company_id" => 3731879 "url" => "https://be.linkedin.com/company/novosanis" "created" => "2021-01-18 16:27:10" "last_updated" => "2021-02-12 17:31:54" "deleted" => 1 ] [ "id" => 356642765 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/bio-rad" "created" => "2021-01-18 16:27:10" "last_updated" => "2021-06-21 01:35:30" "deleted" => 1 ] [ "id" => 370422755 "company_id" => 3731879 "url" => "https://it.linkedin.com/company/diasorin" "created" => "2021-02-12 17:31:54" "last_updated" => "2021-06-21 01:35:30" "deleted" => 1 ] [ "id" => 370422756 "company_id" => 3731879 "url" => "https://de.linkedin.com/company/siemens-healthineers" "created" => "2021-02-12 17:31:54" "last_updated" => "2021-06-21 01:35:30" "deleted" => 1 ] [ "id" => 405996810 "company_id" => 3731879 "url" => "https://jp.linkedin.com/company/fujirebio-holdings" "created" => "2021-04-26 05:37:46" "last_updated" => "2021-06-21 01:35:30" "deleted" => 1 ] [ "id" => 405996811 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/thermo-fisher-scientific" "created" => "2021-04-26 05:37:46" "last_updated" => "2021-06-21 01:35:30" "deleted" => 1 ] [ "id" => 514063089 "company_id" => 3731879 "url" => "https://se.linkedin.com/company/fujirebio-diagnostics-ab" "created" => "2021-09-23 00:36:57" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 514063090 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/fujirebio-us" "created" => "2021-09-23 00:36:57" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 514063091 "company_id" => 3731879 "url" => "https://jp.linkedin.com/company/miraca" "created" => "2021-09-23 00:36:57" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 514063092 "company_id" => 3731879 "url" => "https://ch.linkedin.com/company/roche" "created" => "2021-09-23 00:36:57" "last_updated" => "2022-03-01 11:18:39" "deleted" => 1 ] [ "id" => 514063093 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/bio-rad" "created" => "2021-09-23 00:36:57" "last_updated" => "2022-03-01 11:18:39" "deleted" => 1 ] [ "id" => 514063094 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/abbott-" "created" => "2021-09-23 00:36:57" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 514063095 "company_id" => 3731879 "url" => "https://jp.linkedin.com/company/fujirebio-holdings" "created" => "2021-09-23 00:36:57" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 514063096 "company_id" => 3731879 "url" => "https://de.linkedin.com/company/siemens-healthineers" "created" => "2021-09-23 00:36:57" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 514063097 "company_id" => 3731879 "url" => "https://it.linkedin.com/company/diasorin" "created" => "2021-09-23 00:36:57" "last_updated" => "2022-03-01 11:18:39" "deleted" => 1 ] [ "id" => 514063098 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/thermo-fisher-scientific" "created" => "2021-09-23 00:36:57" "last_updated" => "2022-06-19 20:35:36" "deleted" => 1 ] [ "id" => 557830980 "company_id" => 3731879 "url" => "https://nl.linkedin.com/company/themagrouppartnerinlifesciencerecruitment" "created" => "2022-03-01 11:18:39" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 557830981 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/beckman-coulter" "created" => "2022-03-01 11:18:39" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 557830982 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/cepheid" "created" => "2022-03-01 11:18:39" "last_updated" => "2022-06-19 20:35:36" "deleted" => 1 ] [ "id" => 638859544 "company_id" => 3731879 "url" => "https://it.linkedin.com/company/diasorin" "created" => "2022-06-19 20:35:36" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 638859546 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/bd1" "created" => "2022-06-19 20:35:36" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 662090398 "company_id" => 3731879 "url" => "https://se.linkedin.com/company/fujirebio-diagnostics-ab" "created" => "2022-07-15 06:37:30" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 662090399 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/fujirebio-us" "created" => "2022-07-15 06:37:30" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 662090400 "company_id" => 3731879 "url" => "https://jp.linkedin.com/company/miraca" "created" => "2022-07-15 06:37:30" "last_updated" => "2024-06-10 07:20:07" "deleted" => 1 ] [ "id" => 662090401 "company_id" => 3731879 "url" => "https://be.linkedin.com/company/adx-neurosciences-nv" "created" => "2022-07-15 06:37:30" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 662090402 "company_id" => 3731879 "url" => "https://jp.linkedin.com/company/fujirebio-holdings" "created" => "2022-07-15 06:37:30" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 662090404 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/abbott-" "created" => "2022-07-15 06:37:30" "last_updated" => "2023-12-12 05:55:23" "deleted" => 1 ] [ "id" => 662090405 "company_id" => 3731879 "url" => "https://it.linkedin.com/company/diasorin" "created" => "2022-07-15 06:37:30" "last_updated" => "2023-10-20 15:03:25" "deleted" => 1 ] [ "id" => 662090406 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/beckman-coulter" "created" => "2022-07-15 06:37:30" "last_updated" => "2023-04-09 11:58:46" "deleted" => 1 ] [ "id" => 662090407 "company_id" => 3731879 "url" => "https://nl.linkedin.com/company/themagrouppartnerinlifesciencerecruitment" "created" => "2022-07-15 06:37:30" "last_updated" => "2022-11-27 10:36:39" "deleted" => 1 ] [ "id" => 662090408 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/bd1" "created" => "2022-07-15 06:37:30" "last_updated" => "2022-08-11 16:57:17" "deleted" => 1 ] [ "id" => 700075349 "company_id" => 3731879 "url" => "https://de.linkedin.com/company/siemens-healthineers" "created" => "2022-08-11 16:57:17" "last_updated" => "2022-09-16 08:13:55" "deleted" => 1 ] [ "id" => 708520820 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/bd1" "created" => "2022-09-16 08:13:55" "last_updated" => "2022-10-16 10:19:51" "deleted" => 1 ] [ "id" => 728439740 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/thermo-fisher-scientific" "created" => "2022-10-16 10:19:51" "last_updated" => "2022-11-27 10:36:39" "deleted" => 1 ] [ "id" => 745166688 "company_id" => 3731879 "url" => "https://ch.linkedin.com/company/roche" "created" => "2022-11-27 10:36:39" "last_updated" => "2024-09-09 23:22:25" "deleted" => 1 ] [ "id" => 745166689 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/bd1" "created" => "2022-11-27 10:36:39" "last_updated" => "2023-05-01 17:20:16" "deleted" => 1 ] [ "id" => 799231332 "company_id" => 3731879 "url" => "https://de.linkedin.com/company/siemens-healthineers" "created" => "2023-04-09 11:58:46" "last_updated" => "2023-09-11 14:34:53" "deleted" => 1 ] [ "id" => 816762677 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2023-05-01 17:20:16" "last_updated" => "2023-08-15 17:00:19" "deleted" => 1 ] [ "id" => 869268663 "company_id" => 3731879 "url" => "https://be.linkedin.com/company/aphea-bio" "created" => "2023-08-15 17:00:19" "last_updated" => "2023-09-11 14:34:53" "deleted" => 1 ] [ "id" => 877873858 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/argenx" "created" => "2023-09-11 14:34:53" "last_updated" => "2024-02-13 20:51:09" "deleted" => 1 ] [ "id" => 877873859 "company_id" => 3731879 "url" => "https://es.linkedin.com/company/solimix-s-a-" "created" => "2023-09-11 14:34:53" "last_updated" => "2023-11-26 19:26:20" "deleted" => 1 ] [ "id" => 897129456 "company_id" => 3731879 "url" => "https://be.linkedin.com/company/aphea-bio" "created" => "2023-10-20 15:03:25" "last_updated" => "2024-04-05 12:17:43" "deleted" => 1 ] [ "id" => 917229250 "company_id" => 3731879 "url" => "https://be.linkedin.com/company/tmc-be" "created" => "2023-11-26 19:26:20" "last_updated" => "2024-02-13 20:51:09" "deleted" => 1 ] [ "id" => 923210298 "company_id" => 3731879 "url" => "https://uk.linkedin.com/company/ids" "created" => "2023-12-12 05:55:23" "last_updated" => "2024-01-15 23:45:57" "deleted" => 1 ] [ "id" => 937277556 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/abbott-" "created" => "2024-01-15 23:45:57" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 948988173 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/thermo-fisher-scientific" "created" => "2024-02-13 20:51:09" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 948988174 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/bio-rad" "created" => "2024-02-13 20:51:09" "last_updated" => "2024-03-02 00:09:31" "deleted" => 1 ] [ "id" => 962149489 "company_id" => 3731879 "url" => "https://uk.linkedin.com/company/ids" "created" => "2024-03-02 00:09:31" "last_updated" => "2024-04-05 12:17:43" "deleted" => 1 ] [ "id" => 979835945 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/argenx" "created" => "2024-04-05 12:17:43" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 979835946 "company_id" => 3731879 "url" => "https://es.linkedin.com/company/feedbackground" "created" => "2024-04-05 12:17:43" "last_updated" => "2024-05-10 17:26:36" "deleted" => 1 ] [ "id" => 997322083 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/beckman-coulter" "created" => "2024-05-10 17:26:36" "last_updated" => "2024-06-10 07:20:07" "deleted" => 1 ] [ "id" => 1015739742 "company_id" => 3731879 "url" => "https://es.linkedin.com/company/feedbackground" "created" => "2024-06-10 07:20:07" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 1015739743 "company_id" => 3731879 "url" => "https://fr.linkedin.com/company/sanofi" "created" => "2024-06-10 07:20:07" "last_updated" => "2024-07-16 04:58:42" "deleted" => 1 ] [ "id" => 1033609980 "company_id" => 3731879 "url" => "https://www.linkedin.com/company/beckman-coulter" "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 1 ] [ "id" => 1065050463 "company_id" => 3731879 "url" => "https://es.linkedin.com/company/solimix-s-a-" "created" => "2024-09-09 23:22:25" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 1065050464 "company_id" => 3731879 "url" => "https://fr.linkedin.com/company/sanofi" "created" => "2024-09-09 23:22:25" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] ] "company_specialties_collection" => [ [ "id" => 5303720 "company_id" => 3731879 "specialty" => "IVD" "created" => "2016-06-22 23:38:37" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 5303721 "company_id" => 3731879 "specialty" => "in vitro diagnostics" "created" => "2016-06-22 23:38:37" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 5303722 "company_id" => 3731879 "specialty" => "immunoassays" "created" => "2016-06-22 23:38:37" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 5303723 "company_id" => 3731879 "specialty" => "molecular diagnostics" "created" => "2016-06-22 23:38:37" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 5303724 "company_id" => 3731879 "specialty" => "multiparameter testing" "created" => "2016-06-22 23:38:37" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 5303725 "company_id" => 3731879 "specialty" => "strip-based diagnostics" "created" => "2016-06-22 23:38:37" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 5303726 "company_id" => 3731879 "specialty" => "infectious diseases" "created" => "2016-06-22 23:38:37" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 5303727 "company_id" => 3731879 "specialty" => "tumour markers" "created" => "2016-06-22 23:38:37" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 5303728 "company_id" => 3731879 "specialty" => "genetic testing" "created" => "2016-06-22 23:38:37" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 5303729 "company_id" => 3731879 "specialty" => "thyroid" "created" => "2016-06-22 23:38:37" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 5303730 "company_id" => 3731879 "specialty" => "fertility" "created" => "2016-06-22 23:38:37" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 5303731 "company_id" => 3731879 "specialty" => "tissue typing" "created" => "2016-06-22 23:38:37" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 5303732 "company_id" => 3731879 "specialty" => "neurodegeneration" "created" => "2016-06-22 23:38:37" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 5303733 "company_id" => 3731879 "specialty" => "bone testing" "created" => "2016-06-22 23:38:37" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 5303734 "company_id" => 3731879 "specialty" => "alzheimer's disease" "created" => "2016-06-22 23:38:37" "last_updated" => "2018-03-13 06:57:14" "deleted" => 1 ] [ "id" => 20911934 "company_id" => 3731879 "specialty" => "alzheimer's disease" "created" => "2018-03-13 06:57:14" "last_updated" => "2019-10-25 16:24:16" "deleted" => 1 ] [ "id" => 38707273 "company_id" => 3731879 "specialty" => "virology" "created" => "2019-05-28 05:40:00" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 38707274 "company_id" => 3731879 "specialty" => "line immunoassays" "created" => "2019-05-28 05:40:00" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 46465121 "company_id" => 3731879 "specialty" => "alzheimer's disease" "created" => "2019-10-25 16:24:16" "last_updated" => "2022-07-11 09:49:31" "deleted" => 1 ] [ "id" => 106363012 "company_id" => 3731879 "specialty" => "IVD" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363013 "company_id" => 3731879 "specialty" => "in vitro diagnostics" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363014 "company_id" => 3731879 "specialty" => "immunoassays" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363015 "company_id" => 3731879 "specialty" => "molecular diagnostics" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363016 "company_id" => 3731879 "specialty" => "multiparameter testing" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363017 "company_id" => 3731879 "specialty" => "strip-based diagnostics" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363018 "company_id" => 3731879 "specialty" => "infectious diseases" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363019 "company_id" => 3731879 "specialty" => "tumour markers" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363020 "company_id" => 3731879 "specialty" => "genetic testing" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363021 "company_id" => 3731879 "specialty" => "thyroid" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363022 "company_id" => 3731879 "specialty" => "fertility" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363023 "company_id" => 3731879 "specialty" => "tissue typing" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363024 "company_id" => 3731879 "specialty" => "neurodegeneration" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363025 "company_id" => 3731879 "specialty" => "bone testing" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363026 "company_id" => 3731879 "specialty" => "alzheimer's disease" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363027 "company_id" => 3731879 "specialty" => "virology" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 106363028 "company_id" => 3731879 "specialty" => "line immunoassays" "created" => "2022-08-11 16:57:18" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 116260271 "company_id" => 3731879 "specialty" => "CDMO" "created" => "2022-09-16 08:13:55" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 116260272 "company_id" => 3731879 "specialty" => "OEM" "created" => "2022-09-16 08:13:55" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 131757034 "company_id" => 3731879 "specialty" => "parkinson's disease" "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 131757035 "company_id" => 3731879 "specialty" => "multiple sclerosis" "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 131757036 "company_id" => 3731879 "specialty" => "HPV" "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 131757037 "company_id" => 3731879 "specialty" => "DNA methylation" "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 131757038 "company_id" => 3731879 "specialty" => "molecular biology" "created" => "2024-07-16 04:58:42" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] ] "company_stock_info_collection" => [] "company_updates_collection" => [ [ "id" => 12401810 "company_id" => 3731879 "urn" => "urn:li:activity:7006513680578170880" "followers" => 6155 "date" => "5d" "description" => "Season's greetings from Fujirebio! 💖 This year we choose to donate our traditional greetings budget to the EMSP - European Multiple Sclerosis Platform, a non-profit organization that raises the voice 📣 of people affected by #multiplesclerosis (MS) 💪" "reactions_count" => 68 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-05 09:08:34" "deleted" => 1 ] [ "id" => 12401811 "company_id" => 3731879 "urn" => "urn:li:activity:7003034206234660865" "followers" => 6155 "date" => "2w" "description" => "Non-US LinkedIn users can also visit: https://lnkd.in/eVTZZZmr 🧠" "reactions_count" => 15 "comments_count" => null "reshared_post_author" => "Fujirebio US" "reshared_post_author_url" => "https://www.linkedin.com/company/fujirebio-us" "reshared_post_author_headline" => null "reshared_post_description" => """ We will be at #CTAD22 from November 29 - December 2 in San Francisco, CA. Schedule a meeting with us to learn all about the fully-automated Lumipulse platform for CSF and blood 👉 email neuro@fdi.com or visit https://bit.ly/3u8s6xq \n #CTAD22 #CTAD #alzheimersdisease #clinicaltrials """ "reshared_post_followers" => 2931 "reshared_post_date" => "2w" "last_updated" => "2023-01-05 09:08:34" "deleted" => 1 ] [ "id" => 12401812 "company_id" => 3731879 "urn" => "urn:li:activity:7001142343533785088" "followers" => 6155 "date" => "2w" "description" => "Bonjour 👋 - we are recruiting an Account Manager for North-East/West France! Are you our new French colleague? 🤩 More here 👉 https://lnkd.in/eFkz-hME #salesjobs #ventes #recrutement #joboffers #joinus #teamfujirebio" "reactions_count" => 23 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-05 09:08:34" "deleted" => 1 ] [ "id" => 12401813 "company_id" => 3731879 "urn" => "urn:li:activity:7001117404365737985" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Corinna Orsini" "reshared_post_author_url" => "https://it.linkedin.com/in/corinna-orsini-3403a094/en" "reshared_post_author_headline" => "Customer Support Director presso Fujirebio Italia" "reshared_post_description" => """ #ELAS2022 vi aspettiamo oggi al nostro workshop alle 10.30:\n \n 🧪 Biomarcatori Plasmatici nelle malattie neurodegenerative: nuove frontiere diagnostiche 🧪\n \n Rikkert Maertens MICHELE MARFORI Maria Assunta Melone Pietro Pellegatta Alberto Perego Guido Marelli Daniela Militello Giulia Alfedi Nathalie Le Bastard Christian Lindknud, MSc \n \n Fujirebio Europe \n \n #alzheimerdisease #biomarkers #CSF #neurocenterofexcellence #neurodegeneration #fujirebio """ "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2023-01-05 09:08:34" "deleted" => 1 ] [ "id" => 12401814 "company_id" => 3731879 "urn" => "urn:li:activity:6999323827285413890" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Eurofins ADME BIOANALYSES" "reshared_post_author_url" => "https://fr.linkedin.com/company/eurofins-adme-bioanalyses" "reshared_post_author_headline" => null "reshared_post_description" => """ New equipment for extending our services to our clients.\n \n Eurofins ADME BIOANALYSES is pleased to announce the addition of the LUMIPULSE® G1200 to expand our biomarker platform capabilities:\n \n - β-Amyloid Ratio (1-42/1-40) in vitro diagnostic (IVD) test – FDA authorized - Alzheimer’s disease and other causes of cognitive decline.\n - Sensitive detection of gold standard neurobiomarkers in both CSF and blood\n - Diversified test menu (oncology, syphilis, thyroid, fertility, diabetes, bone and others…)\n - Chemiluminescence assays\n - 120 tests per hour throughput \n \n #biomarkers #neurobiology #oncology #invitro """ "reshared_post_followers" => 2112 "reshared_post_date" => "3w" "last_updated" => "2023-01-05 09:08:34" "deleted" => 1 ] [ "id" => 12401815 "company_id" => 3731879 "urn" => "urn:li:activity:6999323386849939456" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Alícia Nadal Solà" "reshared_post_author_url" => "https://es.linkedin.com/in/al%C3%ADcia-nadal-sol%C3%A0-4b796597/en" "reshared_post_author_headline" => "Marketing Manager en Fujirebio Iberia (formerly Innogenetics Diagnóstica Iberia)" "reshared_post_description" => """ Ahí seguimos. Congreso #SEN2022\n Os esperamos en el stand 35.\n \n #biomarkers #csf #blood \n #alzheimer #multiplesclerosis #fujirebioteam """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2023-01-05 09:08:34" "deleted" => 1 ] [ "id" => 12401816 "company_id" => 3731879 "urn" => "urn:li:activity:6990925129786523648" "followers" => 6155 "date" => "1mo" "description" => "Are you joining the #ECTRIMS2022 this week? 👋 Come by booth D22 to meet our expert team 👉 Nathalie Le Bastard, Dr. Peter Jagiello and more 🤩 - they are keen to meet you and discuss Multiple Sclerosis testing solutions: https://lnkd.in/eP-wve7T #MS #multiplesclerosis #fnce" "reactions_count" => 27 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-05 09:08:34" "deleted" => 1 ] [ "id" => 12401817 "company_id" => 3731879 "urn" => "urn:li:activity:6987742125392023552" "followers" => 6155 "date" => "1mo" "description" => "What are the new criteria for different stages of #Alzheimer's disease, as suggested by the IWG and NIA-AA? Read 👉 https://lnkd.in/e-HBjd6X our insight articles in which we highlight the current state of knowledge 💡 and the latest developments in the field of AD testing 🧠" "reactions_count" => 60 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-05 09:08:34" "deleted" => 1 ] [ "id" => 12401818 "company_id" => 3731879 "urn" => "urn:li:activity:6985495118719909889" "followers" => 6155 "date" => "2mo" "description" => "📰 Breaking news! 👉 https://lnkd.in/e-Er8kwC Fujirebio Europe and Self-screen announce distribution by Fujirebio of the PreCursor-M+ #methylation-specific molecular assay, intended for the qualitative detection of elevated methylation levels of #cervicalcancer biomarkers #hpv" "reactions_count" => 78 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-05 09:08:34" "deleted" => 1 ] [ "id" => 12401819 "company_id" => 3731879 "urn" => "urn:li:activity:6985098480889294848" "followers" => 6155 "date" => "2mo" "description" => "Our most recent Insight article 👉 https://lnkd.in/eCcRUPkS looks closer at Aβ deposition and clearance as a key feature of the ageing brain. Learn more about the current state of knowledge and the latest developments in the field of #Alzheimer’s disease testing in our series." "reactions_count" => 42 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-05 09:08:34" "deleted" => 1 ] [ "id" => 30891959 "company_id" => 3731879 "urn" => "urn:li:activity:7006513680578170880" "followers" => 6169 "date" => "4w" "description" => "Season's greetings from Fujirebio! 💖 This year we choose to donate our traditional greetings budget to the EMSP - European Multiple Sclerosis Platform, a non-profit organization that raises the voice 📣 of people affected by #multiplesclerosis (MS) 💪" "reactions_count" => 84 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-10 23:26:27" "deleted" => 1 ] [ "id" => 30891960 "company_id" => 3731879 "urn" => "urn:li:activity:7003034206234660865" "followers" => 6169 "date" => "1mo" "description" => "Non-US LinkedIn users can also visit: https://lnkd.in/eVTZZZmr 🧠" "reactions_count" => 18 "comments_count" => null "reshared_post_author" => "Fujirebio US" "reshared_post_author_url" => "https://www.linkedin.com/company/fujirebio-us" "reshared_post_author_headline" => null "reshared_post_description" => """ We will be at #CTAD22 from November 29 - December 2 in San Francisco, CA. Schedule a meeting with us to learn all about the fully-automated Lumipulse platform for CSF and blood 👉 email neuro@fdi.com or visit https://bit.ly/3u8s6xq \n #CTAD22 #CTAD #alzheimersdisease #clinicaltrials """ "reshared_post_followers" => 2942 "reshared_post_date" => "1mo" "last_updated" => "2023-02-10 23:26:27" "deleted" => 1 ] [ "id" => 30891961 "company_id" => 3731879 "urn" => "urn:li:activity:7001142343533785088" "followers" => 6169 "date" => "1mo" "description" => "Bonjour 👋 - we are recruiting an Account Manager for North-East/West France! Are you our new French colleague? 🤩 More here 👉 https://lnkd.in/eFkz-hME #salesjobs #ventes #recrutement #joboffers #joinus #teamfujirebio" "reactions_count" => 28 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-10 23:26:27" "deleted" => 1 ] [ "id" => 30891962 "company_id" => 3731879 "urn" => "urn:li:activity:7001117404365737985" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Corinna Orsini" "reshared_post_author_url" => "https://it.linkedin.com/in/corinna-orsini-3403a094/en" "reshared_post_author_headline" => "Customer Support Director presso Fujirebio Italia" "reshared_post_description" => """ #ELAS2022 vi aspettiamo oggi al nostro workshop alle 10.30:\n \n 🧪 Biomarcatori Plasmatici nelle malattie neurodegenerative: nuove frontiere diagnostiche 🧪\n \n Rikkert Maertens MICHELE MARFORI Maria Assunta Melone Pietro Pellegatta Alberto Perego Guido Marelli Daniela Militello Giulia Alfedi Nathalie Le Bastard Christian Lindknud, MSc \n \n Fujirebio Europe \n \n #alzheimerdisease #biomarkers #CSF #neurocenterofexcellence #neurodegeneration #fujirebio """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-02-10 23:26:27" "deleted" => 1 ] [ "id" => 30891963 "company_id" => 3731879 "urn" => "urn:li:activity:6999323827285413890" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Eurofins ADME BIOANALYSES" "reshared_post_author_url" => "https://fr.linkedin.com/company/eurofins-adme-bioanalyses" "reshared_post_author_headline" => null "reshared_post_description" => """ New equipment for extending our services to our clients.\n \n Eurofins ADME BIOANALYSES is pleased to announce the addition of the LUMIPULSE® G1200 to expand our biomarker platform capabilities:\n \n - β-Amyloid Ratio (1-42/1-40) in vitro diagnostic (IVD) test – FDA authorized - Alzheimer’s disease and other causes of cognitive decline.\n - Sensitive detection of gold standard neurobiomarkers in both CSF and blood\n - Diversified test menu (oncology, syphilis, thyroid, fertility, diabetes, bone and others…)\n - Chemiluminescence assays\n - 120 tests per hour throughput \n \n #biomarkers #neurobiology #oncology #invitro """ "reshared_post_followers" => 2118 "reshared_post_date" => "1mo" "last_updated" => "2023-02-10 23:26:27" "deleted" => 1 ] [ "id" => 30891964 "company_id" => 3731879 "urn" => "urn:li:activity:6999323386849939456" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Alícia Nadal Solà" "reshared_post_author_url" => "https://es.linkedin.com/in/al%C3%ADcia-nadal-sol%C3%A0-4b796597/en" "reshared_post_author_headline" => "Marketing Manager en Fujirebio Iberia (formerly Innogenetics Diagnóstica Iberia)" "reshared_post_description" => """ Ahí seguimos. Congreso #SEN2022\n Os esperamos en el stand 35.\n \n #biomarkers #csf #blood \n #alzheimer #multiplesclerosis #fujirebioteam """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-02-10 23:26:27" "deleted" => 1 ] [ "id" => 30891965 "company_id" => 3731879 "urn" => "urn:li:activity:6990925129786523648" "followers" => 6169 "date" => "2mo" "description" => "Are you joining the #ECTRIMS2022 this week? 👋 Come by booth D22 to meet our expert team 👉 Nathalie Le Bastard, Dr. Peter Jagiello and more 🤩 - they are keen to meet you and discuss Multiple Sclerosis testing solutions: https://lnkd.in/eP-wve7T #MS #multiplesclerosis #fnce" "reactions_count" => 27 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-10 23:26:27" "deleted" => 1 ] [ "id" => 30891966 "company_id" => 3731879 "urn" => "urn:li:activity:6987742125392023552" "followers" => 6169 "date" => "2mo" "description" => "What are the new criteria for different stages of #Alzheimer's disease, as suggested by the IWG and NIA-AA? Read 👉 https://lnkd.in/e-HBjd6X our insight articles in which we highlight the current state of knowledge 💡 and the latest developments in the field of AD testing 🧠" "reactions_count" => 60 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-10 23:26:27" "deleted" => 1 ] [ "id" => 30891967 "company_id" => 3731879 "urn" => "urn:li:activity:6985495118719909889" "followers" => 6169 "date" => "2mo" "description" => "📰 Breaking news! 👉 https://lnkd.in/e-Er8kwC Fujirebio Europe and Self-screen announce distribution by Fujirebio of the PreCursor-M+ #methylation-specific molecular assay, intended for the qualitative detection of elevated methylation levels of #cervicalcancer biomarkers #hpv" "reactions_count" => 78 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-10 23:26:27" "deleted" => 1 ] [ "id" => 30891968 "company_id" => 3731879 "urn" => "urn:li:activity:6985098480889294848" "followers" => 6169 "date" => "2mo" "description" => "Our most recent Insight article 👉 https://lnkd.in/eCcRUPkS looks closer at Aβ deposition and clearance as a key feature of the ageing brain. Learn more about the current state of knowledge and the latest developments in the field of #Alzheimer’s disease testing in our series." "reactions_count" => 42 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-10 23:26:27" "deleted" => 1 ] [ "id" => 65718003 "company_id" => 3731879 "urn" => "urn:li:activity:6933325907239575552" "followers" => 6234 "date" => "8mo" "description" => """ We are hard at work 💪 at the Fujirebio Neuro Center of Excellence (👉 https://lnkd.in/eXeAuGTk) and our doors are open for partnerships and new ideas 💡 to develop the next diagnostic solutions to neurodegenerative diseases 🧠 \n \n #fnce #neurodegeneration #biomarkers #diagnostics #research #development #newideas #teamfujirebio """ "reactions_count" => 111 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-04 10:41:19" "deleted" => 1 ] [ "id" => 65718004 "company_id" => 3731879 "urn" => "urn:li:activity:7029005120268828673" "followers" => 6234 "date" => "2d" "description" => "Eurogin 2023 in Bilbao has opened its doors 🎬🌟 Come by our booth, C17, to pick up your copy of the Methylation booklet and talk to our experts, including our friends from Self-screen B.V. and Atila Biosystems 👋 We are easy to find (see below) and look forward to discussing! EUROGIN Conference #hpvtesting #eurogin" "reactions_count" => 52 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-04 10:41:19" "deleted" => 1 ] [ "id" => 65718005 "company_id" => 3731879 "urn" => "urn:li:activity:7027643759672623104" "followers" => 6234 "date" => "6d" "description" => "Will you be at Medlab Middle East 2023 in Dubai? ✋ So will we! Come by our booth Z5.B19 and meet our team (Christiaan De Wilde, Rikkert Maertens and Amr Aleem) and discuss how we can join forces in making IVD progress 🤝 https://lnkd.in/esSZWdy5 #medlabmiddleeast #medlab2023 #partnerships" "reactions_count" => 35 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-04 10:41:19" "deleted" => 1 ] [ "id" => 65718006 "company_id" => 3731879 "urn" => "urn:li:activity:7026467495981010944" "followers" => 6234 "date" => "1w" "description" => "Curious to see beyond #HPV? 👋 Visit us at #EUROGIN booth C17 🎯 to find out about effective and accurate solutions for #triage, #screening, and #genotyping, and pick up our new #Methylation booklet (or download one right here 👉 https://lnkd.in/eav69Cv4) #diagnostics #testing" "reactions_count" => 55 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-04 10:41:19" "deleted" => 1 ] [ "id" => 65718007 "company_id" => 3731879 "urn" => "urn:li:activity:7024651309353984000" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Self-screen B.V." "reshared_post_author_url" => "https://nl.linkedin.com/company/self-screen-b-v" "reshared_post_author_headline" => null "reshared_post_description" => """ Cervical Cancer is Preventable!\n A cancer that is actually preventable is not a fantasy. Cervical cancer and precancer stadia can very accurately be detected by HPV testing. This is because cervical cancer results from a persistent infection with the HPV virus, that does not clear in time.\n Many countries therefore screen women from the age of about 30 years on such persistency. When HPV testing is negative, the participant is safe and can wait for the new screening invite in 3-5 years. When HPV positive, she is at increased risk and shall be referred to a gynaecologist for further examination of the cervix. Luckily then the majority can also return home safe when no abnormal cells are detected. \n So yes, cervical cancer screening matters! Especially upon a negative HPV test women can be confident that they are at low-no risk of cervical cancer.\n Isn't that thought powerful enough to reconsider any objections of having a test appointment done? #cervicalcancerawarenessmonth #HPV, #HPVRiskAssay, #prevention """ "reshared_post_followers" => 420 "reshared_post_date" => "2w" "last_updated" => "2023-03-04 10:41:19" "deleted" => 1 ] [ "id" => 65718008 "company_id" => 3731879 "urn" => "urn:li:activity:7020693632894541824" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Self-screen B.V." "reshared_post_author_url" => "https://nl.linkedin.com/company/self-screen-b-v" "reshared_post_author_headline" => null "reshared_post_description" => """ WHY CERVICAL CANCER SCREENING?\n \n 7 in 10 cancer diagnosis are prevented through cervical screening.\n \n Cervical cancer screening is vital as hrHPV is strongly linked to abnormalities and (pre) cancerous cells developing within the cervix.\n \n By regular screening those women at higher risk can be identified and given any treatment they need earlier, improving the outcome and even preventing diagnosis.\n \n Why not?\n - It is for women, typically aged 25-64 years (check your country)\n - It is free\n - It can be done by your doctor, or by yourself at home\n \n January is Cervical Cancer Awareness month. January is also the one month of new years' resolutions.\n As women it so important to adopt a mindset to make yourself the priority. Quite a good idea for 2023, isn't it?\n \n #cervicalcancerawareness, #screening, #HPV, #prevention, #happy2023 """ "reshared_post_followers" => 420 "reshared_post_date" => "3w" "last_updated" => "2023-03-04 10:41:19" "deleted" => 1 ] [ "id" => 65718009 "company_id" => 3731879 "urn" => "urn:li:activity:7018124415317991424" "followers" => 6234 "date" => "1mo" "description" => "In this CTAD 2022 poster 👉 https://lnkd.in/ednQh_6x we examine the utility of CSF #biomarker ratios to correct for pre-analytical variability #Alzheimers #neurodegeneration #diagnostics #FNCE 🧠" "reactions_count" => 39 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-04 10:41:19" "deleted" => 1 ] [ "id" => 65718010 "company_id" => 3731879 "urn" => "urn:li:activity:7006513680578170880" "followers" => 6234 "date" => "2mo" "description" => "Season's greetings from Fujirebio! 💖 This year we choose to donate our traditional greetings budget to the EMSP - European Multiple Sclerosis Platform, a non-profit organization that raises the voice 📣 of people affected by #multiplesclerosis (MS) 💪" "reactions_count" => 87 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-04 10:41:19" "deleted" => 1 ] [ "id" => 65718011 "company_id" => 3731879 "urn" => "urn:li:activity:7003034206234660865" "followers" => 6234 "date" => "2mo" "description" => "Non-US LinkedIn users can also visit: https://lnkd.in/eVTZZZmr 🧠" "reactions_count" => 18 "comments_count" => null "reshared_post_author" => "Fujirebio US" "reshared_post_author_url" => "https://www.linkedin.com/company/fujirebio-us" "reshared_post_author_headline" => null "reshared_post_description" => """ We will be at #CTAD22 from November 29 - December 2 in San Francisco, CA. Schedule a meeting with us to learn all about the fully-automated Lumipulse platform for CSF and blood 👉 email neuro@fdi.com or visit https://bit.ly/3u8s6xq \n #CTAD22 #CTAD #alzheimersdisease #clinicaltrials """ "reshared_post_followers" => 2970 "reshared_post_date" => "2mo" "last_updated" => "2023-03-04 10:41:19" "deleted" => 1 ] [ "id" => 65718012 "company_id" => 3731879 "urn" => "urn:li:activity:7001142343533785088" "followers" => 6234 "date" => "2mo" "description" => "Bonjour 👋 - we are recruiting an Account Manager for North-East/West France! Are you our new French colleague? 🤩 More here 👉 https://lnkd.in/eFkz-hME #salesjobs #ventes #recrutement #joboffers #joinus #teamfujirebio" "reactions_count" => 30 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-04 10:41:19" "deleted" => 1 ] [ "id" => 95165017 "company_id" => 3731879 "urn" => "urn:li:activity:6933325907239575552" "followers" => 6283 "date" => "9mo" "description" => """ We are hard at work 💪 at the Fujirebio Neuro Center of Excellence (👉 https://lnkd.in/eXeAuGTk) and our doors are open for partnerships and new ideas 💡 to develop the next diagnostic solutions to neurodegenerative diseases 🧠 \n \n #fnce #neurodegeneration #biomarkers #diagnostics #research #development #newideas #teamfujirebio """ "reactions_count" => 112 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-09 11:58:46" "deleted" => 1 ] [ "id" => 95165018 "company_id" => 3731879 "urn" => "urn:li:activity:7033711165369131008" "followers" => 6283 "date" => "1w" "description" => "How is science changing your life? 👩🔬 Find out in the latest #NaturesBuildingBlocks series streaming now 📽👉 https://lnkd.in/eFriHdkC - Fujirebio (and ADx NeuroSciences) features once more with a branded film in this excellent series! 🤩 #neurodegenerativediseases #diagnostics #biotechnology #sciencecommunication #neurosciences" "reactions_count" => 36 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-09 11:58:46" "deleted" => 1 ] [ "id" => 95165019 "company_id" => 3731879 "urn" => "urn:li:activity:7032259181214584833" "followers" => 6283 "date" => "2w" "description" => "Science gives us tools to take the building blocks of nature and rebuild better. 💪❤️ Next week, immerse yourself in the Nature’s Building Blocks and get a glimpse of our scientifically strengthened future. Our branded film features in the latest #NaturesBuildingBlocks series! 🤩 #neurodegenerativediseases #diagnostics #biotechnology" "reactions_count" => 43 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-09 11:58:46" "deleted" => 1 ] [ "id" => 95165020 "company_id" => 3731879 "urn" => "urn:li:activity:7030762482642087936" "followers" => 6283 "date" => "3w" "description" => """ Curious about improved #triage of hrHPV positive women with FAM19A4/miR124-2 methylation analysis? ✋ \n \n Download a copy of our popular #Methylation booklet 👉 https://lnkd.in/eav69Cv4 and let's have a talk about the PreCursor-M+ assay 🤩 (from Self-screen B.V.) #hpvtesting #hpvtriage #methylationanalysis """ "reactions_count" => 68 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-09 11:58:46" "deleted" => 1 ] [ "id" => 95165021 "company_id" => 3731879 "urn" => "urn:li:activity:7029005120268828673" "followers" => 6283 "date" => "3w" "description" => "Eurogin 2023 in Bilbao has opened its doors 🎬🌟 Come by our booth, C17, to pick up your copy of the Methylation booklet and talk to our experts, including our friends from Self-screen B.V. and Atila Biosystems 👋 We are easy to find (see below) and look forward to discussing! EUROGIN Conference #hpvtesting #eurogin" "reactions_count" => 63 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-09 11:58:46" "deleted" => 1 ] [ "id" => 95165022 "company_id" => 3731879 "urn" => "urn:li:activity:7027643759672623104" "followers" => 6283 "date" => "3w" "description" => "Will you be at Medlab Middle East 2023 in Dubai? ✋ So will we! Come by our booth Z5.B19 and meet our team (Christiaan De Wilde, Rikkert Maertens and Amr Aleem) and discuss how we can join forces in making IVD progress 🤝 https://lnkd.in/esSZWdy5 #medlabmiddleeast #medlab2023 #partnerships" "reactions_count" => 36 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-09 11:58:46" "deleted" => 1 ] [ "id" => 95165023 "company_id" => 3731879 "urn" => "urn:li:activity:7026467495981010944" "followers" => 6283 "date" => "1mo" "description" => "Curious to see beyond #HPV? 👋 Visit us at #EUROGIN booth C17 🎯 to find out about effective and accurate solutions for #triage, #screening, and #genotyping, and pick up our new #Methylation booklet (or download one right here 👉 https://lnkd.in/eav69Cv4) #diagnostics #testing" "reactions_count" => 59 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-09 11:58:46" "deleted" => 1 ] [ "id" => 95165024 "company_id" => 3731879 "urn" => "urn:li:activity:7024651309353984000" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Self-screen B.V." "reshared_post_author_url" => "https://nl.linkedin.com/company/self-screen-b-v" "reshared_post_author_headline" => null "reshared_post_description" => """ Cervical Cancer is Preventable!\n A cancer that is actually preventable is not a fantasy. Cervical cancer and precancer stadia can very accurately be detected by HPV testing. This is because cervical cancer results from a persistent infection with the HPV virus, that does not clear in time.\n Many countries therefore screen women from the age of about 30 years on such persistency. When HPV testing is negative, the participant is safe and can wait for the new screening invite in 3-5 years. When HPV positive, she is at increased risk and shall be referred to a gynaecologist for further examination of the cervix. Luckily then the majority can also return home safe when no abnormal cells are detected. \n So yes, cervical cancer screening matters! Especially upon a negative HPV test women can be confident that they are at low-no risk of cervical cancer.\n Isn't that thought powerful enough to reconsider any objections of having a test appointment done? #cervicalcancerawarenessmonth #HPV, #HPVRiskAssay, #prevention """ "reshared_post_followers" => 425 "reshared_post_date" => "1mo" "last_updated" => "2023-04-09 11:58:46" "deleted" => 1 ] [ "id" => 95165025 "company_id" => 3731879 "urn" => "urn:li:activity:7020693632894541824" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Self-screen B.V." "reshared_post_author_url" => "https://nl.linkedin.com/company/self-screen-b-v" "reshared_post_author_headline" => null "reshared_post_description" => """ WHY CERVICAL CANCER SCREENING?\n \n 7 in 10 cancer diagnosis are prevented through cervical screening.\n \n Cervical cancer screening is vital as hrHPV is strongly linked to abnormalities and (pre) cancerous cells developing within the cervix.\n \n By regular screening those women at higher risk can be identified and given any treatment they need earlier, improving the outcome and even preventing diagnosis.\n \n Why not?\n - It is for women, typically aged 25-64 years (check your country)\n - It is free\n - It can be done by your doctor, or by yourself at home\n \n January is Cervical Cancer Awareness month. January is also the one month of new years' resolutions.\n As women it so important to adopt a mindset to make yourself the priority. Quite a good idea for 2023, isn't it?\n \n #cervicalcancerawareness, #screening, #HPV, #prevention, #happy2023 """ "reshared_post_followers" => 425 "reshared_post_date" => "1mo" "last_updated" => "2023-04-09 11:58:46" "deleted" => 1 ] [ "id" => 95165026 "company_id" => 3731879 "urn" => "urn:li:activity:7018124415317991424" "followers" => 6283 "date" => "1mo" "description" => "In this CTAD 2022 poster 👉 https://lnkd.in/ednQh_6x we examine the utility of CSF #biomarker ratios to correct for pre-analytical variability #Alzheimers #neurodegeneration #diagnostics #FNCE 🧠" "reactions_count" => 39 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-09 11:58:46" "deleted" => 1 ] [ "id" => 125589025 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => 6373 "date" => "1mo" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 95 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-01 17:20:16" "deleted" => 1 ] [ "id" => 125589026 "company_id" => 3731879 "urn" => "urn:li:activity:7047447474424197120" "followers" => 6373 "date" => "1w" "description" => """ More Breaking News! 📰 🔥 Announcing the availability of the automated blood-based Lumipulse® G ApoE4 and Pan-ApoE assays, both for Research Use Only, for the LUMIPULSE® G immunoassay systems 👉 https://lnkd.in/gynws7xJ\n \n These CLEIA assays allow for the fully automated quantitative measurement of the E4 isoform of the apolipoprotein E (ApoE4), specifically, and for all isoforms of the same protein (Pan-ApoE), respectively, in human plasma within just 35 minutes.\n \n #neurodegeneration #development #bloodtesting #apoe #fnce #teamfujirebio 💪 """ "reactions_count" => 87 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-01 17:20:16" "deleted" => 1 ] [ "id" => 125589027 "company_id" => 3731879 "urn" => "urn:li:activity:7046345312537378816" "followers" => 6373 "date" => "1w" "description" => """ Breaking News! 📰 🔥 Announcing the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems, both for Research Use Only 👉 https://lnkd.in/gvJqe2bd\n \n These CLEIA assays allow for the quantitative measurement of Neurofilament light (NfL) in human CSF and plasma/serum, respectively, within just 35 minutes. \n \n #neurodegeneration #development #bloodtesting #nfl """ "reactions_count" => 85 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-01 17:20:16" "deleted" => 1 ] [ "id" => 125589028 "company_id" => 3731879 "urn" => "urn:li:activity:7046121011544547329" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Corinna Orsini" "reshared_post_author_url" => "https://it.linkedin.com/in/corinna-orsini-3403a094/en" "reshared_post_author_headline" => "Customer Support Director presso Fujirebio Italia" "reshared_post_description" => """ 🌹🧬 Fujirebio “The Art Accuracy” 🧬🌹\n \n #AMCLI2023 Corinna Orsini, MICHELE MARFORI e Giulia Alfedi sono pronti ad accogliervi per questa chiusura di congresso.\n \n Ringraziamo tutti i clienti che ci sono venuti a trovare in questi giorni. Grazie per il vostro interesse, ci vediamo presto nei vostri laboratori per iniziare a lavorare insieme! \n \n Fujirebio Europe """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2023-05-01 17:20:16" "deleted" => 1 ] [ "id" => 125589029 "company_id" => 3731879 "urn" => "urn:li:activity:7045420771086594049" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Alberto Perego" "reshared_post_author_url" => "https://it.linkedin.com/in/alberto-perego-57998594/en" "reshared_post_author_headline" => "Product Specialist presso Fujirebio Europe" "reshared_post_description" => "Apertura Congresso AMCLI Rimini! Pronti a partire!" "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2023-05-01 17:20:16" "deleted" => 1 ] [ "id" => 125589030 "company_id" => 3731879 "urn" => "urn:li:activity:7044710487221035008" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Corinna Orsini" "reshared_post_author_url" => "https://it.linkedin.com/in/corinna-orsini-3403a094/en" "reshared_post_author_headline" => "Customer Support Director presso Fujirebio Italia" "reshared_post_description" => """ Il Team Fujirebio Italia vi aspetta domani al 50º congresso nazionale #AMCLI2023, saremo lieti di illustrarvi le nostre nuove e uniche soluzioni diagnostiche! \n \n Veniteci a trovare allo stand n.12 \n 🧬🌹”The art of Accuracy” 🌹🧬\n \n Fujirebio Europe Rikkert Maertens Rebecca Millecamps Victor Ruiz de Gracia Christian Lindknud, MSc """ "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2023-05-01 17:20:16" "deleted" => 1 ] [ "id" => 125589031 "company_id" => 3731879 "urn" => "urn:li:activity:7042115849737883648" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "ADx NeuroSciences" "reshared_post_author_url" => "https://be.linkedin.com/company/adx-neurosciences-nv" "reshared_post_author_headline" => null "reshared_post_description" => """ ADx will be attending #ADPD2023!\n Looking forward to present exciting results on our new prototype immunoassays for VAMP-2, SNAP-25 and N-terminal alpha-synuclein.\n \n 👉 Check out our posters & presentations: \n \n https://lnkd.in/ezxNXMkg """ "reshared_post_followers" => 1108 "reshared_post_date" => "3w" "last_updated" => "2023-05-01 17:20:16" "deleted" => 1 ] [ "id" => 125589032 "company_id" => 3731879 "urn" => "urn:li:activity:7040924447888789504" "followers" => 6373 "date" => "4w" "description" => """ ✋ What were the key #insights from keynote lectures at the recent #EUROGIN 2023 conference in Bilbao? 💡 This article 👉 https://lnkd.in/ehEW9W-4 looks back at the most essential challenges around #HPV diseases, cancer #screening, and prevention. \n \n 👋 EUROGIN Conference """ "reactions_count" => 31 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-01 17:20:16" "deleted" => 1 ] [ "id" => 125589033 "company_id" => 3731879 "urn" => "urn:li:activity:7039223562116722689" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Fujirebio US" "reshared_post_author_url" => "https://www.linkedin.com/company/fujirebio-us" "reshared_post_author_headline" => null "reshared_post_description" => """ Breaking News! 📰 🔥 Announcing our strategic partnership with AriBio Co., Ltd. to advance biomarker development for Alzheimer’s disease and neurodegenerative conditions.\n \n This agreement provides access to clinical samples and data collected as part of the ongoing Phase 3 Alzheimer’s disease study launched by AriBio in December 2022.\n \n Learn More 👉 https://bit.ly/3SXQayJ\n \n #alzheimers #alzheimersdisease #neurodegeneration #development #partnership """ "reshared_post_followers" => 3041 "reshared_post_date" => "1mo" "last_updated" => "2023-05-01 17:20:16" "deleted" => 1 ] [ "id" => 125589034 "company_id" => 3731879 "urn" => "urn:li:activity:7039112503066284032" "followers" => 6373 "date" => "1mo" "description" => """ Over the past decades, FFPE tissue specimens have been used in #HPV prevalence studies to investigate HPV association with a variety of clinical conditions. 💡\n \n SPF10 PCR-based methods are mentioned as effective and suitable for HPV DNA detection in such samples.\n \n Read why in this article 👉 \n https://lnkd.in/eiiwvUbW """ "reactions_count" => 30 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-01 17:20:16" "deleted" => 1 ] [ "id" => 158705792 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => 6404 "date" => "1mo" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 103 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-24 06:34:27" "deleted" => 1 ] [ "id" => 158705793 "company_id" => 3731879 "urn" => "urn:li:activity:7054078134580596737" "followers" => 6404 "date" => "1w" "description" => "In this #HPV Insight article 👉 https://lnkd.in/eJP8Kb2U we look at studies, that demonstrate how FAM19A4/miR124-2 methylation can be considered as an alternative to #cytology as follow-up test for hrHPV positive women 💘 and a key to full #molecular screening, incorporating even a predictive value. 💪" "reactions_count" => 34 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-24 06:34:27" "deleted" => 1 ] [ "id" => 158705794 "company_id" => 3731879 "urn" => "urn:li:activity:7052255636121612288" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "ADx NeuroSciences" "reshared_post_author_url" => "https://be.linkedin.com/company/adx-neurosciences-nv" "reshared_post_author_headline" => null "reshared_post_description" => """ Reliable biomarkers are essential for the management of #parkinsonsdisease \n Biomarkers can be used to support early diagnosis, patient screening, monitoring of disease progression and therapeutic effects.\n \n #parkinsonsawareness #parkinsonsresearch #ADx #biomarkers\n \n 👉 https://lnkd.in/ezCeVbXn """ "reshared_post_followers" => 1130 "reshared_post_date" => "2w" "last_updated" => "2023-05-24 06:34:27" "deleted" => 1 ] [ "id" => 158705795 "company_id" => 3731879 "urn" => "urn:li:activity:7047447474424197120" "followers" => 6404 "date" => "1mo" "description" => """ More Breaking News! 📰 🔥 Announcing the availability of the automated blood-based Lumipulse® G ApoE4 and Pan-ApoE assays, both for Research Use Only, for the LUMIPULSE® G immunoassay systems 👉 https://lnkd.in/gynws7xJ\n \n These CLEIA assays allow for the fully automated quantitative measurement of the E4 isoform of the apolipoprotein E (ApoE4), specifically, and for all isoforms of the same protein (Pan-ApoE), respectively, in human plasma within just 35 minutes.\n \n #neurodegeneration #development #bloodtesting #apoe #fnce #teamfujirebio 💪 """ "reactions_count" => 106 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-24 06:34:27" "deleted" => 1 ] [ "id" => 158705796 "company_id" => 3731879 "urn" => "urn:li:activity:7046345312537378816" "followers" => 6404 "date" => "1mo" "description" => """ Breaking News! 📰 🔥 Announcing the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems, both for Research Use Only 👉 https://lnkd.in/gvJqe2bd\n \n These CLEIA assays allow for the quantitative measurement of Neurofilament light (NfL) in human CSF and plasma/serum, respectively, within just 35 minutes. \n \n #neurodegeneration #development #bloodtesting #nfl """ "reactions_count" => 108 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-24 06:34:27" "deleted" => 1 ] [ "id" => 158705797 "company_id" => 3731879 "urn" => "urn:li:activity:7046121011544547329" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Corinna Orsini" "reshared_post_author_url" => "https://it.linkedin.com/in/corinna-orsini-3403a094/en" "reshared_post_author_headline" => "Customer Support Director presso Fujirebio Italia" "reshared_post_description" => """ 🌹🧬 Fujirebio “The Art Accuracy” 🧬🌹\n \n #AMCLI2023 Corinna Orsini, MICHELE MARFORI e Giulia Alfedi sono pronti ad accogliervi per questa chiusura di congresso.\n \n Ringraziamo tutti i clienti che ci sono venuti a trovare in questi giorni. Grazie per il vostro interesse, ci vediamo presto nei vostri laboratori per iniziare a lavorare insieme! \n \n Fujirebio Europe """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-06-21 10:10:57" "deleted" => 1 ] [ "id" => 158705798 "company_id" => 3731879 "urn" => "urn:li:activity:7045420771086594049" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Alberto Perego" "reshared_post_author_url" => "https://it.linkedin.com/in/alberto-perego-57998594/en" "reshared_post_author_headline" => "Product Specialist presso Fujirebio Europe" "reshared_post_description" => "Apertura Congresso AMCLI Rimini! Pronti a partire!" "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-06-21 10:10:57" "deleted" => 1 ] [ "id" => 158705799 "company_id" => 3731879 "urn" => "urn:li:activity:7044710487221035008" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Corinna Orsini" "reshared_post_author_url" => "https://it.linkedin.com/in/corinna-orsini-3403a094/en" "reshared_post_author_headline" => "Customer Support Director presso Fujirebio Italia" "reshared_post_description" => """ Il Team Fujirebio Italia vi aspetta domani al 50º congresso nazionale #AMCLI2023, saremo lieti di illustrarvi le nostre nuove e uniche soluzioni diagnostiche! \n \n Veniteci a trovare allo stand n.12 \n 🧬🌹”The art of Accuracy” 🌹🧬\n \n Fujirebio Europe Rikkert Maertens Rebecca Millecamps Victor Ruiz de Gracia Christian Lindknud, MSc """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-06-21 10:10:57" "deleted" => 1 ] [ "id" => 158705800 "company_id" => 3731879 "urn" => "urn:li:activity:7042115849737883648" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "ADx NeuroSciences" "reshared_post_author_url" => "https://be.linkedin.com/company/adx-neurosciences-nv" "reshared_post_author_headline" => null "reshared_post_description" => """ ADx will be attending #ADPD2023!\n Looking forward to present exciting results on our new prototype immunoassays for VAMP-2, SNAP-25 and N-terminal alpha-synuclein.\n \n 👉 Check out our posters & presentations: \n \n https://lnkd.in/ezxNXMkg """ "reshared_post_followers" => 1130 "reshared_post_date" => "1mo" "last_updated" => "2023-05-24 06:34:27" "deleted" => 1 ] [ "id" => 158705801 "company_id" => 3731879 "urn" => "urn:li:activity:7040924447888789504" "followers" => 6404 "date" => "1mo" "description" => """ ✋ What were the key #insights from keynote lectures at the recent #EUROGIN 2023 conference in Bilbao? 💡 This article 👉 https://lnkd.in/ehEW9W-4 looks back at the most essential challenges around #HPV diseases, cancer #screening, and prevention. \n \n 👋 EUROGIN Conference """ "reactions_count" => 31 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-24 06:34:27" "deleted" => 1 ] [ "id" => 185517051 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => 6435 "date" => "2mo" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 107 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-21 10:10:57" "deleted" => 1 ] [ "id" => 185517052 "company_id" => 3731879 "urn" => "urn:li:activity:7064873870574452736" "followers" => 6435 "date" => "1d" "description" => "We will be at IFCC-EFLM EuroMedLab-WorldLab 2023 - will you? 👋 Our team will be happy to greet you 🤝 from Sunday through Thursday - or at our booth N.200 from Monday through Wednesday, 09:00-17:30 - see you there? 🙂 #ifcc #euromedlab2023" "reactions_count" => 40 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-21 10:10:57" "deleted" => 1 ] [ "id" => 185517053 "company_id" => 3731879 "urn" => "urn:li:activity:7060252379916447744" "followers" => 6435 "date" => "2w" "description" => null "reactions_count" => 32 "comments_count" => 2 "reshared_post_author" => "Janina Becker" "reshared_post_author_url" => "https://de.linkedin.com/in/janina-becker-693069174/en" "reshared_post_author_headline" => "Marketing Manager Germany/Austria at sebia" "reshared_post_description" => """ Fujirebio auf der DGLN Jahrestagung 2023\n \n Besuchen Sie uns am 05. und 06.05.2023 auf der DGLN Jahrestagung in Dresden.\n Wir freuen uns auf Sie!\n \n https://lnkd.in/eetDbvMW """ "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2023-06-21 10:10:57" "deleted" => 1 ] [ "id" => 185517054 "company_id" => 3731879 "urn" => "urn:li:activity:7054078134580596737" "followers" => 6435 "date" => "1mo" "description" => "In this #HPV Insight article 👉 https://lnkd.in/eJP8Kb2U we look at studies, that demonstrate how FAM19A4/miR124-2 methylation can be considered as an alternative to #cytology as follow-up test for hrHPV positive women 💘 and a key to full #molecular screening, incorporating even a predictive value. 💪" "reactions_count" => 36 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-21 10:10:57" "deleted" => 1 ] [ "id" => 185517055 "company_id" => 3731879 "urn" => "urn:li:activity:7052255636121612288" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "ADx NeuroSciences" "reshared_post_author_url" => "https://be.linkedin.com/company/adx-neurosciences-nv" "reshared_post_author_headline" => null "reshared_post_description" => """ Reliable biomarkers are essential for the management of #parkinsonsdisease \n Biomarkers can be used to support early diagnosis, patient screening, monitoring of disease progression and therapeutic effects.\n \n #parkinsonsawareness #parkinsonsresearch #ADx #biomarkers\n \n 👉 https://lnkd.in/ezCeVbXn """ "reshared_post_followers" => 1146 "reshared_post_date" => "1mo" "last_updated" => "2023-06-21 10:10:57" "deleted" => 1 ] [ "id" => 185517056 "company_id" => 3731879 "urn" => "urn:li:activity:7047447474424197120" "followers" => 6435 "date" => "1mo" "description" => """ More Breaking News! 📰 🔥 Announcing the availability of the automated blood-based Lumipulse® G ApoE4 and Pan-ApoE assays, both for Research Use Only, for the LUMIPULSE® G immunoassay systems 👉 https://lnkd.in/gynws7xJ\n \n These CLEIA assays allow for the fully automated quantitative measurement of the E4 isoform of the apolipoprotein E (ApoE4), specifically, and for all isoforms of the same protein (Pan-ApoE), respectively, in human plasma within just 35 minutes.\n \n #neurodegeneration #development #bloodtesting #apoe #fnce #teamfujirebio 💪 """ "reactions_count" => 107 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-21 10:10:57" "deleted" => 1 ] [ "id" => 185517057 "company_id" => 3731879 "urn" => "urn:li:activity:7046345312537378816" "followers" => 6435 "date" => "1mo" "description" => """ Breaking News! 📰 🔥 Announcing the availability of the Lumipulse G NfL CSF and Lumipulse G NfL Blood assays for the fully automated random-access LUMIPULSE® G immunoassay systems, both for Research Use Only 👉 https://lnkd.in/gvJqe2bd\n \n These CLEIA assays allow for the quantitative measurement of Neurofilament light (NfL) in human CSF and plasma/serum, respectively, within just 35 minutes. \n \n #neurodegeneration #development #bloodtesting #nfl """ "reactions_count" => 108 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-21 10:10:57" "deleted" => 1 ] [ "id" => 219102083 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => 6473 "date" => "3mo" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 115 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-07 23:22:49" "deleted" => 1 ] [ "id" => 219102084 "company_id" => 3731879 "urn" => "urn:li:activity:7075845903298768897" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Cristiana Filipa Peixoto" "reshared_post_author_url" => "https://pt.linkedin.com/in/cristiana-filipa-peixoto-727993108" "reshared_post_author_headline" => "Technical Sales Specialist na Bioportugal - Químico, Farmacêutica, Lda. & Eligen Diagnostica" "reshared_post_description" => "37a Reunião do Grupo de Estudos de Envelhecimento Cerebral e Demência - Bioportugal e Fujirebio" "reshared_post_followers" => null "reshared_post_date" => "4d" "last_updated" => "2023-07-07 23:22:49" "deleted" => 1 ] [ "id" => 219102085 "company_id" => 3731879 "urn" => "urn:li:activity:7075511811206180864" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Alícia Nadal Solà" "reshared_post_author_url" => "https://es.linkedin.com/in/al%C3%ADcia-nadal-sol%C3%A0-4b796597" "reshared_post_author_headline" => "Marketing Manager en Fujirebio Iberia (formerly Innogenetics Diagnóstica Iberia)" "reshared_post_description" => """ 37a Reunião Anual GEECD \n Grupo de Estudos de Envelhecimento Cerebral e Demência\n \n Visit us to learn how to anticipate Alzheimer Disease diagnosis with Biomarkers\n \n #CSFbiomarkers #BLOODbiomarkers\n #earlydiagnosis #alzheimersdisease \n #fujirebioteam #bioportugal """ "reshared_post_followers" => null "reshared_post_date" => "4d" "last_updated" => "2023-07-07 23:22:49" "deleted" => 1 ] [ "id" => 219102086 "company_id" => 3731879 "urn" => "urn:li:activity:7073979049823334401" "followers" => 6473 "date" => "1w" "description" => "Job offer! ✋ For our Fujirebio location in Zwijnaarde (Belgium) we are looking for a process operator to strengthen our teams! 💪 Find out more here 👉 https://lnkd.in/e_2EQ85R" "reactions_count" => 20 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-07 23:22:49" "deleted" => 1 ] [ "id" => 219102087 "company_id" => 3731879 "urn" => "urn:li:activity:7072969306497511424" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Fujirebio Diagnostics AB" "reshared_post_author_url" => "https://se.linkedin.com/company/fujirebio-diagnostics-ab" "reshared_post_author_headline" => null "reshared_post_description" => """ Fujirebio Diagnostics söker nu en HR-generalist\n Vi söker dig som brinner för det breda HR arbetet. Som HR-generalist hos oss kommer du till en delvis ny funktion på företaget. Ditt huvudsakliga fokus är att driva det breda HR arbetet som innebär allt från att ansvara för den löpande administrationen till att leda både påbörjade och nya projekt inom ex arbetsmiljö och ledarskap samt utveckla våra processer. \n \n I den här rekryteringen samarbetar vi med Wise Professionals. Har du frågor om tjänsten kan du kontakta ansvarig Rekryteringskonsult Jenny Mellberg på jenny.mellberg@wise.se. Vi arbetar med löpande urval och tjänsten kan komma att tillsättas omgående. Ansök senast 23 juni, 2023.\n \n Välkommen med din ansökan!\n \n https://lnkd.in/eHypT_aP\n \n #nyttjobb #wearehiring #recruitment #joinus #teamfujirebio """ "reshared_post_followers" => 1965 "reshared_post_date" => "1w" "last_updated" => "2023-07-07 23:22:49" "deleted" => 1 ] [ "id" => 219102088 "company_id" => 3731879 "urn" => "urn:li:activity:7072125656414728192" "followers" => 6473 "date" => "2w" "description" => "Are you our new #accountmanager in #Switzerland ? 👋 As our new colleague in the DACH team you are responsible for selling our IVD products and systems in the Swiss market by guiding your customers to state of the art solutions in line with their needs and challenges. 💪 Read more and apply here: https://lnkd.in/eWaJp7By #jobalerts #swissjobs #joinourteam #ivd" "reactions_count" => 21 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-07 23:22:49" "deleted" => 1 ] [ "id" => 219102089 "company_id" => 3731879 "urn" => "urn:li:activity:7070347112437161984" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Alícia Nadal Solà" "reshared_post_author_url" => "https://es.linkedin.com/in/al%C3%ADcia-nadal-sol%C3%A0-4b796597" "reshared_post_author_headline" => "Marketing Manager en Fujirebio Iberia (formerly Innogenetics Diagnóstica Iberia)" "reshared_post_description" => """ Interesante conferencia sobre el Alzheimer en Málaga. \n VII CONFERENCIA MÁLAGA ALZHEIMER\n 1-3 junio, IANEC\n \n Os esperamos para explicaros todas las novedades sobre los biomarcadores en LCR y plasma para la detección y diagnóstico tempranos de la enfermedad.\n \n #fujirebioteam #biomarkers #becauseearlydiagnosisreallymatters """ "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2023-07-07 23:22:49" "deleted" => 1 ] [ "id" => 219102090 "company_id" => 3731879 "urn" => "urn:li:activity:7070346815744679936" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Javier Garcia Bonilla" "reshared_post_author_url" => "https://es.linkedin.com/in/javier-garcia-bonilla-13045724" "reshared_post_author_headline" => "Sales Manager at Fujirebio Iberia" "reshared_post_description" => "Back in the Spanish Microbiology congress XXVI SEIMC…visit us!!" "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2023-07-07 23:22:49" "deleted" => 1 ] [ "id" => 219102091 "company_id" => 3731879 "urn" => "urn:li:activity:7069900384600760320" "followers" => 6473 "date" => "2w" "description" => "Curious 🤔 about ongoing reviews of cervical cancer screening? This article 👉 https://lnkd.in/ejJkh_qU teaches you how combining existing and available methods could offer the most optimal triage strategy #hpvtesting #cervicalcancer #diagnostics" "reactions_count" => 46 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-07 23:22:49" "deleted" => 1 ] [ "id" => 219102092 "company_id" => 3731879 "urn" => "urn:li:activity:7067542948057346049" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Janina Becker" "reshared_post_author_url" => "https://de.linkedin.com/in/janina-becker-693069174/en" "reshared_post_author_headline" => "Marketing Manager Germany/Austria at sebia" "reshared_post_description" => """ Fujirebio auf dem Symposium Brain Health and Dementia!\n \n 25. Mai 2023 in Bern.\n \n https://lnkd.in/eSGdnBdj """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2023-07-07 23:22:49" "deleted" => 1 ] [ "id" => 234948571 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => 6505 "date" => "4mo" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 119 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 17:00:19" "deleted" => 1 ] [ "id" => 234948572 "company_id" => 3731879 "urn" => "urn:li:activity:7082822729678114816" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Janina Becker" "reshared_post_author_url" => "https://de.linkedin.com/in/janina-becker-693069174/en" "reshared_post_author_headline" => "Marketing Manager Germany/Austria at sebia" "reshared_post_description" => """ Fujirebio auf dem Liquordiagnostik-Kurs vom 06.-07.07.2023 in Ulm.\n https://lnkd.in/eetDbvMW """ "reshared_post_followers" => null "reshared_post_date" => "1d" "last_updated" => "2023-08-15 17:00:19" "deleted" => 1 ] [ "id" => 234948573 "company_id" => 3731879 "urn" => "urn:li:activity:7075845903298768897" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Cristiana Filipa Peixoto" "reshared_post_author_url" => "https://pt.linkedin.com/in/cristiana-filipa-peixoto-727993108" "reshared_post_author_headline" => "Technical Sales Specialist na Bioportugal - Químico, Farmacêutica, Lda. & Eligen Diagnostica" "reshared_post_description" => "37a Reunião do Grupo de Estudos de Envelhecimento Cerebral e Demência - Bioportugal e Fujirebio" "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2023-08-15 17:00:19" "deleted" => 1 ] [ "id" => 234948574 "company_id" => 3731879 "urn" => "urn:li:activity:7075511811206180864" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Alícia Nadal Solà" "reshared_post_author_url" => "https://es.linkedin.com/in/al%C3%ADcia-nadal-sol%C3%A0-4b796597" "reshared_post_author_headline" => "Marketing Manager en Fujirebio Iberia (formerly Innogenetics Diagnóstica Iberia)" "reshared_post_description" => """ 37a Reunião Anual GEECD \n Grupo de Estudos de Envelhecimento Cerebral e Demência\n \n Visit us to learn how to anticipate Alzheimer Disease diagnosis with Biomarkers\n \n #CSFbiomarkers #BLOODbiomarkers\n #earlydiagnosis #alzheimersdisease \n #fujirebioteam #bioportugal """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2023-08-15 17:00:19" "deleted" => 1 ] [ "id" => 234948575 "company_id" => 3731879 "urn" => "urn:li:activity:7073979049823334401" "followers" => 6505 "date" => "3w" "description" => "Job offer! ✋ For our Fujirebio location in Zwijnaarde (Belgium) we are looking for a process operator to strengthen our teams! 💪 Find out more here 👉 https://lnkd.in/e_2EQ85R" "reactions_count" => 23 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 17:00:19" "deleted" => 1 ] [ "id" => 234948576 "company_id" => 3731879 "urn" => "urn:li:activity:7072969306497511424" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Fujirebio Diagnostics AB" "reshared_post_author_url" => "https://se.linkedin.com/company/fujirebio-diagnostics-ab" "reshared_post_author_headline" => null "reshared_post_description" => """ Fujirebio Diagnostics söker nu en HR-generalist\n Vi söker dig som brinner för det breda HR arbetet. Som HR-generalist hos oss kommer du till en delvis ny funktion på företaget. Ditt huvudsakliga fokus är att driva det breda HR arbetet som innebär allt från att ansvara för den löpande administrationen till att leda både påbörjade och nya projekt inom ex arbetsmiljö och ledarskap samt utveckla våra processer. \n \n I den här rekryteringen samarbetar vi med Wise Professionals. Har du frågor om tjänsten kan du kontakta ansvarig Rekryteringskonsult Jenny Mellberg på jenny.mellberg@wise.se. Vi arbetar med löpande urval och tjänsten kan komma att tillsättas omgående. Ansök senast 23 juni, 2023.\n \n Välkommen med din ansökan!\n \n https://lnkd.in/eHypT_aP\n \n #nyttjobb #wearehiring #recruitment #joinus #teamfujirebio """ "reshared_post_followers" => 1981 "reshared_post_date" => "4w" "last_updated" => "2023-08-15 17:00:19" "deleted" => 1 ] [ "id" => 234948577 "company_id" => 3731879 "urn" => "urn:li:activity:7072125656414728192" "followers" => 6505 "date" => "1mo" "description" => "Are you our new #accountmanager in #Switzerland ? 👋 As our new colleague in the DACH team you are responsible for selling our IVD products and systems in the Swiss market by guiding your customers to state of the art solutions in line with their needs and challenges. 💪 Read more and apply here: https://lnkd.in/eWaJp7By #jobalerts #swissjobs #joinourteam #ivd" "reactions_count" => 28 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 17:00:19" "deleted" => 1 ] [ "id" => 234948578 "company_id" => 3731879 "urn" => "urn:li:activity:7070347112437161984" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Alícia Nadal Solà" "reshared_post_author_url" => "https://es.linkedin.com/in/al%C3%ADcia-nadal-sol%C3%A0-4b796597" "reshared_post_author_headline" => "Marketing Manager en Fujirebio Iberia (formerly Innogenetics Diagnóstica Iberia)" "reshared_post_description" => """ Interesante conferencia sobre el Alzheimer en Málaga. \n VII CONFERENCIA MÁLAGA ALZHEIMER\n 1-3 junio, IANEC\n \n Os esperamos para explicaros todas las novedades sobre los biomarcadores en LCR y plasma para la detección y diagnóstico tempranos de la enfermedad.\n \n #fujirebioteam #biomarkers #becauseearlydiagnosisreallymatters """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-08-15 17:00:19" "deleted" => 1 ] [ "id" => 234948579 "company_id" => 3731879 "urn" => "urn:li:activity:7070346815744679936" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Javier Garcia Bonilla" "reshared_post_author_url" => "https://es.linkedin.com/in/javier-garcia-bonilla-13045724" "reshared_post_author_headline" => "Sales Manager at Fujirebio Iberia" "reshared_post_description" => "Back in the Spanish Microbiology congress XXVI SEIMC…visit us!!" "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-08-15 17:00:19" "deleted" => 1 ] [ "id" => 234948580 "company_id" => 3731879 "urn" => "urn:li:activity:7069900384600760320" "followers" => 6505 "date" => "1mo" "description" => "Curious 🤔 about ongoing reviews of cervical cancer screening? This article 👉 https://lnkd.in/ejJkh_qU teaches you how combining existing and available methods could offer the most optimal triage strategy #hpvtesting #cervicalcancer #diagnostics" "reactions_count" => 46 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 17:00:19" "deleted" => 1 ] [ "id" => 295531430 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => null "date" => "5mo" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 130 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-11 14:34:53" "deleted" => 1 ] [ "id" => 295531431 "company_id" => 3731879 "urn" => "urn:li:activity:7087789763625107456" "followers" => null "date" => "3w" "description" => """ Curious 🤔 about new #perspectives in #biomarkers of #neurodegeneration?\n Find your insights and resources here  👉  https://lnkd.in/eBxASV33 \n \n Read about #development of neuro biomarker tests for routine and research at the Fujirebio Neuro Center of Excellence. """ "reactions_count" => 65 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-11 14:34:53" "deleted" => 1 ] [ "id" => 295531432 "company_id" => 3731879 "urn" => "urn:li:activity:7086683780509261824" "followers" => null "date" => "4w" "description" => "Breaking news! 📣 https://lnkd.in/ehB2-n7r 👉 Beckman Coulter and Fujirebio partner to bolster access to patient-friendly, blood-based Alzheimer’s disease test therapeutics #Alzheimers #biomarkers #FNCE" "reactions_count" => 91 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-11 14:34:53" "deleted" => 1 ] [ "id" => 295531433 "company_id" => 3731879 "urn" => "urn:li:activity:7085159015365627905" "followers" => null "date" => "1mo" "description" => """ Going to #AAIC2023 in Amsterdam? 👋  We are! \n \n Visit Booth 312 to hear about the latest in robust and high-quality biomarkers of neurodegeneration. See here which scientific posters and presentations not to miss  👉  https://lnkd.in/eQUH2u7D """ "reactions_count" => 52 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-11 14:34:53" "deleted" => 1 ] [ "id" => 295531434 "company_id" => 3731879 "urn" => "urn:li:activity:7082822729678114816" "followers" => null "date" => null "description" => null "reactions_count" => 58 "comments_count" => null "reshared_post_author" => "Janina Becker" "reshared_post_author_url" => "https://de.linkedin.com/in/janina-becker-693069174/en" "reshared_post_author_headline" => "Marketing Manager Germany/Austria at sebia" "reshared_post_description" => """ Fujirebio auf dem Liquordiagnostik-Kurs vom 06.-07.07.2023 in Ulm.\n https://lnkd.in/eetDbvMW """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-09-11 14:34:53" "deleted" => 1 ] [ "id" => 295531435 "company_id" => 3731879 "urn" => "urn:li:activity:7075845903298768897" "followers" => null "date" => null "description" => null "reactions_count" => 39 "comments_count" => null "reshared_post_author" => "Cristiana Filipa Peixoto" "reshared_post_author_url" => "https://pt.linkedin.com/in/cristiana-filipa-peixoto-727993108" "reshared_post_author_headline" => "Technical Sales Specialist na Bioportugal - Químico, Farmacêutica, Lda. & Eligen Diagnostica" "reshared_post_description" => "37a Reunião do Grupo de Estudos de Envelhecimento Cerebral e Demência - Bioportugal e Fujirebio" "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-09-11 14:34:53" "deleted" => 1 ] [ "id" => 295531436 "company_id" => 3731879 "urn" => "urn:li:activity:7075511811206180864" "followers" => null "date" => null "description" => null "reactions_count" => 51 "comments_count" => 1 "reshared_post_author" => "Alícia Nadal Solà" "reshared_post_author_url" => "https://es.linkedin.com/in/al%C3%ADcia-nadal-sol%C3%A0-4b796597" "reshared_post_author_headline" => "Marketing Manager en Fujirebio Iberia (formerly Innogenetics Diagnóstica Iberia)" "reshared_post_description" => """ 37a Reunião Anual GEECD \n Grupo de Estudos de Envelhecimento Cerebral e Demência\n \n Visit us to learn how to anticipate Alzheimer Disease diagnosis with Biomarkers\n \n #CSFbiomarkers #BLOODbiomarkers\n #earlydiagnosis #alzheimersdisease \n #fujirebioteam #bioportugal """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2023-10-20 15:03:25" "deleted" => 1 ] [ "id" => 295531437 "company_id" => 3731879 "urn" => "urn:li:activity:7073979049823334401" "followers" => null "date" => "2mo" "description" => "Job offer! ✋ For our Fujirebio location in Zwijnaarde (Belgium) we are looking for a process operator to strengthen our teams! 💪 Find out more here 👉 https://lnkd.in/e_2EQ85R" "reactions_count" => 24 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-11 14:34:53" "deleted" => 1 ] [ "id" => 295531438 "company_id" => 3731879 "urn" => "urn:li:activity:7072969306497511424" "followers" => null "date" => null "description" => null "reactions_count" => 36 "comments_count" => 1 "reshared_post_author" => "Fujirebio Diagnostics AB" "reshared_post_author_url" => "https://se.linkedin.com/company/fujirebio-diagnostics-ab" "reshared_post_author_headline" => null "reshared_post_description" => """ Fujirebio Diagnostics söker nu en HR-generalist\n Vi söker dig som brinner för det breda HR arbetet. Som HR-generalist hos oss kommer du till en delvis ny funktion på företaget. Ditt huvudsakliga fokus är att driva det breda HR arbetet som innebär allt från att ansvara för den löpande administrationen till att leda både påbörjade och nya projekt inom ex arbetsmiljö och ledarskap samt utveckla våra processer. \n \n I den här rekryteringen samarbetar vi med Wise Professionals. Har du frågor om tjänsten kan du kontakta ansvarig Rekryteringskonsult Jenny Mellberg på jenny.mellberg@wise.se. Vi arbetar med löpande urval och tjänsten kan komma att tillsättas omgående. Ansök senast 23 juni, 2023.\n \n Välkommen med din ansökan!\n \n https://lnkd.in/eHypT_aP\n \n #nyttjobb #wearehiring #recruitment #joinus #teamfujirebio """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2023-09-11 14:34:53" "deleted" => 1 ] [ "id" => 295531439 "company_id" => 3731879 "urn" => "urn:li:activity:7072125656414728192" "followers" => null "date" => "2mo" "description" => "Are you our new #accountmanager in #Switzerland ? 👋 As our new colleague in the DACH team you are responsible for selling our IVD products and systems in the Swiss market by guiding your customers to state of the art solutions in line with their needs and challenges. 💪 Read more and apply here: https://lnkd.in/eWaJp7By #jobalerts #swissjobs #joinourteam #ivd" "reactions_count" => 28 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-11 14:34:53" "deleted" => 1 ] [ "id" => 316236656 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => null "date" => "6mo" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 145 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-20 15:03:25" "deleted" => 1 ] [ "id" => 316236657 "company_id" => 3731879 "urn" => "urn:li:activity:7105233687759204352" "followers" => null "date" => "4d" "description" => "Thank you 🙏 to the mayor of Ghent, Burgemeester Mathias De Clercq, for receiving us in the persons of Christiaan De Wilde and Goki Ishikawa!" "reactions_count" => 40 "comments_count" => 1 "reshared_post_author" => "Mathias De Clercq" "reshared_post_author_url" => "https://be.linkedin.com/in/mathiasdeclercqburgemeestergent/en" "reshared_post_author_headline" => null "reshared_post_description" => """ De dag gestart met een fantastische ontmoeting. ✅\n \n Vanmorgen mochten schepen Sofie Bracke en ik Goki Ishikawa (CEO Fujirebio Holdings, Inc.) en Christiaan De Wilde (CEO Fujirebio Europe) ontvangen in het stadhuis. Het Japanse Fujirebio heeft 3 grote hoofdkwartieren: in Japan, in de VS en in ...Gent. Tijdens mijn bezoek aan Japan in juli viel op dat Japan en de rest van de wereld sterk opkijken naar Gent en onze innovatie in de biotechsector. De Gentse werknemers werken momenteel aan een middel om Alzheimer sneller op te sporen. \n \n #healthtech #technologiehoofdstad """ "reshared_post_followers" => null "reshared_post_date" => "5d" "last_updated" => "2023-10-20 15:03:25" "deleted" => 1 ] [ "id" => 316236658 "company_id" => 3731879 "urn" => "urn:li:activity:7099693080684974080" "followers" => null "date" => "2w" "description" => """ #HPV - Pregnant women with abnormal cytological findings are a challenge for clinicians; see here 👉 https://lnkd.in/ez2gY2Ed\n how biomarkers help them identify and manage pregnant women with progressive CIN who require a treatment 💡 """ "reactions_count" => 33 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-20 15:03:25" "deleted" => 1 ] [ "id" => 316236659 "company_id" => 3731879 "urn" => "urn:li:activity:7087789763625107456" "followers" => null "date" => "1mo" "description" => """ Curious 🤔 about new #perspectives in #biomarkers of #neurodegeneration?\n Find your insights and resources here  👉  https://lnkd.in/eBxASV33 \n \n Read about #development of neuro biomarker tests for routine and research at the Fujirebio Neuro Center of Excellence. """ "reactions_count" => 71 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-20 15:03:25" "deleted" => 1 ] [ "id" => 316236660 "company_id" => 3731879 "urn" => "urn:li:activity:7086683780509261824" "followers" => null "date" => "1mo" "description" => "Breaking news! 📣 https://lnkd.in/ehB2-n7r 👉 Beckman Coulter and Fujirebio partner to bolster access to patient-friendly, blood-based Alzheimer’s disease test therapeutics #Alzheimers #biomarkers #FNCE" "reactions_count" => 92 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-20 15:03:25" "deleted" => 1 ] [ "id" => 316236661 "company_id" => 3731879 "urn" => "urn:li:activity:7085159015365627905" "followers" => null "date" => "2mo" "description" => """ Going to #AAIC2023 in Amsterdam? 👋  We are! \n \n Visit Booth 312 to hear about the latest in robust and high-quality biomarkers of neurodegeneration. See here which scientific posters and presentations not to miss  👉  https://lnkd.in/eQUH2u7D """ "reactions_count" => 52 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-20 15:03:25" "deleted" => 1 ] [ "id" => 316236662 "company_id" => 3731879 "urn" => "urn:li:activity:7082822729678114816" "followers" => null "date" => null "description" => null "reactions_count" => 58 "comments_count" => null "reshared_post_author" => "Janina Becker" "reshared_post_author_url" => "https://de.linkedin.com/in/janina-becker-693069174/en" "reshared_post_author_headline" => "Marketing Manager Germany/Austria at sebia" "reshared_post_description" => """ Fujirebio auf dem Liquordiagnostik-Kurs vom 06.-07.07.2023 in Ulm.\n https://lnkd.in/eetDbvMW """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2023-10-20 15:03:25" "deleted" => 1 ] [ "id" => 316236663 "company_id" => 3731879 "urn" => "urn:li:activity:7075845903298768897" "followers" => null "date" => null "description" => null "reactions_count" => 39 "comments_count" => null "reshared_post_author" => "Cristiana Filipa Peixoto" "reshared_post_author_url" => "https://pt.linkedin.com/in/cristiana-filipa-peixoto-727993108" "reshared_post_author_headline" => "Technical Sales Specialist na Bioportugal - Químico, Farmacêutica, Lda. & Eligen Diagnostica" "reshared_post_description" => "37a Reunião do Grupo de Estudos de Envelhecimento Cerebral e Demência - Bioportugal e Fujirebio" "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2023-10-20 15:03:25" "deleted" => 1 ] [ "id" => 316236664 "company_id" => 3731879 "urn" => "urn:li:activity:7073979049823334401" "followers" => null "date" => "3mo" "description" => "Job offer! ✋ For our Fujirebio location in Zwijnaarde (Belgium) we are looking for a process operator to strengthen our teams! 💪 Find out more here 👉 https://lnkd.in/e_2EQ85R" "reactions_count" => 24 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-20 15:03:25" "deleted" => 1 ] [ "id" => 351569247 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => null "date" => "7mo" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 152 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:26:20" "deleted" => 1 ] [ "id" => 351569248 "company_id" => 3731879 "urn" => "urn:li:activity:7120447714185617408" "followers" => null "date" => "2d" "description" => """ Our partner Fujirebio Europe is looking forward to speaking to you at the upcoming Belgian Week of Pathology in Brussels. \n HPV testing and molecular triaging by methylation based testing is their key expertise. \n Do you want to know more about methylation - see this: https://lnkd.in/eeP-KbTa and feel free to contact Rebecca Millecamps and Lore Schoutteten on site. www.self-screen.nl, #HPV, #methylation """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:26:20" "deleted" => 1 ] [ "id" => 351569249 "company_id" => 3731879 "urn" => "urn:li:activity:7120356701827932160" "followers" => null "date" => "2d" "description" => "Will you be at the LABCLIN 2023 in Zaragoza, Spain? 👋 Don't forget to come by the Fujirebio booth and meet our Spanish team, Alícia Nadal Solà, Javier Garcia Bonilla, Verónica Olmedo Cubi are eager to discuss testing solutions with you! #teamfujirebio" "reactions_count" => 30 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:26:20" "deleted" => 1 ] [ "id" => 351569250 "company_id" => 3731879 "urn" => "urn:li:activity:7120316351017037824" "followers" => null "date" => "2d" "description" => "Más de sesenta especialistas en neurociencias participaron hoy en la conferencia sobre biomarcadores de #Alzheimer impartida por el director científico de #Fujirebio Eliseu Mota , se presentaron las nuevas tendencias en el área de #neuro y el equipo automatizado #Lumipulse que ya está disponible en Chile cómo apoyo al personal de salud en el diagnóstico de las #demencias" "reactions_count" => 19 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:26:20" "deleted" => 1 ] [ "id" => 351569251 "company_id" => 3731879 "urn" => "urn:li:activity:7118604537078145024" "followers" => null "date" => "1w" "description" => "En el segundo día del Congreso Nacional de Bacteriología #Fujirebio continúa junto a #Quimiolab presentando los beneficios de la genotipificación del #VPH , las nuevas tendencias en #Neuro y #CFTR, visítanos en el booth 44." "reactions_count" => 79 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:26:20" "deleted" => 1 ] [ "id" => 351569252 "company_id" => 3731879 "urn" => "urn:li:activity:7118278050626031616" "followers" => null "date" => "1w" "description" => "En el Congreso Nacional de Bacteriología de Colombia podrá conocer los productos y servicios que #Fujirebio tiene disponibles para su laboratorio; acompañenos en la ciudad de la eterna primavera, Medellín, y conversemos sobre #neuro, #hpv, #hiv entre otras tecnologías. Le esperamos!" "reactions_count" => 25 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:26:20" "deleted" => 1 ] [ "id" => 351569253 "company_id" => 3731879 "urn" => "urn:li:activity:7118277843746217984" "followers" => null "date" => "1w" "description" => """ La team Fujirebio est sur le stand 44 des JFBM 2023 au Palais des Congrès de Juan-Les-Pins (11 au 13 Octobre) 😎 \n #Alzheimer #HPV #IST """ "reactions_count" => 41 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:26:20" "deleted" => 1 ] [ "id" => 351569254 "company_id" => 3731879 "urn" => "urn:li:activity:7118274276528381953" "followers" => null "date" => "1w" "description" => """ Besuchen Sie Fujirebio auf der Jahrestagung der DGKL in Mannheim!\n https://lnkd.in/eRbaSNYK """ "reactions_count" => 30 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:26:20" "deleted" => 1 ] [ "id" => 351569255 "company_id" => 3731879 "urn" => "urn:li:activity:7118142308117581825" "followers" => null "date" => "1w" "description" => "Our colleagues Dr. Peter Jagiello and Nathalie Le Bastard 👋 are pleased to welcome you at our booth during the #ECTRIMS (European Committee for Treatment and Research in Multiple Sclerosis) Congress 2023 in Milano, Italy - come and discuss present and future #neurodegenerative disease testing solutions! 🧠" "reactions_count" => 57 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:26:20" "deleted" => 1 ] [ "id" => 351569256 "company_id" => 3731879 "urn" => "urn:li:activity:7117511087528239105" "followers" => null "date" => "1w" "description" => """ ¡Empieza una nueva edición del #LabClin, este año en Zaragoza! 👋 Os esperamos en nuestro stand los días 18, 19 y 20 de octubre para contaros todas las novedades que tenemos en el campo de los #biomarcadores para enfermedades #neurodegenerativas. 🧠 \n ¡No faltéis a la cita! #LabClin23 #teamfujirebio """ "reactions_count" => 13 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:26:20" "deleted" => 1 ] [ "id" => 393552229 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => null "date" => "8mo" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 163 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 05:55:23" "deleted" => 1 ] [ "id" => 393552230 "company_id" => 3731879 "urn" => "urn:li:activity:7133835668174036992" "followers" => null "date" => "2d" "description" => """ 🔈 Fujirebio Italia e’ presente al XVIII Congresso Nazionale SINdem 🔈\n \n Oggi ci sarà il nostro workshop: \n 🧠”Potenziale diagnostico e prognostico dei Neurofilamenti leggeri (NfL) nelle fasi iniziali di demenza” 🧠\n \n Il Dott. Lorenzo Gaetani illustrerà le interessanti applicazioni di questo importante biomarcatore! \n \n 🔛🔛🔛🔛🔛\n \n Fujirebio Europe Rikkert Maertens Nathalie Le Bastard Dr. Peter Jagiello \n \n MICHELE MARFORI Guido Marelli Pietro Pellegatta Maria Assunta Melone Vincenzo Mercolino Alberto Perego Giulia Alfedi Daniela Militello """ "reactions_count" => 29 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 05:55:23" "deleted" => 1 ] [ "id" => 393552231 "company_id" => 3731879 "urn" => "urn:li:activity:7133159860958830592" "followers" => null "date" => "4d" "description" => """ 🔈Fujirebio Italia vi aspetta all’ELAS 2023🔈\n \n 🧠Oggi ci sarà il nostro workshop🧠\n “ Progressi nell’utilizzo dei biomarcatori plasmatici nelle malattie neurodegenerative “ \n \n Il Dott. Gaetani e il Dott. Bellomo vi daranno tutte le informazioni, ad oggi note, in questo campo di grande interesse!\n \n 🔛🔛🔛🔛\n \n Fujirebio Europe Rikkert Maertens Nathalie Le Bastard Dr. Peter Jagiello \n \n MICHELE MARFORI Guido Marelli Pietro Pellegatta Maria Assunta Melone Vincenzo Mercolino Alberto Perego Giulia Alfedi Daniela Militello Giovanni Bellomo Lorenzo Gaetani """ "reactions_count" => 58 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 05:55:23" "deleted" => 1 ] [ "id" => 393552232 "company_id" => 3731879 "urn" => "urn:li:activity:7128275051015012352" "followers" => null "date" => "2w" "description" => "Will you be at #Medica2023 in Düsseldorf, Germany? 👋 Come by stand 3B42 to meet our excellent expert team, including Rikkert Maertens, Amr Aleem, Geert Jannes, Roland Andersson, Zoran Vasic, Jan Jirous, Victor Ruiz de Gracia, Rebecca Millecamps, Nathalie Dekeersmaeker and Ahmed Fawzy, who all will be eager to discuss testing solutions with you! #teamfujirebio 💪" "reactions_count" => 49 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 05:55:23" "deleted" => 1 ] [ "id" => 393552233 "company_id" => 3731879 "urn" => "urn:li:activity:7127206369958465537" "followers" => null "date" => "2w" "description" => "New Insight article 💡 https://lnkd.in/e7_HtFK8 - Post-treatment detection of recurrent CIN in women treated for CIN2/3: How can #HPV #genotyping and DNA #methylation analysis help discriminate women in need of re-treatment from those to be managed conservatively, preventing over-treatment? ❤️" "reactions_count" => 36 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 05:55:23" "deleted" => 1 ] [ "id" => 393552234 "company_id" => 3731879 "urn" => "urn:li:activity:7125406181551935491" "followers" => null "date" => "3w" "description" => "Aguascalientes, será la sede del LIII Congreso Mexicano de Patología Clínica, #Fujirebio estará presente junto a #Kabla en el stand F4 con todo lo nuevo en la detección de #HPV, #Alzheimer y pruebas infecciosas, te esperamos!" "reactions_count" => 23 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 05:55:23" "deleted" => 1 ] [ "id" => 393552235 "company_id" => 3731879 "urn" => "urn:li:activity:7125148497971957760" "followers" => null "date" => "3w" "description" => """ 3, 2, 1…..🚀 \n Listos para que arranque la LXXV Reunión Anual de la SEN\n \n 👉🏻 Os esperamos en el stand de FUJIREBIO para comentar con vosotros nuestras novedades en biomarcadores para enfermedades neurodegenerativas 🧠\n \n 👉🏻 ¡No faltéis a la cita!\n \n #neurodegeneration\n #biomarkers\n #FNCE\n #teamfujirebio\n #raSEN23 """ "reactions_count" => 34 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 05:55:23" "deleted" => 1 ] [ "id" => 393552236 "company_id" => 3731879 "urn" => "urn:li:activity:7124706285253484544" "followers" => null "date" => "4w" "description" => """ Fujirebio Europe werft aan: Accountant (Gent).\n 🔎 https://lnkd.in/eETb7ZbX """ "reactions_count" => 14 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 05:55:23" "deleted" => 1 ] [ "id" => 393552237 "company_id" => 3731879 "urn" => "urn:li:activity:7123247439318282241" "followers" => null "date" => "1mo" "description" => """ Fujirebio Italia è presente al Convegno Nazionale GISCI. \n \n Saremo felici di illustrarvi tutte le nostre soluzioni per lo screening e il Triage dell’HPV. Il nostro fiore all’occhiello il kit Precursor-M+ per lo studio dei livelli di ipermetilazione, che possono aiutare ad identificare le donne a rischio elevato di progressione verso il cervicocarcinoma. \n Corinna Orsini , Guido Marelli , Alberto Perego e Giulia Alfedi vi aspettano per parlarne insieme!! \n \n Fujirebio Europe Self-screen B.V. \n \n #GSCI2023 \n #HPVscreening\n #HPVsolutions """ "reactions_count" => 49 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-12 05:55:23" "deleted" => 1 ] [ "id" => 393552238 "company_id" => 3731879 "urn" => "urn:li:activity:7122860986490920960" "followers" => null "date" => "1mo" "description" => "Are you at #CTAD23 in Boston, USA? Be sure to meet and discuss with Dr. Nathalie Le Bastard 👋" "reactions_count" => 4 "comments_count" => null "reshared_post_author" => "Fujirebio US" "reshared_post_author_url" => "https://www.linkedin.com/company/fujirebio-us" "reshared_post_author_headline" => null "reshared_post_description" => """ We are in Boston for #CTAD23 from October 24 - 27. Schedule a meeting to learn more about our robust menu of high quality biomarkers of neurodegeneration 👉 email us at neuro@fdi.com to schedule a meeting!\n #CTAD23 #CTAD #alzheimersdisease #clinicaltrials """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-12-12 05:55:23" "deleted" => 1 ] [ "id" => 410080720 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => null "date" => "9mo" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 168 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 23:45:57" "deleted" => 1 ] [ "id" => 410080721 "company_id" => 3731879 "urn" => "urn:li:activity:7137415398605377537" "followers" => null "date" => "1w" "description" => "Season's greetings from Fujirebio! 💖 This year we have donated our traditional greetings budget to the EMSP - European Multiple Sclerosis Platform - https://emsp.org - a non-profit organization that raises the voice of people affected by #multiplesclerosis (MS) 📣💪" "reactions_count" => 32 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 23:45:57" "deleted" => 1 ] [ "id" => 410080722 "company_id" => 3731879 "urn" => "urn:li:activity:7136269779715133440" "followers" => null "date" => "1w" "description" => "Did you miss the recent CTAD 2023 in Boston, USA? 🖐 We look back at the key findings here 👉 https://lnkd.in/eH-dvqmZ. Evidence for the potential of blood-based #biomarkers is accumulating, and in combination with the pending availability of disease-modifying treatments there is good reason for the #Alzheimer's disease field to be optimistic. There are, however, key elements to consider before implementation." "reactions_count" => 16 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 23:45:57" "deleted" => 1 ] [ "id" => 410080723 "company_id" => 3731879 "urn" => "urn:li:activity:7135877623729004544" "followers" => null "date" => "1w" "description" => "📢 Fujirebio and Sysmex announce to expand CDMO partnership into the field of neurodegenerative diseases under their immunoassay collaboration 👉 https://lnkd.in/eW5eBdyV #CDMO #OEM #immunoassays" "reactions_count" => 70 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 23:45:57" "deleted" => 1 ] [ "id" => 410080724 "company_id" => 3731879 "urn" => "urn:li:activity:7133835668174036992" "followers" => null "date" => "2w" "description" => """ 🔈 Fujirebio Italia e’ presente al XVIII Congresso Nazionale SINdem 🔈\n \n Oggi ci sarà il nostro workshop: \n 🧠”Potenziale diagnostico e prognostico dei Neurofilamenti leggeri (NfL) nelle fasi iniziali di demenza” 🧠\n \n Il Dott. Lorenzo Gaetani illustrerà le interessanti applicazioni di questo importante biomarcatore! \n \n 🔛🔛🔛🔛🔛\n \n Fujirebio Europe Rikkert Maertens Nathalie Le Bastard Dr. Peter Jagiello \n \n MICHELE MARFORI Guido Marelli Pietro Pellegatta Maria Assunta Melone Vincenzo Mercolino Alberto Perego Giulia Alfedi Daniela Militello """ "reactions_count" => 38 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 23:45:57" "deleted" => 1 ] [ "id" => 410080725 "company_id" => 3731879 "urn" => "urn:li:activity:7133159860958830592" "followers" => null "date" => "2w" "description" => """ 🔈Fujirebio Italia vi aspetta all’ELAS 2023🔈\n \n 🧠Oggi ci sarà il nostro workshop🧠\n “ Progressi nell’utilizzo dei biomarcatori plasmatici nelle malattie neurodegenerative “ \n \n Il Dott. Gaetani e il Dott. Bellomo vi daranno tutte le informazioni, ad oggi note, in questo campo di grande interesse!\n \n 🔛🔛🔛🔛\n \n Fujirebio Europe Rikkert Maertens Nathalie Le Bastard Dr. Peter Jagiello \n \n MICHELE MARFORI Guido Marelli Pietro Pellegatta Maria Assunta Melone Vincenzo Mercolino Alberto Perego Giulia Alfedi Daniela Militello Giovanni Bellomo Lorenzo Gaetani """ "reactions_count" => 65 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 23:45:57" "deleted" => 1 ] [ "id" => 410080726 "company_id" => 3731879 "urn" => "urn:li:activity:7128275051015012352" "followers" => null "date" => "1mo" "description" => "Will you be at #Medica2023 in Düsseldorf, Germany? 👋 Come by stand 3B42 to meet our excellent expert team, including Rikkert Maertens, Amr Aleem, Geert Jannes, Roland Andersson, Zoran Vasic, Jan Jirous, Victor Ruiz de Gracia, Rebecca Millecamps, Nathalie Dekeersmaeker and Ahmed Fawzy, who all will be eager to discuss testing solutions with you! #teamfujirebio 💪" "reactions_count" => 50 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 23:45:57" "deleted" => 1 ] [ "id" => 410080727 "company_id" => 3731879 "urn" => "urn:li:activity:7127206369958465537" "followers" => null "date" => "1mo" "description" => "New Insight article 💡 https://lnkd.in/e7_HtFK8 - Post-treatment detection of recurrent CIN in women treated for CIN2/3: How can #HPV #genotyping and DNA #methylation analysis help discriminate women in need of re-treatment from those to be managed conservatively, preventing over-treatment? ❤️" "reactions_count" => 37 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 23:45:57" "deleted" => 1 ] [ "id" => 410080728 "company_id" => 3731879 "urn" => "urn:li:activity:7125406181551935491" "followers" => null "date" => "1mo" "description" => "Aguascalientes, será la sede del LIII Congreso Mexicano de Patología Clínica, #Fujirebio estará presente junto a #Kabla en el stand F4 con todo lo nuevo en la detección de #HPV, #Alzheimer y pruebas infecciosas, te esperamos!" "reactions_count" => 23 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 23:45:57" "deleted" => 1 ] [ "id" => 410080729 "company_id" => 3731879 "urn" => "urn:li:activity:7125148497971957760" "followers" => null "date" => "1mo" "description" => """ 3, 2, 1…..🚀 \n Listos para que arranque la LXXV Reunión Anual de la SEN\n \n 👉🏻 Os esperamos en el stand de FUJIREBIO para comentar con vosotros nuestras novedades en biomarcadores para enfermedades neurodegenerativas 🧠\n \n 👉🏻 ¡No faltéis a la cita!\n \n #neurodegeneration\n #biomarkers\n #FNCE\n #teamfujirebio\n #raSEN23 """ "reactions_count" => 34 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-15 23:45:57" "deleted" => 1 ] [ "id" => 444568735 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => null "date" => "10mo" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 175 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 20:51:09" "deleted" => 1 ] [ "id" => 444568736 "company_id" => 3731879 "urn" => "urn:li:activity:7144017899488256000" "followers" => null "date" => "3w" "description" => """ ✨Warm Season's Greetings from across the road!\n \n As the year comes to a close, we find ourselves on the brink of a new chapter. Our relocation to Fujirebio Europe signifies a new era of collaboration and innovation.\n \n We remain dedicated to delivering high-quality biomarkers and immunoassays on various platforms. We’re grateful for your continued support and partnership throughout our journey. 🙏\n \n May the approaching year be adorned with remarkable milestones and countless successes.\n \n Warmest wishes for a joyous holiday season and a thriving New Year! 🥂\n \n #seasonsgreetings #newyear2024 """ "reactions_count" => 83 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 20:51:09" "deleted" => 1 ] [ "id" => 444568737 "company_id" => 3731879 "urn" => "urn:li:activity:7144016656279764992" "followers" => null "date" => "3w" "description" => "📢 Fujirebio expands its Alzheimer’s disease test menu with the much awaited and fully automated Lumipulse® G pTau 217 Plasma assay for RUO 👉 https://lnkd.in/ewbX_wXM" "reactions_count" => 119 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 20:51:09" "deleted" => 1 ] [ "id" => 444568738 "company_id" => 3731879 "urn" => "urn:li:activity:7143170263059222528" "followers" => null "date" => "3w" "description" => "Desde Fujirebio Iberia os deseamos unas felices fiestas y un gran año 2024" "reactions_count" => 30 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 20:51:09" "deleted" => 1 ] [ "id" => 444568739 "company_id" => 3731879 "urn" => "urn:li:activity:7140945837353861120" "followers" => null "date" => "1mo" "description" => "📢 Fujirebio and Sysmex have signed agreement for the mutual supply of reagent raw materials owned by both companies, in the field of immunoassays 👉 https://lnkd.in/d97jhuxk #CDMO #OEM #immunoassays" "reactions_count" => 98 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 20:51:09" "deleted" => 1 ] [ "id" => 444568740 "company_id" => 3731879 "urn" => "urn:li:activity:7137415398605377537" "followers" => null "date" => "1mo" "description" => "Season's greetings from Fujirebio! 💖 This year we have donated our traditional greetings budget to the EMSP - European Multiple Sclerosis Platform - https://emsp.org - a non-profit organization that raises the voice of people affected by #multiplesclerosis (MS) 📣💪" "reactions_count" => 53 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 20:51:09" "deleted" => 1 ] [ "id" => 444568741 "company_id" => 3731879 "urn" => "urn:li:activity:7136269779715133440" "followers" => null "date" => "1mo" "description" => "Did you miss the recent CTAD 2023 in Boston, USA? 🖐 We look back at the key findings here 👉 https://lnkd.in/eH-dvqmZ. Evidence for the potential of blood-based #biomarkers is accumulating, and in combination with the pending availability of disease-modifying treatments there is good reason for the #Alzheimer's disease field to be optimistic. There are, however, key elements to consider before implementation." "reactions_count" => 18 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 20:51:09" "deleted" => 1 ] [ "id" => 444568742 "company_id" => 3731879 "urn" => "urn:li:activity:7135877623729004544" "followers" => null "date" => "1mo" "description" => "📢 Fujirebio and Sysmex announce to expand CDMO partnership into the field of neurodegenerative diseases under their immunoassay collaboration 👉 https://lnkd.in/eW5eBdyV #CDMO #OEM #immunoassays" "reactions_count" => 77 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 20:51:09" "deleted" => 1 ] [ "id" => 444568743 "company_id" => 3731879 "urn" => "urn:li:activity:7133835668174036992" "followers" => null "date" => "1mo" "description" => """ 🔈 Fujirebio Italia e’ presente al XVIII Congresso Nazionale SINdem 🔈\n \n Oggi ci sarà il nostro workshop: \n 🧠”Potenziale diagnostico e prognostico dei Neurofilamenti leggeri (NfL) nelle fasi iniziali di demenza” 🧠\n \n Il Dott. Lorenzo Gaetani illustrerà le interessanti applicazioni di questo importante biomarcatore! \n \n 🔛🔛🔛🔛🔛\n \n Fujirebio Europe Rikkert Maertens Nathalie Le Bastard Dr. Peter Jagiello \n \n MICHELE MARFORI Guido Marelli Pietro Pellegatta Maria Assunta Melone Vincenzo Mercolino Alberto Perego Giulia Alfedi Daniela Militello """ "reactions_count" => 42 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 20:51:09" "deleted" => 1 ] [ "id" => 444568744 "company_id" => 3731879 "urn" => "urn:li:activity:7133159860958830592" "followers" => null "date" => "1mo" "description" => """ 🔈Fujirebio Italia vi aspetta all’ELAS 2023🔈\n \n 🧠Oggi ci sarà il nostro workshop🧠\n “ Progressi nell’utilizzo dei biomarcatori plasmatici nelle malattie neurodegenerative “ \n \n Il Dott. Gaetani e il Dott. Bellomo vi daranno tutte le informazioni, ad oggi note, in questo campo di grande interesse!\n \n 🔛🔛🔛🔛\n \n Fujirebio Europe Rikkert Maertens Nathalie Le Bastard Dr. Peter Jagiello \n \n MICHELE MARFORI Guido Marelli Pietro Pellegatta Maria Assunta Melone Vincenzo Mercolino Alberto Perego Giulia Alfedi Daniela Militello Giovanni Bellomo Lorenzo Gaetani """ "reactions_count" => 66 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-13 20:51:09" "deleted" => 1 ] [ "id" => 470253098 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => null "date" => "11mo" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 177 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 00:09:31" "deleted" => 1 ] [ "id" => 470253099 "company_id" => 3731879 "urn" => "urn:li:activity:7158853599471484928" "followers" => null "date" => "1w" "description" => "Are you, too, heading for #Medlab Middle East 2024 in Dubai? 👋 Come meet #teamfujirebio Rikkert Maertens, Amr Aleem, Christiaan De Wilde, Zoran Vasic, Ahmed Fawzy at our booth Z5,C18 👉 https://lnkd.in/e2GmiBFB #MedlabMiddleEast" "reactions_count" => 39 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 00:09:31" "deleted" => 1 ] [ "id" => 470253100 "company_id" => 3731879 "urn" => "urn:li:activity:7158053434510688256" "followers" => null "date" => "2w" "description" => "🤝 Fujirebio is excited to join the AD-RIDDLE project, a groundbreaking #collaboration between 24 partners to bridge the gap between #Alzheimer’s research, implementation science, and precision medicine ❤️" "reactions_count" => 52 "comments_count" => null "reshared_post_author" => "AD-RIDDLE" "reshared_post_author_url" => "https://se.linkedin.com/company/ad-riddle" "reshared_post_author_headline" => null "reshared_post_description" => """ Hello from the AD-RIDDLE consortium! Today marks the start of our initiative to bridge the gap between #Alzheimers research and precision medicine. \n \n Thanks to funding from the Innovative Health Initiative (IHI), we’re beginning a 5-year effort to transform the detection, diagnosis, and treatment of #Alzheimer's disease across healthcare settings in Europe. \n \n Read our press release ➡ \n https://lnkd.in/e_8VexVr\n \n Follow our progress here, and sign up for our newsletter for updates ➡️ www.ad-riddle.org \n \n Gates Ventures Karolinska Institutet Region Stockholm FINGERS Brain Health Institute University of Gothenburg Lund University University of Eastern Finland Amsterdam UMC Maastricht University Fundación Pasqual Maragall SYNAPSE Research Management Partners Alzheimer Europe Alzheimer's Disease International Università degli Studi di Perugia Davos Alzheimer's Collaborative Combinostics Fujirebio Europe Sanofi C2N Diagnostics neotiv Cambridge Cognition University of Leicester Imperial College London NICE - National Institute for Health and Care Excellence """ "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2024-03-02 00:09:31" "deleted" => 1 ] [ "id" => 470253101 "company_id" => 3731879 "urn" => "urn:li:activity:7153989913212764160" "followers" => null "date" => "3w" "description" => "📢 Fujirebio and Agappe Diagnostics announce agreement, 👉 https://lnkd.in/ebZphTm4, for CDMO partnership in cartridge-based CLIA reagent manufacturing on the immunology equipment Mispa i60 and Mispa i121, spurring the expansion of India's immunoassay market and impacting the evolution and enhancement of immunoassay solutions in the country #cdmo #businesspartnership #india Agappe Diagnostics Ltd 👋" "reactions_count" => 69 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 00:09:31" "deleted" => 1 ] [ "id" => 470253102 "company_id" => 3731879 "urn" => "urn:li:activity:7152940753382436865" "followers" => null "date" => "4w" "description" => """ CERVICAL CANCER AWARENESS MONTH\n \n Many countries in the world have adopted the WHO\n global strategy for eliminating cervical cancer worldwide within the next century. National screening programs and vaccination play a vital key in protecting women. \n The programs are being improved continuously. \n \n The introduction of self-sampling demonstrates that the screening programs coverage goes up.\n And improved triage strategies avoid unneccessary referrals and treatment, making the programs more effective with less burden for the women involved.\n At Self-screen B.V. we continue to support these improvements. And offer therefore a full molecular screening and triage solution, which we believe is advantageous for the patients, the health institutes, the lab and the doctors.\n If you want to know more, we are happy to help. Contact us at info@self-screen.nl or our partners QIAGEN or Fujirebio Europe\n \n https://self-screen.nl/\n https://lnkd.in/e-d5x3k6\n https://lnkd.in/eKtxbHB5 """ "reactions_count" => 46 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 00:09:31" "deleted" => 1 ] [ "id" => 470253103 "company_id" => 3731879 "urn" => "urn:li:activity:7144017899488256000" "followers" => null "date" => "1mo" "description" => """ ✨Warm Season's Greetings from across the road!\n \n As the year comes to a close, we find ourselves on the brink of a new chapter. Our relocation to Fujirebio Europe signifies a new era of collaboration and innovation.\n \n We remain dedicated to delivering high-quality biomarkers and immunoassays on various platforms. We’re grateful for your continued support and partnership throughout our journey. 🙏\n \n May the approaching year be adorned with remarkable milestones and countless successes.\n \n Warmest wishes for a joyous holiday season and a thriving New Year! 🥂\n \n #seasonsgreetings #newyear2024 """ "reactions_count" => 87 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 00:09:31" "deleted" => 1 ] [ "id" => 470253104 "company_id" => 3731879 "urn" => "urn:li:activity:7144016656279764992" "followers" => null "date" => "1mo" "description" => "📢 Fujirebio expands its Alzheimer’s disease test menu with the much awaited and fully automated Lumipulse® G pTau 217 Plasma assay for RUO 👉 https://lnkd.in/ewbX_wXM" "reactions_count" => 120 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 00:09:31" "deleted" => 1 ] [ "id" => 470253106 "company_id" => 3731879 "urn" => "urn:li:activity:7143170263059222528" "followers" => null "date" => "1mo" "description" => "Desde Fujirebio Iberia os deseamos unas felices fiestas y un gran año 2024" "reactions_count" => 30 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 00:09:31" "deleted" => 1 ] [ "id" => 470253108 "company_id" => 3731879 "urn" => "urn:li:activity:7140945837353861120" "followers" => null "date" => "2mo" "description" => "📢 Fujirebio and Sysmex have signed agreement for the mutual supply of reagent raw materials owned by both companies, in the field of immunoassays 👉 https://lnkd.in/d97jhuxk #CDMO #OEM #immunoassays" "reactions_count" => 100 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 00:09:31" "deleted" => 1 ] [ "id" => 470253110 "company_id" => 3731879 "urn" => "urn:li:activity:7137415398605377537" "followers" => null "date" => "2mo" "description" => "Season's greetings from Fujirebio! 💖 This year we have donated our traditional greetings budget to the EMSP - European Multiple Sclerosis Platform - https://emsp.org - a non-profit organization that raises the voice of people affected by #multiplesclerosis (MS) 📣💪" "reactions_count" => 53 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-02 00:09:31" "deleted" => 1 ] [ "id" => 493661189 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => null "date" => "12mo" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 180 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:17:43" "deleted" => 1 ] [ "id" => 493661190 "company_id" => 3731879 "urn" => "urn:li:activity:7168143257758076928" "followers" => null "date" => "3d" "description" => "Are you, too, heading for AD/PD 2024 in Lisbon, Portugal? 👋 Come meet our #teamfujirebio with experts from Marketing, Sales and R&D (see comments 👇 for details) who are eager to discuss the latest within the field of neurodegenerative disease testing - find us at booth 6 👉 https://lnkd.in/eMZcHtum #ADPD #neurodegeneration #alzheimersdisease #parkinsonsdisease" "reactions_count" => 40 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:17:43" "deleted" => 1 ] [ "id" => 493661191 "company_id" => 3731879 "urn" => "urn:li:activity:7166870615365246976" "followers" => null "date" => "1w" "description" => """ Fujirebio beim Neuro Update 2024.\n https://neuro-update.com/ """ "reactions_count" => 52 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:17:43" "deleted" => 1 ] [ "id" => 493661192 "company_id" => 3731879 "urn" => "urn:li:activity:7158853599471484928" "followers" => null "date" => "4w" "description" => "Are you, too, heading for #Medlab Middle East 2024 in Dubai? 👋 Come meet #teamfujirebio Rikkert Maertens, Amr Aleem, Christiaan De Wilde, Zoran Vasic, Ahmed Fawzy at our booth Z5,C18 👉 https://lnkd.in/e2GmiBFB #MedlabMiddleEast" "reactions_count" => 40 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:17:43" "deleted" => 1 ] [ "id" => 493661193 "company_id" => 3731879 "urn" => "urn:li:activity:7158053434510688256" "followers" => null "date" => "1mo" "description" => "🤝 Fujirebio is excited to join the AD-RIDDLE project, a groundbreaking #collaboration between 24 partners to bridge the gap between #Alzheimer’s research, implementation science, and precision medicine ❤️" "reactions_count" => 58 "comments_count" => null "reshared_post_author" => "AD-RIDDLE" "reshared_post_author_url" => "https://se.linkedin.com/company/ad-riddle" "reshared_post_author_headline" => null "reshared_post_description" => """ Hello from the AD-RIDDLE consortium! Today marks the start of our initiative to bridge the gap between #Alzheimers research and precision medicine. \n \n Thanks to funding from the Innovative Health Initiative (IHI), we’re beginning a 5-year effort to transform the detection, diagnosis, and treatment of #Alzheimer's disease across healthcare settings in Europe. \n \n Read our press release ➡ \n https://lnkd.in/e_8VexVr\n \n Follow our progress here, and sign up for our newsletter for updates ➡️ www.ad-riddle.org \n \n Gates Ventures Karolinska Institutet Region Stockholm FINGERS Brain Health Institute University of Gothenburg Lund University University of Eastern Finland Amsterdam UMC Maastricht University Fundación Pasqual Maragall SYNAPSE Research Management Partners Alzheimer Europe Alzheimer's Disease International Università degli Studi di Perugia Davos Alzheimer's Collaborative Combinostics Fujirebio Europe Sanofi C2N Diagnostics neotiv Cambridge Cognition University of Leicester Imperial College London NICE - National Institute for Health and Care Excellence """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-04-05 12:17:43" "deleted" => 1 ] [ "id" => 493661194 "company_id" => 3731879 "urn" => "urn:li:activity:7153989913212764160" "followers" => null "date" => "1mo" "description" => "📢 Fujirebio and Agappe Diagnostics announce agreement, 👉 https://lnkd.in/ebZphTm4, for CDMO partnership in cartridge-based CLIA reagent manufacturing on the immunology equipment Mispa i60 and Mispa i121, spurring the expansion of India's immunoassay market and impacting the evolution and enhancement of immunoassay solutions in the country #cdmo #businesspartnership #india Agappe Diagnostics Ltd 👋" "reactions_count" => 69 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:17:43" "deleted" => 1 ] [ "id" => 493661195 "company_id" => 3731879 "urn" => "urn:li:activity:7152940753382436865" "followers" => null "date" => "1mo" "description" => """ CERVICAL CANCER AWARENESS MONTH\n \n Many countries in the world have adopted the WHO\n global strategy for eliminating cervical cancer worldwide within the next century. National screening programs and vaccination play a vital key in protecting women. \n The programs are being improved continuously. \n \n The introduction of self-sampling demonstrates that the screening programs coverage goes up.\n And improved triage strategies avoid unneccessary referrals and treatment, making the programs more effective with less burden for the women involved.\n At Self-screen B.V. we continue to support these improvements. And offer therefore a full molecular screening and triage solution, which we believe is advantageous for the patients, the health institutes, the lab and the doctors.\n If you want to know more, we are happy to help. Contact us at info@self-screen.nl or our partners QIAGEN or Fujirebio Europe\n \n https://self-screen.nl/\n https://lnkd.in/e-d5x3k6\n https://lnkd.in/eKtxbHB5 """ "reactions_count" => 46 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:17:43" "deleted" => 1 ] [ "id" => 493661196 "company_id" => 3731879 "urn" => "urn:li:activity:7144017899488256000" "followers" => null "date" => "2mo" "description" => """ ✨Warm Season's Greetings from across the road!\n \n As the year comes to a close, we find ourselves on the brink of a new chapter. Our relocation to Fujirebio Europe signifies a new era of collaboration and innovation.\n \n We remain dedicated to delivering high-quality biomarkers and immunoassays on various platforms. We’re grateful for your continued support and partnership throughout our journey. 🙏\n \n May the approaching year be adorned with remarkable milestones and countless successes.\n \n Warmest wishes for a joyous holiday season and a thriving New Year! 🥂\n \n #seasonsgreetings #newyear2024 """ "reactions_count" => 87 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:17:43" "deleted" => 1 ] [ "id" => 493661197 "company_id" => 3731879 "urn" => "urn:li:activity:7144016656279764992" "followers" => null "date" => "2mo" "description" => "📢 Fujirebio expands its Alzheimer’s disease test menu with the much awaited and fully automated Lumipulse® G pTau 217 Plasma assay for RUO 👉 https://lnkd.in/ewbX_wXM" "reactions_count" => 120 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:17:43" "deleted" => 1 ] [ "id" => 493661198 "company_id" => 3731879 "urn" => "urn:li:activity:7143170263059222528" "followers" => null "date" => "2mo" "description" => "Desde Fujirebio Iberia os deseamos unas felices fiestas y un gran año 2024" "reactions_count" => 30 "comments_count" => 10 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-05 12:17:43" "deleted" => 1 ] [ "id" => 529376935 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => null "date" => "1y" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 185 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 17:26:36" "deleted" => 1 ] [ "id" => 529376936 "company_id" => 3731879 "urn" => "urn:li:activity:7181546091035656192" "followers" => null "date" => "1d" "description" => """ 📢 We will be at the 2024 American Academy of Neurology Annual Meeting in Denver April 13 – April 18. \n \n If you would like to schedule a meeting in advance, please submit a meeting request on our events page 👉 https://bit.ly/3VHaCY4 or email us at 𝗻𝗲𝘂𝗿𝗼@𝗳𝗱𝗶.𝗰𝗼𝗺\n \n See you at the 2024 AAN Annual Meeting!\n \n #aan2024 #neurodegeneration #neurology #neuroscience #alzheimersdisease #denver """ "reactions_count" => 19 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 17:26:36" "deleted" => 1 ] [ "id" => 529376937 "company_id" => 3731879 "urn" => "urn:li:activity:7174307003119333377" "followers" => null "date" => "3w" "description" => """ It’s #BrainAwarenessWeek2024! \n \n #dyk that ~40% of #dementias could be prevented by targeting 12 modifiable risk factors across the life course? \n \n Our consortium members developed the pioneering FINGER multimodal #dementia risk detection and prevention model, showing that older people at risk for dementia could benefit from a multidomain lifestyle intervention 🖐️ \n \n In AD-RIDDLE, we are working across sectors to develop tools & resources for early detection, diagnosis & treatment - so people with or at risk of #dementia can benefit from precision prevention & personalised medicine 🧠\n \n Read more in the Innovative Health Initiative (IHI) article ⤵️\n \n https://lnkd.in/eWZheihA\n \n Gates Ventures Amsterdam UMC Alzheimer Europe Alzheimer's Disease International Fundación Pasqual Maragall Cambridge Cognition C2N Diagnostics Combinostics Davos Alzheimer's Collaborative Fujirebio Europe FINGERS Brain Health Institute Imperial College London Karolinska Institutet Maastricht University NICE - National Institute for Health and Care Excellence neotiv University of Leicester Lund University University of Gothenburg University of Eastern Finland SYNAPSE Research Management Partners Università degli Studi di Perugia """ "reactions_count" => 41 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 17:26:36" "deleted" => 1 ] [ "id" => 529376938 "company_id" => 3731879 "urn" => "urn:li:activity:7173320927433207811" "followers" => null "date" => "3w" "description" => "📣 Beckman Coulter and Fujirebio expand partnership to develop patient-friendly blood-based #neurodegenerative disease #diagnostics - https://lnkd.in/eXqVbuAj #fnce #neuro #cdmo #partnership 🤝 Beckman Coulter Diagnostics" "reactions_count" => 89 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 17:26:36" "deleted" => 1 ] [ "id" => 529376939 "company_id" => 3731879 "urn" => "urn:li:activity:7172896743095783424" "followers" => null "date" => "3w" "description" => "Are you, too, heading for EUROGIN 2024 in Stockholm, Sweden? 👋 Come meet our #teamfujirebio of experts, who will be eager to discuss the latest within the field of #HPV testing - find us at booth #A04 👉 https://lnkd.in/eb59YZ-H #eurogin2024 #eurogin #eurogin24 #biomarkers" "reactions_count" => 30 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 17:26:36" "deleted" => 1 ] [ "id" => 529376940 "company_id" => 3731879 "urn" => "urn:li:activity:7172895559509233664" "followers" => null "date" => "3w" "description" => """ EUROGIN Presentation "Automated workflow for FAM19A4/miR124-2 methylation analysis" \n \n During the annual EUROGIN Conference, starting in two days in Stockholm, our Senior Scientific Officer Bart Hesselink will present about automation of pretreatment of Self-screen B.V.'s PreCursor-M+/ QIAsure Methylation assay.\n \n Feel free to join during session FC17 Methylation II on Friday 15th - 18.00-19.30 and hear about the workflow improvements on ease of use, hands-on time, and standardization. \n \n Our collaboration with GC biotech BV has lead to an improved bisulfite pretreatment workflow which is automated, standardized and robust without any loss of clinical performance.\n #methylation, #cervicalcancer, #automation """ "reactions_count" => 49 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 17:26:36" "deleted" => 1 ] [ "id" => 529376941 "company_id" => 3731879 "urn" => "urn:li:activity:7172643380890439680" "followers" => null "date" => "3w" "description" => """ 🦠🧫 AMCLI 2024 🧫🦠\n \n Ringraziamo tutti i clienti che ci sono venuti a trovare in questi primi due giorni di congresso e che come sempre hanno apprezzato il nostro impegno nella promozione dell’accuratezza diagnostica nel capo della Microbiologia. \n \n 🔛 Vi aspettiamo fino a domani presso il Booth n.12 \n \n Fujirebio Italia Team: MICHELE MARFORI Pietro Pellegatta Vincenzo Mercolino Guido Marelli Alberto Perego Giulia Alfedi Maria Assunta Melone Daniela Militello \n \n Fujirebio Europe Christian Lindknud, MSc Rikkert Maertens Rebecca Millecamps """ "reactions_count" => 56 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 17:26:36" "deleted" => 1 ] [ "id" => 529376942 "company_id" => 3731879 "urn" => "urn:li:activity:7170610767212326912" "followers" => null "date" => "1mo" "description" => "📣 Fujirebio Europe launches the innovative PreCursor-M AnoGYN assay (RUO) from Self-screen B.V. for methylation testing in anal specimens 👉 https://lnkd.in/eCUFFNpf - it complements Fujirebio's HPV-associated molecular test portfolio #analcancer #diagnostics #methylation #molecularbiology" "reactions_count" => 53 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 17:26:36" "deleted" => 1 ] [ "id" => 529376943 "company_id" => 3731879 "urn" => "urn:li:activity:7168143257758076928" "followers" => null "date" => "1mo" "description" => "Are you, too, heading for AD/PD 2024 in Lisbon, Portugal? 👋 Come meet our #teamfujirebio with experts from Marketing, Sales and R&D (see comments 👇 for details) who are eager to discuss the latest within the field of neurodegenerative disease testing - find us at booth 6 👉 https://lnkd.in/eMZcHtum #ADPD #neurodegeneration #alzheimersdisease #parkinsonsdisease" "reactions_count" => 49 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 17:26:36" "deleted" => 1 ] [ "id" => 529376944 "company_id" => 3731879 "urn" => "urn:li:activity:7166870615365246976" "followers" => null "date" => "1mo" "description" => """ Fujirebio beim Neuro Update 2024.\n https://neuro-update.com/ """ "reactions_count" => 61 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-10 17:26:36" "deleted" => 1 ] [ "id" => 563870879 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => null "date" => "1y" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 189 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-10 07:20:07" "deleted" => 1 ] [ "id" => 563870880 "company_id" => 3731879 "urn" => "urn:li:activity:7181546091035656192" "followers" => null "date" => "1mo" "description" => """ 📢 We will be at the 2024 American Academy of Neurology Annual Meeting in Denver April 13 – April 18. \n \n If you would like to schedule a meeting in advance, please submit a meeting request on our events page 👉 https://bit.ly/3VHaCY4 or email us at 𝗻𝗲𝘂𝗿𝗼@𝗳𝗱𝗶.𝗰𝗼𝗺\n \n See you at the 2024 AAN Annual Meeting!\n \n #aan2024 #neurodegeneration #neurology #neuroscience #alzheimersdisease #denver """ "reactions_count" => 37 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-10 07:20:07" "deleted" => 1 ] [ "id" => 563870881 "company_id" => 3731879 "urn" => "urn:li:activity:7174307003119333377" "followers" => null "date" => "1mo" "description" => """ It’s #BrainAwarenessWeek2024! \n \n #dyk that ~40% of #dementias could be prevented by targeting 12 modifiable risk factors across the life course? \n \n Our consortium members developed the pioneering FINGER multimodal #dementia risk detection and prevention model, showing that older people at risk for dementia could benefit from a multidomain lifestyle intervention 🖐️ \n \n In AD-RIDDLE, we are working across sectors to develop tools & resources for early detection, diagnosis & treatment - so people with or at risk of #dementia can benefit from precision prevention & personalised medicine 🧠\n \n Read more in the Innovative Health Initiative (IHI) article ⤵️\n \n https://lnkd.in/eWZheihA\n \n Gates Ventures Amsterdam UMC Alzheimer Europe Alzheimer's Disease International Fundación Pasqual Maragall Cambridge Cognition C2N Diagnostics Combinostics Davos Alzheimer's Collaborative Fujirebio Europe FINGERS Brain Health Institute Imperial College London Karolinska Institutet Maastricht University NICE - National Institute for Health and Care Excellence neotiv University of Leicester Lund University University of Gothenburg University of Eastern Finland SYNAPSE Research Management Partners Università degli Studi di Perugia """ "reactions_count" => 41 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-10 07:20:07" "deleted" => 1 ] [ "id" => 563870882 "company_id" => 3731879 "urn" => "urn:li:activity:7173320927433207811" "followers" => null "date" => "1mo" "description" => "📣 Beckman Coulter and Fujirebio expand partnership to develop patient-friendly blood-based #neurodegenerative disease #diagnostics - https://lnkd.in/eXqVbuAj #fnce #neuro #cdmo #partnership 🤝 Beckman Coulter Diagnostics" "reactions_count" => 94 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-10 07:20:07" "deleted" => 1 ] [ "id" => 563870883 "company_id" => 3731879 "urn" => "urn:li:activity:7172896743095783424" "followers" => null "date" => "2mo" "description" => "Are you, too, heading for EUROGIN 2024 in Stockholm, Sweden? 👋 Come meet our #teamfujirebio of experts, who will be eager to discuss the latest within the field of #HPV testing - find us at booth #A04 👉 https://lnkd.in/eb59YZ-H #eurogin2024 #eurogin #eurogin24 #biomarkers" "reactions_count" => 30 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-16 04:58:42" "deleted" => 1 ] [ "id" => 563870884 "company_id" => 3731879 "urn" => "urn:li:activity:7172895559509233664" "followers" => null "date" => "2mo" "description" => """ EUROGIN Presentation "Automated workflow for FAM19A4/miR124-2 methylation analysis" \n \n During the annual EUROGIN Conference, starting in two days in Stockholm, our Senior Scientific Officer Bart Hesselink will present about automation of pretreatment of Self-screen B.V.'s PreCursor-M+/ QIAsure Methylation assay.\n \n Feel free to join during session FC17 Methylation II on Friday 15th - 18.00-19.30 and hear about the workflow improvements on ease of use, hands-on time, and standardization. \n \n Our collaboration with GC biotech BV has lead to an improved bisulfite pretreatment workflow which is automated, standardized and robust without any loss of clinical performance.\n #methylation, #cervicalcancer, #automation """ "reactions_count" => 49 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-16 04:58:42" "deleted" => 1 ] [ "id" => 563870885 "company_id" => 3731879 "urn" => "urn:li:activity:7172643380890439680" "followers" => null "date" => "2mo" "description" => """ 🦠🧫 AMCLI 2024 🧫🦠\n \n Ringraziamo tutti i clienti che ci sono venuti a trovare in questi primi due giorni di congresso e che come sempre hanno apprezzato il nostro impegno nella promozione dell’accuratezza diagnostica nel capo della Microbiologia. \n \n 🔛 Vi aspettiamo fino a domani presso il Booth n.12 \n \n Fujirebio Italia Team: MICHELE MARFORI Pietro Pellegatta Vincenzo Mercolino Guido Marelli Alberto Perego Giulia Alfedi Maria Assunta Melone Daniela Militello \n \n Fujirebio Europe Christian Lindknud, MSc Rikkert Maertens Rebecca Millecamps """ "reactions_count" => 56 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-10 07:20:07" "deleted" => 1 ] [ "id" => 563870886 "company_id" => 3731879 "urn" => "urn:li:activity:7170610767212326912" "followers" => null "date" => "2mo" "description" => "📣 Fujirebio Europe launches the innovative PreCursor-M AnoGYN assay (RUO) from Self-screen B.V. for methylation testing in anal specimens 👉 https://lnkd.in/eCUFFNpf - it complements Fujirebio's HPV-associated molecular test portfolio #analcancer #diagnostics #methylation #molecularbiology" "reactions_count" => 53 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-10 07:20:07" "deleted" => 1 ] [ "id" => 563870887 "company_id" => 3731879 "urn" => "urn:li:activity:7168143257758076928" "followers" => null "date" => "2mo" "description" => "Are you, too, heading for AD/PD 2024 in Lisbon, Portugal? 👋 Come meet our #teamfujirebio with experts from Marketing, Sales and R&D (see comments 👇 for details) who are eager to discuss the latest within the field of neurodegenerative disease testing - find us at booth 6 👉 https://lnkd.in/eMZcHtum #ADPD #neurodegeneration #alzheimersdisease #parkinsonsdisease" "reactions_count" => 49 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-10 07:20:07" "deleted" => 1 ] [ "id" => 563870888 "company_id" => 3731879 "urn" => "urn:li:activity:7166870615365246976" "followers" => null "date" => "2mo" "description" => """ Fujirebio beim Neuro Update 2024.\n https://neuro-update.com/ """ "reactions_count" => 61 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-10 07:20:07" "deleted" => 1 ] [ "id" => 602549220 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => null "date" => "1y" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 192 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-16 04:58:42" "deleted" => 1 ] [ "id" => 602549221 "company_id" => 3731879 "urn" => "urn:li:activity:7201897296932839424" "followers" => null "date" => "4d" "description" => """ 3, 2, 1 ….. 🚀 arranca #SEIMC2024!\n \n Te esperamos en el stand 16 para contarte nuestras novedades en el campo de la microbiología y la virología. \n \n #teamfujirebio\n #SEIMC\n #diagnosticomolecular\n #serología\n #metilaciónHPV """ "reactions_count" => 60 "comments_count" => 8 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-16 04:58:42" "deleted" => 1 ] [ "id" => 602549222 "company_id" => 3731879 "urn" => "urn:li:activity:7197253396817399809" "followers" => null "date" => "2w" "description" => """ Don’t miss our workshop to learn about blood-based biomarkers for AD this afternoon at GEECD congress\n \n #GEECD #bloodbasedbiomarkers #alzheimerdisease #FNCE\n #fujirebio #bioportugal """ "reactions_count" => 16 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-16 04:58:42" "deleted" => 1 ] [ "id" => 602549223 "company_id" => 3731879 "urn" => "urn:li:activity:7197174365199712256" "followers" => null "date" => "2w" "description" => """ We look forward to seeing you at this new edition of the GEECD congress, in Braga, to discover what’s new in the field of dementias\n \n #GEECD #bioportugal #fujirebio\n #alzheimerbiomarkers\n #becauseearlydiagnosisreallymatters\n #dementia """ "reactions_count" => 24 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-16 04:58:42" "deleted" => 1 ] [ "id" => 602549224 "company_id" => 3731879 "urn" => "urn:li:activity:7195808030226087936" "followers" => null "date" => "3w" "description" => """ 🧬 Latest news on Precursor- M+ from Italy!🧬\n \n 🔛Last week we officially kicked off the Study we will be conducting with the Umbria Region on the possibility of using methylation analysis for an alternative triage to be included in the Regional Screening Program for cervical cancer prevention🔛\n \n 🔜 The Study, approved by a National Ethic Committee, will enroll about 400 patients. The Umbria Region is a pioneer in Italy of a structured study aimed at establishing the role of biomarkers in this important health project. \n \n 🔬 We would like to thank Dr. Malagigi, the Principal Investigator of the Study, Dr. Bulletti and Dr. Brozzetti, the expert referents of the Study, and all those present (the operators and coordinators from the sampling and colposcopy centres of the regional territory) who have enthusiastically welcomed and participated in this project that will see us working together!\n \n Keep in touch with Fujirebio Art of Accuracy! \n \n Corinna Orsini Giulia Alfedi Maria Assunta Melone \n Rikkert Maertens Rebecca Millecamps Fujirebio Europe Christian Lindknud, MSc Self-screen B.V. Michelle Meijer \n MICHELE MARFORI Pietro Pellegatta Vincenzo Mercolino Guido Marelli Alberto Perego Daniela Militello """ "reactions_count" => 46 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-16 04:58:42" "deleted" => 1 ] [ "id" => 602549225 "company_id" => 3731879 "urn" => "urn:li:activity:7181546091035656192" "followers" => null "date" => "2mo" "description" => """ 📢 We will be at the 2024 American Academy of Neurology Annual Meeting in Denver April 13 – April 18. \n \n If you would like to schedule a meeting in advance, please submit a meeting request on our events page 👉 https://bit.ly/3VHaCY4 or email us at 𝗻𝗲𝘂𝗿𝗼@𝗳𝗱𝗶.𝗰𝗼𝗺\n \n See you at the 2024 AAN Annual Meeting!\n \n #aan2024 #neurodegeneration #neurology #neuroscience #alzheimersdisease #denver """ "reactions_count" => 39 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-16 04:58:42" "deleted" => 1 ] [ "id" => 602549226 "company_id" => 3731879 "urn" => "urn:li:activity:7174307003119333377" "followers" => null "date" => "2mo" "description" => """ It’s #BrainAwarenessWeek2024! \n \n #dyk that ~40% of #dementias could be prevented by targeting 12 modifiable risk factors across the life course? \n \n Our consortium members developed the pioneering FINGER multimodal #dementia risk detection and prevention model, showing that older people at risk for dementia could benefit from a multidomain lifestyle intervention 🖐️ \n \n In AD-RIDDLE, we are working across sectors to develop tools & resources for early detection, diagnosis & treatment - so people with or at risk of #dementia can benefit from precision prevention & personalised medicine 🧠\n \n Read more in the Innovative Health Initiative (IHI) article ⤵️\n \n https://lnkd.in/eWZheihA\n \n Gates Ventures Amsterdam UMC Alzheimer Europe Alzheimer's Disease International Fundación Pasqual Maragall Cambridge Cognition C2N Diagnostics Combinostics Davos Alzheimer's Collaborative Fujirebio Europe FINGERS Brain Health Institute Imperial College London Karolinska Institutet Maastricht University NICE - National Institute for Health and Care Excellence neotiv University of Leicester Lund University University of Gothenburg University of Eastern Finland SYNAPSE Research Management Partners Università degli Studi di Perugia """ "reactions_count" => 41 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-16 04:58:42" "deleted" => 1 ] [ "id" => 602549227 "company_id" => 3731879 "urn" => "urn:li:activity:7173320927433207811" "followers" => null "date" => "2mo" "description" => "📣 Beckman Coulter and Fujirebio expand partnership to develop patient-friendly blood-based #neurodegenerative disease #diagnostics - https://lnkd.in/eXqVbuAj #fnce #neuro #cdmo #partnership 🤝 Beckman Coulter Diagnostics" "reactions_count" => 94 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-16 04:58:42" "deleted" => 1 ] [ "id" => 643610599 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => null "date" => "1y" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 195 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 23:47:38" "deleted" => 1 ] [ "id" => 643610600 "company_id" => 3731879 "urn" => "urn:li:activity:7217560305130713089" "followers" => null "date" => "3d" "description" => "We're #hiring a new Senior Research Associate in Sunnyvale, California. Apply today or share this post with your network." "reactions_count" => 11 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 23:47:38" "deleted" => 1 ] [ "id" => 643610601 "company_id" => 3731879 "urn" => "urn:li:activity:7217511184130863104" "followers" => null "date" => "4d" "description" => """ We will be at AAIC 2024 in Philadelphia!\n \n Schedule a meeting with us or stop by our booth to learn about our high-quality assays for assessing neurodegenerative disorders. \n \n 👉 https://bit.ly/4bxAqdu or email us at neuro@fdi.com. \n \n We look forward to meeting with you. #AAIC24 """ "reactions_count" => 33 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 23:47:38" "deleted" => 1 ] [ "id" => 643610602 "company_id" => 3731879 "urn" => "urn:li:activity:7214915162162540545" "followers" => null "date" => "1w" "description" => """ 🔊 We are ready for a new adventure🔊\n \n 🧬We have installed our first fully automated, traceable and userfriendly system that combines the extraction and preparation of the Masmec S.p.A. - Biomed division OMNIA LH 75 Pro with the real time detection and interpretation of the BMS Mic qPCR🧬\n \n Our Giulia Alfedi completed the installation and training at our first customer who will use our HPV unique solution: Self-screen B.V. HPV screening (HPV Risk Assay), HPV genotyping (INNOLiPA HPV genotyping Extra II) and methylation analysis (Precursor-M+).\n \n 🔬 The Fujirebio Europe Art of Accuracy in everyday life and at the service of precision medicine! \n \n Rikkert Maertens Rebecca Millecamps Christian Lindknud, MSc Michelle Meijer Vincenzo Costantino MICHELE MARFORI Maria Assunta Melone Guido Marelli Iosto Doneddu """ "reactions_count" => 59 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 23:47:38" "deleted" => 1 ] [ "id" => 643610603 "company_id" => 3731879 "urn" => "urn:li:activity:7213487100107571200" "followers" => null "date" => "2w" "description" => "Discover our interview to our collaborators ADx NeuroSciences and Fujirebio Europe within the NEuroBioStand project. Thanks to Eugeen Vanmechelen and Nathalie Le Bastard (article in French). EURAMET - The European Association of National Metrology Institutes #EUpartnership #metrology LNE" "reactions_count" => 30 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 23:47:38" "deleted" => 1 ] [ "id" => 643610604 "company_id" => 3731879 "urn" => "urn:li:activity:7211630461503066113" "followers" => null "date" => "2w" "description" => "🌐 BE - The Fujirebio Neuro Center of Excellence was proudly featured in the Belgian newspaper De Morgen in this interview with our own Dr. Nathalie Le Bastard and Manu Vandijck; learn about the past, present and future of this exciting place... and the current state of neuro testing in general 👉 https://lnkd.in/enzJM_QV 👏" "reactions_count" => 73 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 23:47:38" "deleted" => 1 ] [ "id" => 643610605 "company_id" => 3731879 "urn" => "urn:li:activity:7209848715195400195" "followers" => null "date" => "3w" "description" => """ Are you our new IT Business Analyst? 🤗 We are strengthening our IT team in Ghent, Belgium 👉 https://lnkd.in/gdFN7ui5\n \n In taking up this job you will analyse, redesign and improve business processes, and you will manage the full life cycle of corporate business applications and/or Business Intelligence systems. 💪 \n \n #joinus #teamfujirebio """ "reactions_count" => 20 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 23:47:38" "deleted" => 1 ] [ "id" => 643610606 "company_id" => 3731879 "urn" => "urn:li:activity:7209847658612445185" "followers" => null "date" => "3w" "description" => """ Will you be at the #EAN2024 next week in Helsinki, Finland? 👋 We will! Come and meet with us at booth E50 - Dr. Peter Jagiello, Rikkert Maertens and our friends from Immuno Diagnostic Oy will be eager to discuss with you about new perspectives on early neuro testing and diagnostics! \n \n Book a meeting with us here: https://lnkd.in/eH8PNhiS """ "reactions_count" => 34 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 23:47:38" "deleted" => 1 ] [ "id" => 643610607 "company_id" => 3731879 "urn" => "urn:li:activity:7209536501343232000" "followers" => null "date" => "3w" "description" => """ Vi söker nu en Manufacturing Technician (produktionstekniker) till vårt team. Det är en bred lab support-roll där du kommer stödja labben inom både produktutveckling och produktion. Huvudsakliga arbetsuppgifter är tillverkning av lösningar, filtrering och koncentrering av skördmedium, städning av rum med högre renhetskrav. \n \n Anställningen är en tillsvidareanställning med en omfattning på 100 % dagtid. Tillträdesdatum är 2024-09-01 eller enligt överenskommelse.\n \n Du skickar din ansökan och hittar mer information via https://lnkd.in/dfejsVGj\n \n Ansök redan nu eller senast 2024-08-11.\n \n Välkommen med din ansökan! """ "reactions_count" => 32 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 23:47:38" "deleted" => 1 ] [ "id" => 643610608 "company_id" => 3731879 "urn" => "urn:li:activity:7208362085477421056" "followers" => null "date" => "4w" "description" => "🌐 BE - The Fujirebio Neuro Center of Excellence was proudly featured in the Belgian newspaper De Morgen over the weekend in this interview with our own Dr. Nathalie Le Bastard and Manu Vandijck; learn about the past, present and future of this exciting place... and the current state of neuro testing in general 👉 https://lnkd.in/enzJM_QV 👏" "reactions_count" => 34 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 23:47:38" "deleted" => 1 ] [ "id" => 673811513 "company_id" => 3731879 "urn" => "urn:li:activity:7038750115347464192" "followers" => null "date" => "1y" "description" => """ Meet Dr. Charlotte Teunissen, Professor in Neurochemistry, and her lifelong friend Christa Reinhoudt, diagnosed with Alzheimer's disease in Charlotte's own laboratory 👉 https://lnkd.in/eV363SQN\n \n Hear them talk about the difficult acceptance of the diagnosis and\n how to live with the disease. And hear about partnering in the search for earlier and better diagnostic testing solutions. 🔬 👩🔬\n \n 👋 ADx NeuroSciences Ann De Vos Amsterdam UMC Amsterdam UMC - Alzheimer Center Amsterdam #FNCE #alzheimersdisease """ "reactions_count" => 196 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 1 ] [ "id" => 673811514 "company_id" => 3731879 "urn" => "urn:li:activity:7226940927984971776" "followers" => null "date" => "5d" "description" => "We're #hiring a new Senior Research Associate in Sunnyvale, California. Apply today or share this post with your network." "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 1 ] [ "id" => 673811515 "company_id" => 3731879 "urn" => "urn:li:activity:7224085271766597632" "followers" => null "date" => "1w" "description" => "Aquí estamos, en una nueva sesión de la #ADLM para darle la bienvenida a todos nuestros clientes y distribuidores de Latinoamérica; visítenos en el booth #1032, para conversar sobre las novedades que #Fujirebio tiene para su laboratorio: pruebas de neuro para detección de #Alzheimer, genotipado de #HPV, pruebas confirmatorias, entre otras. ¡te esperamos!" "reactions_count" => 44 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 1 ] [ "id" => 673811516 "company_id" => 3731879 "urn" => "urn:li:activity:7224014165848268800" "followers" => null "date" => "1w" "description" => """ 📰 Biogen, Beckman Coulter and Fujirebio announced today a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialize new tests for tau pathology in Alzheimer’s disease (AD).\n \n Through this collaboration, the companies will work to identify new blood-based biomarkers and advance known blood-based biomarkers for tau pathology in AD.\n \n Read more here 👉 https://lnkd.in/gzr3q8et """ "reactions_count" => 199 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 1 ] [ "id" => 673811517 "company_id" => 3731879 "urn" => "urn:li:activity:7222560177013600256" "followers" => null "date" => "2w" "description" => """ 📰 Tokyo, Japan, Malvern PA, and Gent, Belgium, July 26, 2024 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced today the availability of the Lumipulse® G GFAP assay for the fully automated, random-access LUMIPULSE® G immunoassay systems. \n \n The Research Use Only (RUO) assay is now available in the United States and will be available in Japan, Europe and other regions* as of September this year. The Chemiluminescent Enzyme Immunoassay (CLEIA) test allows for the quantitative measurement of glial fibrillary acidic protein (GFAP) in human plasma and serum in just 35 minutes. \n \n Learn more 👉 https://bit.ly/3LwJ5SS """ "reactions_count" => 103 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 1 ] [ "id" => 673811518 "company_id" => 3731879 "urn" => "urn:li:activity:7219295826274123776" "followers" => null "date" => "3w" "description" => """ We will be at ADLM 2024 in Chicago! Visit us at our booth, 1032.\n \n Please contact us for more information on our contract, development and manufacturing capabilities.\n \n Learn more👉 https://bit.ly/3zHdgEr """ "reactions_count" => 38 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 1 ] [ "id" => 673811519 "company_id" => 3731879 "urn" => "urn:li:activity:7218965578894487552" "followers" => null "date" => "3w" "description" => """ 📰 San Diego, CA, Tokyo, Japan and Malvern, PA -- (BUSINESS WIRE), July 12th, 2024 – Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced earlier this week the attainment of the first milestone in a strategic partnership to advance the development of biomarkers for Alzheimer’s disease (AD) and other neurodegenerative conditions. This milestone marks a key achievement which provides Fujirebio access to clinical samples and data collected as part of the ongoing Phase 3 Alzheimer’s disease study, POLARIS-AD.\n \n Learn more 👉 https://bit.ly/4f0cUsz """ "reactions_count" => 99 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 1 ] [ "id" => 673811520 "company_id" => 3731879 "urn" => "urn:li:activity:7217560305130713089" "followers" => null "date" => "1mo" "description" => "We're #hiring a new Senior Research Associate in Sunnyvale, California. Apply today or share this post with your network." "reactions_count" => 13 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 1 ] [ "id" => 673811521 "company_id" => 3731879 "urn" => "urn:li:activity:7217511184130863104" "followers" => null "date" => "1mo" "description" => """ We will be at AAIC 2024 in Philadelphia!\n \n Schedule a meeting with us or stop by our booth to learn about our high-quality assays for assessing neurodegenerative disorders. \n \n 👉 https://bit.ly/4bxAqdu or email us at neuro@fdi.com. \n \n We look forward to meeting with you. #AAIC24 """ "reactions_count" => 44 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 1 ] [ "id" => 673811522 "company_id" => 3731879 "urn" => "urn:li:activity:7214915162162540545" "followers" => null "date" => "1mo" "description" => """ 🔊 We are ready for a new adventure🔊\n \n 🧬We have installed our first fully automated, traceable and userfriendly system that combines the extraction and preparation of the Masmec S.p.A. - Biomed division OMNIA LH 75 Pro with the real time detection and interpretation of the BMS Mic qPCR🧬\n \n Our Giulia Alfedi completed the installation and training at our first customer who will use our HPV unique solution: Self-screen B.V. HPV screening (HPV Risk Assay), HPV genotyping (INNOLiPA HPV genotyping Extra II) and methylation analysis (Precursor-M+).\n \n 🔬 The Fujirebio Europe Art of Accuracy in everyday life and at the service of precision medicine! \n \n Rikkert Maertens Rebecca Millecamps Christian Lindknud, MSc Michelle Meijer Vincenzo Costantino MICHELE MARFORI Maria Assunta Melone Guido Marelli Iosto Doneddu """ "reactions_count" => 67 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 1 ] [ "id" => 710622322 "company_id" => 3731879 "urn" => "urn:li:activity:7238997690364096512" "followers" => null "date" => "9h" "description" => """ Research and Development Scientist sökes till Fujirebio Diagnostics\n \n Dina huvudsakliga arbetsuppgifter blir att deltaga i prestandautvärdering av IVD tester utvecklade för ett automatiserat IVD system. Du kan också komma att arbeta i projekt med utveckling, processoptimering och karaktärisering av immunoreagens för automatiserat IVD system.\n \n Anställningen är en tillsvidareanställning med en omfattning på 100 % dagtid. Tillträdesdatum är 2024-11-01 eller enligt överenskommelse.\n \n Ansök redan nu eller senast 2024–09–24 med personligt brev och CV. \n Du hittar mer information och ansöker via https://lnkd.in/dZBTUhMf """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 710622323 "company_id" => 3731879 "urn" => "urn:li:activity:7236419520813232129" "followers" => null "date" => "1w" "description" => "We're #hiring a new Associate Scientist - Assay Development in Sunnyvale, California. Apply today or share this post with your network." "reactions_count" => 9 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 710622324 "company_id" => 3731879 "urn" => "urn:li:activity:7233192331422633984" "followers" => null "date" => "2w" "description" => """ Join Our Team as a Business Officer!\n \n 📋 Do you want to play a crucial role in coordinating and managing contract work to support our growing global business with pharma and IVD companies?\n \n 🤝 Would you like to act as a liaison between the ADx team and our valuable network of partners?\n \n 🧠 Do you thrive in a dynamic environment and want to be part of an enthusiastic team specialized in the Neuro field?\n \n If so, we invite you to apply for our Business Officer position: https://lnkd.in/e9C6Wteh \n \n Take the next step in your career and become an integral part of our innovative team! 🌟 """ "reactions_count" => 26 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 710622325 "company_id" => 3731879 "urn" => "urn:li:activity:7232110385842073601" "followers" => null "date" => "2w" "description" => "Bill Gates visited the Indiana University School of Medicine, touring the laboratory to learn more about their Alzheimer’s Program. He is pictured below standing in front of Fujirebio Diagnostic’s LUMIPULSE® G1200 Analyzer." "reactions_count" => 82 "comments_count" => 2 "reshared_post_author" => "Indiana University School of Medicine" "reshared_post_author_url" => "https://www.linkedin.com/school/indiana-university-school-of-medicine" "reshared_post_author_headline" => null "reshared_post_description" => "This afternoon, we welcomed Bill Gates as he toured labs at the Indiana University School of Medicine and met with key faculty members to learn more about the expansive Alzheimer’s disease research happening right here in Indianapolis." "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 710622326 "company_id" => 3731879 "urn" => "urn:li:activity:7226940927984971776" "followers" => null "date" => "1mo" "description" => "We're #hiring a new Senior Research Associate in Sunnyvale, California. Apply today or share this post with your network." "reactions_count" => 13 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 710622327 "company_id" => 3731879 "urn" => "urn:li:activity:7224085271766597632" "followers" => null "date" => "1mo" "description" => "Aquí estamos, en una nueva sesión de la #ADLM para darle la bienvenida a todos nuestros clientes y distribuidores de Latinoamérica; visítenos en el booth #1032, para conversar sobre las novedades que #Fujirebio tiene para su laboratorio: pruebas de neuro para detección de #Alzheimer, genotipado de #HPV, pruebas confirmatorias, entre otras. ¡te esperamos!" "reactions_count" => 48 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 710622328 "company_id" => 3731879 "urn" => "urn:li:activity:7224014165848268800" "followers" => null "date" => "1mo" "description" => """ 📰 Biogen, Beckman Coulter and Fujirebio announced today a collaboration to potentially identify and develop blood-based biomarkers for tau pathology in the brain and to potentially clinically advance and potentially commercialize new tests for tau pathology in Alzheimer’s disease (AD).\n \n Through this collaboration, the companies will work to identify new blood-based biomarkers and advance known blood-based biomarkers for tau pathology in AD.\n \n Read more here 👉 https://lnkd.in/gzr3q8et """ "reactions_count" => 222 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 710622329 "company_id" => 3731879 "urn" => "urn:li:activity:7222560177013600256" "followers" => null "date" => "1mo" "description" => """ 📰 Tokyo, Japan, Malvern PA, and Gent, Belgium, July 26, 2024 – H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio announced today the availability of the Lumipulse® G GFAP assay for the fully automated, random-access LUMIPULSE® G immunoassay systems. \n \n The Research Use Only (RUO) assay is now available in the United States and will be available in Japan, Europe and other regions* as of September this year. The Chemiluminescent Enzyme Immunoassay (CLEIA) test allows for the quantitative measurement of glial fibrillary acidic protein (GFAP) in human plasma and serum in just 35 minutes. \n \n Learn more 👉 https://bit.ly/3LwJ5SS """ "reactions_count" => 112 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 710622330 "company_id" => 3731879 "urn" => "urn:li:activity:7219295826274123776" "followers" => null "date" => "1mo" "description" => """ We will be at ADLM 2024 in Chicago! Visit us at our booth, 1032.\n \n Please contact us for more information on our contract, development and manufacturing capabilities.\n \n Learn more👉 https://bit.ly/3zHdgEr """ "reactions_count" => 39 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] [ "id" => 710622331 "company_id" => 3731879 "urn" => "urn:li:activity:7218965578894487552" "followers" => null "date" => "1mo" "description" => """ 📰 San Diego, CA, Tokyo, Japan and Malvern, PA -- (BUSINESS WIRE), July 12th, 2024 – Fujirebio Holdings Inc., its wholly-owned subsidiary Fujirebio Diagnostics, Inc., and AriBio Co., Ltd. announced earlier this week the attainment of the first milestone in a strategic partnership to advance the development of biomarkers for Alzheimer’s disease (AD) and other neurodegenerative conditions. This milestone marks a key achievement which provides Fujirebio access to clinical samples and data collected as part of the ongoing Phase 3 Alzheimer’s disease study, POLARIS-AD.\n \n Learn more 👉 https://bit.ly/4f0cUsz """ "reactions_count" => 105 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-09 23:22:25" "deleted" => 0 ] ] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4830 …} -companyTags: Doctrine\ORM\PersistentCollection {#4832 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4834 …} -users: Doctrine\ORM\PersistentCollection {#4836 …} -logoImageName: "20250226144424-fujiribio-logo-67bf1ab881590567764182.png" -coverImageName: "20250227162811-fujirebio-favicon-67c0848b9407f091454059.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4838 …} -tagline: "Führend in der In-vitro-Diagnostik – Innovationen in Biomarkern für eine bessere Gesundheitsversorgung weltweit" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4840 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4842 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4844 …} -industry: "Fujirebio" -size: "250" -address1: null -address2: null -city: null -postalCode: null -state: null -country: "Belgium" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4846 …} #createdAt: DateTime @1740062044 {#4807 date: 2025-02-20 14:34:04.0 UTC (+00:00) } #updatedAt: DateTime @1750924965 {#4806 date: 2025-06-26 08:02:45.0 UTC (+00:00) } } App\Entity\Company {#4850 -id: 29 -name: "GE Medical Systems Information Technologies GmbH" -website: "https://gehealthcare.de" -description: null -externalId: "94036801" -details: [ "id" => 94036801 "url" => "https://www.linkedin.com/company/ge-medical-systems-information-technologies-gmbh" "hash" => "4dd54039a0484d3fea7e8a1258101e53" "name" => "GE Medical Systems Information Technologies GmbH" "website" => "http://gehealthcare.de" "size" => null "industry" => null "description" => null "followers" => 1 "founded" => null "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://static.licdn.com/aero-v1/sc/h/cs8pjfgyw96g44ln9r7tct85f" "created" => "2023-09-18 23:55:13" "last_updated" => "2025-02-06 05:28:57" "last_response_code" => 200 "type" => null "headquarters_new_address" => "Freiburg, Badenwürttemberg" "employees_count" => null "headquarters_country_restored" => null "headquarters_country_parsed" => "Germany" "company_shorthand_name" => "ge-medical-systems-information-technologies-gmbh" "company_shorthand_name_hash" => "8f72ee1fae82f2d66739b00e53f22c10" "canonical_url" => "https://de.linkedin.com/company/ge-medical-systems-information-technologies-gmbh" "canonical_hash" => "16269684aa03a570e1f32ad27416b848" "canonical_shorthand_name" => "ge-medical-systems-information-technologies-gmbh" "canonical_shorthand_name_hash" => "8f72ee1fae82f2d66739b00e53f22c10" "deleted" => 0 "last_updated_ux" => 1738819736 "source_id" => 95660747 "company_affiliated_collection" => [] "company_also_viewed_collection" => [] "company_crunchbase_info_collection" => [] "company_featured_employees_collection" => [] "company_featured_investors_collection" => [] "company_funding_rounds_collection" => [] "company_locations_collection" => [ [ "id" => 136868386 "company_id" => 94036801 "location_address" => "Freiburg, Badenwürttemberg 79111, DE" "is_primary" => 0 "created" => "2023-09-18 23:55:12" "last_updated" => "2025-02-06 05:28:56" "deleted" => 0 ] ] "company_similar_collection" => [] "company_specialties_collection" => [] "company_stock_info_collection" => [] "company_updates_collection" => [] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4851 …} -companyTags: Doctrine\ORM\PersistentCollection {#4853 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4855 …} -users: Doctrine\ORM\PersistentCollection {#4857 …} -logoImageName: "20250226144450-ge-healthcare-logo-67bf1ad2d0a6e659776234.png" -coverImageName: "20250227162830-ge-healthcare-favicon-67c0849e152cc113910996.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4859 …} -tagline: "Fortschrittliche Medizintechnologien für präzisere Diagnosen und verbesserte Patientenversorgung weltweit" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4861 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4863 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4865 …} -industry: "" -size: null -address1: null -address2: null -city: null -postalCode: null -state: null -country: "Germany" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4867 …} #createdAt: DateTime @1740062672 {#4828 date: 2025-02-20 14:44:32.0 UTC (+00:00) } #updatedAt: DateTime @1750924989 {#4827 date: 2025-06-26 08:03:09.0 UTC (+00:00) } } App\Entity\Company {#4871 -id: 30 -name: "Idorsia Pharmaceuticals Ltd" -website: "https://idorsia.com" -description: """ Bei Idorsia haben wir ambitionierte Ziele – wir haben mehr Ideen, sehen mehr Möglichkeiten und wollen mehr Patienten helfen. Um diesen Zielen gerecht zu werden, möchten wir Idorsia zu einem führenden biopharmazeutischen Unternehmen mit einem leistungsfähigen wissenschaftlichen Kern weiterentwickeln.\n \n \n \n Am Hauptsitz des Unternehmens bei Basel in der Schweiz hat sich Idorsia auf die Entdeckung, Entwicklung und Kommerzialisierung von niedermolekularen Wirkstoffen zur Erschließung neuer Behandlungsmöglichkeiten spezialisiert. Mit einem umfassenden Portfolio innovativer Arzneimittel in der Pipeline, einem erfahrenen Team von Experten aller Disziplinen vom Labor bis zur Klinik, hochmodernen Forschungseinrichtungen und einer soliden Bilanzstruktur verfügt Idorsia über ideale Voraussetzungen, um Patienten Innovationen aus der Forschung und Entwicklung zugänglich zu machen. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4872 …} -companyTags: Doctrine\ORM\PersistentCollection {#4874 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4876 …} -users: Doctrine\ORM\PersistentCollection {#4878 …} -logoImageName: "20250226144537-artboard-1-67bf1b014315f722703707.png" -coverImageName: "20250227162859-favicon-128x128-2-67c084bb83c5f318122268.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4880 …} -tagline: "Innovationen in der biopharmazeutischen Forschung für neue Behandlungsmöglichkeiten und bessere Patientenversorgung" -contactEmail: "" -phone: "41588440000" -streamUrl: "https://youtu.be/cwpLAsdXfWA" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4882 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4884 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4886 …} -industry: "" -size: "" -address1: "Hegenheimermattweg 91" -address2: "" -city: "Allschwil" -postalCode: "4123" -state: "" -country: "" -socialLinkedin: "https://www.linkedin.com/company/11051230" -socialX: "https://twitter.com/Idorsia" -socialFacebook: "https://www.facebook.com/idorsia" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4888 …} #createdAt: DateTime @1740063464 {#4849 date: 2025-02-20 14:57:44.0 UTC (+00:00) } #updatedAt: DateTime @1750925010 {#4848 date: 2025-06-26 08:03:30.0 UTC (+00:00) } } App\Entity\Company {#4892 -id: 31 -name: "Inspire Medical Systems, Inc." -website: "https://inspiresleep.ch" -description: """ Inspire Medical Systems, Inc. ist ein innovatives medizinisches Unternehmen mit Sitz in Minneapolis, MN, das sich zum Ziel gesetzt hat, den Standard für die Behandlung der obstruktiven Schlafapnoe zu verbessern und neu zu definieren.\n \n \n \n Bei Inspire setzen wir uns zu 100 % für unsere Patienten ein. Wir glauben an den Aufbau enger Beziehungen zu Ärzten und medizinischem Fachpersonal, damit wir unsere Patienten bei der Bewältigung dieser schwierigen Erkrankung direkt unterstützen und für sie eintreten können. Wir haben ein tiefes Verständnis für die Komplexität und die Schwierigkeiten, die eine obstruktive Schlafapnoe mit sich bringt, und sind daher stets bestrebt, jedem Patienten die Hilfe zukommen zu lassen, die er benötigt.\n \n \n \n Unsere revolutionäre Technologie ist das erste von der FDA zugelassene Gerät für obstruktive Schlafapnoe, das die eigentliche Ursache der Schlafapnoe behandelt, indem es im Inneren des Körpers mit dem natürlichen Atmungsprozess des Patienten zusammenarbeitet. Unsere sichere und nachweislich wirksame Technologie verbessert die Lebensqualität, indem sie denjenigen, die mit ihrer derzeitigen Behandlung der obstruktiven Schlafapnoe zu kämpfen haben, einen lebensverändernden Schlaf ermöglicht.\n \n \n \n Inspire wurde im Jahr 2007 gegründet, als die Inspire-Technologie, sowie das technologische Portfolio und Patente von Medtronic (NYSE: MDT) ausgegliedert wurden.\n \n \n \n Besuchen Sie uns auch auf Youtube » oder Instagram »\n \n www.InspireSleep.ch\n \n www.InspireSleep.com\n \n Inspire Therapie – Schlafapnoe-Behandlung ohne CPAP-Maske """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4893 …} -companyTags: Doctrine\ORM\PersistentCollection {#4895 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4897 …} -users: Doctrine\ORM\PersistentCollection {#4899 …} -logoImageName: "20251009122253-logo-inspire-002--68e78cfdf2cc1426035122.png" -coverImageName: "20250227162937-images-1--67c084e1c659f152178725.jpeg" -companyProducts: Doctrine\ORM\PersistentCollection {#4901 …} -tagline: "Revolutionäre Technologie zur Behandlung der obstruktiven Schlafapnoe für eine verbesserte Lebensqualität" -contactEmail: "sandrabonnard@inspiresleep.com" -phone: null -streamUrl: "https://www.youtube.com/embed/eB2LyB7JDoA" -streamType: "YOUTUBE" -followers: Doctrine\ORM\PersistentCollection {#4903 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4905 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4907 …} -industry: "" -size: "" -address1: "Neuer Wall 80" -address2: "" -city: "Hamburg" -postalCode: "20354" -state: "" -country: "DE" -socialLinkedin: "https://www.linkedin.com/company/inspire-medical-systems-eu" -socialX: "" -socialFacebook: "https://www.facebook.com/inspiresleepCH" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4909 …} #createdAt: DateTime @1740063960 {#4870 date: 2025-02-20 15:06:00.0 UTC (+00:00) } #updatedAt: DateTime @1760005374 {#4869 date: 2025-10-09 10:22:54.0 UTC (+00:00) } } App\Entity\Company {#4913 -id: 32 -name: "Ipsen Pharma Schweiz GmbH" -website: "https://ipsen.ch" -description: """ Ipsen ist ein führendes, global agierendes, mittelständisches Biopharmaunternehmen mit Fokus auf der Entwicklung und dem Vertrieb transformativer Medikamente in den Therapiebereichen Onkologie, Neurowissenschaften und seltene Erkrankungen. \n \n Wir widmen uns der Verlängerung und Verbesserung des Lebens unserer Patient:innen und sind immer auf der Suche nach neuen Lösungen für medizinische Herausforderungen. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4914 …} -companyTags: Doctrine\ORM\PersistentCollection {#4916 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4918 …} -users: Doctrine\ORM\PersistentCollection {#4920 …} -logoImageName: "20250226144636-logo-ipsen-rgb-67bf1b3c152c0106405085.png" -coverImageName: "20250227162958-ipsen-favicon-67c084f6afba9439591221.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4922 …} -tagline: "Globale Innovationen in Onkologie, Neurowissenschaften und seltenen Erkrankungen für eine bessere Lebensqualität" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4924 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4926 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4928 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4930 …} #createdAt: DateTime @1740064196 {#4891 date: 2025-02-20 15:09:56.0 UTC (+00:00) } #updatedAt: DateTime @1750925079 {#4890 date: 2025-06-26 08:04:39.0 UTC (+00:00) } } App\Entity\Company {#4934 -id: 33 -name: "Janssen-Cilag AG" -website: "https://jmc.link" -description: """ Bei Janssen arbeiten wir daran, eine Welt zu schaffen, in der Krankheiten der Vergangenheit angehören. Wir arbeiten unermüdlich daran, diesen Zukunftstraum für Patienten überall auf der Welt Wirklichkeit werden zu lassen, in dem wir Krankheiten mit Hilfe der Wissenschaft bekämpfen, den Zugang zu neuen Behandlungsmöglichkeiten verbessern und den Menschen neue Hoffnung geben, Dabei konzentrieren wir uns auf die medizinischen Bereiche, in denen wir am meisten bewirken können: Herz-, Kreislauf- und Stoffwechselerkrankungen, Immunomolgie, Infektionskrankheiten und Impfstoffe, Neurowissenschaften, Onkologie und pulmonale Hypertonie. \n \n Mehr Informationen finden Sie unter:\n \n www.janssen.com/switzerland """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4935 …} -companyTags: Doctrine\ORM\PersistentCollection {#4937 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4939 …} -users: Doctrine\ORM\PersistentCollection {#4941 …} -logoImageName: "20250227163031-janssen-logo-67c08517abe27691146246.png" -coverImageName: "20250227163032-logo-janssen-icon-1024-67c08518129d3277469812.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4943 …} -tagline: "Wissenschaftlich getriebene Innovationen für eine Zukunft ohne Krankheiten – Fortschritte in Onkologie, Neurowissenschaften und mehr" -contactEmail: "ajuhasdu@its.jnj.com" -phone: "41763584720" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4945 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4947 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4949 …} -industry: "" -size: "" -address1: "Gubelstrasse 34 " -address2: "" -city: "Zug" -postalCode: "6300" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4951 …} #createdAt: DateTime @1740064515 {#4912 date: 2025-02-20 15:15:15.0 UTC (+00:00) } #updatedAt: DateTime @1750925100 {#4911 date: 2025-06-26 08:05:00.0 UTC (+00:00) } } App\Entity\Company {#4955 -id: 34 -name: "Jazz Pharmaceuticals" -website: "https://jazzpharma.com" -description: """ Wir sind Jazz\n \n Wir konzentrieren uns auf die Entwicklung von lebensverändernden Arzneimitteln für Menschen mit schweren Erkrankungen – die oft wenige bis gar keine Optionen haben – und leisten damit einen Beitrag zu mehr Lebensqualität. Durch das Umwandeln von biopharmazeutischen Entdeckungen in neuartige Arzneimittel geben wir Menschen weltweit die Möglichkeit, ihre Optionen neu zu definieren – und die „kleinen Siege“ zu feiern.\n \n Unser Ziel: Mit Innovationen das Leben von Patienten und ihren Angehörigen verändern.\n \n Jazz in der Neurologie\n \n Wir arbeiten an der Bereitstellung von Therapien und Unterstützung für Patienten, die an schweren, degenerativen neurologischen Erkrankungen leiden.\n \n Unser Fokus:\n • Seltene, schwere Epilepsie mit Beginn im Kindesalter \n • Epilepsie mit myoklonisch-atonischen Anfällen (EMAS)\n • Essentieller Tremor und Spastik aufgrund von Multipler Sklerose und Rückenmarksverletzungen \n • PTBS (posttraumatische Belastungsstörung) \n • Autismus-Spektrum-Störung (ASS)\n • Neonatale ischämische Enzephalopathie \n • Neuropsychiatrie \n • Narkolepsie und Schlafstörungen """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4956 …} -companyTags: Doctrine\ORM\PersistentCollection {#4958 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4960 …} -users: Doctrine\ORM\PersistentCollection {#4962 …} -logoImageName: "20250227163055-jazz-pharmaceuticals3676-67c0852f68c0a361578441.jpg" -coverImageName: "20250227163055-jazz-a825d5fe-67c0852fd85d2967508632.png" -companyProducts: Doctrine\ORM\PersistentCollection {#4964 …} -tagline: "" -contactEmail: "Katharina.Boner@jazzpharma.com" -phone: "41799119998" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#4966 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4968 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4970 …} -industry: "" -size: "" -address1: "Grafenauweg 8" -address2: "" -city: "Zug" -postalCode: "6300" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4972 …} #createdAt: DateTime @1740064835 {#4933 date: 2025-02-20 15:20:35.0 UTC (+00:00) } #updatedAt: DateTime @1750925129 {#4932 date: 2025-06-26 08:05:29.0 UTC (+00:00) } } App\Entity\Company {#4976 -id: 35 -name: "Löwenstein Medical Schweiz AG" -website: "https://loewensteinmedical.com/ch-de/" -description: """ In Zusammenarbeit mit weltweit führenden Herstellern ist Löwenstein Medical einer der Marktführer in der Schlafmedizin und entwickelt seit Jahrzehnten dafür maßgeschneiderte, verlässliche Technologien. Dabei stehen Sicherheit, Therapieerfolg und Bedienungskomfort im Mittelpunkt. \n \n Das Produktangebot von Löwenstein Medical zur Diagnose und Behandlung der Schlafapnoe repräsentiert ein breites Spektrum moderner Analyse- und Therapiegeräte, welches praktisch alle der derzeit bekannten Beatmungstechniken umfasst, sowie ein komplettes Sortiment von Atemmasken und Zubehörartikeln. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4977 …} -companyTags: Doctrine\ORM\PersistentCollection {#4979 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#4981 …} -users: Doctrine\ORM\PersistentCollection {#4983 …} -logoImageName: "20250227163244-lm-logo-rgb-300-67c0859ce9330718878028.jpg" -coverImageName: "20250227163245-logo-loewenstein-gruppe-67c0859d65396032943086.jpg" -companyProducts: Doctrine\ORM\PersistentCollection {#4985 …} -tagline: "Innovative Technologien für eine erfolgreiche Schlafapnoe-Therapie" -contactEmail: "Linda.Strub@loewensteinmedical.ch" -phone: "41564164111" -streamUrl: "https://www.youtube.com/@LoewensteinMedicalDeutschland" -streamType: "YOUTUBE" -followers: Doctrine\ORM\PersistentCollection {#4987 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#4989 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#4991 …} -industry: "" -size: "" -address1: "Seestrasse 14 b" -address2: "" -city: "Neuenhof" -postalCode: "5432" -state: "" -country: "CH" -socialLinkedin: "https://ch.linkedin.com/company/l%C3%B6wenstein-medical-schweiz-ag?trk=similar-pages" -socialX: "" -socialFacebook: "https://www.facebook.com/loewensteinmedical" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#4993 …} #createdAt: DateTime @1740065144 {#4954 date: 2025-02-20 15:25:44.0 UTC (+00:00) } #updatedAt: DateTime @1759999710 {#4953 date: 2025-10-09 08:48:30.0 UTC (+00:00) } } App\Entity\Company {#4997 -id: 36 -name: "Lungenliga Schweiz" -website: "https://lungenliga.ch" -description: """ Seit 120 Jahren setzt sich die Lungenliga dafür ein, dass Menschen mit Lungen- und Atemwegserkrankungen möglichst selbständig und ohne Beschwerden leben können. \n \n Die Lungenliga ist eine nationale, nicht gewinnorientierte Gesundheitsorganisation. Sie engagiert sich in der Gesundheitsförderung und Prävention, bildet Fachpersonen aus und fördert Forschungsprojekte.\n \n Die Lungenliga begleitet über 114 000 Patientinnen und Patienten an 61 Standorten in der ganzen Schweiz. Die 17 kantonalen und regionalen Lungenligen und die Dachorganisation Lungenliga Schweiz beschäftigen insgesamt rund 800 Mitarbeitende. """ -externalId: "8375742" -details: [ "id" => 8375742 "url" => "https://www.linkedin.com/company/lungenliga-schweiz" "hash" => "7361131c909e8a693665d0f8f0ece7a8" "name" => "Lungenliga Schweiz" "website" => "http://www.lungenliga.ch" "size" => "501-1,000 employees" "industry" => "Hospitals and Health Care" "description" => """ Seit 120 Jahren setzt sich die Lungenliga dafür ein, dass Menschen mit Lungen- und Atemwegserkrankungen möglichst selbständig und ohne Beschwerden leben können. \n \n Die Lungenliga ist eine nationale, nicht gewinnorientierte Gesundheitsorganisation. Sie engagiert sich in der Gesundheitsförderung und Prävention, bildet Fachpersonen aus und fördert Forschungsprojekte.\n \n Die Lungenliga begleitet über 114 000 Patientinnen und Patienten an 61 Standorten in der ganzen Schweiz. Die 17 kantonalen und regionalen Lungenligen und die Dachorganisation Lungenliga Schweiz beschäftigen insgesamt rund 800 Mitarbeitende. """ "followers" => 1952 "founded" => 1903 "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://media.licdn.com/dms/image/v2/C4D0BAQG0fJxpc2e2AA/company-logo_200_200/company-logo_200_200/0/1630562431239/lungenliga_schweiz_logo?e=2147483647&v=beta&t=SsCBz9iTpR_PcqpKQ4uMctAvSn6X4gUYMIizI6DL2MQ" "created" => "2016-06-25 07:40:10" "last_updated" => "2025-02-06 18:17:30" "last_response_code" => 200 "type" => "Nonprofit" "headquarters_new_address" => "Köniz, Berne" "employees_count" => 52 "headquarters_country_restored" => "Switzerland" "headquarters_country_parsed" => "Switzerland" "company_shorthand_name" => "lungenliga-schweiz" "company_shorthand_name_hash" => "5bfcc139b7c0f6f8b7724dbc4cf40b0f" "canonical_url" => "https://ch.linkedin.com/company/lungenliga-schweiz" "canonical_hash" => "d3c3d1266cd4cf5a65d22f2d48135848" "canonical_shorthand_name" => "lungenliga-schweiz" "canonical_shorthand_name_hash" => "5bfcc139b7c0f6f8b7724dbc4cf40b0f" "deleted" => 0 "last_updated_ux" => 1738865849 "source_id" => 3848289 "company_affiliated_collection" => [] "company_also_viewed_collection" => [ [ "id" => 31526247 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/krebsliga-schweiz" "viewed_company_id" => null "created" => "2016-06-25 07:40:10" "last_updated" => "2018-03-12 09:31:37" "deleted" => 1 ] [ "id" => 31526248 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/caritas-schweiz" "viewed_company_id" => null "created" => "2016-06-25 07:40:10" "last_updated" => "2016-12-12 11:15:09" "deleted" => 1 ] [ "id" => 31526249 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/stiftung-kinderdorf-pestalozzi" "viewed_company_id" => null "created" => "2016-06-25 07:40:10" "last_updated" => "2016-12-12 11:15:09" "deleted" => 1 ] [ "id" => 31526250 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/schweizerisches-rotes-kreuz" "viewed_company_id" => null "created" => "2016-06-25 07:40:10" "last_updated" => "2018-08-08 09:00:34" "deleted" => 1 ] [ "id" => 31526251 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/sdv-schweizer-dialogmarketing-verband" "viewed_company_id" => null "created" => "2016-06-25 07:40:10" "last_updated" => "2016-12-12 11:15:09" "deleted" => 1 ] [ "id" => 31526252 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/aetas-kinderstiftung" "viewed_company_id" => null "created" => "2016-06-25 07:40:10" "last_updated" => "2016-12-12 11:15:09" "deleted" => 1 ] [ "id" => 47051142 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/hirslanden" "viewed_company_id" => null "created" => "2016-12-12 11:15:08" "last_updated" => "2017-08-06 16:18:12" "deleted" => 1 ] [ "id" => 47051143 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/inselspital-bern" "viewed_company_id" => null "created" => "2016-12-12 11:15:08" "last_updated" => "2017-08-06 16:18:12" "deleted" => 1 ] [ "id" => 47051144 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/kantonsspital-aarau-ag" "viewed_company_id" => null "created" => "2016-12-12 11:15:08" "last_updated" => "2017-01-26 15:22:12" "deleted" => 1 ] [ "id" => 47051145 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/local-ch-und-search-ch" "viewed_company_id" => null "created" => "2016-12-12 11:15:08" "last_updated" => "2017-01-26 15:22:12" "deleted" => 1 ] [ "id" => 75868242 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/lungenliga-beider-basel" "viewed_company_id" => null "created" => "2017-01-26 15:22:11" "last_updated" => "2019-08-01 20:52:56" "deleted" => 1 ] [ "id" => 75868243 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/klinische-sozialarbeit" "viewed_company_id" => null "created" => "2017-01-26 15:22:11" "last_updated" => "2017-08-06 16:18:12" "deleted" => 1 ] [ "id" => 98026562 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/medinf.ch" "viewed_company_id" => null "created" => "2017-08-06 16:18:11" "last_updated" => "2017-12-03 13:36:00" "deleted" => 1 ] [ "id" => 98026563 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/verein-lunge-z%C3%BCrich" "viewed_company_id" => null "created" => "2017-08-06 16:18:11" "last_updated" => "2017-12-03 13:36:00" "deleted" => 1 ] [ "id" => 98026564 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/lungenliga-luzern-zug" "viewed_company_id" => null "created" => "2017-08-06 16:18:11" "last_updated" => "2019-02-17 15:07:57" "deleted" => 1 ] [ "id" => 118901294 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/spital-sts-ag" "viewed_company_id" => null "created" => "2017-12-03 13:35:59" "last_updated" => "2018-08-08 09:00:34" "deleted" => 1 ] [ "id" => 118901295 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/inselgruppe" "viewed_company_id" => null "created" => "2017-12-03 13:35:59" "last_updated" => "2018-03-12 09:31:37" "deleted" => 1 ] [ "id" => 131851688 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/bundesamt-f-r-gesundheit" "viewed_company_id" => null "created" => "2018-03-12 09:31:37" "last_updated" => "2019-02-17 15:07:57" "deleted" => 1 ] [ "id" => 131851690 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/office-of-governor-arnold-schwarzenegger" "viewed_company_id" => null "created" => "2018-03-12 09:31:37" "last_updated" => "2018-08-08 09:00:34" "deleted" => 1 ] [ "id" => 153086576 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/verein-lunge-z%C3%BCrich" "viewed_company_id" => null "created" => "2018-08-08 09:00:34" "last_updated" => "2018-10-01 03:27:36" "deleted" => 1 ] [ "id" => 153086577 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/krebsliga-schweiz" "viewed_company_id" => null "created" => "2018-08-08 09:00:34" "last_updated" => "2019-08-01 20:52:56" "deleted" => 1 ] [ "id" => 153086578 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/j-rg-sommer-consultant" "viewed_company_id" => null "created" => "2018-08-08 09:00:34" "last_updated" => "2018-10-01 03:27:36" "deleted" => 1 ] [ "id" => 163389526 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/promotion-sant%C3%A9-suisse" "viewed_company_id" => null "created" => "2018-10-01 03:27:36" "last_updated" => "2019-01-03 07:06:25" "deleted" => 1 ] [ "id" => 163389527 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/schweizerische-herzstiftung" "viewed_company_id" => null "created" => "2018-10-01 03:27:36" "last_updated" => "2019-08-01 20:52:56" "deleted" => 1 ] [ "id" => 181391503 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/schweizerisches-rotes-kreuz" "viewed_company_id" => null "created" => "2019-01-03 07:06:25" "last_updated" => "2019-08-01 20:52:56" "deleted" => 1 ] [ "id" => 186832451 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/sakk-schweizerische-arbeitsgemeinschaft-f%C3%BCr-klinische-krebsforschung" "viewed_company_id" => null "created" => "2019-02-17 15:07:56" "last_updated" => "2019-08-01 20:52:56" "deleted" => 1 ] [ "id" => 186832452 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/caritas-schweiz" "viewed_company_id" => null "created" => "2019-02-17 15:07:56" "last_updated" => "2019-05-28 22:51:59" "deleted" => 1 ] [ "id" => 228008812 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/copd-tv-llc" "viewed_company_id" => null "created" => "2019-05-28 22:51:59" "last_updated" => "2019-06-02 11:25:02" "deleted" => 1 ] [ "id" => 230796216 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/malteser-lungen" "viewed_company_id" => null "created" => "2019-06-02 11:25:02" "last_updated" => "2019-06-15 03:46:45" "deleted" => 1 ] [ "id" => 240608574 "company_id" => 8375742 "viewed_company_url" => "https://www.linkedin.com/company/lungenliga-luzern-zug" "viewed_company_id" => null "created" => "2019-06-15 03:46:45" "last_updated" => "2019-08-01 20:52:56" "deleted" => 1 ] [ "id" => 255319292 "company_id" => 8375742 "viewed_company_url" => "https://au.linkedin.com/company/krebsliga-schweiz" "viewed_company_id" => null "created" => "2019-08-01 20:52:56" "last_updated" => "2019-10-18 22:54:33" "deleted" => 1 ] [ "id" => 255319293 "company_id" => 8375742 "viewed_company_url" => "https://au.linkedin.com/company/lungenliga-beider-basel" "viewed_company_id" => null "created" => "2019-08-01 20:52:56" "last_updated" => "2019-10-18 22:54:33" "deleted" => 1 ] [ "id" => 255319294 "company_id" => 8375742 "viewed_company_url" => "https://au.linkedin.com/company/schweizerisches-rotes-kreuz" "viewed_company_id" => null "created" => "2019-08-01 20:52:56" "last_updated" => "2019-10-18 22:54:33" "deleted" => 1 ] [ "id" => 255319295 "company_id" => 8375742 "viewed_company_url" => "https://au.linkedin.com/company/lungenklinik-lostau-ggmbh" "viewed_company_id" => null "created" => "2019-08-01 20:52:56" "last_updated" => "2019-10-18 22:54:33" "deleted" => 1 ] [ "id" => 255319296 "company_id" => 8375742 "viewed_company_url" => "https://au.linkedin.com/company/sakk-schweizerische-arbeitsgemeinschaft-f%C3%BCr-klinische-krebsforschung" "viewed_company_id" => null "created" => "2019-08-01 20:52:56" "last_updated" => "2019-10-18 22:54:33" "deleted" => 1 ] [ "id" => 255319297 "company_id" => 8375742 "viewed_company_url" => "https://au.linkedin.com/company/schweizerische-herzstiftung" "viewed_company_id" => null "created" => "2019-08-01 20:52:56" "last_updated" => "2019-10-18 22:54:33" "deleted" => 1 ] ] "company_crunchbase_info_collection" => [] "company_featured_employees_collection" => [ [ "id" => 10047806 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/stephanie-reuter-0a3347" "created" => "2019-10-18 22:54:33" "last_updated" => "2020-01-26 08:36:30" "deleted" => 1 ] [ "id" => 10047807 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/alexdezeeuw" "created" => "2019-10-18 22:54:33" "last_updated" => "2021-05-11 20:34:27" "deleted" => 1 ] [ "id" => 10047808 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/andrea-adam" "created" => "2019-10-18 22:54:33" "last_updated" => "2020-01-26 08:36:30" "deleted" => 1 ] [ "id" => 10047809 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/katharina-von-allmen-974a561b" "created" => "2019-10-18 22:54:33" "last_updated" => "2020-01-26 08:36:30" "deleted" => 1 ] [ "id" => 33126762 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/christine-achermann-4174a534" "created" => "2020-01-26 08:36:30" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 33126763 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/mentor-arapi-27a41036" "created" => "2020-01-26 08:36:30" "last_updated" => "2020-11-21 10:38:13" "deleted" => 1 ] [ "id" => 33126765 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/jean-marie-egger-1abb7b3a" "created" => "2020-01-26 08:36:30" "last_updated" => "2021-11-30 02:25:20" "deleted" => 1 ] [ "id" => 56176568 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/fabian-putzing-07a13952" "created" => "2020-11-21 10:38:13" "last_updated" => "2021-01-11 00:33:14" "deleted" => 1 ] [ "id" => 59048001 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/thomasburgener" "created" => "2021-01-11 00:33:14" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 65258017 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/fabian-putzing-07a13952" "created" => "2021-05-11 20:34:27" "last_updated" => "2021-09-10 02:07:26" "deleted" => 1 ] [ "id" => 72635334 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/meyer-franca-36380863" "created" => "2021-09-10 02:07:26" "last_updated" => "2021-10-07 03:44:14" "deleted" => 1 ] [ "id" => 77293908 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/christophe-gut-33931353" "created" => "2021-10-07 03:44:14" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 79821887 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/meyer-franca-36380863" "created" => "2021-11-30 02:25:20" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 107237855 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/thomasburgener/en" "created" => "2022-07-22 05:36:47" "last_updated" => "2022-09-15 03:33:38" "deleted" => 1 ] [ "id" => 107237856 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/christine-achermann-4174a534/en" "created" => "2022-07-22 05:36:47" "last_updated" => "2022-09-15 03:33:38" "deleted" => 1 ] [ "id" => 107237857 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/christophe-gut-33931353/en" "created" => "2022-07-22 05:36:47" "last_updated" => "2022-09-15 03:33:38" "deleted" => 1 ] [ "id" => 107237858 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/meyer-franca-36380863/en" "created" => "2022-07-22 05:36:47" "last_updated" => "2022-09-15 03:33:38" "deleted" => 1 ] [ "id" => 131500804 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/thomasburgener" "created" => "2022-09-15 03:33:38" "last_updated" => "2022-10-16 08:08:02" "deleted" => 1 ] [ "id" => 131500805 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/monika-h%C3%A4nni-5a24611a" "created" => "2022-09-15 03:33:38" "last_updated" => "2022-10-16 08:08:02" "deleted" => 1 ] [ "id" => 131500806 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/christine-achermann-4174a534" "created" => "2022-09-15 03:33:38" "last_updated" => "2022-10-16 08:08:02" "deleted" => 1 ] [ "id" => 131500807 "company_id" => 8375742 "url" => "https://www.linkedin.com/in/christophe-gut-33931353" "created" => "2022-09-15 03:33:38" "last_updated" => "2022-10-16 08:08:02" "deleted" => 1 ] [ "id" => 150371498 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/thomasburgener/en" "created" => "2022-10-16 08:08:02" "last_updated" => "2023-06-08 02:19:15" "deleted" => 1 ] [ "id" => 150371499 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/monika-h%C3%A4nni-5a24611a/en" "created" => "2022-10-16 08:08:02" "last_updated" => "2023-06-08 02:19:15" "deleted" => 1 ] [ "id" => 150371500 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/christine-achermann-4174a534/en" "created" => "2022-10-16 08:08:02" "last_updated" => "2023-06-08 02:19:15" "deleted" => 1 ] [ "id" => 150371501 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/christophe-gut-33931353/en" "created" => "2022-10-16 08:08:02" "last_updated" => "2023-06-08 02:19:15" "deleted" => 1 ] [ "id" => 166040556 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/thomasburgener" "created" => "2023-06-08 02:19:15" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 166040557 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/monika-h%C3%A4nni-5a24611a" "created" => "2023-06-08 02:19:15" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 166040558 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/christine-achermann-4174a534" "created" => "2023-06-08 02:19:15" "last_updated" => "2023-07-17 06:46:57" "deleted" => 1 ] [ "id" => 166040559 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/meyer-franca-36380863" "created" => "2023-06-08 02:19:15" "last_updated" => "2024-08-12 08:22:37" "deleted" => 1 ] [ "id" => 182375278 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/bertschy-nicole-9b511464" "created" => "2023-07-17 06:46:57" "last_updated" => "2023-11-26 19:21:39" "deleted" => 1 ] [ "id" => 197337274 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/markus-h%C3%A4nni-00030718" "created" => "2023-11-26 19:21:39" "last_updated" => "2024-02-21 07:57:30" "deleted" => 1 ] [ "id" => 201783683 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/melody-schmid-6b72a740" "created" => "2024-02-21 07:57:30" "last_updated" => "2025-02-06 18:17:29" "deleted" => 1 ] [ "id" => 210618418 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/mixage-st%C3%A9phanie-eger-487a8839" "created" => "2024-08-12 08:22:37" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 219994834 "company_id" => 8375742 "url" => "https://ch.linkedin.com/in/michael-schwitter/en" "created" => "2025-02-06 18:17:29" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] ] "company_featured_investors_collection" => [] "company_funding_rounds_collection" => [] "company_locations_collection" => [ [ "id" => 4102361 "company_id" => 8375742 "location_address" => "Chutzenstrasse 10; Bern, CH" "is_primary" => 0 "created" => "2019-10-18 22:54:33" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 83161160 "company_id" => 8375742 "location_address" => "Chutzenstrasse 10; Bern, CH" "is_primary" => 0 "created" => "2022-07-22 05:36:47" "last_updated" => "2023-09-03 03:01:47" "deleted" => 1 ] [ "id" => 127326892 "company_id" => 8375742 "location_address" => "Chutzenstrasse 10; Bern, 3007, CH" "is_primary" => 0 "created" => "2023-09-03 03:01:47" "last_updated" => "2024-04-04 07:19:14" "deleted" => 1 ] [ "id" => 141839610 "company_id" => 8375742 "location_address" => "Sägestrasse 79; Köniz, Berne 3098, CH" "is_primary" => 0 "created" => "2024-04-04 07:19:14" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] ] "company_similar_collection" => [ [ "id" => 15524995 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/lungenliga-beider-basel" "created" => "2019-10-18 22:54:33" "last_updated" => "2020-11-21 10:38:13" "deleted" => 1 ] [ "id" => 15524996 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/krebsliga-schweiz" "created" => "2019-10-18 22:54:33" "last_updated" => "2020-11-21 10:38:13" "deleted" => 1 ] [ "id" => 15524997 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/schweizerisches-rotes-kreuz" "created" => "2019-10-18 22:54:33" "last_updated" => "2019-12-25 05:18:22" "deleted" => 1 ] [ "id" => 15524998 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/universitatsspital-zurich" "created" => "2019-10-18 22:54:33" "last_updated" => "2019-11-23 16:19:23" "deleted" => 1 ] [ "id" => 15524999 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/lungenliga-luzern-zug" "created" => "2019-10-18 22:54:33" "last_updated" => "2019-11-23 16:19:23" "deleted" => 1 ] [ "id" => 15525000 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/lungenklinik-lostau-ggmbh" "created" => "2019-10-18 22:54:33" "last_updated" => "2019-11-23 16:19:23" "deleted" => 1 ] [ "id" => 49519339 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/bag-ofsp" "created" => "2019-11-23 16:19:23" "last_updated" => "2020-07-16 01:04:37" "deleted" => 1 ] [ "id" => 49519340 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/schweizer-paraplegiker-gruppe" "created" => "2019-11-23 16:19:23" "last_updated" => "2020-01-26 08:36:30" "deleted" => 1 ] [ "id" => 49519341 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/sakk-schweizerische-arbeitsgemeinschaft-f%C3%BCr-klinische-krebsforschung" "created" => "2019-11-23 16:19:23" "last_updated" => "2019-12-25 05:18:22" "deleted" => 1 ] [ "id" => 60294344 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/lungenliga-thurgau" "created" => "2019-12-25 05:18:22" "last_updated" => "2020-04-11 04:15:30" "deleted" => 1 ] [ "id" => 60294345 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/verein-lunge-z%C3%BCrich" "created" => "2019-12-25 05:18:22" "last_updated" => "2020-02-21 16:16:48" "deleted" => 1 ] [ "id" => 73352682 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/australasian-society-for-hiv-medicine" "created" => "2020-01-26 08:36:30" "last_updated" => "2020-10-31 07:04:47" "deleted" => 1 ] [ "id" => 73352683 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/vifor-pharma" "created" => "2020-01-26 08:36:30" "last_updated" => "2020-08-25 10:40:43" "deleted" => 1 ] [ "id" => 73352684 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/lungenliga-luzern-zug" "created" => "2020-01-26 08:36:30" "last_updated" => "2020-03-18 05:38:44" "deleted" => 1 ] [ "id" => 73352685 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/gesundheitsfoerderung-schweiz" "created" => "2020-01-26 08:36:30" "last_updated" => "2020-02-21 16:16:48" "deleted" => 1 ] [ "id" => 73352687 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/kantonsspital-st.gallen" "created" => "2020-01-26 08:36:30" "last_updated" => "2020-02-21 16:16:48" "deleted" => 1 ] [ "id" => 97634189 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/schweizerische-herzstiftung" "created" => "2020-02-21 16:16:48" "last_updated" => "2020-05-29 08:01:28" "deleted" => 1 ] [ "id" => 97634190 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/medgateschweiz" "created" => "2020-02-21 16:16:48" "last_updated" => "2020-04-11 04:15:30" "deleted" => 1 ] [ "id" => 97634191 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/barmelweid" "created" => "2020-02-21 16:16:48" "last_updated" => "2020-04-11 04:15:30" "deleted" => 1 ] [ "id" => 111925404 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/verein-lunge-z%C3%BCrich" "created" => "2020-03-18 05:38:44" "last_updated" => "2020-11-21 10:38:13" "deleted" => 1 ] [ "id" => 129240049 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/gesundheitsfoerderung-schweiz" "created" => "2020-04-11 04:15:30" "last_updated" => "2020-05-29 08:01:28" "deleted" => 1 ] [ "id" => 129240050 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/pro-senectute" "created" => "2020-04-11 04:15:30" "last_updated" => "2020-05-29 08:01:28" "deleted" => 1 ] [ "id" => 129240051 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/pro-senectute-schweiz" "created" => "2020-04-11 04:15:30" "last_updated" => "2020-05-29 08:01:28" "deleted" => 1 ] [ "id" => 159893839 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/lungenliga-thurgau" "created" => "2020-05-29 08:01:28" "last_updated" => "2020-11-21 10:38:13" "deleted" => 1 ] [ "id" => 159893840 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/lungenliga-luzern-zug" "created" => "2020-05-29 08:01:28" "last_updated" => "2020-11-21 10:38:13" "deleted" => 1 ] [ "id" => 159893841 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/lungenliga-bern-ligue-pulmonaire-bernoise" "created" => "2020-05-29 08:01:28" "last_updated" => "2020-11-21 10:38:13" "deleted" => 1 ] [ "id" => 159893842 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/lungenliga-thurgau-gesch%C3%A4ftsstelle-beratungsstelle" "created" => "2020-05-29 08:01:28" "last_updated" => "2020-06-12 21:23:28" "deleted" => 1 ] [ "id" => 168723764 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/helvetas" "created" => "2020-06-12 21:23:28" "last_updated" => "2020-10-31 07:04:47" "deleted" => 1 ] [ "id" => 183131225 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/lungenliga-thurgau-gesch%C3%A4ftsstelle-beratungsstelle" "created" => "2020-07-16 01:04:37" "last_updated" => "2020-08-25 10:40:43" "deleted" => 1 ] [ "id" => 216610275 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/solothurner-spitaeler-ag---soh" "created" => "2020-08-25 10:40:43" "last_updated" => "2020-11-21 10:38:13" "deleted" => 1 ] [ "id" => 216610276 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/schweizerische-herzstiftung" "created" => "2020-08-25 10:40:43" "last_updated" => "2020-09-24 14:49:25" "deleted" => 1 ] [ "id" => 237553648 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/schweizerische-multiple-sklerose-gesellschaft" "created" => "2020-09-24 14:49:25" "last_updated" => "2020-10-31 07:04:47" "deleted" => 1 ] [ "id" => 258852960 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/bag-ofsp" "created" => "2020-10-31 07:04:47" "last_updated" => "2020-11-21 10:38:13" "deleted" => 1 ] [ "id" => 258852961 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/spitex-kanton-bern" "created" => "2020-10-31 07:04:47" "last_updated" => "2020-11-21 10:38:13" "deleted" => 1 ] [ "id" => 258852962 "company_id" => 8375742 "url" => "https://www.linkedin.com/company/krebsligasolothurn" "created" => "2020-10-31 07:04:47" "last_updated" => "2020-11-21 10:38:13" "deleted" => 1 ] [ "id" => 290346537 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/krebsliga-schweiz" "created" => "2020-11-21 10:38:13" "last_updated" => "2021-06-24 07:35:00" "deleted" => 1 ] [ "id" => 290346538 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/verein-lunge-z%C3%BCrich" "created" => "2020-11-21 10:38:13" "last_updated" => "2021-06-24 07:35:00" "deleted" => 1 ] [ "id" => 290346539 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-thurgau" "created" => "2020-11-21 10:38:13" "last_updated" => "2021-06-24 07:35:00" "deleted" => 1 ] [ "id" => 290346540 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-bern-ligue-pulmonaire-bernoise" "created" => "2020-11-21 10:38:13" "last_updated" => "2021-06-24 07:35:00" "deleted" => 1 ] [ "id" => 290346541 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/solothurner-spitaeler-ag---soh" "created" => "2020-11-21 10:38:13" "last_updated" => "2021-05-11 20:34:27" "deleted" => 1 ] [ "id" => 290346542 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-beider-basel" "created" => "2020-11-21 10:38:13" "last_updated" => "2021-02-21 20:48:35" "deleted" => 1 ] [ "id" => 290346543 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/spitex-kanton-bern" "created" => "2020-11-21 10:38:13" "last_updated" => "2020-12-21 10:33:34" "deleted" => 1 ] [ "id" => 290346544 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/krebsligasolothurn" "created" => "2020-11-21 10:38:13" "last_updated" => "2020-12-21 10:33:34" "deleted" => 1 ] [ "id" => 290346545 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-luzern-zug" "created" => "2020-11-21 10:38:13" "last_updated" => "2020-12-21 10:33:34" "deleted" => 1 ] [ "id" => 290346546 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/bag-ofsp" "created" => "2020-11-21 10:38:13" "last_updated" => "2021-05-11 20:34:27" "deleted" => 1 ] [ "id" => 340513710 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/schweizerisches-rotes-kreuz" "created" => "2020-12-21 10:33:34" "last_updated" => "2021-06-24 07:35:00" "deleted" => 1 ] [ "id" => 340513711 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/pro-infirmis" "created" => "2020-12-21 10:33:34" "last_updated" => "2021-06-24 07:35:00" "deleted" => 1 ] [ "id" => 340513712 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/pro-senectute-schweiz" "created" => "2020-12-21 10:33:34" "last_updated" => "2021-06-24 07:35:00" "deleted" => 1 ] [ "id" => 378574629 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-aargau" "created" => "2021-02-21 20:48:35" "last_updated" => "2021-06-24 07:35:00" "deleted" => 1 ] [ "id" => 412060030 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/curaviva" "created" => "2021-05-11 20:34:27" "last_updated" => "2021-06-24 07:35:00" "deleted" => 1 ] [ "id" => 412060031 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/palliative-ch" "created" => "2021-05-11 20:34:27" "last_updated" => "2021-06-24 07:35:00" "deleted" => 1 ] [ "id" => 482577609 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/krebsliga-schweiz" "created" => "2021-09-10 02:07:26" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 482577610 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-aargau" "created" => "2021-09-10 02:07:26" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 482577611 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/verein-lunge-z%C3%BCrich" "created" => "2021-09-10 02:07:26" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 482577612 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-bern-ligue-pulmonaire-bernoise" "created" => "2021-09-10 02:07:26" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 482577613 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/pro-senectute-schweiz" "created" => "2021-09-10 02:07:26" "last_updated" => "2022-03-03 21:42:02" "deleted" => 1 ] [ "id" => 482577614 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-thurgau" "created" => "2021-09-10 02:07:26" "last_updated" => "2022-03-03 21:42:02" "deleted" => 1 ] [ "id" => 482577615 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/pro-infirmis" "created" => "2021-09-10 02:07:26" "last_updated" => "2022-03-03 21:42:02" "deleted" => 1 ] [ "id" => 482577616 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/curaviva" "created" => "2021-09-10 02:07:26" "last_updated" => "2022-03-03 21:42:02" "deleted" => 1 ] [ "id" => 482577617 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/palliative-ch" "created" => "2021-09-10 02:07:26" "last_updated" => "2022-03-03 21:42:02" "deleted" => 1 ] [ "id" => 482577618 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/schweizerisches-rotes-kreuz" "created" => "2021-09-10 02:07:26" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 571961418 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-zentralschweiz" "created" => "2022-03-03 21:42:02" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 571961419 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/krebsligabern" "created" => "2022-03-03 21:42:02" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 571961420 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-beider-basel" "created" => "2022-03-03 21:42:02" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 571961421 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/kantonsspital-graub%C3%BCnden" "created" => "2022-03-03 21:42:02" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 571961422 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/genossenschaft-migros-aare" "created" => "2022-03-03 21:42:02" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 677034044 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/krebsliga-schweiz" "created" => "2022-07-22 05:36:47" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 677034045 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-zentralschweiz" "created" => "2022-07-22 05:36:47" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 677034046 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/verein-lunge-z%C3%BCrich" "created" => "2022-07-22 05:36:47" "last_updated" => "2024-09-10 16:50:44" "deleted" => 1 ] [ "id" => 677034047 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-aargau" "created" => "2022-07-22 05:36:47" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 677034048 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-bern-ligue-pulmonaire-bernoise" "created" => "2022-07-22 05:36:47" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 677034049 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/schweizerisches-rotes-kreuz" "created" => "2022-07-22 05:36:47" "last_updated" => "2023-01-24 16:15:35" "deleted" => 1 ] [ "id" => 677034050 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/gesundheitsfoerderung-schweiz" "created" => "2022-07-22 05:36:47" "last_updated" => "2024-06-22 11:15:38" "deleted" => 1 ] [ "id" => 677034051 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/bag-ofsp" "created" => "2022-07-22 05:36:47" "last_updated" => "2022-10-16 08:08:02" "deleted" => 1 ] [ "id" => 677034052 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/pro-senectute-schweiz" "created" => "2022-07-22 05:36:47" "last_updated" => "2023-04-12 16:05:20" "deleted" => 1 ] [ "id" => 677034053 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-beider-basel" "created" => "2022-07-22 05:36:47" "last_updated" => "2024-07-08 09:49:02" "deleted" => 1 ] [ "id" => 728388964 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/krebsligabern" "created" => "2022-10-16 08:08:02" "last_updated" => "2022-12-04 21:11:49" "deleted" => 1 ] [ "id" => 746691010 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/projuventute" "created" => "2022-12-04 21:11:49" "last_updated" => "2023-02-06 11:44:14" "deleted" => 1 ] [ "id" => 768057775 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/krebsligabern" "created" => "2023-01-24 16:15:35" "last_updated" => "2023-02-06 11:44:14" "deleted" => 1 ] [ "id" => 768600363 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/kantonsspital-graub%C3%BCnden" "created" => "2023-02-06 11:44:14" "last_updated" => "2024-02-21 07:57:30" "deleted" => 1 ] [ "id" => 768600364 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/spital-davos-ag" "created" => "2023-02-06 11:44:14" "last_updated" => "2024-02-21 07:57:30" "deleted" => 1 ] [ "id" => 800947608 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/krebsligabern" "created" => "2023-04-12 16:05:20" "last_updated" => "2023-10-27 20:54:28" "deleted" => 1 ] [ "id" => 902456247 "company_id" => 8375742 "url" => "https://li.linkedin.com/company/liechtensteinische-alters-und-krankenhilfe" "created" => "2023-10-27 20:54:28" "last_updated" => "2023-11-26 19:21:39" "deleted" => 1 ] [ "id" => 917225688 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/bag-ofsp" "created" => "2023-11-26 19:21:39" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 953193242 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/ligue-pulmonaire-jurassienne" "created" => "2024-02-21 07:57:30" "last_updated" => "2024-08-12 08:22:37" "deleted" => 1 ] [ "id" => 953193243 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/gruenech" "created" => "2024-02-21 07:57:30" "last_updated" => "2024-03-16 07:00:00" "deleted" => 1 ] [ "id" => 968776677 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/universitatsspital-zurich" "created" => "2024-03-16 07:00:00" "last_updated" => "2024-04-04 07:19:14" "deleted" => 1 ] [ "id" => 979260171 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/pulmotion" "created" => "2024-04-04 07:19:14" "last_updated" => "2024-11-06 23:17:51" "deleted" => 1 ] [ "id" => 1024210291 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/pro-senectute-schweiz" "created" => "2024-06-22 11:15:38" "last_updated" => "2024-08-12 08:22:37" "deleted" => 1 ] [ "id" => 1028815333 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/gesundheitsfoerderung-schweiz" "created" => "2024-07-08 09:49:02" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 1047760345 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/public-health-schweiz" "created" => "2024-08-12 08:22:37" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 1047760346 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-beider-basel" "created" => "2024-08-12 08:22:37" "last_updated" => "2024-09-10 16:50:44" "deleted" => 1 ] [ "id" => 1065857417 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/swissmedic" "created" => "2024-09-10 16:50:44" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 1065857418 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/pro-senectute-schweiz" "created" => "2024-09-10 16:50:44" "last_updated" => "2024-10-04 20:44:05" "deleted" => 1 ] [ "id" => 1079340505 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/lungenliga-beider-basel" "created" => "2024-10-04 20:44:05" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 1099462443 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/verein-lunge-z%C3%BCrich" "created" => "2024-11-06 23:17:51" "last_updated" => "2024-12-07 01:53:33" "deleted" => 1 ] [ "id" => 1118499240 "company_id" => 8375742 "url" => "https://ch.linkedin.com/company/pr%C3%A4vention-gesundheitsf%C3%B6rderung-kanton-z%C3%BCrich" "created" => "2024-12-07 01:53:33" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] ] "company_specialties_collection" => [ [ "id" => 22494955 "company_id" => 8375742 "specialty" => "medizin" "created" => "2018-07-29 20:41:35" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 22494956 "company_id" => 8375742 "specialty" => "lungenkrankheiten" "created" => "2018-07-29 20:41:35" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 22494957 "company_id" => 8375742 "specialty" => "tabak" "created" => "2018-07-29 20:41:35" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 22494958 "company_id" => 8375742 "specialty" => "schlafapnoe" "created" => "2018-07-29 20:41:35" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 22494959 "company_id" => 8375742 "specialty" => "beatmung" "created" => "2018-07-29 20:41:35" "last_updated" => "2022-06-28 09:07:32" "deleted" => 1 ] [ "id" => 98203119 "company_id" => 8375742 "specialty" => "medizin" "created" => "2022-08-08 15:57:00" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 98203120 "company_id" => 8375742 "specialty" => "lungenkrankheiten" "created" => "2022-08-08 15:57:00" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 98203121 "company_id" => 8375742 "specialty" => "tabak" "created" => "2022-08-08 15:57:00" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 98203122 "company_id" => 8375742 "specialty" => "schlafapnoe" "created" => "2022-08-08 15:57:00" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 98203123 "company_id" => 8375742 "specialty" => "beatmung" "created" => "2022-08-08 15:57:00" "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] ] "company_stock_info_collection" => [] "company_updates_collection" => [ [ "id" => 3587625 "company_id" => 8375742 "urn" => "urn:li:activity:7004454138822471681" "followers" => 1070 "date" => "2d" "description" => """ Die Schweiz befindet sich im europäischen Vergleich bei der Tabakprävention noch immer auf dem unrühmlichen zweitletzten Platz. So zeigt es der "Tobacco Control Scale".\n Zur Medienmitteilung der Arbeitsgemeinschaft Tabakprävention Schweiz: 👉https://lnkd.in/d2e_2zaB """ "reactions_count" => 11 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-24 16:15:35" "deleted" => 1 ] [ "id" => 3587626 "company_id" => 8375742 "urn" => "urn:li:activity:7004094390931464192" "followers" => 1070 "date" => "3d" "description" => """ Was bedeutet es, wenn man auf eine Spenderlunge wartet? Carlo Tamburini ist an COPD erkrankt und gibt uns einen Einblick in seine persönliche Geschichte.\n \n Text& Fotos: Lungenliga Thurgauhttps://lnkd.in/evqzV5Un\n \n #copd #lunge #lungenliga #lungentransplantation """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-24 16:15:35" "deleted" => 1 ] [ "id" => 3587627 "company_id" => 8375742 "urn" => "urn:li:activity:7001840851098161152" "followers" => 1070 "date" => "1w" "description" => """ Das Projekt «zackstark - rauchfrei durch die Lehre» richtet sich an Ausbildungsbetriebe und motiviert ihre Lernenden, während der Lehre rauch- und nikotinfrei zu bleiben. Im Beitrag erzählen Anita und Beatriz von ihren Erfahrungen.\n #rauchfrei #gesundheitsförderung #zackstark """ "reactions_count" => 2 "comments_count" => null "reshared_post_author" => "zackstark - rauchfrei durch die Lehre" "reshared_post_author_url" => "https://ch.linkedin.com/company/zackstark" "reshared_post_author_headline" => null "reshared_post_description" => """ Anita und Beatriz haben soeben ihre Lehre imSüssbach Pflegezentrum AG inkl. Teilnahme bei "zackstark" erfolgreich abgeschlossen. Im neu erschienen Magazin des Gesundheits-Netz Aargau Ost erzählen die beiden, wie sie das Thema Rauchen und Nikotin während der Lehrzeit erlebt haben.\n \n #rauchfrei #zackstark """ "reshared_post_followers" => 176 "reshared_post_date" => "2mo" "last_updated" => "2023-01-24 16:15:35" "deleted" => 1 ] [ "id" => 3587628 "company_id" => 8375742 "urn" => "urn:li:activity:7001225718781116417" "followers" => 1070 "date" => "1w" "description" => "Wer an der chronisch obstruktiven Lungenkrankheit (COPD) leidet, hat mit einigen Einschränkungen zu kämpfen. Die gute Nachricht ist: Wie stark die Krankheit den Alltag der Betroffenen und ihrer Angehörigen beeinträchtigt, können sie selbst beeinflussen. Das Selbstmanagement-Coaching «Besser leben mit COPD» der Lungenliga hilft Betroffenen nachweislich zu einer höheren Lebensqualität. Mehr Infos:https://lnkd.in/dY5hqUXP" "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-24 16:15:35" "deleted" => 1 ] [ "id" => 3587629 "company_id" => 8375742 "urn" => "urn:li:activity:7001193945766449152" "followers" => 1070 "date" => "1w" "description" => """ Wir suchen nach Vereinbarung eine\n Teamleitung Kommunikation/Marketing, 40-50 %https://lnkd.in/eGkJe49g """ "reactions_count" => 3 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-24 16:15:35" "deleted" => 1 ] [ "id" => 3587630 "company_id" => 8375742 "urn" => "urn:li:activity:7001152760435859456" "followers" => 1070 "date" => "1w" "description" => """ Schlägt Ihr Herz für ICT? \n \n Wir suchen ab sofort oder nach Vereinbarung ein/eine\n \n Service Manager/in Patientendatenmanagement-System (80 bis 100%)https://lnkd.in/dBHZXSgP """ "reactions_count" => 4 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-24 16:15:35" "deleted" => 1 ] [ "id" => 3587631 "company_id" => 8375742 "urn" => "urn:li:activity:6999322823034814464" "followers" => 1070 "date" => "2w" "description" => """ Die Luftholtage der Lungenliga sind für viele Menschen mit Atemwegs- und Lungenerkrankungen sowie ihre Angehörigen eine Möglichkeit, sorgenfreie Ferien zu verbringen. Das Ehepaar Kurt und Susanne Zimmermann gibt uns einen Einblick in die Gruppenreise in Sarnen.\n 👉https://lnkd.in/eKfMD8-f \n \n Text&Bilder: Lungenliga Zentralschweiz """ "reactions_count" => 29 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-24 16:15:35" "deleted" => 1 ] [ "id" => 3587632 "company_id" => 8375742 "urn" => "urn:li:activity:6998601818784026624" "followers" => 1070 "date" => "2w" "description" => """ Für eine Mutterschaftsvertretung suchen wir ab Januar 2023 eine/n\n \n 𝗣𝗿𝗼𝗷𝗲𝗸𝘁𝗹𝗲𝗶𝘁𝗲𝗿/𝗶𝗻 𝗖𝗢𝗣𝗗 𝘂𝗻𝗱 𝗦𝗮𝘂𝗲𝗿𝘀𝘁𝗼𝗳𝗳𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲 (𝟴𝟬-𝟭𝟬𝟬%)\n \n Es erwarten Sie abwechslungsreiche Aufgaben mit grossem Handlungsspielraum und ein engagiertes Team.\n \n Zum Inserat:https://lnkd.in/e6DPWuaR\n \n #lungenliga #jobsinbern #bern #gesundheitswesen #gesundheitsmanagement """ "reactions_count" => 6 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-24 16:15:35" "deleted" => 1 ] [ "id" => 3587633 "company_id" => 8375742 "urn" => "urn:li:activity:6998564634047696896" "followers" => 1070 "date" => "2w" "description" => """ Für eine Mutterschaftsvertretung suchen wir ab Januar 2023 eine/n\n \n 𝗣𝗿𝗼𝗷𝗲𝗸𝘁𝗹𝗲𝗶𝘁𝗲𝗿/𝗶𝗻 𝗖𝗢𝗣𝗗 𝘂𝗻𝗱 𝗦𝗮𝘂𝗲𝗿𝘀𝘁𝗼𝗳𝗳𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲 (𝟴𝟬-𝟭𝟬𝟬%)\n \n Es erwarten Sie abwechslungsreiche Aufgaben mit grossem Handlungsspielraum und ein engagiertes Team.\n \n Zum Inserat:https://lnkd.in/e6DPWuaR\n \n #lungenliga #jobsinbern #bern #gesundheitswesen #gesundheitsmanagement """ "reactions_count" => 14 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-24 16:15:35" "deleted" => 1 ] [ "id" => 3587634 "company_id" => 8375742 "urn" => "urn:li:activity:6998556875394797568" "followers" => 1070 "date" => "2w" "description" => """ Heute ist Welt-COPD-Tag! 💝 \n \n Rund 400'000 Menschen in der Schweiz leiden an der chronisch obstruktiven Lungenkrankheit COPD. \n \n Die Lungenliga setzt sich für die Beratung & Betreuung von Patientinnen und Patienten und ihren Angehörigen ein. \n \n 👉https://lnkd.in/e3baAs-m\n \n #copd #weltcopdtag #worldcopdday #lungenliga """ "reactions_count" => 21 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-24 16:15:35" "deleted" => 1 ] [ "id" => 54071605 "company_id" => 8375742 "urn" => "urn:li:activity:7023567541260165120" "followers" => 1105 "date" => "3h" "description" => """ «Sie sehen aus wie Stabilos und kommen in trendigen Farben und Geschmacksrichtungen daher.» #Einweg-E-#Zigaretten sind bei Jugendlichen im Trend. Laut Claudia Künzli, Leiterin Gesundheitsförderung & Prävention bei der Lungenliga Schweiz, eine besorgniserregende Entwicklung.\n 👉 https://lnkd.in/ek2QDD8M \n Beitrag von SRF - Schweizer Radio und Fernsehen """ "reactions_count" => 2 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 11:44:14" "deleted" => 1 ] [ "id" => 54071606 "company_id" => 8375742 "urn" => "urn:li:activity:7023181808737378304" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Lungenliga Schweiz" "reshared_post_author_url" => "https://ch.linkedin.com/company/lungenliga-schweiz" "reshared_post_author_headline" => null "reshared_post_description" => """ Schlägt ihr Herz für eine sinnstiftende, verantwortungsvolle Rolle, die #Menschen und #ICT zusammenführt? Wir suchen an der Geschäftsstelle in Bern Verstärkung als\n \n 𝗦𝘆𝘀𝘁𝗲𝗺𝘃𝗲𝗿𝗮𝗻𝘁𝘄𝗼𝗿𝘁𝗹𝗶𝗰𝗵𝗲/𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗲𝗻𝗱𝗮𝘁𝗲𝗻𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 (40-50%)\n \n Wir freuen uns auf Ihre Bewerbung!\n \n #ict #it #systemadministration #datenmanagement #systemverantwortlicher #lungenliga """ "reshared_post_followers" => 1105 "reshared_post_date" => "4d" "last_updated" => "2023-02-06 11:44:14" "deleted" => 1 ] [ "id" => 54071607 "company_id" => 8375742 "urn" => "urn:li:activity:7021876768231817216" "followers" => 1105 "date" => "4d" "description" => """ Est-ce que votre cœur bat pour les #technologies de l'#information et de la #communication (#TIC)? \n \n Pour la gestion opérationnelle ainsi que le développement de notre \n système, nous recherchons à Berne un/une \n \n 👉Responsable du système de gestion des données des patients (40-50%)\n \n Nous nous réjouissons de votre candidature! """ "reactions_count" => 1 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 11:44:14" "deleted" => 1 ] [ "id" => 54071608 "company_id" => 8375742 "urn" => "urn:li:activity:7021874455261933569" "followers" => 1105 "date" => "4d" "description" => """ Schlägt ihr Herz für eine sinnstiftende, verantwortungsvolle Rolle, die #Menschen und #ICT zusammenführt? Wir suchen an der Geschäftsstelle in Bern Verstärkung als\n \n 𝗦𝘆𝘀𝘁𝗲𝗺𝘃𝗲𝗿𝗮𝗻𝘁𝘄𝗼𝗿𝘁𝗹𝗶𝗰𝗵𝗲/𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗲𝗻𝗱𝗮𝘁𝗲𝗻𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 (40-50%)\n \n Wir freuen uns auf Ihre Bewerbung!\n \n #ict #it #systemadministration #datenmanagement #systemverantwortlicher #lungenliga """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 11:44:14" "deleted" => 1 ] [ "id" => 54071609 "company_id" => 8375742 "urn" => "urn:li:activity:7021505526844829696" "followers" => 1105 "date" => "5d" "description" => """ Bei diesem Wetter möchte man lieber keine kalte #Luft in die Warme Stube lassen. ❄️ Regelmässiges #Lüften ist aber auch im Winter wichtig für das Wohlbefinden und die #Gesundheit. \n 👉 Öffnen Sie die Fenster 3 bis 4 Mal täglich für ein paar Minuten.\n \n 💡 Je tiefer die Raumtemperatur ist, desto öfter muss gelüftet werden. Dasselbe gilt bei stark isolierten Fenstern. Zusätzliches Lüften empfiehlt sich nach dem Kochen, Duschen, Baden, Wäschewaschen und Bügeln. \n \n #lüften #tipps #luft #lungengesundheit #frischeluft """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 11:44:14" "deleted" => 1 ] [ "id" => 54071610 "company_id" => 8375742 "urn" => "urn:li:activity:7019242019881373697" "followers" => 1105 "date" => "1w" "description" => """ Tolles Ferienangebot für Menschen mit Atemwegs- und\n Lungenerkrankungen und ihre Angehörigen: Erleben Sie die unvergessliche Fluss-Kreuzfahrt auf der MS Antonio Bellucci (Basel – Rotterdam – Amsterdam – Basel) vom 12. bis 20. April. \n \n Melden Sie sich jetzt an! 👉 https://lnkd.in/evHD8i7y\n \n #luftholtage #ferien #lungenliga #lungenerkrankung """ "reactions_count" => 14 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 11:44:14" "deleted" => 1 ] [ "id" => 54071611 "company_id" => 8375742 "urn" => "urn:li:activity:7018489226665066496" "followers" => 1105 "date" => "2w" "description" => """ Auch im Alter lohnt es sich, mit dem Rauchen aufzuhören. Denn der positive Effekt eines Rauchstopps ist bereits nach kürzester Zeit spürbar. Das Zauberwort lautet dabei: Durchhalten!\n \n 👉 https://lnkd.in/e-6NN9UD\n \n #rauchstopp #mitdemrauchenaufhören #nikotin #gesundheitsförderung """ "reactions_count" => 19 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 11:44:14" "deleted" => 1 ] [ "id" => 54071612 "company_id" => 8375742 "urn" => "urn:li:activity:7012095773399998464" "followers" => 1105 "date" => "1mo" "description" => """ Wir wünschen allen eine frohe und besinnliche Weihnachtszeit sowie gute Gesundheit und viel Freude im neuen Jahr 2023. 🌟 💚 ❄️ 🎄 \n \n #lungenliga #weihnacht #neujahr #2023 """ "reactions_count" => 24 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 11:44:14" "deleted" => 1 ] [ "id" => 54071613 "company_id" => 8375742 "urn" => "urn:li:activity:7008727143186604034" "followers" => 1105 "date" => "1mo" "description" => """ Es hat noch freie Plätze für den 𝗕𝗮𝘀𝗶𝘀𝗸𝘂𝗿𝘀 𝗧𝘂𝗯𝗲𝗿𝗸𝘂𝗹𝗼𝘀𝗲 vom 15. - 16. Februar 2023 in Olten! \n ▫️ Wie und unter welchen Bedingungen wird Tuberkulose übertragen? \n ▫️ Welche Symptome treten auf und wie wird sie behandelt?\n ▫️ Wie läuft eine Umgebungsuntersuchung ab?\n Die Anmeldung ist noch 𝗯𝗶𝘀 𝟮𝟵. 𝗗𝗲𝘇𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟮 möglich. """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 11:44:14" "deleted" => 1 ] [ "id" => 54071614 "company_id" => 8375742 "urn" => "urn:li:activity:7006572171149856768" "followers" => 1105 "date" => "1mo" "description" => """ Für eine rund 7-monatige Mutterschaftsvertretung suchen wir eine/n\n \n 𝗣𝗿𝗼𝗷𝗲𝗸𝘁𝗹𝗲𝗶𝘁𝗲𝗿/𝗶𝗻 𝗖𝗢𝗣𝗗 𝘂𝗻𝗱 𝗦𝗮𝘂𝗲𝗿𝘀𝘁𝗼𝗳𝗳𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲 (𝟴𝟬-𝟭𝟬𝟬%)\n \n Es erwarten Sie abwechslungsreiche Aufgaben mit grossem Handlungsspielraum und ein engagiertes Team!\n \n Zum Inserat: https://lnkd.in/e6DPWuaR\n \n #lungenliga #jobsinbern #bern #gesundheitswesen #gesundheitsmanagement """ "reactions_count" => 6 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-06 11:44:14" "deleted" => 1 ] [ "id" => 55828398 "company_id" => 8375742 "urn" => "urn:li:activity:7027531193310969856" "followers" => 1110 "date" => "2d" "description" => """ Heute ist #Welt-Krebs-Tag. 💝 \n \n #Lungenkrebs ist in der Schweiz die dritthäufigste Diagnose. Erfahren Sie im Video der @krebsliga-schweiz, wie Lungenkrebs entsteht, wie die #Behandlungsmöglichkeiten aussehen und wo Betroffene Unterstützung finden. \n \n Auch die Lungenliga unterstützt mit #Rauchstoppberatung, #Information, #Prävention und Hilfestellungen wie #Sozialberatung für Betroffene. """ "reactions_count" => 13 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-13 03:41:17" "deleted" => 1 ] [ "id" => 55828399 "company_id" => 8375742 "urn" => "urn:li:activity:7023567541260165120" "followers" => 1110 "date" => "1w" "description" => """ «Sie sehen aus wie Stabilos und kommen in trendigen Farben und Geschmacksrichtungen daher.» #Einweg-E-#Zigaretten sind bei Jugendlichen im Trend. Laut Claudia Künzli, Leiterin Gesundheitsförderung & Prävention bei der Lungenliga Schweiz, eine besorgniserregende Entwicklung.\n 👉 https://lnkd.in/ek2QDD8M \n Beitrag von SRF - Schweizer Radio und Fernsehen """ "reactions_count" => 21 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-13 03:41:17" "deleted" => 1 ] [ "id" => 55828400 "company_id" => 8375742 "urn" => "urn:li:activity:7023181808737378304" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Lungenliga Schweiz" "reshared_post_author_url" => "https://ch.linkedin.com/company/lungenliga-schweiz" "reshared_post_author_headline" => null "reshared_post_description" => """ Schlägt ihr Herz für eine sinnstiftende, verantwortungsvolle Rolle, die #Menschen und #ICT zusammenführt? Wir suchen an der Geschäftsstelle in Bern Verstärkung als\n \n 𝗦𝘆𝘀𝘁𝗲𝗺𝘃𝗲𝗿𝗮𝗻𝘁𝘄𝗼𝗿𝘁𝗹𝗶𝗰𝗵𝗲/𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗲𝗻𝗱𝗮𝘁𝗲𝗻𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 (40-50%)\n \n Wir freuen uns auf Ihre Bewerbung!\n \n #ict #it #systemadministration #datenmanagement #systemverantwortlicher #lungenliga """ "reshared_post_followers" => 1110 "reshared_post_date" => "2w" "last_updated" => "2023-03-13 03:41:17" "deleted" => 1 ] [ "id" => 55828401 "company_id" => 8375742 "urn" => "urn:li:activity:7021876768231817216" "followers" => 1110 "date" => "2w" "description" => """ Est-ce que votre cœur bat pour les #technologies de l'#information et de la #communication (#TIC)? \n \n Pour la gestion opérationnelle ainsi que le développement de notre \n système, nous recherchons à Berne un/une \n \n 👉Responsable du système de gestion des données des patients (40-50%)\n \n Nous nous réjouissons de votre candidature! """ "reactions_count" => 2 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-13 03:41:17" "deleted" => 1 ] [ "id" => 55828402 "company_id" => 8375742 "urn" => "urn:li:activity:7021874455261933569" "followers" => 1110 "date" => "2w" "description" => """ Schlägt ihr Herz für eine sinnstiftende, verantwortungsvolle Rolle, die #Menschen und #ICT zusammenführt? Wir suchen an der Geschäftsstelle in Bern Verstärkung als\n \n 𝗦𝘆𝘀𝘁𝗲𝗺𝘃𝗲𝗿𝗮𝗻𝘁𝘄𝗼𝗿𝘁𝗹𝗶𝗰𝗵𝗲/𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗲𝗻𝗱𝗮𝘁𝗲𝗻𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 (40-50%)\n \n Wir freuen uns auf Ihre Bewerbung!\n \n #ict #it #systemadministration #datenmanagement #systemverantwortlicher #lungenliga """ "reactions_count" => 6 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-13 03:41:17" "deleted" => 1 ] [ "id" => 55828403 "company_id" => 8375742 "urn" => "urn:li:activity:7021505526844829696" "followers" => 1110 "date" => "2w" "description" => """ Bei diesem Wetter möchte man lieber keine kalte #Luft in die Warme Stube lassen. ❄️ Regelmässiges #Lüften ist aber auch im Winter wichtig für das Wohlbefinden und die #Gesundheit. \n 👉 Öffnen Sie die Fenster 3 bis 4 Mal täglich für ein paar Minuten.\n \n 💡 Je tiefer die Raumtemperatur ist, desto öfter muss gelüftet werden. Dasselbe gilt bei stark isolierten Fenstern. Zusätzliches Lüften empfiehlt sich nach dem Kochen, Duschen, Baden, Wäschewaschen und Bügeln. \n \n #lüften #tipps #luft #lungengesundheit #frischeluft """ "reactions_count" => 18 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-13 03:41:17" "deleted" => 1 ] [ "id" => 55828404 "company_id" => 8375742 "urn" => "urn:li:activity:7019242019881373697" "followers" => 1110 "date" => "3w" "description" => """ Tolles Ferienangebot für Menschen mit Atemwegs- und\n Lungenerkrankungen und ihre Angehörigen: Erleben Sie die unvergessliche Fluss-Kreuzfahrt auf der MS Antonio Bellucci (Basel – Rotterdam – Amsterdam – Basel) vom 12. bis 20. April. \n \n Melden Sie sich jetzt an! 👉 https://lnkd.in/evHD8i7y\n \n #luftholtage #ferien #lungenliga #lungenerkrankung """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-13 03:41:17" "deleted" => 1 ] [ "id" => 55828405 "company_id" => 8375742 "urn" => "urn:li:activity:7018489226665066496" "followers" => 1110 "date" => "3w" "description" => """ Auch im Alter lohnt es sich, mit dem Rauchen aufzuhören. Denn der positive Effekt eines Rauchstopps ist bereits nach kürzester Zeit spürbar. Das Zauberwort lautet dabei: Durchhalten!\n \n 👉 https://lnkd.in/e-6NN9UD\n \n #rauchstopp #mitdemrauchenaufhören #nikotin #gesundheitsförderung """ "reactions_count" => 21 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-13 03:41:17" "deleted" => 1 ] [ "id" => 55828406 "company_id" => 8375742 "urn" => "urn:li:activity:7012095773399998464" "followers" => 1110 "date" => "1mo" "description" => """ Wir wünschen allen eine frohe und besinnliche Weihnachtszeit sowie gute Gesundheit und viel Freude im neuen Jahr 2023. 🌟 💚 ❄️ 🎄 \n \n #lungenliga #weihnacht #neujahr #2023 """ "reactions_count" => 24 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-13 03:41:17" "deleted" => 1 ] [ "id" => 55828407 "company_id" => 8375742 "urn" => "urn:li:activity:7008727143186604034" "followers" => 1110 "date" => "1mo" "description" => """ Es hat noch freie Plätze für den 𝗕𝗮𝘀𝗶𝘀𝗸𝘂𝗿𝘀 𝗧𝘂𝗯𝗲𝗿𝗸𝘂𝗹𝗼𝘀𝗲 vom 15. - 16. Februar 2023 in Olten! \n ▫️ Wie und unter welchen Bedingungen wird Tuberkulose übertragen? \n ▫️ Welche Symptome treten auf und wie wird sie behandelt?\n ▫️ Wie läuft eine Umgebungsuntersuchung ab?\n Die Anmeldung ist noch 𝗯𝗶𝘀 𝟮𝟵. 𝗗𝗲𝘇𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟮 möglich. """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-13 03:41:17" "deleted" => 1 ] [ "id" => 110509807 "company_id" => 8375742 "urn" => "urn:li:activity:7039897654016798720" "followers" => 1146 "date" => "2d" "description" => """ Wir setzen uns dafür ein, dass #Pensionskassen wie die #Publica nicht mehr in die Tabakbranche investieren.\n \n Beitrag in Nau.ch\n 👉https://lnkd.in/e6kxzpx8 \n \n #tabakfreieinvestitionen #tobaccofreeportfolios """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 16:05:20" "deleted" => 1 ] [ "id" => 110509808 "company_id" => 8375742 "urn" => "urn:li:activity:7034214423959347200" "followers" => 1146 "date" => "2w" "description" => """ Die Produktivität und Motivation am Arbeitsplatz kann durch #betriebliches #Gesundheitsmanagement stark gesteigert werden. Das Programm PulMotion vermittelt den Mitarbeitenden wertvolle Tipps zur #Lungengesundheit mit folgenden vier Modulen:\n •\t#Schlaf und Wohlbefinden\n •\t#Rauchfreiheit\n •\t#Luftqualität im Betrieb\n •\t#Atmung und Regeneration\n 👉 Mehr Infos: https://pulmotion.ch """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 16:05:20" "deleted" => 1 ] [ "id" => 110509809 "company_id" => 8375742 "urn" => "urn:li:activity:7033457745357864962" "followers" => 1146 "date" => "2w" "description" => """ Diese 6 Übungen verhelfen Ihnen zu mehr Bewegung im Alltag! In der Broschüre «Aktiv leben mit COPD» finden Sie Tipps zum Thema Bewegung und Atmung. \n Mehr erfahren: https://lnkd.in/ebuJprF2\n \n #bewegung #übungen #atmung #copd #lungenliga #lungengesundheit """ "reactions_count" => 13 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 16:05:20" "deleted" => 1 ] [ "id" => 110509810 "company_id" => 8375742 "urn" => "urn:li:activity:7031277849965686785" "followers" => 1146 "date" => "3w" "description" => """ Vor rund einem Jahr haben sich Volk und Stände klar für die Volksinitiative «Kinder ohne Tabak» ausgesprochen. 💌 \n \n Eine aktuelle Einschätzung und ein Ausblick zum Thema finden Sie in der Medienmitteilung: https://lnkd.in/ewPpCiR9 """ "reactions_count" => 19 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 16:05:20" "deleted" => 1 ] [ "id" => 110509811 "company_id" => 8375742 "urn" => "urn:li:activity:7029399280654163969" "followers" => 1146 "date" => "1mo" "description" => """ Ein neues Ferienangebot für Menschen mit Atemwegs- und\n \n Lungenerkrankungen und ihre Angehörigen ist online! \n 👉 Wohlfühlmomente am 𝐋𝐚𝐠𝐨 𝐌𝐚𝐠𝐠𝐢𝐨𝐫𝐞 𝐯𝐨𝐦 𝟕. 𝐛𝐢𝐬 𝟏𝟕. 𝐌𝐚𝐢 𝟐𝟎𝟐𝟑\n \n Flanieren Sie gemütlich auf der Piazza Grande, geniessen Sie den Ausblick auf See und Berge und lassen Sie dabei die Seele baumeln. \n \n Mehr Infos 👉 \n https://lnkd.in/evHD8i7y\n \n #luftholtage #ferien #lungenliga #lungenerkrankung """ "reactions_count" => 11 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 16:05:20" "deleted" => 1 ] [ "id" => 110509812 "company_id" => 8375742 "urn" => "urn:li:activity:7027531193310969856" "followers" => 1146 "date" => "1mo" "description" => """ Heute ist #Welt-Krebs-Tag. 💝 \n \n #Lungenkrebs ist in der Schweiz die dritthäufigste Diagnose. Erfahren Sie im Video der @krebsliga-schweiz, wie Lungenkrebs entsteht, wie die #Behandlungsmöglichkeiten aussehen und wo Betroffene Unterstützung finden. \n \n Auch die Lungenliga unterstützt mit #Rauchstoppberatung, #Information, #Prävention und Hilfestellungen wie #Sozialberatung für Betroffene. """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 16:05:20" "deleted" => 1 ] [ "id" => 110509813 "company_id" => 8375742 "urn" => "urn:li:activity:7023567541260165120" "followers" => 1146 "date" => "1mo" "description" => """ «Sie sehen aus wie Stabilos und kommen in trendigen Farben und Geschmacksrichtungen daher.» #Einweg-E-#Zigaretten sind bei Jugendlichen im Trend. Laut Claudia Künzli, Leiterin Gesundheitsförderung & Prävention bei der Lungenliga Schweiz, eine besorgniserregende Entwicklung.\n 👉 https://lnkd.in/ek2QDD8M \n Beitrag von SRF - Schweizer Radio und Fernsehen """ "reactions_count" => 27 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 16:05:20" "deleted" => 1 ] [ "id" => 110509814 "company_id" => 8375742 "urn" => "urn:li:activity:7023181808737378304" "followers" => null "date" => null "description" => null "reactions_count" => null "comments_count" => null "reshared_post_author" => "Lungenliga Schweiz" "reshared_post_author_url" => "https://ch.linkedin.com/company/lungenliga-schweiz" "reshared_post_author_headline" => null "reshared_post_description" => """ Schlägt ihr Herz für eine sinnstiftende, verantwortungsvolle Rolle, die #Menschen und #ICT zusammenführt? Wir suchen an der Geschäftsstelle in Bern Verstärkung als\n \n 𝗦𝘆𝘀𝘁𝗲𝗺𝘃𝗲𝗿𝗮𝗻𝘁𝘄𝗼𝗿𝘁𝗹𝗶𝗰𝗵𝗲/𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗲𝗻𝗱𝗮𝘁𝗲𝗻𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 (40-50%)\n \n Wir freuen uns auf Ihre Bewerbung!\n \n #ict #it #systemadministration #datenmanagement #systemverantwortlicher #lungenliga """ "reshared_post_followers" => 1146 "reshared_post_date" => "1mo" "last_updated" => "2023-04-12 16:05:20" "deleted" => 1 ] [ "id" => 110509815 "company_id" => 8375742 "urn" => "urn:li:activity:7021876768231817216" "followers" => 1146 "date" => "1mo" "description" => """ Est-ce que votre cœur bat pour les #technologies de l'#information et de la #communication (#TIC)? \n \n Pour la gestion opérationnelle ainsi que le développement de notre \n système, nous recherchons à Berne un/une \n \n 👉Responsable du système de gestion des données des patients (40-50%)\n \n Nous nous réjouissons de votre candidature! """ "reactions_count" => 2 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 16:05:20" "deleted" => 1 ] [ "id" => 110509816 "company_id" => 8375742 "urn" => "urn:li:activity:7021874455261933569" "followers" => 1146 "date" => "1mo" "description" => """ Schlägt ihr Herz für eine sinnstiftende, verantwortungsvolle Rolle, die #Menschen und #ICT zusammenführt? Wir suchen an der Geschäftsstelle in Bern Verstärkung als\n \n 𝗦𝘆𝘀𝘁𝗲𝗺𝘃𝗲𝗿𝗮𝗻𝘁𝘄𝗼𝗿𝘁𝗹𝗶𝗰𝗵𝗲/𝗿 𝗣𝗮𝘁𝗶𝗲𝗻𝘁𝗲𝗻𝗱𝗮𝘁𝗲𝗻𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 (40-50%)\n \n Wir freuen uns auf Ihre Bewerbung!\n \n #ict #it #systemadministration #datenmanagement #systemverantwortlicher #lungenliga """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-12 16:05:20" "deleted" => 1 ] [ "id" => 128471766 "company_id" => 8375742 "urn" => "urn:li:activity:7048955108948103169" "followers" => 1179 "date" => "6d" "description" => """ Das neue vivo ist da! 💚 \n Vier Wochen lang wanderte Claudio Menghi auf dem Jakobsweg. Immer mit dabei: sein CPAP-Gerät. Entdecken Sie seine Geschichte und weitere spannende Themen im neuen vivo.\n \n 👉 https://vivo.lungenliga.ch\n \n #magazin #vivo #geschichten #lungenliga """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 09:41:01" "deleted" => 1 ] [ "id" => 128471767 "company_id" => 8375742 "urn" => "urn:li:activity:7047447470498287616" "followers" => 1179 "date" => "1w" "description" => """ #Arbeitswelt Lungenliga Schweiz – Wir haben uns vorgestellt. \n \n Haben wir Ihr Interesse geweckt? Unsere Stellenangebote finden Sie hier: www.lungenliga.ch/jobs\n \n \n Mehr Info unter https://lnkd.in/dTE3A3EN\n \n #arbeitswelt #lungenliga #lungenligaschweiz #wirstellenunsvor #etwasbewirken #arbeitenbeiderlungenliga """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 09:41:01" "deleted" => 1 ] [ "id" => 128471768 "company_id" => 8375742 "urn" => "urn:li:activity:7047141411510493184" "followers" => 1179 "date" => "1w" "description" => null "reactions_count" => 3 "comments_count" => null "reshared_post_author" => "Lungenliga Zentralschweiz" "reshared_post_author_url" => "https://ch.linkedin.com/company/lungenliga-zentralschweiz" "reshared_post_author_headline" => null "reshared_post_description" => """ Zigaretten sind keine Spielzeuge. Trotzdem sind Spielzeugzigaretten bei Schweizer Detailhändlern noch immer im Sortiment zu finden und werden aktuell sogar als Aktion angepriesen. Wer hat Interesse daran, Kinder so ans Rauchen heranzuführen? \n \n #zigarette #spielzeug #rauchen #kinder #lungenligazentralschweiz """ "reshared_post_followers" => 217 "reshared_post_date" => "2w" "last_updated" => "2023-05-03 09:41:01" "deleted" => 1 ] [ "id" => 128471769 "company_id" => 8375742 "urn" => "urn:li:activity:7047121117903265793" "followers" => 1179 "date" => "1w" "description" => "Wir suchen Verstärkung. Haben Sie Lust auf eine sinnstiftende und abwechslungsreiche Tätigkeit? #sinnstiftend #jobsuche #jobsinbern #gesundheitswesen #gesundheitsförderung #sinnstiftend" "reactions_count" => 13 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 09:41:01" "deleted" => 1 ] [ "id" => 128471770 "company_id" => 8375742 "urn" => "urn:li:activity:7046722681236336640" "followers" => 1179 "date" => "1w" "description" => """ #Arbeitswelt Lungenliga Schweiz – wir stellen uns vor. \| Wie kann die Lungenliga einer betroffenen Person helfen?\n \n \n Um Menschen mir Lungen- und Atemwegserkrankungen bestmöglich zu begleiten, sorgen wir für kompetente Beratung und Betreuung, bieten Kurse oder Coachings an und informieren zu vielen Krankheiten auf der Webseite. Zudem sensibilisieren wir die Bevölkerung und teilen spannende Fakten zu unterschiedlichen präventiven Massnahmen, auf die man im Alltag achten kann. So kann zum Beispiel Feuchtigkeit und Schimmel in einer Wohnung die Atemwege stark reizen und zu Asthma führen.\n \n Viele spannende Fakten finden Sie auf unserer Website: https://lnkd.in/d4b-kev4\n \n #arbeitswelt #lungenliga #lungenligaschweiz #wirstellenunsvor #etwasbewirken #arbeitenbeiderlungenliga """ "reactions_count" => 9 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 09:41:01" "deleted" => 1 ] [ "id" => 128471771 "company_id" => 8375742 "urn" => "urn:li:activity:7046070211908648960" "followers" => 1179 "date" => "2w" "description" => """ Sucht Schweiz hat im Auftrag des Bundesamtes für Gesundheit die repräsentative Studie HBSC, Health Behaviour in School-aged-Children, bei 11- bis 15-jährigen Schülerinnen und Schülern durchgeführt.\n Es zeigt sich: Jede/r dritte 15-Jährige hat in den letzten 30 Tagen vor der Befragung mindestens ein Tabak- oder Nikotinprodukt konsumiert. Der höchste Anstieg betrifft den Konsum von E-Zigaretten verzeichnet. Die Zunahme im Vergleich zu 2018 ist besorgniserregend. \n Zur Medienmitteilung:\n https://lnkd.in/dPqUykn9 """ "reactions_count" => 12 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 09:41:01" "deleted" => 1 ] [ "id" => 128471772 "company_id" => 8375742 "urn" => "urn:li:activity:7045997902220976128" "followers" => 1179 "date" => "2w" "description" => """ #Arbeitswelt Lungenliga Schweiz – wir stellen uns vor. \| Aufklärung, Prävention, Beratung – Was bringt die Arbeit der Allgemeinheit?\n \n Die Lungenliga berät nicht nur Betroffene, sondern engagiert sich auch für die Prävention. So zum Beispiel im vergangenen Jahr mit der Volksinitiative «Kinder ohne Tabak». Ein anderes wichtiges Projekt ist das Gesundheitsförderungsprogramm «ready4life», das Lernende über einen bestimmten Zeitraum im Alltag begleitet und zu verschiedenen Themen wie Alkohol-, Tabak- und Nikotinkonsum aufklärt. Auf der Website finden sich weitere spannende Projekte, Anlässe und Informationen.\n \n Mehr zu Ready4life: www.r4l.swiss\n \n #wehire #gesundheitswesen #jobsuche #npo #lungenliga #arbeitenbeiderlungenliga """ "reactions_count" => 20 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 09:41:01" "deleted" => 1 ] [ "id" => 128471773 "company_id" => 8375742 "urn" => "urn:li:activity:7044995249085014016" "followers" => 1179 "date" => "2w" "description" => """ Der heutige Welttag der Tuberkulose erinnert daran, dass die Tuberkulose nach wie vor eine der tödlichsten Infektionskrankheiten der Welt ist. In der Schweiz ist die Zahl der Tuberkulosefälle dank früher Erkennung und konsequenter Behandlung in den letzten Jahren rückläufig. Jährlich erkranken bis zu 400 Menschen an Tuberkulose.\n \n Um die Qualität der Betreuung weiterhin hochzuhalten und eine optimale Versorgung zu gewährleisten ist die Weiterbildung von Fachpersonen zentral.\n \n Am hybriden Tuberkulose-Symposium vom 1. Juni 2023 in Bern präsentieren Fachpersonen im Bereich Tuberkulose aktuelle Daten und Projekte und tauschen sich aus über die Zukunft der Tuberkulosebekämpfung in der Schweiz.\n \n Mehr Infos: https://lnkd.in/e2heKpgQ\n \n #worldtuberculosisday #tuberkulose #welttagtuberkulose #lungenliga """ "reactions_count" => 18 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 09:41:01" "deleted" => 1 ] [ "id" => 128471774 "company_id" => 8375742 "urn" => "urn:li:activity:7044925837871083520" "followers" => 1179 "date" => "2w" "description" => """ #Arbeitswelt Lungenliga Schweiz – wir stellen uns vor. \| Gesundheitsförderung und Prävention – klingt spannend, doch was genau fällt in diesen Bereich?\n \n Mit präventiven und gesundheitsfördernden Massnahmen engagieren wir uns für gesunde Lungen und Atemwege. Wir setzen uns mit verschiedenen Präventionsprojekten dafür ein, dass weniger Menschen an Lungen- und Atemwegen erkranken und die Krankheiten früher erkannt werden. Wir nehmen Einfluss auf die nationale und kantonale Meinungsbildung und Gesetzgebung. Wir engagieren uns politisch, sind aber parteipolitisch unabhängig. So waren wir zum Beispiel an der Volksinitiative «Kinder ohne Tabak» stark beteiligt.\n \n Mehr Infos dazu hier: www.kinderohnetabak.ch\n \n #wehire #gesundheitswesen #jobsuche #npo #lungenliga #arbeitenbeiderlungenliga """ "reactions_count" => 13 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 09:41:01" "deleted" => 1 ] [ "id" => 128471775 "company_id" => 8375742 "urn" => "urn:li:activity:7044563450873667584" "followers" => 1179 "date" => "2w" "description" => """ #Arbeitswelt Lungenliga Schweiz – wir stellen uns vor. \| Der Bereich Weiterbildung kurz erklärt.\n \n In den Aufgabenbereich der Weiterbildung fallen die Organisation von Kursen und Weiterbildungen sowie Berufsprüfungen für Fachpersonen. Die Kurse sind für Beraterinnen und Berater der kantonalen Ligen aber auch für Externe wie zum Beispiel Medizinische Praxisassistentinnen oder -assistenten in pneumologischen oder Hausarztpraxen ausgelegt, damit diese die Patientinnen und Patienten bestmöglich versorgen und beraten können. Die Berufsprüfungen und höheren Fachprüfungen sind essenzielle Bausteine für die Versorgungsqualität der Betroffenen. Zudem unterstützt der Bereich andere Arbeitsbereiche in der Kursadministration, wenn diese einen Kurs organisieren. \n \n Mehr dazu auf unserer Webseite: https://lnkd.in/d8UeKuyy\n \n #wehire #gesundheitswesen #jobsuche #npo #lungenliga #arbeitenbeiderlungenliga """ "reactions_count" => 10 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-03 09:41:01" "deleted" => 1 ] [ "id" => 162260681 "company_id" => 8375742 "urn" => "urn:li:activity:7059091514320150529" "followers" => 1190 "date" => "7h" "description" => """ Heute ist Welt-Asthma-Tag!\n Jedes 10. Kind und jeder 14. Erwachsene in der Schweiz sind betroffen. \n \n Finden Sie bei uns hilfreiche Informationen und Beratung bei Asthmaerkrankungen:\n \n \n 👉 www.lungenliga.ch/asthma\n \n #weltasthmatag #asthma #lungenliga """ "reactions_count" => 4 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 02:19:15" "deleted" => 1 ] [ "id" => 162260682 "company_id" => 8375742 "urn" => "urn:li:activity:7057265270175752192" "followers" => 1190 "date" => "5d" "description" => """ Cours «Connaissances de base sur les maladies pulmonaires et respiratoires»: Approfondissez vos connaissances sur les différentes pathologies dans ce domaine, la pose du diagnostic et les différentes thérapies existantes.\n 📅 Les 6, 7 et 8 juin 2023 à Lausanne.\n \n Information et Inscription ici 👉 https://lnkd.in/espUkfjR """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 02:19:15" "deleted" => 1 ] [ "id" => 162260683 "company_id" => 8375742 "urn" => "urn:li:activity:7054704833290727424" "followers" => 1190 "date" => "1w" "description" => """ Die Arbeitsgemeinschaft Tabakprävention zum heutigen Entscheid der Gesundheitskommission des Ständerates.\n Diese will weiterhin Zusatzstoffe für Tabakprodukte und E-Zigaretten erlauben, welche das Suchtpotenzial oder die Toxizität steigern. Die Arbeitsgemeinschaft Tabakprävention Schweiz nimmt dies mit Bestürzung zur Kenntnis.\n Mehr dazu unter https://lnkd.in/eeZ46ga9 """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 02:19:15" "deleted" => 1 ] [ "id" => 162260684 "company_id" => 8375742 "urn" => "urn:li:activity:7054302633997553664" "followers" => 1190 "date" => "1w" "description" => """ 🔜Tuberkulose-Symposium, 1. Juni 2023 in Bern\n \n Fachpersonen im Bereich Tuberkulose präsentieren aktuelle Daten und Projekte und tauschen sich über die Zukunft der Tuberkulosebekämpfung in der Schweiz aus.\n \n Infos & Anmeldung bis 👉https://lnkd.in/e9J-NrfB\n \n #tuberkulose #kompetenzzentrum #tbinfo #symposium #lungenliga """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 02:19:15" "deleted" => 1 ] [ "id" => 162260685 "company_id" => 8375742 "urn" => "urn:li:activity:7053940218520858625" "followers" => 1190 "date" => "2w" "description" => """ Im Moment klagen viele wieder über Frühjahrsmüdigkeit. Was hinter diesem Phänomen steckt und man dagegen tun kann, erfahren Sie im vivo Beitrag. https://lnkd.in/e7f69-Te\n \n #frühjahrsmüdigkeit #frühling #lungenliga """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 02:19:15" "deleted" => 1 ] [ "id" => 162260686 "company_id" => 8375742 "urn" => "urn:li:activity:7052334726287605761" "followers" => 1190 "date" => "2w" "description" => """ Wir suchen Verstärkung von\n #jobs #jobsuche #marketingjob #kommunikation """ "reactions_count" => 12 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 02:19:15" "deleted" => 1 ] [ "id" => 162260687 "company_id" => 8375742 "urn" => "urn:li:activity:7052211321391443968" "followers" => 1190 "date" => "2w" "description" => """ Zwei Ligen, zwei Wege, ein Ziel 🎯\n \n Zu Besuch bei einer kleinen und einer grossen kantonalen Lungenliga.\n \n \n 👉 https://lnkd.in/edrnkME3\n \n #lungenliga #liguepulmonaire #legapolmonare """ "reactions_count" => 9 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 02:19:15" "deleted" => 1 ] [ "id" => 162260688 "company_id" => 8375742 "urn" => "urn:li:activity:7048955108948103169" "followers" => 1190 "date" => "4w" "description" => """ Das neue vivo ist da! 💚 \n Vier Wochen lang wanderte Claudio Menghi auf dem Jakobsweg. Immer mit dabei: sein CPAP-Gerät. Entdecken Sie seine Geschichte und weitere spannende Themen im neuen vivo.\n \n 👉 https://vivo.lungenliga.ch\n \n #magazin #vivo #geschichten #lungenliga """ "reactions_count" => 9 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 02:19:15" "deleted" => 1 ] [ "id" => 162260689 "company_id" => 8375742 "urn" => "urn:li:activity:7047447470498287616" "followers" => 1190 "date" => "1mo" "description" => """ #Arbeitswelt Lungenliga Schweiz – Wir haben uns vorgestellt. \n \n Haben wir Ihr Interesse geweckt? Unsere Stellenangebote finden Sie hier: www.lungenliga.ch/jobs\n \n \n Mehr Info unter https://lnkd.in/dTE3A3EN\n \n #arbeitswelt #lungenliga #lungenligaschweiz #wirstellenunsvor #etwasbewirken #arbeitenbeiderlungenliga """ "reactions_count" => 9 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-08 02:19:15" "deleted" => 1 ] [ "id" => 162260690 "company_id" => 8375742 "urn" => "urn:li:activity:7047141411510493184" "followers" => 1190 "date" => "1mo" "description" => null "reactions_count" => 4 "comments_count" => null "reshared_post_author" => "Lungenliga Zentralschweiz" "reshared_post_author_url" => "https://ch.linkedin.com/company/lungenliga-zentralschweiz" "reshared_post_author_headline" => null "reshared_post_description" => """ Zigaretten sind keine Spielzeuge. Trotzdem sind Spielzeugzigaretten bei Schweizer Detailhändlern noch immer im Sortiment zu finden und werden aktuell sogar als Aktion angepriesen. Wer hat Interesse daran, Kinder so ans Rauchen heranzuführen? \n \n #zigarette #spielzeug #rauchen #kinder #lungenligazentralschweiz """ "reshared_post_followers" => 219 "reshared_post_date" => "1mo" "last_updated" => "2023-06-08 02:19:15" "deleted" => 1 ] [ "id" => 194723804 "company_id" => 8375742 "urn" => "urn:li:activity:7070031215684149248" "followers" => 1217 "date" => "4d" "description" => """ Bereichernde Begegnungen, bedeutende Neuigkeiten und ein reger Austausch erwarteten heute die Zuschauer am #Tuberkulose-Symposium 2023. Fachpersonen stellten aktuelle Daten und Projekte vor und sprachen über die Zukunft der #Tuberkulosebekämpfung in der Schweiz.\n \n #tuberkulose #kompetenzzentrumtuberkulose #tbsymposium2023 """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-17 06:46:57" "deleted" => 1 ] [ "id" => 194723805 "company_id" => 8375742 "urn" => "urn:li:activity:7069585275634466816" "followers" => 1217 "date" => "5d" "description" => """ Welttag ohne Tabak 2023 💚 \n 32,4 Tonnen: So viel Tabak wird weltweit jedes Jahr auf 4,3 Millionen Hektaren Land angebaut - eine Fläche so gross wie die Schweiz. Unter dem Motto «Grow food, not tobacco» macht die Weltgesundheitsorganisation zum diesjährigen «World No Tobaccco Day» darauf aufmerksam, dass der Tabakanbau unserer Gesundheit, der Gesundheit der Bauern und der Gesundheit des Planeten schadet. \n \n Mehr Infos in der Medienmitteilung 👉 https://lnkd.in/dYYwdEfw\n \n #welttagohnetabak #worldnotobaccoday #weltnichtrauchertag #lungenliga """ "reactions_count" => 21 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-17 06:46:57" "deleted" => 1 ] [ "id" => 194723806 "company_id" => 8375742 "urn" => "urn:li:activity:7069285076940808193" "followers" => 1217 "date" => "6d" "description" => """ Viel frische Luft, etwas Bewegung und einige Übungen: eine gute Kombination, um Energie zu tanken. Wir stellen drei Themenwege in der Schweiz vor.\n \n \n 👉 https://lnkd.in/eHU9jhMq\n \n #vivomagazin #atmemübungen #atmen #lungenliga """ "reactions_count" => 11 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-17 06:46:57" "deleted" => 1 ] [ "id" => 194723807 "company_id" => 8375742 "urn" => "urn:li:activity:7067885657347502081" "followers" => 1217 "date" => "1w" "description" => """ Der Bundesrat schlägt in seiner Botschaft an das Parlament eine angemessene Umsetzung der am 13. Februar 2022 von Volk und Ständen angenommenen #Volksinitiative «Kinder ohne Tabak» vor.👌\n \n Printmedien, Kioske und Festivals werden künftig frei von #Tabakwerbung sein, online wird weder Werbung noch Erwerb ohne Alterskontrolle möglich sein. Das Parlament ist nun angehalten, die Vorlage rasch umzusetzen, damit die Flut an Werbung für #Tabak- und #Nikotinprodukte für Kinder und Jugendliche gebremst werden kann. \n \n Der Initiativverein kommentiert die Botschaft des Bundesrats in ihrer Medienmitteilung: https://lnkd.in/eHmDb89z\n \n #TabPG #kinderohnetabak #jugendschutz """ "reactions_count" => 12 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-17 06:46:57" "deleted" => 1 ] [ "id" => 194723808 "company_id" => 8375742 "urn" => "urn:li:activity:7065914140090880000" "followers" => 1217 "date" => "2w" "description" => """ Nationaler Tag der #Selbsthilfe: #Gemeinsam stark - Dank Selbsthilfe 💪 \n \n Im Rahmen der Aktionswoche «Tag der Selbsthilfe» steht vom 21. – 27. Mai 2023 das Projekt «Selbsthilfefreundliche #Spitäler» im Vordergrund, welches Selbsthilfe Schweiz in Zusammenarbeit mit Gesundheitsförderung Schweiz durchführt. Das Projekt zeigt eindrücklich die zunehmend wichtigere Rolle der Selbsthilfe im Kontext des Schweizer #Gesundheitswesens auf.\n \n Während der Aktionswoche erwartet Sie ein breiter Mix von nationalen und regionalen Aktivitäten der 22 regionalen Selbsthilfezentren und verschiedenen Partner/innen. Vielleicht auch mit Ihnen? \n \n Laufend aktualisierte News zur Aktionswoche finden Sie auf 👉www.selbsthilfe-schweiz.ch """ "reactions_count" => 6 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-17 06:46:57" "deleted" => 1 ] [ "id" => 194723809 "company_id" => 8375742 "urn" => "urn:li:activity:7064266886766563329" "followers" => 1217 "date" => "2w" "description" => """ Merken Sie sich dieses Datum vor: Vom 21. – 27. Mai 2023 veranstaltet selbsthilfeschweiz.infoentraidesuisse eine Aktionswoche mit verschiedenen Aktionen in der ganzen Schweiz und spannenden Berichten von Betroffenen oder Angehörigen über ihre Erfahrungen mit Selbsthilfegruppen.\n 👉 https://lnkd.in/daXjfKus """ "reactions_count" => 9 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-17 06:46:57" "deleted" => 1 ] [ "id" => 194723810 "company_id" => 8375742 "urn" => "urn:li:activity:7064263777147363328" "followers" => 1217 "date" => "2w" "description" => """ SAVE THE DATE 🔜 21. Juni 2023 um 19 Uhr in Basel\n Apéro & Vortragsveranstaltung zum Thema «E-Zigaretten und Tabakerhitzer – Fluch oder Segen?»\n \n (Einweg-)E-Zigaretten und Tabakerhitzer haben sich zu alltäglichen Konsumgütern entwickelt und sind bei Jugendlichen stark im Trend. Erfahren Sie an der öffentlichen Vortragsveranstaltung mehr über die Produkte und ihre gesundheitlichen Auswirkungen und stellen Sie den Experten im anschliessenden Podiumsgespräch Ihre brennendsten Fragen. \n 👉 Infos & Anmeldung unter https://lnkd.in/dqaaKecQ\n \n Der Anlass wird in Zusammenarbeit mit der Schweizerische Herzstiftung organisiert. """ "reactions_count" => 29 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-17 06:46:57" "deleted" => 1 ] [ "id" => 194723811 "company_id" => 8375742 "urn" => "urn:li:activity:7059429972414799872" "followers" => 1217 "date" => "1mo" "description" => """ «Schockprävention» auf eindrückliche Art: Die Sendung «Studio 404» des SRF - Schweizer Radio und Fernsehens vermarktet bei einer verdeckten Aktion über eine gefälschte Website E-Zigaretten an Kinder und erzielt eine grosse Wirkung auf Medien und Öffentlichkeit. Laut Schweizer Gesetzgebung wäre dies legal. Die Aktion zeigt, wie wichtig eine klare, schweizweite Regulierung für E-Zigaretten ist.\n Zur Sendung 👉 https://lnkd.in/drJHv-s8 """ "reactions_count" => 13 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-17 06:46:57" "deleted" => 1 ] [ "id" => 194723812 "company_id" => 8375742 "urn" => "urn:li:activity:7059091514320150529" "followers" => 1217 "date" => "1mo" "description" => """ Heute ist Welt-Asthma-Tag!\n Jedes 10. Kind und jeder 14. Erwachsene in der Schweiz sind betroffen. \n \n Finden Sie bei uns hilfreiche Informationen und Beratung bei Asthmaerkrankungen:\n \n \n 👉 www.lungenliga.ch/asthma\n \n #weltasthmatag #asthma #lungenliga """ "reactions_count" => 13 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-17 06:46:57" "deleted" => 1 ] [ "id" => 194723813 "company_id" => 8375742 "urn" => "urn:li:activity:7057265270175752192" "followers" => 1217 "date" => "1mo" "description" => """ Cours «Connaissances de base sur les maladies pulmonaires et respiratoires»: Approfondissez vos connaissances sur les différentes pathologies dans ce domaine, la pose du diagnostic et les différentes thérapies existantes.\n 📅 Les 6, 7 et 8 juin 2023 à Lausanne.\n \n Information et Inscription ici 👉 https://lnkd.in/espUkfjR """ "reactions_count" => 6 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-17 06:46:57" "deleted" => 1 ] [ "id" => 243837897 "company_id" => 8375742 "urn" => "urn:li:activity:7082750076846002176" "followers" => 1248 "date" => "1w" "description" => """ Abwechslung macht das Leben spannender - schon kleine Veränderungen bereichern den Alltag. Probieren Sie es aus!\n \n 👉 https://lnkd.in/e7_qStqH\n \n #vivomagazin #lungenliga #lungengesundheit """ "reactions_count" => 6 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 08:26:30" "deleted" => 1 ] [ "id" => 243837898 "company_id" => 8375742 "urn" => "urn:li:activity:7079761950653476864" "followers" => 1248 "date" => "2w" "description" => """ Wir freuen uns, auch dieses Jahr wieder am Projekt #rauchfreiermonat teilzunehmen. Diesen November werden die Teilnehmerinnen und Teilnehmer in einem mehrstufigen Programm den Schritt in den Ausstieg wagen - mit wirksamen Übungen, hilfreicher Unterstützung von Expert/innen und immer im Austausch mit der online Community. \n \n Sind Sie an einer Teilnahme interessiert?\n 👉 www.rauchfreiermonat.ch """ "reactions_count" => 14 "comments_count" => null "reshared_post_author" => "Month Without Tobacco" "reshared_post_author_url" => "https://ch.linkedin.com/company/month-without-tobacco" "reshared_post_author_headline" => null "reshared_post_description" => """ 🚭Today we introduce you to our partner organisation Lungenliga Schweiz! 💚\n \n The Swiss Lung League is committed to healthy lungs and airways. Together we take the decisive step to improve health and lead a smoke-free life. 🔥💪\n \n Watch the video of the Swiss Lung League and learn more about your function and expertise in the areas of prevention and smoking cessation counselling.\n \n Visit their website and get the support you need to successfully quit smoking! https://lnkd.in/edbjNKYi\n \n We are very proud to have the Swiss Lung League on board for the 2023 edition of the #MonthWithoutTobacco.\n \n #TogetherWeAreStronger 💚 👉 #StopSmoking #HealthyLungs #SmokeFreeMonth2023 #smokefree """ "reshared_post_followers" => 97 "reshared_post_date" => "3w" "last_updated" => "2023-08-15 08:26:30" "deleted" => 1 ] [ "id" => 243837899 "company_id" => 8375742 "urn" => "urn:li:activity:7079472366992379904" "followers" => 1248 "date" => "2w" "description" => """ Journée de spécialisation apnée du sommeil - 21 septembre 2023 à Lausanne 💡 \n Le bon appareil thérapeutique pour le bon patient! Ce cours vous permet d’échanger sur les difficultés rencontrées avec vos patients sous traitement dans le cadre d’apnée du sommeil et de mettre à jour vos connaissances sur les appareils existants. \n Details & Inscription: https://lnkd.in/eBw7igRx\n \n #formationcontinue #liguepulmonairesuisse #apnéedusommeil """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 08:26:30" "deleted" => 1 ] [ "id" => 243837900 "company_id" => 8375742 "urn" => "urn:li:activity:7079138145488789504" "followers" => 1248 "date" => "2w" "description" => """ Wir suchen Verstärkung. Lust auf eine sinnstiftende Teilzeitrolle?\n #jobs #teilzeit """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 08:26:30" "deleted" => 1 ] [ "id" => 243837901 "company_id" => 8375742 "urn" => "urn:li:activity:7077627995162603521" "followers" => 1248 "date" => "3w" "description" => """ Bereichernde Begegnungen und ein reger Austausch am Stand der #Lungenliga anlässlich der #Jahreskonferenz der Schweizerischen Gesellschaft für #Pneumologie und #Kardiologie! \n \n An unserer öffentlichen Infoveranstaltung informierten Expertinnen und Experten das Publikum über neue Tabak- und Nikotinprodukte und ihre Folgen.\n \n #lungenliga #sgpkongress #sgp #sgk """ "reactions_count" => 42 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 08:26:30" "deleted" => 1 ] [ "id" => 243837902 "company_id" => 8375742 "urn" => "urn:li:activity:7076814142497542145" "followers" => 1248 "date" => "3w" "description" => """ Wir bleiben am Ball - #Jahresbericht Lungenliga Schweiz 💚 \n \n Eine erfolgreiche Abstimmung, intensive Verhandlungen und die Ankunft vieler Menschen aus der Ukraine – dies und vieles mehr prägte das Jahr 2022 der Lungenliga Schweiz. Lesen Sie mehr dazu in unserem Jahresbericht.\n \n 👉 https://lnkd.in/dca5Bu5\n \n #jahresbericht #lungenligaschweiz #mehrluftfürsleben """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 08:26:30" "deleted" => 1 ] [ "id" => 243837903 "company_id" => 8375742 "urn" => "urn:li:activity:7074723259438526464" "followers" => 1248 "date" => "1mo" "description" => """ Die Organisation Rauchfreier Monat sucht weitere Partnerorganisationen im Gesundheitsbereich für die Aktion #rauchfreiermonat im November 2023. \n \n Auch die Lungenliga ist wieder mit dabei 💚 \n \n Mehr Infos 👇 """ "reactions_count" => 8 "comments_count" => 1 "reshared_post_author" => "Month Without Tobacco" "reshared_post_author_url" => "https://ch.linkedin.com/company/month-without-tobacco" "reshared_post_author_headline" => null "reshared_post_description" => """ 📢 The #MonthWithoutTobacco is back and we want YOU to join us!\n \n Looking for an opportunity to have a positive #HealthImpact in Switzerland? As a health organisation, we invite you to partner with us and raise awareness about tobacco consumption. \n \n Did you know that if smokers quit for just one month, they are five times more likely to quit for good? Joining forces with us in this national campaign next November 2023 is the perfect approach, as scientific studies have shown that quitting together increases success rates.\n \n Let's highlight our achievements in 2022: \n 🌟 Supported by 34 partner organisations \n 🌍 National and regional reach 💪 Over 8’000 registered participants \n 📣 Engaged with over two million people through a powerful cross-media campaign\n \n Why should you partner with us? \n ✅ Join a network that prioritises national health and wellbeing \n 🛠️ Access a range of tools for participants (both offline and online) \n 🌍 Be a catalyst for change!\n \n Take action now and contact us to become a valued partner. Together, we can make a difference!\n \n #MonthWithoutTobacco2023 #Rauchfreiermonat2023 #MoisSansTabac2023 #MeseSenzaTabacco2023 #PartnershipOpportunity #JoinTheMovement #HealthAndWellbeing Fondation O2 Unisanté Ligue pulmonaire vaudoise Ligue pulmonaire neuchâteloise Promotion santé Valais Lega polmonare ticinese Santé bernoise Lungenliga Schweiz Lungenliga beider Basel ZHAW Zürcher Hochschule für Angewandte Wissenschaften AT Schweiz - Swiss Association for Tobacco Control Carrefour addictionS Diaspora TV Switzerland Office fédéral de la santé publique OFSP Felix Stähli Jie LI Santu (Alexandra) Boëthius Amanda Byrde Rochelle E. Aberer Marina Cantafio Magali Magistrale Sofia Garbo Julien Abegglen Verazzi Myriam Saad Sebastian Van Eickelen Joanna Drevard """ "reshared_post_followers" => 97 "reshared_post_date" => "1mo" "last_updated" => "2023-08-15 08:26:30" "deleted" => 1 ] [ "id" => 243837904 "company_id" => 8375742 "urn" => "urn:li:activity:7074367112214913024" "followers" => 1248 "date" => "1mo" "description" => """ Auf Schritt und Tritt: Eine Studie von Addiction Suisse zeigt auf, dass Jugendliche der Stadt Genf alle 65 Meter einem Anreiz für Alkohol, Tabak- und Nikotinprodukten ausgesetzt sind. Dies verdeutlicht die erschreckende Normalität dieser Produkte im Alltag der Jugendlichen. Zu ihrem Schutz braucht es deshalb eine konsequente Umsetzung der Volksinitiative «Kinder ohne Tabak».\n Mehr Infos zur Studie 👉 https://lnkd.in/e7iJ7BxS """ "reactions_count" => 13 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 08:26:30" "deleted" => 1 ] [ "id" => 243837905 "company_id" => 8375742 "urn" => "urn:li:activity:7072495571172749312" "followers" => 1248 "date" => "1mo" "description" => """ Wir sind beeindruckt: An der #Zigarettenstummel-Sammelaktion von stop2drop sammelten 2’890 Schulkinder, Jugendliche und Erwachsene 539'331 Zigarettenstummel. Sie haben die Spitze des giftigen Müllbergs freigelegt, der täglich achtlos in die Natur geworfen wird. Mit dem Zigarettenstummel fliegen auch Mikroplastik und chemische Stoffe in die Umwelt. Ihre Beseitigung aus der #Umwelt ist äusserst kosten- und energieintensiv. Mit der Aktion strebt #stop2drop ein Umdenken in der #Gesellschaft und #Politik an.\n https://stop2drop.ch """ "reactions_count" => 65 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 08:26:30" "deleted" => 1 ] [ "id" => 243837906 "company_id" => 8375742 "urn" => "urn:li:activity:7070031215684149248" "followers" => 1248 "date" => "1mo" "description" => """ Bereichernde Begegnungen, bedeutende Neuigkeiten und ein reger Austausch erwarteten heute die Zuschauer am #Tuberkulose-Symposium 2023. Fachpersonen stellten aktuelle Daten und Projekte vor und sprachen über die Zukunft der #Tuberkulosebekämpfung in der Schweiz.\n \n #tuberkulose #kompetenzzentrumtuberkulose #tbsymposium2023 """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-15 08:26:30" "deleted" => 1 ] [ "id" => 294703363 "company_id" => 8375742 "urn" => "urn:li:activity:7095045500822765569" "followers" => null "date" => "5d" "description" => "Für alle Interessierten aus dem Raum Basel: Das #Atemfest vom 2. September ist eine gute Gelegenheit, die Lungenliga beider Basel näher kennenzulernen." "reactions_count" => 4 "comments_count" => null "reshared_post_author" => "Lungenliga beider Basel" "reshared_post_author_url" => "https://ch.linkedin.com/company/lungenliga-beider-basel" "reshared_post_author_headline" => null "reshared_post_description" => """ 🎉 Wir laden Sie herzlich ein, am 𝗦𝗮𝗺𝘀𝘁𝗮𝗴, 𝟮. 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟯 mit uns das 𝗔𝘁𝗲𝗺𝗳𝗲𝘀𝘁 der Lungenliga beider Basel in unserem schönen Hinterhof zu feiern! \n \n Lernen Sie unsere 𝗙𝗮𝗰𝗵𝗽𝗲𝗿𝘀𝗼𝗻𝗲𝗻 kennen und testen Sie Ihre 𝗟𝘂𝗻𝗴𝗲𝗻𝗹𝗲𝗶𝘀𝘁𝘂𝗻𝗴 sowie Ihr 𝗦𝗰𝗵𝗹𝗮𝗳𝗮𝗽𝗻𝗼𝗲-𝗥𝗶𝘀𝗶𝗸𝗼. \n \n Auch für das leibliche Wohl gibt es ein attraktives Angebot. Versuchen Sie zudem Ihr Glück bei unserer 𝗧𝗼𝗺𝗯𝗼𝗹𝗮 𝗺𝗶𝘁 𝘃𝗶𝗲𝗹𝗲𝗻 𝘁𝗼𝗹𝗹𝗲𝗻 𝗣𝗿𝗲𝗶𝘀𝗲𝗻 im Wert von bis zu CHF 500.-\n \n Für unsere kleinen Gäste findet von 14 bis 15 Uhr das 𝗞𝗶𝗻𝗱𝗲𝗿𝘀𝗰𝗵𝗺𝗶𝗻𝗸𝗲𝗻 statt.🎨\n \n Wir freuen uns auf zahlreiche Gäste an der Mittlere Strasse 35 in Basel, von 11.30 bis 16 Uhr.\n \n Aktuelle Infos auf unserer Webseite: https://lnkd.in/eRM2f9Ud \n \n #Atemfest2023 #LungenligabeiderBasel #Lungengesundheit """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2023-09-03 03:01:47" "deleted" => 1 ] [ "id" => 294703364 "company_id" => 8375742 "urn" => "urn:li:activity:7092881382724526080" "followers" => null "date" => "1w" "description" => "Lust auf eine sinnstiftende Tätigkeit? Wir freuen uns auf Ihre Bewerbung bis zum 22. August 2023." "reactions_count" => 9 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-03 03:01:47" "deleted" => 1 ] [ "id" => 294703365 "company_id" => 8375742 "urn" => "urn:li:activity:7088038540499906560" "followers" => null "date" => null "description" => null "reactions_count" => 13 "comments_count" => null "reshared_post_author" => "Month Without Tobacco" "reshared_post_author_url" => "https://ch.linkedin.com/company/month-without-tobacco" "reshared_post_author_headline" => null "reshared_post_description" => """ We are thrilled to partner with over #300partners (cantons, communes, health promotion and prevention actors and way more) in whole Switzerland in 2023! \n \n Together, we are taking another leap towards a healthier and #smokefree future. 🚀\n \n 🤝 On top of all local partners, we are joining forces with national actors such as AT Schweiz - Swiss Association for Tobacco Control, Lungenliga Schweiz, AEH Zentrum für Arbeitsmedizin, Ergonomie und Hygiene AG, #DryJanuary, ENSEMBLE SANS FUMÉE!, Infodrog, Ligue suisse contre le cancer, Oncosuisse Forum & the national stop-tobacco tools (#QuitSmokingHelpine & stopsmoking.ch).\n \n \n And we are combining our expertise, resources, and dedication to make a lasting impact on tobacco prevention and cessation efforts nationwide.\n \n 🌍 Our collaboration aims to reach every corner of the country, empowering individuals to break free from the grip of tobacco addiction and embrace a vibrant, tobacco-free lifestyle with a large panel of online and offline support. Through collective action and innovative strategies, we will create a supportive environment for change.\n \n 💡 Together, we will raise awareness through impactful campaigns, and provide accessible resources for those seeking to quit smoking.\n \n 🗣️ The power of collaboration is undeniable. By working hand in hand with our national partners, we can leverage our strengths, knowledge, and networks to maximize our reach and influence. Together, we will build a strong and united front against tobacco use.\n \n Thank you to all our partners for their unwavering commitment to the cause. It is through their invaluable support that we can make a significant difference in November 2023 and onward.\n \n 📢 Join the Movement: Help us create a smoke-free future! Support our nationwide efforts by spreading the word and sharing our resources with those looking to quit smoking. Together, we can make a difference! 🚀\n \n And to know more about our network of partners, visit our website: https://lnkd.in/e9hkna9a\n \n #CollaborationForChange #TobaccoFree #MonthWithoutTobacco #RauchfreieMonat #MoisSansTabac #MeseSenzaTabacco Jie LI Rochelle E. Aberer Magali Magistrale Marina Cantafio Myriam Saad Felix Stähli Sofia Garbo Julien Abegglen Verazzi Joanna Drevard """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2023-09-03 03:01:47" "deleted" => 1 ] [ "id" => 294703366 "company_id" => 8375742 "urn" => "urn:li:activity:7082750076846002176" "followers" => null "date" => "1mo" "description" => """ Abwechslung macht das Leben spannender - schon kleine Veränderungen bereichern den Alltag. Probieren Sie es aus!\n \n 👉 https://lnkd.in/e7_qStqH\n \n #vivomagazin #lungenliga #lungengesundheit """ "reactions_count" => 7 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-27 20:54:28" "deleted" => 1 ] [ "id" => 294703367 "company_id" => 8375742 "urn" => "urn:li:activity:7079761950653476864" "followers" => null "date" => "1mo" "description" => """ Wir freuen uns, auch dieses Jahr wieder am Projekt #rauchfreiermonat teilzunehmen. Diesen November werden die Teilnehmerinnen und Teilnehmer in einem mehrstufigen Programm den Schritt in den Ausstieg wagen - mit wirksamen Übungen, hilfreicher Unterstützung von Expert/innen und immer im Austausch mit der online Community. \n \n Sind Sie an einer Teilnahme interessiert?\n 👉 www.rauchfreiermonat.ch """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => "Month Without Tobacco" "reshared_post_author_url" => "https://ch.linkedin.com/company/month-without-tobacco" "reshared_post_author_headline" => null "reshared_post_description" => """ 🚭Today we introduce you to our partner organisation Lungenliga Schweiz! 💚\n \n The Swiss Lung League is committed to healthy lungs and airways. Together we take the decisive step to improve health and lead a smoke-free life. 🔥💪\n \n Watch the video of the Swiss Lung League and learn more about your function and expertise in the areas of prevention and smoking cessation counselling.\n \n Visit their website and get the support you need to successfully quit smoking! https://lnkd.in/edbjNKYi\n \n We are very proud to have the Swiss Lung League on board for the 2023 edition of the #MonthWithoutTobacco.\n \n #TogetherWeAreStronger 💚 👉 #StopSmoking #HealthyLungs #SmokeFreeMonth2023 #smokefree """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-09-03 03:01:47" "deleted" => 1 ] [ "id" => 294703368 "company_id" => 8375742 "urn" => "urn:li:activity:7079472366992379904" "followers" => null "date" => "1mo" "description" => """ Journée de spécialisation apnée du sommeil - 21 septembre 2023 à Lausanne 💡 \n Le bon appareil thérapeutique pour le bon patient! Ce cours vous permet d’échanger sur les difficultés rencontrées avec vos patients sous traitement dans le cadre d’apnée du sommeil et de mettre à jour vos connaissances sur les appareils existants. \n Details & Inscription: https://lnkd.in/eBw7igRx\n \n #formationcontinue #liguepulmonairesuisse #apnéedusommeil """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-03 03:01:47" "deleted" => 1 ] [ "id" => 294703369 "company_id" => 8375742 "urn" => "urn:li:activity:7079138145488789504" "followers" => null "date" => "1mo" "description" => """ Wir suchen Verstärkung. Lust auf eine sinnstiftende Teilzeitrolle?\n #jobs #teilzeit """ "reactions_count" => 10 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-03 03:01:47" "deleted" => 1 ] [ "id" => 294703370 "company_id" => 8375742 "urn" => "urn:li:activity:7077627995162603521" "followers" => null "date" => "1mo" "description" => """ Bereichernde Begegnungen und ein reger Austausch am Stand der #Lungenliga anlässlich der #Jahreskonferenz der Schweizerischen Gesellschaft für #Pneumologie und #Kardiologie! \n \n An unserer öffentlichen Infoveranstaltung informierten Expertinnen und Experten das Publikum über neue Tabak- und Nikotinprodukte und ihre Folgen.\n \n #lungenliga #sgpkongress #sgp #sgk """ "reactions_count" => 42 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-03 03:01:47" "deleted" => 1 ] [ "id" => 294703371 "company_id" => 8375742 "urn" => "urn:li:activity:7076814142497542145" "followers" => null "date" => "1mo" "description" => """ Wir bleiben am Ball - #Jahresbericht Lungenliga Schweiz 💚 \n \n Eine erfolgreiche Abstimmung, intensive Verhandlungen und die Ankunft vieler Menschen aus der Ukraine – dies und vieles mehr prägte das Jahr 2022 der Lungenliga Schweiz. Lesen Sie mehr dazu in unserem Jahresbericht.\n \n 👉 https://lnkd.in/dca5Bu5\n \n #jahresbericht #lungenligaschweiz #mehrluftfürsleben """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-03 03:01:47" "deleted" => 1 ] [ "id" => 294703372 "company_id" => 8375742 "urn" => "urn:li:activity:7074723259438526464" "followers" => null "date" => "2mo" "description" => """ Die Organisation Rauchfreier Monat sucht weitere Partnerorganisationen im Gesundheitsbereich für die Aktion #rauchfreiermonat im November 2023. \n \n Auch die Lungenliga ist wieder mit dabei 💚 \n \n Mehr Infos 👇 """ "reactions_count" => 8 "comments_count" => 1 "reshared_post_author" => "Month Without Tobacco" "reshared_post_author_url" => "https://ch.linkedin.com/company/month-without-tobacco" "reshared_post_author_headline" => null "reshared_post_description" => """ 📢 The #MonthWithoutTobacco is back and we want YOU to join us!\n \n Looking for an opportunity to have a positive #HealthImpact in Switzerland? As a health organisation, we invite you to partner with us and raise awareness about tobacco consumption. \n \n Did you know that if smokers quit for just one month, they are five times more likely to quit for good? Joining forces with us in this national campaign next November 2023 is the perfect approach, as scientific studies have shown that quitting together increases success rates.\n \n Let's highlight our achievements in 2022: \n 🌟 Supported by 34 partner organisations \n 🌍 National and regional reach 💪 Over 8’000 registered participants \n 📣 Engaged with over two million people through a powerful cross-media campaign\n \n Why should you partner with us? \n ✅ Join a network that prioritises national health and wellbeing \n 🛠️ Access a range of tools for participants (both offline and online) \n 🌍 Be a catalyst for change!\n \n Take action now and contact us to become a valued partner. Together, we can make a difference!\n \n #MonthWithoutTobacco2023 #Rauchfreiermonat2023 #MoisSansTabac2023 #MeseSenzaTabacco2023 #PartnershipOpportunity #JoinTheMovement #HealthAndWellbeing Fondation O2 Unisanté Ligue pulmonaire vaudoise Ligue pulmonaire neuchâteloise Promotion santé Valais Lega polmonare ticinese Santé bernoise Lungenliga Schweiz Lungenliga beider Basel ZHAW Zürcher Hochschule für Angewandte Wissenschaften AT Schweiz - Swiss Association for Tobacco Control Carrefour addictionS Diaspora TV Switzerland Office fédéral de la santé publique OFSP Felix Stähli Jie LI Santu (Alexandra) Boëthius Amanda Byrde Rochelle E. Aberer Marina Cantafio Magali Magistrale Sofia Garbo Julien Abegglen Verazzi Myriam Saad Sebastian Van Eickelen Joanna Drevard """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2023-09-03 03:01:47" "deleted" => 1 ] [ "id" => 305593725 "company_id" => 8375742 "urn" => "urn:li:activity:7103270252020424704" "followers" => null "date" => "1d" "description" => """ Die Anmeldungen für den #RauchfreienMonat sind jetzt offen!\n Möchten Sie mit dem Rauchen aufhören? Sie haben diesen November die Möglichkeit, sich einer Gemeinschaft anzuschliessen\n und den Weg in ein rauchfreies Leben zu starten. \n \n Nach der Anmeldung erhalten die Teilnehmenden Zugang zu exklusiven Tools, Empfehlungen von ExpertInnen und einer dynamischen Gemeinschaft von Menschen, die das gleiche Ziel verfolgen: ein gesünderes,\n rauchfreies Leben zu führen.\n \n Die Anmeldung ist einfach und kostenlos!\n 👉 www.rauchfreiermonat.ch\n \n #rauchfreiermonat #rauchfrei #rauchstopp """ "reactions_count" => 1 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-27 20:54:28" "deleted" => 1 ] [ "id" => 305593726 "company_id" => 8375742 "urn" => "urn:li:activity:7099800826197471232" "followers" => null "date" => "1w" "description" => """ Lust auf eine abwechslungsreiche und sinnstiftenden Arbeit? Bringen Sie Ihr Fachwissen ein und werden Sie Teil unserer Teams!! Die Lungenliga hat immer wieder attraktive Stellen in verschiedenen Bereichen ausgeschrieben. \n 👉 www.lungenliga.ch/jobs """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-27 20:54:28" "deleted" => 1 ] [ "id" => 305593727 "company_id" => 8375742 "urn" => "urn:li:activity:7098211466226319361" "followers" => null "date" => "2w" "description" => """ Die #Gesundheitskommission des #Ständerates will #Tabakwerbung teilweise weiterhin erlauben und missachtet so den Willen des Volkes. Dieses hat sich an der Volksinitiative im Februar klar für einen besseren Kinder- und #Jugendschutz bei der Werbung ausgesprochen. \n Die Lungenliga setzt sich als Mitglied des Trägervereins für eine adäquate Umsetzung der Volksinitiative ein.\n \n Zur Medienmitteilung: https://lnkd.in/eukS6QKF """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-27 20:54:28" "deleted" => 1 ] [ "id" => 305593728 "company_id" => 8375742 "urn" => "urn:li:activity:7097495124271652865" "followers" => null "date" => "2w" "description" => """ Journée de spécialisation apnée du sommeil - 21 septembre 2023 à Lausanne 💡 \n \n Le bon appareil thérapeutique pour le bon patient! Ce cours vous permet d’échanger sur les difficultés rencontrées avec vos patients sous traitement dans le cadre d’#apnée du sommeil et de mettre à jour vos connaissances sur les appareils existants.\n Details & Inscription: https://lnkd.in/dGbyASnD """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-27 20:54:28" "deleted" => 1 ] [ "id" => 305593729 "company_id" => 8375742 "urn" => "urn:li:activity:7095045500822765569" "followers" => null "date" => "3w" "description" => "Für alle Interessierten aus dem Raum Basel: Das #Atemfest vom 2. September ist eine gute Gelegenheit, die Lungenliga beider Basel näher kennenzulernen." "reactions_count" => 5 "comments_count" => null "reshared_post_author" => "Lungenliga beider Basel" "reshared_post_author_url" => "https://ch.linkedin.com/company/lungenliga-beider-basel" "reshared_post_author_headline" => null "reshared_post_description" => """ 🎉 Wir laden Sie herzlich ein, am 𝗦𝗮𝗺𝘀𝘁𝗮𝗴, 𝟮. 𝗦𝗲𝗽𝘁𝗲𝗺𝗯𝗲𝗿 𝟮𝟬𝟮𝟯 mit uns das 𝗔𝘁𝗲𝗺𝗳𝗲𝘀𝘁 der Lungenliga beider Basel in unserem schönen Hinterhof zu feiern! \n \n Lernen Sie unsere 𝗙𝗮𝗰𝗵𝗽𝗲𝗿𝘀𝗼𝗻𝗲𝗻 kennen und testen Sie Ihre 𝗟𝘂𝗻𝗴𝗲𝗻𝗹𝗲𝗶𝘀𝘁𝘂𝗻𝗴 sowie Ihr 𝗦𝗰𝗵𝗹𝗮𝗳𝗮𝗽𝗻𝗼𝗲-𝗥𝗶𝘀𝗶𝗸𝗼. \n \n Auch für das leibliche Wohl gibt es ein attraktives Angebot. Versuchen Sie zudem Ihr Glück bei unserer 𝗧𝗼𝗺𝗯𝗼𝗹𝗮 𝗺𝗶𝘁 𝘃𝗶𝗲𝗹𝗲𝗻 𝘁𝗼𝗹𝗹𝗲𝗻 𝗣𝗿𝗲𝗶𝘀𝗲𝗻 im Wert von bis zu CHF 500.-\n \n Für unsere kleinen Gäste findet von 14 bis 15 Uhr das 𝗞𝗶𝗻𝗱𝗲𝗿𝘀𝗰𝗵𝗺𝗶𝗻𝗸𝗲𝗻 statt.🎨\n \n Wir freuen uns auf zahlreiche Gäste an der Mittlere Strasse 35 in Basel, von 11.30 bis 16 Uhr.\n \n Aktuelle Infos auf unserer Webseite: https://lnkd.in/eRM2f9Ud \n \n #Atemfest2023 #LungenligabeiderBasel #Lungengesundheit """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2023-10-27 20:54:28" "deleted" => 1 ] [ "id" => 305593730 "company_id" => 8375742 "urn" => "urn:li:activity:7092881382724526080" "followers" => null "date" => "1mo" "description" => "Lust auf eine sinnstiftende Tätigkeit? Wir freuen uns auf Ihre Bewerbung bis zum 22. August 2023." "reactions_count" => 10 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-27 20:54:28" "deleted" => 1 ] [ "id" => 305593731 "company_id" => 8375742 "urn" => "urn:li:activity:7088038540499906560" "followers" => null "date" => null "description" => null "reactions_count" => 15 "comments_count" => null "reshared_post_author" => "Month Without Tobacco" "reshared_post_author_url" => "https://ch.linkedin.com/company/month-without-tobacco" "reshared_post_author_headline" => null "reshared_post_description" => """ We are thrilled to partner with over #300partners (cantons, communes, health promotion and prevention actors and way more) in whole Switzerland in 2023! \n \n Together, we are taking another leap towards a healthier and #smokefree future. 🚀\n \n 🤝 On top of all local partners, we are joining forces with national actors such as AT Schweiz - Swiss Association for Tobacco Control, Lungenliga Schweiz, AEH Zentrum für Arbeitsmedizin, Ergonomie und Hygiene AG, #DryJanuary, ENSEMBLE SANS FUMÉE!, Infodrog, Ligue suisse contre le cancer, Oncosuisse Forum & the national stop-tobacco tools (#QuitSmokingHelpine & stopsmoking.ch).\n \n \n And we are combining our expertise, resources, and dedication to make a lasting impact on tobacco prevention and cessation efforts nationwide.\n \n 🌍 Our collaboration aims to reach every corner of the country, empowering individuals to break free from the grip of tobacco addiction and embrace a vibrant, tobacco-free lifestyle with a large panel of online and offline support. Through collective action and innovative strategies, we will create a supportive environment for change.\n \n 💡 Together, we will raise awareness through impactful campaigns, and provide accessible resources for those seeking to quit smoking.\n \n 🗣️ The power of collaboration is undeniable. By working hand in hand with our national partners, we can leverage our strengths, knowledge, and networks to maximize our reach and influence. Together, we will build a strong and united front against tobacco use.\n \n Thank you to all our partners for their unwavering commitment to the cause. It is through their invaluable support that we can make a significant difference in November 2023 and onward.\n \n 📢 Join the Movement: Help us create a smoke-free future! Support our nationwide efforts by spreading the word and sharing our resources with those looking to quit smoking. Together, we can make a difference! 🚀\n \n And to know more about our network of partners, visit our website: https://lnkd.in/e9hkna9a\n \n #CollaborationForChange #TobaccoFree #MonthWithoutTobacco #RauchfreieMonat #MoisSansTabac #MeseSenzaTabacco Jie LI Rochelle E. Aberer Magali Magistrale Marina Cantafio Myriam Saad Felix Stähli Sofia Garbo Julien Abegglen Verazzi Joanna Drevard """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2023-10-27 20:54:28" "deleted" => 1 ] [ "id" => 305593732 "company_id" => 8375742 "urn" => "urn:li:activity:7079761950653476864" "followers" => null "date" => "2mo" "description" => """ Wir freuen uns, auch dieses Jahr wieder am Projekt #rauchfreiermonat teilzunehmen. Diesen November werden die Teilnehmerinnen und Teilnehmer in einem mehrstufigen Programm den Schritt in den Ausstieg wagen - mit wirksamen Übungen, hilfreicher Unterstützung von Expert/innen und immer im Austausch mit der online Community. \n \n Sind Sie an einer Teilnahme interessiert?\n 👉 www.rauchfreiermonat.ch """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => "Month Without Tobacco" "reshared_post_author_url" => "https://ch.linkedin.com/company/month-without-tobacco" "reshared_post_author_headline" => null "reshared_post_description" => """ 🚭Today we introduce you to our partner organisation Lungenliga Schweiz! 💚\n \n The Swiss Lung League is committed to healthy lungs and airways. Together we take the decisive step to improve health and lead a smoke-free life. 🔥💪\n \n Watch the video of the Swiss Lung League and learn more about your function and expertise in the areas of prevention and smoking cessation counselling.\n \n Visit their website and get the support you need to successfully quit smoking! https://lnkd.in/edbjNKYi\n \n We are very proud to have the Swiss Lung League on board for the 2023 edition of the #MonthWithoutTobacco.\n \n #TogetherWeAreStronger 💚 👉 #StopSmoking #HealthyLungs #SmokeFreeMonth2023 #smokefree """ "reshared_post_followers" => null "reshared_post_date" => "2mo" "last_updated" => "2023-10-27 20:54:28" "deleted" => 1 ] [ "id" => 305593733 "company_id" => 8375742 "urn" => "urn:li:activity:7079472366992379904" "followers" => null "date" => "2mo" "description" => """ Journée de spécialisation apnée du sommeil - 21 septembre 2023 à Lausanne 💡 \n Le bon appareil thérapeutique pour le bon patient! Ce cours vous permet d’échanger sur les difficultés rencontrées avec vos patients sous traitement dans le cadre d’apnée du sommeil et de mettre à jour vos connaissances sur les appareils existants. \n Details & Inscription: https://lnkd.in/eBw7igRx\n \n #formationcontinue #liguepulmonairesuisse #apnéedusommeil """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-10-27 20:54:28" "deleted" => 1 ] [ "id" => 361472819 "company_id" => 8375742 "urn" => "urn:li:activity:7123241868649230336" "followers" => null "date" => "1d" "description" => """ Eine Grippe verläuft nicht immer harmlos: es kann zu schweren Komplikationen und Todesfällen kommen. Die Grippeimpfung bietet einen guten Schutz vor einer Ansteckung und Erkrankung. Sie wird vom Bundesamt für Gesundheit (BAG) empfohlen. \n \n Für: \n 🔸 Risikopersonen und ihr Umfeld\n 🔸 Gesundheitspersonal\n 🔸 Weitere Personen in beruflichem Kontakt mit Risikopersonen\n 🔸 Alle, die eine Grippeerkrankung vermeiden möchten\n \n Weitere Infos: https://lnkd.in/epShpZzJ\n \n #impfengegengrippe #winter #grippe #soschützenwiruns """ "reactions_count" => 10 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:21:39" "deleted" => 1 ] [ "id" => 361472820 "company_id" => 8375742 "urn" => "urn:li:activity:7122574956625842176" "followers" => null "date" => "3d" "description" => """ Die Lungenliga Schweiz gratuliert Flavia Wasserfallen, künftige Präsidentin der Schweizerischen #Gesundheitsligen-Konferenz #Geliko, herzlich zur Wahl in den #Ständerat. Sie tritt damit nicht nur in der Geliko die Nachfolge von Hans Stöckli an. Wir wünschen ihr bei diesen Aufgaben viel Freude und Erfolg. Ihr Engagement ist nicht zuletzt für #chronisch kranke Menschen von unschätzbarem Wert.\n \n www.geliko.ch """ "reactions_count" => 24 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:21:39" "deleted" => 1 ] [ "id" => 361472821 "company_id" => 8375742 "urn" => "urn:li:activity:7120694856087162880" "followers" => null "date" => "1w" "description" => """ Was muss ich über Vapes wissen? Wie schädlich sind sie und was hat es da überhaupt drin? Was ist mit Snus und Schnupftabak? Und ist es nötig, Nikotinsucht bei Jugendlichen bereits dann anzusprechen, wenn sie nur probieren?\n \n Bei diesen Fragen fehlt schnell der Durchblick. Ihnen auch? An der kostenlosen Online-Infoveranstaltung der Lungenliga Zentralschweiz erhalten Sie eine gute Übersicht über die Nikotinprodukte und Tipps, wie Sie das Thema mit Jugendlichen besprechen können.\n \n Die nächste Veranstaltung findet online am 15. November 2023 um 17:30 Uhr statt.\n \n Infos & Anmeldung 👉https://lnkd.in/eANUHc3H """ "reactions_count" => 16 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:21:39" "deleted" => 1 ] [ "id" => 361472822 "company_id" => 8375742 "urn" => "urn:li:activity:7119977850576723969" "followers" => null "date" => "2w" "description" => """ Das Leben mit einer Krankheit wie der chronisch obstruktiven Lungen erkrankung (COPD), Schlafapnoe oder Cystischen Fibrose ist oft mit Einschränkungen verbunden. Um Betroffene zu unterstützen, ihr Leben mit ihrer Krankheit besser zu meistern, bieten die kantonalen Lungenligen verschiedene Beratungen, Kurse und Coachings an. Irène Businger, Projektleiterin Gesundheitsförderung & Prävention der Lungenliga Zentralschweiz, gibt einen Einblick in ihre Coaching-Arbeit. \n 👉 https://lnkd.in/ehtg35gN\n \n #copd #schlafapnoe #lungenerkrankungen #longcovid #coaching #lungenliga """ "reactions_count" => 14 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:21:39" "deleted" => 1 ] [ "id" => 361472823 "company_id" => 8375742 "urn" => "urn:li:activity:7118502957439954944" "followers" => null "date" => "2w" "description" => """ Schauen Sie in unser #Weiterbildungsprogramm 2024 für #Gesundheitsfachpersonen und finden Sie mehr Infos zur höheren Fachprüfung «Fachexpertin/Fachexperte Respiratory Care» 👉 https://lnkd.in/dKPB5Z7\n \n Découvrez notre #programme de #formations #continues 2024 pour les #professionnels de santé et trouvez plus d'infos sur l'examen professionnel supérieur «Experte/Expert Respiratory Care» 👉\n https://lnkd.in/d6WBisK """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:21:39" "deleted" => 1 ] [ "id" => 361472824 "company_id" => 8375742 "urn" => "urn:li:activity:7117365164496015361" "followers" => null "date" => "2w" "description" => """ Warum hat Atemnot nicht zwingend etwas mit der Lunge zu tun? Und wie beeinflussen sich Stress und Atmung? Ein Experte gibt Antworten.\n \n 👉 https://lnkd.in/eDcJSb4N\n \n #atmung #atemnot #übungen #tipps #vivo #lungenliga """ "reactions_count" => 15 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:21:39" "deleted" => 1 ] [ "id" => 361472825 "company_id" => 8375742 "urn" => "urn:li:activity:7115663603155759105" "followers" => null "date" => "3w" "description" => """ Journée de spécialisation tuberculose - le 16 novembre 2023 à Lausanne 💡 \n \n Voulez-vous connaitre les derniers développements dans le domaine de la tuberculose? Inscrivez-vous jusqu’au 15 octobre 2023 sur 👉 https://lnkd.in/eYuKcyMm\n \n #tuberculose #formationcontinue #liguepulmonaire """ "reactions_count" => 3 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:21:39" "deleted" => 1 ] [ "id" => 361472826 "company_id" => 8375742 "urn" => "urn:li:activity:7113503774349873152" "followers" => null "date" => "4w" "description" => "Mit den sogenannten «Luftholtagen» ermöglicht die Lungenliga Schweiz Menschen mit Lungen- und Atemwegserkrankungen sowie ihren Angehörigen sorgenfreie Ferien. Erfahren Sie mehr über die letzte Reise nach Sarnen im Beitrag von der Lungenliga Zentralschweiz 👉" "reactions_count" => 10 "comments_count" => null "reshared_post_author" => "Lungenliga Zentralschweiz" "reshared_post_author_url" => "https://ch.linkedin.com/company/lungenliga-zentralschweiz" "reshared_post_author_headline" => null "reshared_post_description" => """ Traumdestination suchen, buchen, Koffer packen und los geht’s. So einfach sind Ferien für Menschen mit Lungen- und Atemwegserkrankungen nicht, da es oft zu viele Unsicherheiten gibt. Die Luftholtage der Lungenliga sind für viele Betroffene sowie ihre Angehörigen die einzige Möglichkeit, um sorgenfreie Ferien zu verbringen. «Ich traue mich sonst nicht zu verreisen», erklärt Esther Baumli, welche mit ihrem Mann bei den Luftholtagen in Sarnen dabei war. «Aber da die Luftholtage ein Angebot der Lungenliga sind, war ich dabei. Das gibt mir Sicherheit.» \n \n Mehr erfahren: https://lnkd.in/eEewyh7g \n \n #luftholtage #sarnen #kurhaus #ferien #sauerstoff #lungenligazentralschweiz """ "reshared_post_followers" => null "reshared_post_date" => "4w" "last_updated" => "2023-11-26 19:21:39" "deleted" => 1 ] [ "id" => 361472827 "company_id" => 8375742 "urn" => "urn:li:activity:7113124250315550721" "followers" => null "date" => "4w" "description" => """ Das vivo Herbst wartet mit interessanten Geschichten 💚 \n Samuel Graf hat Cystische Fibrose. Dennoch startete er im Frühling mit seiner Freundin an einem Halbmarathon. Lesen Sie im aktuellen Magazin, wie Samuel gelernt hat, Unabänderliches zu akzeptieren, wie er seine Grenzen auslotet und wie er sich auf das konzentriert, was ihm Freude bereitet. \n \n Diese Geschichte und viele weitere spannende Themen erwarten Sie unter 👉 https://lnkd.in/evsaXaqG\n \n Wir wünschen Ihnen eine abwechslungsreiche Lektüre!\n \n #vivomagazin #lungenliga #geschichten #lungengesundheit #copd #cystischefibrose """ "reactions_count" => 18 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:21:39" "deleted" => 1 ] [ "id" => 361472828 "company_id" => 8375742 "urn" => "urn:li:activity:7112789151933947904" "followers" => null "date" => "1mo" "description" => """ Fachtagung Tuberkulose - 30. Oktober in Bern ❕ \n \n Möchten Sie Ihre Kenntnisse im Bereich Tuberkulose auffrischen oder vertiefen? \n \n Weitere Infos und Anmeldung bis am 10. Oktober unter 👉 https://lnkd.in/eh5pHqau\n \n #tuberkulose #kompetenzzentrum #lungenliga #fachtagungtuberkulose """ "reactions_count" => 10 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-11-26 19:21:39" "deleted" => 1 ] [ "id" => 393544890 "company_id" => 8375742 "urn" => "urn:li:activity:7133765443273531392" "followers" => null "date" => "2d" "description" => """ «Die Reise war Balsam für die Seele.» Die COPD-Betroffene Karin Negri hat kürzlich an einer Gruppenreise ans Meer teilgenommen, die von der Lungenliga organisiert wird.\n «Ich habe mich gut erholt. Den Austausch untereinander und die Gesellschaft mit den restlichen Teilnehmern habe ich sehr genossen. Wir hatten viel Spass untereinander. Ich habe jetzt auch den Ansporn, um zu Hause mehr hinaus zu gehen.». Sie wird auf jeden Fall wieder an einer Reise teilnehmen. Die organisierten Gruppenreisen der Lungenliga ermöglichen Menschen mit Lungen- und Atemwegserkrankungen sowie ihren Angehörigen sorgenfreie Ferien. Die Reisen werden jeweils durch ein Team aus medizinischem Fachpersonal begleitet.\n 👉 https://lnkd.in/evHD8i7y\n \n #gruppenreisen #copd #lungenerkrankungen #ferien #lungenliga """ "reactions_count" => 20 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-03 18:04:44" "deleted" => 1 ] [ "id" => 393544891 "company_id" => 8375742 "urn" => "urn:li:activity:7133358584616087552" "followers" => null "date" => "3d" "description" => """ Cours de base Tuberculose : Le 8 février 2024 à Lausanne\n 👉 De quelle manière et dans quelles conditions se transmet la tuberculose? Quels sont les symptômes?\n \n Inscription jusqu’au 4 janvier 2024:\n https://lnkd.in/e3E5qara """ "reactions_count" => 6 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-03 18:04:44" "deleted" => 1 ] [ "id" => 393544892 "company_id" => 8375742 "urn" => "urn:li:activity:7133137145040379904" "followers" => null "date" => "4d" "description" => """ Gezielte Atemübungen helfen, das Zwerchfell zu trainieren und so Atmung und Sauerstoffsättigung zu verbessern. Bewusstes Atmen tut nicht nur dem Körper gut, sondern kann auch helfen, Stress und Verspannungen abzubauen.\n \n Entdecken Sie unsere Atemübungen 👉 \n https://lnkd.in/enknFJX3 \n \n #atmen #atemuebungen #lungengesundheit #lungenliga """ "reactions_count" => 13 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-03 18:04:44" "deleted" => 1 ] [ "id" => 393544893 "company_id" => 8375742 "urn" => "urn:li:activity:7131340479173922816" "followers" => null "date" => "1w" "description" => """ Wer an der chronisch obstruktiven Lungenkrankheit (COPD) leidet, hat mit einigen Einschränkungen zu kämpfen. Medikamente können Beschwerden lindern und körperliches #Training die Leistungsfähigkeit verbessern. Das Selbstmanagement-Coaching «Besser leben mit COPD» der Lungenliga hilft Betroffenen nachweislich zu einer höheren Lebensqualität. Sie entwickeln dabei einen besseren Umgang mit Atemnot, Husten und Auswurf, ein besseres Krankheitsverständnis und mehr Energie und Sicherheit im Alltag.\n Mehr Infos: 👉 https://lnkd.in/dY5hqUXP \n \n #copd #besserlebenmitcopd #copdcoaching #lungenliga """ "reactions_count" => 24 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-03 18:04:44" "deleted" => 1 ] [ "id" => 393544894 "company_id" => 8375742 "urn" => "urn:li:activity:7130896717977120768" "followers" => null "date" => "1w" "description" => """ «Es ist, als ob man nur durch einen Strohhalm Sauerstoff erhält. Da machst du keinen grossen Sprünge» Hans-Rudolf Gafners Körper erhält durch die chronische Lungenerkrankung #COPD zu wenig Sauerstoff. Es gab Zeiten, da wusste er nicht, wie er den Tag überstehen sollte. Schon alleine eine Dusche war ein Kraftakt. Mit der jahrelangen Betreuung der Lungenliga Bern lernte Hans-Rudolf Gafner, mit der Krankheit zu leben.\n Lesen Sie den ganzen Artikel in der Jungfrau Zeitung im Rahmen des Welt-COPD-Tages.\n 👉 https://lnkd.in/esPbzJk4 """ "reactions_count" => 11 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-03 18:04:44" "deleted" => 1 ] [ "id" => 393544895 "company_id" => 8375742 "urn" => "urn:li:activity:7130864608373792769" "followers" => null "date" => "1w" "description" => """ Gestärktes Selbstvertrauen und bessere Fitness: Zwei Betroffene erzählen, was ihnen das Selbstmanagement-Coaching «Besser leben mit COPD» der Lungenliga gebracht hat.\n 👉 https://lnkd.in/eCNBK4ts """ "reactions_count" => 21 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-03 18:04:44" "deleted" => 1 ] [ "id" => 393544896 "company_id" => 8375742 "urn" => "urn:li:activity:7130426694472998912" "followers" => null "date" => "1w" "description" => """ Heute ist Welt-COPD-Tag 💚 \n «Es ist ja nur ein Husten.» Viele Menschen, die ständig husten, warten zu lange, bis sie sich ärztliche Hilfe holen. Die Zerstörung des Lungengewebes ist meist weit fortgeschritten, wenn die Diagnose COPD gestellt wird. Fünf Prozent der Erwachsenen in der Schweiz leiden an COPD. COPD ist nicht heilbar. Doch je früher die Krankheit erkannt und behandelt wird, desto länger können die Betroffenen ein möglichst selbstbestimmtes Leben ohne Beschwerden geniessen. \n Die wichtigste Methode zur Diagnose ist ein Lungenfunktionstest, eine sogenannte Spirometrie. Diese kann auch der Hausarzt oder die Hausärztin durchführen. \n Im November bieten viele kantonale Lungenligen Spirometrien an. Erkundigen Sie sich bei der Lungenliga in Ihrer Nähe. \n Zur Medienmitteilung 👉 https://lnkd.in/erV_f4-p \n \n #weltcopdtag #copd #spirometrie #lungenliga """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-03 18:04:44" "deleted" => 1 ] [ "id" => 393544897 "company_id" => 8375742 "urn" => "urn:li:activity:7130186066631757825" "followers" => null "date" => "1w" "description" => """ Die Schweiz landet im neuen Tabaklobby-Index 2023 erneut auf dem zweitletzten Platz (89/90). Sie ist aufgrund der grösseren Anzahl untersuchter Länder nochmals um 10 Plätze zurückgefallen. Dies verdeutlicht einmal mehr: Der Einfluss der Tabakindustrie auf die Politik in der Schweiz bleibt ungebrochen und verhindert eine wirksame Tabakkontrolle.\n \n Stellungnahme der Arbeitsgemeinschaft Tabakprävention 👉 https://lnkd.in/e-nuCxkt\n \n #tabaklobbyindex #tabakkontrolle #tabakprävention """ "reactions_count" => 13 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-03 18:04:44" "deleted" => 1 ] [ "id" => 393544898 "company_id" => 8375742 "urn" => "urn:li:activity:7129776694915149824" "followers" => null "date" => "1w" "description" => """ 𝐋𝐮𝐧𝐠𝐞𝐧𝐬𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦 𝟑𝟎. 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫 𝟐𝟎𝟐𝟑 - Wie gelingt es, neue wissenschaftliche Erkenntnisse rascher in die Praxis umzusetzen und damit die Behandlung unserer Patientinnen und Patienten laufend zu verbessern? Fachvorträge, Praxisworkshops zu konkreten Problemstellungen und Lösungsansätzen sowie Vorträge zu Anwendungsmöglichkeiten der digitalen Medizin in verschiedenen Disziplinen stehen im Kantonsspital St. Gallen auf dem Programm. \n \n Eine erfolgreiche Umsetzung in die klinische Praxis erfordert oft die Entwicklung zertifizierter und kommerziell verfügbarer medizinischer Lösungen. Im Laufe des Nachmittags werden ausgewählte Start-ups aus dem Bereich der digitalen Gesundheit vorgestellt. Die überzeugendste Lösung wird mit dem «Digital Health Vadian Innovation Prize 2023» ausgezeichnet. \n Anmeldung ist bis 20. November möglich. \n *\n 𝐒𝐲𝐦𝐩𝐨𝐬𝐢𝐮𝐦 𝐝𝐞 𝐩𝐧𝐞𝐮𝐦𝐨𝐥𝐨𝐠𝐢𝐞 𝟑𝟎 𝐧𝐨𝐯𝐞𝐦𝐛𝐫𝐞 𝟐𝟎𝟐𝟑 - Comment exploiter plus rapidement les dernières découvertes scientifiques et améliorer ainsi continuellement le traitement de nos patientes et patients? \n \n Le programme de cette manifestation organisée au sein de l’hôpital cantonal de Saint-Gall inclut des conférences de spécialistes, des ateliers pratiques dédiés à des problématiques concrètes et aux solutions possibles ainsi que des exposés concernant les possibilités d’application de la médecine numérique dans différentes disciplines.\n \n Une bonne mise en œuvre au sein des établissements hospitaliers requiert souvent le développement et la commercialisation de solutions médicales certifiées. Différentes start-up du secteur de la santé numérique feront l’objet d’une présentation au cours de l’après-midi. La solution la plus convaincante se verra décerner le «Digital Health Vadian Innovation Prize 2023».\n \n L'inscription est possible jusqu'au 20 novembre !\n \n https://lnkd.in/emt4jN8a """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-03 18:04:44" "deleted" => 1 ] [ "id" => 393544899 "company_id" => 8375742 "urn" => "urn:li:activity:7128664451330772992" "followers" => null "date" => "2w" "description" => """ Heute ist Nationaler Grippeimpftag! \n Impfinteressierte Personen können sich heute spontan in einer der teilnehmenden Arztpraxen bzw. Impfapotheken impfen lassen.\n \n Die Grippeimpfung bietet einen guten Schutz vor einer Ansteckung und Erkrankung und wird vom Bundesamt für Gesundheit (BAG) empfohlen. Personen über 65 wird zusätzlich die Covid-19 Impfung empfohlen. \n \n Weitere Infos: 👉 https://lnkd.in/ebYxcCtr """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-12-03 18:04:44" "deleted" => 1 ] [ "id" => 398895964 "company_id" => 8375742 "urn" => "urn:li:activity:7136280016245403649" "followers" => null "date" => "2d" "description" => """ Beispielhaftes Vorgehen von der Jugendsession - Session des jeunes - Sessione dei giovani 2023: Sie fordert, dass Rauschmittel in Einheitsverpackungen vermarktet und vertrieben werden müssen. Auch die Lungenliga macht sich für ein sogenanntes «#Plain #Packaging» stark, denn die Verpackung dient derzeit als Werbefläche. Dies steigert insbesondere bei Jugendlichen die Attraktivität des Rauchens. Lesen Sie hier mehr zu unseren Zielen und Forderungen im Bereich Tabakprävention👉 https://lnkd.in/ebHdBvgb \n \n #jugendsession #plainpackaging #tabakwerbung #tabakprävention """ "reactions_count" => 18 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 23:46:28" "deleted" => 1 ] [ "id" => 398895965 "company_id" => 8375742 "urn" => "urn:li:activity:7135137740781674496" "followers" => null "date" => "5d" "description" => """ «Flüssigsauerstoff-Tankstellen» - was ist das? 🤔\n Mit einem tragbaren Sauerstoff-Gerät können sich Lungenkranke, die eine konstante Sauerstoffzufuhr benötigen, ausserhalb der eigenen Wohnung bewegen. Die Lungenliga unterhält ein schweizweites Tankstellennetz, wo diese tragbaren Geräte kostenlos aufgefüllt werden können. Die Tankstellen sind an 365 Tagen im Jahr geöffnet, befinden sich an zentral gelegenen Standorten und sind sowohl mit öffentlichen Verkehrsmitteln als auch mit dem Auto gut erreichbar. 👉 https://lnkd.in/ejzBtCNb\n \n #sauerstofftankstellen #copd #sauerstoff #lungenliga """ "reactions_count" => 26 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 23:46:28" "deleted" => 1 ] [ "id" => 398895966 "company_id" => 8375742 "urn" => "urn:li:activity:7133765443273531392" "followers" => null "date" => "1w" "description" => """ «Die Reise war Balsam für die Seele.» Die COPD-Betroffene Karin Negri hat kürzlich an einer Gruppenreise ans Meer teilgenommen, die von der Lungenliga organisiert wird.\n «Ich habe mich gut erholt. Den Austausch untereinander und die Gesellschaft mit den restlichen Teilnehmern habe ich sehr genossen. Wir hatten viel Spass untereinander. Ich habe jetzt auch den Ansporn, um zu Hause mehr hinaus zu gehen.». Sie wird auf jeden Fall wieder an einer Reise teilnehmen. Die organisierten Gruppenreisen der Lungenliga ermöglichen Menschen mit Lungen- und Atemwegserkrankungen sowie ihren Angehörigen sorgenfreie Ferien. Die Reisen werden jeweils durch ein Team aus medizinischem Fachpersonal begleitet.\n 👉 https://lnkd.in/evHD8i7y\n \n #gruppenreisen #copd #lungenerkrankungen #ferien #lungenliga """ "reactions_count" => 31 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 23:46:28" "deleted" => 1 ] [ "id" => 398895967 "company_id" => 8375742 "urn" => "urn:li:activity:7133358584616087552" "followers" => null "date" => "1w" "description" => """ Cours de base Tuberculose : Le 8 février 2024 à Lausanne\n 👉 De quelle manière et dans quelles conditions se transmet la tuberculose? Quels sont les symptômes?\n \n Inscription jusqu’au 4 janvier 2024:\n https://lnkd.in/e3E5qara """ "reactions_count" => 11 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 23:46:28" "deleted" => 1 ] [ "id" => 398895968 "company_id" => 8375742 "urn" => "urn:li:activity:7133137145040379904" "followers" => null "date" => "1w" "description" => """ Gezielte Atemübungen helfen, das Zwerchfell zu trainieren und so Atmung und Sauerstoffsättigung zu verbessern. Bewusstes Atmen tut nicht nur dem Körper gut, sondern kann auch helfen, Stress und Verspannungen abzubauen.\n \n Entdecken Sie unsere Atemübungen 👉 \n https://lnkd.in/enknFJX3 \n \n #atmen #atemuebungen #lungengesundheit #lungenliga """ "reactions_count" => 19 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 23:46:28" "deleted" => 1 ] [ "id" => 398895969 "company_id" => 8375742 "urn" => "urn:li:activity:7131340479173922816" "followers" => null "date" => "2w" "description" => """ Wer an der chronisch obstruktiven Lungenkrankheit (COPD) leidet, hat mit einigen Einschränkungen zu kämpfen. Medikamente können Beschwerden lindern und körperliches #Training die Leistungsfähigkeit verbessern. Das Selbstmanagement-Coaching «Besser leben mit COPD» der Lungenliga hilft Betroffenen nachweislich zu einer höheren Lebensqualität. Sie entwickeln dabei einen besseren Umgang mit Atemnot, Husten und Auswurf, ein besseres Krankheitsverständnis und mehr Energie und Sicherheit im Alltag.\n Mehr Infos: 👉 https://lnkd.in/dY5hqUXP \n \n #copd #besserlebenmitcopd #copdcoaching #lungenliga """ "reactions_count" => 27 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 23:46:28" "deleted" => 1 ] [ "id" => 398895970 "company_id" => 8375742 "urn" => "urn:li:activity:7130896717977120768" "followers" => null "date" => "2w" "description" => """ «Es ist, als ob man nur durch einen Strohhalm Sauerstoff erhält. Da machst du keinen grossen Sprünge» Hans-Rudolf Gafners Körper erhält durch die chronische Lungenerkrankung #COPD zu wenig Sauerstoff. Es gab Zeiten, da wusste er nicht, wie er den Tag überstehen sollte. Schon alleine eine Dusche war ein Kraftakt. Mit der jahrelangen Betreuung der Lungenliga Bern lernte Hans-Rudolf Gafner, mit der Krankheit zu leben.\n Lesen Sie den ganzen Artikel in der Jungfrau Zeitung im Rahmen des Welt-COPD-Tages.\n 👉 https://lnkd.in/esPbzJk4 """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 23:46:28" "deleted" => 1 ] [ "id" => 398895971 "company_id" => 8375742 "urn" => "urn:li:activity:7130864608373792769" "followers" => null "date" => "2w" "description" => """ Gestärktes Selbstvertrauen und bessere Fitness: Zwei Betroffene erzählen, was ihnen das Selbstmanagement-Coaching «Besser leben mit COPD» der Lungenliga gebracht hat.\n 👉 https://lnkd.in/eCNBK4ts """ "reactions_count" => 22 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 23:46:28" "deleted" => 1 ] [ "id" => 398895972 "company_id" => 8375742 "urn" => "urn:li:activity:7130426694472998912" "followers" => null "date" => "2w" "description" => """ Heute ist Welt-COPD-Tag 💚 \n «Es ist ja nur ein Husten.» Viele Menschen, die ständig husten, warten zu lange, bis sie sich ärztliche Hilfe holen. Die Zerstörung des Lungengewebes ist meist weit fortgeschritten, wenn die Diagnose COPD gestellt wird. Fünf Prozent der Erwachsenen in der Schweiz leiden an COPD. COPD ist nicht heilbar. Doch je früher die Krankheit erkannt und behandelt wird, desto länger können die Betroffenen ein möglichst selbstbestimmtes Leben ohne Beschwerden geniessen. \n Die wichtigste Methode zur Diagnose ist ein Lungenfunktionstest, eine sogenannte Spirometrie. Diese kann auch der Hausarzt oder die Hausärztin durchführen. \n Im November bieten viele kantonale Lungenligen Spirometrien an. Erkundigen Sie sich bei der Lungenliga in Ihrer Nähe. \n Zur Medienmitteilung 👉 https://lnkd.in/erV_f4-p \n \n #weltcopdtag #copd #spirometrie #lungenliga """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 23:46:28" "deleted" => 1 ] [ "id" => 398895973 "company_id" => 8375742 "urn" => "urn:li:activity:7130186066631757825" "followers" => null "date" => "2w" "description" => """ Die Schweiz landet im neuen Tabaklobby-Index 2023 erneut auf dem zweitletzten Platz (89/90). Sie ist aufgrund der grösseren Anzahl untersuchter Länder nochmals um 10 Plätze zurückgefallen. Dies verdeutlicht einmal mehr: Der Einfluss der Tabakindustrie auf die Politik in der Schweiz bleibt ungebrochen und verhindert eine wirksame Tabakkontrolle.\n \n Stellungnahme der Arbeitsgemeinschaft Tabakprävention 👉 https://lnkd.in/e-nuCxkt\n \n #tabaklobbyindex #tabakkontrolle #tabakprävention """ "reactions_count" => 13 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-01-07 23:46:28" "deleted" => 1 ] [ "id" => 433937243 "company_id" => 8375742 "urn" => "urn:li:activity:7148188005822840832" "followers" => null "date" => "4d" "description" => """ ➡️ Projektaufruf Forschungsförderung!\n \n Mit unserem Forschungsfonds unterstützen wir innovative Forschungsprojekte von Jungforschenden, die im Kontext zu Prävention und Behandlung von Lungenkrankheiten und Atemstörungen stehen. \n \n Wir freuen uns auf Projekteingaben bis 14. März 2024. \n \n 👉https://lnkd.in/ekxsApHu """ "reactions_count" => 11 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-21 07:57:30" "deleted" => 1 ] [ "id" => 433937244 "company_id" => 8375742 "urn" => "urn:li:activity:7143910545631432704" "followers" => null "date" => "2w" "description" => """ Glühwein zum Adventsapéro, Wein zum Weihnachtsessen, Prosecco zur Silvesterparty - die festliche Zeit ist zum Geniessen da. Wie wäre es, den Januar für eine alkoholfreie Pause zu nutzen? \n \n Der Dry January ist eine weltweite Bewegung von Millionen von Menschen, die sich einen Januar ohne Alkohol gönnen.\n \n ➡️ Der Alkoholkonsum ist übrigens ein Risikofaktor für Schlafapnoe: Ein dry January könnte also nicht nur für mehr Wohl, sondern auch für einen besseren Schlaf sorgen. \n \n Machen Sie mit! 👉 https://dryjanuary.ch """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-21 07:57:30" "deleted" => 1 ] [ "id" => 433937245 "company_id" => 8375742 "urn" => "urn:li:activity:7143655040841392128" "followers" => null "date" => "2w" "description" => """ Angeblich investieren grüne Banken nach wie vor in Industrien, die Umweltschäden verursachen. Zu diesem Schluss kommt die Europäische Zentralbank in einer aktuellen Studie. Auch die Tabakindustrie verursacht gemäss WHO weltweit grosse Umweltschäden. Als Partnerin von «Tobacco Free Portfolios» setzt sich die Lungenliga Schweiz dafür ein, Finanzinstitute davon zu überzeugen, nicht mehr in die Tabakindustrie zu investieren.\n \n 👉 https://lnkd.in/eqQuaGds """ "reactions_count" => 19 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-21 07:57:30" "deleted" => 1 ] [ "id" => 433937246 "company_id" => 8375742 "urn" => "urn:li:activity:7143620466333646849" "followers" => null "date" => "2w" "description" => """ Die Schweiz bemüht sich, die Verbreitung des elektronischen Patientendossiers (#EPD) voranzubringen. Auch das EDP-Symposium von Public Health Schweiz widmete sich kürzlich diesem Thema. Jörg Spieldenner, Direktor der Lungenliga Schweiz, vertrat an diesem Anlass die Perspektive der Patientenorganisationen. Er sprach sich klar für ein elektronisches Patientendossier aus. Dies aber unter der Voraussetzung, dass es den Patientinnen und Patienten von Anfang an einen klaren Mehrwert bietet.\n Infos & Referate 👉 https://lnkd.in/e5mCydhT """ "reactions_count" => 13 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-21 07:57:30" "deleted" => 1 ] [ "id" => 433937247 "company_id" => 8375742 "urn" => "urn:li:activity:7143262298244132864" "followers" => null "date" => "2w" "description" => """ Für alle mit Netflix-Account: Wer kann sich noch an Juul erinnern? Eine Dokuserie zeigt den Aufstieg des Start-ups zu einem milliardenschweren Unternehmen – bis eine «Vaping-Epidemie» es zu Fall bringt. \n \n 👉 Sehenswert auf https://lnkd.in/deiCiKtf """ "reactions_count" => 13 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-21 07:57:30" "deleted" => 1 ] [ "id" => 433937248 "company_id" => 8375742 "urn" => "urn:li:activity:7142388796997738496" "followers" => null "date" => "2w" "description" => "Diagnose Schlafapnoe am Handgelenk? Digitale Armbanduhren wie die Apple Watch können angeblich Schlafapnoe erkennen. Was halten Experten der Pneumologie und der Schlafmedizin davon? 👉 https://lnkd.in/eQ5n5t2j" "reactions_count" => 26 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-21 07:57:30" "deleted" => 1 ] [ "id" => 433937249 "company_id" => 8375742 "urn" => "urn:li:activity:7141302104618385408" "followers" => null "date" => "3w" "description" => """ Cours «𝐄𝐧𝐬𝐞𝐢𝐠𝐧𝐞𝐦𝐞𝐧𝐭 𝐭𝐡é𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐪𝐮𝐞 𝐝𝐞 𝐥’𝐚𝐬𝐭𝐡𝐦𝐞»\n 📅 Les 20 et 21 février 2024\n Comment enseigner aux personnes souffrant de l’asthme à prévenir une crise et agir quand elle survient ?\n Dans ce cours, la Dre Nicolet spécialiste de ce domaine vous donne les outils et conseils qui vous permettront à votre tour d’enseigner la gestion autonome de l’asthme à vos patient.es.\n 👉 Inscription jusqu’au 30 janvier 2024 sur https://lnkd.in/dXKxX-Ub """ "reactions_count" => 10 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-21 07:57:30" "deleted" => 1 ] [ "id" => 433937250 "company_id" => 8375742 "urn" => "urn:li:activity:7138939927060193280" "followers" => null "date" => "1mo" "description" => """ La première Journée romande du souffle, sur le thème de la dyspnée, aura lieu le 22 février 2024 à l’Y-Parc d’Yverdon-les-Bains. \n Destinée aux professionnels de la santé, cette formation est organisée conjointement par les Ligues pulmonaires de Genève, Neuchâtel, Vaud et Valais.\n \n ℹ Plus d'info sur : https://lnkd.in/eVWFRbsk """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-21 07:57:30" "deleted" => 1 ] [ "id" => 433937251 "company_id" => 8375742 "urn" => "urn:li:activity:7138577259312861184" "followers" => null "date" => "1mo" "description" => """ Unser Forschungsfonds vergibt einen Preis an Jungforschende für die beste wissenschaftliche Publikation auf dem Gebiet der klinischen und respiratorischen Forschung sowie der Epidemiologie, der Diagnose, des Krankheitsmanagements und der translationalen Forschung. Wir freuen uns auf Ihre Bewerbung bis am 06. Januar 2024. 👉 https://lnkd.in/dxprBDcu\n \n \n \n Our research fund awards a prize to young researchers for the best scientific publication in the field of clinical and respiratory research, as well as epidemiology, diagnosis, disease man\x02agement and translational research. We look forward to receiving applications by January 06, 2024.\n 👉https://lnkd.in/dxprBDcu\n \n \n #forschungsförderung #forschung #research #forschungspreis .#researchaward """ "reactions_count" => 13 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-21 07:57:30" "deleted" => 1 ] [ "id" => 433937252 "company_id" => 8375742 "urn" => "urn:li:activity:7138178710460854272" "followers" => null "date" => "1mo" "description" => "Wir wünschen frohe Festtage und ein erfolgreiches neues Jahr! Möge die festliche Zeit von Freude und Gemeinschaft erfüllt sein." "reactions_count" => 19 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-02-21 07:57:30" "deleted" => 1 ] [ "id" => 478887967 "company_id" => 8375742 "urn" => "urn:li:activity:7165706707208290304" "followers" => null "date" => "4h" "description" => """ Wie eine Umfrage der Lungenliga Aargau zeigt, stieg der Konsum von Vapes bei Schülerinnen und Schülern von Mittel- und Berufsschulen in der Deutschschweiz innerhalb von zwei Jahren von 15% auf 25%. Ein Viertel der Jugendlichen gab zudem an, dass sie in den letzten 30 Tagen mindestens einmal Zigaretten geraucht haben. \n Mehr erfahren 👇 """ "reactions_count" => 1 "comments_count" => null "reshared_post_author" => "Lungenliga Aargau" "reshared_post_author_url" => "https://ch.linkedin.com/company/lungenliga-aargau" "reshared_post_author_headline" => null "reshared_post_description" => """ 🛑 Dramatischer Anstieg des Vape-Konsums unter Jugendlichen! 🛑\n \n Im Jahr 2023 führte die Lungenliga Aargau eine umfassende Umfrage zu 14 verschiedenen Tabak-, Nikotin- und Cannabisprodukten bei Jugendlichen durch. Rund 20'000 Schülerinnen und Schüler von Mittel- und Berufsschulen sowie Brückenangeboten in der gesamten Deutschschweiz füllten die Umfrage aus. Die Vielfalt der abgefragten Produkte lieferte einzigartige und aufschlussreiche Informationen. \n \n Besonders alarmierend ist der dramatische Anstieg des Vape-Konsums, der von 15% im Jahr 2021 auf 25% im Jahr 2023 stieg. Auch Nicotine Pouches (Snus ohne Tabak) verzeichnen einen bemerkenswerten Zuwachs, während der Zigarettenkonsum rückläufig ist.\n \n Insgesamt gab fast die Hälfte (47%) der befragten Jugendlichen an, in den letzten 30 Tagen mindestens eines der erfragten Tabak-, Nikotin- oder Cannabisprodukte konsumiert zu haben. Diese Daten sind alarmierend und unterstreichen die dringende Notwendigkeit von weiteren Präventionsmassnahmen!\n \n 👉 Hier gehts zum komplette Factsheet: https://lnkd.in/dVZB8hGB """ "reshared_post_followers" => null "reshared_post_date" => "6d" "last_updated" => "2024-03-16 07:00:00" "deleted" => 1 ] [ "id" => 478887968 "company_id" => 8375742 "urn" => "urn:li:activity:7165652559213367296" "followers" => null "date" => "7h" "description" => """ «Wie neue E-Zigi Jugendliche anfixen»:\n Aufschlussreicher Artikel im Tages-Anzeiger, der die Problematiken zum Trendobjekt «Vapes» aufzeigt. \n \n 👉 https://lnkd.in/eJ-5Neir\n \n #vapes #e-zigaretten #jugendschutz """ "reactions_count" => null "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-16 07:00:00" "deleted" => 1 ] [ "id" => 478887969 "company_id" => 8375742 "urn" => "urn:li:activity:7165283980915757057" "followers" => null "date" => "1d" "description" => """ ➡️ Projektaufruf Forschungsförderung!\n Mit unserem Forschungsfonds unterstützen wir innovative Forschungsprojekte, die im Kontext zu Prävention und Behandlung von Lungenkrankheiten und Atemstörungen stehen. \n Projektanträge können noch bis 14. März 2024 eingereicht werden. \n 👉 https://lnkd.in/eK9nqPpe\n \n ➡️ Fonds de recherche: Appel à projets!\n Notre Fonds de recherche soutient des activités de recherche innovantes qui se situent dans le cadre de la prévention et du traitement de maladies pulmonaires et de troubles respiratoires.\n Les candidatures peuvent être soumises jusqu'au 14 mars 2024.\n 👉 https://lnkd.in/e5bk-Sge """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-16 07:00:00" "deleted" => 1 ] [ "id" => 478887970 "company_id" => 8375742 "urn" => "urn:li:activity:7164243012443701248" "followers" => null "date" => "4d" "description" => """ «Verfassung erhalten – Initiative Kinder ohne Tabak richtig umsetzen» 👉 Mit dieser Botschaft verteilten Mitglieder des Trägervereins der Initiative «Kinder ohne Tabak» heute Flyer an die Parlamentarierinnen und Parlamentarier im Bundeshaus.\n \n Vor rund 2 Jahren haben Volk und Stände die Initiative an der Urne angenommen. Der Auftrag ans Parlament war klar: #Tabakwerbung darf Kinder und Jugendliche nicht mehr erreichen. Doch nun droht die verfassungskonforme Umsetzung am neu gewählten Parlament zu scheitern. Insbesondere bei Promotion und Sponsoring möchte die Gesundheitskommission des Nationalrates Ausnahmen machen, die verfassungswidrig sind. Folgt der Nationalrat den Anträgen seiner Kommission, wäre sogar noch mehr Tabakwerbung erlaubt als im Tabakproduktegesetz von 2021.\n https://lnkd.in/e2Wv6vgX\n \n #kinderohnetabak #jugendschutz """ "reactions_count" => 45 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-16 07:00:00" "deleted" => 1 ] [ "id" => 478887971 "company_id" => 8375742 "urn" => "urn:li:activity:7163411567932346368" "followers" => null "date" => "6d" "description" => """ Wie können Sie zum heutigen Valentinstag einem lieben Menschen ein Lächeln ins Gesicht zaubern? 💝\n Zum Beispiel mit unserem Rezept für selbstgemachte Glückskekse mit persönlichen Nachrichten 👉 https://lnkd.in/e65FECYU """ "reactions_count" => 4 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-16 07:00:00" "deleted" => 1 ] [ "id" => 478887972 "company_id" => 8375742 "urn" => "urn:li:activity:7163154912669872128" "followers" => null "date" => "1w" "description" => """ Auf den Tag genau vor zwei Jahren haben Volk und Stände die Initiative “Kinder ohne Tabak” an der Urne angenommen. Doch nun droht die verfassungskonforme Umsetzung am neu gewählten Parlament zu scheitern. Insbesondere bei Promotion und Sponsoring möchte die Gesundheitskommission des Nationalrates Ausnahmen machen, die gemäss Rechtsexperten eindeutig verfassungswidrig sind.\n \n Zur Medienmitteilung 👉 https://lnkd.in/eMweqzxX """ "reactions_count" => 33 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-16 07:00:00" "deleted" => 1 ] [ "id" => 478887973 "company_id" => 8375742 "urn" => "urn:li:activity:7163071812526940162" "followers" => null "date" => "1w" "description" => """ 📢 Verfassungswidrige Umsetzung 🚨\n Umsetzung der Volksinitiative droht, nicht verfassungskonform zu sein.\n \n Wir appellieren an das Parlament: Kinder müssen vor Tabakwerbung geschützt werden - ein Tabakproduktegesetz, wie es die Verfassung will! """ "reactions_count" => 40 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-16 07:00:00" "deleted" => 1 ] [ "id" => 478887974 "company_id" => 8375742 "urn" => "urn:li:activity:7161628668006494208" "followers" => null "date" => "1w" "description" => """ La première 𝗝𝗼𝘂𝗿𝗻𝗲́𝗲 𝗿𝗼𝗺𝗮𝗻𝗱𝗲 𝗱𝘂 𝘀𝗼𝘂𝗳𝗳𝗹𝗲 approche à grands pas 🌳\n Elle aura lieu le 22 février 2024 à l'Y-Parc d'Yverdon-les-Bains. Destinée aux professionnels de la santé, cette #formation abordera le thème de la dyspnée.\n \n Programme ci-dessous ⬇️ """ "reactions_count" => 12 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-16 07:00:00" "deleted" => 1 ] [ "id" => 478887975 "company_id" => 8375742 "urn" => "urn:li:activity:7161626612524912640" "followers" => null "date" => "1w" "description" => """ Was sollten Eltern und andere Bezugspersonen über neue Nikotinprodukte wissen? Unsere kostenlose Infoveranstaltung 𝗡𝗶𝗸𝗼𝘁𝗶𝗻-𝗗𝘂𝗿𝗰𝗵𝗯𝗹𝗶𝗰𝗸 gibt einen Überblick und zeigt, wie das Thema mit Kindern und Jugendlichen besprochen werden kann. \n \n Auf unserer Website finden Sie die nächsten Termine. Der 𝗡𝗶𝗸𝗼𝘁𝗶𝗻-𝗗𝘂𝗿𝗰𝗵𝗯𝗹𝗶𝗰𝗸 kann auf Anfrage auch individuell durchgeführt werden.\n \n https://lnkd.in/ewiuGphb\n \n #nikotin #durchblick #info #sucht #prävention #lungenligazentralschweiz """ "reactions_count" => 6 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-16 07:00:00" "deleted" => 1 ] [ "id" => 478887976 "company_id" => 8375742 "urn" => "urn:li:activity:7160584164772102147" "followers" => null "date" => "2w" "description" => """ Im Winter halten wir uns oft in unseren eigenen vier Wänden auf. Deshalb ist eine gute Raumluft wichtig für unser Wohlbefinden. Neben dem regelmässigen Lüften können Pflanzen eine gutes Raumklima schaffen. \n Mehr erfahren 👉 https://lnkd.in/ehtQDRwJ """ "reactions_count" => 10 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-03-16 07:00:00" "deleted" => 1 ] [ "id" => 508656471 "company_id" => 8375742 "urn" => "urn:li:activity:7174645580525101056" "followers" => null "date" => "59m" "description" => """ Tagsüber müde und nachts lautes Schnarchen?\n Es könnte Schlafapnoe sein.\n Machen Sie jetzt den Online-Test! \n 👉️ www.lungenliga.ch/test """ "reactions_count" => 1 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-04 07:19:14" "deleted" => 1 ] [ "id" => 508656472 "company_id" => 8375742 "urn" => "urn:li:activity:7174283203350847488" "followers" => null "date" => "1d" "description" => """ Heute ist der Welttag des Schlafes.😴 \n Ein Drittel der Schweizer Bevölkerung leidet an Schlafproblemen. Wenn wir schlecht schlafen, sind wir morgens nicht einfach nur müde: Wir können uns nicht konzentrieren, reagieren langsam, fühlen uns überfordert, sind weniger empathisch und unterschätzen Risiken. Die Lungenliga zeigt Mitarbeitenden in Betrieben in Workshops des Programms PulMotion, wie sie ihren Schlaf verbessern. \n Zur Medienmitteilung 👉️ https://lnkd.in/djqJuXgZ \n \n #schlaf #schlafapnoe #rauchstopp #pulmotion #gesundelunge """ "reactions_count" => 11 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-04 07:19:14" "deleted" => 1 ] [ "id" => 508656473 "company_id" => 8375742 "urn" => "urn:li:activity:7174061108184383490" "followers" => null "date" => "1d" "description" => """ Sind Sie ein Rückenschläfer? Drehen Sie sich auf die Seite? Wir verraten Ihnen die Vor- und Nachteile einzelner Schlaflagen und geben Tipps zum Kopfkissen. Ein grundsätzliches Richtig oder Falsch gibt es nicht.\n 👉️ https://lnkd.in/e8zfTjsk """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-04 07:19:14" "deleted" => 1 ] [ "id" => 508656474 "company_id" => 8375742 "urn" => "urn:li:activity:7173196011903901699" "followers" => null "date" => "4d" "description" => """ Sind Sie ein Bär, Löwe, Wolf oder Delfin? Der amerikanische Schlafmediziner Michael Breus hat diese vier Schlaftypen identifiziert. Wer seinen eigenen kennt, kann mit kleinen Änderungen im Alltag seinen Schlaf optimieren und produktiver werden.\n Finden Sie es raus: 👉️ https://lnkd.in/eSwTVz3K\n \n #schlafen #guterschlaf #schlaftypen """ "reactions_count" => 20 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-04 07:19:14" "deleted" => 1 ] [ "id" => 508656475 "company_id" => 8375742 "urn" => "urn:li:activity:7172884147890278400" "followers" => null "date" => "4d" "description" => null "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-04 07:19:14" "deleted" => 1 ] [ "id" => 508656476 "company_id" => 8375742 "urn" => "urn:li:activity:7171839623801876481" "followers" => null "date" => "1w" "description" => null "reactions_count" => 4 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-04 07:19:14" "deleted" => 1 ] [ "id" => 508656477 "company_id" => 8375742 "urn" => "urn:li:activity:7171836355365314560" "followers" => null "date" => "1w" "description" => null "reactions_count" => 6 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-04 07:19:14" "deleted" => 1 ] [ "id" => 508656478 "company_id" => 8375742 "urn" => "urn:li:activity:7171758276349513728" "followers" => null "date" => "1w" "description" => """ Zum heutigen #Weltfrauentag richtet die AT Schweiz - Swiss Association for Tobacco Control den Blick auf die Gesundheitsrisiken des Rauchens bei Frauen: Während die Zahl der Raucher sinkt, steigt die Zahl der Raucherinnen weiter an. Gleichzeitig sind Frauen durch den Tabakkonsum stärker gefährdet und haben es schwerer als Männer, mit dem Rauchen aufzuhören. \n \n Mehr Infos 👉️ https://lnkd.in/eYB-8A7i """ "reactions_count" => 27 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-04 07:19:14" "deleted" => 1 ] [ "id" => 508656479 "company_id" => 8375742 "urn" => "urn:li:activity:7171165161867624448" "followers" => null "date" => "1w" "description" => """ Die Atmung ist für uns etwas Selbstverständliches. Doch was passiert genau, während wir atmen? Wie sind Lunge und Atemwege aufgebaut? Sie finden viele wissenswerte Infos dazu auf unserer Website 👉️ https://lnkd.in/dcSrWF3G\n \n #lunge #atmung #atmen #gasaustausch """ "reactions_count" => 12 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-04 07:19:14" "deleted" => 1 ] [ "id" => 508656480 "company_id" => 8375742 "urn" => "urn:li:activity:7170767262025527297" "followers" => null "date" => "1w" "description" => """ Jeudi 22 février 2024, les Ligues pulmonaires romandes organisaient la première Journée du souffle sur le thème de la dyspnée.\n Plus de 80 professionnels de la santé ont ainsi pu se tenir informer des nouveautés en oxygénothérapie ou la ventilation non invasive lors de conférences d'experts et d’ateliers pratiques. \n \n Un grand merci aux intervenantes: Prof. Capucine Morélot-Panzini, Dre Aileen Kharat, Dre Maura Prella, Dre Sandra Van den Broecke, Mme Emilie Jossen et Prof. Chantal Berna Renella.\n Ainsi qu'au modérateur: Dr Grégory Clark. """ "reactions_count" => 16 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-04-04 07:19:14" "deleted" => 1 ] [ "id" => 528009195 "company_id" => 8375742 "urn" => "urn:li:activity:7181282924493701121" "followers" => null "date" => "17h" "description" => """ Wer online das Nachrichtenportal 20 Minuten liest, stösst auf einen bezahlten Artikel des Tabakshops von k kiosk. Den Lesenden wird das umfangreiche Tabak- und Nikotin-Sortiment angepriesen und aufgezeigt, wie man von grosszügigen Rabatten profitiert. Auch wenn Jugendliche am Ende die Produkte nicht selber bestellen können, wirkt diese getarnte Werbung verlockend. Wird die Initiative «kinderohnetabak.ch» nach dem Willen des Volks umgesetzt, ist solche Werbung, die auch Kinder und Jugendliche erreicht, zukünftig verboten.\n \n #tabakwerbung #jugendschutz #kinderohnetabak """ "reactions_count" => 21 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-11 01:31:37" "deleted" => 1 ] [ "id" => 528009196 "company_id" => 8375742 "urn" => "urn:li:activity:7181168542069751810" "followers" => null "date" => "1d" "description" => """ vapefree.info bietet Eltern und Lehrkräften wichtige Infos zum Umgang mit dem Thema #vapen.\n \n Helfen Sie mit, die Plattform zu verbessern und füllen Sie die Umfrage aus: https://lnkd.in/enx6e9jD\n \n #vaping #ezigaretten #puffbars #lehrkräfte #eltern """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => "AT Schweiz - Swiss Association for Tobacco Control" "reshared_post_author_url" => "https://ch.linkedin.com/company/swiss-association-for-smoking-prevention-at-schweiz" "reshared_post_author_headline" => null "reshared_post_description" => """ Mit der neuen Webseite Vapefree.info hat AT Schweiz in Zusammenarbeit mit der Lungenliga Tessin die erste Informationsplattform für Eltern und Lehrkräfte zum Thema #Vapes lanciert.\n \n Wir laden Sie ein, an einer kurzen Umfrage teilzunehmen:\n https://lnkd.in/enx6e9jD """ "reshared_post_followers" => null "reshared_post_date" => "1w" "last_updated" => "2024-05-11 01:31:37" "deleted" => 1 ] [ "id" => 528009197 "company_id" => 8375742 "urn" => "urn:li:activity:7180836487620366336" "followers" => null "date" => "1d" "description" => """ Die Schlafapnoe von Claudio Menghi hielt ihn nicht davon ab, vier Wochen lang auf dem Jakobsweg zu wandern. Immer mit dabei: sein CPAP-Gerät, das seine Atemwege in der Nacht offenhält.\n \n 👉️ https://lnkd.in/e9r9sNWY\n \n #schlafapnoe #cpap #lungenliga """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-11 01:31:37" "deleted" => 1 ] [ "id" => 528009198 "company_id" => 8375742 "urn" => "urn:li:activity:7180081382235217920" "followers" => null "date" => "4d" "description" => """ Damit Sie die Zeitumstellung besser wegstecken können: Diese Tipps zum besser Schlafen helfen!\n \n 👉️ https://lnkd.in/eTd33aqQ """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-11 01:31:37" "deleted" => 1 ] [ "id" => 528009199 "company_id" => 8375742 "urn" => "urn:li:activity:7179402193303654400" "followers" => null "date" => "5d" "description" => """ Die Lungenliga wünscht frohe, genussvolle Ostertage🍀\n La Ligue pulmonaire souhaite de joyeuses fêtes de Pâques! 🌷\n La Lega Polmonare augura una buona Pasqua piena di gioia! 🐰 \n \n #ostern #frühling #pâques #printemps #pasqua """ "reactions_count" => 14 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-11 01:31:37" "deleted" => 1 ] [ "id" => 528009200 "company_id" => 8375742 "urn" => "urn:li:activity:7178631842571395072" "followers" => null "date" => "1w" "description" => """ Wie wird Schlafapnoe behandelt?\n \n Eine häufige Form ist die CPAP-Therapie: Das CPAP-Gerät leitet einen sanften Luftstrom in eine Maske, welche die Patientin oder der Patient während der Nacht trägt. Dank dieses Luftstroms bleiben die Atemwege offen, und die Betroffenen können während des Schlafens frei atmen. Das bedeutet: Kein Schnarchen, keine nächtlichen Atempausen, tagsüber wach und fit sein.\n \n Die Lungenliga berät und betreut schweizweit über 90'000\n Schlafapnoe-Betroffene. \n \n 👉️ www.lungenliga.ch/cpap \n \n #schlafapnoe #cpap """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-11 01:31:37" "deleted" => 1 ] [ "id" => 528009201 "company_id" => 8375742 "urn" => "urn:li:activity:7178322301124231170" "followers" => null "date" => "1w" "description" => """ Der Konsum von Einweg-E-Zigaretten von Kindern und Jugendlichen hat in den letzten Jahren massiv zugenommen. So verlockend diese bunten Vapes aussehen, so unberechenbar sind ihre gesundheitlichen Risiken. Aufgrund des hohen Nikotingehaltes machen sie rasch süchtig und begünstigen einen späteren Tabakkonsum. Auf der Informationsplattform www.vapefree.info finden Lehrpersonen und Eltern fundierte Informationen zum Thema Einweg-E-Zigaretten. \n Zur Medienmitteilung 👉️ https://lnkd.in/dzqsARGK """ "reactions_count" => 41 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-11 01:31:37" "deleted" => 1 ] [ "id" => 528009202 "company_id" => 8375742 "urn" => "urn:li:activity:7178293301320507393" "followers" => null "date" => "1w" "description" => """ Michèle Knuchel kann ihren Alltag nur mit Mühe meistern, ihre Arbeit musste sie aufgeben. Oft bekommt sie zu wenig Luft. Unterstützung findet sie unter anderem in der Lungensportgruppe der Lungenliga. SRF - Schweizer Radio und Fernsehen hat die sympathische COPD-Patientin während eines Tages in der Sendung «mitenand» begleitet.\n \n #copd #lungenerkrankung #lungenliga #srfmitenand """ "reactions_count" => 32 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-11 01:31:37" "deleted" => 1 ] [ "id" => 528009203 "company_id" => 8375742 "urn" => "urn:li:activity:7177559784554950656" "followers" => null "date" => "1w" "description" => """ «Yes! We can end TB!» Am heutigen Welt-Tuberkulose-Tag macht die World Health Organization auf die Möglichkeit aufmerksam, die Tuberkulose-Epidemie langfristig zu beenden; mit universellem Zugang zu Prävention und Pflege, sektorübergreifenden Maßnahmen und Innovation.\n 👉️ https://lnkd.in/eWZgbEJ9 \n \n In der Schweiz ist die Zahl der Tuberkulosefälle dank früher Erkennung und konsequenter Behandlung in den letzten Jahren rückläufig.\n \n ➡️ SAVE the DATE: Am Tuberkulose-Symposium vom 30. Oktober 2024 in Bern präsentieren Fachpersonen im Bereich Tuberkulose aktuelle Daten und Projekte und tauschen sich aus über die Zukunft der Tuberkulosebekämpfung in der Schweiz. Dieses Jahr wird es gemeinsam mit dem Translational TB-Forum durchgeführt.\n \n #worldtuberculosisday #wecanendtb #tuberkulose #lungenliga #tbforum """ "reactions_count" => 16 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-11 01:31:37" "deleted" => 1 ] [ "id" => 528009204 "company_id" => 8375742 "urn" => "urn:li:activity:7177227628867653632" "followers" => null "date" => "1w" "description" => """ Schon gewusst? Schlafapnoe äussert sich bei Frauen meistens anders als bei Männern. Nächtliches Schnarchen und Atemaussetzer sind weniger häufig. \n \n Typische Symptome sind:\n ➡️ morgendliche Kopfschmerzen\n ➡️ Verdauungsstörungen\n ➡️ Stimmungsschwankungen und Depressionen\n \n https://lnkd.in/exG_pDuT \n \n #schlafapnoe #symptomeschlafapnoe #gendermedicine """ "reactions_count" => 25 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-05-11 01:31:37" "deleted" => 1 ] [ "id" => 564286934 "company_id" => 8375742 "urn" => "urn:li:activity:7194639856143073284" "followers" => null "date" => "15h" "description" => """ Wie Menschen auf die Diagnose einer schwerwiegenden Krankheit reagieren, ist sehr unterschiedlich. Klar ist nur: Körperliche Erkrankungen beeinflussen die Psyche – und umgekehrt.\n Erfahren Sie mehr im vivo-Beitrag 👉️ https://lnkd.in/e2MVgNCf\n \n #vivo #lungenerkrankung #copd #chronischkrank """ "reactions_count" => 10 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-22 11:15:38" "deleted" => 1 ] [ "id" => 564286935 "company_id" => 8375742 "urn" => "urn:li:activity:7193489732863938560" "followers" => null "date" => "3d" "description" => """ Heute ist Welt-Asthma-Tag! 💚 \n Haben Sie Ihr Asthma unter Kontrolle? \n Der Asthmakontrolltest, welcher die Lungenliga gemeinsam mit dem AHA! Allergiezentrum Schweiz online zur Verfügung stellt, liefert Betroffenen wichtige Anhaltspunkte. \n \n Finden Sie den Test und weitere wertvolle Tipps und Angebote zu Asthma unter www.lungenliga.ch/asthma oder https://lnkd.in/ephuB-c8\n \n #worldasthmaday #asthmakontrolltest #asthma """ "reactions_count" => 12 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-22 11:15:38" "deleted" => 1 ] [ "id" => 564286936 "company_id" => 8375742 "urn" => "urn:li:activity:7192145913920782338" "followers" => null "date" => "1w" "description" => """ Erholung und Genuss am Sarnersee: Die nächsten Luftholtage finden vom 20. bis 30. August 2024 statt. \n \n Der Anmeldebeginn ist am 13. Mai 2024. 👉️ https://lnkd.in/evHD8i7y\n \n Mit organisierten Gruppenreisen ermöglicht die Lungenliga Schweiz Menschen mit Lungen- und Atemwegserkrankungen sowie ihren Angehörigen sorgenfreie Ferien und stellt die Sauerstoffversorgung während des gesamten Aufenthalts sicher. Begleitet werden die Reisen jeweils durch ein Team aus medizinischem Fachpersonal. """ "reactions_count" => 6 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-22 11:15:38" "deleted" => 1 ] [ "id" => 564286937 "company_id" => 8375742 "urn" => "urn:li:activity:7192077939339841538" "followers" => null "date" => "1w" "description" => """ Spazieren regt die Ausschüttung von Glückshormonen an, kräftigt die Muskulatur, lindert Müdigkeit und kurbelt den Stoffwechsel an. Vier Ausflugstipps mit einfachen Spaziergängen für Personen, die nicht mehr so gut zu Fuss sind: https://lnkd.in/e92vnRyZ\n \n #vivo #bewegung #lungenerkrankung #ausflugstipps """ "reactions_count" => 2 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-22 11:15:38" "deleted" => 1 ] [ "id" => 564286938 "company_id" => 8375742 "urn" => "urn:li:activity:7191793392115146755" "followers" => null "date" => "1w" "description" => """ Energie tanken und die Seele über dem Rhein baumeln lassen: Im Rahmen der Luftholtage vom 11.–19. April 2024 verbrachten 24 Personen eine erlebnisreiche Woche auf der MS Antonio Bellucci auf der Route Basel–Amsterdam–Basel. 🚢 \n \n Highlight der Reise war der Besuch des Keukenhofs mit seiner blühenden Tulpenpracht. 🌷 """ "reactions_count" => 19 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-22 11:15:38" "deleted" => 1 ] [ "id" => 564286939 "company_id" => 8375742 "urn" => "urn:li:activity:7191378942572847104" "followers" => null "date" => "1w" "description" => """ Was belastet die Lunge am meisten? Was macht das Rauchen mit dem Atemorgan? Bei welchen Beschwerden muss ein Arzt aufgesucht werden? Prof. Dr. med. Jörg Leuppi erklärt in der Fernsehsendung TOP MED anschaulich und verständlich die medizinischen Zusammenhänge. \n \n 👉️ https://lnkd.in/dycnB6jU\n \n #lunge #atmung #lungenerkrankung #topmed """ "reactions_count" => 43 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-22 11:15:38" "deleted" => 1 ] [ "id" => 564286940 "company_id" => 8375742 "urn" => "urn:li:activity:7188538658054963202" "followers" => null "date" => "2w" "description" => """ Sechs Milliarden Zigarettenstummel landen in der Schweiz jährlich auf dem Boden. Das Problem: Die Filter enthalten schwer abbaubaren Kunststoff und giftige Substanzen. \n Die AT Schweiz - Swiss Association for Tobacco Control ruft die Politik nun auf, die giftigen Filter zu verbieten und verlangt, dass die Tabakindustrie für ihre Umweltschäden zur Verantwortung gezogen wird. \n Die Filter bieten entgegen der Behauptung der Tabakindustrie keinen signifikanten Schutz gegen die Schadstoffe beim Inhalieren und können beim Einatmen Fasern freisetzen, die krebserregende Substanzen enthalten.\n \n Weitere Infos 👇 """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => "AT Schweiz - Swiss Association for Tobacco Control" "reshared_post_author_url" => "https://ch.linkedin.com/company/swiss-association-for-smoking-prevention-at-schweiz" "reshared_post_author_headline" => null "reshared_post_description" => """ ++ Medienmitteilung ++\n \n Ein ökologisches Desaster: Warum wir #Zigarettenfilter verbieten müssen\n \n Die Weltgemeinschaft diskutiert derzeit über den Umgang mit Einwegplastik und dessen Verbot. Zigarettenstummel stellen weltweit die am häufigsten weggeworfene Plastikart dar, wobei die Filter keinerlei gesundheitlichen Nutzen bieten. In der Schweiz hingegen ignoriert der Bundesrat die Fakten und handelt nicht. Die Arbeitsgemeinschaft Tabakprävention Schweiz fordert ein umfassendes Verbot von umwelt- und gesundheitsschädigenden Zigarettenfiltern.\n \n Zur Medienmitteilung: https://lnkd.in/eHXW8cfk\n \n \n #theggtc #exposetobacco """ "reshared_post_followers" => null "reshared_post_date" => "2w" "last_updated" => "2024-06-22 11:15:38" "deleted" => 1 ] [ "id" => 564286941 "company_id" => 8375742 "urn" => "urn:li:activity:7188091690786697217" "followers" => null "date" => "2w" "description" => """ Sie tragen uns durch unser Leben und halten stumm Marathonläufe, High Heels und viele andere Strapazen aus. Es lohnt sich, unsere Füsse ab und zu zu verwöhnen. Erfahren Sie mehr über die positiven Auswirkungen einer Fussreflexzonen-Therapie 👉️https://lnkd.in/e5NmGTiX\n \n #vivo #fussreflexzonenmassage #gesundelunge """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-22 11:15:38" "deleted" => 1 ] [ "id" => 564286942 "company_id" => 8375742 "urn" => "urn:li:activity:7185970926860017664" "followers" => null "date" => "3w" "description" => """ Essen für starke Lungen, geht das?\n Für Menschen, die an Lungen- und Atemwegserkrankungen leiden, ist eine individuell abgestimmte Ernährung besonders wichtig. Zwei Ernährungsberaterinnen erklären, warum es bei einer Ernährungsumstellung nicht nur um das Gewicht geht.\n \n 👉️ https://lnkd.in/eaTTaUAz\n \n #vivo #ernährung #gesundelunge #lungenerkrankung #copd """ "reactions_count" => 14 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-22 11:15:38" "deleted" => 1 ] [ "id" => 564286943 "company_id" => 8375742 "urn" => "urn:li:activity:7185892846636290048" "followers" => null "date" => "3w" "description" => """ Vapen – Einstiegsdroge oder Ausstiegshilfe?\n Die Sendung «Puls» von SRF Schweizer Radio und Fernsehen hat gestern Abend das Thema E-Zigaretten und Nikotin von verschiedenen Seiten beleuchtet. \n \n Fachexpertin Claudia Künzli von der Lungenliga Schweiz gab im «Puls» Live-Chat Auskunft auf Fragen im Publikum zu «Nikotinsucht und Vapen».\n \n Sendung verpasst? 👉 https://lnkd.in/eerrF-jU """ "reactions_count" => 23 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-06-22 11:15:38" "deleted" => 1 ] [ "id" => 621589131 "company_id" => 8375742 "urn" => "urn:li:activity:7207321007164932098" "followers" => null "date" => "3d" "description" => """ Im Coaching «Besser leben mit COPD» lernen Betroffene in verschiedenen Modulen, mit ihrer Krankheit im Alltag besser umgehen zu können. Im fünften Modul lernen die Teilnehmenden, wie sie körperliche Bewegung in ihren Alltag integrieren.\n \n ☑️ Wie finde ich eine körperliche Betätigung, die mir zusagt und die ich regelmässig ausführe?\n ☑️ Worauf muss ich bei körperlicher Betätigung achten?\n ☑️ Wie kann ich meine (Atem-)Muskeln trainieren?\n ☑️ Wie läuft eine ambulante pulmonale Rehabilitation ab?\n \n Weitere Infos zum Coaching 👉https://lnkd.in/dY5hqUXP """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-08 09:49:02" "deleted" => 1 ] [ "id" => 621589132 "company_id" => 8375742 "urn" => "urn:li:activity:7205871429165219841" "followers" => null "date" => "1w" "description" => """ Tipps von Kopf bis Fuss: Im Blog der Lungenliga finden Sie eine kleine, aber feine Sammlung mit Anregungen, die Leichtigkeit in den Alltag zaubern und den Horizont erweitern. 🌅\n \n Jetzt entdecken 👉️ https://lnkd.in/e69ikGBG """ "reactions_count" => 12 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-08 09:49:02" "deleted" => 1 ] [ "id" => 621589133 "company_id" => 8375742 "urn" => "urn:li:activity:7204421770223714305" "followers" => null "date" => "1w" "description" => """ Farbig, süss, verspielt – und schädlich für die Gesundheit: Vapes erleben besonders bei Jugendlichen einen Hype. 🍭🧪 \n \n Das Schweizer ElternMagazin Fritz+Fränzi gibt im Online-Artikel Aufschluss über das beliebte Suchtmittel und dessen Auswirkungen auf junge Erwachsene: https://lnkd.in/gEB5EGer """ "reactions_count" => 33 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-08 09:49:02" "deleted" => 1 ] [ "id" => 621589134 "company_id" => 8375742 "urn" => "urn:li:activity:7203334664940339200" "followers" => null "date" => "2w" "description" => """ Auszeit mit traumhaftem See- und Bergpanorama: Die Luftholtage im Parkhotel Gunten finden vom 24. September bis 4. Oktober 2024 statt. \n \n Der Anmeldebeginn ist am 17. Juni 2024. 👉️https://lnkd.in/evHD8i7y\n \n Unbeschwert verreisen mit der Lungenliga: Tanken Sie neue Energie auf unseren begleiteten Reisen – ob in der Schweiz oder im Ausland. Wir kümmern uns um alles, Sie atmen tief durch und geniessen unbeschwerte Tage. """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-08 09:49:02" "deleted" => 1 ] [ "id" => 621589135 "company_id" => 8375742 "urn" => "urn:li:activity:7202290435820535808" "followers" => null "date" => "2w" "description" => """ Leckeres Essen mit Gift? Genauso absurd wie Gift mit feinem Fruchtaroma.\n \n Heute ist der Welttag ohne Tabak. 🚭\n \n Es ist Zeit, den Einfluss der Tabak- und Nikotinindustrie auf Kinder und die Gesetzgebung zu unterbinden.\n \n Mehr Infos zu den Marketingstrategien der Tabak- und Nikotinindustrie gibt’s auf https://lnkd.in/eS9P4AWi\n \n #TnT\n #TobaccoExposed\n #unfogged """ "reactions_count" => 30 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-08 09:49:02" "deleted" => 1 ] [ "id" => 621589136 "company_id" => 8375742 "urn" => "urn:li:activity:7202202153170391040" "followers" => null "date" => "2w" "description" => """ Leuchtstift oder Vape?\n \n «Es kann doch nicht sein, dass eine ganze Generation nikotinsüchtig gemacht wird und wir dabei zusehen müssen», empört sich die Mutter des zwölfjährigen Luca. Ihr Sohn hat die Vapes mit Taschengeld einem Schulkollegen abgekauft. Inzwischen konsumiert er Snus. \n \n Solange die Politik keine Regulierungen umsetzt, bleibt die Schweiz der Lieblingsspielplatz der Tabakkonzerne.\n \n Die Tabakindustrie nimmt in der Schweiz grossen Einfluss auf die Forschung und auf die Behörden. Deshalb landet die Schweiz im weltweiten Tabak-Lobby-Index auf dem zweitletzten Platz, knapp hinter der Dominikanischen Republik. \n \n Zur Medienmitteilung: https://lnkd.in/e5CT-zdH """ "reactions_count" => 62 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-08 09:49:02" "deleted" => 1 ] [ "id" => 621589137 "company_id" => 8375742 "urn" => "urn:li:activity:7201885851344121856" "followers" => null "date" => "2w" "description" => """ Die Gewinnerin des Forschungspreises 2024 steht fest. 🥇\n \n Einmal jährlich vergibt die Lungenliga einen mit CHF 10 000.– dotierten Preis für die beste Publikation im Wissenschaftsbereich der Atemwegsforschung und Lungengesundheit.\n \n Die Lungenliga gratuliert der diesjährigen Gewinnerin, Dr. Urszula Radzikowska, ganz herzlich. 💐 \n \n Erfahren Sie mehr über die beste Publikation 2024 und über den Forschungspreis der Lungenliga: https://lnkd.in/dGc6-rrR """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-08 09:49:02" "deleted" => 1 ] [ "id" => 621589138 "company_id" => 8375742 "urn" => "urn:li:activity:7201615639529029632" "followers" => null "date" => "2w" "description" => """ Besuchen Sie die Lungenliga am SGP-Kongress und erfahren Sie mehr darüber, wie die Lungenliga Pneumologinnen und Pneumologen im Berufsalltag unterstützt:\n \n ✅️ Weiterbildungsangebote für Mitarbeitende\n ✅️ Kurse und Angebote für Patientinnen und Patienten\n ✅️ Gesellschaftliches und politisches Engagement\n \n Wir freuen uns auf inspirierende Begegnungen und interessante Gespräche – inklusive Glacé.🍦 \n \n Mehr Infos: https://lnkd.in/eAxbcMEw """ "reactions_count" => 44 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-08 09:49:02" "deleted" => 1 ] [ "id" => 621589139 "company_id" => 8375742 "urn" => "urn:li:activity:7199710853397381120" "followers" => null "date" => "3w" "description" => """ Trotz COPD Intimität erfüllend erleben. 🌹 \n \n Bei vielen COPD-Betroffenen tauchen Ängste auf, die sie veranlassen, Intimität zu vermeiden. Auf Sexualität zu verzichten, ist aber keine gute Lösung.\n \n Im Interview mit vivo erklärt Prof. Dr. med. Claudia Steurer-Stey, Fachärztin für Pneumologie und Innere Medizin, wie COPD-Betroffene Ängste loslassen und das sinnliche Erleben neu entdecken können. \n \n Jetzt lesen: 👉️ https://lnkd.in/eb6suYEH """ "reactions_count" => 8 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-08 09:49:02" "deleted" => 1 ] [ "id" => 621589140 "company_id" => 8375742 "urn" => "urn:li:activity:7199393889651224577" "followers" => null "date" => "3w" "description" => """ Die Lungenliga zu Gast am SGP-Kongress 2024:\n \n Am diesjährigen SGP-Kongress vom 29. bis 31. Mai in Baden finden Sie den Stand der Lungenliga unmittelbar neben dem Selbst-Check-In. Geniessen Sie bei uns ein erfrischendes Eis und erfahren Sie vor Ort mehr über unsere Leistungen rund um die Gesundheit der Lunge und Atemwege.\n \n Mehr Infos zum Auftritt der Lungenliga am SGP-Kongress: https://lnkd.in/eAxbcMEw\n \n Die Lungenliga freut sich auf den Austausch mit Ihnen. 🤝💚 """ "reactions_count" => 18 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-07-08 09:49:02" "deleted" => 1 ] [ "id" => 632916100 "company_id" => 8375742 "urn" => "urn:li:activity:7214998056511901696" "followers" => null "date" => "2d" "description" => """ Freiwilliges Engagement ist gelebte Menschlichkeit. ❤️ \n \n Von Kleinkindern bis zu Seniorinnen und Senioren, vom Berner Jura bis ins Oberland: Das SRK Kanton Bern setzt sich im ganzen Kanton für Menschen in Not ein. Zahlreiche Einsätze hat die Organisation dabei ihren Freiwilligen zu verdanken. \n \n Möchten Sie freiwilliges Engagement leisten und dabei Sinnstiftendes bewirken? Das SRK bietet verschiedene Möglichkeiten: \n 👉️ https://lnkd.in/eTntaTbq """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 08:22:37" "deleted" => 1 ] [ "id" => 632916101 "company_id" => 8375742 "urn" => "urn:li:activity:7213467974744055808" "followers" => null "date" => "1w" "description" => """ Der Umzug der Geschäftsstelle, das positive Umfrage-Ergebnis zur Patientenzufriedenheit, die neue Website und erfolgreiche Vertragsabschlüsse – dies und vieles mehr prägte das letzte Geschäftsjahr der Lungenliga Schweiz. \n \n Im Jahresbericht 2023 erfahren Sie mehr 👉️ https://lnkd.in/ecttbQt5 """ "reactions_count" => 10 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 08:22:37" "deleted" => 1 ] [ "id" => 632916102 "company_id" => 8375742 "urn" => "urn:li:activity:7212381698934648833" "followers" => null "date" => "1w" "description" => """ Die Lungenfachärztinnen und -ärzte melden sich zu Wort.\n \n Nachdem die Volksinitiative «Kinder ohne Tabak» im Februar 2022 deutlich angenommen wurde, fordern sie nun deren verfassungskonforme Umsetzung im Sinne des Kinder- und Jugendschutzes.\n \n Lesen Sie hier den Brief an das Parlament und die Medienmitteilung: https://lnkd.in/eJnZbdU2 """ "reactions_count" => 23 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 08:22:37" "deleted" => 1 ] [ "id" => 632916103 "company_id" => 8375742 "urn" => "urn:li:activity:7212077398115151872" "followers" => null "date" => "1w" "description" => """ «Das CPAP-Gerät gebe ich nicht mehr her»\n \n Die Arbeit im Stall war erledigt, die drei Kinder mit dem Zmorge versorgt und unterwegs in die Schule. Danach war Patricia Hauri schon wieder erschöpft. Lange kam niemand auf die Idee, dass Schlafapnoe die Ursache für ihre Müdigkeit sein könnte.\n \n Hier geht's zum Blogbeitrag 👉️ https://lnkd.in/e6H5ZExk """ "reactions_count" => 18 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 08:22:37" "deleted" => 1 ] [ "id" => 632916104 "company_id" => 8375742 "urn" => "urn:li:activity:7210952771678699522" "followers" => null "date" => "1w" "description" => "Lust auf eine sinnstiftende Tätigkeit? Wir freuen uns, dich und deine Stärken kennen zu lernen. Bewerbe dich einfach und unkompliziert über den Link im Inserat. Monika Hänni, Leiterin Human Resources." "reactions_count" => 14 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 08:22:37" "deleted" => 1 ] [ "id" => 632916105 "company_id" => 8375742 "urn" => "urn:li:activity:7209857647196442624" "followers" => null "date" => "2w" "description" => """ Sonne, Strand und Meer: Im Rahmen der Luftholtage verbrachten 27 Personen vom 28.05. – 11.06.2024 zwei erlebnisreiche und erholsame Wochen in Spotorno an der ligurischen Küste in Italien. ☀️ ⛱️ \n \n Highlight war das betreute Baden im Meer, welches auch für Personen mit Sauerstoffgeräten ermöglicht wird. """ "reactions_count" => 60 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 08:22:37" "deleted" => 1 ] [ "id" => 632916106 "company_id" => 8375742 "urn" => "urn:li:activity:7207321007164932098" "followers" => null "date" => "3w" "description" => """ Im Coaching «Besser leben mit COPD» lernen Betroffene in verschiedenen Modulen, mit ihrer Krankheit im Alltag besser umgehen zu können. Im fünften Modul lernen die Teilnehmenden, wie sie körperliche Bewegung in ihren Alltag integrieren.\n \n ☑️ Wie finde ich eine körperliche Betätigung, die mir zusagt und die ich regelmässig ausführe?\n ☑️ Worauf muss ich bei körperlicher Betätigung achten?\n ☑️ Wie kann ich meine (Atem-)Muskeln trainieren?\n ☑️ Wie läuft eine ambulante pulmonale Rehabilitation ab?\n \n Weitere Infos zum Coaching 👉https://lnkd.in/dY5hqUXP """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 08:22:37" "deleted" => 1 ] [ "id" => 632916107 "company_id" => 8375742 "urn" => "urn:li:activity:7205871429165219841" "followers" => null "date" => "3w" "description" => """ Tipps von Kopf bis Fuss: Im Blog der Lungenliga finden Sie eine kleine, aber feine Sammlung mit Anregungen, die Leichtigkeit in den Alltag zaubern und den Horizont erweitern. 🌅\n \n Jetzt entdecken 👉️ https://lnkd.in/e69ikGBG """ "reactions_count" => 14 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 08:22:37" "deleted" => 1 ] [ "id" => 632916108 "company_id" => 8375742 "urn" => "urn:li:activity:7204421770223714305" "followers" => null "date" => "1mo" "description" => """ Farbig, süss, verspielt – und schädlich für die Gesundheit: Vapes erleben besonders bei Jugendlichen einen Hype. 🍭🧪 \n \n Das Schweizer ElternMagazin Fritz+Fränzi gibt im Online-Artikel Aufschluss über das beliebte Suchtmittel und dessen Auswirkungen auf junge Erwachsene: https://lnkd.in/gEB5EGer """ "reactions_count" => 34 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 08:22:37" "deleted" => 1 ] [ "id" => 632916109 "company_id" => 8375742 "urn" => "urn:li:activity:7203334664940339200" "followers" => null "date" => "1mo" "description" => """ Auszeit mit traumhaftem See- und Bergpanorama: Die Luftholtage im Parkhotel Gunten finden vom 24. September bis 4. Oktober 2024 statt. \n \n Der Anmeldebeginn ist am 17. Juni 2024. 👉️https://lnkd.in/evHD8i7y\n \n Unbeschwert verreisen mit der Lungenliga: Tanken Sie neue Energie auf unseren begleiteten Reisen – ob in der Schweiz oder im Ausland. Wir kümmern uns um alles, Sie atmen tief durch und geniessen unbeschwerte Tage. """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-08-12 08:22:37" "deleted" => 1 ] [ "id" => 673007544 "company_id" => 8375742 "urn" => "urn:li:activity:7227615412442533888" "followers" => null "date" => "2d" "description" => """ Rekordwerte bei Kinder-Lungenentzündungen:\n \n Die Kinderspitäler in Zürich, Bern und Basel verzeichnen in den vergangenen Sommermonaten einen deutlichen Anstieg von Lungenentzündungen bei Kindern und Jugendlichen. \n \n Dieser Anstieg ist teilweise auf die fehlende Immunität nach der Corona-Pandemie zurückzuführen.\n \n Zum Newsbeitrag von SRF - Schweizer Radio und Fernsehen: 👉️ https://lnkd.in/end824iy\n \n #lungenerkrankung """ "reactions_count" => null "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-10 16:50:44" "deleted" => 1 ] [ "id" => 673007545 "company_id" => 8375742 "urn" => "urn:li:activity:7226858674126798848" "followers" => null "date" => "5d" "description" => """ Letzten Frühling wurde er im Magazin vivo porträtiert, nun ist COPD-Patient Josef Schuler bald im SRF - Schweizer Radio und Fernsehen zu sehen. \n \n 📺 Samstag, 12. Oktober 2024, um 18.10 Uhr auf SRF1\n \n #copd #lungenerkrankung """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => "Lungenliga Zentralschweiz" "reshared_post_author_url" => "https://ch.linkedin.com/company/lungenliga-zentralschweiz" "reshared_post_author_headline" => null "reshared_post_description" => """ Behind the scenes 🎬 \n \n Offen und emotional erzählt unser Patient Josef Schuler im Beitrag von GESUNDHEITHEUTE, wie sein Leben mit der Lungenkrankheit COPD aussieht. \n \n Unbedingt einschalten am Samstag, 12. Oktober 2024, um 18:10 Uhr auf SRF1!\n \n #copd #geschichte #interview #leben #lungenligazentralschweiz """ "reshared_post_followers" => null "reshared_post_date" => "5d" "last_updated" => "2024-09-10 16:50:44" "deleted" => 1 ] [ "id" => 673007546 "company_id" => 8375742 "urn" => "urn:li:activity:7224353156548206593" "followers" => null "date" => "1w" "description" => """ Zum Thema E-Zigaretten hat die WHO Western Pacific die wichtigsten Fakten zusammengefasst: \n \n - Der Konsum von E-Zigaretten nimmt rapide zu, insbesondere bei Kindern und Jugendlichen.\n \n - E-Zigaretten enthalten giftige Substanzen, die für die Gesundheit schädlich sind.\n \n - Die Wirksamkeit von E-Zigaretten bei der Rauchentwöhnung ist bisher nicht erwiesen, hingegen können diese zu einer dauerhaften Nikotinabhängigkeit führen. \n \n Die WHO Western Pacific plädiert deshalb für ein Verbot oder eine Regulierung von E-Zigaretten im Rahmen eines umfassenden Ansatzes zur Bekämpfung des Tabakkonsums. \n \n Zum Faktenblatt (Englisch) 👉️ \n https://lnkd.in/eBAFUkex\n \n #tabakprävention #nikotin #ezigaretten #vapen #jugendschutz """ "reactions_count" => 22 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-10 16:50:44" "deleted" => 1 ] [ "id" => 673007547 "company_id" => 8375742 "urn" => "urn:li:activity:7221892407200518145" "followers" => null "date" => "2w" "description" => """ Coronavirus wieder vermehrt im Umlauf:\n \n Laut dem Bundesamt für Gesundheit BAG ist die Zahl der laborbestätigten Covid-19-Fälle in den letzten Wochen um rund 50 Prozent gestiegen. Auch Abwasserdaten zeigen ein gestiegenes Infektionsgeschehen.\n \n Hauptgründe sind neue Varianten des Coronavirus und nachlassende Immunität.\n \n Zum Newsbeitrag von SRF - Schweizer Radio und Fernsehen 👉️ https://lnkd.in/dHgbJwyh """ "reactions_count" => 2 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-10 16:50:44" "deleted" => 1 ] [ "id" => 673007548 "company_id" => 8375742 "urn" => "urn:li:activity:7219325002708381697" "followers" => null "date" => "3w" "description" => """ «Das war die Letzte» – oder doch nicht?\n \n Weshalb ist es für Frauen oftmals schwieriger, mit dem Rauchen aufzuhören? Claudia Künzli, Bereichsleiterin Prävention, Weiterbildung und Forschung der Lungenliga Schweiz, gibt in der Zeitschriftenbeilage «Gesund im Alter» Tipps für den erfolgreichen Rauchstopp. \n \n Ab heute im Magazin Brigitte und online zu lesen 👉️ https://lnkd.in/evjj-taP\n \n #rauchfrei #nikotin #rauchstopp #tabakprävention """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-10 16:50:44" "deleted" => 1 ] [ "id" => 673007549 "company_id" => 8375742 "urn" => "urn:li:activity:7218996943736250372" "followers" => null "date" => "3w" "description" => """ TV-Tipp: «Endlich wieder schlafen» 💤 \n \n Die ARD-Fernsehsendung «Die Gesundmacher» begleitet Menschen, welche aus unterschiedlichen Gründen an Schlafstörungen leiden, auf ihrem Weg zu einem erholsameren Schlaf. \n \n Wichtiger Hinweis: Die Ursache von Schlafstörungen sollte ärztlich abgeklärt werden. Die häufigsten Schlafstörungen sind Schlafapnoe sowie Ein- und Durchschlafstörungen. \n \n Zu sehen in der ARD Mediathek & Das Erste https://lnkd.in/gEh4pquX """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-10 16:50:44" "deleted" => 1 ] [ "id" => 673007550 "company_id" => 8375742 "urn" => "urn:li:activity:7217497956633976834" "followers" => null "date" => "1mo" "description" => """ Im Coaching «Besser leben mit COPD» lernen Betroffene in verschiedenen Modulen, mit ihrer Krankheit im Alltag besser umgehen zu können. Im sechsten Modul lernen die Teilnehmenden, wie sie mithilfe von Selbstmanagement einen gesunden Lebensstil führen können.\n \n ☑️ Welche Rauchentwöhnungsmethoden gibt es?\n ☑️ Wie kann ich mich gesund und ausgewogen ernähren?\n ☑️ Welche Tipps helfen mir für einen erholsamen Schlaf?\n ☑️ Wie kann ich meine Reisen planen und geniessen?\n \n Weitere Infos zum Coaching 👉https://lnkd.in/dY5hqUXP """ "reactions_count" => 17 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-10 16:50:44" "deleted" => 1 ] [ "id" => 673007551 "company_id" => 8375742 "urn" => "urn:li:activity:7216372187509731329" "followers" => null "date" => "1mo" "description" => """ In tiefer Trauer verabschieden wir uns von unserem langjährigen und geschätzten Vorstandsmitglied\n \n Verena Diener Lenz\n \n 27. März 1949 – 28. Juni 2024\n \n Der gemeinnützige Einsatz für Menschen mit Lungen- und Atemwegserkrankungen lag ihr sehr am Herzen. Verena setzte sich bis zum Schluss mit viel Engagement, Herzblut und Integrität für die Lungenliga ein. Wir werden ihre kluge, weitsichtige und menschliche Art sehr vermissen und sprechen den Angehörigen unser herzliches Beileid aus.\n \n \n C'est avec une profonde tristesse que nous prenons congé de notre très appréciée membre du Comité centrale de longue date\n \n Verena Diener Lenz\n \n 27 mars 1949 – 28 juin 2024\n \n L'engagement d'utilité publique en faveur des personnes atteintes de maladies pulmonaires et respiratoires lui tenait particulièrement à cœur. Jusqu'à la fin, Verena s'est engagée avec beaucoup de passion, de cœur et d'intégrité pour la Ligue pulmonaire. Sa nature intelligente, clairvoyante et humaine nous manquera beaucoup et nous présentons nos sincères condoléances à ses proches. """ "reactions_count" => 33 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-10 16:50:44" "deleted" => 1 ] [ "id" => 673007552 "company_id" => 8375742 "urn" => "urn:li:activity:7214998056511901696" "followers" => null "date" => "1mo" "description" => """ Freiwilliges Engagement ist gelebte Menschlichkeit. ❤️ \n \n Von Kleinkindern bis zu Seniorinnen und Senioren, vom Berner Jura bis ins Oberland: Das SRK Kanton Bern setzt sich im ganzen Kanton für Menschen in Not ein. Zahlreiche Einsätze hat die Organisation dabei ihren Freiwilligen zu verdanken. \n \n Möchten Sie freiwilliges Engagement leisten und dabei Sinnstiftendes bewirken? Das SRK bietet verschiedene Möglichkeiten: \n 👉️ https://lnkd.in/eTntaTbq """ "reactions_count" => 9 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-10 16:50:44" "deleted" => 1 ] [ "id" => 673007553 "company_id" => 8375742 "urn" => "urn:li:activity:7213467974744055808" "followers" => null "date" => "1mo" "description" => """ Der Umzug der Geschäftsstelle, das positive Umfrage-Ergebnis zur Patientenzufriedenheit, die neue Website und erfolgreiche Vertragsabschlüsse – dies und vieles mehr prägte das letzte Geschäftsjahr der Lungenliga Schweiz. \n \n Im Jahresbericht 2023 erfahren Sie mehr 👉️ https://lnkd.in/ecttbQt5 """ "reactions_count" => 14 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-09-10 16:50:44" "deleted" => 1 ] [ "id" => 712688353 "company_id" => 8375742 "urn" => "urn:li:activity:7239199617299480576" "followers" => null "date" => "6d" "description" => """ 📣 Wir freuen uns, bekanntzugeben, dass ready4life am 1. August 2024 in das neue Projektjahr gestartet ist! 🚀\n \n Passend dazu findet man uns heute im schweizweit grössten Jugend-Special «FOKUS Eusi Jugend» in der Zeitschrift "20 Minuten". Das ist besonders cool, denn dieses Special ist der grösste Karriereguide für Jugendliche und junge Erwachsene in der Schweiz und bietet wertvolle Einblicke in Themen wie Berufsbildung, Weiterbildung, psychische Gesundheit und Digitalisierung.\n \n Für viele Jugendliche ist die Berufswahl eine herausfordernde Entscheidung. Nachdem diese Entscheidung getroffen ist, unterstützt ready4life www.r4l.swiss die Jugendlichen dabei, ihre Lehre bei guter psychischer Gesundheit zu meistern.\n \n Bei Fragen oder für weitere Informationen können Sie sich gerne an unsere nationale Projektleiterin Pia Nobis wenden.\n \n https://lnkd.in/dn6Mja8N\n \n #eusiJugend #r4l #Gesundheit #Jugend #Kampagne #20Minuten #App """ "reactions_count" => 20 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-04 20:44:05" "deleted" => 1 ] [ "id" => 712688354 "company_id" => 8375742 "urn" => "urn:li:activity:7237761482430517249" "followers" => null "date" => "4d" "description" => """ Erholung und Genuss am Sarnersee: Im Rahmen der Luftholtage verbrachten 20 Personen vom 20. bis 30. August 2024 zehn erholsame und erlebnisreiche Tage im Hotel Kurhaus am Sarnersee. Die Gäste schätzten den Austausch mit den anderen Teilnehmenden und das Rahmenprogramm sehr. 🌅 ⛰️ \n \n Begleitet und betreut werden die Luftholtage von einem Team der Lungenliga, bestehend aus medizinischem Fachpersonal. """ "reactions_count" => 25 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-04 20:44:05" "deleted" => 1 ] [ "id" => 712688355 "company_id" => 8375742 "urn" => "urn:li:activity:7236689397864173569" "followers" => null "date" => "1w" "description" => "Hast du Lust, mit deinen Stärken in einem diversen Team zu wirken, das einen wertschätzenden Spirit pflegt und zusammen lachen kann? Wir freuen uns auf deine Bewerbung!" "reactions_count" => 4 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-04 20:44:05" "deleted" => 1 ] [ "id" => 712688356 "company_id" => 8375742 "urn" => "urn:li:activity:7236666431977762816" "followers" => null "date" => "1w" "description" => """ Im Rahmen der Kampagne Rauchfreier Monat werden alle Raucherinnen und Raucher dazu eingeladen, im November gemeinsam mit dem Rauchen aufzuhören. Teilnehmende profitieren von einer kostenlosen fachlichen Unterstützung und Begleitung.\n \n Infos und Anmeldung 👇 """ "reactions_count" => 6 "comments_count" => null "reshared_post_author" => "Month Without Tobacco" "reshared_post_author_url" => "https://ch.linkedin.com/company/month-without-tobacco" "reshared_post_author_headline" => null "reshared_post_description" => """ 🔊 Ready to take on the #MonthWithoutTobacco2024 challenge? Let's quit together this November! 👥\n \n 𝐑𝐞𝐠𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐫𝐞 𝐅𝐑𝐄𝐄 𝐚𝐧𝐝 𝐎𝐏𝐄𝐍 𝐧𝐨𝐰: https://lnkd.in/ep4dqxgP\n \n Join thousands in breaking free from tobacco and embracing a healthier lifestyle. Get the tools, support, and community you need to succeed.\n \n 🗣️ Spread the word and invite others—quitting is easier when we do it together!\n \n #Monthwithouttobacco #november2024 #stopsmoking #impacthub #lifewithouttobacco AT Schweiz - Swiss Association for Tobacco Control, Ligue pulmonaire vaudoise, Ligue pulmonaire neuchâteloise, Unisanté, Carrefour addictionS, Lega polmonare ticinese, Associazione Svizzera Non Fumatori, Lungenliga Schweiz, Fonds de prévention du tabagisme FPT, Ligue suisse contre le cancer, Office fédéral de la santé publique OFSP, Diaspora TV Switzerland, Lungenliga beider Basel, ZHAW Zürcher Hochschule für Angewandte Wissenschaften, Santé bernoise, Jie LI, Felix Stähli, Magali Magistrale, Marina Cantafio, Sofia Garbo, Livia Fuchs, Marina Lehner Godinho, Myriam Saad, Nirosha B. """ "reshared_post_followers" => null "reshared_post_date" => "3w" "last_updated" => "2024-10-04 20:44:05" "deleted" => 1 ] [ "id" => 712688357 "company_id" => 8375742 "urn" => "urn:li:activity:7236645691874324482" "followers" => null "date" => "1w" "description" => """ 🛝⏱️ Heute startet die Spielplatz-Analyse von stop2drop! An der Spielplatz-Analyse können alle teilnehmen: Ob alleine, zu zweit oder in einer grösseren Gruppe. Mit der Aktion vom 3. bis 17. September 2024 wollen wir das Ausmass des Zigaretten-Litterings und Rauchens auf Kinderspielplätzen aufzeigen.\n \n Die gesammelten Daten legen wir den zuständigen Personen vor. Wir wollen, dass Politiker:innen und Gemeindeverwaltungen das Thema ernst nehmen – und handeln. Weil alle Kinder das Recht auf saubere und rauchfreie Spielplätze haben.\n \n Hilfst du mit? 💚🌱\n \n Infos und Teilnahme an der Spielplatz-Analyse: https://lnkd.in/ee9k6JEp\n \n #SpielplatzAnalyse #RauchfreieSpielplätze #SaubereUmwelt #FreeFairFuture #stop2drop """ "reactions_count" => 19 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-04 20:44:05" "deleted" => 1 ] [ "id" => 712688358 "company_id" => 8375742 "urn" => "urn:li:activity:7236401573537460226" "followers" => null "date" => "1w" "description" => """ Hast du auch schon darüber nachgedacht, mit dem Rauchen aufzuhören? 🚭 \n \n Schau dir das inspirierende Video von SRF Impact an und begleite Livio auf seinem Weg, das Rauchen hinter sich zu lassen.\n SRF - Schweizer Radio und Fernsehen\n \n #rauchstopp #nikotinfrei \n \n https://lnkd.in/eVPqDhGt """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-04 20:44:05" "deleted" => 1 ] [ "id" => 712688359 "company_id" => 8375742 "urn" => "urn:li:activity:7235218811535122432" "followers" => null "date" => "1w" "description" => """ WHO-Bericht zu Rauchen und Asthma:\n \n Rauchen erhöht das Risiko, an Asthma zu erkranken und verschlimmert die Erkrankung. Bei Menschen, die mit Asthma leben, verschlimmert das Rauchen die Symptome und kann die Wirksamkeit von Medikamenten reduzieren. Kinder, deren Mutter während der Schwangerschaft geraucht haben, haben ein höheres Risiko für kleinere Lungen sowie für die Entwicklung von Asthma. \n \n Passivrauchen stellt ein erhebliches Risiko für Menschen mit Asthma dar, da es die Wahrscheinlichkeit von Asthmaanfällen erhöht und die Behandlung von Asthma erschwert. E-Zigaretten und andere Geräte zur Abgabe von Nikotin können ähnliche Risiken bergen wie herkömmliche Tabakprodukte.\n \n WHO-News: https://lnkd.in/g6PMW9Ek\n \n WHO-Bericht: https://lnkd.in/gzcJCa9M\n \n Die Lungenliga Schweiz sieht sich darin bestätigt, dass das seit 2010 geltende Bundesgesetz zum Schutz vor Passivrauchen dringend verbessert werden muss.\n \n Mehr Informationen: https://lnkd.in/e2eWx8YJ\n \n #lungenerkrankung #asthma #tabakprävention """ "reactions_count" => 4 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-04 20:44:05" "deleted" => 1 ] [ "id" => 712688360 "company_id" => 8375742 "urn" => "urn:li:activity:7234907683538022402" "followers" => null "date" => "1w" "description" => """ Am 12. September 2024 findet die Fachtagung von Spitex Schweiz zum Thema «Die Spitex in der digitalen Transformation Chancen und Herausforderungen für die ambulante Pflege» statt.\n \n Die Lungenliga Schweiz ist Tagungspartnerin und mit einem Stand vertreten. Wir freuen uns auf den Austausch.\n \n Infos und Anmeldung 👉️ https://lnkd.in/ejqVFt6 """ "reactions_count" => 6 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-04 20:44:05" "deleted" => 1 ] [ "id" => 712688361 "company_id" => 8375742 "urn" => "urn:li:activity:7234818295051276288" "followers" => null "date" => "1w" "description" => """ Journée de spécialisation tuberculose le 10 octobre 2024 à Lausanne\n \n Voulez-vous connaître les derniers développements dans le domaine de la tuberculose ? Inscrivez-vous ici jusqu’au 15 septembre 2024 : https://lnkd.in/eVZw_mWJ\n \n \n Fachtag Tuberkulose am 10. Oktober 2024 in Lausanne (Kurssprache Französisch)\n \n Möchten Sie die neuesten Entwicklungen im Bereich der Tuberkulose erfahren? Melden Sie sich bis zum 15. September 2024 hier an: https://lnkd.in/eVZw_mWJ """ "reactions_count" => 9 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-04 20:44:05" "deleted" => 1 ] [ "id" => 712688362 "company_id" => 8375742 "urn" => "urn:li:activity:7234509804944211968" "followers" => null "date" => "1w" "description" => """ Am 1. Oktober 2024 tritt das neue Tabakproduktegesetz in Kraft. \n \n Neu ist es unter anderem verboten, Tabakprodukte und E-Zigaretten oder ähnliche Produkte wie Snus und Vapes an Minderjährige zu verkaufen.\n \n Warum genügt das nicht?\n Das Tabakproduktegesetz tritt erst 9 Jahre (!) und nach zähen Verhandlungen im Parlament in Kraft. Ein wirksamer und glaubwürdiger Jugendschutz ist damit leider noch lange nicht erreicht. \n \n Werbung in Form von Verkaufsförderung für Tabak- und Nikotinprodukte bleibt im bisherigen Umfang erlaubt, wenn «sichergestellt werden kann», dass sie Minderjährige nicht erreicht. Dies ist in der Praxis nicht umsetzbar. Der Jugendschutz ist somit nicht gewährleistet.\n \n Zur Medienmitteilung von AT Schweiz - Swiss Association for Tobacco Control 👉️ https://lnkd.in/eMuqegjZ """ "reactions_count" => 32 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-04 20:44:05" "deleted" => 1 ] [ "id" => 746266596 "company_id" => 8375742 "urn" => "urn:li:activity:7243151969479983104" "followers" => null "date" => "4d" "description" => """ Wie können Kinder und Jugendliche unterstützt werden, nikotinfrei zu bleiben? Wie soll ich reagieren, wenn mein Kind bereits konsumiert und ich es merke? Und wie kann ich das Thema Nikotin ansprechen, ohne meine Beziehung zu meinem Kind zu belasten?\n \n Die Lungenliga Zentralschweiz bietet am 21. Oktober 2024 den Vertiefungsworkshop «Nikotindurchblick» an. Eltern und andere Bezugspersonen lernen anhand von verschiedenen Beispielen, wie sie mit Jugendlichen über das Thema Nikotin sprechen können und wie es gelingt, im Austausch zu bleiben. \n \n Jetzt online anmelden 👉️ https://lnkd.in/ed-a_cXs """ "reactions_count" => 27 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 12:55:36" "deleted" => 1 ] [ "id" => 746266597 "company_id" => 8375742 "urn" => "urn:li:activity:7241340034157539328" "followers" => null "date" => "1w" "description" => """ Was muss ich als Elternteil, Lehrperson, Jugendarbeiterin oder Jugendarbeiter über Vapes, Snus und andere neue Nikotinprodukte wissen? Wie soll ich die Themen Nikotin und Sucht bei Jugendlichen ansprechen?\n \n Die Lungenliga Zentralschweiz beantwortet in der Info-Veranstaltung «Nikotindurchblick» am 16. Oktober 2024 die wichtigsten Fragen rund um den Nikotinkonsum von Jugendlichen. \n \n Die Veranstaltung ist kostenlos, findet online statt und dauert 45 Minuten.\n \n Jetzt online anmelden 👉️ https://lnkd.in/ewiuGphb """ "reactions_count" => 19 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 12:55:36" "deleted" => 1 ] [ "id" => 746266598 "company_id" => 8375742 "urn" => "urn:li:activity:7240615283600601088" "followers" => null "date" => "1w" "description" => """ Einweg-Vapes sind nicht nur für die Gesundheit problematisch, sondern auch für die Umwelt: Nach Gebrauch landen die Vapes meistens im Abfall. Als Elektrogeräte gehören sie jedoch ins Recycling.\n \n Was wird dagegen unternommen? In diesem Artikel erfahren Sie mehr 👉️ https://lnkd.in/eft-F_y2\n \n #vapen #ezigaretten """ "reactions_count" => 18 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 12:55:36" "deleted" => 1 ] [ "id" => 746266599 "company_id" => 8375742 "urn" => "urn:li:activity:7240252893453328384" "followers" => null "date" => "1w" "description" => """ Am 30. Oktober 2024 findet das Joint TB-Meeting statt. Dies vereint das Tuberkulose Symposium der Lungenliga Schweiz mit dem Swiss translational TB Forum in einer erstmaligen Zusammenarbeit. \n \n Spannende Vorträge aus der Welt der Tuberkulose sowie interessante Gespräche sind vorprogrammiert. Aber schauen Sie selbst in unserem Programm und registrieren Sie sich noch heute 👉️ https://lnkd.in/eWEtPArn\n \n #tuberkulose #tb #lungenerkrankung """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 12:55:36" "deleted" => 1 ] [ "id" => 746266600 "company_id" => 8375742 "urn" => "urn:li:activity:7239935814548303877" "followers" => null "date" => "1w" "description" => """ Samuel Graf hat Cystische Fibrose (CF). Eine Erbkrankheit, die sich stark auf die Lunge auswirkt. Aber Samuel lässt sich nicht von der Krankheit besiegen «Einen Marathon in Angriff zu nehmen, gibt mir das Gefühl, die CF zu besiegen.» \n \n In der Titelgeschichte unseres Magazins vivo berichtete seine Freundin Helena letzten Herbst, wie sie gemeinsam ihren ersten Halbmarathon in St. Gallen erlebt haben. Nächstes Ziel: Dublin-Marathon. Wir haben nachgefragt. Hat er es geschafft? 🏃 \n \n Lesen Sie hier, wie Samuel Graf den Marathon nicht nur geschafft, sondern sogar genossen hat: https://lnkd.in/egmMS8tf\n \n #cystischefibrose #cf #lungenerkrankung """ "reactions_count" => 37 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 12:55:36" "deleted" => 1 ] [ "id" => 746266601 "company_id" => 8375742 "urn" => "urn:li:activity:7239533533579419648" "followers" => null "date" => "2w" "description" => """ 𝗥𝗮𝘂𝗰𝗵𝗲𝗻 𝗮𝘂𝗳 𝗦𝗽𝗶𝗲𝗹𝗽𝗹ä𝘁𝘇𝗲𝗻: 𝗢𝗞 𝗼𝗱𝗲𝗿 𝗻𝗶𝗰𝗵𝘁 𝗢𝗞? \n \n 𝗗𝗲𝗶𝗻𝗲 𝗠𝗲𝗶𝗻𝘂𝗻𝗴 𝗶𝗻𝘁𝗲𝗿𝗲𝘀𝘀𝗶𝗲𝗿𝘁 𝘂𝗻𝘀! \n \n Zusammen mit Sotomo führen wir eine anonyme Online-Befragung durch und wollen wissen: Was denkst du über Zigaretten-Littering und Rauchen auf Spielplätzen? \n \n 🔗 Hier geht's zur Befragung:\n DE: https://s.sotomo.ch/s2dDE\n FR: https://s.sotomo.ch/s2dFR\n IT: https://s.sotomo.ch/s2dIT\n \n ⏱ Die Teilnahme dauert 7 bis 10 Minuten.\n \n ➡ Warum deine Teilnahme wichtig ist: \n Deine Antworten werden für die Entwicklung einer landesweiten Kampagne zur Förderung von rauchfreien Spielplätzen und zur Sensibilisierung bezüglich der Umweltfolgen von Zigaretten-Littering genutzt. \n Ob Raucher:in oder Nichtraucher:in – jede Perspektive zählt!\n \n Bitte teile diesen Beitrag, um möglichst viele Menschen zu erreichen. Jede Teilnahme und jede Weiterempfehlung bringt uns ein Stück weiter! 💡\n \n #Umfrage #ZigarettenLittering #Umweltschutz #Rauchen #Gesundheit #Kinderrecht #Schweiz #stop2drop """ "reactions_count" => 26 "comments_count" => 4 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 12:55:36" "deleted" => 1 ] [ "id" => 746266602 "company_id" => 8375742 "urn" => "urn:li:activity:7239199617299480576" "followers" => null "date" => "3w" "description" => """ 📣 Wir freuen uns, bekanntzugeben, dass ready4life am 1. August 2024 in das neue Projektjahr gestartet ist! 🚀\n \n Passend dazu findet man uns heute im schweizweit grössten Jugend-Special «FOKUS Eusi Jugend» in der Zeitschrift "20 Minuten". Das ist besonders cool, denn dieses Special ist der grösste Karriereguide für Jugendliche und junge Erwachsene in der Schweiz und bietet wertvolle Einblicke in Themen wie Berufsbildung, Weiterbildung, psychische Gesundheit und Digitalisierung.\n \n Für viele Jugendliche ist die Berufswahl eine herausfordernde Entscheidung. Nachdem diese Entscheidung getroffen ist, unterstützt ready4life www.r4l.swiss die Jugendlichen dabei, ihre Lehre bei guter psychischer Gesundheit zu meistern.\n \n Bei Fragen oder für weitere Informationen können Sie sich gerne an unsere nationale Projektleiterin Pia Nobis wenden.\n \n https://lnkd.in/dn6Mja8N\n \n #eusiJugend #r4l #Gesundheit #Jugend #Kampagne #20Minuten #App """ "reactions_count" => 23 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 12:55:36" "deleted" => 1 ] [ "id" => 746266603 "company_id" => 8375742 "urn" => "urn:li:activity:7237761482430517249" "followers" => null "date" => "2w" "description" => """ Erholung und Genuss am Sarnersee: Im Rahmen der Luftholtage verbrachten 20 Personen vom 20. bis 30. August 2024 zehn erholsame und erlebnisreiche Tage im Hotel Kurhaus am Sarnersee. Die Gäste schätzten den Austausch mit den anderen Teilnehmenden und das Rahmenprogramm sehr. 🌅 ⛰️ \n \n Begleitet und betreut werden die Luftholtage von einem Team der Lungenliga, bestehend aus medizinischem Fachpersonal. """ "reactions_count" => 38 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 12:55:36" "deleted" => 1 ] [ "id" => 746266604 "company_id" => 8375742 "urn" => "urn:li:activity:7236689397864173569" "followers" => null "date" => "3w" "description" => "Hast du Lust, mit deinen Stärken in einem diversen Team zu wirken, das einen wertschätzenden Spirit pflegt und zusammen lachen kann? Wir freuen uns auf deine Bewerbung!" "reactions_count" => 10 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-10-18 12:55:36" "deleted" => 1 ] [ "id" => 746266605 "company_id" => 8375742 "urn" => "urn:li:activity:7236666431977762816" "followers" => null "date" => "3w" "description" => """ Im Rahmen der Kampagne Rauchfreier Monat werden alle Raucherinnen und Raucher dazu eingeladen, im November gemeinsam mit dem Rauchen aufzuhören. Teilnehmende profitieren von einer kostenlosen fachlichen Unterstützung und Begleitung.\n \n Infos und Anmeldung 👇 """ "reactions_count" => 6 "comments_count" => null "reshared_post_author" => "Month Without Tobacco" "reshared_post_author_url" => "https://ch.linkedin.com/company/month-without-tobacco" "reshared_post_author_headline" => null "reshared_post_description" => """ 🔊 Ready to take on the #MonthWithoutTobacco2024 challenge? Let's quit together this November! 👥\n \n 𝐑𝐞𝐠𝐢𝐬𝐭𝐫𝐚𝐭𝐢𝐨𝐧𝐬 𝐚𝐫𝐞 𝐅𝐑𝐄𝐄 𝐚𝐧𝐝 𝐎𝐏𝐄𝐍 𝐧𝐨𝐰: https://lnkd.in/ep4dqxgP\n \n Join thousands in breaking free from tobacco and embracing a healthier lifestyle. Get the tools, support, and community you need to succeed.\n \n 🗣️ Spread the word and invite others—quitting is easier when we do it together!\n \n #Monthwithouttobacco #november2024 #stopsmoking #impacthub #lifewithouttobacco AT Schweiz - Swiss Association for Tobacco Control, Ligue pulmonaire vaudoise, Ligue pulmonaire neuchâteloise, Unisanté, Carrefour addictionS, Lega polmonare ticinese, Associazione Svizzera Non Fumatori, Lungenliga Schweiz, Fonds de prévention du tabagisme FPT, Ligue suisse contre le cancer, Office fédéral de la santé publique OFSP, Diaspora TV Switzerland, Lungenliga beider Basel, ZHAW Zürcher Hochschule für Angewandte Wissenschaften, Santé bernoise, Jie LI, Felix Stähli, Magali Magistrale, Marina Cantafio, Sofia Garbo, Livia Fuchs, Marina Lehner Godinho, Myriam Saad, Nirosha B. """ "reshared_post_followers" => null "reshared_post_date" => "1mo" "last_updated" => "2024-10-18 12:55:36" "deleted" => 1 ] [ "id" => 766522179 "company_id" => 8375742 "urn" => "urn:li:activity:7247937661116583936" "followers" => null "date" => "21h" "description" => """ Fachtagung Tuberkulose am 28. November 2024 in Olten:\n \n Wie und unter welchen Bedingungen wird Tuberkulose übertragen? Welche Symptome treten auf? \n \n Melden Sie sich bis zum 15. Oktober 2024 hier an 👉️ https://lnkd.in/eKYqi5TP """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-06 23:17:51" "deleted" => 1 ] [ "id" => 766522180 "company_id" => 8375742 "urn" => "urn:li:activity:7247591219994791936" "followers" => null "date" => "1d" "description" => """ Das neue vivo widmet sich dem Schlaf 💤 \n \n Die Diagnose Schlafapnoe und das CPAP-Gerät stellten das Leben von Anne Neyroud auf den Kopf. Ob es um Schnarchen, Libido oder Besuche bei der Lungenliga geht – mit Humor bricht sie auf der Bühne die Tabus. \n \n Manchen Schlafapnoe-Betroffenen fällt es schwer, sich an die Atemmaske zu gewöhnen. Im Herbst-vivo geben Fachleute Tipps zum Durchhalten.\n \n Unser Körper und unsere Psyche brauchen erholsamen Schlaf, um gesund zu bleiben. Im neuen vivo finden Sie interessante Interviews mit Schlafforschern und zahlreiche Tipps, die Ihnen helfen, zur Ruhe zu kommen. \n \n Schlafen Sie gut! 👉️ https://lnkd.in/ePnqms66 """ "reactions_count" => 14 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-06 23:17:51" "deleted" => 1 ] [ "id" => 766522181 "company_id" => 8375742 "urn" => "urn:li:activity:7247500624173436928" "followers" => null "date" => "2d" "description" => """ Der Schlaf bekommt eine Stimme 💤 \n \n Unser Körper und unsere Psyche brauchen erholsamen Schlaf, um gesund zu bleiben. Das Netzwerk Schlaf setzt sich dafür ein, dass der Schlaf als wichtige Gesundheitsressource anerkannt wird.\n \n Am Mittwochabend, 23. Oktober, feiert das neue Netzwerk in Bern seine Gründung. Der Publikumsevent lockt mit interessanten Inputs für einen besseren Schlaf.\n \n Informationen und Anmeldung 👉️ https://netzwerkschlaf.ch/\n \n Medienmitteilung 👉️ https://lnkd.in/ejU_YM2E """ "reactions_count" => 32 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-06 23:17:51" "deleted" => 1 ] [ "id" => 766522182 "company_id" => 8375742 "urn" => "urn:li:activity:7247184339451416577" "followers" => null "date" => "2d" "description" => """ Journée de spécialisation Spirométrie :\n Vendredi 14 novembre 2024 à Martigny\n \n Envie de maîtriser la spirométrie ?\n Rejoignez notre journée de formation pour apprendre à réaliser et interpréter les résultats avec précision.\n Grâce à des outils pratiques et des conseils d’experts, devenez un véritable pro de la spirométrie !\n \n Inscription ici 👉️ https://lnkd.in/eN-S5ChZ\n \n **\n \n Fachtagung Spirometrie (Kurssprache Französisch)\n Freitag, 14. November 2024 in Martigny\n \n Möchten Sie die Spirometrie beherrschen? \n Nehmen Sie an unserer Fachtagung teil und lernen Sie, wie Sie präzise Ergebnisse erzielen und interpretieren.\n Mit praktischen Hilfsmitteln und Ratschlägen von Expertinnen und Experten werden Sie zu einem echten Spirometrie-Profi!\n \n Hier geht's zur Anmeldung 👉️ https://lnkd.in/eN-S5ChZ """ "reactions_count" => 9 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-06 23:17:51" "deleted" => 1 ] [ "id" => 766522183 "company_id" => 8375742 "urn" => "urn:li:activity:7246775847708164096" "followers" => null "date" => "4d" "description" => """ Die interaktive Coaching-App der Lungenliga 📱 💚 \n \n ready4life ist eine Coaching-App für Jugendliche, die Lebenskompetenzen wie Stressbewältigung, Social Media, Gaming und Suchtprävention stärkt.\n \n Ein virtueller Coach bietet individuell ausgewählte Tipps und Challenges, während Expertinnen und Experten in einem separaten Chat persönliche Fragen beantworten.\n \n Weitere Informationen: https://www.r4l.swiss/\n \n #prävention #jugendschutz #r4l """ "reactions_count" => 10 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-06 23:17:51" "deleted" => 1 ] [ "id" => 766522184 "company_id" => 8375742 "urn" => "urn:li:activity:7245088810076618754" "followers" => null "date" => "1w" "description" => """ Der Schlaf bekommt eine Lobby 💤\n \n Am Mittwochabend, 23. Oktober 2024, feiert das Netzwerk Schlaf in Bern seine Gründung mit einem kostenlosen Publikumsanlass.\n \n Informationen und Anmeldung 👉️ https://netzwerkschlaf.ch/ """ "reactions_count" => 22 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-06 23:17:51" "deleted" => 1 ] [ "id" => 766522185 "company_id" => 8375742 "urn" => "urn:li:activity:7243151969479983104" "followers" => null "date" => "2w" "description" => """ Wie können Kinder und Jugendliche unterstützt werden, nikotinfrei zu bleiben? Wie soll ich reagieren, wenn mein Kind bereits konsumiert und ich es merke? Und wie kann ich das Thema Nikotin ansprechen, ohne meine Beziehung zu meinem Kind zu belasten?\n \n Die Lungenliga Zentralschweiz bietet am 21. Oktober 2024 den Vertiefungsworkshop «Nikotindurchblick» an. Eltern und andere Bezugspersonen lernen anhand von verschiedenen Beispielen, wie sie mit Jugendlichen über das Thema Nikotin sprechen können und wie es gelingt, im Austausch zu bleiben. \n \n Jetzt online anmelden 👉️ https://lnkd.in/ed-a_cXs """ "reactions_count" => 31 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-06 23:17:51" "deleted" => 1 ] [ "id" => 766522186 "company_id" => 8375742 "urn" => "urn:li:activity:7241340034157539328" "followers" => null "date" => "2w" "description" => """ Was muss ich als Elternteil, Lehrperson, Jugendarbeiterin oder Jugendarbeiter über Vapes, Snus und andere neue Nikotinprodukte wissen? Wie soll ich die Themen Nikotin und Sucht bei Jugendlichen ansprechen?\n \n Die Lungenliga Zentralschweiz beantwortet in der Info-Veranstaltung «Nikotindurchblick» am 16. Oktober 2024 die wichtigsten Fragen rund um den Nikotinkonsum von Jugendlichen. \n \n Die Veranstaltung ist kostenlos, findet online statt und dauert 45 Minuten.\n \n Jetzt online anmelden 👉️ https://lnkd.in/ewiuGphb """ "reactions_count" => 19 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-06 23:17:51" "deleted" => 1 ] [ "id" => 766522187 "company_id" => 8375742 "urn" => "urn:li:activity:7240615283600601088" "followers" => null "date" => "3w" "description" => """ Einweg-Vapes sind nicht nur für die Gesundheit problematisch, sondern auch für die Umwelt: Nach Gebrauch landen die Vapes meistens im Abfall. Als Elektrogeräte gehören sie jedoch ins Recycling.\n \n Was wird dagegen unternommen? In diesem Artikel erfahren Sie mehr 👉️ https://lnkd.in/eft-F_y2\n \n #vapen #ezigaretten """ "reactions_count" => 19 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-06 23:17:51" "deleted" => 1 ] [ "id" => 766522188 "company_id" => 8375742 "urn" => "urn:li:activity:7240252893453328384" "followers" => null "date" => "3w" "description" => """ Am 30. Oktober 2024 findet das Joint TB-Meeting statt. Dies vereint das Tuberkulose Symposium der Lungenliga Schweiz mit dem Swiss translational TB Forum in einer erstmaligen Zusammenarbeit. \n \n Spannende Vorträge aus der Welt der Tuberkulose sowie interessante Gespräche sind vorprogrammiert. Aber schauen Sie selbst in unserem Programm und registrieren Sie sich noch heute 👉️ https://lnkd.in/eWEtPArn\n \n #tuberkulose #tb #lungenerkrankung """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-11-06 23:17:51" "deleted" => 1 ] [ "id" => 796959921 "company_id" => 8375742 "urn" => "urn:li:activity:7259836910880145408" "followers" => null "date" => "6h" "description" => """ Wieso bleibt mir die Luft weg? 🤔 \n \n Ursache für eine chronisch obstruktive Lungenerkrankung ist fast immer das Einatmen von Schadstoffen (z. B. Tabakrauch) über lange Zeit. Sind die Schleimhäute der Atemwege und die Lungenbläschen durch diese Dauerbelastung geschädigt, kommt es zu den typischen COPD-Symptomen Husten, Atemnot und teils Auswurf.\n \n 👉 www.lungenliga.ch/copd """ "reactions_count" => 8 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-07 01:53:33" "deleted" => 1 ] [ "id" => 796959922 "company_id" => 8375742 "urn" => "urn:li:activity:7259474531864526849" "followers" => null "date" => "1d" "description" => """ Gut schlafen trotz Schlafapnoe:\n \n Die CPAP-Therapie ist die wirksamste Behandlung von Schlafapnoe. Als Patientin oder Patient können Sie dazu beitragen, die Anzahl der nächtlichen Atemaussetzer zu reduzieren, erklärt der Schlafforscher.\n \n Zum vivo-Beitrag 👉️ https://lnkd.in/erjn6sjc """ "reactions_count" => 9 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-07 01:53:33" "deleted" => 1 ] [ "id" => 796959923 "company_id" => 8375742 "urn" => "urn:li:activity:7258085810728583169" "followers" => null "date" => "5d" "description" => """ Heute startet der Rauchfreie Monat 2024. 🚭 \n \n Kurzentschlossene können sich jetzt noch anmelden und von kostenloser fachlicher Unterstützung profitieren: https://lnkd.in/eT9mmCrV \n \n Gemeinsam schaffen wir den Start in eine rauchfreie Zukunft! """ "reactions_count" => 9 "comments_count" => null "reshared_post_author" => "Month Without Tobacco" "reshared_post_author_url" => "https://ch.linkedin.com/company/month-without-tobacco" "reshared_post_author_headline" => null "reshared_post_description" => """ 🚭 𝐖𝐞𝐥𝐜𝐨𝐦𝐞 𝐭𝐨 𝐭𝐡𝐞 𝐌𝐨𝐧𝐭𝐡 𝐖𝐢𝐭𝐡𝐨𝐮𝐭 𝐓𝐨𝐛𝐚𝐜𝐜𝐨: 𝐎𝐯𝐞𝐫 𝟏𝟎,𝟎𝟎𝟎 𝐨𝐟 𝐲𝐨𝐮 𝐚𝐫𝐞 𝐬𝐭𝐚𝐫𝐭𝐢𝐧𝐠 𝐭𝐡𝐢𝐬 𝐣𝐨𝐮𝐫𝐧𝐞𝐲 𝐭𝐨𝐝𝐚𝐲—𝐥𝐞𝐭’𝐬 𝐦𝐚𝐤𝐞 𝐢𝐭 𝐚 𝐩𝐨𝐰𝐞𝐫𝐟𝐮𝐥, 𝐬𝐦𝐨𝐤𝐞-𝐟𝐫𝐞𝐞 𝐦𝐨𝐧𝐭𝐡 𝐭𝐨𝐠𝐞𝐭𝐡𝐞𝐫! 🎉\n \n Today marks the first step towards a healthier, smoke-free life, YEY! And you’re not alone on this journey! 🌟 \n \n We’re a community here to lift each other up, share tips, and stay motivated together. Whether you’re here for better health, personal growth, or just to feel free, you’ve made an incredible choice. 💪💚\n \n Let’s support each other every step of the way – share your thoughts, challenges, and the little wins that keep you going! This month is all about making real change together, and every message counts. \n \n Not yet registered? It's not too late! Join the movement 👉 https://lnkd.in/e9hkna9a\n \n #TogetherWeCan #MonthWithoutTobaacco #StepByStep #HealthierTogether #QuitTips\n \n AT Schweiz - Swiss Association for Tobacco Control, Ligue pulmonaire vaudoise, Ligue pulmonaire neuchâteloise, Unisanté, Carrefour addictionS, Lega polmonare ticinese, Associazione Svizzera Non Fumatori, Lungenliga Schweiz, Fonds de prévention du tabagisme FPT, Ligue suisse contre le cancer, Office fédéral de la santé publique OFSP, Diaspora TV Switzerland, Lungenliga beider Basel, ZHAW Zürcher Hochschule für Angewandte Wissenschaften, Santé bernoise, Promotion santé Valais """ "reshared_post_followers" => null "reshared_post_date" => "5d" "last_updated" => "2024-12-07 01:53:33" "deleted" => 1 ] [ "id" => 796959924 "company_id" => 8375742 "urn" => "urn:li:activity:7258024985657511936" "followers" => null "date" => "5d" "description" => """ Ständiges 𝗛𝘂𝘀𝘁𝗲𝗻?\n Es könnte COPD sein.\n \n Häufig ignorieren die Betroffenen die ersten Symptome: Husten, Atemnot und teils Auswurf. Rund 400'000 Menschen in der Schweiz sind von der sogenannten chronisch obstruktiven Lungenerkrankung betroffen. COPD engt die Atemwege langsam, aber stetig ein, bis hin zu starker Atemnot. Je früher die Krankheit erkannt wird, desto besser lässt sie sich behandeln.\n \n 𝗠𝗮𝗰𝗵𝗲𝗻 𝗦𝗶𝗲 𝗱𝗲𝗻 𝗖𝗢𝗣𝗗-𝗧𝗲𝘀𝘁! \n 👉 www.lungenliga.ch/copd """ "reactions_count" => 18 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-07 01:53:33" "deleted" => 1 ] [ "id" => 796959925 "company_id" => 8375742 "urn" => "urn:li:activity:7257662611633094658" "followers" => null "date" => "6d" "description" => """ Am 8. November 2024, dem nationalen Grippeimpftag, können sich alle impfinteressierte Personen für CHF 30.– gegen die saisonale Grippe impfen lassen. 💉\n \n Nebst der Grippeimpfung wird auch die Covid-19-Impfung gemäss Empfehlungen des Bundesamt für Gesundheit BAG angeboten. \n \n Gehören Sie zu einer Gruppe mit erhöhtem Komplikationsrisiko bei einer Grippeerkrankung? Machen Sie den Check 👉️ https://lnkd.in/dYM3v_nY\n \n Weitere Informationen rund um die Grippesaison 2024/2025 finden Sie unter https://lnkd.in/exsmf5D6 """ "reactions_count" => 4 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-07 01:53:33" "deleted" => 1 ] [ "id" => 796959926 "company_id" => 8375742 "urn" => "urn:li:activity:7257405960376176641" "followers" => null "date" => "6d" "description" => """ «Schlafprobleme beginnen nicht erst um 22 Uhr»\n \n Viele Menschen erkennen nicht, dass sie zu wenig oder schlecht schlafen. Ruth Kappeler erklärt in Schlafworkshops der Lungenliga, wie lebensnotwendig erholsamer Schlaf ist und zeigt einfache Übungen, die helfen können, besser zu schlafen.\n \n Zum vivo-Beitrag 👉️ https://lnkd.in/dj4sw9wr """ "reactions_count" => 21 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-07 01:53:33" "deleted" => 1 ] [ "id" => 796959927 "company_id" => 8375742 "urn" => "urn:li:activity:7257080357835915264" "followers" => null "date" => "1w" "description" => """ 🌟 Freude an einem sinnstiftenden Job? 🌟\n \n Hast du Lust, mit deinen Stärken in einem diversen Team zu wirken, das einen wertschätzenden Spirit pflegt und zusammen lachen kann? Wir freuen uns auf deine Bewerbung!\n \n #Hiring #Jobs #Weiterbildung \n \n 🌟 Envie d'un emploi porteur de sens ? 🌟\n \n As-tu envie d'utiliser tes forces au sein d'une équipe diversifiée, qui cultive un esprit de valorisation et sait rire ensemble ? Nous avons hâte de recevoir ta candidature ! """ "reactions_count" => 5 "comments_count" => 3 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-07 01:53:33" "deleted" => 1 ] [ "id" => 796959928 "company_id" => 8375742 "urn" => "urn:li:activity:7257061410545844224" "followers" => null "date" => "1w" "description" => """ Das Netzwerk Schlaf blickt zurück auf einen gelungenen Gründungsanlass mit inspirierenden Begegnungen und anregenden Gesprächen rund um das Thema Schlaf. 💡💤 \n \n Herzlicher Dank geht an Nationalrat Christian Lohr (Patronat) für die berührende Eröffnungsrede, \n \n an Urs Z'graggen und Ramon Stadelmann für die Bereitschaft, über ihre Schlafprobleme zu reden,\n \n an die Expertinnen und den Experten für die kompetente medizinische Auskunft:\n - Dr. med. Helen Christina Slawik (UPK Basel),\n - Dr. med. Heydy Gonzáles (Hofklinik Luzern),\n - Dr. rer. nat. Albrecht Vorster (Swiss Sleep House Bern),\n \n an Katharina Locher (SRF) für die souveräne Moderation und an die zahlreichen Teilnehmenden für das Interesse.\n \n Hat das Thema «Schlaf» auch Ihr Interesse geweckt? \n Auf netzwerkschlaf.ch finden Sie aktuelle Informationen und Ressourcen. """ "reactions_count" => 36 "comments_count" => 2 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-07 01:53:33" "deleted" => 1 ] [ "id" => 796959929 "company_id" => 8375742 "urn" => "urn:li:activity:7255548700834377729" "followers" => null "date" => "1w" "description" => """ Die CPAP-Masken-Influencerin 📸 \n \n Anne Neyroud ist eine aktive Frau voller Humor. Als sie die Diagnose Schlafapnoe erhält, stellt das verordnete CPAP-Gerät ihr Leben auf den Kopf. Ob es um Schnarchen, Libido oder Termine bei der Lungenliga geht – mit Humor erzählt sie von ihrem Alltag und bricht Tabus auf.\n \n Zum Porträt 👉️ https://lnkd.in/eYTXJa4F """ "reactions_count" => 12 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-07 01:53:33" "deleted" => 1 ] [ "id" => 796959930 "company_id" => 8375742 "urn" => "urn:li:activity:7254748380390637568" "followers" => null "date" => "2w" "description" => """ Anlässlich des Nationalen Tages der betreuenden Angehörigen vom 30. Oktober 2024 formuliert die Interessengemeinschaft Angehörigenbetreuung IGAB-CIPA vier Forderungen an die Politik auf nationaler Ebene.\n \n 1. Damit alle Bewohnerinnen und Bewohner der Schweiz die gleichen Bedingungen vorfinden, braucht es eine nationale Strategie der betreuenden Angehörigen, die von allen Beteiligten definiert wird;\n 2. Um Einzelpersonen korrekt über alle bestehenden Angebote und Hilfen zu \n informieren, muss eine einzige Anlaufstelle geschaffen werden, was eine Zusammenarbeit auf nationaler Ebene zwischen den Kantonen und den regionalen Verbänden bedeutet;\n 3. Im ganzen Land müssen Entlastungsangebote für möglichst viele Menschen zugänglich sein, sowohl finanziell als auch von den Plätzen;\n 4. Die Finanzierung von Entlastungsangeboten muss landesweit einheitlich sein.\n \n Auf ihrer Website listet sie die Initiativen auf, die in der Schweiz von den kantonalen Behörden und verschiedenen Organisationen anlässlich dieses Tages ergriffen wurden.\n \n Mehr Informationen 👉️ https://lnkd.in/eeB6xmvp """ "reactions_count" => 12 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2024-12-07 01:53:33" "deleted" => 1 ] [ "id" => 844234333 "company_id" => 8375742 "urn" => "urn:li:activity:7270346187944169473" "followers" => null "date" => "1d" "description" => """ Bewusstes Atmen beruhigt:\n \n Mit bewusstem Atmen können wir Herzfrequenz, Blutdruck und Nervensystem beeinflussen. 🧘\n \n Entdecken Sie die neuen Atemübungen im vivo-Artikel:\n 👉️ https://lnkd.in/euZ_mm2d """ "reactions_count" => 23 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 05:48:06" "deleted" => 1 ] [ "id" => 844234334 "company_id" => 8375742 "urn" => "urn:li:activity:7270028835629211648" "followers" => null "date" => "1d" "description" => """ Die Lungenliga Schweiz gratuliert den rund 10'500 Personen, die am Rauchfreien Monat teilgenommen haben und gemeinsam den Weg in eine rauchfreie Zukunft gewählt haben. Unsere Expertinnen und Experten bieten auch weiterhin Unterstützung für den individuellen Rauchstopp an.\n 👉 https://lnkd.in/ezvPhrAC """ "reactions_count" => 21 "comments_count" => 1 "reshared_post_author" => "Month Without Tobacco" "reshared_post_author_url" => "https://ch.linkedin.com/company/month-without-tobacco" "reshared_post_author_headline" => null "reshared_post_description" => """ 𝐈𝐓 𝐈𝐒 𝐓𝐇𝐄 𝐄𝐍𝐃 🌈 ⎮ A heartfelt thank you to our #IncredibleSponsors and #AmazingParticipants! 🌟\n \n As #MonthWithoutTobacco wraps up, we’re grateful for your incredible support. Sponsors, your generous contributions—from colorful pencils to hotel vouchers—have been a true boost to our participants' journey. 🎉\n \n Participants, your dedication and resilience have been inspiring. You’ve tackled this challenge with determination and supported each other every step of the way.\n \n Together, we’ve made a meaningful impact and moved closer to a tobacco-free future. Thank you all for being a part of this transformative month! 🙌\n \n AT Schweiz - Swiss Association for Tobacco Control, Ligue pulmonaire vaudoise, Ligue pulmonaire neuchâteloise, Unisanté, Carrefour addictionS, Lega polmonare ticinese, Associazione Svizzera Non Fumatori, Lungenliga Schweiz, Fonds de prévention du tabagisme FPT, Ligue suisse contre le cancer, Office fédéral de la santé publique OFSP, Diaspora TV Switzerland, Lungenliga beider Basel, ZHAW Zürcher Hochschule für Angewandte Wissenschaften, Santé bernoise, Promotion santé Valais, Fondation O2, Etat de Genève, Etat de Fribourg - Staat Freiburg """ "reshared_post_followers" => null "reshared_post_date" => "2d" "last_updated" => "2025-01-15 05:48:06" "deleted" => 1 ] [ "id" => 844234335 "company_id" => 8375742 "urn" => "urn:li:activity:7269632211627266048" "followers" => null "date" => "3d" "description" => """ 📈🛝 Die Spielplatz-Analyse 2024 zeigt: Auf Kinderspielplätzen liegen viele giftige Zigarettenstummel und es wird oft geraucht. Felicitas und Markus geben dir einen Einblick in die Resultate. \n \n Zusammen mit Unterstützer:innen haben wir 170 Spielplätze in der ganzen Schweiz untersucht und 15'479 Zigarettenstummel eingesammelt. \n \n • Auf 98 Prozent der Spielplätze liegen Zigistummel \n • Im Durchschnitt liegen 91 giftige Stummel auf jedem Spielplatz \n • Jeder vierte Spielplatz ist mit über 100 Zigistummeln stark verschmutzt \n \n 🫵 Aktiv werden: Möchtest du mithelfen, etwas in deiner Gemeinde zu verändern? Schreibe eine E-Mail an deine Gemeinde und lade sie ein, aktiv zu werden. Wir haben eine E-Mail-Vorlage online gestellt. Hilfst du mit? Link: https://lnkd.in/eFC7zdMZ\n \n Gemeinsam für eine saubere und gesunde Umwelt. 🌱💚 \n \n Carine Lehmann Dominique Lorandt Eveline Rohland Fabiola Vincenz Iris Kohler Karin Federer Katja Glogner Kris S. Linda Zimmermann Livia Twiddy Luciano Ruggia Manuel Hirschi Martin Bienlein Nicola Imseng Nicole Räber Oliver Padlina @Sophie Heiniger Stephan Brun Stephanie Unternährer\n \n Tabakpräventionsfonds TPF AT Schweiz - Swiss Association for Tobacco Control Lungenliga Schweiz Associazione Svizzera Non Fumatori The Behavior Lab Cipret JU Cipret NE FMH Verbindung Schweizer Ärztinnen und Ärzte Kanton Aargau Kanton Luzern Kanton St.Gallen kibesuisse Lungenliga Aargau Lungenliga Ost Naturama Aargau PEPra Samowar Sucht Schweiz Suchtpräventionsstelle Bezirk Andelfingen Suchtpräventionsstelle Bezirke Affoltern und Dietikon (Supad) Unisanté \n \n #SpielplatzAnalyse #RauchfreieSpielplätze #SaubereUmwelt #FreeFairFuture #stop2drop """ "reactions_count" => 32 "comments_count" => 5 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 05:48:06" "deleted" => 1 ] [ "id" => 844234336 "company_id" => 8375742 "urn" => "urn:li:activity:7268171860889030656" "followers" => null "date" => "1w" "description" => """ Machen Sie einen Unterschied im Leben derer, die um jeden Atemzug kämpfen.\n \n Ihr Beitrag ermöglicht es der Lungenliga, den Menschen, die mit COPD leben, hilfreiche Angebote und Beratungen zur Verfügung zu stellen.\n \n Herzlichen Dank! 💚 \n \n 👉️ https://lnkd.in/ewnCzDxS """ "reactions_count" => 2 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 05:48:06" "deleted" => 1 ] [ "id" => 844234337 "company_id" => 8375742 "urn" => "urn:li:activity:7267809470393548800" "followers" => null "date" => "1w" "description" => """ Wir können nicht schlafen wollen:\n \n Wenn wir gestresst sind oder uns sorgen, schlafen wir schlecht. Wollen wir das Einschlafen erzwingen, gelingt es erst recht nicht. Die Einstellung zu ändern, kann diesen Teufelskreis durchbrechen.\n \n Mehr dazu im vivo-Artikel: 👉️ https://lnkd.in/eBGD27pa """ "reactions_count" => 9 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 05:48:06" "deleted" => 1 ] [ "id" => 844234338 "company_id" => 8375742 "urn" => "urn:li:activity:7267589753678565377" "followers" => null "date" => "1w" "description" => """ 🌟 Direktor:in Lungenliga Schweiz gesucht: Übernehmen Sie die Führung eines national bedeutsamen Dachverbands im Gesundheitswesen! \n Es erwartet Sie eine vielseitige und sinnstiftende Tätigkeit mit der Möglichkeit, Ihr Netzwerk aus medizinischen Fachpersonen und Entscheidungsträger:innen im Gesundheitswesen weiter auf- und auszubauen 🌟. #gesundheitswesen #führung #Lungenliga #innopool \n \n Für mehr Informationen: \n https://lnkd.in/gc3Z3RSw\n \n 🌟 Directrice/Directeur Ligue pulmonaire suisse recherché(e) : Prenez la responsabilité de la direction d’une association faîtière d’importance nationale dans le secteur de la santé! \n Des tâches variées et valorisantes vous attendent, avec la possibilité de développer et d’élargir votre réseau avec de professionnels de la santé et de décideurs dans le domaine de la santé 🌟. #santé #direction #Lungenliga #innopool\n \n Pour plus d’informations :\n https://lnkd.in/gGWE5GqV """ "reactions_count" => 36 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 05:48:06" "deleted" => 1 ] [ "id" => 844234339 "company_id" => 8375742 "urn" => "urn:li:activity:7267447083932991488" "followers" => null "date" => "1w" "description" => """ «Flüssigsauerstoff-Tankstellen» – was ist das? \n \n Mit einem tragbaren Sauerstoff-Gerät können sich Lungenkranke, die eine konstante Sauerstoffzufuhr benötigen, ausserhalb der eigenen Wohnung bewegen.\n \n Die Lungenliga unterhält ein schweizweites Tankstellennetz, wo diese tragbaren Geräte kostenlos aufgefüllt werden können. Die Tankstellen sind an 365 Tagen im Jahr geöffnet, befinden sich an zentral gelegenen Standorten und sind sowohl mit öffentlichen Verkehrsmitteln als auch mit dem Auto gut erreichbar. \n \n 👉️ https://lnkd.in/e6EpvT7u """ "reactions_count" => 7 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 05:48:06" "deleted" => 1 ] [ "id" => 844234340 "company_id" => 8375742 "urn" => "urn:li:activity:7267183100927922177" "followers" => null "date" => "1w" "description" => """ 🎭 Die Maske der "Grosszügigkeit" fällt! 🚬\n \n Heute veröffentlicht Transparency and Truth einen aufschlussreichen Bericht über das kulturelle und karitative Sponsoring der Tabakindustrie.\n \n Was der Bericht enthüllt? Diese Spenden sind alles andere als unschuldig und verfolgen klare Ziele:\n 📌 Ihr Image aufpolieren: Sich als „engagierte“ Mäzene in Kultur und Gesellschaft präsentieren und so ihr tödliches Geschäft normalisieren.\n 📌 Verbündete gewinnen: Ein Gefühl der Dankbarkeit bei diesen Organisationen schaffen, die früher oder später die Interessen der Tabakkonzerne verteidigen – auf Kosten der Prävention und des Gesundheitsschutzes.\n \n ❗ Die Beweise? Interne Dokumente der Industrie zeigen, dass ihre „Philanthropie“ nichts anderes als eine Strategie für PR und kommerzielle Zwecke ist.\n \n 💥 Ein wichtiger Reminder: Die Tabakindustrie ist KEINE Industrie wie jede andere.\n 📉 10.000 Tote pro Jahr in der Schweiz durch Tabakkonsum.\n 🚬 30.000 Jugendliche in der Schweiz fangen jedes Jahr an zu rauchen.\n \n Mehr Informationen : https://lnkd.in/ek6SJnXH \n \n #Gesundheitsschutz #Prävention #Tabakindustrie #Transparenz #Transparencyandtruth\n AT Schweiz - Swiss Association for Tobacco Control """ "reactions_count" => 10 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 05:48:06" "deleted" => 1 ] [ "id" => 844234341 "company_id" => 8375742 "urn" => "urn:li:activity:7265635143262814208" "followers" => null "date" => "2w" "description" => """ Auf der Suche nach einem ausgewogenen und einfachen Herbstrezept? Lassen Sie sich von unserem köstlichen Gericht mit asiatischen Noten verführen! 🥬🥣\n \n Zum Blogbeitrag: https://lnkd.in/eDhN6Ebj """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 05:48:06" "deleted" => 1 ] [ "id" => 844234342 "company_id" => 8375742 "urn" => "urn:li:activity:7264910340843352065" "followers" => null "date" => "2w" "description" => """ Heute ist der Welt-COPD-Tag.\n \n In der Schweiz leiden 400 000 Personen an der unheilbaren Lungenkrankheit COPD, früher Raucherlunge genannt.\n \n Das Gruppencoaching «Besser leben mit COPD» der Lungenliga etabliert sich als wirksamer Teil der Behandlung. Im Kanton Wallis läuft das Programm überdurchschnittlich erfolgreich.\n \n Zur Medienmitteilung 👉️ https://lnkd.in/enyTjRNp """ "reactions_count" => 9 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-01-15 05:48:06" "deleted" => 1 ] [ "id" => 886214477 "company_id" => 8375742 "urn" => "urn:li:activity:7284803932134989824" "followers" => null "date" => "1d" "description" => """ Die kürzlich überarbeitete Plattform stopsmoking.ch bietet Informationen und Tools, um Menschen beim Rauchstopp zu unterstützen. Sie finden eine Übersicht über Beratungen der Lungenliga vor Ort in der ganzen Schweiz sowie die Möglichkeit einer persönlichen Beratung per Telefon oder online.\n 👉️ https://stopsmoking.ch\n \n #stopsmoking #rauchstopp #rauchfrei """ "reactions_count" => 11 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 1 ] [ "id" => 886214478 "company_id" => 8375742 "urn" => "urn:li:activity:7283133084168818688" "followers" => null "date" => "5d" "description" => """ Kinder vor Passivrauch schützen: Studienteilnehmende gesucht 📲 \n Das Universitätsspital Bern Insel Gruppe sucht rauchende Eltern mit Kindern unter 6 Jahren. Ziel: mit einer App lernen, Kinder besser vor Passivrauch zu schützen.\n \n Weitere Informationen:\n 👉️ https://lnkd.in/dxJ5EM5Z """ "reactions_count" => 4 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 1 ] [ "id" => 886214479 "company_id" => 8375742 "urn" => "urn:li:activity:7282274796531322881" "followers" => null "date" => "1w" "description" => """ Bald starten die Luftholtage im 2025! Die Ferienangebote der Lungenliga Schweiz sind speziell abgestimmt auf Menschen mit Lungen- und Atemwegserkrankungen sowie ihre Angehörigen. \n Vom 9. bis 17. April 2025 findet die Rhein-Kreuzfahrt (Basel – Amsterdam – Basel) statt. Die Teilnehmenden können dank der Betreuung der Lungenliga unbeschwerte Tage geniessen und richtig Energie tanken.\n \n ➡️ Die Anmeldung ist ab dem 13. Januar möglich.\n \n Mehr Infos 👉️ https://lnkd.in/evHD8i7y """ "reactions_count" => 11 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 1 ] [ "id" => 886214480 "company_id" => 8375742 "urn" => "urn:li:activity:7281973100492034049" "followers" => null "date" => "1w" "description" => """ «Das war die Letzte.» Was nach einem einfachen Entschluss klingt, ist für viele Rauchende nicht so einfach. Ein Rückschlag ist jedoch kein Grund, sich entmutigen zu lassen. Die meisten brauchen mehrere Anläufe, bis sie endgültig vom Rauchen loskommen. \n ➡️ Weshalb nicht das neue Jahr nutzen, um den Vorsatz in die Tat umzusetzen?\n Ein Rauchstopp gelingt mit sozialer und fachlicher Unterstützung besser. Entdecken Sie hilfreiche Angebote und Tipps unter https://lnkd.in/egcC35Yk\n \n #rauchstopp #rauchfrei2025 #lungenliga """ "reactions_count" => 36 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 1 ] [ "id" => 886214481 "company_id" => 8375742 "urn" => "urn:li:activity:7277593914826473472" "followers" => null "date" => "2w" "description" => "Die Lungenliga Schweiz wünscht Ihnen frohe Weihnachten und viel Luft zum «Dureschnuufe»! 🎄💚" "reactions_count" => 27 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 1 ] [ "id" => 886214482 "company_id" => 8375742 "urn" => "urn:li:activity:7275782012060270619" "followers" => null "date" => "3w" "description" => """ Ist Passivrauch von Vapes ungesund? 🤔\n \n Die Videoclips der WDR-Wissenschafts-Plattform «Quarks» richten sich an Jugendliche, die unter anderem auf TikTok aktiv sind.\n \n In diesem Clip werden die gesundheitlichen Folgen von Passivrauch aufgezeigt, die beim Vape-Konsum entstehen. Erstellt wurde der Beitrag mit fachlicher Unterstützung von Claudia Künzli, Leiterin Gesundheitsförderung und Prävention der Lungenliga Schweiz.\n \n Hier geht's zum Video: 👉️ https://lnkd.in/enT65x8Q """ "reactions_count" => 4 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 1 ] [ "id" => 886214483 "company_id" => 8375742 "urn" => "urn:li:activity:7275419619920678913" "followers" => null "date" => "3w" "description" => """ In der dunkleren Jahreszeit ist es besonders wichtig, spazieren zu gehen. Am Tageslicht produzieren wir Vitamin D, und die Bewegung an der frischen Luft stärkt die Immunabwehr.\n \n Erfahren Sie mehr über das Reussdelta als Ausflugsziel 👉️ https://lnkd.in/ey7kwKBy """ "reactions_count" => 8 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 1 ] [ "id" => 886214484 "company_id" => 8375742 "urn" => "urn:li:activity:7273257958061359104" "followers" => null "date" => "1mo" "description" => """ Wir können nicht schlafen wollen. Doch was bedeutet dies genau?\n \n Dieser Frage geht Schlafforscher Björn Rasch in der vivo-Herbstausgabe auf den Grund. Nun wurde der Artikel in der Zeitschriftenbeilage «Gesund im Alter» des Magazins «Brigitte» publiziert und ist ab sofort online verfügbar: 👉️ https://lnkd.in/eMvAvsDS\n \n Zusätzlich erscheint das Magazin am 15. Januar 2025 in der gedruckten Ausgabe. """ "reactions_count" => 10 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 1 ] [ "id" => 886214485 "company_id" => 8375742 "urn" => "urn:li:activity:7272882905712939011" "followers" => null "date" => "1mo" "description" => """ Historische Altstädte, romantische Seen und schöne Landschaften fernab vom Massentourismus: Der Kanton Aargau überrascht mit seiner Vielseitigkeit. \n \n Neugierde geweckt? Hier erfahren Sie mehr: 👉️ https://lnkd.in/eMCRvrfZ """ "reactions_count" => 10 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 1 ] [ "id" => 886214486 "company_id" => 8375742 "urn" => "urn:li:activity:7272158099296161792" "followers" => null "date" => "1mo" "description" => """ Beste Publikation von Jungforschenden: Anmeldefenster eröffnet 🔬📖\n \n Die Lungenliga Schweiz vergibt jedes Jahr einen mit CHF 10'000.– dotierten Preis für die beste Publikation im Wissenschaftsbereich der Atemwegsforschung und Lungengesundheit. \n \n Interessierte Forscherinnen und Forscher können sich bis zum 6. Januar 2025 anmelden.\n \n Weitere Informationen: https://lnkd.in/dGc6-rrR """ "reactions_count" => 14 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 1 ] [ "id" => 921547825 "company_id" => 8375742 "urn" => "urn:li:activity:7290761364581576705" "followers" => null "date" => "6d" "description" => """ Das Leben von Maria wurde nach der Diagnose #Lungenkrebs auf den Kopf gestellt. Im Beitrag von Leben mit Lungenkrebs erzählt sie von ihrer eindrücklichen Reise.\n \n Der Verein Leben mit Lungenkrebs engagiert sich für Betroffene mit Vernetzung und Sensibilisierung.\n \n 👉 https://lnkd.in/dPJwiq_K """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 921547826 "company_id" => 8375742 "urn" => "urn:li:activity:7289657189336559616" "followers" => null "date" => "1w" "description" => """ Jung, sportlich, Nichtraucher: Bis vor einem Jahr konnte sich der Familienvater Benny Heimberg nicht vorstellen, dass eine seltene #Lungenkrankheit bald sein Leben auf den Kopf stellen wird: #Bronchiektasen. Er möchte sich dafür einsetzen, dass andere Patientinnen und Patienten einfacheren Zugang zu Informationen über diese Krankheit finden.\n \n Erfahren Sie mehr über seine Geschichte\n 👉️ https://lnkd.in/e9_uCKKN """ "reactions_count" => 69 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 921547827 "company_id" => 8375742 "urn" => "urn:li:activity:7288103193585102849" "followers" => null "date" => "2w" "description" => """ Auf der Suche nach einem ausgewogenen und einfachen Wintergericht? Unsere neueste Rezept-Idee mit einem Hauch von indischen Noten wärmt von innen heraus!\n \n Zum Rezept 👉️ https://lnkd.in/gNEfUxJP """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 921547828 "company_id" => 8375742 "urn" => "urn:li:activity:7287133264291508224" "followers" => null "date" => "2w" "description" => """ Rejoignez notre formation sur le CPET et devenez un expert en test d’effort cardiopulmonaire ! 💡 \n Grâce à un apprentissage mêlant théorie approfondie et pratique encadrée, ce cours vous permettra de maîtriser un outil essentiel pour améliorer l’évaluation et la prise en charge de vos patients. Un programme unique conçu pour les #techniciens en fonction pulmonaire, #physiothérapeutes, #médecin et #pneumologues qui souhaitent se perfectionner et se démarquer dans leur domaine.\n \n Ne manquez pas cette opportunité exceptionnelle de booster vos compétences ! Inscrivez-vous dès maintenant !\n \n Infos et inscription 👉https://lnkd.in/eB4byjcy\n \n Ce cours a obtenu le label de qualité du Special Interest Group (SIG) Airways disease and respiratory physiology de la Société Suisse de Pneumologie (SSP) """ "reactions_count" => 2 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 921547829 "company_id" => 8375742 "urn" => "urn:li:activity:7285344235153678336" "followers" => null "date" => "3w" "description" => """ Rhein-Kreuzfahrt im April 2025 – es hat noch freie Plätze! ⚓️🛳️ \n Gönnen Sie sich eine Auszeit auf dem Wasser! Vom 9. – 17. April 2025 findet die Rhein-Kreuzfahrt mit der Route Basel – Amsterdam – Basel statt. \n \n Die Lungenliga Schweiz kümmert sich um die gesamte Organisation inklusive Sauerstoffversorgung und ein Betreuungsteam aus medizinischem Fachpersonal ist während der Reise für Sie da.\n \n Aktuell hat es noch freie Plätze – wir freuen uns auf Ihre Anmeldung.\n \n 👉️https://lnkd.in/eTiSb6hU """ "reactions_count" => 11 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 921547830 "company_id" => 8375742 "urn" => "urn:li:activity:7285204062122180608" "followers" => null "date" => "3w" "description" => """ Macht rauchen dumm? 🤔\n \n Die Videoclips der Wissenschafts-Plattform «Quarks» richten sich an Jugendliche, die unter anderem auf TikTok aktiv sind.\n \n In diesem Clip werden die gesundheitlichen Folgen von Tabakkonsum als jugendliche Person thematisiert. Erstellt wurde das Video mit fachlicher Unterstützung von Claudia Künzli, Leiterin Gesundheitsförderung und Prävention der Lungenliga Schweiz.\n \n Hier geht's zum Video: 👉️ \n https://lnkd.in/ePk-9DSb """ "reactions_count" => 2 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 921547831 "company_id" => 8375742 "urn" => "urn:li:activity:7284803932134989824" "followers" => null "date" => "3w" "description" => """ Die kürzlich überarbeitete Plattform stopsmoking.ch bietet Informationen und Tools, um Menschen beim Rauchstopp zu unterstützen. Sie finden eine Übersicht über Beratungen der Lungenliga vor Ort in der ganzen Schweiz sowie die Möglichkeit einer persönlichen Beratung per Telefon oder online.\n 👉️ https://stopsmoking.ch\n \n #stopsmoking #rauchstopp #rauchfrei """ "reactions_count" => 30 "comments_count" => 1 "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 921547832 "company_id" => 8375742 "urn" => "urn:li:activity:7283133084168818688" "followers" => null "date" => "3w" "description" => """ Kinder vor Passivrauch schützen: Studienteilnehmende gesucht 📲 \n Das Universitätsspital Bern Insel Gruppe sucht rauchende Eltern mit Kindern unter 6 Jahren. Ziel: mit einer App lernen, Kinder besser vor Passivrauch zu schützen.\n \n Weitere Informationen:\n 👉️ https://lnkd.in/dxJ5EM5Z """ "reactions_count" => 5 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 921547833 "company_id" => 8375742 "urn" => "urn:li:activity:7282274796531322881" "followers" => null "date" => "1mo" "description" => """ Bald starten die Luftholtage im 2025! Die Ferienangebote der Lungenliga Schweiz sind speziell abgestimmt auf Menschen mit Lungen- und Atemwegserkrankungen sowie ihre Angehörigen. \n Vom 9. bis 17. April 2025 findet die Rhein-Kreuzfahrt (Basel – Amsterdam – Basel) statt. Die Teilnehmenden können dank der Betreuung der Lungenliga unbeschwerte Tage geniessen und richtig Energie tanken.\n \n ➡️ Die Anmeldung ist ab dem 13. Januar möglich.\n \n Mehr Infos 👉️ https://lnkd.in/evHD8i7y """ "reactions_count" => 15 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] [ "id" => 921547834 "company_id" => 8375742 "urn" => "urn:li:activity:7281973100492034049" "followers" => null "date" => "1mo" "description" => """ «Das war die Letzte.» Was nach einem einfachen Entschluss klingt, ist für viele Rauchende nicht so einfach. Ein Rückschlag ist jedoch kein Grund, sich entmutigen zu lassen. Die meisten brauchen mehrere Anläufe, bis sie endgültig vom Rauchen loskommen. \n ➡️ Weshalb nicht das neue Jahr nutzen, um den Vorsatz in die Tat umzusetzen?\n Ein Rauchstopp gelingt mit sozialer und fachlicher Unterstützung besser. Entdecken Sie hilfreiche Angebote und Tipps unter https://lnkd.in/egcC35Yk\n \n #rauchstopp #rauchfrei2025 #lungenliga """ "reactions_count" => 39 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2025-02-06 18:17:29" "deleted" => 0 ] ] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#4998 …} -companyTags: Doctrine\ORM\PersistentCollection {#5000 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5002 …} -users: Doctrine\ORM\PersistentCollection {#5004 …} -logoImageName: "20250227163313-lungenligabern-logo-67c085b9b4fd0883900503.png" -coverImageName: "20250227163314-lungenligabern-favicon-67c085ba238cb451746088.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5006 …} -tagline: "120 Jahre Engagement für ein selbstbestimmtes Leben mit gesunden Atemwegen" -contactEmail: "m.huehnli@lungenliga-be.ch" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5008 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5010 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5012 …} -industry: "" -size: "52" -address1: null -address2: null -city: null -postalCode: null -state: null -country: "Switzerland" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5014 …} #createdAt: DateTime @1740066535 {#4975 date: 2025-02-20 15:48:55.0 UTC (+00:00) } #updatedAt: DateTime @1750925189 {#4974 date: 2025-06-26 08:06:29.0 UTC (+00:00) } } App\Entity\Company {#5018 -id: 37 -name: "Medtronic (Schweiz) AG" -website: "https://medtronic.com" -description: "Medtronic ist das größte Medizintechnik-Unternehmen der Welt. 1949 in einer Garage in Minneapolis gegründet, beschäftigt das Unternehmen heute mehr als 90.000 Mitarbeiterinnen und Mitarbeiter und ist an 150 Standorten weltweit tätig. Mit Therapien von Medtronic können rund 70 Krankheitsfelder des menschlichen Körpers behandelt werden – darunter Erkrankungen der Wirbelsäule, Parkinson, Harn- und Stuhlinkontinenz, Herz-Kreislauferkrankungen, Diabetes, Krebserkrankungen, Adipositas oder Bluthochdruck. Zu den etwa 50.000 Produkten, die in der Schweiz auf dem Markt sind, gehören u. a. chirurgische Robotersysteme, Systeme zur tiefen Hirnstimulation, Herzschrittmacher, Transkatheter Aortenklappen, Insulinpumpen, Künstliche Intelligenz zur Darmkrebsvorsorge oder Kapselendoskopie." -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5019 …} -companyTags: Doctrine\ORM\PersistentCollection {#5021 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5023 …} -users: Doctrine\ORM\PersistentCollection {#5025 …} -logoImageName: "20250226145026-medtronic-logo-67bf1c2277543396343164.png" -coverImageName: "20250227163353-favicon-medtronic-67c085e193f99104070744.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5027 …} -tagline: "Weltweit führend in Medizintechnik – Innovative Therapien für eine bessere Lebensqualität" -contactEmail: "kai.lutz@medtronic.com" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5029 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5031 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5033 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5035 …} #createdAt: DateTime @1740066799 {#4996 date: 2025-02-20 15:53:19.0 UTC (+00:00) } #updatedAt: DateTime @1750925216 {#4995 date: 2025-06-26 08:06:56.0 UTC (+00:00) } } App\Entity\Company {#5039 -id: 38 -name: "Merck AG" -website: "https://merckgroup.com" -description: """ Wir sind Merck, ein lebendiges Wissenschafts- und Technologieunternehmen\n \n Wissenschaft ist das Herzstück unserer Arbeit. Sie ist die Grundlage unserer Entdeckungen und der Technologien, die wir entwickeln. \n \n \n Im Leben von Millionen von Menschen macht die Leidenschaft unserer neugierigen Köpfe täglich einen entscheidenden Unterschied.\n \n In unserem Healthcare-Bereich erforschen wir neue Möglichkeiten zur Behandlung schwerer Krankheiten wie Multiple Sklerose und Krebs. Unsere Life-Science-Experten unterstützen Wissenschaftler bei der Entwicklung von Lösungen, die ihnen schnellere und sichere Erfolge ermöglichen. Und im Bereich Performance Materials steckt unser Know-how in Technologien, die die Art und Weise verändern, wie wir Informationen verarbeiten und zugänglich machen.\n \n \n Wir glauben an die positive Kraft von Wissenschaft und Technologie. Sie bestimmt unser Tun seit 1668 und inspiriert uns dazu, weiter für eine lebenswerte Zukunft zu forschen.\n \n Unsere Neugier ist dem menschlichen Fortschritt verpflichtet. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5040 …} -companyTags: Doctrine\ORM\PersistentCollection {#5042 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5044 …} -users: Doctrine\ORM\PersistentCollection {#5046 …} -logoImageName: "20250227163439-merck-logo-67c0860fb8756733295091.png" -coverImageName: "20250227163440-mrk-7f8ec2c5-67c0861021c26613780604.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5048 …} -tagline: "Leidenschaft für Wissenschaft und Technologie – Für eine bessere Zukunft" -contactEmail: "elisabeth.holzinger@merckgroup.com" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5050 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5052 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5054 …} -industry: "" -size: "" -address1: "Chamerstrasse 174" -address2: "" -city: "Zug" -postalCode: "6300" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5056 …} #createdAt: DateTime @1740067199 {#5017 date: 2025-02-20 15:59:59.0 UTC (+00:00) } #updatedAt: DateTime @1750925238 {#5016 date: 2025-06-26 08:07:18.0 UTC (+00:00) } } App\Entity\Company {#5060 -id: 39 -name: "Merz Pharma AG" -website: "https://merztherapeutics.com" -description: """ Die Merz Pharma (Schweiz) AG ist eine Tochtergesellschaft der Merz Pharmaceuticals GmbH Frankfurt mit Sitz in Allschwil BL. Unsere Kerntätigkeit umfasst die Vermarktung und den Vertrieb von innovativen medizinischen Produkten in folgenden Bereichen: Ästhetik und Schönheit, Medizinische Dermatologie, Neurologie, Selbstmedikation und Wellness. \n \n Informieren Sie sich über die Behandlung mit XEOMIN® und besuchen Sie unsere neue Webseite für Fachkreise. Loggen Sie sich unter www.merz.ch/swissrx/ ein und erfahren Sie mehr. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5061 …} -companyTags: Doctrine\ORM\PersistentCollection {#5063 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5065 …} -users: Doctrine\ORM\PersistentCollection {#5067 …} -logoImageName: "20250226145104-merz-logo-67bf1c4855976966081510.png" -coverImageName: "20250227163504-merz-favicon-67c08628c040b237773092.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5069 …} -tagline: "Innovative medizinische Lösungen für Ästhetik, Neurologie und Dermatologie – Ihre Gesundheit im Fokus" -contactEmail: "Bastian.Rasser@merz.ch" -phone: "41614863600" -streamUrl: "20250221092707-20230213140511-symposium-bewegungsst-rungen-02-03-2023-v1-63ea358751877937961497-67b838db40a46421374997.mp4" -streamType: "FILE" -followers: Doctrine\ORM\PersistentCollection {#5071 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5073 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5075 …} -industry: "" -size: "" -address1: "Hegenheimermattweg 57, 4123 Allschwil, " -address2: "" -city: "" -postalCode: "" -state: "" -country: "CH" -socialLinkedin: "" -socialX: "https://twitter.com/merz_pharma?lang=de" -socialFacebook: "https://www.facebook.com/merzpharmaschweiz/" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5077 …} #createdAt: DateTime @1740126427 {#5038 date: 2025-02-21 08:27:07.0 UTC (+00:00) } #updatedAt: DateTime @1759133667 {#5037 date: 2025-09-29 08:14:27.0 UTC (+00:00) } } App\Entity\Company {#5081 -id: 40 -name: "Mitsubishi Tanabe Pharma GmbH" -website: "https://mt-pharma-ch.com" -description: "" -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5082 …} -companyTags: Doctrine\ORM\PersistentCollection {#5084 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5086 …} -users: Doctrine\ORM\PersistentCollection {#5088 …} -logoImageName: "20250226145132-mitsubishi-tanabe-pharma-logo-67bf1c64577aa523453578.png" -coverImageName: "20250227163559-mitsubishi-tanabe-pharma-favicon-67c0865f84f97798744223.jpeg" -companyProducts: Doctrine\ORM\PersistentCollection {#5090 …} -tagline: "Wegweisende Innovationen für die Gesundheit von morgen – Fokussiert auf seltene und komplexe Erkrankungen" -contactEmail: "b.barriguete@mt-pharma-ch.com" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5092 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5094 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5096 …} -industry: "" -size: "" -address1: "Talstrasse 70" -address2: "" -city: "Zürich" -postalCode: "8001" -state: "" -country: "CH" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5098 …} #createdAt: DateTime @1740128596 {#5059 date: 2025-02-21 09:03:16.0 UTC (+00:00) } #updatedAt: DateTime @1750925288 {#5058 date: 2025-06-26 08:08:08.0 UTC (+00:00) } } App\Entity\Company {#5102 -id: 41 -name: "Neurim Pharmaceuticals AG" -website: "https://neurim.ch" -description: """ Neurim Pharmaceuticals is a neuroscience drug discovery and development company creating drugs for brain restoration & reinforcement, focusing on the central nervous system (CNS) with the goal of improving quality of life.\n \n Neurim Pharmaceuticals has developed innovative products and holds a promising pipeline of new chemical entities effective in CNS disorders.\n \n It was founded in 1991 and is a privately owned company and part of the RAD group (RAD.com) with its headquarters in Tel Aviv. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5103 …} -companyTags: Doctrine\ORM\PersistentCollection {#5105 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5107 …} -users: Doctrine\ORM\PersistentCollection {#5109 …} -logoImageName: "20250226145244-neurim-logo-67bf1cac458b3786350323.png" -coverImageName: "20250227163619-neurim-favicon-67c086735e2f6727890903.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5111 …} -tagline: "Innovationen für das zentrale Nervensystem – Neue Wege zur Wiederherstellung und Verstärkung der Gehirnfunktion" -contactEmail: "d.rothenfluh@neurim.com" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5113 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5115 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5117 …} -industry: "" -size: "" -address1: "Turmstrasse 18" -address2: "" -city: "Steinhausen" -postalCode: "6312" -state: "" -country: "CH" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5119 …} #createdAt: DateTime @1740128794 {#5080 date: 2025-02-21 09:06:34.0 UTC (+00:00) } #updatedAt: DateTime @1750925313 {#5079 date: 2025-06-26 08:08:33.0 UTC (+00:00) } } App\Entity\Company {#5123 -id: 42 -name: "Neurolite AG" -website: "https://neurolite.ch" -description: """ Willkommen bei Neurolite! Wir sind ein Berner Unternehmen auf dem Gebiet der Neurotechnologie und stolz darauf, innovative Lösungen für Patienten, Ärzte und Forscher anzubieten. Wir vertreiben und unterstützen qualitativ hochwertige medizinische Systeme und Produkte, die hauptsächlich in der Neurologie und verwandten Bereichen Verwendung finden, und stellen deren Support sicher. Seit unserer Gründung haben wir es uns zur Aufgabe gemacht, bahnbrechende Technologien als Partner in der Schweiz zu vertreten, Nutzer:innen zu schulen und zu begleiten.\n \n Unsere Produktpalette ist breit gefächert und umfasst Systeme in den Bereichen Neurologie, Psychiatrie sowie Schmerzdiagnostik und -behandlung. Wir sind stolz darauf, international renommierte Marken wie Natus (Keypoint), Magventure, EBNeuro, Artinis, BEL EEG, Storz Medical und andere zu vertreten. \n \n \n \n Zusätzlich bieten wir eine breite Palette an Zubehörmaterial an. Darüber hinaus führen wir wegweisende Produkte im Bereich der Forschung. Unser Sortiment ist umfangreich und stets auf dem neuesten Stand der Technologie. Zögern Sie nicht, uns direkt mit Ihren Anforderungen zu kontaktieren. Wir freuen uns darauf, Ihnen weiterhelfen zu können.\n \n Neben unseren klinischen Produkten für Spitäler, Kliniken und Praxen bieten wir auch innovative Geräte an, die direkt von Ihnen an Ihre Patienten verschrieben werden können. Zum einen das etablierte Cefaly zur Prävention und akuten Behandlung von Migräne, das sich bereits auf dem Schweizer Markt bewährt hat und eine wirksame Lösung für Migränepatienten darstellt. Zum anderen das neue Flow Neuroscience tDCS Depressionsheadset, ein vielversprechendes System, das Patienten die Möglichkeit bietet, tDCS zu Hause anzuwenden. Die Anwendung ist einfach, die Wirksamkeit klinisch nachgewiesen und die Behandlung erfolgt ohne signifikante Nebenwirkungen, was einen Mehrwert gegenüber Antidepressiva darstellt. Flow kann eigenständig oder in Kombination mit bestehenden Behandlungen eingesetzt werden.\n \n Wir sind bereit, Sie auf dem Weg zu Innovation und Patientenversorgung zu unterstützen und freuen uns darauf Sie kennenzulernen. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5124 …} -companyTags: Doctrine\ORM\PersistentCollection {#5126 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5128 …} -users: Doctrine\ORM\PersistentCollection {#5130 …} -logoImageName: "20250226145321-neurolite-logo-67bf1cd1e038e702573169.png" -coverImageName: "20250227163653-neurolite-favicon-67c08695dccf0239861753.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5132 …} -tagline: "Innovative Neurotechnologie für eine bessere Patientenversorgung – Ihre Partner für neueste Lösungen in Neurologie, Psychiatrie und Schmerzbehandlung" -contactEmail: "info@neurolite.ch" -phone: "41031812282" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5134 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5136 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5138 …} -industry: "" -size: "" -address1: "Hühnerhubelstrasse 79" -address2: "" -city: "Belp" -postalCode: "3123" -state: "" -country: "" -socialLinkedin: "https://www.linkedin.com/company/neurolite-ag/" -socialX: "" -socialFacebook: "https://www.facebook.com/cefalyschweizsuisse" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5140 …} #createdAt: DateTime @1740129126 {#5101 date: 2025-02-21 09:12:06.0 UTC (+00:00) } #updatedAt: DateTime @1750850427 {#5100 date: 2025-06-25 11:20:27.0 UTC (+00:00) } } App\Entity\Company {#5144 -id: 43 -name: "Neuroswiss AG" -website: "https://neuroswiss.ch" -description: """ neuroswiss ist Ihr Partner für neurologische Geräte\n \n Seit mehr als 20 Jahren haben wir Erfahrung in den Bereichen Neurologie, Schlaf, Gefäss- Diagnostik und Gleichgewichts-Analyse. Unsere langjährige Tätigkeit in der Neurologie erlauben uns, Ihnen die optimale Lösung anzubieten. Universitätsspitäler, Kantonsspitäler, Private Kliniken und Neurologische Praxen zählen zu unseren zufriedenen Kunden. Zusätzlich zu unseren Neurologischen Diagnosegeräten liefern wir Zubehöre, zum Beispiel diverse Nadeln, Elektroden, Kabel, Hauben, Gele und Pasten. Unser Service verfügt über eine genügende Anzahl Ersatzgeräte, so dass auch im unwahrscheinlichen Fall einer Störung innerhalb kürzester Zeit geholfen werden kann. Dadurch sind Verschiebungen von Patienten und damit verbundene finanzielle Ausfälle auf ein Minimum beschränkt. Wir helfen unseren Kunden mit einem Internet Fernsupport kleinere Probleme (Bedienung) sofort zu beheben. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5145 …} -companyTags: Doctrine\ORM\PersistentCollection {#5147 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5149 …} -users: Doctrine\ORM\PersistentCollection {#5151 …} -logoImageName: "20250226145435-neuroswiss-logo-67bf1d1b5b996892626352.png" -coverImageName: "20250227163747-neuroswiss-logo-67c086cba1550163429893.jpg" -companyProducts: Doctrine\ORM\PersistentCollection {#5153 …} -tagline: "Ihr Partner für hochwertige neurologische Geräte und Lösungen – Über 20 Jahre Erfahrung in Diagnostik, Schlaf, Gefäßanalyse und mehr" -contactEmail: "olivier.jaccard@neuroswiss.ch" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5155 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5157 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5159 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5161 …} #createdAt: DateTime @1740129703 {#5122 date: 2025-02-21 09:21:43.0 UTC (+00:00) } #updatedAt: DateTime @1750925342 {#5121 date: 2025-06-26 08:09:02.0 UTC (+00:00) } } App\Entity\Company {#5165 -id: 44 -name: "Novartis Pharma Schweiz AG" -website: "https://novartis.ch" -description: """ Novartis denkt Medizin neu, um Menschen zu einem besseren und längeren Leben zu verhelfen. Als führendes globales Pharmaunternehmen nutzen wir wissenschaftliche Innovationen und digitale Technologien, um bahnbrechende Therapien in Bereichen mit grossem medizinischem Bedarf zu entwickeln. Dabei gehören wir regelmässig zu jenen Unternehmen, die weltweit am meisten in Forschung und Entwicklung investieren. Die Produkte von Novartis erreichen global fast 800 Millionen Menschen, und wir suchen nach neuen Möglichkeiten, den Zugang zu unseren neuesten Therapien zu erweitern. Weltweit sind bei Novartis rund 110 000 Menschen aus über 140 Nationen beschäftigt. \n \n Novartis Pharma Schweiz ist für die Vermarktung der rund 100 verschreibungspflichtigen Medikamente des Novartis-Konzerns in der Schweiz zuständig. Zu den wichtigsten Therapiegebieten zählen Neurologie, Immunologie, Dermatologie, Augenheilkunde sowie Kardiologie, Atemwegserkrankungen und Onkologie. Die meisten der rund 270 Mitarbeiter sind in Marketing und Vertrieb tätig oder betreuen Projekte in der klinischen Forschung, der wissenschaftlichen Dokumentation oder der Registrierung von neuen Medikamenten. Der Firmensitz von Novartis Pharma Schweiz ist in Rotkreuz.\n \n Novartis ist stolz darauf, Menschen mit neurologischen Erkrankungen rund um den Globus zu unterstützen. Im Mittelpunkt unserer Arbeit steht die Zusammenarbeit mit Patienten, medizinischen Fachkräften und Gesundheitssystemen, um lebensverändernde Lösungen und Behandlungen anzubieten. Mehr zu unseren Produkten und wissenschaftliche Informationen bietet Ihnen unsere Plattform www.medportal.ch\n \n Novartis. Wir denken Medizin neu. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5166 …} -companyTags: Doctrine\ORM\PersistentCollection {#5168 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5170 …} -users: Doctrine\ORM\PersistentCollection {#5172 …} -logoImageName: "20250226145503-novartis-logo-67bf1d374ba17409589101.png" -coverImageName: "20250227163830-novartis-favicon-67c086f6d31a4589931105.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5174 …} -tagline: "Medizin neu gedacht – Wissenschaftliche Innovationen für ein besseres und längeres Leben" -contactEmail: "neuro.aussendienst@novartis.com" -phone: "417637111" -streamUrl: "https://www.youtube.com/P-T_RUcO5SE" -streamType: "YOUTUBE" -followers: Doctrine\ORM\PersistentCollection {#5176 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5178 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5180 …} -industry: "" -size: "" -address1: "Suurstoffi 14" -address2: "" -city: "Rotkreuz" -postalCode: "6343" -state: "" -country: "" -socialLinkedin: "https://www.linkedin.com/company/novartis/mycompany/" -socialX: "" -socialFacebook: "https://www.facebook.com/NovartisCH/" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5182 …} #createdAt: DateTime @1740129986 {#5143 date: 2025-02-21 09:26:26.0 UTC (+00:00) } #updatedAt: DateTime @1750925359 {#5142 date: 2025-06-26 08:09:19.0 UTC (+00:00) } } App\Entity\Company {#5186 -id: 45 -name: "Octapharma (Schweiz) AG" -website: "https://octapharma.ch" -description: """ Das Schweizer Unternehmen Octapharma zählt weltweit zu den grössten Herstellern von Arzneimitteln mit menschlichen Proteinprodukten als Wirkstoff. Das Unternehmen widmet sich der Entwicklung und Herstellung von Proteinen aus menschlichem Plasma und – Zelllinien.\n \n Als Familienunternehmen legt Octapharma grossen Wert auf Investitionen, um etwas im Leben der Menschen zu bewirken und folgt diesem Leitmotiv seit der Unternehmensgründung im Jahr 1983 – denn es liegt uns im Blut. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5187 …} -companyTags: Doctrine\ORM\PersistentCollection {#5189 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5191 …} -users: Doctrine\ORM\PersistentCollection {#5193 …} -logoImageName: "20250227163911-octapharma-share-1200x630-67c0871fd04df154767076.png" -coverImageName: "20250227163912-octapharma-favicon-67c0872034423037247114.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5195 …} -tagline: "Innovation aus menschlichem Plasma – Seit 1983 im Dienst der Gesundheit" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5197 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5199 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5201 …} -industry: "" -size: "" -address1: "Seidenstrasse 2" -address2: "" -city: "Lachen" -postalCode: "8853" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5203 …} #createdAt: DateTime @1740130173 {#5164 date: 2025-02-21 09:29:33.0 UTC (+00:00) } #updatedAt: DateTime @1750925378 {#5163 date: 2025-06-26 08:09:38.0 UTC (+00:00) } } App\Entity\Company {#5207 -id: 46 -name: "OM Pharma Suisse SA" -website: "https://omniamed.ch" -description: "OM Pharma ist ein globales biopharmazeutisches Unternehmen mit Sitz in Genf. Wir sind führend in der Prävention von wiederkehrenden Atemwegs- und Harnwegsinfektionen und auch bei der Behandlung von Gefässerkrankungen aktiv. Das Portfolio von OM Pharma umfasst Produkte für Atemwegsinfektionen, harnwegsarme Infektionen, chronische Veneninsuffizienz, Mikroangiopathien (z.B. diabetische Retinopathie), Hämorrhoiden und Menometrorrhagie (starke Menstruationsblutungen). Broncho-Vaxom® und Uro-Vaxom® Produkte werden in Genf hergestellt und in 100 Ländern der Welt vertrieben. OM Pharma Suisse ist die Filiale des voll integrierten biopharmazeutischen Unternehmens OM Pharma." -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5208 …} -companyTags: Doctrine\ORM\PersistentCollection {#5210 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5212 …} -users: Doctrine\ORM\PersistentCollection {#5214 …} -logoImageName: "20250227164046-ompharma-logo-67c0877e32aa7761770639.jpg" -coverImageName: "20250227164046-ompharma-logo-67c0877e8e1b3894714837.jpg" -companyProducts: Doctrine\ORM\PersistentCollection {#5216 …} -tagline: "Führend in der Prävention und Behandlung von Atemwegs- und Harnwegsinfektionen – Innovation für eine bessere Lebensqualität" -contactEmail: "villars@ompharma.com" -phone: "41227831666" -streamUrl: "https://www.youtube.com/watch?v=zCCMa1FThTA" -streamType: "YOUTUBE" -followers: Doctrine\ORM\PersistentCollection {#5218 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5220 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5222 …} -industry: "" -size: "" -address1: "Route du Petit-Moncor 1D" -address2: "" -city: "Villars-sur-Glâne" -postalCode: "1752" -state: "" -country: "" -socialLinkedin: "https://www.linkedin.com/company/om-pharma/posts/?feedView=all&viewAsMember=true" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5224 …} #createdAt: DateTime @1740130474 {#5185 date: 2025-02-21 09:34:34.0 UTC (+00:00) } #updatedAt: DateTime @1750925403 {#5184 date: 2025-06-26 08:10:03.0 UTC (+00:00) } } App\Entity\Company {#5228 -id: 47 -name: "Ortho Team" -website: "https://ortho-team.ch" -description: "" -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5229 …} -companyTags: Doctrine\ORM\PersistentCollection {#5231 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5233 …} -users: Doctrine\ORM\PersistentCollection {#5235 …} -logoImageName: "20250226145611-orthoteam-logo-67bf1d7bb1524783081001.png" -coverImageName: "20250227164125-orthoteam-favicon-67c087a576ebd990512214.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5237 …} -tagline: "Ihr Partner für hochwertige orthopädische Lösungen und individuelle Patientenbetreuung" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5239 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5241 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5243 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5245 …} #createdAt: DateTime @1740130760 {#5206 date: 2025-02-21 09:39:20.0 UTC (+00:00) } #updatedAt: DateTime @1750925420 {#5205 date: 2025-06-26 08:10:20.0 UTC (+00:00) } } App\Entity\Company {#5249 -id: 48 -name: "Philips Sleep & Respirotary Care" -website: "https://philips.de" -description: """ Innovativ, vernetzt und patientenzentriert\n \n Schlaftherapie-Lösungen\n \n Wir sind davon überzeugt, dass eine wirksame Schlaftherapie Patienten in die Lage versetzt, ihre Träume wiederzuentdecken und ein erfülltes Leben zu führen, indem sie ihre Fähigkeit wiedererlangen, komfortabel zu schlafen - so wie es für den Schlaf vorgesehen ist. Als weltweit führender Anbieter von Schlafdiagnose- und -Therapielösungen setzen wir uns mit Leidenschaft für die Bereitstellung von patientenorientierten Produkten ein, die den Patienten helfen, ein gesundes Leben zu führen, und für die Anbieter bieten wir Lösungen in der Schlaftherapie, die die Akzeptanz bei den Patienten, die langfristige Nutzung und die Effizienz steigern und ihnen helfen, sich um die Bedürfnisse der Patienten zu kümmern.\n \n Unser Portfolio an preisgekrönten Produkten für die Schlaftherapie umfasst das gesamte Spektrum des Gesundheitswesens, von der Diagnostik über Lösungen für die häusliche Pflege bis hin zu einer Reihe von Unternehmenssoftware- und Servicelösungen, die Anbietern dabei helfen sollen, die sich verändernde Landschaft des heutigen Gesundheitswesens zu meistern. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5250 …} -companyTags: Doctrine\ORM\PersistentCollection {#5252 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5254 …} -users: Doctrine\ORM\PersistentCollection {#5256 …} -logoImageName: "20250226145730-philips-logo-67bf1dca86039500961817.png" -coverImageName: "20250227164207-philips-logo-67c087cf61377630948922.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5258 …} -tagline: "Innovative, vernetzte und patientenzentrierte Schlaftherapie-Lösungen für ein besseres Leben" -contactEmail: "vladimir.stojiljkovic@philips.com" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5260 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5262 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5264 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "https://www.linkedin.com/company/philips/" -socialX: "https://twitter.com/Philips_aktuell" -socialFacebook: "https://www.facebook.com/Philips.DACH/" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5266 …} #createdAt: DateTime @1740131082 {#5227 date: 2025-02-21 09:44:42.0 UTC (+00:00) } #updatedAt: DateTime @1750925463 {#5226 date: 2025-06-26 08:11:03.0 UTC (+00:00) } } App\Entity\Company {#5270 -id: 49 -name: "ResMed Schweiz GmbH" -website: "https://resmed.ch" -description: """ ResMed – Improving people’s lives\n \n We help hundreds of millions of people sleep better, breathe better, and live longer, happier, and higher-quality lives well away from a hospital.\n \n Everything we do at ResMed – the medical devices we design and build; the software solutions we provide; the culture we enable and scale; and the business ethics, integrity, and environmental stewardship with which we conduct business – is focused on the goal to help improve the lives of people in over 140 countries. The needs of people in chronic disease and respiratory medicine are incredible; We aim to serve:\n \n \n Over 936 million people living with sleep apnoea; \n Over 800 million people living with insomnia; \n Over 480 million people living with COPD; \n Over 330 million people living with asthma; and countless more who rely on various out-of-hospital care services, medical and otherwise, to live a healthy and happy life, preferably in the comfort of their own home.\n \n Our team of over 10,000 ResMedians is making a positive impact on millions of lives in more than 140 countries. Through innovative digital solutions, our goal is to change the lives of 250 million people by 2025. By enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 140 countries. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5271 …} -companyTags: Doctrine\ORM\PersistentCollection {#5273 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5275 …} -users: Doctrine\ORM\PersistentCollection {#5277 …} -logoImageName: "20250520143138-resmed260x160-682c762a998a5365702789.jpg" -coverImageName: "20250227164228-resmed-favicon-67c087e4a2654259199370.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5279 …} -tagline: "Improving Lives by Enhancing Sleep, Breathing, and Health for Millions Worldwide" -contactEmail: "info@resmed.ch" -phone: null -streamUrl: "https://vimeo.com/639847168" -streamType: "VIMEO" -followers: Doctrine\ORM\PersistentCollection {#5281 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5283 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5285 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "https://twitter.com/ResMedEurope" -socialFacebook: "https://www.facebook.com/ResMed/" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5287 …} #createdAt: DateTime @1740131388 {#5248 date: 2025-02-21 09:49:48.0 UTC (+00:00) } #updatedAt: DateTime @1750925514 {#5247 date: 2025-06-26 08:11:54.0 UTC (+00:00) } } App\Entity\Company {#5291 -id: 50 -name: "Roche Pharma (Switzerland)" -website: "https://roche.com" -description: """ Roche Pharma (Switzerland) Ltd is Roche's Swiss national affiliate and its approximately 180 employees ensure that patients in Switzerland have access to Roche's innovative portfolio of medicines. Its therapeutic areas focus on oncology, rheumatology, pneumology, neurology and rare diseases. In 2019, around 260,000 patients in Switzerland were treated with a Roche medicine.\n \n \n Neuroscience is a major focus of research and development at Roche. Our goal is to pursue groundbreaking science to develop new treatments that help improve the lives of people with chronic and potentially devastating diseases.\n \n Roche is investigating more than a dozen medicines for neurological disorders, including multiple sclerosis, neuromyelitis optica spectrum disorder, Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, Duchenne muscular dystrophy and autism spectrum disorder. Together with our partners, we are committed to pushing the boundaries of scientific understanding to solve some of the most difficult challenges in neuroscience today.\n \n For more than 120 years, we have been committed to improving people's lives. Our commitment goes far beyond developing innovative diagnostics and therapeutics. Our greatest contribution to patients and society is sustainable innovation, true to our motto "better outcomes for more patients faster".\n \n OCREVUS® (Ocrelizumab)1\n \n Ocrevus ist ein rekombinanter humanisierter monoklonaler Antikörper, der selektiv die CD20 exprimierenden B-Zellen zum Ziel hat.\n \n Ocrevus ist für die Behandlung von erwachsenen Patienten mit aktiven schubförmigen Verlaufsformen der Multiplen Sklerose (MS) indiziert.\n \n Ocrevus ist für die Behandlung von erwachsenen Patienten mit primär progredienter Multipler Sklerose (PPMS) zur Verlangsamung der Krankheitsprogression und zur Reduzierung der Verschlechterung der Gehgeschwindigkeit indiziert.\n \n Ausführliche Informationen zu Ocrevus unter www.swissmedicinfo.ch\n \n Referenz: 1. OCREVUS® Fachinformation www.swissmedicinfo.ch\n \n \n ENSPRYNG® (Satralizumab)1 \n \n Enspryng ist ein humanisierter monoklonaler IgG2-Antikörper (mAk), der an löslichen und membrangebundenen humanen IL-6-Rezeptoren (IL-6R) bindet und dadurch die IL-6 vermittelte Signalübertragung durch diese Rezeptoren verhindert.\n \n \n Enspryng wird als Monotherapie oder in Kombination mit einer Immunsuppressionstherapie (IST) zur Behandlung von Neuromyelitis-Optica-Spektrum-Erkrankungen (NMOSD) bei Erwachsenen und Jugendlichen angewendet, bei denen Aquaporin-4-IgG-Antikörper nachweisbar sind (d.h. die AQP4-IgG-seropositiv sind).\n \n Ausführliche Informationen zu Enspryng unter www.swissmedicinfo.ch\n \n Referenz: 1. ENSPRYNG® Fachinformation www.swissmedicinfo.ch """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5292 …} -companyTags: Doctrine\ORM\PersistentCollection {#5294 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5296 …} -users: Doctrine\ORM\PersistentCollection {#5298 …} -logoImageName: "20250226145846-roche-logo-67bf1e164db3e274752581.png" -coverImageName: "20250227164252-roche-logo-67c087fcd719a743112858.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5300 …} -tagline: "Pioneering Neuroscience and Transforming Patient Outcomes with Innovative Therapies" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5302 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5304 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5306 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5308 …} #createdAt: DateTime @1740131588 {#5269 date: 2025-02-21 09:53:08.0 UTC (+00:00) } #updatedAt: DateTime @1750925533 {#5268 date: 2025-06-26 08:12:13.0 UTC (+00:00) } } App\Entity\Company {#5312 -id: 51 -name: "Salmon Pharma" -website: "https://medice.com" -description: """ Salmon Pharma vertreibt in der Schweiz seit über 40 Jahren hauptsächlich verschreibungspflichtige Medikamente. Unser Erfolg als mittelständisches Familienunternehmen basiert auf langjähriger Kompetenz und grosser Erfahrung.\n \n In der Schweizer Niederlassung der MEDICE verfügen wir über ein Team von hoch qualifizierten Fachleuten aus dem Pharmabereich.\n \n Salmon Pharma GmbH hat sich zum Ziel gesetzt, täglich höchste Qualität anzustreben – und unsere Leidenschaft für das Wohl der Patienten teilen. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5313 …} -companyTags: Doctrine\ORM\PersistentCollection {#5315 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5317 …} -users: Doctrine\ORM\PersistentCollection {#5319 …} -logoImageName: "20250226145949-salmonpharma-logo-67bf1e556e9e4305941944.png" -coverImageName: "20250227164321-salmonpharma-favicon-67c08819e76b8718154433.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5321 …} -tagline: "Über 40 Jahre Erfahrung in der Bereitstellung von Qualitätsmedikamenten für das Wohl der Patienten" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5323 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5325 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5327 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5329 …} #createdAt: DateTime @1740131824 {#5290 date: 2025-02-21 09:57:04.0 UTC (+00:00) } #updatedAt: DateTime @1750925562 {#5289 date: 2025-06-26 08:12:42.0 UTC (+00:00) } } App\Entity\Company {#5333 -id: 52 -name: "Sandoz Pharmaceuticals AG" -website: "https://sandoz-pharmaceuticals.ch" -description: """ Sandoz Pharmaceuticals ist einer der führenden Anbieter im Bereich Generika und Biosimilars in der Schweiz. Das Produktportfolio beinhaltet über 200 Wirkstoffe in rund 1000 verschiedenen Stärken und Packungsgrössen und deckt alle wichtigen Indikationsgebiete ab.\n \n Bei Sandoz wollen wir neue Wege finden, um die Lebensqualität der Menschen zu verbessern. Wir entwickeln innovative Lösungen, um Menschen weltweit den Zugang zu hochwertigen Medikamenten zu erleichtern. Um dies zu erreichen, verfolgen wir eine integrierte Zugangsstrategie, die unsere Arbeit darauf ausrichtet, den Zugang zu Medikamenten, zu medizinischen Informationen und zu medizinischer Kompetenz zu verbessern; hierzu zählen auch unsere Bemühungen, geeignete Schulungen für medizinische Fachkräfte anzubieten und zu fördern.\n \n Mehr Informationen finden Sie auf unserem Fachportal www.mysandoz.ch """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5334 …} -companyTags: Doctrine\ORM\PersistentCollection {#5336 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5338 …} -users: Doctrine\ORM\PersistentCollection {#5340 …} -logoImageName: "20250226150044-sandoz-logo-67bf1e8c0b1df865232057.png" -coverImageName: "20250227164356-sandoz-favicon-67c0883c16dc8749677974.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5342 …} -tagline: "Führend in Generika und Biosimilars – Wir verbessern den Zugang zu hochwertigen Medikamenten für eine bessere Lebensqualität weltweit" -contactEmail: "service.sandoz@sandoz.com" -phone: "41080085888" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5344 …} -totalFollowers: 0 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5346 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5348 …} -industry: "" -size: "" -address1: "Suurstoffi 14" -address2: "" -city: "Rotkreuz" -postalCode: "6343" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5350 …} #createdAt: DateTime @1740132169 {#5311 date: 2025-02-21 10:02:49.0 UTC (+00:00) } #updatedAt: DateTime @1750925584 {#5310 date: 2025-06-26 08:13:04.0 UTC (+00:00) } } App\Entity\Company {#5354 -id: 53 -name: "Sanofi Specialty Care" -website: "https://sanofi.com" -description: "Sanofi Specialty Care ist die Globale Business Unit von Sanofi, die sich auf die Bereiche seltene Krankheiten, Multiple Sklerose, Onkologie und Immunologie spezialisiert hat. Wir helfen Menschen mit komplexen und stark beeinträchtigenden Krankheiten, deren Diagnose und Behandlung oftmals schwierig sind. Wir haben uns der Erforschung und Weiterentwicklung neuer Therapiemöglichkeiten verschrieben, um damit Patienten und ihren Familien weltweit Hoffnung zu bringen. " -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5355 …} -companyTags: Doctrine\ORM\PersistentCollection {#5357 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5359 …} -users: Doctrine\ORM\PersistentCollection {#5361 …} -logoImageName: "20250227164431-sanofi-logo-67c0885fd9282252740593.jpeg" -coverImageName: "20250227164432-sanofi-favicon-67c08860417aa515221478.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5363 …} -tagline: "Pionierarbeit in der Behandlung seltener Krankheiten, MS, Onkologie und Immunologie – Wir bringen Hoffnung für Menschen mit komplexen Gesundheitsherausforderungen" -contactEmail: "sandro.stutz@sanofi.com" -phone: "41796622276" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5365 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5367 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5369 …} -industry: "" -size: "" -address1: "Suurstoffi 2" -address2: "" -city: "Rotkreuz" -postalCode: "6343" -state: "" -country: "" -socialLinkedin: "https://www.linkedin.com/company/sanofi" -socialX: "https://twitter.com/sanofi" -socialFacebook: "https://www.facebook.com/sanofi/" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5371 …} #createdAt: DateTime @1740132423 {#5332 date: 2025-02-21 10:07:03.0 UTC (+00:00) } #updatedAt: DateTime @1750925606 {#5331 date: 2025-06-26 08:13:26.0 UTC (+00:00) } } App\Entity\Company {#5375 -id: 54 -name: "Schwabe Pharma AG" -website: "https://schwabegruppe.ch" -description: """ Schwabe Pharma AG ist der weltweit führende Hersteller hochwertiger pflanzlicher Arzneimittel (Phytopharmaka).\n \n Die Firma hat ihren Sitzt AG in Küssnacht am Rigi. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5376 …} -companyTags: Doctrine\ORM\PersistentCollection {#5378 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5380 …} -users: Doctrine\ORM\PersistentCollection {#5382 …} -logoImageName: "20250226150111-schwabepharma-logo-67bf1ea73b222923836873.png" -coverImageName: "20250227164452-schwabepharma-favicon-67c0887492e75630525481.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5384 …} -tagline: "Weltweit führend in der Entwicklung hochwertiger pflanzlicher Arzneimittel für eine gesunde Zukunft" -contactEmail: "info@schwabepharma.ch" -phone: "41418541868" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5386 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5388 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5390 …} -industry: "" -size: "" -address1: "Erlistrasse 2" -address2: "" -city: "Küssnacht am Rig" -postalCode: "" -state: "" -country: "CH" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5392 …} #createdAt: DateTime @1740132774 {#5353 date: 2025-02-21 10:12:54.0 UTC (+00:00) } #updatedAt: DateTime @1750925626 {#5352 date: 2025-06-26 08:13:46.0 UTC (+00:00) } } App\Entity\Company {#5396 -id: 55 -name: "Somnovum" -website: "https://somnovum.ch" -description: """ Somnovum a Partner of SOMNOmedics\n \n Angetrieben durch unsere Freude an Innovativen Lösungen ist die Firma Somnovum mit Sitz in Oberentfelden, der Schweizer Partner des seit 20 Jahren tätigen Schlafdiagnostik Produkte Hersteller SOMNOmedics aus Randersacker (Deutschland).\n \n In enger Zusammenarbeit mit SOMNOMedics bietet Ihnen Somnovum die innovativen Produkte und den bekannten SOMNOmedics Support nun direkt aus der Schweiz an.\n \n Broschüren und Flyer\n \n Home Sleep Test zur Insomiediagnostik HST\n \n Aktigraphie SOMNOwatch Plus\n \n Polygraphie SOMNOtouch RESP eco und SOMNOtouch RESP\n \n Polysomnographie SOMNO HD mit Wireless PLM's und HD eco\n \n Cardio Diagnostics SOMNOtouch NIBP und ABPM PRO\n \n \n \n Videos auf Vimeo\n \n SOMNOmedics Showcase\n \n HST HOME SLEEP TEST \n \n SOMNOTouch RESP\n \n ABPM PRO """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5397 …} -companyTags: Doctrine\ORM\PersistentCollection {#5399 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5401 …} -users: Doctrine\ORM\PersistentCollection {#5403 …} -logoImageName: "20250226150122-somnovum-logo-67bf1eb2e0c57118103015.png" -coverImageName: "20250227164529-somnovum-favicon-67c08899ce99e284799146.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5405 …} -tagline: "Ihr Schweizer Partner für innovative Schlafdiagnostiklösungen in Zusammenarbeit mit SOMNOmedics" -contactEmail: "contact@somnovum.ch" -phone: "41062724111" -streamUrl: "https://vimeo.com/434320761" -streamType: "VIMEO" -followers: Doctrine\ORM\PersistentCollection {#5407 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5409 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5411 …} -industry: "" -size: "" -address1: "Industriestrasse 14" -address2: "" -city: "Oberentfelden" -postalCode: "5036" -state: "" -country: "" -socialLinkedin: "https://de.linkedin.com/company/somnovum" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5413 …} #createdAt: DateTime @1740133295 {#5374 date: 2025-02-21 10:21:35.0 UTC (+00:00) } #updatedAt: DateTime @1750925705 {#5373 date: 2025-06-26 08:15:05.0 UTC (+00:00) } } App\Entity\Company {#5417 -id: 56 -name: "Spirig HealthCare AG" -website: "https://spirig-healthcare.ch" -description: """ Die Spirig HealthCare AG ist ein junges Unternehmen mit Tradition im Schweizer Pharmamarkt. Bekannt ist sier als Anbieter von Marken und Generika sowie als Grosshändler und Servicepartner.\n \n Über 200 Produkte mit mehr als 700 verschiedenen Dosierungen und Packungsgrössen zählt das vielseitige Produkteportfolio der Spirig HealthCare AG. Dieses beinhaltet Generika, Eigenmarken, OTC-Produkte sowie Nahrungsergänzungsmittel.\n \n Als erfahrener Generikaspezialist und Logistikpartner bieten wir Ärzten und Apotheken alles aus einer Hand an.\n Profitieren Sie von unserem praktischen Lieferservice und lassen Sie sich unsere Kundennähe täglich beweisen. Wir gehen auf Ihre Bedürfnisse ein und richten unser Leistungsangebot auf Ihre individuellen Anforderungen aus. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5418 …} -companyTags: Doctrine\ORM\PersistentCollection {#5420 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5422 …} -users: Doctrine\ORM\PersistentCollection {#5424 …} -logoImageName: "20250226150204-springhealthcare-logo-67bf1edc58b64536794977.png" -coverImageName: "20250227164709-springhealthcare-favicon-67c088fd1bdc7388383831.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5426 …} -tagline: "Ihr zuverlässiger Partner für Generika, Markenprodukte und maßgeschneiderte Gesundheitslösungen in der Schweiz" -contactEmail: "info@spirig-healthcare.ch" -phone: "41062388850" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5428 …} -totalFollowers: 0 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5430 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5432 …} -industry: "" -size: "" -address1: "Industriestrasse 30" -address2: "" -city: "Egerkingen" -postalCode: "4622" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5434 …} #createdAt: DateTime @1740134210 {#5395 date: 2025-02-21 10:36:50.0 UTC (+00:00) } #updatedAt: DateTime @1750925725 {#5394 date: 2025-06-26 08:15:25.0 UTC (+00:00) } } App\Entity\Company {#5438 -id: 57 -name: "Takeda Pharma AG" -website: "https://takedapro.ch" -description: """ Takeda ist ein patientenorientiertes, wertebasiertes biopharmazeutisches Unternehmen, das global operiert. Mit dem Forschungs- & Entwicklungsbereich als Herz und Motor hat es sich zum Ziel gesetzt, Menschen weltweit mehr Gesundheit und eine bessere Zukunft zu bieten. Unsere Leidenschaft und unser Streben nach potenziell lebensverändernden Behandlungen für Patienten sind in einer in Japan seit über 230 Jahre währenden erfolgreichen Geschichte tief verwurzelt.\n \n Für weiterführende Informationen besuchen Sie unsere Website oder kontaktieren Sie uns. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5439 …} -companyTags: Doctrine\ORM\PersistentCollection {#5441 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5443 …} -users: Doctrine\ORM\PersistentCollection {#5445 …} -logoImageName: "20250226150225-takeda-logo-67bf1ef163ba2842168966.png" -coverImageName: "20250227164735-takeda-favicon-67c089177dce4392206956.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5447 …} -tagline: "Forschung und Innovation für eine gesündere Zukunft – Lebensverändernde Behandlungen für Patienten weltweit" -contactEmail: "alicia.arndt@takeda.com" -phone: null -streamUrl: "20250221114906-20240506092907-scribble-movie-herstellung-plasmaprodukte-public-663886c3c619e094442743-67b85a2289f22970438295.mp4" -streamType: "FILE" -followers: Doctrine\ORM\PersistentCollection {#5449 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5451 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5453 …} -industry: "" -size: "" -address1: "Thurgauerstrasse 130" -address2: "" -city: "Glattpark-Opfikon" -postalCode: "8152" -state: "Zürich" -country: "CH" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5455 …} #createdAt: DateTime @1740134948 {#5416 date: 2025-02-21 10:49:08.0 UTC (+00:00) } #updatedAt: DateTime @1750925746 {#5415 date: 2025-06-26 08:15:46.0 UTC (+00:00) } } App\Entity\Company {#5459 -id: 58 -name: "Teva Pharma AG" -website: "https://mepha.ch" -description: "Die Mepha Schweiz AG ist eine der führenden Pharmafirmen in der Schweiz und seit 2011 Teil der Teva Gruppe, der weltweiten Nummer eins im Generika-Markt. Zur Mepha Schweiz mit Sitz in Basel gehören die Firmen Teva Pharma AG sowie die Mepha Pharma AG, welche die führende Rolle im Schweizer Generika-Markt einnimmt." -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5460 …} -companyTags: Doctrine\ORM\PersistentCollection {#5462 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5464 …} -users: Doctrine\ORM\PersistentCollection {#5466 …} -logoImageName: "20250226150234-tevapharme-logo-67bf1efaee3c1232832944.png" -coverImageName: "20250227164958-tevapharme-logo-67c089a690434759022350.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5468 …} -tagline: "Führend im Generika-Markt – Mepha Schweiz als Schlüssel zur hochwertigen, erschwinglichen Gesundheitsversorgung" -contactEmail: "Joelle.Nguyen@tevapharma.ch" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5470 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5472 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5474 …} -industry: "" -size: "" -address1: "Kirschgartenstrasse 14" -address2: "" -city: "Basel" -postalCode: "4010" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5476 …} #createdAt: DateTime @1740135204 {#5437 date: 2025-02-21 10:53:24.0 UTC (+00:00) } #updatedAt: DateTime @1750925768 {#5436 date: 2025-06-26 08:16:08.0 UTC (+00:00) } } App\Entity\Company {#5480 -id: 59 -name: "UCB-Pharma AG" -website: "https://www.ucb.com" -description: "UCB ist ein weltweit tätiges biopharmazeutisches Unternehmen, das sich der Erforschung und Entwicklung von innovativer Medizin und Behandlungsmöglichkeiten in den Bereichen Zentrales Nervensystem, Immun- und Entzündungserkrankungen sowie der Osteologie widmet, um Menschen mit schweren Krankheiten eine bessere Lebensqualität zu ermöglichen. Das Ziel des Unternehmens ist es, jetzt und in Zukunft einen Mehrwert für Patientinnen und Patienten zu schaffen, sodass UCB auf einen nachhaltigen Geschäftsansatz setzt, dem das Wohlergehen seiner Mitarbeiterinnen und Mitarbeiter und der Umwelt sehr am Herzen liegt. UCB greift auf ein fundiertes wissenschaftliches Know-how zurück, das es durch Partnerschaften mit anderen Biotech-Unternehmen und prominenten Universitäten weiter ausbaut, denn für seine Patientinnen und Patienten entwickelt sich das belgische Unternehmen seit 1928 stets weiter. UCB erreichte 2019 ein Umsatzvolumen von 4,9 Mrd. € und beschäftigt mehr als 7.600 Mitarbeiter in rund 40 Ländern." -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5481 …} -companyTags: Doctrine\ORM\PersistentCollection {#5483 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5485 …} -users: Doctrine\ORM\PersistentCollection {#5487 …} -logoImageName: "20250226150246-ucb-logo-67bf1f064a05a881724100.png" -coverImageName: "20250227165107-ucb-favicon-67c089eb51d1b733977273.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5489 …} -tagline: "Innovation für eine bessere Lebensqualität – Führend in der Behandlung von ZNS-, Immun- und Entzündungserkrankungen" -contactEmail: "nadja.olini@ucb.com" -phone: "41792639689" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5491 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5493 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5495 …} -industry: "UCB - Pharma AG" -size: "" -address1: "Chemin de Croix - Blanche 10" -address2: "" -city: "Bulle" -postalCode: "1630" -state: "" -country: "CH" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5497 …} #createdAt: DateTime @1740135339 {#5458 date: 2025-02-21 10:55:39.0 UTC (+00:00) } #updatedAt: DateTime @1751623475 {#5457 date: 2025-07-04 10:04:35.0 UTC (+00:00) } } App\Entity\Company {#5501 -id: 60 -name: "VitalAire Schweiz AG" -website: "https://vitalaire.ch" -description: "" -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5502 …} -companyTags: Doctrine\ORM\PersistentCollection {#5504 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5506 …} -users: Doctrine\ORM\PersistentCollection {#5508 …} -logoImageName: "20250226150256-vitalair-logo-67bf1f1039c40533902094.png" -coverImageName: "20250227165127-vitalair-favicon-67c089ff98ec1062110486.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5510 …} -tagline: "Innovative Lösungen für die Atemtherapie – Ihr Partner für eine bessere Lebensqualität" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5512 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5514 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5516 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5518 …} #createdAt: DateTime @1740135553 {#5479 date: 2025-02-21 10:59:13.0 UTC (+00:00) } #updatedAt: DateTime @1750926106 {#5478 date: 2025-06-26 08:21:46.0 UTC (+00:00) } } App\Entity\Company {#5522 -id: 61 -name: "Zambon Schweiz AG" -website: "https://zambonpharma.com" -description: """ Seit 1906 etablieren wir innovative Produkte, welche die Lebensqualität der Patienten verbessern. Nun wollen wir darüber hinaus Menschen mit ihren Familien begleiten und sie dabei unterstützen, ihre Träume und Leidenschaften besser zu verwirklichen. Ob sie einfach wieder aktiver sein wollen, mit anderen mehr Zeit verbringen oder sich ganz einfach besser fühlen möchten.\n \n Unsere Mission ist es, Medikamente und moderne Konzepte für die Erhaltung der Gesundheit zu entwickeln, um das Leben lebenswerter zu gestalten. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5523 …} -companyTags: Doctrine\ORM\PersistentCollection {#5525 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5527 …} -users: Doctrine\ORM\PersistentCollection {#5529 …} -logoImageName: "20250226150308-zambonbiotech-logo-67bf1f1c14cd6670572285.png" -coverImageName: "20250227165147-zambonbiotech-favicon-67c08a130a7d1981411127.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5531 …} -tagline: "Innovative Gesundheitslösungen für ein aktives, erfülltes Leben – Ihre Gesundheit, unsere Mission" -contactEmail: "nadia.jordan@zambongroup.com" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5533 …} -totalFollowers: 1 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5535 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5537 …} -industry: "" -size: "" -address1: "Via Industria 13" -address2: "" -city: "Cadempino" -postalCode: "6814" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5539 …} #createdAt: DateTime @1740135819 {#5500 date: 2025-02-21 11:03:39.0 UTC (+00:00) } #updatedAt: DateTime @1750926129 {#5499 date: 2025-06-26 08:22:09.0 UTC (+00:00) } } App\Entity\Company {#5543 -id: 63 -name: "Amicus Therapeutics Switzerland GmbH" -website: "https://amicusrx.com" -description: "We are a biotechnology company at the forefront of advanced therapies to treat a range of devastating rare diseases." -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5544 …} -companyTags: Doctrine\ORM\PersistentCollection {#5546 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5548 …} -users: Doctrine\ORM\PersistentCollection {#5550 …} -logoImageName: "20250304170329-amicus-logo-67c72451d9409839818253.png" -coverImageName: "20250304170330-amicus-favicon-67c7245260257402366706.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5552 …} -tagline: "" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5554 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5556 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5558 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5560 …} #createdAt: DateTime @1741104210 {#5521 date: 2025-03-04 16:03:30.0 UTC (+00:00) } #updatedAt: DateTime @1750924453 {#5520 date: 2025-06-26 07:54:13.0 UTC (+00:00) } } App\Entity\Company {#5564 -id: 64 -name: "doclift" -website: "https://doclift.com" -description: "" -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5565 …} -companyTags: Doctrine\ORM\PersistentCollection {#5567 …} -companyCategory: null -owners: Doctrine\ORM\PersistentCollection {#5569 …} -users: Doctrine\ORM\PersistentCollection {#5571 …} -logoImageName: "20250307105142-doclift-final-logo1-67cac1ae763dd501318032.png" -coverImageName: "20250307105142-fav111-67cac1aeebdf6514548227.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5573 …} -tagline: "" -contactEmail: "info@doclift.com" -phone: "41565521255" -streamUrl: "https://vimeo.com/772498055" -streamType: "VIMEO" -followers: Doctrine\ORM\PersistentCollection {#5575 …} -totalFollowers: 2 -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5577 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5579 …} -industry: "IT" -size: "25-50" -address1: "Ländliweg 4a" -address2: "" -city: "Baden" -postalCode: "5400" -state: "AG" -country: "CH" -socialLinkedin: "https://www.linkedin.com/company/doclift-ag" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5581 …} #createdAt: DateTime @1741341103 {#5542 date: 2025-03-07 09:51:43.0 UTC (+00:00) } #updatedAt: DateTime @1750924826 {#5541 date: 2025-06-26 08:00:26.0 UTC (+00:00) } } App\Entity\Company {#5585 -id: 65 -name: "Insightec Europe Gmbh" -website: "https://insightec.com" -description: "This is your opportunity to potentially change lives through the therapeutic power of focused ultrasound. Explore how Incisionless Focused Ultrasound could be revolutionary for your patients suffering from a variety of conditions." -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5586 …} -companyTags: Doctrine\ORM\PersistentCollection {#5588 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5590 …} -users: Doctrine\ORM\PersistentCollection {#5592 …} -logoImageName: "20250311085031-ogp-nobg-67cfeb4771bde406654487.webp" -coverImageName: "20250311085031-insightec-favicon-32x32-1-67cfeb47da318517720359.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5594 …} -tagline: "Transform Patient Care with Incisionless Focused Ultrasound: A Revolutionary Therapeutic Breakthrough" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5596 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5598 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5600 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5602 …} #createdAt: DateTime @1741679432 {#5563 date: 2025-03-11 07:50:32.0 UTC (+00:00) } #updatedAt: DateTime @1750925037 {#5562 date: 2025-06-26 08:03:57.0 UTC (+00:00) } } App\Entity\Company {#5606 -id: 68 -name: "Sciensus AG" -website: "https://sciensus.ch/" -description: """ Sciensus, Ihr Partner zur medikamentösen Behandlung seltener und chronischer Krankheiten in Heimtherapie.\n Sciensus bietet alles aus einer Hand – Spitex, Apotheke und Grossist. Die Sciensus Spitex operierte bis Ende April 2024 unter dem Namen HTHC High Tech Home Care AG, gegründet als private Spitex mit Sitz in Kanton Zug. Sciensus betreut in der ganzen Schweiz Menschen mit chronischen, hauptsächlich seltenen, Erkrankungen. Das umfassende Dienstleistungs- und Therapieangebot berücksichtigt die individuellen Bedürfnisse für Infusions- oder Injektionstherapien im gewohnten Umfeld. Sciensus arbeitet eng mit Fachärzten zusammen und setzt bedürfnisorientierte Lösungen in höchster Qualität um.\n \n Unsere Dienstleistungen\n Wir bieten langjährige Erfahrung in der Heimtherapie bei seltenen und chronischen Krankheiten.\n Wir arbeiten nach höchsten Qualitäts- und Sicherheitsstandards.\n Wir informieren Sie regelmässig über den Therapieverlauf und geben sofort Rückmeldung bei Veränderungen des Gesundheitszustandes Ihrer Patienten.\n Wir sind regelmässig in Kontakt mit Ihren Patienten und stellen die Therapietreue und Einhaltung der geplanten Arztbesuche sicher.\n Wir haben konstante Teams, die das Coaching von prophylaktischen Massnahmen zur besseren Verträglichkeit sicherstellen.\n Wir ermöglichen eine kontinuierliche persönliche Betreuung bei Änderung der Therapie.\n Wir unterstützen Sie in administrativen Belangen (z.B. Abklärungen mit Krankenversicherungen, IV-Stellen, Überwachung von Kostengutsprache- und Rezeptgültigkeit).\n Wir arbeiten mit der Sciensus Apotheke zusammen, die Medikamente GDP-konform ausliefert.\n Wir profitieren als Tochtergesellschaft von Sciensus Pharma Services Ltd. von einem internationalen Knowhow-Transfer, einer Erweiterung des Therapie-Portfolios und stetiger Verbesserung der Qualitäts- und Sicherheitsstandards. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5607 …} -companyTags: Doctrine\ORM\PersistentCollection {#5609 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5611 …} -users: Doctrine\ORM\PersistentCollection {#5613 …} -logoImageName: "20250530104635-images-6839706b879ab888873765.png" -coverImageName: "20250530104635-channels4-profile-6839706bdf90b414965344.jpg" -companyProducts: Doctrine\ORM\PersistentCollection {#5615 …} -tagline: "" -contactEmail: "info@sciensus.ch" -phone: "41417499900" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5617 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5619 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5621 …} -industry: "" -size: "" -address1: "Buonaserstrasse 30" -address2: "" -city: "Rotkreuz" -postalCode: "6343" -state: "ZG" -country: "CH" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5623 …} #createdAt: DateTime @1748594687 {#5584 date: 2025-05-30 08:44:47.0 UTC (+00:00) } #updatedAt: DateTime @1750925647 {#5583 date: 2025-06-26 08:14:07.0 UTC (+00:00) } } App\Entity\Company {#5627 -id: 69 -name: "Boehringer Ingelheim" -website: "https://www.boehringer-ingelheim.com" -description: "" -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5628 …} -companyTags: Doctrine\ORM\PersistentCollection {#5630 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5632 …} -users: Doctrine\ORM\PersistentCollection {#5634 …} -logoImageName: "20250812162113-boehringer-ingelheim-260x160-689b4dd94e17c632048880.jpg" -coverImageName: null -companyProducts: Doctrine\ORM\PersistentCollection {#5636 …} -tagline: "" -contactEmail: "" -phone: "496132770" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5638 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5640 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5642 …} -industry: "Pharmaindustrie" -size: "Rund 54500 Mitarbeitende" -address1: "Binger Strasse 173 " -address2: "" -city: "Ingelheim am Rhein" -postalCode: "55216" -state: "Rheinland-Pfalz" -country: "DE" -socialLinkedin: "https://www.linkedin.com/company/boehringer-ingelheim" -socialX: "" -socialFacebook: "https://www.facebook.com/boehringeringelheim" -socialInstagram: "https://www.instagram.com/boehringer_ingelheim" -socialYoutube: "https://www.boehringer-ingelheim.com/disclaimer/external?path=https%3A%2F%2Fwww.youtube.com%2Fc%2FBoehringerIngelheimPharma" -ownerContainers: Doctrine\ORM\PersistentCollection {#5644 …} #createdAt: DateTime @1754999426 {#5605 date: 2025-08-12 11:50:26.0 UTC (+00:00) } #updatedAt: DateTime @1755008473 {#5604 date: 2025-08-12 14:21:13.0 UTC (+00:00) } } App\Entity\Company {#5648 -id: 70 -name: "Novo Nordisk" -website: "https://novonordisk.ch" -description: """ We refuse to accept the status quo for people living with serious chronic diseases. For more than century, we have translated unmet medical needs into innovative medicines and delivery systems, like our insulin pens, and today we continue to reimagine what’s possible through bold science.\n \n From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to people living with diabetes, obesity, and rare blood and endocrine diseases around the world.\n \n Once a breakthrough treatment is created in our labs, we want it to reach as many people as possible. To keep up with demand, we scale fast. We build big. We optimise at every opportunity. By building capacity to a level previously unheard of in our industry, we can make a difference in more lives than ever before. """ -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5649 …} -companyTags: Doctrine\ORM\PersistentCollection {#5651 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5653 …} -users: Doctrine\ORM\PersistentCollection {#5655 …} -logoImageName: "20250814184459-novo-nordisk-logo-svg-689e128bf2846328548906.png" -coverImageName: "20250814184500-novo-nordisk-logo-svg-689e128c6a32d687876769.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5657 …} -tagline: "Driving long-term health by discovering, developing and delivering" -contactEmail: "" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5659 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5661 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5663 …} -industry: "" -size: "" -address1: "" -address2: "" -city: "" -postalCode: "" -state: "" -country: "" -socialLinkedin: "" -socialX: "" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5665 …} #createdAt: DateTime @1755189901 {#5626 date: 2025-08-14 16:45:01.0 UTC (+00:00) } #updatedAt: DateTime @1755240981 {#5625 date: 2025-08-15 06:56:21.0 UTC (+00:00) } } App\Entity\Company {#5669 -id: 71 -name: "EffRx" -website: "https://www.effrx.com" -description: "EffRx Pharmaceuticals is a Swiss-based commercial-stage pharmaceutical company focused on the late-stage development and commercialization of medications for niche endocrine, metabolic and musculoskeletal disorders." -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5670 …} -companyTags: Doctrine\ORM\PersistentCollection {#5672 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5674 …} -users: Doctrine\ORM\PersistentCollection {#5676 …} -logoImageName: "20250825134823-effrx-logo-cmyk-68ac4d87d3392094874233.jpg" -coverImageName: "20250825134824-favicon-512px-150x150effrex-68ac4d882ed0b951890510.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5678 …} -tagline: "Commercial-Stage Pharmaceutical Company Focused on Niche Therapeutics" -contactEmail: "info@effrx.com" -phone: "41445037860" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5680 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5682 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5684 …} -industry: "Pharmaindustrie" -size: "15" -address1: "Wolleraustrasse 41B" -address2: "" -city: "Freienbach" -postalCode: "8807" -state: "Schwyz" -country: "CH" -socialLinkedin: "https://www.linkedin.com/company/effrx-pharmaceuticals-sa" -socialX: "https://twitter.com/effrx" -socialFacebook: "" -socialInstagram: "" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5686 …} #createdAt: DateTime @1756122504 {#5647 date: 2025-08-25 11:48:24.0 UTC (+00:00) } #updatedAt: DateTime @1756122504 {#5646 date: 2025-08-25 11:48:24.0 UTC (+00:00) } } Proxies\__CG__\App\Entity\Company {#3651 -id: 81 -name: "Inselspital, Universitätsspital Bern" -website: "http://insel.ch" -description: "Das Universitätsspital Bern kombiniert Spitzenmedizin mit individueller Betreuung. Innovationen und neue Erkenntnisse aus der medizinischen Forschung und Pflege werden zugunsten unserer Patientinnen und Patienten kompetent im Spitalalltag angewandt." -externalId: "27795914" -details: [ "id" => 27795914 "url" => "https://www.linkedin.com/company/inselspital-universit%c3%a4tsspital-bern" "hash" => "472fc55188ae2a95393c813086005556" "name" => "Inselspital, Universitätsspital Bern" "website" => "http://insel.ch" "size" => null "industry" => "Medical Practice" "description" => "Das Universitätsspital Bern kombiniert Spitzenmedizin mit individueller Betreuung. Innovationen und neue Erkenntnisse aus der medizinischen Forschung und Pflege werden zugunsten unserer Patientinnen und Patienten kompetent im Spitalalltag angewandt." "followers" => null "founded" => 1354 "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://static-exp1.licdn.com/sc/h/9rxpcj33wtsq3w7nxb3u3ku6e" "created" => "2020-05-09 11:07:22" "last_updated" => "2025-08-01 09:59:41" "last_response_code" => 404 "type" => null "headquarters_new_address" => "Bern" "employees_count" => 284 "headquarters_country_restored" => null "headquarters_country_parsed" => "Switzerland" "company_shorthand_name" => "inselspital-universit%c3%a4tsspital-bern" "company_shorthand_name_hash" => "7f127a48c0cc4b8985cfdaa92015c938" "canonical_url" => "https://www.linkedin.com/company/inselspital-universit%c3%a4tsspital-bern" "canonical_hash" => "472fc55188ae2a95393c813086005556" "canonical_shorthand_name" => "inselspital-universit%c3%a4tsspital-bern" "canonical_shorthand_name_hash" => "7f127a48c0cc4b8985cfdaa92015c938" "deleted" => 1 "last_updated_ux" => 1754042381 "source_id" => 65193104 "company_affiliated_collection" => [] "company_also_viewed_collection" => [] "company_crunchbase_info_collection" => [] "company_featured_employees_collection" => [ [ "id" => 44076092 "company_id" => 27795914 "url" => "https://www.linkedin.com/in/valgimigli-marco-0a2b329" "created" => "2020-05-09 11:07:21" "last_updated" => "2020-06-27 13:37:44" "deleted" => 1 ] [ "id" => 44076093 "company_id" => 27795914 "url" => "https://www.linkedin.com/in/naomi-porret-574a95a" "created" => "2020-05-09 11:07:21" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] [ "id" => 44076094 "company_id" => 27795914 "url" => "https://www.linkedin.com/in/jo%C3%A3o-seabra-do-amaral-35b12a30" "created" => "2020-05-09 11:07:21" "last_updated" => "2020-06-27 13:37:44" "deleted" => 1 ] [ "id" => 44076095 "company_id" => 27795914 "url" => "https://www.linkedin.com/in/lenka-bosanska-8b542a4b" "created" => "2020-05-09 11:07:21" "last_updated" => "2020-11-04 14:46:01" "deleted" => 1 ] [ "id" => 46464847 "company_id" => 27795914 "url" => "https://www.linkedin.com/in/carmen-andrea-pfortmueller-24015570" "created" => "2020-06-27 13:37:44" "last_updated" => "2020-10-07 06:00:19" "deleted" => 1 ] [ "id" => 46464848 "company_id" => 27795914 "url" => "https://www.linkedin.com/in/michelle-wetzel-do-espirito-santo-43332b7a" "created" => "2020-06-27 13:37:44" "last_updated" => "2020-08-08 03:09:19" "deleted" => 1 ] [ "id" => 49534119 "company_id" => 27795914 "url" => "https://www.linkedin.com/in/rporz" "created" => "2020-08-08 03:09:19" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] [ "id" => 54431048 "company_id" => 27795914 "url" => "https://www.linkedin.com/in/vincent-pernet-09b0bb45" "created" => "2020-10-07 06:00:19" "last_updated" => "2020-11-04 14:46:01" "deleted" => 1 ] [ "id" => 55516553 "company_id" => 27795914 "url" => "https://www.linkedin.com/in/mariajosecolomacea" "created" => "2020-11-04 14:46:01" "last_updated" => "2021-01-13 17:03:38" "deleted" => 1 ] [ "id" => 55516554 "company_id" => 27795914 "url" => "https://www.linkedin.com/in/pascal-bader-2a3b2321" "created" => "2020-11-04 14:46:01" "last_updated" => "2021-01-02 16:48:21" "deleted" => 1 ] [ "id" => 58529752 "company_id" => 27795914 "url" => "https://www.linkedin.com/in/aebuechi" "created" => "2021-01-02 16:48:21" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] [ "id" => 59219779 "company_id" => 27795914 "url" => "https://www.linkedin.com/in/daniel-m-aebersold-75b38ab" "created" => "2021-01-13 17:03:38" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] ] "company_featured_investors_collection" => [] "company_funding_rounds_collection" => [] "company_locations_collection" => [ [ "id" => 15776871 "company_id" => 27795914 "location_address" => "BEREICH KOMMUNIKATION UND MARKETING; Bern, CH" "is_primary" => 0 "created" => "2020-05-09 11:07:21" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] ] "company_similar_collection" => [ [ "id" => 145366610 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/inselspital-stiftung" "created" => "2020-05-09 11:07:21" "last_updated" => "2020-12-13 21:21:59" "deleted" => 1 ] [ "id" => 145366611 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/inselspital-spitalpharmacie" "created" => "2020-05-09 11:07:21" "last_updated" => "2020-09-16 17:38:39" "deleted" => 1 ] [ "id" => 145366612 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/avc-audio-video-communication-service-gmbh" "created" => "2020-05-09 11:07:21" "last_updated" => "2020-06-01 08:21:06" "deleted" => 1 ] [ "id" => 145366613 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/gemeindewerke" "created" => "2020-05-09 11:07:21" "last_updated" => "2020-06-01 08:21:06" "deleted" => 1 ] [ "id" => 145366614 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/sun-store" "created" => "2020-05-09 11:07:21" "last_updated" => "2020-05-26 18:54:53" "deleted" => 1 ] [ "id" => 145366615 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/b%C3%BCrgerspital" "created" => "2020-05-09 11:07:21" "last_updated" => "2020-05-26 18:54:53" "deleted" => 1 ] [ "id" => 145366616 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/medifilm-ag" "created" => "2020-05-09 11:07:21" "last_updated" => "2020-05-26 18:54:53" "deleted" => 1 ] [ "id" => 145366617 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/coop-vitality-ag" "created" => "2020-05-09 11:07:21" "last_updated" => "2020-05-18 13:07:36" "deleted" => 1 ] [ "id" => 145366618 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/schaffhauser-kantonalbank" "created" => "2020-05-09 11:07:21" "last_updated" => "2020-05-11 15:50:23" "deleted" => 1 ] [ "id" => 145366619 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/kpt-die-krankenkasse-mit-dem-plus" "created" => "2020-05-09 11:07:21" "last_updated" => "2020-05-11 15:50:23" "deleted" => 1 ] [ "id" => 147311559 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/inselgruppe" "created" => "2020-05-11 15:50:23" "last_updated" => "2020-12-13 21:21:59" "deleted" => 1 ] [ "id" => 147311560 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/privatklinik-bethanien" "created" => "2020-05-11 15:50:23" "last_updated" => "2020-05-26 18:54:53" "deleted" => 1 ] [ "id" => 151545959 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/centivax" "created" => "2020-05-18 13:07:36" "last_updated" => "2020-06-01 08:21:06" "deleted" => 1 ] [ "id" => 157886807 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/universitatsspital-zurich" "created" => "2020-05-26 18:54:53" "last_updated" => "2020-12-13 21:21:59" "deleted" => 1 ] [ "id" => 157886809 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/unispital-basel" "created" => "2020-05-26 18:54:53" "last_updated" => "2020-12-13 21:21:59" "deleted" => 1 ] [ "id" => 157886810 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/hopitaux-universitaires-de-geneve" "created" => "2020-05-26 18:54:53" "last_updated" => "2020-07-26 06:00:50" "deleted" => 1 ] [ "id" => 157886811 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/sonnata-creative-agency" "created" => "2020-05-26 18:54:53" "last_updated" => "2020-07-10 03:24:37" "deleted" => 1 ] [ "id" => 160334555 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/rodent" "created" => "2020-06-01 08:21:06" "last_updated" => "2020-06-15 06:20:53" "deleted" => 1 ] [ "id" => 160334556 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/mikrona-technologie-ag" "created" => "2020-06-01 08:21:06" "last_updated" => "2020-06-15 06:20:53" "deleted" => 1 ] [ "id" => 160334557 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/usz" "created" => "2020-06-01 08:21:06" "last_updated" => "2020-06-09 12:43:47" "deleted" => 1 ] [ "id" => 165989684 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/allianz-suisse-versicherungs-gesellschaft-ag" "created" => "2020-06-09 12:43:47" "last_updated" => "2020-07-10 03:24:37" "deleted" => 1 ] [ "id" => 169505899 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/sci-montaigne-50" "created" => "2020-06-15 06:20:53" "last_updated" => "2020-07-26 06:00:50" "deleted" => 1 ] [ "id" => 169505900 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/sci-50-avenue-montaigne" "created" => "2020-06-15 06:20:53" "last_updated" => "2020-07-26 06:00:50" "deleted" => 1 ] [ "id" => 179551153 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/kpt-die-krankenkasse-mit-dem-plus" "created" => "2020-07-10 03:24:37" "last_updated" => "2020-08-03 20:10:33" "deleted" => 1 ] [ "id" => 179551154 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/visana" "created" => "2020-07-10 03:24:37" "last_updated" => "2020-08-03 20:10:33" "deleted" => 1 ] [ "id" => 191594310 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/luzerner-kantonsspital" "created" => "2020-07-26 06:00:50" "last_updated" => "2020-12-13 21:21:59" "deleted" => 1 ] [ "id" => 191594311 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/artorg-center-for-biomedical-engineering-research" "created" => "2020-07-26 06:00:50" "last_updated" => "2020-08-20 16:08:08" "deleted" => 1 ] [ "id" => 191594312 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/hirslanden" "created" => "2020-07-26 06:00:50" "last_updated" => "2020-12-13 21:21:59" "deleted" => 1 ] [ "id" => 200738268 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/chuv" "created" => "2020-08-03 20:10:33" "last_updated" => "2020-12-13 21:21:59" "deleted" => 1 ] [ "id" => 200738269 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/hopitaux-universitaires-de-geneve" "created" => "2020-08-03 20:10:33" "last_updated" => "2020-10-19 15:24:33" "deleted" => 1 ] [ "id" => 212092984 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/hfr-hopital-fribourgeois" "created" => "2020-08-20 16:08:08" "last_updated" => "2020-09-14 18:48:33" "deleted" => 1 ] [ "id" => 227171692 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/solothurner-spitaeler-ag---soh" "created" => "2020-09-14 18:48:33" "last_updated" => "2020-09-16 17:38:39" "deleted" => 1 ] [ "id" => 231218475 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/hopitalduvalais-spitalwallis" "created" => "2020-09-16 17:38:39" "last_updated" => "2020-10-15 05:05:57" "deleted" => 1 ] [ "id" => 231218476 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/kantonsspital-graub%C3%BCnden" "created" => "2020-09-16 17:38:39" "last_updated" => "2020-09-21 00:14:12" "deleted" => 1 ] [ "id" => 235238430 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/inselspital-spitalpharmacie" "created" => "2020-09-21 00:14:12" "last_updated" => "2020-10-19 15:24:33" "deleted" => 1 ] [ "id" => 250038500 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/bag-ofsp" "created" => "2020-10-15 05:05:57" "last_updated" => "2020-12-13 21:21:59" "deleted" => 1 ] [ "id" => 251400502 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/spital-thurgau-ag" "created" => "2020-10-19 15:24:33" "last_updated" => "2020-12-13 21:21:59" "deleted" => 1 ] [ "id" => 251400503 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/hopitalduvalais-spitalwallis" "created" => "2020-10-19 15:24:33" "last_updated" => "2020-11-04 14:46:01" "deleted" => 1 ] [ "id" => 262203006 "company_id" => 27795914 "url" => "https://www.linkedin.com/company/kantonsspital-st.gallen" "created" => "2020-11-04 14:46:01" "last_updated" => "2020-12-13 21:21:59" "deleted" => 1 ] [ "id" => 322202552 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/inselgruppe" "created" => "2020-12-13 21:21:59" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] [ "id" => 322202553 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/universitatsspital-zurich" "created" => "2020-12-13 21:21:59" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] [ "id" => 322202554 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/unispital-basel" "created" => "2020-12-13 21:21:59" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] [ "id" => 322202555 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/inselspital-stiftung" "created" => "2020-12-13 21:21:59" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] [ "id" => 322202556 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/luzerner-kantonsspital" "created" => "2020-12-13 21:21:59" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] [ "id" => 322202557 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/hirslanden" "created" => "2020-12-13 21:21:59" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] [ "id" => 322202558 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/chuv" "created" => "2020-12-13 21:21:59" "last_updated" => "2021-01-18 11:36:19" "deleted" => 1 ] [ "id" => 322202559 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/bag-ofsp" "created" => "2020-12-13 21:21:59" "last_updated" => "2021-01-18 11:36:19" "deleted" => 1 ] [ "id" => 322202560 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/kantonsspital-aarau-ag" "created" => "2020-12-13 21:21:59" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] [ "id" => 322202561 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/stadtspital-waid-und-triemli" "created" => "2020-12-13 21:21:59" "last_updated" => "2020-12-21 11:56:27" "deleted" => 1 ] [ "id" => 340632378 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/sitem-insel" "created" => "2020-12-21 11:56:27" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] [ "id" => 356506778 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/kinderspital-z-rich" "created" => "2021-01-18 11:36:19" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] [ "id" => 356506779 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/stadtspital-waid-und-triemli" "created" => "2021-01-18 11:36:19" "last_updated" => "2021-02-04 08:19:22" "deleted" => 1 ] [ "id" => 364308162 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/lindenhofgruppe" "created" => "2021-02-04 08:19:22" "last_updated" => "2021-04-14 22:31:35" "deleted" => 1 ] [ "id" => 395118312 "company_id" => 27795914 "url" => "https://ch.linkedin.com/company/stadtspital-waid-und-triemli" "created" => "2021-04-14 22:31:35" "last_updated" => "2021-04-25 03:35:46" "deleted" => 1 ] ] "company_specialties_collection" => [] "company_stock_info_collection" => [] "company_updates_collection" => [] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5690 …} -companyTags: Doctrine\ORM\PersistentCollection {#5692 …} -companyCategory: null -owners: Doctrine\ORM\PersistentCollection {#5694 …} -users: Doctrine\ORM\PersistentCollection {#5696 …} -logoImageName: null -coverImageName: null -companyProducts: Doctrine\ORM\PersistentCollection {#5698 …} -tagline: "Inselspital, Universitätsspital Bern" -contactEmail: null -phone: null -streamUrl: null -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5700 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5702 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5704 …} -industry: "Medical Practice" -size: "284" -address1: null -address2: null -city: null -postalCode: null -state: null -country: "Switzerland" -socialLinkedin: null -socialX: null -socialFacebook: null -socialInstagram: null -socialYoutube: null -ownerContainers: Doctrine\ORM\PersistentCollection {#5706 …} #createdAt: DateTime @1756305063 {#5668 date: 2025-08-27 14:31:03.0 UTC (+00:00) } #updatedAt: DateTime @1756317735 {#5667 date: 2025-08-27 18:02:15.0 UTC (+00:00) } +__isInitialized__: true …2 } App\Entity\Company {#5710 -id: 85 -name: "TAKEDA PHARMACEUTICALS INTERNATIONAL GMBH GLATTPARK CH" -website: "https://www.takeda.com/" -description: "TAKEDA PHARMACEUTICALS INTERNATIONAL GMBH GLATTPARK CH is a wholesale company based out of THURGAUERSTRASSE 130, Ch-8152 Glattpark (Opfikon), Switzerland. The double-blind, randomized, placebo-controlled Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial is evaluating the safety and efficacy of two doses of TAK-003 in the prevention of laboratory-confirmed symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in children and adolescents.8 Study participants were randomized 2:1 to receive two doses of TAK-003 0.5 mL or placebo on Months 0 and 3, administered subcutaneously.8 The study is comprised of five parts. Part 1 and the primary endpoint analysis evaluated vaccine efficacy (VE) and safety through 12 months after the second dose.8 Part 2 continued for an additional six months to complete the assessment of the secondary endpoints of VE by serotype, baseline serostatus and disease severity, including VE against hospitalized dengue.8 Part 3 evaluated VE and long-term safety by following participants for an additional two and a half to three years, as per World Health Organization (WHO) recommendations.11 Part 4 will evaluate efficacy and safety for 13 months following booster vaccination, and Part 5 will evaluate long-term efficacy and safety for one year after completion of Part" -externalId: "28738946" -details: [ "id" => 28738946 "url" => "https://www.linkedin.com/company/takeda-pharmaceuticals-international-gmbh-glattpark-ch" "hash" => "d26807ab86df627f33b3fc4a79585d5d" "name" => "TAKEDA PHARMACEUTICALS INTERNATIONAL GMBH GLATTPARK CH" "website" => "https://www.takeda.com/" "size" => "51-200 employees" "industry" => "Wholesale" "description" => "TAKEDA PHARMACEUTICALS INTERNATIONAL GMBH GLATTPARK CH is a wholesale company based out of THURGAUERSTRASSE 130, Ch-8152 Glattpark (Opfikon), Switzerland. The double-blind, randomized, placebo-controlled Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial is evaluating the safety and efficacy of two doses of TAK-003 in the prevention of laboratory-confirmed symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in children and adolescents.8 Study participants were randomized 2:1 to receive two doses of TAK-003 0.5 mL or placebo on Months 0 and 3, administered subcutaneously.8 The study is comprised of five parts. Part 1 and the primary endpoint analysis evaluated vaccine efficacy (VE) and safety through 12 months after the second dose.8 Part 2 continued for an additional six months to complete the assessment of the secondary endpoints of VE by serotype, baseline serostatus and disease severity, including VE against hospitalized dengue.8 Part 3 evaluated VE and long-term safety by following participants for an additional two and a half to three years, as per World Health Organization (WHO) recommendations.11 Part 4 will evaluate efficacy and safety for 13 months following booster vaccination, and Part 5 will evaluate long-term efficacy and safety for one year after completion of Part" "followers" => null "founded" => null "headquarters_city" => null "headquarters_country" => null "headquarters_state" => null "headquarters_street1" => null "headquarters_street2" => null "headquarters_zip" => null "logo_url" => "https://media.licdn.com/dms/image/v2/C4E0BAQGA9k-yE2rdfQ/company-logo_200_200/company-logo_200_200/0/1661856874322/takeda_pharmaceuticals_international_gmbh_glattpark_ch_logo?e=2147483647&v=beta&t=cOLAVCyB8wcPNyyxh_muj0gAmvM9L7SCN-S40J7ugFs" "created" => "2020-06-22 06:53:49" "last_updated" => "2025-08-25 14:35:28" "last_response_code" => 200 "type" => "Public Company" "headquarters_new_address" => "Ch-8152 Glattpark (Opfikon)" "employees_count" => 93 "headquarters_country_restored" => null "headquarters_country_parsed" => "Switzerland" "company_shorthand_name" => "takeda-pharmaceuticals-international-gmbh-glattpark-ch" "company_shorthand_name_hash" => "1a92eee4e4141fbad98c002d82b24466" "canonical_url" => "https://ch.linkedin.com/company/takeda-pharmaceuticals-international-gmbh-glattpark-ch" "canonical_hash" => "96ae5fb772fd2afb13616e1a31ef6b17" "canonical_shorthand_name" => "takeda-pharmaceuticals-international-gmbh-glattpark-ch" "canonical_shorthand_name_hash" => "1a92eee4e4141fbad98c002d82b24466" "deleted" => 0 "last_updated_ux" => 1756132527 "source_id" => 65234793 "company_affiliated_collection" => [] "company_also_viewed_collection" => [] "company_crunchbase_info_collection" => [] "company_featured_employees_collection" => [ [ "id" => 46293401 "company_id" => 28738946 "url" => "https://www.linkedin.com/in/annette-oeltjen" "created" => "2020-06-22 06:53:48" "last_updated" => "2020-12-04 03:34:29" "deleted" => 1 ] [ "id" => 47705699 "company_id" => 28738946 "url" => "https://www.linkedin.com/in/elena-malagarriga-palanques-349b8018" "created" => "2020-07-26 20:26:02" "last_updated" => "2022-07-26 04:57:37" "deleted" => 1 ] [ "id" => 47705700 "company_id" => 28738946 "url" => "https://www.linkedin.com/in/dennis-schulz-0453a6143" "created" => "2020-07-26 20:26:02" "last_updated" => "2021-01-25 22:39:37" "deleted" => 1 ] [ "id" => 53472372 "company_id" => 28738946 "url" => "https://www.linkedin.com/in/inara-medeiros-macedo-d-57948bb5" "created" => "2020-09-14 15:31:48" "last_updated" => "2021-03-11 09:30:25" "deleted" => 1 ] [ "id" => 61736455 "company_id" => 28738946 "url" => "https://www.linkedin.com/in/timo-schulte-28b4607b" "created" => "2021-03-11 09:30:25" "last_updated" => "2021-04-22 17:01:42" "deleted" => 1 ] [ "id" => 64116091 "company_id" => 28738946 "url" => "https://www.linkedin.com/in/michelle-vejtorp-birch-492a5942" "created" => "2021-04-22 17:01:42" "last_updated" => "2022-07-26 04:57:37" "deleted" => 1 ] [ "id" => 69711645 "company_id" => 28738946 "url" => "https://www.linkedin.com/in/mathias-bruns-93377557" "created" => "2021-07-22 03:50:04" "last_updated" => "2021-08-11 16:41:11" "deleted" => 1 ] [ "id" => 79478438 "company_id" => 28738946 "url" => "https://www.linkedin.com/in/anna-schnekenburger-855368224" "created" => "2021-11-22 04:03:48" "last_updated" => "2022-02-21 16:15:02" "deleted" => 1 ] [ "id" => 86388721 "company_id" => 28738946 "url" => "https://www.linkedin.com/in/thomas-wittmer-0b8101a" "created" => "2022-02-21 16:15:02" "last_updated" => "2022-07-26 04:57:37" "deleted" => 1 ] [ "id" => 86388722 "company_id" => 28738946 "url" => "https://www.linkedin.com/in/anabel-immoos-dailly-637359100" "created" => "2022-02-21 16:15:02" "last_updated" => "2022-07-26 04:57:37" "deleted" => 1 ] [ "id" => 119250925 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/gdiciancia" "created" => "2022-07-26 04:57:37" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] [ "id" => 119250926 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/thomas-wittmer-0b8101a" "created" => "2022-07-26 04:57:37" "last_updated" => "2023-02-17 14:12:56" "deleted" => 1 ] [ "id" => 119250927 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/elena-malagarriga-palanques-349b8018" "created" => "2022-07-26 04:57:37" "last_updated" => "2022-11-17 11:56:20" "deleted" => 1 ] [ "id" => 119250928 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/michelle-vejtorp-birch-492a5942" "created" => "2022-07-26 04:57:37" "last_updated" => "2022-10-11 15:36:58" "deleted" => 1 ] [ "id" => 146369274 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/selimach" "created" => "2022-10-11 15:36:58" "last_updated" => "2024-03-13 02:34:46" "deleted" => 1 ] [ "id" => 153922932 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/attilakonkol" "created" => "2022-11-17 11:56:20" "last_updated" => "2023-01-12 01:52:40" "deleted" => 1 ] [ "id" => 157626013 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/georgearezina" "created" => "2023-01-12 01:52:40" "last_updated" => "2024-01-20 08:34:44" "deleted" => 1 ] [ "id" => 159957108 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/kelly-gasser-matos-2b205211" "created" => "2023-02-17 14:12:56" "last_updated" => "2023-04-19 02:25:32" "deleted" => 1 ] [ "id" => 162669213 "company_id" => 28738946 "url" => "https://www.linkedin.com/in/deborah-pileggi" "created" => "2023-04-19 02:25:32" "last_updated" => "2023-06-02 00:53:24" "deleted" => 1 ] [ "id" => 164554493 "company_id" => 28738946 "url" => "https://www.linkedin.com/in/atakan-yesil-msc" "created" => "2023-06-02 00:53:24" "last_updated" => "2023-08-05 20:44:18" "deleted" => 1 ] [ "id" => 185998328 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/atakan-yesil-msc" "created" => "2023-08-05 20:44:18" "last_updated" => "2024-09-27 20:47:34" "deleted" => 1 ] [ "id" => 200193676 "company_id" => 28738946 "url" => "https://www.linkedin.com/in/deborah-pileggi" "created" => "2024-01-20 08:34:44" "last_updated" => "2024-04-08 22:41:45" "deleted" => 1 ] [ "id" => 203087810 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/alessandrocuccioletta" "created" => "2024-03-13 02:34:46" "last_updated" => "2024-07-26 02:15:59" "deleted" => 1 ] [ "id" => 204382595 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/selimach" "created" => "2024-04-08 22:41:45" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] [ "id" => 210129240 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/jaco-botha-a946314" "created" => "2024-07-26 02:15:59" "last_updated" => "2024-08-06 07:02:05" "deleted" => 1 ] [ "id" => 210360708 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/alessandrocuccioletta" "created" => "2024-08-06 07:02:05" "last_updated" => "2025-08-10 00:09:29" "deleted" => 1 ] [ "id" => 213330556 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/sasank-mohanty-b81b06a" "created" => "2024-09-27 20:47:34" "last_updated" => "2025-03-08 12:23:49" "deleted" => 1 ] [ "id" => 221498581 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/virginie-poupault-procurement-sourcing-strategy" "created" => "2025-03-08 12:23:49" "last_updated" => "2025-06-02 09:59:15" "deleted" => 1 ] [ "id" => 225986832 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/virginie-poupault-procurement" "created" => "2025-06-02 09:59:15" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] [ "id" => 230476554 "company_id" => 28738946 "url" => "https://ch.linkedin.com/in/omar-arciniega-5956891" "created" => "2025-08-10 00:09:29" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] ] "company_featured_investors_collection" => [] "company_funding_rounds_collection" => [] "company_locations_collection" => [ [ "id" => 16747469 "company_id" => 28738946 "location_address" => "THURGAUERSTRASSE 130; Ch-8152 Glattpark (Opfikon), CH" "is_primary" => 0 "created" => "2020-06-22 06:53:48" "last_updated" => "2022-07-26 04:57:37" "deleted" => 1 ] [ "id" => 95165058 "company_id" => 28738946 "location_address" => "THURGAUERSTRASSE 130; Ch-8152 Glattpark (Opfikon), ch" "is_primary" => 0 "created" => "2022-07-26 04:57:37" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] ] "company_similar_collection" => [ [ "id" => 172622869 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/takeda-pharmaceuticals-america-inc." "created" => "2020-06-22 06:53:48" "last_updated" => "2021-06-22 07:40:14" "deleted" => 1 ] [ "id" => 172622870 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/nycomed" "created" => "2020-06-22 06:53:48" "last_updated" => "2020-11-22 02:42:49" "deleted" => 1 ] [ "id" => 172622871 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/biomarin" "created" => "2020-06-22 06:53:48" "last_updated" => "2020-07-26 20:26:02" "deleted" => 1 ] [ "id" => 172622872 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/bio-rad" "created" => "2020-06-22 06:53:48" "last_updated" => "2020-07-26 20:26:02" "deleted" => 1 ] [ "id" => 172622873 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/biogen-" "created" => "2020-06-22 06:53:48" "last_updated" => "2020-07-26 20:26:02" "deleted" => 1 ] [ "id" => 172622874 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/alcon" "created" => "2020-06-22 06:53:48" "last_updated" => "2020-07-26 20:26:02" "deleted" => 1 ] [ "id" => 191962687 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/takeda-pharmaceuticals-international-inc." "created" => "2020-07-26 20:26:02" "last_updated" => "2021-06-22 07:40:14" "deleted" => 1 ] [ "id" => 191962688 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/spfpl-takeda-pharmaceuticals" "created" => "2020-07-26 20:26:02" "last_updated" => "2020-11-22 02:42:49" "deleted" => 1 ] [ "id" => 191962689 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/pharmtastic" "created" => "2020-07-26 20:26:02" "last_updated" => "2020-11-22 02:42:49" "deleted" => 1 ] [ "id" => 191962691 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/arztpraxis-glattpark" "created" => "2020-07-26 20:26:02" "last_updated" => "2020-11-22 02:42:49" "deleted" => 1 ] [ "id" => 191962693 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/tmc-fashion-square-ag" "created" => "2020-07-26 20:26:02" "last_updated" => "2020-11-22 02:42:49" "deleted" => 1 ] [ "id" => 191962696 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/takeda-pharmaceuticals" "created" => "2020-07-26 20:26:02" "last_updated" => "2020-11-22 02:42:49" "deleted" => 1 ] [ "id" => 191962699 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/takado" "created" => "2020-07-26 20:26:02" "last_updated" => "2020-11-22 02:42:49" "deleted" => 1 ] [ "id" => 191962701 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/takeda-pharmaceuticals-india-pvt-ltd-" "created" => "2020-07-26 20:26:02" "last_updated" => "2020-08-23 06:01:50" "deleted" => 1 ] [ "id" => 213570896 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/fitnesspark-glattpark" "created" => "2020-08-23 06:01:50" "last_updated" => "2020-11-22 02:42:49" "deleted" => 1 ] [ "id" => 292012364 "company_id" => 28738946 "url" => "https://jp.linkedin.com/company/takeda-pharmaceuticals" "created" => "2020-11-22 02:42:49" "last_updated" => "2021-06-22 07:40:14" "deleted" => 1 ] [ "id" => 292012365 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/nycomed" "created" => "2020-11-22 02:42:49" "last_updated" => "2021-06-22 07:40:14" "deleted" => 1 ] [ "id" => 292012366 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/fitnesspark-glattpark" "created" => "2020-11-22 02:42:49" "last_updated" => "2021-06-22 07:40:14" "deleted" => 1 ] [ "id" => 292012367 "company_id" => 28738946 "url" => "https://fr.linkedin.com/company/spfpl-takeda-pharmaceuticals" "created" => "2020-11-22 02:42:49" "last_updated" => "2021-06-22 07:40:14" "deleted" => 1 ] [ "id" => 292012368 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/pharmtastic" "created" => "2020-11-22 02:42:49" "last_updated" => "2021-06-22 07:40:14" "deleted" => 1 ] [ "id" => 292012369 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/arztpraxis-glattpark" "created" => "2020-11-22 02:42:49" "last_updated" => "2021-01-25 22:39:37" "deleted" => 1 ] [ "id" => 292012370 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/tmc-fashion-square-ag" "created" => "2020-11-22 02:42:49" "last_updated" => "2021-01-25 22:39:37" "deleted" => 1 ] [ "id" => 292012371 "company_id" => 28738946 "url" => "https://ma.linkedin.com/company/takado" "created" => "2020-11-22 02:42:49" "last_updated" => "2021-01-25 22:39:37" "deleted" => 1 ] [ "id" => 360684985 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/msd-croatia" "created" => "2021-01-25 22:39:37" "last_updated" => "2021-06-22 07:40:14" "deleted" => 1 ] [ "id" => 360684986 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/msd-global" "created" => "2021-01-25 22:39:37" "last_updated" => "2021-06-22 07:40:14" "deleted" => 1 ] [ "id" => 360684987 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/merck" "created" => "2021-01-25 22:39:37" "last_updated" => "2021-06-22 07:40:14" "deleted" => 1 ] [ "id" => 513125718 "company_id" => 28738946 "url" => "https://jp.linkedin.com/company/takeda-pharmaceuticals" "created" => "2021-09-22 21:24:02" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] [ "id" => 513125719 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/nycomed" "created" => "2021-09-22 21:24:02" "last_updated" => "2022-02-21 16:15:02" "deleted" => 1 ] [ "id" => 513125720 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/takeda-pharmaceuticals-international-inc." "created" => "2021-09-22 21:24:02" "last_updated" => "2023-03-13 01:12:54" "deleted" => 1 ] [ "id" => 513125721 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/msd-croatia" "created" => "2021-09-22 21:24:02" "last_updated" => "2022-01-19 19:00:50" "deleted" => 1 ] [ "id" => 513125722 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/msd-global" "created" => "2021-09-22 21:24:02" "last_updated" => "2022-02-21 16:15:02" "deleted" => 1 ] [ "id" => 513125723 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/merck" "created" => "2021-09-22 21:24:02" "last_updated" => "2022-02-21 16:15:02" "deleted" => 1 ] [ "id" => 513125724 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/takeda-pharmaceuticals-america-inc." "created" => "2021-09-22 21:24:02" "last_updated" => "2022-02-21 16:15:02" "deleted" => 1 ] [ "id" => 513125725 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/fitnesspark-glattpark" "created" => "2021-09-22 21:24:02" "last_updated" => "2022-02-21 16:15:02" "deleted" => 1 ] [ "id" => 513125726 "company_id" => 28738946 "url" => "https://fr.linkedin.com/company/spfpl-takeda-pharmaceuticals" "created" => "2021-09-22 21:24:02" "last_updated" => "2022-02-21 16:15:02" "deleted" => 1 ] [ "id" => 513125727 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/pharmtastic" "created" => "2021-09-22 21:24:02" "last_updated" => "2022-02-21 16:15:02" "deleted" => 1 ] [ "id" => 535431462 "company_id" => 28738946 "url" => "https://hr.linkedin.com/company/msd-croatia" "created" => "2022-01-19 19:00:50" "last_updated" => "2022-02-21 16:15:02" "deleted" => 1 ] [ "id" => 540729787 "company_id" => 28738946 "url" => "https://de.linkedin.com/company/dr-shufani-gmbh" "created" => "2022-02-21 16:15:02" "last_updated" => "2022-10-11 15:36:58" "deleted" => 1 ] [ "id" => 540729789 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/fcsischweiz" "created" => "2022-02-21 16:15:02" "last_updated" => "2022-10-11 15:36:58" "deleted" => 1 ] [ "id" => 540729790 "company_id" => 28738946 "url" => "https://dk.linkedin.com/company/aros-capital-fondsmaeglerselskab" "created" => "2022-02-21 16:15:02" "last_updated" => "2022-11-17 11:56:20" "deleted" => 1 ] [ "id" => 540729791 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/helvetica-property-investors-ag" "created" => "2022-02-21 16:15:02" "last_updated" => "2022-06-25 10:08:49" "deleted" => 1 ] [ "id" => 540729792 "company_id" => 28738946 "url" => "https://de.linkedin.com/company/brainlab" "created" => "2022-02-21 16:15:02" "last_updated" => "2022-06-25 10:08:49" "deleted" => 1 ] [ "id" => 540729793 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/advent_eng" "created" => "2022-02-21 16:15:02" "last_updated" => "2022-06-25 10:08:49" "deleted" => 1 ] [ "id" => 540729794 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/evolution-rock-fitness" "created" => "2022-02-21 16:15:02" "last_updated" => "2022-06-25 10:08:49" "deleted" => 1 ] [ "id" => 540729795 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/inscopix-inc-" "created" => "2022-02-21 16:15:02" "last_updated" => "2022-06-25 10:08:49" "deleted" => 1 ] [ "id" => 649430607 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/nycomed" "created" => "2022-06-25 10:08:49" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] [ "id" => 649430608 "company_id" => 28738946 "url" => "https://fr.linkedin.com/company/spfpl-takeda-pharmaceuticals" "created" => "2022-06-25 10:08:49" "last_updated" => "2022-10-11 15:36:58" "deleted" => 1 ] [ "id" => 649430609 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/takeda-pharmaceuticals-america-inc." "created" => "2022-06-25 10:08:49" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] [ "id" => 649430610 "company_id" => 28738946 "url" => "https://in.linkedin.com/company/takeda-pharmaceuticals-india-pvt-ltd-" "created" => "2022-06-25 10:08:49" "last_updated" => "2022-09-05 21:32:53" "deleted" => 1 ] [ "id" => 649430611 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/emerald-therapeutics" "created" => "2022-06-25 10:08:49" "last_updated" => "2022-10-11 15:36:58" "deleted" => 1 ] [ "id" => 704784616 "company_id" => 28738946 "url" => "https://hu.linkedin.com/company/cyclolab-cyclodextrin-r&d-laboratory" "created" => "2022-09-05 21:32:53" "last_updated" => "2022-11-17 11:56:20" "deleted" => 1 ] [ "id" => 723055417 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/takedaoncology" "created" => "2022-10-11 15:36:58" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] [ "id" => 723055420 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/novartis" "created" => "2022-10-11 15:36:58" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] [ "id" => 723055423 "company_id" => 28738946 "url" => "https://uk.linkedin.com/company/glaxosmithkline" "created" => "2022-10-11 15:36:58" "last_updated" => "2022-11-17 11:56:20" "deleted" => 1 ] [ "id" => 723055425 "company_id" => 28738946 "url" => "https://br.linkedin.com/company/eurofarma" "created" => "2022-10-11 15:36:58" "last_updated" => "2022-11-17 11:56:20" "deleted" => 1 ] [ "id" => 737082505 "company_id" => 28738946 "url" => "https://fr.linkedin.com/company/spfpl-takeda-pharmaceuticals" "created" => "2022-11-17 11:56:20" "last_updated" => "2023-08-05 20:44:18" "deleted" => 1 ] [ "id" => 737082506 "company_id" => 28738946 "url" => "https://fr.linkedin.com/company/sanofi" "created" => "2022-11-17 11:56:20" "last_updated" => "2025-05-03 08:10:13" "deleted" => 1 ] [ "id" => 737082507 "company_id" => 28738946 "url" => "https://uk.linkedin.com/company/gsk" "created" => "2022-11-17 11:56:20" "last_updated" => "2023-07-21 06:27:32" "deleted" => 1 ] [ "id" => 737082508 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/pfizer" "created" => "2022-11-17 11:56:20" "last_updated" => "2024-12-02 22:26:34" "deleted" => 1 ] [ "id" => 792934319 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/roche" "created" => "2023-03-13 01:12:54" "last_updated" => "2023-05-01 10:29:30" "deleted" => 1 ] [ "id" => 816565186 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/takeda-pharmaceuticals-international-inc." "created" => "2023-05-01 10:29:30" "last_updated" => "2023-06-02 00:53:24" "deleted" => 1 ] [ "id" => 828689293 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/roche" "created" => "2023-06-02 00:53:24" "last_updated" => "2023-07-21 06:27:32" "deleted" => 1 ] [ "id" => 854190452 "company_id" => 28738946 "url" => "https://uk.linkedin.com/company/astrazeneca" "created" => "2023-07-21 06:27:32" "last_updated" => "2023-12-03 13:15:20" "deleted" => 1 ] [ "id" => 854190453 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2023-07-21 06:27:32" "last_updated" => "2024-08-06 07:02:05" "deleted" => 1 ] [ "id" => 862466212 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/roche" "created" => "2023-08-05 20:44:18" "last_updated" => "2023-09-02 09:26:11" "deleted" => 1 ] [ "id" => 872479953 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/takeda-pharmaceuticals-international-inc." "created" => "2023-09-02 09:26:11" "last_updated" => "2023-10-08 19:12:43" "deleted" => 1 ] [ "id" => 889921267 "company_id" => 28738946 "url" => "https://dk.linkedin.com/company/novo-nordisk" "created" => "2023-10-08 19:12:43" "last_updated" => "2023-11-05 09:47:55" "deleted" => 1 ] [ "id" => 904703716 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/takeda-pharmaceuticals-international-inc." "created" => "2023-11-05 09:47:55" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] [ "id" => 919028541 "company_id" => 28738946 "url" => "https://dk.linkedin.com/company/novo-nordisk" "created" => "2023-12-03 13:15:20" "last_updated" => "2024-01-20 08:34:44" "deleted" => 1 ] [ "id" => 940096481 "company_id" => 28738946 "url" => "https://uk.linkedin.com/company/astrazeneca" "created" => "2024-01-20 08:34:44" "last_updated" => "2024-05-18 18:34:06" "deleted" => 1 ] [ "id" => 1001291625 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/roche" "created" => "2024-05-18 18:34:06" "last_updated" => "2024-06-06 09:03:23" "deleted" => 1 ] [ "id" => 1012896059 "company_id" => 28738946 "url" => "https://dk.linkedin.com/company/novo-nordisk" "created" => "2024-06-06 09:03:23" "last_updated" => "2024-07-26 02:15:59" "deleted" => 1 ] [ "id" => 1041839430 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/roche" "created" => "2024-07-26 02:15:59" "last_updated" => "2024-09-05 09:58:01" "deleted" => 1 ] [ "id" => 1044626244 "company_id" => 28738946 "url" => "https://uk.linkedin.com/company/gsk" "created" => "2024-08-06 07:02:05" "last_updated" => "2024-09-27 20:47:34" "deleted" => 1 ] [ "id" => 1059362847 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/johnson-&-johnson" "created" => "2024-09-05 09:58:01" "last_updated" => "2024-11-26 16:05:04" "deleted" => 1 ] [ "id" => 1075826452 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/roche" "created" => "2024-09-27 20:47:34" "last_updated" => "2024-11-03 12:33:15" "deleted" => 1 ] [ "id" => 1095117291 "company_id" => 28738946 "url" => "https://fr.linkedin.com/company/spfpl-takeda-pharmaceuticals" "created" => "2024-11-03 12:33:15" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] [ "id" => 1110151690 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/abbvie" "created" => "2024-11-26 16:05:04" "last_updated" => "2025-04-07 01:49:16" "deleted" => 1 ] [ "id" => 1115706740 "company_id" => 28738946 "url" => "https://ch.linkedin.com/company/roche" "created" => "2024-12-02 22:26:34" "last_updated" => "2025-01-04 21:43:20" "deleted" => 1 ] [ "id" => 1127454484 "company_id" => 28738946 "url" => "https://uk.linkedin.com/company/gsk" "created" => "2025-01-04 21:43:20" "last_updated" => "2025-04-07 01:49:16" "deleted" => 1 ] [ "id" => 1182163702 "company_id" => 28738946 "url" => "https://it.linkedin.com/company/takeda-italia" "created" => "2025-04-07 01:49:16" "last_updated" => "2025-07-08 15:36:59" "deleted" => 1 ] [ "id" => 1182163703 "company_id" => 28738946 "url" => "https://uk.linkedin.com/company/astrazeneca" "created" => "2025-04-07 01:49:16" "last_updated" => "2025-06-02 09:59:15" "deleted" => 1 ] [ "id" => 1200178857 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/bristol-myers-squibb" "created" => "2025-05-03 08:10:13" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] [ "id" => 1215676532 "company_id" => 28738946 "url" => "https://de.linkedin.com/company/takeda-in-deutschland" "created" => "2025-06-02 09:59:15" "last_updated" => "2025-08-25 14:35:27" "deleted" => 1 ] [ "id" => 1239603603 "company_id" => 28738946 "url" => "https://uk.linkedin.com/company/astrazeneca" "created" => "2025-07-08 15:36:59" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] [ "id" => 1272081191 "company_id" => 28738946 "url" => "https://www.linkedin.com/company/abbvie" "created" => "2025-08-25 14:35:27" "last_updated" => "2025-08-25 14:35:27" "deleted" => 0 ] ] "company_specialties_collection" => [] "company_stock_info_collection" => [] "company_updates_collection" => [ [ "id" => 23088388 "company_id" => 28738946 "urn" => "urn:li:activity:6970332995937255424" "followers" => 182 "date" => "3mo" "description" => "We’ve just updated our Page. Visit our Page to see the latest updates." "reactions_count" => null "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-01-12 01:52:40" "deleted" => 1 ] [ "id" => 40640317 "company_id" => 28738946 "urn" => "urn:li:activity:6970332995937255424" "followers" => 207 "date" => "4mo" "description" => "We’ve just updated our Page. Visit our Page to see the latest updates." "reactions_count" => null "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-02-17 14:12:56" "deleted" => 1 ] [ "id" => 80711605 "company_id" => 28738946 "urn" => "urn:li:activity:6970332995937255424" "followers" => 280 "date" => "5mo" "description" => "We’ve just updated our Page. Visit our Page to see the latest updates." "reactions_count" => null "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-03-13 01:12:54" "deleted" => 1 ] [ "id" => 110295393 "company_id" => 28738946 "urn" => "urn:li:activity:6970332995937255424" "followers" => 323 "date" => "6mo" "description" => "We’ve just updated our Page. Visit our Page to see the latest updates." "reactions_count" => null "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-04-19 02:25:32" "deleted" => 1 ] [ "id" => 138578421 "company_id" => 28738946 "urn" => "urn:li:activity:6970332995937255424" "followers" => 389 "date" => "7mo" "description" => "We’ve just updated our Page. Visit our Page to see the latest updates." "reactions_count" => null "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-01 10:29:30" "deleted" => 1 ] [ "id" => 158048904 "company_id" => 28738946 "urn" => "urn:li:activity:6970332995937255424" "followers" => 410 "date" => "8mo" "description" => "We’ve just updated our Page. Visit our Page to see the latest updates." "reactions_count" => null "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-05-15 08:28:05" "deleted" => 1 ] [ "id" => 178904859 "company_id" => 28738946 "urn" => "urn:li:activity:6970332995937255424" "followers" => 442 "date" => "8mo" "description" => "We’ve just updated our Page. Visit our Page to see the latest updates." "reactions_count" => null "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-06-02 00:53:24" "deleted" => 1 ] [ "id" => 190238835 "company_id" => 28738946 "urn" => "urn:li:activity:6970332995937255424" "followers" => 493 "date" => "9mo" "description" => "We’ve just updated our Page. Visit our Page to see the latest updates." "reactions_count" => 1 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-07-21 06:27:32" "deleted" => 1 ] [ "id" => 250930780 "company_id" => 28738946 "urn" => "urn:li:activity:6970332995937255424" "followers" => 639 "date" => "10mo" "description" => "We’ve just updated our Page. Visit our Page to see the latest updates." "reactions_count" => 1 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-08-05 20:44:18" "deleted" => 1 ] [ "id" => 274465168 "company_id" => 28738946 "urn" => "urn:li:activity:6970332995937255424" "followers" => 684 "date" => "11mo" "description" => "We’ve just updated our Page. Visit our Page to see the latest updates." "reactions_count" => 1 "comments_count" => null "reshared_post_author" => null "reshared_post_author_url" => null "reshared_post_author_headline" => null "reshared_post_description" => null "reshared_post_followers" => null "reshared_post_date" => null "last_updated" => "2023-09-02 09:26:11" "deleted" => 1 ] ] ] -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5711 …} -companyTags: Doctrine\ORM\PersistentCollection {#5713 …} -companyCategory: null -owners: Doctrine\ORM\PersistentCollection {#5715 …} -users: Doctrine\ORM\PersistentCollection {#5717 …} -logoImageName: null -coverImageName: null -companyProducts: Doctrine\ORM\PersistentCollection {#5719 …} -tagline: "TAKEDA PHARMACEUTICALS INTERNATIONAL GMBH GLATTPARK CH" -contactEmail: null -phone: null -streamUrl: null -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5721 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5723 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5725 …} -industry: "Wholesale" -size: "93" -address1: null -address2: null -city: null -postalCode: null -state: null -country: "Switzerland" -socialLinkedin: null -socialX: null -socialFacebook: null -socialInstagram: null -socialYoutube: null -ownerContainers: Doctrine\ORM\PersistentCollection {#5727 …} #createdAt: DateTime @1756305077 {#5689 date: 2025-08-27 14:31:17.0 UTC (+00:00) } #updatedAt: DateTime @1756308818 {#5688 date: 2025-08-27 15:33:38.0 UTC (+00:00) } } App\Entity\Company {#5731 -id: 279 -name: "Lundbeck" -website: "https://lundbeck.com" -description: "Lundbeck is a pharmaceutical firm headquartered in Copenhagen, laser-focused on treating brain diseases—from depression and schizophrenia to Alzheimer’s and Parkinson’s. Founded in 1915 by Hans Lundbeck, it now employs roughly 5,400 people globally and is majority-owned (about 70 %) by the Lundbeck Foundation. Their products are registered in over 100 countries—and yes, people worldwide rely on them for brain health, not because they asked for it, but because occasionally science does something useful." -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5732 …} -companyTags: Doctrine\ORM\PersistentCollection {#5734 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#4263 …} -owners: Doctrine\ORM\PersistentCollection {#5736 …} -users: Doctrine\ORM\PersistentCollection {#5738 …} -logoImageName: "20250908183010-lundbeck-logo-png-seeklogo-86327-68bf049297277054314986.png" -coverImageName: "20250908183010-favicon-lundbeck-68bf0492e60a8844430822.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5740 …} -tagline: "Lundbeck is a Danish pharmaceutical company focused on brain health, developing treatments for mental and neurological disorders worldwide." -contactEmail: "switzerland@lundbeck.com" -phone: "41582698181" -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5742 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5744 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5746 …} -industry: "Pharmaindustrie" -size: "5400" -address1: "Balz-Zimmermann-Strasse 7" -address2: "" -city: "Glattbrugg" -postalCode: "8152" -state: "Zürich" -country: "CH" -socialLinkedin: "https://www.linkedin.com/company/lundbeck" -socialX: "https://twitter.com/Lundbeck" -socialFacebook: "" -socialInstagram: "https://www.instagram.com/h_lundbeck/?hl=en" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5748 …} #createdAt: DateTime @1757349011 {#5709 date: 2025-09-08 16:30:11.0 UTC (+00:00) } #updatedAt: DateTime @1757349365 {#5708 date: 2025-09-08 16:36:05.0 UTC (+00:00) } } App\Entity\Company {#5752 -id: 306 -name: "tVNS Technologies GmbH" -website: "https://t-vns.com" -description: "Since 2003, tVNS Technologies GmbH (Germany) has developed advanced medical devices for non-invasive vagus nerve stimulation (tVNS®). Their device, tVNS® E, is certified as a Class IIa medical device under EU MDR, and targets neurological conditions through a safe, patient-friendly, drug-free approach." -externalId: null -details: null -client: Proxies\__CG__\App\Entity\Client {#3323 …} -containers: Doctrine\ORM\PersistentCollection {#5753 …} -companyTags: Doctrine\ORM\PersistentCollection {#5755 …} -companyCategory: Proxies\__CG__\App\Entity\CommonCategory {#5757 …} -owners: Doctrine\ORM\PersistentCollection {#5758 …} -users: Doctrine\ORM\PersistentCollection {#5760 …} -logoImageName: "20251013161805-tvns-logo-icon-tm--68ed0a1da91e4120668612.png" -coverImageName: "20251013161806-tvns-logo-icon-tm--68ed0a1e16384694274054.png" -companyProducts: Doctrine\ORM\PersistentCollection {#5762 …} -tagline: "tVNS Technologies – German Innovator in Vagus Nerve Stimulation" -contactEmail: "joerg@tech.t-vns.com" -phone: null -streamUrl: "" -streamType: null -followers: Doctrine\ORM\PersistentCollection {#5764 …} -totalFollowers: null -offNotificationUsers: Doctrine\ORM\PersistentCollection {#5766 …} -newsfeeds: Doctrine\ORM\PersistentCollection {#5768 …} -industry: "Neuromodulationstechnologie" -size: "" -address1: "Wetterkreuz 5" -address2: "" -city: "Erlangen" -postalCode: "91058" -state: "Bayern" -country: "DE" -socialLinkedin: "https://de.linkedin.com/company/tvns-technologies" -socialX: "" -socialFacebook: "https://www.facebook.com/profile.php?id=61558228833184&sk=about" -socialInstagram: "https://www.instagram.com/tvnstechnologies/" -socialYoutube: "" -ownerContainers: Doctrine\ORM\PersistentCollection {#5770 …} #createdAt: DateTime @1760365086 {#5730 date: 2025-10-13 14:18:06.0 UTC (+00:00) } #updatedAt: DateTime @1760368931 {#5729 date: 2025-10-13 15:22:11.0 UTC (+00:00) } }]

Request Headers

Header	Value
accept	"application/ld+json"
accept-encoding	"gzip, deflate, br, zstd"
accept-language	"de,de-DE;q=0.9,en;q=0.8,en-GB;q=0.7,en-US;q=0.6"
authorization	"Bearer eyJ0eXAiOiJKV1QiLCJhbGciOiJSUzI1NiJ9.eyJpYXQiOjE3NjExOTgyMTksImV4cCI6MTc2MTI4NDYxOSwicm9sZXMiOlsiUk9MRV9BRE1JTiJdLCJ1c2VybmFtZSI6ImNlY2lsZS5rZWxsZXJAaW5zZWwuY2giLCJpcCI6IjE2MS42Mi4yNTIuMzQiLCJjaWQiOjU5LCJjbnRpZCI6MTh9.CN3MeG1EC3rFpjos-ZKy7BOxLYdIPZnkWZXp8977sG856ISevwqhP7eM5MOqN5cv2XAJZKiBxYTPe5vJq9R8w1DMYY2ES7rBmfKVtc8mYMopoMwZP7U7Ano1xe9o26xl-xrMyJ-LdAy9MSO-jMOklqgMVOWQFGabTyVwi324k73aYIiBAN4STYEoleOSZeWPjp7jw3tY0wN1ZPXL0hvdujdlR_qw7-sfPuNo0Ds9zW1JlphDhUgxYZyBoLrYZBVvm6x6iOL_WmExMNqEomdovhicNyWRV3N3MApwgxOojbGyclc8fBviniZTHszVmf0UGTNPyaSdAONvJR73VsVLuw"
connection	"keep-alive"
content-length	""
content-type	""
es-key	"nhAdtDbmV1cm9uZXdzLmNozzoZ31"
es-timezone	"Europe/Zurich"
host	"apiprod.expertshare.live"
if-none-match	""2bebea0ef48edfa32032d8f226741749""
origin	"https://neuronews.ch"
referer	"https://neuronews.ch/"
sec-ch-ua	""Not)A;Brand";v="8", "Chromium";v="138", "Microsoft Edge";v="138""
sec-ch-ua-mobile	"?0"
sec-ch-ua-platform	""Windows""
sec-fetch-dest	"empty"
sec-fetch-mode	"cors"
sec-fetch-site	"cross-site"
user-agent	"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/138.0.0.0 Safari/537.36 Edg/138.0.0.0"
x-php-ob-level	"1"

Request Content

Request content not available (it was retrieved as a resource).

Response

Response Headers

Header	Value
access-control-allow-origin	"https://neuronews.ch"
access-control-expose-headers	"link"
cache-control	"no-cache, private"
content-type	"application/ld+json; charset=utf-8"
date	"Thu, 23 Oct 2025 06:47:32 GMT"
etag	""2bebea0ef48edfa32032d8f226741749""
link	"<https://apiprod.expertshare.live/api/docs.jsonld>; rel="http://www.w3.org/ns/hydra/core#apiDocumentation""
vary	"Accept"
x-content-type-options	"nosniff"
x-debug-token	"b3e596"
x-frame-options	"deny"

Cookies

Request Cookies

No request cookies

Response Cookies

No response cookies

Session

Session Metadata

No session metadata

Session Attributes

No session attributes

Session Usage

0 Usages

Stateless check enabled

Session not used.

Flashes

No flash messages were created.

Server Parameters

Defined in .env

Key	Value
APP_ENV	"dev"
APP_ENV_TYPE	"ES"
APP_SECRET	"b543fadabe7483f2a799ca5ec2628e78"
AWS_KMS_ACCESS_KEY_ID	""
AWS_KMS_ACCESS_KEY_SECRET	""
AWS_KMS_ARN	""
AWS_KMS_ENC_KEY	""
AWS_KMS_REGION	"eu-central-1"
AWS_KMS_TTL	""
AZURE_CLIENT_ID	"3d23b36d-3037-49ba-a8fc-70d6597ff2d4"
AZURE_CLIENT_SECRET	"PQP8Q~OGDO.c2YwdCAekoOuFoG7Ie3o_wUoNia.w"
BASE_URL_8N8	"https://buchner.app.n8n.cloud"
BASIC_AUTH_8N8	"buchner:M6on#efHrk5MATCB"
CLAMAV_CONNECTION	"unix:///var/run/clamav/clamd.ctl"
CORESIGNAL_API_TOKEN	"NQXgWuDxLxvibE5PJS8fMvM2n9cpkK4t"
CORS_ALLOW_ORIGIN	"*"
CSSSO_CONTACT_EMAIL	""
CSSSO_CONTACT_NAME	""
CSSSO_IDP_CERT	""
CSSSO_IDP_ENTITY_ID	""
CSSSO_IDP_LOGIN_BINDING	""
CSSSO_IDP_LOGIN_URL	""
CSSSO_SP_ACS_BINDING	""
CSSSO_SP_ACS_URL	""
CSSSO_SP_ENTITY_ID	""
CS_ENV	""
DATABASE_URL	"mysql://root:ihnDvCE8fpGQ0Q09@116.203.238.46:3306/expertshare_backend?mariadb-10.6.16"
DATA_ENCRYPTION	"false"
ELASTICSEARCH_URL	"http://116.203.91.86:9200"
GOOGLE_CLIENT_ID	"583691346362-rrqj5c3rq7g1s5841jp9ugfpdnubf2u5.apps.googleusercontent.com"
GOOGLE_CLIENT_SECRET	"Sc5nAm0YWT1mhgVPG3DLCZdb"
GOOGLE_TRANSLATE_API_KEY	"AIzaSyCSmA4UHivnR_UrXqGv_S4i1Hi6u_qMzBo"
INSTANCE_NO	"1"
JWT_PASSPHRASE	"5107f723d3514531a5d51fc03aff8bed"
JWT_PUBLIC_KEY	"%kernel.project_dir%/config/jwt/public.pem"
JWT_SECRET_KEY	"%kernel.project_dir%/config/jwt/private.pem"
LINKEDIN_CLIENT_ID	"77l8jx5blqcb5r"
LINKEDIN_CLIENT_SECRET	"oQN2ghAJxE3ybTbQ"
LOCAL_STORAGE_PATH	"uploads/"
MAILER_DSN	"postmark+api://da2b15e2-c661-4f22-bead-119274d93131@default"
OPENAI_API_KEY	"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"
OPENAI_BASE_URL	"https://api.openai.com/v1"
OPENAI_MODEL	"gpt-4.1"
REDIS_CLUSTER_DSN	"redis://116.203.147.213:6379"
REDIS_HOST	"116.203.147.213"
REDIS_PORT	"6379"
REPLY_TO_IMAP_MAILBOX	"{imap.gmail.com:993/imap/ssl}INBOX"
REPLY_TO_IMAP_PASSWORD	"zcwixahkyrdmssym"
REPLY_TO_IMAP_USERNAME	"reply@expertshare.live"
STRIPE_API_SECRET	"sk_test_gZUbgF8fEyCOf8BLK5qOnAy2"
SWISSRX_AUTHORIZE_URL	"https://swiss-rx-login.ch/oauth/authorize"
SWISSRX_CLIENT_ID	"7601002998758"
SWISSRX_CLIENT_SECRET	"SM991003"
SWISSRX_ENABLE	"1"
SWISSRX_TOKEN_URL	"https://swiss-rx-login.ch/oauth/token"
TOTAL_INSTANCE	"1"
WKHTMLTOIMAGE_PATH	"/usr/bin/wkhtmltoimage"
WKHTMLTOPDF_PATH	"/usr/bin/wkhtmltopdf"

Defined as regular env variables

Key	Value
APP_DEBUG	"1"
CONTENT_LENGTH	""
CONTENT_TYPE	""
DOCUMENT_ROOT	"/home/srm/web/project/expertshare-backend/public"
DOCUMENT_URI	"/index.php"
FCGI_ROLE	"RESPONDER"
GATEWAY_INTERFACE	"CGI/1.1"
HOME	"/var/www"
HTTPS	"on"
HTTP_ACCEPT	"application/ld+json"
HTTP_ACCEPT_ENCODING	"gzip, deflate, br, zstd"
HTTP_ACCEPT_LANGUAGE	"de,de-DE;q=0.9,en;q=0.8,en-GB;q=0.7,en-US;q=0.6"
HTTP_AUTHORIZATION	"Bearer eyJ0eXAiOiJKV1QiLCJhbGciOiJSUzI1NiJ9.eyJpYXQiOjE3NjExOTgyMTksImV4cCI6MTc2MTI4NDYxOSwicm9sZXMiOlsiUk9MRV9BRE1JTiJdLCJ1c2VybmFtZSI6ImNlY2lsZS5rZWxsZXJAaW5zZWwuY2giLCJpcCI6IjE2MS42Mi4yNTIuMzQiLCJjaWQiOjU5LCJjbnRpZCI6MTh9.CN3MeG1EC3rFpjos-ZKy7BOxLYdIPZnkWZXp8977sG856ISevwqhP7eM5MOqN5cv2XAJZKiBxYTPe5vJq9R8w1DMYY2ES7rBmfKVtc8mYMopoMwZP7U7Ano1xe9o26xl-xrMyJ-LdAy9MSO-jMOklqgMVOWQFGabTyVwi324k73aYIiBAN4STYEoleOSZeWPjp7jw3tY0wN1ZPXL0hvdujdlR_qw7-sfPuNo0Ds9zW1JlphDhUgxYZyBoLrYZBVvm6x6iOL_WmExMNqEomdovhicNyWRV3N3MApwgxOojbGyclc8fBviniZTHszVmf0UGTNPyaSdAONvJR73VsVLuw"
HTTP_CONNECTION	"keep-alive"
HTTP_ES_KEY	"nhAdtDbmV1cm9uZXdzLmNozzoZ31"
HTTP_ES_TIMEZONE	"Europe/Zurich"
HTTP_HOST	"apiprod.expertshare.live"
HTTP_IF_NONE_MATCH	""2bebea0ef48edfa32032d8f226741749""
HTTP_ORIGIN	"https://neuronews.ch"
HTTP_REFERER	"https://neuronews.ch/"
HTTP_SEC_CH_UA	""Not)A;Brand";v="8", "Chromium";v="138", "Microsoft Edge";v="138""
HTTP_SEC_CH_UA_MOBILE	"?0"
HTTP_SEC_CH_UA_PLATFORM	""Windows""
HTTP_SEC_FETCH_DEST	"empty"
HTTP_SEC_FETCH_MODE	"cors"
HTTP_SEC_FETCH_SITE	"cross-site"
HTTP_USER_AGENT	"Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/138.0.0.0 Safari/537.36 Edg/138.0.0.0"
PATH_INFO	""
PHP_SELF	"/index.php"
QUERY_STRING	"client.id=59&containers.id=18&pagination=false&locale=de"
REDIRECT_STATUS	"200"
REMOTE_ADDR	"161.62.252.34"
REMOTE_PORT	"18718"
REMOTE_USER	""
REQUEST_METHOD	"GET"
REQUEST_SCHEME	"https"
REQUEST_TIME	1761202045
REQUEST_TIME_FLOAT	1761202045.7663
REQUEST_URI	"/api/companies/get-all?client.id=59&containers.id=18&pagination=false&locale=de"
SCRIPT_FILENAME	"/home/srm/web/project/expertshare-backend/public/index.php"
SCRIPT_NAME	"/index.php"
SERVER_ADDR	"49.13.32.242"
SERVER_NAME	"apiprod.expertshare.live"
SERVER_PORT	"443"
SERVER_PROTOCOL	"HTTP/1.1"
SERVER_SOFTWARE	"nginx/1.24.0"
SYMFONY_DOTENV_VARS	"APP_ENV,APP_SECRET,DATABASE_URL,JWT_SECRET_KEY,JWT_PUBLIC_KEY,JWT_PASSPHRASE,CORS_ALLOW_ORIGIN,REDIS_HOST,REDIS_PORT,REDIS_CLUSTER_DSN,LOCAL_STORAGE_PATH,MAILER_DSN,REPLY_TO_IMAP_MAILBOX,REPLY_TO_IMAP_USERNAME,REPLY_TO_IMAP_PASSWORD,GOOGLE_CLIENT_ID,GOOGLE_CLIENT_SECRET,LINKEDIN_CLIENT_ID,LINKEDIN_CLIENT_SECRET,AZURE_CLIENT_ID,AZURE_CLIENT_SECRET,DATA_ENCRYPTION,AWS_KMS_REGION,AWS_KMS_ACCESS_KEY_ID,AWS_KMS_ACCESS_KEY_SECRET,AWS_KMS_ARN,AWS_KMS_ENC_KEY,AWS_KMS_TTL,INSTANCE_NO,TOTAL_INSTANCE,CS_ENV,CSSSO_IDP_ENTITY_ID,CSSSO_IDP_LOGIN_URL,CSSSO_IDP_LOGIN_BINDING,CSSSO_IDP_CERT,CSSSO_SP_ENTITY_ID,CSSSO_SP_ACS_URL,CSSSO_SP_ACS_BINDING,CSSSO_CONTACT_NAME,CSSSO_CONTACT_EMAIL,SWISSRX_ENABLE,SWISSRX_CLIENT_ID,SWISSRX_CLIENT_SECRET,SWISSRX_AUTHORIZE_URL,SWISSRX_TOKEN_URL,CLAMAV_CONNECTION,APP_ENV_TYPE,WKHTMLTOPDF_PATH,WKHTMLTOIMAGE_PATH,OPENAI_API_KEY,OPENAI_BASE_URL,OPENAI_MODEL,ELASTICSEARCH_URL,GOOGLE_TRANSLATE_API_KEY,CORESIGNAL_API_TOKEN,STRIPE_API_SECRET,BASE_URL_8N8,BASIC_AUTH_8N8"
USER	"www-data"

Symfony Profiler

https://apiprod.expertshare.live/api/companies/get-all?client.id=59&containers.id=18&locale=de&pagination=false

Configuration Settings

Theme

Page Width

PlaceholderAction

Request

GET Parameters

POST Parameters

Uploaded Files

Request Attributes

Request Headers

Request Content

Response

Response Headers

Cookies

Request Cookies

Response Cookies

Session

Session Metadata

Session Attributes

Session Usage

Flashes

Flashes

Server Parameters

Server Parameters

Defined in .env

Defined as regular env variables